{"docstore/data": {"2d1dcccb-3e02-46e0-abde-55680070466f": {"__data__": {"id_": "2d1dcccb-3e02-46e0-abde-55680070466f", "embedding": null, "metadata": {"window": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 21 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n31-Jul-2019  \nMcKesson Corp.   (MCK ) \nQ1 2020 Earnings Call    ", "original_text": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 21 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n31-Jul-2019  \nMcKesson Corp.  ", "page_label": "1", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "eec7d66c-3454-4514-a032-b03193f8a1ea", "node_type": "4", "metadata": {"page_label": "1", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8fc0b98a140737296005d592fecb3c627dd3c927a61c60020f40e75f62a5c8a9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a0fe1be5-d0ec-4ba8-b3d0-1b9b60524dc9", "node_type": "1", "metadata": {"window": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 21 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n31-Jul-2019  \nMcKesson Corp.   (MCK ) \nQ1 2020 Earnings Call    ", "original_text": "(MCK ) \nQ1 2020 Earnings Call    "}, "hash": "31bbaf74936a0acbc53c2db6bab6c2bff91fefc2ffbff29272f8a3dedfc92f10", "class_name": "RelatedNodeInfo"}}, "text": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 21 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n31-Jul-2019  \nMcKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 165, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a0fe1be5-d0ec-4ba8-b3d0-1b9b60524dc9": {"__data__": {"id_": "a0fe1be5-d0ec-4ba8-b3d0-1b9b60524dc9", "embedding": null, "metadata": {"window": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 21 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n31-Jul-2019  \nMcKesson Corp.   (MCK ) \nQ1 2020 Earnings Call    ", "original_text": "(MCK ) \nQ1 2020 Earnings Call    ", "page_label": "1", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "eec7d66c-3454-4514-a032-b03193f8a1ea", "node_type": "4", "metadata": {"page_label": "1", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8fc0b98a140737296005d592fecb3c627dd3c927a61c60020f40e75f62a5c8a9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2d1dcccb-3e02-46e0-abde-55680070466f", "node_type": "1", "metadata": {"window": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 21 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n31-Jul-2019  \nMcKesson Corp.   (MCK ) \nQ1 2020 Earnings Call    ", "original_text": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 21 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n31-Jul-2019  \nMcKesson Corp.  ", "page_label": "1", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ca7c1c6e7bbf2fe00fcbe016852094d982b4d7681faaa7b3dc5304c2b2e4c051", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "042d8547-70e6-4b64-8f8b-b17e83e56818", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n ", "original_text": "McKesson Corp.  "}, "hash": "793acea57ab2b2d2ee5495128ed764bd33be6e93ee051eb0b3af98b7382105d5", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ1 2020 Earnings Call    ", "start_char_idx": 165, "end_char_idx": 198, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "042d8547-70e6-4b64-8f8b-b17e83e56818": {"__data__": {"id_": "042d8547-70e6-4b64-8f8b-b17e83e56818", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n ", "original_text": "McKesson Corp.  ", "page_label": "2", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ddcd894d-3a7b-418b-b056-c1eebfbff48a", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d8d95ce637ceaac9a10eb060d492d3e8b211428ec223d20fd917993a4fef6ead", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a0fe1be5-d0ec-4ba8-b3d0-1b9b60524dc9", "node_type": "1", "metadata": {"window": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 21 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n31-Jul-2019  \nMcKesson Corp.   (MCK ) \nQ1 2020 Earnings Call    ", "original_text": "(MCK ) \nQ1 2020 Earnings Call    ", "page_label": "1", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d3be67f5117efbe3418957d50b816ff3d1bb8ca705aeebca46c3eb9b039ff1bb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d1bfb804-0d26-45bd-a7f8-7c8995ed6bfb", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. ", "original_text": "(MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n"}, "hash": "918024d88808826f25e4eaf9453414452638562fb61513d7eed3ad0e00c7cf37", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d1bfb804-0d26-45bd-a7f8-7c8995ed6bfb": {"__data__": {"id_": "d1bfb804-0d26-45bd-a7f8-7c8995ed6bfb", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. ", "original_text": "(MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n", "page_label": "2", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ddcd894d-3a7b-418b-b056-c1eebfbff48a", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d8d95ce637ceaac9a10eb060d492d3e8b211428ec223d20fd917993a4fef6ead", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "042d8547-70e6-4b64-8f8b-b17e83e56818", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n ", "original_text": "McKesson Corp.  ", "page_label": "2", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4d5a2511878e048b91b34b5eb878093ade95624db342637bd3753830f1566170", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "137edc29-0866-49af-a115-71690aa287f1", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  \nRoss Muken  \nAnalyst, Evercore ISI  \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Eric Percher  \nAnalyst, Nephron Research LLC  \nBrian Gil Tanquilut  \nAnalyst, Jefferies LLC  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co. ", "original_text": "Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  "}, "hash": "40d9074a127a2b57c3c3c85c25fd03a98184cf5675b1db43cff3d7b3851f435b", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n", "start_char_idx": 16, "end_char_idx": 283, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "137edc29-0866-49af-a115-71690aa287f1": {"__data__": {"id_": "137edc29-0866-49af-a115-71690aa287f1", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  \nRoss Muken  \nAnalyst, Evercore ISI  \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Eric Percher  \nAnalyst, Nephron Research LLC  \nBrian Gil Tanquilut  \nAnalyst, Jefferies LLC  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co. ", "original_text": "Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "2", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ddcd894d-3a7b-418b-b056-c1eebfbff48a", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d8d95ce637ceaac9a10eb060d492d3e8b211428ec223d20fd917993a4fef6ead", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d1bfb804-0d26-45bd-a7f8-7c8995ed6bfb", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. ", "original_text": "(MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n", "page_label": "2", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "836e94779146bc19f5bb6ade25e1cf623ffc583e5f87b3d687149e03031acf07", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e9093e6c-2bb6-47cc-94fb-4158f0563efb", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  \nRoss Muken  \nAnalyst, Evercore ISI  \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Eric Percher  \nAnalyst, Nephron Research LLC  \nBrian Gil Tanquilut  \nAnalyst, Jefferies LLC  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  \nCharles Rhyee  \nAnalyst, Cowen & Co. ", "original_text": "Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n "}, "hash": "a2fec0f7ca2d2bfc87073f14e93fd3211ee507fb6b7f49b8847008c905a85abb", "class_name": "RelatedNodeInfo"}}, "text": "Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "start_char_idx": 283, "end_char_idx": 355, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e9093e6c-2bb6-47cc-94fb-4158f0563efb": {"__data__": {"id_": "e9093e6c-2bb6-47cc-94fb-4158f0563efb", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  \nRoss Muken  \nAnalyst, Evercore ISI  \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Eric Percher  \nAnalyst, Nephron Research LLC  \nBrian Gil Tanquilut  \nAnalyst, Jefferies LLC  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  \nCharles Rhyee  \nAnalyst, Cowen & Co. ", "original_text": "Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n ", "page_label": "2", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ddcd894d-3a7b-418b-b056-c1eebfbff48a", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d8d95ce637ceaac9a10eb060d492d3e8b211428ec223d20fd917993a4fef6ead", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "137edc29-0866-49af-a115-71690aa287f1", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  \nRoss Muken  \nAnalyst, Evercore ISI  \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Eric Percher  \nAnalyst, Nephron Research LLC  \nBrian Gil Tanquilut  \nAnalyst, Jefferies LLC  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co. ", "original_text": "Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "2", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4c42d51721573b2c9e1f9ae15536f4650dc8e4b64a85b4e620d3e05a936cc2b5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6b38cf73-8d96-4feb-a60b-7d3f1a4f6b17", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  \nRoss Muken  \nAnalyst, Evercore ISI  \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Eric Percher  \nAnalyst, Nephron Research LLC  \nBrian Gil Tanquilut  \nAnalyst, Jefferies LLC  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC \nEric W. Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. "}, "hash": "2528c75987d82333c1ff7cce798dc16e0fb69d811e77d005ef5350c29f444fea", "class_name": "RelatedNodeInfo"}}, "text": "Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n ", "start_char_idx": 355, "end_char_idx": 445, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6b38cf73-8d96-4feb-a60b-7d3f1a4f6b17": {"__data__": {"id_": "6b38cf73-8d96-4feb-a60b-7d3f1a4f6b17", "embedding": null, "metadata": {"window": "(MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  \nRoss Muken  \nAnalyst, Evercore ISI  \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Eric Percher  \nAnalyst, Nephron Research LLC  \nBrian Gil Tanquilut  \nAnalyst, Jefferies LLC  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC \nEric W. Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. ", "page_label": "2", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ddcd894d-3a7b-418b-b056-c1eebfbff48a", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d8d95ce637ceaac9a10eb060d492d3e8b211428ec223d20fd917993a4fef6ead", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e9093e6c-2bb6-47cc-94fb-4158f0563efb", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  \nRoss Muken  \nAnalyst, Evercore ISI  \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Eric Percher  \nAnalyst, Nephron Research LLC  \nBrian Gil Tanquilut  \nAnalyst, Jefferies LLC  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  \nCharles Rhyee  \nAnalyst, Cowen & Co. ", "original_text": "Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n ", "page_label": "2", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2a3c6aa6a1bfcc964ff22e7233ec8e92caa591596cfb18eccf454be65708b51c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2d4f0610-1d29-4956-9851-f97d9aac6562", "node_type": "1", "metadata": {"window": "Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  \nRoss Muken  \nAnalyst, Evercore ISI  \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Eric Percher  \nAnalyst, Nephron Research LLC  \nBrian Gil Tanquilut  \nAnalyst, Jefferies LLC  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC \nEric W. Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n  ", "original_text": "LLC  \nRoss Muken  \nAnalyst, Evercore ISI  \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Eric Percher  \nAnalyst, Nephron Research LLC  \nBrian Gil Tanquilut  \nAnalyst, Jefferies LLC  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co. "}, "hash": "f688bcf2305f09a28ceca7bb1f85498f75a0bf47805ec4c85212be54bd2670e7", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. ", "start_char_idx": 445, "end_char_idx": 934, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2d4f0610-1d29-4956-9851-f97d9aac6562": {"__data__": {"id_": "2d4f0610-1d29-4956-9851-f97d9aac6562", "embedding": null, "metadata": {"window": "Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  \nRoss Muken  \nAnalyst, Evercore ISI  \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Eric Percher  \nAnalyst, Nephron Research LLC  \nBrian Gil Tanquilut  \nAnalyst, Jefferies LLC  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC \nEric W. Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n  ", "original_text": "LLC  \nRoss Muken  \nAnalyst, Evercore ISI  \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Eric Percher  \nAnalyst, Nephron Research LLC  \nBrian Gil Tanquilut  \nAnalyst, Jefferies LLC  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co. ", "page_label": "2", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ddcd894d-3a7b-418b-b056-c1eebfbff48a", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d8d95ce637ceaac9a10eb060d492d3e8b211428ec223d20fd917993a4fef6ead", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6b38cf73-8d96-4feb-a60b-7d3f1a4f6b17", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  \nRoss Muken  \nAnalyst, Evercore ISI  \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Eric Percher  \nAnalyst, Nephron Research LLC  \nBrian Gil Tanquilut  \nAnalyst, Jefferies LLC  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC \nEric W. Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. ", "page_label": "2", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9b5ff6fd8453f09e08a8deddf47f6119c0029a1f94bea66bb484d8ec2191da65", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f1bf7e7f-5b9b-4083-9fce-384e3629541e", "node_type": "1", "metadata": {"window": "Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  \nRoss Muken  \nAnalyst, Evercore ISI  \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Eric Percher  \nAnalyst, Nephron Research LLC  \nBrian Gil Tanquilut  \nAnalyst, Jefferies LLC  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC \nEric W. Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n  ", "original_text": "LLC  \nCharles Rhyee  \nAnalyst, Cowen & Co. "}, "hash": "ab130e251f4048a5335d6c6278c72b2208ab79ff23b6be3969a72c58a86bcf6c", "class_name": "RelatedNodeInfo"}}, "text": "LLC  \nRoss Muken  \nAnalyst, Evercore ISI  \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Eric Percher  \nAnalyst, Nephron Research LLC  \nBrian Gil Tanquilut  \nAnalyst, Jefferies LLC  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co. ", "start_char_idx": 934, "end_char_idx": 1164, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f1bf7e7f-5b9b-4083-9fce-384e3629541e": {"__data__": {"id_": "f1bf7e7f-5b9b-4083-9fce-384e3629541e", "embedding": null, "metadata": {"window": "Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  \nRoss Muken  \nAnalyst, Evercore ISI  \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Eric Percher  \nAnalyst, Nephron Research LLC  \nBrian Gil Tanquilut  \nAnalyst, Jefferies LLC  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC \nEric W. Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n  ", "original_text": "LLC  \nCharles Rhyee  \nAnalyst, Cowen & Co. ", "page_label": "2", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ddcd894d-3a7b-418b-b056-c1eebfbff48a", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d8d95ce637ceaac9a10eb060d492d3e8b211428ec223d20fd917993a4fef6ead", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2d4f0610-1d29-4956-9851-f97d9aac6562", "node_type": "1", "metadata": {"window": "Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  \nRoss Muken  \nAnalyst, Evercore ISI  \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Eric Percher  \nAnalyst, Nephron Research LLC  \nBrian Gil Tanquilut  \nAnalyst, Jefferies LLC  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC \nEric W. Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n  ", "original_text": "LLC  \nRoss Muken  \nAnalyst, Evercore ISI  \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Eric Percher  \nAnalyst, Nephron Research LLC  \nBrian Gil Tanquilut  \nAnalyst, Jefferies LLC  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co. ", "page_label": "2", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "465da3132b2083d7035bb8b188b219d4fc71f1a1beadc46cc238db233101c640", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "afe63832-3b76-47a7-8870-b2fddf186363", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  \nRoss Muken  \nAnalyst, Evercore ISI  \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Eric Percher  \nAnalyst, Nephron Research LLC  \nBrian Gil Tanquilut  \nAnalyst, Jefferies LLC  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC \nEric W. Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n  ", "original_text": "LLC \nEric W. Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n  "}, "hash": "ab2486e94076900f19e5dbc57f7fc8192dfd8e432f0e636cb7c72c3651e04222", "class_name": "RelatedNodeInfo"}}, "text": "LLC  \nCharles Rhyee  \nAnalyst, Cowen & Co. ", "start_char_idx": 1164, "end_char_idx": 1207, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "afe63832-3b76-47a7-8870-b2fddf186363": {"__data__": {"id_": "afe63832-3b76-47a7-8870-b2fddf186363", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  \nRoss Muken  \nAnalyst, Evercore ISI  \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Eric Percher  \nAnalyst, Nephron Research LLC  \nBrian Gil Tanquilut  \nAnalyst, Jefferies LLC  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC \nEric W. Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n  ", "original_text": "LLC \nEric W. Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n  ", "page_label": "2", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ddcd894d-3a7b-418b-b056-c1eebfbff48a", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d8d95ce637ceaac9a10eb060d492d3e8b211428ec223d20fd917993a4fef6ead", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f1bf7e7f-5b9b-4083-9fce-384e3629541e", "node_type": "1", "metadata": {"window": "Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  \nRoss Muken  \nAnalyst, Evercore ISI  \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Eric Percher  \nAnalyst, Nephron Research LLC  \nBrian Gil Tanquilut  \nAnalyst, Jefferies LLC  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC \nEric W. Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n  ", "original_text": "LLC  \nCharles Rhyee  \nAnalyst, Cowen & Co. ", "page_label": "2", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c9521f78c5a276512af0d22fff33aa4ba9a63e864ac1081cb4de8ec04fb44a00", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c94e8c4b-317a-49c0-a8e9-34204d6247f9", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Good day, and welcome to the McKesson Q1 Earnings Call.  Today's conference is being recorded.  \n \n At this time, I'd like to turn the conference over to Holly Weiss. ", "original_text": "McKesson Corp.  "}, "hash": "537521413e13910d32748eff1ba7eb3f51db19daef3abc5c289465953fbe7b82", "class_name": "RelatedNodeInfo"}}, "text": "LLC \nEric W. Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n  ", "start_char_idx": 1207, "end_char_idx": 1272, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c94e8c4b-317a-49c0-a8e9-34204d6247f9": {"__data__": {"id_": "c94e8c4b-317a-49c0-a8e9-34204d6247f9", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Good day, and welcome to the McKesson Q1 Earnings Call.  Today's conference is being recorded.  \n \n At this time, I'd like to turn the conference over to Holly Weiss. ", "original_text": "McKesson Corp.  ", "page_label": "3", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "510e1ab1-9110-4db6-842c-2a73346ced15", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d0157eff77ad852371cbdffac150e7b96841650fa8206e3590e533a6d9217d48", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "afe63832-3b76-47a7-8870-b2fddf186363", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOTHER PARTICIPANTS  \n \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  \nRoss Muken  \nAnalyst, Evercore ISI  \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Eric Percher  \nAnalyst, Nephron Research LLC  \nBrian Gil Tanquilut  \nAnalyst, Jefferies LLC  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC \nEric W. Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n  ", "original_text": "LLC \nEric W. Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n  ", "page_label": "2", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f34a98a87bdb8837e9fe4b9cf3a2ac00e8a87f085d96dfbacd97f3d9a6adb42f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5f6b894a-10d3-4b4c-8aca-dcd10b821458", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Good day, and welcome to the McKesson Q1 Earnings Call.  Today's conference is being recorded.  \n \n At this time, I'd like to turn the conference over to Holly Weiss.  Please go ahead.  \n ", "original_text": "(MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Good day, and welcome to the McKesson Q1 Earnings Call. "}, "hash": "7c82d70f2b4fa5aebe9596989d35b5a4cb9cd14b3c18e507a8feb8bd4c53bf1e", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5f6b894a-10d3-4b4c-8aca-dcd10b821458": {"__data__": {"id_": "5f6b894a-10d3-4b4c-8aca-dcd10b821458", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Good day, and welcome to the McKesson Q1 Earnings Call.  Today's conference is being recorded.  \n \n At this time, I'd like to turn the conference over to Holly Weiss.  Please go ahead.  \n ", "original_text": "(MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Good day, and welcome to the McKesson Q1 Earnings Call. ", "page_label": "3", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "510e1ab1-9110-4db6-842c-2a73346ced15", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d0157eff77ad852371cbdffac150e7b96841650fa8206e3590e533a6d9217d48", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c94e8c4b-317a-49c0-a8e9-34204d6247f9", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Good day, and welcome to the McKesson Q1 Earnings Call.  Today's conference is being recorded.  \n \n At this time, I'd like to turn the conference over to Holly Weiss. ", "original_text": "McKesson Corp.  ", "page_label": "3", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5060935750eae594aff18e6da96bd4a8206b42ec0e60b210e187650b1614b563", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4a548413-05f6-466f-bbac-14ea5ca94e28", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Good day, and welcome to the McKesson Q1 Earnings Call.  Today's conference is being recorded.  \n \n At this time, I'd like to turn the conference over to Holly Weiss.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n", "original_text": "Today's conference is being recorded.  \n \n"}, "hash": "9e8ff2d906ddc67fc2ca447598ed469fa1782ef6df8d1cd83bd503434da4e8f6", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Good day, and welcome to the McKesson Q1 Earnings Call. ", "start_char_idx": 16, "end_char_idx": 284, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4a548413-05f6-466f-bbac-14ea5ca94e28": {"__data__": {"id_": "4a548413-05f6-466f-bbac-14ea5ca94e28", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Good day, and welcome to the McKesson Q1 Earnings Call.  Today's conference is being recorded.  \n \n At this time, I'd like to turn the conference over to Holly Weiss.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n", "original_text": "Today's conference is being recorded.  \n \n", "page_label": "3", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "510e1ab1-9110-4db6-842c-2a73346ced15", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d0157eff77ad852371cbdffac150e7b96841650fa8206e3590e533a6d9217d48", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5f6b894a-10d3-4b4c-8aca-dcd10b821458", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Good day, and welcome to the McKesson Q1 Earnings Call.  Today's conference is being recorded.  \n \n At this time, I'd like to turn the conference over to Holly Weiss.  Please go ahead.  \n ", "original_text": "(MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Good day, and welcome to the McKesson Q1 Earnings Call. ", "page_label": "3", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0983f3482e0a3ac3776293289d10f732b810466107b72b4f4a334a5551662c6c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a6d40933-9750-409c-ad15-988033bd0423", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Good day, and welcome to the McKesson Q1 Earnings Call.  Today's conference is being recorded.  \n \n At this time, I'd like to turn the conference over to Holly Weiss.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Thank you, Justine. ", "original_text": "At this time, I'd like to turn the conference over to Holly Weiss. "}, "hash": "7214823a9b96f737ce4f889941e529e860151281ddbc3e1801ae7c00fc7bc060", "class_name": "RelatedNodeInfo"}}, "text": "Today's conference is being recorded.  \n \n", "start_char_idx": 284, "end_char_idx": 326, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a6d40933-9750-409c-ad15-988033bd0423": {"__data__": {"id_": "a6d40933-9750-409c-ad15-988033bd0423", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Good day, and welcome to the McKesson Q1 Earnings Call.  Today's conference is being recorded.  \n \n At this time, I'd like to turn the conference over to Holly Weiss.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Thank you, Justine. ", "original_text": "At this time, I'd like to turn the conference over to Holly Weiss. ", "page_label": "3", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "510e1ab1-9110-4db6-842c-2a73346ced15", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d0157eff77ad852371cbdffac150e7b96841650fa8206e3590e533a6d9217d48", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4a548413-05f6-466f-bbac-14ea5ca94e28", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Good day, and welcome to the McKesson Q1 Earnings Call.  Today's conference is being recorded.  \n \n At this time, I'd like to turn the conference over to Holly Weiss.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n", "original_text": "Today's conference is being recorded.  \n \n", "page_label": "3", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "14d4912fcbdba2aa050c648688bca7dcebaba5e64d3474b72f86a1bdd436ba45", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "04b603d8-3aaa-4ddf-a1b4-dfdc70dee8af", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Good day, and welcome to the McKesson Q1 Earnings Call.  Today's conference is being recorded.  \n \n At this time, I'd like to turn the conference over to Holly Weiss.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Thank you, Justine.  Good afternoon, and welcome everyone to McKesson's first quarter fiscal 2020 earnings call. \n", "original_text": "Please go ahead.  \n "}, "hash": "88784c7a30977b1763b56723845fc6a05e270b1e5bf0e2d0b7d921b3ceba9bbc", "class_name": "RelatedNodeInfo"}}, "text": "At this time, I'd like to turn the conference over to Holly Weiss. ", "start_char_idx": 326, "end_char_idx": 393, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "04b603d8-3aaa-4ddf-a1b4-dfdc70dee8af": {"__data__": {"id_": "04b603d8-3aaa-4ddf-a1b4-dfdc70dee8af", "embedding": null, "metadata": {"window": "(MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Good day, and welcome to the McKesson Q1 Earnings Call.  Today's conference is being recorded.  \n \n At this time, I'd like to turn the conference over to Holly Weiss.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Thank you, Justine.  Good afternoon, and welcome everyone to McKesson's first quarter fiscal 2020 earnings call. \n", "original_text": "Please go ahead.  \n ", "page_label": "3", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "510e1ab1-9110-4db6-842c-2a73346ced15", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d0157eff77ad852371cbdffac150e7b96841650fa8206e3590e533a6d9217d48", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a6d40933-9750-409c-ad15-988033bd0423", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Good day, and welcome to the McKesson Q1 Earnings Call.  Today's conference is being recorded.  \n \n At this time, I'd like to turn the conference over to Holly Weiss.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Thank you, Justine. ", "original_text": "At this time, I'd like to turn the conference over to Holly Weiss. ", "page_label": "3", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1355e3d7f89f47c8980e750ba6faf34fb6e2ffef14551764a571d4f63f0a9ccd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6b4227af-0b0c-41f4-898f-5c90e3baebd5", "node_type": "1", "metadata": {"window": "Today's conference is being recorded.  \n \n At this time, I'd like to turn the conference over to Holly Weiss.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Thank you, Justine.  Good afternoon, and welcome everyone to McKesson's first quarter fiscal 2020 earnings call. \n Today I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n"}, "hash": "4ca0e3a4bc9345bd382c0d7b35af3d229714ba12a2507be76cbbb2c0e5252199", "class_name": "RelatedNodeInfo"}}, "text": "Please go ahead.  \n ", "start_char_idx": 393, "end_char_idx": 413, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6b4227af-0b0c-41f4-898f-5c90e3baebd5": {"__data__": {"id_": "6b4227af-0b0c-41f4-898f-5c90e3baebd5", "embedding": null, "metadata": {"window": "Today's conference is being recorded.  \n \n At this time, I'd like to turn the conference over to Holly Weiss.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Thank you, Justine.  Good afternoon, and welcome everyone to McKesson's first quarter fiscal 2020 earnings call. \n Today I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n", "page_label": "3", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "510e1ab1-9110-4db6-842c-2a73346ced15", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d0157eff77ad852371cbdffac150e7b96841650fa8206e3590e533a6d9217d48", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "04b603d8-3aaa-4ddf-a1b4-dfdc70dee8af", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Good day, and welcome to the McKesson Q1 Earnings Call.  Today's conference is being recorded.  \n \n At this time, I'd like to turn the conference over to Holly Weiss.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Thank you, Justine.  Good afternoon, and welcome everyone to McKesson's first quarter fiscal 2020 earnings call. \n", "original_text": "Please go ahead.  \n ", "page_label": "3", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cbec86cf827e783e6c251610d7be10acbfec6aaad67073d11f39a42d2bfe64cb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "65359aa5-d207-4662-b88e-38fcda29bbac", "node_type": "1", "metadata": {"window": "At this time, I'd like to turn the conference over to Holly Weiss.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Thank you, Justine.  Good afternoon, and welcome everyone to McKesson's first quarter fiscal 2020 earnings call. \n Today I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer.  Brian \nwill lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n", "original_text": "Thank you, Justine. "}, "hash": "ae47af7087ef750949c69829350daa62b59af8ad99a193c0adb0f1a85dce92b0", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n", "start_char_idx": 413, "end_char_idx": 744, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "65359aa5-d207-4662-b88e-38fcda29bbac": {"__data__": {"id_": "65359aa5-d207-4662-b88e-38fcda29bbac", "embedding": null, "metadata": {"window": "At this time, I'd like to turn the conference over to Holly Weiss.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Thank you, Justine.  Good afternoon, and welcome everyone to McKesson's first quarter fiscal 2020 earnings call. \n Today I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer.  Brian \nwill lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n", "original_text": "Thank you, Justine. ", "page_label": "3", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "510e1ab1-9110-4db6-842c-2a73346ced15", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d0157eff77ad852371cbdffac150e7b96841650fa8206e3590e533a6d9217d48", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6b4227af-0b0c-41f4-898f-5c90e3baebd5", "node_type": "1", "metadata": {"window": "Today's conference is being recorded.  \n \n At this time, I'd like to turn the conference over to Holly Weiss.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Thank you, Justine.  Good afternoon, and welcome everyone to McKesson's first quarter fiscal 2020 earnings call. \n Today I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n", "page_label": "3", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0d012ecbb99c54432880a7ca6d4cbc338f1a41ac189e6e48b9b491ee144d64cf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dbf544b8-b4b2-4f4e-8493-df208f552536", "node_type": "1", "metadata": {"window": "Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Thank you, Justine.  Good afternoon, and welcome everyone to McKesson's first quarter fiscal 2020 earnings call. \n Today I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer.  Brian \nwill lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements such as f orecasts about McKesson's operations and \nfuture results. ", "original_text": "Good afternoon, and welcome everyone to McKesson's first quarter fiscal 2020 earnings call. \n"}, "hash": "5a29055a84c4090f6feb8a79497851fe86ea425cc2f598d442edb5dbeb546efe", "class_name": "RelatedNodeInfo"}}, "text": "Thank you, Justine. ", "start_char_idx": 744, "end_char_idx": 764, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dbf544b8-b4b2-4f4e-8493-df208f552536": {"__data__": {"id_": "dbf544b8-b4b2-4f4e-8493-df208f552536", "embedding": null, "metadata": {"window": "Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Thank you, Justine.  Good afternoon, and welcome everyone to McKesson's first quarter fiscal 2020 earnings call. \n Today I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer.  Brian \nwill lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements such as f orecasts about McKesson's operations and \nfuture results. ", "original_text": "Good afternoon, and welcome everyone to McKesson's first quarter fiscal 2020 earnings call. \n", "page_label": "3", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "510e1ab1-9110-4db6-842c-2a73346ced15", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d0157eff77ad852371cbdffac150e7b96841650fa8206e3590e533a6d9217d48", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "65359aa5-d207-4662-b88e-38fcda29bbac", "node_type": "1", "metadata": {"window": "At this time, I'd like to turn the conference over to Holly Weiss.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Thank you, Justine.  Good afternoon, and welcome everyone to McKesson's first quarter fiscal 2020 earnings call. \n Today I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer.  Brian \nwill lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n", "original_text": "Thank you, Justine. ", "page_label": "3", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8c3f2c49cf36b69e21b4276e6bd3436c673154c0b2d825e10a9519e2204a8861", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3761d2ed-93be-42c2-8ab3-d6e17f14ab1f", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Thank you, Justine.  Good afternoon, and welcome everyone to McKesson's first quarter fiscal 2020 earnings call. \n Today I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer.  Brian \nwill lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements such as f orecasts about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's press release and our slide presentation and to \nthe Risk Factors section of our periodic SEC filings for additional information concerning risk fa ctors that could \ncause our actual results to materially differ from those in our forward -looking statements.  \n \n", "original_text": "Today I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. "}, "hash": "0661c0066963d0baad4119625f2eeafc514617ee07d17c8ca6f07441eb4a85bb", "class_name": "RelatedNodeInfo"}}, "text": "Good afternoon, and welcome everyone to McKesson's first quarter fiscal 2020 earnings call. \n", "start_char_idx": 764, "end_char_idx": 857, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3761d2ed-93be-42c2-8ab3-d6e17f14ab1f": {"__data__": {"id_": "3761d2ed-93be-42c2-8ab3-d6e17f14ab1f", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Thank you, Justine.  Good afternoon, and welcome everyone to McKesson's first quarter fiscal 2020 earnings call. \n Today I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer.  Brian \nwill lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements such as f orecasts about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's press release and our slide presentation and to \nthe Risk Factors section of our periodic SEC filings for additional information concerning risk fa ctors that could \ncause our actual results to materially differ from those in our forward -looking statements.  \n \n", "original_text": "Today I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. ", "page_label": "3", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "510e1ab1-9110-4db6-842c-2a73346ced15", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d0157eff77ad852371cbdffac150e7b96841650fa8206e3590e533a6d9217d48", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dbf544b8-b4b2-4f4e-8493-df208f552536", "node_type": "1", "metadata": {"window": "Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Thank you, Justine.  Good afternoon, and welcome everyone to McKesson's first quarter fiscal 2020 earnings call. \n Today I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer.  Brian \nwill lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements such as f orecasts about McKesson's operations and \nfuture results. ", "original_text": "Good afternoon, and welcome everyone to McKesson's first quarter fiscal 2020 earnings call. \n", "page_label": "3", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1bdeb2fa6f49df11c55fea1d8ac13efb92b1ee3ea98228e0965d7b300eac5417", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ddc62d7f-414d-432a-82a4-6e576ca8518d", "node_type": "1", "metadata": {"window": "Thank you, Justine.  Good afternoon, and welcome everyone to McKesson's first quarter fiscal 2020 earnings call. \n Today I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer.  Brian \nwill lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements such as f orecasts about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's press release and our slide presentation and to \nthe Risk Factors section of our periodic SEC filings for additional information concerning risk fa ctors that could \ncause our actual results to materially differ from those in our forward -looking statements.  \n \n During this call, we will discuss non -GAAP financial measures. ", "original_text": "Brian \nwill lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n"}, "hash": "b6972c1a6783fbd269fb7791fd05705d393c024bb2244dd8a68521e51f42a186", "class_name": "RelatedNodeInfo"}}, "text": "Today I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. ", "start_char_idx": 857, "end_char_idx": 968, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ddc62d7f-414d-432a-82a4-6e576ca8518d": {"__data__": {"id_": "ddc62d7f-414d-432a-82a4-6e576ca8518d", "embedding": null, "metadata": {"window": "Thank you, Justine.  Good afternoon, and welcome everyone to McKesson's first quarter fiscal 2020 earnings call. \n Today I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer.  Brian \nwill lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements such as f orecasts about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's press release and our slide presentation and to \nthe Risk Factors section of our periodic SEC filings for additional information concerning risk fa ctors that could \ncause our actual results to materially differ from those in our forward -looking statements.  \n \n During this call, we will discuss non -GAAP financial measures. ", "original_text": "Brian \nwill lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n", "page_label": "3", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "510e1ab1-9110-4db6-842c-2a73346ced15", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d0157eff77ad852371cbdffac150e7b96841650fa8206e3590e533a6d9217d48", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3761d2ed-93be-42c2-8ab3-d6e17f14ab1f", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Thank you, Justine.  Good afternoon, and welcome everyone to McKesson's first quarter fiscal 2020 earnings call. \n Today I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer.  Brian \nwill lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements such as f orecasts about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's press release and our slide presentation and to \nthe Risk Factors section of our periodic SEC filings for additional information concerning risk fa ctors that could \ncause our actual results to materially differ from those in our forward -looking statements.  \n \n", "original_text": "Today I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer. ", "page_label": "3", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f079b86f8c5773a30986217d4bed48507983585d61561a56e258022df4d7c7eb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6825a9c2-9943-45d3-8548-947c26484975", "node_type": "1", "metadata": {"window": "Good afternoon, and welcome everyone to McKesson's first quarter fiscal 2020 earnings call. \n Today I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer.  Brian \nwill lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements such as f orecasts about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's press release and our slide presentation and to \nthe Risk Factors section of our periodic SEC filings for additional information concerning risk fa ctors that could \ncause our actual results to materially differ from those in our forward -looking statements.  \n \n During this call, we will discuss non -GAAP financial measures.  Additional information about our non -GAAP \nfinancial measures including a reconcilia tion of those measures to GAAP results is included in today's press \nrelease and presentation slides which are available on our website at investor.mckesson.com.  \n \n", "original_text": "Today's discussion will include forward -looking statements such as f orecasts about McKesson's operations and \nfuture results. "}, "hash": "39dbe1fed3ca3af403f3137bc96c9bc3e727bca816d0590eb4ad3aaabb24d4e3", "class_name": "RelatedNodeInfo"}}, "text": "Brian \nwill lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n", "start_char_idx": 968, "end_char_idx": 1070, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6825a9c2-9943-45d3-8548-947c26484975": {"__data__": {"id_": "6825a9c2-9943-45d3-8548-947c26484975", "embedding": null, "metadata": {"window": "Good afternoon, and welcome everyone to McKesson's first quarter fiscal 2020 earnings call. \n Today I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer.  Brian \nwill lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements such as f orecasts about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's press release and our slide presentation and to \nthe Risk Factors section of our periodic SEC filings for additional information concerning risk fa ctors that could \ncause our actual results to materially differ from those in our forward -looking statements.  \n \n During this call, we will discuss non -GAAP financial measures.  Additional information about our non -GAAP \nfinancial measures including a reconcilia tion of those measures to GAAP results is included in today's press \nrelease and presentation slides which are available on our website at investor.mckesson.com.  \n \n", "original_text": "Today's discussion will include forward -looking statements such as f orecasts about McKesson's operations and \nfuture results. ", "page_label": "3", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "510e1ab1-9110-4db6-842c-2a73346ced15", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d0157eff77ad852371cbdffac150e7b96841650fa8206e3590e533a6d9217d48", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ddc62d7f-414d-432a-82a4-6e576ca8518d", "node_type": "1", "metadata": {"window": "Thank you, Justine.  Good afternoon, and welcome everyone to McKesson's first quarter fiscal 2020 earnings call. \n Today I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer.  Brian \nwill lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements such as f orecasts about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's press release and our slide presentation and to \nthe Risk Factors section of our periodic SEC filings for additional information concerning risk fa ctors that could \ncause our actual results to materially differ from those in our forward -looking statements.  \n \n During this call, we will discuss non -GAAP financial measures. ", "original_text": "Brian \nwill lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n", "page_label": "3", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c344d96678120a5edd0428de14792f32ad33e9751293e80b9c31607b3ba114b1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0ac50c5f-036f-4466-8f15-ec86b2ccf906", "node_type": "1", "metadata": {"window": "Today I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer.  Brian \nwill lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements such as f orecasts about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's press release and our slide presentation and to \nthe Risk Factors section of our periodic SEC filings for additional information concerning risk fa ctors that could \ncause our actual results to materially differ from those in our forward -looking statements.  \n \n During this call, we will discuss non -GAAP financial measures.  Additional information about our non -GAAP \nfinancial measures including a reconcilia tion of those measures to GAAP results is included in today's press \nrelease and presentation slides which are available on our website at investor.mckesson.com.  \n \n With that, let me turn it over the Brian.  \n ", "original_text": "Please refer to the cautionary statements in today's press release and our slide presentation and to \nthe Risk Factors section of our periodic SEC filings for additional information concerning risk fa ctors that could \ncause our actual results to materially differ from those in our forward -looking statements.  \n \n"}, "hash": "2c2a97b4ac0af033b4921e7955c513c937908b4972ab29563738dd929e65e5fa", "class_name": "RelatedNodeInfo"}}, "text": "Today's discussion will include forward -looking statements such as f orecasts about McKesson's operations and \nfuture results. ", "start_char_idx": 1070, "end_char_idx": 1198, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0ac50c5f-036f-4466-8f15-ec86b2ccf906": {"__data__": {"id_": "0ac50c5f-036f-4466-8f15-ec86b2ccf906", "embedding": null, "metadata": {"window": "Today I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer.  Brian \nwill lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements such as f orecasts about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's press release and our slide presentation and to \nthe Risk Factors section of our periodic SEC filings for additional information concerning risk fa ctors that could \ncause our actual results to materially differ from those in our forward -looking statements.  \n \n During this call, we will discuss non -GAAP financial measures.  Additional information about our non -GAAP \nfinancial measures including a reconcilia tion of those measures to GAAP results is included in today's press \nrelease and presentation slides which are available on our website at investor.mckesson.com.  \n \n With that, let me turn it over the Brian.  \n ", "original_text": "Please refer to the cautionary statements in today's press release and our slide presentation and to \nthe Risk Factors section of our periodic SEC filings for additional information concerning risk fa ctors that could \ncause our actual results to materially differ from those in our forward -looking statements.  \n \n", "page_label": "3", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "510e1ab1-9110-4db6-842c-2a73346ced15", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d0157eff77ad852371cbdffac150e7b96841650fa8206e3590e533a6d9217d48", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6825a9c2-9943-45d3-8548-947c26484975", "node_type": "1", "metadata": {"window": "Good afternoon, and welcome everyone to McKesson's first quarter fiscal 2020 earnings call. \n Today I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer.  Brian \nwill lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements such as f orecasts about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's press release and our slide presentation and to \nthe Risk Factors section of our periodic SEC filings for additional information concerning risk fa ctors that could \ncause our actual results to materially differ from those in our forward -looking statements.  \n \n During this call, we will discuss non -GAAP financial measures.  Additional information about our non -GAAP \nfinancial measures including a reconcilia tion of those measures to GAAP results is included in today's press \nrelease and presentation slides which are available on our website at investor.mckesson.com.  \n \n", "original_text": "Today's discussion will include forward -looking statements such as f orecasts about McKesson's operations and \nfuture results. ", "page_label": "3", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f3d87cec0879ee6b377a9fef25086faaa98d5a0a5d9f8a5d5eb8440cd5682c35", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f14b3c48-5f97-4c9d-9fb5-a3e8d35c4e3f", "node_type": "1", "metadata": {"window": "Brian \nwill lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements such as f orecasts about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's press release and our slide presentation and to \nthe Risk Factors section of our periodic SEC filings for additional information concerning risk fa ctors that could \ncause our actual results to materially differ from those in our forward -looking statements.  \n \n During this call, we will discuss non -GAAP financial measures.  Additional information about our non -GAAP \nfinancial measures including a reconcilia tion of those measures to GAAP results is included in today's press \nrelease and presentation slides which are available on our website at investor.mckesson.com.  \n \n With that, let me turn it over the Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Direct or, McKesson Corp.  \n", "original_text": "During this call, we will discuss non -GAAP financial measures. "}, "hash": "2276546ff45c4504e2517fd10931bda97af8f8e8dbbe30d6603b5e6ad1b0f87d", "class_name": "RelatedNodeInfo"}}, "text": "Please refer to the cautionary statements in today's press release and our slide presentation and to \nthe Risk Factors section of our periodic SEC filings for additional information concerning risk fa ctors that could \ncause our actual results to materially differ from those in our forward -looking statements.  \n \n", "start_char_idx": 1198, "end_char_idx": 1514, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f14b3c48-5f97-4c9d-9fb5-a3e8d35c4e3f": {"__data__": {"id_": "f14b3c48-5f97-4c9d-9fb5-a3e8d35c4e3f", "embedding": null, "metadata": {"window": "Brian \nwill lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements such as f orecasts about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's press release and our slide presentation and to \nthe Risk Factors section of our periodic SEC filings for additional information concerning risk fa ctors that could \ncause our actual results to materially differ from those in our forward -looking statements.  \n \n During this call, we will discuss non -GAAP financial measures.  Additional information about our non -GAAP \nfinancial measures including a reconcilia tion of those measures to GAAP results is included in today's press \nrelease and presentation slides which are available on our website at investor.mckesson.com.  \n \n With that, let me turn it over the Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Direct or, McKesson Corp.  \n", "original_text": "During this call, we will discuss non -GAAP financial measures. ", "page_label": "3", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "510e1ab1-9110-4db6-842c-2a73346ced15", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d0157eff77ad852371cbdffac150e7b96841650fa8206e3590e533a6d9217d48", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0ac50c5f-036f-4466-8f15-ec86b2ccf906", "node_type": "1", "metadata": {"window": "Today I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vitalone, our Chief Financial Officer.  Brian \nwill lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements such as f orecasts about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's press release and our slide presentation and to \nthe Risk Factors section of our periodic SEC filings for additional information concerning risk fa ctors that could \ncause our actual results to materially differ from those in our forward -looking statements.  \n \n During this call, we will discuss non -GAAP financial measures.  Additional information about our non -GAAP \nfinancial measures including a reconcilia tion of those measures to GAAP results is included in today's press \nrelease and presentation slides which are available on our website at investor.mckesson.com.  \n \n With that, let me turn it over the Brian.  \n ", "original_text": "Please refer to the cautionary statements in today's press release and our slide presentation and to \nthe Risk Factors section of our periodic SEC filings for additional information concerning risk fa ctors that could \ncause our actual results to materially differ from those in our forward -looking statements.  \n \n", "page_label": "3", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "34fe31135f8f083e37fa1fdd2e3201e7809d166fdd3a59a5f35e0276a8423eef", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "540ca450-1e83-42c3-a043-160f09e87f0c", "node_type": "1", "metadata": {"window": "Today's discussion will include forward -looking statements such as f orecasts about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's press release and our slide presentation and to \nthe Risk Factors section of our periodic SEC filings for additional information concerning risk fa ctors that could \ncause our actual results to materially differ from those in our forward -looking statements.  \n \n During this call, we will discuss non -GAAP financial measures.  Additional information about our non -GAAP \nfinancial measures including a reconcilia tion of those measures to GAAP results is included in today's press \nrelease and presentation slides which are available on our website at investor.mckesson.com.  \n \n With that, let me turn it over the Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Direct or, McKesson Corp.  \n Thank you, Holly, and thanks to everyone for joining us on our call today. ", "original_text": "Additional information about our non -GAAP \nfinancial measures including a reconcilia tion of those measures to GAAP results is included in today's press \nrelease and presentation slides which are available on our website at investor.mckesson.com.  \n \n"}, "hash": "7e4aebd75002615a35ecc094741ebe7d687b66305379ad4fdcc4e7c96ba871ae", "class_name": "RelatedNodeInfo"}}, "text": "During this call, we will discuss non -GAAP financial measures. ", "start_char_idx": 1514, "end_char_idx": 1578, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "540ca450-1e83-42c3-a043-160f09e87f0c": {"__data__": {"id_": "540ca450-1e83-42c3-a043-160f09e87f0c", "embedding": null, "metadata": {"window": "Today's discussion will include forward -looking statements such as f orecasts about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's press release and our slide presentation and to \nthe Risk Factors section of our periodic SEC filings for additional information concerning risk fa ctors that could \ncause our actual results to materially differ from those in our forward -looking statements.  \n \n During this call, we will discuss non -GAAP financial measures.  Additional information about our non -GAAP \nfinancial measures including a reconcilia tion of those measures to GAAP results is included in today's press \nrelease and presentation slides which are available on our website at investor.mckesson.com.  \n \n With that, let me turn it over the Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Direct or, McKesson Corp.  \n Thank you, Holly, and thanks to everyone for joining us on our call today. ", "original_text": "Additional information about our non -GAAP \nfinancial measures including a reconcilia tion of those measures to GAAP results is included in today's press \nrelease and presentation slides which are available on our website at investor.mckesson.com.  \n \n", "page_label": "3", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "510e1ab1-9110-4db6-842c-2a73346ced15", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d0157eff77ad852371cbdffac150e7b96841650fa8206e3590e533a6d9217d48", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f14b3c48-5f97-4c9d-9fb5-a3e8d35c4e3f", "node_type": "1", "metadata": {"window": "Brian \nwill lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements such as f orecasts about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's press release and our slide presentation and to \nthe Risk Factors section of our periodic SEC filings for additional information concerning risk fa ctors that could \ncause our actual results to materially differ from those in our forward -looking statements.  \n \n During this call, we will discuss non -GAAP financial measures.  Additional information about our non -GAAP \nfinancial measures including a reconcilia tion of those measures to GAAP results is included in today's press \nrelease and presentation slides which are available on our website at investor.mckesson.com.  \n \n With that, let me turn it over the Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Direct or, McKesson Corp.  \n", "original_text": "During this call, we will discuss non -GAAP financial measures. ", "page_label": "3", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "78ddc3fad70ddb5f6070766f52ee746f358e1bfc5f15646ae5ed62705f86301e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f2f3411f-2105-433d-8628-34b271d7b98e", "node_type": "1", "metadata": {"window": "Please refer to the cautionary statements in today's press release and our slide presentation and to \nthe Risk Factors section of our periodic SEC filings for additional information concerning risk fa ctors that could \ncause our actual results to materially differ from those in our forward -looking statements.  \n \n During this call, we will discuss non -GAAP financial measures.  Additional information about our non -GAAP \nfinancial measures including a reconcilia tion of those measures to GAAP results is included in today's press \nrelease and presentation slides which are available on our website at investor.mckesson.com.  \n \n With that, let me turn it over the Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Direct or, McKesson Corp.  \n Thank you, Holly, and thanks to everyone for joining us on our call today.  We're pleased today to be able to report \na strong start to our fiscal year 2020. ", "original_text": "With that, let me turn it over the Brian.  \n "}, "hash": "964521218140bb087054879db8c80ad4d437b787043d069bd6a89c4168aca45f", "class_name": "RelatedNodeInfo"}}, "text": "Additional information about our non -GAAP \nfinancial measures including a reconcilia tion of those measures to GAAP results is included in today's press \nrelease and presentation slides which are available on our website at investor.mckesson.com.  \n \n", "start_char_idx": 1578, "end_char_idx": 1830, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f2f3411f-2105-433d-8628-34b271d7b98e": {"__data__": {"id_": "f2f3411f-2105-433d-8628-34b271d7b98e", "embedding": null, "metadata": {"window": "Please refer to the cautionary statements in today's press release and our slide presentation and to \nthe Risk Factors section of our periodic SEC filings for additional information concerning risk fa ctors that could \ncause our actual results to materially differ from those in our forward -looking statements.  \n \n During this call, we will discuss non -GAAP financial measures.  Additional information about our non -GAAP \nfinancial measures including a reconcilia tion of those measures to GAAP results is included in today's press \nrelease and presentation slides which are available on our website at investor.mckesson.com.  \n \n With that, let me turn it over the Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Direct or, McKesson Corp.  \n Thank you, Holly, and thanks to everyone for joining us on our call today.  We're pleased today to be able to report \na strong start to our fiscal year 2020. ", "original_text": "With that, let me turn it over the Brian.  \n ", "page_label": "3", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "510e1ab1-9110-4db6-842c-2a73346ced15", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d0157eff77ad852371cbdffac150e7b96841650fa8206e3590e533a6d9217d48", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "540ca450-1e83-42c3-a043-160f09e87f0c", "node_type": "1", "metadata": {"window": "Today's discussion will include forward -looking statements such as f orecasts about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's press release and our slide presentation and to \nthe Risk Factors section of our periodic SEC filings for additional information concerning risk fa ctors that could \ncause our actual results to materially differ from those in our forward -looking statements.  \n \n During this call, we will discuss non -GAAP financial measures.  Additional information about our non -GAAP \nfinancial measures including a reconcilia tion of those measures to GAAP results is included in today's press \nrelease and presentation slides which are available on our website at investor.mckesson.com.  \n \n With that, let me turn it over the Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Direct or, McKesson Corp.  \n Thank you, Holly, and thanks to everyone for joining us on our call today. ", "original_text": "Additional information about our non -GAAP \nfinancial measures including a reconcilia tion of those measures to GAAP results is included in today's press \nrelease and presentation slides which are available on our website at investor.mckesson.com.  \n \n", "page_label": "3", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b599738eb3d3e24dbcfaebcd6a46f24e44d457f56c11e36d18dcbebc27570f62", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "845d54cc-a4b7-436a-b879-d5a0c34075b3", "node_type": "1", "metadata": {"window": "During this call, we will discuss non -GAAP financial measures.  Additional information about our non -GAAP \nfinancial measures including a reconcilia tion of those measures to GAAP results is included in today's press \nrelease and presentation slides which are available on our website at investor.mckesson.com.  \n \n With that, let me turn it over the Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Direct or, McKesson Corp.  \n Thank you, Holly, and thanks to everyone for joining us on our call today.  We're pleased today to be able to report \na strong start to our fiscal year 2020.  For the first quarter, we achieved total company revenues in excess of $55 \nbillion and adjusted earnings per diluted share of $3.31, ahead of our original expectations. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Direct or, McKesson Corp.  \n"}, "hash": "97c3392ac02a41c9fd2fbb890bc6efd201b36d33c4a7842eb01aa49c42f25c5c", "class_name": "RelatedNodeInfo"}}, "text": "With that, let me turn it over the Brian.  \n ", "start_char_idx": 1830, "end_char_idx": 1875, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "845d54cc-a4b7-436a-b879-d5a0c34075b3": {"__data__": {"id_": "845d54cc-a4b7-436a-b879-d5a0c34075b3", "embedding": null, "metadata": {"window": "During this call, we will discuss non -GAAP financial measures.  Additional information about our non -GAAP \nfinancial measures including a reconcilia tion of those measures to GAAP results is included in today's press \nrelease and presentation slides which are available on our website at investor.mckesson.com.  \n \n With that, let me turn it over the Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Direct or, McKesson Corp.  \n Thank you, Holly, and thanks to everyone for joining us on our call today.  We're pleased today to be able to report \na strong start to our fiscal year 2020.  For the first quarter, we achieved total company revenues in excess of $55 \nbillion and adjusted earnings per diluted share of $3.31, ahead of our original expectations. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Direct or, McKesson Corp.  \n", "page_label": "3", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "510e1ab1-9110-4db6-842c-2a73346ced15", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d0157eff77ad852371cbdffac150e7b96841650fa8206e3590e533a6d9217d48", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f2f3411f-2105-433d-8628-34b271d7b98e", "node_type": "1", "metadata": {"window": "Please refer to the cautionary statements in today's press release and our slide presentation and to \nthe Risk Factors section of our periodic SEC filings for additional information concerning risk fa ctors that could \ncause our actual results to materially differ from those in our forward -looking statements.  \n \n During this call, we will discuss non -GAAP financial measures.  Additional information about our non -GAAP \nfinancial measures including a reconcilia tion of those measures to GAAP results is included in today's press \nrelease and presentation slides which are available on our website at investor.mckesson.com.  \n \n With that, let me turn it over the Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Direct or, McKesson Corp.  \n Thank you, Holly, and thanks to everyone for joining us on our call today.  We're pleased today to be able to report \na strong start to our fiscal year 2020. ", "original_text": "With that, let me turn it over the Brian.  \n ", "page_label": "3", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ea0d5024594c52c02a0a1297d1efc1fa08535ea0f62f3eab7ec20fcace6e8224", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2ea94fe1-e35b-4702-b7b8-6053495abbd8", "node_type": "1", "metadata": {"window": "Additional information about our non -GAAP \nfinancial measures including a reconcilia tion of those measures to GAAP results is included in today's press \nrelease and presentation slides which are available on our website at investor.mckesson.com.  \n \n With that, let me turn it over the Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Direct or, McKesson Corp.  \n Thank you, Holly, and thanks to everyone for joining us on our call today.  We're pleased today to be able to report \na strong start to our fiscal year 2020.  For the first quarter, we achieved total company revenues in excess of $55 \nbillion and adjusted earnings per diluted share of $3.31, ahead of our original expectations.  On our fourth quarter \ncall in May, I discussed that we were entering the fiscal year with positive momentum and I feel really good about \nthis underpinning our first qu arter results.  \n \n", "original_text": "Thank you, Holly, and thanks to everyone for joining us on our call today. "}, "hash": "0a6143053df0c3e6f1be7fb0da7be989e5e1779afda5e64ac16bd402b12b8d32", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Direct or, McKesson Corp.  \n", "start_char_idx": 1875, "end_char_idx": 2206, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2ea94fe1-e35b-4702-b7b8-6053495abbd8": {"__data__": {"id_": "2ea94fe1-e35b-4702-b7b8-6053495abbd8", "embedding": null, "metadata": {"window": "Additional information about our non -GAAP \nfinancial measures including a reconcilia tion of those measures to GAAP results is included in today's press \nrelease and presentation slides which are available on our website at investor.mckesson.com.  \n \n With that, let me turn it over the Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Direct or, McKesson Corp.  \n Thank you, Holly, and thanks to everyone for joining us on our call today.  We're pleased today to be able to report \na strong start to our fiscal year 2020.  For the first quarter, we achieved total company revenues in excess of $55 \nbillion and adjusted earnings per diluted share of $3.31, ahead of our original expectations.  On our fourth quarter \ncall in May, I discussed that we were entering the fiscal year with positive momentum and I feel really good about \nthis underpinning our first qu arter results.  \n \n", "original_text": "Thank you, Holly, and thanks to everyone for joining us on our call today. ", "page_label": "3", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "510e1ab1-9110-4db6-842c-2a73346ced15", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d0157eff77ad852371cbdffac150e7b96841650fa8206e3590e533a6d9217d48", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "845d54cc-a4b7-436a-b879-d5a0c34075b3", "node_type": "1", "metadata": {"window": "During this call, we will discuss non -GAAP financial measures.  Additional information about our non -GAAP \nfinancial measures including a reconcilia tion of those measures to GAAP results is included in today's press \nrelease and presentation slides which are available on our website at investor.mckesson.com.  \n \n With that, let me turn it over the Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Direct or, McKesson Corp.  \n Thank you, Holly, and thanks to everyone for joining us on our call today.  We're pleased today to be able to report \na strong start to our fiscal year 2020.  For the first quarter, we achieved total company revenues in excess of $55 \nbillion and adjusted earnings per diluted share of $3.31, ahead of our original expectations. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Direct or, McKesson Corp.  \n", "page_label": "3", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1675f4102396583c0ffc83ed2ca1ea5bd13bf8b299f9cebf0a381f51642587af", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a5aa0458-4fd8-443a-9b71-02263ec53191", "node_type": "1", "metadata": {"window": "With that, let me turn it over the Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Direct or, McKesson Corp.  \n Thank you, Holly, and thanks to everyone for joining us on our call today.  We're pleased today to be able to report \na strong start to our fiscal year 2020.  For the first quarter, we achieved total company revenues in excess of $55 \nbillion and adjusted earnings per diluted share of $3.31, ahead of our original expectations.  On our fourth quarter \ncall in May, I discussed that we were entering the fiscal year with positive momentum and I feel really good about \nthis underpinning our first qu arter results.  \n \n We're seeing healthy growth across many parts of our business, which is a direct result of the actions we have \nbeen and are taking to execute on our strategic imperatives, which are enabling us to become a more focused \nand efficient company . ", "original_text": "We're pleased today to be able to report \na strong start to our fiscal year 2020. "}, "hash": "1564389e236bf697f70d8cc29d40e3e679380b57d6371388c3a24c6c41b3bae5", "class_name": "RelatedNodeInfo"}}, "text": "Thank you, Holly, and thanks to everyone for joining us on our call today. ", "start_char_idx": 2206, "end_char_idx": 2281, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a5aa0458-4fd8-443a-9b71-02263ec53191": {"__data__": {"id_": "a5aa0458-4fd8-443a-9b71-02263ec53191", "embedding": null, "metadata": {"window": "With that, let me turn it over the Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Direct or, McKesson Corp.  \n Thank you, Holly, and thanks to everyone for joining us on our call today.  We're pleased today to be able to report \na strong start to our fiscal year 2020.  For the first quarter, we achieved total company revenues in excess of $55 \nbillion and adjusted earnings per diluted share of $3.31, ahead of our original expectations.  On our fourth quarter \ncall in May, I discussed that we were entering the fiscal year with positive momentum and I feel really good about \nthis underpinning our first qu arter results.  \n \n We're seeing healthy growth across many parts of our business, which is a direct result of the actions we have \nbeen and are taking to execute on our strategic imperatives, which are enabling us to become a more focused \nand efficient company . ", "original_text": "We're pleased today to be able to report \na strong start to our fiscal year 2020. ", "page_label": "3", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "510e1ab1-9110-4db6-842c-2a73346ced15", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d0157eff77ad852371cbdffac150e7b96841650fa8206e3590e533a6d9217d48", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2ea94fe1-e35b-4702-b7b8-6053495abbd8", "node_type": "1", "metadata": {"window": "Additional information about our non -GAAP \nfinancial measures including a reconcilia tion of those measures to GAAP results is included in today's press \nrelease and presentation slides which are available on our website at investor.mckesson.com.  \n \n With that, let me turn it over the Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Direct or, McKesson Corp.  \n Thank you, Holly, and thanks to everyone for joining us on our call today.  We're pleased today to be able to report \na strong start to our fiscal year 2020.  For the first quarter, we achieved total company revenues in excess of $55 \nbillion and adjusted earnings per diluted share of $3.31, ahead of our original expectations.  On our fourth quarter \ncall in May, I discussed that we were entering the fiscal year with positive momentum and I feel really good about \nthis underpinning our first qu arter results.  \n \n", "original_text": "Thank you, Holly, and thanks to everyone for joining us on our call today. ", "page_label": "3", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5afa54095b0863314641ce0d81f0518f72a7697597103b96a4ffe57ed466b4ae", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "703cece9-a1a1-4c14-b3c0-18d2342a6dd5", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Direct or, McKesson Corp.  \n Thank you, Holly, and thanks to everyone for joining us on our call today.  We're pleased today to be able to report \na strong start to our fiscal year 2020.  For the first quarter, we achieved total company revenues in excess of $55 \nbillion and adjusted earnings per diluted share of $3.31, ahead of our original expectations.  On our fourth quarter \ncall in May, I discussed that we were entering the fiscal year with positive momentum and I feel really good about \nthis underpinning our first qu arter results.  \n \n We're seeing healthy growth across many parts of our business, which is a direct result of the actions we have \nbeen and are taking to execute on our strategic imperatives, which are enabling us to become a more focused \nand efficient company .  And our balance sheet remained strong, giving us the flexibility to deploy capital that can \ndifferentiate McKesson and create shareholder value. ", "original_text": "For the first quarter, we achieved total company revenues in excess of $55 \nbillion and adjusted earnings per diluted share of $3.31, ahead of our original expectations. "}, "hash": "e35b5e688d876f0b6599a868c990451cfe3f8a41842671a226806489cd6a8762", "class_name": "RelatedNodeInfo"}}, "text": "We're pleased today to be able to report \na strong start to our fiscal year 2020. ", "start_char_idx": 2281, "end_char_idx": 2363, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "703cece9-a1a1-4c14-b3c0-18d2342a6dd5": {"__data__": {"id_": "703cece9-a1a1-4c14-b3c0-18d2342a6dd5", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Direct or, McKesson Corp.  \n Thank you, Holly, and thanks to everyone for joining us on our call today.  We're pleased today to be able to report \na strong start to our fiscal year 2020.  For the first quarter, we achieved total company revenues in excess of $55 \nbillion and adjusted earnings per diluted share of $3.31, ahead of our original expectations.  On our fourth quarter \ncall in May, I discussed that we were entering the fiscal year with positive momentum and I feel really good about \nthis underpinning our first qu arter results.  \n \n We're seeing healthy growth across many parts of our business, which is a direct result of the actions we have \nbeen and are taking to execute on our strategic imperatives, which are enabling us to become a more focused \nand efficient company .  And our balance sheet remained strong, giving us the flexibility to deploy capital that can \ndifferentiate McKesson and create shareholder value. ", "original_text": "For the first quarter, we achieved total company revenues in excess of $55 \nbillion and adjusted earnings per diluted share of $3.31, ahead of our original expectations. ", "page_label": "3", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "510e1ab1-9110-4db6-842c-2a73346ced15", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d0157eff77ad852371cbdffac150e7b96841650fa8206e3590e533a6d9217d48", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a5aa0458-4fd8-443a-9b71-02263ec53191", "node_type": "1", "metadata": {"window": "With that, let me turn it over the Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Direct or, McKesson Corp.  \n Thank you, Holly, and thanks to everyone for joining us on our call today.  We're pleased today to be able to report \na strong start to our fiscal year 2020.  For the first quarter, we achieved total company revenues in excess of $55 \nbillion and adjusted earnings per diluted share of $3.31, ahead of our original expectations.  On our fourth quarter \ncall in May, I discussed that we were entering the fiscal year with positive momentum and I feel really good about \nthis underpinning our first qu arter results.  \n \n We're seeing healthy growth across many parts of our business, which is a direct result of the actions we have \nbeen and are taking to execute on our strategic imperatives, which are enabling us to become a more focused \nand efficient company . ", "original_text": "We're pleased today to be able to report \na strong start to our fiscal year 2020. ", "page_label": "3", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b43c7609b931f663171e35fb1fb031aecb29a6e6622d8d1b685903729f1bbf1f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3839b9ce-9e53-40fa-ba33-5477fdc60ef3", "node_type": "1", "metadata": {"window": "Thank you, Holly, and thanks to everyone for joining us on our call today.  We're pleased today to be able to report \na strong start to our fiscal year 2020.  For the first quarter, we achieved total company revenues in excess of $55 \nbillion and adjusted earnings per diluted share of $3.31, ahead of our original expectations.  On our fourth quarter \ncall in May, I discussed that we were entering the fiscal year with positive momentum and I feel really good about \nthis underpinning our first qu arter results.  \n \n We're seeing healthy growth across many parts of our business, which is a direct result of the actions we have \nbeen and are taking to execute on our strategic imperatives, which are enabling us to become a more focused \nand efficient company .  And our balance sheet remained strong, giving us the flexibility to deploy capital that can \ndifferentiate McKesson and create shareholder value.  As a result of our first quarter performance, combined with \nour confidence in the business as we look ahead, we're raising our fiscal 2020 adjusted EPS guidance range of \n$14.00 to $14.60. ", "original_text": "On our fourth quarter \ncall in May, I discussed that we were entering the fiscal year with positive momentum and I feel really good about \nthis underpinning our first qu arter results.  \n \n"}, "hash": "a6c1b4c35d9f2a9abeced3e19d3ffa5dfdfd4b48bb1be991efa2eb66edf9531a", "class_name": "RelatedNodeInfo"}}, "text": "For the first quarter, we achieved total company revenues in excess of $55 \nbillion and adjusted earnings per diluted share of $3.31, ahead of our original expectations. ", "start_char_idx": 2363, "end_char_idx": 2533, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3839b9ce-9e53-40fa-ba33-5477fdc60ef3": {"__data__": {"id_": "3839b9ce-9e53-40fa-ba33-5477fdc60ef3", "embedding": null, "metadata": {"window": "Thank you, Holly, and thanks to everyone for joining us on our call today.  We're pleased today to be able to report \na strong start to our fiscal year 2020.  For the first quarter, we achieved total company revenues in excess of $55 \nbillion and adjusted earnings per diluted share of $3.31, ahead of our original expectations.  On our fourth quarter \ncall in May, I discussed that we were entering the fiscal year with positive momentum and I feel really good about \nthis underpinning our first qu arter results.  \n \n We're seeing healthy growth across many parts of our business, which is a direct result of the actions we have \nbeen and are taking to execute on our strategic imperatives, which are enabling us to become a more focused \nand efficient company .  And our balance sheet remained strong, giving us the flexibility to deploy capital that can \ndifferentiate McKesson and create shareholder value.  As a result of our first quarter performance, combined with \nour confidence in the business as we look ahead, we're raising our fiscal 2020 adjusted EPS guidance range of \n$14.00 to $14.60. ", "original_text": "On our fourth quarter \ncall in May, I discussed that we were entering the fiscal year with positive momentum and I feel really good about \nthis underpinning our first qu arter results.  \n \n", "page_label": "3", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "510e1ab1-9110-4db6-842c-2a73346ced15", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d0157eff77ad852371cbdffac150e7b96841650fa8206e3590e533a6d9217d48", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "703cece9-a1a1-4c14-b3c0-18d2342a6dd5", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Direct or, McKesson Corp.  \n Thank you, Holly, and thanks to everyone for joining us on our call today.  We're pleased today to be able to report \na strong start to our fiscal year 2020.  For the first quarter, we achieved total company revenues in excess of $55 \nbillion and adjusted earnings per diluted share of $3.31, ahead of our original expectations.  On our fourth quarter \ncall in May, I discussed that we were entering the fiscal year with positive momentum and I feel really good about \nthis underpinning our first qu arter results.  \n \n We're seeing healthy growth across many parts of our business, which is a direct result of the actions we have \nbeen and are taking to execute on our strategic imperatives, which are enabling us to become a more focused \nand efficient company .  And our balance sheet remained strong, giving us the flexibility to deploy capital that can \ndifferentiate McKesson and create shareholder value. ", "original_text": "For the first quarter, we achieved total company revenues in excess of $55 \nbillion and adjusted earnings per diluted share of $3.31, ahead of our original expectations. ", "page_label": "3", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f4dcc7c221a3759f757ecca55651673e15532f16e08d70adfa30a741f36d580d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7a530be8-360f-486a-9fcc-85e479f7dd3b", "node_type": "1", "metadata": {"window": "We're pleased today to be able to report \na strong start to our fiscal year 2020.  For the first quarter, we achieved total company revenues in excess of $55 \nbillion and adjusted earnings per diluted share of $3.31, ahead of our original expectations.  On our fourth quarter \ncall in May, I discussed that we were entering the fiscal year with positive momentum and I feel really good about \nthis underpinning our first qu arter results.  \n \n We're seeing healthy growth across many parts of our business, which is a direct result of the actions we have \nbeen and are taking to execute on our strategic imperatives, which are enabling us to become a more focused \nand efficient company .  And our balance sheet remained strong, giving us the flexibility to deploy capital that can \ndifferentiate McKesson and create shareholder value.  As a result of our first quarter performance, combined with \nour confidence in the business as we look ahead, we're raising our fiscal 2020 adjusted EPS guidance range of \n$14.00 to $14.60.  This is from our previous range of $13.85 to $14.45.  \n \n", "original_text": "We're seeing healthy growth across many parts of our business, which is a direct result of the actions we have \nbeen and are taking to execute on our strategic imperatives, which are enabling us to become a more focused \nand efficient company . "}, "hash": "0332ca7da9507f2360773c3a4ec465fd774aaa3a4ea634a39c03b27097e90f42", "class_name": "RelatedNodeInfo"}}, "text": "On our fourth quarter \ncall in May, I discussed that we were entering the fiscal year with positive momentum and I feel really good about \nthis underpinning our first qu arter results.  \n \n", "start_char_idx": 2533, "end_char_idx": 2722, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7a530be8-360f-486a-9fcc-85e479f7dd3b": {"__data__": {"id_": "7a530be8-360f-486a-9fcc-85e479f7dd3b", "embedding": null, "metadata": {"window": "We're pleased today to be able to report \na strong start to our fiscal year 2020.  For the first quarter, we achieved total company revenues in excess of $55 \nbillion and adjusted earnings per diluted share of $3.31, ahead of our original expectations.  On our fourth quarter \ncall in May, I discussed that we were entering the fiscal year with positive momentum and I feel really good about \nthis underpinning our first qu arter results.  \n \n We're seeing healthy growth across many parts of our business, which is a direct result of the actions we have \nbeen and are taking to execute on our strategic imperatives, which are enabling us to become a more focused \nand efficient company .  And our balance sheet remained strong, giving us the flexibility to deploy capital that can \ndifferentiate McKesson and create shareholder value.  As a result of our first quarter performance, combined with \nour confidence in the business as we look ahead, we're raising our fiscal 2020 adjusted EPS guidance range of \n$14.00 to $14.60.  This is from our previous range of $13.85 to $14.45.  \n \n", "original_text": "We're seeing healthy growth across many parts of our business, which is a direct result of the actions we have \nbeen and are taking to execute on our strategic imperatives, which are enabling us to become a more focused \nand efficient company . ", "page_label": "3", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "510e1ab1-9110-4db6-842c-2a73346ced15", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d0157eff77ad852371cbdffac150e7b96841650fa8206e3590e533a6d9217d48", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3839b9ce-9e53-40fa-ba33-5477fdc60ef3", "node_type": "1", "metadata": {"window": "Thank you, Holly, and thanks to everyone for joining us on our call today.  We're pleased today to be able to report \na strong start to our fiscal year 2020.  For the first quarter, we achieved total company revenues in excess of $55 \nbillion and adjusted earnings per diluted share of $3.31, ahead of our original expectations.  On our fourth quarter \ncall in May, I discussed that we were entering the fiscal year with positive momentum and I feel really good about \nthis underpinning our first qu arter results.  \n \n We're seeing healthy growth across many parts of our business, which is a direct result of the actions we have \nbeen and are taking to execute on our strategic imperatives, which are enabling us to become a more focused \nand efficient company .  And our balance sheet remained strong, giving us the flexibility to deploy capital that can \ndifferentiate McKesson and create shareholder value.  As a result of our first quarter performance, combined with \nour confidence in the business as we look ahead, we're raising our fiscal 2020 adjusted EPS guidance range of \n$14.00 to $14.60. ", "original_text": "On our fourth quarter \ncall in May, I discussed that we were entering the fiscal year with positive momentum and I feel really good about \nthis underpinning our first qu arter results.  \n \n", "page_label": "3", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a7e5dba542c8e91de86158e77e83f9653e1f71110c68b8b18c534286c401dc9a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b79b7c91-e179-48c8-a243-9e50dc60b8af", "node_type": "1", "metadata": {"window": "For the first quarter, we achieved total company revenues in excess of $55 \nbillion and adjusted earnings per diluted share of $3.31, ahead of our original expectations.  On our fourth quarter \ncall in May, I discussed that we were entering the fiscal year with positive momentum and I feel really good about \nthis underpinning our first qu arter results.  \n \n We're seeing healthy growth across many parts of our business, which is a direct result of the actions we have \nbeen and are taking to execute on our strategic imperatives, which are enabling us to become a more focused \nand efficient company .  And our balance sheet remained strong, giving us the flexibility to deploy capital that can \ndifferentiate McKesson and create shareholder value.  As a result of our first quarter performance, combined with \nour confidence in the business as we look ahead, we're raising our fiscal 2020 adjusted EPS guidance range of \n$14.00 to $14.60.  This is from our previous range of $13.85 to $14.45.  \n \n Now, turning to the business. ", "original_text": "And our balance sheet remained strong, giving us the flexibility to deploy capital that can \ndifferentiate McKesson and create shareholder value. "}, "hash": "d8e569b9dc24924fc4b7c1ddad5ecdab8ee4628df2f6029e8981b2a2c3fbcb42", "class_name": "RelatedNodeInfo"}}, "text": "We're seeing healthy growth across many parts of our business, which is a direct result of the actions we have \nbeen and are taking to execute on our strategic imperatives, which are enabling us to become a more focused \nand efficient company . ", "start_char_idx": 2722, "end_char_idx": 2967, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b79b7c91-e179-48c8-a243-9e50dc60b8af": {"__data__": {"id_": "b79b7c91-e179-48c8-a243-9e50dc60b8af", "embedding": null, "metadata": {"window": "For the first quarter, we achieved total company revenues in excess of $55 \nbillion and adjusted earnings per diluted share of $3.31, ahead of our original expectations.  On our fourth quarter \ncall in May, I discussed that we were entering the fiscal year with positive momentum and I feel really good about \nthis underpinning our first qu arter results.  \n \n We're seeing healthy growth across many parts of our business, which is a direct result of the actions we have \nbeen and are taking to execute on our strategic imperatives, which are enabling us to become a more focused \nand efficient company .  And our balance sheet remained strong, giving us the flexibility to deploy capital that can \ndifferentiate McKesson and create shareholder value.  As a result of our first quarter performance, combined with \nour confidence in the business as we look ahead, we're raising our fiscal 2020 adjusted EPS guidance range of \n$14.00 to $14.60.  This is from our previous range of $13.85 to $14.45.  \n \n Now, turning to the business. ", "original_text": "And our balance sheet remained strong, giving us the flexibility to deploy capital that can \ndifferentiate McKesson and create shareholder value. ", "page_label": "3", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "510e1ab1-9110-4db6-842c-2a73346ced15", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d0157eff77ad852371cbdffac150e7b96841650fa8206e3590e533a6d9217d48", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7a530be8-360f-486a-9fcc-85e479f7dd3b", "node_type": "1", "metadata": {"window": "We're pleased today to be able to report \na strong start to our fiscal year 2020.  For the first quarter, we achieved total company revenues in excess of $55 \nbillion and adjusted earnings per diluted share of $3.31, ahead of our original expectations.  On our fourth quarter \ncall in May, I discussed that we were entering the fiscal year with positive momentum and I feel really good about \nthis underpinning our first qu arter results.  \n \n We're seeing healthy growth across many parts of our business, which is a direct result of the actions we have \nbeen and are taking to execute on our strategic imperatives, which are enabling us to become a more focused \nand efficient company .  And our balance sheet remained strong, giving us the flexibility to deploy capital that can \ndifferentiate McKesson and create shareholder value.  As a result of our first quarter performance, combined with \nour confidence in the business as we look ahead, we're raising our fiscal 2020 adjusted EPS guidance range of \n$14.00 to $14.60.  This is from our previous range of $13.85 to $14.45.  \n \n", "original_text": "We're seeing healthy growth across many parts of our business, which is a direct result of the actions we have \nbeen and are taking to execute on our strategic imperatives, which are enabling us to become a more focused \nand efficient company . ", "page_label": "3", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dd45261b197361c9f8d1a8717d8f8842e3efad83ff523927e65e5b1b5ef041ea", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0f3a01b7-e381-4705-a971-cb610e1b0e43", "node_type": "1", "metadata": {"window": "On our fourth quarter \ncall in May, I discussed that we were entering the fiscal year with positive momentum and I feel really good about \nthis underpinning our first qu arter results.  \n \n We're seeing healthy growth across many parts of our business, which is a direct result of the actions we have \nbeen and are taking to execute on our strategic imperatives, which are enabling us to become a more focused \nand efficient company .  And our balance sheet remained strong, giving us the flexibility to deploy capital that can \ndifferentiate McKesson and create shareholder value.  As a result of our first quarter performance, combined with \nour confidence in the business as we look ahead, we're raising our fiscal 2020 adjusted EPS guidance range of \n$14.00 to $14.60.  This is from our previous range of $13.85 to $14.45.  \n \n Now, turning to the business.  I'll summarize our first quarter results and then turn the call over to Britt to elaborate. \n", "original_text": "As a result of our first quarter performance, combined with \nour confidence in the business as we look ahead, we're raising our fiscal 2020 adjusted EPS guidance range of \n$14.00 to $14.60. "}, "hash": "cfb78fe575df4b3ac3fa617673e440f8557971cd6d0667a8ba6d8e2ef04c4254", "class_name": "RelatedNodeInfo"}}, "text": "And our balance sheet remained strong, giving us the flexibility to deploy capital that can \ndifferentiate McKesson and create shareholder value. ", "start_char_idx": 2967, "end_char_idx": 3113, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0f3a01b7-e381-4705-a971-cb610e1b0e43": {"__data__": {"id_": "0f3a01b7-e381-4705-a971-cb610e1b0e43", "embedding": null, "metadata": {"window": "On our fourth quarter \ncall in May, I discussed that we were entering the fiscal year with positive momentum and I feel really good about \nthis underpinning our first qu arter results.  \n \n We're seeing healthy growth across many parts of our business, which is a direct result of the actions we have \nbeen and are taking to execute on our strategic imperatives, which are enabling us to become a more focused \nand efficient company .  And our balance sheet remained strong, giving us the flexibility to deploy capital that can \ndifferentiate McKesson and create shareholder value.  As a result of our first quarter performance, combined with \nour confidence in the business as we look ahead, we're raising our fiscal 2020 adjusted EPS guidance range of \n$14.00 to $14.60.  This is from our previous range of $13.85 to $14.45.  \n \n Now, turning to the business.  I'll summarize our first quarter results and then turn the call over to Britt to elaborate. \n", "original_text": "As a result of our first quarter performance, combined with \nour confidence in the business as we look ahead, we're raising our fiscal 2020 adjusted EPS guidance range of \n$14.00 to $14.60. ", "page_label": "3", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "510e1ab1-9110-4db6-842c-2a73346ced15", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d0157eff77ad852371cbdffac150e7b96841650fa8206e3590e533a6d9217d48", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b79b7c91-e179-48c8-a243-9e50dc60b8af", "node_type": "1", "metadata": {"window": "For the first quarter, we achieved total company revenues in excess of $55 \nbillion and adjusted earnings per diluted share of $3.31, ahead of our original expectations.  On our fourth quarter \ncall in May, I discussed that we were entering the fiscal year with positive momentum and I feel really good about \nthis underpinning our first qu arter results.  \n \n We're seeing healthy growth across many parts of our business, which is a direct result of the actions we have \nbeen and are taking to execute on our strategic imperatives, which are enabling us to become a more focused \nand efficient company .  And our balance sheet remained strong, giving us the flexibility to deploy capital that can \ndifferentiate McKesson and create shareholder value.  As a result of our first quarter performance, combined with \nour confidence in the business as we look ahead, we're raising our fiscal 2020 adjusted EPS guidance range of \n$14.00 to $14.60.  This is from our previous range of $13.85 to $14.45.  \n \n Now, turning to the business. ", "original_text": "And our balance sheet remained strong, giving us the flexibility to deploy capital that can \ndifferentiate McKesson and create shareholder value. ", "page_label": "3", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "871446acb8bac0aa1ae716797a5cd8404d6fb8b9de9fcf5c6a8c5d26797f35c0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8403517e-0c7d-42e3-98c3-7569ecfa508f", "node_type": "1", "metadata": {"window": "We're seeing healthy growth across many parts of our business, which is a direct result of the actions we have \nbeen and are taking to execute on our strategic imperatives, which are enabling us to become a more focused \nand efficient company .  And our balance sheet remained strong, giving us the flexibility to deploy capital that can \ndifferentiate McKesson and create shareholder value.  As a result of our first quarter performance, combined with \nour confidence in the business as we look ahead, we're raising our fiscal 2020 adjusted EPS guidance range of \n$14.00 to $14.60.  This is from our previous range of $13.85 to $14.45.  \n \n Now, turning to the business.  I'll summarize our first quarter results and then turn the call over to Britt to elaborate. \n The U.S. ", "original_text": "This is from our previous range of $13.85 to $14.45.  \n \n"}, "hash": "35bc36b3c547dee614e8cc38a0eb32465caadb1a8d98ff168b4bc59198e47c8f", "class_name": "RelatedNodeInfo"}}, "text": "As a result of our first quarter performance, combined with \nour confidence in the business as we look ahead, we're raising our fiscal 2020 adjusted EPS guidance range of \n$14.00 to $14.60. ", "start_char_idx": 3113, "end_char_idx": 3303, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8403517e-0c7d-42e3-98c3-7569ecfa508f": {"__data__": {"id_": "8403517e-0c7d-42e3-98c3-7569ecfa508f", "embedding": null, "metadata": {"window": "We're seeing healthy growth across many parts of our business, which is a direct result of the actions we have \nbeen and are taking to execute on our strategic imperatives, which are enabling us to become a more focused \nand efficient company .  And our balance sheet remained strong, giving us the flexibility to deploy capital that can \ndifferentiate McKesson and create shareholder value.  As a result of our first quarter performance, combined with \nour confidence in the business as we look ahead, we're raising our fiscal 2020 adjusted EPS guidance range of \n$14.00 to $14.60.  This is from our previous range of $13.85 to $14.45.  \n \n Now, turning to the business.  I'll summarize our first quarter results and then turn the call over to Britt to elaborate. \n The U.S. ", "original_text": "This is from our previous range of $13.85 to $14.45.  \n \n", "page_label": "3", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "510e1ab1-9110-4db6-842c-2a73346ced15", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d0157eff77ad852371cbdffac150e7b96841650fa8206e3590e533a6d9217d48", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0f3a01b7-e381-4705-a971-cb610e1b0e43", "node_type": "1", "metadata": {"window": "On our fourth quarter \ncall in May, I discussed that we were entering the fiscal year with positive momentum and I feel really good about \nthis underpinning our first qu arter results.  \n \n We're seeing healthy growth across many parts of our business, which is a direct result of the actions we have \nbeen and are taking to execute on our strategic imperatives, which are enabling us to become a more focused \nand efficient company .  And our balance sheet remained strong, giving us the flexibility to deploy capital that can \ndifferentiate McKesson and create shareholder value.  As a result of our first quarter performance, combined with \nour confidence in the business as we look ahead, we're raising our fiscal 2020 adjusted EPS guidance range of \n$14.00 to $14.60.  This is from our previous range of $13.85 to $14.45.  \n \n Now, turning to the business.  I'll summarize our first quarter results and then turn the call over to Britt to elaborate. \n", "original_text": "As a result of our first quarter performance, combined with \nour confidence in the business as we look ahead, we're raising our fiscal 2020 adjusted EPS guidance range of \n$14.00 to $14.60. ", "page_label": "3", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0eada1b70843209c1285c20379a2943fbc766f620dfa2781aadf84e995803646", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ee0d08db-6fa2-44f2-b5cb-354e79460d6c", "node_type": "1", "metadata": {"window": "And our balance sheet remained strong, giving us the flexibility to deploy capital that can \ndifferentiate McKesson and create shareholder value.  As a result of our first quarter performance, combined with \nour confidence in the business as we look ahead, we're raising our fiscal 2020 adjusted EPS guidance range of \n$14.00 to $14.60.  This is from our previous range of $13.85 to $14.45.  \n \n Now, turning to the business.  I'll summarize our first quarter results and then turn the call over to Britt to elaborate. \n The U.S.  Pharmaceutical and Specialty Solutions had a good start to the year, driven by our broad set of specialty \nbiopharmaceutical capabilities focused on both providers and manufacturers. ", "original_text": "Now, turning to the business. "}, "hash": "49f5149262a3d00df9aab0a481ba2e8ff3cc9204bc5856a08de4d46f9ce2d253", "class_name": "RelatedNodeInfo"}}, "text": "This is from our previous range of $13.85 to $14.45.  \n \n", "start_char_idx": 3303, "end_char_idx": 3360, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ee0d08db-6fa2-44f2-b5cb-354e79460d6c": {"__data__": {"id_": "ee0d08db-6fa2-44f2-b5cb-354e79460d6c", "embedding": null, "metadata": {"window": "And our balance sheet remained strong, giving us the flexibility to deploy capital that can \ndifferentiate McKesson and create shareholder value.  As a result of our first quarter performance, combined with \nour confidence in the business as we look ahead, we're raising our fiscal 2020 adjusted EPS guidance range of \n$14.00 to $14.60.  This is from our previous range of $13.85 to $14.45.  \n \n Now, turning to the business.  I'll summarize our first quarter results and then turn the call over to Britt to elaborate. \n The U.S.  Pharmaceutical and Specialty Solutions had a good start to the year, driven by our broad set of specialty \nbiopharmaceutical capabilities focused on both providers and manufacturers. ", "original_text": "Now, turning to the business. ", "page_label": "3", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "510e1ab1-9110-4db6-842c-2a73346ced15", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d0157eff77ad852371cbdffac150e7b96841650fa8206e3590e533a6d9217d48", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8403517e-0c7d-42e3-98c3-7569ecfa508f", "node_type": "1", "metadata": {"window": "We're seeing healthy growth across many parts of our business, which is a direct result of the actions we have \nbeen and are taking to execute on our strategic imperatives, which are enabling us to become a more focused \nand efficient company .  And our balance sheet remained strong, giving us the flexibility to deploy capital that can \ndifferentiate McKesson and create shareholder value.  As a result of our first quarter performance, combined with \nour confidence in the business as we look ahead, we're raising our fiscal 2020 adjusted EPS guidance range of \n$14.00 to $14.60.  This is from our previous range of $13.85 to $14.45.  \n \n Now, turning to the business.  I'll summarize our first quarter results and then turn the call over to Britt to elaborate. \n The U.S. ", "original_text": "This is from our previous range of $13.85 to $14.45.  \n \n", "page_label": "3", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e7d290780a87fb1adafe19ac7b431955d17de4efb882be652970c4331e22af28", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "912d1d33-24da-40d2-ac43-adb2554a1f0a", "node_type": "1", "metadata": {"window": "As a result of our first quarter performance, combined with \nour confidence in the business as we look ahead, we're raising our fiscal 2020 adjusted EPS guidance range of \n$14.00 to $14.60.  This is from our previous range of $13.85 to $14.45.  \n \n Now, turning to the business.  I'll summarize our first quarter results and then turn the call over to Britt to elaborate. \n The U.S.  Pharmaceutical and Specialty Solutions had a good start to the year, driven by our broad set of specialty \nbiopharmaceutical capabilities focused on both providers and manufacturers.  I'm particularly pleased as this \ndemonstrates the progress we're m aking on one of our three key strategic imperatives. ", "original_text": "I'll summarize our first quarter results and then turn the call over to Britt to elaborate. \n"}, "hash": "7112dada259f73496b5d5965f3365f410cf856dce17017fbb5d7143a8295ee32", "class_name": "RelatedNodeInfo"}}, "text": "Now, turning to the business. ", "start_char_idx": 3360, "end_char_idx": 3390, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "912d1d33-24da-40d2-ac43-adb2554a1f0a": {"__data__": {"id_": "912d1d33-24da-40d2-ac43-adb2554a1f0a", "embedding": null, "metadata": {"window": "As a result of our first quarter performance, combined with \nour confidence in the business as we look ahead, we're raising our fiscal 2020 adjusted EPS guidance range of \n$14.00 to $14.60.  This is from our previous range of $13.85 to $14.45.  \n \n Now, turning to the business.  I'll summarize our first quarter results and then turn the call over to Britt to elaborate. \n The U.S.  Pharmaceutical and Specialty Solutions had a good start to the year, driven by our broad set of specialty \nbiopharmaceutical capabilities focused on both providers and manufacturers.  I'm particularly pleased as this \ndemonstrates the progress we're m aking on one of our three key strategic imperatives. ", "original_text": "I'll summarize our first quarter results and then turn the call over to Britt to elaborate. \n", "page_label": "3", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "510e1ab1-9110-4db6-842c-2a73346ced15", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d0157eff77ad852371cbdffac150e7b96841650fa8206e3590e533a6d9217d48", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ee0d08db-6fa2-44f2-b5cb-354e79460d6c", "node_type": "1", "metadata": {"window": "And our balance sheet remained strong, giving us the flexibility to deploy capital that can \ndifferentiate McKesson and create shareholder value.  As a result of our first quarter performance, combined with \nour confidence in the business as we look ahead, we're raising our fiscal 2020 adjusted EPS guidance range of \n$14.00 to $14.60.  This is from our previous range of $13.85 to $14.45.  \n \n Now, turning to the business.  I'll summarize our first quarter results and then turn the call over to Britt to elaborate. \n The U.S.  Pharmaceutical and Specialty Solutions had a good start to the year, driven by our broad set of specialty \nbiopharmaceutical capabilities focused on both providers and manufacturers. ", "original_text": "Now, turning to the business. ", "page_label": "3", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "37de916329798eebb9c3258ec07804ac8a680313156da200de282e2882b154a0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "23d1f47f-b84c-4484-a9b6-6d471b9ca078", "node_type": "1", "metadata": {"window": "This is from our previous range of $13.85 to $14.45.  \n \n Now, turning to the business.  I'll summarize our first quarter results and then turn the call over to Britt to elaborate. \n The U.S.  Pharmaceutical and Specialty Solutions had a good start to the year, driven by our broad set of specialty \nbiopharmaceutical capabilities focused on both providers and manufacturers.  I'm particularly pleased as this \ndemonstrates the progress we're m aking on one of our three key strategic imperatives.  We continue to see \nbiopharma dynamics that are trending in line with our annual guide of mid -single digit price increases on branded \ndrugs. ", "original_text": "The U.S. "}, "hash": "e1b4ac838b6ff0408cf98f4d19a2de300fde388c2ce889d7a2fa589216313ab6", "class_name": "RelatedNodeInfo"}}, "text": "I'll summarize our first quarter results and then turn the call over to Britt to elaborate. \n", "start_char_idx": 3390, "end_char_idx": 3483, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "23d1f47f-b84c-4484-a9b6-6d471b9ca078": {"__data__": {"id_": "23d1f47f-b84c-4484-a9b6-6d471b9ca078", "embedding": null, "metadata": {"window": "This is from our previous range of $13.85 to $14.45.  \n \n Now, turning to the business.  I'll summarize our first quarter results and then turn the call over to Britt to elaborate. \n The U.S.  Pharmaceutical and Specialty Solutions had a good start to the year, driven by our broad set of specialty \nbiopharmaceutical capabilities focused on both providers and manufacturers.  I'm particularly pleased as this \ndemonstrates the progress we're m aking on one of our three key strategic imperatives.  We continue to see \nbiopharma dynamics that are trending in line with our annual guide of mid -single digit price increases on branded \ndrugs. ", "original_text": "The U.S. ", "page_label": "3", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "510e1ab1-9110-4db6-842c-2a73346ced15", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d0157eff77ad852371cbdffac150e7b96841650fa8206e3590e533a6d9217d48", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "912d1d33-24da-40d2-ac43-adb2554a1f0a", "node_type": "1", "metadata": {"window": "As a result of our first quarter performance, combined with \nour confidence in the business as we look ahead, we're raising our fiscal 2020 adjusted EPS guidance range of \n$14.00 to $14.60.  This is from our previous range of $13.85 to $14.45.  \n \n Now, turning to the business.  I'll summarize our first quarter results and then turn the call over to Britt to elaborate. \n The U.S.  Pharmaceutical and Specialty Solutions had a good start to the year, driven by our broad set of specialty \nbiopharmaceutical capabilities focused on both providers and manufacturers.  I'm particularly pleased as this \ndemonstrates the progress we're m aking on one of our three key strategic imperatives. ", "original_text": "I'll summarize our first quarter results and then turn the call over to Britt to elaborate. \n", "page_label": "3", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8a656131b1b91dcb12eb536228dc4e93efb5faeac060bd9d8df2baced95d3fcf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8241b658-ff7f-4c11-9c80-c405798b4663", "node_type": "1", "metadata": {"window": "Now, turning to the business.  I'll summarize our first quarter results and then turn the call over to Britt to elaborate. \n The U.S.  Pharmaceutical and Specialty Solutions had a good start to the year, driven by our broad set of specialty \nbiopharmaceutical capabilities focused on both providers and manufacturers.  I'm particularly pleased as this \ndemonstrates the progress we're m aking on one of our three key strategic imperatives.  We continue to see \nbiopharma dynamics that are trending in line with our annual guide of mid -single digit price increases on branded \ndrugs.  In addition, given our presence in the provider space and parti cularly oncology where we are well \npositioned as biosimilars continue to become prevalent.  ", "original_text": "Pharmaceutical and Specialty Solutions had a good start to the year, driven by our broad set of specialty \nbiopharmaceutical capabilities focused on both providers and manufacturers. "}, "hash": "1cca0413983ac33c503b1d3d76e1ca0157f35273375f94a7be9c9d4deb2479e9", "class_name": "RelatedNodeInfo"}}, "text": "The U.S. ", "start_char_idx": 3483, "end_char_idx": 3492, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8241b658-ff7f-4c11-9c80-c405798b4663": {"__data__": {"id_": "8241b658-ff7f-4c11-9c80-c405798b4663", "embedding": null, "metadata": {"window": "Now, turning to the business.  I'll summarize our first quarter results and then turn the call over to Britt to elaborate. \n The U.S.  Pharmaceutical and Specialty Solutions had a good start to the year, driven by our broad set of specialty \nbiopharmaceutical capabilities focused on both providers and manufacturers.  I'm particularly pleased as this \ndemonstrates the progress we're m aking on one of our three key strategic imperatives.  We continue to see \nbiopharma dynamics that are trending in line with our annual guide of mid -single digit price increases on branded \ndrugs.  In addition, given our presence in the provider space and parti cularly oncology where we are well \npositioned as biosimilars continue to become prevalent.  ", "original_text": "Pharmaceutical and Specialty Solutions had a good start to the year, driven by our broad set of specialty \nbiopharmaceutical capabilities focused on both providers and manufacturers. ", "page_label": "3", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "510e1ab1-9110-4db6-842c-2a73346ced15", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d0157eff77ad852371cbdffac150e7b96841650fa8206e3590e533a6d9217d48", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "23d1f47f-b84c-4484-a9b6-6d471b9ca078", "node_type": "1", "metadata": {"window": "This is from our previous range of $13.85 to $14.45.  \n \n Now, turning to the business.  I'll summarize our first quarter results and then turn the call over to Britt to elaborate. \n The U.S.  Pharmaceutical and Specialty Solutions had a good start to the year, driven by our broad set of specialty \nbiopharmaceutical capabilities focused on both providers and manufacturers.  I'm particularly pleased as this \ndemonstrates the progress we're m aking on one of our three key strategic imperatives.  We continue to see \nbiopharma dynamics that are trending in line with our annual guide of mid -single digit price increases on branded \ndrugs. ", "original_text": "The U.S. ", "page_label": "3", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "42fb3762c97e8d44a7149ed28168b66f9188df1b0745ffb06353e3172ec3bc56", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "173384bc-a7af-419a-b31e-4fb0de064c61", "node_type": "1", "metadata": {"window": "I'll summarize our first quarter results and then turn the call over to Britt to elaborate. \n The U.S.  Pharmaceutical and Specialty Solutions had a good start to the year, driven by our broad set of specialty \nbiopharmaceutical capabilities focused on both providers and manufacturers.  I'm particularly pleased as this \ndemonstrates the progress we're m aking on one of our three key strategic imperatives.  We continue to see \nbiopharma dynamics that are trending in line with our annual guide of mid -single digit price increases on branded \ndrugs.  In addition, given our presence in the provider space and parti cularly oncology where we are well \npositioned as biosimilars continue to become prevalent.  ", "original_text": "I'm particularly pleased as this \ndemonstrates the progress we're m aking on one of our three key strategic imperatives. "}, "hash": "5d30e9c8883d6a1584d80ce88b12e7812104bb389d6f2873166d29fa4b822f4e", "class_name": "RelatedNodeInfo"}}, "text": "Pharmaceutical and Specialty Solutions had a good start to the year, driven by our broad set of specialty \nbiopharmaceutical capabilities focused on both providers and manufacturers. ", "start_char_idx": 3492, "end_char_idx": 3675, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "173384bc-a7af-419a-b31e-4fb0de064c61": {"__data__": {"id_": "173384bc-a7af-419a-b31e-4fb0de064c61", "embedding": null, "metadata": {"window": "I'll summarize our first quarter results and then turn the call over to Britt to elaborate. \n The U.S.  Pharmaceutical and Specialty Solutions had a good start to the year, driven by our broad set of specialty \nbiopharmaceutical capabilities focused on both providers and manufacturers.  I'm particularly pleased as this \ndemonstrates the progress we're m aking on one of our three key strategic imperatives.  We continue to see \nbiopharma dynamics that are trending in line with our annual guide of mid -single digit price increases on branded \ndrugs.  In addition, given our presence in the provider space and parti cularly oncology where we are well \npositioned as biosimilars continue to become prevalent.  ", "original_text": "I'm particularly pleased as this \ndemonstrates the progress we're m aking on one of our three key strategic imperatives. ", "page_label": "3", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "510e1ab1-9110-4db6-842c-2a73346ced15", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d0157eff77ad852371cbdffac150e7b96841650fa8206e3590e533a6d9217d48", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8241b658-ff7f-4c11-9c80-c405798b4663", "node_type": "1", "metadata": {"window": "Now, turning to the business.  I'll summarize our first quarter results and then turn the call over to Britt to elaborate. \n The U.S.  Pharmaceutical and Specialty Solutions had a good start to the year, driven by our broad set of specialty \nbiopharmaceutical capabilities focused on both providers and manufacturers.  I'm particularly pleased as this \ndemonstrates the progress we're m aking on one of our three key strategic imperatives.  We continue to see \nbiopharma dynamics that are trending in line with our annual guide of mid -single digit price increases on branded \ndrugs.  In addition, given our presence in the provider space and parti cularly oncology where we are well \npositioned as biosimilars continue to become prevalent.  ", "original_text": "Pharmaceutical and Specialty Solutions had a good start to the year, driven by our broad set of specialty \nbiopharmaceutical capabilities focused on both providers and manufacturers. ", "page_label": "3", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "37ceada24de9ba41c9c0ae478e709beadb921e4c457c8db058d1655a868d20f9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "49220002-ecf8-441a-952f-c7585d1a2e3c", "node_type": "1", "metadata": {"window": "The U.S.  Pharmaceutical and Specialty Solutions had a good start to the year, driven by our broad set of specialty \nbiopharmaceutical capabilities focused on both providers and manufacturers.  I'm particularly pleased as this \ndemonstrates the progress we're m aking on one of our three key strategic imperatives.  We continue to see \nbiopharma dynamics that are trending in line with our annual guide of mid -single digit price increases on branded \ndrugs.  In addition, given our presence in the provider space and parti cularly oncology where we are well \npositioned as biosimilars continue to become prevalent.  ", "original_text": "We continue to see \nbiopharma dynamics that are trending in line with our annual guide of mid -single digit price increases on branded \ndrugs. "}, "hash": "70d340ef70cbbd40d4ffcc684773cc0c7e14cb46dfcd4a21fb0b428aec283847", "class_name": "RelatedNodeInfo"}}, "text": "I'm particularly pleased as this \ndemonstrates the progress we're m aking on one of our three key strategic imperatives. ", "start_char_idx": 3675, "end_char_idx": 3796, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "49220002-ecf8-441a-952f-c7585d1a2e3c": {"__data__": {"id_": "49220002-ecf8-441a-952f-c7585d1a2e3c", "embedding": null, "metadata": {"window": "The U.S.  Pharmaceutical and Specialty Solutions had a good start to the year, driven by our broad set of specialty \nbiopharmaceutical capabilities focused on both providers and manufacturers.  I'm particularly pleased as this \ndemonstrates the progress we're m aking on one of our three key strategic imperatives.  We continue to see \nbiopharma dynamics that are trending in line with our annual guide of mid -single digit price increases on branded \ndrugs.  In addition, given our presence in the provider space and parti cularly oncology where we are well \npositioned as biosimilars continue to become prevalent.  ", "original_text": "We continue to see \nbiopharma dynamics that are trending in line with our annual guide of mid -single digit price increases on branded \ndrugs. ", "page_label": "3", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "510e1ab1-9110-4db6-842c-2a73346ced15", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d0157eff77ad852371cbdffac150e7b96841650fa8206e3590e533a6d9217d48", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "173384bc-a7af-419a-b31e-4fb0de064c61", "node_type": "1", "metadata": {"window": "I'll summarize our first quarter results and then turn the call over to Britt to elaborate. \n The U.S.  Pharmaceutical and Specialty Solutions had a good start to the year, driven by our broad set of specialty \nbiopharmaceutical capabilities focused on both providers and manufacturers.  I'm particularly pleased as this \ndemonstrates the progress we're m aking on one of our three key strategic imperatives.  We continue to see \nbiopharma dynamics that are trending in line with our annual guide of mid -single digit price increases on branded \ndrugs.  In addition, given our presence in the provider space and parti cularly oncology where we are well \npositioned as biosimilars continue to become prevalent.  ", "original_text": "I'm particularly pleased as this \ndemonstrates the progress we're m aking on one of our three key strategic imperatives. ", "page_label": "3", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "06dbfbfab01452cfa6095661213a6ca3c3230927ae2e54eafbceab76247bb663", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "de974110-2bb8-48eb-b188-4ec7d734a672", "node_type": "1", "metadata": {"window": "Pharmaceutical and Specialty Solutions had a good start to the year, driven by our broad set of specialty \nbiopharmaceutical capabilities focused on both providers and manufacturers.  I'm particularly pleased as this \ndemonstrates the progress we're m aking on one of our three key strategic imperatives.  We continue to see \nbiopharma dynamics that are trending in line with our annual guide of mid -single digit price increases on branded \ndrugs.  In addition, given our presence in the provider space and parti cularly oncology where we are well \npositioned as biosimilars continue to become prevalent.  ", "original_text": "In addition, given our presence in the provider space and parti cularly oncology where we are well \npositioned as biosimilars continue to become prevalent.  "}, "hash": "2c8aa3c5cb31b56e5dcd2c97b438e112bf585108c422663067b919bda1adcaab", "class_name": "RelatedNodeInfo"}}, "text": "We continue to see \nbiopharma dynamics that are trending in line with our annual guide of mid -single digit price increases on branded \ndrugs. ", "start_char_idx": 3796, "end_char_idx": 3939, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "de974110-2bb8-48eb-b188-4ec7d734a672": {"__data__": {"id_": "de974110-2bb8-48eb-b188-4ec7d734a672", "embedding": null, "metadata": {"window": "Pharmaceutical and Specialty Solutions had a good start to the year, driven by our broad set of specialty \nbiopharmaceutical capabilities focused on both providers and manufacturers.  I'm particularly pleased as this \ndemonstrates the progress we're m aking on one of our three key strategic imperatives.  We continue to see \nbiopharma dynamics that are trending in line with our annual guide of mid -single digit price increases on branded \ndrugs.  In addition, given our presence in the provider space and parti cularly oncology where we are well \npositioned as biosimilars continue to become prevalent.  ", "original_text": "In addition, given our presence in the provider space and parti cularly oncology where we are well \npositioned as biosimilars continue to become prevalent.  ", "page_label": "3", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "510e1ab1-9110-4db6-842c-2a73346ced15", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d0157eff77ad852371cbdffac150e7b96841650fa8206e3590e533a6d9217d48", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "49220002-ecf8-441a-952f-c7585d1a2e3c", "node_type": "1", "metadata": {"window": "The U.S.  Pharmaceutical and Specialty Solutions had a good start to the year, driven by our broad set of specialty \nbiopharmaceutical capabilities focused on both providers and manufacturers.  I'm particularly pleased as this \ndemonstrates the progress we're m aking on one of our three key strategic imperatives.  We continue to see \nbiopharma dynamics that are trending in line with our annual guide of mid -single digit price increases on branded \ndrugs.  In addition, given our presence in the provider space and parti cularly oncology where we are well \npositioned as biosimilars continue to become prevalent.  ", "original_text": "We continue to see \nbiopharma dynamics that are trending in line with our annual guide of mid -single digit price increases on branded \ndrugs. ", "page_label": "3", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e9240708def0528acdcdc49f48f5c57e83f92c652c54c1a4626205404290795f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f59075a0-c3ff-43fa-be60-f8e271ea2cfd", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nTalking about generics for a moment.  Similar to the last few quarters, our ClarusONE sourcing platform continues \nto deliver yield in line with our expectations.  With its scale, we're able to buy at prices that are competitive with our \npeers. ", "original_text": "McKesson Corp.  "}, "hash": "3d78825e6fae67c4f5132c1bdfb655d3eea52346f3550e9f08ede35ca586bd12", "class_name": "RelatedNodeInfo"}}, "text": "In addition, given our presence in the provider space and parti cularly oncology where we are well \npositioned as biosimilars continue to become prevalent.  ", "start_char_idx": 3939, "end_char_idx": 4096, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f59075a0-c3ff-43fa-be60-f8e271ea2cfd": {"__data__": {"id_": "f59075a0-c3ff-43fa-be60-f8e271ea2cfd", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nTalking about generics for a moment.  Similar to the last few quarters, our ClarusONE sourcing platform continues \nto deliver yield in line with our expectations.  With its scale, we're able to buy at prices that are competitive with our \npeers. ", "original_text": "McKesson Corp.  ", "page_label": "4", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bdb1c12e-5d92-4655-a0ce-a7bbe0044e67", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a37f6d614ba6c866b525bc57f54d512d14dd72c8762cff21f8dcf9285f204612", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "de974110-2bb8-48eb-b188-4ec7d734a672", "node_type": "1", "metadata": {"window": "Pharmaceutical and Specialty Solutions had a good start to the year, driven by our broad set of specialty \nbiopharmaceutical capabilities focused on both providers and manufacturers.  I'm particularly pleased as this \ndemonstrates the progress we're m aking on one of our three key strategic imperatives.  We continue to see \nbiopharma dynamics that are trending in line with our annual guide of mid -single digit price increases on branded \ndrugs.  In addition, given our presence in the provider space and parti cularly oncology where we are well \npositioned as biosimilars continue to become prevalent.  ", "original_text": "In addition, given our presence in the provider space and parti cularly oncology where we are well \npositioned as biosimilars continue to become prevalent.  ", "page_label": "3", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a4e4306bed3d840e1b5758a5c61162412e790b9b869d2696541ace96a7a05528", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fcaef1ae-b5f0-47a1-b6f7-9bbcd9f3fece", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nTalking about generics for a moment.  Similar to the last few quarters, our ClarusONE sourcing platform continues \nto deliver yield in line with our expectations.  With its scale, we're able to buy at prices that are competitive with our \npeers.  On the sell side, we continue to see a market that is competitive, but stable. ", "original_text": "(MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nTalking about generics for a moment. "}, "hash": "dbd5485738da8d625432844d03fbd6f7fbb9d9118fd86589352bdedf604c985f", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fcaef1ae-b5f0-47a1-b6f7-9bbcd9f3fece": {"__data__": {"id_": "fcaef1ae-b5f0-47a1-b6f7-9bbcd9f3fece", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nTalking about generics for a moment.  Similar to the last few quarters, our ClarusONE sourcing platform continues \nto deliver yield in line with our expectations.  With its scale, we're able to buy at prices that are competitive with our \npeers.  On the sell side, we continue to see a market that is competitive, but stable. ", "original_text": "(MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nTalking about generics for a moment. ", "page_label": "4", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bdb1c12e-5d92-4655-a0ce-a7bbe0044e67", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a37f6d614ba6c866b525bc57f54d512d14dd72c8762cff21f8dcf9285f204612", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f59075a0-c3ff-43fa-be60-f8e271ea2cfd", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nTalking about generics for a moment.  Similar to the last few quarters, our ClarusONE sourcing platform continues \nto deliver yield in line with our expectations.  With its scale, we're able to buy at prices that are competitive with our \npeers. ", "original_text": "McKesson Corp.  ", "page_label": "4", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c7a23cba7f44de85036162b1463e97c9a3d01c45159c15e76cff75a0ee06f2ed", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "95e67569-2322-44d3-8ae1-d96c53212b59", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nTalking about generics for a moment.  Similar to the last few quarters, our ClarusONE sourcing platform continues \nto deliver yield in line with our expectations.  With its scale, we're able to buy at prices that are competitive with our \npeers.  On the sell side, we continue to see a market that is competitive, but stable.  A few comments on Europe. \n", "original_text": "Similar to the last few quarters, our ClarusONE sourcing platform continues \nto deliver yield in line with our expectations. "}, "hash": "7830ecf7bd3a3bc4ca26552dba81e4eb8f169d9589cece8a5f22aead42bc668d", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nTalking about generics for a moment. ", "start_char_idx": 16, "end_char_idx": 219, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "95e67569-2322-44d3-8ae1-d96c53212b59": {"__data__": {"id_": "95e67569-2322-44d3-8ae1-d96c53212b59", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nTalking about generics for a moment.  Similar to the last few quarters, our ClarusONE sourcing platform continues \nto deliver yield in line with our expectations.  With its scale, we're able to buy at prices that are competitive with our \npeers.  On the sell side, we continue to see a market that is competitive, but stable.  A few comments on Europe. \n", "original_text": "Similar to the last few quarters, our ClarusONE sourcing platform continues \nto deliver yield in line with our expectations. ", "page_label": "4", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bdb1c12e-5d92-4655-a0ce-a7bbe0044e67", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a37f6d614ba6c866b525bc57f54d512d14dd72c8762cff21f8dcf9285f204612", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fcaef1ae-b5f0-47a1-b6f7-9bbcd9f3fece", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nTalking about generics for a moment.  Similar to the last few quarters, our ClarusONE sourcing platform continues \nto deliver yield in line with our expectations.  With its scale, we're able to buy at prices that are competitive with our \npeers.  On the sell side, we continue to see a market that is competitive, but stable. ", "original_text": "(MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nTalking about generics for a moment. ", "page_label": "4", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8f61ff268d36e56ed1e75eafc8cfd7ddb0ad3a51a51096793f639d60fb74c65e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "898deb2c-2255-4de3-967e-ce52864b7d43", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nTalking about generics for a moment.  Similar to the last few quarters, our ClarusONE sourcing platform continues \nto deliver yield in line with our expectations.  With its scale, we're able to buy at prices that are competitive with our \npeers.  On the sell side, we continue to see a market that is competitive, but stable.  A few comments on Europe. \n Our UK retail business performance was impacted primarily by temporary -wide NHS underfunding, which we \nbelieve should improve in the second half; and to a lesser extent, volume weakness. ", "original_text": "With its scale, we're able to buy at prices that are competitive with our \npeers. "}, "hash": "cf5fbd7aa924bed92bf21564d6dae5a10c8e9c923c40f019c3cd3102d6bae1da", "class_name": "RelatedNodeInfo"}}, "text": "Similar to the last few quarters, our ClarusONE sourcing platform continues \nto deliver yield in line with our expectations. ", "start_char_idx": 219, "end_char_idx": 344, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "898deb2c-2255-4de3-967e-ce52864b7d43": {"__data__": {"id_": "898deb2c-2255-4de3-967e-ce52864b7d43", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nTalking about generics for a moment.  Similar to the last few quarters, our ClarusONE sourcing platform continues \nto deliver yield in line with our expectations.  With its scale, we're able to buy at prices that are competitive with our \npeers.  On the sell side, we continue to see a market that is competitive, but stable.  A few comments on Europe. \n Our UK retail business performance was impacted primarily by temporary -wide NHS underfunding, which we \nbelieve should improve in the second half; and to a lesser extent, volume weakness. ", "original_text": "With its scale, we're able to buy at prices that are competitive with our \npeers. ", "page_label": "4", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bdb1c12e-5d92-4655-a0ce-a7bbe0044e67", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a37f6d614ba6c866b525bc57f54d512d14dd72c8762cff21f8dcf9285f204612", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "95e67569-2322-44d3-8ae1-d96c53212b59", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nTalking about generics for a moment.  Similar to the last few quarters, our ClarusONE sourcing platform continues \nto deliver yield in line with our expectations.  With its scale, we're able to buy at prices that are competitive with our \npeers.  On the sell side, we continue to see a market that is competitive, but stable.  A few comments on Europe. \n", "original_text": "Similar to the last few quarters, our ClarusONE sourcing platform continues \nto deliver yield in line with our expectations. ", "page_label": "4", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7d8869ccad7778ccb494eb095524d20182adb019b79707e136e04725dc9f6535", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "87d9acdf-98c7-4ae2-a90c-3d3109d5890e", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nTalking about generics for a moment.  Similar to the last few quarters, our ClarusONE sourcing platform continues \nto deliver yield in line with our expectations.  With its scale, we're able to buy at prices that are competitive with our \npeers.  On the sell side, we continue to see a market that is competitive, but stable.  A few comments on Europe. \n Our UK retail business performance was impacted primarily by temporary -wide NHS underfunding, which we \nbelieve should improve in the second half; and to a lesser extent, volume weakness.  Performance in the other \nEuropean countries was not enough to fully offset these challenges. ", "original_text": "On the sell side, we continue to see a market that is competitive, but stable. "}, "hash": "2988c7c83dce5a6026b46bdef070ade3ccad7d0bd4d26a9e92008e1387d094d4", "class_name": "RelatedNodeInfo"}}, "text": "With its scale, we're able to buy at prices that are competitive with our \npeers. ", "start_char_idx": 344, "end_char_idx": 426, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "87d9acdf-98c7-4ae2-a90c-3d3109d5890e": {"__data__": {"id_": "87d9acdf-98c7-4ae2-a90c-3d3109d5890e", "embedding": null, "metadata": {"window": "(MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nTalking about generics for a moment.  Similar to the last few quarters, our ClarusONE sourcing platform continues \nto deliver yield in line with our expectations.  With its scale, we're able to buy at prices that are competitive with our \npeers.  On the sell side, we continue to see a market that is competitive, but stable.  A few comments on Europe. \n Our UK retail business performance was impacted primarily by temporary -wide NHS underfunding, which we \nbelieve should improve in the second half; and to a lesser extent, volume weakness.  Performance in the other \nEuropean countries was not enough to fully offset these challenges. ", "original_text": "On the sell side, we continue to see a market that is competitive, but stable. ", "page_label": "4", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bdb1c12e-5d92-4655-a0ce-a7bbe0044e67", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a37f6d614ba6c866b525bc57f54d512d14dd72c8762cff21f8dcf9285f204612", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "898deb2c-2255-4de3-967e-ce52864b7d43", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nTalking about generics for a moment.  Similar to the last few quarters, our ClarusONE sourcing platform continues \nto deliver yield in line with our expectations.  With its scale, we're able to buy at prices that are competitive with our \npeers.  On the sell side, we continue to see a market that is competitive, but stable.  A few comments on Europe. \n Our UK retail business performance was impacted primarily by temporary -wide NHS underfunding, which we \nbelieve should improve in the second half; and to a lesser extent, volume weakness. ", "original_text": "With its scale, we're able to buy at prices that are competitive with our \npeers. ", "page_label": "4", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ff0e1dc15d7c7861602e8fa2dc5ec3fa5ba872ef6a0dcb064233cc6b6b39e03b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2d58f180-c875-43fc-919a-9c78245ddf59", "node_type": "1", "metadata": {"window": "Similar to the last few quarters, our ClarusONE sourcing platform continues \nto deliver yield in line with our expectations.  With its scale, we're able to buy at prices that are competitive with our \npeers.  On the sell side, we continue to see a market that is competitive, but stable.  A few comments on Europe. \n Our UK retail business performance was impacted primarily by temporary -wide NHS underfunding, which we \nbelieve should improve in the second half; and to a lesser extent, volume weakness.  Performance in the other \nEuropean countries was not enough to fully offset these challenges.  Britt will speak to the expected full year \nimpact. \n \n", "original_text": "A few comments on Europe. \n"}, "hash": "b828abc551b681277a5e7773c90ba9f1e97ac043432ec5fcc1b9b09ab8ebce15", "class_name": "RelatedNodeInfo"}}, "text": "On the sell side, we continue to see a market that is competitive, but stable. ", "start_char_idx": 426, "end_char_idx": 505, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2d58f180-c875-43fc-919a-9c78245ddf59": {"__data__": {"id_": "2d58f180-c875-43fc-919a-9c78245ddf59", "embedding": null, "metadata": {"window": "Similar to the last few quarters, our ClarusONE sourcing platform continues \nto deliver yield in line with our expectations.  With its scale, we're able to buy at prices that are competitive with our \npeers.  On the sell side, we continue to see a market that is competitive, but stable.  A few comments on Europe. \n Our UK retail business performance was impacted primarily by temporary -wide NHS underfunding, which we \nbelieve should improve in the second half; and to a lesser extent, volume weakness.  Performance in the other \nEuropean countries was not enough to fully offset these challenges.  Britt will speak to the expected full year \nimpact. \n \n", "original_text": "A few comments on Europe. \n", "page_label": "4", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bdb1c12e-5d92-4655-a0ce-a7bbe0044e67", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a37f6d614ba6c866b525bc57f54d512d14dd72c8762cff21f8dcf9285f204612", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "87d9acdf-98c7-4ae2-a90c-3d3109d5890e", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nTalking about generics for a moment.  Similar to the last few quarters, our ClarusONE sourcing platform continues \nto deliver yield in line with our expectations.  With its scale, we're able to buy at prices that are competitive with our \npeers.  On the sell side, we continue to see a market that is competitive, but stable.  A few comments on Europe. \n Our UK retail business performance was impacted primarily by temporary -wide NHS underfunding, which we \nbelieve should improve in the second half; and to a lesser extent, volume weakness.  Performance in the other \nEuropean countries was not enough to fully offset these challenges. ", "original_text": "On the sell side, we continue to see a market that is competitive, but stable. ", "page_label": "4", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fb97e19bf6cefce988fc075fb5bcb1e85abed4b8a7c33ee29538159fa046f696", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "242df766-237e-4e47-8008-345462602d18", "node_type": "1", "metadata": {"window": "With its scale, we're able to buy at prices that are competitive with our \npeers.  On the sell side, we continue to see a market that is competitive, but stable.  A few comments on Europe. \n Our UK retail business performance was impacted primarily by temporary -wide NHS underfunding, which we \nbelieve should improve in the second half; and to a lesser extent, volume weakness.  Performance in the other \nEuropean countries was not enough to fully offset these challenges.  Britt will speak to the expected full year \nimpact. \n \n Before I address the NHS more specifically, let me remind you of the actions we've previously taken in the UK \nand across Europe to reposition the business for long -term profitability. ", "original_text": "Our UK retail business performance was impacted primarily by temporary -wide NHS underfunding, which we \nbelieve should improve in the second half; and to a lesser extent, volume weakness. "}, "hash": "8e58fc47ab47e8bb0df3535ff7bf723cdfe199d99930f1ecb7f4ff2943d11499", "class_name": "RelatedNodeInfo"}}, "text": "A few comments on Europe. \n", "start_char_idx": 505, "end_char_idx": 532, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "242df766-237e-4e47-8008-345462602d18": {"__data__": {"id_": "242df766-237e-4e47-8008-345462602d18", "embedding": null, "metadata": {"window": "With its scale, we're able to buy at prices that are competitive with our \npeers.  On the sell side, we continue to see a market that is competitive, but stable.  A few comments on Europe. \n Our UK retail business performance was impacted primarily by temporary -wide NHS underfunding, which we \nbelieve should improve in the second half; and to a lesser extent, volume weakness.  Performance in the other \nEuropean countries was not enough to fully offset these challenges.  Britt will speak to the expected full year \nimpact. \n \n Before I address the NHS more specifically, let me remind you of the actions we've previously taken in the UK \nand across Europe to reposition the business for long -term profitability. ", "original_text": "Our UK retail business performance was impacted primarily by temporary -wide NHS underfunding, which we \nbelieve should improve in the second half; and to a lesser extent, volume weakness. ", "page_label": "4", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bdb1c12e-5d92-4655-a0ce-a7bbe0044e67", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a37f6d614ba6c866b525bc57f54d512d14dd72c8762cff21f8dcf9285f204612", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2d58f180-c875-43fc-919a-9c78245ddf59", "node_type": "1", "metadata": {"window": "Similar to the last few quarters, our ClarusONE sourcing platform continues \nto deliver yield in line with our expectations.  With its scale, we're able to buy at prices that are competitive with our \npeers.  On the sell side, we continue to see a market that is competitive, but stable.  A few comments on Europe. \n Our UK retail business performance was impacted primarily by temporary -wide NHS underfunding, which we \nbelieve should improve in the second half; and to a lesser extent, volume weakness.  Performance in the other \nEuropean countries was not enough to fully offset these challenges.  Britt will speak to the expected full year \nimpact. \n \n", "original_text": "A few comments on Europe. \n", "page_label": "4", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "45d74ad70737f3da58ca933f8b36db1dc4c8b8f1fd4efc943582bc4434cf43e0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "217834d1-f017-405a-9575-d32274bb2a3e", "node_type": "1", "metadata": {"window": "On the sell side, we continue to see a market that is competitive, but stable.  A few comments on Europe. \n Our UK retail business performance was impacted primarily by temporary -wide NHS underfunding, which we \nbelieve should improve in the second half; and to a lesser extent, volume weakness.  Performance in the other \nEuropean countries was not enough to fully offset these challenges.  Britt will speak to the expected full year \nimpact. \n \n Before I address the NHS more specifically, let me remind you of the actions we've previously taken in the UK \nand across Europe to reposition the business for long -term profitability.  With new leadership at the helm, we're \nmaking solid progress towar ds further rationalizing our store footprint and streamlining our back -office functions, \nand we continue to evaluate our cost structure as we do in all our businesses.  \n \n", "original_text": "Performance in the other \nEuropean countries was not enough to fully offset these challenges. "}, "hash": "c8c1075593255c3becf169a8a67aef5f66f12403b03aa041cc8d3a4a471ef8c6", "class_name": "RelatedNodeInfo"}}, "text": "Our UK retail business performance was impacted primarily by temporary -wide NHS underfunding, which we \nbelieve should improve in the second half; and to a lesser extent, volume weakness. ", "start_char_idx": 532, "end_char_idx": 721, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "217834d1-f017-405a-9575-d32274bb2a3e": {"__data__": {"id_": "217834d1-f017-405a-9575-d32274bb2a3e", "embedding": null, "metadata": {"window": "On the sell side, we continue to see a market that is competitive, but stable.  A few comments on Europe. \n Our UK retail business performance was impacted primarily by temporary -wide NHS underfunding, which we \nbelieve should improve in the second half; and to a lesser extent, volume weakness.  Performance in the other \nEuropean countries was not enough to fully offset these challenges.  Britt will speak to the expected full year \nimpact. \n \n Before I address the NHS more specifically, let me remind you of the actions we've previously taken in the UK \nand across Europe to reposition the business for long -term profitability.  With new leadership at the helm, we're \nmaking solid progress towar ds further rationalizing our store footprint and streamlining our back -office functions, \nand we continue to evaluate our cost structure as we do in all our businesses.  \n \n", "original_text": "Performance in the other \nEuropean countries was not enough to fully offset these challenges. ", "page_label": "4", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bdb1c12e-5d92-4655-a0ce-a7bbe0044e67", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a37f6d614ba6c866b525bc57f54d512d14dd72c8762cff21f8dcf9285f204612", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "242df766-237e-4e47-8008-345462602d18", "node_type": "1", "metadata": {"window": "With its scale, we're able to buy at prices that are competitive with our \npeers.  On the sell side, we continue to see a market that is competitive, but stable.  A few comments on Europe. \n Our UK retail business performance was impacted primarily by temporary -wide NHS underfunding, which we \nbelieve should improve in the second half; and to a lesser extent, volume weakness.  Performance in the other \nEuropean countries was not enough to fully offset these challenges.  Britt will speak to the expected full year \nimpact. \n \n Before I address the NHS more specifically, let me remind you of the actions we've previously taken in the UK \nand across Europe to reposition the business for long -term profitability. ", "original_text": "Our UK retail business performance was impacted primarily by temporary -wide NHS underfunding, which we \nbelieve should improve in the second half; and to a lesser extent, volume weakness. ", "page_label": "4", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fec646bd6c7962da770f00ba1b4a2d8b52e902e4a1b88a4ffd0a20e18823fe63", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "298c53fb-0134-404f-abdf-03d0bc27b627", "node_type": "1", "metadata": {"window": "A few comments on Europe. \n Our UK retail business performance was impacted primarily by temporary -wide NHS underfunding, which we \nbelieve should improve in the second half; and to a lesser extent, volume weakness.  Performance in the other \nEuropean countries was not enough to fully offset these challenges.  Britt will speak to the expected full year \nimpact. \n \n Before I address the NHS more specifically, let me remind you of the actions we've previously taken in the UK \nand across Europe to reposition the business for long -term profitability.  With new leadership at the helm, we're \nmaking solid progress towar ds further rationalizing our store footprint and streamlining our back -office functions, \nand we continue to evaluate our cost structure as we do in all our businesses.  \n \n Turning back to the NHS, we're pleased by recent announcements, first, to increase the retail tariff beginning in \nAugust, and we would expect to see further upward revisions in tariff later in the year which should make up \npartially for any underfunding. ", "original_text": "Britt will speak to the expected full year \nimpact. \n \n"}, "hash": "529491d229748226b3d81b127ff31d5ad64c84542847841dac512a62dd7bb0fa", "class_name": "RelatedNodeInfo"}}, "text": "Performance in the other \nEuropean countries was not enough to fully offset these challenges. ", "start_char_idx": 721, "end_char_idx": 815, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "298c53fb-0134-404f-abdf-03d0bc27b627": {"__data__": {"id_": "298c53fb-0134-404f-abdf-03d0bc27b627", "embedding": null, "metadata": {"window": "A few comments on Europe. \n Our UK retail business performance was impacted primarily by temporary -wide NHS underfunding, which we \nbelieve should improve in the second half; and to a lesser extent, volume weakness.  Performance in the other \nEuropean countries was not enough to fully offset these challenges.  Britt will speak to the expected full year \nimpact. \n \n Before I address the NHS more specifically, let me remind you of the actions we've previously taken in the UK \nand across Europe to reposition the business for long -term profitability.  With new leadership at the helm, we're \nmaking solid progress towar ds further rationalizing our store footprint and streamlining our back -office functions, \nand we continue to evaluate our cost structure as we do in all our businesses.  \n \n Turning back to the NHS, we're pleased by recent announcements, first, to increase the retail tariff beginning in \nAugust, and we would expect to see further upward revisions in tariff later in the year which should make up \npartially for any underfunding. ", "original_text": "Britt will speak to the expected full year \nimpact. \n \n", "page_label": "4", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bdb1c12e-5d92-4655-a0ce-a7bbe0044e67", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a37f6d614ba6c866b525bc57f54d512d14dd72c8762cff21f8dcf9285f204612", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "217834d1-f017-405a-9575-d32274bb2a3e", "node_type": "1", "metadata": {"window": "On the sell side, we continue to see a market that is competitive, but stable.  A few comments on Europe. \n Our UK retail business performance was impacted primarily by temporary -wide NHS underfunding, which we \nbelieve should improve in the second half; and to a lesser extent, volume weakness.  Performance in the other \nEuropean countries was not enough to fully offset these challenges.  Britt will speak to the expected full year \nimpact. \n \n Before I address the NHS more specifically, let me remind you of the actions we've previously taken in the UK \nand across Europe to reposition the business for long -term profitability.  With new leadership at the helm, we're \nmaking solid progress towar ds further rationalizing our store footprint and streamlining our back -office functions, \nand we continue to evaluate our cost structure as we do in all our businesses.  \n \n", "original_text": "Performance in the other \nEuropean countries was not enough to fully offset these challenges. ", "page_label": "4", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5712b0494b86c28643852bb407f544ba26f373d8d24b9d95f4cc275b90ffe313", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "066bad57-a56b-433e-8fce-4387dddfcbce", "node_type": "1", "metadata": {"window": "Our UK retail business performance was impacted primarily by temporary -wide NHS underfunding, which we \nbelieve should improve in the second half; and to a lesser extent, volume weakness.  Performance in the other \nEuropean countries was not enough to fully offset these challenges.  Britt will speak to the expected full year \nimpact. \n \n Before I address the NHS more specifically, let me remind you of the actions we've previously taken in the UK \nand across Europe to reposition the business for long -term profitability.  With new leadership at the helm, we're \nmaking solid progress towar ds further rationalizing our store footprint and streamlining our back -office functions, \nand we continue to evaluate our cost structure as we do in all our businesses.  \n \n Turning back to the NHS, we're pleased by recent announcements, first, to increase the retail tariff beginning in \nAugust, and we would expect to see further upward revisions in tariff later in the year which should make up \npartially for any underfunding.  The NHS also announced a new five -year community pharmacy contractual \nframework. ", "original_text": "Before I address the NHS more specifically, let me remind you of the actions we've previously taken in the UK \nand across Europe to reposition the business for long -term profitability. "}, "hash": "b05521d822f5fb48446ac8abc07d4dea92406ad1278b3786956669af65e0deab", "class_name": "RelatedNodeInfo"}}, "text": "Britt will speak to the expected full year \nimpact. \n \n", "start_char_idx": 815, "end_char_idx": 870, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "066bad57-a56b-433e-8fce-4387dddfcbce": {"__data__": {"id_": "066bad57-a56b-433e-8fce-4387dddfcbce", "embedding": null, "metadata": {"window": "Our UK retail business performance was impacted primarily by temporary -wide NHS underfunding, which we \nbelieve should improve in the second half; and to a lesser extent, volume weakness.  Performance in the other \nEuropean countries was not enough to fully offset these challenges.  Britt will speak to the expected full year \nimpact. \n \n Before I address the NHS more specifically, let me remind you of the actions we've previously taken in the UK \nand across Europe to reposition the business for long -term profitability.  With new leadership at the helm, we're \nmaking solid progress towar ds further rationalizing our store footprint and streamlining our back -office functions, \nand we continue to evaluate our cost structure as we do in all our businesses.  \n \n Turning back to the NHS, we're pleased by recent announcements, first, to increase the retail tariff beginning in \nAugust, and we would expect to see further upward revisions in tariff later in the year which should make up \npartially for any underfunding.  The NHS also announced a new five -year community pharmacy contractual \nframework. ", "original_text": "Before I address the NHS more specifically, let me remind you of the actions we've previously taken in the UK \nand across Europe to reposition the business for long -term profitability. ", "page_label": "4", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bdb1c12e-5d92-4655-a0ce-a7bbe0044e67", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a37f6d614ba6c866b525bc57f54d512d14dd72c8762cff21f8dcf9285f204612", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "298c53fb-0134-404f-abdf-03d0bc27b627", "node_type": "1", "metadata": {"window": "A few comments on Europe. \n Our UK retail business performance was impacted primarily by temporary -wide NHS underfunding, which we \nbelieve should improve in the second half; and to a lesser extent, volume weakness.  Performance in the other \nEuropean countries was not enough to fully offset these challenges.  Britt will speak to the expected full year \nimpact. \n \n Before I address the NHS more specifically, let me remind you of the actions we've previously taken in the UK \nand across Europe to reposition the business for long -term profitability.  With new leadership at the helm, we're \nmaking solid progress towar ds further rationalizing our store footprint and streamlining our back -office functions, \nand we continue to evaluate our cost structure as we do in all our businesses.  \n \n Turning back to the NHS, we're pleased by recent announcements, first, to increase the retail tariff beginning in \nAugust, and we would expect to see further upward revisions in tariff later in the year which should make up \npartially for any underfunding. ", "original_text": "Britt will speak to the expected full year \nimpact. \n \n", "page_label": "4", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9663c3ce0cfd9d7f9b4b59d78b6938001aaedb87194f81a37995a0635771c806", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4bc03c69-e4b8-4d53-84ab-9496f2cf992e", "node_type": "1", "metadata": {"window": "Performance in the other \nEuropean countries was not enough to fully offset these challenges.  Britt will speak to the expected full year \nimpact. \n \n Before I address the NHS more specifically, let me remind you of the actions we've previously taken in the UK \nand across Europe to reposition the business for long -term profitability.  With new leadership at the helm, we're \nmaking solid progress towar ds further rationalizing our store footprint and streamlining our back -office functions, \nand we continue to evaluate our cost structure as we do in all our businesses.  \n \n Turning back to the NHS, we're pleased by recent announcements, first, to increase the retail tariff beginning in \nAugust, and we would expect to see further upward revisions in tariff later in the year which should make up \npartially for any underfunding.  The NHS also announced a new five -year community pharmacy contractual \nframework.  This fr amework brings greater clarity and long -term certainty by maintaining the current level of \nindustry funding for community pharmacies for the next five years.  \n \n", "original_text": "With new leadership at the helm, we're \nmaking solid progress towar ds further rationalizing our store footprint and streamlining our back -office functions, \nand we continue to evaluate our cost structure as we do in all our businesses.  \n \n"}, "hash": "96a0640aa66ed9ee926a30899ab2ef18cc2ebc55d905c43541e3b31064237ae1", "class_name": "RelatedNodeInfo"}}, "text": "Before I address the NHS more specifically, let me remind you of the actions we've previously taken in the UK \nand across Europe to reposition the business for long -term profitability. ", "start_char_idx": 870, "end_char_idx": 1056, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4bc03c69-e4b8-4d53-84ab-9496f2cf992e": {"__data__": {"id_": "4bc03c69-e4b8-4d53-84ab-9496f2cf992e", "embedding": null, "metadata": {"window": "Performance in the other \nEuropean countries was not enough to fully offset these challenges.  Britt will speak to the expected full year \nimpact. \n \n Before I address the NHS more specifically, let me remind you of the actions we've previously taken in the UK \nand across Europe to reposition the business for long -term profitability.  With new leadership at the helm, we're \nmaking solid progress towar ds further rationalizing our store footprint and streamlining our back -office functions, \nand we continue to evaluate our cost structure as we do in all our businesses.  \n \n Turning back to the NHS, we're pleased by recent announcements, first, to increase the retail tariff beginning in \nAugust, and we would expect to see further upward revisions in tariff later in the year which should make up \npartially for any underfunding.  The NHS also announced a new five -year community pharmacy contractual \nframework.  This fr amework brings greater clarity and long -term certainty by maintaining the current level of \nindustry funding for community pharmacies for the next five years.  \n \n", "original_text": "With new leadership at the helm, we're \nmaking solid progress towar ds further rationalizing our store footprint and streamlining our back -office functions, \nand we continue to evaluate our cost structure as we do in all our businesses.  \n \n", "page_label": "4", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bdb1c12e-5d92-4655-a0ce-a7bbe0044e67", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a37f6d614ba6c866b525bc57f54d512d14dd72c8762cff21f8dcf9285f204612", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "066bad57-a56b-433e-8fce-4387dddfcbce", "node_type": "1", "metadata": {"window": "Our UK retail business performance was impacted primarily by temporary -wide NHS underfunding, which we \nbelieve should improve in the second half; and to a lesser extent, volume weakness.  Performance in the other \nEuropean countries was not enough to fully offset these challenges.  Britt will speak to the expected full year \nimpact. \n \n Before I address the NHS more specifically, let me remind you of the actions we've previously taken in the UK \nand across Europe to reposition the business for long -term profitability.  With new leadership at the helm, we're \nmaking solid progress towar ds further rationalizing our store footprint and streamlining our back -office functions, \nand we continue to evaluate our cost structure as we do in all our businesses.  \n \n Turning back to the NHS, we're pleased by recent announcements, first, to increase the retail tariff beginning in \nAugust, and we would expect to see further upward revisions in tariff later in the year which should make up \npartially for any underfunding.  The NHS also announced a new five -year community pharmacy contractual \nframework. ", "original_text": "Before I address the NHS more specifically, let me remind you of the actions we've previously taken in the UK \nand across Europe to reposition the business for long -term profitability. ", "page_label": "4", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "906e17e138b12773f916e48fceeb50c5057582136cccba9e3f1dfcdfdfd3fa79", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a9fbeda9-d3f2-4f1e-bdae-65b47d387e3d", "node_type": "1", "metadata": {"window": "Britt will speak to the expected full year \nimpact. \n \n Before I address the NHS more specifically, let me remind you of the actions we've previously taken in the UK \nand across Europe to reposition the business for long -term profitability.  With new leadership at the helm, we're \nmaking solid progress towar ds further rationalizing our store footprint and streamlining our back -office functions, \nand we continue to evaluate our cost structure as we do in all our businesses.  \n \n Turning back to the NHS, we're pleased by recent announcements, first, to increase the retail tariff beginning in \nAugust, and we would expect to see further upward revisions in tariff later in the year which should make up \npartially for any underfunding.  The NHS also announced a new five -year community pharmacy contractual \nframework.  This fr amework brings greater clarity and long -term certainty by maintaining the current level of \nindustry funding for community pharmacies for the next five years.  \n \n While certain elements of the funding allocation are yet to be fully defined and could evolve ove r the five -year time \nhorizon, we view this as an incrementally positive development for our European business. ", "original_text": "Turning back to the NHS, we're pleased by recent announcements, first, to increase the retail tariff beginning in \nAugust, and we would expect to see further upward revisions in tariff later in the year which should make up \npartially for any underfunding. "}, "hash": "8276ce25ebfc4ba3b9b51e775d5875d95fbc67f7ef88f25b75e3ccee4dac38c6", "class_name": "RelatedNodeInfo"}}, "text": "With new leadership at the helm, we're \nmaking solid progress towar ds further rationalizing our store footprint and streamlining our back -office functions, \nand we continue to evaluate our cost structure as we do in all our businesses.  \n \n", "start_char_idx": 1056, "end_char_idx": 1298, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a9fbeda9-d3f2-4f1e-bdae-65b47d387e3d": {"__data__": {"id_": "a9fbeda9-d3f2-4f1e-bdae-65b47d387e3d", "embedding": null, "metadata": {"window": "Britt will speak to the expected full year \nimpact. \n \n Before I address the NHS more specifically, let me remind you of the actions we've previously taken in the UK \nand across Europe to reposition the business for long -term profitability.  With new leadership at the helm, we're \nmaking solid progress towar ds further rationalizing our store footprint and streamlining our back -office functions, \nand we continue to evaluate our cost structure as we do in all our businesses.  \n \n Turning back to the NHS, we're pleased by recent announcements, first, to increase the retail tariff beginning in \nAugust, and we would expect to see further upward revisions in tariff later in the year which should make up \npartially for any underfunding.  The NHS also announced a new five -year community pharmacy contractual \nframework.  This fr amework brings greater clarity and long -term certainty by maintaining the current level of \nindustry funding for community pharmacies for the next five years.  \n \n While certain elements of the funding allocation are yet to be fully defined and could evolve ove r the five -year time \nhorizon, we view this as an incrementally positive development for our European business. ", "original_text": "Turning back to the NHS, we're pleased by recent announcements, first, to increase the retail tariff beginning in \nAugust, and we would expect to see further upward revisions in tariff later in the year which should make up \npartially for any underfunding. ", "page_label": "4", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bdb1c12e-5d92-4655-a0ce-a7bbe0044e67", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a37f6d614ba6c866b525bc57f54d512d14dd72c8762cff21f8dcf9285f204612", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4bc03c69-e4b8-4d53-84ab-9496f2cf992e", "node_type": "1", "metadata": {"window": "Performance in the other \nEuropean countries was not enough to fully offset these challenges.  Britt will speak to the expected full year \nimpact. \n \n Before I address the NHS more specifically, let me remind you of the actions we've previously taken in the UK \nand across Europe to reposition the business for long -term profitability.  With new leadership at the helm, we're \nmaking solid progress towar ds further rationalizing our store footprint and streamlining our back -office functions, \nand we continue to evaluate our cost structure as we do in all our businesses.  \n \n Turning back to the NHS, we're pleased by recent announcements, first, to increase the retail tariff beginning in \nAugust, and we would expect to see further upward revisions in tariff later in the year which should make up \npartially for any underfunding.  The NHS also announced a new five -year community pharmacy contractual \nframework.  This fr amework brings greater clarity and long -term certainty by maintaining the current level of \nindustry funding for community pharmacies for the next five years.  \n \n", "original_text": "With new leadership at the helm, we're \nmaking solid progress towar ds further rationalizing our store footprint and streamlining our back -office functions, \nand we continue to evaluate our cost structure as we do in all our businesses.  \n \n", "page_label": "4", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7611768f1e66c8c308f952f97e2b80a5e87fe9e7ea27fd11e96ad417845da6e6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5c2ff04f-d323-48d2-91d4-09ca737c6794", "node_type": "1", "metadata": {"window": "Before I address the NHS more specifically, let me remind you of the actions we've previously taken in the UK \nand across Europe to reposition the business for long -term profitability.  With new leadership at the helm, we're \nmaking solid progress towar ds further rationalizing our store footprint and streamlining our back -office functions, \nand we continue to evaluate our cost structure as we do in all our businesses.  \n \n Turning back to the NHS, we're pleased by recent announcements, first, to increase the retail tariff beginning in \nAugust, and we would expect to see further upward revisions in tariff later in the year which should make up \npartially for any underfunding.  The NHS also announced a new five -year community pharmacy contractual \nframework.  This fr amework brings greater clarity and long -term certainty by maintaining the current level of \nindustry funding for community pharmacies for the next five years.  \n \n While certain elements of the funding allocation are yet to be fully defined and could evolve ove r the five -year time \nhorizon, we view this as an incrementally positive development for our European business.  McKesson remains \nactive in its support of and direct discussions with the UK government on the future of community pharmacy and \nhealth care in th e UK.  \n \n", "original_text": "The NHS also announced a new five -year community pharmacy contractual \nframework. "}, "hash": "2f3236cd95cea2f2f9e01d87db86efb838cc726b0ffc8915d3c33120c09ad99e", "class_name": "RelatedNodeInfo"}}, "text": "Turning back to the NHS, we're pleased by recent announcements, first, to increase the retail tariff beginning in \nAugust, and we would expect to see further upward revisions in tariff later in the year which should make up \npartially for any underfunding. ", "start_char_idx": 1298, "end_char_idx": 1555, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5c2ff04f-d323-48d2-91d4-09ca737c6794": {"__data__": {"id_": "5c2ff04f-d323-48d2-91d4-09ca737c6794", "embedding": null, "metadata": {"window": "Before I address the NHS more specifically, let me remind you of the actions we've previously taken in the UK \nand across Europe to reposition the business for long -term profitability.  With new leadership at the helm, we're \nmaking solid progress towar ds further rationalizing our store footprint and streamlining our back -office functions, \nand we continue to evaluate our cost structure as we do in all our businesses.  \n \n Turning back to the NHS, we're pleased by recent announcements, first, to increase the retail tariff beginning in \nAugust, and we would expect to see further upward revisions in tariff later in the year which should make up \npartially for any underfunding.  The NHS also announced a new five -year community pharmacy contractual \nframework.  This fr amework brings greater clarity and long -term certainty by maintaining the current level of \nindustry funding for community pharmacies for the next five years.  \n \n While certain elements of the funding allocation are yet to be fully defined and could evolve ove r the five -year time \nhorizon, we view this as an incrementally positive development for our European business.  McKesson remains \nactive in its support of and direct discussions with the UK government on the future of community pharmacy and \nhealth care in th e UK.  \n \n", "original_text": "The NHS also announced a new five -year community pharmacy contractual \nframework. ", "page_label": "4", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bdb1c12e-5d92-4655-a0ce-a7bbe0044e67", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a37f6d614ba6c866b525bc57f54d512d14dd72c8762cff21f8dcf9285f204612", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a9fbeda9-d3f2-4f1e-bdae-65b47d387e3d", "node_type": "1", "metadata": {"window": "Britt will speak to the expected full year \nimpact. \n \n Before I address the NHS more specifically, let me remind you of the actions we've previously taken in the UK \nand across Europe to reposition the business for long -term profitability.  With new leadership at the helm, we're \nmaking solid progress towar ds further rationalizing our store footprint and streamlining our back -office functions, \nand we continue to evaluate our cost structure as we do in all our businesses.  \n \n Turning back to the NHS, we're pleased by recent announcements, first, to increase the retail tariff beginning in \nAugust, and we would expect to see further upward revisions in tariff later in the year which should make up \npartially for any underfunding.  The NHS also announced a new five -year community pharmacy contractual \nframework.  This fr amework brings greater clarity and long -term certainty by maintaining the current level of \nindustry funding for community pharmacies for the next five years.  \n \n While certain elements of the funding allocation are yet to be fully defined and could evolve ove r the five -year time \nhorizon, we view this as an incrementally positive development for our European business. ", "original_text": "Turning back to the NHS, we're pleased by recent announcements, first, to increase the retail tariff beginning in \nAugust, and we would expect to see further upward revisions in tariff later in the year which should make up \npartially for any underfunding. ", "page_label": "4", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c8e9c1ef373bcbf940853c189815387a458eee9b5263db2c04c38efb48f36c01", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8b4829b8-3b18-46d4-ac7b-96f2c7771563", "node_type": "1", "metadata": {"window": "With new leadership at the helm, we're \nmaking solid progress towar ds further rationalizing our store footprint and streamlining our back -office functions, \nand we continue to evaluate our cost structure as we do in all our businesses.  \n \n Turning back to the NHS, we're pleased by recent announcements, first, to increase the retail tariff beginning in \nAugust, and we would expect to see further upward revisions in tariff later in the year which should make up \npartially for any underfunding.  The NHS also announced a new five -year community pharmacy contractual \nframework.  This fr amework brings greater clarity and long -term certainty by maintaining the current level of \nindustry funding for community pharmacies for the next five years.  \n \n While certain elements of the funding allocation are yet to be fully defined and could evolve ove r the five -year time \nhorizon, we view this as an incrementally positive development for our European business.  McKesson remains \nactive in its support of and direct discussions with the UK government on the future of community pharmacy and \nhealth care in th e UK.  \n \n Turning to Med -Surg. ", "original_text": "This fr amework brings greater clarity and long -term certainty by maintaining the current level of \nindustry funding for community pharmacies for the next five years.  \n \n"}, "hash": "d75ec00bdccf47799df7c0e1cad18e0c8368a5a922aa7f508689ac89c62e23db", "class_name": "RelatedNodeInfo"}}, "text": "The NHS also announced a new five -year community pharmacy contractual \nframework. ", "start_char_idx": 1555, "end_char_idx": 1638, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8b4829b8-3b18-46d4-ac7b-96f2c7771563": {"__data__": {"id_": "8b4829b8-3b18-46d4-ac7b-96f2c7771563", "embedding": null, "metadata": {"window": "With new leadership at the helm, we're \nmaking solid progress towar ds further rationalizing our store footprint and streamlining our back -office functions, \nand we continue to evaluate our cost structure as we do in all our businesses.  \n \n Turning back to the NHS, we're pleased by recent announcements, first, to increase the retail tariff beginning in \nAugust, and we would expect to see further upward revisions in tariff later in the year which should make up \npartially for any underfunding.  The NHS also announced a new five -year community pharmacy contractual \nframework.  This fr amework brings greater clarity and long -term certainty by maintaining the current level of \nindustry funding for community pharmacies for the next five years.  \n \n While certain elements of the funding allocation are yet to be fully defined and could evolve ove r the five -year time \nhorizon, we view this as an incrementally positive development for our European business.  McKesson remains \nactive in its support of and direct discussions with the UK government on the future of community pharmacy and \nhealth care in th e UK.  \n \n Turning to Med -Surg. ", "original_text": "This fr amework brings greater clarity and long -term certainty by maintaining the current level of \nindustry funding for community pharmacies for the next five years.  \n \n", "page_label": "4", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bdb1c12e-5d92-4655-a0ce-a7bbe0044e67", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a37f6d614ba6c866b525bc57f54d512d14dd72c8762cff21f8dcf9285f204612", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5c2ff04f-d323-48d2-91d4-09ca737c6794", "node_type": "1", "metadata": {"window": "Before I address the NHS more specifically, let me remind you of the actions we've previously taken in the UK \nand across Europe to reposition the business for long -term profitability.  With new leadership at the helm, we're \nmaking solid progress towar ds further rationalizing our store footprint and streamlining our back -office functions, \nand we continue to evaluate our cost structure as we do in all our businesses.  \n \n Turning back to the NHS, we're pleased by recent announcements, first, to increase the retail tariff beginning in \nAugust, and we would expect to see further upward revisions in tariff later in the year which should make up \npartially for any underfunding.  The NHS also announced a new five -year community pharmacy contractual \nframework.  This fr amework brings greater clarity and long -term certainty by maintaining the current level of \nindustry funding for community pharmacies for the next five years.  \n \n While certain elements of the funding allocation are yet to be fully defined and could evolve ove r the five -year time \nhorizon, we view this as an incrementally positive development for our European business.  McKesson remains \nactive in its support of and direct discussions with the UK government on the future of community pharmacy and \nhealth care in th e UK.  \n \n", "original_text": "The NHS also announced a new five -year community pharmacy contractual \nframework. ", "page_label": "4", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9137e6cddbdf645ea9d9163ee88322645d4dd993b2b217d92f0919e6053f5627", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6eb55a15-dab4-4ecd-9dc4-3c438e9911df", "node_type": "1", "metadata": {"window": "Turning back to the NHS, we're pleased by recent announcements, first, to increase the retail tariff beginning in \nAugust, and we would expect to see further upward revisions in tariff later in the year which should make up \npartially for any underfunding.  The NHS also announced a new five -year community pharmacy contractual \nframework.  This fr amework brings greater clarity and long -term certainty by maintaining the current level of \nindustry funding for community pharmacies for the next five years.  \n \n While certain elements of the funding allocation are yet to be fully defined and could evolve ove r the five -year time \nhorizon, we view this as an incrementally positive development for our European business.  McKesson remains \nactive in its support of and direct discussions with the UK government on the future of community pharmacy and \nhealth care in th e UK.  \n \n Turning to Med -Surg.  Our Medical -Surgical business continues to generate above -market, strong organic growth \nwith its focus on delivering care in low -cost patient settings, and we have now lapped the Medical Specialties \nDistributor, or MSD, acquisit ion which is delivering results in line with our expectations. ", "original_text": "While certain elements of the funding allocation are yet to be fully defined and could evolve ove r the five -year time \nhorizon, we view this as an incrementally positive development for our European business. "}, "hash": "b6001f6db64d54045926a7cb392953b08602d0e1dcca9a432d1f290df8ac1cc0", "class_name": "RelatedNodeInfo"}}, "text": "This fr amework brings greater clarity and long -term certainty by maintaining the current level of \nindustry funding for community pharmacies for the next five years.  \n \n", "start_char_idx": 1638, "end_char_idx": 1810, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6eb55a15-dab4-4ecd-9dc4-3c438e9911df": {"__data__": {"id_": "6eb55a15-dab4-4ecd-9dc4-3c438e9911df", "embedding": null, "metadata": {"window": "Turning back to the NHS, we're pleased by recent announcements, first, to increase the retail tariff beginning in \nAugust, and we would expect to see further upward revisions in tariff later in the year which should make up \npartially for any underfunding.  The NHS also announced a new five -year community pharmacy contractual \nframework.  This fr amework brings greater clarity and long -term certainty by maintaining the current level of \nindustry funding for community pharmacies for the next five years.  \n \n While certain elements of the funding allocation are yet to be fully defined and could evolve ove r the five -year time \nhorizon, we view this as an incrementally positive development for our European business.  McKesson remains \nactive in its support of and direct discussions with the UK government on the future of community pharmacy and \nhealth care in th e UK.  \n \n Turning to Med -Surg.  Our Medical -Surgical business continues to generate above -market, strong organic growth \nwith its focus on delivering care in low -cost patient settings, and we have now lapped the Medical Specialties \nDistributor, or MSD, acquisit ion which is delivering results in line with our expectations. ", "original_text": "While certain elements of the funding allocation are yet to be fully defined and could evolve ove r the five -year time \nhorizon, we view this as an incrementally positive development for our European business. ", "page_label": "4", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bdb1c12e-5d92-4655-a0ce-a7bbe0044e67", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a37f6d614ba6c866b525bc57f54d512d14dd72c8762cff21f8dcf9285f204612", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8b4829b8-3b18-46d4-ac7b-96f2c7771563", "node_type": "1", "metadata": {"window": "With new leadership at the helm, we're \nmaking solid progress towar ds further rationalizing our store footprint and streamlining our back -office functions, \nand we continue to evaluate our cost structure as we do in all our businesses.  \n \n Turning back to the NHS, we're pleased by recent announcements, first, to increase the retail tariff beginning in \nAugust, and we would expect to see further upward revisions in tariff later in the year which should make up \npartially for any underfunding.  The NHS also announced a new five -year community pharmacy contractual \nframework.  This fr amework brings greater clarity and long -term certainty by maintaining the current level of \nindustry funding for community pharmacies for the next five years.  \n \n While certain elements of the funding allocation are yet to be fully defined and could evolve ove r the five -year time \nhorizon, we view this as an incrementally positive development for our European business.  McKesson remains \nactive in its support of and direct discussions with the UK government on the future of community pharmacy and \nhealth care in th e UK.  \n \n Turning to Med -Surg. ", "original_text": "This fr amework brings greater clarity and long -term certainty by maintaining the current level of \nindustry funding for community pharmacies for the next five years.  \n \n", "page_label": "4", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "21840d98267a3fe9e80578f2d895adb314e3f8093aa6253e6a80141f56165f5e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7e737d75-e56b-4e89-ae11-0684ad8abe86", "node_type": "1", "metadata": {"window": "The NHS also announced a new five -year community pharmacy contractual \nframework.  This fr amework brings greater clarity and long -term certainty by maintaining the current level of \nindustry funding for community pharmacies for the next five years.  \n \n While certain elements of the funding allocation are yet to be fully defined and could evolve ove r the five -year time \nhorizon, we view this as an incrementally positive development for our European business.  McKesson remains \nactive in its support of and direct discussions with the UK government on the future of community pharmacy and \nhealth care in th e UK.  \n \n Turning to Med -Surg.  Our Medical -Surgical business continues to generate above -market, strong organic growth \nwith its focus on delivering care in low -cost patient settings, and we have now lapped the Medical Specialties \nDistributor, or MSD, acquisit ion which is delivering results in line with our expectations.  We saw good growth \nacross multiple markets and product categories including lab, pharmaceutical and McKesson private label. ", "original_text": "McKesson remains \nactive in its support of and direct discussions with the UK government on the future of community pharmacy and \nhealth care in th e UK.  \n \n"}, "hash": "5ff210338824dd3eb1e1aa4a95f162fd2e83403fad83481fe0fefccc1a094e7f", "class_name": "RelatedNodeInfo"}}, "text": "While certain elements of the funding allocation are yet to be fully defined and could evolve ove r the five -year time \nhorizon, we view this as an incrementally positive development for our European business. ", "start_char_idx": 1810, "end_char_idx": 2021, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7e737d75-e56b-4e89-ae11-0684ad8abe86": {"__data__": {"id_": "7e737d75-e56b-4e89-ae11-0684ad8abe86", "embedding": null, "metadata": {"window": "The NHS also announced a new five -year community pharmacy contractual \nframework.  This fr amework brings greater clarity and long -term certainty by maintaining the current level of \nindustry funding for community pharmacies for the next five years.  \n \n While certain elements of the funding allocation are yet to be fully defined and could evolve ove r the five -year time \nhorizon, we view this as an incrementally positive development for our European business.  McKesson remains \nactive in its support of and direct discussions with the UK government on the future of community pharmacy and \nhealth care in th e UK.  \n \n Turning to Med -Surg.  Our Medical -Surgical business continues to generate above -market, strong organic growth \nwith its focus on delivering care in low -cost patient settings, and we have now lapped the Medical Specialties \nDistributor, or MSD, acquisit ion which is delivering results in line with our expectations.  We saw good growth \nacross multiple markets and product categories including lab, pharmaceutical and McKesson private label. ", "original_text": "McKesson remains \nactive in its support of and direct discussions with the UK government on the future of community pharmacy and \nhealth care in th e UK.  \n \n", "page_label": "4", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bdb1c12e-5d92-4655-a0ce-a7bbe0044e67", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a37f6d614ba6c866b525bc57f54d512d14dd72c8762cff21f8dcf9285f204612", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6eb55a15-dab4-4ecd-9dc4-3c438e9911df", "node_type": "1", "metadata": {"window": "Turning back to the NHS, we're pleased by recent announcements, first, to increase the retail tariff beginning in \nAugust, and we would expect to see further upward revisions in tariff later in the year which should make up \npartially for any underfunding.  The NHS also announced a new five -year community pharmacy contractual \nframework.  This fr amework brings greater clarity and long -term certainty by maintaining the current level of \nindustry funding for community pharmacies for the next five years.  \n \n While certain elements of the funding allocation are yet to be fully defined and could evolve ove r the five -year time \nhorizon, we view this as an incrementally positive development for our European business.  McKesson remains \nactive in its support of and direct discussions with the UK government on the future of community pharmacy and \nhealth care in th e UK.  \n \n Turning to Med -Surg.  Our Medical -Surgical business continues to generate above -market, strong organic growth \nwith its focus on delivering care in low -cost patient settings, and we have now lapped the Medical Specialties \nDistributor, or MSD, acquisit ion which is delivering results in line with our expectations. ", "original_text": "While certain elements of the funding allocation are yet to be fully defined and could evolve ove r the five -year time \nhorizon, we view this as an incrementally positive development for our European business. ", "page_label": "4", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "05b43d95b45829629b62a545df0c33354f9de2bd472115a93c2a71346635ef5a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "57cd1e23-7774-470c-8a8b-bd7ba510b206", "node_type": "1", "metadata": {"window": "This fr amework brings greater clarity and long -term certainty by maintaining the current level of \nindustry funding for community pharmacies for the next five years.  \n \n While certain elements of the funding allocation are yet to be fully defined and could evolve ove r the five -year time \nhorizon, we view this as an incrementally positive development for our European business.  McKesson remains \nactive in its support of and direct discussions with the UK government on the future of community pharmacy and \nhealth care in th e UK.  \n \n Turning to Med -Surg.  Our Medical -Surgical business continues to generate above -market, strong organic growth \nwith its focus on delivering care in low -cost patient settings, and we have now lapped the Medical Specialties \nDistributor, or MSD, acquisit ion which is delivering results in line with our expectations.  We saw good growth \nacross multiple markets and product categories including lab, pharmaceutical and McKesson private label.  The \nnon-acute space continues to be an encouraging area for us.  \n \n", "original_text": "Turning to Med -Surg. "}, "hash": "ee84d81153d99a6b8641ae123c47e0089dd788f1d006b7adddf29db5f93f497f", "class_name": "RelatedNodeInfo"}}, "text": "McKesson remains \nactive in its support of and direct discussions with the UK government on the future of community pharmacy and \nhealth care in th e UK.  \n \n", "start_char_idx": 2021, "end_char_idx": 2179, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "57cd1e23-7774-470c-8a8b-bd7ba510b206": {"__data__": {"id_": "57cd1e23-7774-470c-8a8b-bd7ba510b206", "embedding": null, "metadata": {"window": "This fr amework brings greater clarity and long -term certainty by maintaining the current level of \nindustry funding for community pharmacies for the next five years.  \n \n While certain elements of the funding allocation are yet to be fully defined and could evolve ove r the five -year time \nhorizon, we view this as an incrementally positive development for our European business.  McKesson remains \nactive in its support of and direct discussions with the UK government on the future of community pharmacy and \nhealth care in th e UK.  \n \n Turning to Med -Surg.  Our Medical -Surgical business continues to generate above -market, strong organic growth \nwith its focus on delivering care in low -cost patient settings, and we have now lapped the Medical Specialties \nDistributor, or MSD, acquisit ion which is delivering results in line with our expectations.  We saw good growth \nacross multiple markets and product categories including lab, pharmaceutical and McKesson private label.  The \nnon-acute space continues to be an encouraging area for us.  \n \n", "original_text": "Turning to Med -Surg. ", "page_label": "4", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bdb1c12e-5d92-4655-a0ce-a7bbe0044e67", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a37f6d614ba6c866b525bc57f54d512d14dd72c8762cff21f8dcf9285f204612", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7e737d75-e56b-4e89-ae11-0684ad8abe86", "node_type": "1", "metadata": {"window": "The NHS also announced a new five -year community pharmacy contractual \nframework.  This fr amework brings greater clarity and long -term certainty by maintaining the current level of \nindustry funding for community pharmacies for the next five years.  \n \n While certain elements of the funding allocation are yet to be fully defined and could evolve ove r the five -year time \nhorizon, we view this as an incrementally positive development for our European business.  McKesson remains \nactive in its support of and direct discussions with the UK government on the future of community pharmacy and \nhealth care in th e UK.  \n \n Turning to Med -Surg.  Our Medical -Surgical business continues to generate above -market, strong organic growth \nwith its focus on delivering care in low -cost patient settings, and we have now lapped the Medical Specialties \nDistributor, or MSD, acquisit ion which is delivering results in line with our expectations.  We saw good growth \nacross multiple markets and product categories including lab, pharmaceutical and McKesson private label. ", "original_text": "McKesson remains \nactive in its support of and direct discussions with the UK government on the future of community pharmacy and \nhealth care in th e UK.  \n \n", "page_label": "4", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "976ce0bc336ef32dc95525232080d17927b1ee4326eca160fa3a628d74bf62c5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8d2f9994-83e2-47a8-8f00-54240a431d37", "node_type": "1", "metadata": {"window": "While certain elements of the funding allocation are yet to be fully defined and could evolve ove r the five -year time \nhorizon, we view this as an incrementally positive development for our European business.  McKesson remains \nactive in its support of and direct discussions with the UK government on the future of community pharmacy and \nhealth care in th e UK.  \n \n Turning to Med -Surg.  Our Medical -Surgical business continues to generate above -market, strong organic growth \nwith its focus on delivering care in low -cost patient settings, and we have now lapped the Medical Specialties \nDistributor, or MSD, acquisit ion which is delivering results in line with our expectations.  We saw good growth \nacross multiple markets and product categories including lab, pharmaceutical and McKesson private label.  The \nnon-acute space continues to be an encouraging area for us.  \n \n Like others in health care, we continue to see care shift to these non -acute settings where we currently operate. \n", "original_text": "Our Medical -Surgical business continues to generate above -market, strong organic growth \nwith its focus on delivering care in low -cost patient settings, and we have now lapped the Medical Specialties \nDistributor, or MSD, acquisit ion which is delivering results in line with our expectations. "}, "hash": "006adeb7230572f2582c2ed76156f02fa1d120e24f173729f792f0260e10bebe", "class_name": "RelatedNodeInfo"}}, "text": "Turning to Med -Surg. ", "start_char_idx": 2179, "end_char_idx": 2201, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8d2f9994-83e2-47a8-8f00-54240a431d37": {"__data__": {"id_": "8d2f9994-83e2-47a8-8f00-54240a431d37", "embedding": null, "metadata": {"window": "While certain elements of the funding allocation are yet to be fully defined and could evolve ove r the five -year time \nhorizon, we view this as an incrementally positive development for our European business.  McKesson remains \nactive in its support of and direct discussions with the UK government on the future of community pharmacy and \nhealth care in th e UK.  \n \n Turning to Med -Surg.  Our Medical -Surgical business continues to generate above -market, strong organic growth \nwith its focus on delivering care in low -cost patient settings, and we have now lapped the Medical Specialties \nDistributor, or MSD, acquisit ion which is delivering results in line with our expectations.  We saw good growth \nacross multiple markets and product categories including lab, pharmaceutical and McKesson private label.  The \nnon-acute space continues to be an encouraging area for us.  \n \n Like others in health care, we continue to see care shift to these non -acute settings where we currently operate. \n", "original_text": "Our Medical -Surgical business continues to generate above -market, strong organic growth \nwith its focus on delivering care in low -cost patient settings, and we have now lapped the Medical Specialties \nDistributor, or MSD, acquisit ion which is delivering results in line with our expectations. ", "page_label": "4", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bdb1c12e-5d92-4655-a0ce-a7bbe0044e67", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a37f6d614ba6c866b525bc57f54d512d14dd72c8762cff21f8dcf9285f204612", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "57cd1e23-7774-470c-8a8b-bd7ba510b206", "node_type": "1", "metadata": {"window": "This fr amework brings greater clarity and long -term certainty by maintaining the current level of \nindustry funding for community pharmacies for the next five years.  \n \n While certain elements of the funding allocation are yet to be fully defined and could evolve ove r the five -year time \nhorizon, we view this as an incrementally positive development for our European business.  McKesson remains \nactive in its support of and direct discussions with the UK government on the future of community pharmacy and \nhealth care in th e UK.  \n \n Turning to Med -Surg.  Our Medical -Surgical business continues to generate above -market, strong organic growth \nwith its focus on delivering care in low -cost patient settings, and we have now lapped the Medical Specialties \nDistributor, or MSD, acquisit ion which is delivering results in line with our expectations.  We saw good growth \nacross multiple markets and product categories including lab, pharmaceutical and McKesson private label.  The \nnon-acute space continues to be an encouraging area for us.  \n \n", "original_text": "Turning to Med -Surg. ", "page_label": "4", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d7223f0ae20f00c5c64bf30afc3c62e3fcfa87ff9edd4c8fb9d7bd151eb52bff", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3944dc64-9e91-4729-99b5-9ef44d1f01c6", "node_type": "1", "metadata": {"window": "McKesson remains \nactive in its support of and direct discussions with the UK government on the future of community pharmacy and \nhealth care in th e UK.  \n \n Turning to Med -Surg.  Our Medical -Surgical business continues to generate above -market, strong organic growth \nwith its focus on delivering care in low -cost patient settings, and we have now lapped the Medical Specialties \nDistributor, or MSD, acquisit ion which is delivering results in line with our expectations.  We saw good growth \nacross multiple markets and product categories including lab, pharmaceutical and McKesson private label.  The \nnon-acute space continues to be an encouraging area for us.  \n \n Like others in health care, we continue to see care shift to these non -acute settings where we currently operate. \n With investments such as MSD and our new technology in our distribution centers, we're continuing to expand our \nservices to these providers and to  their patients.  \n \n", "original_text": "We saw good growth \nacross multiple markets and product categories including lab, pharmaceutical and McKesson private label. "}, "hash": "3aa146c6c2e9e04590583283ba98ecd96b93cd3add51e3d172e9fa49980ad432", "class_name": "RelatedNodeInfo"}}, "text": "Our Medical -Surgical business continues to generate above -market, strong organic growth \nwith its focus on delivering care in low -cost patient settings, and we have now lapped the Medical Specialties \nDistributor, or MSD, acquisit ion which is delivering results in line with our expectations. ", "start_char_idx": 2201, "end_char_idx": 2498, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3944dc64-9e91-4729-99b5-9ef44d1f01c6": {"__data__": {"id_": "3944dc64-9e91-4729-99b5-9ef44d1f01c6", "embedding": null, "metadata": {"window": "McKesson remains \nactive in its support of and direct discussions with the UK government on the future of community pharmacy and \nhealth care in th e UK.  \n \n Turning to Med -Surg.  Our Medical -Surgical business continues to generate above -market, strong organic growth \nwith its focus on delivering care in low -cost patient settings, and we have now lapped the Medical Specialties \nDistributor, or MSD, acquisit ion which is delivering results in line with our expectations.  We saw good growth \nacross multiple markets and product categories including lab, pharmaceutical and McKesson private label.  The \nnon-acute space continues to be an encouraging area for us.  \n \n Like others in health care, we continue to see care shift to these non -acute settings where we currently operate. \n With investments such as MSD and our new technology in our distribution centers, we're continuing to expand our \nservices to these providers and to  their patients.  \n \n", "original_text": "We saw good growth \nacross multiple markets and product categories including lab, pharmaceutical and McKesson private label. ", "page_label": "4", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bdb1c12e-5d92-4655-a0ce-a7bbe0044e67", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a37f6d614ba6c866b525bc57f54d512d14dd72c8762cff21f8dcf9285f204612", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8d2f9994-83e2-47a8-8f00-54240a431d37", "node_type": "1", "metadata": {"window": "While certain elements of the funding allocation are yet to be fully defined and could evolve ove r the five -year time \nhorizon, we view this as an incrementally positive development for our European business.  McKesson remains \nactive in its support of and direct discussions with the UK government on the future of community pharmacy and \nhealth care in th e UK.  \n \n Turning to Med -Surg.  Our Medical -Surgical business continues to generate above -market, strong organic growth \nwith its focus on delivering care in low -cost patient settings, and we have now lapped the Medical Specialties \nDistributor, or MSD, acquisit ion which is delivering results in line with our expectations.  We saw good growth \nacross multiple markets and product categories including lab, pharmaceutical and McKesson private label.  The \nnon-acute space continues to be an encouraging area for us.  \n \n Like others in health care, we continue to see care shift to these non -acute settings where we currently operate. \n", "original_text": "Our Medical -Surgical business continues to generate above -market, strong organic growth \nwith its focus on delivering care in low -cost patient settings, and we have now lapped the Medical Specialties \nDistributor, or MSD, acquisit ion which is delivering results in line with our expectations. ", "page_label": "4", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1be76fecd922aba0ba36fb4d4bdb5af9b5a8d7e9cc7c6733c5f17ae19d3baf34", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cfa28579-ab4a-4fee-873f-1e7a317ff886", "node_type": "1", "metadata": {"window": "Turning to Med -Surg.  Our Medical -Surgical business continues to generate above -market, strong organic growth \nwith its focus on delivering care in low -cost patient settings, and we have now lapped the Medical Specialties \nDistributor, or MSD, acquisit ion which is delivering results in line with our expectations.  We saw good growth \nacross multiple markets and product categories including lab, pharmaceutical and McKesson private label.  The \nnon-acute space continues to be an encouraging area for us.  \n \n Like others in health care, we continue to see care shift to these non -acute settings where we currently operate. \n With investments such as MSD and our new technology in our distribution centers, we're continuing to expand our \nservices to these providers and to  their patients.  \n \n Turning to the Other segment which primarily consists of Canada, McKesson Prescription Technology Solutions, \nor MRxTS, and our investment in Change Healthcare. ", "original_text": "The \nnon-acute space continues to be an encouraging area for us.  \n \n"}, "hash": "297c5035968ae5cc102753f4b35a93afeb23cbb8761fc5a126a8b24c8ae2592c", "class_name": "RelatedNodeInfo"}}, "text": "We saw good growth \nacross multiple markets and product categories including lab, pharmaceutical and McKesson private label. ", "start_char_idx": 2498, "end_char_idx": 2623, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cfa28579-ab4a-4fee-873f-1e7a317ff886": {"__data__": {"id_": "cfa28579-ab4a-4fee-873f-1e7a317ff886", "embedding": null, "metadata": {"window": "Turning to Med -Surg.  Our Medical -Surgical business continues to generate above -market, strong organic growth \nwith its focus on delivering care in low -cost patient settings, and we have now lapped the Medical Specialties \nDistributor, or MSD, acquisit ion which is delivering results in line with our expectations.  We saw good growth \nacross multiple markets and product categories including lab, pharmaceutical and McKesson private label.  The \nnon-acute space continues to be an encouraging area for us.  \n \n Like others in health care, we continue to see care shift to these non -acute settings where we currently operate. \n With investments such as MSD and our new technology in our distribution centers, we're continuing to expand our \nservices to these providers and to  their patients.  \n \n Turning to the Other segment which primarily consists of Canada, McKesson Prescription Technology Solutions, \nor MRxTS, and our investment in Change Healthcare. ", "original_text": "The \nnon-acute space continues to be an encouraging area for us.  \n \n", "page_label": "4", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bdb1c12e-5d92-4655-a0ce-a7bbe0044e67", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a37f6d614ba6c866b525bc57f54d512d14dd72c8762cff21f8dcf9285f204612", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3944dc64-9e91-4729-99b5-9ef44d1f01c6", "node_type": "1", "metadata": {"window": "McKesson remains \nactive in its support of and direct discussions with the UK government on the future of community pharmacy and \nhealth care in th e UK.  \n \n Turning to Med -Surg.  Our Medical -Surgical business continues to generate above -market, strong organic growth \nwith its focus on delivering care in low -cost patient settings, and we have now lapped the Medical Specialties \nDistributor, or MSD, acquisit ion which is delivering results in line with our expectations.  We saw good growth \nacross multiple markets and product categories including lab, pharmaceutical and McKesson private label.  The \nnon-acute space continues to be an encouraging area for us.  \n \n Like others in health care, we continue to see care shift to these non -acute settings where we currently operate. \n With investments such as MSD and our new technology in our distribution centers, we're continuing to expand our \nservices to these providers and to  their patients.  \n \n", "original_text": "We saw good growth \nacross multiple markets and product categories including lab, pharmaceutical and McKesson private label. ", "page_label": "4", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a06edf6f7f2887ce28fbc8cd30938b732fc8d5edefbc7ff38de74f4ed7953495", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2181b13a-7841-4233-bd5b-240511f0bd06", "node_type": "1", "metadata": {"window": "Our Medical -Surgical business continues to generate above -market, strong organic growth \nwith its focus on delivering care in low -cost patient settings, and we have now lapped the Medical Specialties \nDistributor, or MSD, acquisit ion which is delivering results in line with our expectations.  We saw good growth \nacross multiple markets and product categories including lab, pharmaceutical and McKesson private label.  The \nnon-acute space continues to be an encouraging area for us.  \n \n Like others in health care, we continue to see care shift to these non -acute settings where we currently operate. \n With investments such as MSD and our new technology in our distribution centers, we're continuing to expand our \nservices to these providers and to  their patients.  \n \n Turning to the Other segment which primarily consists of Canada, McKesson Prescription Technology Solutions, \nor MRxTS, and our investment in Change Healthcare.  We see improving prescription trends in our owned \nCanadian retail business, wh ich reflects our focus on the retail customer experience. ", "original_text": "Like others in health care, we continue to see care shift to these non -acute settings where we currently operate. \n"}, "hash": "5524c791d798c4d402c6123ee9906917013b65c6a96f6c05bf4eade41224bb29", "class_name": "RelatedNodeInfo"}}, "text": "The \nnon-acute space continues to be an encouraging area for us.  \n \n", "start_char_idx": 2623, "end_char_idx": 2692, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2181b13a-7841-4233-bd5b-240511f0bd06": {"__data__": {"id_": "2181b13a-7841-4233-bd5b-240511f0bd06", "embedding": null, "metadata": {"window": "Our Medical -Surgical business continues to generate above -market, strong organic growth \nwith its focus on delivering care in low -cost patient settings, and we have now lapped the Medical Specialties \nDistributor, or MSD, acquisit ion which is delivering results in line with our expectations.  We saw good growth \nacross multiple markets and product categories including lab, pharmaceutical and McKesson private label.  The \nnon-acute space continues to be an encouraging area for us.  \n \n Like others in health care, we continue to see care shift to these non -acute settings where we currently operate. \n With investments such as MSD and our new technology in our distribution centers, we're continuing to expand our \nservices to these providers and to  their patients.  \n \n Turning to the Other segment which primarily consists of Canada, McKesson Prescription Technology Solutions, \nor MRxTS, and our investment in Change Healthcare.  We see improving prescription trends in our owned \nCanadian retail business, wh ich reflects our focus on the retail customer experience. ", "original_text": "Like others in health care, we continue to see care shift to these non -acute settings where we currently operate. \n", "page_label": "4", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bdb1c12e-5d92-4655-a0ce-a7bbe0044e67", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a37f6d614ba6c866b525bc57f54d512d14dd72c8762cff21f8dcf9285f204612", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cfa28579-ab4a-4fee-873f-1e7a317ff886", "node_type": "1", "metadata": {"window": "Turning to Med -Surg.  Our Medical -Surgical business continues to generate above -market, strong organic growth \nwith its focus on delivering care in low -cost patient settings, and we have now lapped the Medical Specialties \nDistributor, or MSD, acquisit ion which is delivering results in line with our expectations.  We saw good growth \nacross multiple markets and product categories including lab, pharmaceutical and McKesson private label.  The \nnon-acute space continues to be an encouraging area for us.  \n \n Like others in health care, we continue to see care shift to these non -acute settings where we currently operate. \n With investments such as MSD and our new technology in our distribution centers, we're continuing to expand our \nservices to these providers and to  their patients.  \n \n Turning to the Other segment which primarily consists of Canada, McKesson Prescription Technology Solutions, \nor MRxTS, and our investment in Change Healthcare. ", "original_text": "The \nnon-acute space continues to be an encouraging area for us.  \n \n", "page_label": "4", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "82e3e9e929b91046a72a2a6ca7c15b7d72640ea09311e9ddd745fbe89fd4c036", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "789ec73e-ce22-4c6e-b2be-da716b1bf211", "node_type": "1", "metadata": {"window": "We saw good growth \nacross multiple markets and product categories including lab, pharmaceutical and McKesson private label.  The \nnon-acute space continues to be an encouraging area for us.  \n \n Like others in health care, we continue to see care shift to these non -acute settings where we currently operate. \n With investments such as MSD and our new technology in our distribution centers, we're continuing to expand our \nservices to these providers and to  their patients.  \n \n Turning to the Other segment which primarily consists of Canada, McKesson Prescription Technology Solutions, \nor MRxTS, and our investment in Change Healthcare.  We see improving prescription trends in our owned \nCanadian retail business, wh ich reflects our focus on the retail customer experience.  We've made investments in \npeople and in reconfigured pharmacy formats. ", "original_text": "With investments such as MSD and our new technology in our distribution centers, we're continuing to expand our \nservices to these providers and to  their patients.  \n \n"}, "hash": "4012b20fae3265d15d90caa512084c1544cc3157f214a3637e6e11786e72b7c3", "class_name": "RelatedNodeInfo"}}, "text": "Like others in health care, we continue to see care shift to these non -acute settings where we currently operate. \n", "start_char_idx": 2692, "end_char_idx": 2808, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "789ec73e-ce22-4c6e-b2be-da716b1bf211": {"__data__": {"id_": "789ec73e-ce22-4c6e-b2be-da716b1bf211", "embedding": null, "metadata": {"window": "We saw good growth \nacross multiple markets and product categories including lab, pharmaceutical and McKesson private label.  The \nnon-acute space continues to be an encouraging area for us.  \n \n Like others in health care, we continue to see care shift to these non -acute settings where we currently operate. \n With investments such as MSD and our new technology in our distribution centers, we're continuing to expand our \nservices to these providers and to  their patients.  \n \n Turning to the Other segment which primarily consists of Canada, McKesson Prescription Technology Solutions, \nor MRxTS, and our investment in Change Healthcare.  We see improving prescription trends in our owned \nCanadian retail business, wh ich reflects our focus on the retail customer experience.  We've made investments in \npeople and in reconfigured pharmacy formats. ", "original_text": "With investments such as MSD and our new technology in our distribution centers, we're continuing to expand our \nservices to these providers and to  their patients.  \n \n", "page_label": "4", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bdb1c12e-5d92-4655-a0ce-a7bbe0044e67", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a37f6d614ba6c866b525bc57f54d512d14dd72c8762cff21f8dcf9285f204612", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2181b13a-7841-4233-bd5b-240511f0bd06", "node_type": "1", "metadata": {"window": "Our Medical -Surgical business continues to generate above -market, strong organic growth \nwith its focus on delivering care in low -cost patient settings, and we have now lapped the Medical Specialties \nDistributor, or MSD, acquisit ion which is delivering results in line with our expectations.  We saw good growth \nacross multiple markets and product categories including lab, pharmaceutical and McKesson private label.  The \nnon-acute space continues to be an encouraging area for us.  \n \n Like others in health care, we continue to see care shift to these non -acute settings where we currently operate. \n With investments such as MSD and our new technology in our distribution centers, we're continuing to expand our \nservices to these providers and to  their patients.  \n \n Turning to the Other segment which primarily consists of Canada, McKesson Prescription Technology Solutions, \nor MRxTS, and our investment in Change Healthcare.  We see improving prescription trends in our owned \nCanadian retail business, wh ich reflects our focus on the retail customer experience. ", "original_text": "Like others in health care, we continue to see care shift to these non -acute settings where we currently operate. \n", "page_label": "4", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "09d070ba2412d9ae788df9609ec7b716800c6402a93e3d38ce53bdfbe17e5845", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "00dfda7b-15c7-4616-9fb9-150e804f4cfb", "node_type": "1", "metadata": {"window": "The \nnon-acute space continues to be an encouraging area for us.  \n \n Like others in health care, we continue to see care shift to these non -acute settings where we currently operate. \n With investments such as MSD and our new technology in our distribution centers, we're continuing to expand our \nservices to these providers and to  their patients.  \n \n Turning to the Other segment which primarily consists of Canada, McKesson Prescription Technology Solutions, \nor MRxTS, and our investment in Change Healthcare.  We see improving prescription trends in our owned \nCanadian retail business, wh ich reflects our focus on the retail customer experience.  We've made investments in \npeople and in reconfigured pharmacy formats.  With strengthening fundamentals, we believe this can reinforce the \nrole that community pharmacy plays in Canadian health care.  \n \n", "original_text": "Turning to the Other segment which primarily consists of Canada, McKesson Prescription Technology Solutions, \nor MRxTS, and our investment in Change Healthcare. "}, "hash": "3b0135cd2dfc02da554afb271347000c222fc44edc1f20191ea0808b2b885aa1", "class_name": "RelatedNodeInfo"}}, "text": "With investments such as MSD and our new technology in our distribution centers, we're continuing to expand our \nservices to these providers and to  their patients.  \n \n", "start_char_idx": 2808, "end_char_idx": 2977, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "00dfda7b-15c7-4616-9fb9-150e804f4cfb": {"__data__": {"id_": "00dfda7b-15c7-4616-9fb9-150e804f4cfb", "embedding": null, "metadata": {"window": "The \nnon-acute space continues to be an encouraging area for us.  \n \n Like others in health care, we continue to see care shift to these non -acute settings where we currently operate. \n With investments such as MSD and our new technology in our distribution centers, we're continuing to expand our \nservices to these providers and to  their patients.  \n \n Turning to the Other segment which primarily consists of Canada, McKesson Prescription Technology Solutions, \nor MRxTS, and our investment in Change Healthcare.  We see improving prescription trends in our owned \nCanadian retail business, wh ich reflects our focus on the retail customer experience.  We've made investments in \npeople and in reconfigured pharmacy formats.  With strengthening fundamentals, we believe this can reinforce the \nrole that community pharmacy plays in Canadian health care.  \n \n", "original_text": "Turning to the Other segment which primarily consists of Canada, McKesson Prescription Technology Solutions, \nor MRxTS, and our investment in Change Healthcare. ", "page_label": "4", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bdb1c12e-5d92-4655-a0ce-a7bbe0044e67", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a37f6d614ba6c866b525bc57f54d512d14dd72c8762cff21f8dcf9285f204612", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "789ec73e-ce22-4c6e-b2be-da716b1bf211", "node_type": "1", "metadata": {"window": "We saw good growth \nacross multiple markets and product categories including lab, pharmaceutical and McKesson private label.  The \nnon-acute space continues to be an encouraging area for us.  \n \n Like others in health care, we continue to see care shift to these non -acute settings where we currently operate. \n With investments such as MSD and our new technology in our distribution centers, we're continuing to expand our \nservices to these providers and to  their patients.  \n \n Turning to the Other segment which primarily consists of Canada, McKesson Prescription Technology Solutions, \nor MRxTS, and our investment in Change Healthcare.  We see improving prescription trends in our owned \nCanadian retail business, wh ich reflects our focus on the retail customer experience.  We've made investments in \npeople and in reconfigured pharmacy formats. ", "original_text": "With investments such as MSD and our new technology in our distribution centers, we're continuing to expand our \nservices to these providers and to  their patients.  \n \n", "page_label": "4", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "874d577369ef0cc4e2232d08894b1d9f1146101ea08518dd5af5e48442fda847", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1a102e81-2d73-4f3f-a832-112d767301bf", "node_type": "1", "metadata": {"window": "Like others in health care, we continue to see care shift to these non -acute settings where we currently operate. \n With investments such as MSD and our new technology in our distribution centers, we're continuing to expand our \nservices to these providers and to  their patients.  \n \n Turning to the Other segment which primarily consists of Canada, McKesson Prescription Technology Solutions, \nor MRxTS, and our investment in Change Healthcare.  We see improving prescription trends in our owned \nCanadian retail business, wh ich reflects our focus on the retail customer experience.  We've made investments in \npeople and in reconfigured pharmacy formats.  With strengthening fundamentals, we believe this can reinforce the \nrole that community pharmacy plays in Canadian health care.  \n \n Within MRxTS, we continue to see good growth in CoverMyMeds and the RelayHealth pharmacy, driven by \nunique technology offerings that resonate with both our retail and biopharma partners. ", "original_text": "We see improving prescription trends in our owned \nCanadian retail business, wh ich reflects our focus on the retail customer experience. "}, "hash": "14ccf9751613975c42b89b9182150f326f03ad3b8ad27ec3db89a880854846cc", "class_name": "RelatedNodeInfo"}}, "text": "Turning to the Other segment which primarily consists of Canada, McKesson Prescription Technology Solutions, \nor MRxTS, and our investment in Change Healthcare. ", "start_char_idx": 2977, "end_char_idx": 3138, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1a102e81-2d73-4f3f-a832-112d767301bf": {"__data__": {"id_": "1a102e81-2d73-4f3f-a832-112d767301bf", "embedding": null, "metadata": {"window": "Like others in health care, we continue to see care shift to these non -acute settings where we currently operate. \n With investments such as MSD and our new technology in our distribution centers, we're continuing to expand our \nservices to these providers and to  their patients.  \n \n Turning to the Other segment which primarily consists of Canada, McKesson Prescription Technology Solutions, \nor MRxTS, and our investment in Change Healthcare.  We see improving prescription trends in our owned \nCanadian retail business, wh ich reflects our focus on the retail customer experience.  We've made investments in \npeople and in reconfigured pharmacy formats.  With strengthening fundamentals, we believe this can reinforce the \nrole that community pharmacy plays in Canadian health care.  \n \n Within MRxTS, we continue to see good growth in CoverMyMeds and the RelayHealth pharmacy, driven by \nunique technology offerings that resonate with both our retail and biopharma partners. ", "original_text": "We see improving prescription trends in our owned \nCanadian retail business, wh ich reflects our focus on the retail customer experience. ", "page_label": "4", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bdb1c12e-5d92-4655-a0ce-a7bbe0044e67", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a37f6d614ba6c866b525bc57f54d512d14dd72c8762cff21f8dcf9285f204612", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "00dfda7b-15c7-4616-9fb9-150e804f4cfb", "node_type": "1", "metadata": {"window": "The \nnon-acute space continues to be an encouraging area for us.  \n \n Like others in health care, we continue to see care shift to these non -acute settings where we currently operate. \n With investments such as MSD and our new technology in our distribution centers, we're continuing to expand our \nservices to these providers and to  their patients.  \n \n Turning to the Other segment which primarily consists of Canada, McKesson Prescription Technology Solutions, \nor MRxTS, and our investment in Change Healthcare.  We see improving prescription trends in our owned \nCanadian retail business, wh ich reflects our focus on the retail customer experience.  We've made investments in \npeople and in reconfigured pharmacy formats.  With strengthening fundamentals, we believe this can reinforce the \nrole that community pharmacy plays in Canadian health care.  \n \n", "original_text": "Turning to the Other segment which primarily consists of Canada, McKesson Prescription Technology Solutions, \nor MRxTS, and our investment in Change Healthcare. ", "page_label": "4", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d468cd52305eca01c26761a6f5f0b8ab6c53a71274a34cdd264717eee1117ccf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "334e2248-5a39-4019-911e-a1f5576b5fc6", "node_type": "1", "metadata": {"window": "With investments such as MSD and our new technology in our distribution centers, we're continuing to expand our \nservices to these providers and to  their patients.  \n \n Turning to the Other segment which primarily consists of Canada, McKesson Prescription Technology Solutions, \nor MRxTS, and our investment in Change Healthcare.  We see improving prescription trends in our owned \nCanadian retail business, wh ich reflects our focus on the retail customer experience.  We've made investments in \npeople and in reconfigured pharmacy formats.  With strengthening fundamentals, we believe this can reinforce the \nrole that community pharmacy plays in Canadian health care.  \n \n Within MRxTS, we continue to see good growth in CoverMyMeds and the RelayHealth pharmacy, driven by \nunique technology offerings that resonate with both our retail and biopharma partners.  We continue to make \ninvestments in this business to position us for future growth. ", "original_text": "We've made investments in \npeople and in reconfigured pharmacy formats. "}, "hash": "e974d9d1f0d40242e349d5e9dfb74b5191749cad04bf6b2c512e8e01e3370445", "class_name": "RelatedNodeInfo"}}, "text": "We see improving prescription trends in our owned \nCanadian retail business, wh ich reflects our focus on the retail customer experience. ", "start_char_idx": 3138, "end_char_idx": 3276, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "334e2248-5a39-4019-911e-a1f5576b5fc6": {"__data__": {"id_": "334e2248-5a39-4019-911e-a1f5576b5fc6", "embedding": null, "metadata": {"window": "With investments such as MSD and our new technology in our distribution centers, we're continuing to expand our \nservices to these providers and to  their patients.  \n \n Turning to the Other segment which primarily consists of Canada, McKesson Prescription Technology Solutions, \nor MRxTS, and our investment in Change Healthcare.  We see improving prescription trends in our owned \nCanadian retail business, wh ich reflects our focus on the retail customer experience.  We've made investments in \npeople and in reconfigured pharmacy formats.  With strengthening fundamentals, we believe this can reinforce the \nrole that community pharmacy plays in Canadian health care.  \n \n Within MRxTS, we continue to see good growth in CoverMyMeds and the RelayHealth pharmacy, driven by \nunique technology offerings that resonate with both our retail and biopharma partners.  We continue to make \ninvestments in this business to position us for future growth. ", "original_text": "We've made investments in \npeople and in reconfigured pharmacy formats. ", "page_label": "4", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bdb1c12e-5d92-4655-a0ce-a7bbe0044e67", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a37f6d614ba6c866b525bc57f54d512d14dd72c8762cff21f8dcf9285f204612", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1a102e81-2d73-4f3f-a832-112d767301bf", "node_type": "1", "metadata": {"window": "Like others in health care, we continue to see care shift to these non -acute settings where we currently operate. \n With investments such as MSD and our new technology in our distribution centers, we're continuing to expand our \nservices to these providers and to  their patients.  \n \n Turning to the Other segment which primarily consists of Canada, McKesson Prescription Technology Solutions, \nor MRxTS, and our investment in Change Healthcare.  We see improving prescription trends in our owned \nCanadian retail business, wh ich reflects our focus on the retail customer experience.  We've made investments in \npeople and in reconfigured pharmacy formats.  With strengthening fundamentals, we believe this can reinforce the \nrole that community pharmacy plays in Canadian health care.  \n \n Within MRxTS, we continue to see good growth in CoverMyMeds and the RelayHealth pharmacy, driven by \nunique technology offerings that resonate with both our retail and biopharma partners. ", "original_text": "We see improving prescription trends in our owned \nCanadian retail business, wh ich reflects our focus on the retail customer experience. ", "page_label": "4", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9faf016cc16e004941f99e425d1fe7c800a93b3f717120c94e6a8d443f634be2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ccf78060-5d2c-41ad-843a-4e7ebfd20161", "node_type": "1", "metadata": {"window": "Turning to the Other segment which primarily consists of Canada, McKesson Prescription Technology Solutions, \nor MRxTS, and our investment in Change Healthcare.  We see improving prescription trends in our owned \nCanadian retail business, wh ich reflects our focus on the retail customer experience.  We've made investments in \npeople and in reconfigured pharmacy formats.  With strengthening fundamentals, we believe this can reinforce the \nrole that community pharmacy plays in Canadian health care.  \n \n Within MRxTS, we continue to see good growth in CoverMyMeds and the RelayHealth pharmacy, driven by \nunique technology offerings that resonate with both our retail and biopharma partners.  We continue to make \ninvestments in this business to position us for future growth.  Change Healthcare achieved an important milestone \nwith the completion of its initial public offering in June. ", "original_text": "With strengthening fundamentals, we believe this can reinforce the \nrole that community pharmacy plays in Canadian health care.  \n \n"}, "hash": "d1732f1308d7d139345a6fcbfa62fda4333e1dc153282aa7ba240ee23fdd39c6", "class_name": "RelatedNodeInfo"}}, "text": "We've made investments in \npeople and in reconfigured pharmacy formats. ", "start_char_idx": 3276, "end_char_idx": 3348, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ccf78060-5d2c-41ad-843a-4e7ebfd20161": {"__data__": {"id_": "ccf78060-5d2c-41ad-843a-4e7ebfd20161", "embedding": null, "metadata": {"window": "Turning to the Other segment which primarily consists of Canada, McKesson Prescription Technology Solutions, \nor MRxTS, and our investment in Change Healthcare.  We see improving prescription trends in our owned \nCanadian retail business, wh ich reflects our focus on the retail customer experience.  We've made investments in \npeople and in reconfigured pharmacy formats.  With strengthening fundamentals, we believe this can reinforce the \nrole that community pharmacy plays in Canadian health care.  \n \n Within MRxTS, we continue to see good growth in CoverMyMeds and the RelayHealth pharmacy, driven by \nunique technology offerings that resonate with both our retail and biopharma partners.  We continue to make \ninvestments in this business to position us for future growth.  Change Healthcare achieved an important milestone \nwith the completion of its initial public offering in June. ", "original_text": "With strengthening fundamentals, we believe this can reinforce the \nrole that community pharmacy plays in Canadian health care.  \n \n", "page_label": "4", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bdb1c12e-5d92-4655-a0ce-a7bbe0044e67", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a37f6d614ba6c866b525bc57f54d512d14dd72c8762cff21f8dcf9285f204612", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "334e2248-5a39-4019-911e-a1f5576b5fc6", "node_type": "1", "metadata": {"window": "With investments such as MSD and our new technology in our distribution centers, we're continuing to expand our \nservices to these providers and to  their patients.  \n \n Turning to the Other segment which primarily consists of Canada, McKesson Prescription Technology Solutions, \nor MRxTS, and our investment in Change Healthcare.  We see improving prescription trends in our owned \nCanadian retail business, wh ich reflects our focus on the retail customer experience.  We've made investments in \npeople and in reconfigured pharmacy formats.  With strengthening fundamentals, we believe this can reinforce the \nrole that community pharmacy plays in Canadian health care.  \n \n Within MRxTS, we continue to see good growth in CoverMyMeds and the RelayHealth pharmacy, driven by \nunique technology offerings that resonate with both our retail and biopharma partners.  We continue to make \ninvestments in this business to position us for future growth. ", "original_text": "We've made investments in \npeople and in reconfigured pharmacy formats. ", "page_label": "4", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1d23900626b3a009d688dd82f5d7d26b829b143ff45b96c8d1ff742f45c5e826", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3f72e92b-d01d-4023-91cd-03bc06cb7682", "node_type": "1", "metadata": {"window": "We see improving prescription trends in our owned \nCanadian retail business, wh ich reflects our focus on the retail customer experience.  We've made investments in \npeople and in reconfigured pharmacy formats.  With strengthening fundamentals, we believe this can reinforce the \nrole that community pharmacy plays in Canadian health care.  \n \n Within MRxTS, we continue to see good growth in CoverMyMeds and the RelayHealth pharmacy, driven by \nunique technology offerings that resonate with both our retail and biopharma partners.  We continue to make \ninvestments in this business to position us for future growth.  Change Healthcare achieved an important milestone \nwith the completion of its initial public offering in June.  Britt will speak more about this and what we can expect \ngoing forward. ", "original_text": "Within MRxTS, we continue to see good growth in CoverMyMeds and the RelayHealth pharmacy, driven by \nunique technology offerings that resonate with both our retail and biopharma partners. "}, "hash": "e82c6066c92d99e9a8b51271f69617c11d5e1ae1087a1690d64deadb0bb9cb80", "class_name": "RelatedNodeInfo"}}, "text": "With strengthening fundamentals, we believe this can reinforce the \nrole that community pharmacy plays in Canadian health care.  \n \n", "start_char_idx": 3348, "end_char_idx": 3480, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3f72e92b-d01d-4023-91cd-03bc06cb7682": {"__data__": {"id_": "3f72e92b-d01d-4023-91cd-03bc06cb7682", "embedding": null, "metadata": {"window": "We see improving prescription trends in our owned \nCanadian retail business, wh ich reflects our focus on the retail customer experience.  We've made investments in \npeople and in reconfigured pharmacy formats.  With strengthening fundamentals, we believe this can reinforce the \nrole that community pharmacy plays in Canadian health care.  \n \n Within MRxTS, we continue to see good growth in CoverMyMeds and the RelayHealth pharmacy, driven by \nunique technology offerings that resonate with both our retail and biopharma partners.  We continue to make \ninvestments in this business to position us for future growth.  Change Healthcare achieved an important milestone \nwith the completion of its initial public offering in June.  Britt will speak more about this and what we can expect \ngoing forward. ", "original_text": "Within MRxTS, we continue to see good growth in CoverMyMeds and the RelayHealth pharmacy, driven by \nunique technology offerings that resonate with both our retail and biopharma partners. ", "page_label": "4", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bdb1c12e-5d92-4655-a0ce-a7bbe0044e67", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a37f6d614ba6c866b525bc57f54d512d14dd72c8762cff21f8dcf9285f204612", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ccf78060-5d2c-41ad-843a-4e7ebfd20161", "node_type": "1", "metadata": {"window": "Turning to the Other segment which primarily consists of Canada, McKesson Prescription Technology Solutions, \nor MRxTS, and our investment in Change Healthcare.  We see improving prescription trends in our owned \nCanadian retail business, wh ich reflects our focus on the retail customer experience.  We've made investments in \npeople and in reconfigured pharmacy formats.  With strengthening fundamentals, we believe this can reinforce the \nrole that community pharmacy plays in Canadian health care.  \n \n Within MRxTS, we continue to see good growth in CoverMyMeds and the RelayHealth pharmacy, driven by \nunique technology offerings that resonate with both our retail and biopharma partners.  We continue to make \ninvestments in this business to position us for future growth.  Change Healthcare achieved an important milestone \nwith the completion of its initial public offering in June. ", "original_text": "With strengthening fundamentals, we believe this can reinforce the \nrole that community pharmacy plays in Canadian health care.  \n \n", "page_label": "4", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0390ce853e656f1cf2e4dd9a7fa28a91b9457ac25f388df733e7d0aa053e544a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7d104f6a-b1cf-47f7-b320-94ac2a52073d", "node_type": "1", "metadata": {"window": "We've made investments in \npeople and in reconfigured pharmacy formats.  With strengthening fundamentals, we believe this can reinforce the \nrole that community pharmacy plays in Canadian health care.  \n \n Within MRxTS, we continue to see good growth in CoverMyMeds and the RelayHealth pharmacy, driven by \nunique technology offerings that resonate with both our retail and biopharma partners.  We continue to make \ninvestments in this business to position us for future growth.  Change Healthcare achieved an important milestone \nwith the completion of its initial public offering in June.  Britt will speak more about this and what we can expect \ngoing forward.  We're also investing in platforms that enhance our data and analytics capabilities. ", "original_text": "We continue to make \ninvestments in this business to position us for future growth. "}, "hash": "a1fd61e973aa55c7a68b0114604ef1d0c368fbd3ccb3c624f0e0881604ffd27a", "class_name": "RelatedNodeInfo"}}, "text": "Within MRxTS, we continue to see good growth in CoverMyMeds and the RelayHealth pharmacy, driven by \nunique technology offerings that resonate with both our retail and biopharma partners. ", "start_char_idx": 3480, "end_char_idx": 3668, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7d104f6a-b1cf-47f7-b320-94ac2a52073d": {"__data__": {"id_": "7d104f6a-b1cf-47f7-b320-94ac2a52073d", "embedding": null, "metadata": {"window": "We've made investments in \npeople and in reconfigured pharmacy formats.  With strengthening fundamentals, we believe this can reinforce the \nrole that community pharmacy plays in Canadian health care.  \n \n Within MRxTS, we continue to see good growth in CoverMyMeds and the RelayHealth pharmacy, driven by \nunique technology offerings that resonate with both our retail and biopharma partners.  We continue to make \ninvestments in this business to position us for future growth.  Change Healthcare achieved an important milestone \nwith the completion of its initial public offering in June.  Britt will speak more about this and what we can expect \ngoing forward.  We're also investing in platforms that enhance our data and analytics capabilities. ", "original_text": "We continue to make \ninvestments in this business to position us for future growth. ", "page_label": "4", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bdb1c12e-5d92-4655-a0ce-a7bbe0044e67", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a37f6d614ba6c866b525bc57f54d512d14dd72c8762cff21f8dcf9285f204612", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3f72e92b-d01d-4023-91cd-03bc06cb7682", "node_type": "1", "metadata": {"window": "We see improving prescription trends in our owned \nCanadian retail business, wh ich reflects our focus on the retail customer experience.  We've made investments in \npeople and in reconfigured pharmacy formats.  With strengthening fundamentals, we believe this can reinforce the \nrole that community pharmacy plays in Canadian health care.  \n \n Within MRxTS, we continue to see good growth in CoverMyMeds and the RelayHealth pharmacy, driven by \nunique technology offerings that resonate with both our retail and biopharma partners.  We continue to make \ninvestments in this business to position us for future growth.  Change Healthcare achieved an important milestone \nwith the completion of its initial public offering in June.  Britt will speak more about this and what we can expect \ngoing forward. ", "original_text": "Within MRxTS, we continue to see good growth in CoverMyMeds and the RelayHealth pharmacy, driven by \nunique technology offerings that resonate with both our retail and biopharma partners. ", "page_label": "4", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5303da0b4a4424ad87ec1c10645deef1c2cf1397a5f869162325d6428e4cea05", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "78597274-6618-442f-b136-8f09dac5cf11", "node_type": "1", "metadata": {"window": "With strengthening fundamentals, we believe this can reinforce the \nrole that community pharmacy plays in Canadian health care.  \n \n Within MRxTS, we continue to see good growth in CoverMyMeds and the RelayHealth pharmacy, driven by \nunique technology offerings that resonate with both our retail and biopharma partners.  We continue to make \ninvestments in this business to position us for future growth.  Change Healthcare achieved an important milestone \nwith the completion of its initial public offering in June.  Britt will speak more about this and what we can expect \ngoing forward.  We're also investing in platforms that enhance our data and analytics capabilities.  We realized \nbenefits across the enterprise in the first quarter and we expect to see expanding benefits in the future.  \n ", "original_text": "Change Healthcare achieved an important milestone \nwith the completion of its initial public offering in June. "}, "hash": "c0308c905a538a0cc2c2667c59bf71e91341f4b3d1e9557909ee8c5ed9bd40a0", "class_name": "RelatedNodeInfo"}}, "text": "We continue to make \ninvestments in this business to position us for future growth. ", "start_char_idx": 3668, "end_char_idx": 3752, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "78597274-6618-442f-b136-8f09dac5cf11": {"__data__": {"id_": "78597274-6618-442f-b136-8f09dac5cf11", "embedding": null, "metadata": {"window": "With strengthening fundamentals, we believe this can reinforce the \nrole that community pharmacy plays in Canadian health care.  \n \n Within MRxTS, we continue to see good growth in CoverMyMeds and the RelayHealth pharmacy, driven by \nunique technology offerings that resonate with both our retail and biopharma partners.  We continue to make \ninvestments in this business to position us for future growth.  Change Healthcare achieved an important milestone \nwith the completion of its initial public offering in June.  Britt will speak more about this and what we can expect \ngoing forward.  We're also investing in platforms that enhance our data and analytics capabilities.  We realized \nbenefits across the enterprise in the first quarter and we expect to see expanding benefits in the future.  \n ", "original_text": "Change Healthcare achieved an important milestone \nwith the completion of its initial public offering in June. ", "page_label": "4", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bdb1c12e-5d92-4655-a0ce-a7bbe0044e67", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a37f6d614ba6c866b525bc57f54d512d14dd72c8762cff21f8dcf9285f204612", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7d104f6a-b1cf-47f7-b320-94ac2a52073d", "node_type": "1", "metadata": {"window": "We've made investments in \npeople and in reconfigured pharmacy formats.  With strengthening fundamentals, we believe this can reinforce the \nrole that community pharmacy plays in Canadian health care.  \n \n Within MRxTS, we continue to see good growth in CoverMyMeds and the RelayHealth pharmacy, driven by \nunique technology offerings that resonate with both our retail and biopharma partners.  We continue to make \ninvestments in this business to position us for future growth.  Change Healthcare achieved an important milestone \nwith the completion of its initial public offering in June.  Britt will speak more about this and what we can expect \ngoing forward.  We're also investing in platforms that enhance our data and analytics capabilities. ", "original_text": "We continue to make \ninvestments in this business to position us for future growth. ", "page_label": "4", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a87dc378042d04a0b5bdf456b484ae4482a263978e3c47cf1d85f42cc8ed6dd4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2fa9a331-7749-4406-8074-a6cf7efea413", "node_type": "1", "metadata": {"window": "Within MRxTS, we continue to see good growth in CoverMyMeds and the RelayHealth pharmacy, driven by \nunique technology offerings that resonate with both our retail and biopharma partners.  We continue to make \ninvestments in this business to position us for future growth.  Change Healthcare achieved an important milestone \nwith the completion of its initial public offering in June.  Britt will speak more about this and what we can expect \ngoing forward.  We're also investing in platforms that enhance our data and analytics capabilities.  We realized \nbenefits across the enterprise in the first quarter and we expect to see expanding benefits in the future.  \n ", "original_text": "Britt will speak more about this and what we can expect \ngoing forward. "}, "hash": "9605756330d3e49abf4e51d30ee18958248aa459feb9d44f1e799148a7ef9f98", "class_name": "RelatedNodeInfo"}}, "text": "Change Healthcare achieved an important milestone \nwith the completion of its initial public offering in June. ", "start_char_idx": 3752, "end_char_idx": 3863, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2fa9a331-7749-4406-8074-a6cf7efea413": {"__data__": {"id_": "2fa9a331-7749-4406-8074-a6cf7efea413", "embedding": null, "metadata": {"window": "Within MRxTS, we continue to see good growth in CoverMyMeds and the RelayHealth pharmacy, driven by \nunique technology offerings that resonate with both our retail and biopharma partners.  We continue to make \ninvestments in this business to position us for future growth.  Change Healthcare achieved an important milestone \nwith the completion of its initial public offering in June.  Britt will speak more about this and what we can expect \ngoing forward.  We're also investing in platforms that enhance our data and analytics capabilities.  We realized \nbenefits across the enterprise in the first quarter and we expect to see expanding benefits in the future.  \n ", "original_text": "Britt will speak more about this and what we can expect \ngoing forward. ", "page_label": "4", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bdb1c12e-5d92-4655-a0ce-a7bbe0044e67", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a37f6d614ba6c866b525bc57f54d512d14dd72c8762cff21f8dcf9285f204612", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "78597274-6618-442f-b136-8f09dac5cf11", "node_type": "1", "metadata": {"window": "With strengthening fundamentals, we believe this can reinforce the \nrole that community pharmacy plays in Canadian health care.  \n \n Within MRxTS, we continue to see good growth in CoverMyMeds and the RelayHealth pharmacy, driven by \nunique technology offerings that resonate with both our retail and biopharma partners.  We continue to make \ninvestments in this business to position us for future growth.  Change Healthcare achieved an important milestone \nwith the completion of its initial public offering in June.  Britt will speak more about this and what we can expect \ngoing forward.  We're also investing in platforms that enhance our data and analytics capabilities.  We realized \nbenefits across the enterprise in the first quarter and we expect to see expanding benefits in the future.  \n ", "original_text": "Change Healthcare achieved an important milestone \nwith the completion of its initial public offering in June. ", "page_label": "4", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8baef23fcbe7c534886621a25f4067a3a41b21cec3398357ca260f44a97ea482", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4e579875-9e14-4d0e-9450-8c0f82e47a4c", "node_type": "1", "metadata": {"window": "We continue to make \ninvestments in this business to position us for future growth.  Change Healthcare achieved an important milestone \nwith the completion of its initial public offering in June.  Britt will speak more about this and what we can expect \ngoing forward.  We're also investing in platforms that enhance our data and analytics capabilities.  We realized \nbenefits across the enterprise in the first quarter and we expect to see expanding benefits in the future.  \n ", "original_text": "We're also investing in platforms that enhance our data and analytics capabilities. "}, "hash": "bc767fe79d0c44e9d1c62424f3bfcb01c1447a97519be3ac8bec75863bcc776b", "class_name": "RelatedNodeInfo"}}, "text": "Britt will speak more about this and what we can expect \ngoing forward. ", "start_char_idx": 3863, "end_char_idx": 3935, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4e579875-9e14-4d0e-9450-8c0f82e47a4c": {"__data__": {"id_": "4e579875-9e14-4d0e-9450-8c0f82e47a4c", "embedding": null, "metadata": {"window": "We continue to make \ninvestments in this business to position us for future growth.  Change Healthcare achieved an important milestone \nwith the completion of its initial public offering in June.  Britt will speak more about this and what we can expect \ngoing forward.  We're also investing in platforms that enhance our data and analytics capabilities.  We realized \nbenefits across the enterprise in the first quarter and we expect to see expanding benefits in the future.  \n ", "original_text": "We're also investing in platforms that enhance our data and analytics capabilities. ", "page_label": "4", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bdb1c12e-5d92-4655-a0ce-a7bbe0044e67", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a37f6d614ba6c866b525bc57f54d512d14dd72c8762cff21f8dcf9285f204612", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2fa9a331-7749-4406-8074-a6cf7efea413", "node_type": "1", "metadata": {"window": "Within MRxTS, we continue to see good growth in CoverMyMeds and the RelayHealth pharmacy, driven by \nunique technology offerings that resonate with both our retail and biopharma partners.  We continue to make \ninvestments in this business to position us for future growth.  Change Healthcare achieved an important milestone \nwith the completion of its initial public offering in June.  Britt will speak more about this and what we can expect \ngoing forward.  We're also investing in platforms that enhance our data and analytics capabilities.  We realized \nbenefits across the enterprise in the first quarter and we expect to see expanding benefits in the future.  \n ", "original_text": "Britt will speak more about this and what we can expect \ngoing forward. ", "page_label": "4", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b305d06fdd214ac64aeff19116b18ffd1ee815e295c90c1c1e66a066768d0666", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "54ba985a-d148-4b52-b06c-409a13bc5b10", "node_type": "1", "metadata": {"window": "Change Healthcare achieved an important milestone \nwith the completion of its initial public offering in June.  Britt will speak more about this and what we can expect \ngoing forward.  We're also investing in platforms that enhance our data and analytics capabilities.  We realized \nbenefits across the enterprise in the first quarter and we expect to see expanding benefits in the future.  \n ", "original_text": "We realized \nbenefits across the enterprise in the first quarter and we expect to see expanding benefits in the future.  \n "}, "hash": "73ff325bacf2d5281bfa437b03cd885f41c4ea9501cdc04d42e44e4f3c01a675", "class_name": "RelatedNodeInfo"}}, "text": "We're also investing in platforms that enhance our data and analytics capabilities. ", "start_char_idx": 3935, "end_char_idx": 4019, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "54ba985a-d148-4b52-b06c-409a13bc5b10": {"__data__": {"id_": "54ba985a-d148-4b52-b06c-409a13bc5b10", "embedding": null, "metadata": {"window": "Change Healthcare achieved an important milestone \nwith the completion of its initial public offering in June.  Britt will speak more about this and what we can expect \ngoing forward.  We're also investing in platforms that enhance our data and analytics capabilities.  We realized \nbenefits across the enterprise in the first quarter and we expect to see expanding benefits in the future.  \n ", "original_text": "We realized \nbenefits across the enterprise in the first quarter and we expect to see expanding benefits in the future.  \n ", "page_label": "4", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bdb1c12e-5d92-4655-a0ce-a7bbe0044e67", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a37f6d614ba6c866b525bc57f54d512d14dd72c8762cff21f8dcf9285f204612", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4e579875-9e14-4d0e-9450-8c0f82e47a4c", "node_type": "1", "metadata": {"window": "We continue to make \ninvestments in this business to position us for future growth.  Change Healthcare achieved an important milestone \nwith the completion of its initial public offering in June.  Britt will speak more about this and what we can expect \ngoing forward.  We're also investing in platforms that enhance our data and analytics capabilities.  We realized \nbenefits across the enterprise in the first quarter and we expect to see expanding benefits in the future.  \n ", "original_text": "We're also investing in platforms that enhance our data and analytics capabilities. ", "page_label": "4", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1a77e5291b089c9d46a4e3ee2b4721188c96e585b39670fa2dffdfdfb9a042b7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "45e3c679-800a-4112-a3e6-495bfa752306", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nI now want to touch upon drug pricing reform and the policy landscape.  I had the opportunity recently to spend a  \nfew days in Washington, D.C.  McKesson continues to engage as a key stakeholder in educating policymakers to \naddress issues that may impact patients, our industry, and community -based pharmacy and medical practices, \nand helping to drive the necessary chang e to support access, quality and affordability for a sustainable health \ncare system. ", "original_text": "McKesson Corp.  "}, "hash": "484897ad3f98265fea66028471a494e6835fef01dde1f294fb0b5dc18c016481", "class_name": "RelatedNodeInfo"}}, "text": "We realized \nbenefits across the enterprise in the first quarter and we expect to see expanding benefits in the future.  \n ", "start_char_idx": 4019, "end_char_idx": 4142, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "45e3c679-800a-4112-a3e6-495bfa752306": {"__data__": {"id_": "45e3c679-800a-4112-a3e6-495bfa752306", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nI now want to touch upon drug pricing reform and the policy landscape.  I had the opportunity recently to spend a  \nfew days in Washington, D.C.  McKesson continues to engage as a key stakeholder in educating policymakers to \naddress issues that may impact patients, our industry, and community -based pharmacy and medical practices, \nand helping to drive the necessary chang e to support access, quality and affordability for a sustainable health \ncare system. ", "original_text": "McKesson Corp.  ", "page_label": "5", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fa648db0-cb11-4d5d-95db-126c70dfc60f", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a2e50e180463329be007e15f0e2ac9f4740ffc072bf24ff7fd0f4c06ceab2e59", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "54ba985a-d148-4b52-b06c-409a13bc5b10", "node_type": "1", "metadata": {"window": "Change Healthcare achieved an important milestone \nwith the completion of its initial public offering in June.  Britt will speak more about this and what we can expect \ngoing forward.  We're also investing in platforms that enhance our data and analytics capabilities.  We realized \nbenefits across the enterprise in the first quarter and we expect to see expanding benefits in the future.  \n ", "original_text": "We realized \nbenefits across the enterprise in the first quarter and we expect to see expanding benefits in the future.  \n ", "page_label": "4", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fccdbacedbebe0ea2f718f92897fb35dd25f506a9f14d76f68faf73539de54c4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0b9c0736-bb70-42d6-bfdc-13f1fb3fd114", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nI now want to touch upon drug pricing reform and the policy landscape.  I had the opportunity recently to spend a  \nfew days in Washington, D.C.  McKesson continues to engage as a key stakeholder in educating policymakers to \naddress issues that may impact patients, our industry, and community -based pharmacy and medical practices, \nand helping to drive the necessary chang e to support access, quality and affordability for a sustainable health \ncare system.  These objectives align with the administration's goals and we're committed to continuing the \ndialogue with policymakers and industry partners on sound, sustainable and pra gmatic solutions.  \n \n", "original_text": "(MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nI now want to touch upon drug pricing reform and the policy landscape. "}, "hash": "b7aebc3223e9365faad9d3668f274f8552b61d483782ae643fb343deb08a37d6", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0b9c0736-bb70-42d6-bfdc-13f1fb3fd114": {"__data__": {"id_": "0b9c0736-bb70-42d6-bfdc-13f1fb3fd114", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nI now want to touch upon drug pricing reform and the policy landscape.  I had the opportunity recently to spend a  \nfew days in Washington, D.C.  McKesson continues to engage as a key stakeholder in educating policymakers to \naddress issues that may impact patients, our industry, and community -based pharmacy and medical practices, \nand helping to drive the necessary chang e to support access, quality and affordability for a sustainable health \ncare system.  These objectives align with the administration's goals and we're committed to continuing the \ndialogue with policymakers and industry partners on sound, sustainable and pra gmatic solutions.  \n \n", "original_text": "(MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nI now want to touch upon drug pricing reform and the policy landscape. ", "page_label": "5", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fa648db0-cb11-4d5d-95db-126c70dfc60f", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a2e50e180463329be007e15f0e2ac9f4740ffc072bf24ff7fd0f4c06ceab2e59", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "45e3c679-800a-4112-a3e6-495bfa752306", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nI now want to touch upon drug pricing reform and the policy landscape.  I had the opportunity recently to spend a  \nfew days in Washington, D.C.  McKesson continues to engage as a key stakeholder in educating policymakers to \naddress issues that may impact patients, our industry, and community -based pharmacy and medical practices, \nand helping to drive the necessary chang e to support access, quality and affordability for a sustainable health \ncare system. ", "original_text": "McKesson Corp.  ", "page_label": "5", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a7251c2bae627bc730d71964c702d44daaebea87030c6e7431b17e34a3d4632e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f85d4de8-a923-41a0-91cc-c36ea7ad67d4", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nI now want to touch upon drug pricing reform and the policy landscape.  I had the opportunity recently to spend a  \nfew days in Washington, D.C.  McKesson continues to engage as a key stakeholder in educating policymakers to \naddress issues that may impact patients, our industry, and community -based pharmacy and medical practices, \nand helping to drive the necessary chang e to support access, quality and affordability for a sustainable health \ncare system.  These objectives align with the administration's goals and we're committed to continuing the \ndialogue with policymakers and industry partners on sound, sustainable and pra gmatic solutions.  \n \n It remains a dynamic environment, yet we remain confident in McKesson's path forward. ", "original_text": "I had the opportunity recently to spend a  \nfew days in Washington, D.C. "}, "hash": "77b377372b00bee2ad0ec5072593fad847a22df246b1487a94f46ffd640783a4", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nI now want to touch upon drug pricing reform and the policy landscape. ", "start_char_idx": 16, "end_char_idx": 251, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f85d4de8-a923-41a0-91cc-c36ea7ad67d4": {"__data__": {"id_": "f85d4de8-a923-41a0-91cc-c36ea7ad67d4", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nI now want to touch upon drug pricing reform and the policy landscape.  I had the opportunity recently to spend a  \nfew days in Washington, D.C.  McKesson continues to engage as a key stakeholder in educating policymakers to \naddress issues that may impact patients, our industry, and community -based pharmacy and medical practices, \nand helping to drive the necessary chang e to support access, quality and affordability for a sustainable health \ncare system.  These objectives align with the administration's goals and we're committed to continuing the \ndialogue with policymakers and industry partners on sound, sustainable and pra gmatic solutions.  \n \n It remains a dynamic environment, yet we remain confident in McKesson's path forward. ", "original_text": "I had the opportunity recently to spend a  \nfew days in Washington, D.C. ", "page_label": "5", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fa648db0-cb11-4d5d-95db-126c70dfc60f", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a2e50e180463329be007e15f0e2ac9f4740ffc072bf24ff7fd0f4c06ceab2e59", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0b9c0736-bb70-42d6-bfdc-13f1fb3fd114", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nI now want to touch upon drug pricing reform and the policy landscape.  I had the opportunity recently to spend a  \nfew days in Washington, D.C.  McKesson continues to engage as a key stakeholder in educating policymakers to \naddress issues that may impact patients, our industry, and community -based pharmacy and medical practices, \nand helping to drive the necessary chang e to support access, quality and affordability for a sustainable health \ncare system.  These objectives align with the administration's goals and we're committed to continuing the \ndialogue with policymakers and industry partners on sound, sustainable and pra gmatic solutions.  \n \n", "original_text": "(MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nI now want to touch upon drug pricing reform and the policy landscape. ", "page_label": "5", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8f9e6b76c947a5bb05b74c22a619e6abdd79f70524c1042e79aa75cd909f4d3d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bb3c5391-6453-4972-a842-38324bf16c1e", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nI now want to touch upon drug pricing reform and the policy landscape.  I had the opportunity recently to spend a  \nfew days in Washington, D.C.  McKesson continues to engage as a key stakeholder in educating policymakers to \naddress issues that may impact patients, our industry, and community -based pharmacy and medical practices, \nand helping to drive the necessary chang e to support access, quality and affordability for a sustainable health \ncare system.  These objectives align with the administration's goals and we're committed to continuing the \ndialogue with policymakers and industry partners on sound, sustainable and pra gmatic solutions.  \n \n It remains a dynamic environment, yet we remain confident in McKesson's path forward.  The critical role of the \nservices we provide to the health care industry today and our ability to identify and apply solutions to address the \nmost pres sing challenges to the health care system globally. ", "original_text": "McKesson continues to engage as a key stakeholder in educating policymakers to \naddress issues that may impact patients, our industry, and community -based pharmacy and medical practices, \nand helping to drive the necessary chang e to support access, quality and affordability for a sustainable health \ncare system. "}, "hash": "7743cd4eb17e9a6a3d70b5d4d6a79ee842fa4c2b91c270db9b2aaf02a0083d2f", "class_name": "RelatedNodeInfo"}}, "text": "I had the opportunity recently to spend a  \nfew days in Washington, D.C. ", "start_char_idx": 251, "end_char_idx": 324, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bb3c5391-6453-4972-a842-38324bf16c1e": {"__data__": {"id_": "bb3c5391-6453-4972-a842-38324bf16c1e", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nI now want to touch upon drug pricing reform and the policy landscape.  I had the opportunity recently to spend a  \nfew days in Washington, D.C.  McKesson continues to engage as a key stakeholder in educating policymakers to \naddress issues that may impact patients, our industry, and community -based pharmacy and medical practices, \nand helping to drive the necessary chang e to support access, quality and affordability for a sustainable health \ncare system.  These objectives align with the administration's goals and we're committed to continuing the \ndialogue with policymakers and industry partners on sound, sustainable and pra gmatic solutions.  \n \n It remains a dynamic environment, yet we remain confident in McKesson's path forward.  The critical role of the \nservices we provide to the health care industry today and our ability to identify and apply solutions to address the \nmost pres sing challenges to the health care system globally. ", "original_text": "McKesson continues to engage as a key stakeholder in educating policymakers to \naddress issues that may impact patients, our industry, and community -based pharmacy and medical practices, \nand helping to drive the necessary chang e to support access, quality and affordability for a sustainable health \ncare system. ", "page_label": "5", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fa648db0-cb11-4d5d-95db-126c70dfc60f", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a2e50e180463329be007e15f0e2ac9f4740ffc072bf24ff7fd0f4c06ceab2e59", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f85d4de8-a923-41a0-91cc-c36ea7ad67d4", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nI now want to touch upon drug pricing reform and the policy landscape.  I had the opportunity recently to spend a  \nfew days in Washington, D.C.  McKesson continues to engage as a key stakeholder in educating policymakers to \naddress issues that may impact patients, our industry, and community -based pharmacy and medical practices, \nand helping to drive the necessary chang e to support access, quality and affordability for a sustainable health \ncare system.  These objectives align with the administration's goals and we're committed to continuing the \ndialogue with policymakers and industry partners on sound, sustainable and pra gmatic solutions.  \n \n It remains a dynamic environment, yet we remain confident in McKesson's path forward. ", "original_text": "I had the opportunity recently to spend a  \nfew days in Washington, D.C. ", "page_label": "5", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c9bdeaa25aa6b3317cbf628e619715a9ed6607563deff671b0d3ffe111affc02", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ff9dfb3f-5250-4739-b81b-032b85308639", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nI now want to touch upon drug pricing reform and the policy landscape.  I had the opportunity recently to spend a  \nfew days in Washington, D.C.  McKesson continues to engage as a key stakeholder in educating policymakers to \naddress issues that may impact patients, our industry, and community -based pharmacy and medical practices, \nand helping to drive the necessary chang e to support access, quality and affordability for a sustainable health \ncare system.  These objectives align with the administration's goals and we're committed to continuing the \ndialogue with policymakers and industry partners on sound, sustainable and pra gmatic solutions.  \n \n It remains a dynamic environment, yet we remain confident in McKesson's path forward.  The critical role of the \nservices we provide to the health care industry today and our ability to identify and apply solutions to address the \nmost pres sing challenges to the health care system globally.  Let me address two of the most recent \ndevelopments.  \n \n", "original_text": "These objectives align with the administration's goals and we're committed to continuing the \ndialogue with policymakers and industry partners on sound, sustainable and pra gmatic solutions.  \n \n"}, "hash": "a882405164f0e5100430b350d63041fc27ae99b05c05eb5a954a5945f0dee4cb", "class_name": "RelatedNodeInfo"}}, "text": "McKesson continues to engage as a key stakeholder in educating policymakers to \naddress issues that may impact patients, our industry, and community -based pharmacy and medical practices, \nand helping to drive the necessary chang e to support access, quality and affordability for a sustainable health \ncare system. ", "start_char_idx": 324, "end_char_idx": 640, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ff9dfb3f-5250-4739-b81b-032b85308639": {"__data__": {"id_": "ff9dfb3f-5250-4739-b81b-032b85308639", "embedding": null, "metadata": {"window": "(MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nI now want to touch upon drug pricing reform and the policy landscape.  I had the opportunity recently to spend a  \nfew days in Washington, D.C.  McKesson continues to engage as a key stakeholder in educating policymakers to \naddress issues that may impact patients, our industry, and community -based pharmacy and medical practices, \nand helping to drive the necessary chang e to support access, quality and affordability for a sustainable health \ncare system.  These objectives align with the administration's goals and we're committed to continuing the \ndialogue with policymakers and industry partners on sound, sustainable and pra gmatic solutions.  \n \n It remains a dynamic environment, yet we remain confident in McKesson's path forward.  The critical role of the \nservices we provide to the health care industry today and our ability to identify and apply solutions to address the \nmost pres sing challenges to the health care system globally.  Let me address two of the most recent \ndevelopments.  \n \n", "original_text": "These objectives align with the administration's goals and we're committed to continuing the \ndialogue with policymakers and industry partners on sound, sustainable and pra gmatic solutions.  \n \n", "page_label": "5", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fa648db0-cb11-4d5d-95db-126c70dfc60f", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a2e50e180463329be007e15f0e2ac9f4740ffc072bf24ff7fd0f4c06ceab2e59", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bb3c5391-6453-4972-a842-38324bf16c1e", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nI now want to touch upon drug pricing reform and the policy landscape.  I had the opportunity recently to spend a  \nfew days in Washington, D.C.  McKesson continues to engage as a key stakeholder in educating policymakers to \naddress issues that may impact patients, our industry, and community -based pharmacy and medical practices, \nand helping to drive the necessary chang e to support access, quality and affordability for a sustainable health \ncare system.  These objectives align with the administration's goals and we're committed to continuing the \ndialogue with policymakers and industry partners on sound, sustainable and pra gmatic solutions.  \n \n It remains a dynamic environment, yet we remain confident in McKesson's path forward.  The critical role of the \nservices we provide to the health care industry today and our ability to identify and apply solutions to address the \nmost pres sing challenges to the health care system globally. ", "original_text": "McKesson continues to engage as a key stakeholder in educating policymakers to \naddress issues that may impact patients, our industry, and community -based pharmacy and medical practices, \nand helping to drive the necessary chang e to support access, quality and affordability for a sustainable health \ncare system. ", "page_label": "5", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5c0e1631fdb1851ba4111586537c015f76d30829fc8f40744e4b9a2505678066", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "24e0617d-aa36-460f-a3dd-c16333e1b571", "node_type": "1", "metadata": {"window": "I had the opportunity recently to spend a  \nfew days in Washington, D.C.  McKesson continues to engage as a key stakeholder in educating policymakers to \naddress issues that may impact patients, our industry, and community -based pharmacy and medical practices, \nand helping to drive the necessary chang e to support access, quality and affordability for a sustainable health \ncare system.  These objectives align with the administration's goals and we're committed to continuing the \ndialogue with policymakers and industry partners on sound, sustainable and pra gmatic solutions.  \n \n It remains a dynamic environment, yet we remain confident in McKesson's path forward.  The critical role of the \nservices we provide to the health care industry today and our ability to identify and apply solutions to address the \nmost pres sing challenges to the health care system globally.  Let me address two of the most recent \ndevelopments.  \n \n The Senate Finance Committee published a package of measures last week. ", "original_text": "It remains a dynamic environment, yet we remain confident in McKesson's path forward. "}, "hash": "8c574c0747dc291577ca6752addde0ced24486277b2cc167cdf2e256dd9ba6c0", "class_name": "RelatedNodeInfo"}}, "text": "These objectives align with the administration's goals and we're committed to continuing the \ndialogue with policymakers and industry partners on sound, sustainable and pra gmatic solutions.  \n \n", "start_char_idx": 640, "end_char_idx": 835, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "24e0617d-aa36-460f-a3dd-c16333e1b571": {"__data__": {"id_": "24e0617d-aa36-460f-a3dd-c16333e1b571", "embedding": null, "metadata": {"window": "I had the opportunity recently to spend a  \nfew days in Washington, D.C.  McKesson continues to engage as a key stakeholder in educating policymakers to \naddress issues that may impact patients, our industry, and community -based pharmacy and medical practices, \nand helping to drive the necessary chang e to support access, quality and affordability for a sustainable health \ncare system.  These objectives align with the administration's goals and we're committed to continuing the \ndialogue with policymakers and industry partners on sound, sustainable and pra gmatic solutions.  \n \n It remains a dynamic environment, yet we remain confident in McKesson's path forward.  The critical role of the \nservices we provide to the health care industry today and our ability to identify and apply solutions to address the \nmost pres sing challenges to the health care system globally.  Let me address two of the most recent \ndevelopments.  \n \n The Senate Finance Committee published a package of measures last week. ", "original_text": "It remains a dynamic environment, yet we remain confident in McKesson's path forward. ", "page_label": "5", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fa648db0-cb11-4d5d-95db-126c70dfc60f", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a2e50e180463329be007e15f0e2ac9f4740ffc072bf24ff7fd0f4c06ceab2e59", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ff9dfb3f-5250-4739-b81b-032b85308639", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nI now want to touch upon drug pricing reform and the policy landscape.  I had the opportunity recently to spend a  \nfew days in Washington, D.C.  McKesson continues to engage as a key stakeholder in educating policymakers to \naddress issues that may impact patients, our industry, and community -based pharmacy and medical practices, \nand helping to drive the necessary chang e to support access, quality and affordability for a sustainable health \ncare system.  These objectives align with the administration's goals and we're committed to continuing the \ndialogue with policymakers and industry partners on sound, sustainable and pra gmatic solutions.  \n \n It remains a dynamic environment, yet we remain confident in McKesson's path forward.  The critical role of the \nservices we provide to the health care industry today and our ability to identify and apply solutions to address the \nmost pres sing challenges to the health care system globally.  Let me address two of the most recent \ndevelopments.  \n \n", "original_text": "These objectives align with the administration's goals and we're committed to continuing the \ndialogue with policymakers and industry partners on sound, sustainable and pra gmatic solutions.  \n \n", "page_label": "5", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "44b17e970b18fb49762ff3318d0a10516a67b86b9d57c42b7a0320b2a71cfd57", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "85787496-f0d0-46dd-90c5-85b55314a160", "node_type": "1", "metadata": {"window": "McKesson continues to engage as a key stakeholder in educating policymakers to \naddress issues that may impact patients, our industry, and community -based pharmacy and medical practices, \nand helping to drive the necessary chang e to support access, quality and affordability for a sustainable health \ncare system.  These objectives align with the administration's goals and we're committed to continuing the \ndialogue with policymakers and industry partners on sound, sustainable and pra gmatic solutions.  \n \n It remains a dynamic environment, yet we remain confident in McKesson's path forward.  The critical role of the \nservices we provide to the health care industry today and our ability to identify and apply solutions to address the \nmost pres sing challenges to the health care system globally.  Let me address two of the most recent \ndevelopments.  \n \n The Senate Finance Committee published a package of measures last week.  We anticipate there might be further \nmodifications as the package makes its way  through the legislative process. ", "original_text": "The critical role of the \nservices we provide to the health care industry today and our ability to identify and apply solutions to address the \nmost pres sing challenges to the health care system globally. "}, "hash": "0a84c77704b822979163cb12a13351e4847af64456f6a612cd37de91ac218ae3", "class_name": "RelatedNodeInfo"}}, "text": "It remains a dynamic environment, yet we remain confident in McKesson's path forward. ", "start_char_idx": 835, "end_char_idx": 921, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "85787496-f0d0-46dd-90c5-85b55314a160": {"__data__": {"id_": "85787496-f0d0-46dd-90c5-85b55314a160", "embedding": null, "metadata": {"window": "McKesson continues to engage as a key stakeholder in educating policymakers to \naddress issues that may impact patients, our industry, and community -based pharmacy and medical practices, \nand helping to drive the necessary chang e to support access, quality and affordability for a sustainable health \ncare system.  These objectives align with the administration's goals and we're committed to continuing the \ndialogue with policymakers and industry partners on sound, sustainable and pra gmatic solutions.  \n \n It remains a dynamic environment, yet we remain confident in McKesson's path forward.  The critical role of the \nservices we provide to the health care industry today and our ability to identify and apply solutions to address the \nmost pres sing challenges to the health care system globally.  Let me address two of the most recent \ndevelopments.  \n \n The Senate Finance Committee published a package of measures last week.  We anticipate there might be further \nmodifications as the package makes its way  through the legislative process. ", "original_text": "The critical role of the \nservices we provide to the health care industry today and our ability to identify and apply solutions to address the \nmost pres sing challenges to the health care system globally. ", "page_label": "5", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fa648db0-cb11-4d5d-95db-126c70dfc60f", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a2e50e180463329be007e15f0e2ac9f4740ffc072bf24ff7fd0f4c06ceab2e59", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "24e0617d-aa36-460f-a3dd-c16333e1b571", "node_type": "1", "metadata": {"window": "I had the opportunity recently to spend a  \nfew days in Washington, D.C.  McKesson continues to engage as a key stakeholder in educating policymakers to \naddress issues that may impact patients, our industry, and community -based pharmacy and medical practices, \nand helping to drive the necessary chang e to support access, quality and affordability for a sustainable health \ncare system.  These objectives align with the administration's goals and we're committed to continuing the \ndialogue with policymakers and industry partners on sound, sustainable and pra gmatic solutions.  \n \n It remains a dynamic environment, yet we remain confident in McKesson's path forward.  The critical role of the \nservices we provide to the health care industry today and our ability to identify and apply solutions to address the \nmost pres sing challenges to the health care system globally.  Let me address two of the most recent \ndevelopments.  \n \n The Senate Finance Committee published a package of measures last week. ", "original_text": "It remains a dynamic environment, yet we remain confident in McKesson's path forward. ", "page_label": "5", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1a9871ee84bea4d5ca2253dba79c32c12e499a40f75e39cfbd1df0635c732680", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f6c7733a-0b1d-4941-a768-1335bf498f0a", "node_type": "1", "metadata": {"window": "These objectives align with the administration's goals and we're committed to continuing the \ndialogue with policymakers and industry partners on sound, sustainable and pra gmatic solutions.  \n \n It remains a dynamic environment, yet we remain confident in McKesson's path forward.  The critical role of the \nservices we provide to the health care industry today and our ability to identify and apply solutions to address the \nmost pres sing challenges to the health care system globally.  Let me address two of the most recent \ndevelopments.  \n \n The Senate Finance Committee published a package of measures last week.  We anticipate there might be further \nmodifications as the package makes its way  through the legislative process.  So at this point, we're not in a \nposition to go into great detail on specific provisions. ", "original_text": "Let me address two of the most recent \ndevelopments.  \n \n"}, "hash": "c40addd0051c2c39502cac1f09701033390f23b1258c19f6d0de5e407329621e", "class_name": "RelatedNodeInfo"}}, "text": "The critical role of the \nservices we provide to the health care industry today and our ability to identify and apply solutions to address the \nmost pres sing challenges to the health care system globally. ", "start_char_idx": 921, "end_char_idx": 1127, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f6c7733a-0b1d-4941-a768-1335bf498f0a": {"__data__": {"id_": "f6c7733a-0b1d-4941-a768-1335bf498f0a", "embedding": null, "metadata": {"window": "These objectives align with the administration's goals and we're committed to continuing the \ndialogue with policymakers and industry partners on sound, sustainable and pra gmatic solutions.  \n \n It remains a dynamic environment, yet we remain confident in McKesson's path forward.  The critical role of the \nservices we provide to the health care industry today and our ability to identify and apply solutions to address the \nmost pres sing challenges to the health care system globally.  Let me address two of the most recent \ndevelopments.  \n \n The Senate Finance Committee published a package of measures last week.  We anticipate there might be further \nmodifications as the package makes its way  through the legislative process.  So at this point, we're not in a \nposition to go into great detail on specific provisions. ", "original_text": "Let me address two of the most recent \ndevelopments.  \n \n", "page_label": "5", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fa648db0-cb11-4d5d-95db-126c70dfc60f", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a2e50e180463329be007e15f0e2ac9f4740ffc072bf24ff7fd0f4c06ceab2e59", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "85787496-f0d0-46dd-90c5-85b55314a160", "node_type": "1", "metadata": {"window": "McKesson continues to engage as a key stakeholder in educating policymakers to \naddress issues that may impact patients, our industry, and community -based pharmacy and medical practices, \nand helping to drive the necessary chang e to support access, quality and affordability for a sustainable health \ncare system.  These objectives align with the administration's goals and we're committed to continuing the \ndialogue with policymakers and industry partners on sound, sustainable and pra gmatic solutions.  \n \n It remains a dynamic environment, yet we remain confident in McKesson's path forward.  The critical role of the \nservices we provide to the health care industry today and our ability to identify and apply solutions to address the \nmost pres sing challenges to the health care system globally.  Let me address two of the most recent \ndevelopments.  \n \n The Senate Finance Committee published a package of measures last week.  We anticipate there might be further \nmodifications as the package makes its way  through the legislative process. ", "original_text": "The critical role of the \nservices we provide to the health care industry today and our ability to identify and apply solutions to address the \nmost pres sing challenges to the health care system globally. ", "page_label": "5", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2deb80d541839c48b1c0721020e49c9680948c885a5f3dff564e22f6d3f062f3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8a213aea-cba9-4051-af4a-ae935d9c8e4d", "node_type": "1", "metadata": {"window": "It remains a dynamic environment, yet we remain confident in McKesson's path forward.  The critical role of the \nservices we provide to the health care industry today and our ability to identify and apply solutions to address the \nmost pres sing challenges to the health care system globally.  Let me address two of the most recent \ndevelopments.  \n \n The Senate Finance Committee published a package of measures last week.  We anticipate there might be further \nmodifications as the package makes its way  through the legislative process.  So at this point, we're not in a \nposition to go into great detail on specific provisions.  However, we will continue to engage with policymakers and \nindustry partners to ensure that these reforms support the efficiency, sus tainability and security of the supply \nchain as we seek to improve cost, quality and access.  \n \n", "original_text": "The Senate Finance Committee published a package of measures last week. "}, "hash": "b7b8bdd9839688bf7efcebf950e9f72475da5c257f3616ab2842b6cb197560ae", "class_name": "RelatedNodeInfo"}}, "text": "Let me address two of the most recent \ndevelopments.  \n \n", "start_char_idx": 1127, "end_char_idx": 1184, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8a213aea-cba9-4051-af4a-ae935d9c8e4d": {"__data__": {"id_": "8a213aea-cba9-4051-af4a-ae935d9c8e4d", "embedding": null, "metadata": {"window": "It remains a dynamic environment, yet we remain confident in McKesson's path forward.  The critical role of the \nservices we provide to the health care industry today and our ability to identify and apply solutions to address the \nmost pres sing challenges to the health care system globally.  Let me address two of the most recent \ndevelopments.  \n \n The Senate Finance Committee published a package of measures last week.  We anticipate there might be further \nmodifications as the package makes its way  through the legislative process.  So at this point, we're not in a \nposition to go into great detail on specific provisions.  However, we will continue to engage with policymakers and \nindustry partners to ensure that these reforms support the efficiency, sus tainability and security of the supply \nchain as we seek to improve cost, quality and access.  \n \n", "original_text": "The Senate Finance Committee published a package of measures last week. ", "page_label": "5", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fa648db0-cb11-4d5d-95db-126c70dfc60f", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a2e50e180463329be007e15f0e2ac9f4740ffc072bf24ff7fd0f4c06ceab2e59", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f6c7733a-0b1d-4941-a768-1335bf498f0a", "node_type": "1", "metadata": {"window": "These objectives align with the administration's goals and we're committed to continuing the \ndialogue with policymakers and industry partners on sound, sustainable and pra gmatic solutions.  \n \n It remains a dynamic environment, yet we remain confident in McKesson's path forward.  The critical role of the \nservices we provide to the health care industry today and our ability to identify and apply solutions to address the \nmost pres sing challenges to the health care system globally.  Let me address two of the most recent \ndevelopments.  \n \n The Senate Finance Committee published a package of measures last week.  We anticipate there might be further \nmodifications as the package makes its way  through the legislative process.  So at this point, we're not in a \nposition to go into great detail on specific provisions. ", "original_text": "Let me address two of the most recent \ndevelopments.  \n \n", "page_label": "5", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bdde1c6544d01053f653999e4625ed41c46c06e41dd2de68f7d57abffc556233", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5bda2734-c4fc-4c73-831c-e3aa1c26cf3e", "node_type": "1", "metadata": {"window": "The critical role of the \nservices we provide to the health care industry today and our ability to identify and apply solutions to address the \nmost pres sing challenges to the health care system globally.  Let me address two of the most recent \ndevelopments.  \n \n The Senate Finance Committee published a package of measures last week.  We anticipate there might be further \nmodifications as the package makes its way  through the legislative process.  So at this point, we're not in a \nposition to go into great detail on specific provisions.  However, we will continue to engage with policymakers and \nindustry partners to ensure that these reforms support the efficiency, sus tainability and security of the supply \nchain as we seek to improve cost, quality and access.  \n \n Finally, earlier today the U.S. ", "original_text": "We anticipate there might be further \nmodifications as the package makes its way  through the legislative process. "}, "hash": "a4c20d874d4fb0db4e88f46b0a2fe430a9aa2f9b637e9bd8ed83e62896765571", "class_name": "RelatedNodeInfo"}}, "text": "The Senate Finance Committee published a package of measures last week. ", "start_char_idx": 1184, "end_char_idx": 1256, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5bda2734-c4fc-4c73-831c-e3aa1c26cf3e": {"__data__": {"id_": "5bda2734-c4fc-4c73-831c-e3aa1c26cf3e", "embedding": null, "metadata": {"window": "The critical role of the \nservices we provide to the health care industry today and our ability to identify and apply solutions to address the \nmost pres sing challenges to the health care system globally.  Let me address two of the most recent \ndevelopments.  \n \n The Senate Finance Committee published a package of measures last week.  We anticipate there might be further \nmodifications as the package makes its way  through the legislative process.  So at this point, we're not in a \nposition to go into great detail on specific provisions.  However, we will continue to engage with policymakers and \nindustry partners to ensure that these reforms support the efficiency, sus tainability and security of the supply \nchain as we seek to improve cost, quality and access.  \n \n Finally, earlier today the U.S. ", "original_text": "We anticipate there might be further \nmodifications as the package makes its way  through the legislative process. ", "page_label": "5", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fa648db0-cb11-4d5d-95db-126c70dfc60f", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a2e50e180463329be007e15f0e2ac9f4740ffc072bf24ff7fd0f4c06ceab2e59", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8a213aea-cba9-4051-af4a-ae935d9c8e4d", "node_type": "1", "metadata": {"window": "It remains a dynamic environment, yet we remain confident in McKesson's path forward.  The critical role of the \nservices we provide to the health care industry today and our ability to identify and apply solutions to address the \nmost pres sing challenges to the health care system globally.  Let me address two of the most recent \ndevelopments.  \n \n The Senate Finance Committee published a package of measures last week.  We anticipate there might be further \nmodifications as the package makes its way  through the legislative process.  So at this point, we're not in a \nposition to go into great detail on specific provisions.  However, we will continue to engage with policymakers and \nindustry partners to ensure that these reforms support the efficiency, sus tainability and security of the supply \nchain as we seek to improve cost, quality and access.  \n \n", "original_text": "The Senate Finance Committee published a package of measures last week. ", "page_label": "5", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2d58e86aec114e2f43f3947e23bf09e0e5b51a75cb952b1561122afcc2b737c8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "537858a7-42fc-4fae-92e8-76413fe0ce80", "node_type": "1", "metadata": {"window": "Let me address two of the most recent \ndevelopments.  \n \n The Senate Finance Committee published a package of measures last week.  We anticipate there might be further \nmodifications as the package makes its way  through the legislative process.  So at this point, we're not in a \nposition to go into great detail on specific provisions.  However, we will continue to engage with policymakers and \nindustry partners to ensure that these reforms support the efficiency, sus tainability and security of the supply \nchain as we seek to improve cost, quality and access.  \n \n Finally, earlier today the U.S.  Department of Health and Human Services, or HHS, and the U.S. ", "original_text": "So at this point, we're not in a \nposition to go into great detail on specific provisions. "}, "hash": "c43a3f479cb5373f6d1da8c09abb94ab7b3f43341007ebd7a738f7bb239dae3b", "class_name": "RelatedNodeInfo"}}, "text": "We anticipate there might be further \nmodifications as the package makes its way  through the legislative process. ", "start_char_idx": 1256, "end_char_idx": 1371, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "537858a7-42fc-4fae-92e8-76413fe0ce80": {"__data__": {"id_": "537858a7-42fc-4fae-92e8-76413fe0ce80", "embedding": null, "metadata": {"window": "Let me address two of the most recent \ndevelopments.  \n \n The Senate Finance Committee published a package of measures last week.  We anticipate there might be further \nmodifications as the package makes its way  through the legislative process.  So at this point, we're not in a \nposition to go into great detail on specific provisions.  However, we will continue to engage with policymakers and \nindustry partners to ensure that these reforms support the efficiency, sus tainability and security of the supply \nchain as we seek to improve cost, quality and access.  \n \n Finally, earlier today the U.S.  Department of Health and Human Services, or HHS, and the U.S. ", "original_text": "So at this point, we're not in a \nposition to go into great detail on specific provisions. ", "page_label": "5", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fa648db0-cb11-4d5d-95db-126c70dfc60f", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a2e50e180463329be007e15f0e2ac9f4740ffc072bf24ff7fd0f4c06ceab2e59", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5bda2734-c4fc-4c73-831c-e3aa1c26cf3e", "node_type": "1", "metadata": {"window": "The critical role of the \nservices we provide to the health care industry today and our ability to identify and apply solutions to address the \nmost pres sing challenges to the health care system globally.  Let me address two of the most recent \ndevelopments.  \n \n The Senate Finance Committee published a package of measures last week.  We anticipate there might be further \nmodifications as the package makes its way  through the legislative process.  So at this point, we're not in a \nposition to go into great detail on specific provisions.  However, we will continue to engage with policymakers and \nindustry partners to ensure that these reforms support the efficiency, sus tainability and security of the supply \nchain as we seek to improve cost, quality and access.  \n \n Finally, earlier today the U.S. ", "original_text": "We anticipate there might be further \nmodifications as the package makes its way  through the legislative process. ", "page_label": "5", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "559dd968b1c6b244f0fb6b1b16f556b539b062f0a6eee0a02a0a010f6b4bb0b7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1bcfc1ac-4381-4dae-867d-386e3bc27f98", "node_type": "1", "metadata": {"window": "The Senate Finance Committee published a package of measures last week.  We anticipate there might be further \nmodifications as the package makes its way  through the legislative process.  So at this point, we're not in a \nposition to go into great detail on specific provisions.  However, we will continue to engage with policymakers and \nindustry partners to ensure that these reforms support the efficiency, sus tainability and security of the supply \nchain as we seek to improve cost, quality and access.  \n \n Finally, earlier today the U.S.  Department of Health and Human Services, or HHS, and the U.S.  Food and Drug \nAdministration, or FDA, announced a Safe Importation A ction Plan. ", "original_text": "However, we will continue to engage with policymakers and \nindustry partners to ensure that these reforms support the efficiency, sus tainability and security of the supply \nchain as we seek to improve cost, quality and access.  \n \n"}, "hash": "dbd8a89caf32000757907586110d5bb78d4d74e231c7385ee591d0d2d6938cc1", "class_name": "RelatedNodeInfo"}}, "text": "So at this point, we're not in a \nposition to go into great detail on specific provisions. ", "start_char_idx": 1371, "end_char_idx": 1462, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1bcfc1ac-4381-4dae-867d-386e3bc27f98": {"__data__": {"id_": "1bcfc1ac-4381-4dae-867d-386e3bc27f98", "embedding": null, "metadata": {"window": "The Senate Finance Committee published a package of measures last week.  We anticipate there might be further \nmodifications as the package makes its way  through the legislative process.  So at this point, we're not in a \nposition to go into great detail on specific provisions.  However, we will continue to engage with policymakers and \nindustry partners to ensure that these reforms support the efficiency, sus tainability and security of the supply \nchain as we seek to improve cost, quality and access.  \n \n Finally, earlier today the U.S.  Department of Health and Human Services, or HHS, and the U.S.  Food and Drug \nAdministration, or FDA, announced a Safe Importation A ction Plan. ", "original_text": "However, we will continue to engage with policymakers and \nindustry partners to ensure that these reforms support the efficiency, sus tainability and security of the supply \nchain as we seek to improve cost, quality and access.  \n \n", "page_label": "5", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fa648db0-cb11-4d5d-95db-126c70dfc60f", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a2e50e180463329be007e15f0e2ac9f4740ffc072bf24ff7fd0f4c06ceab2e59", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "537858a7-42fc-4fae-92e8-76413fe0ce80", "node_type": "1", "metadata": {"window": "Let me address two of the most recent \ndevelopments.  \n \n The Senate Finance Committee published a package of measures last week.  We anticipate there might be further \nmodifications as the package makes its way  through the legislative process.  So at this point, we're not in a \nposition to go into great detail on specific provisions.  However, we will continue to engage with policymakers and \nindustry partners to ensure that these reforms support the efficiency, sus tainability and security of the supply \nchain as we seek to improve cost, quality and access.  \n \n Finally, earlier today the U.S.  Department of Health and Human Services, or HHS, and the U.S. ", "original_text": "So at this point, we're not in a \nposition to go into great detail on specific provisions. ", "page_label": "5", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "eea3153b76db482f020b88266e7e4e080d1e49d0f0da575e8a028fd64cfa2d46", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "29d7850c-8458-4464-803e-12a11044813d", "node_type": "1", "metadata": {"window": "We anticipate there might be further \nmodifications as the package makes its way  through the legislative process.  So at this point, we're not in a \nposition to go into great detail on specific provisions.  However, we will continue to engage with policymakers and \nindustry partners to ensure that these reforms support the efficiency, sus tainability and security of the supply \nchain as we seek to improve cost, quality and access.  \n \n Finally, earlier today the U.S.  Department of Health and Human Services, or HHS, and the U.S.  Food and Drug \nAdministration, or FDA, announced a Safe Importation A ction Plan.  Given how recent this announcement is, we \nhaven't yet had the full time we'd like to digest this or study this plan, but maybe a few just quick preliminary \nthoughts. ", "original_text": "Finally, earlier today the U.S. "}, "hash": "03bf215fab6ed1960c83381a0d495d318742ee4b26bfd7bc67e8c77b2274d6e6", "class_name": "RelatedNodeInfo"}}, "text": "However, we will continue to engage with policymakers and \nindustry partners to ensure that these reforms support the efficiency, sus tainability and security of the supply \nchain as we seek to improve cost, quality and access.  \n \n", "start_char_idx": 1462, "end_char_idx": 1694, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "29d7850c-8458-4464-803e-12a11044813d": {"__data__": {"id_": "29d7850c-8458-4464-803e-12a11044813d", "embedding": null, "metadata": {"window": "We anticipate there might be further \nmodifications as the package makes its way  through the legislative process.  So at this point, we're not in a \nposition to go into great detail on specific provisions.  However, we will continue to engage with policymakers and \nindustry partners to ensure that these reforms support the efficiency, sus tainability and security of the supply \nchain as we seek to improve cost, quality and access.  \n \n Finally, earlier today the U.S.  Department of Health and Human Services, or HHS, and the U.S.  Food and Drug \nAdministration, or FDA, announced a Safe Importation A ction Plan.  Given how recent this announcement is, we \nhaven't yet had the full time we'd like to digest this or study this plan, but maybe a few just quick preliminary \nthoughts. ", "original_text": "Finally, earlier today the U.S. ", "page_label": "5", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fa648db0-cb11-4d5d-95db-126c70dfc60f", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a2e50e180463329be007e15f0e2ac9f4740ffc072bf24ff7fd0f4c06ceab2e59", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1bcfc1ac-4381-4dae-867d-386e3bc27f98", "node_type": "1", "metadata": {"window": "The Senate Finance Committee published a package of measures last week.  We anticipate there might be further \nmodifications as the package makes its way  through the legislative process.  So at this point, we're not in a \nposition to go into great detail on specific provisions.  However, we will continue to engage with policymakers and \nindustry partners to ensure that these reforms support the efficiency, sus tainability and security of the supply \nchain as we seek to improve cost, quality and access.  \n \n Finally, earlier today the U.S.  Department of Health and Human Services, or HHS, and the U.S.  Food and Drug \nAdministration, or FDA, announced a Safe Importation A ction Plan. ", "original_text": "However, we will continue to engage with policymakers and \nindustry partners to ensure that these reforms support the efficiency, sus tainability and security of the supply \nchain as we seek to improve cost, quality and access.  \n \n", "page_label": "5", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "263b45dae06ba4d4cff359faf848e83e5d2375e018ec9bcc1672b64c39f62494", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "058006ce-aa5c-445d-abe2-9d3eef8d84a9", "node_type": "1", "metadata": {"window": "So at this point, we're not in a \nposition to go into great detail on specific provisions.  However, we will continue to engage with policymakers and \nindustry partners to ensure that these reforms support the efficiency, sus tainability and security of the supply \nchain as we seek to improve cost, quality and access.  \n \n Finally, earlier today the U.S.  Department of Health and Human Services, or HHS, and the U.S.  Food and Drug \nAdministration, or FDA, announced a Safe Importation A ction Plan.  Given how recent this announcement is, we \nhaven't yet had the full time we'd like to digest this or study this plan, but maybe a few just quick preliminary \nthoughts.  Obviously, McKesson's presence in both U.S. ", "original_text": "Department of Health and Human Services, or HHS, and the U.S. "}, "hash": "58e1e01f4fca32899dc4a57ffc1ff772dc29a9fa299f19c7d0b31fd76c5592af", "class_name": "RelatedNodeInfo"}}, "text": "Finally, earlier today the U.S. ", "start_char_idx": 1694, "end_char_idx": 1726, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "058006ce-aa5c-445d-abe2-9d3eef8d84a9": {"__data__": {"id_": "058006ce-aa5c-445d-abe2-9d3eef8d84a9", "embedding": null, "metadata": {"window": "So at this point, we're not in a \nposition to go into great detail on specific provisions.  However, we will continue to engage with policymakers and \nindustry partners to ensure that these reforms support the efficiency, sus tainability and security of the supply \nchain as we seek to improve cost, quality and access.  \n \n Finally, earlier today the U.S.  Department of Health and Human Services, or HHS, and the U.S.  Food and Drug \nAdministration, or FDA, announced a Safe Importation A ction Plan.  Given how recent this announcement is, we \nhaven't yet had the full time we'd like to digest this or study this plan, but maybe a few just quick preliminary \nthoughts.  Obviously, McKesson's presence in both U.S. ", "original_text": "Department of Health and Human Services, or HHS, and the U.S. ", "page_label": "5", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fa648db0-cb11-4d5d-95db-126c70dfc60f", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a2e50e180463329be007e15f0e2ac9f4740ffc072bf24ff7fd0f4c06ceab2e59", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "29d7850c-8458-4464-803e-12a11044813d", "node_type": "1", "metadata": {"window": "We anticipate there might be further \nmodifications as the package makes its way  through the legislative process.  So at this point, we're not in a \nposition to go into great detail on specific provisions.  However, we will continue to engage with policymakers and \nindustry partners to ensure that these reforms support the efficiency, sus tainability and security of the supply \nchain as we seek to improve cost, quality and access.  \n \n Finally, earlier today the U.S.  Department of Health and Human Services, or HHS, and the U.S.  Food and Drug \nAdministration, or FDA, announced a Safe Importation A ction Plan.  Given how recent this announcement is, we \nhaven't yet had the full time we'd like to digest this or study this plan, but maybe a few just quick preliminary \nthoughts. ", "original_text": "Finally, earlier today the U.S. ", "page_label": "5", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5bd195f05da0fa0b0aa3412f8ab7528b854142a3f52d3d96a720db08075fb72d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "36206bc7-5142-4b5e-8696-abe87db3102d", "node_type": "1", "metadata": {"window": "However, we will continue to engage with policymakers and \nindustry partners to ensure that these reforms support the efficiency, sus tainability and security of the supply \nchain as we seek to improve cost, quality and access.  \n \n Finally, earlier today the U.S.  Department of Health and Human Services, or HHS, and the U.S.  Food and Drug \nAdministration, or FDA, announced a Safe Importation A ction Plan.  Given how recent this announcement is, we \nhaven't yet had the full time we'd like to digest this or study this plan, but maybe a few just quick preliminary \nthoughts.  Obviously, McKesson's presence in both U.S.  and Canada gives us a unique persp ective on supply \nchain considerations and the impacts to stakeholders and patients as we navigate this complex question of \nimportation.  \n \n", "original_text": "Food and Drug \nAdministration, or FDA, announced a Safe Importation A ction Plan. "}, "hash": "130661e6af65451de123fa109c4481b67be50e2701da0d0b92747b870357d9ff", "class_name": "RelatedNodeInfo"}}, "text": "Department of Health and Human Services, or HHS, and the U.S. ", "start_char_idx": 1726, "end_char_idx": 1788, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "36206bc7-5142-4b5e-8696-abe87db3102d": {"__data__": {"id_": "36206bc7-5142-4b5e-8696-abe87db3102d", "embedding": null, "metadata": {"window": "However, we will continue to engage with policymakers and \nindustry partners to ensure that these reforms support the efficiency, sus tainability and security of the supply \nchain as we seek to improve cost, quality and access.  \n \n Finally, earlier today the U.S.  Department of Health and Human Services, or HHS, and the U.S.  Food and Drug \nAdministration, or FDA, announced a Safe Importation A ction Plan.  Given how recent this announcement is, we \nhaven't yet had the full time we'd like to digest this or study this plan, but maybe a few just quick preliminary \nthoughts.  Obviously, McKesson's presence in both U.S.  and Canada gives us a unique persp ective on supply \nchain considerations and the impacts to stakeholders and patients as we navigate this complex question of \nimportation.  \n \n", "original_text": "Food and Drug \nAdministration, or FDA, announced a Safe Importation A ction Plan. ", "page_label": "5", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fa648db0-cb11-4d5d-95db-126c70dfc60f", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a2e50e180463329be007e15f0e2ac9f4740ffc072bf24ff7fd0f4c06ceab2e59", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "058006ce-aa5c-445d-abe2-9d3eef8d84a9", "node_type": "1", "metadata": {"window": "So at this point, we're not in a \nposition to go into great detail on specific provisions.  However, we will continue to engage with policymakers and \nindustry partners to ensure that these reforms support the efficiency, sus tainability and security of the supply \nchain as we seek to improve cost, quality and access.  \n \n Finally, earlier today the U.S.  Department of Health and Human Services, or HHS, and the U.S.  Food and Drug \nAdministration, or FDA, announced a Safe Importation A ction Plan.  Given how recent this announcement is, we \nhaven't yet had the full time we'd like to digest this or study this plan, but maybe a few just quick preliminary \nthoughts.  Obviously, McKesson's presence in both U.S. ", "original_text": "Department of Health and Human Services, or HHS, and the U.S. ", "page_label": "5", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dcfc36a3c7a0b49d2f7acc84f18e7def274055d90a28c784ae175ba6cd6c120d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "63eb23c9-0685-419e-a720-8640f93a97ec", "node_type": "1", "metadata": {"window": "Finally, earlier today the U.S.  Department of Health and Human Services, or HHS, and the U.S.  Food and Drug \nAdministration, or FDA, announced a Safe Importation A ction Plan.  Given how recent this announcement is, we \nhaven't yet had the full time we'd like to digest this or study this plan, but maybe a few just quick preliminary \nthoughts.  Obviously, McKesson's presence in both U.S.  and Canada gives us a unique persp ective on supply \nchain considerations and the impacts to stakeholders and patients as we navigate this complex question of \nimportation.  \n \n There are legitimate concerns that importation could potentially introduce counterfeit or fraudulent products into \nthe U.S. ", "original_text": "Given how recent this announcement is, we \nhaven't yet had the full time we'd like to digest this or study this plan, but maybe a few just quick preliminary \nthoughts. "}, "hash": "be8a6bf328615a2ff950fac65320e0827a7f36f2a16b4c46f7342c15c8de86cc", "class_name": "RelatedNodeInfo"}}, "text": "Food and Drug \nAdministration, or FDA, announced a Safe Importation A ction Plan. ", "start_char_idx": 1788, "end_char_idx": 1870, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "63eb23c9-0685-419e-a720-8640f93a97ec": {"__data__": {"id_": "63eb23c9-0685-419e-a720-8640f93a97ec", "embedding": null, "metadata": {"window": "Finally, earlier today the U.S.  Department of Health and Human Services, or HHS, and the U.S.  Food and Drug \nAdministration, or FDA, announced a Safe Importation A ction Plan.  Given how recent this announcement is, we \nhaven't yet had the full time we'd like to digest this or study this plan, but maybe a few just quick preliminary \nthoughts.  Obviously, McKesson's presence in both U.S.  and Canada gives us a unique persp ective on supply \nchain considerations and the impacts to stakeholders and patients as we navigate this complex question of \nimportation.  \n \n There are legitimate concerns that importation could potentially introduce counterfeit or fraudulent products into \nthe U.S. ", "original_text": "Given how recent this announcement is, we \nhaven't yet had the full time we'd like to digest this or study this plan, but maybe a few just quick preliminary \nthoughts. ", "page_label": "5", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fa648db0-cb11-4d5d-95db-126c70dfc60f", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a2e50e180463329be007e15f0e2ac9f4740ffc072bf24ff7fd0f4c06ceab2e59", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "36206bc7-5142-4b5e-8696-abe87db3102d", "node_type": "1", "metadata": {"window": "However, we will continue to engage with policymakers and \nindustry partners to ensure that these reforms support the efficiency, sus tainability and security of the supply \nchain as we seek to improve cost, quality and access.  \n \n Finally, earlier today the U.S.  Department of Health and Human Services, or HHS, and the U.S.  Food and Drug \nAdministration, or FDA, announced a Safe Importation A ction Plan.  Given how recent this announcement is, we \nhaven't yet had the full time we'd like to digest this or study this plan, but maybe a few just quick preliminary \nthoughts.  Obviously, McKesson's presence in both U.S.  and Canada gives us a unique persp ective on supply \nchain considerations and the impacts to stakeholders and patients as we navigate this complex question of \nimportation.  \n \n", "original_text": "Food and Drug \nAdministration, or FDA, announced a Safe Importation A ction Plan. ", "page_label": "5", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "85d3550e358fc5ce797c177233eaef3e05ee3e04396fded22812d9cf2aa16cb0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0673fb43-ef6a-4289-b293-61356273ba1a", "node_type": "1", "metadata": {"window": "Department of Health and Human Services, or HHS, and the U.S.  Food and Drug \nAdministration, or FDA, announced a Safe Importation A ction Plan.  Given how recent this announcement is, we \nhaven't yet had the full time we'd like to digest this or study this plan, but maybe a few just quick preliminary \nthoughts.  Obviously, McKesson's presence in both U.S.  and Canada gives us a unique persp ective on supply \nchain considerations and the impacts to stakeholders and patients as we navigate this complex question of \nimportation.  \n \n There are legitimate concerns that importation could potentially introduce counterfeit or fraudulent products into \nthe U.S.  Importantly, we have a primary responsibility to maintain a safe, secure and efficient supply chain and to \nensure that we conform to FDA safety and efficacy standards in addition to the safeguards put in place by the \n2013 passage of the Drug Supply Ch ain Security Act. ", "original_text": "Obviously, McKesson's presence in both U.S. "}, "hash": "572f3ca151aafbaca7e4617bbe5b49457a43685fc580db2b79236b9f899a9a29", "class_name": "RelatedNodeInfo"}}, "text": "Given how recent this announcement is, we \nhaven't yet had the full time we'd like to digest this or study this plan, but maybe a few just quick preliminary \nthoughts. ", "start_char_idx": 1870, "end_char_idx": 2038, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0673fb43-ef6a-4289-b293-61356273ba1a": {"__data__": {"id_": "0673fb43-ef6a-4289-b293-61356273ba1a", "embedding": null, "metadata": {"window": "Department of Health and Human Services, or HHS, and the U.S.  Food and Drug \nAdministration, or FDA, announced a Safe Importation A ction Plan.  Given how recent this announcement is, we \nhaven't yet had the full time we'd like to digest this or study this plan, but maybe a few just quick preliminary \nthoughts.  Obviously, McKesson's presence in both U.S.  and Canada gives us a unique persp ective on supply \nchain considerations and the impacts to stakeholders and patients as we navigate this complex question of \nimportation.  \n \n There are legitimate concerns that importation could potentially introduce counterfeit or fraudulent products into \nthe U.S.  Importantly, we have a primary responsibility to maintain a safe, secure and efficient supply chain and to \nensure that we conform to FDA safety and efficacy standards in addition to the safeguards put in place by the \n2013 passage of the Drug Supply Ch ain Security Act. ", "original_text": "Obviously, McKesson's presence in both U.S. ", "page_label": "5", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fa648db0-cb11-4d5d-95db-126c70dfc60f", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a2e50e180463329be007e15f0e2ac9f4740ffc072bf24ff7fd0f4c06ceab2e59", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "63eb23c9-0685-419e-a720-8640f93a97ec", "node_type": "1", "metadata": {"window": "Finally, earlier today the U.S.  Department of Health and Human Services, or HHS, and the U.S.  Food and Drug \nAdministration, or FDA, announced a Safe Importation A ction Plan.  Given how recent this announcement is, we \nhaven't yet had the full time we'd like to digest this or study this plan, but maybe a few just quick preliminary \nthoughts.  Obviously, McKesson's presence in both U.S.  and Canada gives us a unique persp ective on supply \nchain considerations and the impacts to stakeholders and patients as we navigate this complex question of \nimportation.  \n \n There are legitimate concerns that importation could potentially introduce counterfeit or fraudulent products into \nthe U.S. ", "original_text": "Given how recent this announcement is, we \nhaven't yet had the full time we'd like to digest this or study this plan, but maybe a few just quick preliminary \nthoughts. ", "page_label": "5", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a1829b84c4dbb8445f3610f47f7266d7d8f14fa4f4e65a75dad77a42b87c596e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e9254940-bcd2-4c34-b682-de7b9ed04074", "node_type": "1", "metadata": {"window": "Food and Drug \nAdministration, or FDA, announced a Safe Importation A ction Plan.  Given how recent this announcement is, we \nhaven't yet had the full time we'd like to digest this or study this plan, but maybe a few just quick preliminary \nthoughts.  Obviously, McKesson's presence in both U.S.  and Canada gives us a unique persp ective on supply \nchain considerations and the impacts to stakeholders and patients as we navigate this complex question of \nimportation.  \n \n There are legitimate concerns that importation could potentially introduce counterfeit or fraudulent products into \nthe U.S.  Importantly, we have a primary responsibility to maintain a safe, secure and efficient supply chain and to \nensure that we conform to FDA safety and efficacy standards in addition to the safeguards put in place by the \n2013 passage of the Drug Supply Ch ain Security Act.  These objectives are paramount as we evaluate the two \npathways announced in today's plan.  \n \n", "original_text": "and Canada gives us a unique persp ective on supply \nchain considerations and the impacts to stakeholders and patients as we navigate this complex question of \nimportation.  \n \n"}, "hash": "d6ad8c1a137f6f9a982518416d3af2c63828bb27c639da6adc438d5da9b31511", "class_name": "RelatedNodeInfo"}}, "text": "Obviously, McKesson's presence in both U.S. ", "start_char_idx": 2038, "end_char_idx": 2082, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e9254940-bcd2-4c34-b682-de7b9ed04074": {"__data__": {"id_": "e9254940-bcd2-4c34-b682-de7b9ed04074", "embedding": null, "metadata": {"window": "Food and Drug \nAdministration, or FDA, announced a Safe Importation A ction Plan.  Given how recent this announcement is, we \nhaven't yet had the full time we'd like to digest this or study this plan, but maybe a few just quick preliminary \nthoughts.  Obviously, McKesson's presence in both U.S.  and Canada gives us a unique persp ective on supply \nchain considerations and the impacts to stakeholders and patients as we navigate this complex question of \nimportation.  \n \n There are legitimate concerns that importation could potentially introduce counterfeit or fraudulent products into \nthe U.S.  Importantly, we have a primary responsibility to maintain a safe, secure and efficient supply chain and to \nensure that we conform to FDA safety and efficacy standards in addition to the safeguards put in place by the \n2013 passage of the Drug Supply Ch ain Security Act.  These objectives are paramount as we evaluate the two \npathways announced in today's plan.  \n \n", "original_text": "and Canada gives us a unique persp ective on supply \nchain considerations and the impacts to stakeholders and patients as we navigate this complex question of \nimportation.  \n \n", "page_label": "5", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fa648db0-cb11-4d5d-95db-126c70dfc60f", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a2e50e180463329be007e15f0e2ac9f4740ffc072bf24ff7fd0f4c06ceab2e59", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0673fb43-ef6a-4289-b293-61356273ba1a", "node_type": "1", "metadata": {"window": "Department of Health and Human Services, or HHS, and the U.S.  Food and Drug \nAdministration, or FDA, announced a Safe Importation A ction Plan.  Given how recent this announcement is, we \nhaven't yet had the full time we'd like to digest this or study this plan, but maybe a few just quick preliminary \nthoughts.  Obviously, McKesson's presence in both U.S.  and Canada gives us a unique persp ective on supply \nchain considerations and the impacts to stakeholders and patients as we navigate this complex question of \nimportation.  \n \n There are legitimate concerns that importation could potentially introduce counterfeit or fraudulent products into \nthe U.S.  Importantly, we have a primary responsibility to maintain a safe, secure and efficient supply chain and to \nensure that we conform to FDA safety and efficacy standards in addition to the safeguards put in place by the \n2013 passage of the Drug Supply Ch ain Security Act. ", "original_text": "Obviously, McKesson's presence in both U.S. ", "page_label": "5", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "497d9a67070ec6db089aa1c66a8ffe4db9785837e7118d1cdcee5e69d7e45853", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b1bc4d2d-8225-408a-b0b3-a77cbc18c478", "node_type": "1", "metadata": {"window": "Given how recent this announcement is, we \nhaven't yet had the full time we'd like to digest this or study this plan, but maybe a few just quick preliminary \nthoughts.  Obviously, McKesson's presence in both U.S.  and Canada gives us a unique persp ective on supply \nchain considerations and the impacts to stakeholders and patients as we navigate this complex question of \nimportation.  \n \n There are legitimate concerns that importation could potentially introduce counterfeit or fraudulent products into \nthe U.S.  Importantly, we have a primary responsibility to maintain a safe, secure and efficient supply chain and to \nensure that we conform to FDA safety and efficacy standards in addition to the safeguards put in place by the \n2013 passage of the Drug Supply Ch ain Security Act.  These objectives are paramount as we evaluate the two \npathways announced in today's plan.  \n \n Before I wrap up, I'd like to spend a couple of minutes on the opioid epidemic. ", "original_text": "There are legitimate concerns that importation could potentially introduce counterfeit or fraudulent products into \nthe U.S. "}, "hash": "0ec26cef80e98547316e121b73784ec4c299bef26c3910b065390d3fd3a36186", "class_name": "RelatedNodeInfo"}}, "text": "and Canada gives us a unique persp ective on supply \nchain considerations and the impacts to stakeholders and patients as we navigate this complex question of \nimportation.  \n \n", "start_char_idx": 2082, "end_char_idx": 2259, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b1bc4d2d-8225-408a-b0b3-a77cbc18c478": {"__data__": {"id_": "b1bc4d2d-8225-408a-b0b3-a77cbc18c478", "embedding": null, "metadata": {"window": "Given how recent this announcement is, we \nhaven't yet had the full time we'd like to digest this or study this plan, but maybe a few just quick preliminary \nthoughts.  Obviously, McKesson's presence in both U.S.  and Canada gives us a unique persp ective on supply \nchain considerations and the impacts to stakeholders and patients as we navigate this complex question of \nimportation.  \n \n There are legitimate concerns that importation could potentially introduce counterfeit or fraudulent products into \nthe U.S.  Importantly, we have a primary responsibility to maintain a safe, secure and efficient supply chain and to \nensure that we conform to FDA safety and efficacy standards in addition to the safeguards put in place by the \n2013 passage of the Drug Supply Ch ain Security Act.  These objectives are paramount as we evaluate the two \npathways announced in today's plan.  \n \n Before I wrap up, I'd like to spend a couple of minutes on the opioid epidemic. ", "original_text": "There are legitimate concerns that importation could potentially introduce counterfeit or fraudulent products into \nthe U.S. ", "page_label": "5", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fa648db0-cb11-4d5d-95db-126c70dfc60f", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a2e50e180463329be007e15f0e2ac9f4740ffc072bf24ff7fd0f4c06ceab2e59", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e9254940-bcd2-4c34-b682-de7b9ed04074", "node_type": "1", "metadata": {"window": "Food and Drug \nAdministration, or FDA, announced a Safe Importation A ction Plan.  Given how recent this announcement is, we \nhaven't yet had the full time we'd like to digest this or study this plan, but maybe a few just quick preliminary \nthoughts.  Obviously, McKesson's presence in both U.S.  and Canada gives us a unique persp ective on supply \nchain considerations and the impacts to stakeholders and patients as we navigate this complex question of \nimportation.  \n \n There are legitimate concerns that importation could potentially introduce counterfeit or fraudulent products into \nthe U.S.  Importantly, we have a primary responsibility to maintain a safe, secure and efficient supply chain and to \nensure that we conform to FDA safety and efficacy standards in addition to the safeguards put in place by the \n2013 passage of the Drug Supply Ch ain Security Act.  These objectives are paramount as we evaluate the two \npathways announced in today's plan.  \n \n", "original_text": "and Canada gives us a unique persp ective on supply \nchain considerations and the impacts to stakeholders and patients as we navigate this complex question of \nimportation.  \n \n", "page_label": "5", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b5361638803614b070c5cc266ab6a12e9cd5d1fb2c900847694ae41d1e1af0c0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f25c81c3-0a73-4b5f-9388-9692af8073f8", "node_type": "1", "metadata": {"window": "Obviously, McKesson's presence in both U.S.  and Canada gives us a unique persp ective on supply \nchain considerations and the impacts to stakeholders and patients as we navigate this complex question of \nimportation.  \n \n There are legitimate concerns that importation could potentially introduce counterfeit or fraudulent products into \nthe U.S.  Importantly, we have a primary responsibility to maintain a safe, secure and efficient supply chain and to \nensure that we conform to FDA safety and efficacy standards in addition to the safeguards put in place by the \n2013 passage of the Drug Supply Ch ain Security Act.  These objectives are paramount as we evaluate the two \npathways announced in today's plan.  \n \n Before I wrap up, I'd like to spend a couple of minutes on the opioid epidemic.  We continue to believe distributors \nare being disproportionally tar geted, given our important but limited role in the supply chain, filling orders from \nlicensed pharmacies who are in turn filling prescriptions written by licensed health care providers. ", "original_text": "Importantly, we have a primary responsibility to maintain a safe, secure and efficient supply chain and to \nensure that we conform to FDA safety and efficacy standards in addition to the safeguards put in place by the \n2013 passage of the Drug Supply Ch ain Security Act. "}, "hash": "04b251c28cd3fde39d2e8791f67da0faf9c5fc27cd619c3845e71516845c179e", "class_name": "RelatedNodeInfo"}}, "text": "There are legitimate concerns that importation could potentially introduce counterfeit or fraudulent products into \nthe U.S. ", "start_char_idx": 2259, "end_char_idx": 2384, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f25c81c3-0a73-4b5f-9388-9692af8073f8": {"__data__": {"id_": "f25c81c3-0a73-4b5f-9388-9692af8073f8", "embedding": null, "metadata": {"window": "Obviously, McKesson's presence in both U.S.  and Canada gives us a unique persp ective on supply \nchain considerations and the impacts to stakeholders and patients as we navigate this complex question of \nimportation.  \n \n There are legitimate concerns that importation could potentially introduce counterfeit or fraudulent products into \nthe U.S.  Importantly, we have a primary responsibility to maintain a safe, secure and efficient supply chain and to \nensure that we conform to FDA safety and efficacy standards in addition to the safeguards put in place by the \n2013 passage of the Drug Supply Ch ain Security Act.  These objectives are paramount as we evaluate the two \npathways announced in today's plan.  \n \n Before I wrap up, I'd like to spend a couple of minutes on the opioid epidemic.  We continue to believe distributors \nare being disproportionally tar geted, given our important but limited role in the supply chain, filling orders from \nlicensed pharmacies who are in turn filling prescriptions written by licensed health care providers. ", "original_text": "Importantly, we have a primary responsibility to maintain a safe, secure and efficient supply chain and to \nensure that we conform to FDA safety and efficacy standards in addition to the safeguards put in place by the \n2013 passage of the Drug Supply Ch ain Security Act. ", "page_label": "5", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fa648db0-cb11-4d5d-95db-126c70dfc60f", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a2e50e180463329be007e15f0e2ac9f4740ffc072bf24ff7fd0f4c06ceab2e59", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b1bc4d2d-8225-408a-b0b3-a77cbc18c478", "node_type": "1", "metadata": {"window": "Given how recent this announcement is, we \nhaven't yet had the full time we'd like to digest this or study this plan, but maybe a few just quick preliminary \nthoughts.  Obviously, McKesson's presence in both U.S.  and Canada gives us a unique persp ective on supply \nchain considerations and the impacts to stakeholders and patients as we navigate this complex question of \nimportation.  \n \n There are legitimate concerns that importation could potentially introduce counterfeit or fraudulent products into \nthe U.S.  Importantly, we have a primary responsibility to maintain a safe, secure and efficient supply chain and to \nensure that we conform to FDA safety and efficacy standards in addition to the safeguards put in place by the \n2013 passage of the Drug Supply Ch ain Security Act.  These objectives are paramount as we evaluate the two \npathways announced in today's plan.  \n \n Before I wrap up, I'd like to spend a couple of minutes on the opioid epidemic. ", "original_text": "There are legitimate concerns that importation could potentially introduce counterfeit or fraudulent products into \nthe U.S. ", "page_label": "5", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c7c8749cb2cc29733d23cc3a46d860139cbb84212c6ed102f631b8dfb2a6cd0b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a3a2277c-688a-4d68-8d9e-94488789f010", "node_type": "1", "metadata": {"window": "and Canada gives us a unique persp ective on supply \nchain considerations and the impacts to stakeholders and patients as we navigate this complex question of \nimportation.  \n \n There are legitimate concerns that importation could potentially introduce counterfeit or fraudulent products into \nthe U.S.  Importantly, we have a primary responsibility to maintain a safe, secure and efficient supply chain and to \nensure that we conform to FDA safety and efficacy standards in addition to the safeguards put in place by the \n2013 passage of the Drug Supply Ch ain Security Act.  These objectives are paramount as we evaluate the two \npathways announced in today's plan.  \n \n Before I wrap up, I'd like to spend a couple of minutes on the opioid epidemic.  We continue to believe distributors \nare being disproportionally tar geted, given our important but limited role in the supply chain, filling orders from \nlicensed pharmacies who are in turn filling prescriptions written by licensed health care providers.  Any suggestion \nthat McKesson drove demand for opioids in this country would reflect a fundamental misunderstanding and \nmischaracterization of our role as a distributor.  \n \n", "original_text": "These objectives are paramount as we evaluate the two \npathways announced in today's plan.  \n \n"}, "hash": "81d94c854889fa45db1abb2b929861d0481472a0f215036c612346984985fa6e", "class_name": "RelatedNodeInfo"}}, "text": "Importantly, we have a primary responsibility to maintain a safe, secure and efficient supply chain and to \nensure that we conform to FDA safety and efficacy standards in addition to the safeguards put in place by the \n2013 passage of the Drug Supply Ch ain Security Act. ", "start_char_idx": 2384, "end_char_idx": 2656, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a3a2277c-688a-4d68-8d9e-94488789f010": {"__data__": {"id_": "a3a2277c-688a-4d68-8d9e-94488789f010", "embedding": null, "metadata": {"window": "and Canada gives us a unique persp ective on supply \nchain considerations and the impacts to stakeholders and patients as we navigate this complex question of \nimportation.  \n \n There are legitimate concerns that importation could potentially introduce counterfeit or fraudulent products into \nthe U.S.  Importantly, we have a primary responsibility to maintain a safe, secure and efficient supply chain and to \nensure that we conform to FDA safety and efficacy standards in addition to the safeguards put in place by the \n2013 passage of the Drug Supply Ch ain Security Act.  These objectives are paramount as we evaluate the two \npathways announced in today's plan.  \n \n Before I wrap up, I'd like to spend a couple of minutes on the opioid epidemic.  We continue to believe distributors \nare being disproportionally tar geted, given our important but limited role in the supply chain, filling orders from \nlicensed pharmacies who are in turn filling prescriptions written by licensed health care providers.  Any suggestion \nthat McKesson drove demand for opioids in this country would reflect a fundamental misunderstanding and \nmischaracterization of our role as a distributor.  \n \n", "original_text": "These objectives are paramount as we evaluate the two \npathways announced in today's plan.  \n \n", "page_label": "5", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fa648db0-cb11-4d5d-95db-126c70dfc60f", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a2e50e180463329be007e15f0e2ac9f4740ffc072bf24ff7fd0f4c06ceab2e59", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f25c81c3-0a73-4b5f-9388-9692af8073f8", "node_type": "1", "metadata": {"window": "Obviously, McKesson's presence in both U.S.  and Canada gives us a unique persp ective on supply \nchain considerations and the impacts to stakeholders and patients as we navigate this complex question of \nimportation.  \n \n There are legitimate concerns that importation could potentially introduce counterfeit or fraudulent products into \nthe U.S.  Importantly, we have a primary responsibility to maintain a safe, secure and efficient supply chain and to \nensure that we conform to FDA safety and efficacy standards in addition to the safeguards put in place by the \n2013 passage of the Drug Supply Ch ain Security Act.  These objectives are paramount as we evaluate the two \npathways announced in today's plan.  \n \n Before I wrap up, I'd like to spend a couple of minutes on the opioid epidemic.  We continue to believe distributors \nare being disproportionally tar geted, given our important but limited role in the supply chain, filling orders from \nlicensed pharmacies who are in turn filling prescriptions written by licensed health care providers. ", "original_text": "Importantly, we have a primary responsibility to maintain a safe, secure and efficient supply chain and to \nensure that we conform to FDA safety and efficacy standards in addition to the safeguards put in place by the \n2013 passage of the Drug Supply Ch ain Security Act. ", "page_label": "5", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "15168bf97d781d20d64b44d167395fbb094668b79ed4b1bc30fd5604ea0f33e8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "95bf8a2b-9d7c-421a-92ca-8ac05f27a45c", "node_type": "1", "metadata": {"window": "There are legitimate concerns that importation could potentially introduce counterfeit or fraudulent products into \nthe U.S.  Importantly, we have a primary responsibility to maintain a safe, secure and efficient supply chain and to \nensure that we conform to FDA safety and efficacy standards in addition to the safeguards put in place by the \n2013 passage of the Drug Supply Ch ain Security Act.  These objectives are paramount as we evaluate the two \npathways announced in today's plan.  \n \n Before I wrap up, I'd like to spend a couple of minutes on the opioid epidemic.  We continue to believe distributors \nare being disproportionally tar geted, given our important but limited role in the supply chain, filling orders from \nlicensed pharmacies who are in turn filling prescriptions written by licensed health care providers.  Any suggestion \nthat McKesson drove demand for opioids in this country would reflect a fundamental misunderstanding and \nmischaracterization of our role as a distributor.  \n \n We will continue to fight that mischaracterization in the multiple venues both state and federal, where lawsuits \nhave been filed by thousands of plaintiffs.  ", "original_text": "Before I wrap up, I'd like to spend a couple of minutes on the opioid epidemic. "}, "hash": "89d0b0326806df62aac2dffa7580bf8723feb8240bf468081bb29873f462cca6", "class_name": "RelatedNodeInfo"}}, "text": "These objectives are paramount as we evaluate the two \npathways announced in today's plan.  \n \n", "start_char_idx": 2656, "end_char_idx": 2751, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "95bf8a2b-9d7c-421a-92ca-8ac05f27a45c": {"__data__": {"id_": "95bf8a2b-9d7c-421a-92ca-8ac05f27a45c", "embedding": null, "metadata": {"window": "There are legitimate concerns that importation could potentially introduce counterfeit or fraudulent products into \nthe U.S.  Importantly, we have a primary responsibility to maintain a safe, secure and efficient supply chain and to \nensure that we conform to FDA safety and efficacy standards in addition to the safeguards put in place by the \n2013 passage of the Drug Supply Ch ain Security Act.  These objectives are paramount as we evaluate the two \npathways announced in today's plan.  \n \n Before I wrap up, I'd like to spend a couple of minutes on the opioid epidemic.  We continue to believe distributors \nare being disproportionally tar geted, given our important but limited role in the supply chain, filling orders from \nlicensed pharmacies who are in turn filling prescriptions written by licensed health care providers.  Any suggestion \nthat McKesson drove demand for opioids in this country would reflect a fundamental misunderstanding and \nmischaracterization of our role as a distributor.  \n \n We will continue to fight that mischaracterization in the multiple venues both state and federal, where lawsuits \nhave been filed by thousands of plaintiffs.  ", "original_text": "Before I wrap up, I'd like to spend a couple of minutes on the opioid epidemic. ", "page_label": "5", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fa648db0-cb11-4d5d-95db-126c70dfc60f", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a2e50e180463329be007e15f0e2ac9f4740ffc072bf24ff7fd0f4c06ceab2e59", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a3a2277c-688a-4d68-8d9e-94488789f010", "node_type": "1", "metadata": {"window": "and Canada gives us a unique persp ective on supply \nchain considerations and the impacts to stakeholders and patients as we navigate this complex question of \nimportation.  \n \n There are legitimate concerns that importation could potentially introduce counterfeit or fraudulent products into \nthe U.S.  Importantly, we have a primary responsibility to maintain a safe, secure and efficient supply chain and to \nensure that we conform to FDA safety and efficacy standards in addition to the safeguards put in place by the \n2013 passage of the Drug Supply Ch ain Security Act.  These objectives are paramount as we evaluate the two \npathways announced in today's plan.  \n \n Before I wrap up, I'd like to spend a couple of minutes on the opioid epidemic.  We continue to believe distributors \nare being disproportionally tar geted, given our important but limited role in the supply chain, filling orders from \nlicensed pharmacies who are in turn filling prescriptions written by licensed health care providers.  Any suggestion \nthat McKesson drove demand for opioids in this country would reflect a fundamental misunderstanding and \nmischaracterization of our role as a distributor.  \n \n", "original_text": "These objectives are paramount as we evaluate the two \npathways announced in today's plan.  \n \n", "page_label": "5", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ea2276ed9c047c305001474da24127491cc15646ecc3b24d5a113353342cdb07", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d49520e5-d56b-4012-9c4e-1c21b8a67585", "node_type": "1", "metadata": {"window": "Importantly, we have a primary responsibility to maintain a safe, secure and efficient supply chain and to \nensure that we conform to FDA safety and efficacy standards in addition to the safeguards put in place by the \n2013 passage of the Drug Supply Ch ain Security Act.  These objectives are paramount as we evaluate the two \npathways announced in today's plan.  \n \n Before I wrap up, I'd like to spend a couple of minutes on the opioid epidemic.  We continue to believe distributors \nare being disproportionally tar geted, given our important but limited role in the supply chain, filling orders from \nlicensed pharmacies who are in turn filling prescriptions written by licensed health care providers.  Any suggestion \nthat McKesson drove demand for opioids in this country would reflect a fundamental misunderstanding and \nmischaracterization of our role as a distributor.  \n \n We will continue to fight that mischaracterization in the multiple venues both state and federal, where lawsuits \nhave been filed by thousands of plaintiffs.   These are clearly novel, complex and unprecedented claims that must \nbe navigated. ", "original_text": "We continue to believe distributors \nare being disproportionally tar geted, given our important but limited role in the supply chain, filling orders from \nlicensed pharmacies who are in turn filling prescriptions written by licensed health care providers. "}, "hash": "47b5fdd2bc0865289133fe5700555e2331ce59025b069f9c699826b966e0f653", "class_name": "RelatedNodeInfo"}}, "text": "Before I wrap up, I'd like to spend a couple of minutes on the opioid epidemic. ", "start_char_idx": 2751, "end_char_idx": 2831, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d49520e5-d56b-4012-9c4e-1c21b8a67585": {"__data__": {"id_": "d49520e5-d56b-4012-9c4e-1c21b8a67585", "embedding": null, "metadata": {"window": "Importantly, we have a primary responsibility to maintain a safe, secure and efficient supply chain and to \nensure that we conform to FDA safety and efficacy standards in addition to the safeguards put in place by the \n2013 passage of the Drug Supply Ch ain Security Act.  These objectives are paramount as we evaluate the two \npathways announced in today's plan.  \n \n Before I wrap up, I'd like to spend a couple of minutes on the opioid epidemic.  We continue to believe distributors \nare being disproportionally tar geted, given our important but limited role in the supply chain, filling orders from \nlicensed pharmacies who are in turn filling prescriptions written by licensed health care providers.  Any suggestion \nthat McKesson drove demand for opioids in this country would reflect a fundamental misunderstanding and \nmischaracterization of our role as a distributor.  \n \n We will continue to fight that mischaracterization in the multiple venues both state and federal, where lawsuits \nhave been filed by thousands of plaintiffs.   These are clearly novel, complex and unprecedented claims that must \nbe navigated. ", "original_text": "We continue to believe distributors \nare being disproportionally tar geted, given our important but limited role in the supply chain, filling orders from \nlicensed pharmacies who are in turn filling prescriptions written by licensed health care providers. ", "page_label": "5", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fa648db0-cb11-4d5d-95db-126c70dfc60f", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a2e50e180463329be007e15f0e2ac9f4740ffc072bf24ff7fd0f4c06ceab2e59", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "95bf8a2b-9d7c-421a-92ca-8ac05f27a45c", "node_type": "1", "metadata": {"window": "There are legitimate concerns that importation could potentially introduce counterfeit or fraudulent products into \nthe U.S.  Importantly, we have a primary responsibility to maintain a safe, secure and efficient supply chain and to \nensure that we conform to FDA safety and efficacy standards in addition to the safeguards put in place by the \n2013 passage of the Drug Supply Ch ain Security Act.  These objectives are paramount as we evaluate the two \npathways announced in today's plan.  \n \n Before I wrap up, I'd like to spend a couple of minutes on the opioid epidemic.  We continue to believe distributors \nare being disproportionally tar geted, given our important but limited role in the supply chain, filling orders from \nlicensed pharmacies who are in turn filling prescriptions written by licensed health care providers.  Any suggestion \nthat McKesson drove demand for opioids in this country would reflect a fundamental misunderstanding and \nmischaracterization of our role as a distributor.  \n \n We will continue to fight that mischaracterization in the multiple venues both state and federal, where lawsuits \nhave been filed by thousands of plaintiffs.  ", "original_text": "Before I wrap up, I'd like to spend a couple of minutes on the opioid epidemic. ", "page_label": "5", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1e6e0b4132570f95fb3c69e4126566dd32ea5253bbe060ffeb895f14320d3b48", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "87684e1d-97f7-44b4-8cdf-88d9ef9d3239", "node_type": "1", "metadata": {"window": "These objectives are paramount as we evaluate the two \npathways announced in today's plan.  \n \n Before I wrap up, I'd like to spend a couple of minutes on the opioid epidemic.  We continue to believe distributors \nare being disproportionally tar geted, given our important but limited role in the supply chain, filling orders from \nlicensed pharmacies who are in turn filling prescriptions written by licensed health care providers.  Any suggestion \nthat McKesson drove demand for opioids in this country would reflect a fundamental misunderstanding and \nmischaracterization of our role as a distributor.  \n \n We will continue to fight that mischaracterization in the multiple venues both state and federal, where lawsuits \nhave been filed by thousands of plaintiffs.   These are clearly novel, complex and unprecedented claims that must \nbe navigated.  And we remain deeply concerned about the impact that this crisis is having on families and \ncommunities across the U.S. ", "original_text": "Any suggestion \nthat McKesson drove demand for opioids in this country would reflect a fundamental misunderstanding and \nmischaracterization of our role as a distributor.  \n \n"}, "hash": "1dd28f7980fdf1aa97486867bbe3d86e4ffdea00cbf9cf283c800496c85228a0", "class_name": "RelatedNodeInfo"}}, "text": "We continue to believe distributors \nare being disproportionally tar geted, given our important but limited role in the supply chain, filling orders from \nlicensed pharmacies who are in turn filling prescriptions written by licensed health care providers. ", "start_char_idx": 2831, "end_char_idx": 3087, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "87684e1d-97f7-44b4-8cdf-88d9ef9d3239": {"__data__": {"id_": "87684e1d-97f7-44b4-8cdf-88d9ef9d3239", "embedding": null, "metadata": {"window": "These objectives are paramount as we evaluate the two \npathways announced in today's plan.  \n \n Before I wrap up, I'd like to spend a couple of minutes on the opioid epidemic.  We continue to believe distributors \nare being disproportionally tar geted, given our important but limited role in the supply chain, filling orders from \nlicensed pharmacies who are in turn filling prescriptions written by licensed health care providers.  Any suggestion \nthat McKesson drove demand for opioids in this country would reflect a fundamental misunderstanding and \nmischaracterization of our role as a distributor.  \n \n We will continue to fight that mischaracterization in the multiple venues both state and federal, where lawsuits \nhave been filed by thousands of plaintiffs.   These are clearly novel, complex and unprecedented claims that must \nbe navigated.  And we remain deeply concerned about the impact that this crisis is having on families and \ncommunities across the U.S. ", "original_text": "Any suggestion \nthat McKesson drove demand for opioids in this country would reflect a fundamental misunderstanding and \nmischaracterization of our role as a distributor.  \n \n", "page_label": "5", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fa648db0-cb11-4d5d-95db-126c70dfc60f", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a2e50e180463329be007e15f0e2ac9f4740ffc072bf24ff7fd0f4c06ceab2e59", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d49520e5-d56b-4012-9c4e-1c21b8a67585", "node_type": "1", "metadata": {"window": "Importantly, we have a primary responsibility to maintain a safe, secure and efficient supply chain and to \nensure that we conform to FDA safety and efficacy standards in addition to the safeguards put in place by the \n2013 passage of the Drug Supply Ch ain Security Act.  These objectives are paramount as we evaluate the two \npathways announced in today's plan.  \n \n Before I wrap up, I'd like to spend a couple of minutes on the opioid epidemic.  We continue to believe distributors \nare being disproportionally tar geted, given our important but limited role in the supply chain, filling orders from \nlicensed pharmacies who are in turn filling prescriptions written by licensed health care providers.  Any suggestion \nthat McKesson drove demand for opioids in this country would reflect a fundamental misunderstanding and \nmischaracterization of our role as a distributor.  \n \n We will continue to fight that mischaracterization in the multiple venues both state and federal, where lawsuits \nhave been filed by thousands of plaintiffs.   These are clearly novel, complex and unprecedented claims that must \nbe navigated. ", "original_text": "We continue to believe distributors \nare being disproportionally tar geted, given our important but limited role in the supply chain, filling orders from \nlicensed pharmacies who are in turn filling prescriptions written by licensed health care providers. ", "page_label": "5", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cc42504df7e1f273851b228147fbbcfb5e4c23c5c7bbb3771c973d75631361d8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ce7fb8af-0d4f-4cc3-a45c-c6c926a2fda9", "node_type": "1", "metadata": {"window": "Before I wrap up, I'd like to spend a couple of minutes on the opioid epidemic.  We continue to believe distributors \nare being disproportionally tar geted, given our important but limited role in the supply chain, filling orders from \nlicensed pharmacies who are in turn filling prescriptions written by licensed health care providers.  Any suggestion \nthat McKesson drove demand for opioids in this country would reflect a fundamental misunderstanding and \nmischaracterization of our role as a distributor.  \n \n We will continue to fight that mischaracterization in the multiple venues both state and federal, where lawsuits \nhave been filed by thousands of plaintiffs.   These are clearly novel, complex and unprecedented claims that must \nbe navigated.  And we remain deeply concerned about the impact that this crisis is having on families and \ncommunities across the U.S.  and are passionately committed to using McKesson's cap abilities to be part of the \nsolution. ", "original_text": "We will continue to fight that mischaracterization in the multiple venues both state and federal, where lawsuits \nhave been filed by thousands of plaintiffs.  "}, "hash": "8de318135223e7d3d530186fc15bb898ba127ca93a71f02fed2c4ad91a70c810", "class_name": "RelatedNodeInfo"}}, "text": "Any suggestion \nthat McKesson drove demand for opioids in this country would reflect a fundamental misunderstanding and \nmischaracterization of our role as a distributor.  \n \n", "start_char_idx": 3087, "end_char_idx": 3262, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ce7fb8af-0d4f-4cc3-a45c-c6c926a2fda9": {"__data__": {"id_": "ce7fb8af-0d4f-4cc3-a45c-c6c926a2fda9", "embedding": null, "metadata": {"window": "Before I wrap up, I'd like to spend a couple of minutes on the opioid epidemic.  We continue to believe distributors \nare being disproportionally tar geted, given our important but limited role in the supply chain, filling orders from \nlicensed pharmacies who are in turn filling prescriptions written by licensed health care providers.  Any suggestion \nthat McKesson drove demand for opioids in this country would reflect a fundamental misunderstanding and \nmischaracterization of our role as a distributor.  \n \n We will continue to fight that mischaracterization in the multiple venues both state and federal, where lawsuits \nhave been filed by thousands of plaintiffs.   These are clearly novel, complex and unprecedented claims that must \nbe navigated.  And we remain deeply concerned about the impact that this crisis is having on families and \ncommunities across the U.S.  and are passionately committed to using McKesson's cap abilities to be part of the \nsolution. ", "original_text": "We will continue to fight that mischaracterization in the multiple venues both state and federal, where lawsuits \nhave been filed by thousands of plaintiffs.  ", "page_label": "5", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fa648db0-cb11-4d5d-95db-126c70dfc60f", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a2e50e180463329be007e15f0e2ac9f4740ffc072bf24ff7fd0f4c06ceab2e59", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "87684e1d-97f7-44b4-8cdf-88d9ef9d3239", "node_type": "1", "metadata": {"window": "These objectives are paramount as we evaluate the two \npathways announced in today's plan.  \n \n Before I wrap up, I'd like to spend a couple of minutes on the opioid epidemic.  We continue to believe distributors \nare being disproportionally tar geted, given our important but limited role in the supply chain, filling orders from \nlicensed pharmacies who are in turn filling prescriptions written by licensed health care providers.  Any suggestion \nthat McKesson drove demand for opioids in this country would reflect a fundamental misunderstanding and \nmischaracterization of our role as a distributor.  \n \n We will continue to fight that mischaracterization in the multiple venues both state and federal, where lawsuits \nhave been filed by thousands of plaintiffs.   These are clearly novel, complex and unprecedented claims that must \nbe navigated.  And we remain deeply concerned about the impact that this crisis is having on families and \ncommunities across the U.S. ", "original_text": "Any suggestion \nthat McKesson drove demand for opioids in this country would reflect a fundamental misunderstanding and \nmischaracterization of our role as a distributor.  \n \n", "page_label": "5", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "16fec55671e5daaaa77af8f5165f5bb415a2b8de672f10a1988585cb1ed4f8c8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "198dcd87-3bfa-4c18-95ae-0d1244513a75", "node_type": "1", "metadata": {"window": "We continue to believe distributors \nare being disproportionally tar geted, given our important but limited role in the supply chain, filling orders from \nlicensed pharmacies who are in turn filling prescriptions written by licensed health care providers.  Any suggestion \nthat McKesson drove demand for opioids in this country would reflect a fundamental misunderstanding and \nmischaracterization of our role as a distributor.  \n \n We will continue to fight that mischaracterization in the multiple venues both state and federal, where lawsuits \nhave been filed by thousands of plaintiffs.   These are clearly novel, complex and unprecedented claims that must \nbe navigated.  And we remain deeply concerned about the impact that this crisis is having on families and \ncommunities across the U.S.  and are passionately committed to using McKesson's cap abilities to be part of the \nsolution.  This includes partnering with government, industry, social institutions and other players to help bring this \ncrisis to an end.  \n \n", "original_text": "These are clearly novel, complex and unprecedented claims that must \nbe navigated. "}, "hash": "196e2ecd89fd1e72f90896558386cf690a799c752870fc1cd62f2fb67b7c6f73", "class_name": "RelatedNodeInfo"}}, "text": "We will continue to fight that mischaracterization in the multiple venues both state and federal, where lawsuits \nhave been filed by thousands of plaintiffs.  ", "start_char_idx": 3262, "end_char_idx": 3421, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "198dcd87-3bfa-4c18-95ae-0d1244513a75": {"__data__": {"id_": "198dcd87-3bfa-4c18-95ae-0d1244513a75", "embedding": null, "metadata": {"window": "We continue to believe distributors \nare being disproportionally tar geted, given our important but limited role in the supply chain, filling orders from \nlicensed pharmacies who are in turn filling prescriptions written by licensed health care providers.  Any suggestion \nthat McKesson drove demand for opioids in this country would reflect a fundamental misunderstanding and \nmischaracterization of our role as a distributor.  \n \n We will continue to fight that mischaracterization in the multiple venues both state and federal, where lawsuits \nhave been filed by thousands of plaintiffs.   These are clearly novel, complex and unprecedented claims that must \nbe navigated.  And we remain deeply concerned about the impact that this crisis is having on families and \ncommunities across the U.S.  and are passionately committed to using McKesson's cap abilities to be part of the \nsolution.  This includes partnering with government, industry, social institutions and other players to help bring this \ncrisis to an end.  \n \n", "original_text": "These are clearly novel, complex and unprecedented claims that must \nbe navigated. ", "page_label": "5", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fa648db0-cb11-4d5d-95db-126c70dfc60f", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a2e50e180463329be007e15f0e2ac9f4740ffc072bf24ff7fd0f4c06ceab2e59", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ce7fb8af-0d4f-4cc3-a45c-c6c926a2fda9", "node_type": "1", "metadata": {"window": "Before I wrap up, I'd like to spend a couple of minutes on the opioid epidemic.  We continue to believe distributors \nare being disproportionally tar geted, given our important but limited role in the supply chain, filling orders from \nlicensed pharmacies who are in turn filling prescriptions written by licensed health care providers.  Any suggestion \nthat McKesson drove demand for opioids in this country would reflect a fundamental misunderstanding and \nmischaracterization of our role as a distributor.  \n \n We will continue to fight that mischaracterization in the multiple venues both state and federal, where lawsuits \nhave been filed by thousands of plaintiffs.   These are clearly novel, complex and unprecedented claims that must \nbe navigated.  And we remain deeply concerned about the impact that this crisis is having on families and \ncommunities across the U.S.  and are passionately committed to using McKesson's cap abilities to be part of the \nsolution. ", "original_text": "We will continue to fight that mischaracterization in the multiple venues both state and federal, where lawsuits \nhave been filed by thousands of plaintiffs.  ", "page_label": "5", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6fd9542c35de64dbb380a1bd8f86c903b3ef9857ec165677f3ab244f525d0f77", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "340369b9-e29f-48ae-bae5-cd7d242349f8", "node_type": "1", "metadata": {"window": "Any suggestion \nthat McKesson drove demand for opioids in this country would reflect a fundamental misunderstanding and \nmischaracterization of our role as a distributor.  \n \n We will continue to fight that mischaracterization in the multiple venues both state and federal, where lawsuits \nhave been filed by thousands of plaintiffs.   These are clearly novel, complex and unprecedented claims that must \nbe navigated.  And we remain deeply concerned about the impact that this crisis is having on families and \ncommunities across the U.S.  and are passionately committed to using McKesson's cap abilities to be part of the \nsolution.  This includes partnering with government, industry, social institutions and other players to help bring this \ncrisis to an end.  \n \n I've spoken about it before, but let me remind you of the investments we've made and conti nue to make in our \nprograms, our processes, our technologies dedicated to preventing diversion and in our corporate initiatives \nannounced last spring to help address the epidemic. ", "original_text": "And we remain deeply concerned about the impact that this crisis is having on families and \ncommunities across the U.S. "}, "hash": "ec2a308942778c060b151cc15a8dd0e3e1fbfe009e23b9e2965881fd1d67af6b", "class_name": "RelatedNodeInfo"}}, "text": "These are clearly novel, complex and unprecedented claims that must \nbe navigated. ", "start_char_idx": 3421, "end_char_idx": 3504, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "340369b9-e29f-48ae-bae5-cd7d242349f8": {"__data__": {"id_": "340369b9-e29f-48ae-bae5-cd7d242349f8", "embedding": null, "metadata": {"window": "Any suggestion \nthat McKesson drove demand for opioids in this country would reflect a fundamental misunderstanding and \nmischaracterization of our role as a distributor.  \n \n We will continue to fight that mischaracterization in the multiple venues both state and federal, where lawsuits \nhave been filed by thousands of plaintiffs.   These are clearly novel, complex and unprecedented claims that must \nbe navigated.  And we remain deeply concerned about the impact that this crisis is having on families and \ncommunities across the U.S.  and are passionately committed to using McKesson's cap abilities to be part of the \nsolution.  This includes partnering with government, industry, social institutions and other players to help bring this \ncrisis to an end.  \n \n I've spoken about it before, but let me remind you of the investments we've made and conti nue to make in our \nprograms, our processes, our technologies dedicated to preventing diversion and in our corporate initiatives \nannounced last spring to help address the epidemic. ", "original_text": "And we remain deeply concerned about the impact that this crisis is having on families and \ncommunities across the U.S. ", "page_label": "5", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fa648db0-cb11-4d5d-95db-126c70dfc60f", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a2e50e180463329be007e15f0e2ac9f4740ffc072bf24ff7fd0f4c06ceab2e59", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "198dcd87-3bfa-4c18-95ae-0d1244513a75", "node_type": "1", "metadata": {"window": "We continue to believe distributors \nare being disproportionally tar geted, given our important but limited role in the supply chain, filling orders from \nlicensed pharmacies who are in turn filling prescriptions written by licensed health care providers.  Any suggestion \nthat McKesson drove demand for opioids in this country would reflect a fundamental misunderstanding and \nmischaracterization of our role as a distributor.  \n \n We will continue to fight that mischaracterization in the multiple venues both state and federal, where lawsuits \nhave been filed by thousands of plaintiffs.   These are clearly novel, complex and unprecedented claims that must \nbe navigated.  And we remain deeply concerned about the impact that this crisis is having on families and \ncommunities across the U.S.  and are passionately committed to using McKesson's cap abilities to be part of the \nsolution.  This includes partnering with government, industry, social institutions and other players to help bring this \ncrisis to an end.  \n \n", "original_text": "These are clearly novel, complex and unprecedented claims that must \nbe navigated. ", "page_label": "5", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dfa26b9d1137461af7b6353241dc6449d52e7123a720196608b25e507337216e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d64f37bc-55df-4648-8d80-3d91ff8b614e", "node_type": "1", "metadata": {"window": "We will continue to fight that mischaracterization in the multiple venues both state and federal, where lawsuits \nhave been filed by thousands of plaintiffs.   These are clearly novel, complex and unprecedented claims that must \nbe navigated.  And we remain deeply concerned about the impact that this crisis is having on families and \ncommunities across the U.S.  and are passionately committed to using McKesson's cap abilities to be part of the \nsolution.  This includes partnering with government, industry, social institutions and other players to help bring this \ncrisis to an end.  \n \n I've spoken about it before, but let me remind you of the investments we've made and conti nue to make in our \nprograms, our processes, our technologies dedicated to preventing diversion and in our corporate initiatives \nannounced last spring to help address the epidemic.  Those include educating the pharmacies and hospitals to \nwhom we deliver abou t the importance of compliance with DEA regulations, creating a nationwide clinical alert ", "original_text": "and are passionately committed to using McKesson's cap abilities to be part of the \nsolution. "}, "hash": "06348aefb9a4e1f35dcec164554344dbaeec5e933b256783cb8505c0b6e48532", "class_name": "RelatedNodeInfo"}}, "text": "And we remain deeply concerned about the impact that this crisis is having on families and \ncommunities across the U.S. ", "start_char_idx": 3504, "end_char_idx": 3624, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d64f37bc-55df-4648-8d80-3d91ff8b614e": {"__data__": {"id_": "d64f37bc-55df-4648-8d80-3d91ff8b614e", "embedding": null, "metadata": {"window": "We will continue to fight that mischaracterization in the multiple venues both state and federal, where lawsuits \nhave been filed by thousands of plaintiffs.   These are clearly novel, complex and unprecedented claims that must \nbe navigated.  And we remain deeply concerned about the impact that this crisis is having on families and \ncommunities across the U.S.  and are passionately committed to using McKesson's cap abilities to be part of the \nsolution.  This includes partnering with government, industry, social institutions and other players to help bring this \ncrisis to an end.  \n \n I've spoken about it before, but let me remind you of the investments we've made and conti nue to make in our \nprograms, our processes, our technologies dedicated to preventing diversion and in our corporate initiatives \nannounced last spring to help address the epidemic.  Those include educating the pharmacies and hospitals to \nwhom we deliver abou t the importance of compliance with DEA regulations, creating a nationwide clinical alert ", "original_text": "and are passionately committed to using McKesson's cap abilities to be part of the \nsolution. ", "page_label": "5", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fa648db0-cb11-4d5d-95db-126c70dfc60f", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a2e50e180463329be007e15f0e2ac9f4740ffc072bf24ff7fd0f4c06ceab2e59", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "340369b9-e29f-48ae-bae5-cd7d242349f8", "node_type": "1", "metadata": {"window": "Any suggestion \nthat McKesson drove demand for opioids in this country would reflect a fundamental misunderstanding and \nmischaracterization of our role as a distributor.  \n \n We will continue to fight that mischaracterization in the multiple venues both state and federal, where lawsuits \nhave been filed by thousands of plaintiffs.   These are clearly novel, complex and unprecedented claims that must \nbe navigated.  And we remain deeply concerned about the impact that this crisis is having on families and \ncommunities across the U.S.  and are passionately committed to using McKesson's cap abilities to be part of the \nsolution.  This includes partnering with government, industry, social institutions and other players to help bring this \ncrisis to an end.  \n \n I've spoken about it before, but let me remind you of the investments we've made and conti nue to make in our \nprograms, our processes, our technologies dedicated to preventing diversion and in our corporate initiatives \nannounced last spring to help address the epidemic. ", "original_text": "And we remain deeply concerned about the impact that this crisis is having on families and \ncommunities across the U.S. ", "page_label": "5", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "69562cca007382790787efe52d195d1f85f58f1955e88040b98a71010ce07ad4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8dc0a584-fd6d-4354-aff9-71e7cf9da50e", "node_type": "1", "metadata": {"window": "These are clearly novel, complex and unprecedented claims that must \nbe navigated.  And we remain deeply concerned about the impact that this crisis is having on families and \ncommunities across the U.S.  and are passionately committed to using McKesson's cap abilities to be part of the \nsolution.  This includes partnering with government, industry, social institutions and other players to help bring this \ncrisis to an end.  \n \n I've spoken about it before, but let me remind you of the investments we've made and conti nue to make in our \nprograms, our processes, our technologies dedicated to preventing diversion and in our corporate initiatives \nannounced last spring to help address the epidemic.  Those include educating the pharmacies and hospitals to \nwhom we deliver abou t the importance of compliance with DEA regulations, creating a nationwide clinical alert ", "original_text": "This includes partnering with government, industry, social institutions and other players to help bring this \ncrisis to an end.  \n \n"}, "hash": "9a54e0c151ec95f877a7416057fe3c2b8e65b54bb88a50c66c9543e9d670f67b", "class_name": "RelatedNodeInfo"}}, "text": "and are passionately committed to using McKesson's cap abilities to be part of the \nsolution. ", "start_char_idx": 3624, "end_char_idx": 3718, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8dc0a584-fd6d-4354-aff9-71e7cf9da50e": {"__data__": {"id_": "8dc0a584-fd6d-4354-aff9-71e7cf9da50e", "embedding": null, "metadata": {"window": "These are clearly novel, complex and unprecedented claims that must \nbe navigated.  And we remain deeply concerned about the impact that this crisis is having on families and \ncommunities across the U.S.  and are passionately committed to using McKesson's cap abilities to be part of the \nsolution.  This includes partnering with government, industry, social institutions and other players to help bring this \ncrisis to an end.  \n \n I've spoken about it before, but let me remind you of the investments we've made and conti nue to make in our \nprograms, our processes, our technologies dedicated to preventing diversion and in our corporate initiatives \nannounced last spring to help address the epidemic.  Those include educating the pharmacies and hospitals to \nwhom we deliver abou t the importance of compliance with DEA regulations, creating a nationwide clinical alert ", "original_text": "This includes partnering with government, industry, social institutions and other players to help bring this \ncrisis to an end.  \n \n", "page_label": "5", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fa648db0-cb11-4d5d-95db-126c70dfc60f", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a2e50e180463329be007e15f0e2ac9f4740ffc072bf24ff7fd0f4c06ceab2e59", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d64f37bc-55df-4648-8d80-3d91ff8b614e", "node_type": "1", "metadata": {"window": "We will continue to fight that mischaracterization in the multiple venues both state and federal, where lawsuits \nhave been filed by thousands of plaintiffs.   These are clearly novel, complex and unprecedented claims that must \nbe navigated.  And we remain deeply concerned about the impact that this crisis is having on families and \ncommunities across the U.S.  and are passionately committed to using McKesson's cap abilities to be part of the \nsolution.  This includes partnering with government, industry, social institutions and other players to help bring this \ncrisis to an end.  \n \n I've spoken about it before, but let me remind you of the investments we've made and conti nue to make in our \nprograms, our processes, our technologies dedicated to preventing diversion and in our corporate initiatives \nannounced last spring to help address the epidemic.  Those include educating the pharmacies and hospitals to \nwhom we deliver abou t the importance of compliance with DEA regulations, creating a nationwide clinical alert ", "original_text": "and are passionately committed to using McKesson's cap abilities to be part of the \nsolution. ", "page_label": "5", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9761d301b76076db0732842573ca4c283a2b03b499b5e8544322fd161bdcf107", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4c80ef3b-9f39-4835-8fde-5d0625a0286a", "node_type": "1", "metadata": {"window": "And we remain deeply concerned about the impact that this crisis is having on families and \ncommunities across the U.S.  and are passionately committed to using McKesson's cap abilities to be part of the \nsolution.  This includes partnering with government, industry, social institutions and other players to help bring this \ncrisis to an end.  \n \n I've spoken about it before, but let me remind you of the investments we've made and conti nue to make in our \nprograms, our processes, our technologies dedicated to preventing diversion and in our corporate initiatives \nannounced last spring to help address the epidemic.  Those include educating the pharmacies and hospitals to \nwhom we deliver abou t the importance of compliance with DEA regulations, creating a nationwide clinical alert ", "original_text": "I've spoken about it before, but let me remind you of the investments we've made and conti nue to make in our \nprograms, our processes, our technologies dedicated to preventing diversion and in our corporate initiatives \nannounced last spring to help address the epidemic. "}, "hash": "3a706aec830ca0b63082b65fdc98a9b442d6f9a57f151217e7505f2de5078a04", "class_name": "RelatedNodeInfo"}}, "text": "This includes partnering with government, industry, social institutions and other players to help bring this \ncrisis to an end.  \n \n", "start_char_idx": 3718, "end_char_idx": 3850, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4c80ef3b-9f39-4835-8fde-5d0625a0286a": {"__data__": {"id_": "4c80ef3b-9f39-4835-8fde-5d0625a0286a", "embedding": null, "metadata": {"window": "And we remain deeply concerned about the impact that this crisis is having on families and \ncommunities across the U.S.  and are passionately committed to using McKesson's cap abilities to be part of the \nsolution.  This includes partnering with government, industry, social institutions and other players to help bring this \ncrisis to an end.  \n \n I've spoken about it before, but let me remind you of the investments we've made and conti nue to make in our \nprograms, our processes, our technologies dedicated to preventing diversion and in our corporate initiatives \nannounced last spring to help address the epidemic.  Those include educating the pharmacies and hospitals to \nwhom we deliver abou t the importance of compliance with DEA regulations, creating a nationwide clinical alert ", "original_text": "I've spoken about it before, but let me remind you of the investments we've made and conti nue to make in our \nprograms, our processes, our technologies dedicated to preventing diversion and in our corporate initiatives \nannounced last spring to help address the epidemic. ", "page_label": "5", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fa648db0-cb11-4d5d-95db-126c70dfc60f", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a2e50e180463329be007e15f0e2ac9f4740ffc072bf24ff7fd0f4c06ceab2e59", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8dc0a584-fd6d-4354-aff9-71e7cf9da50e", "node_type": "1", "metadata": {"window": "These are clearly novel, complex and unprecedented claims that must \nbe navigated.  And we remain deeply concerned about the impact that this crisis is having on families and \ncommunities across the U.S.  and are passionately committed to using McKesson's cap abilities to be part of the \nsolution.  This includes partnering with government, industry, social institutions and other players to help bring this \ncrisis to an end.  \n \n I've spoken about it before, but let me remind you of the investments we've made and conti nue to make in our \nprograms, our processes, our technologies dedicated to preventing diversion and in our corporate initiatives \nannounced last spring to help address the epidemic.  Those include educating the pharmacies and hospitals to \nwhom we deliver abou t the importance of compliance with DEA regulations, creating a nationwide clinical alert ", "original_text": "This includes partnering with government, industry, social institutions and other players to help bring this \ncrisis to an end.  \n \n", "page_label": "5", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e660da78a38a599efe8eb836b59ce5d2eb90774204cb95f919de8941571364d5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "651d7927-2379-4a11-8a45-c9c419c71943", "node_type": "1", "metadata": {"window": "and are passionately committed to using McKesson's cap abilities to be part of the \nsolution.  This includes partnering with government, industry, social institutions and other players to help bring this \ncrisis to an end.  \n \n I've spoken about it before, but let me remind you of the investments we've made and conti nue to make in our \nprograms, our processes, our technologies dedicated to preventing diversion and in our corporate initiatives \nannounced last spring to help address the epidemic.  Those include educating the pharmacies and hospitals to \nwhom we deliver abou t the importance of compliance with DEA regulations, creating a nationwide clinical alert ", "original_text": "Those include educating the pharmacies and hospitals to \nwhom we deliver abou t the importance of compliance with DEA regulations, creating a nationwide clinical alert "}, "hash": "05e28ccbe31011272059c27be675dcc616fb8f10885efeab2c873e0e00a5a85e", "class_name": "RelatedNodeInfo"}}, "text": "I've spoken about it before, but let me remind you of the investments we've made and conti nue to make in our \nprograms, our processes, our technologies dedicated to preventing diversion and in our corporate initiatives \nannounced last spring to help address the epidemic. ", "start_char_idx": 3850, "end_char_idx": 4123, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "651d7927-2379-4a11-8a45-c9c419c71943": {"__data__": {"id_": "651d7927-2379-4a11-8a45-c9c419c71943", "embedding": null, "metadata": {"window": "and are passionately committed to using McKesson's cap abilities to be part of the \nsolution.  This includes partnering with government, industry, social institutions and other players to help bring this \ncrisis to an end.  \n \n I've spoken about it before, but let me remind you of the investments we've made and conti nue to make in our \nprograms, our processes, our technologies dedicated to preventing diversion and in our corporate initiatives \nannounced last spring to help address the epidemic.  Those include educating the pharmacies and hospitals to \nwhom we deliver abou t the importance of compliance with DEA regulations, creating a nationwide clinical alert ", "original_text": "Those include educating the pharmacies and hospitals to \nwhom we deliver abou t the importance of compliance with DEA regulations, creating a nationwide clinical alert ", "page_label": "5", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fa648db0-cb11-4d5d-95db-126c70dfc60f", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a2e50e180463329be007e15f0e2ac9f4740ffc072bf24ff7fd0f4c06ceab2e59", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4c80ef3b-9f39-4835-8fde-5d0625a0286a", "node_type": "1", "metadata": {"window": "And we remain deeply concerned about the impact that this crisis is having on families and \ncommunities across the U.S.  and are passionately committed to using McKesson's cap abilities to be part of the \nsolution.  This includes partnering with government, industry, social institutions and other players to help bring this \ncrisis to an end.  \n \n I've spoken about it before, but let me remind you of the investments we've made and conti nue to make in our \nprograms, our processes, our technologies dedicated to preventing diversion and in our corporate initiatives \nannounced last spring to help address the epidemic.  Those include educating the pharmacies and hospitals to \nwhom we deliver abou t the importance of compliance with DEA regulations, creating a nationwide clinical alert ", "original_text": "I've spoken about it before, but let me remind you of the investments we've made and conti nue to make in our \nprograms, our processes, our technologies dedicated to preventing diversion and in our corporate initiatives \nannounced last spring to help address the epidemic. ", "page_label": "5", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0e0032e084dc100b1f7d3d9bc5c4b02ac82a10876ae2ea9200f4c01767e66489", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7848ed03-ba91-4498-bb31-de74029a260b", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nsystem that uses patient prescription history to identify patients at risk of opioid overuse, abuse, addiction or \nmisuse; and actively advocating for public policies that will help address the opioid epidemic.  \n \n In addition, we contributed $100 million to establish the Foundation for Opioid Response Effort, a foundation \ndedicated solely to driving solutions for the epidemic.  I'm proud of our teams and our team members w ho ensure \nthe safety and security of our supply chain day in, day out.  \n \n", "original_text": "McKesson Corp.  "}, "hash": "eda2657236a3b2fd0071ee07a44e0c9c66bb8bd82a2d7c09a18da08b1eeb9d7f", "class_name": "RelatedNodeInfo"}}, "text": "Those include educating the pharmacies and hospitals to \nwhom we deliver abou t the importance of compliance with DEA regulations, creating a nationwide clinical alert ", "start_char_idx": 4123, "end_char_idx": 4291, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7848ed03-ba91-4498-bb31-de74029a260b": {"__data__": {"id_": "7848ed03-ba91-4498-bb31-de74029a260b", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nsystem that uses patient prescription history to identify patients at risk of opioid overuse, abuse, addiction or \nmisuse; and actively advocating for public policies that will help address the opioid epidemic.  \n \n In addition, we contributed $100 million to establish the Foundation for Opioid Response Effort, a foundation \ndedicated solely to driving solutions for the epidemic.  I'm proud of our teams and our team members w ho ensure \nthe safety and security of our supply chain day in, day out.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "6", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "74aa42ba-8aa4-40bb-8e6b-4b4438973fe6", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "96fe23ab3f28da6c3b9e65abfaebdf377433fd3e2f0b15afab5b613df6915c96", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "651d7927-2379-4a11-8a45-c9c419c71943", "node_type": "1", "metadata": {"window": "and are passionately committed to using McKesson's cap abilities to be part of the \nsolution.  This includes partnering with government, industry, social institutions and other players to help bring this \ncrisis to an end.  \n \n I've spoken about it before, but let me remind you of the investments we've made and conti nue to make in our \nprograms, our processes, our technologies dedicated to preventing diversion and in our corporate initiatives \nannounced last spring to help address the epidemic.  Those include educating the pharmacies and hospitals to \nwhom we deliver abou t the importance of compliance with DEA regulations, creating a nationwide clinical alert ", "original_text": "Those include educating the pharmacies and hospitals to \nwhom we deliver abou t the importance of compliance with DEA regulations, creating a nationwide clinical alert ", "page_label": "5", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d5572dc6ab0095a4bd4527774f9a1e786523751e6c1dc5aa14a72648d5fa2aa9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d12cb688-a1d9-4cd0-b62d-cc3856b9fb1a", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nsystem that uses patient prescription history to identify patients at risk of opioid overuse, abuse, addiction or \nmisuse; and actively advocating for public policies that will help address the opioid epidemic.  \n \n In addition, we contributed $100 million to establish the Foundation for Opioid Response Effort, a foundation \ndedicated solely to driving solutions for the epidemic.  I'm proud of our teams and our team members w ho ensure \nthe safety and security of our supply chain day in, day out.  \n \n With that, let me turn the call over to Britt.  \n ", "original_text": "(MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nsystem that uses patient prescription history to identify patients at risk of opioid overuse, abuse, addiction or \nmisuse; and actively advocating for public policies that will help address the opioid epidemic.  \n \n"}, "hash": "122c5d4a0a6255b721519801ee59837a54647030ad6253b9d03907dd750d3e86", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d12cb688-a1d9-4cd0-b62d-cc3856b9fb1a": {"__data__": {"id_": "d12cb688-a1d9-4cd0-b62d-cc3856b9fb1a", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nsystem that uses patient prescription history to identify patients at risk of opioid overuse, abuse, addiction or \nmisuse; and actively advocating for public policies that will help address the opioid epidemic.  \n \n In addition, we contributed $100 million to establish the Foundation for Opioid Response Effort, a foundation \ndedicated solely to driving solutions for the epidemic.  I'm proud of our teams and our team members w ho ensure \nthe safety and security of our supply chain day in, day out.  \n \n With that, let me turn the call over to Britt.  \n ", "original_text": "(MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nsystem that uses patient prescription history to identify patients at risk of opioid overuse, abuse, addiction or \nmisuse; and actively advocating for public policies that will help address the opioid epidemic.  \n \n", "page_label": "6", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "74aa42ba-8aa4-40bb-8e6b-4b4438973fe6", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "96fe23ab3f28da6c3b9e65abfaebdf377433fd3e2f0b15afab5b613df6915c96", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7848ed03-ba91-4498-bb31-de74029a260b", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nsystem that uses patient prescription history to identify patients at risk of opioid overuse, abuse, addiction or \nmisuse; and actively advocating for public policies that will help address the opioid epidemic.  \n \n In addition, we contributed $100 million to establish the Foundation for Opioid Response Effort, a foundation \ndedicated solely to driving solutions for the epidemic.  I'm proud of our teams and our team members w ho ensure \nthe safety and security of our supply chain day in, day out.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "6", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "638750de0b888bbe046c2ea700bed3efa705622a8158fb5258d7a0ac475c6e9e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d4ee4b0a-26f9-4a51-8b54-2c2908268571", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nsystem that uses patient prescription history to identify patients at risk of opioid overuse, abuse, addiction or \nmisuse; and actively advocating for public policies that will help address the opioid epidemic.  \n \n In addition, we contributed $100 million to establish the Foundation for Opioid Response Effort, a foundation \ndedicated solely to driving solutions for the epidemic.  I'm proud of our teams and our team members w ho ensure \nthe safety and security of our supply chain day in, day out.  \n \n With that, let me turn the call over to Britt.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n", "original_text": "In addition, we contributed $100 million to establish the Foundation for Opioid Response Effort, a foundation \ndedicated solely to driving solutions for the epidemic. "}, "hash": "06c861fdbf0741bb1540a1cdaf39a247e77e17de9a2245a5b41a04210286b7b2", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nsystem that uses patient prescription history to identify patients at risk of opioid overuse, abuse, addiction or \nmisuse; and actively advocating for public policies that will help address the opioid epidemic.  \n \n", "start_char_idx": 16, "end_char_idx": 395, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d4ee4b0a-26f9-4a51-8b54-2c2908268571": {"__data__": {"id_": "d4ee4b0a-26f9-4a51-8b54-2c2908268571", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nsystem that uses patient prescription history to identify patients at risk of opioid overuse, abuse, addiction or \nmisuse; and actively advocating for public policies that will help address the opioid epidemic.  \n \n In addition, we contributed $100 million to establish the Foundation for Opioid Response Effort, a foundation \ndedicated solely to driving solutions for the epidemic.  I'm proud of our teams and our team members w ho ensure \nthe safety and security of our supply chain day in, day out.  \n \n With that, let me turn the call over to Britt.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n", "original_text": "In addition, we contributed $100 million to establish the Foundation for Opioid Response Effort, a foundation \ndedicated solely to driving solutions for the epidemic. ", "page_label": "6", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "74aa42ba-8aa4-40bb-8e6b-4b4438973fe6", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "96fe23ab3f28da6c3b9e65abfaebdf377433fd3e2f0b15afab5b613df6915c96", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d12cb688-a1d9-4cd0-b62d-cc3856b9fb1a", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nsystem that uses patient prescription history to identify patients at risk of opioid overuse, abuse, addiction or \nmisuse; and actively advocating for public policies that will help address the opioid epidemic.  \n \n In addition, we contributed $100 million to establish the Foundation for Opioid Response Effort, a foundation \ndedicated solely to driving solutions for the epidemic.  I'm proud of our teams and our team members w ho ensure \nthe safety and security of our supply chain day in, day out.  \n \n With that, let me turn the call over to Britt.  \n ", "original_text": "(MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nsystem that uses patient prescription history to identify patients at risk of opioid overuse, abuse, addiction or \nmisuse; and actively advocating for public policies that will help address the opioid epidemic.  \n \n", "page_label": "6", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e859e9bbb0225ae0c112480b48da36c674d61367a23b0f7f69b7055d9fb6b2c7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "19838fb3-dcee-4060-9667-3945e4e8f602", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nsystem that uses patient prescription history to identify patients at risk of opioid overuse, abuse, addiction or \nmisuse; and actively advocating for public policies that will help address the opioid epidemic.  \n \n In addition, we contributed $100 million to establish the Foundation for Opioid Response Effort, a foundation \ndedicated solely to driving solutions for the epidemic.  I'm proud of our teams and our team members w ho ensure \nthe safety and security of our supply chain day in, day out.  \n \n With that, let me turn the call over to Britt.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n Thanks, Brian, and good afternoon. ", "original_text": "I'm proud of our teams and our team members w ho ensure \nthe safety and security of our supply chain day in, day out.  \n \n"}, "hash": "2a498d4ac14964cb2a321ae763c6b5536e5c874244755967124c79cb8e1b3c13", "class_name": "RelatedNodeInfo"}}, "text": "In addition, we contributed $100 million to establish the Foundation for Opioid Response Effort, a foundation \ndedicated solely to driving solutions for the epidemic. ", "start_char_idx": 395, "end_char_idx": 562, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "19838fb3-dcee-4060-9667-3945e4e8f602": {"__data__": {"id_": "19838fb3-dcee-4060-9667-3945e4e8f602", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nsystem that uses patient prescription history to identify patients at risk of opioid overuse, abuse, addiction or \nmisuse; and actively advocating for public policies that will help address the opioid epidemic.  \n \n In addition, we contributed $100 million to establish the Foundation for Opioid Response Effort, a foundation \ndedicated solely to driving solutions for the epidemic.  I'm proud of our teams and our team members w ho ensure \nthe safety and security of our supply chain day in, day out.  \n \n With that, let me turn the call over to Britt.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n Thanks, Brian, and good afternoon. ", "original_text": "I'm proud of our teams and our team members w ho ensure \nthe safety and security of our supply chain day in, day out.  \n \n", "page_label": "6", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "74aa42ba-8aa4-40bb-8e6b-4b4438973fe6", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "96fe23ab3f28da6c3b9e65abfaebdf377433fd3e2f0b15afab5b613df6915c96", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d4ee4b0a-26f9-4a51-8b54-2c2908268571", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nsystem that uses patient prescription history to identify patients at risk of opioid overuse, abuse, addiction or \nmisuse; and actively advocating for public policies that will help address the opioid epidemic.  \n \n In addition, we contributed $100 million to establish the Foundation for Opioid Response Effort, a foundation \ndedicated solely to driving solutions for the epidemic.  I'm proud of our teams and our team members w ho ensure \nthe safety and security of our supply chain day in, day out.  \n \n With that, let me turn the call over to Britt.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n", "original_text": "In addition, we contributed $100 million to establish the Foundation for Opioid Response Effort, a foundation \ndedicated solely to driving solutions for the epidemic. ", "page_label": "6", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "43de855c8c89355246891fc543c15aeff2d4891b565479845735b87146071af0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3d5d61d8-dd77-474b-9d6f-8d593083c8be", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nsystem that uses patient prescription history to identify patients at risk of opioid overuse, abuse, addiction or \nmisuse; and actively advocating for public policies that will help address the opioid epidemic.  \n \n In addition, we contributed $100 million to establish the Foundation for Opioid Response Effort, a foundation \ndedicated solely to driving solutions for the epidemic.  I'm proud of our teams and our team members w ho ensure \nthe safety and security of our supply chain day in, day out.  \n \n With that, let me turn the call over to Britt.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n Thanks, Brian, and good afternoon.  McKesson poste d another solid quarter and strong start to fiscal 2020. ", "original_text": "With that, let me turn the call over to Britt.  \n "}, "hash": "834716900ea0076aee072034847fddb36fac48f95284d92cadab648ce54dd4af", "class_name": "RelatedNodeInfo"}}, "text": "I'm proud of our teams and our team members w ho ensure \nthe safety and security of our supply chain day in, day out.  \n \n", "start_char_idx": 562, "end_char_idx": 684, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3d5d61d8-dd77-474b-9d6f-8d593083c8be": {"__data__": {"id_": "3d5d61d8-dd77-474b-9d6f-8d593083c8be", "embedding": null, "metadata": {"window": "(MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nsystem that uses patient prescription history to identify patients at risk of opioid overuse, abuse, addiction or \nmisuse; and actively advocating for public policies that will help address the opioid epidemic.  \n \n In addition, we contributed $100 million to establish the Foundation for Opioid Response Effort, a foundation \ndedicated solely to driving solutions for the epidemic.  I'm proud of our teams and our team members w ho ensure \nthe safety and security of our supply chain day in, day out.  \n \n With that, let me turn the call over to Britt.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n Thanks, Brian, and good afternoon.  McKesson poste d another solid quarter and strong start to fiscal 2020. ", "original_text": "With that, let me turn the call over to Britt.  \n ", "page_label": "6", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "74aa42ba-8aa4-40bb-8e6b-4b4438973fe6", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "96fe23ab3f28da6c3b9e65abfaebdf377433fd3e2f0b15afab5b613df6915c96", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "19838fb3-dcee-4060-9667-3945e4e8f602", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nsystem that uses patient prescription history to identify patients at risk of opioid overuse, abuse, addiction or \nmisuse; and actively advocating for public policies that will help address the opioid epidemic.  \n \n In addition, we contributed $100 million to establish the Foundation for Opioid Response Effort, a foundation \ndedicated solely to driving solutions for the epidemic.  I'm proud of our teams and our team members w ho ensure \nthe safety and security of our supply chain day in, day out.  \n \n With that, let me turn the call over to Britt.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n Thanks, Brian, and good afternoon. ", "original_text": "I'm proud of our teams and our team members w ho ensure \nthe safety and security of our supply chain day in, day out.  \n \n", "page_label": "6", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e0aabbdb6a1c4f3c9f70032f74763da787a3b379615a79717f9d758f90aab695", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "80f4cb25-9810-47fd-9ee9-c85528b9692c", "node_type": "1", "metadata": {"window": "In addition, we contributed $100 million to establish the Foundation for Opioid Response Effort, a foundation \ndedicated solely to driving solutions for the epidemic.  I'm proud of our teams and our team members w ho ensure \nthe safety and security of our supply chain day in, day out.  \n \n With that, let me turn the call over to Britt.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n Thanks, Brian, and good afternoon.  McKesson poste d another solid quarter and strong start to fiscal 2020.  Slides \nI'm reviewing with you this afternoon are posted to the Investors section of our website and include our full year \nfiscal 2020 guidance assumptions. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n"}, "hash": "f150ef247a961bf88166dfb1c41b4e1d8128c7e15d5376346b6427a660aba643", "class_name": "RelatedNodeInfo"}}, "text": "With that, let me turn the call over to Britt.  \n ", "start_char_idx": 684, "end_char_idx": 734, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "80f4cb25-9810-47fd-9ee9-c85528b9692c": {"__data__": {"id_": "80f4cb25-9810-47fd-9ee9-c85528b9692c", "embedding": null, "metadata": {"window": "In addition, we contributed $100 million to establish the Foundation for Opioid Response Effort, a foundation \ndedicated solely to driving solutions for the epidemic.  I'm proud of our teams and our team members w ho ensure \nthe safety and security of our supply chain day in, day out.  \n \n With that, let me turn the call over to Britt.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n Thanks, Brian, and good afternoon.  McKesson poste d another solid quarter and strong start to fiscal 2020.  Slides \nI'm reviewing with you this afternoon are posted to the Investors section of our website and include our full year \nfiscal 2020 guidance assumptions. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n", "page_label": "6", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "74aa42ba-8aa4-40bb-8e6b-4b4438973fe6", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "96fe23ab3f28da6c3b9e65abfaebdf377433fd3e2f0b15afab5b613df6915c96", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3d5d61d8-dd77-474b-9d6f-8d593083c8be", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nsystem that uses patient prescription history to identify patients at risk of opioid overuse, abuse, addiction or \nmisuse; and actively advocating for public policies that will help address the opioid epidemic.  \n \n In addition, we contributed $100 million to establish the Foundation for Opioid Response Effort, a foundation \ndedicated solely to driving solutions for the epidemic.  I'm proud of our teams and our team members w ho ensure \nthe safety and security of our supply chain day in, day out.  \n \n With that, let me turn the call over to Britt.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n Thanks, Brian, and good afternoon.  McKesson poste d another solid quarter and strong start to fiscal 2020. ", "original_text": "With that, let me turn the call over to Britt.  \n ", "page_label": "6", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "19c73dd8cf6a299e97d342b2d18ebb40110b87a093a237926f748018abaa6966", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "66f535e7-4850-4596-8324-b10779e4628d", "node_type": "1", "metadata": {"window": "I'm proud of our teams and our team members w ho ensure \nthe safety and security of our supply chain day in, day out.  \n \n With that, let me turn the call over to Britt.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n Thanks, Brian, and good afternoon.  McKesson poste d another solid quarter and strong start to fiscal 2020.  Slides \nI'm reviewing with you this afternoon are posted to the Investors section of our website and include our full year \nfiscal 2020 guidance assumptions.  Today we reported first quarter adjusted ea rnings of $3.31 per diluted share, \nahead of our original expectations, and we're raising the full year fiscal 2020 outlook by $0.15 to a range of \n$14.00 to $14.60 per diluted share from our previous outlook of $13.85 to $14.45 per diluted share.  \n \n", "original_text": "Thanks, Brian, and good afternoon. "}, "hash": "219fb47048fd2857a3a4990b0a91a75a0eb89cac8ec9e33ef21bc7a4cd7a792a", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n", "start_char_idx": 734, "end_char_idx": 1080, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "66f535e7-4850-4596-8324-b10779e4628d": {"__data__": {"id_": "66f535e7-4850-4596-8324-b10779e4628d", "embedding": null, "metadata": {"window": "I'm proud of our teams and our team members w ho ensure \nthe safety and security of our supply chain day in, day out.  \n \n With that, let me turn the call over to Britt.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n Thanks, Brian, and good afternoon.  McKesson poste d another solid quarter and strong start to fiscal 2020.  Slides \nI'm reviewing with you this afternoon are posted to the Investors section of our website and include our full year \nfiscal 2020 guidance assumptions.  Today we reported first quarter adjusted ea rnings of $3.31 per diluted share, \nahead of our original expectations, and we're raising the full year fiscal 2020 outlook by $0.15 to a range of \n$14.00 to $14.60 per diluted share from our previous outlook of $13.85 to $14.45 per diluted share.  \n \n", "original_text": "Thanks, Brian, and good afternoon. ", "page_label": "6", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "74aa42ba-8aa4-40bb-8e6b-4b4438973fe6", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "96fe23ab3f28da6c3b9e65abfaebdf377433fd3e2f0b15afab5b613df6915c96", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "80f4cb25-9810-47fd-9ee9-c85528b9692c", "node_type": "1", "metadata": {"window": "In addition, we contributed $100 million to establish the Foundation for Opioid Response Effort, a foundation \ndedicated solely to driving solutions for the epidemic.  I'm proud of our teams and our team members w ho ensure \nthe safety and security of our supply chain day in, day out.  \n \n With that, let me turn the call over to Britt.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n Thanks, Brian, and good afternoon.  McKesson poste d another solid quarter and strong start to fiscal 2020.  Slides \nI'm reviewing with you this afternoon are posted to the Investors section of our website and include our full year \nfiscal 2020 guidance assumptions. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n", "page_label": "6", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0589611ae27feb5f1f8f4ab6618d0ff7ed689b25c513af3a4d5e0428388be902", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d6ed34b8-6f2d-4c70-a5b5-4d952d94f18d", "node_type": "1", "metadata": {"window": "With that, let me turn the call over to Britt.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n Thanks, Brian, and good afternoon.  McKesson poste d another solid quarter and strong start to fiscal 2020.  Slides \nI'm reviewing with you this afternoon are posted to the Investors section of our website and include our full year \nfiscal 2020 guidance assumptions.  Today we reported first quarter adjusted ea rnings of $3.31 per diluted share, \nahead of our original expectations, and we're raising the full year fiscal 2020 outlook by $0.15 to a range of \n$14.00 to $14.60 per diluted share from our previous outlook of $13.85 to $14.45 per diluted share.  \n \n Let's mov e right to our first quarter results. ", "original_text": "McKesson poste d another solid quarter and strong start to fiscal 2020. "}, "hash": "d68684f1cdb64748f03cf39dcb5fb85a2f63592023b6a763f5260196464d4d59", "class_name": "RelatedNodeInfo"}}, "text": "Thanks, Brian, and good afternoon. ", "start_char_idx": 1080, "end_char_idx": 1115, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d6ed34b8-6f2d-4c70-a5b5-4d952d94f18d": {"__data__": {"id_": "d6ed34b8-6f2d-4c70-a5b5-4d952d94f18d", "embedding": null, "metadata": {"window": "With that, let me turn the call over to Britt.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n Thanks, Brian, and good afternoon.  McKesson poste d another solid quarter and strong start to fiscal 2020.  Slides \nI'm reviewing with you this afternoon are posted to the Investors section of our website and include our full year \nfiscal 2020 guidance assumptions.  Today we reported first quarter adjusted ea rnings of $3.31 per diluted share, \nahead of our original expectations, and we're raising the full year fiscal 2020 outlook by $0.15 to a range of \n$14.00 to $14.60 per diluted share from our previous outlook of $13.85 to $14.45 per diluted share.  \n \n Let's mov e right to our first quarter results. ", "original_text": "McKesson poste d another solid quarter and strong start to fiscal 2020. ", "page_label": "6", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "74aa42ba-8aa4-40bb-8e6b-4b4438973fe6", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "96fe23ab3f28da6c3b9e65abfaebdf377433fd3e2f0b15afab5b613df6915c96", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "66f535e7-4850-4596-8324-b10779e4628d", "node_type": "1", "metadata": {"window": "I'm proud of our teams and our team members w ho ensure \nthe safety and security of our supply chain day in, day out.  \n \n With that, let me turn the call over to Britt.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n Thanks, Brian, and good afternoon.  McKesson poste d another solid quarter and strong start to fiscal 2020.  Slides \nI'm reviewing with you this afternoon are posted to the Investors section of our website and include our full year \nfiscal 2020 guidance assumptions.  Today we reported first quarter adjusted ea rnings of $3.31 per diluted share, \nahead of our original expectations, and we're raising the full year fiscal 2020 outlook by $0.15 to a range of \n$14.00 to $14.60 per diluted share from our previous outlook of $13.85 to $14.45 per diluted share.  \n \n", "original_text": "Thanks, Brian, and good afternoon. ", "page_label": "6", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e276bdeb41187e734c87c2cf8486b99a63165ba199e02a2d043bfb27541ae7e4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "83464f70-87d8-493c-a37c-c84d2560c026", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n Thanks, Brian, and good afternoon.  McKesson poste d another solid quarter and strong start to fiscal 2020.  Slides \nI'm reviewing with you this afternoon are posted to the Investors section of our website and include our full year \nfiscal 2020 guidance assumptions.  Today we reported first quarter adjusted ea rnings of $3.31 per diluted share, \nahead of our original expectations, and we're raising the full year fiscal 2020 outlook by $0.15 to a range of \n$14.00 to $14.60 per diluted share from our previous outlook of $13.85 to $14.45 per diluted share.  \n \n Let's mov e right to our first quarter results.  Our first quarter adjusted earnings of $3.31 per diluted share were up \n14% year -over-year, driven by strong performance in the U.S. ", "original_text": "Slides \nI'm reviewing with you this afternoon are posted to the Investors section of our website and include our full year \nfiscal 2020 guidance assumptions. "}, "hash": "8c6eff23b17818b7bc6fdc10ac47cebb8c77575dad50db7386e9e6b0a79b50c8", "class_name": "RelatedNodeInfo"}}, "text": "McKesson poste d another solid quarter and strong start to fiscal 2020. ", "start_char_idx": 1115, "end_char_idx": 1187, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "83464f70-87d8-493c-a37c-c84d2560c026": {"__data__": {"id_": "83464f70-87d8-493c-a37c-c84d2560c026", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n Thanks, Brian, and good afternoon.  McKesson poste d another solid quarter and strong start to fiscal 2020.  Slides \nI'm reviewing with you this afternoon are posted to the Investors section of our website and include our full year \nfiscal 2020 guidance assumptions.  Today we reported first quarter adjusted ea rnings of $3.31 per diluted share, \nahead of our original expectations, and we're raising the full year fiscal 2020 outlook by $0.15 to a range of \n$14.00 to $14.60 per diluted share from our previous outlook of $13.85 to $14.45 per diluted share.  \n \n Let's mov e right to our first quarter results.  Our first quarter adjusted earnings of $3.31 per diluted share were up \n14% year -over-year, driven by strong performance in the U.S. ", "original_text": "Slides \nI'm reviewing with you this afternoon are posted to the Investors section of our website and include our full year \nfiscal 2020 guidance assumptions. ", "page_label": "6", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "74aa42ba-8aa4-40bb-8e6b-4b4438973fe6", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "96fe23ab3f28da6c3b9e65abfaebdf377433fd3e2f0b15afab5b613df6915c96", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d6ed34b8-6f2d-4c70-a5b5-4d952d94f18d", "node_type": "1", "metadata": {"window": "With that, let me turn the call over to Britt.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n Thanks, Brian, and good afternoon.  McKesson poste d another solid quarter and strong start to fiscal 2020.  Slides \nI'm reviewing with you this afternoon are posted to the Investors section of our website and include our full year \nfiscal 2020 guidance assumptions.  Today we reported first quarter adjusted ea rnings of $3.31 per diluted share, \nahead of our original expectations, and we're raising the full year fiscal 2020 outlook by $0.15 to a range of \n$14.00 to $14.60 per diluted share from our previous outlook of $13.85 to $14.45 per diluted share.  \n \n Let's mov e right to our first quarter results. ", "original_text": "McKesson poste d another solid quarter and strong start to fiscal 2020. ", "page_label": "6", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "939ee3546fc581ffc45a60f5353b6e8bcdb01daedb499457ad1589aeaff23807", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0d7a9d36-ad02-43b3-bd87-6a82804acc76", "node_type": "1", "metadata": {"window": "Thanks, Brian, and good afternoon.  McKesson poste d another solid quarter and strong start to fiscal 2020.  Slides \nI'm reviewing with you this afternoon are posted to the Investors section of our website and include our full year \nfiscal 2020 guidance assumptions.  Today we reported first quarter adjusted ea rnings of $3.31 per diluted share, \nahead of our original expectations, and we're raising the full year fiscal 2020 outlook by $0.15 to a range of \n$14.00 to $14.60 per diluted share from our previous outlook of $13.85 to $14.45 per diluted share.  \n \n Let's mov e right to our first quarter results.  Our first quarter adjusted earnings of $3.31 per diluted share were up \n14% year -over-year, driven by strong performance in the U.S.  Pharmaceutical and Specialty Solutions business, \nMedical -Surgical Solutions and our MR xTS businesses; a lower share count; higher contribution from our equity \ninvestment in Change Healthcare; a one -time gain from investment activities; and expense timing. ", "original_text": "Today we reported first quarter adjusted ea rnings of $3.31 per diluted share, \nahead of our original expectations, and we're raising the full year fiscal 2020 outlook by $0.15 to a range of \n$14.00 to $14.60 per diluted share from our previous outlook of $13.85 to $14.45 per diluted share.  \n \n"}, "hash": "5fca849c033726e1c99d4870023f3a815385628db2737e7dc2f63943165d4fe2", "class_name": "RelatedNodeInfo"}}, "text": "Slides \nI'm reviewing with you this afternoon are posted to the Investors section of our website and include our full year \nfiscal 2020 guidance assumptions. ", "start_char_idx": 1187, "end_char_idx": 1345, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0d7a9d36-ad02-43b3-bd87-6a82804acc76": {"__data__": {"id_": "0d7a9d36-ad02-43b3-bd87-6a82804acc76", "embedding": null, "metadata": {"window": "Thanks, Brian, and good afternoon.  McKesson poste d another solid quarter and strong start to fiscal 2020.  Slides \nI'm reviewing with you this afternoon are posted to the Investors section of our website and include our full year \nfiscal 2020 guidance assumptions.  Today we reported first quarter adjusted ea rnings of $3.31 per diluted share, \nahead of our original expectations, and we're raising the full year fiscal 2020 outlook by $0.15 to a range of \n$14.00 to $14.60 per diluted share from our previous outlook of $13.85 to $14.45 per diluted share.  \n \n Let's mov e right to our first quarter results.  Our first quarter adjusted earnings of $3.31 per diluted share were up \n14% year -over-year, driven by strong performance in the U.S.  Pharmaceutical and Specialty Solutions business, \nMedical -Surgical Solutions and our MR xTS businesses; a lower share count; higher contribution from our equity \ninvestment in Change Healthcare; a one -time gain from investment activities; and expense timing. ", "original_text": "Today we reported first quarter adjusted ea rnings of $3.31 per diluted share, \nahead of our original expectations, and we're raising the full year fiscal 2020 outlook by $0.15 to a range of \n$14.00 to $14.60 per diluted share from our previous outlook of $13.85 to $14.45 per diluted share.  \n \n", "page_label": "6", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "74aa42ba-8aa4-40bb-8e6b-4b4438973fe6", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "96fe23ab3f28da6c3b9e65abfaebdf377433fd3e2f0b15afab5b613df6915c96", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "83464f70-87d8-493c-a37c-c84d2560c026", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n Thanks, Brian, and good afternoon.  McKesson poste d another solid quarter and strong start to fiscal 2020.  Slides \nI'm reviewing with you this afternoon are posted to the Investors section of our website and include our full year \nfiscal 2020 guidance assumptions.  Today we reported first quarter adjusted ea rnings of $3.31 per diluted share, \nahead of our original expectations, and we're raising the full year fiscal 2020 outlook by $0.15 to a range of \n$14.00 to $14.60 per diluted share from our previous outlook of $13.85 to $14.45 per diluted share.  \n \n Let's mov e right to our first quarter results.  Our first quarter adjusted earnings of $3.31 per diluted share were up \n14% year -over-year, driven by strong performance in the U.S. ", "original_text": "Slides \nI'm reviewing with you this afternoon are posted to the Investors section of our website and include our full year \nfiscal 2020 guidance assumptions. ", "page_label": "6", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b0b8f2e4a8d96b5f849e7499821696f3e32cbd6ade2155d4a7872759bfcdb611", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e9e98cff-6a63-4461-96dc-2e1097b54401", "node_type": "1", "metadata": {"window": "McKesson poste d another solid quarter and strong start to fiscal 2020.  Slides \nI'm reviewing with you this afternoon are posted to the Investors section of our website and include our full year \nfiscal 2020 guidance assumptions.  Today we reported first quarter adjusted ea rnings of $3.31 per diluted share, \nahead of our original expectations, and we're raising the full year fiscal 2020 outlook by $0.15 to a range of \n$14.00 to $14.60 per diluted share from our previous outlook of $13.85 to $14.45 per diluted share.  \n \n Let's mov e right to our first quarter results.  Our first quarter adjusted earnings of $3.31 per diluted share were up \n14% year -over-year, driven by strong performance in the U.S.  Pharmaceutical and Specialty Solutions business, \nMedical -Surgical Solutions and our MR xTS businesses; a lower share count; higher contribution from our equity \ninvestment in Change Healthcare; a one -time gain from investment activities; and expense timing.  These items \nwere partially offset by the anticipated year -over-year increase in opioid  litigation and technology costs, which we \noutlined with our initial outlook in May. ", "original_text": "Let's mov e right to our first quarter results. "}, "hash": "608358179c74e812d66aa47fe7461e21127caed10ed91bda8d7b5652e1c55445", "class_name": "RelatedNodeInfo"}}, "text": "Today we reported first quarter adjusted ea rnings of $3.31 per diluted share, \nahead of our original expectations, and we're raising the full year fiscal 2020 outlook by $0.15 to a range of \n$14.00 to $14.60 per diluted share from our previous outlook of $13.85 to $14.45 per diluted share.  \n \n", "start_char_idx": 1345, "end_char_idx": 1641, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e9e98cff-6a63-4461-96dc-2e1097b54401": {"__data__": {"id_": "e9e98cff-6a63-4461-96dc-2e1097b54401", "embedding": null, "metadata": {"window": "McKesson poste d another solid quarter and strong start to fiscal 2020.  Slides \nI'm reviewing with you this afternoon are posted to the Investors section of our website and include our full year \nfiscal 2020 guidance assumptions.  Today we reported first quarter adjusted ea rnings of $3.31 per diluted share, \nahead of our original expectations, and we're raising the full year fiscal 2020 outlook by $0.15 to a range of \n$14.00 to $14.60 per diluted share from our previous outlook of $13.85 to $14.45 per diluted share.  \n \n Let's mov e right to our first quarter results.  Our first quarter adjusted earnings of $3.31 per diluted share were up \n14% year -over-year, driven by strong performance in the U.S.  Pharmaceutical and Specialty Solutions business, \nMedical -Surgical Solutions and our MR xTS businesses; a lower share count; higher contribution from our equity \ninvestment in Change Healthcare; a one -time gain from investment activities; and expense timing.  These items \nwere partially offset by the anticipated year -over-year increase in opioid  litigation and technology costs, which we \noutlined with our initial outlook in May. ", "original_text": "Let's mov e right to our first quarter results. ", "page_label": "6", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "74aa42ba-8aa4-40bb-8e6b-4b4438973fe6", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "96fe23ab3f28da6c3b9e65abfaebdf377433fd3e2f0b15afab5b613df6915c96", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0d7a9d36-ad02-43b3-bd87-6a82804acc76", "node_type": "1", "metadata": {"window": "Thanks, Brian, and good afternoon.  McKesson poste d another solid quarter and strong start to fiscal 2020.  Slides \nI'm reviewing with you this afternoon are posted to the Investors section of our website and include our full year \nfiscal 2020 guidance assumptions.  Today we reported first quarter adjusted ea rnings of $3.31 per diluted share, \nahead of our original expectations, and we're raising the full year fiscal 2020 outlook by $0.15 to a range of \n$14.00 to $14.60 per diluted share from our previous outlook of $13.85 to $14.45 per diluted share.  \n \n Let's mov e right to our first quarter results.  Our first quarter adjusted earnings of $3.31 per diluted share were up \n14% year -over-year, driven by strong performance in the U.S.  Pharmaceutical and Specialty Solutions business, \nMedical -Surgical Solutions and our MR xTS businesses; a lower share count; higher contribution from our equity \ninvestment in Change Healthcare; a one -time gain from investment activities; and expense timing. ", "original_text": "Today we reported first quarter adjusted ea rnings of $3.31 per diluted share, \nahead of our original expectations, and we're raising the full year fiscal 2020 outlook by $0.15 to a range of \n$14.00 to $14.60 per diluted share from our previous outlook of $13.85 to $14.45 per diluted share.  \n \n", "page_label": "6", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d3034dc6adc19255807d24d505b78938e56b1dc90c56da99553bed60111f8743", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2c15394b-eede-4a15-8c7d-c43e95e8ddb2", "node_type": "1", "metadata": {"window": "Slides \nI'm reviewing with you this afternoon are posted to the Investors section of our website and include our full year \nfiscal 2020 guidance assumptions.  Today we reported first quarter adjusted ea rnings of $3.31 per diluted share, \nahead of our original expectations, and we're raising the full year fiscal 2020 outlook by $0.15 to a range of \n$14.00 to $14.60 per diluted share from our previous outlook of $13.85 to $14.45 per diluted share.  \n \n Let's mov e right to our first quarter results.  Our first quarter adjusted earnings of $3.31 per diluted share were up \n14% year -over-year, driven by strong performance in the U.S.  Pharmaceutical and Specialty Solutions business, \nMedical -Surgical Solutions and our MR xTS businesses; a lower share count; higher contribution from our equity \ninvestment in Change Healthcare; a one -time gain from investment activities; and expense timing.  These items \nwere partially offset by the anticipated year -over-year increase in opioid  litigation and technology costs, which we \noutlined with our initial outlook in May.  Also had a lower profit contribution from the Europe segment and a higher \nadjusted tax rate.  \n \n", "original_text": "Our first quarter adjusted earnings of $3.31 per diluted share were up \n14% year -over-year, driven by strong performance in the U.S. "}, "hash": "e8be232b15a037a6a9b62444761d4f34c3dbe4407c92d39e14016c8c8b8fb615", "class_name": "RelatedNodeInfo"}}, "text": "Let's mov e right to our first quarter results. ", "start_char_idx": 1641, "end_char_idx": 1689, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2c15394b-eede-4a15-8c7d-c43e95e8ddb2": {"__data__": {"id_": "2c15394b-eede-4a15-8c7d-c43e95e8ddb2", "embedding": null, "metadata": {"window": "Slides \nI'm reviewing with you this afternoon are posted to the Investors section of our website and include our full year \nfiscal 2020 guidance assumptions.  Today we reported first quarter adjusted ea rnings of $3.31 per diluted share, \nahead of our original expectations, and we're raising the full year fiscal 2020 outlook by $0.15 to a range of \n$14.00 to $14.60 per diluted share from our previous outlook of $13.85 to $14.45 per diluted share.  \n \n Let's mov e right to our first quarter results.  Our first quarter adjusted earnings of $3.31 per diluted share were up \n14% year -over-year, driven by strong performance in the U.S.  Pharmaceutical and Specialty Solutions business, \nMedical -Surgical Solutions and our MR xTS businesses; a lower share count; higher contribution from our equity \ninvestment in Change Healthcare; a one -time gain from investment activities; and expense timing.  These items \nwere partially offset by the anticipated year -over-year increase in opioid  litigation and technology costs, which we \noutlined with our initial outlook in May.  Also had a lower profit contribution from the Europe segment and a higher \nadjusted tax rate.  \n \n", "original_text": "Our first quarter adjusted earnings of $3.31 per diluted share were up \n14% year -over-year, driven by strong performance in the U.S. ", "page_label": "6", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "74aa42ba-8aa4-40bb-8e6b-4b4438973fe6", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "96fe23ab3f28da6c3b9e65abfaebdf377433fd3e2f0b15afab5b613df6915c96", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e9e98cff-6a63-4461-96dc-2e1097b54401", "node_type": "1", "metadata": {"window": "McKesson poste d another solid quarter and strong start to fiscal 2020.  Slides \nI'm reviewing with you this afternoon are posted to the Investors section of our website and include our full year \nfiscal 2020 guidance assumptions.  Today we reported first quarter adjusted ea rnings of $3.31 per diluted share, \nahead of our original expectations, and we're raising the full year fiscal 2020 outlook by $0.15 to a range of \n$14.00 to $14.60 per diluted share from our previous outlook of $13.85 to $14.45 per diluted share.  \n \n Let's mov e right to our first quarter results.  Our first quarter adjusted earnings of $3.31 per diluted share were up \n14% year -over-year, driven by strong performance in the U.S.  Pharmaceutical and Specialty Solutions business, \nMedical -Surgical Solutions and our MR xTS businesses; a lower share count; higher contribution from our equity \ninvestment in Change Healthcare; a one -time gain from investment activities; and expense timing.  These items \nwere partially offset by the anticipated year -over-year increase in opioid  litigation and technology costs, which we \noutlined with our initial outlook in May. ", "original_text": "Let's mov e right to our first quarter results. ", "page_label": "6", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ed22bcbf6f61fbb09d813bd9c6ba1addcd7c843382e4eacc4030f21ce63a3380", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "396cb89d-55f0-4a4d-adbe-fada4fa9735a", "node_type": "1", "metadata": {"window": "Today we reported first quarter adjusted ea rnings of $3.31 per diluted share, \nahead of our original expectations, and we're raising the full year fiscal 2020 outlook by $0.15 to a range of \n$14.00 to $14.60 per diluted share from our previous outlook of $13.85 to $14.45 per diluted share.  \n \n Let's mov e right to our first quarter results.  Our first quarter adjusted earnings of $3.31 per diluted share were up \n14% year -over-year, driven by strong performance in the U.S.  Pharmaceutical and Specialty Solutions business, \nMedical -Surgical Solutions and our MR xTS businesses; a lower share count; higher contribution from our equity \ninvestment in Change Healthcare; a one -time gain from investment activities; and expense timing.  These items \nwere partially offset by the anticipated year -over-year increase in opioid  litigation and technology costs, which we \noutlined with our initial outlook in May.  Also had a lower profit contribution from the Europe segment and a higher \nadjusted tax rate.  \n \n Let me start with the details of our consolidated results, which can be found  on slide 4. ", "original_text": "Pharmaceutical and Specialty Solutions business, \nMedical -Surgical Solutions and our MR xTS businesses; a lower share count; higher contribution from our equity \ninvestment in Change Healthcare; a one -time gain from investment activities; and expense timing. "}, "hash": "8a1d200a8910e3e7cc40bc5153e4449935745c49054338c68c07f2a17ae0355b", "class_name": "RelatedNodeInfo"}}, "text": "Our first quarter adjusted earnings of $3.31 per diluted share were up \n14% year -over-year, driven by strong performance in the U.S. ", "start_char_idx": 1689, "end_char_idx": 1823, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "396cb89d-55f0-4a4d-adbe-fada4fa9735a": {"__data__": {"id_": "396cb89d-55f0-4a4d-adbe-fada4fa9735a", "embedding": null, "metadata": {"window": "Today we reported first quarter adjusted ea rnings of $3.31 per diluted share, \nahead of our original expectations, and we're raising the full year fiscal 2020 outlook by $0.15 to a range of \n$14.00 to $14.60 per diluted share from our previous outlook of $13.85 to $14.45 per diluted share.  \n \n Let's mov e right to our first quarter results.  Our first quarter adjusted earnings of $3.31 per diluted share were up \n14% year -over-year, driven by strong performance in the U.S.  Pharmaceutical and Specialty Solutions business, \nMedical -Surgical Solutions and our MR xTS businesses; a lower share count; higher contribution from our equity \ninvestment in Change Healthcare; a one -time gain from investment activities; and expense timing.  These items \nwere partially offset by the anticipated year -over-year increase in opioid  litigation and technology costs, which we \noutlined with our initial outlook in May.  Also had a lower profit contribution from the Europe segment and a higher \nadjusted tax rate.  \n \n Let me start with the details of our consolidated results, which can be found  on slide 4. ", "original_text": "Pharmaceutical and Specialty Solutions business, \nMedical -Surgical Solutions and our MR xTS businesses; a lower share count; higher contribution from our equity \ninvestment in Change Healthcare; a one -time gain from investment activities; and expense timing. ", "page_label": "6", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "74aa42ba-8aa4-40bb-8e6b-4b4438973fe6", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "96fe23ab3f28da6c3b9e65abfaebdf377433fd3e2f0b15afab5b613df6915c96", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2c15394b-eede-4a15-8c7d-c43e95e8ddb2", "node_type": "1", "metadata": {"window": "Slides \nI'm reviewing with you this afternoon are posted to the Investors section of our website and include our full year \nfiscal 2020 guidance assumptions.  Today we reported first quarter adjusted ea rnings of $3.31 per diluted share, \nahead of our original expectations, and we're raising the full year fiscal 2020 outlook by $0.15 to a range of \n$14.00 to $14.60 per diluted share from our previous outlook of $13.85 to $14.45 per diluted share.  \n \n Let's mov e right to our first quarter results.  Our first quarter adjusted earnings of $3.31 per diluted share were up \n14% year -over-year, driven by strong performance in the U.S.  Pharmaceutical and Specialty Solutions business, \nMedical -Surgical Solutions and our MR xTS businesses; a lower share count; higher contribution from our equity \ninvestment in Change Healthcare; a one -time gain from investment activities; and expense timing.  These items \nwere partially offset by the anticipated year -over-year increase in opioid  litigation and technology costs, which we \noutlined with our initial outlook in May.  Also had a lower profit contribution from the Europe segment and a higher \nadjusted tax rate.  \n \n", "original_text": "Our first quarter adjusted earnings of $3.31 per diluted share were up \n14% year -over-year, driven by strong performance in the U.S. ", "page_label": "6", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7d4142835173786da3b87420b24397c45bba5a9c3eecfd5b1339d216db6b6044", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f5238269-abeb-4cb9-aee6-d9746877019e", "node_type": "1", "metadata": {"window": "Let's mov e right to our first quarter results.  Our first quarter adjusted earnings of $3.31 per diluted share were up \n14% year -over-year, driven by strong performance in the U.S.  Pharmaceutical and Specialty Solutions business, \nMedical -Surgical Solutions and our MR xTS businesses; a lower share count; higher contribution from our equity \ninvestment in Change Healthcare; a one -time gain from investment activities; and expense timing.  These items \nwere partially offset by the anticipated year -over-year increase in opioid  litigation and technology costs, which we \noutlined with our initial outlook in May.  Also had a lower profit contribution from the Europe segment and a higher \nadjusted tax rate.  \n \n Let me start with the details of our consolidated results, which can be found  on slide 4.  Consolidated revenues for \nthe quarter increased 6% year -over-year, primarily driven by growth in our U.S. ", "original_text": "These items \nwere partially offset by the anticipated year -over-year increase in opioid  litigation and technology costs, which we \noutlined with our initial outlook in May. "}, "hash": "64c7b58c835cc62ef45f41bdc850319f6ed9e686a900d07c585f49d7739b28af", "class_name": "RelatedNodeInfo"}}, "text": "Pharmaceutical and Specialty Solutions business, \nMedical -Surgical Solutions and our MR xTS businesses; a lower share count; higher contribution from our equity \ninvestment in Change Healthcare; a one -time gain from investment activities; and expense timing. ", "start_char_idx": 1823, "end_char_idx": 2084, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f5238269-abeb-4cb9-aee6-d9746877019e": {"__data__": {"id_": "f5238269-abeb-4cb9-aee6-d9746877019e", "embedding": null, "metadata": {"window": "Let's mov e right to our first quarter results.  Our first quarter adjusted earnings of $3.31 per diluted share were up \n14% year -over-year, driven by strong performance in the U.S.  Pharmaceutical and Specialty Solutions business, \nMedical -Surgical Solutions and our MR xTS businesses; a lower share count; higher contribution from our equity \ninvestment in Change Healthcare; a one -time gain from investment activities; and expense timing.  These items \nwere partially offset by the anticipated year -over-year increase in opioid  litigation and technology costs, which we \noutlined with our initial outlook in May.  Also had a lower profit contribution from the Europe segment and a higher \nadjusted tax rate.  \n \n Let me start with the details of our consolidated results, which can be found  on slide 4.  Consolidated revenues for \nthe quarter increased 6% year -over-year, primarily driven by growth in our U.S. ", "original_text": "These items \nwere partially offset by the anticipated year -over-year increase in opioid  litigation and technology costs, which we \noutlined with our initial outlook in May. ", "page_label": "6", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "74aa42ba-8aa4-40bb-8e6b-4b4438973fe6", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "96fe23ab3f28da6c3b9e65abfaebdf377433fd3e2f0b15afab5b613df6915c96", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "396cb89d-55f0-4a4d-adbe-fada4fa9735a", "node_type": "1", "metadata": {"window": "Today we reported first quarter adjusted ea rnings of $3.31 per diluted share, \nahead of our original expectations, and we're raising the full year fiscal 2020 outlook by $0.15 to a range of \n$14.00 to $14.60 per diluted share from our previous outlook of $13.85 to $14.45 per diluted share.  \n \n Let's mov e right to our first quarter results.  Our first quarter adjusted earnings of $3.31 per diluted share were up \n14% year -over-year, driven by strong performance in the U.S.  Pharmaceutical and Specialty Solutions business, \nMedical -Surgical Solutions and our MR xTS businesses; a lower share count; higher contribution from our equity \ninvestment in Change Healthcare; a one -time gain from investment activities; and expense timing.  These items \nwere partially offset by the anticipated year -over-year increase in opioid  litigation and technology costs, which we \noutlined with our initial outlook in May.  Also had a lower profit contribution from the Europe segment and a higher \nadjusted tax rate.  \n \n Let me start with the details of our consolidated results, which can be found  on slide 4. ", "original_text": "Pharmaceutical and Specialty Solutions business, \nMedical -Surgical Solutions and our MR xTS businesses; a lower share count; higher contribution from our equity \ninvestment in Change Healthcare; a one -time gain from investment activities; and expense timing. ", "page_label": "6", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9edbfff5ecd59999c93d1884b915ed293d5cfec0c895ea1c25b4ef4e0ca74bb0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dcb9e7a2-cc72-46cc-a500-e2b27cd176fe", "node_type": "1", "metadata": {"window": "Our first quarter adjusted earnings of $3.31 per diluted share were up \n14% year -over-year, driven by strong performance in the U.S.  Pharmaceutical and Specialty Solutions business, \nMedical -Surgical Solutions and our MR xTS businesses; a lower share count; higher contribution from our equity \ninvestment in Change Healthcare; a one -time gain from investment activities; and expense timing.  These items \nwere partially offset by the anticipated year -over-year increase in opioid  litigation and technology costs, which we \noutlined with our initial outlook in May.  Also had a lower profit contribution from the Europe segment and a higher \nadjusted tax rate.  \n \n Let me start with the details of our consolidated results, which can be found  on slide 4.  Consolidated revenues for \nthe quarter increased 6% year -over-year, primarily driven by growth in our U.S.  Pharmaceutical and Specialty \nSolutions segment. ", "original_text": "Also had a lower profit contribution from the Europe segment and a higher \nadjusted tax rate.  \n \n"}, "hash": "e3df6337d21dd58e996dce62f154d4703bff06a055a375e8355e7f4fb6cbfb26", "class_name": "RelatedNodeInfo"}}, "text": "These items \nwere partially offset by the anticipated year -over-year increase in opioid  litigation and technology costs, which we \noutlined with our initial outlook in May. ", "start_char_idx": 2084, "end_char_idx": 2259, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dcb9e7a2-cc72-46cc-a500-e2b27cd176fe": {"__data__": {"id_": "dcb9e7a2-cc72-46cc-a500-e2b27cd176fe", "embedding": null, "metadata": {"window": "Our first quarter adjusted earnings of $3.31 per diluted share were up \n14% year -over-year, driven by strong performance in the U.S.  Pharmaceutical and Specialty Solutions business, \nMedical -Surgical Solutions and our MR xTS businesses; a lower share count; higher contribution from our equity \ninvestment in Change Healthcare; a one -time gain from investment activities; and expense timing.  These items \nwere partially offset by the anticipated year -over-year increase in opioid  litigation and technology costs, which we \noutlined with our initial outlook in May.  Also had a lower profit contribution from the Europe segment and a higher \nadjusted tax rate.  \n \n Let me start with the details of our consolidated results, which can be found  on slide 4.  Consolidated revenues for \nthe quarter increased 6% year -over-year, primarily driven by growth in our U.S.  Pharmaceutical and Specialty \nSolutions segment. ", "original_text": "Also had a lower profit contribution from the Europe segment and a higher \nadjusted tax rate.  \n \n", "page_label": "6", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "74aa42ba-8aa4-40bb-8e6b-4b4438973fe6", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "96fe23ab3f28da6c3b9e65abfaebdf377433fd3e2f0b15afab5b613df6915c96", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f5238269-abeb-4cb9-aee6-d9746877019e", "node_type": "1", "metadata": {"window": "Let's mov e right to our first quarter results.  Our first quarter adjusted earnings of $3.31 per diluted share were up \n14% year -over-year, driven by strong performance in the U.S.  Pharmaceutical and Specialty Solutions business, \nMedical -Surgical Solutions and our MR xTS businesses; a lower share count; higher contribution from our equity \ninvestment in Change Healthcare; a one -time gain from investment activities; and expense timing.  These items \nwere partially offset by the anticipated year -over-year increase in opioid  litigation and technology costs, which we \noutlined with our initial outlook in May.  Also had a lower profit contribution from the Europe segment and a higher \nadjusted tax rate.  \n \n Let me start with the details of our consolidated results, which can be found  on slide 4.  Consolidated revenues for \nthe quarter increased 6% year -over-year, primarily driven by growth in our U.S. ", "original_text": "These items \nwere partially offset by the anticipated year -over-year increase in opioid  litigation and technology costs, which we \noutlined with our initial outlook in May. ", "page_label": "6", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3deea2281ac4facad0baf207498af15e6eee4c115a14e02cef3f149429a10ba0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7d853738-d27f-47e6-ab10-83c61ffb4873", "node_type": "1", "metadata": {"window": "Pharmaceutical and Specialty Solutions business, \nMedical -Surgical Solutions and our MR xTS businesses; a lower share count; higher contribution from our equity \ninvestment in Change Healthcare; a one -time gain from investment activities; and expense timing.  These items \nwere partially offset by the anticipated year -over-year increase in opioid  litigation and technology costs, which we \noutlined with our initial outlook in May.  Also had a lower profit contribution from the Europe segment and a higher \nadjusted tax rate.  \n \n Let me start with the details of our consolidated results, which can be found  on slide 4.  Consolidated revenues for \nthe quarter increased 6% year -over-year, primarily driven by growth in our U.S.  Pharmaceutical and Specialty \nSolutions segment.  Adjusted gross profit increased 2% year -over-year, mainly driven by a few key operational  \nitems: within our Medical -Surgical business, the contribution from the MSD acquisition which we have now \nlapped; and above -market growth from pharmaceutical products; volume growth across our MRxTS offerings; and \ngrowth in our Specialty Provider Solutions  business within the U.S. ", "original_text": "Let me start with the details of our consolidated results, which can be found  on slide 4. "}, "hash": "2774e88778b015204d81a5570c83dfaeae644e7b845e2d78ba14dda91c8a61d8", "class_name": "RelatedNodeInfo"}}, "text": "Also had a lower profit contribution from the Europe segment and a higher \nadjusted tax rate.  \n \n", "start_char_idx": 2259, "end_char_idx": 2357, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7d853738-d27f-47e6-ab10-83c61ffb4873": {"__data__": {"id_": "7d853738-d27f-47e6-ab10-83c61ffb4873", "embedding": null, "metadata": {"window": "Pharmaceutical and Specialty Solutions business, \nMedical -Surgical Solutions and our MR xTS businesses; a lower share count; higher contribution from our equity \ninvestment in Change Healthcare; a one -time gain from investment activities; and expense timing.  These items \nwere partially offset by the anticipated year -over-year increase in opioid  litigation and technology costs, which we \noutlined with our initial outlook in May.  Also had a lower profit contribution from the Europe segment and a higher \nadjusted tax rate.  \n \n Let me start with the details of our consolidated results, which can be found  on slide 4.  Consolidated revenues for \nthe quarter increased 6% year -over-year, primarily driven by growth in our U.S.  Pharmaceutical and Specialty \nSolutions segment.  Adjusted gross profit increased 2% year -over-year, mainly driven by a few key operational  \nitems: within our Medical -Surgical business, the contribution from the MSD acquisition which we have now \nlapped; and above -market growth from pharmaceutical products; volume growth across our MRxTS offerings; and \ngrowth in our Specialty Provider Solutions  business within the U.S. ", "original_text": "Let me start with the details of our consolidated results, which can be found  on slide 4. ", "page_label": "6", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "74aa42ba-8aa4-40bb-8e6b-4b4438973fe6", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "96fe23ab3f28da6c3b9e65abfaebdf377433fd3e2f0b15afab5b613df6915c96", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dcb9e7a2-cc72-46cc-a500-e2b27cd176fe", "node_type": "1", "metadata": {"window": "Our first quarter adjusted earnings of $3.31 per diluted share were up \n14% year -over-year, driven by strong performance in the U.S.  Pharmaceutical and Specialty Solutions business, \nMedical -Surgical Solutions and our MR xTS businesses; a lower share count; higher contribution from our equity \ninvestment in Change Healthcare; a one -time gain from investment activities; and expense timing.  These items \nwere partially offset by the anticipated year -over-year increase in opioid  litigation and technology costs, which we \noutlined with our initial outlook in May.  Also had a lower profit contribution from the Europe segment and a higher \nadjusted tax rate.  \n \n Let me start with the details of our consolidated results, which can be found  on slide 4.  Consolidated revenues for \nthe quarter increased 6% year -over-year, primarily driven by growth in our U.S.  Pharmaceutical and Specialty \nSolutions segment. ", "original_text": "Also had a lower profit contribution from the Europe segment and a higher \nadjusted tax rate.  \n \n", "page_label": "6", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "527357beee8d71166da60f72aed76a975c2a2d651042356c7037c50cf4348462", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "64d55880-895b-4823-a959-254b43d00846", "node_type": "1", "metadata": {"window": "These items \nwere partially offset by the anticipated year -over-year increase in opioid  litigation and technology costs, which we \noutlined with our initial outlook in May.  Also had a lower profit contribution from the Europe segment and a higher \nadjusted tax rate.  \n \n Let me start with the details of our consolidated results, which can be found  on slide 4.  Consolidated revenues for \nthe quarter increased 6% year -over-year, primarily driven by growth in our U.S.  Pharmaceutical and Specialty \nSolutions segment.  Adjusted gross profit increased 2% year -over-year, mainly driven by a few key operational  \nitems: within our Medical -Surgical business, the contribution from the MSD acquisition which we have now \nlapped; and above -market growth from pharmaceutical products; volume growth across our MRxTS offerings; and \ngrowth in our Specialty Provider Solutions  business within the U.S.  Pharmaceutical and Specialty Solutions \nsegment. ", "original_text": "Consolidated revenues for \nthe quarter increased 6% year -over-year, primarily driven by growth in our U.S. "}, "hash": "01cc3f6690da6758b5c27cff96e3a1f4c416f83894d8f8bb8034e362189ec382", "class_name": "RelatedNodeInfo"}}, "text": "Let me start with the details of our consolidated results, which can be found  on slide 4. ", "start_char_idx": 2357, "end_char_idx": 2448, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "64d55880-895b-4823-a959-254b43d00846": {"__data__": {"id_": "64d55880-895b-4823-a959-254b43d00846", "embedding": null, "metadata": {"window": "These items \nwere partially offset by the anticipated year -over-year increase in opioid  litigation and technology costs, which we \noutlined with our initial outlook in May.  Also had a lower profit contribution from the Europe segment and a higher \nadjusted tax rate.  \n \n Let me start with the details of our consolidated results, which can be found  on slide 4.  Consolidated revenues for \nthe quarter increased 6% year -over-year, primarily driven by growth in our U.S.  Pharmaceutical and Specialty \nSolutions segment.  Adjusted gross profit increased 2% year -over-year, mainly driven by a few key operational  \nitems: within our Medical -Surgical business, the contribution from the MSD acquisition which we have now \nlapped; and above -market growth from pharmaceutical products; volume growth across our MRxTS offerings; and \ngrowth in our Specialty Provider Solutions  business within the U.S.  Pharmaceutical and Specialty Solutions \nsegment. ", "original_text": "Consolidated revenues for \nthe quarter increased 6% year -over-year, primarily driven by growth in our U.S. ", "page_label": "6", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "74aa42ba-8aa4-40bb-8e6b-4b4438973fe6", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "96fe23ab3f28da6c3b9e65abfaebdf377433fd3e2f0b15afab5b613df6915c96", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7d853738-d27f-47e6-ab10-83c61ffb4873", "node_type": "1", "metadata": {"window": "Pharmaceutical and Specialty Solutions business, \nMedical -Surgical Solutions and our MR xTS businesses; a lower share count; higher contribution from our equity \ninvestment in Change Healthcare; a one -time gain from investment activities; and expense timing.  These items \nwere partially offset by the anticipated year -over-year increase in opioid  litigation and technology costs, which we \noutlined with our initial outlook in May.  Also had a lower profit contribution from the Europe segment and a higher \nadjusted tax rate.  \n \n Let me start with the details of our consolidated results, which can be found  on slide 4.  Consolidated revenues for \nthe quarter increased 6% year -over-year, primarily driven by growth in our U.S.  Pharmaceutical and Specialty \nSolutions segment.  Adjusted gross profit increased 2% year -over-year, mainly driven by a few key operational  \nitems: within our Medical -Surgical business, the contribution from the MSD acquisition which we have now \nlapped; and above -market growth from pharmaceutical products; volume growth across our MRxTS offerings; and \ngrowth in our Specialty Provider Solutions  business within the U.S. ", "original_text": "Let me start with the details of our consolidated results, which can be found  on slide 4. ", "page_label": "6", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "719d1f82cba1028af434bdcde5843040c3d20637f8b095570fbb8bd3749b9ffa", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e8693b1a-7cb2-4e79-adb2-ec1c8a343185", "node_type": "1", "metadata": {"window": "Also had a lower profit contribution from the Europe segment and a higher \nadjusted tax rate.  \n \n Let me start with the details of our consolidated results, which can be found  on slide 4.  Consolidated revenues for \nthe quarter increased 6% year -over-year, primarily driven by growth in our U.S.  Pharmaceutical and Specialty \nSolutions segment.  Adjusted gross profit increased 2% year -over-year, mainly driven by a few key operational  \nitems: within our Medical -Surgical business, the contribution from the MSD acquisition which we have now \nlapped; and above -market growth from pharmaceutical products; volume growth across our MRxTS offerings; and \ngrowth in our Specialty Provider Solutions  business within the U.S.  Pharmaceutical and Specialty Solutions \nsegment.  These items were partially offset by foreign currency effect and lower retail pharmacy margins in the \nUK. \n \n", "original_text": "Pharmaceutical and Specialty \nSolutions segment. "}, "hash": "cbe7e391084f1898a62c749083ceda72a659a0ee5b0890582f61d1b1c3a925d6", "class_name": "RelatedNodeInfo"}}, "text": "Consolidated revenues for \nthe quarter increased 6% year -over-year, primarily driven by growth in our U.S. ", "start_char_idx": 2448, "end_char_idx": 2556, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e8693b1a-7cb2-4e79-adb2-ec1c8a343185": {"__data__": {"id_": "e8693b1a-7cb2-4e79-adb2-ec1c8a343185", "embedding": null, "metadata": {"window": "Also had a lower profit contribution from the Europe segment and a higher \nadjusted tax rate.  \n \n Let me start with the details of our consolidated results, which can be found  on slide 4.  Consolidated revenues for \nthe quarter increased 6% year -over-year, primarily driven by growth in our U.S.  Pharmaceutical and Specialty \nSolutions segment.  Adjusted gross profit increased 2% year -over-year, mainly driven by a few key operational  \nitems: within our Medical -Surgical business, the contribution from the MSD acquisition which we have now \nlapped; and above -market growth from pharmaceutical products; volume growth across our MRxTS offerings; and \ngrowth in our Specialty Provider Solutions  business within the U.S.  Pharmaceutical and Specialty Solutions \nsegment.  These items were partially offset by foreign currency effect and lower retail pharmacy margins in the \nUK. \n \n", "original_text": "Pharmaceutical and Specialty \nSolutions segment. ", "page_label": "6", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "74aa42ba-8aa4-40bb-8e6b-4b4438973fe6", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "96fe23ab3f28da6c3b9e65abfaebdf377433fd3e2f0b15afab5b613df6915c96", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "64d55880-895b-4823-a959-254b43d00846", "node_type": "1", "metadata": {"window": "These items \nwere partially offset by the anticipated year -over-year increase in opioid  litigation and technology costs, which we \noutlined with our initial outlook in May.  Also had a lower profit contribution from the Europe segment and a higher \nadjusted tax rate.  \n \n Let me start with the details of our consolidated results, which can be found  on slide 4.  Consolidated revenues for \nthe quarter increased 6% year -over-year, primarily driven by growth in our U.S.  Pharmaceutical and Specialty \nSolutions segment.  Adjusted gross profit increased 2% year -over-year, mainly driven by a few key operational  \nitems: within our Medical -Surgical business, the contribution from the MSD acquisition which we have now \nlapped; and above -market growth from pharmaceutical products; volume growth across our MRxTS offerings; and \ngrowth in our Specialty Provider Solutions  business within the U.S.  Pharmaceutical and Specialty Solutions \nsegment. ", "original_text": "Consolidated revenues for \nthe quarter increased 6% year -over-year, primarily driven by growth in our U.S. ", "page_label": "6", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fd3090db861bbf7f2db331c11f7f53358b56e8c9a149efe8bc3374167f2b10ea", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c4ae4d27-c9bb-466e-bd49-8e9745a6eb5b", "node_type": "1", "metadata": {"window": "Let me start with the details of our consolidated results, which can be found  on slide 4.  Consolidated revenues for \nthe quarter increased 6% year -over-year, primarily driven by growth in our U.S.  Pharmaceutical and Specialty \nSolutions segment.  Adjusted gross profit increased 2% year -over-year, mainly driven by a few key operational  \nitems: within our Medical -Surgical business, the contribution from the MSD acquisition which we have now \nlapped; and above -market growth from pharmaceutical products; volume growth across our MRxTS offerings; and \ngrowth in our Specialty Provider Solutions  business within the U.S.  Pharmaceutical and Specialty Solutions \nsegment.  These items were partially offset by foreign currency effect and lower retail pharmacy margins in the \nUK. \n \n First quarter adjusted operating expenses increased 1% year -over-year, partially driven by the acquisition of MSD \nin the prior year. ", "original_text": "Adjusted gross profit increased 2% year -over-year, mainly driven by a few key operational  \nitems: within our Medical -Surgical business, the contribution from the MSD acquisition which we have now \nlapped; and above -market growth from pharmaceutical products; volume growth across our MRxTS offerings; and \ngrowth in our Specialty Provider Solutions  business within the U.S. "}, "hash": "094c5cf754e41f334d28a16e06d02abb3ee6290fccc14e249ab1551be535d984", "class_name": "RelatedNodeInfo"}}, "text": "Pharmaceutical and Specialty \nSolutions segment. ", "start_char_idx": 2556, "end_char_idx": 2605, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c4ae4d27-c9bb-466e-bd49-8e9745a6eb5b": {"__data__": {"id_": "c4ae4d27-c9bb-466e-bd49-8e9745a6eb5b", "embedding": null, "metadata": {"window": "Let me start with the details of our consolidated results, which can be found  on slide 4.  Consolidated revenues for \nthe quarter increased 6% year -over-year, primarily driven by growth in our U.S.  Pharmaceutical and Specialty \nSolutions segment.  Adjusted gross profit increased 2% year -over-year, mainly driven by a few key operational  \nitems: within our Medical -Surgical business, the contribution from the MSD acquisition which we have now \nlapped; and above -market growth from pharmaceutical products; volume growth across our MRxTS offerings; and \ngrowth in our Specialty Provider Solutions  business within the U.S.  Pharmaceutical and Specialty Solutions \nsegment.  These items were partially offset by foreign currency effect and lower retail pharmacy margins in the \nUK. \n \n First quarter adjusted operating expenses increased 1% year -over-year, partially driven by the acquisition of MSD \nin the prior year. ", "original_text": "Adjusted gross profit increased 2% year -over-year, mainly driven by a few key operational  \nitems: within our Medical -Surgical business, the contribution from the MSD acquisition which we have now \nlapped; and above -market growth from pharmaceutical products; volume growth across our MRxTS offerings; and \ngrowth in our Specialty Provider Solutions  business within the U.S. ", "page_label": "6", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "74aa42ba-8aa4-40bb-8e6b-4b4438973fe6", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "96fe23ab3f28da6c3b9e65abfaebdf377433fd3e2f0b15afab5b613df6915c96", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e8693b1a-7cb2-4e79-adb2-ec1c8a343185", "node_type": "1", "metadata": {"window": "Also had a lower profit contribution from the Europe segment and a higher \nadjusted tax rate.  \n \n Let me start with the details of our consolidated results, which can be found  on slide 4.  Consolidated revenues for \nthe quarter increased 6% year -over-year, primarily driven by growth in our U.S.  Pharmaceutical and Specialty \nSolutions segment.  Adjusted gross profit increased 2% year -over-year, mainly driven by a few key operational  \nitems: within our Medical -Surgical business, the contribution from the MSD acquisition which we have now \nlapped; and above -market growth from pharmaceutical products; volume growth across our MRxTS offerings; and \ngrowth in our Specialty Provider Solutions  business within the U.S.  Pharmaceutical and Specialty Solutions \nsegment.  These items were partially offset by foreign currency effect and lower retail pharmacy margins in the \nUK. \n \n", "original_text": "Pharmaceutical and Specialty \nSolutions segment. ", "page_label": "6", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ad29982a31afdd251b8764a8e30fc47a4f11439ebe1e64783ea5dcb392aad31d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7cdc9798-4237-41cf-a16e-5d9208f2084e", "node_type": "1", "metadata": {"window": "Consolidated revenues for \nthe quarter increased 6% year -over-year, primarily driven by growth in our U.S.  Pharmaceutical and Specialty \nSolutions segment.  Adjusted gross profit increased 2% year -over-year, mainly driven by a few key operational  \nitems: within our Medical -Surgical business, the contribution from the MSD acquisition which we have now \nlapped; and above -market growth from pharmaceutical products; volume growth across our MRxTS offerings; and \ngrowth in our Specialty Provider Solutions  business within the U.S.  Pharmaceutical and Specialty Solutions \nsegment.  These items were partially offset by foreign currency effect and lower retail pharmacy margins in the \nUK. \n \n First quarter adjusted operating expenses increased 1% year -over-year, partially driven by the acquisition of MSD \nin the prior year.  Adjusted income from operations was $933 million for the quarter, 9% above the prior year. \n", "original_text": "Pharmaceutical and Specialty Solutions \nsegment. "}, "hash": "9cd5757fcffb25707809d67f63defe7159b5c2a2a3bef7266c2b746117dcdb86", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted gross profit increased 2% year -over-year, mainly driven by a few key operational  \nitems: within our Medical -Surgical business, the contribution from the MSD acquisition which we have now \nlapped; and above -market growth from pharmaceutical products; volume growth across our MRxTS offerings; and \ngrowth in our Specialty Provider Solutions  business within the U.S. ", "start_char_idx": 2605, "end_char_idx": 2984, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7cdc9798-4237-41cf-a16e-5d9208f2084e": {"__data__": {"id_": "7cdc9798-4237-41cf-a16e-5d9208f2084e", "embedding": null, "metadata": {"window": "Consolidated revenues for \nthe quarter increased 6% year -over-year, primarily driven by growth in our U.S.  Pharmaceutical and Specialty \nSolutions segment.  Adjusted gross profit increased 2% year -over-year, mainly driven by a few key operational  \nitems: within our Medical -Surgical business, the contribution from the MSD acquisition which we have now \nlapped; and above -market growth from pharmaceutical products; volume growth across our MRxTS offerings; and \ngrowth in our Specialty Provider Solutions  business within the U.S.  Pharmaceutical and Specialty Solutions \nsegment.  These items were partially offset by foreign currency effect and lower retail pharmacy margins in the \nUK. \n \n First quarter adjusted operating expenses increased 1% year -over-year, partially driven by the acquisition of MSD \nin the prior year.  Adjusted income from operations was $933 million for the quarter, 9% above the prior year. \n", "original_text": "Pharmaceutical and Specialty Solutions \nsegment. ", "page_label": "6", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "74aa42ba-8aa4-40bb-8e6b-4b4438973fe6", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "96fe23ab3f28da6c3b9e65abfaebdf377433fd3e2f0b15afab5b613df6915c96", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c4ae4d27-c9bb-466e-bd49-8e9745a6eb5b", "node_type": "1", "metadata": {"window": "Let me start with the details of our consolidated results, which can be found  on slide 4.  Consolidated revenues for \nthe quarter increased 6% year -over-year, primarily driven by growth in our U.S.  Pharmaceutical and Specialty \nSolutions segment.  Adjusted gross profit increased 2% year -over-year, mainly driven by a few key operational  \nitems: within our Medical -Surgical business, the contribution from the MSD acquisition which we have now \nlapped; and above -market growth from pharmaceutical products; volume growth across our MRxTS offerings; and \ngrowth in our Specialty Provider Solutions  business within the U.S.  Pharmaceutical and Specialty Solutions \nsegment.  These items were partially offset by foreign currency effect and lower retail pharmacy margins in the \nUK. \n \n First quarter adjusted operating expenses increased 1% year -over-year, partially driven by the acquisition of MSD \nin the prior year. ", "original_text": "Adjusted gross profit increased 2% year -over-year, mainly driven by a few key operational  \nitems: within our Medical -Surgical business, the contribution from the MSD acquisition which we have now \nlapped; and above -market growth from pharmaceutical products; volume growth across our MRxTS offerings; and \ngrowth in our Specialty Provider Solutions  business within the U.S. ", "page_label": "6", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7d6daf8774c81fcfb9d57397b16be9025a79eeb2f1bd2dafbce08eaa4073a677", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "195946fe-780d-44f7-b4cd-9ac12e66ce81", "node_type": "1", "metadata": {"window": "Pharmaceutical and Specialty \nSolutions segment.  Adjusted gross profit increased 2% year -over-year, mainly driven by a few key operational  \nitems: within our Medical -Surgical business, the contribution from the MSD acquisition which we have now \nlapped; and above -market growth from pharmaceutical products; volume growth across our MRxTS offerings; and \ngrowth in our Specialty Provider Solutions  business within the U.S.  Pharmaceutical and Specialty Solutions \nsegment.  These items were partially offset by foreign currency effect and lower retail pharmacy margins in the \nUK. \n \n First quarter adjusted operating expenses increased 1% year -over-year, partially driven by the acquisition of MSD \nin the prior year.  Adjusted income from operations was $933 million for the quarter, 9% above the prior year. \n Interest expense was $56 million for the quarter, a decrease of 8% compared to the prior year, primaril y due to \nlower commercial paper balances. ", "original_text": "These items were partially offset by foreign currency effect and lower retail pharmacy margins in the \nUK. \n \n"}, "hash": "3e45b268fb68326170d6eaf1dec40d45b1d5eac25e8328cbdfb61349f1fb062b", "class_name": "RelatedNodeInfo"}}, "text": "Pharmaceutical and Specialty Solutions \nsegment. ", "start_char_idx": 2984, "end_char_idx": 3033, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "195946fe-780d-44f7-b4cd-9ac12e66ce81": {"__data__": {"id_": "195946fe-780d-44f7-b4cd-9ac12e66ce81", "embedding": null, "metadata": {"window": "Pharmaceutical and Specialty \nSolutions segment.  Adjusted gross profit increased 2% year -over-year, mainly driven by a few key operational  \nitems: within our Medical -Surgical business, the contribution from the MSD acquisition which we have now \nlapped; and above -market growth from pharmaceutical products; volume growth across our MRxTS offerings; and \ngrowth in our Specialty Provider Solutions  business within the U.S.  Pharmaceutical and Specialty Solutions \nsegment.  These items were partially offset by foreign currency effect and lower retail pharmacy margins in the \nUK. \n \n First quarter adjusted operating expenses increased 1% year -over-year, partially driven by the acquisition of MSD \nin the prior year.  Adjusted income from operations was $933 million for the quarter, 9% above the prior year. \n Interest expense was $56 million for the quarter, a decrease of 8% compared to the prior year, primaril y due to \nlower commercial paper balances. ", "original_text": "These items were partially offset by foreign currency effect and lower retail pharmacy margins in the \nUK. \n \n", "page_label": "6", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "74aa42ba-8aa4-40bb-8e6b-4b4438973fe6", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "96fe23ab3f28da6c3b9e65abfaebdf377433fd3e2f0b15afab5b613df6915c96", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7cdc9798-4237-41cf-a16e-5d9208f2084e", "node_type": "1", "metadata": {"window": "Consolidated revenues for \nthe quarter increased 6% year -over-year, primarily driven by growth in our U.S.  Pharmaceutical and Specialty \nSolutions segment.  Adjusted gross profit increased 2% year -over-year, mainly driven by a few key operational  \nitems: within our Medical -Surgical business, the contribution from the MSD acquisition which we have now \nlapped; and above -market growth from pharmaceutical products; volume growth across our MRxTS offerings; and \ngrowth in our Specialty Provider Solutions  business within the U.S.  Pharmaceutical and Specialty Solutions \nsegment.  These items were partially offset by foreign currency effect and lower retail pharmacy margins in the \nUK. \n \n First quarter adjusted operating expenses increased 1% year -over-year, partially driven by the acquisition of MSD \nin the prior year.  Adjusted income from operations was $933 million for the quarter, 9% above the prior year. \n", "original_text": "Pharmaceutical and Specialty Solutions \nsegment. ", "page_label": "6", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8bce247c77ea5df6f722125ae3ead08fd5a164842b4052aa3ca1f8687090e29f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d9292600-28fa-4da5-8467-c7999482b5da", "node_type": "1", "metadata": {"window": "Adjusted gross profit increased 2% year -over-year, mainly driven by a few key operational  \nitems: within our Medical -Surgical business, the contribution from the MSD acquisition which we have now \nlapped; and above -market growth from pharmaceutical products; volume growth across our MRxTS offerings; and \ngrowth in our Specialty Provider Solutions  business within the U.S.  Pharmaceutical and Specialty Solutions \nsegment.  These items were partially offset by foreign currency effect and lower retail pharmacy margins in the \nUK. \n \n First quarter adjusted operating expenses increased 1% year -over-year, partially driven by the acquisition of MSD \nin the prior year.  Adjusted income from operations was $933 million for the quarter, 9% above the prior year. \n Interest expense was $56 million for the quarter, a decrease of 8% compared to the prior year, primaril y due to \nlower commercial paper balances.  Our adjusted tax rate was 22.6% for the quarter, mainly driven by our mix of \nbusiness. ", "original_text": "First quarter adjusted operating expenses increased 1% year -over-year, partially driven by the acquisition of MSD \nin the prior year. "}, "hash": "093cc07fbd95b4fd844fbfadb83ec54bc65dff99be6971349ac1a4db30c7bd0c", "class_name": "RelatedNodeInfo"}}, "text": "These items were partially offset by foreign currency effect and lower retail pharmacy margins in the \nUK. \n \n", "start_char_idx": 3033, "end_char_idx": 3143, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d9292600-28fa-4da5-8467-c7999482b5da": {"__data__": {"id_": "d9292600-28fa-4da5-8467-c7999482b5da", "embedding": null, "metadata": {"window": "Adjusted gross profit increased 2% year -over-year, mainly driven by a few key operational  \nitems: within our Medical -Surgical business, the contribution from the MSD acquisition which we have now \nlapped; and above -market growth from pharmaceutical products; volume growth across our MRxTS offerings; and \ngrowth in our Specialty Provider Solutions  business within the U.S.  Pharmaceutical and Specialty Solutions \nsegment.  These items were partially offset by foreign currency effect and lower retail pharmacy margins in the \nUK. \n \n First quarter adjusted operating expenses increased 1% year -over-year, partially driven by the acquisition of MSD \nin the prior year.  Adjusted income from operations was $933 million for the quarter, 9% above the prior year. \n Interest expense was $56 million for the quarter, a decrease of 8% compared to the prior year, primaril y due to \nlower commercial paper balances.  Our adjusted tax rate was 22.6% for the quarter, mainly driven by our mix of \nbusiness. ", "original_text": "First quarter adjusted operating expenses increased 1% year -over-year, partially driven by the acquisition of MSD \nin the prior year. ", "page_label": "6", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "74aa42ba-8aa4-40bb-8e6b-4b4438973fe6", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "96fe23ab3f28da6c3b9e65abfaebdf377433fd3e2f0b15afab5b613df6915c96", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "195946fe-780d-44f7-b4cd-9ac12e66ce81", "node_type": "1", "metadata": {"window": "Pharmaceutical and Specialty \nSolutions segment.  Adjusted gross profit increased 2% year -over-year, mainly driven by a few key operational  \nitems: within our Medical -Surgical business, the contribution from the MSD acquisition which we have now \nlapped; and above -market growth from pharmaceutical products; volume growth across our MRxTS offerings; and \ngrowth in our Specialty Provider Solutions  business within the U.S.  Pharmaceutical and Specialty Solutions \nsegment.  These items were partially offset by foreign currency effect and lower retail pharmacy margins in the \nUK. \n \n First quarter adjusted operating expenses increased 1% year -over-year, partially driven by the acquisition of MSD \nin the prior year.  Adjusted income from operations was $933 million for the quarter, 9% above the prior year. \n Interest expense was $56 million for the quarter, a decrease of 8% compared to the prior year, primaril y due to \nlower commercial paper balances. ", "original_text": "These items were partially offset by foreign currency effect and lower retail pharmacy margins in the \nUK. \n \n", "page_label": "6", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4d4b891edef06183b54d2518532da2a62b939647a1e2b240fbd05057be7f78c6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4e63fdfb-b136-48d2-9687-c59a508a732d", "node_type": "1", "metadata": {"window": "Pharmaceutical and Specialty Solutions \nsegment.  These items were partially offset by foreign currency effect and lower retail pharmacy margins in the \nUK. \n \n First quarter adjusted operating expenses increased 1% year -over-year, partially driven by the acquisition of MSD \nin the prior year.  Adjusted income from operations was $933 million for the quarter, 9% above the prior year. \n Interest expense was $56 million for the quarter, a decrease of 8% compared to the prior year, primaril y due to \nlower commercial paper balances.  Our adjusted tax rate was 22.6% for the quarter, mainly driven by our mix of \nbusiness.  We continue to assume a full year adjusted tax rate of approximately 18% to 19%, which may vary from \nquarter -to-quarter and inc ludes anticipated discrete tax items that we expect to realize during the course of the \nyear.  \n \n", "original_text": "Adjusted income from operations was $933 million for the quarter, 9% above the prior year. \n"}, "hash": "c117291530d0313fff74cb2c8111785e214a3cd326c69725c917e45299c58ae8", "class_name": "RelatedNodeInfo"}}, "text": "First quarter adjusted operating expenses increased 1% year -over-year, partially driven by the acquisition of MSD \nin the prior year. ", "start_char_idx": 3143, "end_char_idx": 3278, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4e63fdfb-b136-48d2-9687-c59a508a732d": {"__data__": {"id_": "4e63fdfb-b136-48d2-9687-c59a508a732d", "embedding": null, "metadata": {"window": "Pharmaceutical and Specialty Solutions \nsegment.  These items were partially offset by foreign currency effect and lower retail pharmacy margins in the \nUK. \n \n First quarter adjusted operating expenses increased 1% year -over-year, partially driven by the acquisition of MSD \nin the prior year.  Adjusted income from operations was $933 million for the quarter, 9% above the prior year. \n Interest expense was $56 million for the quarter, a decrease of 8% compared to the prior year, primaril y due to \nlower commercial paper balances.  Our adjusted tax rate was 22.6% for the quarter, mainly driven by our mix of \nbusiness.  We continue to assume a full year adjusted tax rate of approximately 18% to 19%, which may vary from \nquarter -to-quarter and inc ludes anticipated discrete tax items that we expect to realize during the course of the \nyear.  \n \n", "original_text": "Adjusted income from operations was $933 million for the quarter, 9% above the prior year. \n", "page_label": "6", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "74aa42ba-8aa4-40bb-8e6b-4b4438973fe6", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "96fe23ab3f28da6c3b9e65abfaebdf377433fd3e2f0b15afab5b613df6915c96", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d9292600-28fa-4da5-8467-c7999482b5da", "node_type": "1", "metadata": {"window": "Adjusted gross profit increased 2% year -over-year, mainly driven by a few key operational  \nitems: within our Medical -Surgical business, the contribution from the MSD acquisition which we have now \nlapped; and above -market growth from pharmaceutical products; volume growth across our MRxTS offerings; and \ngrowth in our Specialty Provider Solutions  business within the U.S.  Pharmaceutical and Specialty Solutions \nsegment.  These items were partially offset by foreign currency effect and lower retail pharmacy margins in the \nUK. \n \n First quarter adjusted operating expenses increased 1% year -over-year, partially driven by the acquisition of MSD \nin the prior year.  Adjusted income from operations was $933 million for the quarter, 9% above the prior year. \n Interest expense was $56 million for the quarter, a decrease of 8% compared to the prior year, primaril y due to \nlower commercial paper balances.  Our adjusted tax rate was 22.6% for the quarter, mainly driven by our mix of \nbusiness. ", "original_text": "First quarter adjusted operating expenses increased 1% year -over-year, partially driven by the acquisition of MSD \nin the prior year. ", "page_label": "6", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ef2c26c39652ad5b199da55fb780cdb2fd2c0d73390d3a3b92cc110dc44eef49", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4c034a36-849c-44ad-ab57-eff0ba32e3a7", "node_type": "1", "metadata": {"window": "These items were partially offset by foreign currency effect and lower retail pharmacy margins in the \nUK. \n \n First quarter adjusted operating expenses increased 1% year -over-year, partially driven by the acquisition of MSD \nin the prior year.  Adjusted income from operations was $933 million for the quarter, 9% above the prior year. \n Interest expense was $56 million for the quarter, a decrease of 8% compared to the prior year, primaril y due to \nlower commercial paper balances.  Our adjusted tax rate was 22.6% for the quarter, mainly driven by our mix of \nbusiness.  We continue to assume a full year adjusted tax rate of approximately 18% to 19%, which may vary from \nquarter -to-quarter and inc ludes anticipated discrete tax items that we expect to realize during the course of the \nyear.  \n \n Income attributable to non -controlling interests was $54 million for the quarter, a decrease of 7% compared to the \nprior year and in line with our expectations. ", "original_text": "Interest expense was $56 million for the quarter, a decrease of 8% compared to the prior year, primaril y due to \nlower commercial paper balances. "}, "hash": "24aedb5d3c2999d88550fc36260e3ec957b6b465d1d2c8fd8fb487a38efae4d7", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted income from operations was $933 million for the quarter, 9% above the prior year. \n", "start_char_idx": 3278, "end_char_idx": 3370, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4c034a36-849c-44ad-ab57-eff0ba32e3a7": {"__data__": {"id_": "4c034a36-849c-44ad-ab57-eff0ba32e3a7", "embedding": null, "metadata": {"window": "These items were partially offset by foreign currency effect and lower retail pharmacy margins in the \nUK. \n \n First quarter adjusted operating expenses increased 1% year -over-year, partially driven by the acquisition of MSD \nin the prior year.  Adjusted income from operations was $933 million for the quarter, 9% above the prior year. \n Interest expense was $56 million for the quarter, a decrease of 8% compared to the prior year, primaril y due to \nlower commercial paper balances.  Our adjusted tax rate was 22.6% for the quarter, mainly driven by our mix of \nbusiness.  We continue to assume a full year adjusted tax rate of approximately 18% to 19%, which may vary from \nquarter -to-quarter and inc ludes anticipated discrete tax items that we expect to realize during the course of the \nyear.  \n \n Income attributable to non -controlling interests was $54 million for the quarter, a decrease of 7% compared to the \nprior year and in line with our expectations. ", "original_text": "Interest expense was $56 million for the quarter, a decrease of 8% compared to the prior year, primaril y due to \nlower commercial paper balances. ", "page_label": "6", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "74aa42ba-8aa4-40bb-8e6b-4b4438973fe6", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "96fe23ab3f28da6c3b9e65abfaebdf377433fd3e2f0b15afab5b613df6915c96", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4e63fdfb-b136-48d2-9687-c59a508a732d", "node_type": "1", "metadata": {"window": "Pharmaceutical and Specialty Solutions \nsegment.  These items were partially offset by foreign currency effect and lower retail pharmacy margins in the \nUK. \n \n First quarter adjusted operating expenses increased 1% year -over-year, partially driven by the acquisition of MSD \nin the prior year.  Adjusted income from operations was $933 million for the quarter, 9% above the prior year. \n Interest expense was $56 million for the quarter, a decrease of 8% compared to the prior year, primaril y due to \nlower commercial paper balances.  Our adjusted tax rate was 22.6% for the quarter, mainly driven by our mix of \nbusiness.  We continue to assume a full year adjusted tax rate of approximately 18% to 19%, which may vary from \nquarter -to-quarter and inc ludes anticipated discrete tax items that we expect to realize during the course of the \nyear.  \n \n", "original_text": "Adjusted income from operations was $933 million for the quarter, 9% above the prior year. \n", "page_label": "6", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9d1ff4147e5d5be3e0f8cc1a507d74daa252669a003ce173a2051cb911e65601", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2b5aae8c-706f-485d-9f68-ffd29966148f", "node_type": "1", "metadata": {"window": "First quarter adjusted operating expenses increased 1% year -over-year, partially driven by the acquisition of MSD \nin the prior year.  Adjusted income from operations was $933 million for the quarter, 9% above the prior year. \n Interest expense was $56 million for the quarter, a decrease of 8% compared to the prior year, primaril y due to \nlower commercial paper balances.  Our adjusted tax rate was 22.6% for the quarter, mainly driven by our mix of \nbusiness.  We continue to assume a full year adjusted tax rate of approximately 18% to 19%, which may vary from \nquarter -to-quarter and inc ludes anticipated discrete tax items that we expect to realize during the course of the \nyear.  \n \n Income attributable to non -controlling interests was $54 million for the quarter, a decrease of 7% compared to the \nprior year and in line with our expectations.  Our adjusted net income from continuing operations totaled $625 \nmillion; and our diluted weighted average shares outstanding were 189 million for the quarter, a decrease of 7% \nyear-over-year.  \n ", "original_text": "Our adjusted tax rate was 22.6% for the quarter, mainly driven by our mix of \nbusiness. "}, "hash": "a4c17a7d675e91b1313c52ec9bc8145f95ed251a8b5e5c71d3bd4fd85f90526a", "class_name": "RelatedNodeInfo"}}, "text": "Interest expense was $56 million for the quarter, a decrease of 8% compared to the prior year, primaril y due to \nlower commercial paper balances. ", "start_char_idx": 3370, "end_char_idx": 3517, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2b5aae8c-706f-485d-9f68-ffd29966148f": {"__data__": {"id_": "2b5aae8c-706f-485d-9f68-ffd29966148f", "embedding": null, "metadata": {"window": "First quarter adjusted operating expenses increased 1% year -over-year, partially driven by the acquisition of MSD \nin the prior year.  Adjusted income from operations was $933 million for the quarter, 9% above the prior year. \n Interest expense was $56 million for the quarter, a decrease of 8% compared to the prior year, primaril y due to \nlower commercial paper balances.  Our adjusted tax rate was 22.6% for the quarter, mainly driven by our mix of \nbusiness.  We continue to assume a full year adjusted tax rate of approximately 18% to 19%, which may vary from \nquarter -to-quarter and inc ludes anticipated discrete tax items that we expect to realize during the course of the \nyear.  \n \n Income attributable to non -controlling interests was $54 million for the quarter, a decrease of 7% compared to the \nprior year and in line with our expectations.  Our adjusted net income from continuing operations totaled $625 \nmillion; and our diluted weighted average shares outstanding were 189 million for the quarter, a decrease of 7% \nyear-over-year.  \n ", "original_text": "Our adjusted tax rate was 22.6% for the quarter, mainly driven by our mix of \nbusiness. ", "page_label": "6", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "74aa42ba-8aa4-40bb-8e6b-4b4438973fe6", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "96fe23ab3f28da6c3b9e65abfaebdf377433fd3e2f0b15afab5b613df6915c96", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4c034a36-849c-44ad-ab57-eff0ba32e3a7", "node_type": "1", "metadata": {"window": "These items were partially offset by foreign currency effect and lower retail pharmacy margins in the \nUK. \n \n First quarter adjusted operating expenses increased 1% year -over-year, partially driven by the acquisition of MSD \nin the prior year.  Adjusted income from operations was $933 million for the quarter, 9% above the prior year. \n Interest expense was $56 million for the quarter, a decrease of 8% compared to the prior year, primaril y due to \nlower commercial paper balances.  Our adjusted tax rate was 22.6% for the quarter, mainly driven by our mix of \nbusiness.  We continue to assume a full year adjusted tax rate of approximately 18% to 19%, which may vary from \nquarter -to-quarter and inc ludes anticipated discrete tax items that we expect to realize during the course of the \nyear.  \n \n Income attributable to non -controlling interests was $54 million for the quarter, a decrease of 7% compared to the \nprior year and in line with our expectations. ", "original_text": "Interest expense was $56 million for the quarter, a decrease of 8% compared to the prior year, primaril y due to \nlower commercial paper balances. ", "page_label": "6", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a06e34070c253ebcd10864b7155f9f0ba22054ee136754a31e50cec6ff414448", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "539dbe6e-196d-44f9-971d-82e1f37eb2e8", "node_type": "1", "metadata": {"window": "Adjusted income from operations was $933 million for the quarter, 9% above the prior year. \n Interest expense was $56 million for the quarter, a decrease of 8% compared to the prior year, primaril y due to \nlower commercial paper balances.  Our adjusted tax rate was 22.6% for the quarter, mainly driven by our mix of \nbusiness.  We continue to assume a full year adjusted tax rate of approximately 18% to 19%, which may vary from \nquarter -to-quarter and inc ludes anticipated discrete tax items that we expect to realize during the course of the \nyear.  \n \n Income attributable to non -controlling interests was $54 million for the quarter, a decrease of 7% compared to the \nprior year and in line with our expectations.  Our adjusted net income from continuing operations totaled $625 \nmillion; and our diluted weighted average shares outstanding were 189 million for the quarter, a decrease of 7% \nyear-over-year.  \n ", "original_text": "We continue to assume a full year adjusted tax rate of approximately 18% to 19%, which may vary from \nquarter -to-quarter and inc ludes anticipated discrete tax items that we expect to realize during the course of the \nyear.  \n \n"}, "hash": "057aeaaabfb7774262a13846564e49134ef3b4338b1b03d905ee73e8ecd66911", "class_name": "RelatedNodeInfo"}}, "text": "Our adjusted tax rate was 22.6% for the quarter, mainly driven by our mix of \nbusiness. ", "start_char_idx": 3517, "end_char_idx": 3605, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "539dbe6e-196d-44f9-971d-82e1f37eb2e8": {"__data__": {"id_": "539dbe6e-196d-44f9-971d-82e1f37eb2e8", "embedding": null, "metadata": {"window": "Adjusted income from operations was $933 million for the quarter, 9% above the prior year. \n Interest expense was $56 million for the quarter, a decrease of 8% compared to the prior year, primaril y due to \nlower commercial paper balances.  Our adjusted tax rate was 22.6% for the quarter, mainly driven by our mix of \nbusiness.  We continue to assume a full year adjusted tax rate of approximately 18% to 19%, which may vary from \nquarter -to-quarter and inc ludes anticipated discrete tax items that we expect to realize during the course of the \nyear.  \n \n Income attributable to non -controlling interests was $54 million for the quarter, a decrease of 7% compared to the \nprior year and in line with our expectations.  Our adjusted net income from continuing operations totaled $625 \nmillion; and our diluted weighted average shares outstanding were 189 million for the quarter, a decrease of 7% \nyear-over-year.  \n ", "original_text": "We continue to assume a full year adjusted tax rate of approximately 18% to 19%, which may vary from \nquarter -to-quarter and inc ludes anticipated discrete tax items that we expect to realize during the course of the \nyear.  \n \n", "page_label": "6", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "74aa42ba-8aa4-40bb-8e6b-4b4438973fe6", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "96fe23ab3f28da6c3b9e65abfaebdf377433fd3e2f0b15afab5b613df6915c96", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2b5aae8c-706f-485d-9f68-ffd29966148f", "node_type": "1", "metadata": {"window": "First quarter adjusted operating expenses increased 1% year -over-year, partially driven by the acquisition of MSD \nin the prior year.  Adjusted income from operations was $933 million for the quarter, 9% above the prior year. \n Interest expense was $56 million for the quarter, a decrease of 8% compared to the prior year, primaril y due to \nlower commercial paper balances.  Our adjusted tax rate was 22.6% for the quarter, mainly driven by our mix of \nbusiness.  We continue to assume a full year adjusted tax rate of approximately 18% to 19%, which may vary from \nquarter -to-quarter and inc ludes anticipated discrete tax items that we expect to realize during the course of the \nyear.  \n \n Income attributable to non -controlling interests was $54 million for the quarter, a decrease of 7% compared to the \nprior year and in line with our expectations.  Our adjusted net income from continuing operations totaled $625 \nmillion; and our diluted weighted average shares outstanding were 189 million for the quarter, a decrease of 7% \nyear-over-year.  \n ", "original_text": "Our adjusted tax rate was 22.6% for the quarter, mainly driven by our mix of \nbusiness. ", "page_label": "6", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a11de9e40a07c06addd1219b904841b54d96fcf6861064864e209174e9c04c8d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8601b132-b9c1-4904-af0c-c9d5deabac06", "node_type": "1", "metadata": {"window": "Interest expense was $56 million for the quarter, a decrease of 8% compared to the prior year, primaril y due to \nlower commercial paper balances.  Our adjusted tax rate was 22.6% for the quarter, mainly driven by our mix of \nbusiness.  We continue to assume a full year adjusted tax rate of approximately 18% to 19%, which may vary from \nquarter -to-quarter and inc ludes anticipated discrete tax items that we expect to realize during the course of the \nyear.  \n \n Income attributable to non -controlling interests was $54 million for the quarter, a decrease of 7% compared to the \nprior year and in line with our expectations.  Our adjusted net income from continuing operations totaled $625 \nmillion; and our diluted weighted average shares outstanding were 189 million for the quarter, a decrease of 7% \nyear-over-year.  \n ", "original_text": "Income attributable to non -controlling interests was $54 million for the quarter, a decrease of 7% compared to the \nprior year and in line with our expectations. "}, "hash": "26dce73cac31bdf1271c83787e7771aa121455a089935cf7ca1dc70542be51df", "class_name": "RelatedNodeInfo"}}, "text": "We continue to assume a full year adjusted tax rate of approximately 18% to 19%, which may vary from \nquarter -to-quarter and inc ludes anticipated discrete tax items that we expect to realize during the course of the \nyear.  \n \n", "start_char_idx": 3605, "end_char_idx": 3834, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8601b132-b9c1-4904-af0c-c9d5deabac06": {"__data__": {"id_": "8601b132-b9c1-4904-af0c-c9d5deabac06", "embedding": null, "metadata": {"window": "Interest expense was $56 million for the quarter, a decrease of 8% compared to the prior year, primaril y due to \nlower commercial paper balances.  Our adjusted tax rate was 22.6% for the quarter, mainly driven by our mix of \nbusiness.  We continue to assume a full year adjusted tax rate of approximately 18% to 19%, which may vary from \nquarter -to-quarter and inc ludes anticipated discrete tax items that we expect to realize during the course of the \nyear.  \n \n Income attributable to non -controlling interests was $54 million for the quarter, a decrease of 7% compared to the \nprior year and in line with our expectations.  Our adjusted net income from continuing operations totaled $625 \nmillion; and our diluted weighted average shares outstanding were 189 million for the quarter, a decrease of 7% \nyear-over-year.  \n ", "original_text": "Income attributable to non -controlling interests was $54 million for the quarter, a decrease of 7% compared to the \nprior year and in line with our expectations. ", "page_label": "6", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "74aa42ba-8aa4-40bb-8e6b-4b4438973fe6", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "96fe23ab3f28da6c3b9e65abfaebdf377433fd3e2f0b15afab5b613df6915c96", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "539dbe6e-196d-44f9-971d-82e1f37eb2e8", "node_type": "1", "metadata": {"window": "Adjusted income from operations was $933 million for the quarter, 9% above the prior year. \n Interest expense was $56 million for the quarter, a decrease of 8% compared to the prior year, primaril y due to \nlower commercial paper balances.  Our adjusted tax rate was 22.6% for the quarter, mainly driven by our mix of \nbusiness.  We continue to assume a full year adjusted tax rate of approximately 18% to 19%, which may vary from \nquarter -to-quarter and inc ludes anticipated discrete tax items that we expect to realize during the course of the \nyear.  \n \n Income attributable to non -controlling interests was $54 million for the quarter, a decrease of 7% compared to the \nprior year and in line with our expectations.  Our adjusted net income from continuing operations totaled $625 \nmillion; and our diluted weighted average shares outstanding were 189 million for the quarter, a decrease of 7% \nyear-over-year.  \n ", "original_text": "We continue to assume a full year adjusted tax rate of approximately 18% to 19%, which may vary from \nquarter -to-quarter and inc ludes anticipated discrete tax items that we expect to realize during the course of the \nyear.  \n \n", "page_label": "6", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6d6cfdb83d8b08aa29df7984cb1c5f0e773c44706ef29a8e1764659ce2766f9c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0a4a53e1-92b3-4b69-bcec-d7367f636132", "node_type": "1", "metadata": {"window": "Our adjusted tax rate was 22.6% for the quarter, mainly driven by our mix of \nbusiness.  We continue to assume a full year adjusted tax rate of approximately 18% to 19%, which may vary from \nquarter -to-quarter and inc ludes anticipated discrete tax items that we expect to realize during the course of the \nyear.  \n \n Income attributable to non -controlling interests was $54 million for the quarter, a decrease of 7% compared to the \nprior year and in line with our expectations.  Our adjusted net income from continuing operations totaled $625 \nmillion; and our diluted weighted average shares outstanding were 189 million for the quarter, a decrease of 7% \nyear-over-year.  \n ", "original_text": "Our adjusted net income from continuing operations totaled $625 \nmillion; and our diluted weighted average shares outstanding were 189 million for the quarter, a decrease of 7% \nyear-over-year.  \n "}, "hash": "80bcb92b4f1709792c26a15548c6d005811e17767a7150c1017779f152ad2196", "class_name": "RelatedNodeInfo"}}, "text": "Income attributable to non -controlling interests was $54 million for the quarter, a decrease of 7% compared to the \nprior year and in line with our expectations. ", "start_char_idx": 3834, "end_char_idx": 3997, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0a4a53e1-92b3-4b69-bcec-d7367f636132": {"__data__": {"id_": "0a4a53e1-92b3-4b69-bcec-d7367f636132", "embedding": null, "metadata": {"window": "Our adjusted tax rate was 22.6% for the quarter, mainly driven by our mix of \nbusiness.  We continue to assume a full year adjusted tax rate of approximately 18% to 19%, which may vary from \nquarter -to-quarter and inc ludes anticipated discrete tax items that we expect to realize during the course of the \nyear.  \n \n Income attributable to non -controlling interests was $54 million for the quarter, a decrease of 7% compared to the \nprior year and in line with our expectations.  Our adjusted net income from continuing operations totaled $625 \nmillion; and our diluted weighted average shares outstanding were 189 million for the quarter, a decrease of 7% \nyear-over-year.  \n ", "original_text": "Our adjusted net income from continuing operations totaled $625 \nmillion; and our diluted weighted average shares outstanding were 189 million for the quarter, a decrease of 7% \nyear-over-year.  \n ", "page_label": "6", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "74aa42ba-8aa4-40bb-8e6b-4b4438973fe6", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "96fe23ab3f28da6c3b9e65abfaebdf377433fd3e2f0b15afab5b613df6915c96", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8601b132-b9c1-4904-af0c-c9d5deabac06", "node_type": "1", "metadata": {"window": "Interest expense was $56 million for the quarter, a decrease of 8% compared to the prior year, primaril y due to \nlower commercial paper balances.  Our adjusted tax rate was 22.6% for the quarter, mainly driven by our mix of \nbusiness.  We continue to assume a full year adjusted tax rate of approximately 18% to 19%, which may vary from \nquarter -to-quarter and inc ludes anticipated discrete tax items that we expect to realize during the course of the \nyear.  \n \n Income attributable to non -controlling interests was $54 million for the quarter, a decrease of 7% compared to the \nprior year and in line with our expectations.  Our adjusted net income from continuing operations totaled $625 \nmillion; and our diluted weighted average shares outstanding were 189 million for the quarter, a decrease of 7% \nyear-over-year.  \n ", "original_text": "Income attributable to non -controlling interests was $54 million for the quarter, a decrease of 7% compared to the \nprior year and in line with our expectations. ", "page_label": "6", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "df8f6d192d29e7e96ca53d2e27984bdc92732464ab1cda71eac490724977879c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "58a58dbc-b08d-4315-b3df-80d2ef81abf9", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nNext, I'll discuss our segment results which can be found on sl ides 5 through 8; and I'd like to start with U.S. \n Pharmaceutical and Specialty Solutions.  First quarter revenues were $44.2 billion, up 8% year -over-year, driven \nby solid contributions from our largest retail national pharmacy customers, growth across our specialty businesses \nand continued solid performance within our health systems segment, partially offset by branded to generic \nconversions. ", "original_text": "McKesson Corp.  "}, "hash": "5a5fb4c18bed697a78babe45b69a0e8413574e36d04484deb899f3d410e02993", "class_name": "RelatedNodeInfo"}}, "text": "Our adjusted net income from continuing operations totaled $625 \nmillion; and our diluted weighted average shares outstanding were 189 million for the quarter, a decrease of 7% \nyear-over-year.  \n ", "start_char_idx": 3997, "end_char_idx": 4194, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "58a58dbc-b08d-4315-b3df-80d2ef81abf9": {"__data__": {"id_": "58a58dbc-b08d-4315-b3df-80d2ef81abf9", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nNext, I'll discuss our segment results which can be found on sl ides 5 through 8; and I'd like to start with U.S. \n Pharmaceutical and Specialty Solutions.  First quarter revenues were $44.2 billion, up 8% year -over-year, driven \nby solid contributions from our largest retail national pharmacy customers, growth across our specialty businesses \nand continued solid performance within our health systems segment, partially offset by branded to generic \nconversions. ", "original_text": "McKesson Corp.  ", "page_label": "7", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "35248f45-6429-4b21-a274-8a0d5bf89987", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ff40d2d5dc0dba9a817069970d6b3d524f65b7bc0ecc61c92c5aca424bb597bd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0a4a53e1-92b3-4b69-bcec-d7367f636132", "node_type": "1", "metadata": {"window": "Our adjusted tax rate was 22.6% for the quarter, mainly driven by our mix of \nbusiness.  We continue to assume a full year adjusted tax rate of approximately 18% to 19%, which may vary from \nquarter -to-quarter and inc ludes anticipated discrete tax items that we expect to realize during the course of the \nyear.  \n \n Income attributable to non -controlling interests was $54 million for the quarter, a decrease of 7% compared to the \nprior year and in line with our expectations.  Our adjusted net income from continuing operations totaled $625 \nmillion; and our diluted weighted average shares outstanding were 189 million for the quarter, a decrease of 7% \nyear-over-year.  \n ", "original_text": "Our adjusted net income from continuing operations totaled $625 \nmillion; and our diluted weighted average shares outstanding were 189 million for the quarter, a decrease of 7% \nyear-over-year.  \n ", "page_label": "6", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "94fdb554a6505ca181ca5ea326eb799329577f6229507144918e41bd46a9e0a6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "812e151e-2542-4084-865f-a4e97193495e", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nNext, I'll discuss our segment results which can be found on sl ides 5 through 8; and I'd like to start with U.S. \n Pharmaceutical and Specialty Solutions.  First quarter revenues were $44.2 billion, up 8% year -over-year, driven \nby solid contributions from our largest retail national pharmacy customers, growth across our specialty businesses \nand continued solid performance within our health systems segment, partially offset by branded to generic \nconversions.  Segment adjusted operating profit for the quarter increased 11% to $600 million, primarily due to \nstrong growth in o ur specialty businesses, continued strong performance by our sourcing operations, and the \nlapping of prior -year opioid -related expenses.  \n \n", "original_text": "(MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nNext, I'll discuss our segment results which can be found on sl ides 5 through 8; and I'd like to start with U.S. \n"}, "hash": "3bcdce127d6533688c04c78307b447c86dfc1e0e207b186726b48eaab944c694", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "812e151e-2542-4084-865f-a4e97193495e": {"__data__": {"id_": "812e151e-2542-4084-865f-a4e97193495e", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nNext, I'll discuss our segment results which can be found on sl ides 5 through 8; and I'd like to start with U.S. \n Pharmaceutical and Specialty Solutions.  First quarter revenues were $44.2 billion, up 8% year -over-year, driven \nby solid contributions from our largest retail national pharmacy customers, growth across our specialty businesses \nand continued solid performance within our health systems segment, partially offset by branded to generic \nconversions.  Segment adjusted operating profit for the quarter increased 11% to $600 million, primarily due to \nstrong growth in o ur specialty businesses, continued strong performance by our sourcing operations, and the \nlapping of prior -year opioid -related expenses.  \n \n", "original_text": "(MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nNext, I'll discuss our segment results which can be found on sl ides 5 through 8; and I'd like to start with U.S. \n", "page_label": "7", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "35248f45-6429-4b21-a274-8a0d5bf89987", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ff40d2d5dc0dba9a817069970d6b3d524f65b7bc0ecc61c92c5aca424bb597bd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "58a58dbc-b08d-4315-b3df-80d2ef81abf9", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nNext, I'll discuss our segment results which can be found on sl ides 5 through 8; and I'd like to start with U.S. \n Pharmaceutical and Specialty Solutions.  First quarter revenues were $44.2 billion, up 8% year -over-year, driven \nby solid contributions from our largest retail national pharmacy customers, growth across our specialty businesses \nand continued solid performance within our health systems segment, partially offset by branded to generic \nconversions. ", "original_text": "McKesson Corp.  ", "page_label": "7", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "477e9b5fdcbc5a53c34760b837d8d924a1efcae2d3d7cf684fbee47db00158fa", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f4bdb64e-7f79-4927-849d-4db90a62a851", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nNext, I'll discuss our segment results which can be found on sl ides 5 through 8; and I'd like to start with U.S. \n Pharmaceutical and Specialty Solutions.  First quarter revenues were $44.2 billion, up 8% year -over-year, driven \nby solid contributions from our largest retail national pharmacy customers, growth across our specialty businesses \nand continued solid performance within our health systems segment, partially offset by branded to generic \nconversions.  Segment adjusted operating profit for the quarter increased 11% to $600 million, primarily due to \nstrong growth in o ur specialty businesses, continued strong performance by our sourcing operations, and the \nlapping of prior -year opioid -related expenses.  \n \n As a reminder, the State of New York adopted the Opioid Stewardship Act in the first quarter of McKesson's fiscal \n2019 . ", "original_text": "Pharmaceutical and Specialty Solutions. "}, "hash": "9a00c8c8dcf3c289dd6bdc8941ec938eb412526847f3354a8ff3d865ed22f6f8", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nNext, I'll discuss our segment results which can be found on sl ides 5 through 8; and I'd like to start with U.S. \n", "start_char_idx": 16, "end_char_idx": 295, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f4bdb64e-7f79-4927-849d-4db90a62a851": {"__data__": {"id_": "f4bdb64e-7f79-4927-849d-4db90a62a851", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nNext, I'll discuss our segment results which can be found on sl ides 5 through 8; and I'd like to start with U.S. \n Pharmaceutical and Specialty Solutions.  First quarter revenues were $44.2 billion, up 8% year -over-year, driven \nby solid contributions from our largest retail national pharmacy customers, growth across our specialty businesses \nand continued solid performance within our health systems segment, partially offset by branded to generic \nconversions.  Segment adjusted operating profit for the quarter increased 11% to $600 million, primarily due to \nstrong growth in o ur specialty businesses, continued strong performance by our sourcing operations, and the \nlapping of prior -year opioid -related expenses.  \n \n As a reminder, the State of New York adopted the Opioid Stewardship Act in the first quarter of McKesson's fiscal \n2019 . ", "original_text": "Pharmaceutical and Specialty Solutions. ", "page_label": "7", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "35248f45-6429-4b21-a274-8a0d5bf89987", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ff40d2d5dc0dba9a817069970d6b3d524f65b7bc0ecc61c92c5aca424bb597bd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "812e151e-2542-4084-865f-a4e97193495e", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nNext, I'll discuss our segment results which can be found on sl ides 5 through 8; and I'd like to start with U.S. \n Pharmaceutical and Specialty Solutions.  First quarter revenues were $44.2 billion, up 8% year -over-year, driven \nby solid contributions from our largest retail national pharmacy customers, growth across our specialty businesses \nand continued solid performance within our health systems segment, partially offset by branded to generic \nconversions.  Segment adjusted operating profit for the quarter increased 11% to $600 million, primarily due to \nstrong growth in o ur specialty businesses, continued strong performance by our sourcing operations, and the \nlapping of prior -year opioid -related expenses.  \n \n", "original_text": "(MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nNext, I'll discuss our segment results which can be found on sl ides 5 through 8; and I'd like to start with U.S. \n", "page_label": "7", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9d17d8c3e0f8a0a15be17aa9b1b3bb8bf0fb70d0e481f8d4c16e4149405ef4d2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "50f18d3c-d78e-4cb9-b46f-3c1143589def", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nNext, I'll discuss our segment results which can be found on sl ides 5 through 8; and I'd like to start with U.S. \n Pharmaceutical and Specialty Solutions.  First quarter revenues were $44.2 billion, up 8% year -over-year, driven \nby solid contributions from our largest retail national pharmacy customers, growth across our specialty businesses \nand continued solid performance within our health systems segment, partially offset by branded to generic \nconversions.  Segment adjusted operating profit for the quarter increased 11% to $600 million, primarily due to \nstrong growth in o ur specialty businesses, continued strong performance by our sourcing operations, and the \nlapping of prior -year opioid -related expenses.  \n \n As a reminder, the State of New York adopted the Opioid Stewardship Act in the first quarter of McKesson's fiscal \n2019 .  Although the act was being challenged in court, we recorded an accrual in both our GAAP and adjusted \nresults of $15 million in the first quarter of fiscal 2019 in our U.S. ", "original_text": "First quarter revenues were $44.2 billion, up 8% year -over-year, driven \nby solid contributions from our largest retail national pharmacy customers, growth across our specialty businesses \nand continued solid performance within our health systems segment, partially offset by branded to generic \nconversions. "}, "hash": "82fe6da888f4f312bbba1ec0c9597e989fef8728d364883fc5d6e3f22a719fa0", "class_name": "RelatedNodeInfo"}}, "text": "Pharmaceutical and Specialty Solutions. ", "start_char_idx": 295, "end_char_idx": 335, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "50f18d3c-d78e-4cb9-b46f-3c1143589def": {"__data__": {"id_": "50f18d3c-d78e-4cb9-b46f-3c1143589def", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nNext, I'll discuss our segment results which can be found on sl ides 5 through 8; and I'd like to start with U.S. \n Pharmaceutical and Specialty Solutions.  First quarter revenues were $44.2 billion, up 8% year -over-year, driven \nby solid contributions from our largest retail national pharmacy customers, growth across our specialty businesses \nand continued solid performance within our health systems segment, partially offset by branded to generic \nconversions.  Segment adjusted operating profit for the quarter increased 11% to $600 million, primarily due to \nstrong growth in o ur specialty businesses, continued strong performance by our sourcing operations, and the \nlapping of prior -year opioid -related expenses.  \n \n As a reminder, the State of New York adopted the Opioid Stewardship Act in the first quarter of McKesson's fiscal \n2019 .  Although the act was being challenged in court, we recorded an accrual in both our GAAP and adjusted \nresults of $15 million in the first quarter of fiscal 2019 in our U.S. ", "original_text": "First quarter revenues were $44.2 billion, up 8% year -over-year, driven \nby solid contributions from our largest retail national pharmacy customers, growth across our specialty businesses \nand continued solid performance within our health systems segment, partially offset by branded to generic \nconversions. ", "page_label": "7", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "35248f45-6429-4b21-a274-8a0d5bf89987", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ff40d2d5dc0dba9a817069970d6b3d524f65b7bc0ecc61c92c5aca424bb597bd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f4bdb64e-7f79-4927-849d-4db90a62a851", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nNext, I'll discuss our segment results which can be found on sl ides 5 through 8; and I'd like to start with U.S. \n Pharmaceutical and Specialty Solutions.  First quarter revenues were $44.2 billion, up 8% year -over-year, driven \nby solid contributions from our largest retail national pharmacy customers, growth across our specialty businesses \nand continued solid performance within our health systems segment, partially offset by branded to generic \nconversions.  Segment adjusted operating profit for the quarter increased 11% to $600 million, primarily due to \nstrong growth in o ur specialty businesses, continued strong performance by our sourcing operations, and the \nlapping of prior -year opioid -related expenses.  \n \n As a reminder, the State of New York adopted the Opioid Stewardship Act in the first quarter of McKesson's fiscal \n2019 . ", "original_text": "Pharmaceutical and Specialty Solutions. ", "page_label": "7", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ecec10176f210a0d65eefe3b78a61f03b23351f5deb81a2876b8756cfae236f0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "89553ef2-aaf5-4be4-a353-edc08b44f2cc", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nNext, I'll discuss our segment results which can be found on sl ides 5 through 8; and I'd like to start with U.S. \n Pharmaceutical and Specialty Solutions.  First quarter revenues were $44.2 billion, up 8% year -over-year, driven \nby solid contributions from our largest retail national pharmacy customers, growth across our specialty businesses \nand continued solid performance within our health systems segment, partially offset by branded to generic \nconversions.  Segment adjusted operating profit for the quarter increased 11% to $600 million, primarily due to \nstrong growth in o ur specialty businesses, continued strong performance by our sourcing operations, and the \nlapping of prior -year opioid -related expenses.  \n \n As a reminder, the State of New York adopted the Opioid Stewardship Act in the first quarter of McKesson's fiscal \n2019 .  Although the act was being challenged in court, we recorded an accrual in both our GAAP and adjusted \nresults of $15 million in the first quarter of fiscal 2019 in our U.S.  Pharmaceutical and Specialty Solutions \nsegment, which accounted for the estimated portion of the annual assessment. ", "original_text": "Segment adjusted operating profit for the quarter increased 11% to $600 million, primarily due to \nstrong growth in o ur specialty businesses, continued strong performance by our sourcing operations, and the \nlapping of prior -year opioid -related expenses.  \n \n"}, "hash": "8987018b2d842dd0e5212248fd905ff007497a8438494c9b35baeee91ec30b54", "class_name": "RelatedNodeInfo"}}, "text": "First quarter revenues were $44.2 billion, up 8% year -over-year, driven \nby solid contributions from our largest retail national pharmacy customers, growth across our specialty businesses \nand continued solid performance within our health systems segment, partially offset by branded to generic \nconversions. ", "start_char_idx": 335, "end_char_idx": 645, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "89553ef2-aaf5-4be4-a353-edc08b44f2cc": {"__data__": {"id_": "89553ef2-aaf5-4be4-a353-edc08b44f2cc", "embedding": null, "metadata": {"window": "(MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nNext, I'll discuss our segment results which can be found on sl ides 5 through 8; and I'd like to start with U.S. \n Pharmaceutical and Specialty Solutions.  First quarter revenues were $44.2 billion, up 8% year -over-year, driven \nby solid contributions from our largest retail national pharmacy customers, growth across our specialty businesses \nand continued solid performance within our health systems segment, partially offset by branded to generic \nconversions.  Segment adjusted operating profit for the quarter increased 11% to $600 million, primarily due to \nstrong growth in o ur specialty businesses, continued strong performance by our sourcing operations, and the \nlapping of prior -year opioid -related expenses.  \n \n As a reminder, the State of New York adopted the Opioid Stewardship Act in the first quarter of McKesson's fiscal \n2019 .  Although the act was being challenged in court, we recorded an accrual in both our GAAP and adjusted \nresults of $15 million in the first quarter of fiscal 2019 in our U.S.  Pharmaceutical and Specialty Solutions \nsegment, which accounted for the estimated portion of the annual assessment. ", "original_text": "Segment adjusted operating profit for the quarter increased 11% to $600 million, primarily due to \nstrong growth in o ur specialty businesses, continued strong performance by our sourcing operations, and the \nlapping of prior -year opioid -related expenses.  \n \n", "page_label": "7", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "35248f45-6429-4b21-a274-8a0d5bf89987", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ff40d2d5dc0dba9a817069970d6b3d524f65b7bc0ecc61c92c5aca424bb597bd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "50f18d3c-d78e-4cb9-b46f-3c1143589def", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nNext, I'll discuss our segment results which can be found on sl ides 5 through 8; and I'd like to start with U.S. \n Pharmaceutical and Specialty Solutions.  First quarter revenues were $44.2 billion, up 8% year -over-year, driven \nby solid contributions from our largest retail national pharmacy customers, growth across our specialty businesses \nand continued solid performance within our health systems segment, partially offset by branded to generic \nconversions.  Segment adjusted operating profit for the quarter increased 11% to $600 million, primarily due to \nstrong growth in o ur specialty businesses, continued strong performance by our sourcing operations, and the \nlapping of prior -year opioid -related expenses.  \n \n As a reminder, the State of New York adopted the Opioid Stewardship Act in the first quarter of McKesson's fiscal \n2019 .  Although the act was being challenged in court, we recorded an accrual in both our GAAP and adjusted \nresults of $15 million in the first quarter of fiscal 2019 in our U.S. ", "original_text": "First quarter revenues were $44.2 billion, up 8% year -over-year, driven \nby solid contributions from our largest retail national pharmacy customers, growth across our specialty businesses \nand continued solid performance within our health systems segment, partially offset by branded to generic \nconversions. ", "page_label": "7", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "80d5ebdf9e7e38656057641998a9ebb33326715eddb123503b0a6edb15c5c9ec", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a46b753d-74f2-45f8-8de4-d33e15ae82c5", "node_type": "1", "metadata": {"window": "Pharmaceutical and Specialty Solutions.  First quarter revenues were $44.2 billion, up 8% year -over-year, driven \nby solid contributions from our largest retail national pharmacy customers, growth across our specialty businesses \nand continued solid performance within our health systems segment, partially offset by branded to generic \nconversions.  Segment adjusted operating profit for the quarter increased 11% to $600 million, primarily due to \nstrong growth in o ur specialty businesses, continued strong performance by our sourcing operations, and the \nlapping of prior -year opioid -related expenses.  \n \n As a reminder, the State of New York adopted the Opioid Stewardship Act in the first quarter of McKesson's fiscal \n2019 .  Although the act was being challenged in court, we recorded an accrual in both our GAAP and adjusted \nresults of $15 million in the first quarter of fiscal 2019 in our U.S.  Pharmaceutical and Specialty Solutions \nsegment, which accounted for the estimated portion of the annual assessment.  This legislation was later ruled \nunconstitutional and the accrual was reversed in the third quarter fiscal 2019. ", "original_text": "As a reminder, the State of New York adopted the Opioid Stewardship Act in the first quarter of McKesson's fiscal \n2019 . "}, "hash": "fa92f0621720cc5d8abc87bf8f8145701df24684bd7b57e82bcc0bea7642afbb", "class_name": "RelatedNodeInfo"}}, "text": "Segment adjusted operating profit for the quarter increased 11% to $600 million, primarily due to \nstrong growth in o ur specialty businesses, continued strong performance by our sourcing operations, and the \nlapping of prior -year opioid -related expenses.  \n \n", "start_char_idx": 645, "end_char_idx": 907, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a46b753d-74f2-45f8-8de4-d33e15ae82c5": {"__data__": {"id_": "a46b753d-74f2-45f8-8de4-d33e15ae82c5", "embedding": null, "metadata": {"window": "Pharmaceutical and Specialty Solutions.  First quarter revenues were $44.2 billion, up 8% year -over-year, driven \nby solid contributions from our largest retail national pharmacy customers, growth across our specialty businesses \nand continued solid performance within our health systems segment, partially offset by branded to generic \nconversions.  Segment adjusted operating profit for the quarter increased 11% to $600 million, primarily due to \nstrong growth in o ur specialty businesses, continued strong performance by our sourcing operations, and the \nlapping of prior -year opioid -related expenses.  \n \n As a reminder, the State of New York adopted the Opioid Stewardship Act in the first quarter of McKesson's fiscal \n2019 .  Although the act was being challenged in court, we recorded an accrual in both our GAAP and adjusted \nresults of $15 million in the first quarter of fiscal 2019 in our U.S.  Pharmaceutical and Specialty Solutions \nsegment, which accounted for the estimated portion of the annual assessment.  This legislation was later ruled \nunconstitutional and the accrual was reversed in the third quarter fiscal 2019. ", "original_text": "As a reminder, the State of New York adopted the Opioid Stewardship Act in the first quarter of McKesson's fiscal \n2019 . ", "page_label": "7", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "35248f45-6429-4b21-a274-8a0d5bf89987", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ff40d2d5dc0dba9a817069970d6b3d524f65b7bc0ecc61c92c5aca424bb597bd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "89553ef2-aaf5-4be4-a353-edc08b44f2cc", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nNext, I'll discuss our segment results which can be found on sl ides 5 through 8; and I'd like to start with U.S. \n Pharmaceutical and Specialty Solutions.  First quarter revenues were $44.2 billion, up 8% year -over-year, driven \nby solid contributions from our largest retail national pharmacy customers, growth across our specialty businesses \nand continued solid performance within our health systems segment, partially offset by branded to generic \nconversions.  Segment adjusted operating profit for the quarter increased 11% to $600 million, primarily due to \nstrong growth in o ur specialty businesses, continued strong performance by our sourcing operations, and the \nlapping of prior -year opioid -related expenses.  \n \n As a reminder, the State of New York adopted the Opioid Stewardship Act in the first quarter of McKesson's fiscal \n2019 .  Although the act was being challenged in court, we recorded an accrual in both our GAAP and adjusted \nresults of $15 million in the first quarter of fiscal 2019 in our U.S.  Pharmaceutical and Specialty Solutions \nsegment, which accounted for the estimated portion of the annual assessment. ", "original_text": "Segment adjusted operating profit for the quarter increased 11% to $600 million, primarily due to \nstrong growth in o ur specialty businesses, continued strong performance by our sourcing operations, and the \nlapping of prior -year opioid -related expenses.  \n \n", "page_label": "7", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "09a49e360eef1888816d8be2271728e365a914794daa0b27699fe4565d605ebc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fa6880b7-70c1-46b7-9856-eab1aa168626", "node_type": "1", "metadata": {"window": "First quarter revenues were $44.2 billion, up 8% year -over-year, driven \nby solid contributions from our largest retail national pharmacy customers, growth across our specialty businesses \nand continued solid performance within our health systems segment, partially offset by branded to generic \nconversions.  Segment adjusted operating profit for the quarter increased 11% to $600 million, primarily due to \nstrong growth in o ur specialty businesses, continued strong performance by our sourcing operations, and the \nlapping of prior -year opioid -related expenses.  \n \n As a reminder, the State of New York adopted the Opioid Stewardship Act in the first quarter of McKesson's fiscal \n2019 .  Although the act was being challenged in court, we recorded an accrual in both our GAAP and adjusted \nresults of $15 million in the first quarter of fiscal 2019 in our U.S.  Pharmaceutical and Specialty Solutions \nsegment, which accounted for the estimated portion of the annual assessment.  This legislation was later ruled \nunconstitutional and the accrual was reversed in the third quarter fiscal 2019.  The segment adjusted operating \nmargin rate was 136 basis points, an increase of 4 basis points.  \n \n", "original_text": "Although the act was being challenged in court, we recorded an accrual in both our GAAP and adjusted \nresults of $15 million in the first quarter of fiscal 2019 in our U.S. "}, "hash": "0932683bbbc46dbc175a2f5c457c3bf541e88624894772a1ef94e892b8b56fd2", "class_name": "RelatedNodeInfo"}}, "text": "As a reminder, the State of New York adopted the Opioid Stewardship Act in the first quarter of McKesson's fiscal \n2019 . ", "start_char_idx": 907, "end_char_idx": 1029, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fa6880b7-70c1-46b7-9856-eab1aa168626": {"__data__": {"id_": "fa6880b7-70c1-46b7-9856-eab1aa168626", "embedding": null, "metadata": {"window": "First quarter revenues were $44.2 billion, up 8% year -over-year, driven \nby solid contributions from our largest retail national pharmacy customers, growth across our specialty businesses \nand continued solid performance within our health systems segment, partially offset by branded to generic \nconversions.  Segment adjusted operating profit for the quarter increased 11% to $600 million, primarily due to \nstrong growth in o ur specialty businesses, continued strong performance by our sourcing operations, and the \nlapping of prior -year opioid -related expenses.  \n \n As a reminder, the State of New York adopted the Opioid Stewardship Act in the first quarter of McKesson's fiscal \n2019 .  Although the act was being challenged in court, we recorded an accrual in both our GAAP and adjusted \nresults of $15 million in the first quarter of fiscal 2019 in our U.S.  Pharmaceutical and Specialty Solutions \nsegment, which accounted for the estimated portion of the annual assessment.  This legislation was later ruled \nunconstitutional and the accrual was reversed in the third quarter fiscal 2019.  The segment adjusted operating \nmargin rate was 136 basis points, an increase of 4 basis points.  \n \n", "original_text": "Although the act was being challenged in court, we recorded an accrual in both our GAAP and adjusted \nresults of $15 million in the first quarter of fiscal 2019 in our U.S. ", "page_label": "7", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "35248f45-6429-4b21-a274-8a0d5bf89987", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ff40d2d5dc0dba9a817069970d6b3d524f65b7bc0ecc61c92c5aca424bb597bd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a46b753d-74f2-45f8-8de4-d33e15ae82c5", "node_type": "1", "metadata": {"window": "Pharmaceutical and Specialty Solutions.  First quarter revenues were $44.2 billion, up 8% year -over-year, driven \nby solid contributions from our largest retail national pharmacy customers, growth across our specialty businesses \nand continued solid performance within our health systems segment, partially offset by branded to generic \nconversions.  Segment adjusted operating profit for the quarter increased 11% to $600 million, primarily due to \nstrong growth in o ur specialty businesses, continued strong performance by our sourcing operations, and the \nlapping of prior -year opioid -related expenses.  \n \n As a reminder, the State of New York adopted the Opioid Stewardship Act in the first quarter of McKesson's fiscal \n2019 .  Although the act was being challenged in court, we recorded an accrual in both our GAAP and adjusted \nresults of $15 million in the first quarter of fiscal 2019 in our U.S.  Pharmaceutical and Specialty Solutions \nsegment, which accounted for the estimated portion of the annual assessment.  This legislation was later ruled \nunconstitutional and the accrual was reversed in the third quarter fiscal 2019. ", "original_text": "As a reminder, the State of New York adopted the Opioid Stewardship Act in the first quarter of McKesson's fiscal \n2019 . ", "page_label": "7", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e4700d65aeec0ddadaca8a7a748ea58c9c04df5360ec90bb73b11210f7d8ec9d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d2c05ecd-a7ff-4f74-aa20-74508ba888aa", "node_type": "1", "metadata": {"window": "Segment adjusted operating profit for the quarter increased 11% to $600 million, primarily due to \nstrong growth in o ur specialty businesses, continued strong performance by our sourcing operations, and the \nlapping of prior -year opioid -related expenses.  \n \n As a reminder, the State of New York adopted the Opioid Stewardship Act in the first quarter of McKesson's fiscal \n2019 .  Although the act was being challenged in court, we recorded an accrual in both our GAAP and adjusted \nresults of $15 million in the first quarter of fiscal 2019 in our U.S.  Pharmaceutical and Specialty Solutions \nsegment, which accounted for the estimated portion of the annual assessment.  This legislation was later ruled \nunconstitutional and the accrual was reversed in the third quarter fiscal 2019.  The segment adjusted operating \nmargin rate was 136 basis points, an increase of 4 basis points.  \n \n Next, Europe an Pharmaceutical Solutions. ", "original_text": "Pharmaceutical and Specialty Solutions \nsegment, which accounted for the estimated portion of the annual assessment. "}, "hash": "92598b046f7f4e8904cec8deac2b67d27a272896b6e95fabf7e25e0d27d9c40d", "class_name": "RelatedNodeInfo"}}, "text": "Although the act was being challenged in court, we recorded an accrual in both our GAAP and adjusted \nresults of $15 million in the first quarter of fiscal 2019 in our U.S. ", "start_char_idx": 1029, "end_char_idx": 1202, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d2c05ecd-a7ff-4f74-aa20-74508ba888aa": {"__data__": {"id_": "d2c05ecd-a7ff-4f74-aa20-74508ba888aa", "embedding": null, "metadata": {"window": "Segment adjusted operating profit for the quarter increased 11% to $600 million, primarily due to \nstrong growth in o ur specialty businesses, continued strong performance by our sourcing operations, and the \nlapping of prior -year opioid -related expenses.  \n \n As a reminder, the State of New York adopted the Opioid Stewardship Act in the first quarter of McKesson's fiscal \n2019 .  Although the act was being challenged in court, we recorded an accrual in both our GAAP and adjusted \nresults of $15 million in the first quarter of fiscal 2019 in our U.S.  Pharmaceutical and Specialty Solutions \nsegment, which accounted for the estimated portion of the annual assessment.  This legislation was later ruled \nunconstitutional and the accrual was reversed in the third quarter fiscal 2019.  The segment adjusted operating \nmargin rate was 136 basis points, an increase of 4 basis points.  \n \n Next, Europe an Pharmaceutical Solutions. ", "original_text": "Pharmaceutical and Specialty Solutions \nsegment, which accounted for the estimated portion of the annual assessment. ", "page_label": "7", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "35248f45-6429-4b21-a274-8a0d5bf89987", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ff40d2d5dc0dba9a817069970d6b3d524f65b7bc0ecc61c92c5aca424bb597bd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fa6880b7-70c1-46b7-9856-eab1aa168626", "node_type": "1", "metadata": {"window": "First quarter revenues were $44.2 billion, up 8% year -over-year, driven \nby solid contributions from our largest retail national pharmacy customers, growth across our specialty businesses \nand continued solid performance within our health systems segment, partially offset by branded to generic \nconversions.  Segment adjusted operating profit for the quarter increased 11% to $600 million, primarily due to \nstrong growth in o ur specialty businesses, continued strong performance by our sourcing operations, and the \nlapping of prior -year opioid -related expenses.  \n \n As a reminder, the State of New York adopted the Opioid Stewardship Act in the first quarter of McKesson's fiscal \n2019 .  Although the act was being challenged in court, we recorded an accrual in both our GAAP and adjusted \nresults of $15 million in the first quarter of fiscal 2019 in our U.S.  Pharmaceutical and Specialty Solutions \nsegment, which accounted for the estimated portion of the annual assessment.  This legislation was later ruled \nunconstitutional and the accrual was reversed in the third quarter fiscal 2019.  The segment adjusted operating \nmargin rate was 136 basis points, an increase of 4 basis points.  \n \n", "original_text": "Although the act was being challenged in court, we recorded an accrual in both our GAAP and adjusted \nresults of $15 million in the first quarter of fiscal 2019 in our U.S. ", "page_label": "7", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "255219ac63f5c22bfd475349aa882e977c3a432adea2ac473db4303b1e129255", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "30ca020c-5455-4475-b476-e6bc5021f654", "node_type": "1", "metadata": {"window": "As a reminder, the State of New York adopted the Opioid Stewardship Act in the first quarter of McKesson's fiscal \n2019 .  Although the act was being challenged in court, we recorded an accrual in both our GAAP and adjusted \nresults of $15 million in the first quarter of fiscal 2019 in our U.S.  Pharmaceutical and Specialty Solutions \nsegment, which accounted for the estimated portion of the annual assessment.  This legislation was later ruled \nunconstitutional and the accrual was reversed in the third quarter fiscal 2019.  The segment adjusted operating \nmargin rate was 136 basis points, an increase of 4 basis points.  \n \n Next, Europe an Pharmaceutical Solutions.  First quarter revenues were down 3% year -over-year to $6.7 billion. \n", "original_text": "This legislation was later ruled \nunconstitutional and the accrual was reversed in the third quarter fiscal 2019. "}, "hash": "d896583eb0659252fc2f726ddf57a0d8fdf1b23f683fb3eaae4f38780c0b6c19", "class_name": "RelatedNodeInfo"}}, "text": "Pharmaceutical and Specialty Solutions \nsegment, which accounted for the estimated portion of the annual assessment. ", "start_char_idx": 1202, "end_char_idx": 1319, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "30ca020c-5455-4475-b476-e6bc5021f654": {"__data__": {"id_": "30ca020c-5455-4475-b476-e6bc5021f654", "embedding": null, "metadata": {"window": "As a reminder, the State of New York adopted the Opioid Stewardship Act in the first quarter of McKesson's fiscal \n2019 .  Although the act was being challenged in court, we recorded an accrual in both our GAAP and adjusted \nresults of $15 million in the first quarter of fiscal 2019 in our U.S.  Pharmaceutical and Specialty Solutions \nsegment, which accounted for the estimated portion of the annual assessment.  This legislation was later ruled \nunconstitutional and the accrual was reversed in the third quarter fiscal 2019.  The segment adjusted operating \nmargin rate was 136 basis points, an increase of 4 basis points.  \n \n Next, Europe an Pharmaceutical Solutions.  First quarter revenues were down 3% year -over-year to $6.7 billion. \n", "original_text": "This legislation was later ruled \nunconstitutional and the accrual was reversed in the third quarter fiscal 2019. ", "page_label": "7", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "35248f45-6429-4b21-a274-8a0d5bf89987", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ff40d2d5dc0dba9a817069970d6b3d524f65b7bc0ecc61c92c5aca424bb597bd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d2c05ecd-a7ff-4f74-aa20-74508ba888aa", "node_type": "1", "metadata": {"window": "Segment adjusted operating profit for the quarter increased 11% to $600 million, primarily due to \nstrong growth in o ur specialty businesses, continued strong performance by our sourcing operations, and the \nlapping of prior -year opioid -related expenses.  \n \n As a reminder, the State of New York adopted the Opioid Stewardship Act in the first quarter of McKesson's fiscal \n2019 .  Although the act was being challenged in court, we recorded an accrual in both our GAAP and adjusted \nresults of $15 million in the first quarter of fiscal 2019 in our U.S.  Pharmaceutical and Specialty Solutions \nsegment, which accounted for the estimated portion of the annual assessment.  This legislation was later ruled \nunconstitutional and the accrual was reversed in the third quarter fiscal 2019.  The segment adjusted operating \nmargin rate was 136 basis points, an increase of 4 basis points.  \n \n Next, Europe an Pharmaceutical Solutions. ", "original_text": "Pharmaceutical and Specialty Solutions \nsegment, which accounted for the estimated portion of the annual assessment. ", "page_label": "7", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d2070053ed614239ec98b35a4d4860c511b798293eb09099d266209db5a094d7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "edfc314c-bd41-4ff1-9265-3ffa35910abd", "node_type": "1", "metadata": {"window": "Although the act was being challenged in court, we recorded an accrual in both our GAAP and adjusted \nresults of $15 million in the first quarter of fiscal 2019 in our U.S.  Pharmaceutical and Specialty Solutions \nsegment, which accounted for the estimated portion of the annual assessment.  This legislation was later ruled \nunconstitutional and the accrual was reversed in the third quarter fiscal 2019.  The segment adjusted operating \nmargin rate was 136 basis points, an increase of 4 basis points.  \n \n Next, Europe an Pharmaceutical Solutions.  First quarter revenues were down 3% year -over-year to $6.7 billion. \n On an FX adjusted basis, revenues were up 3% driven by market growth in the distribution wholesale business. \n", "original_text": "The segment adjusted operating \nmargin rate was 136 basis points, an increase of 4 basis points.  \n \n"}, "hash": "674fce33704be3f85da1091b0b435d43659c35cb99680098ff590f9d4435c084", "class_name": "RelatedNodeInfo"}}, "text": "This legislation was later ruled \nunconstitutional and the accrual was reversed in the third quarter fiscal 2019. ", "start_char_idx": 1319, "end_char_idx": 1433, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "edfc314c-bd41-4ff1-9265-3ffa35910abd": {"__data__": {"id_": "edfc314c-bd41-4ff1-9265-3ffa35910abd", "embedding": null, "metadata": {"window": "Although the act was being challenged in court, we recorded an accrual in both our GAAP and adjusted \nresults of $15 million in the first quarter of fiscal 2019 in our U.S.  Pharmaceutical and Specialty Solutions \nsegment, which accounted for the estimated portion of the annual assessment.  This legislation was later ruled \nunconstitutional and the accrual was reversed in the third quarter fiscal 2019.  The segment adjusted operating \nmargin rate was 136 basis points, an increase of 4 basis points.  \n \n Next, Europe an Pharmaceutical Solutions.  First quarter revenues were down 3% year -over-year to $6.7 billion. \n On an FX adjusted basis, revenues were up 3% driven by market growth in the distribution wholesale business. \n", "original_text": "The segment adjusted operating \nmargin rate was 136 basis points, an increase of 4 basis points.  \n \n", "page_label": "7", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "35248f45-6429-4b21-a274-8a0d5bf89987", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ff40d2d5dc0dba9a817069970d6b3d524f65b7bc0ecc61c92c5aca424bb597bd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "30ca020c-5455-4475-b476-e6bc5021f654", "node_type": "1", "metadata": {"window": "As a reminder, the State of New York adopted the Opioid Stewardship Act in the first quarter of McKesson's fiscal \n2019 .  Although the act was being challenged in court, we recorded an accrual in both our GAAP and adjusted \nresults of $15 million in the first quarter of fiscal 2019 in our U.S.  Pharmaceutical and Specialty Solutions \nsegment, which accounted for the estimated portion of the annual assessment.  This legislation was later ruled \nunconstitutional and the accrual was reversed in the third quarter fiscal 2019.  The segment adjusted operating \nmargin rate was 136 basis points, an increase of 4 basis points.  \n \n Next, Europe an Pharmaceutical Solutions.  First quarter revenues were down 3% year -over-year to $6.7 billion. \n", "original_text": "This legislation was later ruled \nunconstitutional and the accrual was reversed in the third quarter fiscal 2019. ", "page_label": "7", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c8256a830e0a411e16f0477bd5c6b2c317b925f350366353e390eadcea9f0809", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7405a68b-0a9a-4474-9943-28183b3d7097", "node_type": "1", "metadata": {"window": "Pharmaceutical and Specialty Solutions \nsegment, which accounted for the estimated portion of the annual assessment.  This legislation was later ruled \nunconstitutional and the accrual was reversed in the third quarter fiscal 2019.  The segment adjusted operating \nmargin rate was 136 basis points, an increase of 4 basis points.  \n \n Next, Europe an Pharmaceutical Solutions.  First quarter revenues were down 3% year -over-year to $6.7 billion. \n On an FX adjusted basis, revenues were up 3% driven by market growth in the distribution wholesale business. \n Segment adjusted operating profit was down 50% to $37 million on an FX adjusted basis, mainly due to the weak \nretail pharmacy environment in the UK. ", "original_text": "Next, Europe an Pharmaceutical Solutions. "}, "hash": "94de99f5fef291a05dce878351b97684a1a15d37f7f6259e14c70baa3cbedabc", "class_name": "RelatedNodeInfo"}}, "text": "The segment adjusted operating \nmargin rate was 136 basis points, an increase of 4 basis points.  \n \n", "start_char_idx": 1433, "end_char_idx": 1534, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7405a68b-0a9a-4474-9943-28183b3d7097": {"__data__": {"id_": "7405a68b-0a9a-4474-9943-28183b3d7097", "embedding": null, "metadata": {"window": "Pharmaceutical and Specialty Solutions \nsegment, which accounted for the estimated portion of the annual assessment.  This legislation was later ruled \nunconstitutional and the accrual was reversed in the third quarter fiscal 2019.  The segment adjusted operating \nmargin rate was 136 basis points, an increase of 4 basis points.  \n \n Next, Europe an Pharmaceutical Solutions.  First quarter revenues were down 3% year -over-year to $6.7 billion. \n On an FX adjusted basis, revenues were up 3% driven by market growth in the distribution wholesale business. \n Segment adjusted operating profit was down 50% to $37 million on an FX adjusted basis, mainly due to the weak \nretail pharmacy environment in the UK. ", "original_text": "Next, Europe an Pharmaceutical Solutions. ", "page_label": "7", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "35248f45-6429-4b21-a274-8a0d5bf89987", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ff40d2d5dc0dba9a817069970d6b3d524f65b7bc0ecc61c92c5aca424bb597bd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "edfc314c-bd41-4ff1-9265-3ffa35910abd", "node_type": "1", "metadata": {"window": "Although the act was being challenged in court, we recorded an accrual in both our GAAP and adjusted \nresults of $15 million in the first quarter of fiscal 2019 in our U.S.  Pharmaceutical and Specialty Solutions \nsegment, which accounted for the estimated portion of the annual assessment.  This legislation was later ruled \nunconstitutional and the accrual was reversed in the third quarter fiscal 2019.  The segment adjusted operating \nmargin rate was 136 basis points, an increase of 4 basis points.  \n \n Next, Europe an Pharmaceutical Solutions.  First quarter revenues were down 3% year -over-year to $6.7 billion. \n On an FX adjusted basis, revenues were up 3% driven by market growth in the distribution wholesale business. \n", "original_text": "The segment adjusted operating \nmargin rate was 136 basis points, an increase of 4 basis points.  \n \n", "page_label": "7", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f149e4eb0e3f447af6a7c8bdea819a9a62505ae1e41dc887d3c118a8b7d656f8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e0890805-d8f0-47da-83fd-020088c35590", "node_type": "1", "metadata": {"window": "This legislation was later ruled \nunconstitutional and the accrual was reversed in the third quarter fiscal 2019.  The segment adjusted operating \nmargin rate was 136 basis points, an increase of 4 basis points.  \n \n Next, Europe an Pharmaceutical Solutions.  First quarter revenues were down 3% year -over-year to $6.7 billion. \n On an FX adjusted basis, revenues were up 3% driven by market growth in the distribution wholesale business. \n Segment adjusted operating profit was down 50% to $37 million on an FX adjusted basis, mainly due to the weak \nretail pharmacy environment in the UK.  The segment adjusted operating margin rate was 52 basis points on an \nFX adjusted basis, a decrease of 55 basis points. ", "original_text": "First quarter revenues were down 3% year -over-year to $6.7 billion. \n"}, "hash": "0c5b4d1d4617f2c40055958123e58a187386d55c20385b768dffc9279fe61fff", "class_name": "RelatedNodeInfo"}}, "text": "Next, Europe an Pharmaceutical Solutions. ", "start_char_idx": 1534, "end_char_idx": 1576, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e0890805-d8f0-47da-83fd-020088c35590": {"__data__": {"id_": "e0890805-d8f0-47da-83fd-020088c35590", "embedding": null, "metadata": {"window": "This legislation was later ruled \nunconstitutional and the accrual was reversed in the third quarter fiscal 2019.  The segment adjusted operating \nmargin rate was 136 basis points, an increase of 4 basis points.  \n \n Next, Europe an Pharmaceutical Solutions.  First quarter revenues were down 3% year -over-year to $6.7 billion. \n On an FX adjusted basis, revenues were up 3% driven by market growth in the distribution wholesale business. \n Segment adjusted operating profit was down 50% to $37 million on an FX adjusted basis, mainly due to the weak \nretail pharmacy environment in the UK.  The segment adjusted operating margin rate was 52 basis points on an \nFX adjusted basis, a decrease of 55 basis points. ", "original_text": "First quarter revenues were down 3% year -over-year to $6.7 billion. \n", "page_label": "7", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "35248f45-6429-4b21-a274-8a0d5bf89987", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ff40d2d5dc0dba9a817069970d6b3d524f65b7bc0ecc61c92c5aca424bb597bd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7405a68b-0a9a-4474-9943-28183b3d7097", "node_type": "1", "metadata": {"window": "Pharmaceutical and Specialty Solutions \nsegment, which accounted for the estimated portion of the annual assessment.  This legislation was later ruled \nunconstitutional and the accrual was reversed in the third quarter fiscal 2019.  The segment adjusted operating \nmargin rate was 136 basis points, an increase of 4 basis points.  \n \n Next, Europe an Pharmaceutical Solutions.  First quarter revenues were down 3% year -over-year to $6.7 billion. \n On an FX adjusted basis, revenues were up 3% driven by market growth in the distribution wholesale business. \n Segment adjusted operating profit was down 50% to $37 million on an FX adjusted basis, mainly due to the weak \nretail pharmacy environment in the UK. ", "original_text": "Next, Europe an Pharmaceutical Solutions. ", "page_label": "7", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "05a026b961757b727d2f51a0ea4586c9abc46e20b29ffa7bf20daa715391dccf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a472dc04-577a-4825-8b50-f8864b22efa5", "node_type": "1", "metadata": {"window": "The segment adjusted operating \nmargin rate was 136 basis points, an increase of 4 basis points.  \n \n Next, Europe an Pharmaceutical Solutions.  First quarter revenues were down 3% year -over-year to $6.7 billion. \n On an FX adjusted basis, revenues were up 3% driven by market growth in the distribution wholesale business. \n Segment adjusted operating profit was down 50% to $37 million on an FX adjusted basis, mainly due to the weak \nretail pharmacy environment in the UK.  The segment adjusted operating margin rate was 52 basis points on an \nFX adjusted basis, a decrease of 55 basis points.  Our first quarter results were lower t han expectations, resulting \nfrom weak retail pharmacy margins in the UK due to industry -wide underfunding by the NHS. ", "original_text": "On an FX adjusted basis, revenues were up 3% driven by market growth in the distribution wholesale business. \n"}, "hash": "90373fee8066790c6d5e8a9d054b384fdc10776dde299ab2dca611466ed353ad", "class_name": "RelatedNodeInfo"}}, "text": "First quarter revenues were down 3% year -over-year to $6.7 billion. \n", "start_char_idx": 1576, "end_char_idx": 1646, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a472dc04-577a-4825-8b50-f8864b22efa5": {"__data__": {"id_": "a472dc04-577a-4825-8b50-f8864b22efa5", "embedding": null, "metadata": {"window": "The segment adjusted operating \nmargin rate was 136 basis points, an increase of 4 basis points.  \n \n Next, Europe an Pharmaceutical Solutions.  First quarter revenues were down 3% year -over-year to $6.7 billion. \n On an FX adjusted basis, revenues were up 3% driven by market growth in the distribution wholesale business. \n Segment adjusted operating profit was down 50% to $37 million on an FX adjusted basis, mainly due to the weak \nretail pharmacy environment in the UK.  The segment adjusted operating margin rate was 52 basis points on an \nFX adjusted basis, a decrease of 55 basis points.  Our first quarter results were lower t han expectations, resulting \nfrom weak retail pharmacy margins in the UK due to industry -wide underfunding by the NHS. ", "original_text": "On an FX adjusted basis, revenues were up 3% driven by market growth in the distribution wholesale business. \n", "page_label": "7", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "35248f45-6429-4b21-a274-8a0d5bf89987", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ff40d2d5dc0dba9a817069970d6b3d524f65b7bc0ecc61c92c5aca424bb597bd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e0890805-d8f0-47da-83fd-020088c35590", "node_type": "1", "metadata": {"window": "This legislation was later ruled \nunconstitutional and the accrual was reversed in the third quarter fiscal 2019.  The segment adjusted operating \nmargin rate was 136 basis points, an increase of 4 basis points.  \n \n Next, Europe an Pharmaceutical Solutions.  First quarter revenues were down 3% year -over-year to $6.7 billion. \n On an FX adjusted basis, revenues were up 3% driven by market growth in the distribution wholesale business. \n Segment adjusted operating profit was down 50% to $37 million on an FX adjusted basis, mainly due to the weak \nretail pharmacy environment in the UK.  The segment adjusted operating margin rate was 52 basis points on an \nFX adjusted basis, a decrease of 55 basis points. ", "original_text": "First quarter revenues were down 3% year -over-year to $6.7 billion. \n", "page_label": "7", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5bb28d5269e63d77c83bb2ce82fd0c5c4ae0d9ac9ad4a5f9a0b7c5ba9f5f2064", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b6d3d68c-1684-4714-bbc1-010c44f1b824", "node_type": "1", "metadata": {"window": "Next, Europe an Pharmaceutical Solutions.  First quarter revenues were down 3% year -over-year to $6.7 billion. \n On an FX adjusted basis, revenues were up 3% driven by market growth in the distribution wholesale business. \n Segment adjusted operating profit was down 50% to $37 million on an FX adjusted basis, mainly due to the weak \nretail pharmacy environment in the UK.  The segment adjusted operating margin rate was 52 basis points on an \nFX adjusted basis, a decrease of 55 basis points.  Our first quarter results were lower t han expectations, resulting \nfrom weak retail pharmacy margins in the UK due to industry -wide underfunding by the NHS.  We anticipate this \nunderfunding will modestly improve in the second half of fiscal 2020.  \n \n", "original_text": "Segment adjusted operating profit was down 50% to $37 million on an FX adjusted basis, mainly due to the weak \nretail pharmacy environment in the UK. "}, "hash": "4fc1ace94d49f6566a2e37089cd152576cc2d9378043104e55882259b55ccf6d", "class_name": "RelatedNodeInfo"}}, "text": "On an FX adjusted basis, revenues were up 3% driven by market growth in the distribution wholesale business. \n", "start_char_idx": 1646, "end_char_idx": 1756, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b6d3d68c-1684-4714-bbc1-010c44f1b824": {"__data__": {"id_": "b6d3d68c-1684-4714-bbc1-010c44f1b824", "embedding": null, "metadata": {"window": "Next, Europe an Pharmaceutical Solutions.  First quarter revenues were down 3% year -over-year to $6.7 billion. \n On an FX adjusted basis, revenues were up 3% driven by market growth in the distribution wholesale business. \n Segment adjusted operating profit was down 50% to $37 million on an FX adjusted basis, mainly due to the weak \nretail pharmacy environment in the UK.  The segment adjusted operating margin rate was 52 basis points on an \nFX adjusted basis, a decrease of 55 basis points.  Our first quarter results were lower t han expectations, resulting \nfrom weak retail pharmacy margins in the UK due to industry -wide underfunding by the NHS.  We anticipate this \nunderfunding will modestly improve in the second half of fiscal 2020.  \n \n", "original_text": "Segment adjusted operating profit was down 50% to $37 million on an FX adjusted basis, mainly due to the weak \nretail pharmacy environment in the UK. ", "page_label": "7", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "35248f45-6429-4b21-a274-8a0d5bf89987", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ff40d2d5dc0dba9a817069970d6b3d524f65b7bc0ecc61c92c5aca424bb597bd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a472dc04-577a-4825-8b50-f8864b22efa5", "node_type": "1", "metadata": {"window": "The segment adjusted operating \nmargin rate was 136 basis points, an increase of 4 basis points.  \n \n Next, Europe an Pharmaceutical Solutions.  First quarter revenues were down 3% year -over-year to $6.7 billion. \n On an FX adjusted basis, revenues were up 3% driven by market growth in the distribution wholesale business. \n Segment adjusted operating profit was down 50% to $37 million on an FX adjusted basis, mainly due to the weak \nretail pharmacy environment in the UK.  The segment adjusted operating margin rate was 52 basis points on an \nFX adjusted basis, a decrease of 55 basis points.  Our first quarter results were lower t han expectations, resulting \nfrom weak retail pharmacy margins in the UK due to industry -wide underfunding by the NHS. ", "original_text": "On an FX adjusted basis, revenues were up 3% driven by market growth in the distribution wholesale business. \n", "page_label": "7", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f96253dc30822158d7b20cb9b03f64c3cf4d19759157903e1b367f0cf8e987cb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "24ddf7bb-2192-4193-82a1-017339c0b92c", "node_type": "1", "metadata": {"window": "First quarter revenues were down 3% year -over-year to $6.7 billion. \n On an FX adjusted basis, revenues were up 3% driven by market growth in the distribution wholesale business. \n Segment adjusted operating profit was down 50% to $37 million on an FX adjusted basis, mainly due to the weak \nretail pharmacy environment in the UK.  The segment adjusted operating margin rate was 52 basis points on an \nFX adjusted basis, a decrease of 55 basis points.  Our first quarter results were lower t han expectations, resulting \nfrom weak retail pharmacy margins in the UK due to industry -wide underfunding by the NHS.  We anticipate this \nunderfunding will modestly improve in the second half of fiscal 2020.  \n \n As Brian discussed earlier, in fiscal 2019 we to ok actions in the UK and across Europe to reposition the business \nfor long -term profitability. ", "original_text": "The segment adjusted operating margin rate was 52 basis points on an \nFX adjusted basis, a decrease of 55 basis points. "}, "hash": "67082616d752b5943f8add379ca3e8f1fffd1b6305615e62b858e21d496c9b20", "class_name": "RelatedNodeInfo"}}, "text": "Segment adjusted operating profit was down 50% to $37 million on an FX adjusted basis, mainly due to the weak \nretail pharmacy environment in the UK. ", "start_char_idx": 1756, "end_char_idx": 1906, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "24ddf7bb-2192-4193-82a1-017339c0b92c": {"__data__": {"id_": "24ddf7bb-2192-4193-82a1-017339c0b92c", "embedding": null, "metadata": {"window": "First quarter revenues were down 3% year -over-year to $6.7 billion. \n On an FX adjusted basis, revenues were up 3% driven by market growth in the distribution wholesale business. \n Segment adjusted operating profit was down 50% to $37 million on an FX adjusted basis, mainly due to the weak \nretail pharmacy environment in the UK.  The segment adjusted operating margin rate was 52 basis points on an \nFX adjusted basis, a decrease of 55 basis points.  Our first quarter results were lower t han expectations, resulting \nfrom weak retail pharmacy margins in the UK due to industry -wide underfunding by the NHS.  We anticipate this \nunderfunding will modestly improve in the second half of fiscal 2020.  \n \n As Brian discussed earlier, in fiscal 2019 we to ok actions in the UK and across Europe to reposition the business \nfor long -term profitability. ", "original_text": "The segment adjusted operating margin rate was 52 basis points on an \nFX adjusted basis, a decrease of 55 basis points. ", "page_label": "7", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "35248f45-6429-4b21-a274-8a0d5bf89987", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ff40d2d5dc0dba9a817069970d6b3d524f65b7bc0ecc61c92c5aca424bb597bd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b6d3d68c-1684-4714-bbc1-010c44f1b824", "node_type": "1", "metadata": {"window": "Next, Europe an Pharmaceutical Solutions.  First quarter revenues were down 3% year -over-year to $6.7 billion. \n On an FX adjusted basis, revenues were up 3% driven by market growth in the distribution wholesale business. \n Segment adjusted operating profit was down 50% to $37 million on an FX adjusted basis, mainly due to the weak \nretail pharmacy environment in the UK.  The segment adjusted operating margin rate was 52 basis points on an \nFX adjusted basis, a decrease of 55 basis points.  Our first quarter results were lower t han expectations, resulting \nfrom weak retail pharmacy margins in the UK due to industry -wide underfunding by the NHS.  We anticipate this \nunderfunding will modestly improve in the second half of fiscal 2020.  \n \n", "original_text": "Segment adjusted operating profit was down 50% to $37 million on an FX adjusted basis, mainly due to the weak \nretail pharmacy environment in the UK. ", "page_label": "7", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1dd7e8ccaf5a86298411ba3dd457d293cb0949319af4a2b35f6385bc4178a4be", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3b4b21be-d688-44fd-84b9-ec8a09419254", "node_type": "1", "metadata": {"window": "On an FX adjusted basis, revenues were up 3% driven by market growth in the distribution wholesale business. \n Segment adjusted operating profit was down 50% to $37 million on an FX adjusted basis, mainly due to the weak \nretail pharmacy environment in the UK.  The segment adjusted operating margin rate was 52 basis points on an \nFX adjusted basis, a decrease of 55 basis points.  Our first quarter results were lower t han expectations, resulting \nfrom weak retail pharmacy margins in the UK due to industry -wide underfunding by the NHS.  We anticipate this \nunderfunding will modestly improve in the second half of fiscal 2020.  \n \n As Brian discussed earlier, in fiscal 2019 we to ok actions in the UK and across Europe to reposition the business \nfor long -term profitability.  These actions included further store rationalization and cost actions, and we continue to \nexecute against these restructuring actions as we further evaluate our cost position. ", "original_text": "Our first quarter results were lower t han expectations, resulting \nfrom weak retail pharmacy margins in the UK due to industry -wide underfunding by the NHS. "}, "hash": "3df38f294eea01b7e9912dd550f1997aff87db74af573f0e381f512c642ed041", "class_name": "RelatedNodeInfo"}}, "text": "The segment adjusted operating margin rate was 52 basis points on an \nFX adjusted basis, a decrease of 55 basis points. ", "start_char_idx": 1906, "end_char_idx": 2026, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3b4b21be-d688-44fd-84b9-ec8a09419254": {"__data__": {"id_": "3b4b21be-d688-44fd-84b9-ec8a09419254", "embedding": null, "metadata": {"window": "On an FX adjusted basis, revenues were up 3% driven by market growth in the distribution wholesale business. \n Segment adjusted operating profit was down 50% to $37 million on an FX adjusted basis, mainly due to the weak \nretail pharmacy environment in the UK.  The segment adjusted operating margin rate was 52 basis points on an \nFX adjusted basis, a decrease of 55 basis points.  Our first quarter results were lower t han expectations, resulting \nfrom weak retail pharmacy margins in the UK due to industry -wide underfunding by the NHS.  We anticipate this \nunderfunding will modestly improve in the second half of fiscal 2020.  \n \n As Brian discussed earlier, in fiscal 2019 we to ok actions in the UK and across Europe to reposition the business \nfor long -term profitability.  These actions included further store rationalization and cost actions, and we continue to \nexecute against these restructuring actions as we further evaluate our cost position. ", "original_text": "Our first quarter results were lower t han expectations, resulting \nfrom weak retail pharmacy margins in the UK due to industry -wide underfunding by the NHS. ", "page_label": "7", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "35248f45-6429-4b21-a274-8a0d5bf89987", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ff40d2d5dc0dba9a817069970d6b3d524f65b7bc0ecc61c92c5aca424bb597bd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "24ddf7bb-2192-4193-82a1-017339c0b92c", "node_type": "1", "metadata": {"window": "First quarter revenues were down 3% year -over-year to $6.7 billion. \n On an FX adjusted basis, revenues were up 3% driven by market growth in the distribution wholesale business. \n Segment adjusted operating profit was down 50% to $37 million on an FX adjusted basis, mainly due to the weak \nretail pharmacy environment in the UK.  The segment adjusted operating margin rate was 52 basis points on an \nFX adjusted basis, a decrease of 55 basis points.  Our first quarter results were lower t han expectations, resulting \nfrom weak retail pharmacy margins in the UK due to industry -wide underfunding by the NHS.  We anticipate this \nunderfunding will modestly improve in the second half of fiscal 2020.  \n \n As Brian discussed earlier, in fiscal 2019 we to ok actions in the UK and across Europe to reposition the business \nfor long -term profitability. ", "original_text": "The segment adjusted operating margin rate was 52 basis points on an \nFX adjusted basis, a decrease of 55 basis points. ", "page_label": "7", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ed81d2bd7d41dbc845d9a69125ad1cda15252855b87b27ac574b240691f867e4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "13144fd7-2eed-42d3-8864-e90b17cd7d5d", "node_type": "1", "metadata": {"window": "Segment adjusted operating profit was down 50% to $37 million on an FX adjusted basis, mainly due to the weak \nretail pharmacy environment in the UK.  The segment adjusted operating margin rate was 52 basis points on an \nFX adjusted basis, a decrease of 55 basis points.  Our first quarter results were lower t han expectations, resulting \nfrom weak retail pharmacy margins in the UK due to industry -wide underfunding by the NHS.  We anticipate this \nunderfunding will modestly improve in the second half of fiscal 2020.  \n \n As Brian discussed earlier, in fiscal 2019 we to ok actions in the UK and across Europe to reposition the business \nfor long -term profitability.  These actions included further store rationalization and cost actions, and we continue to \nexecute against these restructuring actions as we further evaluate our cost position.  As a result of the UK outlook, \nwe now expect European segment adjusted operating profit growth to be on the low end of our original \nassumption of low - to mid -single digit percent growth.  \n \n", "original_text": "We anticipate this \nunderfunding will modestly improve in the second half of fiscal 2020.  \n \n"}, "hash": "2e4ca65c6206bd22e2e5fd285e6ba419dcf9dbaa90db76ff65c1671c827315bf", "class_name": "RelatedNodeInfo"}}, "text": "Our first quarter results were lower t han expectations, resulting \nfrom weak retail pharmacy margins in the UK due to industry -wide underfunding by the NHS. ", "start_char_idx": 2026, "end_char_idx": 2185, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "13144fd7-2eed-42d3-8864-e90b17cd7d5d": {"__data__": {"id_": "13144fd7-2eed-42d3-8864-e90b17cd7d5d", "embedding": null, "metadata": {"window": "Segment adjusted operating profit was down 50% to $37 million on an FX adjusted basis, mainly due to the weak \nretail pharmacy environment in the UK.  The segment adjusted operating margin rate was 52 basis points on an \nFX adjusted basis, a decrease of 55 basis points.  Our first quarter results were lower t han expectations, resulting \nfrom weak retail pharmacy margins in the UK due to industry -wide underfunding by the NHS.  We anticipate this \nunderfunding will modestly improve in the second half of fiscal 2020.  \n \n As Brian discussed earlier, in fiscal 2019 we to ok actions in the UK and across Europe to reposition the business \nfor long -term profitability.  These actions included further store rationalization and cost actions, and we continue to \nexecute against these restructuring actions as we further evaluate our cost position.  As a result of the UK outlook, \nwe now expect European segment adjusted operating profit growth to be on the low end of our original \nassumption of low - to mid -single digit percent growth.  \n \n", "original_text": "We anticipate this \nunderfunding will modestly improve in the second half of fiscal 2020.  \n \n", "page_label": "7", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "35248f45-6429-4b21-a274-8a0d5bf89987", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ff40d2d5dc0dba9a817069970d6b3d524f65b7bc0ecc61c92c5aca424bb597bd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3b4b21be-d688-44fd-84b9-ec8a09419254", "node_type": "1", "metadata": {"window": "On an FX adjusted basis, revenues were up 3% driven by market growth in the distribution wholesale business. \n Segment adjusted operating profit was down 50% to $37 million on an FX adjusted basis, mainly due to the weak \nretail pharmacy environment in the UK.  The segment adjusted operating margin rate was 52 basis points on an \nFX adjusted basis, a decrease of 55 basis points.  Our first quarter results were lower t han expectations, resulting \nfrom weak retail pharmacy margins in the UK due to industry -wide underfunding by the NHS.  We anticipate this \nunderfunding will modestly improve in the second half of fiscal 2020.  \n \n As Brian discussed earlier, in fiscal 2019 we to ok actions in the UK and across Europe to reposition the business \nfor long -term profitability.  These actions included further store rationalization and cost actions, and we continue to \nexecute against these restructuring actions as we further evaluate our cost position. ", "original_text": "Our first quarter results were lower t han expectations, resulting \nfrom weak retail pharmacy margins in the UK due to industry -wide underfunding by the NHS. ", "page_label": "7", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8d94bf8c844f24ca338297a7e72a8d67a3e3d3795c4e0fec20ae823b27da3450", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8b81511c-9f77-496b-8532-45877feb53d4", "node_type": "1", "metadata": {"window": "The segment adjusted operating margin rate was 52 basis points on an \nFX adjusted basis, a decrease of 55 basis points.  Our first quarter results were lower t han expectations, resulting \nfrom weak retail pharmacy margins in the UK due to industry -wide underfunding by the NHS.  We anticipate this \nunderfunding will modestly improve in the second half of fiscal 2020.  \n \n As Brian discussed earlier, in fiscal 2019 we to ok actions in the UK and across Europe to reposition the business \nfor long -term profitability.  These actions included further store rationalization and cost actions, and we continue to \nexecute against these restructuring actions as we further evaluate our cost position.  As a result of the UK outlook, \nwe now expect European segment adjusted operating profit growth to be on the low end of our original \nassumption of low - to mid -single digit percent growth.  \n \n Moving now to Medical -Surgical Solutions. ", "original_text": "As Brian discussed earlier, in fiscal 2019 we to ok actions in the UK and across Europe to reposition the business \nfor long -term profitability. "}, "hash": "07dec2e25ebd7c3b38208ee4cefd82bda86a469ace29b6c07e67c38da4b8b3db", "class_name": "RelatedNodeInfo"}}, "text": "We anticipate this \nunderfunding will modestly improve in the second half of fiscal 2020.  \n \n", "start_char_idx": 2185, "end_char_idx": 2279, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8b81511c-9f77-496b-8532-45877feb53d4": {"__data__": {"id_": "8b81511c-9f77-496b-8532-45877feb53d4", "embedding": null, "metadata": {"window": "The segment adjusted operating margin rate was 52 basis points on an \nFX adjusted basis, a decrease of 55 basis points.  Our first quarter results were lower t han expectations, resulting \nfrom weak retail pharmacy margins in the UK due to industry -wide underfunding by the NHS.  We anticipate this \nunderfunding will modestly improve in the second half of fiscal 2020.  \n \n As Brian discussed earlier, in fiscal 2019 we to ok actions in the UK and across Europe to reposition the business \nfor long -term profitability.  These actions included further store rationalization and cost actions, and we continue to \nexecute against these restructuring actions as we further evaluate our cost position.  As a result of the UK outlook, \nwe now expect European segment adjusted operating profit growth to be on the low end of our original \nassumption of low - to mid -single digit percent growth.  \n \n Moving now to Medical -Surgical Solutions. ", "original_text": "As Brian discussed earlier, in fiscal 2019 we to ok actions in the UK and across Europe to reposition the business \nfor long -term profitability. ", "page_label": "7", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "35248f45-6429-4b21-a274-8a0d5bf89987", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ff40d2d5dc0dba9a817069970d6b3d524f65b7bc0ecc61c92c5aca424bb597bd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "13144fd7-2eed-42d3-8864-e90b17cd7d5d", "node_type": "1", "metadata": {"window": "Segment adjusted operating profit was down 50% to $37 million on an FX adjusted basis, mainly due to the weak \nretail pharmacy environment in the UK.  The segment adjusted operating margin rate was 52 basis points on an \nFX adjusted basis, a decrease of 55 basis points.  Our first quarter results were lower t han expectations, resulting \nfrom weak retail pharmacy margins in the UK due to industry -wide underfunding by the NHS.  We anticipate this \nunderfunding will modestly improve in the second half of fiscal 2020.  \n \n As Brian discussed earlier, in fiscal 2019 we to ok actions in the UK and across Europe to reposition the business \nfor long -term profitability.  These actions included further store rationalization and cost actions, and we continue to \nexecute against these restructuring actions as we further evaluate our cost position.  As a result of the UK outlook, \nwe now expect European segment adjusted operating profit growth to be on the low end of our original \nassumption of low - to mid -single digit percent growth.  \n \n", "original_text": "We anticipate this \nunderfunding will modestly improve in the second half of fiscal 2020.  \n \n", "page_label": "7", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e2bd5faaa94aa887945962469bfac4730b35a809cd3c102c6c59e2e696a858b0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e82ab1d9-fd01-4e4b-84e5-8cf815327437", "node_type": "1", "metadata": {"window": "Our first quarter results were lower t han expectations, resulting \nfrom weak retail pharmacy margins in the UK due to industry -wide underfunding by the NHS.  We anticipate this \nunderfunding will modestly improve in the second half of fiscal 2020.  \n \n As Brian discussed earlier, in fiscal 2019 we to ok actions in the UK and across Europe to reposition the business \nfor long -term profitability.  These actions included further store rationalization and cost actions, and we continue to \nexecute against these restructuring actions as we further evaluate our cost position.  As a result of the UK outlook, \nwe now expect European segment adjusted operating profit growth to be on the low end of our original \nassumption of low - to mid -single digit percent growth.  \n \n Moving now to Medical -Surgical Solutions.  First quart er revenues were $1.9 billion, up 12% year -over-year. \n", "original_text": "These actions included further store rationalization and cost actions, and we continue to \nexecute against these restructuring actions as we further evaluate our cost position. "}, "hash": "802f8d290ca9cfcfbc83990c99f1fef4f137d41ec614bd2f7c034e42d84a3dbb", "class_name": "RelatedNodeInfo"}}, "text": "As Brian discussed earlier, in fiscal 2019 we to ok actions in the UK and across Europe to reposition the business \nfor long -term profitability. ", "start_char_idx": 2279, "end_char_idx": 2425, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e82ab1d9-fd01-4e4b-84e5-8cf815327437": {"__data__": {"id_": "e82ab1d9-fd01-4e4b-84e5-8cf815327437", "embedding": null, "metadata": {"window": "Our first quarter results were lower t han expectations, resulting \nfrom weak retail pharmacy margins in the UK due to industry -wide underfunding by the NHS.  We anticipate this \nunderfunding will modestly improve in the second half of fiscal 2020.  \n \n As Brian discussed earlier, in fiscal 2019 we to ok actions in the UK and across Europe to reposition the business \nfor long -term profitability.  These actions included further store rationalization and cost actions, and we continue to \nexecute against these restructuring actions as we further evaluate our cost position.  As a result of the UK outlook, \nwe now expect European segment adjusted operating profit growth to be on the low end of our original \nassumption of low - to mid -single digit percent growth.  \n \n Moving now to Medical -Surgical Solutions.  First quart er revenues were $1.9 billion, up 12% year -over-year. \n", "original_text": "These actions included further store rationalization and cost actions, and we continue to \nexecute against these restructuring actions as we further evaluate our cost position. ", "page_label": "7", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "35248f45-6429-4b21-a274-8a0d5bf89987", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ff40d2d5dc0dba9a817069970d6b3d524f65b7bc0ecc61c92c5aca424bb597bd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8b81511c-9f77-496b-8532-45877feb53d4", "node_type": "1", "metadata": {"window": "The segment adjusted operating margin rate was 52 basis points on an \nFX adjusted basis, a decrease of 55 basis points.  Our first quarter results were lower t han expectations, resulting \nfrom weak retail pharmacy margins in the UK due to industry -wide underfunding by the NHS.  We anticipate this \nunderfunding will modestly improve in the second half of fiscal 2020.  \n \n As Brian discussed earlier, in fiscal 2019 we to ok actions in the UK and across Europe to reposition the business \nfor long -term profitability.  These actions included further store rationalization and cost actions, and we continue to \nexecute against these restructuring actions as we further evaluate our cost position.  As a result of the UK outlook, \nwe now expect European segment adjusted operating profit growth to be on the low end of our original \nassumption of low - to mid -single digit percent growth.  \n \n Moving now to Medical -Surgical Solutions. ", "original_text": "As Brian discussed earlier, in fiscal 2019 we to ok actions in the UK and across Europe to reposition the business \nfor long -term profitability. ", "page_label": "7", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "007d3821c5f108cf05bf5f9fcb338ff49fdde4cf25015741596d2fa66fab2d2e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d6a4d243-6d7d-404d-b62e-c138d441dc93", "node_type": "1", "metadata": {"window": "We anticipate this \nunderfunding will modestly improve in the second half of fiscal 2020.  \n \n As Brian discussed earlier, in fiscal 2019 we to ok actions in the UK and across Europe to reposition the business \nfor long -term profitability.  These actions included further store rationalization and cost actions, and we continue to \nexecute against these restructuring actions as we further evaluate our cost position.  As a result of the UK outlook, \nwe now expect European segment adjusted operating profit growth to be on the low end of our original \nassumption of low - to mid -single digit percent growth.  \n \n Moving now to Medical -Surgical Solutions.  First quart er revenues were $1.9 billion, up 12% year -over-year. \n Excluding the MSD acquisition which closed on June 1 of 2018, segment revenue increased 4% driven by growth \nin our Primary Care and Extended Care businesses, including strength in pharmaceutical product s and our home \ndelivery business. ", "original_text": "As a result of the UK outlook, \nwe now expect European segment adjusted operating profit growth to be on the low end of our original \nassumption of low - to mid -single digit percent growth.  \n \n"}, "hash": "c6790d1fac89dca296103353250872d662d5db5ee86b9d964ac5ef573a9d72bf", "class_name": "RelatedNodeInfo"}}, "text": "These actions included further store rationalization and cost actions, and we continue to \nexecute against these restructuring actions as we further evaluate our cost position. ", "start_char_idx": 2425, "end_char_idx": 2602, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d6a4d243-6d7d-404d-b62e-c138d441dc93": {"__data__": {"id_": "d6a4d243-6d7d-404d-b62e-c138d441dc93", "embedding": null, "metadata": {"window": "We anticipate this \nunderfunding will modestly improve in the second half of fiscal 2020.  \n \n As Brian discussed earlier, in fiscal 2019 we to ok actions in the UK and across Europe to reposition the business \nfor long -term profitability.  These actions included further store rationalization and cost actions, and we continue to \nexecute against these restructuring actions as we further evaluate our cost position.  As a result of the UK outlook, \nwe now expect European segment adjusted operating profit growth to be on the low end of our original \nassumption of low - to mid -single digit percent growth.  \n \n Moving now to Medical -Surgical Solutions.  First quart er revenues were $1.9 billion, up 12% year -over-year. \n Excluding the MSD acquisition which closed on June 1 of 2018, segment revenue increased 4% driven by growth \nin our Primary Care and Extended Care businesses, including strength in pharmaceutical product s and our home \ndelivery business. ", "original_text": "As a result of the UK outlook, \nwe now expect European segment adjusted operating profit growth to be on the low end of our original \nassumption of low - to mid -single digit percent growth.  \n \n", "page_label": "7", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "35248f45-6429-4b21-a274-8a0d5bf89987", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ff40d2d5dc0dba9a817069970d6b3d524f65b7bc0ecc61c92c5aca424bb597bd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e82ab1d9-fd01-4e4b-84e5-8cf815327437", "node_type": "1", "metadata": {"window": "Our first quarter results were lower t han expectations, resulting \nfrom weak retail pharmacy margins in the UK due to industry -wide underfunding by the NHS.  We anticipate this \nunderfunding will modestly improve in the second half of fiscal 2020.  \n \n As Brian discussed earlier, in fiscal 2019 we to ok actions in the UK and across Europe to reposition the business \nfor long -term profitability.  These actions included further store rationalization and cost actions, and we continue to \nexecute against these restructuring actions as we further evaluate our cost position.  As a result of the UK outlook, \nwe now expect European segment adjusted operating profit growth to be on the low end of our original \nassumption of low - to mid -single digit percent growth.  \n \n Moving now to Medical -Surgical Solutions.  First quart er revenues were $1.9 billion, up 12% year -over-year. \n", "original_text": "These actions included further store rationalization and cost actions, and we continue to \nexecute against these restructuring actions as we further evaluate our cost position. ", "page_label": "7", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5593e2d13805f2c8f87a42c74118a0c6d16e10c5f5ca869643f9407eab32567f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7a14bf58-bbcf-46c3-8681-16391e566fe4", "node_type": "1", "metadata": {"window": "As Brian discussed earlier, in fiscal 2019 we to ok actions in the UK and across Europe to reposition the business \nfor long -term profitability.  These actions included further store rationalization and cost actions, and we continue to \nexecute against these restructuring actions as we further evaluate our cost position.  As a result of the UK outlook, \nwe now expect European segment adjusted operating profit growth to be on the low end of our original \nassumption of low - to mid -single digit percent growth.  \n \n Moving now to Medical -Surgical Solutions.  First quart er revenues were $1.9 billion, up 12% year -over-year. \n Excluding the MSD acquisition which closed on June 1 of 2018, segment revenue increased 4% driven by growth \nin our Primary Care and Extended Care businesses, including strength in pharmaceutical product s and our home \ndelivery business.  Segment adjusted operating profit for the quarter increased 27% to $159 million, driven by \norganic growth and contribution from the MSD acquisition. ", "original_text": "Moving now to Medical -Surgical Solutions. "}, "hash": "f119936be027e3376ce510cb9a250481ccdfd52e11a3d2e194f3833a9dccc58f", "class_name": "RelatedNodeInfo"}}, "text": "As a result of the UK outlook, \nwe now expect European segment adjusted operating profit growth to be on the low end of our original \nassumption of low - to mid -single digit percent growth.  \n \n", "start_char_idx": 2602, "end_char_idx": 2797, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7a14bf58-bbcf-46c3-8681-16391e566fe4": {"__data__": {"id_": "7a14bf58-bbcf-46c3-8681-16391e566fe4", "embedding": null, "metadata": {"window": "As Brian discussed earlier, in fiscal 2019 we to ok actions in the UK and across Europe to reposition the business \nfor long -term profitability.  These actions included further store rationalization and cost actions, and we continue to \nexecute against these restructuring actions as we further evaluate our cost position.  As a result of the UK outlook, \nwe now expect European segment adjusted operating profit growth to be on the low end of our original \nassumption of low - to mid -single digit percent growth.  \n \n Moving now to Medical -Surgical Solutions.  First quart er revenues were $1.9 billion, up 12% year -over-year. \n Excluding the MSD acquisition which closed on June 1 of 2018, segment revenue increased 4% driven by growth \nin our Primary Care and Extended Care businesses, including strength in pharmaceutical product s and our home \ndelivery business.  Segment adjusted operating profit for the quarter increased 27% to $159 million, driven by \norganic growth and contribution from the MSD acquisition. ", "original_text": "Moving now to Medical -Surgical Solutions. ", "page_label": "7", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "35248f45-6429-4b21-a274-8a0d5bf89987", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ff40d2d5dc0dba9a817069970d6b3d524f65b7bc0ecc61c92c5aca424bb597bd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d6a4d243-6d7d-404d-b62e-c138d441dc93", "node_type": "1", "metadata": {"window": "We anticipate this \nunderfunding will modestly improve in the second half of fiscal 2020.  \n \n As Brian discussed earlier, in fiscal 2019 we to ok actions in the UK and across Europe to reposition the business \nfor long -term profitability.  These actions included further store rationalization and cost actions, and we continue to \nexecute against these restructuring actions as we further evaluate our cost position.  As a result of the UK outlook, \nwe now expect European segment adjusted operating profit growth to be on the low end of our original \nassumption of low - to mid -single digit percent growth.  \n \n Moving now to Medical -Surgical Solutions.  First quart er revenues were $1.9 billion, up 12% year -over-year. \n Excluding the MSD acquisition which closed on June 1 of 2018, segment revenue increased 4% driven by growth \nin our Primary Care and Extended Care businesses, including strength in pharmaceutical product s and our home \ndelivery business. ", "original_text": "As a result of the UK outlook, \nwe now expect European segment adjusted operating profit growth to be on the low end of our original \nassumption of low - to mid -single digit percent growth.  \n \n", "page_label": "7", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "28525c393245b951b91d99353da3ee16f03ca5be7232d0ccc849ce5a77971ae2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d0d5c4c8-e56c-4559-942f-c1451bd5c1e2", "node_type": "1", "metadata": {"window": "These actions included further store rationalization and cost actions, and we continue to \nexecute against these restructuring actions as we further evaluate our cost position.  As a result of the UK outlook, \nwe now expect European segment adjusted operating profit growth to be on the low end of our original \nassumption of low - to mid -single digit percent growth.  \n \n Moving now to Medical -Surgical Solutions.  First quart er revenues were $1.9 billion, up 12% year -over-year. \n Excluding the MSD acquisition which closed on June 1 of 2018, segment revenue increased 4% driven by growth \nin our Primary Care and Extended Care businesses, including strength in pharmaceutical product s and our home \ndelivery business.  Segment adjusted operating profit for the quarter increased 27% to $159 million, driven by \norganic growth and contribution from the MSD acquisition.  The segment adjusted operating margin rate was 836 \nbasis points, an incre ase of 102 basis points due to market growth and cost management.  \n \n", "original_text": "First quart er revenues were $1.9 billion, up 12% year -over-year. \n"}, "hash": "cb19c1f6e5f7dd428cc0c1c47b540ba7c60313aa9e47d496570dd2033e6cb1ca", "class_name": "RelatedNodeInfo"}}, "text": "Moving now to Medical -Surgical Solutions. ", "start_char_idx": 2797, "end_char_idx": 2840, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d0d5c4c8-e56c-4559-942f-c1451bd5c1e2": {"__data__": {"id_": "d0d5c4c8-e56c-4559-942f-c1451bd5c1e2", "embedding": null, "metadata": {"window": "These actions included further store rationalization and cost actions, and we continue to \nexecute against these restructuring actions as we further evaluate our cost position.  As a result of the UK outlook, \nwe now expect European segment adjusted operating profit growth to be on the low end of our original \nassumption of low - to mid -single digit percent growth.  \n \n Moving now to Medical -Surgical Solutions.  First quart er revenues were $1.9 billion, up 12% year -over-year. \n Excluding the MSD acquisition which closed on June 1 of 2018, segment revenue increased 4% driven by growth \nin our Primary Care and Extended Care businesses, including strength in pharmaceutical product s and our home \ndelivery business.  Segment adjusted operating profit for the quarter increased 27% to $159 million, driven by \norganic growth and contribution from the MSD acquisition.  The segment adjusted operating margin rate was 836 \nbasis points, an incre ase of 102 basis points due to market growth and cost management.  \n \n", "original_text": "First quart er revenues were $1.9 billion, up 12% year -over-year. \n", "page_label": "7", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "35248f45-6429-4b21-a274-8a0d5bf89987", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ff40d2d5dc0dba9a817069970d6b3d524f65b7bc0ecc61c92c5aca424bb597bd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7a14bf58-bbcf-46c3-8681-16391e566fe4", "node_type": "1", "metadata": {"window": "As Brian discussed earlier, in fiscal 2019 we to ok actions in the UK and across Europe to reposition the business \nfor long -term profitability.  These actions included further store rationalization and cost actions, and we continue to \nexecute against these restructuring actions as we further evaluate our cost position.  As a result of the UK outlook, \nwe now expect European segment adjusted operating profit growth to be on the low end of our original \nassumption of low - to mid -single digit percent growth.  \n \n Moving now to Medical -Surgical Solutions.  First quart er revenues were $1.9 billion, up 12% year -over-year. \n Excluding the MSD acquisition which closed on June 1 of 2018, segment revenue increased 4% driven by growth \nin our Primary Care and Extended Care businesses, including strength in pharmaceutical product s and our home \ndelivery business.  Segment adjusted operating profit for the quarter increased 27% to $159 million, driven by \norganic growth and contribution from the MSD acquisition. ", "original_text": "Moving now to Medical -Surgical Solutions. ", "page_label": "7", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b88ac4850f82762ffd1ea6ec666567aa8c3b34d1b743a796a816377542b67bb3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "29fc1cf6-a79c-4b0a-b2ff-d71328832b3f", "node_type": "1", "metadata": {"window": "As a result of the UK outlook, \nwe now expect European segment adjusted operating profit growth to be on the low end of our original \nassumption of low - to mid -single digit percent growth.  \n \n Moving now to Medical -Surgical Solutions.  First quart er revenues were $1.9 billion, up 12% year -over-year. \n Excluding the MSD acquisition which closed on June 1 of 2018, segment revenue increased 4% driven by growth \nin our Primary Care and Extended Care businesses, including strength in pharmaceutical product s and our home \ndelivery business.  Segment adjusted operating profit for the quarter increased 27% to $159 million, driven by \norganic growth and contribution from the MSD acquisition.  The segment adjusted operating margin rate was 836 \nbasis points, an incre ase of 102 basis points due to market growth and cost management.  \n \n Finishing our business review with Other, revenues were $3 billion for the quarter, down 1% year -over-year. ", "original_text": "Excluding the MSD acquisition which closed on June 1 of 2018, segment revenue increased 4% driven by growth \nin our Primary Care and Extended Care businesses, including strength in pharmaceutical product s and our home \ndelivery business. "}, "hash": "949b3b43f4cfaa70074bce3b209bca9510d77b4c3362ec1f649129693951eec8", "class_name": "RelatedNodeInfo"}}, "text": "First quart er revenues were $1.9 billion, up 12% year -over-year. \n", "start_char_idx": 2840, "end_char_idx": 2908, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "29fc1cf6-a79c-4b0a-b2ff-d71328832b3f": {"__data__": {"id_": "29fc1cf6-a79c-4b0a-b2ff-d71328832b3f", "embedding": null, "metadata": {"window": "As a result of the UK outlook, \nwe now expect European segment adjusted operating profit growth to be on the low end of our original \nassumption of low - to mid -single digit percent growth.  \n \n Moving now to Medical -Surgical Solutions.  First quart er revenues were $1.9 billion, up 12% year -over-year. \n Excluding the MSD acquisition which closed on June 1 of 2018, segment revenue increased 4% driven by growth \nin our Primary Care and Extended Care businesses, including strength in pharmaceutical product s and our home \ndelivery business.  Segment adjusted operating profit for the quarter increased 27% to $159 million, driven by \norganic growth and contribution from the MSD acquisition.  The segment adjusted operating margin rate was 836 \nbasis points, an incre ase of 102 basis points due to market growth and cost management.  \n \n Finishing our business review with Other, revenues were $3 billion for the quarter, down 1% year -over-year. ", "original_text": "Excluding the MSD acquisition which closed on June 1 of 2018, segment revenue increased 4% driven by growth \nin our Primary Care and Extended Care businesses, including strength in pharmaceutical product s and our home \ndelivery business. ", "page_label": "7", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "35248f45-6429-4b21-a274-8a0d5bf89987", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ff40d2d5dc0dba9a817069970d6b3d524f65b7bc0ecc61c92c5aca424bb597bd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d0d5c4c8-e56c-4559-942f-c1451bd5c1e2", "node_type": "1", "metadata": {"window": "These actions included further store rationalization and cost actions, and we continue to \nexecute against these restructuring actions as we further evaluate our cost position.  As a result of the UK outlook, \nwe now expect European segment adjusted operating profit growth to be on the low end of our original \nassumption of low - to mid -single digit percent growth.  \n \n Moving now to Medical -Surgical Solutions.  First quart er revenues were $1.9 billion, up 12% year -over-year. \n Excluding the MSD acquisition which closed on June 1 of 2018, segment revenue increased 4% driven by growth \nin our Primary Care and Extended Care businesses, including strength in pharmaceutical product s and our home \ndelivery business.  Segment adjusted operating profit for the quarter increased 27% to $159 million, driven by \norganic growth and contribution from the MSD acquisition.  The segment adjusted operating margin rate was 836 \nbasis points, an incre ase of 102 basis points due to market growth and cost management.  \n \n", "original_text": "First quart er revenues were $1.9 billion, up 12% year -over-year. \n", "page_label": "7", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e6a7a326341982809a0ad6059b084ef3cd8b6fff5341d679c582dd7ca5a009ff", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "23776c64-afac-4f1d-8e10-f9b54eb3b83a", "node_type": "1", "metadata": {"window": "Moving now to Medical -Surgical Solutions.  First quart er revenues were $1.9 billion, up 12% year -over-year. \n Excluding the MSD acquisition which closed on June 1 of 2018, segment revenue increased 4% driven by growth \nin our Primary Care and Extended Care businesses, including strength in pharmaceutical product s and our home \ndelivery business.  Segment adjusted operating profit for the quarter increased 27% to $159 million, driven by \norganic growth and contribution from the MSD acquisition.  The segment adjusted operating margin rate was 836 \nbasis points, an incre ase of 102 basis points due to market growth and cost management.  \n \n Finishing our business review with Other, revenues were $3 billion for the quarter, down 1% year -over-year.  On \nan FX adjusted basis, revenues grew 2% driven primarily by growth in our MRxTS  business. ", "original_text": "Segment adjusted operating profit for the quarter increased 27% to $159 million, driven by \norganic growth and contribution from the MSD acquisition. "}, "hash": "c274e462b77d6b534cb360091551701cdf2e0d7e565258f594ed6a4dc7165200", "class_name": "RelatedNodeInfo"}}, "text": "Excluding the MSD acquisition which closed on June 1 of 2018, segment revenue increased 4% driven by growth \nin our Primary Care and Extended Care businesses, including strength in pharmaceutical product s and our home \ndelivery business. ", "start_char_idx": 2908, "end_char_idx": 3147, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "23776c64-afac-4f1d-8e10-f9b54eb3b83a": {"__data__": {"id_": "23776c64-afac-4f1d-8e10-f9b54eb3b83a", "embedding": null, "metadata": {"window": "Moving now to Medical -Surgical Solutions.  First quart er revenues were $1.9 billion, up 12% year -over-year. \n Excluding the MSD acquisition which closed on June 1 of 2018, segment revenue increased 4% driven by growth \nin our Primary Care and Extended Care businesses, including strength in pharmaceutical product s and our home \ndelivery business.  Segment adjusted operating profit for the quarter increased 27% to $159 million, driven by \norganic growth and contribution from the MSD acquisition.  The segment adjusted operating margin rate was 836 \nbasis points, an incre ase of 102 basis points due to market growth and cost management.  \n \n Finishing our business review with Other, revenues were $3 billion for the quarter, down 1% year -over-year.  On \nan FX adjusted basis, revenues grew 2% driven primarily by growth in our MRxTS  business. ", "original_text": "Segment adjusted operating profit for the quarter increased 27% to $159 million, driven by \norganic growth and contribution from the MSD acquisition. ", "page_label": "7", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "35248f45-6429-4b21-a274-8a0d5bf89987", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ff40d2d5dc0dba9a817069970d6b3d524f65b7bc0ecc61c92c5aca424bb597bd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "29fc1cf6-a79c-4b0a-b2ff-d71328832b3f", "node_type": "1", "metadata": {"window": "As a result of the UK outlook, \nwe now expect European segment adjusted operating profit growth to be on the low end of our original \nassumption of low - to mid -single digit percent growth.  \n \n Moving now to Medical -Surgical Solutions.  First quart er revenues were $1.9 billion, up 12% year -over-year. \n Excluding the MSD acquisition which closed on June 1 of 2018, segment revenue increased 4% driven by growth \nin our Primary Care and Extended Care businesses, including strength in pharmaceutical product s and our home \ndelivery business.  Segment adjusted operating profit for the quarter increased 27% to $159 million, driven by \norganic growth and contribution from the MSD acquisition.  The segment adjusted operating margin rate was 836 \nbasis points, an incre ase of 102 basis points due to market growth and cost management.  \n \n Finishing our business review with Other, revenues were $3 billion for the quarter, down 1% year -over-year. ", "original_text": "Excluding the MSD acquisition which closed on June 1 of 2018, segment revenue increased 4% driven by growth \nin our Primary Care and Extended Care businesses, including strength in pharmaceutical product s and our home \ndelivery business. ", "page_label": "7", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bbe44d3c14e93eb280f2a27aedeb58f63748f8266bcbb5a44f6712a51647b87e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8ae70278-5ff8-4591-9717-ec181cb7de50", "node_type": "1", "metadata": {"window": "First quart er revenues were $1.9 billion, up 12% year -over-year. \n Excluding the MSD acquisition which closed on June 1 of 2018, segment revenue increased 4% driven by growth \nin our Primary Care and Extended Care businesses, including strength in pharmaceutical product s and our home \ndelivery business.  Segment adjusted operating profit for the quarter increased 27% to $159 million, driven by \norganic growth and contribution from the MSD acquisition.  The segment adjusted operating margin rate was 836 \nbasis points, an incre ase of 102 basis points due to market growth and cost management.  \n \n Finishing our business review with Other, revenues were $3 billion for the quarter, down 1% year -over-year.  On \nan FX adjusted basis, revenues grew 2% driven primarily by growth in our MRxTS  business.  Other adjusted \noperating profit increased 31% to $279 million on an FX adjusted basis, mainly driven by increased equity income \nfrom our investment in Change Healthcare and continued strength in our MRxTS business. ", "original_text": "The segment adjusted operating margin rate was 836 \nbasis points, an incre ase of 102 basis points due to market growth and cost management.  \n \n"}, "hash": "efdf2a980690521a7061d1975733553630b112af4cbd069615d609cc96ddcc27", "class_name": "RelatedNodeInfo"}}, "text": "Segment adjusted operating profit for the quarter increased 27% to $159 million, driven by \norganic growth and contribution from the MSD acquisition. ", "start_char_idx": 3147, "end_char_idx": 3297, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8ae70278-5ff8-4591-9717-ec181cb7de50": {"__data__": {"id_": "8ae70278-5ff8-4591-9717-ec181cb7de50", "embedding": null, "metadata": {"window": "First quart er revenues were $1.9 billion, up 12% year -over-year. \n Excluding the MSD acquisition which closed on June 1 of 2018, segment revenue increased 4% driven by growth \nin our Primary Care and Extended Care businesses, including strength in pharmaceutical product s and our home \ndelivery business.  Segment adjusted operating profit for the quarter increased 27% to $159 million, driven by \norganic growth and contribution from the MSD acquisition.  The segment adjusted operating margin rate was 836 \nbasis points, an incre ase of 102 basis points due to market growth and cost management.  \n \n Finishing our business review with Other, revenues were $3 billion for the quarter, down 1% year -over-year.  On \nan FX adjusted basis, revenues grew 2% driven primarily by growth in our MRxTS  business.  Other adjusted \noperating profit increased 31% to $279 million on an FX adjusted basis, mainly driven by increased equity income \nfrom our investment in Change Healthcare and continued strength in our MRxTS business. ", "original_text": "The segment adjusted operating margin rate was 836 \nbasis points, an incre ase of 102 basis points due to market growth and cost management.  \n \n", "page_label": "7", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "35248f45-6429-4b21-a274-8a0d5bf89987", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ff40d2d5dc0dba9a817069970d6b3d524f65b7bc0ecc61c92c5aca424bb597bd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "23776c64-afac-4f1d-8e10-f9b54eb3b83a", "node_type": "1", "metadata": {"window": "Moving now to Medical -Surgical Solutions.  First quart er revenues were $1.9 billion, up 12% year -over-year. \n Excluding the MSD acquisition which closed on June 1 of 2018, segment revenue increased 4% driven by growth \nin our Primary Care and Extended Care businesses, including strength in pharmaceutical product s and our home \ndelivery business.  Segment adjusted operating profit for the quarter increased 27% to $159 million, driven by \norganic growth and contribution from the MSD acquisition.  The segment adjusted operating margin rate was 836 \nbasis points, an incre ase of 102 basis points due to market growth and cost management.  \n \n Finishing our business review with Other, revenues were $3 billion for the quarter, down 1% year -over-year.  On \nan FX adjusted basis, revenues grew 2% driven primarily by growth in our MRxTS  business. ", "original_text": "Segment adjusted operating profit for the quarter increased 27% to $159 million, driven by \norganic growth and contribution from the MSD acquisition. ", "page_label": "7", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1fa1768ab8fc93841f2ce33f6c056de5f7699e02fde25494d2acfcb72f8801e7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4502874e-f391-4fe6-896e-7854f8559b5c", "node_type": "1", "metadata": {"window": "Excluding the MSD acquisition which closed on June 1 of 2018, segment revenue increased 4% driven by growth \nin our Primary Care and Extended Care businesses, including strength in pharmaceutical product s and our home \ndelivery business.  Segment adjusted operating profit for the quarter increased 27% to $159 million, driven by \norganic growth and contribution from the MSD acquisition.  The segment adjusted operating margin rate was 836 \nbasis points, an incre ase of 102 basis points due to market growth and cost management.  \n \n Finishing our business review with Other, revenues were $3 billion for the quarter, down 1% year -over-year.  On \nan FX adjusted basis, revenues grew 2% driven primarily by growth in our MRxTS  business.  Other adjusted \noperating profit increased 31% to $279 million on an FX adjusted basis, mainly driven by increased equity income \nfrom our investment in Change Healthcare and continued strength in our MRxTS business.  Included in Other, \nadjusted eq uity income from Change Healthcare was $108 million for the quarter as compared to $64 million in \nthe prior period.  \n \n", "original_text": "Finishing our business review with Other, revenues were $3 billion for the quarter, down 1% year -over-year. "}, "hash": "0757aea520c572db5ef27a6f35fdc66995f8f07e6a03e69188941c818660e9f0", "class_name": "RelatedNodeInfo"}}, "text": "The segment adjusted operating margin rate was 836 \nbasis points, an incre ase of 102 basis points due to market growth and cost management.  \n \n", "start_char_idx": 3297, "end_char_idx": 3442, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4502874e-f391-4fe6-896e-7854f8559b5c": {"__data__": {"id_": "4502874e-f391-4fe6-896e-7854f8559b5c", "embedding": null, "metadata": {"window": "Excluding the MSD acquisition which closed on June 1 of 2018, segment revenue increased 4% driven by growth \nin our Primary Care and Extended Care businesses, including strength in pharmaceutical product s and our home \ndelivery business.  Segment adjusted operating profit for the quarter increased 27% to $159 million, driven by \norganic growth and contribution from the MSD acquisition.  The segment adjusted operating margin rate was 836 \nbasis points, an incre ase of 102 basis points due to market growth and cost management.  \n \n Finishing our business review with Other, revenues were $3 billion for the quarter, down 1% year -over-year.  On \nan FX adjusted basis, revenues grew 2% driven primarily by growth in our MRxTS  business.  Other adjusted \noperating profit increased 31% to $279 million on an FX adjusted basis, mainly driven by increased equity income \nfrom our investment in Change Healthcare and continued strength in our MRxTS business.  Included in Other, \nadjusted eq uity income from Change Healthcare was $108 million for the quarter as compared to $64 million in \nthe prior period.  \n \n", "original_text": "Finishing our business review with Other, revenues were $3 billion for the quarter, down 1% year -over-year. ", "page_label": "7", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "35248f45-6429-4b21-a274-8a0d5bf89987", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ff40d2d5dc0dba9a817069970d6b3d524f65b7bc0ecc61c92c5aca424bb597bd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8ae70278-5ff8-4591-9717-ec181cb7de50", "node_type": "1", "metadata": {"window": "First quart er revenues were $1.9 billion, up 12% year -over-year. \n Excluding the MSD acquisition which closed on June 1 of 2018, segment revenue increased 4% driven by growth \nin our Primary Care and Extended Care businesses, including strength in pharmaceutical product s and our home \ndelivery business.  Segment adjusted operating profit for the quarter increased 27% to $159 million, driven by \norganic growth and contribution from the MSD acquisition.  The segment adjusted operating margin rate was 836 \nbasis points, an incre ase of 102 basis points due to market growth and cost management.  \n \n Finishing our business review with Other, revenues were $3 billion for the quarter, down 1% year -over-year.  On \nan FX adjusted basis, revenues grew 2% driven primarily by growth in our MRxTS  business.  Other adjusted \noperating profit increased 31% to $279 million on an FX adjusted basis, mainly driven by increased equity income \nfrom our investment in Change Healthcare and continued strength in our MRxTS business. ", "original_text": "The segment adjusted operating margin rate was 836 \nbasis points, an incre ase of 102 basis points due to market growth and cost management.  \n \n", "page_label": "7", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2c558122c23ce4d80f19632dc8a437a493477671d4650f62a59288a1a9565166", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f0083b3e-0fbc-42b9-b444-c24fc86e3882", "node_type": "1", "metadata": {"window": "Segment adjusted operating profit for the quarter increased 27% to $159 million, driven by \norganic growth and contribution from the MSD acquisition.  The segment adjusted operating margin rate was 836 \nbasis points, an incre ase of 102 basis points due to market growth and cost management.  \n \n Finishing our business review with Other, revenues were $3 billion for the quarter, down 1% year -over-year.  On \nan FX adjusted basis, revenues grew 2% driven primarily by growth in our MRxTS  business.  Other adjusted \noperating profit increased 31% to $279 million on an FX adjusted basis, mainly driven by increased equity income \nfrom our investment in Change Healthcare and continued strength in our MRxTS business.  Included in Other, \nadjusted eq uity income from Change Healthcare was $108 million for the quarter as compared to $64 million in \nthe prior period.  \n \n Let me take a minute and update you on our equity investment in Change Healthcare. ", "original_text": "On \nan FX adjusted basis, revenues grew 2% driven primarily by growth in our MRxTS  business. "}, "hash": "470368eab35967bfe0fde6b3a437de4f46676d0cb7cfe881dc4bcd3342a92e2a", "class_name": "RelatedNodeInfo"}}, "text": "Finishing our business review with Other, revenues were $3 billion for the quarter, down 1% year -over-year. ", "start_char_idx": 3442, "end_char_idx": 3551, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f0083b3e-0fbc-42b9-b444-c24fc86e3882": {"__data__": {"id_": "f0083b3e-0fbc-42b9-b444-c24fc86e3882", "embedding": null, "metadata": {"window": "Segment adjusted operating profit for the quarter increased 27% to $159 million, driven by \norganic growth and contribution from the MSD acquisition.  The segment adjusted operating margin rate was 836 \nbasis points, an incre ase of 102 basis points due to market growth and cost management.  \n \n Finishing our business review with Other, revenues were $3 billion for the quarter, down 1% year -over-year.  On \nan FX adjusted basis, revenues grew 2% driven primarily by growth in our MRxTS  business.  Other adjusted \noperating profit increased 31% to $279 million on an FX adjusted basis, mainly driven by increased equity income \nfrom our investment in Change Healthcare and continued strength in our MRxTS business.  Included in Other, \nadjusted eq uity income from Change Healthcare was $108 million for the quarter as compared to $64 million in \nthe prior period.  \n \n Let me take a minute and update you on our equity investment in Change Healthcare. ", "original_text": "On \nan FX adjusted basis, revenues grew 2% driven primarily by growth in our MRxTS  business. ", "page_label": "7", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "35248f45-6429-4b21-a274-8a0d5bf89987", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ff40d2d5dc0dba9a817069970d6b3d524f65b7bc0ecc61c92c5aca424bb597bd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4502874e-f391-4fe6-896e-7854f8559b5c", "node_type": "1", "metadata": {"window": "Excluding the MSD acquisition which closed on June 1 of 2018, segment revenue increased 4% driven by growth \nin our Primary Care and Extended Care businesses, including strength in pharmaceutical product s and our home \ndelivery business.  Segment adjusted operating profit for the quarter increased 27% to $159 million, driven by \norganic growth and contribution from the MSD acquisition.  The segment adjusted operating margin rate was 836 \nbasis points, an incre ase of 102 basis points due to market growth and cost management.  \n \n Finishing our business review with Other, revenues were $3 billion for the quarter, down 1% year -over-year.  On \nan FX adjusted basis, revenues grew 2% driven primarily by growth in our MRxTS  business.  Other adjusted \noperating profit increased 31% to $279 million on an FX adjusted basis, mainly driven by increased equity income \nfrom our investment in Change Healthcare and continued strength in our MRxTS business.  Included in Other, \nadjusted eq uity income from Change Healthcare was $108 million for the quarter as compared to $64 million in \nthe prior period.  \n \n", "original_text": "Finishing our business review with Other, revenues were $3 billion for the quarter, down 1% year -over-year. ", "page_label": "7", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d7332e87b4c33ecd02c1ae1870dc07f2894f035a84c33b8e93814cf8c6daae11", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5435749e-9d0a-48de-bfae-739546af6dca", "node_type": "1", "metadata": {"window": "The segment adjusted operating margin rate was 836 \nbasis points, an incre ase of 102 basis points due to market growth and cost management.  \n \n Finishing our business review with Other, revenues were $3 billion for the quarter, down 1% year -over-year.  On \nan FX adjusted basis, revenues grew 2% driven primarily by growth in our MRxTS  business.  Other adjusted \noperating profit increased 31% to $279 million on an FX adjusted basis, mainly driven by increased equity income \nfrom our investment in Change Healthcare and continued strength in our MRxTS business.  Included in Other, \nadjusted eq uity income from Change Healthcare was $108 million for the quarter as compared to $64 million in \nthe prior period.  \n \n Let me take a minute and update you on our equity investment in Change Healthcare.  On June 27 of 2019, \nChange Healthcare began trading on t he Nasdaq. ", "original_text": "Other adjusted \noperating profit increased 31% to $279 million on an FX adjusted basis, mainly driven by increased equity income \nfrom our investment in Change Healthcare and continued strength in our MRxTS business. "}, "hash": "ddd7e44c2bd6171a41f79d5e4a39cf16a95379c7b234f19cc94b78cebfb6333b", "class_name": "RelatedNodeInfo"}}, "text": "On \nan FX adjusted basis, revenues grew 2% driven primarily by growth in our MRxTS  business. ", "start_char_idx": 3551, "end_char_idx": 3645, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5435749e-9d0a-48de-bfae-739546af6dca": {"__data__": {"id_": "5435749e-9d0a-48de-bfae-739546af6dca", "embedding": null, "metadata": {"window": "The segment adjusted operating margin rate was 836 \nbasis points, an incre ase of 102 basis points due to market growth and cost management.  \n \n Finishing our business review with Other, revenues were $3 billion for the quarter, down 1% year -over-year.  On \nan FX adjusted basis, revenues grew 2% driven primarily by growth in our MRxTS  business.  Other adjusted \noperating profit increased 31% to $279 million on an FX adjusted basis, mainly driven by increased equity income \nfrom our investment in Change Healthcare and continued strength in our MRxTS business.  Included in Other, \nadjusted eq uity income from Change Healthcare was $108 million for the quarter as compared to $64 million in \nthe prior period.  \n \n Let me take a minute and update you on our equity investment in Change Healthcare.  On June 27 of 2019, \nChange Healthcare began trading on t he Nasdaq. ", "original_text": "Other adjusted \noperating profit increased 31% to $279 million on an FX adjusted basis, mainly driven by increased equity income \nfrom our investment in Change Healthcare and continued strength in our MRxTS business. ", "page_label": "7", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "35248f45-6429-4b21-a274-8a0d5bf89987", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ff40d2d5dc0dba9a817069970d6b3d524f65b7bc0ecc61c92c5aca424bb597bd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f0083b3e-0fbc-42b9-b444-c24fc86e3882", "node_type": "1", "metadata": {"window": "Segment adjusted operating profit for the quarter increased 27% to $159 million, driven by \norganic growth and contribution from the MSD acquisition.  The segment adjusted operating margin rate was 836 \nbasis points, an incre ase of 102 basis points due to market growth and cost management.  \n \n Finishing our business review with Other, revenues were $3 billion for the quarter, down 1% year -over-year.  On \nan FX adjusted basis, revenues grew 2% driven primarily by growth in our MRxTS  business.  Other adjusted \noperating profit increased 31% to $279 million on an FX adjusted basis, mainly driven by increased equity income \nfrom our investment in Change Healthcare and continued strength in our MRxTS business.  Included in Other, \nadjusted eq uity income from Change Healthcare was $108 million for the quarter as compared to $64 million in \nthe prior period.  \n \n Let me take a minute and update you on our equity investment in Change Healthcare. ", "original_text": "On \nan FX adjusted basis, revenues grew 2% driven primarily by growth in our MRxTS  business. ", "page_label": "7", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "21fbe6f23fe2dc5e39ab5e62a79418493b016c7aa2344cad3a5205416a8b4b77", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c8229b65-2bda-47d0-bccc-fce54fe3117b", "node_type": "1", "metadata": {"window": "Finishing our business review with Other, revenues were $3 billion for the quarter, down 1% year -over-year.  On \nan FX adjusted basis, revenues grew 2% driven primarily by growth in our MRxTS  business.  Other adjusted \noperating profit increased 31% to $279 million on an FX adjusted basis, mainly driven by increased equity income \nfrom our investment in Change Healthcare and continued strength in our MRxTS business.  Included in Other, \nadjusted eq uity income from Change Healthcare was $108 million for the quarter as compared to $64 million in \nthe prior period.  \n \n Let me take a minute and update you on our equity investment in Change Healthcare.  On June 27 of 2019, \nChange Healthcare began trading on t he Nasdaq.  This was an important milestone for Change Healthcare. ", "original_text": "Included in Other, \nadjusted eq uity income from Change Healthcare was $108 million for the quarter as compared to $64 million in \nthe prior period.  \n \n"}, "hash": "8a1e032a6720135b96a82c62cea6a5c65f133ba2e818a342c8d5d2bedcc56dc5", "class_name": "RelatedNodeInfo"}}, "text": "Other adjusted \noperating profit increased 31% to $279 million on an FX adjusted basis, mainly driven by increased equity income \nfrom our investment in Change Healthcare and continued strength in our MRxTS business. ", "start_char_idx": 3645, "end_char_idx": 3862, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c8229b65-2bda-47d0-bccc-fce54fe3117b": {"__data__": {"id_": "c8229b65-2bda-47d0-bccc-fce54fe3117b", "embedding": null, "metadata": {"window": "Finishing our business review with Other, revenues were $3 billion for the quarter, down 1% year -over-year.  On \nan FX adjusted basis, revenues grew 2% driven primarily by growth in our MRxTS  business.  Other adjusted \noperating profit increased 31% to $279 million on an FX adjusted basis, mainly driven by increased equity income \nfrom our investment in Change Healthcare and continued strength in our MRxTS business.  Included in Other, \nadjusted eq uity income from Change Healthcare was $108 million for the quarter as compared to $64 million in \nthe prior period.  \n \n Let me take a minute and update you on our equity investment in Change Healthcare.  On June 27 of 2019, \nChange Healthcare began trading on t he Nasdaq.  This was an important milestone for Change Healthcare. ", "original_text": "Included in Other, \nadjusted eq uity income from Change Healthcare was $108 million for the quarter as compared to $64 million in \nthe prior period.  \n \n", "page_label": "7", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "35248f45-6429-4b21-a274-8a0d5bf89987", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ff40d2d5dc0dba9a817069970d6b3d524f65b7bc0ecc61c92c5aca424bb597bd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5435749e-9d0a-48de-bfae-739546af6dca", "node_type": "1", "metadata": {"window": "The segment adjusted operating margin rate was 836 \nbasis points, an incre ase of 102 basis points due to market growth and cost management.  \n \n Finishing our business review with Other, revenues were $3 billion for the quarter, down 1% year -over-year.  On \nan FX adjusted basis, revenues grew 2% driven primarily by growth in our MRxTS  business.  Other adjusted \noperating profit increased 31% to $279 million on an FX adjusted basis, mainly driven by increased equity income \nfrom our investment in Change Healthcare and continued strength in our MRxTS business.  Included in Other, \nadjusted eq uity income from Change Healthcare was $108 million for the quarter as compared to $64 million in \nthe prior period.  \n \n Let me take a minute and update you on our equity investment in Change Healthcare.  On June 27 of 2019, \nChange Healthcare began trading on t he Nasdaq. ", "original_text": "Other adjusted \noperating profit increased 31% to $279 million on an FX adjusted basis, mainly driven by increased equity income \nfrom our investment in Change Healthcare and continued strength in our MRxTS business. ", "page_label": "7", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a1b9d8e7764adaad939847e04ef40b1ae41a87f76e051b9b23b252dcdfac40d7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8017e292-c84a-4d87-8736-eb240ab45205", "node_type": "1", "metadata": {"window": "On \nan FX adjusted basis, revenues grew 2% driven primarily by growth in our MRxTS  business.  Other adjusted \noperating profit increased 31% to $279 million on an FX adjusted basis, mainly driven by increased equity income \nfrom our investment in Change Healthcare and continued strength in our MRxTS business.  Included in Other, \nadjusted eq uity income from Change Healthcare was $108 million for the quarter as compared to $64 million in \nthe prior period.  \n \n Let me take a minute and update you on our equity investment in Change Healthcare.  On June 27 of 2019, \nChange Healthcare began trading on t he Nasdaq.  This was an important milestone for Change Healthcare.  While \nChange Healthcare is now a publicly -traded company, McKesson will continue to report the equity income from \nour interest in Change Healthcare based on our equity ownership percentage a nd we'll continue to report Change \nHealthcare results on a one -month lag.  ", "original_text": "Let me take a minute and update you on our equity investment in Change Healthcare. "}, "hash": "5e4eb608b1c84f619dd20b3fb2abefaaa491f81744747bfdb412528c401758e3", "class_name": "RelatedNodeInfo"}}, "text": "Included in Other, \nadjusted eq uity income from Change Healthcare was $108 million for the quarter as compared to $64 million in \nthe prior period.  \n \n", "start_char_idx": 3862, "end_char_idx": 4015, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8017e292-c84a-4d87-8736-eb240ab45205": {"__data__": {"id_": "8017e292-c84a-4d87-8736-eb240ab45205", "embedding": null, "metadata": {"window": "On \nan FX adjusted basis, revenues grew 2% driven primarily by growth in our MRxTS  business.  Other adjusted \noperating profit increased 31% to $279 million on an FX adjusted basis, mainly driven by increased equity income \nfrom our investment in Change Healthcare and continued strength in our MRxTS business.  Included in Other, \nadjusted eq uity income from Change Healthcare was $108 million for the quarter as compared to $64 million in \nthe prior period.  \n \n Let me take a minute and update you on our equity investment in Change Healthcare.  On June 27 of 2019, \nChange Healthcare began trading on t he Nasdaq.  This was an important milestone for Change Healthcare.  While \nChange Healthcare is now a publicly -traded company, McKesson will continue to report the equity income from \nour interest in Change Healthcare based on our equity ownership percentage a nd we'll continue to report Change \nHealthcare results on a one -month lag.  ", "original_text": "Let me take a minute and update you on our equity investment in Change Healthcare. ", "page_label": "7", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "35248f45-6429-4b21-a274-8a0d5bf89987", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ff40d2d5dc0dba9a817069970d6b3d524f65b7bc0ecc61c92c5aca424bb597bd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c8229b65-2bda-47d0-bccc-fce54fe3117b", "node_type": "1", "metadata": {"window": "Finishing our business review with Other, revenues were $3 billion for the quarter, down 1% year -over-year.  On \nan FX adjusted basis, revenues grew 2% driven primarily by growth in our MRxTS  business.  Other adjusted \noperating profit increased 31% to $279 million on an FX adjusted basis, mainly driven by increased equity income \nfrom our investment in Change Healthcare and continued strength in our MRxTS business.  Included in Other, \nadjusted eq uity income from Change Healthcare was $108 million for the quarter as compared to $64 million in \nthe prior period.  \n \n Let me take a minute and update you on our equity investment in Change Healthcare.  On June 27 of 2019, \nChange Healthcare began trading on t he Nasdaq.  This was an important milestone for Change Healthcare. ", "original_text": "Included in Other, \nadjusted eq uity income from Change Healthcare was $108 million for the quarter as compared to $64 million in \nthe prior period.  \n \n", "page_label": "7", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "99a20cddc9fe1223a09c2e089734b8fbc13f7464c488c2d6146b35680d7af187", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "80a2bea2-8f79-4384-8614-0af09979e2ce", "node_type": "1", "metadata": {"window": "Other adjusted \noperating profit increased 31% to $279 million on an FX adjusted basis, mainly driven by increased equity income \nfrom our investment in Change Healthcare and continued strength in our MRxTS business.  Included in Other, \nadjusted eq uity income from Change Healthcare was $108 million for the quarter as compared to $64 million in \nthe prior period.  \n \n Let me take a minute and update you on our equity investment in Change Healthcare.  On June 27 of 2019, \nChange Healthcare began trading on t he Nasdaq.  This was an important milestone for Change Healthcare.  While \nChange Healthcare is now a publicly -traded company, McKesson will continue to report the equity income from \nour interest in Change Healthcare based on our equity ownership percentage a nd we'll continue to report Change \nHealthcare results on a one -month lag.  ", "original_text": "On June 27 of 2019, \nChange Healthcare began trading on t he Nasdaq. "}, "hash": "342fdc74d8a79ac937cd7c9b6cc3fa71d86e11bff0328ac9f347bf260c7c1131", "class_name": "RelatedNodeInfo"}}, "text": "Let me take a minute and update you on our equity investment in Change Healthcare. ", "start_char_idx": 4015, "end_char_idx": 4098, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "80a2bea2-8f79-4384-8614-0af09979e2ce": {"__data__": {"id_": "80a2bea2-8f79-4384-8614-0af09979e2ce", "embedding": null, "metadata": {"window": "Other adjusted \noperating profit increased 31% to $279 million on an FX adjusted basis, mainly driven by increased equity income \nfrom our investment in Change Healthcare and continued strength in our MRxTS business.  Included in Other, \nadjusted eq uity income from Change Healthcare was $108 million for the quarter as compared to $64 million in \nthe prior period.  \n \n Let me take a minute and update you on our equity investment in Change Healthcare.  On June 27 of 2019, \nChange Healthcare began trading on t he Nasdaq.  This was an important milestone for Change Healthcare.  While \nChange Healthcare is now a publicly -traded company, McKesson will continue to report the equity income from \nour interest in Change Healthcare based on our equity ownership percentage a nd we'll continue to report Change \nHealthcare results on a one -month lag.  ", "original_text": "On June 27 of 2019, \nChange Healthcare began trading on t he Nasdaq. ", "page_label": "7", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "35248f45-6429-4b21-a274-8a0d5bf89987", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ff40d2d5dc0dba9a817069970d6b3d524f65b7bc0ecc61c92c5aca424bb597bd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8017e292-c84a-4d87-8736-eb240ab45205", "node_type": "1", "metadata": {"window": "On \nan FX adjusted basis, revenues grew 2% driven primarily by growth in our MRxTS  business.  Other adjusted \noperating profit increased 31% to $279 million on an FX adjusted basis, mainly driven by increased equity income \nfrom our investment in Change Healthcare and continued strength in our MRxTS business.  Included in Other, \nadjusted eq uity income from Change Healthcare was $108 million for the quarter as compared to $64 million in \nthe prior period.  \n \n Let me take a minute and update you on our equity investment in Change Healthcare.  On June 27 of 2019, \nChange Healthcare began trading on t he Nasdaq.  This was an important milestone for Change Healthcare.  While \nChange Healthcare is now a publicly -traded company, McKesson will continue to report the equity income from \nour interest in Change Healthcare based on our equity ownership percentage a nd we'll continue to report Change \nHealthcare results on a one -month lag.  ", "original_text": "Let me take a minute and update you on our equity investment in Change Healthcare. ", "page_label": "7", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8502c21115c7c17ea63733dc0cc4409194f1c07172dbd2b5d772523aed516224", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dcc3c2ef-0fd4-4e25-a7fa-bb58165f3beb", "node_type": "1", "metadata": {"window": "Included in Other, \nadjusted eq uity income from Change Healthcare was $108 million for the quarter as compared to $64 million in \nthe prior period.  \n \n Let me take a minute and update you on our equity investment in Change Healthcare.  On June 27 of 2019, \nChange Healthcare began trading on t he Nasdaq.  This was an important milestone for Change Healthcare.  While \nChange Healthcare is now a publicly -traded company, McKesson will continue to report the equity income from \nour interest in Change Healthcare based on our equity ownership percentage a nd we'll continue to report Change \nHealthcare results on a one -month lag.  ", "original_text": "This was an important milestone for Change Healthcare. "}, "hash": "81972bc99498957fb0291cb797f5259a96aaf834c15bede591be2f2696deec44", "class_name": "RelatedNodeInfo"}}, "text": "On June 27 of 2019, \nChange Healthcare began trading on t he Nasdaq. ", "start_char_idx": 4098, "end_char_idx": 4167, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dcc3c2ef-0fd4-4e25-a7fa-bb58165f3beb": {"__data__": {"id_": "dcc3c2ef-0fd4-4e25-a7fa-bb58165f3beb", "embedding": null, "metadata": {"window": "Included in Other, \nadjusted eq uity income from Change Healthcare was $108 million for the quarter as compared to $64 million in \nthe prior period.  \n \n Let me take a minute and update you on our equity investment in Change Healthcare.  On June 27 of 2019, \nChange Healthcare began trading on t he Nasdaq.  This was an important milestone for Change Healthcare.  While \nChange Healthcare is now a publicly -traded company, McKesson will continue to report the equity income from \nour interest in Change Healthcare based on our equity ownership percentage a nd we'll continue to report Change \nHealthcare results on a one -month lag.  ", "original_text": "This was an important milestone for Change Healthcare. ", "page_label": "7", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "35248f45-6429-4b21-a274-8a0d5bf89987", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ff40d2d5dc0dba9a817069970d6b3d524f65b7bc0ecc61c92c5aca424bb597bd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "80a2bea2-8f79-4384-8614-0af09979e2ce", "node_type": "1", "metadata": {"window": "Other adjusted \noperating profit increased 31% to $279 million on an FX adjusted basis, mainly driven by increased equity income \nfrom our investment in Change Healthcare and continued strength in our MRxTS business.  Included in Other, \nadjusted eq uity income from Change Healthcare was $108 million for the quarter as compared to $64 million in \nthe prior period.  \n \n Let me take a minute and update you on our equity investment in Change Healthcare.  On June 27 of 2019, \nChange Healthcare began trading on t he Nasdaq.  This was an important milestone for Change Healthcare.  While \nChange Healthcare is now a publicly -traded company, McKesson will continue to report the equity income from \nour interest in Change Healthcare based on our equity ownership percentage a nd we'll continue to report Change \nHealthcare results on a one -month lag.  ", "original_text": "On June 27 of 2019, \nChange Healthcare began trading on t he Nasdaq. ", "page_label": "7", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0d9ae1e6772870a599ef85c09b5165125c05eff952e34345777a8d989e6b3eb7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "306f4786-9b13-43c3-afba-a19ebbf2d0c8", "node_type": "1", "metadata": {"window": "Let me take a minute and update you on our equity investment in Change Healthcare.  On June 27 of 2019, \nChange Healthcare began trading on t he Nasdaq.  This was an important milestone for Change Healthcare.  While \nChange Healthcare is now a publicly -traded company, McKesson will continue to report the equity income from \nour interest in Change Healthcare based on our equity ownership percentage a nd we'll continue to report Change \nHealthcare results on a one -month lag.  ", "original_text": "While \nChange Healthcare is now a publicly -traded company, McKesson will continue to report the equity income from \nour interest in Change Healthcare based on our equity ownership percentage a nd we'll continue to report Change \nHealthcare results on a one -month lag.  "}, "hash": "9fd907aa12b93d47f4c42ccd58d084b511e583370d17759c65917a1bc59a5228", "class_name": "RelatedNodeInfo"}}, "text": "This was an important milestone for Change Healthcare. ", "start_char_idx": 4167, "end_char_idx": 4222, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "306f4786-9b13-43c3-afba-a19ebbf2d0c8": {"__data__": {"id_": "306f4786-9b13-43c3-afba-a19ebbf2d0c8", "embedding": null, "metadata": {"window": "Let me take a minute and update you on our equity investment in Change Healthcare.  On June 27 of 2019, \nChange Healthcare began trading on t he Nasdaq.  This was an important milestone for Change Healthcare.  While \nChange Healthcare is now a publicly -traded company, McKesson will continue to report the equity income from \nour interest in Change Healthcare based on our equity ownership percentage a nd we'll continue to report Change \nHealthcare results on a one -month lag.  ", "original_text": "While \nChange Healthcare is now a publicly -traded company, McKesson will continue to report the equity income from \nour interest in Change Healthcare based on our equity ownership percentage a nd we'll continue to report Change \nHealthcare results on a one -month lag.  ", "page_label": "7", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "35248f45-6429-4b21-a274-8a0d5bf89987", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ff40d2d5dc0dba9a817069970d6b3d524f65b7bc0ecc61c92c5aca424bb597bd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dcc3c2ef-0fd4-4e25-a7fa-bb58165f3beb", "node_type": "1", "metadata": {"window": "Included in Other, \nadjusted eq uity income from Change Healthcare was $108 million for the quarter as compared to $64 million in \nthe prior period.  \n \n Let me take a minute and update you on our equity investment in Change Healthcare.  On June 27 of 2019, \nChange Healthcare began trading on t he Nasdaq.  This was an important milestone for Change Healthcare.  While \nChange Healthcare is now a publicly -traded company, McKesson will continue to report the equity income from \nour interest in Change Healthcare based on our equity ownership percentage a nd we'll continue to report Change \nHealthcare results on a one -month lag.  ", "original_text": "This was an important milestone for Change Healthcare. ", "page_label": "7", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e1f1e6728278f1a1ae42d39dcf9b822e3244f69c10103f3714d7aea812af9e5d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c35d176f-8605-4d05-96ad-e30d0f300ae9", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nAs a result of the IPO, McKesson's equity ownership in Change Healthcare is approximately 58.5%, effective \nbeginning with McKesson's second quarter.  When taking into account McKesso n's new equity ownership \npercentage as well as Change Healthcare's repayment of long -term debt following the completion of its IPO, we \nanticipate the adjusted equity income attributable to our interest in Change Healthcare in fiscal 2020 to be \nunchanged fr om the prior range of $250 million to $270 million, which it assumes 70% ownership throughout fiscal \n2020.  \n \n I would point out that our adjusted equity interest assumption for Change Healthcare as well as our future results \nand commentary on Change Healthca re will be specific to McKesson's ownership interest based on the \nMcKesson definition of adjusted earnings, our equity ownership percentage in Change Healthcare, and the period \nfor which we are reporting which again will be on a one -month lag. ", "original_text": "McKesson Corp.  "}, "hash": "ccf2f7918799919e9cf121c6968de1626e2edfae1dfb8d195585c6114e9bb8f9", "class_name": "RelatedNodeInfo"}}, "text": "While \nChange Healthcare is now a publicly -traded company, McKesson will continue to report the equity income from \nour interest in Change Healthcare based on our equity ownership percentage a nd we'll continue to report Change \nHealthcare results on a one -month lag.  ", "start_char_idx": 4222, "end_char_idx": 4493, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c35d176f-8605-4d05-96ad-e30d0f300ae9": {"__data__": {"id_": "c35d176f-8605-4d05-96ad-e30d0f300ae9", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nAs a result of the IPO, McKesson's equity ownership in Change Healthcare is approximately 58.5%, effective \nbeginning with McKesson's second quarter.  When taking into account McKesso n's new equity ownership \npercentage as well as Change Healthcare's repayment of long -term debt following the completion of its IPO, we \nanticipate the adjusted equity income attributable to our interest in Change Healthcare in fiscal 2020 to be \nunchanged fr om the prior range of $250 million to $270 million, which it assumes 70% ownership throughout fiscal \n2020.  \n \n I would point out that our adjusted equity interest assumption for Change Healthcare as well as our future results \nand commentary on Change Healthca re will be specific to McKesson's ownership interest based on the \nMcKesson definition of adjusted earnings, our equity ownership percentage in Change Healthcare, and the period \nfor which we are reporting which again will be on a one -month lag. ", "original_text": "McKesson Corp.  ", "page_label": "8", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "68a8ea83-af8c-4d84-b574-69c27c2d1620", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "51657597309f60a3f2276ac016167f188501585cd83bd1ad682ca61ddd689734", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "306f4786-9b13-43c3-afba-a19ebbf2d0c8", "node_type": "1", "metadata": {"window": "Let me take a minute and update you on our equity investment in Change Healthcare.  On June 27 of 2019, \nChange Healthcare began trading on t he Nasdaq.  This was an important milestone for Change Healthcare.  While \nChange Healthcare is now a publicly -traded company, McKesson will continue to report the equity income from \nour interest in Change Healthcare based on our equity ownership percentage a nd we'll continue to report Change \nHealthcare results on a one -month lag.  ", "original_text": "While \nChange Healthcare is now a publicly -traded company, McKesson will continue to report the equity income from \nour interest in Change Healthcare based on our equity ownership percentage a nd we'll continue to report Change \nHealthcare results on a one -month lag.  ", "page_label": "7", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ad1382a64fc18a0dd2d508944697a91504f07abe6cbe651b7a24c342464566a9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5676d38f-85d5-49f5-92ec-1920e9318d62", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nAs a result of the IPO, McKesson's equity ownership in Change Healthcare is approximately 58.5%, effective \nbeginning with McKesson's second quarter.  When taking into account McKesso n's new equity ownership \npercentage as well as Change Healthcare's repayment of long -term debt following the completion of its IPO, we \nanticipate the adjusted equity income attributable to our interest in Change Healthcare in fiscal 2020 to be \nunchanged fr om the prior range of $250 million to $270 million, which it assumes 70% ownership throughout fiscal \n2020.  \n \n I would point out that our adjusted equity interest assumption for Change Healthcare as well as our future results \nand commentary on Change Healthca re will be specific to McKesson's ownership interest based on the \nMcKesson definition of adjusted earnings, our equity ownership percentage in Change Healthcare, and the period \nfor which we are reporting which again will be on a one -month lag.  Any question s related to the operating \nperformance or the outlook for Change Healthcare will be addressed by the Change management team.  \n \n", "original_text": "(MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nAs a result of the IPO, McKesson's equity ownership in Change Healthcare is approximately 58.5%, effective \nbeginning with McKesson's second quarter. "}, "hash": "7d92c3c8d1e898fd02feaa5754ab0e89e2388c314890863df164e1be08fc4d5b", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5676d38f-85d5-49f5-92ec-1920e9318d62": {"__data__": {"id_": "5676d38f-85d5-49f5-92ec-1920e9318d62", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nAs a result of the IPO, McKesson's equity ownership in Change Healthcare is approximately 58.5%, effective \nbeginning with McKesson's second quarter.  When taking into account McKesso n's new equity ownership \npercentage as well as Change Healthcare's repayment of long -term debt following the completion of its IPO, we \nanticipate the adjusted equity income attributable to our interest in Change Healthcare in fiscal 2020 to be \nunchanged fr om the prior range of $250 million to $270 million, which it assumes 70% ownership throughout fiscal \n2020.  \n \n I would point out that our adjusted equity interest assumption for Change Healthcare as well as our future results \nand commentary on Change Healthca re will be specific to McKesson's ownership interest based on the \nMcKesson definition of adjusted earnings, our equity ownership percentage in Change Healthcare, and the period \nfor which we are reporting which again will be on a one -month lag.  Any question s related to the operating \nperformance or the outlook for Change Healthcare will be addressed by the Change management team.  \n \n", "original_text": "(MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nAs a result of the IPO, McKesson's equity ownership in Change Healthcare is approximately 58.5%, effective \nbeginning with McKesson's second quarter. ", "page_label": "8", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "68a8ea83-af8c-4d84-b574-69c27c2d1620", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "51657597309f60a3f2276ac016167f188501585cd83bd1ad682ca61ddd689734", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c35d176f-8605-4d05-96ad-e30d0f300ae9", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nAs a result of the IPO, McKesson's equity ownership in Change Healthcare is approximately 58.5%, effective \nbeginning with McKesson's second quarter.  When taking into account McKesso n's new equity ownership \npercentage as well as Change Healthcare's repayment of long -term debt following the completion of its IPO, we \nanticipate the adjusted equity income attributable to our interest in Change Healthcare in fiscal 2020 to be \nunchanged fr om the prior range of $250 million to $270 million, which it assumes 70% ownership throughout fiscal \n2020.  \n \n I would point out that our adjusted equity interest assumption for Change Healthcare as well as our future results \nand commentary on Change Healthca re will be specific to McKesson's ownership interest based on the \nMcKesson definition of adjusted earnings, our equity ownership percentage in Change Healthcare, and the period \nfor which we are reporting which again will be on a one -month lag. ", "original_text": "McKesson Corp.  ", "page_label": "8", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0277c863540ceedb9c4742b2ed52cf1c5b34ea549ad684622b642ab10f2d399f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "988fea0d-f71e-49ed-bc3e-70cefb82da27", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nAs a result of the IPO, McKesson's equity ownership in Change Healthcare is approximately 58.5%, effective \nbeginning with McKesson's second quarter.  When taking into account McKesso n's new equity ownership \npercentage as well as Change Healthcare's repayment of long -term debt following the completion of its IPO, we \nanticipate the adjusted equity income attributable to our interest in Change Healthcare in fiscal 2020 to be \nunchanged fr om the prior range of $250 million to $270 million, which it assumes 70% ownership throughout fiscal \n2020.  \n \n I would point out that our adjusted equity interest assumption for Change Healthcare as well as our future results \nand commentary on Change Healthca re will be specific to McKesson's ownership interest based on the \nMcKesson definition of adjusted earnings, our equity ownership percentage in Change Healthcare, and the period \nfor which we are reporting which again will be on a one -month lag.  Any question s related to the operating \nperformance or the outlook for Change Healthcare will be addressed by the Change management team.  \n \n The IPO was an important next step in McKesson's efforts to unlock value for our shareholders, as we progress \ntowards exiting our investment in Change Healthcare in a tax -efficient manner. ", "original_text": "When taking into account McKesso n's new equity ownership \npercentage as well as Change Healthcare's repayment of long -term debt following the completion of its IPO, we \nanticipate the adjusted equity income attributable to our interest in Change Healthcare in fiscal 2020 to be \nunchanged fr om the prior range of $250 million to $270 million, which it assumes 70% ownership throughout fiscal \n2020.  \n \n"}, "hash": "91e117f57a166850116f6bc5e7987ca7bebf67def3fbf81d909827ab943a623e", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nAs a result of the IPO, McKesson's equity ownership in Change Healthcare is approximately 58.5%, effective \nbeginning with McKesson's second quarter. ", "start_char_idx": 16, "end_char_idx": 332, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "988fea0d-f71e-49ed-bc3e-70cefb82da27": {"__data__": {"id_": "988fea0d-f71e-49ed-bc3e-70cefb82da27", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nAs a result of the IPO, McKesson's equity ownership in Change Healthcare is approximately 58.5%, effective \nbeginning with McKesson's second quarter.  When taking into account McKesso n's new equity ownership \npercentage as well as Change Healthcare's repayment of long -term debt following the completion of its IPO, we \nanticipate the adjusted equity income attributable to our interest in Change Healthcare in fiscal 2020 to be \nunchanged fr om the prior range of $250 million to $270 million, which it assumes 70% ownership throughout fiscal \n2020.  \n \n I would point out that our adjusted equity interest assumption for Change Healthcare as well as our future results \nand commentary on Change Healthca re will be specific to McKesson's ownership interest based on the \nMcKesson definition of adjusted earnings, our equity ownership percentage in Change Healthcare, and the period \nfor which we are reporting which again will be on a one -month lag.  Any question s related to the operating \nperformance or the outlook for Change Healthcare will be addressed by the Change management team.  \n \n The IPO was an important next step in McKesson's efforts to unlock value for our shareholders, as we progress \ntowards exiting our investment in Change Healthcare in a tax -efficient manner. ", "original_text": "When taking into account McKesso n's new equity ownership \npercentage as well as Change Healthcare's repayment of long -term debt following the completion of its IPO, we \nanticipate the adjusted equity income attributable to our interest in Change Healthcare in fiscal 2020 to be \nunchanged fr om the prior range of $250 million to $270 million, which it assumes 70% ownership throughout fiscal \n2020.  \n \n", "page_label": "8", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "68a8ea83-af8c-4d84-b574-69c27c2d1620", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "51657597309f60a3f2276ac016167f188501585cd83bd1ad682ca61ddd689734", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5676d38f-85d5-49f5-92ec-1920e9318d62", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nAs a result of the IPO, McKesson's equity ownership in Change Healthcare is approximately 58.5%, effective \nbeginning with McKesson's second quarter.  When taking into account McKesso n's new equity ownership \npercentage as well as Change Healthcare's repayment of long -term debt following the completion of its IPO, we \nanticipate the adjusted equity income attributable to our interest in Change Healthcare in fiscal 2020 to be \nunchanged fr om the prior range of $250 million to $270 million, which it assumes 70% ownership throughout fiscal \n2020.  \n \n I would point out that our adjusted equity interest assumption for Change Healthcare as well as our future results \nand commentary on Change Healthca re will be specific to McKesson's ownership interest based on the \nMcKesson definition of adjusted earnings, our equity ownership percentage in Change Healthcare, and the period \nfor which we are reporting which again will be on a one -month lag.  Any question s related to the operating \nperformance or the outlook for Change Healthcare will be addressed by the Change management team.  \n \n", "original_text": "(MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nAs a result of the IPO, McKesson's equity ownership in Change Healthcare is approximately 58.5%, effective \nbeginning with McKesson's second quarter. ", "page_label": "8", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b7c06e47bd52a73be1cd9a049f3a4ec99e1c12aa1be0bd4cd072432b4b93b28a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "df50c38d-32a1-42e9-957f-e689dc6b3999", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nAs a result of the IPO, McKesson's equity ownership in Change Healthcare is approximately 58.5%, effective \nbeginning with McKesson's second quarter.  When taking into account McKesso n's new equity ownership \npercentage as well as Change Healthcare's repayment of long -term debt following the completion of its IPO, we \nanticipate the adjusted equity income attributable to our interest in Change Healthcare in fiscal 2020 to be \nunchanged fr om the prior range of $250 million to $270 million, which it assumes 70% ownership throughout fiscal \n2020.  \n \n I would point out that our adjusted equity interest assumption for Change Healthcare as well as our future results \nand commentary on Change Healthca re will be specific to McKesson's ownership interest based on the \nMcKesson definition of adjusted earnings, our equity ownership percentage in Change Healthcare, and the period \nfor which we are reporting which again will be on a one -month lag.  Any question s related to the operating \nperformance or the outlook for Change Healthcare will be addressed by the Change management team.  \n \n The IPO was an important next step in McKesson's efforts to unlock value for our shareholders, as we progress \ntowards exiting our investment in Change Healthcare in a tax -efficient manner.  As we've detailed in the past, \nthere are lock -up periods and other milestones which must be met prior to our exit which include: first, the \ncustomary six -month lock -up period following the IPO; the n Blackstone, our equity partner in Change Healthcare \nhas the opportunity to do a secondary offering covering up to a three -month period; following that there'd be a \nthree -month lock -up period.  \n \n", "original_text": "I would point out that our adjusted equity interest assumption for Change Healthcare as well as our future results \nand commentary on Change Healthca re will be specific to McKesson's ownership interest based on the \nMcKesson definition of adjusted earnings, our equity ownership percentage in Change Healthcare, and the period \nfor which we are reporting which again will be on a one -month lag. "}, "hash": "aea75abf3274019040e9018a59b294cedaf8c1122d3ada50fb8c1bad1f045d35", "class_name": "RelatedNodeInfo"}}, "text": "When taking into account McKesso n's new equity ownership \npercentage as well as Change Healthcare's repayment of long -term debt following the completion of its IPO, we \nanticipate the adjusted equity income attributable to our interest in Change Healthcare in fiscal 2020 to be \nunchanged fr om the prior range of $250 million to $270 million, which it assumes 70% ownership throughout fiscal \n2020.  \n \n", "start_char_idx": 332, "end_char_idx": 738, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "df50c38d-32a1-42e9-957f-e689dc6b3999": {"__data__": {"id_": "df50c38d-32a1-42e9-957f-e689dc6b3999", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nAs a result of the IPO, McKesson's equity ownership in Change Healthcare is approximately 58.5%, effective \nbeginning with McKesson's second quarter.  When taking into account McKesso n's new equity ownership \npercentage as well as Change Healthcare's repayment of long -term debt following the completion of its IPO, we \nanticipate the adjusted equity income attributable to our interest in Change Healthcare in fiscal 2020 to be \nunchanged fr om the prior range of $250 million to $270 million, which it assumes 70% ownership throughout fiscal \n2020.  \n \n I would point out that our adjusted equity interest assumption for Change Healthcare as well as our future results \nand commentary on Change Healthca re will be specific to McKesson's ownership interest based on the \nMcKesson definition of adjusted earnings, our equity ownership percentage in Change Healthcare, and the period \nfor which we are reporting which again will be on a one -month lag.  Any question s related to the operating \nperformance or the outlook for Change Healthcare will be addressed by the Change management team.  \n \n The IPO was an important next step in McKesson's efforts to unlock value for our shareholders, as we progress \ntowards exiting our investment in Change Healthcare in a tax -efficient manner.  As we've detailed in the past, \nthere are lock -up periods and other milestones which must be met prior to our exit which include: first, the \ncustomary six -month lock -up period following the IPO; the n Blackstone, our equity partner in Change Healthcare \nhas the opportunity to do a secondary offering covering up to a three -month period; following that there'd be a \nthree -month lock -up period.  \n \n", "original_text": "I would point out that our adjusted equity interest assumption for Change Healthcare as well as our future results \nand commentary on Change Healthca re will be specific to McKesson's ownership interest based on the \nMcKesson definition of adjusted earnings, our equity ownership percentage in Change Healthcare, and the period \nfor which we are reporting which again will be on a one -month lag. ", "page_label": "8", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "68a8ea83-af8c-4d84-b574-69c27c2d1620", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "51657597309f60a3f2276ac016167f188501585cd83bd1ad682ca61ddd689734", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "988fea0d-f71e-49ed-bc3e-70cefb82da27", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nAs a result of the IPO, McKesson's equity ownership in Change Healthcare is approximately 58.5%, effective \nbeginning with McKesson's second quarter.  When taking into account McKesso n's new equity ownership \npercentage as well as Change Healthcare's repayment of long -term debt following the completion of its IPO, we \nanticipate the adjusted equity income attributable to our interest in Change Healthcare in fiscal 2020 to be \nunchanged fr om the prior range of $250 million to $270 million, which it assumes 70% ownership throughout fiscal \n2020.  \n \n I would point out that our adjusted equity interest assumption for Change Healthcare as well as our future results \nand commentary on Change Healthca re will be specific to McKesson's ownership interest based on the \nMcKesson definition of adjusted earnings, our equity ownership percentage in Change Healthcare, and the period \nfor which we are reporting which again will be on a one -month lag.  Any question s related to the operating \nperformance or the outlook for Change Healthcare will be addressed by the Change management team.  \n \n The IPO was an important next step in McKesson's efforts to unlock value for our shareholders, as we progress \ntowards exiting our investment in Change Healthcare in a tax -efficient manner. ", "original_text": "When taking into account McKesso n's new equity ownership \npercentage as well as Change Healthcare's repayment of long -term debt following the completion of its IPO, we \nanticipate the adjusted equity income attributable to our interest in Change Healthcare in fiscal 2020 to be \nunchanged fr om the prior range of $250 million to $270 million, which it assumes 70% ownership throughout fiscal \n2020.  \n \n", "page_label": "8", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "34c2144c799fb7998a7f72202cabe5af53dd8e81f905f66b71d7ed6ddf59f85e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "27683b6a-c7a5-454f-bbe7-bb8a704d6a7f", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nAs a result of the IPO, McKesson's equity ownership in Change Healthcare is approximately 58.5%, effective \nbeginning with McKesson's second quarter.  When taking into account McKesso n's new equity ownership \npercentage as well as Change Healthcare's repayment of long -term debt following the completion of its IPO, we \nanticipate the adjusted equity income attributable to our interest in Change Healthcare in fiscal 2020 to be \nunchanged fr om the prior range of $250 million to $270 million, which it assumes 70% ownership throughout fiscal \n2020.  \n \n I would point out that our adjusted equity interest assumption for Change Healthcare as well as our future results \nand commentary on Change Healthca re will be specific to McKesson's ownership interest based on the \nMcKesson definition of adjusted earnings, our equity ownership percentage in Change Healthcare, and the period \nfor which we are reporting which again will be on a one -month lag.  Any question s related to the operating \nperformance or the outlook for Change Healthcare will be addressed by the Change management team.  \n \n The IPO was an important next step in McKesson's efforts to unlock value for our shareholders, as we progress \ntowards exiting our investment in Change Healthcare in a tax -efficient manner.  As we've detailed in the past, \nthere are lock -up periods and other milestones which must be met prior to our exit which include: first, the \ncustomary six -month lock -up period following the IPO; the n Blackstone, our equity partner in Change Healthcare \nhas the opportunity to do a secondary offering covering up to a three -month period; following that there'd be a \nthree -month lock -up period.  \n \n Given all of these factors, our exit could extend to a period  of 12 to 18 months. ", "original_text": "Any question s related to the operating \nperformance or the outlook for Change Healthcare will be addressed by the Change management team.  \n \n"}, "hash": "f650572051062a0001a7bf4e58f8c3a927cf9392414b0cce0de08cfbbbf9a244", "class_name": "RelatedNodeInfo"}}, "text": "I would point out that our adjusted equity interest assumption for Change Healthcare as well as our future results \nand commentary on Change Healthca re will be specific to McKesson's ownership interest based on the \nMcKesson definition of adjusted earnings, our equity ownership percentage in Change Healthcare, and the period \nfor which we are reporting which again will be on a one -month lag. ", "start_char_idx": 738, "end_char_idx": 1135, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "27683b6a-c7a5-454f-bbe7-bb8a704d6a7f": {"__data__": {"id_": "27683b6a-c7a5-454f-bbe7-bb8a704d6a7f", "embedding": null, "metadata": {"window": "(MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nAs a result of the IPO, McKesson's equity ownership in Change Healthcare is approximately 58.5%, effective \nbeginning with McKesson's second quarter.  When taking into account McKesso n's new equity ownership \npercentage as well as Change Healthcare's repayment of long -term debt following the completion of its IPO, we \nanticipate the adjusted equity income attributable to our interest in Change Healthcare in fiscal 2020 to be \nunchanged fr om the prior range of $250 million to $270 million, which it assumes 70% ownership throughout fiscal \n2020.  \n \n I would point out that our adjusted equity interest assumption for Change Healthcare as well as our future results \nand commentary on Change Healthca re will be specific to McKesson's ownership interest based on the \nMcKesson definition of adjusted earnings, our equity ownership percentage in Change Healthcare, and the period \nfor which we are reporting which again will be on a one -month lag.  Any question s related to the operating \nperformance or the outlook for Change Healthcare will be addressed by the Change management team.  \n \n The IPO was an important next step in McKesson's efforts to unlock value for our shareholders, as we progress \ntowards exiting our investment in Change Healthcare in a tax -efficient manner.  As we've detailed in the past, \nthere are lock -up periods and other milestones which must be met prior to our exit which include: first, the \ncustomary six -month lock -up period following the IPO; the n Blackstone, our equity partner in Change Healthcare \nhas the opportunity to do a secondary offering covering up to a three -month period; following that there'd be a \nthree -month lock -up period.  \n \n Given all of these factors, our exit could extend to a period  of 12 to 18 months. ", "original_text": "Any question s related to the operating \nperformance or the outlook for Change Healthcare will be addressed by the Change management team.  \n \n", "page_label": "8", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "68a8ea83-af8c-4d84-b574-69c27c2d1620", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "51657597309f60a3f2276ac016167f188501585cd83bd1ad682ca61ddd689734", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "df50c38d-32a1-42e9-957f-e689dc6b3999", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nAs a result of the IPO, McKesson's equity ownership in Change Healthcare is approximately 58.5%, effective \nbeginning with McKesson's second quarter.  When taking into account McKesso n's new equity ownership \npercentage as well as Change Healthcare's repayment of long -term debt following the completion of its IPO, we \nanticipate the adjusted equity income attributable to our interest in Change Healthcare in fiscal 2020 to be \nunchanged fr om the prior range of $250 million to $270 million, which it assumes 70% ownership throughout fiscal \n2020.  \n \n I would point out that our adjusted equity interest assumption for Change Healthcare as well as our future results \nand commentary on Change Healthca re will be specific to McKesson's ownership interest based on the \nMcKesson definition of adjusted earnings, our equity ownership percentage in Change Healthcare, and the period \nfor which we are reporting which again will be on a one -month lag.  Any question s related to the operating \nperformance or the outlook for Change Healthcare will be addressed by the Change management team.  \n \n The IPO was an important next step in McKesson's efforts to unlock value for our shareholders, as we progress \ntowards exiting our investment in Change Healthcare in a tax -efficient manner.  As we've detailed in the past, \nthere are lock -up periods and other milestones which must be met prior to our exit which include: first, the \ncustomary six -month lock -up period following the IPO; the n Blackstone, our equity partner in Change Healthcare \nhas the opportunity to do a secondary offering covering up to a three -month period; following that there'd be a \nthree -month lock -up period.  \n \n", "original_text": "I would point out that our adjusted equity interest assumption for Change Healthcare as well as our future results \nand commentary on Change Healthca re will be specific to McKesson's ownership interest based on the \nMcKesson definition of adjusted earnings, our equity ownership percentage in Change Healthcare, and the period \nfor which we are reporting which again will be on a one -month lag. ", "page_label": "8", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "07a89ec281f786b7298aaba01b0f2bd90687dee4ba00d389c857ca947321c50b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dd7f1690-258e-4e80-ae7f-e615eb035879", "node_type": "1", "metadata": {"window": "When taking into account McKesso n's new equity ownership \npercentage as well as Change Healthcare's repayment of long -term debt following the completion of its IPO, we \nanticipate the adjusted equity income attributable to our interest in Change Healthcare in fiscal 2020 to be \nunchanged fr om the prior range of $250 million to $270 million, which it assumes 70% ownership throughout fiscal \n2020.  \n \n I would point out that our adjusted equity interest assumption for Change Healthcare as well as our future results \nand commentary on Change Healthca re will be specific to McKesson's ownership interest based on the \nMcKesson definition of adjusted earnings, our equity ownership percentage in Change Healthcare, and the period \nfor which we are reporting which again will be on a one -month lag.  Any question s related to the operating \nperformance or the outlook for Change Healthcare will be addressed by the Change management team.  \n \n The IPO was an important next step in McKesson's efforts to unlock value for our shareholders, as we progress \ntowards exiting our investment in Change Healthcare in a tax -efficient manner.  As we've detailed in the past, \nthere are lock -up periods and other milestones which must be met prior to our exit which include: first, the \ncustomary six -month lock -up period following the IPO; the n Blackstone, our equity partner in Change Healthcare \nhas the opportunity to do a secondary offering covering up to a three -month period; following that there'd be a \nthree -month lock -up period.  \n \n Given all of these factors, our exit could extend to a period  of 12 to 18 months.  However, depending on the \nnecessity of certain milestones, we may have the opportunity to exit by the end of our fiscal 2020. ", "original_text": "The IPO was an important next step in McKesson's efforts to unlock value for our shareholders, as we progress \ntowards exiting our investment in Change Healthcare in a tax -efficient manner. "}, "hash": "f264cee5ec1f8f9ae2f2988bf060fe49c4fd81139988a579a5dad7717d65fc4a", "class_name": "RelatedNodeInfo"}}, "text": "Any question s related to the operating \nperformance or the outlook for Change Healthcare will be addressed by the Change management team.  \n \n", "start_char_idx": 1135, "end_char_idx": 1278, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dd7f1690-258e-4e80-ae7f-e615eb035879": {"__data__": {"id_": "dd7f1690-258e-4e80-ae7f-e615eb035879", "embedding": null, "metadata": {"window": "When taking into account McKesso n's new equity ownership \npercentage as well as Change Healthcare's repayment of long -term debt following the completion of its IPO, we \nanticipate the adjusted equity income attributable to our interest in Change Healthcare in fiscal 2020 to be \nunchanged fr om the prior range of $250 million to $270 million, which it assumes 70% ownership throughout fiscal \n2020.  \n \n I would point out that our adjusted equity interest assumption for Change Healthcare as well as our future results \nand commentary on Change Healthca re will be specific to McKesson's ownership interest based on the \nMcKesson definition of adjusted earnings, our equity ownership percentage in Change Healthcare, and the period \nfor which we are reporting which again will be on a one -month lag.  Any question s related to the operating \nperformance or the outlook for Change Healthcare will be addressed by the Change management team.  \n \n The IPO was an important next step in McKesson's efforts to unlock value for our shareholders, as we progress \ntowards exiting our investment in Change Healthcare in a tax -efficient manner.  As we've detailed in the past, \nthere are lock -up periods and other milestones which must be met prior to our exit which include: first, the \ncustomary six -month lock -up period following the IPO; the n Blackstone, our equity partner in Change Healthcare \nhas the opportunity to do a secondary offering covering up to a three -month period; following that there'd be a \nthree -month lock -up period.  \n \n Given all of these factors, our exit could extend to a period  of 12 to 18 months.  However, depending on the \nnecessity of certain milestones, we may have the opportunity to exit by the end of our fiscal 2020. ", "original_text": "The IPO was an important next step in McKesson's efforts to unlock value for our shareholders, as we progress \ntowards exiting our investment in Change Healthcare in a tax -efficient manner. ", "page_label": "8", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "68a8ea83-af8c-4d84-b574-69c27c2d1620", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "51657597309f60a3f2276ac016167f188501585cd83bd1ad682ca61ddd689734", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "27683b6a-c7a5-454f-bbe7-bb8a704d6a7f", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nAs a result of the IPO, McKesson's equity ownership in Change Healthcare is approximately 58.5%, effective \nbeginning with McKesson's second quarter.  When taking into account McKesso n's new equity ownership \npercentage as well as Change Healthcare's repayment of long -term debt following the completion of its IPO, we \nanticipate the adjusted equity income attributable to our interest in Change Healthcare in fiscal 2020 to be \nunchanged fr om the prior range of $250 million to $270 million, which it assumes 70% ownership throughout fiscal \n2020.  \n \n I would point out that our adjusted equity interest assumption for Change Healthcare as well as our future results \nand commentary on Change Healthca re will be specific to McKesson's ownership interest based on the \nMcKesson definition of adjusted earnings, our equity ownership percentage in Change Healthcare, and the period \nfor which we are reporting which again will be on a one -month lag.  Any question s related to the operating \nperformance or the outlook for Change Healthcare will be addressed by the Change management team.  \n \n The IPO was an important next step in McKesson's efforts to unlock value for our shareholders, as we progress \ntowards exiting our investment in Change Healthcare in a tax -efficient manner.  As we've detailed in the past, \nthere are lock -up periods and other milestones which must be met prior to our exit which include: first, the \ncustomary six -month lock -up period following the IPO; the n Blackstone, our equity partner in Change Healthcare \nhas the opportunity to do a secondary offering covering up to a three -month period; following that there'd be a \nthree -month lock -up period.  \n \n Given all of these factors, our exit could extend to a period  of 12 to 18 months. ", "original_text": "Any question s related to the operating \nperformance or the outlook for Change Healthcare will be addressed by the Change management team.  \n \n", "page_label": "8", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5298ec4001546c725e35e78f62b5f42c62d01d4dc83ead1d8b21ba327a8b9c30", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bc140cf5-7238-45bd-be39-1b15080e6c8b", "node_type": "1", "metadata": {"window": "I would point out that our adjusted equity interest assumption for Change Healthcare as well as our future results \nand commentary on Change Healthca re will be specific to McKesson's ownership interest based on the \nMcKesson definition of adjusted earnings, our equity ownership percentage in Change Healthcare, and the period \nfor which we are reporting which again will be on a one -month lag.  Any question s related to the operating \nperformance or the outlook for Change Healthcare will be addressed by the Change management team.  \n \n The IPO was an important next step in McKesson's efforts to unlock value for our shareholders, as we progress \ntowards exiting our investment in Change Healthcare in a tax -efficient manner.  As we've detailed in the past, \nthere are lock -up periods and other milestones which must be met prior to our exit which include: first, the \ncustomary six -month lock -up period following the IPO; the n Blackstone, our equity partner in Change Healthcare \nhas the opportunity to do a secondary offering covering up to a three -month period; following that there'd be a \nthree -month lock -up period.  \n \n Given all of these factors, our exit could extend to a period  of 12 to 18 months.  However, depending on the \nnecessity of certain milestones, we may have the opportunity to exit by the end of our fiscal 2020.  We will provide \nupdates as we progress through the respective lock -up periods and milestones, as we move clos er to our \neventual exit.  \n \n", "original_text": "As we've detailed in the past, \nthere are lock -up periods and other milestones which must be met prior to our exit which include: first, the \ncustomary six -month lock -up period following the IPO; the n Blackstone, our equity partner in Change Healthcare \nhas the opportunity to do a secondary offering covering up to a three -month period; following that there'd be a \nthree -month lock -up period.  \n \n"}, "hash": "89cc2098f7bdf8bd16b60d0414f341de9b7ff18cd80ff0453d3999b465a6cd8f", "class_name": "RelatedNodeInfo"}}, "text": "The IPO was an important next step in McKesson's efforts to unlock value for our shareholders, as we progress \ntowards exiting our investment in Change Healthcare in a tax -efficient manner. ", "start_char_idx": 1278, "end_char_idx": 1469, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bc140cf5-7238-45bd-be39-1b15080e6c8b": {"__data__": {"id_": "bc140cf5-7238-45bd-be39-1b15080e6c8b", "embedding": null, "metadata": {"window": "I would point out that our adjusted equity interest assumption for Change Healthcare as well as our future results \nand commentary on Change Healthca re will be specific to McKesson's ownership interest based on the \nMcKesson definition of adjusted earnings, our equity ownership percentage in Change Healthcare, and the period \nfor which we are reporting which again will be on a one -month lag.  Any question s related to the operating \nperformance or the outlook for Change Healthcare will be addressed by the Change management team.  \n \n The IPO was an important next step in McKesson's efforts to unlock value for our shareholders, as we progress \ntowards exiting our investment in Change Healthcare in a tax -efficient manner.  As we've detailed in the past, \nthere are lock -up periods and other milestones which must be met prior to our exit which include: first, the \ncustomary six -month lock -up period following the IPO; the n Blackstone, our equity partner in Change Healthcare \nhas the opportunity to do a secondary offering covering up to a three -month period; following that there'd be a \nthree -month lock -up period.  \n \n Given all of these factors, our exit could extend to a period  of 12 to 18 months.  However, depending on the \nnecessity of certain milestones, we may have the opportunity to exit by the end of our fiscal 2020.  We will provide \nupdates as we progress through the respective lock -up periods and milestones, as we move clos er to our \neventual exit.  \n \n", "original_text": "As we've detailed in the past, \nthere are lock -up periods and other milestones which must be met prior to our exit which include: first, the \ncustomary six -month lock -up period following the IPO; the n Blackstone, our equity partner in Change Healthcare \nhas the opportunity to do a secondary offering covering up to a three -month period; following that there'd be a \nthree -month lock -up period.  \n \n", "page_label": "8", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "68a8ea83-af8c-4d84-b574-69c27c2d1620", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "51657597309f60a3f2276ac016167f188501585cd83bd1ad682ca61ddd689734", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dd7f1690-258e-4e80-ae7f-e615eb035879", "node_type": "1", "metadata": {"window": "When taking into account McKesso n's new equity ownership \npercentage as well as Change Healthcare's repayment of long -term debt following the completion of its IPO, we \nanticipate the adjusted equity income attributable to our interest in Change Healthcare in fiscal 2020 to be \nunchanged fr om the prior range of $250 million to $270 million, which it assumes 70% ownership throughout fiscal \n2020.  \n \n I would point out that our adjusted equity interest assumption for Change Healthcare as well as our future results \nand commentary on Change Healthca re will be specific to McKesson's ownership interest based on the \nMcKesson definition of adjusted earnings, our equity ownership percentage in Change Healthcare, and the period \nfor which we are reporting which again will be on a one -month lag.  Any question s related to the operating \nperformance or the outlook for Change Healthcare will be addressed by the Change management team.  \n \n The IPO was an important next step in McKesson's efforts to unlock value for our shareholders, as we progress \ntowards exiting our investment in Change Healthcare in a tax -efficient manner.  As we've detailed in the past, \nthere are lock -up periods and other milestones which must be met prior to our exit which include: first, the \ncustomary six -month lock -up period following the IPO; the n Blackstone, our equity partner in Change Healthcare \nhas the opportunity to do a secondary offering covering up to a three -month period; following that there'd be a \nthree -month lock -up period.  \n \n Given all of these factors, our exit could extend to a period  of 12 to 18 months.  However, depending on the \nnecessity of certain milestones, we may have the opportunity to exit by the end of our fiscal 2020. ", "original_text": "The IPO was an important next step in McKesson's efforts to unlock value for our shareholders, as we progress \ntowards exiting our investment in Change Healthcare in a tax -efficient manner. ", "page_label": "8", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8ed2fa6a81df9c92c0b27f1ca90d901ed0e621680cc2d77c3d46fd61406c1a18", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "72eaffd6-305a-48da-8af0-22969316c03b", "node_type": "1", "metadata": {"window": "Any question s related to the operating \nperformance or the outlook for Change Healthcare will be addressed by the Change management team.  \n \n The IPO was an important next step in McKesson's efforts to unlock value for our shareholders, as we progress \ntowards exiting our investment in Change Healthcare in a tax -efficient manner.  As we've detailed in the past, \nthere are lock -up periods and other milestones which must be met prior to our exit which include: first, the \ncustomary six -month lock -up period following the IPO; the n Blackstone, our equity partner in Change Healthcare \nhas the opportunity to do a secondary offering covering up to a three -month period; following that there'd be a \nthree -month lock -up period.  \n \n Given all of these factors, our exit could extend to a period  of 12 to 18 months.  However, depending on the \nnecessity of certain milestones, we may have the opportunity to exit by the end of our fiscal 2020.  We will provide \nupdates as we progress through the respective lock -up periods and milestones, as we move clos er to our \neventual exit.  \n \n Moving now to corporate expenses. ", "original_text": "Given all of these factors, our exit could extend to a period  of 12 to 18 months. "}, "hash": "e20d7c2560b58e29fd5a6d49938f5fe0fc05344dd35c7fb240d30daddd4fd50b", "class_name": "RelatedNodeInfo"}}, "text": "As we've detailed in the past, \nthere are lock -up periods and other milestones which must be met prior to our exit which include: first, the \ncustomary six -month lock -up period following the IPO; the n Blackstone, our equity partner in Change Healthcare \nhas the opportunity to do a secondary offering covering up to a three -month period; following that there'd be a \nthree -month lock -up period.  \n \n", "start_char_idx": 1469, "end_char_idx": 1875, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "72eaffd6-305a-48da-8af0-22969316c03b": {"__data__": {"id_": "72eaffd6-305a-48da-8af0-22969316c03b", "embedding": null, "metadata": {"window": "Any question s related to the operating \nperformance or the outlook for Change Healthcare will be addressed by the Change management team.  \n \n The IPO was an important next step in McKesson's efforts to unlock value for our shareholders, as we progress \ntowards exiting our investment in Change Healthcare in a tax -efficient manner.  As we've detailed in the past, \nthere are lock -up periods and other milestones which must be met prior to our exit which include: first, the \ncustomary six -month lock -up period following the IPO; the n Blackstone, our equity partner in Change Healthcare \nhas the opportunity to do a secondary offering covering up to a three -month period; following that there'd be a \nthree -month lock -up period.  \n \n Given all of these factors, our exit could extend to a period  of 12 to 18 months.  However, depending on the \nnecessity of certain milestones, we may have the opportunity to exit by the end of our fiscal 2020.  We will provide \nupdates as we progress through the respective lock -up periods and milestones, as we move clos er to our \neventual exit.  \n \n Moving now to corporate expenses. ", "original_text": "Given all of these factors, our exit could extend to a period  of 12 to 18 months. ", "page_label": "8", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "68a8ea83-af8c-4d84-b574-69c27c2d1620", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "51657597309f60a3f2276ac016167f188501585cd83bd1ad682ca61ddd689734", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bc140cf5-7238-45bd-be39-1b15080e6c8b", "node_type": "1", "metadata": {"window": "I would point out that our adjusted equity interest assumption for Change Healthcare as well as our future results \nand commentary on Change Healthca re will be specific to McKesson's ownership interest based on the \nMcKesson definition of adjusted earnings, our equity ownership percentage in Change Healthcare, and the period \nfor which we are reporting which again will be on a one -month lag.  Any question s related to the operating \nperformance or the outlook for Change Healthcare will be addressed by the Change management team.  \n \n The IPO was an important next step in McKesson's efforts to unlock value for our shareholders, as we progress \ntowards exiting our investment in Change Healthcare in a tax -efficient manner.  As we've detailed in the past, \nthere are lock -up periods and other milestones which must be met prior to our exit which include: first, the \ncustomary six -month lock -up period following the IPO; the n Blackstone, our equity partner in Change Healthcare \nhas the opportunity to do a secondary offering covering up to a three -month period; following that there'd be a \nthree -month lock -up period.  \n \n Given all of these factors, our exit could extend to a period  of 12 to 18 months.  However, depending on the \nnecessity of certain milestones, we may have the opportunity to exit by the end of our fiscal 2020.  We will provide \nupdates as we progress through the respective lock -up periods and milestones, as we move clos er to our \neventual exit.  \n \n", "original_text": "As we've detailed in the past, \nthere are lock -up periods and other milestones which must be met prior to our exit which include: first, the \ncustomary six -month lock -up period following the IPO; the n Blackstone, our equity partner in Change Healthcare \nhas the opportunity to do a secondary offering covering up to a three -month period; following that there'd be a \nthree -month lock -up period.  \n \n", "page_label": "8", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1a6d8b93aa321ca121c57c24c2d1226f549cce20b35bd64a4563863a18e068b0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "68b2b4c3-1745-4804-8376-0702abd7db54", "node_type": "1", "metadata": {"window": "The IPO was an important next step in McKesson's efforts to unlock value for our shareholders, as we progress \ntowards exiting our investment in Change Healthcare in a tax -efficient manner.  As we've detailed in the past, \nthere are lock -up periods and other milestones which must be met prior to our exit which include: first, the \ncustomary six -month lock -up period following the IPO; the n Blackstone, our equity partner in Change Healthcare \nhas the opportunity to do a secondary offering covering up to a three -month period; following that there'd be a \nthree -month lock -up period.  \n \n Given all of these factors, our exit could extend to a period  of 12 to 18 months.  However, depending on the \nnecessity of certain milestones, we may have the opportunity to exit by the end of our fiscal 2020.  We will provide \nupdates as we progress through the respective lock -up periods and milestones, as we move clos er to our \neventual exit.  \n \n Moving now to corporate expenses.  McKesson recorded $137 million in adjusted corporate expenses in the first \nquarter, an increase of 44% compared to the prior year. ", "original_text": "However, depending on the \nnecessity of certain milestones, we may have the opportunity to exit by the end of our fiscal 2020. "}, "hash": "51d858fcd02b8cff6ac9211bbfda586be7157a030b6ab7f4be7a07e04210c199", "class_name": "RelatedNodeInfo"}}, "text": "Given all of these factors, our exit could extend to a period  of 12 to 18 months. ", "start_char_idx": 1875, "end_char_idx": 1958, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "68b2b4c3-1745-4804-8376-0702abd7db54": {"__data__": {"id_": "68b2b4c3-1745-4804-8376-0702abd7db54", "embedding": null, "metadata": {"window": "The IPO was an important next step in McKesson's efforts to unlock value for our shareholders, as we progress \ntowards exiting our investment in Change Healthcare in a tax -efficient manner.  As we've detailed in the past, \nthere are lock -up periods and other milestones which must be met prior to our exit which include: first, the \ncustomary six -month lock -up period following the IPO; the n Blackstone, our equity partner in Change Healthcare \nhas the opportunity to do a secondary offering covering up to a three -month period; following that there'd be a \nthree -month lock -up period.  \n \n Given all of these factors, our exit could extend to a period  of 12 to 18 months.  However, depending on the \nnecessity of certain milestones, we may have the opportunity to exit by the end of our fiscal 2020.  We will provide \nupdates as we progress through the respective lock -up periods and milestones, as we move clos er to our \neventual exit.  \n \n Moving now to corporate expenses.  McKesson recorded $137 million in adjusted corporate expenses in the first \nquarter, an increase of 44% compared to the prior year. ", "original_text": "However, depending on the \nnecessity of certain milestones, we may have the opportunity to exit by the end of our fiscal 2020. ", "page_label": "8", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "68a8ea83-af8c-4d84-b574-69c27c2d1620", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "51657597309f60a3f2276ac016167f188501585cd83bd1ad682ca61ddd689734", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "72eaffd6-305a-48da-8af0-22969316c03b", "node_type": "1", "metadata": {"window": "Any question s related to the operating \nperformance or the outlook for Change Healthcare will be addressed by the Change management team.  \n \n The IPO was an important next step in McKesson's efforts to unlock value for our shareholders, as we progress \ntowards exiting our investment in Change Healthcare in a tax -efficient manner.  As we've detailed in the past, \nthere are lock -up periods and other milestones which must be met prior to our exit which include: first, the \ncustomary six -month lock -up period following the IPO; the n Blackstone, our equity partner in Change Healthcare \nhas the opportunity to do a secondary offering covering up to a three -month period; following that there'd be a \nthree -month lock -up period.  \n \n Given all of these factors, our exit could extend to a period  of 12 to 18 months.  However, depending on the \nnecessity of certain milestones, we may have the opportunity to exit by the end of our fiscal 2020.  We will provide \nupdates as we progress through the respective lock -up periods and milestones, as we move clos er to our \neventual exit.  \n \n Moving now to corporate expenses. ", "original_text": "Given all of these factors, our exit could extend to a period  of 12 to 18 months. ", "page_label": "8", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f9a12033f0a5045e6986101f0a70241d64369e2895ad1f2dba09ace3062d2dc2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b41df749-69ce-4033-8f8a-a3a987f0d261", "node_type": "1", "metadata": {"window": "As we've detailed in the past, \nthere are lock -up periods and other milestones which must be met prior to our exit which include: first, the \ncustomary six -month lock -up period following the IPO; the n Blackstone, our equity partner in Change Healthcare \nhas the opportunity to do a secondary offering covering up to a three -month period; following that there'd be a \nthree -month lock -up period.  \n \n Given all of these factors, our exit could extend to a period  of 12 to 18 months.  However, depending on the \nnecessity of certain milestones, we may have the opportunity to exit by the end of our fiscal 2020.  We will provide \nupdates as we progress through the respective lock -up periods and milestones, as we move clos er to our \neventual exit.  \n \n Moving now to corporate expenses.  McKesson recorded $137 million in adjusted corporate expenses in the first \nquarter, an increase of 44% compared to the prior year.  The year -over-year growth was primarily driven by the \nincrease in  opioid -related litigation costs and the overall timing of technology investments in the fiscal year, \npartially offset by a one -time benefit recorded in the first quarter of approximately $0.10.  \n \n", "original_text": "We will provide \nupdates as we progress through the respective lock -up periods and milestones, as we move clos er to our \neventual exit.  \n \n"}, "hash": "11b3fe1095922fef22a266b3928c3c15b3faa832c9b612176af171ae8098ae29", "class_name": "RelatedNodeInfo"}}, "text": "However, depending on the \nnecessity of certain milestones, we may have the opportunity to exit by the end of our fiscal 2020. ", "start_char_idx": 1958, "end_char_idx": 2085, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b41df749-69ce-4033-8f8a-a3a987f0d261": {"__data__": {"id_": "b41df749-69ce-4033-8f8a-a3a987f0d261", "embedding": null, "metadata": {"window": "As we've detailed in the past, \nthere are lock -up periods and other milestones which must be met prior to our exit which include: first, the \ncustomary six -month lock -up period following the IPO; the n Blackstone, our equity partner in Change Healthcare \nhas the opportunity to do a secondary offering covering up to a three -month period; following that there'd be a \nthree -month lock -up period.  \n \n Given all of these factors, our exit could extend to a period  of 12 to 18 months.  However, depending on the \nnecessity of certain milestones, we may have the opportunity to exit by the end of our fiscal 2020.  We will provide \nupdates as we progress through the respective lock -up periods and milestones, as we move clos er to our \neventual exit.  \n \n Moving now to corporate expenses.  McKesson recorded $137 million in adjusted corporate expenses in the first \nquarter, an increase of 44% compared to the prior year.  The year -over-year growth was primarily driven by the \nincrease in  opioid -related litigation costs and the overall timing of technology investments in the fiscal year, \npartially offset by a one -time benefit recorded in the first quarter of approximately $0.10.  \n \n", "original_text": "We will provide \nupdates as we progress through the respective lock -up periods and milestones, as we move clos er to our \neventual exit.  \n \n", "page_label": "8", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "68a8ea83-af8c-4d84-b574-69c27c2d1620", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "51657597309f60a3f2276ac016167f188501585cd83bd1ad682ca61ddd689734", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "68b2b4c3-1745-4804-8376-0702abd7db54", "node_type": "1", "metadata": {"window": "The IPO was an important next step in McKesson's efforts to unlock value for our shareholders, as we progress \ntowards exiting our investment in Change Healthcare in a tax -efficient manner.  As we've detailed in the past, \nthere are lock -up periods and other milestones which must be met prior to our exit which include: first, the \ncustomary six -month lock -up period following the IPO; the n Blackstone, our equity partner in Change Healthcare \nhas the opportunity to do a secondary offering covering up to a three -month period; following that there'd be a \nthree -month lock -up period.  \n \n Given all of these factors, our exit could extend to a period  of 12 to 18 months.  However, depending on the \nnecessity of certain milestones, we may have the opportunity to exit by the end of our fiscal 2020.  We will provide \nupdates as we progress through the respective lock -up periods and milestones, as we move clos er to our \neventual exit.  \n \n Moving now to corporate expenses.  McKesson recorded $137 million in adjusted corporate expenses in the first \nquarter, an increase of 44% compared to the prior year. ", "original_text": "However, depending on the \nnecessity of certain milestones, we may have the opportunity to exit by the end of our fiscal 2020. ", "page_label": "8", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a80ecf1d6c08811f4e89f9a953fe23fce36cd966b5a35668ad948518bce39d8a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "899de88f-9883-4b62-9289-82b3a67d8683", "node_type": "1", "metadata": {"window": "Given all of these factors, our exit could extend to a period  of 12 to 18 months.  However, depending on the \nnecessity of certain milestones, we may have the opportunity to exit by the end of our fiscal 2020.  We will provide \nupdates as we progress through the respective lock -up periods and milestones, as we move clos er to our \neventual exit.  \n \n Moving now to corporate expenses.  McKesson recorded $137 million in adjusted corporate expenses in the first \nquarter, an increase of 44% compared to the prior year.  The year -over-year growth was primarily driven by the \nincrease in  opioid -related litigation costs and the overall timing of technology investments in the fiscal year, \npartially offset by a one -time benefit recorded in the first quarter of approximately $0.10.  \n \n As it relates to opioid -related litigation costs, McKesson recorded $36 million in expenses in the first quarter. ", "original_text": "Moving now to corporate expenses. "}, "hash": "9c259eb02eb6e3f2d688e0ad676a62a7d03a8f19a5a99bdba1862b77c844c774", "class_name": "RelatedNodeInfo"}}, "text": "We will provide \nupdates as we progress through the respective lock -up periods and milestones, as we move clos er to our \neventual exit.  \n \n", "start_char_idx": 2085, "end_char_idx": 2227, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "899de88f-9883-4b62-9289-82b3a67d8683": {"__data__": {"id_": "899de88f-9883-4b62-9289-82b3a67d8683", "embedding": null, "metadata": {"window": "Given all of these factors, our exit could extend to a period  of 12 to 18 months.  However, depending on the \nnecessity of certain milestones, we may have the opportunity to exit by the end of our fiscal 2020.  We will provide \nupdates as we progress through the respective lock -up periods and milestones, as we move clos er to our \neventual exit.  \n \n Moving now to corporate expenses.  McKesson recorded $137 million in adjusted corporate expenses in the first \nquarter, an increase of 44% compared to the prior year.  The year -over-year growth was primarily driven by the \nincrease in  opioid -related litigation costs and the overall timing of technology investments in the fiscal year, \npartially offset by a one -time benefit recorded in the first quarter of approximately $0.10.  \n \n As it relates to opioid -related litigation costs, McKesson recorded $36 million in expenses in the first quarter. ", "original_text": "Moving now to corporate expenses. ", "page_label": "8", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "68a8ea83-af8c-4d84-b574-69c27c2d1620", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "51657597309f60a3f2276ac016167f188501585cd83bd1ad682ca61ddd689734", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b41df749-69ce-4033-8f8a-a3a987f0d261", "node_type": "1", "metadata": {"window": "As we've detailed in the past, \nthere are lock -up periods and other milestones which must be met prior to our exit which include: first, the \ncustomary six -month lock -up period following the IPO; the n Blackstone, our equity partner in Change Healthcare \nhas the opportunity to do a secondary offering covering up to a three -month period; following that there'd be a \nthree -month lock -up period.  \n \n Given all of these factors, our exit could extend to a period  of 12 to 18 months.  However, depending on the \nnecessity of certain milestones, we may have the opportunity to exit by the end of our fiscal 2020.  We will provide \nupdates as we progress through the respective lock -up periods and milestones, as we move clos er to our \neventual exit.  \n \n Moving now to corporate expenses.  McKesson recorded $137 million in adjusted corporate expenses in the first \nquarter, an increase of 44% compared to the prior year.  The year -over-year growth was primarily driven by the \nincrease in  opioid -related litigation costs and the overall timing of technology investments in the fiscal year, \npartially offset by a one -time benefit recorded in the first quarter of approximately $0.10.  \n \n", "original_text": "We will provide \nupdates as we progress through the respective lock -up periods and milestones, as we move clos er to our \neventual exit.  \n \n", "page_label": "8", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "27d919841e242957ba0f0869d5201de74ab49095ffe46f82b50602dcb86cb86c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "95615329-8ee7-4b7f-8d73-a0ad967debaf", "node_type": "1", "metadata": {"window": "However, depending on the \nnecessity of certain milestones, we may have the opportunity to exit by the end of our fiscal 2020.  We will provide \nupdates as we progress through the respective lock -up periods and milestones, as we move clos er to our \neventual exit.  \n \n Moving now to corporate expenses.  McKesson recorded $137 million in adjusted corporate expenses in the first \nquarter, an increase of 44% compared to the prior year.  The year -over-year growth was primarily driven by the \nincrease in  opioid -related litigation costs and the overall timing of technology investments in the fiscal year, \npartially offset by a one -time benefit recorded in the first quarter of approximately $0.10.  \n \n As it relates to opioid -related litigation costs, McKesson recorded $36 million in expenses in the first quarter.  We \ncontinue to assume opioid -related litigation costs will be approximately $150 million in fiscal 2020. ", "original_text": "McKesson recorded $137 million in adjusted corporate expenses in the first \nquarter, an increase of 44% compared to the prior year. "}, "hash": "4e87fb6d729fc0c7042ca9cfe71dc51249e6361609e0a2ec8473176f775975d2", "class_name": "RelatedNodeInfo"}}, "text": "Moving now to corporate expenses. ", "start_char_idx": 2227, "end_char_idx": 2261, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "95615329-8ee7-4b7f-8d73-a0ad967debaf": {"__data__": {"id_": "95615329-8ee7-4b7f-8d73-a0ad967debaf", "embedding": null, "metadata": {"window": "However, depending on the \nnecessity of certain milestones, we may have the opportunity to exit by the end of our fiscal 2020.  We will provide \nupdates as we progress through the respective lock -up periods and milestones, as we move clos er to our \neventual exit.  \n \n Moving now to corporate expenses.  McKesson recorded $137 million in adjusted corporate expenses in the first \nquarter, an increase of 44% compared to the prior year.  The year -over-year growth was primarily driven by the \nincrease in  opioid -related litigation costs and the overall timing of technology investments in the fiscal year, \npartially offset by a one -time benefit recorded in the first quarter of approximately $0.10.  \n \n As it relates to opioid -related litigation costs, McKesson recorded $36 million in expenses in the first quarter.  We \ncontinue to assume opioid -related litigation costs will be approximately $150 million in fiscal 2020. ", "original_text": "McKesson recorded $137 million in adjusted corporate expenses in the first \nquarter, an increase of 44% compared to the prior year. ", "page_label": "8", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "68a8ea83-af8c-4d84-b574-69c27c2d1620", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "51657597309f60a3f2276ac016167f188501585cd83bd1ad682ca61ddd689734", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "899de88f-9883-4b62-9289-82b3a67d8683", "node_type": "1", "metadata": {"window": "Given all of these factors, our exit could extend to a period  of 12 to 18 months.  However, depending on the \nnecessity of certain milestones, we may have the opportunity to exit by the end of our fiscal 2020.  We will provide \nupdates as we progress through the respective lock -up periods and milestones, as we move clos er to our \neventual exit.  \n \n Moving now to corporate expenses.  McKesson recorded $137 million in adjusted corporate expenses in the first \nquarter, an increase of 44% compared to the prior year.  The year -over-year growth was primarily driven by the \nincrease in  opioid -related litigation costs and the overall timing of technology investments in the fiscal year, \npartially offset by a one -time benefit recorded in the first quarter of approximately $0.10.  \n \n As it relates to opioid -related litigation costs, McKesson recorded $36 million in expenses in the first quarter. ", "original_text": "Moving now to corporate expenses. ", "page_label": "8", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e8f9ec83c73a86a79eee97c5d91de441bc0ca68fa7f4c6df627a553da9a705cb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2691fd8f-96f3-4413-97ef-a8af8e0f8012", "node_type": "1", "metadata": {"window": "We will provide \nupdates as we progress through the respective lock -up periods and milestones, as we move clos er to our \neventual exit.  \n \n Moving now to corporate expenses.  McKesson recorded $137 million in adjusted corporate expenses in the first \nquarter, an increase of 44% compared to the prior year.  The year -over-year growth was primarily driven by the \nincrease in  opioid -related litigation costs and the overall timing of technology investments in the fiscal year, \npartially offset by a one -time benefit recorded in the first quarter of approximately $0.10.  \n \n As it relates to opioid -related litigation costs, McKesson recorded $36 million in expenses in the first quarter.  We \ncontinue to assume opioid -related litigation costs will be approximately $150 million in fiscal 2020.  Based on the \none-time benefit recorded in the first quarter, we now anticipate corporate expense s to be on the low end of the \noriginal assumption of $725 million to $775 million.  \n \n", "original_text": "The year -over-year growth was primarily driven by the \nincrease in  opioid -related litigation costs and the overall timing of technology investments in the fiscal year, \npartially offset by a one -time benefit recorded in the first quarter of approximately $0.10.  \n \n"}, "hash": "ba3858fa2f363a817caf961c6789e4368727331fccf557c0363552e3dff5357a", "class_name": "RelatedNodeInfo"}}, "text": "McKesson recorded $137 million in adjusted corporate expenses in the first \nquarter, an increase of 44% compared to the prior year. ", "start_char_idx": 2261, "end_char_idx": 2393, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2691fd8f-96f3-4413-97ef-a8af8e0f8012": {"__data__": {"id_": "2691fd8f-96f3-4413-97ef-a8af8e0f8012", "embedding": null, "metadata": {"window": "We will provide \nupdates as we progress through the respective lock -up periods and milestones, as we move clos er to our \neventual exit.  \n \n Moving now to corporate expenses.  McKesson recorded $137 million in adjusted corporate expenses in the first \nquarter, an increase of 44% compared to the prior year.  The year -over-year growth was primarily driven by the \nincrease in  opioid -related litigation costs and the overall timing of technology investments in the fiscal year, \npartially offset by a one -time benefit recorded in the first quarter of approximately $0.10.  \n \n As it relates to opioid -related litigation costs, McKesson recorded $36 million in expenses in the first quarter.  We \ncontinue to assume opioid -related litigation costs will be approximately $150 million in fiscal 2020.  Based on the \none-time benefit recorded in the first quarter, we now anticipate corporate expense s to be on the low end of the \noriginal assumption of $725 million to $775 million.  \n \n", "original_text": "The year -over-year growth was primarily driven by the \nincrease in  opioid -related litigation costs and the overall timing of technology investments in the fiscal year, \npartially offset by a one -time benefit recorded in the first quarter of approximately $0.10.  \n \n", "page_label": "8", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "68a8ea83-af8c-4d84-b574-69c27c2d1620", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "51657597309f60a3f2276ac016167f188501585cd83bd1ad682ca61ddd689734", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "95615329-8ee7-4b7f-8d73-a0ad967debaf", "node_type": "1", "metadata": {"window": "However, depending on the \nnecessity of certain milestones, we may have the opportunity to exit by the end of our fiscal 2020.  We will provide \nupdates as we progress through the respective lock -up periods and milestones, as we move clos er to our \neventual exit.  \n \n Moving now to corporate expenses.  McKesson recorded $137 million in adjusted corporate expenses in the first \nquarter, an increase of 44% compared to the prior year.  The year -over-year growth was primarily driven by the \nincrease in  opioid -related litigation costs and the overall timing of technology investments in the fiscal year, \npartially offset by a one -time benefit recorded in the first quarter of approximately $0.10.  \n \n As it relates to opioid -related litigation costs, McKesson recorded $36 million in expenses in the first quarter.  We \ncontinue to assume opioid -related litigation costs will be approximately $150 million in fiscal 2020. ", "original_text": "McKesson recorded $137 million in adjusted corporate expenses in the first \nquarter, an increase of 44% compared to the prior year. ", "page_label": "8", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2e0f6ca65b429a5d3396df0261b3c893b574f0459ddb13b4b449e591790b8900", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cdd9d0a3-e9f6-413b-b113-1cde4ad6b6c6", "node_type": "1", "metadata": {"window": "Moving now to corporate expenses.  McKesson recorded $137 million in adjusted corporate expenses in the first \nquarter, an increase of 44% compared to the prior year.  The year -over-year growth was primarily driven by the \nincrease in  opioid -related litigation costs and the overall timing of technology investments in the fiscal year, \npartially offset by a one -time benefit recorded in the first quarter of approximately $0.10.  \n \n As it relates to opioid -related litigation costs, McKesson recorded $36 million in expenses in the first quarter.  We \ncontinue to assume opioid -related litigation costs will be approximately $150 million in fiscal 2020.  Based on the \none-time benefit recorded in the first quarter, we now anticipate corporate expense s to be on the low end of the \noriginal assumption of $725 million to $775 million.  \n \n Turning now to cash, which can be found on slide 9. ", "original_text": "As it relates to opioid -related litigation costs, McKesson recorded $36 million in expenses in the first quarter. "}, "hash": "c89940a2da5f591a10708037918c84ceea7f880891c96fe78e86e9c2dfbe1849", "class_name": "RelatedNodeInfo"}}, "text": "The year -over-year growth was primarily driven by the \nincrease in  opioid -related litigation costs and the overall timing of technology investments in the fiscal year, \npartially offset by a one -time benefit recorded in the first quarter of approximately $0.10.  \n \n", "start_char_idx": 2393, "end_char_idx": 2663, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cdd9d0a3-e9f6-413b-b113-1cde4ad6b6c6": {"__data__": {"id_": "cdd9d0a3-e9f6-413b-b113-1cde4ad6b6c6", "embedding": null, "metadata": {"window": "Moving now to corporate expenses.  McKesson recorded $137 million in adjusted corporate expenses in the first \nquarter, an increase of 44% compared to the prior year.  The year -over-year growth was primarily driven by the \nincrease in  opioid -related litigation costs and the overall timing of technology investments in the fiscal year, \npartially offset by a one -time benefit recorded in the first quarter of approximately $0.10.  \n \n As it relates to opioid -related litigation costs, McKesson recorded $36 million in expenses in the first quarter.  We \ncontinue to assume opioid -related litigation costs will be approximately $150 million in fiscal 2020.  Based on the \none-time benefit recorded in the first quarter, we now anticipate corporate expense s to be on the low end of the \noriginal assumption of $725 million to $775 million.  \n \n Turning now to cash, which can be found on slide 9. ", "original_text": "As it relates to opioid -related litigation costs, McKesson recorded $36 million in expenses in the first quarter. ", "page_label": "8", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "68a8ea83-af8c-4d84-b574-69c27c2d1620", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "51657597309f60a3f2276ac016167f188501585cd83bd1ad682ca61ddd689734", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2691fd8f-96f3-4413-97ef-a8af8e0f8012", "node_type": "1", "metadata": {"window": "We will provide \nupdates as we progress through the respective lock -up periods and milestones, as we move clos er to our \neventual exit.  \n \n Moving now to corporate expenses.  McKesson recorded $137 million in adjusted corporate expenses in the first \nquarter, an increase of 44% compared to the prior year.  The year -over-year growth was primarily driven by the \nincrease in  opioid -related litigation costs and the overall timing of technology investments in the fiscal year, \npartially offset by a one -time benefit recorded in the first quarter of approximately $0.10.  \n \n As it relates to opioid -related litigation costs, McKesson recorded $36 million in expenses in the first quarter.  We \ncontinue to assume opioid -related litigation costs will be approximately $150 million in fiscal 2020.  Based on the \none-time benefit recorded in the first quarter, we now anticipate corporate expense s to be on the low end of the \noriginal assumption of $725 million to $775 million.  \n \n", "original_text": "The year -over-year growth was primarily driven by the \nincrease in  opioid -related litigation costs and the overall timing of technology investments in the fiscal year, \npartially offset by a one -time benefit recorded in the first quarter of approximately $0.10.  \n \n", "page_label": "8", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "829a4d7f924805f555b8088679460bb81fe7fca3093be1ec9a5867ea01ff6772", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "813b5037-8a7c-4015-bfbf-04fa8de582e9", "node_type": "1", "metadata": {"window": "McKesson recorded $137 million in adjusted corporate expenses in the first \nquarter, an increase of 44% compared to the prior year.  The year -over-year growth was primarily driven by the \nincrease in  opioid -related litigation costs and the overall timing of technology investments in the fiscal year, \npartially offset by a one -time benefit recorded in the first quarter of approximately $0.10.  \n \n As it relates to opioid -related litigation costs, McKesson recorded $36 million in expenses in the first quarter.  We \ncontinue to assume opioid -related litigation costs will be approximately $150 million in fiscal 2020.  Based on the \none-time benefit recorded in the first quarter, we now anticipate corporate expense s to be on the low end of the \noriginal assumption of $725 million to $775 million.  \n \n Turning now to cash, which can be found on slide 9.  We ended the quarter with a cash balance of $1.9 billion. \n", "original_text": "We \ncontinue to assume opioid -related litigation costs will be approximately $150 million in fiscal 2020. "}, "hash": "01f6942d9407d07ac1ab008a11c47d721d6b39d0a84701a8ea05e358ef44eb41", "class_name": "RelatedNodeInfo"}}, "text": "As it relates to opioid -related litigation costs, McKesson recorded $36 million in expenses in the first quarter. ", "start_char_idx": 2663, "end_char_idx": 2778, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "813b5037-8a7c-4015-bfbf-04fa8de582e9": {"__data__": {"id_": "813b5037-8a7c-4015-bfbf-04fa8de582e9", "embedding": null, "metadata": {"window": "McKesson recorded $137 million in adjusted corporate expenses in the first \nquarter, an increase of 44% compared to the prior year.  The year -over-year growth was primarily driven by the \nincrease in  opioid -related litigation costs and the overall timing of technology investments in the fiscal year, \npartially offset by a one -time benefit recorded in the first quarter of approximately $0.10.  \n \n As it relates to opioid -related litigation costs, McKesson recorded $36 million in expenses in the first quarter.  We \ncontinue to assume opioid -related litigation costs will be approximately $150 million in fiscal 2020.  Based on the \none-time benefit recorded in the first quarter, we now anticipate corporate expense s to be on the low end of the \noriginal assumption of $725 million to $775 million.  \n \n Turning now to cash, which can be found on slide 9.  We ended the quarter with a cash balance of $1.9 billion. \n", "original_text": "We \ncontinue to assume opioid -related litigation costs will be approximately $150 million in fiscal 2020. ", "page_label": "8", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "68a8ea83-af8c-4d84-b574-69c27c2d1620", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "51657597309f60a3f2276ac016167f188501585cd83bd1ad682ca61ddd689734", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cdd9d0a3-e9f6-413b-b113-1cde4ad6b6c6", "node_type": "1", "metadata": {"window": "Moving now to corporate expenses.  McKesson recorded $137 million in adjusted corporate expenses in the first \nquarter, an increase of 44% compared to the prior year.  The year -over-year growth was primarily driven by the \nincrease in  opioid -related litigation costs and the overall timing of technology investments in the fiscal year, \npartially offset by a one -time benefit recorded in the first quarter of approximately $0.10.  \n \n As it relates to opioid -related litigation costs, McKesson recorded $36 million in expenses in the first quarter.  We \ncontinue to assume opioid -related litigation costs will be approximately $150 million in fiscal 2020.  Based on the \none-time benefit recorded in the first quarter, we now anticipate corporate expense s to be on the low end of the \noriginal assumption of $725 million to $775 million.  \n \n Turning now to cash, which can be found on slide 9. ", "original_text": "As it relates to opioid -related litigation costs, McKesson recorded $36 million in expenses in the first quarter. ", "page_label": "8", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cf61676167b9811ebf4b93a4698268982105de04fb2117ead0c1b8dc6e249413", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1fbb3e6e-2b69-47b8-bf12-b4252545c8f2", "node_type": "1", "metadata": {"window": "The year -over-year growth was primarily driven by the \nincrease in  opioid -related litigation costs and the overall timing of technology investments in the fiscal year, \npartially offset by a one -time benefit recorded in the first quarter of approximately $0.10.  \n \n As it relates to opioid -related litigation costs, McKesson recorded $36 million in expenses in the first quarter.  We \ncontinue to assume opioid -related litigation costs will be approximately $150 million in fiscal 2020.  Based on the \none-time benefit recorded in the first quarter, we now anticipate corporate expense s to be on the low end of the \noriginal assumption of $725 million to $775 million.  \n \n Turning now to cash, which can be found on slide 9.  We ended the quarter with a cash balance of $1.9 billion. \n During the quarter, we had negative free cash flow of $162 million. ", "original_text": "Based on the \none-time benefit recorded in the first quarter, we now anticipate corporate expense s to be on the low end of the \noriginal assumption of $725 million to $775 million.  \n \n"}, "hash": "8fc2e93a72abcec5560ce9fa09d0309d8108dda79fa331943cb13c290eccbaa8", "class_name": "RelatedNodeInfo"}}, "text": "We \ncontinue to assume opioid -related litigation costs will be approximately $150 million in fiscal 2020. ", "start_char_idx": 2778, "end_char_idx": 2885, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1fbb3e6e-2b69-47b8-bf12-b4252545c8f2": {"__data__": {"id_": "1fbb3e6e-2b69-47b8-bf12-b4252545c8f2", "embedding": null, "metadata": {"window": "The year -over-year growth was primarily driven by the \nincrease in  opioid -related litigation costs and the overall timing of technology investments in the fiscal year, \npartially offset by a one -time benefit recorded in the first quarter of approximately $0.10.  \n \n As it relates to opioid -related litigation costs, McKesson recorded $36 million in expenses in the first quarter.  We \ncontinue to assume opioid -related litigation costs will be approximately $150 million in fiscal 2020.  Based on the \none-time benefit recorded in the first quarter, we now anticipate corporate expense s to be on the low end of the \noriginal assumption of $725 million to $775 million.  \n \n Turning now to cash, which can be found on slide 9.  We ended the quarter with a cash balance of $1.9 billion. \n During the quarter, we had negative free cash flow of $162 million. ", "original_text": "Based on the \none-time benefit recorded in the first quarter, we now anticipate corporate expense s to be on the low end of the \noriginal assumption of $725 million to $775 million.  \n \n", "page_label": "8", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "68a8ea83-af8c-4d84-b574-69c27c2d1620", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "51657597309f60a3f2276ac016167f188501585cd83bd1ad682ca61ddd689734", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "813b5037-8a7c-4015-bfbf-04fa8de582e9", "node_type": "1", "metadata": {"window": "McKesson recorded $137 million in adjusted corporate expenses in the first \nquarter, an increase of 44% compared to the prior year.  The year -over-year growth was primarily driven by the \nincrease in  opioid -related litigation costs and the overall timing of technology investments in the fiscal year, \npartially offset by a one -time benefit recorded in the first quarter of approximately $0.10.  \n \n As it relates to opioid -related litigation costs, McKesson recorded $36 million in expenses in the first quarter.  We \ncontinue to assume opioid -related litigation costs will be approximately $150 million in fiscal 2020.  Based on the \none-time benefit recorded in the first quarter, we now anticipate corporate expense s to be on the low end of the \noriginal assumption of $725 million to $775 million.  \n \n Turning now to cash, which can be found on slide 9.  We ended the quarter with a cash balance of $1.9 billion. \n", "original_text": "We \ncontinue to assume opioid -related litigation costs will be approximately $150 million in fiscal 2020. ", "page_label": "8", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a4ea643623a8aebf59461792bb9f60e3d16b39fe41de4308083a1bbe20431eeb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1722b56d-c6fd-469c-b271-e08e8c6f0ad9", "node_type": "1", "metadata": {"window": "As it relates to opioid -related litigation costs, McKesson recorded $36 million in expenses in the first quarter.  We \ncontinue to assume opioid -related litigation costs will be approximately $150 million in fiscal 2020.  Based on the \none-time benefit recorded in the first quarter, we now anticipate corporate expense s to be on the low end of the \noriginal assumption of $725 million to $775 million.  \n \n Turning now to cash, which can be found on slide 9.  We ended the quarter with a cash balance of $1.9 billion. \n During the quarter, we had negative free cash flow of $162 million.  This performance was ahead of our \nexpectations. ", "original_text": "Turning now to cash, which can be found on slide 9. "}, "hash": "152a7b95caa883737d2f1b36950702a91e0ccbbe29ba1f2ca6e2f3cfc2680e54", "class_name": "RelatedNodeInfo"}}, "text": "Based on the \none-time benefit recorded in the first quarter, we now anticipate corporate expense s to be on the low end of the \noriginal assumption of $725 million to $775 million.  \n \n", "start_char_idx": 2885, "end_char_idx": 3071, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1722b56d-c6fd-469c-b271-e08e8c6f0ad9": {"__data__": {"id_": "1722b56d-c6fd-469c-b271-e08e8c6f0ad9", "embedding": null, "metadata": {"window": "As it relates to opioid -related litigation costs, McKesson recorded $36 million in expenses in the first quarter.  We \ncontinue to assume opioid -related litigation costs will be approximately $150 million in fiscal 2020.  Based on the \none-time benefit recorded in the first quarter, we now anticipate corporate expense s to be on the low end of the \noriginal assumption of $725 million to $775 million.  \n \n Turning now to cash, which can be found on slide 9.  We ended the quarter with a cash balance of $1.9 billion. \n During the quarter, we had negative free cash flow of $162 million.  This performance was ahead of our \nexpectations. ", "original_text": "Turning now to cash, which can be found on slide 9. ", "page_label": "8", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "68a8ea83-af8c-4d84-b574-69c27c2d1620", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "51657597309f60a3f2276ac016167f188501585cd83bd1ad682ca61ddd689734", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1fbb3e6e-2b69-47b8-bf12-b4252545c8f2", "node_type": "1", "metadata": {"window": "The year -over-year growth was primarily driven by the \nincrease in  opioid -related litigation costs and the overall timing of technology investments in the fiscal year, \npartially offset by a one -time benefit recorded in the first quarter of approximately $0.10.  \n \n As it relates to opioid -related litigation costs, McKesson recorded $36 million in expenses in the first quarter.  We \ncontinue to assume opioid -related litigation costs will be approximately $150 million in fiscal 2020.  Based on the \none-time benefit recorded in the first quarter, we now anticipate corporate expense s to be on the low end of the \noriginal assumption of $725 million to $775 million.  \n \n Turning now to cash, which can be found on slide 9.  We ended the quarter with a cash balance of $1.9 billion. \n During the quarter, we had negative free cash flow of $162 million. ", "original_text": "Based on the \none-time benefit recorded in the first quarter, we now anticipate corporate expense s to be on the low end of the \noriginal assumption of $725 million to $775 million.  \n \n", "page_label": "8", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ef932b15af3dab23edf9d2f168f52daa6d647dd5ef72cfc5de6d8e6ba1241c55", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "08bbe29e-e651-4275-b888-31366a511d91", "node_type": "1", "metadata": {"window": "We \ncontinue to assume opioid -related litigation costs will be approximately $150 million in fiscal 2020.  Based on the \none-time benefit recorded in the first quarter, we now anticipate corporate expense s to be on the low end of the \noriginal assumption of $725 million to $775 million.  \n \n Turning now to cash, which can be found on slide 9.  We ended the quarter with a cash balance of $1.9 billion. \n During the quarter, we had negative free cash flow of $162 million.  This performance was ahead of our \nexpectations.  I would remind you that cash flow will vary from quarter -to-quarter, impacted by timing, including the \nday of the week that marks the close of a quarter. ", "original_text": "We ended the quarter with a cash balance of $1.9 billion. \n"}, "hash": "151029dd80cc32317b1e0c4f5b41434c0f5e0bc4b0a586e1095489836c461470", "class_name": "RelatedNodeInfo"}}, "text": "Turning now to cash, which can be found on slide 9. ", "start_char_idx": 3071, "end_char_idx": 3123, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "08bbe29e-e651-4275-b888-31366a511d91": {"__data__": {"id_": "08bbe29e-e651-4275-b888-31366a511d91", "embedding": null, "metadata": {"window": "We \ncontinue to assume opioid -related litigation costs will be approximately $150 million in fiscal 2020.  Based on the \none-time benefit recorded in the first quarter, we now anticipate corporate expense s to be on the low end of the \noriginal assumption of $725 million to $775 million.  \n \n Turning now to cash, which can be found on slide 9.  We ended the quarter with a cash balance of $1.9 billion. \n During the quarter, we had negative free cash flow of $162 million.  This performance was ahead of our \nexpectations.  I would remind you that cash flow will vary from quarter -to-quarter, impacted by timing, including the \nday of the week that marks the close of a quarter. ", "original_text": "We ended the quarter with a cash balance of $1.9 billion. \n", "page_label": "8", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "68a8ea83-af8c-4d84-b574-69c27c2d1620", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "51657597309f60a3f2276ac016167f188501585cd83bd1ad682ca61ddd689734", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1722b56d-c6fd-469c-b271-e08e8c6f0ad9", "node_type": "1", "metadata": {"window": "As it relates to opioid -related litigation costs, McKesson recorded $36 million in expenses in the first quarter.  We \ncontinue to assume opioid -related litigation costs will be approximately $150 million in fiscal 2020.  Based on the \none-time benefit recorded in the first quarter, we now anticipate corporate expense s to be on the low end of the \noriginal assumption of $725 million to $775 million.  \n \n Turning now to cash, which can be found on slide 9.  We ended the quarter with a cash balance of $1.9 billion. \n During the quarter, we had negative free cash flow of $162 million.  This performance was ahead of our \nexpectations. ", "original_text": "Turning now to cash, which can be found on slide 9. ", "page_label": "8", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5a419bac2fea693e4cea3fc926e826351a1587861e233f27ecb770d0159ff0ce", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "35ef4042-baba-4fe4-8590-ea33dd55ec92", "node_type": "1", "metadata": {"window": "Based on the \none-time benefit recorded in the first quarter, we now anticipate corporate expense s to be on the low end of the \noriginal assumption of $725 million to $775 million.  \n \n Turning now to cash, which can be found on slide 9.  We ended the quarter with a cash balance of $1.9 billion. \n During the quarter, we had negative free cash flow of $162 million.  This performance was ahead of our \nexpectations.  I would remind you that cash flow will vary from quarter -to-quarter, impacted by timing, including the \nday of the week that marks the close of a quarter.  We continue to expect free cash flow of appro ximately $2.8 \nbillion to $3 billion for fiscal 2020.  \n \n", "original_text": "During the quarter, we had negative free cash flow of $162 million. "}, "hash": "229d46c2f46dd933589dc7e32b0c19f4555bd91ac76b0e95463b4c47f10506a4", "class_name": "RelatedNodeInfo"}}, "text": "We ended the quarter with a cash balance of $1.9 billion. \n", "start_char_idx": 3123, "end_char_idx": 3182, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "35ef4042-baba-4fe4-8590-ea33dd55ec92": {"__data__": {"id_": "35ef4042-baba-4fe4-8590-ea33dd55ec92", "embedding": null, "metadata": {"window": "Based on the \none-time benefit recorded in the first quarter, we now anticipate corporate expense s to be on the low end of the \noriginal assumption of $725 million to $775 million.  \n \n Turning now to cash, which can be found on slide 9.  We ended the quarter with a cash balance of $1.9 billion. \n During the quarter, we had negative free cash flow of $162 million.  This performance was ahead of our \nexpectations.  I would remind you that cash flow will vary from quarter -to-quarter, impacted by timing, including the \nday of the week that marks the close of a quarter.  We continue to expect free cash flow of appro ximately $2.8 \nbillion to $3 billion for fiscal 2020.  \n \n", "original_text": "During the quarter, we had negative free cash flow of $162 million. ", "page_label": "8", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "68a8ea83-af8c-4d84-b574-69c27c2d1620", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "51657597309f60a3f2276ac016167f188501585cd83bd1ad682ca61ddd689734", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "08bbe29e-e651-4275-b888-31366a511d91", "node_type": "1", "metadata": {"window": "We \ncontinue to assume opioid -related litigation costs will be approximately $150 million in fiscal 2020.  Based on the \none-time benefit recorded in the first quarter, we now anticipate corporate expense s to be on the low end of the \noriginal assumption of $725 million to $775 million.  \n \n Turning now to cash, which can be found on slide 9.  We ended the quarter with a cash balance of $1.9 billion. \n During the quarter, we had negative free cash flow of $162 million.  This performance was ahead of our \nexpectations.  I would remind you that cash flow will vary from quarter -to-quarter, impacted by timing, including the \nday of the week that marks the close of a quarter. ", "original_text": "We ended the quarter with a cash balance of $1.9 billion. \n", "page_label": "8", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2b9a7d1469107ef9e7942ce348919fb4aaa5e802f490a786714a13e5dc2f52e5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bb97e640-5e20-4ee8-9e9a-9d4cbb68a854", "node_type": "1", "metadata": {"window": "Turning now to cash, which can be found on slide 9.  We ended the quarter with a cash balance of $1.9 billion. \n During the quarter, we had negative free cash flow of $162 million.  This performance was ahead of our \nexpectations.  I would remind you that cash flow will vary from quarter -to-quarter, impacted by timing, including the \nday of the week that marks the close of a quarter.  We continue to expect free cash flow of appro ximately $2.8 \nbillion to $3 billion for fiscal 2020.  \n \n Investment in growth opportunities remains a key priority for McKesson. ", "original_text": "This performance was ahead of our \nexpectations. "}, "hash": "d406d28e01d5701942325a9592222e77408440630ffcfd4fd464b4445ab9fc02", "class_name": "RelatedNodeInfo"}}, "text": "During the quarter, we had negative free cash flow of $162 million. ", "start_char_idx": 3182, "end_char_idx": 3250, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bb97e640-5e20-4ee8-9e9a-9d4cbb68a854": {"__data__": {"id_": "bb97e640-5e20-4ee8-9e9a-9d4cbb68a854", "embedding": null, "metadata": {"window": "Turning now to cash, which can be found on slide 9.  We ended the quarter with a cash balance of $1.9 billion. \n During the quarter, we had negative free cash flow of $162 million.  This performance was ahead of our \nexpectations.  I would remind you that cash flow will vary from quarter -to-quarter, impacted by timing, including the \nday of the week that marks the close of a quarter.  We continue to expect free cash flow of appro ximately $2.8 \nbillion to $3 billion for fiscal 2020.  \n \n Investment in growth opportunities remains a key priority for McKesson. ", "original_text": "This performance was ahead of our \nexpectations. ", "page_label": "8", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "68a8ea83-af8c-4d84-b574-69c27c2d1620", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "51657597309f60a3f2276ac016167f188501585cd83bd1ad682ca61ddd689734", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "35ef4042-baba-4fe4-8590-ea33dd55ec92", "node_type": "1", "metadata": {"window": "Based on the \none-time benefit recorded in the first quarter, we now anticipate corporate expense s to be on the low end of the \noriginal assumption of $725 million to $775 million.  \n \n Turning now to cash, which can be found on slide 9.  We ended the quarter with a cash balance of $1.9 billion. \n During the quarter, we had negative free cash flow of $162 million.  This performance was ahead of our \nexpectations.  I would remind you that cash flow will vary from quarter -to-quarter, impacted by timing, including the \nday of the week that marks the close of a quarter.  We continue to expect free cash flow of appro ximately $2.8 \nbillion to $3 billion for fiscal 2020.  \n \n", "original_text": "During the quarter, we had negative free cash flow of $162 million. ", "page_label": "8", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3aeb8b48a1b79444b6e734f05408a58a7d49c6747f6584f5219374fc3d4d15c8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "40b6cc91-5f58-4340-b75b-97d01f92d4b1", "node_type": "1", "metadata": {"window": "We ended the quarter with a cash balance of $1.9 billion. \n During the quarter, we had negative free cash flow of $162 million.  This performance was ahead of our \nexpectations.  I would remind you that cash flow will vary from quarter -to-quarter, impacted by timing, including the \nday of the week that marks the close of a quarter.  We continue to expect free cash flow of appro ximately $2.8 \nbillion to $3 billion for fiscal 2020.  \n \n Investment in growth opportunities remains a key priority for McKesson.  During the quarter, we made $111 million \nof capital expenditures and spent $46 million on acquisitions, and we continue to focus o n internal investments in \nareas such as data and analytics and information security. ", "original_text": "I would remind you that cash flow will vary from quarter -to-quarter, impacted by timing, including the \nday of the week that marks the close of a quarter. "}, "hash": "872a59a989c69f3c2ca86524fead0290d86d6387e352b03eb4ee057ac7706fec", "class_name": "RelatedNodeInfo"}}, "text": "This performance was ahead of our \nexpectations. ", "start_char_idx": 3250, "end_char_idx": 3299, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "40b6cc91-5f58-4340-b75b-97d01f92d4b1": {"__data__": {"id_": "40b6cc91-5f58-4340-b75b-97d01f92d4b1", "embedding": null, "metadata": {"window": "We ended the quarter with a cash balance of $1.9 billion. \n During the quarter, we had negative free cash flow of $162 million.  This performance was ahead of our \nexpectations.  I would remind you that cash flow will vary from quarter -to-quarter, impacted by timing, including the \nday of the week that marks the close of a quarter.  We continue to expect free cash flow of appro ximately $2.8 \nbillion to $3 billion for fiscal 2020.  \n \n Investment in growth opportunities remains a key priority for McKesson.  During the quarter, we made $111 million \nof capital expenditures and spent $46 million on acquisitions, and we continue to focus o n internal investments in \nareas such as data and analytics and information security. ", "original_text": "I would remind you that cash flow will vary from quarter -to-quarter, impacted by timing, including the \nday of the week that marks the close of a quarter. ", "page_label": "8", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "68a8ea83-af8c-4d84-b574-69c27c2d1620", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "51657597309f60a3f2276ac016167f188501585cd83bd1ad682ca61ddd689734", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bb97e640-5e20-4ee8-9e9a-9d4cbb68a854", "node_type": "1", "metadata": {"window": "Turning now to cash, which can be found on slide 9.  We ended the quarter with a cash balance of $1.9 billion. \n During the quarter, we had negative free cash flow of $162 million.  This performance was ahead of our \nexpectations.  I would remind you that cash flow will vary from quarter -to-quarter, impacted by timing, including the \nday of the week that marks the close of a quarter.  We continue to expect free cash flow of appro ximately $2.8 \nbillion to $3 billion for fiscal 2020.  \n \n Investment in growth opportunities remains a key priority for McKesson. ", "original_text": "This performance was ahead of our \nexpectations. ", "page_label": "8", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b7175d1831bfb6c709c143d1e936d841153086c57fd3db8b3f78b1dbb9a69baf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "be6f9a45-8cb6-4c82-b1df-01645de87b00", "node_type": "1", "metadata": {"window": "During the quarter, we had negative free cash flow of $162 million.  This performance was ahead of our \nexpectations.  I would remind you that cash flow will vary from quarter -to-quarter, impacted by timing, including the \nday of the week that marks the close of a quarter.  We continue to expect free cash flow of appro ximately $2.8 \nbillion to $3 billion for fiscal 2020.  \n \n Investment in growth opportunities remains a key priority for McKesson.  During the quarter, we made $111 million \nof capital expenditures and spent $46 million on acquisitions, and we continue to focus o n internal investments in \nareas such as data and analytics and information security.  We used cash in the quarter to continue returning \nvalue to our shareholders. ", "original_text": "We continue to expect free cash flow of appro ximately $2.8 \nbillion to $3 billion for fiscal 2020.  \n \n"}, "hash": "1662be9214bf9afd38898df48699d58ce298270ccc48979e1487f5896269d510", "class_name": "RelatedNodeInfo"}}, "text": "I would remind you that cash flow will vary from quarter -to-quarter, impacted by timing, including the \nday of the week that marks the close of a quarter. ", "start_char_idx": 3299, "end_char_idx": 3455, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "be6f9a45-8cb6-4c82-b1df-01645de87b00": {"__data__": {"id_": "be6f9a45-8cb6-4c82-b1df-01645de87b00", "embedding": null, "metadata": {"window": "During the quarter, we had negative free cash flow of $162 million.  This performance was ahead of our \nexpectations.  I would remind you that cash flow will vary from quarter -to-quarter, impacted by timing, including the \nday of the week that marks the close of a quarter.  We continue to expect free cash flow of appro ximately $2.8 \nbillion to $3 billion for fiscal 2020.  \n \n Investment in growth opportunities remains a key priority for McKesson.  During the quarter, we made $111 million \nof capital expenditures and spent $46 million on acquisitions, and we continue to focus o n internal investments in \nareas such as data and analytics and information security.  We used cash in the quarter to continue returning \nvalue to our shareholders. ", "original_text": "We continue to expect free cash flow of appro ximately $2.8 \nbillion to $3 billion for fiscal 2020.  \n \n", "page_label": "8", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "68a8ea83-af8c-4d84-b574-69c27c2d1620", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "51657597309f60a3f2276ac016167f188501585cd83bd1ad682ca61ddd689734", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "40b6cc91-5f58-4340-b75b-97d01f92d4b1", "node_type": "1", "metadata": {"window": "We ended the quarter with a cash balance of $1.9 billion. \n During the quarter, we had negative free cash flow of $162 million.  This performance was ahead of our \nexpectations.  I would remind you that cash flow will vary from quarter -to-quarter, impacted by timing, including the \nday of the week that marks the close of a quarter.  We continue to expect free cash flow of appro ximately $2.8 \nbillion to $3 billion for fiscal 2020.  \n \n Investment in growth opportunities remains a key priority for McKesson.  During the quarter, we made $111 million \nof capital expenditures and spent $46 million on acquisitions, and we continue to focus o n internal investments in \nareas such as data and analytics and information security. ", "original_text": "I would remind you that cash flow will vary from quarter -to-quarter, impacted by timing, including the \nday of the week that marks the close of a quarter. ", "page_label": "8", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2de88212f64ea892d2cda097ea2505dcbc560424820d691350a8933b7462e396", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9082fab7-eed0-4f89-a1d3-8abdf71ab30d", "node_type": "1", "metadata": {"window": "This performance was ahead of our \nexpectations.  I would remind you that cash flow will vary from quarter -to-quarter, impacted by timing, including the \nday of the week that marks the close of a quarter.  We continue to expect free cash flow of appro ximately $2.8 \nbillion to $3 billion for fiscal 2020.  \n \n Investment in growth opportunities remains a key priority for McKesson.  During the quarter, we made $111 million \nof capital expenditures and spent $46 million on acquisitions, and we continue to focus o n internal investments in \nareas such as data and analytics and information security.  We used cash in the quarter to continue returning \nvalue to our shareholders.  We repurchased $684 million in common stock and have $2.8 billion remaining on our \nshare repur chase authorization. ", "original_text": "Investment in growth opportunities remains a key priority for McKesson. "}, "hash": "e2e391bb58d9ccb482a882ff3cff9ccbf565508861e051e441deb330f4e774d1", "class_name": "RelatedNodeInfo"}}, "text": "We continue to expect free cash flow of appro ximately $2.8 \nbillion to $3 billion for fiscal 2020.  \n \n", "start_char_idx": 3455, "end_char_idx": 3559, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9082fab7-eed0-4f89-a1d3-8abdf71ab30d": {"__data__": {"id_": "9082fab7-eed0-4f89-a1d3-8abdf71ab30d", "embedding": null, "metadata": {"window": "This performance was ahead of our \nexpectations.  I would remind you that cash flow will vary from quarter -to-quarter, impacted by timing, including the \nday of the week that marks the close of a quarter.  We continue to expect free cash flow of appro ximately $2.8 \nbillion to $3 billion for fiscal 2020.  \n \n Investment in growth opportunities remains a key priority for McKesson.  During the quarter, we made $111 million \nof capital expenditures and spent $46 million on acquisitions, and we continue to focus o n internal investments in \nareas such as data and analytics and information security.  We used cash in the quarter to continue returning \nvalue to our shareholders.  We repurchased $684 million in common stock and have $2.8 billion remaining on our \nshare repur chase authorization. ", "original_text": "Investment in growth opportunities remains a key priority for McKesson. ", "page_label": "8", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "68a8ea83-af8c-4d84-b574-69c27c2d1620", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "51657597309f60a3f2276ac016167f188501585cd83bd1ad682ca61ddd689734", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "be6f9a45-8cb6-4c82-b1df-01645de87b00", "node_type": "1", "metadata": {"window": "During the quarter, we had negative free cash flow of $162 million.  This performance was ahead of our \nexpectations.  I would remind you that cash flow will vary from quarter -to-quarter, impacted by timing, including the \nday of the week that marks the close of a quarter.  We continue to expect free cash flow of appro ximately $2.8 \nbillion to $3 billion for fiscal 2020.  \n \n Investment in growth opportunities remains a key priority for McKesson.  During the quarter, we made $111 million \nof capital expenditures and spent $46 million on acquisitions, and we continue to focus o n internal investments in \nareas such as data and analytics and information security.  We used cash in the quarter to continue returning \nvalue to our shareholders. ", "original_text": "We continue to expect free cash flow of appro ximately $2.8 \nbillion to $3 billion for fiscal 2020.  \n \n", "page_label": "8", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "585423c25c339f8dec3651b636b51d0053711d37bd36ea6ec83ba34632aaed09", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "27efbbb2-d3e9-4673-bbd2-2755ebe5e703", "node_type": "1", "metadata": {"window": "I would remind you that cash flow will vary from quarter -to-quarter, impacted by timing, including the \nday of the week that marks the close of a quarter.  We continue to expect free cash flow of appro ximately $2.8 \nbillion to $3 billion for fiscal 2020.  \n \n Investment in growth opportunities remains a key priority for McKesson.  During the quarter, we made $111 million \nof capital expenditures and spent $46 million on acquisitions, and we continue to focus o n internal investments in \nareas such as data and analytics and information security.  We used cash in the quarter to continue returning \nvalue to our shareholders.  We repurchased $684 million in common stock and have $2.8 billion remaining on our \nshare repur chase authorization.  We also paid $75 million in dividends in the quarter, and yesterday the board ", "original_text": "During the quarter, we made $111 million \nof capital expenditures and spent $46 million on acquisitions, and we continue to focus o n internal investments in \nareas such as data and analytics and information security. "}, "hash": "cad7ed0fd32551385a87e55b8a205e6cb51e8ea8844692d05e94debf81a7150b", "class_name": "RelatedNodeInfo"}}, "text": "Investment in growth opportunities remains a key priority for McKesson. ", "start_char_idx": 3559, "end_char_idx": 3631, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "27efbbb2-d3e9-4673-bbd2-2755ebe5e703": {"__data__": {"id_": "27efbbb2-d3e9-4673-bbd2-2755ebe5e703", "embedding": null, "metadata": {"window": "I would remind you that cash flow will vary from quarter -to-quarter, impacted by timing, including the \nday of the week that marks the close of a quarter.  We continue to expect free cash flow of appro ximately $2.8 \nbillion to $3 billion for fiscal 2020.  \n \n Investment in growth opportunities remains a key priority for McKesson.  During the quarter, we made $111 million \nof capital expenditures and spent $46 million on acquisitions, and we continue to focus o n internal investments in \nareas such as data and analytics and information security.  We used cash in the quarter to continue returning \nvalue to our shareholders.  We repurchased $684 million in common stock and have $2.8 billion remaining on our \nshare repur chase authorization.  We also paid $75 million in dividends in the quarter, and yesterday the board ", "original_text": "During the quarter, we made $111 million \nof capital expenditures and spent $46 million on acquisitions, and we continue to focus o n internal investments in \nareas such as data and analytics and information security. ", "page_label": "8", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "68a8ea83-af8c-4d84-b574-69c27c2d1620", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "51657597309f60a3f2276ac016167f188501585cd83bd1ad682ca61ddd689734", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9082fab7-eed0-4f89-a1d3-8abdf71ab30d", "node_type": "1", "metadata": {"window": "This performance was ahead of our \nexpectations.  I would remind you that cash flow will vary from quarter -to-quarter, impacted by timing, including the \nday of the week that marks the close of a quarter.  We continue to expect free cash flow of appro ximately $2.8 \nbillion to $3 billion for fiscal 2020.  \n \n Investment in growth opportunities remains a key priority for McKesson.  During the quarter, we made $111 million \nof capital expenditures and spent $46 million on acquisitions, and we continue to focus o n internal investments in \nareas such as data and analytics and information security.  We used cash in the quarter to continue returning \nvalue to our shareholders.  We repurchased $684 million in common stock and have $2.8 billion remaining on our \nshare repur chase authorization. ", "original_text": "Investment in growth opportunities remains a key priority for McKesson. ", "page_label": "8", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "57e6cc97b4f6cc6387b7da4891fcb32dfc8a550e554d856a7182c0c37d88b315", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "645214e4-363f-466d-b99a-92fff05efe3c", "node_type": "1", "metadata": {"window": "We continue to expect free cash flow of appro ximately $2.8 \nbillion to $3 billion for fiscal 2020.  \n \n Investment in growth opportunities remains a key priority for McKesson.  During the quarter, we made $111 million \nof capital expenditures and spent $46 million on acquisitions, and we continue to focus o n internal investments in \nareas such as data and analytics and information security.  We used cash in the quarter to continue returning \nvalue to our shareholders.  We repurchased $684 million in common stock and have $2.8 billion remaining on our \nshare repur chase authorization.  We also paid $75 million in dividends in the quarter, and yesterday the board ", "original_text": "We used cash in the quarter to continue returning \nvalue to our shareholders. "}, "hash": "db74967f29e4c54ade9a181819b48ae92b9c65918d5bb4456aeade898c0dfd84", "class_name": "RelatedNodeInfo"}}, "text": "During the quarter, we made $111 million \nof capital expenditures and spent $46 million on acquisitions, and we continue to focus o n internal investments in \nareas such as data and analytics and information security. ", "start_char_idx": 3631, "end_char_idx": 3849, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "645214e4-363f-466d-b99a-92fff05efe3c": {"__data__": {"id_": "645214e4-363f-466d-b99a-92fff05efe3c", "embedding": null, "metadata": {"window": "We continue to expect free cash flow of appro ximately $2.8 \nbillion to $3 billion for fiscal 2020.  \n \n Investment in growth opportunities remains a key priority for McKesson.  During the quarter, we made $111 million \nof capital expenditures and spent $46 million on acquisitions, and we continue to focus o n internal investments in \nareas such as data and analytics and information security.  We used cash in the quarter to continue returning \nvalue to our shareholders.  We repurchased $684 million in common stock and have $2.8 billion remaining on our \nshare repur chase authorization.  We also paid $75 million in dividends in the quarter, and yesterday the board ", "original_text": "We used cash in the quarter to continue returning \nvalue to our shareholders. ", "page_label": "8", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "68a8ea83-af8c-4d84-b574-69c27c2d1620", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "51657597309f60a3f2276ac016167f188501585cd83bd1ad682ca61ddd689734", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "27efbbb2-d3e9-4673-bbd2-2755ebe5e703", "node_type": "1", "metadata": {"window": "I would remind you that cash flow will vary from quarter -to-quarter, impacted by timing, including the \nday of the week that marks the close of a quarter.  We continue to expect free cash flow of appro ximately $2.8 \nbillion to $3 billion for fiscal 2020.  \n \n Investment in growth opportunities remains a key priority for McKesson.  During the quarter, we made $111 million \nof capital expenditures and spent $46 million on acquisitions, and we continue to focus o n internal investments in \nareas such as data and analytics and information security.  We used cash in the quarter to continue returning \nvalue to our shareholders.  We repurchased $684 million in common stock and have $2.8 billion remaining on our \nshare repur chase authorization.  We also paid $75 million in dividends in the quarter, and yesterday the board ", "original_text": "During the quarter, we made $111 million \nof capital expenditures and spent $46 million on acquisitions, and we continue to focus o n internal investments in \nareas such as data and analytics and information security. ", "page_label": "8", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4c64bbefdd7a426575a7fc3dc42275f65dbf38fb4ec1a78c85ea86054295f847", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7d0c7e51-09f0-464c-9509-21cfc0182b3a", "node_type": "1", "metadata": {"window": "Investment in growth opportunities remains a key priority for McKesson.  During the quarter, we made $111 million \nof capital expenditures and spent $46 million on acquisitions, and we continue to focus o n internal investments in \nareas such as data and analytics and information security.  We used cash in the quarter to continue returning \nvalue to our shareholders.  We repurchased $684 million in common stock and have $2.8 billion remaining on our \nshare repur chase authorization.  We also paid $75 million in dividends in the quarter, and yesterday the board ", "original_text": "We repurchased $684 million in common stock and have $2.8 billion remaining on our \nshare repur chase authorization. "}, "hash": "c29e465f77d68549e479ed4b2953d4fd95774db4f8d35e2566080bce8e89bc64", "class_name": "RelatedNodeInfo"}}, "text": "We used cash in the quarter to continue returning \nvalue to our shareholders. ", "start_char_idx": 3849, "end_char_idx": 3927, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7d0c7e51-09f0-464c-9509-21cfc0182b3a": {"__data__": {"id_": "7d0c7e51-09f0-464c-9509-21cfc0182b3a", "embedding": null, "metadata": {"window": "Investment in growth opportunities remains a key priority for McKesson.  During the quarter, we made $111 million \nof capital expenditures and spent $46 million on acquisitions, and we continue to focus o n internal investments in \nareas such as data and analytics and information security.  We used cash in the quarter to continue returning \nvalue to our shareholders.  We repurchased $684 million in common stock and have $2.8 billion remaining on our \nshare repur chase authorization.  We also paid $75 million in dividends in the quarter, and yesterday the board ", "original_text": "We repurchased $684 million in common stock and have $2.8 billion remaining on our \nshare repur chase authorization. ", "page_label": "8", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "68a8ea83-af8c-4d84-b574-69c27c2d1620", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "51657597309f60a3f2276ac016167f188501585cd83bd1ad682ca61ddd689734", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "645214e4-363f-466d-b99a-92fff05efe3c", "node_type": "1", "metadata": {"window": "We continue to expect free cash flow of appro ximately $2.8 \nbillion to $3 billion for fiscal 2020.  \n \n Investment in growth opportunities remains a key priority for McKesson.  During the quarter, we made $111 million \nof capital expenditures and spent $46 million on acquisitions, and we continue to focus o n internal investments in \nareas such as data and analytics and information security.  We used cash in the quarter to continue returning \nvalue to our shareholders.  We repurchased $684 million in common stock and have $2.8 billion remaining on our \nshare repur chase authorization.  We also paid $75 million in dividends in the quarter, and yesterday the board ", "original_text": "We used cash in the quarter to continue returning \nvalue to our shareholders. ", "page_label": "8", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8c8ebc43f5cbf3b963ef4cd3b9cee183aaa860f2967ebd66f30d297a67d9f468", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "11416211-744c-47e9-8a91-e2825214e143", "node_type": "1", "metadata": {"window": "During the quarter, we made $111 million \nof capital expenditures and spent $46 million on acquisitions, and we continue to focus o n internal investments in \nareas such as data and analytics and information security.  We used cash in the quarter to continue returning \nvalue to our shareholders.  We repurchased $684 million in common stock and have $2.8 billion remaining on our \nshare repur chase authorization.  We also paid $75 million in dividends in the quarter, and yesterday the board ", "original_text": "We also paid $75 million in dividends in the quarter, and yesterday the board "}, "hash": "6389fd7f3594b12f8230daa243c5a25e708b64586d3cadfd6bda6ca4dcb7a4b0", "class_name": "RelatedNodeInfo"}}, "text": "We repurchased $684 million in common stock and have $2.8 billion remaining on our \nshare repur chase authorization. ", "start_char_idx": 3927, "end_char_idx": 4044, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "11416211-744c-47e9-8a91-e2825214e143": {"__data__": {"id_": "11416211-744c-47e9-8a91-e2825214e143", "embedding": null, "metadata": {"window": "During the quarter, we made $111 million \nof capital expenditures and spent $46 million on acquisitions, and we continue to focus o n internal investments in \nareas such as data and analytics and information security.  We used cash in the quarter to continue returning \nvalue to our shareholders.  We repurchased $684 million in common stock and have $2.8 billion remaining on our \nshare repur chase authorization.  We also paid $75 million in dividends in the quarter, and yesterday the board ", "original_text": "We also paid $75 million in dividends in the quarter, and yesterday the board ", "page_label": "8", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "68a8ea83-af8c-4d84-b574-69c27c2d1620", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "51657597309f60a3f2276ac016167f188501585cd83bd1ad682ca61ddd689734", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7d0c7e51-09f0-464c-9509-21cfc0182b3a", "node_type": "1", "metadata": {"window": "Investment in growth opportunities remains a key priority for McKesson.  During the quarter, we made $111 million \nof capital expenditures and spent $46 million on acquisitions, and we continue to focus o n internal investments in \nareas such as data and analytics and information security.  We used cash in the quarter to continue returning \nvalue to our shareholders.  We repurchased $684 million in common stock and have $2.8 billion remaining on our \nshare repur chase authorization.  We also paid $75 million in dividends in the quarter, and yesterday the board ", "original_text": "We repurchased $684 million in common stock and have $2.8 billion remaining on our \nshare repur chase authorization. ", "page_label": "8", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "111626358ba4a468a750eb26cfcd75700e14263cd76195baf36b65c73f0af8df", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "aa605a4a-e5e0-4d9c-8531-663236e34ecd", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \napproved an increase to our quarterly dividend of $0.02 to $0.41, an increase of 5% which will be payable to \nshareholders in October.  \n \n In closing, we are ple ased with the strong start to the year.  In the first quarter, we had growth across the majority \nof our businesses which more than offset the weakness in the retail pharmacy market in the UK. ", "original_text": "McKesson Corp.  "}, "hash": "2c3931c0b6b6ad0c41f285d282fed3a5db598aad9849095c76a0d0223ca2a019", "class_name": "RelatedNodeInfo"}}, "text": "We also paid $75 million in dividends in the quarter, and yesterday the board ", "start_char_idx": 4044, "end_char_idx": 4122, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "aa605a4a-e5e0-4d9c-8531-663236e34ecd": {"__data__": {"id_": "aa605a4a-e5e0-4d9c-8531-663236e34ecd", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \napproved an increase to our quarterly dividend of $0.02 to $0.41, an increase of 5% which will be payable to \nshareholders in October.  \n \n In closing, we are ple ased with the strong start to the year.  In the first quarter, we had growth across the majority \nof our businesses which more than offset the weakness in the retail pharmacy market in the UK. ", "original_text": "McKesson Corp.  ", "page_label": "9", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c9d94875-256d-4a67-9245-80e627b9c808", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "07c592dfde39dbc4d6758a03f76cd94c3f159df451ce7cf68f6adf6966a09924", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "11416211-744c-47e9-8a91-e2825214e143", "node_type": "1", "metadata": {"window": "During the quarter, we made $111 million \nof capital expenditures and spent $46 million on acquisitions, and we continue to focus o n internal investments in \nareas such as data and analytics and information security.  We used cash in the quarter to continue returning \nvalue to our shareholders.  We repurchased $684 million in common stock and have $2.8 billion remaining on our \nshare repur chase authorization.  We also paid $75 million in dividends in the quarter, and yesterday the board ", "original_text": "We also paid $75 million in dividends in the quarter, and yesterday the board ", "page_label": "8", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9092093417d40de225635d04ecb5f437fbeab2042fbdba9a59e6827b78ada753", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cbb64798-76bf-4a06-b792-f369de2c2281", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \napproved an increase to our quarterly dividend of $0.02 to $0.41, an increase of 5% which will be payable to \nshareholders in October.  \n \n In closing, we are ple ased with the strong start to the year.  In the first quarter, we had growth across the majority \nof our businesses which more than offset the weakness in the retail pharmacy market in the UK.  Our results for \nthe first quarter, which include an unplanned one -time benefit of $0.10, have given us confidence in our full year \nfiscal 2020 outlook. ", "original_text": "(MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \napproved an increase to our quarterly dividend of $0.02 to $0.41, an increase of 5% which will be payable to \nshareholders in October.  \n \n"}, "hash": "ba7a5b766f249fe333a9661c8899d4b14e00e9ad7186bd655bf848ed5730c555", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cbb64798-76bf-4a06-b792-f369de2c2281": {"__data__": {"id_": "cbb64798-76bf-4a06-b792-f369de2c2281", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \napproved an increase to our quarterly dividend of $0.02 to $0.41, an increase of 5% which will be payable to \nshareholders in October.  \n \n In closing, we are ple ased with the strong start to the year.  In the first quarter, we had growth across the majority \nof our businesses which more than offset the weakness in the retail pharmacy market in the UK.  Our results for \nthe first quarter, which include an unplanned one -time benefit of $0.10, have given us confidence in our full year \nfiscal 2020 outlook. ", "original_text": "(MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \napproved an increase to our quarterly dividend of $0.02 to $0.41, an increase of 5% which will be payable to \nshareholders in October.  \n \n", "page_label": "9", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c9d94875-256d-4a67-9245-80e627b9c808", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "07c592dfde39dbc4d6758a03f76cd94c3f159df451ce7cf68f6adf6966a09924", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "aa605a4a-e5e0-4d9c-8531-663236e34ecd", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \napproved an increase to our quarterly dividend of $0.02 to $0.41, an increase of 5% which will be payable to \nshareholders in October.  \n \n In closing, we are ple ased with the strong start to the year.  In the first quarter, we had growth across the majority \nof our businesses which more than offset the weakness in the retail pharmacy market in the UK. ", "original_text": "McKesson Corp.  ", "page_label": "9", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "30e25d2a9bce0221a6d9e24d884984638751a9d5516785a47eb744741115b2d1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9bb5f699-fbd0-4399-913c-f4765e4f391a", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \napproved an increase to our quarterly dividend of $0.02 to $0.41, an increase of 5% which will be payable to \nshareholders in October.  \n \n In closing, we are ple ased with the strong start to the year.  In the first quarter, we had growth across the majority \nof our businesses which more than offset the weakness in the retail pharmacy market in the UK.  Our results for \nthe first quarter, which include an unplanned one -time benefit of $0.10, have given us confidence in our full year \nfiscal 2020 outlook.  As a result, we're increasing our adjusted earnings guidance by $0.15 to a range of $14.00 to \n$14.60 per diluted share, which represents solid growth of approximately 5%  at the midpoint versus fiscal 2019.  \n \n", "original_text": "In closing, we are ple ased with the strong start to the year. "}, "hash": "8ae9169597d0c9f76420112d09055d8f74e7cf7328dc51ceb90384910552655a", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \napproved an increase to our quarterly dividend of $0.02 to $0.41, an increase of 5% which will be payable to \nshareholders in October.  \n \n", "start_char_idx": 16, "end_char_idx": 319, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9bb5f699-fbd0-4399-913c-f4765e4f391a": {"__data__": {"id_": "9bb5f699-fbd0-4399-913c-f4765e4f391a", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \napproved an increase to our quarterly dividend of $0.02 to $0.41, an increase of 5% which will be payable to \nshareholders in October.  \n \n In closing, we are ple ased with the strong start to the year.  In the first quarter, we had growth across the majority \nof our businesses which more than offset the weakness in the retail pharmacy market in the UK.  Our results for \nthe first quarter, which include an unplanned one -time benefit of $0.10, have given us confidence in our full year \nfiscal 2020 outlook.  As a result, we're increasing our adjusted earnings guidance by $0.15 to a range of $14.00 to \n$14.60 per diluted share, which represents solid growth of approximately 5%  at the midpoint versus fiscal 2019.  \n \n", "original_text": "In closing, we are ple ased with the strong start to the year. ", "page_label": "9", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c9d94875-256d-4a67-9245-80e627b9c808", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "07c592dfde39dbc4d6758a03f76cd94c3f159df451ce7cf68f6adf6966a09924", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cbb64798-76bf-4a06-b792-f369de2c2281", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \napproved an increase to our quarterly dividend of $0.02 to $0.41, an increase of 5% which will be payable to \nshareholders in October.  \n \n In closing, we are ple ased with the strong start to the year.  In the first quarter, we had growth across the majority \nof our businesses which more than offset the weakness in the retail pharmacy market in the UK.  Our results for \nthe first quarter, which include an unplanned one -time benefit of $0.10, have given us confidence in our full year \nfiscal 2020 outlook. ", "original_text": "(MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \napproved an increase to our quarterly dividend of $0.02 to $0.41, an increase of 5% which will be payable to \nshareholders in October.  \n \n", "page_label": "9", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "def1984b136fecfd8cad067ae7c0fed1dcea697a045a56b7676a758d96383c61", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0182c1fd-e27b-453e-99d6-6972ac923a24", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \napproved an increase to our quarterly dividend of $0.02 to $0.41, an increase of 5% which will be payable to \nshareholders in October.  \n \n In closing, we are ple ased with the strong start to the year.  In the first quarter, we had growth across the majority \nof our businesses which more than offset the weakness in the retail pharmacy market in the UK.  Our results for \nthe first quarter, which include an unplanned one -time benefit of $0.10, have given us confidence in our full year \nfiscal 2020 outlook.  As a result, we're increasing our adjusted earnings guidance by $0.15 to a range of $14.00 to \n$14.60 per diluted share, which represents solid growth of approximately 5%  at the midpoint versus fiscal 2019.  \n \n I would remind you that we do not provide quarterly guidance. ", "original_text": "In the first quarter, we had growth across the majority \nof our businesses which more than offset the weakness in the retail pharmacy market in the UK. "}, "hash": "9ec2218e1eac1a3bd6d8efaee58c926f556f8978fdee10ad2c6c5b3ec705fc39", "class_name": "RelatedNodeInfo"}}, "text": "In closing, we are ple ased with the strong start to the year. ", "start_char_idx": 319, "end_char_idx": 382, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0182c1fd-e27b-453e-99d6-6972ac923a24": {"__data__": {"id_": "0182c1fd-e27b-453e-99d6-6972ac923a24", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \napproved an increase to our quarterly dividend of $0.02 to $0.41, an increase of 5% which will be payable to \nshareholders in October.  \n \n In closing, we are ple ased with the strong start to the year.  In the first quarter, we had growth across the majority \nof our businesses which more than offset the weakness in the retail pharmacy market in the UK.  Our results for \nthe first quarter, which include an unplanned one -time benefit of $0.10, have given us confidence in our full year \nfiscal 2020 outlook.  As a result, we're increasing our adjusted earnings guidance by $0.15 to a range of $14.00 to \n$14.60 per diluted share, which represents solid growth of approximately 5%  at the midpoint versus fiscal 2019.  \n \n I would remind you that we do not provide quarterly guidance. ", "original_text": "In the first quarter, we had growth across the majority \nof our businesses which more than offset the weakness in the retail pharmacy market in the UK. ", "page_label": "9", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c9d94875-256d-4a67-9245-80e627b9c808", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "07c592dfde39dbc4d6758a03f76cd94c3f159df451ce7cf68f6adf6966a09924", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9bb5f699-fbd0-4399-913c-f4765e4f391a", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \napproved an increase to our quarterly dividend of $0.02 to $0.41, an increase of 5% which will be payable to \nshareholders in October.  \n \n In closing, we are ple ased with the strong start to the year.  In the first quarter, we had growth across the majority \nof our businesses which more than offset the weakness in the retail pharmacy market in the UK.  Our results for \nthe first quarter, which include an unplanned one -time benefit of $0.10, have given us confidence in our full year \nfiscal 2020 outlook.  As a result, we're increasing our adjusted earnings guidance by $0.15 to a range of $14.00 to \n$14.60 per diluted share, which represents solid growth of approximately 5%  at the midpoint versus fiscal 2019.  \n \n", "original_text": "In closing, we are ple ased with the strong start to the year. ", "page_label": "9", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4b261ac7d0c625bd38189f10f959322108899b88a5e9fb1ea7404b2d6c1bbe47", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "66253091-2f01-4f13-a3a6-2635dbd75d1f", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \napproved an increase to our quarterly dividend of $0.02 to $0.41, an increase of 5% which will be payable to \nshareholders in October.  \n \n In closing, we are ple ased with the strong start to the year.  In the first quarter, we had growth across the majority \nof our businesses which more than offset the weakness in the retail pharmacy market in the UK.  Our results for \nthe first quarter, which include an unplanned one -time benefit of $0.10, have given us confidence in our full year \nfiscal 2020 outlook.  As a result, we're increasing our adjusted earnings guidance by $0.15 to a range of $14.00 to \n$14.60 per diluted share, which represents solid growth of approximately 5%  at the midpoint versus fiscal 2019.  \n \n I would remind you that we do not provide quarterly guidance.  However, to better inform your modeling, we \ncontinue to expect the percentage of adjusted earnings per diluted share in the first half of the year as compar ed \nto the second half, to be similar to fiscal 2019. ", "original_text": "Our results for \nthe first quarter, which include an unplanned one -time benefit of $0.10, have given us confidence in our full year \nfiscal 2020 outlook. "}, "hash": "0a48c1d68afd24434e373919c98b4c4daa1c91fbe90c9d98215152c5e451b8b1", "class_name": "RelatedNodeInfo"}}, "text": "In the first quarter, we had growth across the majority \nof our businesses which more than offset the weakness in the retail pharmacy market in the UK. ", "start_char_idx": 382, "end_char_idx": 534, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "66253091-2f01-4f13-a3a6-2635dbd75d1f": {"__data__": {"id_": "66253091-2f01-4f13-a3a6-2635dbd75d1f", "embedding": null, "metadata": {"window": "(MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \napproved an increase to our quarterly dividend of $0.02 to $0.41, an increase of 5% which will be payable to \nshareholders in October.  \n \n In closing, we are ple ased with the strong start to the year.  In the first quarter, we had growth across the majority \nof our businesses which more than offset the weakness in the retail pharmacy market in the UK.  Our results for \nthe first quarter, which include an unplanned one -time benefit of $0.10, have given us confidence in our full year \nfiscal 2020 outlook.  As a result, we're increasing our adjusted earnings guidance by $0.15 to a range of $14.00 to \n$14.60 per diluted share, which represents solid growth of approximately 5%  at the midpoint versus fiscal 2019.  \n \n I would remind you that we do not provide quarterly guidance.  However, to better inform your modeling, we \ncontinue to expect the percentage of adjusted earnings per diluted share in the first half of the year as compar ed \nto the second half, to be similar to fiscal 2019. ", "original_text": "Our results for \nthe first quarter, which include an unplanned one -time benefit of $0.10, have given us confidence in our full year \nfiscal 2020 outlook. ", "page_label": "9", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c9d94875-256d-4a67-9245-80e627b9c808", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "07c592dfde39dbc4d6758a03f76cd94c3f159df451ce7cf68f6adf6966a09924", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0182c1fd-e27b-453e-99d6-6972ac923a24", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \napproved an increase to our quarterly dividend of $0.02 to $0.41, an increase of 5% which will be payable to \nshareholders in October.  \n \n In closing, we are ple ased with the strong start to the year.  In the first quarter, we had growth across the majority \nof our businesses which more than offset the weakness in the retail pharmacy market in the UK.  Our results for \nthe first quarter, which include an unplanned one -time benefit of $0.10, have given us confidence in our full year \nfiscal 2020 outlook.  As a result, we're increasing our adjusted earnings guidance by $0.15 to a range of $14.00 to \n$14.60 per diluted share, which represents solid growth of approximately 5%  at the midpoint versus fiscal 2019.  \n \n I would remind you that we do not provide quarterly guidance. ", "original_text": "In the first quarter, we had growth across the majority \nof our businesses which more than offset the weakness in the retail pharmacy market in the UK. ", "page_label": "9", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "22b5ff08b0f2e5b5630b96fff4cf01625190cf2b92c117f262b76205ca32e75b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e7f62783-1f91-46be-b926-f1d4a2cb251a", "node_type": "1", "metadata": {"window": "In closing, we are ple ased with the strong start to the year.  In the first quarter, we had growth across the majority \nof our businesses which more than offset the weakness in the retail pharmacy market in the UK.  Our results for \nthe first quarter, which include an unplanned one -time benefit of $0.10, have given us confidence in our full year \nfiscal 2020 outlook.  As a result, we're increasing our adjusted earnings guidance by $0.15 to a range of $14.00 to \n$14.60 per diluted share, which represents solid growth of approximately 5%  at the midpoint versus fiscal 2019.  \n \n I would remind you that we do not provide quarterly guidance.  However, to better inform your modeling, we \ncontinue to expect the percentage of adjusted earnings per diluted share in the first half of the year as compar ed \nto the second half, to be similar to fiscal 2019.  Overall, we're pleased with the focus, the execution, and the \nperformance across the company, and we're off to a great start in fiscal 2020.  \n \n", "original_text": "As a result, we're increasing our adjusted earnings guidance by $0.15 to a range of $14.00 to \n$14.60 per diluted share, which represents solid growth of approximately 5%  at the midpoint versus fiscal 2019.  \n \n"}, "hash": "94b8e980fddb00b997f3733af0e27c284df3bb24308acf8e27686bd523ef8029", "class_name": "RelatedNodeInfo"}}, "text": "Our results for \nthe first quarter, which include an unplanned one -time benefit of $0.10, have given us confidence in our full year \nfiscal 2020 outlook. ", "start_char_idx": 534, "end_char_idx": 689, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e7f62783-1f91-46be-b926-f1d4a2cb251a": {"__data__": {"id_": "e7f62783-1f91-46be-b926-f1d4a2cb251a", "embedding": null, "metadata": {"window": "In closing, we are ple ased with the strong start to the year.  In the first quarter, we had growth across the majority \nof our businesses which more than offset the weakness in the retail pharmacy market in the UK.  Our results for \nthe first quarter, which include an unplanned one -time benefit of $0.10, have given us confidence in our full year \nfiscal 2020 outlook.  As a result, we're increasing our adjusted earnings guidance by $0.15 to a range of $14.00 to \n$14.60 per diluted share, which represents solid growth of approximately 5%  at the midpoint versus fiscal 2019.  \n \n I would remind you that we do not provide quarterly guidance.  However, to better inform your modeling, we \ncontinue to expect the percentage of adjusted earnings per diluted share in the first half of the year as compar ed \nto the second half, to be similar to fiscal 2019.  Overall, we're pleased with the focus, the execution, and the \nperformance across the company, and we're off to a great start in fiscal 2020.  \n \n", "original_text": "As a result, we're increasing our adjusted earnings guidance by $0.15 to a range of $14.00 to \n$14.60 per diluted share, which represents solid growth of approximately 5%  at the midpoint versus fiscal 2019.  \n \n", "page_label": "9", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c9d94875-256d-4a67-9245-80e627b9c808", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "07c592dfde39dbc4d6758a03f76cd94c3f159df451ce7cf68f6adf6966a09924", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "66253091-2f01-4f13-a3a6-2635dbd75d1f", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \napproved an increase to our quarterly dividend of $0.02 to $0.41, an increase of 5% which will be payable to \nshareholders in October.  \n \n In closing, we are ple ased with the strong start to the year.  In the first quarter, we had growth across the majority \nof our businesses which more than offset the weakness in the retail pharmacy market in the UK.  Our results for \nthe first quarter, which include an unplanned one -time benefit of $0.10, have given us confidence in our full year \nfiscal 2020 outlook.  As a result, we're increasing our adjusted earnings guidance by $0.15 to a range of $14.00 to \n$14.60 per diluted share, which represents solid growth of approximately 5%  at the midpoint versus fiscal 2019.  \n \n I would remind you that we do not provide quarterly guidance.  However, to better inform your modeling, we \ncontinue to expect the percentage of adjusted earnings per diluted share in the first half of the year as compar ed \nto the second half, to be similar to fiscal 2019. ", "original_text": "Our results for \nthe first quarter, which include an unplanned one -time benefit of $0.10, have given us confidence in our full year \nfiscal 2020 outlook. ", "page_label": "9", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f01eafa91875b02324747384ca71e576fcdcd787e9a48745043c2fe558eb8c18", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "702c79bc-a22a-4913-8e2d-46727b97e016", "node_type": "1", "metadata": {"window": "In the first quarter, we had growth across the majority \nof our businesses which more than offset the weakness in the retail pharmacy market in the UK.  Our results for \nthe first quarter, which include an unplanned one -time benefit of $0.10, have given us confidence in our full year \nfiscal 2020 outlook.  As a result, we're increasing our adjusted earnings guidance by $0.15 to a range of $14.00 to \n$14.60 per diluted share, which represents solid growth of approximately 5%  at the midpoint versus fiscal 2019.  \n \n I would remind you that we do not provide quarterly guidance.  However, to better inform your modeling, we \ncontinue to expect the percentage of adjusted earnings per diluted share in the first half of the year as compar ed \nto the second half, to be similar to fiscal 2019.  Overall, we're pleased with the focus, the execution, and the \nperformance across the company, and we're off to a great start in fiscal 2020.  \n \n And with that, Brian and I are happy to take your questions.  \n ", "original_text": "I would remind you that we do not provide quarterly guidance. "}, "hash": "f678fa07eefbed5aee70bf052e324390fdb5444a955bab2c1b77adebdda42e2b", "class_name": "RelatedNodeInfo"}}, "text": "As a result, we're increasing our adjusted earnings guidance by $0.15 to a range of $14.00 to \n$14.60 per diluted share, which represents solid growth of approximately 5%  at the midpoint versus fiscal 2019.  \n \n", "start_char_idx": 689, "end_char_idx": 901, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "702c79bc-a22a-4913-8e2d-46727b97e016": {"__data__": {"id_": "702c79bc-a22a-4913-8e2d-46727b97e016", "embedding": null, "metadata": {"window": "In the first quarter, we had growth across the majority \nof our businesses which more than offset the weakness in the retail pharmacy market in the UK.  Our results for \nthe first quarter, which include an unplanned one -time benefit of $0.10, have given us confidence in our full year \nfiscal 2020 outlook.  As a result, we're increasing our adjusted earnings guidance by $0.15 to a range of $14.00 to \n$14.60 per diluted share, which represents solid growth of approximately 5%  at the midpoint versus fiscal 2019.  \n \n I would remind you that we do not provide quarterly guidance.  However, to better inform your modeling, we \ncontinue to expect the percentage of adjusted earnings per diluted share in the first half of the year as compar ed \nto the second half, to be similar to fiscal 2019.  Overall, we're pleased with the focus, the execution, and the \nperformance across the company, and we're off to a great start in fiscal 2020.  \n \n And with that, Brian and I are happy to take your questions.  \n ", "original_text": "I would remind you that we do not provide quarterly guidance. ", "page_label": "9", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c9d94875-256d-4a67-9245-80e627b9c808", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "07c592dfde39dbc4d6758a03f76cd94c3f159df451ce7cf68f6adf6966a09924", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e7f62783-1f91-46be-b926-f1d4a2cb251a", "node_type": "1", "metadata": {"window": "In closing, we are ple ased with the strong start to the year.  In the first quarter, we had growth across the majority \nof our businesses which more than offset the weakness in the retail pharmacy market in the UK.  Our results for \nthe first quarter, which include an unplanned one -time benefit of $0.10, have given us confidence in our full year \nfiscal 2020 outlook.  As a result, we're increasing our adjusted earnings guidance by $0.15 to a range of $14.00 to \n$14.60 per diluted share, which represents solid growth of approximately 5%  at the midpoint versus fiscal 2019.  \n \n I would remind you that we do not provide quarterly guidance.  However, to better inform your modeling, we \ncontinue to expect the percentage of adjusted earnings per diluted share in the first half of the year as compar ed \nto the second half, to be similar to fiscal 2019.  Overall, we're pleased with the focus, the execution, and the \nperformance across the company, and we're off to a great start in fiscal 2020.  \n \n", "original_text": "As a result, we're increasing our adjusted earnings guidance by $0.15 to a range of $14.00 to \n$14.60 per diluted share, which represents solid growth of approximately 5%  at the midpoint versus fiscal 2019.  \n \n", "page_label": "9", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d01c02b1404add706f8b4f0e37a5305a36ae93a82500e9c3fe9b9fe0f6521ace", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2895a36e-5475-40a9-9c1f-a4e80894cdfe", "node_type": "1", "metadata": {"window": "Our results for \nthe first quarter, which include an unplanned one -time benefit of $0.10, have given us confidence in our full year \nfiscal 2020 outlook.  As a result, we're increasing our adjusted earnings guidance by $0.15 to a range of $14.00 to \n$14.60 per diluted share, which represents solid growth of approximately 5%  at the midpoint versus fiscal 2019.  \n \n I would remind you that we do not provide quarterly guidance.  However, to better inform your modeling, we \ncontinue to expect the percentage of adjusted earnings per diluted share in the first half of the year as compar ed \nto the second half, to be similar to fiscal 2019.  Overall, we're pleased with the focus, the execution, and the \nperformance across the company, and we're off to a great start in fiscal 2020.  \n \n And with that, Brian and I are happy to take your questions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................    \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you. ", "original_text": "However, to better inform your modeling, we \ncontinue to expect the percentage of adjusted earnings per diluted share in the first half of the year as compar ed \nto the second half, to be similar to fiscal 2019. "}, "hash": "61ef002943a3c642ce3a4f859dac21d2c3f1b2f9b5842460e42e965c461d966c", "class_name": "RelatedNodeInfo"}}, "text": "I would remind you that we do not provide quarterly guidance. ", "start_char_idx": 901, "end_char_idx": 963, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2895a36e-5475-40a9-9c1f-a4e80894cdfe": {"__data__": {"id_": "2895a36e-5475-40a9-9c1f-a4e80894cdfe", "embedding": null, "metadata": {"window": "Our results for \nthe first quarter, which include an unplanned one -time benefit of $0.10, have given us confidence in our full year \nfiscal 2020 outlook.  As a result, we're increasing our adjusted earnings guidance by $0.15 to a range of $14.00 to \n$14.60 per diluted share, which represents solid growth of approximately 5%  at the midpoint versus fiscal 2019.  \n \n I would remind you that we do not provide quarterly guidance.  However, to better inform your modeling, we \ncontinue to expect the percentage of adjusted earnings per diluted share in the first half of the year as compar ed \nto the second half, to be similar to fiscal 2019.  Overall, we're pleased with the focus, the execution, and the \nperformance across the company, and we're off to a great start in fiscal 2020.  \n \n And with that, Brian and I are happy to take your questions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................    \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you. ", "original_text": "However, to better inform your modeling, we \ncontinue to expect the percentage of adjusted earnings per diluted share in the first half of the year as compar ed \nto the second half, to be similar to fiscal 2019. ", "page_label": "9", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c9d94875-256d-4a67-9245-80e627b9c808", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "07c592dfde39dbc4d6758a03f76cd94c3f159df451ce7cf68f6adf6966a09924", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "702c79bc-a22a-4913-8e2d-46727b97e016", "node_type": "1", "metadata": {"window": "In the first quarter, we had growth across the majority \nof our businesses which more than offset the weakness in the retail pharmacy market in the UK.  Our results for \nthe first quarter, which include an unplanned one -time benefit of $0.10, have given us confidence in our full year \nfiscal 2020 outlook.  As a result, we're increasing our adjusted earnings guidance by $0.15 to a range of $14.00 to \n$14.60 per diluted share, which represents solid growth of approximately 5%  at the midpoint versus fiscal 2019.  \n \n I would remind you that we do not provide quarterly guidance.  However, to better inform your modeling, we \ncontinue to expect the percentage of adjusted earnings per diluted share in the first half of the year as compar ed \nto the second half, to be similar to fiscal 2019.  Overall, we're pleased with the focus, the execution, and the \nperformance across the company, and we're off to a great start in fiscal 2020.  \n \n And with that, Brian and I are happy to take your questions.  \n ", "original_text": "I would remind you that we do not provide quarterly guidance. ", "page_label": "9", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ea69ee03f5768e2c707fbccd05dbf232db89b7a1e3d0c5b92b5efeaed034172d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c41fffd7-53af-423c-a843-b96f9a7ca6e6", "node_type": "1", "metadata": {"window": "As a result, we're increasing our adjusted earnings guidance by $0.15 to a range of $14.00 to \n$14.60 per diluted share, which represents solid growth of approximately 5%  at the midpoint versus fiscal 2019.  \n \n I would remind you that we do not provide quarterly guidance.  However, to better inform your modeling, we \ncontinue to expect the percentage of adjusted earnings per diluted share in the first half of the year as compar ed \nto the second half, to be similar to fiscal 2019.  Overall, we're pleased with the focus, the execution, and the \nperformance across the company, and we're off to a great start in fiscal 2020.  \n \n And with that, Brian and I are happy to take your questions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................    \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And our first question will come from Lisa Gill with JPMorgan.  \n ", "original_text": "Overall, we're pleased with the focus, the execution, and the \nperformance across the company, and we're off to a great start in fiscal 2020.  \n \n"}, "hash": "9740c7621f666c499ec7a2bb5b38708419966a9a970688260ae8367f9c3c8a23", "class_name": "RelatedNodeInfo"}}, "text": "However, to better inform your modeling, we \ncontinue to expect the percentage of adjusted earnings per diluted share in the first half of the year as compar ed \nto the second half, to be similar to fiscal 2019. ", "start_char_idx": 963, "end_char_idx": 1175, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c41fffd7-53af-423c-a843-b96f9a7ca6e6": {"__data__": {"id_": "c41fffd7-53af-423c-a843-b96f9a7ca6e6", "embedding": null, "metadata": {"window": "As a result, we're increasing our adjusted earnings guidance by $0.15 to a range of $14.00 to \n$14.60 per diluted share, which represents solid growth of approximately 5%  at the midpoint versus fiscal 2019.  \n \n I would remind you that we do not provide quarterly guidance.  However, to better inform your modeling, we \ncontinue to expect the percentage of adjusted earnings per diluted share in the first half of the year as compar ed \nto the second half, to be similar to fiscal 2019.  Overall, we're pleased with the focus, the execution, and the \nperformance across the company, and we're off to a great start in fiscal 2020.  \n \n And with that, Brian and I are happy to take your questions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................    \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And our first question will come from Lisa Gill with JPMorgan.  \n ", "original_text": "Overall, we're pleased with the focus, the execution, and the \nperformance across the company, and we're off to a great start in fiscal 2020.  \n \n", "page_label": "9", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c9d94875-256d-4a67-9245-80e627b9c808", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "07c592dfde39dbc4d6758a03f76cd94c3f159df451ce7cf68f6adf6966a09924", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2895a36e-5475-40a9-9c1f-a4e80894cdfe", "node_type": "1", "metadata": {"window": "Our results for \nthe first quarter, which include an unplanned one -time benefit of $0.10, have given us confidence in our full year \nfiscal 2020 outlook.  As a result, we're increasing our adjusted earnings guidance by $0.15 to a range of $14.00 to \n$14.60 per diluted share, which represents solid growth of approximately 5%  at the midpoint versus fiscal 2019.  \n \n I would remind you that we do not provide quarterly guidance.  However, to better inform your modeling, we \ncontinue to expect the percentage of adjusted earnings per diluted share in the first half of the year as compar ed \nto the second half, to be similar to fiscal 2019.  Overall, we're pleased with the focus, the execution, and the \nperformance across the company, and we're off to a great start in fiscal 2020.  \n \n And with that, Brian and I are happy to take your questions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................    \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you. ", "original_text": "However, to better inform your modeling, we \ncontinue to expect the percentage of adjusted earnings per diluted share in the first half of the year as compar ed \nto the second half, to be similar to fiscal 2019. ", "page_label": "9", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2b6704140010d4008274eab36d1910aa79e995d5b8eda332401e1ab809236d7e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "61add928-15da-45cf-89b9-b17335401cec", "node_type": "1", "metadata": {"window": "I would remind you that we do not provide quarterly guidance.  However, to better inform your modeling, we \ncontinue to expect the percentage of adjusted earnings per diluted share in the first half of the year as compar ed \nto the second half, to be similar to fiscal 2019.  Overall, we're pleased with the focus, the execution, and the \nperformance across the company, and we're off to a great start in fiscal 2020.  \n \n And with that, Brian and I are happy to take your questions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................    \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And our first question will come from Lisa Gill with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much, and good afternoon. ", "original_text": "And with that, Brian and I are happy to take your questions.  \n "}, "hash": "7293cb7a455d24f161537832dc7024392a0a375a6cb774e0952b7a4c56a3e84f", "class_name": "RelatedNodeInfo"}}, "text": "Overall, we're pleased with the focus, the execution, and the \nperformance across the company, and we're off to a great start in fiscal 2020.  \n \n", "start_char_idx": 1175, "end_char_idx": 1321, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "61add928-15da-45cf-89b9-b17335401cec": {"__data__": {"id_": "61add928-15da-45cf-89b9-b17335401cec", "embedding": null, "metadata": {"window": "I would remind you that we do not provide quarterly guidance.  However, to better inform your modeling, we \ncontinue to expect the percentage of adjusted earnings per diluted share in the first half of the year as compar ed \nto the second half, to be similar to fiscal 2019.  Overall, we're pleased with the focus, the execution, and the \nperformance across the company, and we're off to a great start in fiscal 2020.  \n \n And with that, Brian and I are happy to take your questions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................    \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And our first question will come from Lisa Gill with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much, and good afternoon. ", "original_text": "And with that, Brian and I are happy to take your questions.  \n ", "page_label": "9", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c9d94875-256d-4a67-9245-80e627b9c808", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "07c592dfde39dbc4d6758a03f76cd94c3f159df451ce7cf68f6adf6966a09924", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c41fffd7-53af-423c-a843-b96f9a7ca6e6", "node_type": "1", "metadata": {"window": "As a result, we're increasing our adjusted earnings guidance by $0.15 to a range of $14.00 to \n$14.60 per diluted share, which represents solid growth of approximately 5%  at the midpoint versus fiscal 2019.  \n \n I would remind you that we do not provide quarterly guidance.  However, to better inform your modeling, we \ncontinue to expect the percentage of adjusted earnings per diluted share in the first half of the year as compar ed \nto the second half, to be similar to fiscal 2019.  Overall, we're pleased with the focus, the execution, and the \nperformance across the company, and we're off to a great start in fiscal 2020.  \n \n And with that, Brian and I are happy to take your questions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................    \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And our first question will come from Lisa Gill with JPMorgan.  \n ", "original_text": "Overall, we're pleased with the focus, the execution, and the \nperformance across the company, and we're off to a great start in fiscal 2020.  \n \n", "page_label": "9", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4063cf8c0db8bc5c217b6d724e6d2caa759712703d484d24832132a687e46f14", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "50df6136-6c34-40fd-9ef7-274c7de8d89a", "node_type": "1", "metadata": {"window": "However, to better inform your modeling, we \ncontinue to expect the percentage of adjusted earnings per diluted share in the first half of the year as compar ed \nto the second half, to be similar to fiscal 2019.  Overall, we're pleased with the focus, the execution, and the \nperformance across the company, and we're off to a great start in fiscal 2020.  \n \n And with that, Brian and I are happy to take your questions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................    \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And our first question will come from Lisa Gill with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much, and good afternoon.  Congratulations on a nice start to the year. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................    \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you. "}, "hash": "80990ebf9c9b3f135b848716b4fefd39fedd4ec658f60b39f3d8bb6fccab8793", "class_name": "RelatedNodeInfo"}}, "text": "And with that, Brian and I are happy to take your questions.  \n ", "start_char_idx": 1321, "end_char_idx": 1385, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "50df6136-6c34-40fd-9ef7-274c7de8d89a": {"__data__": {"id_": "50df6136-6c34-40fd-9ef7-274c7de8d89a", "embedding": null, "metadata": {"window": "However, to better inform your modeling, we \ncontinue to expect the percentage of adjusted earnings per diluted share in the first half of the year as compar ed \nto the second half, to be similar to fiscal 2019.  Overall, we're pleased with the focus, the execution, and the \nperformance across the company, and we're off to a great start in fiscal 2020.  \n \n And with that, Brian and I are happy to take your questions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................    \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And our first question will come from Lisa Gill with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much, and good afternoon.  Congratulations on a nice start to the year. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................    \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you. ", "page_label": "9", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c9d94875-256d-4a67-9245-80e627b9c808", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "07c592dfde39dbc4d6758a03f76cd94c3f159df451ce7cf68f6adf6966a09924", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "61add928-15da-45cf-89b9-b17335401cec", "node_type": "1", "metadata": {"window": "I would remind you that we do not provide quarterly guidance.  However, to better inform your modeling, we \ncontinue to expect the percentage of adjusted earnings per diluted share in the first half of the year as compar ed \nto the second half, to be similar to fiscal 2019.  Overall, we're pleased with the focus, the execution, and the \nperformance across the company, and we're off to a great start in fiscal 2020.  \n \n And with that, Brian and I are happy to take your questions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................    \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And our first question will come from Lisa Gill with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much, and good afternoon. ", "original_text": "And with that, Brian and I are happy to take your questions.  \n ", "page_label": "9", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "318b65fd10749cdfc10a66f2ff7c912c305b4a2a8601d308790753c0292d318b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cb7dacdd-868a-464f-bd71-1ac41a32f048", "node_type": "1", "metadata": {"window": "Overall, we're pleased with the focus, the execution, and the \nperformance across the company, and we're off to a great start in fiscal 2020.  \n \n And with that, Brian and I are happy to take your questions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................    \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And our first question will come from Lisa Gill with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much, and good afternoon.  Congratulations on a nice start to the year.  Brian, I know that it just came \nout, this new Safe Importation Action Plan. ", "original_text": "[Operator Instructions] And our first question will come from Lisa Gill with JPMorgan.  \n "}, "hash": "5f6fb339daf0c33a2fd359741fe64f0fa099b2d1ed5fd34911d9ebeb5ddfdc39", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................    \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you. ", "start_char_idx": 1385, "end_char_idx": 1698, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cb7dacdd-868a-464f-bd71-1ac41a32f048": {"__data__": {"id_": "cb7dacdd-868a-464f-bd71-1ac41a32f048", "embedding": null, "metadata": {"window": "Overall, we're pleased with the focus, the execution, and the \nperformance across the company, and we're off to a great start in fiscal 2020.  \n \n And with that, Brian and I are happy to take your questions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................    \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And our first question will come from Lisa Gill with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much, and good afternoon.  Congratulations on a nice start to the year.  Brian, I know that it just came \nout, this new Safe Importation Action Plan. ", "original_text": "[Operator Instructions] And our first question will come from Lisa Gill with JPMorgan.  \n ", "page_label": "9", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c9d94875-256d-4a67-9245-80e627b9c808", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "07c592dfde39dbc4d6758a03f76cd94c3f159df451ce7cf68f6adf6966a09924", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "50df6136-6c34-40fd-9ef7-274c7de8d89a", "node_type": "1", "metadata": {"window": "However, to better inform your modeling, we \ncontinue to expect the percentage of adjusted earnings per diluted share in the first half of the year as compar ed \nto the second half, to be similar to fiscal 2019.  Overall, we're pleased with the focus, the execution, and the \nperformance across the company, and we're off to a great start in fiscal 2020.  \n \n And with that, Brian and I are happy to take your questions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................    \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And our first question will come from Lisa Gill with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much, and good afternoon.  Congratulations on a nice start to the year. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................    \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you. ", "page_label": "9", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bfc32e6167292a4cb0c7d3341a22100936ba4a21064a1fa0bae385eb6cb5711a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "73368973-f3a5-4df3-a1cf-8eb94c714933", "node_type": "1", "metadata": {"window": "And with that, Brian and I are happy to take your questions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................    \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And our first question will come from Lisa Gill with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much, and good afternoon.  Congratulations on a nice start to the year.  Brian, I know that it just came \nout, this new Safe Importation Action Plan.  But just being in Canada, how realistic is this that the manufacturers \nare going to allow product to go to Canada and then come back to the U.S. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much, and good afternoon. "}, "hash": "d3c7e534e4296f1beca7d1a00c88ada60433df535009f96ab3803e96cde2619e", "class_name": "RelatedNodeInfo"}}, "text": "[Operator Instructions] And our first question will come from Lisa Gill with JPMorgan.  \n ", "start_char_idx": 1698, "end_char_idx": 1788, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "73368973-f3a5-4df3-a1cf-8eb94c714933": {"__data__": {"id_": "73368973-f3a5-4df3-a1cf-8eb94c714933", "embedding": null, "metadata": {"window": "And with that, Brian and I are happy to take your questions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................    \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And our first question will come from Lisa Gill with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much, and good afternoon.  Congratulations on a nice start to the year.  Brian, I know that it just came \nout, this new Safe Importation Action Plan.  But just being in Canada, how realistic is this that the manufacturers \nare going to allow product to go to Canada and then come back to the U.S. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much, and good afternoon. ", "page_label": "9", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c9d94875-256d-4a67-9245-80e627b9c808", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "07c592dfde39dbc4d6758a03f76cd94c3f159df451ce7cf68f6adf6966a09924", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cb7dacdd-868a-464f-bd71-1ac41a32f048", "node_type": "1", "metadata": {"window": "Overall, we're pleased with the focus, the execution, and the \nperformance across the company, and we're off to a great start in fiscal 2020.  \n \n And with that, Brian and I are happy to take your questions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................    \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And our first question will come from Lisa Gill with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much, and good afternoon.  Congratulations on a nice start to the year.  Brian, I know that it just came \nout, this new Safe Importation Action Plan. ", "original_text": "[Operator Instructions] And our first question will come from Lisa Gill with JPMorgan.  \n ", "page_label": "9", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "419c7a4ce580a7c430f4bb44cee1caf13e777fd8debb452d20be020d12b00a36", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "48db25ce-d226-4004-8f64-4449a47ffca0", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................    \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And our first question will come from Lisa Gill with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much, and good afternoon.  Congratulations on a nice start to the year.  Brian, I know that it just came \nout, this new Safe Importation Action Plan.  But just being in Canada, how realistic is this that the manufacturers \nare going to allow product to go to Canada and then come back to the U.S.  and just given t he size of the \nCanadian market? ", "original_text": "Congratulations on a nice start to the year. "}, "hash": "3fcc7a0d30b64f99b9ad44e94eb2c0cf42a08ac9ec9fba5a80f8c1e25fc10bce", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much, and good afternoon. ", "start_char_idx": 1788, "end_char_idx": 2135, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "48db25ce-d226-4004-8f64-4449a47ffca0": {"__data__": {"id_": "48db25ce-d226-4004-8f64-4449a47ffca0", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................    \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And our first question will come from Lisa Gill with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much, and good afternoon.  Congratulations on a nice start to the year.  Brian, I know that it just came \nout, this new Safe Importation Action Plan.  But just being in Canada, how realistic is this that the manufacturers \nare going to allow product to go to Canada and then come back to the U.S.  and just given t he size of the \nCanadian market? ", "original_text": "Congratulations on a nice start to the year. ", "page_label": "9", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c9d94875-256d-4a67-9245-80e627b9c808", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "07c592dfde39dbc4d6758a03f76cd94c3f159df451ce7cf68f6adf6966a09924", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "73368973-f3a5-4df3-a1cf-8eb94c714933", "node_type": "1", "metadata": {"window": "And with that, Brian and I are happy to take your questions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................    \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And our first question will come from Lisa Gill with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much, and good afternoon.  Congratulations on a nice start to the year.  Brian, I know that it just came \nout, this new Safe Importation Action Plan.  But just being in Canada, how realistic is this that the manufacturers \nare going to allow product to go to Canada and then come back to the U.S. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much, and good afternoon. ", "page_label": "9", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c45fdf6db65ea86f15110fbe93db0e36480ae8901b7a53ee3731d1f744b4c2e2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8f5fb490-f85f-4038-88ad-0dd772b11bab", "node_type": "1", "metadata": {"window": "[Operator Instructions] And our first question will come from Lisa Gill with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much, and good afternoon.  Congratulations on a nice start to the year.  Brian, I know that it just came \nout, this new Safe Importation Action Plan.  But just being in Canada, how realistic is this that the manufacturers \nare going to allow product to go to Canada and then come back to the U.S.  and just given t he size of the \nCanadian market?  And what role do you think that McKesson can play as the largest distributor in Canada to \nmake sure that, one, product that is meant for Canada stays in Canada; and two, anything that does potentially \ncome back to the States  is safe?  \n ", "original_text": "Brian, I know that it just came \nout, this new Safe Importation Action Plan. "}, "hash": "f37ff0e71e1332c375dca5942cc6774ceec388a7bdb5dfcf6126bf53146887e0", "class_name": "RelatedNodeInfo"}}, "text": "Congratulations on a nice start to the year. ", "start_char_idx": 2135, "end_char_idx": 2180, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8f5fb490-f85f-4038-88ad-0dd772b11bab": {"__data__": {"id_": "8f5fb490-f85f-4038-88ad-0dd772b11bab", "embedding": null, "metadata": {"window": "[Operator Instructions] And our first question will come from Lisa Gill with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much, and good afternoon.  Congratulations on a nice start to the year.  Brian, I know that it just came \nout, this new Safe Importation Action Plan.  But just being in Canada, how realistic is this that the manufacturers \nare going to allow product to go to Canada and then come back to the U.S.  and just given t he size of the \nCanadian market?  And what role do you think that McKesson can play as the largest distributor in Canada to \nmake sure that, one, product that is meant for Canada stays in Canada; and two, anything that does potentially \ncome back to the States  is safe?  \n ", "original_text": "Brian, I know that it just came \nout, this new Safe Importation Action Plan. ", "page_label": "9", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c9d94875-256d-4a67-9245-80e627b9c808", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "07c592dfde39dbc4d6758a03f76cd94c3f159df451ce7cf68f6adf6966a09924", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "48db25ce-d226-4004-8f64-4449a47ffca0", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................    \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And our first question will come from Lisa Gill with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much, and good afternoon.  Congratulations on a nice start to the year.  Brian, I know that it just came \nout, this new Safe Importation Action Plan.  But just being in Canada, how realistic is this that the manufacturers \nare going to allow product to go to Canada and then come back to the U.S.  and just given t he size of the \nCanadian market? ", "original_text": "Congratulations on a nice start to the year. ", "page_label": "9", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d4a63ae69ff7c924abe0135496b182d9fec278ad0e5b9f837c06e0d7272362b2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ea121744-c5a3-4b1b-8771-2c5a67df3050", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much, and good afternoon.  Congratulations on a nice start to the year.  Brian, I know that it just came \nout, this new Safe Importation Action Plan.  But just being in Canada, how realistic is this that the manufacturers \nare going to allow product to go to Canada and then come back to the U.S.  and just given t he size of the \nCanadian market?  And what role do you think that McKesson can play as the largest distributor in Canada to \nmake sure that, one, product that is meant for Canada stays in Canada; and two, anything that does potentially \ncome back to the States  is safe?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "But just being in Canada, how realistic is this that the manufacturers \nare going to allow product to go to Canada and then come back to the U.S. "}, "hash": "359253c969de1874baaa80d0010ea4e5258016f231c9ca94259b3edc082c6059", "class_name": "RelatedNodeInfo"}}, "text": "Brian, I know that it just came \nout, this new Safe Importation Action Plan. ", "start_char_idx": 2180, "end_char_idx": 2257, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ea121744-c5a3-4b1b-8771-2c5a67df3050": {"__data__": {"id_": "ea121744-c5a3-4b1b-8771-2c5a67df3050", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much, and good afternoon.  Congratulations on a nice start to the year.  Brian, I know that it just came \nout, this new Safe Importation Action Plan.  But just being in Canada, how realistic is this that the manufacturers \nare going to allow product to go to Canada and then come back to the U.S.  and just given t he size of the \nCanadian market?  And what role do you think that McKesson can play as the largest distributor in Canada to \nmake sure that, one, product that is meant for Canada stays in Canada; and two, anything that does potentially \ncome back to the States  is safe?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "But just being in Canada, how realistic is this that the manufacturers \nare going to allow product to go to Canada and then come back to the U.S. ", "page_label": "9", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c9d94875-256d-4a67-9245-80e627b9c808", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "07c592dfde39dbc4d6758a03f76cd94c3f159df451ce7cf68f6adf6966a09924", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8f5fb490-f85f-4038-88ad-0dd772b11bab", "node_type": "1", "metadata": {"window": "[Operator Instructions] And our first question will come from Lisa Gill with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much, and good afternoon.  Congratulations on a nice start to the year.  Brian, I know that it just came \nout, this new Safe Importation Action Plan.  But just being in Canada, how realistic is this that the manufacturers \nare going to allow product to go to Canada and then come back to the U.S.  and just given t he size of the \nCanadian market?  And what role do you think that McKesson can play as the largest distributor in Canada to \nmake sure that, one, product that is meant for Canada stays in Canada; and two, anything that does potentially \ncome back to the States  is safe?  \n ", "original_text": "Brian, I know that it just came \nout, this new Safe Importation Action Plan. ", "page_label": "9", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c6130b0f02ff3bbe429f97174741a2e03423547fb83b02755e49943a9bb893e3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "84acfb9b-7417-41a2-8d6c-4afea7fac76b", "node_type": "1", "metadata": {"window": "Congratulations on a nice start to the year.  Brian, I know that it just came \nout, this new Safe Importation Action Plan.  But just being in Canada, how realistic is this that the manufacturers \nare going to allow product to go to Canada and then come back to the U.S.  and just given t he size of the \nCanadian market?  And what role do you think that McKesson can play as the largest distributor in Canada to \nmake sure that, one, product that is meant for Canada stays in Canada; and two, anything that does potentially \ncome back to the States  is safe?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you, Lisa, for the question. ", "original_text": "and just given t he size of the \nCanadian market? "}, "hash": "60c0e810162ec58426e7750705fc485cabbd823021a9e22e0a665408f68c47b1", "class_name": "RelatedNodeInfo"}}, "text": "But just being in Canada, how realistic is this that the manufacturers \nare going to allow product to go to Canada and then come back to the U.S. ", "start_char_idx": 2257, "end_char_idx": 2403, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "84acfb9b-7417-41a2-8d6c-4afea7fac76b": {"__data__": {"id_": "84acfb9b-7417-41a2-8d6c-4afea7fac76b", "embedding": null, "metadata": {"window": "Congratulations on a nice start to the year.  Brian, I know that it just came \nout, this new Safe Importation Action Plan.  But just being in Canada, how realistic is this that the manufacturers \nare going to allow product to go to Canada and then come back to the U.S.  and just given t he size of the \nCanadian market?  And what role do you think that McKesson can play as the largest distributor in Canada to \nmake sure that, one, product that is meant for Canada stays in Canada; and two, anything that does potentially \ncome back to the States  is safe?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you, Lisa, for the question. ", "original_text": "and just given t he size of the \nCanadian market? ", "page_label": "9", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c9d94875-256d-4a67-9245-80e627b9c808", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "07c592dfde39dbc4d6758a03f76cd94c3f159df451ce7cf68f6adf6966a09924", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ea121744-c5a3-4b1b-8771-2c5a67df3050", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nThanks very much, and good afternoon.  Congratulations on a nice start to the year.  Brian, I know that it just came \nout, this new Safe Importation Action Plan.  But just being in Canada, how realistic is this that the manufacturers \nare going to allow product to go to Canada and then come back to the U.S.  and just given t he size of the \nCanadian market?  And what role do you think that McKesson can play as the largest distributor in Canada to \nmake sure that, one, product that is meant for Canada stays in Canada; and two, anything that does potentially \ncome back to the States  is safe?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "But just being in Canada, how realistic is this that the manufacturers \nare going to allow product to go to Canada and then come back to the U.S. ", "page_label": "9", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c3a7f9886defd88b0312e1d1a7ac8ea074c1c8d1b70269803f88badea2d1d8be", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ad53b70f-a64d-48dd-9057-84b194140119", "node_type": "1", "metadata": {"window": "Brian, I know that it just came \nout, this new Safe Importation Action Plan.  But just being in Canada, how realistic is this that the manufacturers \nare going to allow product to go to Canada and then come back to the U.S.  and just given t he size of the \nCanadian market?  And what role do you think that McKesson can play as the largest distributor in Canada to \nmake sure that, one, product that is meant for Canada stays in Canada; and two, anything that does potentially \ncome back to the States  is safe?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you, Lisa, for the question.  We do think McKesson is in a uniquely informed position, given our business in \nCanada and our presence here in the U.S. ", "original_text": "And what role do you think that McKesson can play as the largest distributor in Canada to \nmake sure that, one, product that is meant for Canada stays in Canada; and two, anything that does potentially \ncome back to the States  is safe?  \n "}, "hash": "1fa311ae82abc5caf4d99af66f4b547452a5e4f246479078db6a49a49e48857e", "class_name": "RelatedNodeInfo"}}, "text": "and just given t he size of the \nCanadian market? ", "start_char_idx": 2403, "end_char_idx": 2453, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ad53b70f-a64d-48dd-9057-84b194140119": {"__data__": {"id_": "ad53b70f-a64d-48dd-9057-84b194140119", "embedding": null, "metadata": {"window": "Brian, I know that it just came \nout, this new Safe Importation Action Plan.  But just being in Canada, how realistic is this that the manufacturers \nare going to allow product to go to Canada and then come back to the U.S.  and just given t he size of the \nCanadian market?  And what role do you think that McKesson can play as the largest distributor in Canada to \nmake sure that, one, product that is meant for Canada stays in Canada; and two, anything that does potentially \ncome back to the States  is safe?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you, Lisa, for the question.  We do think McKesson is in a uniquely informed position, given our business in \nCanada and our presence here in the U.S. ", "original_text": "And what role do you think that McKesson can play as the largest distributor in Canada to \nmake sure that, one, product that is meant for Canada stays in Canada; and two, anything that does potentially \ncome back to the States  is safe?  \n ", "page_label": "9", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c9d94875-256d-4a67-9245-80e627b9c808", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "07c592dfde39dbc4d6758a03f76cd94c3f159df451ce7cf68f6adf6966a09924", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "84acfb9b-7417-41a2-8d6c-4afea7fac76b", "node_type": "1", "metadata": {"window": "Congratulations on a nice start to the year.  Brian, I know that it just came \nout, this new Safe Importation Action Plan.  But just being in Canada, how realistic is this that the manufacturers \nare going to allow product to go to Canada and then come back to the U.S.  and just given t he size of the \nCanadian market?  And what role do you think that McKesson can play as the largest distributor in Canada to \nmake sure that, one, product that is meant for Canada stays in Canada; and two, anything that does potentially \ncome back to the States  is safe?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you, Lisa, for the question. ", "original_text": "and just given t he size of the \nCanadian market? ", "page_label": "9", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "663c53795bd687300d29844f0bc843b8652e71ace8d2ef38f363d61137505f97", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e283a170-2651-499d-b5d7-8121981eab9e", "node_type": "1", "metadata": {"window": "But just being in Canada, how realistic is this that the manufacturers \nare going to allow product to go to Canada and then come back to the U.S.  and just given t he size of the \nCanadian market?  And what role do you think that McKesson can play as the largest distributor in Canada to \nmake sure that, one, product that is meant for Canada stays in Canada; and two, anything that does potentially \ncome back to the States  is safe?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you, Lisa, for the question.  We do think McKesson is in a uniquely informed position, given our business in \nCanada and our presence here in the U.S.  obviously. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  "}, "hash": "6085e4d7f1896d44feed9e8aef1a354c23ecef2d76f15ef9d65617e5378db382", "class_name": "RelatedNodeInfo"}}, "text": "And what role do you think that McKesson can play as the largest distributor in Canada to \nmake sure that, one, product that is meant for Canada stays in Canada; and two, anything that does potentially \ncome back to the States  is safe?  \n ", "start_char_idx": 2453, "end_char_idx": 2693, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e283a170-2651-499d-b5d7-8121981eab9e": {"__data__": {"id_": "e283a170-2651-499d-b5d7-8121981eab9e", "embedding": null, "metadata": {"window": "But just being in Canada, how realistic is this that the manufacturers \nare going to allow product to go to Canada and then come back to the U.S.  and just given t he size of the \nCanadian market?  And what role do you think that McKesson can play as the largest distributor in Canada to \nmake sure that, one, product that is meant for Canada stays in Canada; and two, anything that does potentially \ncome back to the States  is safe?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you, Lisa, for the question.  We do think McKesson is in a uniquely informed position, given our business in \nCanada and our presence here in the U.S.  obviously. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "9", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c9d94875-256d-4a67-9245-80e627b9c808", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "07c592dfde39dbc4d6758a03f76cd94c3f159df451ce7cf68f6adf6966a09924", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ad53b70f-a64d-48dd-9057-84b194140119", "node_type": "1", "metadata": {"window": "Brian, I know that it just came \nout, this new Safe Importation Action Plan.  But just being in Canada, how realistic is this that the manufacturers \nare going to allow product to go to Canada and then come back to the U.S.  and just given t he size of the \nCanadian market?  And what role do you think that McKesson can play as the largest distributor in Canada to \nmake sure that, one, product that is meant for Canada stays in Canada; and two, anything that does potentially \ncome back to the States  is safe?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you, Lisa, for the question.  We do think McKesson is in a uniquely informed position, given our business in \nCanada and our presence here in the U.S. ", "original_text": "And what role do you think that McKesson can play as the largest distributor in Canada to \nmake sure that, one, product that is meant for Canada stays in Canada; and two, anything that does potentially \ncome back to the States  is safe?  \n ", "page_label": "9", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4599cc8e19744f20928698a6e79d64e94428b00c688e1b17162c6e3d113dc86d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "08e60536-6359-45d6-a4e3-f7de1f44b6d7", "node_type": "1", "metadata": {"window": "and just given t he size of the \nCanadian market?  And what role do you think that McKesson can play as the largest distributor in Canada to \nmake sure that, one, product that is meant for Canada stays in Canada; and two, anything that does potentially \ncome back to the States  is safe?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you, Lisa, for the question.  We do think McKesson is in a uniquely informed position, given our business in \nCanada and our presence here in the U.S.  obviously.  There were two tracks discussed in the plan that came out \ntoday. ", "original_text": "A \nThank you, Lisa, for the question. "}, "hash": "7e41ba13a8d847e6360c29b39d4841d93be9e24170cf12f7b65cce328d3abfc1", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "start_char_idx": 2693, "end_char_idx": 3022, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "08e60536-6359-45d6-a4e3-f7de1f44b6d7": {"__data__": {"id_": "08e60536-6359-45d6-a4e3-f7de1f44b6d7", "embedding": null, "metadata": {"window": "and just given t he size of the \nCanadian market?  And what role do you think that McKesson can play as the largest distributor in Canada to \nmake sure that, one, product that is meant for Canada stays in Canada; and two, anything that does potentially \ncome back to the States  is safe?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you, Lisa, for the question.  We do think McKesson is in a uniquely informed position, given our business in \nCanada and our presence here in the U.S.  obviously.  There were two tracks discussed in the plan that came out \ntoday. ", "original_text": "A \nThank you, Lisa, for the question. ", "page_label": "9", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c9d94875-256d-4a67-9245-80e627b9c808", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "07c592dfde39dbc4d6758a03f76cd94c3f159df451ce7cf68f6adf6966a09924", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e283a170-2651-499d-b5d7-8121981eab9e", "node_type": "1", "metadata": {"window": "But just being in Canada, how realistic is this that the manufacturers \nare going to allow product to go to Canada and then come back to the U.S.  and just given t he size of the \nCanadian market?  And what role do you think that McKesson can play as the largest distributor in Canada to \nmake sure that, one, product that is meant for Canada stays in Canada; and two, anything that does potentially \ncome back to the States  is safe?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you, Lisa, for the question.  We do think McKesson is in a uniquely informed position, given our business in \nCanada and our presence here in the U.S.  obviously. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "9", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "961049e7aebf7f45eaefcaa73ffc449bea41e5d1bd180cd79453b9ef4d77b22a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d1c44e23-aeb2-4752-a867-48f09cc9b8a5", "node_type": "1", "metadata": {"window": "And what role do you think that McKesson can play as the largest distributor in Canada to \nmake sure that, one, product that is meant for Canada stays in Canada; and two, anything that does potentially \ncome back to the States  is safe?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you, Lisa, for the question.  We do think McKesson is in a uniquely informed position, given our business in \nCanada and our presence here in the U.S.  obviously.  There were two tracks discussed in the plan that came out \ntoday.  I will say, I was encouraged by the fact that it was a invitation for industry and industry participants to bring \ntheir perspectives and knowledge into the discussion, and we will plan to be active ly engaged in that. ", "original_text": "We do think McKesson is in a uniquely informed position, given our business in \nCanada and our presence here in the U.S. "}, "hash": "6f851701cb2dd2134e5c463da4081a9874efc02c657040f36ed39ce8e24c9cd3", "class_name": "RelatedNodeInfo"}}, "text": "A \nThank you, Lisa, for the question. ", "start_char_idx": 3022, "end_char_idx": 3060, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d1c44e23-aeb2-4752-a867-48f09cc9b8a5": {"__data__": {"id_": "d1c44e23-aeb2-4752-a867-48f09cc9b8a5", "embedding": null, "metadata": {"window": "And what role do you think that McKesson can play as the largest distributor in Canada to \nmake sure that, one, product that is meant for Canada stays in Canada; and two, anything that does potentially \ncome back to the States  is safe?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you, Lisa, for the question.  We do think McKesson is in a uniquely informed position, given our business in \nCanada and our presence here in the U.S.  obviously.  There were two tracks discussed in the plan that came out \ntoday.  I will say, I was encouraged by the fact that it was a invitation for industry and industry participants to bring \ntheir perspectives and knowledge into the discussion, and we will plan to be active ly engaged in that. ", "original_text": "We do think McKesson is in a uniquely informed position, given our business in \nCanada and our presence here in the U.S. ", "page_label": "9", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c9d94875-256d-4a67-9245-80e627b9c808", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "07c592dfde39dbc4d6758a03f76cd94c3f159df451ce7cf68f6adf6966a09924", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "08e60536-6359-45d6-a4e3-f7de1f44b6d7", "node_type": "1", "metadata": {"window": "and just given t he size of the \nCanadian market?  And what role do you think that McKesson can play as the largest distributor in Canada to \nmake sure that, one, product that is meant for Canada stays in Canada; and two, anything that does potentially \ncome back to the States  is safe?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you, Lisa, for the question.  We do think McKesson is in a uniquely informed position, given our business in \nCanada and our presence here in the U.S.  obviously.  There were two tracks discussed in the plan that came out \ntoday. ", "original_text": "A \nThank you, Lisa, for the question. ", "page_label": "9", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e91d5b10285a1d7991035ad157a702647a1cbd848239dfa351a8569f3f085dcb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9998aaf8-7048-4205-ae56-0926ddc18f20", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you, Lisa, for the question.  We do think McKesson is in a uniquely informed position, given our business in \nCanada and our presence here in the U.S.  obviously.  There were two tracks discussed in the plan that came out \ntoday.  I will say, I was encouraged by the fact that it was a invitation for industry and industry participants to bring \ntheir perspectives and knowledge into the discussion, and we will plan to be active ly engaged in that.  Our first and \nforemost responsibility and priority will be the safety and security of the supply chain both in the U.S. ", "original_text": "obviously. "}, "hash": "c8574a0a6e8c295397df3e449b652a66bb472ffa00a07e76ff5ec49eadcecad0", "class_name": "RelatedNodeInfo"}}, "text": "We do think McKesson is in a uniquely informed position, given our business in \nCanada and our presence here in the U.S. ", "start_char_idx": 3060, "end_char_idx": 3181, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9998aaf8-7048-4205-ae56-0926ddc18f20": {"__data__": {"id_": "9998aaf8-7048-4205-ae56-0926ddc18f20", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you, Lisa, for the question.  We do think McKesson is in a uniquely informed position, given our business in \nCanada and our presence here in the U.S.  obviously.  There were two tracks discussed in the plan that came out \ntoday.  I will say, I was encouraged by the fact that it was a invitation for industry and industry participants to bring \ntheir perspectives and knowledge into the discussion, and we will plan to be active ly engaged in that.  Our first and \nforemost responsibility and priority will be the safety and security of the supply chain both in the U.S. ", "original_text": "obviously. ", "page_label": "9", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c9d94875-256d-4a67-9245-80e627b9c808", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "07c592dfde39dbc4d6758a03f76cd94c3f159df451ce7cf68f6adf6966a09924", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d1c44e23-aeb2-4752-a867-48f09cc9b8a5", "node_type": "1", "metadata": {"window": "And what role do you think that McKesson can play as the largest distributor in Canada to \nmake sure that, one, product that is meant for Canada stays in Canada; and two, anything that does potentially \ncome back to the States  is safe?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you, Lisa, for the question.  We do think McKesson is in a uniquely informed position, given our business in \nCanada and our presence here in the U.S.  obviously.  There were two tracks discussed in the plan that came out \ntoday.  I will say, I was encouraged by the fact that it was a invitation for industry and industry participants to bring \ntheir perspectives and knowledge into the discussion, and we will plan to be active ly engaged in that. ", "original_text": "We do think McKesson is in a uniquely informed position, given our business in \nCanada and our presence here in the U.S. ", "page_label": "9", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cf33cf97e1e720fac633966a766e79d3d89621435d0a9a58f4820372401f6175", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e1268fae-62fe-4bbb-a3d8-8ea658347b4f", "node_type": "1", "metadata": {"window": "A \nThank you, Lisa, for the question.  We do think McKesson is in a uniquely informed position, given our business in \nCanada and our presence here in the U.S.  obviously.  There were two tracks discussed in the plan that came out \ntoday.  I will say, I was encouraged by the fact that it was a invitation for industry and industry participants to bring \ntheir perspectives and knowledge into the discussion, and we will plan to be active ly engaged in that.  Our first and \nforemost responsibility and priority will be the safety and security of the supply chain both in the U.S.  and in \nCanada.  \n \n", "original_text": "There were two tracks discussed in the plan that came out \ntoday. "}, "hash": "d412797ac8275d74aa92046ec7bfeb77e0c0b3bad0a41351593d88a016123e4c", "class_name": "RelatedNodeInfo"}}, "text": "obviously. ", "start_char_idx": 3181, "end_char_idx": 3192, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e1268fae-62fe-4bbb-a3d8-8ea658347b4f": {"__data__": {"id_": "e1268fae-62fe-4bbb-a3d8-8ea658347b4f", "embedding": null, "metadata": {"window": "A \nThank you, Lisa, for the question.  We do think McKesson is in a uniquely informed position, given our business in \nCanada and our presence here in the U.S.  obviously.  There were two tracks discussed in the plan that came out \ntoday.  I will say, I was encouraged by the fact that it was a invitation for industry and industry participants to bring \ntheir perspectives and knowledge into the discussion, and we will plan to be active ly engaged in that.  Our first and \nforemost responsibility and priority will be the safety and security of the supply chain both in the U.S.  and in \nCanada.  \n \n", "original_text": "There were two tracks discussed in the plan that came out \ntoday. ", "page_label": "9", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c9d94875-256d-4a67-9245-80e627b9c808", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "07c592dfde39dbc4d6758a03f76cd94c3f159df451ce7cf68f6adf6966a09924", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9998aaf8-7048-4205-ae56-0926ddc18f20", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you, Lisa, for the question.  We do think McKesson is in a uniquely informed position, given our business in \nCanada and our presence here in the U.S.  obviously.  There were two tracks discussed in the plan that came out \ntoday.  I will say, I was encouraged by the fact that it was a invitation for industry and industry participants to bring \ntheir perspectives and knowledge into the discussion, and we will plan to be active ly engaged in that.  Our first and \nforemost responsibility and priority will be the safety and security of the supply chain both in the U.S. ", "original_text": "obviously. ", "page_label": "9", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1b5d424be1b3a7b5fdf844b3a5542cc3dc82bd3ca12e33e8b947505da7600ffe", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1ce836ef-6b2d-4d74-9a2a-5dd5229b1e07", "node_type": "1", "metadata": {"window": "We do think McKesson is in a uniquely informed position, given our business in \nCanada and our presence here in the U.S.  obviously.  There were two tracks discussed in the plan that came out \ntoday.  I will say, I was encouraged by the fact that it was a invitation for industry and industry participants to bring \ntheir perspectives and knowledge into the discussion, and we will plan to be active ly engaged in that.  Our first and \nforemost responsibility and priority will be the safety and security of the supply chain both in the U.S.  and in \nCanada.  \n \n Now, you rightly point out the Canadian market from a population standpoint is less than a tenth of the U.S., and I \nsuppose that various manufacturers will adopt various perspectives on what they may or may not do. ", "original_text": "I will say, I was encouraged by the fact that it was a invitation for industry and industry participants to bring \ntheir perspectives and knowledge into the discussion, and we will plan to be active ly engaged in that. "}, "hash": "6ec62472b3646f0a26d1ac8d03438bc238f6b1f6b0767f3579f7c8a943daa361", "class_name": "RelatedNodeInfo"}}, "text": "There were two tracks discussed in the plan that came out \ntoday. ", "start_char_idx": 3192, "end_char_idx": 3258, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1ce836ef-6b2d-4d74-9a2a-5dd5229b1e07": {"__data__": {"id_": "1ce836ef-6b2d-4d74-9a2a-5dd5229b1e07", "embedding": null, "metadata": {"window": "We do think McKesson is in a uniquely informed position, given our business in \nCanada and our presence here in the U.S.  obviously.  There were two tracks discussed in the plan that came out \ntoday.  I will say, I was encouraged by the fact that it was a invitation for industry and industry participants to bring \ntheir perspectives and knowledge into the discussion, and we will plan to be active ly engaged in that.  Our first and \nforemost responsibility and priority will be the safety and security of the supply chain both in the U.S.  and in \nCanada.  \n \n Now, you rightly point out the Canadian market from a population standpoint is less than a tenth of the U.S., and I \nsuppose that various manufacturers will adopt various perspectives on what they may or may not do. ", "original_text": "I will say, I was encouraged by the fact that it was a invitation for industry and industry participants to bring \ntheir perspectives and knowledge into the discussion, and we will plan to be active ly engaged in that. ", "page_label": "9", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c9d94875-256d-4a67-9245-80e627b9c808", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "07c592dfde39dbc4d6758a03f76cd94c3f159df451ce7cf68f6adf6966a09924", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e1268fae-62fe-4bbb-a3d8-8ea658347b4f", "node_type": "1", "metadata": {"window": "A \nThank you, Lisa, for the question.  We do think McKesson is in a uniquely informed position, given our business in \nCanada and our presence here in the U.S.  obviously.  There were two tracks discussed in the plan that came out \ntoday.  I will say, I was encouraged by the fact that it was a invitation for industry and industry participants to bring \ntheir perspectives and knowledge into the discussion, and we will plan to be active ly engaged in that.  Our first and \nforemost responsibility and priority will be the safety and security of the supply chain both in the U.S.  and in \nCanada.  \n \n", "original_text": "There were two tracks discussed in the plan that came out \ntoday. ", "page_label": "9", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ee28f0ede2c02e35ce9dde7fac6f7c8255bc2c38e2fad5ab659d738662d09dc3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8c77052c-7dc0-4445-8dd8-610afc9d195b", "node_type": "1", "metadata": {"window": "obviously.  There were two tracks discussed in the plan that came out \ntoday.  I will say, I was encouraged by the fact that it was a invitation for industry and industry participants to bring \ntheir perspectives and knowledge into the discussion, and we will plan to be active ly engaged in that.  Our first and \nforemost responsibility and priority will be the safety and security of the supply chain both in the U.S.  and in \nCanada.  \n \n Now, you rightly point out the Canadian market from a population standpoint is less than a tenth of the U.S., and I \nsuppose that various manufacturers will adopt various perspectives on what they may or may not do.  We will \ncarefully evaluate with various industry partners what the opportunity may be, but the overarching goal will be \nsafety and security f or citizens both north and south of the Canadian -U.S. ", "original_text": "Our first and \nforemost responsibility and priority will be the safety and security of the supply chain both in the U.S. "}, "hash": "434ea85d74de4b2fba8c06636cd917814c9ded49d5ed6403fb047b2acba24cab", "class_name": "RelatedNodeInfo"}}, "text": "I will say, I was encouraged by the fact that it was a invitation for industry and industry participants to bring \ntheir perspectives and knowledge into the discussion, and we will plan to be active ly engaged in that. ", "start_char_idx": 3258, "end_char_idx": 3477, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8c77052c-7dc0-4445-8dd8-610afc9d195b": {"__data__": {"id_": "8c77052c-7dc0-4445-8dd8-610afc9d195b", "embedding": null, "metadata": {"window": "obviously.  There were two tracks discussed in the plan that came out \ntoday.  I will say, I was encouraged by the fact that it was a invitation for industry and industry participants to bring \ntheir perspectives and knowledge into the discussion, and we will plan to be active ly engaged in that.  Our first and \nforemost responsibility and priority will be the safety and security of the supply chain both in the U.S.  and in \nCanada.  \n \n Now, you rightly point out the Canadian market from a population standpoint is less than a tenth of the U.S., and I \nsuppose that various manufacturers will adopt various perspectives on what they may or may not do.  We will \ncarefully evaluate with various industry partners what the opportunity may be, but the overarching goal will be \nsafety and security f or citizens both north and south of the Canadian -U.S. ", "original_text": "Our first and \nforemost responsibility and priority will be the safety and security of the supply chain both in the U.S. ", "page_label": "9", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c9d94875-256d-4a67-9245-80e627b9c808", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "07c592dfde39dbc4d6758a03f76cd94c3f159df451ce7cf68f6adf6966a09924", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1ce836ef-6b2d-4d74-9a2a-5dd5229b1e07", "node_type": "1", "metadata": {"window": "We do think McKesson is in a uniquely informed position, given our business in \nCanada and our presence here in the U.S.  obviously.  There were two tracks discussed in the plan that came out \ntoday.  I will say, I was encouraged by the fact that it was a invitation for industry and industry participants to bring \ntheir perspectives and knowledge into the discussion, and we will plan to be active ly engaged in that.  Our first and \nforemost responsibility and priority will be the safety and security of the supply chain both in the U.S.  and in \nCanada.  \n \n Now, you rightly point out the Canadian market from a population standpoint is less than a tenth of the U.S., and I \nsuppose that various manufacturers will adopt various perspectives on what they may or may not do. ", "original_text": "I will say, I was encouraged by the fact that it was a invitation for industry and industry participants to bring \ntheir perspectives and knowledge into the discussion, and we will plan to be active ly engaged in that. ", "page_label": "9", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0ff92f57db9eb6e0b3332547a6a7b264eb4d3e13833cdb468abfcce620ccc355", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5296fe89-659d-4365-acc4-7c3be8c4ee63", "node_type": "1", "metadata": {"window": "There were two tracks discussed in the plan that came out \ntoday.  I will say, I was encouraged by the fact that it was a invitation for industry and industry participants to bring \ntheir perspectives and knowledge into the discussion, and we will plan to be active ly engaged in that.  Our first and \nforemost responsibility and priority will be the safety and security of the supply chain both in the U.S.  and in \nCanada.  \n \n Now, you rightly point out the Canadian market from a population standpoint is less than a tenth of the U.S., and I \nsuppose that various manufacturers will adopt various perspectives on what they may or may not do.  We will \ncarefully evaluate with various industry partners what the opportunity may be, but the overarching goal will be \nsafety and security f or citizens both north and south of the Canadian -U.S.  border.  \n ", "original_text": "and in \nCanada.  \n \n"}, "hash": "37e668b8722246367407523dd3da098528de0c2ebc14db3a6761c1ab7692c4e1", "class_name": "RelatedNodeInfo"}}, "text": "Our first and \nforemost responsibility and priority will be the safety and security of the supply chain both in the U.S. ", "start_char_idx": 3477, "end_char_idx": 3598, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5296fe89-659d-4365-acc4-7c3be8c4ee63": {"__data__": {"id_": "5296fe89-659d-4365-acc4-7c3be8c4ee63", "embedding": null, "metadata": {"window": "There were two tracks discussed in the plan that came out \ntoday.  I will say, I was encouraged by the fact that it was a invitation for industry and industry participants to bring \ntheir perspectives and knowledge into the discussion, and we will plan to be active ly engaged in that.  Our first and \nforemost responsibility and priority will be the safety and security of the supply chain both in the U.S.  and in \nCanada.  \n \n Now, you rightly point out the Canadian market from a population standpoint is less than a tenth of the U.S., and I \nsuppose that various manufacturers will adopt various perspectives on what they may or may not do.  We will \ncarefully evaluate with various industry partners what the opportunity may be, but the overarching goal will be \nsafety and security f or citizens both north and south of the Canadian -U.S.  border.  \n ", "original_text": "and in \nCanada.  \n \n", "page_label": "9", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c9d94875-256d-4a67-9245-80e627b9c808", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "07c592dfde39dbc4d6758a03f76cd94c3f159df451ce7cf68f6adf6966a09924", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8c77052c-7dc0-4445-8dd8-610afc9d195b", "node_type": "1", "metadata": {"window": "obviously.  There were two tracks discussed in the plan that came out \ntoday.  I will say, I was encouraged by the fact that it was a invitation for industry and industry participants to bring \ntheir perspectives and knowledge into the discussion, and we will plan to be active ly engaged in that.  Our first and \nforemost responsibility and priority will be the safety and security of the supply chain both in the U.S.  and in \nCanada.  \n \n Now, you rightly point out the Canadian market from a population standpoint is less than a tenth of the U.S., and I \nsuppose that various manufacturers will adopt various perspectives on what they may or may not do.  We will \ncarefully evaluate with various industry partners what the opportunity may be, but the overarching goal will be \nsafety and security f or citizens both north and south of the Canadian -U.S. ", "original_text": "Our first and \nforemost responsibility and priority will be the safety and security of the supply chain both in the U.S. ", "page_label": "9", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3f797faf56a2ade3ea53f77a494ad3d459b82aeeccc7348815bbe27346a1a160", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5ee95490-b243-4078-a345-1eb18bff7987", "node_type": "1", "metadata": {"window": "I will say, I was encouraged by the fact that it was a invitation for industry and industry participants to bring \ntheir perspectives and knowledge into the discussion, and we will plan to be active ly engaged in that.  Our first and \nforemost responsibility and priority will be the safety and security of the supply chain both in the U.S.  and in \nCanada.  \n \n Now, you rightly point out the Canadian market from a population standpoint is less than a tenth of the U.S., and I \nsuppose that various manufacturers will adopt various perspectives on what they may or may not do.  We will \ncarefully evaluate with various industry partners what the opportunity may be, but the overarching goal will be \nsafety and security f or citizens both north and south of the Canadian -U.S.  border.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q ", "original_text": "Now, you rightly point out the Canadian market from a population standpoint is less than a tenth of the U.S., and I \nsuppose that various manufacturers will adopt various perspectives on what they may or may not do. "}, "hash": "0b49d157b617468c01f60b706aaaad815614dcb1f1f97906595c0a44b969c09d", "class_name": "RelatedNodeInfo"}}, "text": "and in \nCanada.  \n \n", "start_char_idx": 3598, "end_char_idx": 3618, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5ee95490-b243-4078-a345-1eb18bff7987": {"__data__": {"id_": "5ee95490-b243-4078-a345-1eb18bff7987", "embedding": null, "metadata": {"window": "I will say, I was encouraged by the fact that it was a invitation for industry and industry participants to bring \ntheir perspectives and knowledge into the discussion, and we will plan to be active ly engaged in that.  Our first and \nforemost responsibility and priority will be the safety and security of the supply chain both in the U.S.  and in \nCanada.  \n \n Now, you rightly point out the Canadian market from a population standpoint is less than a tenth of the U.S., and I \nsuppose that various manufacturers will adopt various perspectives on what they may or may not do.  We will \ncarefully evaluate with various industry partners what the opportunity may be, but the overarching goal will be \nsafety and security f or citizens both north and south of the Canadian -U.S.  border.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q ", "original_text": "Now, you rightly point out the Canadian market from a population standpoint is less than a tenth of the U.S., and I \nsuppose that various manufacturers will adopt various perspectives on what they may or may not do. ", "page_label": "9", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c9d94875-256d-4a67-9245-80e627b9c808", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "07c592dfde39dbc4d6758a03f76cd94c3f159df451ce7cf68f6adf6966a09924", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5296fe89-659d-4365-acc4-7c3be8c4ee63", "node_type": "1", "metadata": {"window": "There were two tracks discussed in the plan that came out \ntoday.  I will say, I was encouraged by the fact that it was a invitation for industry and industry participants to bring \ntheir perspectives and knowledge into the discussion, and we will plan to be active ly engaged in that.  Our first and \nforemost responsibility and priority will be the safety and security of the supply chain both in the U.S.  and in \nCanada.  \n \n Now, you rightly point out the Canadian market from a population standpoint is less than a tenth of the U.S., and I \nsuppose that various manufacturers will adopt various perspectives on what they may or may not do.  We will \ncarefully evaluate with various industry partners what the opportunity may be, but the overarching goal will be \nsafety and security f or citizens both north and south of the Canadian -U.S.  border.  \n ", "original_text": "and in \nCanada.  \n \n", "page_label": "9", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f5a52ee6843cb9a2c35b46023d809c8b8f73ae2cd184643fe40dcb84a7849134", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bf7e8794-b6f6-4c09-a71b-3b958c066d67", "node_type": "1", "metadata": {"window": "Our first and \nforemost responsibility and priority will be the safety and security of the supply chain both in the U.S.  and in \nCanada.  \n \n Now, you rightly point out the Canadian market from a population standpoint is less than a tenth of the U.S., and I \nsuppose that various manufacturers will adopt various perspectives on what they may or may not do.  We will \ncarefully evaluate with various industry partners what the opportunity may be, but the overarching goal will be \nsafety and security f or citizens both north and south of the Canadian -U.S.  border.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q ", "original_text": "We will \ncarefully evaluate with various industry partners what the opportunity may be, but the overarching goal will be \nsafety and security f or citizens both north and south of the Canadian -U.S. "}, "hash": "45eeb9cc04de9c7c7538c35540eeb684622b4e28d4a99189e3ebceb1d2105926", "class_name": "RelatedNodeInfo"}}, "text": "Now, you rightly point out the Canadian market from a population standpoint is less than a tenth of the U.S., and I \nsuppose that various manufacturers will adopt various perspectives on what they may or may not do. ", "start_char_idx": 3618, "end_char_idx": 3834, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bf7e8794-b6f6-4c09-a71b-3b958c066d67": {"__data__": {"id_": "bf7e8794-b6f6-4c09-a71b-3b958c066d67", "embedding": null, "metadata": {"window": "Our first and \nforemost responsibility and priority will be the safety and security of the supply chain both in the U.S.  and in \nCanada.  \n \n Now, you rightly point out the Canadian market from a population standpoint is less than a tenth of the U.S., and I \nsuppose that various manufacturers will adopt various perspectives on what they may or may not do.  We will \ncarefully evaluate with various industry partners what the opportunity may be, but the overarching goal will be \nsafety and security f or citizens both north and south of the Canadian -U.S.  border.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q ", "original_text": "We will \ncarefully evaluate with various industry partners what the opportunity may be, but the overarching goal will be \nsafety and security f or citizens both north and south of the Canadian -U.S. ", "page_label": "9", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c9d94875-256d-4a67-9245-80e627b9c808", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "07c592dfde39dbc4d6758a03f76cd94c3f159df451ce7cf68f6adf6966a09924", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5ee95490-b243-4078-a345-1eb18bff7987", "node_type": "1", "metadata": {"window": "I will say, I was encouraged by the fact that it was a invitation for industry and industry participants to bring \ntheir perspectives and knowledge into the discussion, and we will plan to be active ly engaged in that.  Our first and \nforemost responsibility and priority will be the safety and security of the supply chain both in the U.S.  and in \nCanada.  \n \n Now, you rightly point out the Canadian market from a population standpoint is less than a tenth of the U.S., and I \nsuppose that various manufacturers will adopt various perspectives on what they may or may not do.  We will \ncarefully evaluate with various industry partners what the opportunity may be, but the overarching goal will be \nsafety and security f or citizens both north and south of the Canadian -U.S.  border.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q ", "original_text": "Now, you rightly point out the Canadian market from a population standpoint is less than a tenth of the U.S., and I \nsuppose that various manufacturers will adopt various perspectives on what they may or may not do. ", "page_label": "9", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1d28ac877935d84547405bc30dc1f4b5e20b39c7f37a07fdf0229af31585f9e3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4bf78e3d-536b-4092-a4a6-95664d1de595", "node_type": "1", "metadata": {"window": "and in \nCanada.  \n \n Now, you rightly point out the Canadian market from a population standpoint is less than a tenth of the U.S., and I \nsuppose that various manufacturers will adopt various perspectives on what they may or may not do.  We will \ncarefully evaluate with various industry partners what the opportunity may be, but the overarching goal will be \nsafety and security f or citizens both north and south of the Canadian -U.S.  border.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q ", "original_text": "border.  \n "}, "hash": "288705474cc8ac7c4b40420fdfad4125e9ebc749d335adc632930a2fb2deb733", "class_name": "RelatedNodeInfo"}}, "text": "We will \ncarefully evaluate with various industry partners what the opportunity may be, but the overarching goal will be \nsafety and security f or citizens both north and south of the Canadian -U.S. ", "start_char_idx": 3834, "end_char_idx": 4033, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4bf78e3d-536b-4092-a4a6-95664d1de595": {"__data__": {"id_": "4bf78e3d-536b-4092-a4a6-95664d1de595", "embedding": null, "metadata": {"window": "and in \nCanada.  \n \n Now, you rightly point out the Canadian market from a population standpoint is less than a tenth of the U.S., and I \nsuppose that various manufacturers will adopt various perspectives on what they may or may not do.  We will \ncarefully evaluate with various industry partners what the opportunity may be, but the overarching goal will be \nsafety and security f or citizens both north and south of the Canadian -U.S.  border.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q ", "original_text": "border.  \n ", "page_label": "9", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c9d94875-256d-4a67-9245-80e627b9c808", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "07c592dfde39dbc4d6758a03f76cd94c3f159df451ce7cf68f6adf6966a09924", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bf7e8794-b6f6-4c09-a71b-3b958c066d67", "node_type": "1", "metadata": {"window": "Our first and \nforemost responsibility and priority will be the safety and security of the supply chain both in the U.S.  and in \nCanada.  \n \n Now, you rightly point out the Canadian market from a population standpoint is less than a tenth of the U.S., and I \nsuppose that various manufacturers will adopt various perspectives on what they may or may not do.  We will \ncarefully evaluate with various industry partners what the opportunity may be, but the overarching goal will be \nsafety and security f or citizens both north and south of the Canadian -U.S.  border.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q ", "original_text": "We will \ncarefully evaluate with various industry partners what the opportunity may be, but the overarching goal will be \nsafety and security f or citizens both north and south of the Canadian -U.S. ", "page_label": "9", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f04f402bb5b3109d4f0a5418aaaf3af8d7d6f0c560f228083090ebf169fb07b7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f45499d6-d081-40a1-b1d0-422296e2399a", "node_type": "1", "metadata": {"window": "Now, you rightly point out the Canadian market from a population standpoint is less than a tenth of the U.S., and I \nsuppose that various manufacturers will adopt various perspectives on what they may or may not do.  We will \ncarefully evaluate with various industry partners what the opportunity may be, but the overarching goal will be \nsafety and security f or citizens both north and south of the Canadian -U.S.  border.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q "}, "hash": "2f12c54588e2d28b8405478c6b4d912a5649690268a6d589f6d454481a8b5955", "class_name": "RelatedNodeInfo"}}, "text": "border.  \n ", "start_char_idx": 4033, "end_char_idx": 4044, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f45499d6-d081-40a1-b1d0-422296e2399a": {"__data__": {"id_": "f45499d6-d081-40a1-b1d0-422296e2399a", "embedding": null, "metadata": {"window": "Now, you rightly point out the Canadian market from a population standpoint is less than a tenth of the U.S., and I \nsuppose that various manufacturers will adopt various perspectives on what they may or may not do.  We will \ncarefully evaluate with various industry partners what the opportunity may be, but the overarching goal will be \nsafety and security f or citizens both north and south of the Canadian -U.S.  border.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q ", "page_label": "9", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c9d94875-256d-4a67-9245-80e627b9c808", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "07c592dfde39dbc4d6758a03f76cd94c3f159df451ce7cf68f6adf6966a09924", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4bf78e3d-536b-4092-a4a6-95664d1de595", "node_type": "1", "metadata": {"window": "and in \nCanada.  \n \n Now, you rightly point out the Canadian market from a population standpoint is less than a tenth of the U.S., and I \nsuppose that various manufacturers will adopt various perspectives on what they may or may not do.  We will \ncarefully evaluate with various industry partners what the opportunity may be, but the overarching goal will be \nsafety and security f or citizens both north and south of the Canadian -U.S.  border.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q ", "original_text": "border.  \n ", "page_label": "9", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e4a31d924716b13e8dbf08de95709c646a6dedfba629eb0f4d251f6e22b9be96", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "614acf3a-15a9-4cf6-83b6-bdccd7a7710c", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nAnd then just as a follow -up.  Clearly, what they're trying to solve for here is overall drug pricing.  You or Britt, can \nyou talk about what we saw on the quarter around drug price inflation on the branded side as well as the \ngenerics? ", "original_text": "McKesson Corp.  "}, "hash": "5a9b171841890236287baaae1499433491e84c880bc774950395a9a63109bd3a", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q ", "start_char_idx": 1788, "end_char_idx": 2096, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "614acf3a-15a9-4cf6-83b6-bdccd7a7710c": {"__data__": {"id_": "614acf3a-15a9-4cf6-83b6-bdccd7a7710c", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nAnd then just as a follow -up.  Clearly, what they're trying to solve for here is overall drug pricing.  You or Britt, can \nyou talk about what we saw on the quarter around drug price inflation on the branded side as well as the \ngenerics? ", "original_text": "McKesson Corp.  ", "page_label": "10", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6959410c-ab10-4777-9191-d5a85e8e51b3", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "064afa09a15e30ad27bda1a73a8ba51f7b50788ebb028522a98bdffc4f372e61", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f45499d6-d081-40a1-b1d0-422296e2399a", "node_type": "1", "metadata": {"window": "Now, you rightly point out the Canadian market from a population standpoint is less than a tenth of the U.S., and I \nsuppose that various manufacturers will adopt various perspectives on what they may or may not do.  We will \ncarefully evaluate with various industry partners what the opportunity may be, but the overarching goal will be \nsafety and security f or citizens both north and south of the Canadian -U.S.  border.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q ", "page_label": "9", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "41cbdd3f6f59af1102a628bb1c0f78aaa58fe88114725304e373f40a1d863a73", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "28ddf599-8ffe-480a-aa56-7453f8f20064", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nAnd then just as a follow -up.  Clearly, what they're trying to solve for here is overall drug pricing.  You or Britt, can \nyou talk about what we saw on the quarter around drug price inflation on the branded side as well as the \ngenerics?  Clearly, quarterly results coming better and better, especially on the drug distribution U.S. ", "original_text": "(MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nAnd then just as a follow -up. "}, "hash": "dcdb2bb0e22386b928ca0d99082c44476455eef231a0f9cd197aed29bc33e5bb", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "28ddf599-8ffe-480a-aa56-7453f8f20064": {"__data__": {"id_": "28ddf599-8ffe-480a-aa56-7453f8f20064", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nAnd then just as a follow -up.  Clearly, what they're trying to solve for here is overall drug pricing.  You or Britt, can \nyou talk about what we saw on the quarter around drug price inflation on the branded side as well as the \ngenerics?  Clearly, quarterly results coming better and better, especially on the drug distribution U.S. ", "original_text": "(MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nAnd then just as a follow -up. ", "page_label": "10", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6959410c-ab10-4777-9191-d5a85e8e51b3", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "064afa09a15e30ad27bda1a73a8ba51f7b50788ebb028522a98bdffc4f372e61", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "614acf3a-15a9-4cf6-83b6-bdccd7a7710c", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nAnd then just as a follow -up.  Clearly, what they're trying to solve for here is overall drug pricing.  You or Britt, can \nyou talk about what we saw on the quarter around drug price inflation on the branded side as well as the \ngenerics? ", "original_text": "McKesson Corp.  ", "page_label": "10", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c591095d02316b6ffc5654a81a070cc49c5cd27250e617e3ab588c92abe1ae57", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dbdd1526-49cd-43e0-b62f-f6564f88aaf3", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nAnd then just as a follow -up.  Clearly, what they're trying to solve for here is overall drug pricing.  You or Britt, can \nyou talk about what we saw on the quarter around drug price inflation on the branded side as well as the \ngenerics?  Clearly, quarterly results coming better and better, especially on the drug distribution U.S.  component \nof the business. ", "original_text": "Clearly, what they're trying to solve for here is overall drug pricing. "}, "hash": "77e70de28fa04c9688208df42e80e3b06cce2bcb04594074409387ed0eb22519", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nAnd then just as a follow -up. ", "start_char_idx": 16, "end_char_idx": 212, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dbdd1526-49cd-43e0-b62f-f6564f88aaf3": {"__data__": {"id_": "dbdd1526-49cd-43e0-b62f-f6564f88aaf3", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nAnd then just as a follow -up.  Clearly, what they're trying to solve for here is overall drug pricing.  You or Britt, can \nyou talk about what we saw on the quarter around drug price inflation on the branded side as well as the \ngenerics?  Clearly, quarterly results coming better and better, especially on the drug distribution U.S.  component \nof the business. ", "original_text": "Clearly, what they're trying to solve for here is overall drug pricing. ", "page_label": "10", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6959410c-ab10-4777-9191-d5a85e8e51b3", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "064afa09a15e30ad27bda1a73a8ba51f7b50788ebb028522a98bdffc4f372e61", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "28ddf599-8ffe-480a-aa56-7453f8f20064", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nAnd then just as a follow -up.  Clearly, what they're trying to solve for here is overall drug pricing.  You or Britt, can \nyou talk about what we saw on the quarter around drug price inflation on the branded side as well as the \ngenerics?  Clearly, quarterly results coming better and better, especially on the drug distribution U.S. ", "original_text": "(MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nAnd then just as a follow -up. ", "page_label": "10", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "23cbad9e2af49f4a40a23da757ae502f1f68949b960f372b74324e4d64bf17e7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2d29e897-1c64-4be9-9da7-4442e681fe8d", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nAnd then just as a follow -up.  Clearly, what they're trying to solve for here is overall drug pricing.  You or Britt, can \nyou talk about what we saw on the quarter around drug price inflation on the branded side as well as the \ngenerics?  Clearly, quarterly results coming better and better, especially on the drug distribution U.S.  component \nof the business.  So just wondering some of the key drivers t here as well as what you're seeing on both \ninflation/deflation in generics and branded.  \n ", "original_text": "You or Britt, can \nyou talk about what we saw on the quarter around drug price inflation on the branded side as well as the \ngenerics? "}, "hash": "917a652ee4814005483eb79049c371bf387754c41e81942d3a7185d1843532d8", "class_name": "RelatedNodeInfo"}}, "text": "Clearly, what they're trying to solve for here is overall drug pricing. ", "start_char_idx": 212, "end_char_idx": 284, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2d29e897-1c64-4be9-9da7-4442e681fe8d": {"__data__": {"id_": "2d29e897-1c64-4be9-9da7-4442e681fe8d", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nAnd then just as a follow -up.  Clearly, what they're trying to solve for here is overall drug pricing.  You or Britt, can \nyou talk about what we saw on the quarter around drug price inflation on the branded side as well as the \ngenerics?  Clearly, quarterly results coming better and better, especially on the drug distribution U.S.  component \nof the business.  So just wondering some of the key drivers t here as well as what you're seeing on both \ninflation/deflation in generics and branded.  \n ", "original_text": "You or Britt, can \nyou talk about what we saw on the quarter around drug price inflation on the branded side as well as the \ngenerics? ", "page_label": "10", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6959410c-ab10-4777-9191-d5a85e8e51b3", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "064afa09a15e30ad27bda1a73a8ba51f7b50788ebb028522a98bdffc4f372e61", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dbdd1526-49cd-43e0-b62f-f6564f88aaf3", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nAnd then just as a follow -up.  Clearly, what they're trying to solve for here is overall drug pricing.  You or Britt, can \nyou talk about what we saw on the quarter around drug price inflation on the branded side as well as the \ngenerics?  Clearly, quarterly results coming better and better, especially on the drug distribution U.S.  component \nof the business. ", "original_text": "Clearly, what they're trying to solve for here is overall drug pricing. ", "page_label": "10", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f2e0f54e4338d1c45a37df707e2ae7e8eb244ba02b82b2a67ee899ff431c08a0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "74f88487-d730-45ca-8988-2657062d55d0", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nAnd then just as a follow -up.  Clearly, what they're trying to solve for here is overall drug pricing.  You or Britt, can \nyou talk about what we saw on the quarter around drug price inflation on the branded side as well as the \ngenerics?  Clearly, quarterly results coming better and better, especially on the drug distribution U.S.  component \nof the business.  So just wondering some of the key drivers t here as well as what you're seeing on both \ninflation/deflation in generics and branded.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "Clearly, quarterly results coming better and better, especially on the drug distribution U.S. "}, "hash": "fcd316b6c68b62ca03f383f2837cea3d13a483119db8c6e388d0428092322d0b", "class_name": "RelatedNodeInfo"}}, "text": "You or Britt, can \nyou talk about what we saw on the quarter around drug price inflation on the branded side as well as the \ngenerics? ", "start_char_idx": 284, "end_char_idx": 419, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "74f88487-d730-45ca-8988-2657062d55d0": {"__data__": {"id_": "74f88487-d730-45ca-8988-2657062d55d0", "embedding": null, "metadata": {"window": "(MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nAnd then just as a follow -up.  Clearly, what they're trying to solve for here is overall drug pricing.  You or Britt, can \nyou talk about what we saw on the quarter around drug price inflation on the branded side as well as the \ngenerics?  Clearly, quarterly results coming better and better, especially on the drug distribution U.S.  component \nof the business.  So just wondering some of the key drivers t here as well as what you're seeing on both \ninflation/deflation in generics and branded.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "Clearly, quarterly results coming better and better, especially on the drug distribution U.S. ", "page_label": "10", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6959410c-ab10-4777-9191-d5a85e8e51b3", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "064afa09a15e30ad27bda1a73a8ba51f7b50788ebb028522a98bdffc4f372e61", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2d29e897-1c64-4be9-9da7-4442e681fe8d", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nAnd then just as a follow -up.  Clearly, what they're trying to solve for here is overall drug pricing.  You or Britt, can \nyou talk about what we saw on the quarter around drug price inflation on the branded side as well as the \ngenerics?  Clearly, quarterly results coming better and better, especially on the drug distribution U.S.  component \nof the business.  So just wondering some of the key drivers t here as well as what you're seeing on both \ninflation/deflation in generics and branded.  \n ", "original_text": "You or Britt, can \nyou talk about what we saw on the quarter around drug price inflation on the branded side as well as the \ngenerics? ", "page_label": "10", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ae41ca95b4b6dadffb317647b0a044782ad1438ef7578ee10dba28e075a6f3df", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c2c6b4e3-e4fe-42b7-a552-f1b87bae3519", "node_type": "1", "metadata": {"window": "Clearly, what they're trying to solve for here is overall drug pricing.  You or Britt, can \nyou talk about what we saw on the quarter around drug price inflation on the branded side as well as the \ngenerics?  Clearly, quarterly results coming better and better, especially on the drug distribution U.S.  component \nof the business.  So just wondering some of the key drivers t here as well as what you're seeing on both \ninflation/deflation in generics and branded.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nThanks for that question, Lisa. ", "original_text": "component \nof the business. "}, "hash": "63b79ed6113141bc709157509f6d09446aeaeebda5f9d7e5e4257f656e1470bb", "class_name": "RelatedNodeInfo"}}, "text": "Clearly, quarterly results coming better and better, especially on the drug distribution U.S. ", "start_char_idx": 419, "end_char_idx": 513, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c2c6b4e3-e4fe-42b7-a552-f1b87bae3519": {"__data__": {"id_": "c2c6b4e3-e4fe-42b7-a552-f1b87bae3519", "embedding": null, "metadata": {"window": "Clearly, what they're trying to solve for here is overall drug pricing.  You or Britt, can \nyou talk about what we saw on the quarter around drug price inflation on the branded side as well as the \ngenerics?  Clearly, quarterly results coming better and better, especially on the drug distribution U.S.  component \nof the business.  So just wondering some of the key drivers t here as well as what you're seeing on both \ninflation/deflation in generics and branded.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nThanks for that question, Lisa. ", "original_text": "component \nof the business. ", "page_label": "10", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6959410c-ab10-4777-9191-d5a85e8e51b3", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "064afa09a15e30ad27bda1a73a8ba51f7b50788ebb028522a98bdffc4f372e61", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "74f88487-d730-45ca-8988-2657062d55d0", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nAnd then just as a follow -up.  Clearly, what they're trying to solve for here is overall drug pricing.  You or Britt, can \nyou talk about what we saw on the quarter around drug price inflation on the branded side as well as the \ngenerics?  Clearly, quarterly results coming better and better, especially on the drug distribution U.S.  component \nof the business.  So just wondering some of the key drivers t here as well as what you're seeing on both \ninflation/deflation in generics and branded.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "Clearly, quarterly results coming better and better, especially on the drug distribution U.S. ", "page_label": "10", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0e191bbf6b81f7ca0174005a6bb6ce2b77b9bade80546ecb4ea4dbcbdd14436e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e67c6b9f-c752-4a46-9753-be4eb04af28f", "node_type": "1", "metadata": {"window": "You or Britt, can \nyou talk about what we saw on the quarter around drug price inflation on the branded side as well as the \ngenerics?  Clearly, quarterly results coming better and better, especially on the drug distribution U.S.  component \nof the business.  So just wondering some of the key drivers t here as well as what you're seeing on both \ninflation/deflation in generics and branded.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nThanks for that question, Lisa.  I'll start, and Brian can add. ", "original_text": "So just wondering some of the key drivers t here as well as what you're seeing on both \ninflation/deflation in generics and branded.  \n "}, "hash": "9ddbc79995e1e14c6790999f94bc8d1e5151fcb647c8e603e854304028a569fa", "class_name": "RelatedNodeInfo"}}, "text": "component \nof the business. ", "start_char_idx": 513, "end_char_idx": 541, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e67c6b9f-c752-4a46-9753-be4eb04af28f": {"__data__": {"id_": "e67c6b9f-c752-4a46-9753-be4eb04af28f", "embedding": null, "metadata": {"window": "You or Britt, can \nyou talk about what we saw on the quarter around drug price inflation on the branded side as well as the \ngenerics?  Clearly, quarterly results coming better and better, especially on the drug distribution U.S.  component \nof the business.  So just wondering some of the key drivers t here as well as what you're seeing on both \ninflation/deflation in generics and branded.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nThanks for that question, Lisa.  I'll start, and Brian can add. ", "original_text": "So just wondering some of the key drivers t here as well as what you're seeing on both \ninflation/deflation in generics and branded.  \n ", "page_label": "10", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6959410c-ab10-4777-9191-d5a85e8e51b3", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "064afa09a15e30ad27bda1a73a8ba51f7b50788ebb028522a98bdffc4f372e61", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c2c6b4e3-e4fe-42b7-a552-f1b87bae3519", "node_type": "1", "metadata": {"window": "Clearly, what they're trying to solve for here is overall drug pricing.  You or Britt, can \nyou talk about what we saw on the quarter around drug price inflation on the branded side as well as the \ngenerics?  Clearly, quarterly results coming better and better, especially on the drug distribution U.S.  component \nof the business.  So just wondering some of the key drivers t here as well as what you're seeing on both \ninflation/deflation in generics and branded.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nThanks for that question, Lisa. ", "original_text": "component \nof the business. ", "page_label": "10", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "04def6f60d2e6e10673e10d0d1bdb404948006ddbe644a8428ccc5dbdb38c433", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "be72a50b-dcf5-40de-8089-cf02972df366", "node_type": "1", "metadata": {"window": "Clearly, quarterly results coming better and better, especially on the drug distribution U.S.  component \nof the business.  So just wondering some of the key drivers t here as well as what you're seeing on both \ninflation/deflation in generics and branded.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nThanks for that question, Lisa.  I'll start, and Brian can add.  As we talked about in Brian's remarks, on the branded \nside what we saw from an inflation perspective was right along in line with our expectations. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  "}, "hash": "51fd437f65eb25e5e08a4de468d74b3a5bba2084cc4f4e1c756c603eb2e1326b", "class_name": "RelatedNodeInfo"}}, "text": "So just wondering some of the key drivers t here as well as what you're seeing on both \ninflation/deflation in generics and branded.  \n ", "start_char_idx": 541, "end_char_idx": 677, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "be72a50b-dcf5-40de-8089-cf02972df366": {"__data__": {"id_": "be72a50b-dcf5-40de-8089-cf02972df366", "embedding": null, "metadata": {"window": "Clearly, quarterly results coming better and better, especially on the drug distribution U.S.  component \nof the business.  So just wondering some of the key drivers t here as well as what you're seeing on both \ninflation/deflation in generics and branded.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nThanks for that question, Lisa.  I'll start, and Brian can add.  As we talked about in Brian's remarks, on the branded \nside what we saw from an inflation perspective was right along in line with our expectations. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "page_label": "10", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6959410c-ab10-4777-9191-d5a85e8e51b3", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "064afa09a15e30ad27bda1a73a8ba51f7b50788ebb028522a98bdffc4f372e61", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e67c6b9f-c752-4a46-9753-be4eb04af28f", "node_type": "1", "metadata": {"window": "You or Britt, can \nyou talk about what we saw on the quarter around drug price inflation on the branded side as well as the \ngenerics?  Clearly, quarterly results coming better and better, especially on the drug distribution U.S.  component \nof the business.  So just wondering some of the key drivers t here as well as what you're seeing on both \ninflation/deflation in generics and branded.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nThanks for that question, Lisa.  I'll start, and Brian can add. ", "original_text": "So just wondering some of the key drivers t here as well as what you're seeing on both \ninflation/deflation in generics and branded.  \n ", "page_label": "10", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b8a8d9a95f02385207fe01e023d83603e1d59a1a40fd9c04cca623bcebefba5a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "49f20cdd-0e14-4779-8c93-407bc72f3edd", "node_type": "1", "metadata": {"window": "component \nof the business.  So just wondering some of the key drivers t here as well as what you're seeing on both \ninflation/deflation in generics and branded.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nThanks for that question, Lisa.  I'll start, and Brian can add.  As we talked about in Brian's remarks, on the branded \nside what we saw from an inflation perspective was right along in line with our expectations.  As you know, the first \nquarter is generally a softer quarter for brand inflation historically, and what we saw this quart er was really in line \nwith our expectations. ", "original_text": "A \nThanks for that question, Lisa. "}, "hash": "80a212780a94c9d832fc96ab95dcb01769a63b1dd996ac7d2671158b0d1ea7df", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "start_char_idx": 677, "end_char_idx": 1022, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "49f20cdd-0e14-4779-8c93-407bc72f3edd": {"__data__": {"id_": "49f20cdd-0e14-4779-8c93-407bc72f3edd", "embedding": null, "metadata": {"window": "component \nof the business.  So just wondering some of the key drivers t here as well as what you're seeing on both \ninflation/deflation in generics and branded.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nThanks for that question, Lisa.  I'll start, and Brian can add.  As we talked about in Brian's remarks, on the branded \nside what we saw from an inflation perspective was right along in line with our expectations.  As you know, the first \nquarter is generally a softer quarter for brand inflation historically, and what we saw this quart er was really in line \nwith our expectations. ", "original_text": "A \nThanks for that question, Lisa. ", "page_label": "10", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6959410c-ab10-4777-9191-d5a85e8e51b3", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "064afa09a15e30ad27bda1a73a8ba51f7b50788ebb028522a98bdffc4f372e61", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "be72a50b-dcf5-40de-8089-cf02972df366", "node_type": "1", "metadata": {"window": "Clearly, quarterly results coming better and better, especially on the drug distribution U.S.  component \nof the business.  So just wondering some of the key drivers t here as well as what you're seeing on both \ninflation/deflation in generics and branded.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nThanks for that question, Lisa.  I'll start, and Brian can add.  As we talked about in Brian's remarks, on the branded \nside what we saw from an inflation perspective was right along in line with our expectations. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "page_label": "10", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7e124b482e33146de323f7aed7c9ce29525719b9f62acf8bb17ea917a093e914", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "298fae9c-25c8-4649-ba91-a2cd6ef6b10b", "node_type": "1", "metadata": {"window": "So just wondering some of the key drivers t here as well as what you're seeing on both \ninflation/deflation in generics and branded.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nThanks for that question, Lisa.  I'll start, and Brian can add.  As we talked about in Brian's remarks, on the branded \nside what we saw from an inflation perspective was right along in line with our expectations.  As you know, the first \nquarter is generally a softer quarter for brand inflation historically, and what we saw this quart er was really in line \nwith our expectations.  And as we think about the full year, we are reaffirming our guidance of mid -single digit \ninflation on the branded side.  \n \n", "original_text": "I'll start, and Brian can add. "}, "hash": "9ad8f9894f168c1ab14ab299b10100a04b0a152523c05f435fddf3e9de4c773a", "class_name": "RelatedNodeInfo"}}, "text": "A \nThanks for that question, Lisa. ", "start_char_idx": 1022, "end_char_idx": 1057, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "298fae9c-25c8-4649-ba91-a2cd6ef6b10b": {"__data__": {"id_": "298fae9c-25c8-4649-ba91-a2cd6ef6b10b", "embedding": null, "metadata": {"window": "So just wondering some of the key drivers t here as well as what you're seeing on both \ninflation/deflation in generics and branded.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nThanks for that question, Lisa.  I'll start, and Brian can add.  As we talked about in Brian's remarks, on the branded \nside what we saw from an inflation perspective was right along in line with our expectations.  As you know, the first \nquarter is generally a softer quarter for brand inflation historically, and what we saw this quart er was really in line \nwith our expectations.  And as we think about the full year, we are reaffirming our guidance of mid -single digit \ninflation on the branded side.  \n \n", "original_text": "I'll start, and Brian can add. ", "page_label": "10", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6959410c-ab10-4777-9191-d5a85e8e51b3", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "064afa09a15e30ad27bda1a73a8ba51f7b50788ebb028522a98bdffc4f372e61", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "49f20cdd-0e14-4779-8c93-407bc72f3edd", "node_type": "1", "metadata": {"window": "component \nof the business.  So just wondering some of the key drivers t here as well as what you're seeing on both \ninflation/deflation in generics and branded.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nThanks for that question, Lisa.  I'll start, and Brian can add.  As we talked about in Brian's remarks, on the branded \nside what we saw from an inflation perspective was right along in line with our expectations.  As you know, the first \nquarter is generally a softer quarter for brand inflation historically, and what we saw this quart er was really in line \nwith our expectations. ", "original_text": "A \nThanks for that question, Lisa. ", "page_label": "10", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d2f8b5baa2fb2fd42ab759b3ef6e24fb5fd32c01ecc5e630fdaf3a542205970d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f4f4ee72-5fb1-4115-832f-c796654b75f4", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nThanks for that question, Lisa.  I'll start, and Brian can add.  As we talked about in Brian's remarks, on the branded \nside what we saw from an inflation perspective was right along in line with our expectations.  As you know, the first \nquarter is generally a softer quarter for brand inflation historically, and what we saw this quart er was really in line \nwith our expectations.  And as we think about the full year, we are reaffirming our guidance of mid -single digit \ninflation on the branded side.  \n \n On the generic side, we continue to be very pleased with the performance of our sourcing o peration, ClarusONE. \n", "original_text": "As we talked about in Brian's remarks, on the branded \nside what we saw from an inflation perspective was right along in line with our expectations. "}, "hash": "dede5c7fa7ab79926241feb6c1bde090b9eb02490667f5f4711370b91e1810f7", "class_name": "RelatedNodeInfo"}}, "text": "I'll start, and Brian can add. ", "start_char_idx": 1057, "end_char_idx": 1088, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f4f4ee72-5fb1-4115-832f-c796654b75f4": {"__data__": {"id_": "f4f4ee72-5fb1-4115-832f-c796654b75f4", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nThanks for that question, Lisa.  I'll start, and Brian can add.  As we talked about in Brian's remarks, on the branded \nside what we saw from an inflation perspective was right along in line with our expectations.  As you know, the first \nquarter is generally a softer quarter for brand inflation historically, and what we saw this quart er was really in line \nwith our expectations.  And as we think about the full year, we are reaffirming our guidance of mid -single digit \ninflation on the branded side.  \n \n On the generic side, we continue to be very pleased with the performance of our sourcing o peration, ClarusONE. \n", "original_text": "As we talked about in Brian's remarks, on the branded \nside what we saw from an inflation perspective was right along in line with our expectations. ", "page_label": "10", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6959410c-ab10-4777-9191-d5a85e8e51b3", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "064afa09a15e30ad27bda1a73a8ba51f7b50788ebb028522a98bdffc4f372e61", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "298fae9c-25c8-4649-ba91-a2cd6ef6b10b", "node_type": "1", "metadata": {"window": "So just wondering some of the key drivers t here as well as what you're seeing on both \ninflation/deflation in generics and branded.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nThanks for that question, Lisa.  I'll start, and Brian can add.  As we talked about in Brian's remarks, on the branded \nside what we saw from an inflation perspective was right along in line with our expectations.  As you know, the first \nquarter is generally a softer quarter for brand inflation historically, and what we saw this quart er was really in line \nwith our expectations.  And as we think about the full year, we are reaffirming our guidance of mid -single digit \ninflation on the branded side.  \n \n", "original_text": "I'll start, and Brian can add. ", "page_label": "10", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "44686fe3c6f3f3adc6bc69c0bf6a3ddabad422811913838a551095ab5678063e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1939870f-bf3f-4cea-ad30-f85349061b09", "node_type": "1", "metadata": {"window": "A \nThanks for that question, Lisa.  I'll start, and Brian can add.  As we talked about in Brian's remarks, on the branded \nside what we saw from an inflation perspective was right along in line with our expectations.  As you know, the first \nquarter is generally a softer quarter for brand inflation historically, and what we saw this quart er was really in line \nwith our expectations.  And as we think about the full year, we are reaffirming our guidance of mid -single digit \ninflation on the branded side.  \n \n On the generic side, we continue to be very pleased with the performance of our sourcing o peration, ClarusONE. \n What we've seen thus far in terms of our sourcing performance is right in line with our expectations. ", "original_text": "As you know, the first \nquarter is generally a softer quarter for brand inflation historically, and what we saw this quart er was really in line \nwith our expectations. "}, "hash": "e80f1d20a8c96b280decd1957fa7dee0dad97aa4a164906be5131b150f20e7b8", "class_name": "RelatedNodeInfo"}}, "text": "As we talked about in Brian's remarks, on the branded \nside what we saw from an inflation perspective was right along in line with our expectations. ", "start_char_idx": 1088, "end_char_idx": 1237, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1939870f-bf3f-4cea-ad30-f85349061b09": {"__data__": {"id_": "1939870f-bf3f-4cea-ad30-f85349061b09", "embedding": null, "metadata": {"window": "A \nThanks for that question, Lisa.  I'll start, and Brian can add.  As we talked about in Brian's remarks, on the branded \nside what we saw from an inflation perspective was right along in line with our expectations.  As you know, the first \nquarter is generally a softer quarter for brand inflation historically, and what we saw this quart er was really in line \nwith our expectations.  And as we think about the full year, we are reaffirming our guidance of mid -single digit \ninflation on the branded side.  \n \n On the generic side, we continue to be very pleased with the performance of our sourcing o peration, ClarusONE. \n What we've seen thus far in terms of our sourcing performance is right in line with our expectations. ", "original_text": "As you know, the first \nquarter is generally a softer quarter for brand inflation historically, and what we saw this quart er was really in line \nwith our expectations. ", "page_label": "10", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6959410c-ab10-4777-9191-d5a85e8e51b3", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "064afa09a15e30ad27bda1a73a8ba51f7b50788ebb028522a98bdffc4f372e61", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f4f4ee72-5fb1-4115-832f-c796654b75f4", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nThanks for that question, Lisa.  I'll start, and Brian can add.  As we talked about in Brian's remarks, on the branded \nside what we saw from an inflation perspective was right along in line with our expectations.  As you know, the first \nquarter is generally a softer quarter for brand inflation historically, and what we saw this quart er was really in line \nwith our expectations.  And as we think about the full year, we are reaffirming our guidance of mid -single digit \ninflation on the branded side.  \n \n On the generic side, we continue to be very pleased with the performance of our sourcing o peration, ClarusONE. \n", "original_text": "As we talked about in Brian's remarks, on the branded \nside what we saw from an inflation perspective was right along in line with our expectations. ", "page_label": "10", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2a6c8e8c2bfcb98b1ee99fb533345ec25de7f73eccada6034c571095adc96ecc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c551284b-4ee1-4ee5-a253-669eec379c72", "node_type": "1", "metadata": {"window": "I'll start, and Brian can add.  As we talked about in Brian's remarks, on the branded \nside what we saw from an inflation perspective was right along in line with our expectations.  As you know, the first \nquarter is generally a softer quarter for brand inflation historically, and what we saw this quart er was really in line \nwith our expectations.  And as we think about the full year, we are reaffirming our guidance of mid -single digit \ninflation on the branded side.  \n \n On the generic side, we continue to be very pleased with the performance of our sourcing o peration, ClarusONE. \n What we've seen thus far in terms of our sourcing performance is right in line with our expectations.  And on the \nsell side, as Brian mentioned, we continue to see a competitive market, but we continue to see a stable market. \n", "original_text": "And as we think about the full year, we are reaffirming our guidance of mid -single digit \ninflation on the branded side.  \n \n"}, "hash": "f65d78092efe5046e46fa8d03135645b174bbe88f2775b8edd11de6ddf71d3f5", "class_name": "RelatedNodeInfo"}}, "text": "As you know, the first \nquarter is generally a softer quarter for brand inflation historically, and what we saw this quart er was really in line \nwith our expectations. ", "start_char_idx": 1237, "end_char_idx": 1406, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c551284b-4ee1-4ee5-a253-669eec379c72": {"__data__": {"id_": "c551284b-4ee1-4ee5-a253-669eec379c72", "embedding": null, "metadata": {"window": "I'll start, and Brian can add.  As we talked about in Brian's remarks, on the branded \nside what we saw from an inflation perspective was right along in line with our expectations.  As you know, the first \nquarter is generally a softer quarter for brand inflation historically, and what we saw this quart er was really in line \nwith our expectations.  And as we think about the full year, we are reaffirming our guidance of mid -single digit \ninflation on the branded side.  \n \n On the generic side, we continue to be very pleased with the performance of our sourcing o peration, ClarusONE. \n What we've seen thus far in terms of our sourcing performance is right in line with our expectations.  And on the \nsell side, as Brian mentioned, we continue to see a competitive market, but we continue to see a stable market. \n", "original_text": "And as we think about the full year, we are reaffirming our guidance of mid -single digit \ninflation on the branded side.  \n \n", "page_label": "10", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6959410c-ab10-4777-9191-d5a85e8e51b3", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "064afa09a15e30ad27bda1a73a8ba51f7b50788ebb028522a98bdffc4f372e61", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1939870f-bf3f-4cea-ad30-f85349061b09", "node_type": "1", "metadata": {"window": "A \nThanks for that question, Lisa.  I'll start, and Brian can add.  As we talked about in Brian's remarks, on the branded \nside what we saw from an inflation perspective was right along in line with our expectations.  As you know, the first \nquarter is generally a softer quarter for brand inflation historically, and what we saw this quart er was really in line \nwith our expectations.  And as we think about the full year, we are reaffirming our guidance of mid -single digit \ninflation on the branded side.  \n \n On the generic side, we continue to be very pleased with the performance of our sourcing o peration, ClarusONE. \n What we've seen thus far in terms of our sourcing performance is right in line with our expectations. ", "original_text": "As you know, the first \nquarter is generally a softer quarter for brand inflation historically, and what we saw this quart er was really in line \nwith our expectations. ", "page_label": "10", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a4145f18f5eb052059ba61eb38106802da83d4415c0e072bf1e09017b97ef1c2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6c5b71a7-30f2-4297-92d4-3b8ce14c0d3c", "node_type": "1", "metadata": {"window": "As we talked about in Brian's remarks, on the branded \nside what we saw from an inflation perspective was right along in line with our expectations.  As you know, the first \nquarter is generally a softer quarter for brand inflation historically, and what we saw this quart er was really in line \nwith our expectations.  And as we think about the full year, we are reaffirming our guidance of mid -single digit \ninflation on the branded side.  \n \n On the generic side, we continue to be very pleased with the performance of our sourcing o peration, ClarusONE. \n What we've seen thus far in terms of our sourcing performance is right in line with our expectations.  And on the \nsell side, as Brian mentioned, we continue to see a competitive market, but we continue to see a stable market. \n And so, we 're pleased with our ability to continue to source very competitively which is certainly benefiting our \ncustomers. ", "original_text": "On the generic side, we continue to be very pleased with the performance of our sourcing o peration, ClarusONE. \n"}, "hash": "ff4c0adb6c061d1e12195e1c6a48eb7698bf5848feecf6db296bd01483e413d0", "class_name": "RelatedNodeInfo"}}, "text": "And as we think about the full year, we are reaffirming our guidance of mid -single digit \ninflation on the branded side.  \n \n", "start_char_idx": 1406, "end_char_idx": 1532, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6c5b71a7-30f2-4297-92d4-3b8ce14c0d3c": {"__data__": {"id_": "6c5b71a7-30f2-4297-92d4-3b8ce14c0d3c", "embedding": null, "metadata": {"window": "As we talked about in Brian's remarks, on the branded \nside what we saw from an inflation perspective was right along in line with our expectations.  As you know, the first \nquarter is generally a softer quarter for brand inflation historically, and what we saw this quart er was really in line \nwith our expectations.  And as we think about the full year, we are reaffirming our guidance of mid -single digit \ninflation on the branded side.  \n \n On the generic side, we continue to be very pleased with the performance of our sourcing o peration, ClarusONE. \n What we've seen thus far in terms of our sourcing performance is right in line with our expectations.  And on the \nsell side, as Brian mentioned, we continue to see a competitive market, but we continue to see a stable market. \n And so, we 're pleased with our ability to continue to source very competitively which is certainly benefiting our \ncustomers. ", "original_text": "On the generic side, we continue to be very pleased with the performance of our sourcing o peration, ClarusONE. \n", "page_label": "10", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6959410c-ab10-4777-9191-d5a85e8e51b3", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "064afa09a15e30ad27bda1a73a8ba51f7b50788ebb028522a98bdffc4f372e61", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c551284b-4ee1-4ee5-a253-669eec379c72", "node_type": "1", "metadata": {"window": "I'll start, and Brian can add.  As we talked about in Brian's remarks, on the branded \nside what we saw from an inflation perspective was right along in line with our expectations.  As you know, the first \nquarter is generally a softer quarter for brand inflation historically, and what we saw this quart er was really in line \nwith our expectations.  And as we think about the full year, we are reaffirming our guidance of mid -single digit \ninflation on the branded side.  \n \n On the generic side, we continue to be very pleased with the performance of our sourcing o peration, ClarusONE. \n What we've seen thus far in terms of our sourcing performance is right in line with our expectations.  And on the \nsell side, as Brian mentioned, we continue to see a competitive market, but we continue to see a stable market. \n", "original_text": "And as we think about the full year, we are reaffirming our guidance of mid -single digit \ninflation on the branded side.  \n \n", "page_label": "10", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fc9e7a756d5afc36972fa7d6bb7f1f82f23065194a70ad7be8ac7a0e509f9d18", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "454a65ea-76d4-4a0b-a4a7-b419a3195415", "node_type": "1", "metadata": {"window": "As you know, the first \nquarter is generally a softer quarter for brand inflation historically, and what we saw this quart er was really in line \nwith our expectations.  And as we think about the full year, we are reaffirming our guidance of mid -single digit \ninflation on the branded side.  \n \n On the generic side, we continue to be very pleased with the performance of our sourcing o peration, ClarusONE. \n What we've seen thus far in terms of our sourcing performance is right in line with our expectations.  And on the \nsell side, as Brian mentioned, we continue to see a competitive market, but we continue to see a stable market. \n And so, we 're pleased with our ability to continue to source very competitively which is certainly benefiting our \ncustomers.  And we're certainly pleased with the ability to bring that to the sell side and our customers.  \n ", "original_text": "What we've seen thus far in terms of our sourcing performance is right in line with our expectations. "}, "hash": "dda8977be75c60e31d91aeffe54b9da54382a648cc0ce5dcea7c32792a51f050", "class_name": "RelatedNodeInfo"}}, "text": "On the generic side, we continue to be very pleased with the performance of our sourcing o peration, ClarusONE. \n", "start_char_idx": 1532, "end_char_idx": 1645, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "454a65ea-76d4-4a0b-a4a7-b419a3195415": {"__data__": {"id_": "454a65ea-76d4-4a0b-a4a7-b419a3195415", "embedding": null, "metadata": {"window": "As you know, the first \nquarter is generally a softer quarter for brand inflation historically, and what we saw this quart er was really in line \nwith our expectations.  And as we think about the full year, we are reaffirming our guidance of mid -single digit \ninflation on the branded side.  \n \n On the generic side, we continue to be very pleased with the performance of our sourcing o peration, ClarusONE. \n What we've seen thus far in terms of our sourcing performance is right in line with our expectations.  And on the \nsell side, as Brian mentioned, we continue to see a competitive market, but we continue to see a stable market. \n And so, we 're pleased with our ability to continue to source very competitively which is certainly benefiting our \ncustomers.  And we're certainly pleased with the ability to bring that to the sell side and our customers.  \n ", "original_text": "What we've seen thus far in terms of our sourcing performance is right in line with our expectations. ", "page_label": "10", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6959410c-ab10-4777-9191-d5a85e8e51b3", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "064afa09a15e30ad27bda1a73a8ba51f7b50788ebb028522a98bdffc4f372e61", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6c5b71a7-30f2-4297-92d4-3b8ce14c0d3c", "node_type": "1", "metadata": {"window": "As we talked about in Brian's remarks, on the branded \nside what we saw from an inflation perspective was right along in line with our expectations.  As you know, the first \nquarter is generally a softer quarter for brand inflation historically, and what we saw this quart er was really in line \nwith our expectations.  And as we think about the full year, we are reaffirming our guidance of mid -single digit \ninflation on the branded side.  \n \n On the generic side, we continue to be very pleased with the performance of our sourcing o peration, ClarusONE. \n What we've seen thus far in terms of our sourcing performance is right in line with our expectations.  And on the \nsell side, as Brian mentioned, we continue to see a competitive market, but we continue to see a stable market. \n And so, we 're pleased with our ability to continue to source very competitively which is certainly benefiting our \ncustomers. ", "original_text": "On the generic side, we continue to be very pleased with the performance of our sourcing o peration, ClarusONE. \n", "page_label": "10", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3d5167f9596724570c7fafcfc6d466f0ec4c15f8117cce94156f10a3930fba1d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c37f7900-20a5-4ccf-b9e8-bf11b38a33d0", "node_type": "1", "metadata": {"window": "And as we think about the full year, we are reaffirming our guidance of mid -single digit \ninflation on the branded side.  \n \n On the generic side, we continue to be very pleased with the performance of our sourcing o peration, ClarusONE. \n What we've seen thus far in terms of our sourcing performance is right in line with our expectations.  And on the \nsell side, as Brian mentioned, we continue to see a competitive market, but we continue to see a stable market. \n And so, we 're pleased with our ability to continue to source very competitively which is certainly benefiting our \ncustomers.  And we're certainly pleased with the ability to bring that to the sell side and our customers.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LL C Q \nGreat. ", "original_text": "And on the \nsell side, as Brian mentioned, we continue to see a competitive market, but we continue to see a stable market. \n"}, "hash": "1fe21960aa6a9e39b97b968a23e604f3c34d3acb481d8f2891842058f62ca2e4", "class_name": "RelatedNodeInfo"}}, "text": "What we've seen thus far in terms of our sourcing performance is right in line with our expectations. ", "start_char_idx": 1645, "end_char_idx": 1747, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c37f7900-20a5-4ccf-b9e8-bf11b38a33d0": {"__data__": {"id_": "c37f7900-20a5-4ccf-b9e8-bf11b38a33d0", "embedding": null, "metadata": {"window": "And as we think about the full year, we are reaffirming our guidance of mid -single digit \ninflation on the branded side.  \n \n On the generic side, we continue to be very pleased with the performance of our sourcing o peration, ClarusONE. \n What we've seen thus far in terms of our sourcing performance is right in line with our expectations.  And on the \nsell side, as Brian mentioned, we continue to see a competitive market, but we continue to see a stable market. \n And so, we 're pleased with our ability to continue to source very competitively which is certainly benefiting our \ncustomers.  And we're certainly pleased with the ability to bring that to the sell side and our customers.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LL C Q \nGreat. ", "original_text": "And on the \nsell side, as Brian mentioned, we continue to see a competitive market, but we continue to see a stable market. \n", "page_label": "10", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6959410c-ab10-4777-9191-d5a85e8e51b3", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "064afa09a15e30ad27bda1a73a8ba51f7b50788ebb028522a98bdffc4f372e61", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "454a65ea-76d4-4a0b-a4a7-b419a3195415", "node_type": "1", "metadata": {"window": "As you know, the first \nquarter is generally a softer quarter for brand inflation historically, and what we saw this quart er was really in line \nwith our expectations.  And as we think about the full year, we are reaffirming our guidance of mid -single digit \ninflation on the branded side.  \n \n On the generic side, we continue to be very pleased with the performance of our sourcing o peration, ClarusONE. \n What we've seen thus far in terms of our sourcing performance is right in line with our expectations.  And on the \nsell side, as Brian mentioned, we continue to see a competitive market, but we continue to see a stable market. \n And so, we 're pleased with our ability to continue to source very competitively which is certainly benefiting our \ncustomers.  And we're certainly pleased with the ability to bring that to the sell side and our customers.  \n ", "original_text": "What we've seen thus far in terms of our sourcing performance is right in line with our expectations. ", "page_label": "10", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e99c3ca3c514aae50f79118d738044ed28b519bd98d83015c8967d73fd613a0c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f86169d6-a261-4e7c-ab13-8cf1a4d24369", "node_type": "1", "metadata": {"window": "On the generic side, we continue to be very pleased with the performance of our sourcing o peration, ClarusONE. \n What we've seen thus far in terms of our sourcing performance is right in line with our expectations.  And on the \nsell side, as Brian mentioned, we continue to see a competitive market, but we continue to see a stable market. \n And so, we 're pleased with our ability to continue to source very competitively which is certainly benefiting our \ncustomers.  And we're certainly pleased with the ability to bring that to the sell side and our customers.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LL C Q \nGreat.  Thanks for the comments.  \n ", "original_text": "And so, we 're pleased with our ability to continue to source very competitively which is certainly benefiting our \ncustomers. "}, "hash": "616e92432ccdb070d0eb0cebb842f7667a49cc84dcb3d39d1a33a2af792c7018", "class_name": "RelatedNodeInfo"}}, "text": "And on the \nsell side, as Brian mentioned, we continue to see a competitive market, but we continue to see a stable market. \n", "start_char_idx": 1747, "end_char_idx": 1872, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f86169d6-a261-4e7c-ab13-8cf1a4d24369": {"__data__": {"id_": "f86169d6-a261-4e7c-ab13-8cf1a4d24369", "embedding": null, "metadata": {"window": "On the generic side, we continue to be very pleased with the performance of our sourcing o peration, ClarusONE. \n What we've seen thus far in terms of our sourcing performance is right in line with our expectations.  And on the \nsell side, as Brian mentioned, we continue to see a competitive market, but we continue to see a stable market. \n And so, we 're pleased with our ability to continue to source very competitively which is certainly benefiting our \ncustomers.  And we're certainly pleased with the ability to bring that to the sell side and our customers.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LL C Q \nGreat.  Thanks for the comments.  \n ", "original_text": "And so, we 're pleased with our ability to continue to source very competitively which is certainly benefiting our \ncustomers. ", "page_label": "10", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6959410c-ab10-4777-9191-d5a85e8e51b3", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "064afa09a15e30ad27bda1a73a8ba51f7b50788ebb028522a98bdffc4f372e61", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c37f7900-20a5-4ccf-b9e8-bf11b38a33d0", "node_type": "1", "metadata": {"window": "And as we think about the full year, we are reaffirming our guidance of mid -single digit \ninflation on the branded side.  \n \n On the generic side, we continue to be very pleased with the performance of our sourcing o peration, ClarusONE. \n What we've seen thus far in terms of our sourcing performance is right in line with our expectations.  And on the \nsell side, as Brian mentioned, we continue to see a competitive market, but we continue to see a stable market. \n And so, we 're pleased with our ability to continue to source very competitively which is certainly benefiting our \ncustomers.  And we're certainly pleased with the ability to bring that to the sell side and our customers.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LL C Q \nGreat. ", "original_text": "And on the \nsell side, as Brian mentioned, we continue to see a competitive market, but we continue to see a stable market. \n", "page_label": "10", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "35ab8b7a6d33c9dbb3f4dd60a0ffb2faba053a447fa32839a603508e8c1029a2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "32088665-46f8-420d-8c47-2644800736f2", "node_type": "1", "metadata": {"window": "What we've seen thus far in terms of our sourcing performance is right in line with our expectations.  And on the \nsell side, as Brian mentioned, we continue to see a competitive market, but we continue to see a stable market. \n And so, we 're pleased with our ability to continue to source very competitively which is certainly benefiting our \ncustomers.  And we're certainly pleased with the ability to bring that to the sell side and our customers.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LL C Q \nGreat.  Thanks for the comments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Michael Cherny with Bank of America.  \n ", "original_text": "And we're certainly pleased with the ability to bring that to the sell side and our customers.  \n "}, "hash": "317a307e422fa7ec78aba4c71d82b3f9ff0aa8021e56e51a6f9770ebe93c1d45", "class_name": "RelatedNodeInfo"}}, "text": "And so, we 're pleased with our ability to continue to source very competitively which is certainly benefiting our \ncustomers. ", "start_char_idx": 1872, "end_char_idx": 1999, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "32088665-46f8-420d-8c47-2644800736f2": {"__data__": {"id_": "32088665-46f8-420d-8c47-2644800736f2", "embedding": null, "metadata": {"window": "What we've seen thus far in terms of our sourcing performance is right in line with our expectations.  And on the \nsell side, as Brian mentioned, we continue to see a competitive market, but we continue to see a stable market. \n And so, we 're pleased with our ability to continue to source very competitively which is certainly benefiting our \ncustomers.  And we're certainly pleased with the ability to bring that to the sell side and our customers.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LL C Q \nGreat.  Thanks for the comments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Michael Cherny with Bank of America.  \n ", "original_text": "And we're certainly pleased with the ability to bring that to the sell side and our customers.  \n ", "page_label": "10", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6959410c-ab10-4777-9191-d5a85e8e51b3", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "064afa09a15e30ad27bda1a73a8ba51f7b50788ebb028522a98bdffc4f372e61", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f86169d6-a261-4e7c-ab13-8cf1a4d24369", "node_type": "1", "metadata": {"window": "On the generic side, we continue to be very pleased with the performance of our sourcing o peration, ClarusONE. \n What we've seen thus far in terms of our sourcing performance is right in line with our expectations.  And on the \nsell side, as Brian mentioned, we continue to see a competitive market, but we continue to see a stable market. \n And so, we 're pleased with our ability to continue to source very competitively which is certainly benefiting our \ncustomers.  And we're certainly pleased with the ability to bring that to the sell side and our customers.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LL C Q \nGreat.  Thanks for the comments.  \n ", "original_text": "And so, we 're pleased with our ability to continue to source very competitively which is certainly benefiting our \ncustomers. ", "page_label": "10", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "42bf17d20a244186c0418012f32a8dd4f11768137993517b0df6b06273f556bc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2b69c167-97d0-4287-b347-69062c7fdaa6", "node_type": "1", "metadata": {"window": "And on the \nsell side, as Brian mentioned, we continue to see a competitive market, but we continue to see a stable market. \n And so, we 're pleased with our ability to continue to source very competitively which is certainly benefiting our \ncustomers.  And we're certainly pleased with the ability to bring that to the sell side and our customers.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LL C Q \nGreat.  Thanks for the comments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Michael Cherny with Bank of America.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  Q \nGood evening. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LL C Q \nGreat. "}, "hash": "c215dee75364997ca6b58d12425aa823291890a923a521eb1da032ad00406d0a", "class_name": "RelatedNodeInfo"}}, "text": "And we're certainly pleased with the ability to bring that to the sell side and our customers.  \n ", "start_char_idx": 1999, "end_char_idx": 2097, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2b69c167-97d0-4287-b347-69062c7fdaa6": {"__data__": {"id_": "2b69c167-97d0-4287-b347-69062c7fdaa6", "embedding": null, "metadata": {"window": "And on the \nsell side, as Brian mentioned, we continue to see a competitive market, but we continue to see a stable market. \n And so, we 're pleased with our ability to continue to source very competitively which is certainly benefiting our \ncustomers.  And we're certainly pleased with the ability to bring that to the sell side and our customers.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LL C Q \nGreat.  Thanks for the comments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Michael Cherny with Bank of America.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  Q \nGood evening. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LL C Q \nGreat. ", "page_label": "10", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6959410c-ab10-4777-9191-d5a85e8e51b3", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "064afa09a15e30ad27bda1a73a8ba51f7b50788ebb028522a98bdffc4f372e61", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "32088665-46f8-420d-8c47-2644800736f2", "node_type": "1", "metadata": {"window": "What we've seen thus far in terms of our sourcing performance is right in line with our expectations.  And on the \nsell side, as Brian mentioned, we continue to see a competitive market, but we continue to see a stable market. \n And so, we 're pleased with our ability to continue to source very competitively which is certainly benefiting our \ncustomers.  And we're certainly pleased with the ability to bring that to the sell side and our customers.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LL C Q \nGreat.  Thanks for the comments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Michael Cherny with Bank of America.  \n ", "original_text": "And we're certainly pleased with the ability to bring that to the sell side and our customers.  \n ", "page_label": "10", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d857c1b7a5ef10b62c349298d9dfa08447fff3ae9638d50bf3f64699c1ad500c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "884a0316-f23f-4584-ac43-aa9bcf9d0300", "node_type": "1", "metadata": {"window": "And so, we 're pleased with our ability to continue to source very competitively which is certainly benefiting our \ncustomers.  And we're certainly pleased with the ability to bring that to the sell side and our customers.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LL C Q \nGreat.  Thanks for the comments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Michael Cherny with Bank of America.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  Q \nGood evening.  Thanks for all the comments so far. ", "original_text": "Thanks for the comments.  \n "}, "hash": "dbd0f8b9bb9c876c3283fe951cdc84027ed81aecb87a48bbc633c4b1298fe96c", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LL C Q \nGreat. ", "start_char_idx": 2097, "end_char_idx": 2413, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "884a0316-f23f-4584-ac43-aa9bcf9d0300": {"__data__": {"id_": "884a0316-f23f-4584-ac43-aa9bcf9d0300", "embedding": null, "metadata": {"window": "And so, we 're pleased with our ability to continue to source very competitively which is certainly benefiting our \ncustomers.  And we're certainly pleased with the ability to bring that to the sell side and our customers.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LL C Q \nGreat.  Thanks for the comments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Michael Cherny with Bank of America.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  Q \nGood evening.  Thanks for all the comments so far. ", "original_text": "Thanks for the comments.  \n ", "page_label": "10", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6959410c-ab10-4777-9191-d5a85e8e51b3", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "064afa09a15e30ad27bda1a73a8ba51f7b50788ebb028522a98bdffc4f372e61", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2b69c167-97d0-4287-b347-69062c7fdaa6", "node_type": "1", "metadata": {"window": "And on the \nsell side, as Brian mentioned, we continue to see a competitive market, but we continue to see a stable market. \n And so, we 're pleased with our ability to continue to source very competitively which is certainly benefiting our \ncustomers.  And we're certainly pleased with the ability to bring that to the sell side and our customers.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LL C Q \nGreat.  Thanks for the comments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Michael Cherny with Bank of America.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  Q \nGood evening. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LL C Q \nGreat. ", "page_label": "10", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2c46a0f7414f62569c73821c7f50932ef5d48d50bb1a7c52fc85db67075585d1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ac555476-e7a1-43ad-8933-e8711c8eee73", "node_type": "1", "metadata": {"window": "And we're certainly pleased with the ability to bring that to the sell side and our customers.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LL C Q \nGreat.  Thanks for the comments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Michael Cherny with Bank of America.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  Q \nGood evening.  Thanks for all the comments so far.  Britt, I want to dive in a little bit more into the U.S. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Michael Cherny with Bank of America.  \n "}, "hash": "319ed5acd6d344b6f37ea256067eb8f2dbbddb82899235bc5d18839537e5fea9", "class_name": "RelatedNodeInfo"}}, "text": "Thanks for the comments.  \n ", "start_char_idx": 2413, "end_char_idx": 2441, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ac555476-e7a1-43ad-8933-e8711c8eee73": {"__data__": {"id_": "ac555476-e7a1-43ad-8933-e8711c8eee73", "embedding": null, "metadata": {"window": "And we're certainly pleased with the ability to bring that to the sell side and our customers.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LL C Q \nGreat.  Thanks for the comments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Michael Cherny with Bank of America.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  Q \nGood evening.  Thanks for all the comments so far.  Britt, I want to dive in a little bit more into the U.S. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Michael Cherny with Bank of America.  \n ", "page_label": "10", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6959410c-ab10-4777-9191-d5a85e8e51b3", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "064afa09a15e30ad27bda1a73a8ba51f7b50788ebb028522a98bdffc4f372e61", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "884a0316-f23f-4584-ac43-aa9bcf9d0300", "node_type": "1", "metadata": {"window": "And so, we 're pleased with our ability to continue to source very competitively which is certainly benefiting our \ncustomers.  And we're certainly pleased with the ability to bring that to the sell side and our customers.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LL C Q \nGreat.  Thanks for the comments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Michael Cherny with Bank of America.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  Q \nGood evening.  Thanks for all the comments so far. ", "original_text": "Thanks for the comments.  \n ", "page_label": "10", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a5ae7adb73ad09fe8f76da7e80b1177b79dfe5b18fd67857f1debf6012b1ddff", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "27bcd57a-1383-4138-8eb5-c030871d09b1", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LL C Q \nGreat.  Thanks for the comments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Michael Cherny with Bank of America.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  Q \nGood evening.  Thanks for all the comments so far.  Britt, I want to dive in a little bit more into the U.S.  Pharma \nperformance, maybe as a microcosm for the rest of the business. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  Q \nGood evening. "}, "hash": "10d99ac47e4ef873704d8472e8e5bbe1f9dc880efdd4bb141293e013eabc52bf", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Michael Cherny with Bank of America.  \n ", "start_char_idx": 2441, "end_char_idx": 2768, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "27bcd57a-1383-4138-8eb5-c030871d09b1": {"__data__": {"id_": "27bcd57a-1383-4138-8eb5-c030871d09b1", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LL C Q \nGreat.  Thanks for the comments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Michael Cherny with Bank of America.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  Q \nGood evening.  Thanks for all the comments so far.  Britt, I want to dive in a little bit more into the U.S.  Pharma \nperformance, maybe as a microcosm for the rest of the business. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  Q \nGood evening. ", "page_label": "10", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6959410c-ab10-4777-9191-d5a85e8e51b3", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "064afa09a15e30ad27bda1a73a8ba51f7b50788ebb028522a98bdffc4f372e61", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ac555476-e7a1-43ad-8933-e8711c8eee73", "node_type": "1", "metadata": {"window": "And we're certainly pleased with the ability to bring that to the sell side and our customers.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LL C Q \nGreat.  Thanks for the comments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Michael Cherny with Bank of America.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  Q \nGood evening.  Thanks for all the comments so far.  Britt, I want to dive in a little bit more into the U.S. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Michael Cherny with Bank of America.  \n ", "page_label": "10", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8ff9d7dd3ba103be728e90f479c1024667f53ab246c6a804a8d5ca0b66336b36", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ba007c2a-3505-4179-8f56-ba0b01f850db", "node_type": "1", "metadata": {"window": "Thanks for the comments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Michael Cherny with Bank of America.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  Q \nGood evening.  Thanks for all the comments so far.  Britt, I want to dive in a little bit more into the U.S.  Pharma \nperformance, maybe as a microcosm for the rest of the business.  It seems like, just given the sheer magnitude of \nthe performance and the outperformance on revenue relative at least to your guidance that a lot of it had to be \ndriven by pharma. ", "original_text": "Thanks for all the comments so far. "}, "hash": "037fabddf76abcd9ffb8dc2be043323e22822ea0a78e4885863f972879995f96", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  Q \nGood evening. ", "start_char_idx": 2768, "end_char_idx": 3099, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ba007c2a-3505-4179-8f56-ba0b01f850db": {"__data__": {"id_": "ba007c2a-3505-4179-8f56-ba0b01f850db", "embedding": null, "metadata": {"window": "Thanks for the comments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Michael Cherny with Bank of America.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  Q \nGood evening.  Thanks for all the comments so far.  Britt, I want to dive in a little bit more into the U.S.  Pharma \nperformance, maybe as a microcosm for the rest of the business.  It seems like, just given the sheer magnitude of \nthe performance and the outperformance on revenue relative at least to your guidance that a lot of it had to be \ndriven by pharma. ", "original_text": "Thanks for all the comments so far. ", "page_label": "10", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6959410c-ab10-4777-9191-d5a85e8e51b3", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "064afa09a15e30ad27bda1a73a8ba51f7b50788ebb028522a98bdffc4f372e61", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "27bcd57a-1383-4138-8eb5-c030871d09b1", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nLisa C. Gill  \nAnalyst, JPMorgan Securities LL C Q \nGreat.  Thanks for the comments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Michael Cherny with Bank of America.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  Q \nGood evening.  Thanks for all the comments so far.  Britt, I want to dive in a little bit more into the U.S.  Pharma \nperformance, maybe as a microcosm for the rest of the business. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  Q \nGood evening. ", "page_label": "10", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "09daaf511941b289378f0bef844f5645fd5cbe7225e02ec08e950d096224e80f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "39edd615-fd5f-4d29-8850-295961aaf7be", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Michael Cherny with Bank of America.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  Q \nGood evening.  Thanks for all the comments so far.  Britt, I want to dive in a little bit more into the U.S.  Pharma \nperformance, maybe as a microcosm for the rest of the business.  It seems like, just given the sheer magnitude of \nthe performance and the outperformance on revenue relative at least to your guidance that a lot of it had to be \ndriven by pharma.  That being said, we didn't see a ton of gross margin pull -through. ", "original_text": "Britt, I want to dive in a little bit more into the U.S. "}, "hash": "7fe0f48617c723a13c02eb6d310b2318229d3ea29ceeb1fb5607cc006b8a748d", "class_name": "RelatedNodeInfo"}}, "text": "Thanks for all the comments so far. ", "start_char_idx": 3099, "end_char_idx": 3135, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "39edd615-fd5f-4d29-8850-295961aaf7be": {"__data__": {"id_": "39edd615-fd5f-4d29-8850-295961aaf7be", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Michael Cherny with Bank of America.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  Q \nGood evening.  Thanks for all the comments so far.  Britt, I want to dive in a little bit more into the U.S.  Pharma \nperformance, maybe as a microcosm for the rest of the business.  It seems like, just given the sheer magnitude of \nthe performance and the outperformance on revenue relative at least to your guidance that a lot of it had to be \ndriven by pharma.  That being said, we didn't see a ton of gross margin pull -through. ", "original_text": "Britt, I want to dive in a little bit more into the U.S. ", "page_label": "10", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6959410c-ab10-4777-9191-d5a85e8e51b3", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "064afa09a15e30ad27bda1a73a8ba51f7b50788ebb028522a98bdffc4f372e61", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ba007c2a-3505-4179-8f56-ba0b01f850db", "node_type": "1", "metadata": {"window": "Thanks for the comments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Michael Cherny with Bank of America.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  Q \nGood evening.  Thanks for all the comments so far.  Britt, I want to dive in a little bit more into the U.S.  Pharma \nperformance, maybe as a microcosm for the rest of the business.  It seems like, just given the sheer magnitude of \nthe performance and the outperformance on revenue relative at least to your guidance that a lot of it had to be \ndriven by pharma. ", "original_text": "Thanks for all the comments so far. ", "page_label": "10", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "df3486847aa29f5ac6014f0f1483d9bda447c80f5fbb5807b42b49d261050a9e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1bb7b9e0-6aad-4ac0-b82e-dfb57ce79ae4", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  Q \nGood evening.  Thanks for all the comments so far.  Britt, I want to dive in a little bit more into the U.S.  Pharma \nperformance, maybe as a microcosm for the rest of the business.  It seems like, just given the sheer magnitude of \nthe performance and the outperformance on revenue relative at least to your guidance that a lot of it had to be \ndriven by pharma.  That being said, we didn't see a ton of gross margin pull -through.  That might be splitting hairs a \nlittle bit here, but can you just talk a little bit about the dynamics in terms of what was the rationale for the slower \ngross profit growth relative  to the revenue growth?  \n ", "original_text": "Pharma \nperformance, maybe as a microcosm for the rest of the business. "}, "hash": "2d842091243147b5a5008134691eed3eb48deffd6b8cbd30a31a561eb359d004", "class_name": "RelatedNodeInfo"}}, "text": "Britt, I want to dive in a little bit more into the U.S. ", "start_char_idx": 3135, "end_char_idx": 3192, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1bb7b9e0-6aad-4ac0-b82e-dfb57ce79ae4": {"__data__": {"id_": "1bb7b9e0-6aad-4ac0-b82e-dfb57ce79ae4", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  Q \nGood evening.  Thanks for all the comments so far.  Britt, I want to dive in a little bit more into the U.S.  Pharma \nperformance, maybe as a microcosm for the rest of the business.  It seems like, just given the sheer magnitude of \nthe performance and the outperformance on revenue relative at least to your guidance that a lot of it had to be \ndriven by pharma.  That being said, we didn't see a ton of gross margin pull -through.  That might be splitting hairs a \nlittle bit here, but can you just talk a little bit about the dynamics in terms of what was the rationale for the slower \ngross profit growth relative  to the revenue growth?  \n ", "original_text": "Pharma \nperformance, maybe as a microcosm for the rest of the business. ", "page_label": "10", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6959410c-ab10-4777-9191-d5a85e8e51b3", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "064afa09a15e30ad27bda1a73a8ba51f7b50788ebb028522a98bdffc4f372e61", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "39edd615-fd5f-4d29-8850-295961aaf7be", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Michael Cherny with Bank of America.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  Q \nGood evening.  Thanks for all the comments so far.  Britt, I want to dive in a little bit more into the U.S.  Pharma \nperformance, maybe as a microcosm for the rest of the business.  It seems like, just given the sheer magnitude of \nthe performance and the outperformance on revenue relative at least to your guidance that a lot of it had to be \ndriven by pharma.  That being said, we didn't see a ton of gross margin pull -through. ", "original_text": "Britt, I want to dive in a little bit more into the U.S. ", "page_label": "10", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dcc7c8b5baa6e83e44b86fd7171936fefcd1aae1989510400142a0132a4cda3e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8fc60855-dd7c-47be-b88f-33e12d253d69", "node_type": "1", "metadata": {"window": "Thanks for all the comments so far.  Britt, I want to dive in a little bit more into the U.S.  Pharma \nperformance, maybe as a microcosm for the rest of the business.  It seems like, just given the sheer magnitude of \nthe performance and the outperformance on revenue relative at least to your guidance that a lot of it had to be \ndriven by pharma.  That being said, we didn't see a ton of gross margin pull -through.  That might be splitting hairs a \nlittle bit here, but can you just talk a little bit about the dynamics in terms of what was the rationale for the slower \ngross profit growth relative  to the revenue growth?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "It seems like, just given the sheer magnitude of \nthe performance and the outperformance on revenue relative at least to your guidance that a lot of it had to be \ndriven by pharma. "}, "hash": "e3931fbf9537bcef452f4e428332da9b27cedc4daf7f074bfdf0cc0f6570a400", "class_name": "RelatedNodeInfo"}}, "text": "Pharma \nperformance, maybe as a microcosm for the rest of the business. ", "start_char_idx": 3192, "end_char_idx": 3264, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8fc60855-dd7c-47be-b88f-33e12d253d69": {"__data__": {"id_": "8fc60855-dd7c-47be-b88f-33e12d253d69", "embedding": null, "metadata": {"window": "Thanks for all the comments so far.  Britt, I want to dive in a little bit more into the U.S.  Pharma \nperformance, maybe as a microcosm for the rest of the business.  It seems like, just given the sheer magnitude of \nthe performance and the outperformance on revenue relative at least to your guidance that a lot of it had to be \ndriven by pharma.  That being said, we didn't see a ton of gross margin pull -through.  That might be splitting hairs a \nlittle bit here, but can you just talk a little bit about the dynamics in terms of what was the rationale for the slower \ngross profit growth relative  to the revenue growth?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "It seems like, just given the sheer magnitude of \nthe performance and the outperformance on revenue relative at least to your guidance that a lot of it had to be \ndriven by pharma. ", "page_label": "10", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6959410c-ab10-4777-9191-d5a85e8e51b3", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "064afa09a15e30ad27bda1a73a8ba51f7b50788ebb028522a98bdffc4f372e61", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1bb7b9e0-6aad-4ac0-b82e-dfb57ce79ae4", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  Q \nGood evening.  Thanks for all the comments so far.  Britt, I want to dive in a little bit more into the U.S.  Pharma \nperformance, maybe as a microcosm for the rest of the business.  It seems like, just given the sheer magnitude of \nthe performance and the outperformance on revenue relative at least to your guidance that a lot of it had to be \ndriven by pharma.  That being said, we didn't see a ton of gross margin pull -through.  That might be splitting hairs a \nlittle bit here, but can you just talk a little bit about the dynamics in terms of what was the rationale for the slower \ngross profit growth relative  to the revenue growth?  \n ", "original_text": "Pharma \nperformance, maybe as a microcosm for the rest of the business. ", "page_label": "10", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f7031f7f984b86939e87ad02bf3f5da0bbdd3b97d7ac6239a0bb56e30c14b4c4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c96cc293-41fb-4185-a322-2a9ec2bfc690", "node_type": "1", "metadata": {"window": "Britt, I want to dive in a little bit more into the U.S.  Pharma \nperformance, maybe as a microcosm for the rest of the business.  It seems like, just given the sheer magnitude of \nthe performance and the outperformance on revenue relative at least to your guidance that a lot of it had to be \ndriven by pharma.  That being said, we didn't see a ton of gross margin pull -through.  That might be splitting hairs a \nlittle bit here, but can you just talk a little bit about the dynamics in terms of what was the rationale for the slower \ngross profit growth relative  to the revenue growth?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nSure. ", "original_text": "That being said, we didn't see a ton of gross margin pull -through. "}, "hash": "46389cbc7277d9669bcc6f9a3dbe02e147649ba0a2535fb2e77f847bcadb42b4", "class_name": "RelatedNodeInfo"}}, "text": "It seems like, just given the sheer magnitude of \nthe performance and the outperformance on revenue relative at least to your guidance that a lot of it had to be \ndriven by pharma. ", "start_char_idx": 3264, "end_char_idx": 3445, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c96cc293-41fb-4185-a322-2a9ec2bfc690": {"__data__": {"id_": "c96cc293-41fb-4185-a322-2a9ec2bfc690", "embedding": null, "metadata": {"window": "Britt, I want to dive in a little bit more into the U.S.  Pharma \nperformance, maybe as a microcosm for the rest of the business.  It seems like, just given the sheer magnitude of \nthe performance and the outperformance on revenue relative at least to your guidance that a lot of it had to be \ndriven by pharma.  That being said, we didn't see a ton of gross margin pull -through.  That might be splitting hairs a \nlittle bit here, but can you just talk a little bit about the dynamics in terms of what was the rationale for the slower \ngross profit growth relative  to the revenue growth?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nSure. ", "original_text": "That being said, we didn't see a ton of gross margin pull -through. ", "page_label": "10", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6959410c-ab10-4777-9191-d5a85e8e51b3", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "064afa09a15e30ad27bda1a73a8ba51f7b50788ebb028522a98bdffc4f372e61", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8fc60855-dd7c-47be-b88f-33e12d253d69", "node_type": "1", "metadata": {"window": "Thanks for all the comments so far.  Britt, I want to dive in a little bit more into the U.S.  Pharma \nperformance, maybe as a microcosm for the rest of the business.  It seems like, just given the sheer magnitude of \nthe performance and the outperformance on revenue relative at least to your guidance that a lot of it had to be \ndriven by pharma.  That being said, we didn't see a ton of gross margin pull -through.  That might be splitting hairs a \nlittle bit here, but can you just talk a little bit about the dynamics in terms of what was the rationale for the slower \ngross profit growth relative  to the revenue growth?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "It seems like, just given the sheer magnitude of \nthe performance and the outperformance on revenue relative at least to your guidance that a lot of it had to be \ndriven by pharma. ", "page_label": "10", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0aec40d9f15fffa6307c574426b7e450ea14c1a95e28f683da91428d655c0660", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "366cb060-8221-40f2-a3fb-2e1e403658ad", "node_type": "1", "metadata": {"window": "Pharma \nperformance, maybe as a microcosm for the rest of the business.  It seems like, just given the sheer magnitude of \nthe performance and the outperformance on revenue relative at least to your guidance that a lot of it had to be \ndriven by pharma.  That being said, we didn't see a ton of gross margin pull -through.  That might be splitting hairs a \nlittle bit here, but can you just talk a little bit about the dynamics in terms of what was the rationale for the slower \ngross profit growth relative  to the revenue growth?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nSure.  Thanks for the question. ", "original_text": "That might be splitting hairs a \nlittle bit here, but can you just talk a little bit about the dynamics in terms of what was the rationale for the slower \ngross profit growth relative  to the revenue growth?  \n "}, "hash": "7ff732a0b8a25c072247b74fc5f9d7e2f51ed88d4e9e0d6f4d95f11a929ac693", "class_name": "RelatedNodeInfo"}}, "text": "That being said, we didn't see a ton of gross margin pull -through. ", "start_char_idx": 3445, "end_char_idx": 3513, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "366cb060-8221-40f2-a3fb-2e1e403658ad": {"__data__": {"id_": "366cb060-8221-40f2-a3fb-2e1e403658ad", "embedding": null, "metadata": {"window": "Pharma \nperformance, maybe as a microcosm for the rest of the business.  It seems like, just given the sheer magnitude of \nthe performance and the outperformance on revenue relative at least to your guidance that a lot of it had to be \ndriven by pharma.  That being said, we didn't see a ton of gross margin pull -through.  That might be splitting hairs a \nlittle bit here, but can you just talk a little bit about the dynamics in terms of what was the rationale for the slower \ngross profit growth relative  to the revenue growth?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nSure.  Thanks for the question. ", "original_text": "That might be splitting hairs a \nlittle bit here, but can you just talk a little bit about the dynamics in terms of what was the rationale for the slower \ngross profit growth relative  to the revenue growth?  \n ", "page_label": "10", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6959410c-ab10-4777-9191-d5a85e8e51b3", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "064afa09a15e30ad27bda1a73a8ba51f7b50788ebb028522a98bdffc4f372e61", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c96cc293-41fb-4185-a322-2a9ec2bfc690", "node_type": "1", "metadata": {"window": "Britt, I want to dive in a little bit more into the U.S.  Pharma \nperformance, maybe as a microcosm for the rest of the business.  It seems like, just given the sheer magnitude of \nthe performance and the outperformance on revenue relative at least to your guidance that a lot of it had to be \ndriven by pharma.  That being said, we didn't see a ton of gross margin pull -through.  That might be splitting hairs a \nlittle bit here, but can you just talk a little bit about the dynamics in terms of what was the rationale for the slower \ngross profit growth relative  to the revenue growth?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nSure. ", "original_text": "That being said, we didn't see a ton of gross margin pull -through. ", "page_label": "10", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2dd81434a0b0dbe9ff593b89c530308e127d0344c4d06796fbff8a7cd0b00777", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0886c3e0-4219-4c7e-a4d4-1ac46a69bbe1", "node_type": "1", "metadata": {"window": "It seems like, just given the sheer magnitude of \nthe performance and the outperformance on revenue relative at least to your guidance that a lot of it had to be \ndriven by pharma.  That being said, we didn't see a ton of gross margin pull -through.  That might be splitting hairs a \nlittle bit here, but can you just talk a little bit about the dynamics in terms of what was the rationale for the slower \ngross profit growth relative  to the revenue growth?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nSure.  Thanks for the question.  As I mentioned in my comments, some of the revenue growth that we saw came \nfrom some of our largest national re tail customers; and as you might expect, they don't generate as great a \ncontribution to gross profit. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  "}, "hash": "463d6431238fb74917c4561608bca6661ada354e9d150b8f1661eeff86e16730", "class_name": "RelatedNodeInfo"}}, "text": "That might be splitting hairs a \nlittle bit here, but can you just talk a little bit about the dynamics in terms of what was the rationale for the slower \ngross profit growth relative  to the revenue growth?  \n ", "start_char_idx": 3513, "end_char_idx": 3724, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0886c3e0-4219-4c7e-a4d4-1ac46a69bbe1": {"__data__": {"id_": "0886c3e0-4219-4c7e-a4d4-1ac46a69bbe1", "embedding": null, "metadata": {"window": "It seems like, just given the sheer magnitude of \nthe performance and the outperformance on revenue relative at least to your guidance that a lot of it had to be \ndriven by pharma.  That being said, we didn't see a ton of gross margin pull -through.  That might be splitting hairs a \nlittle bit here, but can you just talk a little bit about the dynamics in terms of what was the rationale for the slower \ngross profit growth relative  to the revenue growth?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nSure.  Thanks for the question.  As I mentioned in my comments, some of the revenue growth that we saw came \nfrom some of our largest national re tail customers; and as you might expect, they don't generate as great a \ncontribution to gross profit. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "page_label": "10", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6959410c-ab10-4777-9191-d5a85e8e51b3", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "064afa09a15e30ad27bda1a73a8ba51f7b50788ebb028522a98bdffc4f372e61", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "366cb060-8221-40f2-a3fb-2e1e403658ad", "node_type": "1", "metadata": {"window": "Pharma \nperformance, maybe as a microcosm for the rest of the business.  It seems like, just given the sheer magnitude of \nthe performance and the outperformance on revenue relative at least to your guidance that a lot of it had to be \ndriven by pharma.  That being said, we didn't see a ton of gross margin pull -through.  That might be splitting hairs a \nlittle bit here, but can you just talk a little bit about the dynamics in terms of what was the rationale for the slower \ngross profit growth relative  to the revenue growth?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nSure.  Thanks for the question. ", "original_text": "That might be splitting hairs a \nlittle bit here, but can you just talk a little bit about the dynamics in terms of what was the rationale for the slower \ngross profit growth relative  to the revenue growth?  \n ", "page_label": "10", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e950f22cd20ae43b527fd2dfe98f05cc683e449c094da84602d36c36c0363291", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "92d9df4a-0692-4eea-b526-9d4f1eda11d9", "node_type": "1", "metadata": {"window": "That being said, we didn't see a ton of gross margin pull -through.  That might be splitting hairs a \nlittle bit here, but can you just talk a little bit about the dynamics in terms of what was the rationale for the slower \ngross profit growth relative  to the revenue growth?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nSure.  Thanks for the question.  As I mentioned in my comments, some of the revenue growth that we saw came \nfrom some of our largest national re tail customers; and as you might expect, they don't generate as great a \ncontribution to gross profit.  We did see broad -based strong performance across the segment and not only with \nour largest national retail customers, but we saw good performance in our h ealth systems segment and we \ncontinue to see very strong performance in our specialty business. ", "original_text": "A \nSure. "}, "hash": "ce73e2c2e23385a9780794753d7f5b3fcc1306f57c12e3fa8335c12d755eb217", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "start_char_idx": 677, "end_char_idx": 1022, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "92d9df4a-0692-4eea-b526-9d4f1eda11d9": {"__data__": {"id_": "92d9df4a-0692-4eea-b526-9d4f1eda11d9", "embedding": null, "metadata": {"window": "That being said, we didn't see a ton of gross margin pull -through.  That might be splitting hairs a \nlittle bit here, but can you just talk a little bit about the dynamics in terms of what was the rationale for the slower \ngross profit growth relative  to the revenue growth?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nSure.  Thanks for the question.  As I mentioned in my comments, some of the revenue growth that we saw came \nfrom some of our largest national re tail customers; and as you might expect, they don't generate as great a \ncontribution to gross profit.  We did see broad -based strong performance across the segment and not only with \nour largest national retail customers, but we saw good performance in our h ealth systems segment and we \ncontinue to see very strong performance in our specialty business. ", "original_text": "A \nSure. ", "page_label": "10", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6959410c-ab10-4777-9191-d5a85e8e51b3", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "064afa09a15e30ad27bda1a73a8ba51f7b50788ebb028522a98bdffc4f372e61", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0886c3e0-4219-4c7e-a4d4-1ac46a69bbe1", "node_type": "1", "metadata": {"window": "It seems like, just given the sheer magnitude of \nthe performance and the outperformance on revenue relative at least to your guidance that a lot of it had to be \ndriven by pharma.  That being said, we didn't see a ton of gross margin pull -through.  That might be splitting hairs a \nlittle bit here, but can you just talk a little bit about the dynamics in terms of what was the rationale for the slower \ngross profit growth relative  to the revenue growth?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nSure.  Thanks for the question.  As I mentioned in my comments, some of the revenue growth that we saw came \nfrom some of our largest national re tail customers; and as you might expect, they don't generate as great a \ncontribution to gross profit. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "page_label": "10", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "354ed63fe04b1bfa57a525052942d429cbaa4f9b30f97a06b24f9e56f6a9131f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5f0e99f9-7aef-4b52-9044-6230fc2a373b", "node_type": "1", "metadata": {"window": "That might be splitting hairs a \nlittle bit here, but can you just talk a little bit about the dynamics in terms of what was the rationale for the slower \ngross profit growth relative  to the revenue growth?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nSure.  Thanks for the question.  As I mentioned in my comments, some of the revenue growth that we saw came \nfrom some of our largest national re tail customers; and as you might expect, they don't generate as great a \ncontribution to gross profit.  We did see broad -based strong performance across the segment and not only with \nour largest national retail customers, but we saw good performance in our h ealth systems segment and we \ncontinue to see very strong performance in our specialty business.  And so, we're quite pleased with that.  \n \n", "original_text": "Thanks for the question. "}, "hash": "929d9cb55e9f3ebed9603d60bee45e1b7a00f91c8c8279bb436d848e43bc9ac3", "class_name": "RelatedNodeInfo"}}, "text": "A \nSure. ", "start_char_idx": 4069, "end_char_idx": 4078, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5f0e99f9-7aef-4b52-9044-6230fc2a373b": {"__data__": {"id_": "5f0e99f9-7aef-4b52-9044-6230fc2a373b", "embedding": null, "metadata": {"window": "That might be splitting hairs a \nlittle bit here, but can you just talk a little bit about the dynamics in terms of what was the rationale for the slower \ngross profit growth relative  to the revenue growth?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nSure.  Thanks for the question.  As I mentioned in my comments, some of the revenue growth that we saw came \nfrom some of our largest national re tail customers; and as you might expect, they don't generate as great a \ncontribution to gross profit.  We did see broad -based strong performance across the segment and not only with \nour largest national retail customers, but we saw good performance in our h ealth systems segment and we \ncontinue to see very strong performance in our specialty business.  And so, we're quite pleased with that.  \n \n", "original_text": "Thanks for the question. ", "page_label": "10", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6959410c-ab10-4777-9191-d5a85e8e51b3", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "064afa09a15e30ad27bda1a73a8ba51f7b50788ebb028522a98bdffc4f372e61", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "92d9df4a-0692-4eea-b526-9d4f1eda11d9", "node_type": "1", "metadata": {"window": "That being said, we didn't see a ton of gross margin pull -through.  That might be splitting hairs a \nlittle bit here, but can you just talk a little bit about the dynamics in terms of what was the rationale for the slower \ngross profit growth relative  to the revenue growth?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nSure.  Thanks for the question.  As I mentioned in my comments, some of the revenue growth that we saw came \nfrom some of our largest national re tail customers; and as you might expect, they don't generate as great a \ncontribution to gross profit.  We did see broad -based strong performance across the segment and not only with \nour largest national retail customers, but we saw good performance in our h ealth systems segment and we \ncontinue to see very strong performance in our specialty business. ", "original_text": "A \nSure. ", "page_label": "10", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8bc6e0ea40d220a0d0886907fa1907edc5d70bbd689a793965fc0b2b50e5c499", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "af2d9adb-c565-46fc-bdde-7e5c1f5f52a6", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nSure.  Thanks for the question.  As I mentioned in my comments, some of the revenue growth that we saw came \nfrom some of our largest national re tail customers; and as you might expect, they don't generate as great a \ncontribution to gross profit.  We did see broad -based strong performance across the segment and not only with \nour largest national retail customers, but we saw good performance in our h ealth systems segment and we \ncontinue to see very strong performance in our specialty business.  And so, we're quite pleased with that.  \n \n Overall, in the segment, while our gross profit was lower on a consolidated basis, within our U.S. ", "original_text": "As I mentioned in my comments, some of the revenue growth that we saw came \nfrom some of our largest national re tail customers; and as you might expect, they don't generate as great a \ncontribution to gross profit. "}, "hash": "1c99f9daa6e0e8fe0e9810f220b2e3bfd163f36fff3734b0bf020ceee249adf8", "class_name": "RelatedNodeInfo"}}, "text": "Thanks for the question. ", "start_char_idx": 4078, "end_char_idx": 4103, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "af2d9adb-c565-46fc-bdde-7e5c1f5f52a6": {"__data__": {"id_": "af2d9adb-c565-46fc-bdde-7e5c1f5f52a6", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nSure.  Thanks for the question.  As I mentioned in my comments, some of the revenue growth that we saw came \nfrom some of our largest national re tail customers; and as you might expect, they don't generate as great a \ncontribution to gross profit.  We did see broad -based strong performance across the segment and not only with \nour largest national retail customers, but we saw good performance in our h ealth systems segment and we \ncontinue to see very strong performance in our specialty business.  And so, we're quite pleased with that.  \n \n Overall, in the segment, while our gross profit was lower on a consolidated basis, within our U.S. ", "original_text": "As I mentioned in my comments, some of the revenue growth that we saw came \nfrom some of our largest national re tail customers; and as you might expect, they don't generate as great a \ncontribution to gross profit. ", "page_label": "10", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6959410c-ab10-4777-9191-d5a85e8e51b3", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "064afa09a15e30ad27bda1a73a8ba51f7b50788ebb028522a98bdffc4f372e61", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5f0e99f9-7aef-4b52-9044-6230fc2a373b", "node_type": "1", "metadata": {"window": "That might be splitting hairs a \nlittle bit here, but can you just talk a little bit about the dynamics in terms of what was the rationale for the slower \ngross profit growth relative  to the revenue growth?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nSure.  Thanks for the question.  As I mentioned in my comments, some of the revenue growth that we saw came \nfrom some of our largest national re tail customers; and as you might expect, they don't generate as great a \ncontribution to gross profit.  We did see broad -based strong performance across the segment and not only with \nour largest national retail customers, but we saw good performance in our h ealth systems segment and we \ncontinue to see very strong performance in our specialty business.  And so, we're quite pleased with that.  \n \n", "original_text": "Thanks for the question. ", "page_label": "10", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "09c872f45db231ca021b3d857ef91c73830c45a55707ae2d404866e81664be79", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ac8c212d-87bf-468b-9443-2f9cbae6a5a9", "node_type": "1", "metadata": {"window": "A \nSure.  Thanks for the question.  As I mentioned in my comments, some of the revenue growth that we saw came \nfrom some of our largest national re tail customers; and as you might expect, they don't generate as great a \ncontribution to gross profit.  We did see broad -based strong performance across the segment and not only with \nour largest national retail customers, but we saw good performance in our h ealth systems segment and we \ncontinue to see very strong performance in our specialty business.  And so, we're quite pleased with that.  \n \n Overall, in the segment, while our gross profit was lower on a consolidated basis, within our U.S.  Pharma and \nSpecialty Solutions segment we saw very good performance at the adjusted operating profit line. ", "original_text": "We did see broad -based strong performance across the segment and not only with \nour largest national retail customers, but we saw good performance in our h ealth systems segment and we \ncontinue to see very strong performance in our specialty business. "}, "hash": "b9fe46173feb3dc179b5649e4a070306022eda8b8d89daa7c349cd08b7c3c8ac", "class_name": "RelatedNodeInfo"}}, "text": "As I mentioned in my comments, some of the revenue growth that we saw came \nfrom some of our largest national re tail customers; and as you might expect, they don't generate as great a \ncontribution to gross profit. ", "start_char_idx": 4103, "end_char_idx": 4319, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ac8c212d-87bf-468b-9443-2f9cbae6a5a9": {"__data__": {"id_": "ac8c212d-87bf-468b-9443-2f9cbae6a5a9", "embedding": null, "metadata": {"window": "A \nSure.  Thanks for the question.  As I mentioned in my comments, some of the revenue growth that we saw came \nfrom some of our largest national re tail customers; and as you might expect, they don't generate as great a \ncontribution to gross profit.  We did see broad -based strong performance across the segment and not only with \nour largest national retail customers, but we saw good performance in our h ealth systems segment and we \ncontinue to see very strong performance in our specialty business.  And so, we're quite pleased with that.  \n \n Overall, in the segment, while our gross profit was lower on a consolidated basis, within our U.S.  Pharma and \nSpecialty Solutions segment we saw very good performance at the adjusted operating profit line. ", "original_text": "We did see broad -based strong performance across the segment and not only with \nour largest national retail customers, but we saw good performance in our h ealth systems segment and we \ncontinue to see very strong performance in our specialty business. ", "page_label": "10", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6959410c-ab10-4777-9191-d5a85e8e51b3", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "064afa09a15e30ad27bda1a73a8ba51f7b50788ebb028522a98bdffc4f372e61", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "af2d9adb-c565-46fc-bdde-7e5c1f5f52a6", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nSure.  Thanks for the question.  As I mentioned in my comments, some of the revenue growth that we saw came \nfrom some of our largest national re tail customers; and as you might expect, they don't generate as great a \ncontribution to gross profit.  We did see broad -based strong performance across the segment and not only with \nour largest national retail customers, but we saw good performance in our h ealth systems segment and we \ncontinue to see very strong performance in our specialty business.  And so, we're quite pleased with that.  \n \n Overall, in the segment, while our gross profit was lower on a consolidated basis, within our U.S. ", "original_text": "As I mentioned in my comments, some of the revenue growth that we saw came \nfrom some of our largest national re tail customers; and as you might expect, they don't generate as great a \ncontribution to gross profit. ", "page_label": "10", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4e59a75af1d7ec632da2b7cfc2a771f53c6af9521835080088d6dd3e297acfa0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "66ae863d-2dc8-47fa-a147-d5dd91d59426", "node_type": "1", "metadata": {"window": "Thanks for the question.  As I mentioned in my comments, some of the revenue growth that we saw came \nfrom some of our largest national re tail customers; and as you might expect, they don't generate as great a \ncontribution to gross profit.  We did see broad -based strong performance across the segment and not only with \nour largest national retail customers, but we saw good performance in our h ealth systems segment and we \ncontinue to see very strong performance in our specialty business.  And so, we're quite pleased with that.  \n \n Overall, in the segment, while our gross profit was lower on a consolidated basis, within our U.S.  Pharma and \nSpecialty Solutions segment we saw very good performance at the adjusted operating profit line.  So we're very \npleased with the performance. ", "original_text": "And so, we're quite pleased with that.  \n \n"}, "hash": "67be7b8148e355482de0889116724701bc46e372ccf2986f1551252bbc77f365", "class_name": "RelatedNodeInfo"}}, "text": "We did see broad -based strong performance across the segment and not only with \nour largest national retail customers, but we saw good performance in our h ealth systems segment and we \ncontinue to see very strong performance in our specialty business. ", "start_char_idx": 4319, "end_char_idx": 4573, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "66ae863d-2dc8-47fa-a147-d5dd91d59426": {"__data__": {"id_": "66ae863d-2dc8-47fa-a147-d5dd91d59426", "embedding": null, "metadata": {"window": "Thanks for the question.  As I mentioned in my comments, some of the revenue growth that we saw came \nfrom some of our largest national re tail customers; and as you might expect, they don't generate as great a \ncontribution to gross profit.  We did see broad -based strong performance across the segment and not only with \nour largest national retail customers, but we saw good performance in our h ealth systems segment and we \ncontinue to see very strong performance in our specialty business.  And so, we're quite pleased with that.  \n \n Overall, in the segment, while our gross profit was lower on a consolidated basis, within our U.S.  Pharma and \nSpecialty Solutions segment we saw very good performance at the adjusted operating profit line.  So we're very \npleased with the performance. ", "original_text": "And so, we're quite pleased with that.  \n \n", "page_label": "10", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6959410c-ab10-4777-9191-d5a85e8e51b3", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "064afa09a15e30ad27bda1a73a8ba51f7b50788ebb028522a98bdffc4f372e61", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ac8c212d-87bf-468b-9443-2f9cbae6a5a9", "node_type": "1", "metadata": {"window": "A \nSure.  Thanks for the question.  As I mentioned in my comments, some of the revenue growth that we saw came \nfrom some of our largest national re tail customers; and as you might expect, they don't generate as great a \ncontribution to gross profit.  We did see broad -based strong performance across the segment and not only with \nour largest national retail customers, but we saw good performance in our h ealth systems segment and we \ncontinue to see very strong performance in our specialty business.  And so, we're quite pleased with that.  \n \n Overall, in the segment, while our gross profit was lower on a consolidated basis, within our U.S.  Pharma and \nSpecialty Solutions segment we saw very good performance at the adjusted operating profit line. ", "original_text": "We did see broad -based strong performance across the segment and not only with \nour largest national retail customers, but we saw good performance in our h ealth systems segment and we \ncontinue to see very strong performance in our specialty business. ", "page_label": "10", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "96ea03287a1160c0fcbd265e45945d5556f15548bec044da19adc224468fed7c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "95061b7a-d257-4cbf-9511-e6947c798fcb", "node_type": "1", "metadata": {"window": "As I mentioned in my comments, some of the revenue growth that we saw came \nfrom some of our largest national re tail customers; and as you might expect, they don't generate as great a \ncontribution to gross profit.  We did see broad -based strong performance across the segment and not only with \nour largest national retail customers, but we saw good performance in our h ealth systems segment and we \ncontinue to see very strong performance in our specialty business.  And so, we're quite pleased with that.  \n \n Overall, in the segment, while our gross profit was lower on a consolidated basis, within our U.S.  Pharma and \nSpecialty Solutions segment we saw very good performance at the adjusted operating profit line.  So we're very \npleased with the performance.  We saw a very broad -based performance across that segment, and we think that \nwe're well positioned to continue and achieve our  guidance for the rest of the year.  ", "original_text": "Overall, in the segment, while our gross profit was lower on a consolidated basis, within our U.S. "}, "hash": "c770804ce22b1a203ab506a6500fb5b649aa00ba9dfd8461755ca42db9bb0a70", "class_name": "RelatedNodeInfo"}}, "text": "And so, we're quite pleased with that.  \n \n", "start_char_idx": 4573, "end_char_idx": 4616, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "95061b7a-d257-4cbf-9511-e6947c798fcb": {"__data__": {"id_": "95061b7a-d257-4cbf-9511-e6947c798fcb", "embedding": null, "metadata": {"window": "As I mentioned in my comments, some of the revenue growth that we saw came \nfrom some of our largest national re tail customers; and as you might expect, they don't generate as great a \ncontribution to gross profit.  We did see broad -based strong performance across the segment and not only with \nour largest national retail customers, but we saw good performance in our h ealth systems segment and we \ncontinue to see very strong performance in our specialty business.  And so, we're quite pleased with that.  \n \n Overall, in the segment, while our gross profit was lower on a consolidated basis, within our U.S.  Pharma and \nSpecialty Solutions segment we saw very good performance at the adjusted operating profit line.  So we're very \npleased with the performance.  We saw a very broad -based performance across that segment, and we think that \nwe're well positioned to continue and achieve our  guidance for the rest of the year.  ", "original_text": "Overall, in the segment, while our gross profit was lower on a consolidated basis, within our U.S. ", "page_label": "10", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6959410c-ab10-4777-9191-d5a85e8e51b3", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "064afa09a15e30ad27bda1a73a8ba51f7b50788ebb028522a98bdffc4f372e61", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "66ae863d-2dc8-47fa-a147-d5dd91d59426", "node_type": "1", "metadata": {"window": "Thanks for the question.  As I mentioned in my comments, some of the revenue growth that we saw came \nfrom some of our largest national re tail customers; and as you might expect, they don't generate as great a \ncontribution to gross profit.  We did see broad -based strong performance across the segment and not only with \nour largest national retail customers, but we saw good performance in our h ealth systems segment and we \ncontinue to see very strong performance in our specialty business.  And so, we're quite pleased with that.  \n \n Overall, in the segment, while our gross profit was lower on a consolidated basis, within our U.S.  Pharma and \nSpecialty Solutions segment we saw very good performance at the adjusted operating profit line.  So we're very \npleased with the performance. ", "original_text": "And so, we're quite pleased with that.  \n \n", "page_label": "10", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dbd7fbd75e117587b29a3bf074a927a10fc217c116c4e19c2fb1e48c845a3bf8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f1b29493-3089-4be7-a51e-2ae052e9e55c", "node_type": "1", "metadata": {"window": "We did see broad -based strong performance across the segment and not only with \nour largest national retail customers, but we saw good performance in our h ealth systems segment and we \ncontinue to see very strong performance in our specialty business.  And so, we're quite pleased with that.  \n \n Overall, in the segment, while our gross profit was lower on a consolidated basis, within our U.S.  Pharma and \nSpecialty Solutions segment we saw very good performance at the adjusted operating profit line.  So we're very \npleased with the performance.  We saw a very broad -based performance across that segment, and we think that \nwe're well positioned to continue and achieve our  guidance for the rest of the year.  ", "original_text": "Pharma and \nSpecialty Solutions segment we saw very good performance at the adjusted operating profit line. "}, "hash": "d8fd4d3c2665146878f6da88429c50fb20c9ea6a589e8112d92ec1aeea0ce8d1", "class_name": "RelatedNodeInfo"}}, "text": "Overall, in the segment, while our gross profit was lower on a consolidated basis, within our U.S. ", "start_char_idx": 4616, "end_char_idx": 4715, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f1b29493-3089-4be7-a51e-2ae052e9e55c": {"__data__": {"id_": "f1b29493-3089-4be7-a51e-2ae052e9e55c", "embedding": null, "metadata": {"window": "We did see broad -based strong performance across the segment and not only with \nour largest national retail customers, but we saw good performance in our h ealth systems segment and we \ncontinue to see very strong performance in our specialty business.  And so, we're quite pleased with that.  \n \n Overall, in the segment, while our gross profit was lower on a consolidated basis, within our U.S.  Pharma and \nSpecialty Solutions segment we saw very good performance at the adjusted operating profit line.  So we're very \npleased with the performance.  We saw a very broad -based performance across that segment, and we think that \nwe're well positioned to continue and achieve our  guidance for the rest of the year.  ", "original_text": "Pharma and \nSpecialty Solutions segment we saw very good performance at the adjusted operating profit line. ", "page_label": "10", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6959410c-ab10-4777-9191-d5a85e8e51b3", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "064afa09a15e30ad27bda1a73a8ba51f7b50788ebb028522a98bdffc4f372e61", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "95061b7a-d257-4cbf-9511-e6947c798fcb", "node_type": "1", "metadata": {"window": "As I mentioned in my comments, some of the revenue growth that we saw came \nfrom some of our largest national re tail customers; and as you might expect, they don't generate as great a \ncontribution to gross profit.  We did see broad -based strong performance across the segment and not only with \nour largest national retail customers, but we saw good performance in our h ealth systems segment and we \ncontinue to see very strong performance in our specialty business.  And so, we're quite pleased with that.  \n \n Overall, in the segment, while our gross profit was lower on a consolidated basis, within our U.S.  Pharma and \nSpecialty Solutions segment we saw very good performance at the adjusted operating profit line.  So we're very \npleased with the performance.  We saw a very broad -based performance across that segment, and we think that \nwe're well positioned to continue and achieve our  guidance for the rest of the year.  ", "original_text": "Overall, in the segment, while our gross profit was lower on a consolidated basis, within our U.S. ", "page_label": "10", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "20cb9be34862f5e99272f9916744011195a29448ca0e025afa0844880f84b6d9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "536f4375-d85e-4eb0-87d4-00ac6a5fc56b", "node_type": "1", "metadata": {"window": "And so, we're quite pleased with that.  \n \n Overall, in the segment, while our gross profit was lower on a consolidated basis, within our U.S.  Pharma and \nSpecialty Solutions segment we saw very good performance at the adjusted operating profit line.  So we're very \npleased with the performance.  We saw a very broad -based performance across that segment, and we think that \nwe're well positioned to continue and achieve our  guidance for the rest of the year.  ", "original_text": "So we're very \npleased with the performance. "}, "hash": "2f7ea4864695aef136ad89bed658d8e321eb1d252aeb356ea0d30850e30e75e7", "class_name": "RelatedNodeInfo"}}, "text": "Pharma and \nSpecialty Solutions segment we saw very good performance at the adjusted operating profit line. ", "start_char_idx": 4715, "end_char_idx": 4823, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "536f4375-d85e-4eb0-87d4-00ac6a5fc56b": {"__data__": {"id_": "536f4375-d85e-4eb0-87d4-00ac6a5fc56b", "embedding": null, "metadata": {"window": "And so, we're quite pleased with that.  \n \n Overall, in the segment, while our gross profit was lower on a consolidated basis, within our U.S.  Pharma and \nSpecialty Solutions segment we saw very good performance at the adjusted operating profit line.  So we're very \npleased with the performance.  We saw a very broad -based performance across that segment, and we think that \nwe're well positioned to continue and achieve our  guidance for the rest of the year.  ", "original_text": "So we're very \npleased with the performance. ", "page_label": "10", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6959410c-ab10-4777-9191-d5a85e8e51b3", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "064afa09a15e30ad27bda1a73a8ba51f7b50788ebb028522a98bdffc4f372e61", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f1b29493-3089-4be7-a51e-2ae052e9e55c", "node_type": "1", "metadata": {"window": "We did see broad -based strong performance across the segment and not only with \nour largest national retail customers, but we saw good performance in our h ealth systems segment and we \ncontinue to see very strong performance in our specialty business.  And so, we're quite pleased with that.  \n \n Overall, in the segment, while our gross profit was lower on a consolidated basis, within our U.S.  Pharma and \nSpecialty Solutions segment we saw very good performance at the adjusted operating profit line.  So we're very \npleased with the performance.  We saw a very broad -based performance across that segment, and we think that \nwe're well positioned to continue and achieve our  guidance for the rest of the year.  ", "original_text": "Pharma and \nSpecialty Solutions segment we saw very good performance at the adjusted operating profit line. ", "page_label": "10", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ecd6dbda5dd2ef3cc640c716c59296286fe5adf57ba2a1c109863280974c08e7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d9baee15-bebc-4e37-b0d5-0279b35e932d", "node_type": "1", "metadata": {"window": "Overall, in the segment, while our gross profit was lower on a consolidated basis, within our U.S.  Pharma and \nSpecialty Solutions segment we saw very good performance at the adjusted operating profit line.  So we're very \npleased with the performance.  We saw a very broad -based performance across that segment, and we think that \nwe're well positioned to continue and achieve our  guidance for the rest of the year.  ", "original_text": "We saw a very broad -based performance across that segment, and we think that \nwe're well positioned to continue and achieve our  guidance for the rest of the year.  "}, "hash": "366a5e59a3cdc611e09868b886a40a3b3e8d33079ffcd52f9ef6286ccfbb1e89", "class_name": "RelatedNodeInfo"}}, "text": "So we're very \npleased with the performance. ", "start_char_idx": 4823, "end_char_idx": 4868, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d9baee15-bebc-4e37-b0d5-0279b35e932d": {"__data__": {"id_": "d9baee15-bebc-4e37-b0d5-0279b35e932d", "embedding": null, "metadata": {"window": "Overall, in the segment, while our gross profit was lower on a consolidated basis, within our U.S.  Pharma and \nSpecialty Solutions segment we saw very good performance at the adjusted operating profit line.  So we're very \npleased with the performance.  We saw a very broad -based performance across that segment, and we think that \nwe're well positioned to continue and achieve our  guidance for the rest of the year.  ", "original_text": "We saw a very broad -based performance across that segment, and we think that \nwe're well positioned to continue and achieve our  guidance for the rest of the year.  ", "page_label": "10", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6959410c-ab10-4777-9191-d5a85e8e51b3", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "064afa09a15e30ad27bda1a73a8ba51f7b50788ebb028522a98bdffc4f372e61", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "536f4375-d85e-4eb0-87d4-00ac6a5fc56b", "node_type": "1", "metadata": {"window": "And so, we're quite pleased with that.  \n \n Overall, in the segment, while our gross profit was lower on a consolidated basis, within our U.S.  Pharma and \nSpecialty Solutions segment we saw very good performance at the adjusted operating profit line.  So we're very \npleased with the performance.  We saw a very broad -based performance across that segment, and we think that \nwe're well positioned to continue and achieve our  guidance for the rest of the year.  ", "original_text": "So we're very \npleased with the performance. ", "page_label": "10", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "af8fb72219825193afc3599bd707d8a27968eaa48a73292bd2bce1040487c6c9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b885786c-9ec7-444c-8631-d01811330fc2", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  Q \nAnd just on the contribution from Change, is the way to think about it the fact that the numbers didn't change \ndespite the fact that you had lower ownership stake versus guidance, simply driven by the outperformance \ncontribution for 1Q?  Or is there anything else that changed in terms of just the methodology aside from just a pure \nless ownership stake?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Of ficer, McKesson Corp.  ", "original_text": "McKesson Corp.  "}, "hash": "c251f466d725beeabe1be96d07dfe8013ff3ce9c89034bc77796f09fd0366545", "class_name": "RelatedNodeInfo"}}, "text": "We saw a very broad -based performance across that segment, and we think that \nwe're well positioned to continue and achieve our  guidance for the rest of the year.  ", "start_char_idx": 4868, "end_char_idx": 5034, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b885786c-9ec7-444c-8631-d01811330fc2": {"__data__": {"id_": "b885786c-9ec7-444c-8631-d01811330fc2", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  Q \nAnd just on the contribution from Change, is the way to think about it the fact that the numbers didn't change \ndespite the fact that you had lower ownership stake versus guidance, simply driven by the outperformance \ncontribution for 1Q?  Or is there anything else that changed in terms of just the methodology aside from just a pure \nless ownership stake?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Of ficer, McKesson Corp.  ", "original_text": "McKesson Corp.  ", "page_label": "11", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "35c2d8f8-957b-4d5b-8738-b472dc90faf7", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "595418f09a02257de5e4ed87e5bf57b056233fc91c7851fc596a3fba910582bd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d9baee15-bebc-4e37-b0d5-0279b35e932d", "node_type": "1", "metadata": {"window": "Overall, in the segment, while our gross profit was lower on a consolidated basis, within our U.S.  Pharma and \nSpecialty Solutions segment we saw very good performance at the adjusted operating profit line.  So we're very \npleased with the performance.  We saw a very broad -based performance across that segment, and we think that \nwe're well positioned to continue and achieve our  guidance for the rest of the year.  ", "original_text": "We saw a very broad -based performance across that segment, and we think that \nwe're well positioned to continue and achieve our  guidance for the rest of the year.  ", "page_label": "10", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f4e7431a9d7b08ae47f7d7dedc2895ae36bced2d2cf4239ef6a886dfd3b6646d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6b2d0de1-f3c8-4da1-b0ff-0515235a6f28", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  Q \nAnd just on the contribution from Change, is the way to think about it the fact that the numbers didn't change \ndespite the fact that you had lower ownership stake versus guidance, simply driven by the outperformance \ncontribution for 1Q?  Or is there anything else that changed in terms of just the methodology aside from just a pure \nless ownership stake?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Of ficer, McKesson Corp.   A \nI would say that it's a combination of the lower ownership stake being offset by the deleveraging that changed it \nas a result of raising the funds from the IPO.  \n ", "original_text": "(MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  Q \nAnd just on the contribution from Change, is the way to think about it the fact that the numbers didn't change \ndespite the fact that you had lower ownership stake versus guidance, simply driven by the outperformance \ncontribution for 1Q? "}, "hash": "fb329785757fb86ce6e8690c43628ca83aa58cf4e4f161cc24676af4e1e2d403", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6b2d0de1-f3c8-4da1-b0ff-0515235a6f28": {"__data__": {"id_": "6b2d0de1-f3c8-4da1-b0ff-0515235a6f28", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  Q \nAnd just on the contribution from Change, is the way to think about it the fact that the numbers didn't change \ndespite the fact that you had lower ownership stake versus guidance, simply driven by the outperformance \ncontribution for 1Q?  Or is there anything else that changed in terms of just the methodology aside from just a pure \nless ownership stake?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Of ficer, McKesson Corp.   A \nI would say that it's a combination of the lower ownership stake being offset by the deleveraging that changed it \nas a result of raising the funds from the IPO.  \n ", "original_text": "(MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  Q \nAnd just on the contribution from Change, is the way to think about it the fact that the numbers didn't change \ndespite the fact that you had lower ownership stake versus guidance, simply driven by the outperformance \ncontribution for 1Q? ", "page_label": "11", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "35c2d8f8-957b-4d5b-8738-b472dc90faf7", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "595418f09a02257de5e4ed87e5bf57b056233fc91c7851fc596a3fba910582bd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b885786c-9ec7-444c-8631-d01811330fc2", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  Q \nAnd just on the contribution from Change, is the way to think about it the fact that the numbers didn't change \ndespite the fact that you had lower ownership stake versus guidance, simply driven by the outperformance \ncontribution for 1Q?  Or is there anything else that changed in terms of just the methodology aside from just a pure \nless ownership stake?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Of ficer, McKesson Corp.  ", "original_text": "McKesson Corp.  ", "page_label": "11", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "400e9eebd5cccc30f2e81c2a4ca883eb1faf8286111f23da60e83d36d6d6093b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0f784f26-91bf-44a7-a0de-65da5d0ef0b5", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  Q \nAnd just on the contribution from Change, is the way to think about it the fact that the numbers didn't change \ndespite the fact that you had lower ownership stake versus guidance, simply driven by the outperformance \ncontribution for 1Q?  Or is there anything else that changed in terms of just the methodology aside from just a pure \nless ownership stake?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Of ficer, McKesson Corp.   A \nI would say that it's a combination of the lower ownership stake being offset by the deleveraging that changed it \nas a result of raising the funds from the IPO.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  Q \nOkay. ", "original_text": "Or is there anything else that changed in terms of just the methodology aside from just a pure \nless ownership stake?  \n "}, "hash": "ab40df5955ad9e3278e59cf885e593c12093c19407cded9c0e0d4c611a096591", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  Q \nAnd just on the contribution from Change, is the way to think about it the fact that the numbers didn't change \ndespite the fact that you had lower ownership stake versus guidance, simply driven by the outperformance \ncontribution for 1Q? ", "start_char_idx": 16, "end_char_idx": 480, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0f784f26-91bf-44a7-a0de-65da5d0ef0b5": {"__data__": {"id_": "0f784f26-91bf-44a7-a0de-65da5d0ef0b5", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  Q \nAnd just on the contribution from Change, is the way to think about it the fact that the numbers didn't change \ndespite the fact that you had lower ownership stake versus guidance, simply driven by the outperformance \ncontribution for 1Q?  Or is there anything else that changed in terms of just the methodology aside from just a pure \nless ownership stake?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Of ficer, McKesson Corp.   A \nI would say that it's a combination of the lower ownership stake being offset by the deleveraging that changed it \nas a result of raising the funds from the IPO.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  Q \nOkay. ", "original_text": "Or is there anything else that changed in terms of just the methodology aside from just a pure \nless ownership stake?  \n ", "page_label": "11", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "35c2d8f8-957b-4d5b-8738-b472dc90faf7", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "595418f09a02257de5e4ed87e5bf57b056233fc91c7851fc596a3fba910582bd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6b2d0de1-f3c8-4da1-b0ff-0515235a6f28", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  Q \nAnd just on the contribution from Change, is the way to think about it the fact that the numbers didn't change \ndespite the fact that you had lower ownership stake versus guidance, simply driven by the outperformance \ncontribution for 1Q?  Or is there anything else that changed in terms of just the methodology aside from just a pure \nless ownership stake?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Of ficer, McKesson Corp.   A \nI would say that it's a combination of the lower ownership stake being offset by the deleveraging that changed it \nas a result of raising the funds from the IPO.  \n ", "original_text": "(MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  Q \nAnd just on the contribution from Change, is the way to think about it the fact that the numbers didn't change \ndespite the fact that you had lower ownership stake versus guidance, simply driven by the outperformance \ncontribution for 1Q? ", "page_label": "11", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "27aea82d0ed40517216afaf7f6f897b1e886c3a3d0bdfac1bc6bc1b551205066", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3be69ea5-89f1-456f-8203-74e7784c8d81", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  Q \nAnd just on the contribution from Change, is the way to think about it the fact that the numbers didn't change \ndespite the fact that you had lower ownership stake versus guidance, simply driven by the outperformance \ncontribution for 1Q?  Or is there anything else that changed in terms of just the methodology aside from just a pure \nless ownership stake?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Of ficer, McKesson Corp.   A \nI would say that it's a combination of the lower ownership stake being offset by the deleveraging that changed it \nas a result of raising the funds from the IPO.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  Q \nOkay.  Great . ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Of ficer, McKesson Corp.  "}, "hash": "541ba18145fd4647dcd09a0e17da59f04b61ed79c4cee66001542fc6c21b3e14", "class_name": "RelatedNodeInfo"}}, "text": "Or is there anything else that changed in terms of just the methodology aside from just a pure \nless ownership stake?  \n ", "start_char_idx": 480, "end_char_idx": 601, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3be69ea5-89f1-456f-8203-74e7784c8d81": {"__data__": {"id_": "3be69ea5-89f1-456f-8203-74e7784c8d81", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  Q \nAnd just on the contribution from Change, is the way to think about it the fact that the numbers didn't change \ndespite the fact that you had lower ownership stake versus guidance, simply driven by the outperformance \ncontribution for 1Q?  Or is there anything else that changed in terms of just the methodology aside from just a pure \nless ownership stake?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Of ficer, McKesson Corp.   A \nI would say that it's a combination of the lower ownership stake being offset by the deleveraging that changed it \nas a result of raising the funds from the IPO.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  Q \nOkay.  Great . ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Of ficer, McKesson Corp.  ", "page_label": "11", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "35c2d8f8-957b-4d5b-8738-b472dc90faf7", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "595418f09a02257de5e4ed87e5bf57b056233fc91c7851fc596a3fba910582bd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0f784f26-91bf-44a7-a0de-65da5d0ef0b5", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  Q \nAnd just on the contribution from Change, is the way to think about it the fact that the numbers didn't change \ndespite the fact that you had lower ownership stake versus guidance, simply driven by the outperformance \ncontribution for 1Q?  Or is there anything else that changed in terms of just the methodology aside from just a pure \nless ownership stake?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Of ficer, McKesson Corp.   A \nI would say that it's a combination of the lower ownership stake being offset by the deleveraging that changed it \nas a result of raising the funds from the IPO.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  Q \nOkay. ", "original_text": "Or is there anything else that changed in terms of just the methodology aside from just a pure \nless ownership stake?  \n ", "page_label": "11", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "999f94d78c6eb401706844eca03b3a502075a82700fd9742699487e6134f2143", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "50de4cdc-0905-4fc2-9ecf-6189c0ea260e", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  Q \nAnd just on the contribution from Change, is the way to think about it the fact that the numbers didn't change \ndespite the fact that you had lower ownership stake versus guidance, simply driven by the outperformance \ncontribution for 1Q?  Or is there anything else that changed in terms of just the methodology aside from just a pure \nless ownership stake?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Of ficer, McKesson Corp.   A \nI would say that it's a combination of the lower ownership stake being offset by the deleveraging that changed it \nas a result of raising the funds from the IPO.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  Q \nOkay.  Great .  Thanks so much.  \n ", "original_text": "A \nI would say that it's a combination of the lower ownership stake being offset by the deleveraging that changed it \nas a result of raising the funds from the IPO.  \n "}, "hash": "46bf6d6cac3f7e328d0839ddbc35d2ecde04f058ca2503449a54b3e22c6ac9ea", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Of ficer, McKesson Corp.  ", "start_char_idx": 601, "end_char_idx": 947, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "50de4cdc-0905-4fc2-9ecf-6189c0ea260e": {"__data__": {"id_": "50de4cdc-0905-4fc2-9ecf-6189c0ea260e", "embedding": null, "metadata": {"window": "(MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  Q \nAnd just on the contribution from Change, is the way to think about it the fact that the numbers didn't change \ndespite the fact that you had lower ownership stake versus guidance, simply driven by the outperformance \ncontribution for 1Q?  Or is there anything else that changed in terms of just the methodology aside from just a pure \nless ownership stake?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Of ficer, McKesson Corp.   A \nI would say that it's a combination of the lower ownership stake being offset by the deleveraging that changed it \nas a result of raising the funds from the IPO.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  Q \nOkay.  Great .  Thanks so much.  \n ", "original_text": "A \nI would say that it's a combination of the lower ownership stake being offset by the deleveraging that changed it \nas a result of raising the funds from the IPO.  \n ", "page_label": "11", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "35c2d8f8-957b-4d5b-8738-b472dc90faf7", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "595418f09a02257de5e4ed87e5bf57b056233fc91c7851fc596a3fba910582bd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3be69ea5-89f1-456f-8203-74e7784c8d81", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  Q \nAnd just on the contribution from Change, is the way to think about it the fact that the numbers didn't change \ndespite the fact that you had lower ownership stake versus guidance, simply driven by the outperformance \ncontribution for 1Q?  Or is there anything else that changed in terms of just the methodology aside from just a pure \nless ownership stake?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Of ficer, McKesson Corp.   A \nI would say that it's a combination of the lower ownership stake being offset by the deleveraging that changed it \nas a result of raising the funds from the IPO.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  Q \nOkay.  Great . ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Of ficer, McKesson Corp.  ", "page_label": "11", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "636934f05959cf58462bdaf6a60c9724af5d146776b6239905bc01c519420cce", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "64f70d00-0dbc-4b75-9781-d05a3aa15500", "node_type": "1", "metadata": {"window": "Or is there anything else that changed in terms of just the methodology aside from just a pure \nless ownership stake?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Of ficer, McKesson Corp.   A \nI would say that it's a combination of the lower ownership stake being offset by the deleveraging that changed it \nas a result of raising the funds from the IPO.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  Q \nOkay.  Great .  Thanks so much.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Kevin Caliendo with UBS.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  Q \nOkay. "}, "hash": "db2a51534d90d80d810fa17547cc26e8ea11b90a38522150bcceaadade101b93", "class_name": "RelatedNodeInfo"}}, "text": "A \nI would say that it's a combination of the lower ownership stake being offset by the deleveraging that changed it \nas a result of raising the funds from the IPO.  \n ", "start_char_idx": 947, "end_char_idx": 1115, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "64f70d00-0dbc-4b75-9781-d05a3aa15500": {"__data__": {"id_": "64f70d00-0dbc-4b75-9781-d05a3aa15500", "embedding": null, "metadata": {"window": "Or is there anything else that changed in terms of just the methodology aside from just a pure \nless ownership stake?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Of ficer, McKesson Corp.   A \nI would say that it's a combination of the lower ownership stake being offset by the deleveraging that changed it \nas a result of raising the funds from the IPO.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  Q \nOkay.  Great .  Thanks so much.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Kevin Caliendo with UBS.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  Q \nOkay. ", "page_label": "11", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "35c2d8f8-957b-4d5b-8738-b472dc90faf7", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "595418f09a02257de5e4ed87e5bf57b056233fc91c7851fc596a3fba910582bd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "50de4cdc-0905-4fc2-9ecf-6189c0ea260e", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  Q \nAnd just on the contribution from Change, is the way to think about it the fact that the numbers didn't change \ndespite the fact that you had lower ownership stake versus guidance, simply driven by the outperformance \ncontribution for 1Q?  Or is there anything else that changed in terms of just the methodology aside from just a pure \nless ownership stake?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Of ficer, McKesson Corp.   A \nI would say that it's a combination of the lower ownership stake being offset by the deleveraging that changed it \nas a result of raising the funds from the IPO.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  Q \nOkay.  Great .  Thanks so much.  \n ", "original_text": "A \nI would say that it's a combination of the lower ownership stake being offset by the deleveraging that changed it \nas a result of raising the funds from the IPO.  \n ", "page_label": "11", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "eb661c4424236cfe465c65cb901c1842f1ab03ec9fbcd2ff5959bbcf0c9eb8ec", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "854b7bb7-f874-45a2-845f-9fb6d8144061", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Of ficer, McKesson Corp.   A \nI would say that it's a combination of the lower ownership stake being offset by the deleveraging that changed it \nas a result of raising the funds from the IPO.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  Q \nOkay.  Great .  Thanks so much.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Kevin Caliendo with UBS.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nGreat. ", "original_text": "Great . "}, "hash": "0d9b7ec44372a602f6e3c70bc20e1c754ee8699dee29e7cba0394601b5322b54", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  Q \nOkay. ", "start_char_idx": 1115, "end_char_idx": 1438, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "854b7bb7-f874-45a2-845f-9fb6d8144061": {"__data__": {"id_": "854b7bb7-f874-45a2-845f-9fb6d8144061", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Of ficer, McKesson Corp.   A \nI would say that it's a combination of the lower ownership stake being offset by the deleveraging that changed it \nas a result of raising the funds from the IPO.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  Q \nOkay.  Great .  Thanks so much.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Kevin Caliendo with UBS.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nGreat. ", "original_text": "Great . ", "page_label": "11", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "35c2d8f8-957b-4d5b-8738-b472dc90faf7", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "595418f09a02257de5e4ed87e5bf57b056233fc91c7851fc596a3fba910582bd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "64f70d00-0dbc-4b75-9781-d05a3aa15500", "node_type": "1", "metadata": {"window": "Or is there anything else that changed in terms of just the methodology aside from just a pure \nless ownership stake?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Of ficer, McKesson Corp.   A \nI would say that it's a combination of the lower ownership stake being offset by the deleveraging that changed it \nas a result of raising the funds from the IPO.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  Q \nOkay.  Great .  Thanks so much.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Kevin Caliendo with UBS.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  Q \nOkay. ", "page_label": "11", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "18a476dde82c3e49a5121aab50a7a1bfa97e2e60d175dc494cc88dd089d38671", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4b5a537a-5fa1-47bb-a3ef-b6af42358830", "node_type": "1", "metadata": {"window": "A \nI would say that it's a combination of the lower ownership stake being offset by the deleveraging that changed it \nas a result of raising the funds from the IPO.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  Q \nOkay.  Great .  Thanks so much.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Kevin Caliendo with UBS.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nGreat.  Thanks for taking my call. ", "original_text": "Thanks so much.  \n "}, "hash": "70d50d38836b51b40aa8d796256039d6f3c96bfc4b183285b53a99dd79b14e90", "class_name": "RelatedNodeInfo"}}, "text": "Great . ", "start_char_idx": 1438, "end_char_idx": 1446, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4b5a537a-5fa1-47bb-a3ef-b6af42358830": {"__data__": {"id_": "4b5a537a-5fa1-47bb-a3ef-b6af42358830", "embedding": null, "metadata": {"window": "A \nI would say that it's a combination of the lower ownership stake being offset by the deleveraging that changed it \nas a result of raising the funds from the IPO.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  Q \nOkay.  Great .  Thanks so much.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Kevin Caliendo with UBS.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nGreat.  Thanks for taking my call. ", "original_text": "Thanks so much.  \n ", "page_label": "11", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "35c2d8f8-957b-4d5b-8738-b472dc90faf7", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "595418f09a02257de5e4ed87e5bf57b056233fc91c7851fc596a3fba910582bd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "854b7bb7-f874-45a2-845f-9fb6d8144061", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Of ficer, McKesson Corp.   A \nI would say that it's a combination of the lower ownership stake being offset by the deleveraging that changed it \nas a result of raising the funds from the IPO.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  Q \nOkay.  Great .  Thanks so much.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Kevin Caliendo with UBS.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nGreat. ", "original_text": "Great . ", "page_label": "11", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "eac443eb6d5373ed5e72c3a91972138ade022dbcdc515dee8ebf2c6e74ae5170", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "273e426a-abc2-409a-9056-fac88e8a27c0", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  Q \nOkay.  Great .  Thanks so much.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Kevin Caliendo with UBS.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nGreat.  Thanks for taking my call.  Question around the guidance. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Kevin Caliendo with UBS.  \n "}, "hash": "45efa8be5fbca5fda54d6c6d715998c24e7e47dd6e02eb136ddfd8b5cb120755", "class_name": "RelatedNodeInfo"}}, "text": "Thanks so much.  \n ", "start_char_idx": 1446, "end_char_idx": 1465, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "273e426a-abc2-409a-9056-fac88e8a27c0": {"__data__": {"id_": "273e426a-abc2-409a-9056-fac88e8a27c0", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  Q \nOkay.  Great .  Thanks so much.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Kevin Caliendo with UBS.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nGreat.  Thanks for taking my call.  Question around the guidance. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Kevin Caliendo with UBS.  \n ", "page_label": "11", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "35c2d8f8-957b-4d5b-8738-b472dc90faf7", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "595418f09a02257de5e4ed87e5bf57b056233fc91c7851fc596a3fba910582bd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4b5a537a-5fa1-47bb-a3ef-b6af42358830", "node_type": "1", "metadata": {"window": "A \nI would say that it's a combination of the lower ownership stake being offset by the deleveraging that changed it \nas a result of raising the funds from the IPO.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  Q \nOkay.  Great .  Thanks so much.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Kevin Caliendo with UBS.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nGreat.  Thanks for taking my call. ", "original_text": "Thanks so much.  \n ", "page_label": "11", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "858b2088ebc315964a6383fdc1c362cd5e8f539db1b727aa633902cb9ee0ff57", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bc42432a-0d17-49c3-b02d-45d569317371", "node_type": "1", "metadata": {"window": "Great .  Thanks so much.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Kevin Caliendo with UBS.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nGreat.  Thanks for taking my call.  Question around the guidance.  You beat by $0.30; you only guided up by $0.15. \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nGreat. "}, "hash": "7342ac643c7d8d3224f70d08f5214a1f336bcd201a8f7df64d007e83f7218a65", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Kevin Caliendo with UBS.  \n ", "start_char_idx": 1465, "end_char_idx": 1780, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bc42432a-0d17-49c3-b02d-45d569317371": {"__data__": {"id_": "bc42432a-0d17-49c3-b02d-45d569317371", "embedding": null, "metadata": {"window": "Great .  Thanks so much.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Kevin Caliendo with UBS.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nGreat.  Thanks for taking my call.  Question around the guidance.  You beat by $0.30; you only guided up by $0.15. \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nGreat. ", "page_label": "11", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "35c2d8f8-957b-4d5b-8738-b472dc90faf7", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "595418f09a02257de5e4ed87e5bf57b056233fc91c7851fc596a3fba910582bd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "273e426a-abc2-409a-9056-fac88e8a27c0", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  Q \nOkay.  Great .  Thanks so much.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Kevin Caliendo with UBS.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nGreat.  Thanks for taking my call.  Question around the guidance. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Kevin Caliendo with UBS.  \n ", "page_label": "11", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "270b9f095aa112ac61ed7f71cf92c113fb5b4a15195ac2c2f2552428b79bc28b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3cd02148-2513-468e-83b0-d8eaf4b39f3c", "node_type": "1", "metadata": {"window": "Thanks so much.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Kevin Caliendo with UBS.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nGreat.  Thanks for taking my call.  Question around the guidance.  You beat by $0.30; you only guided up by $0.15. \n I know you mentioned the EU business is now expected to be at the lower end of the range; you also mentioned \ncorporate expenses are going to be lower. ", "original_text": "Thanks for taking my call. "}, "hash": "9d7f89e7b9a766e1ba02150ab8617faf75555d2df6f5bc4b8542954afcf240dd", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nGreat. ", "start_char_idx": 1780, "end_char_idx": 2093, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3cd02148-2513-468e-83b0-d8eaf4b39f3c": {"__data__": {"id_": "3cd02148-2513-468e-83b0-d8eaf4b39f3c", "embedding": null, "metadata": {"window": "Thanks so much.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Kevin Caliendo with UBS.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nGreat.  Thanks for taking my call.  Question around the guidance.  You beat by $0.30; you only guided up by $0.15. \n I know you mentioned the EU business is now expected to be at the lower end of the range; you also mentioned \ncorporate expenses are going to be lower. ", "original_text": "Thanks for taking my call. ", "page_label": "11", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "35c2d8f8-957b-4d5b-8738-b472dc90faf7", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "595418f09a02257de5e4ed87e5bf57b056233fc91c7851fc596a3fba910582bd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bc42432a-0d17-49c3-b02d-45d569317371", "node_type": "1", "metadata": {"window": "Great .  Thanks so much.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Kevin Caliendo with UBS.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nGreat.  Thanks for taking my call.  Question around the guidance.  You beat by $0.30; you only guided up by $0.15. \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nGreat. ", "page_label": "11", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a8ffd4dcf261c2e4f7c4b2d9bacedf515faaca55edf05d91a9128825d2f11635", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c4c3892d-debe-47cc-8d32-4308c6c97e2b", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Kevin Caliendo with UBS.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nGreat.  Thanks for taking my call.  Question around the guidance.  You beat by $0.30; you only guided up by $0.15. \n I know you mentioned the EU business is now expected to be at the lower end of the range; you also mentioned \ncorporate expenses are going to be lower.  Is there any other delta there? ", "original_text": "Question around the guidance. "}, "hash": "8a25ac48bedfe62259080bacaa9e21e659f08651cc07e6f5571de8a0ec6d596d", "class_name": "RelatedNodeInfo"}}, "text": "Thanks for taking my call. ", "start_char_idx": 2093, "end_char_idx": 2120, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c4c3892d-debe-47cc-8d32-4308c6c97e2b": {"__data__": {"id_": "c4c3892d-debe-47cc-8d32-4308c6c97e2b", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Kevin Caliendo with UBS.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nGreat.  Thanks for taking my call.  Question around the guidance.  You beat by $0.30; you only guided up by $0.15. \n I know you mentioned the EU business is now expected to be at the lower end of the range; you also mentioned \ncorporate expenses are going to be lower.  Is there any other delta there? ", "original_text": "Question around the guidance. ", "page_label": "11", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "35c2d8f8-957b-4d5b-8738-b472dc90faf7", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "595418f09a02257de5e4ed87e5bf57b056233fc91c7851fc596a3fba910582bd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3cd02148-2513-468e-83b0-d8eaf4b39f3c", "node_type": "1", "metadata": {"window": "Thanks so much.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Kevin Caliendo with UBS.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nGreat.  Thanks for taking my call.  Question around the guidance.  You beat by $0.30; you only guided up by $0.15. \n I know you mentioned the EU business is now expected to be at the lower end of the range; you also mentioned \ncorporate expenses are going to be lower. ", "original_text": "Thanks for taking my call. ", "page_label": "11", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8879d48b3db2f3bf1b01778384eb1d5b6a76b62e2cd1be063e6e9b4a74f8175d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "479e150c-c137-471d-b412-233342bb212d", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nGreat.  Thanks for taking my call.  Question around the guidance.  You beat by $0.30; you only guided up by $0.15. \n I know you mentioned the EU business is now expected to be at the lower end of the range; you also mentioned \ncorporate expenses are going to be lower.  Is there any other delta there?  Is this conservatism? ", "original_text": "You beat by $0.30; you only guided up by $0.15. \n"}, "hash": "4df9a2749df0f89d1004ee329c9d36d2548b08a33b067c9400c8d4eebea2c4f5", "class_name": "RelatedNodeInfo"}}, "text": "Question around the guidance. ", "start_char_idx": 2120, "end_char_idx": 2150, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "479e150c-c137-471d-b412-233342bb212d": {"__data__": {"id_": "479e150c-c137-471d-b412-233342bb212d", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nGreat.  Thanks for taking my call.  Question around the guidance.  You beat by $0.30; you only guided up by $0.15. \n I know you mentioned the EU business is now expected to be at the lower end of the range; you also mentioned \ncorporate expenses are going to be lower.  Is there any other delta there?  Is this conservatism? ", "original_text": "You beat by $0.30; you only guided up by $0.15. \n", "page_label": "11", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "35c2d8f8-957b-4d5b-8738-b472dc90faf7", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "595418f09a02257de5e4ed87e5bf57b056233fc91c7851fc596a3fba910582bd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c4c3892d-debe-47cc-8d32-4308c6c97e2b", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Kevin Caliendo with UBS.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nGreat.  Thanks for taking my call.  Question around the guidance.  You beat by $0.30; you only guided up by $0.15. \n I know you mentioned the EU business is now expected to be at the lower end of the range; you also mentioned \ncorporate expenses are going to be lower.  Is there any other delta there? ", "original_text": "Question around the guidance. ", "page_label": "11", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1f716f14ca318c199673de2b9634ba4901e32273c7e0fc74ba7413b05734acc7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "468ed811-09eb-4b00-a6ba-241a993e98a0", "node_type": "1", "metadata": {"window": "Thanks for taking my call.  Question around the guidance.  You beat by $0.30; you only guided up by $0.15. \n I know you mentioned the EU business is now expected to be at the lower end of the range; you also mentioned \ncorporate expenses are going to be lower.  Is there any other delta there?  Is this conservatism?  How should we \nthink about the guidance relative to the beat in the quart er? \n ", "original_text": "I know you mentioned the EU business is now expected to be at the lower end of the range; you also mentioned \ncorporate expenses are going to be lower. "}, "hash": "f2be116e5bee3588e77725001c2a5a4b965327b8f35d94fd653d0d3dd56ec992", "class_name": "RelatedNodeInfo"}}, "text": "You beat by $0.30; you only guided up by $0.15. \n", "start_char_idx": 2150, "end_char_idx": 2199, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "468ed811-09eb-4b00-a6ba-241a993e98a0": {"__data__": {"id_": "468ed811-09eb-4b00-a6ba-241a993e98a0", "embedding": null, "metadata": {"window": "Thanks for taking my call.  Question around the guidance.  You beat by $0.30; you only guided up by $0.15. \n I know you mentioned the EU business is now expected to be at the lower end of the range; you also mentioned \ncorporate expenses are going to be lower.  Is there any other delta there?  Is this conservatism?  How should we \nthink about the guidance relative to the beat in the quart er? \n ", "original_text": "I know you mentioned the EU business is now expected to be at the lower end of the range; you also mentioned \ncorporate expenses are going to be lower. ", "page_label": "11", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "35c2d8f8-957b-4d5b-8738-b472dc90faf7", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "595418f09a02257de5e4ed87e5bf57b056233fc91c7851fc596a3fba910582bd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "479e150c-c137-471d-b412-233342bb212d", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nGreat.  Thanks for taking my call.  Question around the guidance.  You beat by $0.30; you only guided up by $0.15. \n I know you mentioned the EU business is now expected to be at the lower end of the range; you also mentioned \ncorporate expenses are going to be lower.  Is there any other delta there?  Is this conservatism? ", "original_text": "You beat by $0.30; you only guided up by $0.15. \n", "page_label": "11", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2971c83287114fe75a30d8a3773c76008352290e74706c95b0227abf83e74e83", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "35b297ee-c556-4245-ab12-662fde91a3ef", "node_type": "1", "metadata": {"window": "Question around the guidance.  You beat by $0.30; you only guided up by $0.15. \n I know you mentioned the EU business is now expected to be at the lower end of the range; you also mentioned \ncorporate expenses are going to be lower.  Is there any other delta there?  Is this conservatism?  How should we \nthink about the guidance relative to the beat in the quart er? \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "Is there any other delta there? "}, "hash": "9a2c31b310b7d5875d9ead94011a1a3ccc0d810ea96c741f0846068e93721d37", "class_name": "RelatedNodeInfo"}}, "text": "I know you mentioned the EU business is now expected to be at the lower end of the range; you also mentioned \ncorporate expenses are going to be lower. ", "start_char_idx": 2199, "end_char_idx": 2351, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "35b297ee-c556-4245-ab12-662fde91a3ef": {"__data__": {"id_": "35b297ee-c556-4245-ab12-662fde91a3ef", "embedding": null, "metadata": {"window": "Question around the guidance.  You beat by $0.30; you only guided up by $0.15. \n I know you mentioned the EU business is now expected to be at the lower end of the range; you also mentioned \ncorporate expenses are going to be lower.  Is there any other delta there?  Is this conservatism?  How should we \nthink about the guidance relative to the beat in the quart er? \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "Is there any other delta there? ", "page_label": "11", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "35c2d8f8-957b-4d5b-8738-b472dc90faf7", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "595418f09a02257de5e4ed87e5bf57b056233fc91c7851fc596a3fba910582bd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "468ed811-09eb-4b00-a6ba-241a993e98a0", "node_type": "1", "metadata": {"window": "Thanks for taking my call.  Question around the guidance.  You beat by $0.30; you only guided up by $0.15. \n I know you mentioned the EU business is now expected to be at the lower end of the range; you also mentioned \ncorporate expenses are going to be lower.  Is there any other delta there?  Is this conservatism?  How should we \nthink about the guidance relative to the beat in the quart er? \n ", "original_text": "I know you mentioned the EU business is now expected to be at the lower end of the range; you also mentioned \ncorporate expenses are going to be lower. ", "page_label": "11", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "912592d681323d2749c25aefba822cd1ae9c8edc49550af39186f6f50cd7ec60", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bb066e5b-9ba8-41cb-8e49-58ce2f5489c4", "node_type": "1", "metadata": {"window": "You beat by $0.30; you only guided up by $0.15. \n I know you mentioned the EU business is now expected to be at the lower end of the range; you also mentioned \ncorporate expenses are going to be lower.  Is there any other delta there?  Is this conservatism?  How should we \nthink about the guidance relative to the beat in the quart er? \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nSure. ", "original_text": "Is this conservatism? "}, "hash": "b646392836152457e4ab698c29761ae3b092165b775af940efa22d3f705120df", "class_name": "RelatedNodeInfo"}}, "text": "Is there any other delta there? ", "start_char_idx": 2351, "end_char_idx": 2383, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bb066e5b-9ba8-41cb-8e49-58ce2f5489c4": {"__data__": {"id_": "bb066e5b-9ba8-41cb-8e49-58ce2f5489c4", "embedding": null, "metadata": {"window": "You beat by $0.30; you only guided up by $0.15. \n I know you mentioned the EU business is now expected to be at the lower end of the range; you also mentioned \ncorporate expenses are going to be lower.  Is there any other delta there?  Is this conservatism?  How should we \nthink about the guidance relative to the beat in the quart er? \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nSure. ", "original_text": "Is this conservatism? ", "page_label": "11", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "35c2d8f8-957b-4d5b-8738-b472dc90faf7", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "595418f09a02257de5e4ed87e5bf57b056233fc91c7851fc596a3fba910582bd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "35b297ee-c556-4245-ab12-662fde91a3ef", "node_type": "1", "metadata": {"window": "Question around the guidance.  You beat by $0.30; you only guided up by $0.15. \n I know you mentioned the EU business is now expected to be at the lower end of the range; you also mentioned \ncorporate expenses are going to be lower.  Is there any other delta there?  Is this conservatism?  How should we \nthink about the guidance relative to the beat in the quart er? \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "Is there any other delta there? ", "page_label": "11", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6b21841f01b6d64a87f839ba1ca517ddf7effdc94498d3faf11b3782f255dd29", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "47dc4911-494c-42ee-a2b8-f354785539ae", "node_type": "1", "metadata": {"window": "I know you mentioned the EU business is now expected to be at the lower end of the range; you also mentioned \ncorporate expenses are going to be lower.  Is there any other delta there?  Is this conservatism?  How should we \nthink about the guidance relative to the beat in the quart er? \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nSure.  I think there's a couple of things here, Kevin. ", "original_text": "How should we \nthink about the guidance relative to the beat in the quart er? \n "}, "hash": "35e439f4d309039a16919a9b333d4c564341ca6e10af26c5246d460ffd5ca84c", "class_name": "RelatedNodeInfo"}}, "text": "Is this conservatism? ", "start_char_idx": 2383, "end_char_idx": 2405, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "47dc4911-494c-42ee-a2b8-f354785539ae": {"__data__": {"id_": "47dc4911-494c-42ee-a2b8-f354785539ae", "embedding": null, "metadata": {"window": "I know you mentioned the EU business is now expected to be at the lower end of the range; you also mentioned \ncorporate expenses are going to be lower.  Is there any other delta there?  Is this conservatism?  How should we \nthink about the guidance relative to the beat in the quart er? \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nSure.  I think there's a couple of things here, Kevin. ", "original_text": "How should we \nthink about the guidance relative to the beat in the quart er? \n ", "page_label": "11", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "35c2d8f8-957b-4d5b-8738-b472dc90faf7", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "595418f09a02257de5e4ed87e5bf57b056233fc91c7851fc596a3fba910582bd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bb066e5b-9ba8-41cb-8e49-58ce2f5489c4", "node_type": "1", "metadata": {"window": "You beat by $0.30; you only guided up by $0.15. \n I know you mentioned the EU business is now expected to be at the lower end of the range; you also mentioned \ncorporate expenses are going to be lower.  Is there any other delta there?  Is this conservatism?  How should we \nthink about the guidance relative to the beat in the quart er? \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nSure. ", "original_text": "Is this conservatism? ", "page_label": "11", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fc481faec93f4592c7d76929469762f1418b191af6771c77a1a590edb381c6a8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bd279ce8-3116-4a81-acaa-e20ea3ff98f6", "node_type": "1", "metadata": {"window": "Is there any other delta there?  Is this conservatism?  How should we \nthink about the guidance relative to the beat in the quart er? \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nSure.  I think there's a couple of things here, Kevin.  First of all, we had good performance. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  "}, "hash": "954f03b29c427f10e15b4d35feae6ab510cb9c9d860d661383fa0efcec72bfc2", "class_name": "RelatedNodeInfo"}}, "text": "How should we \nthink about the guidance relative to the beat in the quart er? \n ", "start_char_idx": 2405, "end_char_idx": 2485, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bd279ce8-3116-4a81-acaa-e20ea3ff98f6": {"__data__": {"id_": "bd279ce8-3116-4a81-acaa-e20ea3ff98f6", "embedding": null, "metadata": {"window": "Is there any other delta there?  Is this conservatism?  How should we \nthink about the guidance relative to the beat in the quart er? \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nSure.  I think there's a couple of things here, Kevin.  First of all, we had good performance. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "page_label": "11", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "35c2d8f8-957b-4d5b-8738-b472dc90faf7", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "595418f09a02257de5e4ed87e5bf57b056233fc91c7851fc596a3fba910582bd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "47dc4911-494c-42ee-a2b8-f354785539ae", "node_type": "1", "metadata": {"window": "I know you mentioned the EU business is now expected to be at the lower end of the range; you also mentioned \ncorporate expenses are going to be lower.  Is there any other delta there?  Is this conservatism?  How should we \nthink about the guidance relative to the beat in the quart er? \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nSure.  I think there's a couple of things here, Kevin. ", "original_text": "How should we \nthink about the guidance relative to the beat in the quart er? \n ", "page_label": "11", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "181ec42296c6111b72ae6b1cb04e893bb31d9efdc4a8f8ff22e28c18725c41a7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1c48794a-870b-496e-ab03-70a15136e414", "node_type": "1", "metadata": {"window": "Is this conservatism?  How should we \nthink about the guidance relative to the beat in the quart er? \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nSure.  I think there's a couple of things here, Kevin.  First of all, we had good performance.  We also called out a \none-time gain from investment activities that is  within our corporate expenses; that was about $0.10. ", "original_text": "A \nSure. "}, "hash": "3ae9ba637f66515bb0c073fcf93f70289e4b3d7a0c465e0c1da7fccd293759d2", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "start_char_idx": 2485, "end_char_idx": 2830, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1c48794a-870b-496e-ab03-70a15136e414": {"__data__": {"id_": "1c48794a-870b-496e-ab03-70a15136e414", "embedding": null, "metadata": {"window": "Is this conservatism?  How should we \nthink about the guidance relative to the beat in the quart er? \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nSure.  I think there's a couple of things here, Kevin.  First of all, we had good performance.  We also called out a \none-time gain from investment activities that is  within our corporate expenses; that was about $0.10. ", "original_text": "A \nSure. ", "page_label": "11", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "35c2d8f8-957b-4d5b-8738-b472dc90faf7", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "595418f09a02257de5e4ed87e5bf57b056233fc91c7851fc596a3fba910582bd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bd279ce8-3116-4a81-acaa-e20ea3ff98f6", "node_type": "1", "metadata": {"window": "Is there any other delta there?  Is this conservatism?  How should we \nthink about the guidance relative to the beat in the quart er? \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nSure.  I think there's a couple of things here, Kevin.  First of all, we had good performance. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "page_label": "11", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4c1d3666dc413a7091d8500c16436bbd4af6b1cef6c9cdd109f659555b8ac6c2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "db81ef93-afd8-4b45-81f1-65d2f9a5344b", "node_type": "1", "metadata": {"window": "How should we \nthink about the guidance relative to the beat in the quart er? \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nSure.  I think there's a couple of things here, Kevin.  First of all, we had good performance.  We also called out a \none-time gain from investment activities that is  within our corporate expenses; that was about $0.10.  So while we \nhad strong performance across really a broad base of our businesses, we did see weaker performance in our \nEuropean business and we did lower the range for the full year as a result of that. ", "original_text": "I think there's a couple of things here, Kevin. "}, "hash": "783ab5123ea5696783e40f592df6455189329cbdfd4f552f04d04b9195686a50", "class_name": "RelatedNodeInfo"}}, "text": "A \nSure. ", "start_char_idx": 2830, "end_char_idx": 2839, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "db81ef93-afd8-4b45-81f1-65d2f9a5344b": {"__data__": {"id_": "db81ef93-afd8-4b45-81f1-65d2f9a5344b", "embedding": null, "metadata": {"window": "How should we \nthink about the guidance relative to the beat in the quart er? \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nSure.  I think there's a couple of things here, Kevin.  First of all, we had good performance.  We also called out a \none-time gain from investment activities that is  within our corporate expenses; that was about $0.10.  So while we \nhad strong performance across really a broad base of our businesses, we did see weaker performance in our \nEuropean business and we did lower the range for the full year as a result of that. ", "original_text": "I think there's a couple of things here, Kevin. ", "page_label": "11", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "35c2d8f8-957b-4d5b-8738-b472dc90faf7", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "595418f09a02257de5e4ed87e5bf57b056233fc91c7851fc596a3fba910582bd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1c48794a-870b-496e-ab03-70a15136e414", "node_type": "1", "metadata": {"window": "Is this conservatism?  How should we \nthink about the guidance relative to the beat in the quart er? \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nSure.  I think there's a couple of things here, Kevin.  First of all, we had good performance.  We also called out a \none-time gain from investment activities that is  within our corporate expenses; that was about $0.10. ", "original_text": "A \nSure. ", "page_label": "11", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9de2810a39d7a6ca4f9344a2e5155d4255ec60a4a0c5cb670989c1f13236e325", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8d1e0cf1-5d63-4f07-b998-e7392bbf3d85", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nSure.  I think there's a couple of things here, Kevin.  First of all, we had good performance.  We also called out a \none-time gain from investment activities that is  within our corporate expenses; that was about $0.10.  So while we \nhad strong performance across really a broad base of our businesses, we did see weaker performance in our \nEuropean business and we did lower the range for the full year as a result of that.  We had the one -time \nunplanned benefit.  \n \n", "original_text": "First of all, we had good performance. "}, "hash": "c214dfad5bc2fedfaba7f079f3f34551c360822b2346a0bd3be81576217c5810", "class_name": "RelatedNodeInfo"}}, "text": "I think there's a couple of things here, Kevin. ", "start_char_idx": 2839, "end_char_idx": 2887, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8d1e0cf1-5d63-4f07-b998-e7392bbf3d85": {"__data__": {"id_": "8d1e0cf1-5d63-4f07-b998-e7392bbf3d85", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nSure.  I think there's a couple of things here, Kevin.  First of all, we had good performance.  We also called out a \none-time gain from investment activities that is  within our corporate expenses; that was about $0.10.  So while we \nhad strong performance across really a broad base of our businesses, we did see weaker performance in our \nEuropean business and we did lower the range for the full year as a result of that.  We had the one -time \nunplanned benefit.  \n \n", "original_text": "First of all, we had good performance. ", "page_label": "11", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "35c2d8f8-957b-4d5b-8738-b472dc90faf7", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "595418f09a02257de5e4ed87e5bf57b056233fc91c7851fc596a3fba910582bd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "db81ef93-afd8-4b45-81f1-65d2f9a5344b", "node_type": "1", "metadata": {"window": "How should we \nthink about the guidance relative to the beat in the quart er? \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nSure.  I think there's a couple of things here, Kevin.  First of all, we had good performance.  We also called out a \none-time gain from investment activities that is  within our corporate expenses; that was about $0.10.  So while we \nhad strong performance across really a broad base of our businesses, we did see weaker performance in our \nEuropean business and we did lower the range for the full year as a result of that. ", "original_text": "I think there's a couple of things here, Kevin. ", "page_label": "11", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "25a721815129f67e3e5eca1ab2ac0da266910fd74f79616c226b31c14f82ec4f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "aa33a422-3aee-4720-ac28-2083369241b1", "node_type": "1", "metadata": {"window": "A \nSure.  I think there's a couple of things here, Kevin.  First of all, we had good performance.  We also called out a \none-time gain from investment activities that is  within our corporate expenses; that was about $0.10.  So while we \nhad strong performance across really a broad base of our businesses, we did see weaker performance in our \nEuropean business and we did lower the range for the full year as a result of that.  We had the one -time \nunplanned benefit.  \n \n We had some favorable timing in our corporate expense line. ", "original_text": "We also called out a \none-time gain from investment activities that is  within our corporate expenses; that was about $0.10. "}, "hash": "3db570ee719b512cc6033cd332389a80e255cf2c37d188e68af130ff3e9162e7", "class_name": "RelatedNodeInfo"}}, "text": "First of all, we had good performance. ", "start_char_idx": 2887, "end_char_idx": 2926, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "aa33a422-3aee-4720-ac28-2083369241b1": {"__data__": {"id_": "aa33a422-3aee-4720-ac28-2083369241b1", "embedding": null, "metadata": {"window": "A \nSure.  I think there's a couple of things here, Kevin.  First of all, we had good performance.  We also called out a \none-time gain from investment activities that is  within our corporate expenses; that was about $0.10.  So while we \nhad strong performance across really a broad base of our businesses, we did see weaker performance in our \nEuropean business and we did lower the range for the full year as a result of that.  We had the one -time \nunplanned benefit.  \n \n We had some favorable timing in our corporate expense line. ", "original_text": "We also called out a \none-time gain from investment activities that is  within our corporate expenses; that was about $0.10. ", "page_label": "11", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "35c2d8f8-957b-4d5b-8738-b472dc90faf7", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "595418f09a02257de5e4ed87e5bf57b056233fc91c7851fc596a3fba910582bd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8d1e0cf1-5d63-4f07-b998-e7392bbf3d85", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nSure.  I think there's a couple of things here, Kevin.  First of all, we had good performance.  We also called out a \none-time gain from investment activities that is  within our corporate expenses; that was about $0.10.  So while we \nhad strong performance across really a broad base of our businesses, we did see weaker performance in our \nEuropean business and we did lower the range for the full year as a result of that.  We had the one -time \nunplanned benefit.  \n \n", "original_text": "First of all, we had good performance. ", "page_label": "11", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9192f8c4ed1828b33f32173953d99875d51475e345ff1f12da7428d320e7d8fc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a3317d4a-3c1f-4860-b894-71d87b904b46", "node_type": "1", "metadata": {"window": "I think there's a couple of things here, Kevin.  First of all, we had good performance.  We also called out a \none-time gain from investment activities that is  within our corporate expenses; that was about $0.10.  So while we \nhad strong performance across really a broad base of our businesses, we did see weaker performance in our \nEuropean business and we did lower the range for the full year as a result of that.  We had the one -time \nunplanned benefit.  \n \n We had some favorable timing in our corporate expense line.  Again, as we called out at the beginning of the year, \nwe intend to continue make investments in our business both on a data and the analytics side and in a technology \nside. ", "original_text": "So while we \nhad strong performance across really a broad base of our businesses, we did see weaker performance in our \nEuropean business and we did lower the range for the full year as a result of that. "}, "hash": "aaa5084931aa4a0b3ac1faa2794da0302af25e430390cc986faaa020f454dac8", "class_name": "RelatedNodeInfo"}}, "text": "We also called out a \none-time gain from investment activities that is  within our corporate expenses; that was about $0.10. ", "start_char_idx": 2926, "end_char_idx": 3051, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a3317d4a-3c1f-4860-b894-71d87b904b46": {"__data__": {"id_": "a3317d4a-3c1f-4860-b894-71d87b904b46", "embedding": null, "metadata": {"window": "I think there's a couple of things here, Kevin.  First of all, we had good performance.  We also called out a \none-time gain from investment activities that is  within our corporate expenses; that was about $0.10.  So while we \nhad strong performance across really a broad base of our businesses, we did see weaker performance in our \nEuropean business and we did lower the range for the full year as a result of that.  We had the one -time \nunplanned benefit.  \n \n We had some favorable timing in our corporate expense line.  Again, as we called out at the beginning of the year, \nwe intend to continue make investments in our business both on a data and the analytics side and in a technology \nside. ", "original_text": "So while we \nhad strong performance across really a broad base of our businesses, we did see weaker performance in our \nEuropean business and we did lower the range for the full year as a result of that. ", "page_label": "11", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "35c2d8f8-957b-4d5b-8738-b472dc90faf7", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "595418f09a02257de5e4ed87e5bf57b056233fc91c7851fc596a3fba910582bd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "aa33a422-3aee-4720-ac28-2083369241b1", "node_type": "1", "metadata": {"window": "A \nSure.  I think there's a couple of things here, Kevin.  First of all, we had good performance.  We also called out a \none-time gain from investment activities that is  within our corporate expenses; that was about $0.10.  So while we \nhad strong performance across really a broad base of our businesses, we did see weaker performance in our \nEuropean business and we did lower the range for the full year as a result of that.  We had the one -time \nunplanned benefit.  \n \n We had some favorable timing in our corporate expense line. ", "original_text": "We also called out a \none-time gain from investment activities that is  within our corporate expenses; that was about $0.10. ", "page_label": "11", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "de30b26e8e71066214c3eb07234106c39e8a6724e98854ee7e99e91ac67159f7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "85e5e580-b589-4860-8e32-c8cef7b3b93d", "node_type": "1", "metadata": {"window": "First of all, we had good performance.  We also called out a \none-time gain from investment activities that is  within our corporate expenses; that was about $0.10.  So while we \nhad strong performance across really a broad base of our businesses, we did see weaker performance in our \nEuropean business and we did lower the range for the full year as a result of that.  We had the one -time \nunplanned benefit.  \n \n We had some favorable timing in our corporate expense line.  Again, as we called out at the beginning of the year, \nwe intend to continue make investments in our business both on a data and the analytics side and in a technology \nside.  So, we had strong broad -based performance across the business. ", "original_text": "We had the one -time \nunplanned benefit.  \n \n"}, "hash": "0334f8bf91ff947700ab5ab80784c3d7352197c7eb1c0235a373a347cebe00bf", "class_name": "RelatedNodeInfo"}}, "text": "So while we \nhad strong performance across really a broad base of our businesses, we did see weaker performance in our \nEuropean business and we did lower the range for the full year as a result of that. ", "start_char_idx": 3051, "end_char_idx": 3255, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "85e5e580-b589-4860-8e32-c8cef7b3b93d": {"__data__": {"id_": "85e5e580-b589-4860-8e32-c8cef7b3b93d", "embedding": null, "metadata": {"window": "First of all, we had good performance.  We also called out a \none-time gain from investment activities that is  within our corporate expenses; that was about $0.10.  So while we \nhad strong performance across really a broad base of our businesses, we did see weaker performance in our \nEuropean business and we did lower the range for the full year as a result of that.  We had the one -time \nunplanned benefit.  \n \n We had some favorable timing in our corporate expense line.  Again, as we called out at the beginning of the year, \nwe intend to continue make investments in our business both on a data and the analytics side and in a technology \nside.  So, we had strong broad -based performance across the business. ", "original_text": "We had the one -time \nunplanned benefit.  \n \n", "page_label": "11", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "35c2d8f8-957b-4d5b-8738-b472dc90faf7", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "595418f09a02257de5e4ed87e5bf57b056233fc91c7851fc596a3fba910582bd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a3317d4a-3c1f-4860-b894-71d87b904b46", "node_type": "1", "metadata": {"window": "I think there's a couple of things here, Kevin.  First of all, we had good performance.  We also called out a \none-time gain from investment activities that is  within our corporate expenses; that was about $0.10.  So while we \nhad strong performance across really a broad base of our businesses, we did see weaker performance in our \nEuropean business and we did lower the range for the full year as a result of that.  We had the one -time \nunplanned benefit.  \n \n We had some favorable timing in our corporate expense line.  Again, as we called out at the beginning of the year, \nwe intend to continue make investments in our business both on a data and the analytics side and in a technology \nside. ", "original_text": "So while we \nhad strong performance across really a broad base of our businesses, we did see weaker performance in our \nEuropean business and we did lower the range for the full year as a result of that. ", "page_label": "11", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5cbe58ed773a219b9a48c9f267c1b415220a0bab1906a632dcddaeecaf331b75", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2747792e-035b-4106-a123-3c9e712b541a", "node_type": "1", "metadata": {"window": "We also called out a \none-time gain from investment activities that is  within our corporate expenses; that was about $0.10.  So while we \nhad strong performance across really a broad base of our businesses, we did see weaker performance in our \nEuropean business and we did lower the range for the full year as a result of that.  We had the one -time \nunplanned benefit.  \n \n We had some favorable timing in our corporate expense line.  Again, as we called out at the beginning of the year, \nwe intend to continue make investments in our business both on a data and the analytics side and in a technology \nside.  So, we had strong broad -based performance across the business.  We had a one -time gain within our \ncorporate expense line. ", "original_text": "We had some favorable timing in our corporate expense line. "}, "hash": "c7632aadb438079b99faf260e389bcebd778b5dfc56c2406311ff1b68cec4a90", "class_name": "RelatedNodeInfo"}}, "text": "We had the one -time \nunplanned benefit.  \n \n", "start_char_idx": 3255, "end_char_idx": 3300, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2747792e-035b-4106-a123-3c9e712b541a": {"__data__": {"id_": "2747792e-035b-4106-a123-3c9e712b541a", "embedding": null, "metadata": {"window": "We also called out a \none-time gain from investment activities that is  within our corporate expenses; that was about $0.10.  So while we \nhad strong performance across really a broad base of our businesses, we did see weaker performance in our \nEuropean business and we did lower the range for the full year as a result of that.  We had the one -time \nunplanned benefit.  \n \n We had some favorable timing in our corporate expense line.  Again, as we called out at the beginning of the year, \nwe intend to continue make investments in our business both on a data and the analytics side and in a technology \nside.  So, we had strong broad -based performance across the business.  We had a one -time gain within our \ncorporate expense line. ", "original_text": "We had some favorable timing in our corporate expense line. ", "page_label": "11", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "35c2d8f8-957b-4d5b-8738-b472dc90faf7", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "595418f09a02257de5e4ed87e5bf57b056233fc91c7851fc596a3fba910582bd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "85e5e580-b589-4860-8e32-c8cef7b3b93d", "node_type": "1", "metadata": {"window": "First of all, we had good performance.  We also called out a \none-time gain from investment activities that is  within our corporate expenses; that was about $0.10.  So while we \nhad strong performance across really a broad base of our businesses, we did see weaker performance in our \nEuropean business and we did lower the range for the full year as a result of that.  We had the one -time \nunplanned benefit.  \n \n We had some favorable timing in our corporate expense line.  Again, as we called out at the beginning of the year, \nwe intend to continue make investments in our business both on a data and the analytics side and in a technology \nside.  So, we had strong broad -based performance across the business. ", "original_text": "We had the one -time \nunplanned benefit.  \n \n", "page_label": "11", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "600653551738ca2cce434660033e0e986bb74cc8862e5802e94d4d1beda6f32f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e883e528-df0a-48e4-b4b0-ce26b7723ac0", "node_type": "1", "metadata": {"window": "So while we \nhad strong performance across really a broad base of our businesses, we did see weaker performance in our \nEuropean business and we did lower the range for the full year as a result of that.  We had the one -time \nunplanned benefit.  \n \n We had some favorable timing in our corporate expense line.  Again, as we called out at the beginning of the year, \nwe intend to continue make investments in our business both on a data and the analytics side and in a technology \nside.  So, we had strong broad -based performance across the business.  We had a one -time gain within our \ncorporate expense line.  And I think it's early in the year, but we feel very confident and confident enough to raise \nby $0.15.  \n ", "original_text": "Again, as we called out at the beginning of the year, \nwe intend to continue make investments in our business both on a data and the analytics side and in a technology \nside. "}, "hash": "ad85ab1b080ab26da34199ff97f5cc46a05ade1b4346963c357f12300e3dc7fe", "class_name": "RelatedNodeInfo"}}, "text": "We had some favorable timing in our corporate expense line. ", "start_char_idx": 3300, "end_char_idx": 3360, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e883e528-df0a-48e4-b4b0-ce26b7723ac0": {"__data__": {"id_": "e883e528-df0a-48e4-b4b0-ce26b7723ac0", "embedding": null, "metadata": {"window": "So while we \nhad strong performance across really a broad base of our businesses, we did see weaker performance in our \nEuropean business and we did lower the range for the full year as a result of that.  We had the one -time \nunplanned benefit.  \n \n We had some favorable timing in our corporate expense line.  Again, as we called out at the beginning of the year, \nwe intend to continue make investments in our business both on a data and the analytics side and in a technology \nside.  So, we had strong broad -based performance across the business.  We had a one -time gain within our \ncorporate expense line.  And I think it's early in the year, but we feel very confident and confident enough to raise \nby $0.15.  \n ", "original_text": "Again, as we called out at the beginning of the year, \nwe intend to continue make investments in our business both on a data and the analytics side and in a technology \nside. ", "page_label": "11", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "35c2d8f8-957b-4d5b-8738-b472dc90faf7", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "595418f09a02257de5e4ed87e5bf57b056233fc91c7851fc596a3fba910582bd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2747792e-035b-4106-a123-3c9e712b541a", "node_type": "1", "metadata": {"window": "We also called out a \none-time gain from investment activities that is  within our corporate expenses; that was about $0.10.  So while we \nhad strong performance across really a broad base of our businesses, we did see weaker performance in our \nEuropean business and we did lower the range for the full year as a result of that.  We had the one -time \nunplanned benefit.  \n \n We had some favorable timing in our corporate expense line.  Again, as we called out at the beginning of the year, \nwe intend to continue make investments in our business both on a data and the analytics side and in a technology \nside.  So, we had strong broad -based performance across the business.  We had a one -time gain within our \ncorporate expense line. ", "original_text": "We had some favorable timing in our corporate expense line. ", "page_label": "11", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9ca72ad269cb8fcbabbe41ff0fe55e49849a27887cb81a7dd154448bda2380ed", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2faeb3c7-aefd-47fb-9a82-1ef435be68e1", "node_type": "1", "metadata": {"window": "We had the one -time \nunplanned benefit.  \n \n We had some favorable timing in our corporate expense line.  Again, as we called out at the beginning of the year, \nwe intend to continue make investments in our business both on a data and the analytics side and in a technology \nside.  So, we had strong broad -based performance across the business.  We had a one -time gain within our \ncorporate expense line.  And I think it's early in the year, but we feel very confident and confident enough to raise \nby $0.15.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliend o \nAnalyst, UBS Securities LLC  Q \nOkay. ", "original_text": "So, we had strong broad -based performance across the business. "}, "hash": "6fff9bea9a979670f50fa6a1554461513f3a14a76bcf2c799fd4c3fd89e13960", "class_name": "RelatedNodeInfo"}}, "text": "Again, as we called out at the beginning of the year, \nwe intend to continue make investments in our business both on a data and the analytics side and in a technology \nside. ", "start_char_idx": 3360, "end_char_idx": 3535, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2faeb3c7-aefd-47fb-9a82-1ef435be68e1": {"__data__": {"id_": "2faeb3c7-aefd-47fb-9a82-1ef435be68e1", "embedding": null, "metadata": {"window": "We had the one -time \nunplanned benefit.  \n \n We had some favorable timing in our corporate expense line.  Again, as we called out at the beginning of the year, \nwe intend to continue make investments in our business both on a data and the analytics side and in a technology \nside.  So, we had strong broad -based performance across the business.  We had a one -time gain within our \ncorporate expense line.  And I think it's early in the year, but we feel very confident and confident enough to raise \nby $0.15.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliend o \nAnalyst, UBS Securities LLC  Q \nOkay. ", "original_text": "So, we had strong broad -based performance across the business. ", "page_label": "11", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "35c2d8f8-957b-4d5b-8738-b472dc90faf7", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "595418f09a02257de5e4ed87e5bf57b056233fc91c7851fc596a3fba910582bd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e883e528-df0a-48e4-b4b0-ce26b7723ac0", "node_type": "1", "metadata": {"window": "So while we \nhad strong performance across really a broad base of our businesses, we did see weaker performance in our \nEuropean business and we did lower the range for the full year as a result of that.  We had the one -time \nunplanned benefit.  \n \n We had some favorable timing in our corporate expense line.  Again, as we called out at the beginning of the year, \nwe intend to continue make investments in our business both on a data and the analytics side and in a technology \nside.  So, we had strong broad -based performance across the business.  We had a one -time gain within our \ncorporate expense line.  And I think it's early in the year, but we feel very confident and confident enough to raise \nby $0.15.  \n ", "original_text": "Again, as we called out at the beginning of the year, \nwe intend to continue make investments in our business both on a data and the analytics side and in a technology \nside. ", "page_label": "11", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "59e850c1b3d962e8b6e852db61dcd8486f8b4f2a725d2b5cf067442735bdca74", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "377a1de2-81b7-49cf-81e9-0485f9482662", "node_type": "1", "metadata": {"window": "We had some favorable timing in our corporate expense line.  Again, as we called out at the beginning of the year, \nwe intend to continue make investments in our business both on a data and the analytics side and in a technology \nside.  So, we had strong broad -based performance across the business.  We had a one -time gain within our \ncorporate expense line.  And I think it's early in the year, but we feel very confident and confident enough to raise \nby $0.15.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliend o \nAnalyst, UBS Securities LLC  Q \nOkay.  And just a quick follow -up on the Medical segment. ", "original_text": "We had a one -time gain within our \ncorporate expense line. "}, "hash": "cfddbff08bdc43359fe02ddb66d2356201eef3abd93605a697761fb54efe75ca", "class_name": "RelatedNodeInfo"}}, "text": "So, we had strong broad -based performance across the business. ", "start_char_idx": 3535, "end_char_idx": 3599, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "377a1de2-81b7-49cf-81e9-0485f9482662": {"__data__": {"id_": "377a1de2-81b7-49cf-81e9-0485f9482662", "embedding": null, "metadata": {"window": "We had some favorable timing in our corporate expense line.  Again, as we called out at the beginning of the year, \nwe intend to continue make investments in our business both on a data and the analytics side and in a technology \nside.  So, we had strong broad -based performance across the business.  We had a one -time gain within our \ncorporate expense line.  And I think it's early in the year, but we feel very confident and confident enough to raise \nby $0.15.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliend o \nAnalyst, UBS Securities LLC  Q \nOkay.  And just a quick follow -up on the Medical segment. ", "original_text": "We had a one -time gain within our \ncorporate expense line. ", "page_label": "11", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "35c2d8f8-957b-4d5b-8738-b472dc90faf7", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "595418f09a02257de5e4ed87e5bf57b056233fc91c7851fc596a3fba910582bd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2faeb3c7-aefd-47fb-9a82-1ef435be68e1", "node_type": "1", "metadata": {"window": "We had the one -time \nunplanned benefit.  \n \n We had some favorable timing in our corporate expense line.  Again, as we called out at the beginning of the year, \nwe intend to continue make investments in our business both on a data and the analytics side and in a technology \nside.  So, we had strong broad -based performance across the business.  We had a one -time gain within our \ncorporate expense line.  And I think it's early in the year, but we feel very confident and confident enough to raise \nby $0.15.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliend o \nAnalyst, UBS Securities LLC  Q \nOkay. ", "original_text": "So, we had strong broad -based performance across the business. ", "page_label": "11", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "336e6b6731c0ba1ad1ac19155dacf2fbef35787f186ae24d9eacc02ad69db7b8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "df13586f-3827-4c7e-8d0c-3115fb8cb73b", "node_type": "1", "metadata": {"window": "Again, as we called out at the beginning of the year, \nwe intend to continue make investments in our business both on a data and the analytics side and in a technology \nside.  So, we had strong broad -based performance across the business.  We had a one -time gain within our \ncorporate expense line.  And I think it's early in the year, but we feel very confident and confident enough to raise \nby $0.15.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliend o \nAnalyst, UBS Securities LLC  Q \nOkay.  And just a quick follow -up on the Medical segment.  You give us revenues ex MSD they'd have been a 4%. \n", "original_text": "And I think it's early in the year, but we feel very confident and confident enough to raise \nby $0.15.  \n "}, "hash": "7b9b608691884f8e8c703d5ee48329069a44d8a2596a69b3776b1cd8f7ff561e", "class_name": "RelatedNodeInfo"}}, "text": "We had a one -time gain within our \ncorporate expense line. ", "start_char_idx": 3599, "end_char_idx": 3659, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "df13586f-3827-4c7e-8d0c-3115fb8cb73b": {"__data__": {"id_": "df13586f-3827-4c7e-8d0c-3115fb8cb73b", "embedding": null, "metadata": {"window": "Again, as we called out at the beginning of the year, \nwe intend to continue make investments in our business both on a data and the analytics side and in a technology \nside.  So, we had strong broad -based performance across the business.  We had a one -time gain within our \ncorporate expense line.  And I think it's early in the year, but we feel very confident and confident enough to raise \nby $0.15.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliend o \nAnalyst, UBS Securities LLC  Q \nOkay.  And just a quick follow -up on the Medical segment.  You give us revenues ex MSD they'd have been a 4%. \n", "original_text": "And I think it's early in the year, but we feel very confident and confident enough to raise \nby $0.15.  \n ", "page_label": "11", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "35c2d8f8-957b-4d5b-8738-b472dc90faf7", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "595418f09a02257de5e4ed87e5bf57b056233fc91c7851fc596a3fba910582bd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "377a1de2-81b7-49cf-81e9-0485f9482662", "node_type": "1", "metadata": {"window": "We had some favorable timing in our corporate expense line.  Again, as we called out at the beginning of the year, \nwe intend to continue make investments in our business both on a data and the analytics side and in a technology \nside.  So, we had strong broad -based performance across the business.  We had a one -time gain within our \ncorporate expense line.  And I think it's early in the year, but we feel very confident and confident enough to raise \nby $0.15.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliend o \nAnalyst, UBS Securities LLC  Q \nOkay.  And just a quick follow -up on the Medical segment. ", "original_text": "We had a one -time gain within our \ncorporate expense line. ", "page_label": "11", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7ef59962acecb806a772f6af0abaf0138007e225a77f0bf65e8821334e39665e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a3e3f8b4-f1f0-4495-a0ff-691d2ab152b6", "node_type": "1", "metadata": {"window": "So, we had strong broad -based performance across the business.  We had a one -time gain within our \ncorporate expense line.  And I think it's early in the year, but we feel very confident and confident enough to raise \nby $0.15.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliend o \nAnalyst, UBS Securities LLC  Q \nOkay.  And just a quick follow -up on the Medical segment.  You give us revenues ex MSD they'd have been a 4%. \n What would the EBIT growth have been ex MSD in Medical, as we're now lapping it? ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliend o \nAnalyst, UBS Securities LLC  Q \nOkay. "}, "hash": "e040034a5e5618f31a89a4a1d3ff601c38455db82f83d4f2ef5a4a386112033d", "class_name": "RelatedNodeInfo"}}, "text": "And I think it's early in the year, but we feel very confident and confident enough to raise \nby $0.15.  \n ", "start_char_idx": 3659, "end_char_idx": 3766, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a3e3f8b4-f1f0-4495-a0ff-691d2ab152b6": {"__data__": {"id_": "a3e3f8b4-f1f0-4495-a0ff-691d2ab152b6", "embedding": null, "metadata": {"window": "So, we had strong broad -based performance across the business.  We had a one -time gain within our \ncorporate expense line.  And I think it's early in the year, but we feel very confident and confident enough to raise \nby $0.15.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliend o \nAnalyst, UBS Securities LLC  Q \nOkay.  And just a quick follow -up on the Medical segment.  You give us revenues ex MSD they'd have been a 4%. \n What would the EBIT growth have been ex MSD in Medical, as we're now lapping it? ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliend o \nAnalyst, UBS Securities LLC  Q \nOkay. ", "page_label": "11", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "35c2d8f8-957b-4d5b-8738-b472dc90faf7", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "595418f09a02257de5e4ed87e5bf57b056233fc91c7851fc596a3fba910582bd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "df13586f-3827-4c7e-8d0c-3115fb8cb73b", "node_type": "1", "metadata": {"window": "Again, as we called out at the beginning of the year, \nwe intend to continue make investments in our business both on a data and the analytics side and in a technology \nside.  So, we had strong broad -based performance across the business.  We had a one -time gain within our \ncorporate expense line.  And I think it's early in the year, but we feel very confident and confident enough to raise \nby $0.15.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliend o \nAnalyst, UBS Securities LLC  Q \nOkay.  And just a quick follow -up on the Medical segment.  You give us revenues ex MSD they'd have been a 4%. \n", "original_text": "And I think it's early in the year, but we feel very confident and confident enough to raise \nby $0.15.  \n ", "page_label": "11", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fdf139b7af9527c7bcc9b747ef8ef64b3633fceb9f9bc67115e5537e84536a9c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a794ca7d-f311-4641-a210-200a4428c589", "node_type": "1", "metadata": {"window": "We had a one -time gain within our \ncorporate expense line.  And I think it's early in the year, but we feel very confident and confident enough to raise \nby $0.15.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliend o \nAnalyst, UBS Securities LLC  Q \nOkay.  And just a quick follow -up on the Medical segment.  You give us revenues ex MSD they'd have been a 4%. \n What would the EBIT growth have been ex MSD in Medical, as we're now lapping it?  Just to give us a little bit of a \nbetter view of sort of what that business might look like going forward.  \n ", "original_text": "And just a quick follow -up on the Medical segment. "}, "hash": "c34daa3f851a66fd09eee5168128d18b94676a9dd747187ff3c7e7cea7921815", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliend o \nAnalyst, UBS Securities LLC  Q \nOkay. ", "start_char_idx": 3766, "end_char_idx": 4078, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a794ca7d-f311-4641-a210-200a4428c589": {"__data__": {"id_": "a794ca7d-f311-4641-a210-200a4428c589", "embedding": null, "metadata": {"window": "We had a one -time gain within our \ncorporate expense line.  And I think it's early in the year, but we feel very confident and confident enough to raise \nby $0.15.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliend o \nAnalyst, UBS Securities LLC  Q \nOkay.  And just a quick follow -up on the Medical segment.  You give us revenues ex MSD they'd have been a 4%. \n What would the EBIT growth have been ex MSD in Medical, as we're now lapping it?  Just to give us a little bit of a \nbetter view of sort of what that business might look like going forward.  \n ", "original_text": "And just a quick follow -up on the Medical segment. ", "page_label": "11", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "35c2d8f8-957b-4d5b-8738-b472dc90faf7", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "595418f09a02257de5e4ed87e5bf57b056233fc91c7851fc596a3fba910582bd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a3e3f8b4-f1f0-4495-a0ff-691d2ab152b6", "node_type": "1", "metadata": {"window": "So, we had strong broad -based performance across the business.  We had a one -time gain within our \ncorporate expense line.  And I think it's early in the year, but we feel very confident and confident enough to raise \nby $0.15.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliend o \nAnalyst, UBS Securities LLC  Q \nOkay.  And just a quick follow -up on the Medical segment.  You give us revenues ex MSD they'd have been a 4%. \n What would the EBIT growth have been ex MSD in Medical, as we're now lapping it? ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliend o \nAnalyst, UBS Securities LLC  Q \nOkay. ", "page_label": "11", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "05249fbafb87f72e2eb2312ea63ec43c766943fb8ad7337fa3042d06a7332905", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "518955ef-f08e-451d-a041-82995e04529c", "node_type": "1", "metadata": {"window": "And I think it's early in the year, but we feel very confident and confident enough to raise \nby $0.15.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliend o \nAnalyst, UBS Securities LLC  Q \nOkay.  And just a quick follow -up on the Medical segment.  You give us revenues ex MSD they'd have been a 4%. \n What would the EBIT growth have been ex MSD in Medical, as we're now lapping it?  Just to give us a little bit of a \nbetter view of sort of what that business might look like going forward.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "You give us revenues ex MSD they'd have been a 4%. \n"}, "hash": "edef5ee02bd7fc7e3ee75e8b0330ae478049fef923a4c3f0207dc8e84353edb4", "class_name": "RelatedNodeInfo"}}, "text": "And just a quick follow -up on the Medical segment. ", "start_char_idx": 4078, "end_char_idx": 4130, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "518955ef-f08e-451d-a041-82995e04529c": {"__data__": {"id_": "518955ef-f08e-451d-a041-82995e04529c", "embedding": null, "metadata": {"window": "And I think it's early in the year, but we feel very confident and confident enough to raise \nby $0.15.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliend o \nAnalyst, UBS Securities LLC  Q \nOkay.  And just a quick follow -up on the Medical segment.  You give us revenues ex MSD they'd have been a 4%. \n What would the EBIT growth have been ex MSD in Medical, as we're now lapping it?  Just to give us a little bit of a \nbetter view of sort of what that business might look like going forward.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "You give us revenues ex MSD they'd have been a 4%. \n", "page_label": "11", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "35c2d8f8-957b-4d5b-8738-b472dc90faf7", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "595418f09a02257de5e4ed87e5bf57b056233fc91c7851fc596a3fba910582bd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a794ca7d-f311-4641-a210-200a4428c589", "node_type": "1", "metadata": {"window": "We had a one -time gain within our \ncorporate expense line.  And I think it's early in the year, but we feel very confident and confident enough to raise \nby $0.15.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliend o \nAnalyst, UBS Securities LLC  Q \nOkay.  And just a quick follow -up on the Medical segment.  You give us revenues ex MSD they'd have been a 4%. \n What would the EBIT growth have been ex MSD in Medical, as we're now lapping it?  Just to give us a little bit of a \nbetter view of sort of what that business might look like going forward.  \n ", "original_text": "And just a quick follow -up on the Medical segment. ", "page_label": "11", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fa57bae47ef469b19a9a7c3204706e11c10731f942ee4171332a97a108c7d0c2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ab19b7a4-4252-48b3-b281-ae3d6058b8ae", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliend o \nAnalyst, UBS Securities LLC  Q \nOkay.  And just a quick follow -up on the Medical segment.  You give us revenues ex MSD they'd have been a 4%. \n What would the EBIT growth have been ex MSD in Medical, as we're now lapping it?  Just to give us a little bit of a \nbetter view of sort of what that business might look like going forward.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "What would the EBIT growth have been ex MSD in Medical, as we're now lapping it? "}, "hash": "abe89fa7cf42f2363786f502728d630dc8c404bc8f509a3be47b8e240f3a064f", "class_name": "RelatedNodeInfo"}}, "text": "You give us revenues ex MSD they'd have been a 4%. \n", "start_char_idx": 4130, "end_char_idx": 4182, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ab19b7a4-4252-48b3-b281-ae3d6058b8ae": {"__data__": {"id_": "ab19b7a4-4252-48b3-b281-ae3d6058b8ae", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliend o \nAnalyst, UBS Securities LLC  Q \nOkay.  And just a quick follow -up on the Medical segment.  You give us revenues ex MSD they'd have been a 4%. \n What would the EBIT growth have been ex MSD in Medical, as we're now lapping it?  Just to give us a little bit of a \nbetter view of sort of what that business might look like going forward.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "What would the EBIT growth have been ex MSD in Medical, as we're now lapping it? ", "page_label": "11", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "35c2d8f8-957b-4d5b-8738-b472dc90faf7", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "595418f09a02257de5e4ed87e5bf57b056233fc91c7851fc596a3fba910582bd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "518955ef-f08e-451d-a041-82995e04529c", "node_type": "1", "metadata": {"window": "And I think it's early in the year, but we feel very confident and confident enough to raise \nby $0.15.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliend o \nAnalyst, UBS Securities LLC  Q \nOkay.  And just a quick follow -up on the Medical segment.  You give us revenues ex MSD they'd have been a 4%. \n What would the EBIT growth have been ex MSD in Medical, as we're now lapping it?  Just to give us a little bit of a \nbetter view of sort of what that business might look like going forward.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "You give us revenues ex MSD they'd have been a 4%. \n", "page_label": "11", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "adfb5287b6b7894eccb99f57161e14d04899c56e5b3075f96d88af350e9b0ee5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4be43cdc-1608-4d77-a77b-795c78f6f6be", "node_type": "1", "metadata": {"window": "And just a quick follow -up on the Medical segment.  You give us revenues ex MSD they'd have been a 4%. \n What would the EBIT growth have been ex MSD in Medical, as we're now lapping it?  Just to give us a little bit of a \nbetter view of sort of what that business might look like going forward.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "Just to give us a little bit of a \nbetter view of sort of what that business might look like going forward.  \n "}, "hash": "b24a23427e3cbad2d647790273e8a7e38b0cf3f177fb5d69fa07693e1532452c", "class_name": "RelatedNodeInfo"}}, "text": "What would the EBIT growth have been ex MSD in Medical, as we're now lapping it? ", "start_char_idx": 4182, "end_char_idx": 4263, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4be43cdc-1608-4d77-a77b-795c78f6f6be": {"__data__": {"id_": "4be43cdc-1608-4d77-a77b-795c78f6f6be", "embedding": null, "metadata": {"window": "And just a quick follow -up on the Medical segment.  You give us revenues ex MSD they'd have been a 4%. \n What would the EBIT growth have been ex MSD in Medical, as we're now lapping it?  Just to give us a little bit of a \nbetter view of sort of what that business might look like going forward.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "Just to give us a little bit of a \nbetter view of sort of what that business might look like going forward.  \n ", "page_label": "11", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "35c2d8f8-957b-4d5b-8738-b472dc90faf7", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "595418f09a02257de5e4ed87e5bf57b056233fc91c7851fc596a3fba910582bd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ab19b7a4-4252-48b3-b281-ae3d6058b8ae", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliend o \nAnalyst, UBS Securities LLC  Q \nOkay.  And just a quick follow -up on the Medical segment.  You give us revenues ex MSD they'd have been a 4%. \n What would the EBIT growth have been ex MSD in Medical, as we're now lapping it?  Just to give us a little bit of a \nbetter view of sort of what that business might look like going forward.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "What would the EBIT growth have been ex MSD in Medical, as we're now lapping it? ", "page_label": "11", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "202b90ab968b653d317190cd51b33176255dcc0ebc93b47522bec0f8757d619d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "74317d02-ac3e-458e-9c91-0967d06137bc", "node_type": "1", "metadata": {"window": "You give us revenues ex MSD they'd have been a 4%. \n What would the EBIT growth have been ex MSD in Medical, as we're now lapping it?  Just to give us a little bit of a \nbetter view of sort of what that business might look like going forward.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   "}, "hash": "6221f57c4afd579976281bb0b7febae876ccc4dd140ad0c17ab69bc64bee7b79", "class_name": "RelatedNodeInfo"}}, "text": "Just to give us a little bit of a \nbetter view of sort of what that business might look like going forward.  \n ", "start_char_idx": 4263, "end_char_idx": 4374, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "74317d02-ac3e-458e-9c91-0967d06137bc": {"__data__": {"id_": "74317d02-ac3e-458e-9c91-0967d06137bc", "embedding": null, "metadata": {"window": "You give us revenues ex MSD they'd have been a 4%. \n What would the EBIT growth have been ex MSD in Medical, as we're now lapping it?  Just to give us a little bit of a \nbetter view of sort of what that business might look like going forward.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "page_label": "11", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "35c2d8f8-957b-4d5b-8738-b472dc90faf7", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "595418f09a02257de5e4ed87e5bf57b056233fc91c7851fc596a3fba910582bd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4be43cdc-1608-4d77-a77b-795c78f6f6be", "node_type": "1", "metadata": {"window": "And just a quick follow -up on the Medical segment.  You give us revenues ex MSD they'd have been a 4%. \n What would the EBIT growth have been ex MSD in Medical, as we're now lapping it?  Just to give us a little bit of a \nbetter view of sort of what that business might look like going forward.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "Just to give us a little bit of a \nbetter view of sort of what that business might look like going forward.  \n ", "page_label": "11", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "67cc29b530e5e399f0dd0fda5d210ef8da2a3c3eba88dcb3c2fbe6657c9f30bc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4cebd535-62cb-479e-a3ae-4fa9e11de700", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  We don't break that down specifically, Kevin. ", "original_text": "McKesson Corp.  "}, "hash": "d5b3dbde0b6b68d4c3d31cc12976107136af7504b9fe3f994f47ca53537994cb", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "start_char_idx": 601, "end_char_idx": 857, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4cebd535-62cb-479e-a3ae-4fa9e11de700": {"__data__": {"id_": "4cebd535-62cb-479e-a3ae-4fa9e11de700", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  We don't break that down specifically, Kevin. ", "original_text": "McKesson Corp.  ", "page_label": "12", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cc6b623a-67fb-4def-b7c6-1646af81356a", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8c55c9938d8d2c43ba4b14bbda249654dae3315ccdb5e7d18bc1ccf45ad67b55", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "74317d02-ac3e-458e-9c91-0967d06137bc", "node_type": "1", "metadata": {"window": "You give us revenues ex MSD they'd have been a 4%. \n What would the EBIT growth have been ex MSD in Medical, as we're now lapping it?  Just to give us a little bit of a \nbetter view of sort of what that business might look like going forward.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   ", "page_label": "11", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4c8e77f4335f12f9e980d8b75d8305d851f1750f0e4be0f9a64a77fdbc1f4bc5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "151e5f23-2d8a-43d8-baea-b6400d4c32cf", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  We don't break that down specifically, Kevin.  But what I would tell you is, we had stro ng organic \nperformance within that business. ", "original_text": "(MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  "}, "hash": "7c1dc08b7200a0f04fa5e82648b11ec7c9e308eaa89788f184db00fa9f228999", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "151e5f23-2d8a-43d8-baea-b6400d4c32cf": {"__data__": {"id_": "151e5f23-2d8a-43d8-baea-b6400d4c32cf", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  We don't break that down specifically, Kevin.  But what I would tell you is, we had stro ng organic \nperformance within that business. ", "original_text": "(MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "page_label": "12", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cc6b623a-67fb-4def-b7c6-1646af81356a", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8c55c9938d8d2c43ba4b14bbda249654dae3315ccdb5e7d18bc1ccf45ad67b55", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4cebd535-62cb-479e-a3ae-4fa9e11de700", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  We don't break that down specifically, Kevin. ", "original_text": "McKesson Corp.  ", "page_label": "12", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3992f5efb36e9f9bac704ab7870c83616a6974a420758e41710b08b564c2e129", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bd318f62-409b-45a9-a4eb-17426a0eb570", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  We don't break that down specifically, Kevin.  But what I would tell you is, we had stro ng organic \nperformance within that business.  And as I mentioned, we had strong pharmaceutical sales performance as well \nas continued strong performance in our home delivery business. ", "original_text": "A \nYeah. "}, "hash": "b5ffdfd531cf76fdd3bab6ea4c0e878d855a2eafeaa7aa2bf5aeb4e736e748fc", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "start_char_idx": 16, "end_char_idx": 269, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bd318f62-409b-45a9-a4eb-17426a0eb570": {"__data__": {"id_": "bd318f62-409b-45a9-a4eb-17426a0eb570", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  We don't break that down specifically, Kevin.  But what I would tell you is, we had stro ng organic \nperformance within that business.  And as I mentioned, we had strong pharmaceutical sales performance as well \nas continued strong performance in our home delivery business. ", "original_text": "A \nYeah. ", "page_label": "12", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cc6b623a-67fb-4def-b7c6-1646af81356a", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8c55c9938d8d2c43ba4b14bbda249654dae3315ccdb5e7d18bc1ccf45ad67b55", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "151e5f23-2d8a-43d8-baea-b6400d4c32cf", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  We don't break that down specifically, Kevin.  But what I would tell you is, we had stro ng organic \nperformance within that business. ", "original_text": "(MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "page_label": "12", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "491c4353fc81ef3811c98756a7d354f9b9c19fae6b293ef5e61ea74823bc80aa", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ccbea32b-0272-4ae8-843b-e85ec72f18c1", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  We don't break that down specifically, Kevin.  But what I would tell you is, we had stro ng organic \nperformance within that business.  And as I mentioned, we had strong pharmaceutical sales performance as well \nas continued strong performance in our home delivery business.  So, we're pleased with the overall performance \nof the segment. ", "original_text": "We don't break that down specifically, Kevin. "}, "hash": "24693d790bc4774364996a7673785b19dfc9a0aeab8581653ebdfd1b4460d681", "class_name": "RelatedNodeInfo"}}, "text": "A \nYeah. ", "start_char_idx": 269, "end_char_idx": 278, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ccbea32b-0272-4ae8-843b-e85ec72f18c1": {"__data__": {"id_": "ccbea32b-0272-4ae8-843b-e85ec72f18c1", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  We don't break that down specifically, Kevin.  But what I would tell you is, we had stro ng organic \nperformance within that business.  And as I mentioned, we had strong pharmaceutical sales performance as well \nas continued strong performance in our home delivery business.  So, we're pleased with the overall performance \nof the segment. ", "original_text": "We don't break that down specifically, Kevin. ", "page_label": "12", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cc6b623a-67fb-4def-b7c6-1646af81356a", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8c55c9938d8d2c43ba4b14bbda249654dae3315ccdb5e7d18bc1ccf45ad67b55", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bd318f62-409b-45a9-a4eb-17426a0eb570", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  We don't break that down specifically, Kevin.  But what I would tell you is, we had stro ng organic \nperformance within that business.  And as I mentioned, we had strong pharmaceutical sales performance as well \nas continued strong performance in our home delivery business. ", "original_text": "A \nYeah. ", "page_label": "12", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "027982c6a929e6ac74f8c8dad3a34bb7463c9528f40be4a4bf9cdcba49d3b18a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8f87e018-301f-4610-9252-c9eaad5928af", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  We don't break that down specifically, Kevin.  But what I would tell you is, we had stro ng organic \nperformance within that business.  And as I mentioned, we had strong pharmaceutical sales performance as well \nas continued strong performance in our home delivery business.  So, we're pleased with the overall performance \nof the segment.  We're plea sed with the execution against the MSD acquisition.  \n \n", "original_text": "But what I would tell you is, we had stro ng organic \nperformance within that business. "}, "hash": "af78a72e5ed3db73f549cd38c3573765d371c8b0ffff4cf26d8ac1ebefa3fd22", "class_name": "RelatedNodeInfo"}}, "text": "We don't break that down specifically, Kevin. ", "start_char_idx": 278, "end_char_idx": 324, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8f87e018-301f-4610-9252-c9eaad5928af": {"__data__": {"id_": "8f87e018-301f-4610-9252-c9eaad5928af", "embedding": null, "metadata": {"window": "(MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  We don't break that down specifically, Kevin.  But what I would tell you is, we had stro ng organic \nperformance within that business.  And as I mentioned, we had strong pharmaceutical sales performance as well \nas continued strong performance in our home delivery business.  So, we're pleased with the overall performance \nof the segment.  We're plea sed with the execution against the MSD acquisition.  \n \n", "original_text": "But what I would tell you is, we had stro ng organic \nperformance within that business. ", "page_label": "12", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cc6b623a-67fb-4def-b7c6-1646af81356a", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8c55c9938d8d2c43ba4b14bbda249654dae3315ccdb5e7d18bc1ccf45ad67b55", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ccbea32b-0272-4ae8-843b-e85ec72f18c1", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  We don't break that down specifically, Kevin.  But what I would tell you is, we had stro ng organic \nperformance within that business.  And as I mentioned, we had strong pharmaceutical sales performance as well \nas continued strong performance in our home delivery business.  So, we're pleased with the overall performance \nof the segment. ", "original_text": "We don't break that down specifically, Kevin. ", "page_label": "12", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "50af8ed03a7da0fa2340a031a6f8fc3360c0991d97ebd03fe1afe4c8f8c97d24", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fb47711d-2f21-4e9c-bf67-1e60ee40dc49", "node_type": "1", "metadata": {"window": "A \nYeah.  We don't break that down specifically, Kevin.  But what I would tell you is, we had stro ng organic \nperformance within that business.  And as I mentioned, we had strong pharmaceutical sales performance as well \nas continued strong performance in our home delivery business.  So, we're pleased with the overall performance \nof the segment.  We're plea sed with the execution against the MSD acquisition.  \n \n And as I mentioned, across the broad base of that business, we had growth in pharmaceuticals, we had growth in \nour primary care business as well as our home delivery business. ", "original_text": "And as I mentioned, we had strong pharmaceutical sales performance as well \nas continued strong performance in our home delivery business. "}, "hash": "ade657574e81492263cfe5cdb225970270e8bc3ec27ab65617541058543ad604", "class_name": "RelatedNodeInfo"}}, "text": "But what I would tell you is, we had stro ng organic \nperformance within that business. ", "start_char_idx": 324, "end_char_idx": 412, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fb47711d-2f21-4e9c-bf67-1e60ee40dc49": {"__data__": {"id_": "fb47711d-2f21-4e9c-bf67-1e60ee40dc49", "embedding": null, "metadata": {"window": "A \nYeah.  We don't break that down specifically, Kevin.  But what I would tell you is, we had stro ng organic \nperformance within that business.  And as I mentioned, we had strong pharmaceutical sales performance as well \nas continued strong performance in our home delivery business.  So, we're pleased with the overall performance \nof the segment.  We're plea sed with the execution against the MSD acquisition.  \n \n And as I mentioned, across the broad base of that business, we had growth in pharmaceuticals, we had growth in \nour primary care business as well as our home delivery business. ", "original_text": "And as I mentioned, we had strong pharmaceutical sales performance as well \nas continued strong performance in our home delivery business. ", "page_label": "12", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cc6b623a-67fb-4def-b7c6-1646af81356a", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8c55c9938d8d2c43ba4b14bbda249654dae3315ccdb5e7d18bc1ccf45ad67b55", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8f87e018-301f-4610-9252-c9eaad5928af", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  We don't break that down specifically, Kevin.  But what I would tell you is, we had stro ng organic \nperformance within that business.  And as I mentioned, we had strong pharmaceutical sales performance as well \nas continued strong performance in our home delivery business.  So, we're pleased with the overall performance \nof the segment.  We're plea sed with the execution against the MSD acquisition.  \n \n", "original_text": "But what I would tell you is, we had stro ng organic \nperformance within that business. ", "page_label": "12", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8217db19708fa7545b8ecef764e0bce9364d49e8ab4c4172aafea04aa899fda4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "627fa0ff-72f5-44f8-9d45-443f85b4f6a2", "node_type": "1", "metadata": {"window": "We don't break that down specifically, Kevin.  But what I would tell you is, we had stro ng organic \nperformance within that business.  And as I mentioned, we had strong pharmaceutical sales performance as well \nas continued strong performance in our home delivery business.  So, we're pleased with the overall performance \nof the segment.  We're plea sed with the execution against the MSD acquisition.  \n \n And as I mentioned, across the broad base of that business, we had growth in pharmaceuticals, we had growth in \nour primary care business as well as our home delivery business.  So, good organic growth as well as the MSD \ncontribution.  \n ", "original_text": "So, we're pleased with the overall performance \nof the segment. "}, "hash": "5e207cfed8e34c90b07f0b4fca1130d7b458b55494d7146c146ef2ac0401ad2c", "class_name": "RelatedNodeInfo"}}, "text": "And as I mentioned, we had strong pharmaceutical sales performance as well \nas continued strong performance in our home delivery business. ", "start_char_idx": 412, "end_char_idx": 551, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "627fa0ff-72f5-44f8-9d45-443f85b4f6a2": {"__data__": {"id_": "627fa0ff-72f5-44f8-9d45-443f85b4f6a2", "embedding": null, "metadata": {"window": "We don't break that down specifically, Kevin.  But what I would tell you is, we had stro ng organic \nperformance within that business.  And as I mentioned, we had strong pharmaceutical sales performance as well \nas continued strong performance in our home delivery business.  So, we're pleased with the overall performance \nof the segment.  We're plea sed with the execution against the MSD acquisition.  \n \n And as I mentioned, across the broad base of that business, we had growth in pharmaceuticals, we had growth in \nour primary care business as well as our home delivery business.  So, good organic growth as well as the MSD \ncontribution.  \n ", "original_text": "So, we're pleased with the overall performance \nof the segment. ", "page_label": "12", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cc6b623a-67fb-4def-b7c6-1646af81356a", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8c55c9938d8d2c43ba4b14bbda249654dae3315ccdb5e7d18bc1ccf45ad67b55", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fb47711d-2f21-4e9c-bf67-1e60ee40dc49", "node_type": "1", "metadata": {"window": "A \nYeah.  We don't break that down specifically, Kevin.  But what I would tell you is, we had stro ng organic \nperformance within that business.  And as I mentioned, we had strong pharmaceutical sales performance as well \nas continued strong performance in our home delivery business.  So, we're pleased with the overall performance \nof the segment.  We're plea sed with the execution against the MSD acquisition.  \n \n And as I mentioned, across the broad base of that business, we had growth in pharmaceuticals, we had growth in \nour primary care business as well as our home delivery business. ", "original_text": "And as I mentioned, we had strong pharmaceutical sales performance as well \nas continued strong performance in our home delivery business. ", "page_label": "12", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3d08ec33a5473eea38fcaf86d402ee59f60e7a28db58284da02829e9748bf9c2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c1fad619-f966-4ad1-874e-2b5f6815acde", "node_type": "1", "metadata": {"window": "But what I would tell you is, we had stro ng organic \nperformance within that business.  And as I mentioned, we had strong pharmaceutical sales performance as well \nas continued strong performance in our home delivery business.  So, we're pleased with the overall performance \nof the segment.  We're plea sed with the execution against the MSD acquisition.  \n \n And as I mentioned, across the broad base of that business, we had growth in pharmaceuticals, we had growth in \nour primary care business as well as our home delivery business.  So, good organic growth as well as the MSD \ncontribution.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nGreat. ", "original_text": "We're plea sed with the execution against the MSD acquisition.  \n \n"}, "hash": "7ffe6f178c665f7165528543aad2715eb236f9896bb3b4cef527df713f9ae28b", "class_name": "RelatedNodeInfo"}}, "text": "So, we're pleased with the overall performance \nof the segment. ", "start_char_idx": 551, "end_char_idx": 615, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c1fad619-f966-4ad1-874e-2b5f6815acde": {"__data__": {"id_": "c1fad619-f966-4ad1-874e-2b5f6815acde", "embedding": null, "metadata": {"window": "But what I would tell you is, we had stro ng organic \nperformance within that business.  And as I mentioned, we had strong pharmaceutical sales performance as well \nas continued strong performance in our home delivery business.  So, we're pleased with the overall performance \nof the segment.  We're plea sed with the execution against the MSD acquisition.  \n \n And as I mentioned, across the broad base of that business, we had growth in pharmaceuticals, we had growth in \nour primary care business as well as our home delivery business.  So, good organic growth as well as the MSD \ncontribution.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nGreat. ", "original_text": "We're plea sed with the execution against the MSD acquisition.  \n \n", "page_label": "12", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cc6b623a-67fb-4def-b7c6-1646af81356a", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8c55c9938d8d2c43ba4b14bbda249654dae3315ccdb5e7d18bc1ccf45ad67b55", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "627fa0ff-72f5-44f8-9d45-443f85b4f6a2", "node_type": "1", "metadata": {"window": "We don't break that down specifically, Kevin.  But what I would tell you is, we had stro ng organic \nperformance within that business.  And as I mentioned, we had strong pharmaceutical sales performance as well \nas continued strong performance in our home delivery business.  So, we're pleased with the overall performance \nof the segment.  We're plea sed with the execution against the MSD acquisition.  \n \n And as I mentioned, across the broad base of that business, we had growth in pharmaceuticals, we had growth in \nour primary care business as well as our home delivery business.  So, good organic growth as well as the MSD \ncontribution.  \n ", "original_text": "So, we're pleased with the overall performance \nof the segment. ", "page_label": "12", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "12925a9c8ddfe661b8cfef47f8aeb4d64fd139f358351082a7ca2e58e8c01b2d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a0d0c792-6d79-4915-86fe-2d0895f2af17", "node_type": "1", "metadata": {"window": "And as I mentioned, we had strong pharmaceutical sales performance as well \nas continued strong performance in our home delivery business.  So, we're pleased with the overall performance \nof the segment.  We're plea sed with the execution against the MSD acquisition.  \n \n And as I mentioned, across the broad base of that business, we had growth in pharmaceuticals, we had growth in \nour primary care business as well as our home delivery business.  So, good organic growth as well as the MSD \ncontribution.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nGreat.  Thanks so much.  \n ", "original_text": "And as I mentioned, across the broad base of that business, we had growth in pharmaceuticals, we had growth in \nour primary care business as well as our home delivery business. "}, "hash": "4ffa2dec5a8bf34ea976b93515335e5b46c858d04c0f4ca77de25b3a0dee5e58", "class_name": "RelatedNodeInfo"}}, "text": "We're plea sed with the execution against the MSD acquisition.  \n \n", "start_char_idx": 615, "end_char_idx": 682, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a0d0c792-6d79-4915-86fe-2d0895f2af17": {"__data__": {"id_": "a0d0c792-6d79-4915-86fe-2d0895f2af17", "embedding": null, "metadata": {"window": "And as I mentioned, we had strong pharmaceutical sales performance as well \nas continued strong performance in our home delivery business.  So, we're pleased with the overall performance \nof the segment.  We're plea sed with the execution against the MSD acquisition.  \n \n And as I mentioned, across the broad base of that business, we had growth in pharmaceuticals, we had growth in \nour primary care business as well as our home delivery business.  So, good organic growth as well as the MSD \ncontribution.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nGreat.  Thanks so much.  \n ", "original_text": "And as I mentioned, across the broad base of that business, we had growth in pharmaceuticals, we had growth in \nour primary care business as well as our home delivery business. ", "page_label": "12", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cc6b623a-67fb-4def-b7c6-1646af81356a", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8c55c9938d8d2c43ba4b14bbda249654dae3315ccdb5e7d18bc1ccf45ad67b55", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c1fad619-f966-4ad1-874e-2b5f6815acde", "node_type": "1", "metadata": {"window": "But what I would tell you is, we had stro ng organic \nperformance within that business.  And as I mentioned, we had strong pharmaceutical sales performance as well \nas continued strong performance in our home delivery business.  So, we're pleased with the overall performance \nof the segment.  We're plea sed with the execution against the MSD acquisition.  \n \n And as I mentioned, across the broad base of that business, we had growth in pharmaceuticals, we had growth in \nour primary care business as well as our home delivery business.  So, good organic growth as well as the MSD \ncontribution.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nGreat. ", "original_text": "We're plea sed with the execution against the MSD acquisition.  \n \n", "page_label": "12", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e9536635d778f460eb5e45888f21ee0e7d635cb6d32b267a630e85a72b4feeb3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ef9cc6e7-44db-4362-ac50-63a7296184be", "node_type": "1", "metadata": {"window": "So, we're pleased with the overall performance \nof the segment.  We're plea sed with the execution against the MSD acquisition.  \n \n And as I mentioned, across the broad base of that business, we had growth in pharmaceuticals, we had growth in \nour primary care business as well as our home delivery business.  So, good organic growth as well as the MSD \ncontribution.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nGreat.  Thanks so much.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Next will be Ricky Goldwasser with Morgan Stanley.  \n ", "original_text": "So, good organic growth as well as the MSD \ncontribution.  \n "}, "hash": "bf649722e5884b9a98b5e74da5a011b6ea30e5eba100f56a4a22e7202548a6d1", "class_name": "RelatedNodeInfo"}}, "text": "And as I mentioned, across the broad base of that business, we had growth in pharmaceuticals, we had growth in \nour primary care business as well as our home delivery business. ", "start_char_idx": 682, "end_char_idx": 859, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ef9cc6e7-44db-4362-ac50-63a7296184be": {"__data__": {"id_": "ef9cc6e7-44db-4362-ac50-63a7296184be", "embedding": null, "metadata": {"window": "So, we're pleased with the overall performance \nof the segment.  We're plea sed with the execution against the MSD acquisition.  \n \n And as I mentioned, across the broad base of that business, we had growth in pharmaceuticals, we had growth in \nour primary care business as well as our home delivery business.  So, good organic growth as well as the MSD \ncontribution.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nGreat.  Thanks so much.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Next will be Ricky Goldwasser with Morgan Stanley.  \n ", "original_text": "So, good organic growth as well as the MSD \ncontribution.  \n ", "page_label": "12", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cc6b623a-67fb-4def-b7c6-1646af81356a", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8c55c9938d8d2c43ba4b14bbda249654dae3315ccdb5e7d18bc1ccf45ad67b55", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a0d0c792-6d79-4915-86fe-2d0895f2af17", "node_type": "1", "metadata": {"window": "And as I mentioned, we had strong pharmaceutical sales performance as well \nas continued strong performance in our home delivery business.  So, we're pleased with the overall performance \nof the segment.  We're plea sed with the execution against the MSD acquisition.  \n \n And as I mentioned, across the broad base of that business, we had growth in pharmaceuticals, we had growth in \nour primary care business as well as our home delivery business.  So, good organic growth as well as the MSD \ncontribution.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nGreat.  Thanks so much.  \n ", "original_text": "And as I mentioned, across the broad base of that business, we had growth in pharmaceuticals, we had growth in \nour primary care business as well as our home delivery business. ", "page_label": "12", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "aff4231a93f3c0001b4f2f579510d05cd3aea4afd68320f63384c031120c0b9a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c4b1b850-9ee1-452a-9735-67ba524bb266", "node_type": "1", "metadata": {"window": "We're plea sed with the execution against the MSD acquisition.  \n \n And as I mentioned, across the broad base of that business, we had growth in pharmaceuticals, we had growth in \nour primary care business as well as our home delivery business.  So, good organic growth as well as the MSD \ncontribution.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nGreat.  Thanks so much.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Next will be Ricky Goldwasser with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nGreat. "}, "hash": "e69259cc560be5aefddb07eab4e5f751892af57cc9d2d891292996df83ec5e35", "class_name": "RelatedNodeInfo"}}, "text": "So, good organic growth as well as the MSD \ncontribution.  \n ", "start_char_idx": 859, "end_char_idx": 920, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c4b1b850-9ee1-452a-9735-67ba524bb266": {"__data__": {"id_": "c4b1b850-9ee1-452a-9735-67ba524bb266", "embedding": null, "metadata": {"window": "We're plea sed with the execution against the MSD acquisition.  \n \n And as I mentioned, across the broad base of that business, we had growth in pharmaceuticals, we had growth in \nour primary care business as well as our home delivery business.  So, good organic growth as well as the MSD \ncontribution.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nGreat.  Thanks so much.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Next will be Ricky Goldwasser with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nGreat. ", "page_label": "12", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cc6b623a-67fb-4def-b7c6-1646af81356a", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8c55c9938d8d2c43ba4b14bbda249654dae3315ccdb5e7d18bc1ccf45ad67b55", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ef9cc6e7-44db-4362-ac50-63a7296184be", "node_type": "1", "metadata": {"window": "So, we're pleased with the overall performance \nof the segment.  We're plea sed with the execution against the MSD acquisition.  \n \n And as I mentioned, across the broad base of that business, we had growth in pharmaceuticals, we had growth in \nour primary care business as well as our home delivery business.  So, good organic growth as well as the MSD \ncontribution.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nGreat.  Thanks so much.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Next will be Ricky Goldwasser with Morgan Stanley.  \n ", "original_text": "So, good organic growth as well as the MSD \ncontribution.  \n ", "page_label": "12", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "682d8cf45818c6cf05fe8fee5b60fcd70f1a7058f775ed493bef8dae4101b631", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d1e11199-8d41-4d25-bd25-5647c2e784e6", "node_type": "1", "metadata": {"window": "And as I mentioned, across the broad base of that business, we had growth in pharmaceuticals, we had growth in \nour primary care business as well as our home delivery business.  So, good organic growth as well as the MSD \ncontribution.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nGreat.  Thanks so much.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Next will be Ricky Goldwasser with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah. ", "original_text": "Thanks so much.  \n "}, "hash": "4b475cbec8ea3991faf1042873490d25cc9a8d8742248fdfb4659f9db1bca0c3", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nGreat. ", "start_char_idx": 920, "end_char_idx": 1233, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d1e11199-8d41-4d25-bd25-5647c2e784e6": {"__data__": {"id_": "d1e11199-8d41-4d25-bd25-5647c2e784e6", "embedding": null, "metadata": {"window": "And as I mentioned, across the broad base of that business, we had growth in pharmaceuticals, we had growth in \nour primary care business as well as our home delivery business.  So, good organic growth as well as the MSD \ncontribution.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nGreat.  Thanks so much.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Next will be Ricky Goldwasser with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah. ", "original_text": "Thanks so much.  \n ", "page_label": "12", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cc6b623a-67fb-4def-b7c6-1646af81356a", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8c55c9938d8d2c43ba4b14bbda249654dae3315ccdb5e7d18bc1ccf45ad67b55", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c4b1b850-9ee1-452a-9735-67ba524bb266", "node_type": "1", "metadata": {"window": "We're plea sed with the execution against the MSD acquisition.  \n \n And as I mentioned, across the broad base of that business, we had growth in pharmaceuticals, we had growth in \nour primary care business as well as our home delivery business.  So, good organic growth as well as the MSD \ncontribution.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nGreat.  Thanks so much.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Next will be Ricky Goldwasser with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nGreat. ", "page_label": "12", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ed768fb44428a08350b9d5950c27eef37944bb1c31450003009a77b1f1e1cda8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ea71d05f-aa3d-4570-a38a-b96137cf6391", "node_type": "1", "metadata": {"window": "So, good organic growth as well as the MSD \ncontribution.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nGreat.  Thanks so much.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Next will be Ricky Goldwasser with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah.  Hi. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Next will be Ricky Goldwasser with Morgan Stanley.  \n "}, "hash": "cb5f8f0a14809bcc271515ca499b5e7f4a8ff95332f6cb40c532f9f26504bc23", "class_name": "RelatedNodeInfo"}}, "text": "Thanks so much.  \n ", "start_char_idx": 1233, "end_char_idx": 1252, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ea71d05f-aa3d-4570-a38a-b96137cf6391": {"__data__": {"id_": "ea71d05f-aa3d-4570-a38a-b96137cf6391", "embedding": null, "metadata": {"window": "So, good organic growth as well as the MSD \ncontribution.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nGreat.  Thanks so much.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Next will be Ricky Goldwasser with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah.  Hi. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Next will be Ricky Goldwasser with Morgan Stanley.  \n ", "page_label": "12", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cc6b623a-67fb-4def-b7c6-1646af81356a", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8c55c9938d8d2c43ba4b14bbda249654dae3315ccdb5e7d18bc1ccf45ad67b55", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d1e11199-8d41-4d25-bd25-5647c2e784e6", "node_type": "1", "metadata": {"window": "And as I mentioned, across the broad base of that business, we had growth in pharmaceuticals, we had growth in \nour primary care business as well as our home delivery business.  So, good organic growth as well as the MSD \ncontribution.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nGreat.  Thanks so much.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Next will be Ricky Goldwasser with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah. ", "original_text": "Thanks so much.  \n ", "page_label": "12", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "94d66c6578343563d32981e21968ceeaadfb0beae1c9f05b89d5ec0c3742023f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dcb71f60-18cd-457d-b1dd-57a041e511a1", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nGreat.  Thanks so much.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Next will be Ricky Goldwasser with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah.  Hi.  Good evening. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. "}, "hash": "2040f9d4414c55648c0c53884d21a77ee55b29fb35543c2145637a144703f022", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Next will be Ricky Goldwasser with Morgan Stanley.  \n ", "start_char_idx": 1252, "end_char_idx": 1576, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dcb71f60-18cd-457d-b1dd-57a041e511a1": {"__data__": {"id_": "dcb71f60-18cd-457d-b1dd-57a041e511a1", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nGreat.  Thanks so much.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Next will be Ricky Goldwasser with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah.  Hi.  Good evening. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. ", "page_label": "12", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cc6b623a-67fb-4def-b7c6-1646af81356a", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8c55c9938d8d2c43ba4b14bbda249654dae3315ccdb5e7d18bc1ccf45ad67b55", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ea71d05f-aa3d-4570-a38a-b96137cf6391", "node_type": "1", "metadata": {"window": "So, good organic growth as well as the MSD \ncontribution.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nGreat.  Thanks so much.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Next will be Ricky Goldwasser with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah.  Hi. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Next will be Ricky Goldwasser with Morgan Stanley.  \n ", "page_label": "12", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8d9eb3fddc67c0446eb74473bf754fd28cc4bf0e8f3da8afa402b0222ff12005", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ff654a67-8a39-4b50-bca6-7f5e83a3749c", "node_type": "1", "metadata": {"window": "Thanks so much.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Next will be Ricky Goldwasser with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah.  Hi.  Good evening.  So, some  follow -up questions here on the guidance. ", "original_text": "LLC  Q \nYeah. "}, "hash": "f9d05d1975eb12f35d93746163a6f4e3d3a992e00e413ab225fce0b7cf821fdb", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. ", "start_char_idx": 1576, "end_char_idx": 1885, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ff654a67-8a39-4b50-bca6-7f5e83a3749c": {"__data__": {"id_": "ff654a67-8a39-4b50-bca6-7f5e83a3749c", "embedding": null, "metadata": {"window": "Thanks so much.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Next will be Ricky Goldwasser with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah.  Hi.  Good evening.  So, some  follow -up questions here on the guidance. ", "original_text": "LLC  Q \nYeah. ", "page_label": "12", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cc6b623a-67fb-4def-b7c6-1646af81356a", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8c55c9938d8d2c43ba4b14bbda249654dae3315ccdb5e7d18bc1ccf45ad67b55", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dcb71f60-18cd-457d-b1dd-57a041e511a1", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nGreat.  Thanks so much.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Next will be Ricky Goldwasser with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah.  Hi.  Good evening. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. ", "page_label": "12", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4dbaeeca35f68613e3c5083e9270839268abf98578ceb96764908a14a2ebca66", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2ac32cbc-14aa-4775-9770-25275775c33d", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Next will be Ricky Goldwasser with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah.  Hi.  Good evening.  So, some  follow -up questions here on the guidance.  So obviously you had a very good \nperformance on the top line, but when we look at your U.S. ", "original_text": "Hi. "}, "hash": "935ba5829f5c81ad99a16fe0b591ffb1c5c5350de4ddee5aad108fe033110095", "class_name": "RelatedNodeInfo"}}, "text": "LLC  Q \nYeah. ", "start_char_idx": 1885, "end_char_idx": 1899, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2ac32cbc-14aa-4775-9770-25275775c33d": {"__data__": {"id_": "2ac32cbc-14aa-4775-9770-25275775c33d", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Next will be Ricky Goldwasser with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah.  Hi.  Good evening.  So, some  follow -up questions here on the guidance.  So obviously you had a very good \nperformance on the top line, but when we look at your U.S. ", "original_text": "Hi. ", "page_label": "12", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cc6b623a-67fb-4def-b7c6-1646af81356a", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8c55c9938d8d2c43ba4b14bbda249654dae3315ccdb5e7d18bc1ccf45ad67b55", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ff654a67-8a39-4b50-bca6-7f5e83a3749c", "node_type": "1", "metadata": {"window": "Thanks so much.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Next will be Ricky Goldwasser with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah.  Hi.  Good evening.  So, some  follow -up questions here on the guidance. ", "original_text": "LLC  Q \nYeah. ", "page_label": "12", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7bbfd9a029de1ba6296ebad488baef1dfaae834430c8fd6b04316e0e920e8c7c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8a303eaf-55b6-472a-9c0d-43ffb7b20ad6", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah.  Hi.  Good evening.  So, some  follow -up questions here on the guidance.  So obviously you had a very good \nperformance on the top line, but when we look at your U.S.  Pharmaceutical and Specialty Solutions' guidance for \nthe remainder of the year, it would suggest that revenues are going to normalize, while we're getting to around \nplus 4% to negative 1% on the revenue; and on the operating profit as well kind of like negative 2% to about 3.3% \ngrowth.  \n \n", "original_text": "Good evening. "}, "hash": "5295234140af74cb73c750a8f2ac252abb15450234d325ea391c87d45a7784ad", "class_name": "RelatedNodeInfo"}}, "text": "Hi. ", "start_char_idx": 1899, "end_char_idx": 1903, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8a303eaf-55b6-472a-9c0d-43ffb7b20ad6": {"__data__": {"id_": "8a303eaf-55b6-472a-9c0d-43ffb7b20ad6", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah.  Hi.  Good evening.  So, some  follow -up questions here on the guidance.  So obviously you had a very good \nperformance on the top line, but when we look at your U.S.  Pharmaceutical and Specialty Solutions' guidance for \nthe remainder of the year, it would suggest that revenues are going to normalize, while we're getting to around \nplus 4% to negative 1% on the revenue; and on the operating profit as well kind of like negative 2% to about 3.3% \ngrowth.  \n \n", "original_text": "Good evening. ", "page_label": "12", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cc6b623a-67fb-4def-b7c6-1646af81356a", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8c55c9938d8d2c43ba4b14bbda249654dae3315ccdb5e7d18bc1ccf45ad67b55", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2ac32cbc-14aa-4775-9770-25275775c33d", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Next will be Ricky Goldwasser with Morgan Stanley.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah.  Hi.  Good evening.  So, some  follow -up questions here on the guidance.  So obviously you had a very good \nperformance on the top line, but when we look at your U.S. ", "original_text": "Hi. ", "page_label": "12", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "315024eb4584e148cfc14e2f334bb7a3968e8a2712aa98c3f169102410ca422b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f43155f1-8ce1-415a-844c-f81027f79e42", "node_type": "1", "metadata": {"window": "LLC  Q \nYeah.  Hi.  Good evening.  So, some  follow -up questions here on the guidance.  So obviously you had a very good \nperformance on the top line, but when we look at your U.S.  Pharmaceutical and Specialty Solutions' guidance for \nthe remainder of the year, it would suggest that revenues are going to normalize, while we're getting to around \nplus 4% to negative 1% on the revenue; and on the operating profit as well kind of like negative 2% to about 3.3% \ngrowth.  \n \n So, was there any kind of like pull -forward of revenues this quarter that's going to norm alize for the remainder of \nthe year? ", "original_text": "So, some  follow -up questions here on the guidance. "}, "hash": "37220e31889a9076e42c4f0b0813f065fb939bee4b4187fabf6cac4494ebb2d5", "class_name": "RelatedNodeInfo"}}, "text": "Good evening. ", "start_char_idx": 1903, "end_char_idx": 1917, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f43155f1-8ce1-415a-844c-f81027f79e42": {"__data__": {"id_": "f43155f1-8ce1-415a-844c-f81027f79e42", "embedding": null, "metadata": {"window": "LLC  Q \nYeah.  Hi.  Good evening.  So, some  follow -up questions here on the guidance.  So obviously you had a very good \nperformance on the top line, but when we look at your U.S.  Pharmaceutical and Specialty Solutions' guidance for \nthe remainder of the year, it would suggest that revenues are going to normalize, while we're getting to around \nplus 4% to negative 1% on the revenue; and on the operating profit as well kind of like negative 2% to about 3.3% \ngrowth.  \n \n So, was there any kind of like pull -forward of revenues this quarter that's going to norm alize for the remainder of \nthe year? ", "original_text": "So, some  follow -up questions here on the guidance. ", "page_label": "12", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cc6b623a-67fb-4def-b7c6-1646af81356a", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8c55c9938d8d2c43ba4b14bbda249654dae3315ccdb5e7d18bc1ccf45ad67b55", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8a303eaf-55b6-472a-9c0d-43ffb7b20ad6", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah.  Hi.  Good evening.  So, some  follow -up questions here on the guidance.  So obviously you had a very good \nperformance on the top line, but when we look at your U.S.  Pharmaceutical and Specialty Solutions' guidance for \nthe remainder of the year, it would suggest that revenues are going to normalize, while we're getting to around \nplus 4% to negative 1% on the revenue; and on the operating profit as well kind of like negative 2% to about 3.3% \ngrowth.  \n \n", "original_text": "Good evening. ", "page_label": "12", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "08523ebdbb87093a3c0d54ccb6300272c69c3f13d4b8a05db3e6df5cc9c1a2ff", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c89b9b16-03a5-44ad-9d77-2acee6250e61", "node_type": "1", "metadata": {"window": "Hi.  Good evening.  So, some  follow -up questions here on the guidance.  So obviously you had a very good \nperformance on the top line, but when we look at your U.S.  Pharmaceutical and Specialty Solutions' guidance for \nthe remainder of the year, it would suggest that revenues are going to normalize, while we're getting to around \nplus 4% to negative 1% on the revenue; and on the operating profit as well kind of like negative 2% to about 3.3% \ngrowth.  \n \n So, was there any kind of like pull -forward of revenues this quarter that's going to norm alize for the remainder of \nthe year?  Or what kind of like drove that strength? ", "original_text": "So obviously you had a very good \nperformance on the top line, but when we look at your U.S. "}, "hash": "81568b9212af11c8820c4860bdb7bdba9feb115d8c7fcd4dbaebfb3869037ff3", "class_name": "RelatedNodeInfo"}}, "text": "So, some  follow -up questions here on the guidance. ", "start_char_idx": 1917, "end_char_idx": 1970, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c89b9b16-03a5-44ad-9d77-2acee6250e61": {"__data__": {"id_": "c89b9b16-03a5-44ad-9d77-2acee6250e61", "embedding": null, "metadata": {"window": "Hi.  Good evening.  So, some  follow -up questions here on the guidance.  So obviously you had a very good \nperformance on the top line, but when we look at your U.S.  Pharmaceutical and Specialty Solutions' guidance for \nthe remainder of the year, it would suggest that revenues are going to normalize, while we're getting to around \nplus 4% to negative 1% on the revenue; and on the operating profit as well kind of like negative 2% to about 3.3% \ngrowth.  \n \n So, was there any kind of like pull -forward of revenues this quarter that's going to norm alize for the remainder of \nthe year?  Or what kind of like drove that strength? ", "original_text": "So obviously you had a very good \nperformance on the top line, but when we look at your U.S. ", "page_label": "12", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cc6b623a-67fb-4def-b7c6-1646af81356a", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8c55c9938d8d2c43ba4b14bbda249654dae3315ccdb5e7d18bc1ccf45ad67b55", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f43155f1-8ce1-415a-844c-f81027f79e42", "node_type": "1", "metadata": {"window": "LLC  Q \nYeah.  Hi.  Good evening.  So, some  follow -up questions here on the guidance.  So obviously you had a very good \nperformance on the top line, but when we look at your U.S.  Pharmaceutical and Specialty Solutions' guidance for \nthe remainder of the year, it would suggest that revenues are going to normalize, while we're getting to around \nplus 4% to negative 1% on the revenue; and on the operating profit as well kind of like negative 2% to about 3.3% \ngrowth.  \n \n So, was there any kind of like pull -forward of revenues this quarter that's going to norm alize for the remainder of \nthe year? ", "original_text": "So, some  follow -up questions here on the guidance. ", "page_label": "12", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4d74e7f0d98d43db020bb136ebbbeeb24d444f79697fda4f8e9358b41af3822f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1159090b-8052-4c86-a0a7-87ad4e707f0c", "node_type": "1", "metadata": {"window": "Good evening.  So, some  follow -up questions here on the guidance.  So obviously you had a very good \nperformance on the top line, but when we look at your U.S.  Pharmaceutical and Specialty Solutions' guidance for \nthe remainder of the year, it would suggest that revenues are going to normalize, while we're getting to around \nplus 4% to negative 1% on the revenue; and on the operating profit as well kind of like negative 2% to about 3.3% \ngrowth.  \n \n So, was there any kind of like pull -forward of revenues this quarter that's going to norm alize for the remainder of \nthe year?  Or what kind of like drove that strength?  I understand it is your largest customers, but if you can give us \nsome more color behind that?  \n ", "original_text": "Pharmaceutical and Specialty Solutions' guidance for \nthe remainder of the year, it would suggest that revenues are going to normalize, while we're getting to around \nplus 4% to negative 1% on the revenue; and on the operating profit as well kind of like negative 2% to about 3.3% \ngrowth.  \n \n"}, "hash": "aea8c07faa4b74c589b5253946b25446c1732b3b047c559a697d57aa62206041", "class_name": "RelatedNodeInfo"}}, "text": "So obviously you had a very good \nperformance on the top line, but when we look at your U.S. ", "start_char_idx": 1970, "end_char_idx": 2063, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1159090b-8052-4c86-a0a7-87ad4e707f0c": {"__data__": {"id_": "1159090b-8052-4c86-a0a7-87ad4e707f0c", "embedding": null, "metadata": {"window": "Good evening.  So, some  follow -up questions here on the guidance.  So obviously you had a very good \nperformance on the top line, but when we look at your U.S.  Pharmaceutical and Specialty Solutions' guidance for \nthe remainder of the year, it would suggest that revenues are going to normalize, while we're getting to around \nplus 4% to negative 1% on the revenue; and on the operating profit as well kind of like negative 2% to about 3.3% \ngrowth.  \n \n So, was there any kind of like pull -forward of revenues this quarter that's going to norm alize for the remainder of \nthe year?  Or what kind of like drove that strength?  I understand it is your largest customers, but if you can give us \nsome more color behind that?  \n ", "original_text": "Pharmaceutical and Specialty Solutions' guidance for \nthe remainder of the year, it would suggest that revenues are going to normalize, while we're getting to around \nplus 4% to negative 1% on the revenue; and on the operating profit as well kind of like negative 2% to about 3.3% \ngrowth.  \n \n", "page_label": "12", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cc6b623a-67fb-4def-b7c6-1646af81356a", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8c55c9938d8d2c43ba4b14bbda249654dae3315ccdb5e7d18bc1ccf45ad67b55", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c89b9b16-03a5-44ad-9d77-2acee6250e61", "node_type": "1", "metadata": {"window": "Hi.  Good evening.  So, some  follow -up questions here on the guidance.  So obviously you had a very good \nperformance on the top line, but when we look at your U.S.  Pharmaceutical and Specialty Solutions' guidance for \nthe remainder of the year, it would suggest that revenues are going to normalize, while we're getting to around \nplus 4% to negative 1% on the revenue; and on the operating profit as well kind of like negative 2% to about 3.3% \ngrowth.  \n \n So, was there any kind of like pull -forward of revenues this quarter that's going to norm alize for the remainder of \nthe year?  Or what kind of like drove that strength? ", "original_text": "So obviously you had a very good \nperformance on the top line, but when we look at your U.S. ", "page_label": "12", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b49825041a43493a8278807d8925d916f6f03b5d6a1bba2ab1644154e9485fcb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2d0d09da-ed72-4093-8e37-3023053fc28a", "node_type": "1", "metadata": {"window": "So, some  follow -up questions here on the guidance.  So obviously you had a very good \nperformance on the top line, but when we look at your U.S.  Pharmaceutical and Specialty Solutions' guidance for \nthe remainder of the year, it would suggest that revenues are going to normalize, while we're getting to around \nplus 4% to negative 1% on the revenue; and on the operating profit as well kind of like negative 2% to about 3.3% \ngrowth.  \n \n So, was there any kind of like pull -forward of revenues this quarter that's going to norm alize for the remainder of \nthe year?  Or what kind of like drove that strength?  I understand it is your largest customers, but if you can give us \nsome more color behind that?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson C orp. ", "original_text": "So, was there any kind of like pull -forward of revenues this quarter that's going to norm alize for the remainder of \nthe year? "}, "hash": "3dc2f0cd4a7e0b40b048edd80fab265128c53a9a0734c1566f1ed92af4d06742", "class_name": "RelatedNodeInfo"}}, "text": "Pharmaceutical and Specialty Solutions' guidance for \nthe remainder of the year, it would suggest that revenues are going to normalize, while we're getting to around \nplus 4% to negative 1% on the revenue; and on the operating profit as well kind of like negative 2% to about 3.3% \ngrowth.  \n \n", "start_char_idx": 2063, "end_char_idx": 2357, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2d0d09da-ed72-4093-8e37-3023053fc28a": {"__data__": {"id_": "2d0d09da-ed72-4093-8e37-3023053fc28a", "embedding": null, "metadata": {"window": "So, some  follow -up questions here on the guidance.  So obviously you had a very good \nperformance on the top line, but when we look at your U.S.  Pharmaceutical and Specialty Solutions' guidance for \nthe remainder of the year, it would suggest that revenues are going to normalize, while we're getting to around \nplus 4% to negative 1% on the revenue; and on the operating profit as well kind of like negative 2% to about 3.3% \ngrowth.  \n \n So, was there any kind of like pull -forward of revenues this quarter that's going to norm alize for the remainder of \nthe year?  Or what kind of like drove that strength?  I understand it is your largest customers, but if you can give us \nsome more color behind that?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson C orp. ", "original_text": "So, was there any kind of like pull -forward of revenues this quarter that's going to norm alize for the remainder of \nthe year? ", "page_label": "12", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cc6b623a-67fb-4def-b7c6-1646af81356a", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8c55c9938d8d2c43ba4b14bbda249654dae3315ccdb5e7d18bc1ccf45ad67b55", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1159090b-8052-4c86-a0a7-87ad4e707f0c", "node_type": "1", "metadata": {"window": "Good evening.  So, some  follow -up questions here on the guidance.  So obviously you had a very good \nperformance on the top line, but when we look at your U.S.  Pharmaceutical and Specialty Solutions' guidance for \nthe remainder of the year, it would suggest that revenues are going to normalize, while we're getting to around \nplus 4% to negative 1% on the revenue; and on the operating profit as well kind of like negative 2% to about 3.3% \ngrowth.  \n \n So, was there any kind of like pull -forward of revenues this quarter that's going to norm alize for the remainder of \nthe year?  Or what kind of like drove that strength?  I understand it is your largest customers, but if you can give us \nsome more color behind that?  \n ", "original_text": "Pharmaceutical and Specialty Solutions' guidance for \nthe remainder of the year, it would suggest that revenues are going to normalize, while we're getting to around \nplus 4% to negative 1% on the revenue; and on the operating profit as well kind of like negative 2% to about 3.3% \ngrowth.  \n \n", "page_label": "12", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e868aed1c1236561e57582e07382cdfca446b8b8ea4132134579b2dd9a9d125f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "eb127ca6-a270-478a-9526-c9311e574093", "node_type": "1", "metadata": {"window": "So obviously you had a very good \nperformance on the top line, but when we look at your U.S.  Pharmaceutical and Specialty Solutions' guidance for \nthe remainder of the year, it would suggest that revenues are going to normalize, while we're getting to around \nplus 4% to negative 1% on the revenue; and on the operating profit as well kind of like negative 2% to about 3.3% \ngrowth.  \n \n So, was there any kind of like pull -forward of revenues this quarter that's going to norm alize for the remainder of \nthe year?  Or what kind of like drove that strength?  I understand it is your largest customers, but if you can give us \nsome more color behind that?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson C orp.  A \nSure. ", "original_text": "Or what kind of like drove that strength? "}, "hash": "bf108e742d848920438ea64efab583ec66101353a1abdb1e4791a0e4cd155b0a", "class_name": "RelatedNodeInfo"}}, "text": "So, was there any kind of like pull -forward of revenues this quarter that's going to norm alize for the remainder of \nthe year? ", "start_char_idx": 2357, "end_char_idx": 2486, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "eb127ca6-a270-478a-9526-c9311e574093": {"__data__": {"id_": "eb127ca6-a270-478a-9526-c9311e574093", "embedding": null, "metadata": {"window": "So obviously you had a very good \nperformance on the top line, but when we look at your U.S.  Pharmaceutical and Specialty Solutions' guidance for \nthe remainder of the year, it would suggest that revenues are going to normalize, while we're getting to around \nplus 4% to negative 1% on the revenue; and on the operating profit as well kind of like negative 2% to about 3.3% \ngrowth.  \n \n So, was there any kind of like pull -forward of revenues this quarter that's going to norm alize for the remainder of \nthe year?  Or what kind of like drove that strength?  I understand it is your largest customers, but if you can give us \nsome more color behind that?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson C orp.  A \nSure. ", "original_text": "Or what kind of like drove that strength? ", "page_label": "12", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cc6b623a-67fb-4def-b7c6-1646af81356a", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8c55c9938d8d2c43ba4b14bbda249654dae3315ccdb5e7d18bc1ccf45ad67b55", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2d0d09da-ed72-4093-8e37-3023053fc28a", "node_type": "1", "metadata": {"window": "So, some  follow -up questions here on the guidance.  So obviously you had a very good \nperformance on the top line, but when we look at your U.S.  Pharmaceutical and Specialty Solutions' guidance for \nthe remainder of the year, it would suggest that revenues are going to normalize, while we're getting to around \nplus 4% to negative 1% on the revenue; and on the operating profit as well kind of like negative 2% to about 3.3% \ngrowth.  \n \n So, was there any kind of like pull -forward of revenues this quarter that's going to norm alize for the remainder of \nthe year?  Or what kind of like drove that strength?  I understand it is your largest customers, but if you can give us \nsome more color behind that?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson C orp. ", "original_text": "So, was there any kind of like pull -forward of revenues this quarter that's going to norm alize for the remainder of \nthe year? ", "page_label": "12", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5bc2f7cab45db5bed5d12f06eccd2e830b40058a4a7ec40a93e13e6c8941c262", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8d165ebc-1af8-4b0f-9131-8e40c1f5c379", "node_type": "1", "metadata": {"window": "Pharmaceutical and Specialty Solutions' guidance for \nthe remainder of the year, it would suggest that revenues are going to normalize, while we're getting to around \nplus 4% to negative 1% on the revenue; and on the operating profit as well kind of like negative 2% to about 3.3% \ngrowth.  \n \n So, was there any kind of like pull -forward of revenues this quarter that's going to norm alize for the remainder of \nthe year?  Or what kind of like drove that strength?  I understand it is your largest customers, but if you can give us \nsome more color behind that?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson C orp.  A \nSure.  Thanks, Ricky. ", "original_text": "I understand it is your largest customers, but if you can give us \nsome more color behind that?  \n "}, "hash": "8bade08ddcf5df3fa08f9e189261c94bac95abaaed0a2ba26b7ab300cd88323c", "class_name": "RelatedNodeInfo"}}, "text": "Or what kind of like drove that strength? ", "start_char_idx": 2486, "end_char_idx": 2528, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8d165ebc-1af8-4b0f-9131-8e40c1f5c379": {"__data__": {"id_": "8d165ebc-1af8-4b0f-9131-8e40c1f5c379", "embedding": null, "metadata": {"window": "Pharmaceutical and Specialty Solutions' guidance for \nthe remainder of the year, it would suggest that revenues are going to normalize, while we're getting to around \nplus 4% to negative 1% on the revenue; and on the operating profit as well kind of like negative 2% to about 3.3% \ngrowth.  \n \n So, was there any kind of like pull -forward of revenues this quarter that's going to norm alize for the remainder of \nthe year?  Or what kind of like drove that strength?  I understand it is your largest customers, but if you can give us \nsome more color behind that?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson C orp.  A \nSure.  Thanks, Ricky. ", "original_text": "I understand it is your largest customers, but if you can give us \nsome more color behind that?  \n ", "page_label": "12", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cc6b623a-67fb-4def-b7c6-1646af81356a", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8c55c9938d8d2c43ba4b14bbda249654dae3315ccdb5e7d18bc1ccf45ad67b55", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "eb127ca6-a270-478a-9526-c9311e574093", "node_type": "1", "metadata": {"window": "So obviously you had a very good \nperformance on the top line, but when we look at your U.S.  Pharmaceutical and Specialty Solutions' guidance for \nthe remainder of the year, it would suggest that revenues are going to normalize, while we're getting to around \nplus 4% to negative 1% on the revenue; and on the operating profit as well kind of like negative 2% to about 3.3% \ngrowth.  \n \n So, was there any kind of like pull -forward of revenues this quarter that's going to norm alize for the remainder of \nthe year?  Or what kind of like drove that strength?  I understand it is your largest customers, but if you can give us \nsome more color behind that?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson C orp.  A \nSure. ", "original_text": "Or what kind of like drove that strength? ", "page_label": "12", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f7d7c7e8bf1808986fd6edebae0cb85b2e6f12be36fc3f09f9f5925005a6ba02", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c6e023ea-ea58-4ccf-ba1d-94d2d4d01776", "node_type": "1", "metadata": {"window": "So, was there any kind of like pull -forward of revenues this quarter that's going to norm alize for the remainder of \nthe year?  Or what kind of like drove that strength?  I understand it is your largest customers, but if you can give us \nsome more color behind that?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson C orp.  A \nSure.  Thanks, Ricky.  There's nothing unusual about the revenue development in the quarter. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson C orp. "}, "hash": "65bfb2f461b2a396e339b2e8f934ded49c36cded49977bec63aa2853a985ceeb", "class_name": "RelatedNodeInfo"}}, "text": "I understand it is your largest customers, but if you can give us \nsome more color behind that?  \n ", "start_char_idx": 2528, "end_char_idx": 2627, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c6e023ea-ea58-4ccf-ba1d-94d2d4d01776": {"__data__": {"id_": "c6e023ea-ea58-4ccf-ba1d-94d2d4d01776", "embedding": null, "metadata": {"window": "So, was there any kind of like pull -forward of revenues this quarter that's going to norm alize for the remainder of \nthe year?  Or what kind of like drove that strength?  I understand it is your largest customers, but if you can give us \nsome more color behind that?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson C orp.  A \nSure.  Thanks, Ricky.  There's nothing unusual about the revenue development in the quarter. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson C orp. ", "page_label": "12", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cc6b623a-67fb-4def-b7c6-1646af81356a", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8c55c9938d8d2c43ba4b14bbda249654dae3315ccdb5e7d18bc1ccf45ad67b55", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8d165ebc-1af8-4b0f-9131-8e40c1f5c379", "node_type": "1", "metadata": {"window": "Pharmaceutical and Specialty Solutions' guidance for \nthe remainder of the year, it would suggest that revenues are going to normalize, while we're getting to around \nplus 4% to negative 1% on the revenue; and on the operating profit as well kind of like negative 2% to about 3.3% \ngrowth.  \n \n So, was there any kind of like pull -forward of revenues this quarter that's going to norm alize for the remainder of \nthe year?  Or what kind of like drove that strength?  I understand it is your largest customers, but if you can give us \nsome more color behind that?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson C orp.  A \nSure.  Thanks, Ricky. ", "original_text": "I understand it is your largest customers, but if you can give us \nsome more color behind that?  \n ", "page_label": "12", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "70afbdcb88c925360b6a2ac3d6a9e8137c9e172f152349b12f46f860d0171047", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "54e7dde3-0d5e-4132-bf34-a4abd0669395", "node_type": "1", "metadata": {"window": "Or what kind of like drove that strength?  I understand it is your largest customers, but if you can give us \nsome more color behind that?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson C orp.  A \nSure.  Thanks, Ricky.  There's nothing unusual about the revenue development in the quarter.  There's nothing that \nI would call out as a pull -forward, to use your terminology. ", "original_text": "A \nSure. "}, "hash": "9e957f4e2f6a59f1ef2f9136a83ecd1758d9dd9b366838e1e401a554807ad574", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson C orp. ", "start_char_idx": 2627, "end_char_idx": 2972, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "54e7dde3-0d5e-4132-bf34-a4abd0669395": {"__data__": {"id_": "54e7dde3-0d5e-4132-bf34-a4abd0669395", "embedding": null, "metadata": {"window": "Or what kind of like drove that strength?  I understand it is your largest customers, but if you can give us \nsome more color behind that?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson C orp.  A \nSure.  Thanks, Ricky.  There's nothing unusual about the revenue development in the quarter.  There's nothing that \nI would call out as a pull -forward, to use your terminology. ", "original_text": "A \nSure. ", "page_label": "12", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cc6b623a-67fb-4def-b7c6-1646af81356a", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8c55c9938d8d2c43ba4b14bbda249654dae3315ccdb5e7d18bc1ccf45ad67b55", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c6e023ea-ea58-4ccf-ba1d-94d2d4d01776", "node_type": "1", "metadata": {"window": "So, was there any kind of like pull -forward of revenues this quarter that's going to norm alize for the remainder of \nthe year?  Or what kind of like drove that strength?  I understand it is your largest customers, but if you can give us \nsome more color behind that?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson C orp.  A \nSure.  Thanks, Ricky.  There's nothing unusual about the revenue development in the quarter. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson C orp. ", "page_label": "12", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "76a070a8f80e9045ed0233ea402aeb1f57059cb48efb7fa35f5f6c60d7673c82", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a3a52f21-46ff-4e00-96b4-670b79f9e583", "node_type": "1", "metadata": {"window": "I understand it is your largest customers, but if you can give us \nsome more color behind that?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson C orp.  A \nSure.  Thanks, Ricky.  There's nothing unusual about the revenue development in the quarter.  There's nothing that \nI would call out as a pull -forward, to use your terminology.  We had very strong performance. ", "original_text": "Thanks, Ricky. "}, "hash": "e6c6376ab541c1a76f142163fd51faf91c7989527025f35403dddd72349f5231", "class_name": "RelatedNodeInfo"}}, "text": "A \nSure. ", "start_char_idx": 2972, "end_char_idx": 2981, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a3a52f21-46ff-4e00-96b4-670b79f9e583": {"__data__": {"id_": "a3a52f21-46ff-4e00-96b4-670b79f9e583", "embedding": null, "metadata": {"window": "I understand it is your largest customers, but if you can give us \nsome more color behind that?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson C orp.  A \nSure.  Thanks, Ricky.  There's nothing unusual about the revenue development in the quarter.  There's nothing that \nI would call out as a pull -forward, to use your terminology.  We had very strong performance. ", "original_text": "Thanks, Ricky. ", "page_label": "12", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cc6b623a-67fb-4def-b7c6-1646af81356a", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8c55c9938d8d2c43ba4b14bbda249654dae3315ccdb5e7d18bc1ccf45ad67b55", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "54e7dde3-0d5e-4132-bf34-a4abd0669395", "node_type": "1", "metadata": {"window": "Or what kind of like drove that strength?  I understand it is your largest customers, but if you can give us \nsome more color behind that?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson C orp.  A \nSure.  Thanks, Ricky.  There's nothing unusual about the revenue development in the quarter.  There's nothing that \nI would call out as a pull -forward, to use your terminology. ", "original_text": "A \nSure. ", "page_label": "12", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "62f19979ecabcd216348559b6e68e65376ec7ac7bca8b1eb754b01d19008e4a9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "91c12713-0b72-40df-a520-731eac0263da", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson C orp.  A \nSure.  Thanks, Ricky.  There's nothing unusual about the revenue development in the quarter.  There's nothing that \nI would call out as a pull -forward, to use your terminology.  We had very strong performance.  It was primarily in our \nlargest retail nati onal accounts. ", "original_text": "There's nothing unusual about the revenue development in the quarter. "}, "hash": "e52268bc6d4ec2aa3ba99be03da86f9efe673c2371191a5daf461f6aa2c31e75", "class_name": "RelatedNodeInfo"}}, "text": "Thanks, Ricky. ", "start_char_idx": 2981, "end_char_idx": 2996, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "91c12713-0b72-40df-a520-731eac0263da": {"__data__": {"id_": "91c12713-0b72-40df-a520-731eac0263da", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson C orp.  A \nSure.  Thanks, Ricky.  There's nothing unusual about the revenue development in the quarter.  There's nothing that \nI would call out as a pull -forward, to use your terminology.  We had very strong performance.  It was primarily in our \nlargest retail nati onal accounts. ", "original_text": "There's nothing unusual about the revenue development in the quarter. ", "page_label": "12", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cc6b623a-67fb-4def-b7c6-1646af81356a", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8c55c9938d8d2c43ba4b14bbda249654dae3315ccdb5e7d18bc1ccf45ad67b55", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a3a52f21-46ff-4e00-96b4-670b79f9e583", "node_type": "1", "metadata": {"window": "I understand it is your largest customers, but if you can give us \nsome more color behind that?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson C orp.  A \nSure.  Thanks, Ricky.  There's nothing unusual about the revenue development in the quarter.  There's nothing that \nI would call out as a pull -forward, to use your terminology.  We had very strong performance. ", "original_text": "Thanks, Ricky. ", "page_label": "12", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4f85921b4b7dfb377a28fa6b9534263db3d2bf6072c24726d167c8c8b85038c2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e40f1d1c-f051-4c8b-bb88-03a8c01b3752", "node_type": "1", "metadata": {"window": "A \nSure.  Thanks, Ricky.  There's nothing unusual about the revenue development in the quarter.  There's nothing that \nI would call out as a pull -forward, to use your terminology.  We had very strong performance.  It was primarily in our \nlargest retail nati onal accounts.  But again, as I mentioned, we had broad base of revenue growth across the \nbusiness.  \n \n", "original_text": "There's nothing that \nI would call out as a pull -forward, to use your terminology. "}, "hash": "7bb99b4290e7952e93ddf06f1fa2720c963842d86cc22d1cea5733889b600c2b", "class_name": "RelatedNodeInfo"}}, "text": "There's nothing unusual about the revenue development in the quarter. ", "start_char_idx": 2996, "end_char_idx": 3066, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e40f1d1c-f051-4c8b-bb88-03a8c01b3752": {"__data__": {"id_": "e40f1d1c-f051-4c8b-bb88-03a8c01b3752", "embedding": null, "metadata": {"window": "A \nSure.  Thanks, Ricky.  There's nothing unusual about the revenue development in the quarter.  There's nothing that \nI would call out as a pull -forward, to use your terminology.  We had very strong performance.  It was primarily in our \nlargest retail nati onal accounts.  But again, as I mentioned, we had broad base of revenue growth across the \nbusiness.  \n \n", "original_text": "There's nothing that \nI would call out as a pull -forward, to use your terminology. ", "page_label": "12", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cc6b623a-67fb-4def-b7c6-1646af81356a", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8c55c9938d8d2c43ba4b14bbda249654dae3315ccdb5e7d18bc1ccf45ad67b55", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "91c12713-0b72-40df-a520-731eac0263da", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson C orp.  A \nSure.  Thanks, Ricky.  There's nothing unusual about the revenue development in the quarter.  There's nothing that \nI would call out as a pull -forward, to use your terminology.  We had very strong performance.  It was primarily in our \nlargest retail nati onal accounts. ", "original_text": "There's nothing unusual about the revenue development in the quarter. ", "page_label": "12", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "984b92d8147dfb25f322f4c3f2fe5b3477e048ab330a1a2ede0f5e61ed152b7f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "566a6a1a-7a14-4711-838f-71f75e52483f", "node_type": "1", "metadata": {"window": "Thanks, Ricky.  There's nothing unusual about the revenue development in the quarter.  There's nothing that \nI would call out as a pull -forward, to use your terminology.  We had very strong performance.  It was primarily in our \nlargest retail nati onal accounts.  But again, as I mentioned, we had broad base of revenue growth across the \nbusiness.  \n \n But one thing I would point out about our adjusted operating profit for the quarter, as I talked about in my opening \nremarks, last year we did have the opioid litigation costs that were included in that segment's results. ", "original_text": "We had very strong performance. "}, "hash": "e1849fd69f29c5ee96b1a986d214dcb9511d54f88bdac8e05766720cf191ef99", "class_name": "RelatedNodeInfo"}}, "text": "There's nothing that \nI would call out as a pull -forward, to use your terminology. ", "start_char_idx": 3066, "end_char_idx": 3150, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "566a6a1a-7a14-4711-838f-71f75e52483f": {"__data__": {"id_": "566a6a1a-7a14-4711-838f-71f75e52483f", "embedding": null, "metadata": {"window": "Thanks, Ricky.  There's nothing unusual about the revenue development in the quarter.  There's nothing that \nI would call out as a pull -forward, to use your terminology.  We had very strong performance.  It was primarily in our \nlargest retail nati onal accounts.  But again, as I mentioned, we had broad base of revenue growth across the \nbusiness.  \n \n But one thing I would point out about our adjusted operating profit for the quarter, as I talked about in my opening \nremarks, last year we did have the opioid litigation costs that were included in that segment's results. ", "original_text": "We had very strong performance. ", "page_label": "12", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cc6b623a-67fb-4def-b7c6-1646af81356a", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8c55c9938d8d2c43ba4b14bbda249654dae3315ccdb5e7d18bc1ccf45ad67b55", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e40f1d1c-f051-4c8b-bb88-03a8c01b3752", "node_type": "1", "metadata": {"window": "A \nSure.  Thanks, Ricky.  There's nothing unusual about the revenue development in the quarter.  There's nothing that \nI would call out as a pull -forward, to use your terminology.  We had very strong performance.  It was primarily in our \nlargest retail nati onal accounts.  But again, as I mentioned, we had broad base of revenue growth across the \nbusiness.  \n \n", "original_text": "There's nothing that \nI would call out as a pull -forward, to use your terminology. ", "page_label": "12", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f75e9b80173f68bc2016e8637caed75f4ac03261ca97829b117957eb291b2739", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "55327c0f-94d0-4d84-9c0f-7b1c219433f3", "node_type": "1", "metadata": {"window": "There's nothing unusual about the revenue development in the quarter.  There's nothing that \nI would call out as a pull -forward, to use your terminology.  We had very strong performance.  It was primarily in our \nlargest retail nati onal accounts.  But again, as I mentioned, we had broad base of revenue growth across the \nbusiness.  \n \n But one thing I would point out about our adjusted operating profit for the quarter, as I talked about in my opening \nremarks, last year we did have the opioid litigation costs that were included in that segment's results.  And as I \nmentioned, we recorded $15 million last year for the New York state assessment. ", "original_text": "It was primarily in our \nlargest retail nati onal accounts. "}, "hash": "11e892af9eec044b154af3eedd0201036ee1a71270b926aa9b32f18dcbbf1267", "class_name": "RelatedNodeInfo"}}, "text": "We had very strong performance. ", "start_char_idx": 3150, "end_char_idx": 3182, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "55327c0f-94d0-4d84-9c0f-7b1c219433f3": {"__data__": {"id_": "55327c0f-94d0-4d84-9c0f-7b1c219433f3", "embedding": null, "metadata": {"window": "There's nothing unusual about the revenue development in the quarter.  There's nothing that \nI would call out as a pull -forward, to use your terminology.  We had very strong performance.  It was primarily in our \nlargest retail nati onal accounts.  But again, as I mentioned, we had broad base of revenue growth across the \nbusiness.  \n \n But one thing I would point out about our adjusted operating profit for the quarter, as I talked about in my opening \nremarks, last year we did have the opioid litigation costs that were included in that segment's results.  And as I \nmentioned, we recorded $15 million last year for the New York state assessment. ", "original_text": "It was primarily in our \nlargest retail nati onal accounts. ", "page_label": "12", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cc6b623a-67fb-4def-b7c6-1646af81356a", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8c55c9938d8d2c43ba4b14bbda249654dae3315ccdb5e7d18bc1ccf45ad67b55", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "566a6a1a-7a14-4711-838f-71f75e52483f", "node_type": "1", "metadata": {"window": "Thanks, Ricky.  There's nothing unusual about the revenue development in the quarter.  There's nothing that \nI would call out as a pull -forward, to use your terminology.  We had very strong performance.  It was primarily in our \nlargest retail nati onal accounts.  But again, as I mentioned, we had broad base of revenue growth across the \nbusiness.  \n \n But one thing I would point out about our adjusted operating profit for the quarter, as I talked about in my opening \nremarks, last year we did have the opioid litigation costs that were included in that segment's results. ", "original_text": "We had very strong performance. ", "page_label": "12", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2e70a1e78265bbd8574523ddfc6d369ced5d4aa0292153227a734f8ada92d478", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "428672d8-6806-45fb-8d24-9183662d8c5b", "node_type": "1", "metadata": {"window": "There's nothing that \nI would call out as a pull -forward, to use your terminology.  We had very strong performance.  It was primarily in our \nlargest retail nati onal accounts.  But again, as I mentioned, we had broad base of revenue growth across the \nbusiness.  \n \n But one thing I would point out about our adjusted operating profit for the quarter, as I talked about in my opening \nremarks, last year we did have the opioid litigation costs that were included in that segment's results.  And as I \nmentioned, we recorded $15 million last year for the New York state assessment.  So I think you should factor that \nin. ", "original_text": "But again, as I mentioned, we had broad base of revenue growth across the \nbusiness.  \n \n"}, "hash": "27a795961fb48e51c07351bb89d1d60185942bc2b6fb8fbf03d8b9833d81d566", "class_name": "RelatedNodeInfo"}}, "text": "It was primarily in our \nlargest retail nati onal accounts. ", "start_char_idx": 3182, "end_char_idx": 3242, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "428672d8-6806-45fb-8d24-9183662d8c5b": {"__data__": {"id_": "428672d8-6806-45fb-8d24-9183662d8c5b", "embedding": null, "metadata": {"window": "There's nothing that \nI would call out as a pull -forward, to use your terminology.  We had very strong performance.  It was primarily in our \nlargest retail nati onal accounts.  But again, as I mentioned, we had broad base of revenue growth across the \nbusiness.  \n \n But one thing I would point out about our adjusted operating profit for the quarter, as I talked about in my opening \nremarks, last year we did have the opioid litigation costs that were included in that segment's results.  And as I \nmentioned, we recorded $15 million last year for the New York state assessment.  So I think you should factor that \nin. ", "original_text": "But again, as I mentioned, we had broad base of revenue growth across the \nbusiness.  \n \n", "page_label": "12", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cc6b623a-67fb-4def-b7c6-1646af81356a", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8c55c9938d8d2c43ba4b14bbda249654dae3315ccdb5e7d18bc1ccf45ad67b55", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "55327c0f-94d0-4d84-9c0f-7b1c219433f3", "node_type": "1", "metadata": {"window": "There's nothing unusual about the revenue development in the quarter.  There's nothing that \nI would call out as a pull -forward, to use your terminology.  We had very strong performance.  It was primarily in our \nlargest retail nati onal accounts.  But again, as I mentioned, we had broad base of revenue growth across the \nbusiness.  \n \n But one thing I would point out about our adjusted operating profit for the quarter, as I talked about in my opening \nremarks, last year we did have the opioid litigation costs that were included in that segment's results.  And as I \nmentioned, we recorded $15 million last year for the New York state assessment. ", "original_text": "It was primarily in our \nlargest retail nati onal accounts. ", "page_label": "12", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9c33d59a2a737ced7dbb2f653689537857eb1b1385b21c40219d3ecc3bb29448", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0718d8a2-d0f8-4c87-a7c7-8ca5e57beb83", "node_type": "1", "metadata": {"window": "We had very strong performance.  It was primarily in our \nlargest retail nati onal accounts.  But again, as I mentioned, we had broad base of revenue growth across the \nbusiness.  \n \n But one thing I would point out about our adjusted operating profit for the quarter, as I talked about in my opening \nremarks, last year we did have the opioid litigation costs that were included in that segment's results.  And as I \nmentioned, we recorded $15 million last year for the New York state assessment.  So I think you should factor that \nin.  We're very pleased with the performance. ", "original_text": "But one thing I would point out about our adjusted operating profit for the quarter, as I talked about in my opening \nremarks, last year we did have the opioid litigation costs that were included in that segment's results. "}, "hash": "fdcd6ffb83aa58d703217502863f9e309c9d70c69eac0ece337625bfad5c191d", "class_name": "RelatedNodeInfo"}}, "text": "But again, as I mentioned, we had broad base of revenue growth across the \nbusiness.  \n \n", "start_char_idx": 3242, "end_char_idx": 3331, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0718d8a2-d0f8-4c87-a7c7-8ca5e57beb83": {"__data__": {"id_": "0718d8a2-d0f8-4c87-a7c7-8ca5e57beb83", "embedding": null, "metadata": {"window": "We had very strong performance.  It was primarily in our \nlargest retail nati onal accounts.  But again, as I mentioned, we had broad base of revenue growth across the \nbusiness.  \n \n But one thing I would point out about our adjusted operating profit for the quarter, as I talked about in my opening \nremarks, last year we did have the opioid litigation costs that were included in that segment's results.  And as I \nmentioned, we recorded $15 million last year for the New York state assessment.  So I think you should factor that \nin.  We're very pleased with the performance. ", "original_text": "But one thing I would point out about our adjusted operating profit for the quarter, as I talked about in my opening \nremarks, last year we did have the opioid litigation costs that were included in that segment's results. ", "page_label": "12", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cc6b623a-67fb-4def-b7c6-1646af81356a", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8c55c9938d8d2c43ba4b14bbda249654dae3315ccdb5e7d18bc1ccf45ad67b55", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "428672d8-6806-45fb-8d24-9183662d8c5b", "node_type": "1", "metadata": {"window": "There's nothing that \nI would call out as a pull -forward, to use your terminology.  We had very strong performance.  It was primarily in our \nlargest retail nati onal accounts.  But again, as I mentioned, we had broad base of revenue growth across the \nbusiness.  \n \n But one thing I would point out about our adjusted operating profit for the quarter, as I talked about in my opening \nremarks, last year we did have the opioid litigation costs that were included in that segment's results.  And as I \nmentioned, we recorded $15 million last year for the New York state assessment.  So I think you should factor that \nin. ", "original_text": "But again, as I mentioned, we had broad base of revenue growth across the \nbusiness.  \n \n", "page_label": "12", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1c48a4f4859aea53a9e7cddcbc6a2aeb1f2082728a4222c969522d2e303ff0a3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bbe721ca-e603-4a49-aab1-ca501c0d6b59", "node_type": "1", "metadata": {"window": "It was primarily in our \nlargest retail nati onal accounts.  But again, as I mentioned, we had broad base of revenue growth across the \nbusiness.  \n \n But one thing I would point out about our adjusted operating profit for the quarter, as I talked about in my opening \nremarks, last year we did have the opioid litigation costs that were included in that segment's results.  And as I \nmentioned, we recorded $15 million last year for the New York state assessment.  So I think you should factor that \nin.  We're very pleased with the performance.  We continue to exp ect to see growth in this segment for the \nremainder of the year, and we're very pleased with the revenue development.  \n ", "original_text": "And as I \nmentioned, we recorded $15 million last year for the New York state assessment. "}, "hash": "6c803301eed139158b154aeeed4841b99b101e5b0d3d01202b4ed54504da7265", "class_name": "RelatedNodeInfo"}}, "text": "But one thing I would point out about our adjusted operating profit for the quarter, as I talked about in my opening \nremarks, last year we did have the opioid litigation costs that were included in that segment's results. ", "start_char_idx": 3331, "end_char_idx": 3554, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bbe721ca-e603-4a49-aab1-ca501c0d6b59": {"__data__": {"id_": "bbe721ca-e603-4a49-aab1-ca501c0d6b59", "embedding": null, "metadata": {"window": "It was primarily in our \nlargest retail nati onal accounts.  But again, as I mentioned, we had broad base of revenue growth across the \nbusiness.  \n \n But one thing I would point out about our adjusted operating profit for the quarter, as I talked about in my opening \nremarks, last year we did have the opioid litigation costs that were included in that segment's results.  And as I \nmentioned, we recorded $15 million last year for the New York state assessment.  So I think you should factor that \nin.  We're very pleased with the performance.  We continue to exp ect to see growth in this segment for the \nremainder of the year, and we're very pleased with the revenue development.  \n ", "original_text": "And as I \nmentioned, we recorded $15 million last year for the New York state assessment. ", "page_label": "12", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cc6b623a-67fb-4def-b7c6-1646af81356a", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8c55c9938d8d2c43ba4b14bbda249654dae3315ccdb5e7d18bc1ccf45ad67b55", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0718d8a2-d0f8-4c87-a7c7-8ca5e57beb83", "node_type": "1", "metadata": {"window": "We had very strong performance.  It was primarily in our \nlargest retail nati onal accounts.  But again, as I mentioned, we had broad base of revenue growth across the \nbusiness.  \n \n But one thing I would point out about our adjusted operating profit for the quarter, as I talked about in my opening \nremarks, last year we did have the opioid litigation costs that were included in that segment's results.  And as I \nmentioned, we recorded $15 million last year for the New York state assessment.  So I think you should factor that \nin.  We're very pleased with the performance. ", "original_text": "But one thing I would point out about our adjusted operating profit for the quarter, as I talked about in my opening \nremarks, last year we did have the opioid litigation costs that were included in that segment's results. ", "page_label": "12", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "457abf9dfa6b9aa4aab0ffc5c5aa9a741081f5f5cb3336423b7cde3d5236ef40", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2dda4f68-40b4-4813-af0e-3ad77aeb83a0", "node_type": "1", "metadata": {"window": "But again, as I mentioned, we had broad base of revenue growth across the \nbusiness.  \n \n But one thing I would point out about our adjusted operating profit for the quarter, as I talked about in my opening \nremarks, last year we did have the opioid litigation costs that were included in that segment's results.  And as I \nmentioned, we recorded $15 million last year for the New York state assessment.  So I think you should factor that \nin.  We're very pleased with the performance.  We continue to exp ect to see growth in this segment for the \nremainder of the year, and we're very pleased with the revenue development.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. ", "original_text": "So I think you should factor that \nin. "}, "hash": "6df29c7ee1ae75ece4d51ff40eafbea0d86e5c8ae56e9c2235fd04d04f314641", "class_name": "RelatedNodeInfo"}}, "text": "And as I \nmentioned, we recorded $15 million last year for the New York state assessment. ", "start_char_idx": 3554, "end_char_idx": 3644, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2dda4f68-40b4-4813-af0e-3ad77aeb83a0": {"__data__": {"id_": "2dda4f68-40b4-4813-af0e-3ad77aeb83a0", "embedding": null, "metadata": {"window": "But again, as I mentioned, we had broad base of revenue growth across the \nbusiness.  \n \n But one thing I would point out about our adjusted operating profit for the quarter, as I talked about in my opening \nremarks, last year we did have the opioid litigation costs that were included in that segment's results.  And as I \nmentioned, we recorded $15 million last year for the New York state assessment.  So I think you should factor that \nin.  We're very pleased with the performance.  We continue to exp ect to see growth in this segment for the \nremainder of the year, and we're very pleased with the revenue development.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. ", "original_text": "So I think you should factor that \nin. ", "page_label": "12", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cc6b623a-67fb-4def-b7c6-1646af81356a", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8c55c9938d8d2c43ba4b14bbda249654dae3315ccdb5e7d18bc1ccf45ad67b55", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bbe721ca-e603-4a49-aab1-ca501c0d6b59", "node_type": "1", "metadata": {"window": "It was primarily in our \nlargest retail nati onal accounts.  But again, as I mentioned, we had broad base of revenue growth across the \nbusiness.  \n \n But one thing I would point out about our adjusted operating profit for the quarter, as I talked about in my opening \nremarks, last year we did have the opioid litigation costs that were included in that segment's results.  And as I \nmentioned, we recorded $15 million last year for the New York state assessment.  So I think you should factor that \nin.  We're very pleased with the performance.  We continue to exp ect to see growth in this segment for the \nremainder of the year, and we're very pleased with the revenue development.  \n ", "original_text": "And as I \nmentioned, we recorded $15 million last year for the New York state assessment. ", "page_label": "12", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "08b5d10414ff3a6a7aca57953bf4c93c8873ae3bc9979a28e2323047d1fb511b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "04054c87-39f1-46aa-8a72-6511e1f5d32e", "node_type": "1", "metadata": {"window": "But one thing I would point out about our adjusted operating profit for the quarter, as I talked about in my opening \nremarks, last year we did have the opioid litigation costs that were included in that segment's results.  And as I \nmentioned, we recorded $15 million last year for the New York state assessment.  So I think you should factor that \nin.  We're very pleased with the performance.  We continue to exp ect to see growth in this segment for the \nremainder of the year, and we're very pleased with the revenue development.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nOkay. ", "original_text": "We're very pleased with the performance. "}, "hash": "8c94b5350db5fb7284e5e72d43782e2be8077a57415b1bc7be1e4408c7de0db4", "class_name": "RelatedNodeInfo"}}, "text": "So I think you should factor that \nin. ", "start_char_idx": 3644, "end_char_idx": 3683, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "04054c87-39f1-46aa-8a72-6511e1f5d32e": {"__data__": {"id_": "04054c87-39f1-46aa-8a72-6511e1f5d32e", "embedding": null, "metadata": {"window": "But one thing I would point out about our adjusted operating profit for the quarter, as I talked about in my opening \nremarks, last year we did have the opioid litigation costs that were included in that segment's results.  And as I \nmentioned, we recorded $15 million last year for the New York state assessment.  So I think you should factor that \nin.  We're very pleased with the performance.  We continue to exp ect to see growth in this segment for the \nremainder of the year, and we're very pleased with the revenue development.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nOkay. ", "original_text": "We're very pleased with the performance. ", "page_label": "12", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cc6b623a-67fb-4def-b7c6-1646af81356a", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8c55c9938d8d2c43ba4b14bbda249654dae3315ccdb5e7d18bc1ccf45ad67b55", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2dda4f68-40b4-4813-af0e-3ad77aeb83a0", "node_type": "1", "metadata": {"window": "But again, as I mentioned, we had broad base of revenue growth across the \nbusiness.  \n \n But one thing I would point out about our adjusted operating profit for the quarter, as I talked about in my opening \nremarks, last year we did have the opioid litigation costs that were included in that segment's results.  And as I \nmentioned, we recorded $15 million last year for the New York state assessment.  So I think you should factor that \nin.  We're very pleased with the performance.  We continue to exp ect to see growth in this segment for the \nremainder of the year, and we're very pleased with the revenue development.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. ", "original_text": "So I think you should factor that \nin. ", "page_label": "12", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f8007632926fad371a792845a29b82ea288f4002b54334b3ff96b40de1db8977", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e181e04d-9c91-44ea-95fe-837fe2324522", "node_type": "1", "metadata": {"window": "And as I \nmentioned, we recorded $15 million last year for the New York state assessment.  So I think you should factor that \nin.  We're very pleased with the performance.  We continue to exp ect to see growth in this segment for the \nremainder of the year, and we're very pleased with the revenue development.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nOkay.  So, let me ask a follow -up on specialty. ", "original_text": "We continue to exp ect to see growth in this segment for the \nremainder of the year, and we're very pleased with the revenue development.  \n "}, "hash": "fc1eb9e8090ffa40eea5e22e4b5e4f9f395182eb858c6ea10fa70986180cd435", "class_name": "RelatedNodeInfo"}}, "text": "We're very pleased with the performance. ", "start_char_idx": 3683, "end_char_idx": 3724, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e181e04d-9c91-44ea-95fe-837fe2324522": {"__data__": {"id_": "e181e04d-9c91-44ea-95fe-837fe2324522", "embedding": null, "metadata": {"window": "And as I \nmentioned, we recorded $15 million last year for the New York state assessment.  So I think you should factor that \nin.  We're very pleased with the performance.  We continue to exp ect to see growth in this segment for the \nremainder of the year, and we're very pleased with the revenue development.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nOkay.  So, let me ask a follow -up on specialty. ", "original_text": "We continue to exp ect to see growth in this segment for the \nremainder of the year, and we're very pleased with the revenue development.  \n ", "page_label": "12", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cc6b623a-67fb-4def-b7c6-1646af81356a", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8c55c9938d8d2c43ba4b14bbda249654dae3315ccdb5e7d18bc1ccf45ad67b55", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "04054c87-39f1-46aa-8a72-6511e1f5d32e", "node_type": "1", "metadata": {"window": "But one thing I would point out about our adjusted operating profit for the quarter, as I talked about in my opening \nremarks, last year we did have the opioid litigation costs that were included in that segment's results.  And as I \nmentioned, we recorded $15 million last year for the New York state assessment.  So I think you should factor that \nin.  We're very pleased with the performance.  We continue to exp ect to see growth in this segment for the \nremainder of the year, and we're very pleased with the revenue development.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nOkay. ", "original_text": "We're very pleased with the performance. ", "page_label": "12", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f0b69c211ec4942d35aa182611161f0d5ede7998924175ae1e30b551e6f62a46", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8369262a-3eb5-4ddf-978c-b2d774c7e0de", "node_type": "1", "metadata": {"window": "So I think you should factor that \nin.  We're very pleased with the performance.  We continue to exp ect to see growth in this segment for the \nremainder of the year, and we're very pleased with the revenue development.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nOkay.  So, let me ask a follow -up on specialty.  This is kind of like the third q uarter both you and your peers are \nhighlighting the strength in specialty is benefiting results. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. "}, "hash": "d9f9ac2c5ca2d6ef9651337bc7f706af70cf41c784f6e64ad0741bd22b6be774", "class_name": "RelatedNodeInfo"}}, "text": "We continue to exp ect to see growth in this segment for the \nremainder of the year, and we're very pleased with the revenue development.  \n ", "start_char_idx": 3724, "end_char_idx": 3865, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8369262a-3eb5-4ddf-978c-b2d774c7e0de": {"__data__": {"id_": "8369262a-3eb5-4ddf-978c-b2d774c7e0de", "embedding": null, "metadata": {"window": "So I think you should factor that \nin.  We're very pleased with the performance.  We continue to exp ect to see growth in this segment for the \nremainder of the year, and we're very pleased with the revenue development.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nOkay.  So, let me ask a follow -up on specialty.  This is kind of like the third q uarter both you and your peers are \nhighlighting the strength in specialty is benefiting results. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. ", "page_label": "12", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cc6b623a-67fb-4def-b7c6-1646af81356a", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8c55c9938d8d2c43ba4b14bbda249654dae3315ccdb5e7d18bc1ccf45ad67b55", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e181e04d-9c91-44ea-95fe-837fe2324522", "node_type": "1", "metadata": {"window": "And as I \nmentioned, we recorded $15 million last year for the New York state assessment.  So I think you should factor that \nin.  We're very pleased with the performance.  We continue to exp ect to see growth in this segment for the \nremainder of the year, and we're very pleased with the revenue development.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nOkay.  So, let me ask a follow -up on specialty. ", "original_text": "We continue to exp ect to see growth in this segment for the \nremainder of the year, and we're very pleased with the revenue development.  \n ", "page_label": "12", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7fe595067c330079d88b06201c09b99c6bd4ccfb60a01e050e4a4f509b2fd41d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "14465b3f-6e21-487b-8ba9-c8ed3776d96a", "node_type": "1", "metadata": {"window": "We're very pleased with the performance.  We continue to exp ect to see growth in this segment for the \nremainder of the year, and we're very pleased with the revenue development.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nOkay.  So, let me ask a follow -up on specialty.  This is kind of like the third q uarter both you and your peers are \nhighlighting the strength in specialty is benefiting results.  So, can you just share with us a little bit more color on ", "original_text": "LLC  Q \nOkay. "}, "hash": "b0e9c0245a282d50f474178e1c3111c2c5cba57c0f8cf065851364262faea67c", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. ", "start_char_idx": 1576, "end_char_idx": 1885, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "14465b3f-6e21-487b-8ba9-c8ed3776d96a": {"__data__": {"id_": "14465b3f-6e21-487b-8ba9-c8ed3776d96a", "embedding": null, "metadata": {"window": "We're very pleased with the performance.  We continue to exp ect to see growth in this segment for the \nremainder of the year, and we're very pleased with the revenue development.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nOkay.  So, let me ask a follow -up on specialty.  This is kind of like the third q uarter both you and your peers are \nhighlighting the strength in specialty is benefiting results.  So, can you just share with us a little bit more color on ", "original_text": "LLC  Q \nOkay. ", "page_label": "12", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cc6b623a-67fb-4def-b7c6-1646af81356a", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8c55c9938d8d2c43ba4b14bbda249654dae3315ccdb5e7d18bc1ccf45ad67b55", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8369262a-3eb5-4ddf-978c-b2d774c7e0de", "node_type": "1", "metadata": {"window": "So I think you should factor that \nin.  We're very pleased with the performance.  We continue to exp ect to see growth in this segment for the \nremainder of the year, and we're very pleased with the revenue development.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nOkay.  So, let me ask a follow -up on specialty.  This is kind of like the third q uarter both you and your peers are \nhighlighting the strength in specialty is benefiting results. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. ", "page_label": "12", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f89d23b6801e58beaf2901e1da9d131fe3e3c843343b2c5b03f14fd4ca581c55", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "43bc3b6f-ac54-4391-ade6-dc6333dc0684", "node_type": "1", "metadata": {"window": "We continue to exp ect to see growth in this segment for the \nremainder of the year, and we're very pleased with the revenue development.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nOkay.  So, let me ask a follow -up on specialty.  This is kind of like the third q uarter both you and your peers are \nhighlighting the strength in specialty is benefiting results.  So, can you just share with us a little bit more color on ", "original_text": "So, let me ask a follow -up on specialty. "}, "hash": "6255b10d84dfb775fa15191bd65b9c74abd00338e789efb5d4097043f8c4bde0", "class_name": "RelatedNodeInfo"}}, "text": "LLC  Q \nOkay. ", "start_char_idx": 4174, "end_char_idx": 4188, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "43bc3b6f-ac54-4391-ade6-dc6333dc0684": {"__data__": {"id_": "43bc3b6f-ac54-4391-ade6-dc6333dc0684", "embedding": null, "metadata": {"window": "We continue to exp ect to see growth in this segment for the \nremainder of the year, and we're very pleased with the revenue development.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nOkay.  So, let me ask a follow -up on specialty.  This is kind of like the third q uarter both you and your peers are \nhighlighting the strength in specialty is benefiting results.  So, can you just share with us a little bit more color on ", "original_text": "So, let me ask a follow -up on specialty. ", "page_label": "12", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cc6b623a-67fb-4def-b7c6-1646af81356a", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8c55c9938d8d2c43ba4b14bbda249654dae3315ccdb5e7d18bc1ccf45ad67b55", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "14465b3f-6e21-487b-8ba9-c8ed3776d96a", "node_type": "1", "metadata": {"window": "We're very pleased with the performance.  We continue to exp ect to see growth in this segment for the \nremainder of the year, and we're very pleased with the revenue development.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nOkay.  So, let me ask a follow -up on specialty.  This is kind of like the third q uarter both you and your peers are \nhighlighting the strength in specialty is benefiting results.  So, can you just share with us a little bit more color on ", "original_text": "LLC  Q \nOkay. ", "page_label": "12", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5a80a2374ebbda85971f7959693490b8c2551a244b65c7bd29cfe7f0fb02b969", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2258f1df-1c5a-418f-a18e-d6f198195ae3", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nOkay.  So, let me ask a follow -up on specialty.  This is kind of like the third q uarter both you and your peers are \nhighlighting the strength in specialty is benefiting results.  So, can you just share with us a little bit more color on ", "original_text": "This is kind of like the third q uarter both you and your peers are \nhighlighting the strength in specialty is benefiting results. "}, "hash": "9670df14aeb894f2d944dd67b2ac13329acd06bc2c24f8e83188ed699946e476", "class_name": "RelatedNodeInfo"}}, "text": "So, let me ask a follow -up on specialty. ", "start_char_idx": 4188, "end_char_idx": 4230, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2258f1df-1c5a-418f-a18e-d6f198195ae3": {"__data__": {"id_": "2258f1df-1c5a-418f-a18e-d6f198195ae3", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nOkay.  So, let me ask a follow -up on specialty.  This is kind of like the third q uarter both you and your peers are \nhighlighting the strength in specialty is benefiting results.  So, can you just share with us a little bit more color on ", "original_text": "This is kind of like the third q uarter both you and your peers are \nhighlighting the strength in specialty is benefiting results. ", "page_label": "12", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cc6b623a-67fb-4def-b7c6-1646af81356a", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8c55c9938d8d2c43ba4b14bbda249654dae3315ccdb5e7d18bc1ccf45ad67b55", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "43bc3b6f-ac54-4391-ade6-dc6333dc0684", "node_type": "1", "metadata": {"window": "We continue to exp ect to see growth in this segment for the \nremainder of the year, and we're very pleased with the revenue development.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nOkay.  So, let me ask a follow -up on specialty.  This is kind of like the third q uarter both you and your peers are \nhighlighting the strength in specialty is benefiting results.  So, can you just share with us a little bit more color on ", "original_text": "So, let me ask a follow -up on specialty. ", "page_label": "12", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "83645a7dc341aaca9faf80c6b161e541b8632f116c39962b910c2205db8d0ad3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2c0c606b-1bce-4d72-8d10-8c1face69fda", "node_type": "1", "metadata": {"window": "LLC  Q \nOkay.  So, let me ask a follow -up on specialty.  This is kind of like the third q uarter both you and your peers are \nhighlighting the strength in specialty is benefiting results.  So, can you just share with us a little bit more color on ", "original_text": "So, can you just share with us a little bit more color on "}, "hash": "52b8abd36c1d8a7aa434249db9e4b32ef595f5206d802d6ff49b4068b2c270ad", "class_name": "RelatedNodeInfo"}}, "text": "This is kind of like the third q uarter both you and your peers are \nhighlighting the strength in specialty is benefiting results. ", "start_char_idx": 4230, "end_char_idx": 4361, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2c0c606b-1bce-4d72-8d10-8c1face69fda": {"__data__": {"id_": "2c0c606b-1bce-4d72-8d10-8c1face69fda", "embedding": null, "metadata": {"window": "LLC  Q \nOkay.  So, let me ask a follow -up on specialty.  This is kind of like the third q uarter both you and your peers are \nhighlighting the strength in specialty is benefiting results.  So, can you just share with us a little bit more color on ", "original_text": "So, can you just share with us a little bit more color on ", "page_label": "12", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "cc6b623a-67fb-4def-b7c6-1646af81356a", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8c55c9938d8d2c43ba4b14bbda249654dae3315ccdb5e7d18bc1ccf45ad67b55", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2258f1df-1c5a-418f-a18e-d6f198195ae3", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nOkay.  So, let me ask a follow -up on specialty.  This is kind of like the third q uarter both you and your peers are \nhighlighting the strength in specialty is benefiting results.  So, can you just share with us a little bit more color on ", "original_text": "This is kind of like the third q uarter both you and your peers are \nhighlighting the strength in specialty is benefiting results. ", "page_label": "12", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "76c720f789e95c11200cc8e01438e7f05f2a9e282cc323c7a9c16effba0095c2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "18ecde31-c3b8-4a78-aa9d-15909c15cae3", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nspecialty?  And whether you've seen any contractual changes in the last year that would explain the im provement \nin benefit?  Because I'm assuming that it's not coming from branded inflation. ", "original_text": "McKesson Corp.  "}, "hash": "37eea59ccfafb52ecb0d5798e4bb6d8b15c23a93f80061c8b62f297b2c73463f", "class_name": "RelatedNodeInfo"}}, "text": "So, can you just share with us a little bit more color on ", "start_char_idx": 4361, "end_char_idx": 4419, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "18ecde31-c3b8-4a78-aa9d-15909c15cae3": {"__data__": {"id_": "18ecde31-c3b8-4a78-aa9d-15909c15cae3", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nspecialty?  And whether you've seen any contractual changes in the last year that would explain the im provement \nin benefit?  Because I'm assuming that it's not coming from branded inflation. ", "original_text": "McKesson Corp.  ", "page_label": "13", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "96bdaac5-0d0b-446a-a4f2-842ca3d0f989", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d9a01bab1c7e7579e6b2264d464318b2b353793824d62a549e4f1bdfa87de423", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2c0c606b-1bce-4d72-8d10-8c1face69fda", "node_type": "1", "metadata": {"window": "LLC  Q \nOkay.  So, let me ask a follow -up on specialty.  This is kind of like the third q uarter both you and your peers are \nhighlighting the strength in specialty is benefiting results.  So, can you just share with us a little bit more color on ", "original_text": "So, can you just share with us a little bit more color on ", "page_label": "12", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "25dc96c8bba8eb8fdace508e5892faaae04e038a9562e2ff03741f8601986797", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5bcfa5be-f7c6-43f4-9d05-4051af52ef6f", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nspecialty?  And whether you've seen any contractual changes in the last year that would explain the im provement \nin benefit?  Because I'm assuming that it's not coming from branded inflation.  So how should we think about that \nbenefit and how should we think about the sustainability of that benefit? ", "original_text": "(MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nspecialty? "}, "hash": "b9432da6f94d210264920b7c54514f4442a1664e46486e7dae693e50855bf925", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5bcfa5be-f7c6-43f4-9d05-4051af52ef6f": {"__data__": {"id_": "5bcfa5be-f7c6-43f4-9d05-4051af52ef6f", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nspecialty?  And whether you've seen any contractual changes in the last year that would explain the im provement \nin benefit?  Because I'm assuming that it's not coming from branded inflation.  So how should we think about that \nbenefit and how should we think about the sustainability of that benefit? ", "original_text": "(MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nspecialty? ", "page_label": "13", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "96bdaac5-0d0b-446a-a4f2-842ca3d0f989", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d9a01bab1c7e7579e6b2264d464318b2b353793824d62a549e4f1bdfa87de423", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "18ecde31-c3b8-4a78-aa9d-15909c15cae3", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nspecialty?  And whether you've seen any contractual changes in the last year that would explain the im provement \nin benefit?  Because I'm assuming that it's not coming from branded inflation. ", "original_text": "McKesson Corp.  ", "page_label": "13", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5ec6533118228f9d9b1727fe71c8c27c66e56a2a59f26e502f5ab1869b3fc417", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "83c01bd2-cbda-4200-818e-10902be97bac", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nspecialty?  And whether you've seen any contractual changes in the last year that would explain the im provement \nin benefit?  Because I'm assuming that it's not coming from branded inflation.  So how should we think about that \nbenefit and how should we think about the sustainability of that benefit?  And I think that historically you talked \nabout specialty mar gin as being below traditional branded drugs. ", "original_text": "And whether you've seen any contractual changes in the last year that would explain the im provement \nin benefit? "}, "hash": "fe8e835f28c00298d4a2b3a7a002759881be0eadeb079426c05c3705eee1e5f8", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nspecialty? ", "start_char_idx": 16, "end_char_idx": 192, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "83c01bd2-cbda-4200-818e-10902be97bac": {"__data__": {"id_": "83c01bd2-cbda-4200-818e-10902be97bac", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nspecialty?  And whether you've seen any contractual changes in the last year that would explain the im provement \nin benefit?  Because I'm assuming that it's not coming from branded inflation.  So how should we think about that \nbenefit and how should we think about the sustainability of that benefit?  And I think that historically you talked \nabout specialty mar gin as being below traditional branded drugs. ", "original_text": "And whether you've seen any contractual changes in the last year that would explain the im provement \nin benefit? ", "page_label": "13", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "96bdaac5-0d0b-446a-a4f2-842ca3d0f989", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d9a01bab1c7e7579e6b2264d464318b2b353793824d62a549e4f1bdfa87de423", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5bcfa5be-f7c6-43f4-9d05-4051af52ef6f", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nspecialty?  And whether you've seen any contractual changes in the last year that would explain the im provement \nin benefit?  Because I'm assuming that it's not coming from branded inflation.  So how should we think about that \nbenefit and how should we think about the sustainability of that benefit? ", "original_text": "(MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nspecialty? ", "page_label": "13", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9043a5d438b6e67ec0dc3e78c97eeccbd23ec6a17ef4f24ba6ea3c3e6df08aaf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5d6c5ba8-d63f-4946-a20e-0d9f715c11e5", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nspecialty?  And whether you've seen any contractual changes in the last year that would explain the im provement \nin benefit?  Because I'm assuming that it's not coming from branded inflation.  So how should we think about that \nbenefit and how should we think about the sustainability of that benefit?  And I think that historically you talked \nabout specialty mar gin as being below traditional branded drugs.  Is that still the case or should we assume that \nmargins have re -rated higher?  \n ", "original_text": "Because I'm assuming that it's not coming from branded inflation. "}, "hash": "7fd8c4d18192e597a79034fe8e759799a04b5afd9fce75c3ed59b89703fb1c39", "class_name": "RelatedNodeInfo"}}, "text": "And whether you've seen any contractual changes in the last year that would explain the im provement \nin benefit? ", "start_char_idx": 192, "end_char_idx": 306, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5d6c5ba8-d63f-4946-a20e-0d9f715c11e5": {"__data__": {"id_": "5d6c5ba8-d63f-4946-a20e-0d9f715c11e5", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nspecialty?  And whether you've seen any contractual changes in the last year that would explain the im provement \nin benefit?  Because I'm assuming that it's not coming from branded inflation.  So how should we think about that \nbenefit and how should we think about the sustainability of that benefit?  And I think that historically you talked \nabout specialty mar gin as being below traditional branded drugs.  Is that still the case or should we assume that \nmargins have re -rated higher?  \n ", "original_text": "Because I'm assuming that it's not coming from branded inflation. ", "page_label": "13", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "96bdaac5-0d0b-446a-a4f2-842ca3d0f989", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d9a01bab1c7e7579e6b2264d464318b2b353793824d62a549e4f1bdfa87de423", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "83c01bd2-cbda-4200-818e-10902be97bac", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nspecialty?  And whether you've seen any contractual changes in the last year that would explain the im provement \nin benefit?  Because I'm assuming that it's not coming from branded inflation.  So how should we think about that \nbenefit and how should we think about the sustainability of that benefit?  And I think that historically you talked \nabout specialty mar gin as being below traditional branded drugs. ", "original_text": "And whether you've seen any contractual changes in the last year that would explain the im provement \nin benefit? ", "page_label": "13", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b7eaa640d23018b6c31e2214cd68143785a9482558b5568d78004d58300bcc4f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a1323848-6d9f-4657-8f8f-5192366e4d68", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nspecialty?  And whether you've seen any contractual changes in the last year that would explain the im provement \nin benefit?  Because I'm assuming that it's not coming from branded inflation.  So how should we think about that \nbenefit and how should we think about the sustainability of that benefit?  And I think that historically you talked \nabout specialty mar gin as being below traditional branded drugs.  Is that still the case or should we assume that \nmargins have re -rated higher?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "So how should we think about that \nbenefit and how should we think about the sustainability of that benefit? "}, "hash": "f59e62e6227aa1817f69256e061491a811632ec52cd91515a6ad572f10639429", "class_name": "RelatedNodeInfo"}}, "text": "Because I'm assuming that it's not coming from branded inflation. ", "start_char_idx": 306, "end_char_idx": 372, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a1323848-6d9f-4657-8f8f-5192366e4d68": {"__data__": {"id_": "a1323848-6d9f-4657-8f8f-5192366e4d68", "embedding": null, "metadata": {"window": "(MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nspecialty?  And whether you've seen any contractual changes in the last year that would explain the im provement \nin benefit?  Because I'm assuming that it's not coming from branded inflation.  So how should we think about that \nbenefit and how should we think about the sustainability of that benefit?  And I think that historically you talked \nabout specialty mar gin as being below traditional branded drugs.  Is that still the case or should we assume that \nmargins have re -rated higher?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "So how should we think about that \nbenefit and how should we think about the sustainability of that benefit? ", "page_label": "13", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "96bdaac5-0d0b-446a-a4f2-842ca3d0f989", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d9a01bab1c7e7579e6b2264d464318b2b353793824d62a549e4f1bdfa87de423", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5d6c5ba8-d63f-4946-a20e-0d9f715c11e5", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nspecialty?  And whether you've seen any contractual changes in the last year that would explain the im provement \nin benefit?  Because I'm assuming that it's not coming from branded inflation.  So how should we think about that \nbenefit and how should we think about the sustainability of that benefit?  And I think that historically you talked \nabout specialty mar gin as being below traditional branded drugs.  Is that still the case or should we assume that \nmargins have re -rated higher?  \n ", "original_text": "Because I'm assuming that it's not coming from branded inflation. ", "page_label": "13", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f2b3c6f2855930a6c5e2dc4b7702d3280faef42b3b3a94b1191dbb8b3ead0b74", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "507dcfc2-7dbc-430e-9483-5ab5d4b07911", "node_type": "1", "metadata": {"window": "And whether you've seen any contractual changes in the last year that would explain the im provement \nin benefit?  Because I'm assuming that it's not coming from branded inflation.  So how should we think about that \nbenefit and how should we think about the sustainability of that benefit?  And I think that historically you talked \nabout specialty mar gin as being below traditional branded drugs.  Is that still the case or should we assume that \nmargins have re -rated higher?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nI'll take this one, and Britt can jump in if he'd like. ", "original_text": "And I think that historically you talked \nabout specialty mar gin as being below traditional branded drugs. "}, "hash": "29f4cd86b6e257b4e1bb21bbeb1cfddc3f83693c34ffeab1b7f52dbf00432c82", "class_name": "RelatedNodeInfo"}}, "text": "So how should we think about that \nbenefit and how should we think about the sustainability of that benefit? ", "start_char_idx": 372, "end_char_idx": 481, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "507dcfc2-7dbc-430e-9483-5ab5d4b07911": {"__data__": {"id_": "507dcfc2-7dbc-430e-9483-5ab5d4b07911", "embedding": null, "metadata": {"window": "And whether you've seen any contractual changes in the last year that would explain the im provement \nin benefit?  Because I'm assuming that it's not coming from branded inflation.  So how should we think about that \nbenefit and how should we think about the sustainability of that benefit?  And I think that historically you talked \nabout specialty mar gin as being below traditional branded drugs.  Is that still the case or should we assume that \nmargins have re -rated higher?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nI'll take this one, and Britt can jump in if he'd like. ", "original_text": "And I think that historically you talked \nabout specialty mar gin as being below traditional branded drugs. ", "page_label": "13", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "96bdaac5-0d0b-446a-a4f2-842ca3d0f989", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d9a01bab1c7e7579e6b2264d464318b2b353793824d62a549e4f1bdfa87de423", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a1323848-6d9f-4657-8f8f-5192366e4d68", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nspecialty?  And whether you've seen any contractual changes in the last year that would explain the im provement \nin benefit?  Because I'm assuming that it's not coming from branded inflation.  So how should we think about that \nbenefit and how should we think about the sustainability of that benefit?  And I think that historically you talked \nabout specialty mar gin as being below traditional branded drugs.  Is that still the case or should we assume that \nmargins have re -rated higher?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "So how should we think about that \nbenefit and how should we think about the sustainability of that benefit? ", "page_label": "13", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dd0057f3834b1668304e45d471897ea53afa06497dc8120c5f414f16fbc838db", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1f3cd0f3-0507-492e-baae-cfb09b181d7c", "node_type": "1", "metadata": {"window": "Because I'm assuming that it's not coming from branded inflation.  So how should we think about that \nbenefit and how should we think about the sustainability of that benefit?  And I think that historically you talked \nabout specialty mar gin as being below traditional branded drugs.  Is that still the case or should we assume that \nmargins have re -rated higher?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nI'll take this one, and Britt can jump in if he'd like.  So  when you think about the specialty as a segment, obviously \nthe pipeline of innovation continues to be heavily slanted towards these types of products. ", "original_text": "Is that still the case or should we assume that \nmargins have re -rated higher?  \n "}, "hash": "059584077c7cb3c4170f31665bde34556f634c458005121327ff4a90d130acef", "class_name": "RelatedNodeInfo"}}, "text": "And I think that historically you talked \nabout specialty mar gin as being below traditional branded drugs. ", "start_char_idx": 481, "end_char_idx": 589, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1f3cd0f3-0507-492e-baae-cfb09b181d7c": {"__data__": {"id_": "1f3cd0f3-0507-492e-baae-cfb09b181d7c", "embedding": null, "metadata": {"window": "Because I'm assuming that it's not coming from branded inflation.  So how should we think about that \nbenefit and how should we think about the sustainability of that benefit?  And I think that historically you talked \nabout specialty mar gin as being below traditional branded drugs.  Is that still the case or should we assume that \nmargins have re -rated higher?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nI'll take this one, and Britt can jump in if he'd like.  So  when you think about the specialty as a segment, obviously \nthe pipeline of innovation continues to be heavily slanted towards these types of products. ", "original_text": "Is that still the case or should we assume that \nmargins have re -rated higher?  \n ", "page_label": "13", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "96bdaac5-0d0b-446a-a4f2-842ca3d0f989", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d9a01bab1c7e7579e6b2264d464318b2b353793824d62a549e4f1bdfa87de423", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "507dcfc2-7dbc-430e-9483-5ab5d4b07911", "node_type": "1", "metadata": {"window": "And whether you've seen any contractual changes in the last year that would explain the im provement \nin benefit?  Because I'm assuming that it's not coming from branded inflation.  So how should we think about that \nbenefit and how should we think about the sustainability of that benefit?  And I think that historically you talked \nabout specialty mar gin as being below traditional branded drugs.  Is that still the case or should we assume that \nmargins have re -rated higher?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nI'll take this one, and Britt can jump in if he'd like. ", "original_text": "And I think that historically you talked \nabout specialty mar gin as being below traditional branded drugs. ", "page_label": "13", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5ee21b021fb099babef68f3eebffc333a70938cafdcf66f3a339120811db059c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3b0380de-3d34-4099-ba06-8be0dcfdb58a", "node_type": "1", "metadata": {"window": "So how should we think about that \nbenefit and how should we think about the sustainability of that benefit?  And I think that historically you talked \nabout specialty mar gin as being below traditional branded drugs.  Is that still the case or should we assume that \nmargins have re -rated higher?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nI'll take this one, and Britt can jump in if he'd like.  So  when you think about the specialty as a segment, obviously \nthe pipeline of innovation continues to be heavily slanted towards these types of products.  In the old legacy core \nU.S. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  "}, "hash": "fff67a0bf10f10a6374293a6de07073e9c14c2e9708c42490b42bff651fbaf1a", "class_name": "RelatedNodeInfo"}}, "text": "Is that still the case or should we assume that \nmargins have re -rated higher?  \n ", "start_char_idx": 589, "end_char_idx": 672, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3b0380de-3d34-4099-ba06-8be0dcfdb58a": {"__data__": {"id_": "3b0380de-3d34-4099-ba06-8be0dcfdb58a", "embedding": null, "metadata": {"window": "So how should we think about that \nbenefit and how should we think about the sustainability of that benefit?  And I think that historically you talked \nabout specialty mar gin as being below traditional branded drugs.  Is that still the case or should we assume that \nmargins have re -rated higher?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nI'll take this one, and Britt can jump in if he'd like.  So  when you think about the specialty as a segment, obviously \nthe pipeline of innovation continues to be heavily slanted towards these types of products.  In the old legacy core \nU.S. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "13", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "96bdaac5-0d0b-446a-a4f2-842ca3d0f989", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d9a01bab1c7e7579e6b2264d464318b2b353793824d62a549e4f1bdfa87de423", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1f3cd0f3-0507-492e-baae-cfb09b181d7c", "node_type": "1", "metadata": {"window": "Because I'm assuming that it's not coming from branded inflation.  So how should we think about that \nbenefit and how should we think about the sustainability of that benefit?  And I think that historically you talked \nabout specialty mar gin as being below traditional branded drugs.  Is that still the case or should we assume that \nmargins have re -rated higher?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nI'll take this one, and Britt can jump in if he'd like.  So  when you think about the specialty as a segment, obviously \nthe pipeline of innovation continues to be heavily slanted towards these types of products. ", "original_text": "Is that still the case or should we assume that \nmargins have re -rated higher?  \n ", "page_label": "13", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f1706b40af37d70fdcaee0d821a0667a543c302eef47f0b8b8713e264fa8158f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "33abf695-0813-4dae-8c31-fabe77c4f3ba", "node_type": "1", "metadata": {"window": "And I think that historically you talked \nabout specialty mar gin as being below traditional branded drugs.  Is that still the case or should we assume that \nmargins have re -rated higher?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nI'll take this one, and Britt can jump in if he'd like.  So  when you think about the specialty as a segment, obviously \nthe pipeline of innovation continues to be heavily slanted towards these types of products.  In the old legacy core \nU.S.  Pharma business, the margin profiles and structures you'd be accustomed to, I would characterize as still \nbeing in place. ", "original_text": "A \nI'll take this one, and Britt can jump in if he'd like. "}, "hash": "22006264a6108ec1b9281833906bd93c816b81e937bab611a99e1c008b249027", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "start_char_idx": 672, "end_char_idx": 1001, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "33abf695-0813-4dae-8c31-fabe77c4f3ba": {"__data__": {"id_": "33abf695-0813-4dae-8c31-fabe77c4f3ba", "embedding": null, "metadata": {"window": "And I think that historically you talked \nabout specialty mar gin as being below traditional branded drugs.  Is that still the case or should we assume that \nmargins have re -rated higher?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nI'll take this one, and Britt can jump in if he'd like.  So  when you think about the specialty as a segment, obviously \nthe pipeline of innovation continues to be heavily slanted towards these types of products.  In the old legacy core \nU.S.  Pharma business, the margin profiles and structures you'd be accustomed to, I would characterize as still \nbeing in place. ", "original_text": "A \nI'll take this one, and Britt can jump in if he'd like. ", "page_label": "13", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "96bdaac5-0d0b-446a-a4f2-842ca3d0f989", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d9a01bab1c7e7579e6b2264d464318b2b353793824d62a549e4f1bdfa87de423", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3b0380de-3d34-4099-ba06-8be0dcfdb58a", "node_type": "1", "metadata": {"window": "So how should we think about that \nbenefit and how should we think about the sustainability of that benefit?  And I think that historically you talked \nabout specialty mar gin as being below traditional branded drugs.  Is that still the case or should we assume that \nmargins have re -rated higher?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nI'll take this one, and Britt can jump in if he'd like.  So  when you think about the specialty as a segment, obviously \nthe pipeline of innovation continues to be heavily slanted towards these types of products.  In the old legacy core \nU.S. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "13", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6c7f1970e69d99bf49dc8e1b43e5b0d0b23c9ff47bb77f9618a7ec8fcb7fd1ec", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f9b41b16-ef2f-4456-864c-e8cb43b830dc", "node_type": "1", "metadata": {"window": "Is that still the case or should we assume that \nmargins have re -rated higher?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nI'll take this one, and Britt can jump in if he'd like.  So  when you think about the specialty as a segment, obviously \nthe pipeline of innovation continues to be heavily slanted towards these types of products.  In the old legacy core \nU.S.  Pharma business, the margin profiles and structures you'd be accustomed to, I would characterize as still \nbeing in place.  And so while we do benefit from that specialty growth through good volumes and it is beneficial for \nus on the gross profit line, it does continue to be modestly dilutive to the rate.  \n \n", "original_text": "So  when you think about the specialty as a segment, obviously \nthe pipeline of innovation continues to be heavily slanted towards these types of products. "}, "hash": "aa21dc004541091d304398a32afab6456a3713894806a75f83155015dfc3338c", "class_name": "RelatedNodeInfo"}}, "text": "A \nI'll take this one, and Britt can jump in if he'd like. ", "start_char_idx": 1001, "end_char_idx": 1060, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f9b41b16-ef2f-4456-864c-e8cb43b830dc": {"__data__": {"id_": "f9b41b16-ef2f-4456-864c-e8cb43b830dc", "embedding": null, "metadata": {"window": "Is that still the case or should we assume that \nmargins have re -rated higher?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nI'll take this one, and Britt can jump in if he'd like.  So  when you think about the specialty as a segment, obviously \nthe pipeline of innovation continues to be heavily slanted towards these types of products.  In the old legacy core \nU.S.  Pharma business, the margin profiles and structures you'd be accustomed to, I would characterize as still \nbeing in place.  And so while we do benefit from that specialty growth through good volumes and it is beneficial for \nus on the gross profit line, it does continue to be modestly dilutive to the rate.  \n \n", "original_text": "So  when you think about the specialty as a segment, obviously \nthe pipeline of innovation continues to be heavily slanted towards these types of products. ", "page_label": "13", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "96bdaac5-0d0b-446a-a4f2-842ca3d0f989", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d9a01bab1c7e7579e6b2264d464318b2b353793824d62a549e4f1bdfa87de423", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "33abf695-0813-4dae-8c31-fabe77c4f3ba", "node_type": "1", "metadata": {"window": "And I think that historically you talked \nabout specialty mar gin as being below traditional branded drugs.  Is that still the case or should we assume that \nmargins have re -rated higher?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nI'll take this one, and Britt can jump in if he'd like.  So  when you think about the specialty as a segment, obviously \nthe pipeline of innovation continues to be heavily slanted towards these types of products.  In the old legacy core \nU.S.  Pharma business, the margin profiles and structures you'd be accustomed to, I would characterize as still \nbeing in place. ", "original_text": "A \nI'll take this one, and Britt can jump in if he'd like. ", "page_label": "13", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "107144bb33be867d994419d2daa338a338ddb805106557ab4cfa8b027de4d438", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f63dfece-8a2d-482a-9fa9-79d80c5c1d2e", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nI'll take this one, and Britt can jump in if he'd like.  So  when you think about the specialty as a segment, obviously \nthe pipeline of innovation continues to be heavily slanted towards these types of products.  In the old legacy core \nU.S.  Pharma business, the margin profiles and structures you'd be accustomed to, I would characterize as still \nbeing in place.  And so while we do benefit from that specialty growth through good volumes and it is beneficial for \nus on the gross profit line, it does continue to be modestly dilutive to the rate.  \n \n I would remind you though,  we also have a very good business in the community setting related to specialty \nproducts, and that's both our U.S. ", "original_text": "In the old legacy core \nU.S. "}, "hash": "79b27f74891ece21654e90ddff9ebf4a74ee5c848b4293071c0e324760206a00", "class_name": "RelatedNodeInfo"}}, "text": "So  when you think about the specialty as a segment, obviously \nthe pipeline of innovation continues to be heavily slanted towards these types of products. ", "start_char_idx": 1060, "end_char_idx": 1216, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f63dfece-8a2d-482a-9fa9-79d80c5c1d2e": {"__data__": {"id_": "f63dfece-8a2d-482a-9fa9-79d80c5c1d2e", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nI'll take this one, and Britt can jump in if he'd like.  So  when you think about the specialty as a segment, obviously \nthe pipeline of innovation continues to be heavily slanted towards these types of products.  In the old legacy core \nU.S.  Pharma business, the margin profiles and structures you'd be accustomed to, I would characterize as still \nbeing in place.  And so while we do benefit from that specialty growth through good volumes and it is beneficial for \nus on the gross profit line, it does continue to be modestly dilutive to the rate.  \n \n I would remind you though,  we also have a very good business in the community setting related to specialty \nproducts, and that's both our U.S. ", "original_text": "In the old legacy core \nU.S. ", "page_label": "13", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "96bdaac5-0d0b-446a-a4f2-842ca3d0f989", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d9a01bab1c7e7579e6b2264d464318b2b353793824d62a549e4f1bdfa87de423", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f9b41b16-ef2f-4456-864c-e8cb43b830dc", "node_type": "1", "metadata": {"window": "Is that still the case or should we assume that \nmargins have re -rated higher?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nI'll take this one, and Britt can jump in if he'd like.  So  when you think about the specialty as a segment, obviously \nthe pipeline of innovation continues to be heavily slanted towards these types of products.  In the old legacy core \nU.S.  Pharma business, the margin profiles and structures you'd be accustomed to, I would characterize as still \nbeing in place.  And so while we do benefit from that specialty growth through good volumes and it is beneficial for \nus on the gross profit line, it does continue to be modestly dilutive to the rate.  \n \n", "original_text": "So  when you think about the specialty as a segment, obviously \nthe pipeline of innovation continues to be heavily slanted towards these types of products. ", "page_label": "13", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fc0591561cf51a2b2ce6ecbffde4862a86f61678e0e03f05966dd24699e228fe", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "70753d3c-6df6-4ba9-8796-a2a8e0e3afd3", "node_type": "1", "metadata": {"window": "A \nI'll take this one, and Britt can jump in if he'd like.  So  when you think about the specialty as a segment, obviously \nthe pipeline of innovation continues to be heavily slanted towards these types of products.  In the old legacy core \nU.S.  Pharma business, the margin profiles and structures you'd be accustomed to, I would characterize as still \nbeing in place.  And so while we do benefit from that specialty growth through good volumes and it is beneficial for \nus on the gross profit line, it does continue to be modestly dilutive to the rate.  \n \n I would remind you though,  we also have a very good business in the community setting related to specialty \nproducts, and that's both our U.S.  oncology network and our unaffiliated community provider business. ", "original_text": "Pharma business, the margin profiles and structures you'd be accustomed to, I would characterize as still \nbeing in place. "}, "hash": "925ebd5dd2bd775fdd1578608a37e4f0efce1c412937355bccee385949a1c40d", "class_name": "RelatedNodeInfo"}}, "text": "In the old legacy core \nU.S. ", "start_char_idx": 1216, "end_char_idx": 1245, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "70753d3c-6df6-4ba9-8796-a2a8e0e3afd3": {"__data__": {"id_": "70753d3c-6df6-4ba9-8796-a2a8e0e3afd3", "embedding": null, "metadata": {"window": "A \nI'll take this one, and Britt can jump in if he'd like.  So  when you think about the specialty as a segment, obviously \nthe pipeline of innovation continues to be heavily slanted towards these types of products.  In the old legacy core \nU.S.  Pharma business, the margin profiles and structures you'd be accustomed to, I would characterize as still \nbeing in place.  And so while we do benefit from that specialty growth through good volumes and it is beneficial for \nus on the gross profit line, it does continue to be modestly dilutive to the rate.  \n \n I would remind you though,  we also have a very good business in the community setting related to specialty \nproducts, and that's both our U.S.  oncology network and our unaffiliated community provider business. ", "original_text": "Pharma business, the margin profiles and structures you'd be accustomed to, I would characterize as still \nbeing in place. ", "page_label": "13", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "96bdaac5-0d0b-446a-a4f2-842ca3d0f989", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d9a01bab1c7e7579e6b2264d464318b2b353793824d62a549e4f1bdfa87de423", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f63dfece-8a2d-482a-9fa9-79d80c5c1d2e", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nI'll take this one, and Britt can jump in if he'd like.  So  when you think about the specialty as a segment, obviously \nthe pipeline of innovation continues to be heavily slanted towards these types of products.  In the old legacy core \nU.S.  Pharma business, the margin profiles and structures you'd be accustomed to, I would characterize as still \nbeing in place.  And so while we do benefit from that specialty growth through good volumes and it is beneficial for \nus on the gross profit line, it does continue to be modestly dilutive to the rate.  \n \n I would remind you though,  we also have a very good business in the community setting related to specialty \nproducts, and that's both our U.S. ", "original_text": "In the old legacy core \nU.S. ", "page_label": "13", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a2057ba7d3626874a3ee633cc68c0eeec976be6524d7e3fc6115eb498dd849c7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f721e429-722c-49bf-95c2-1f68faf90c3e", "node_type": "1", "metadata": {"window": "So  when you think about the specialty as a segment, obviously \nthe pipeline of innovation continues to be heavily slanted towards these types of products.  In the old legacy core \nU.S.  Pharma business, the margin profiles and structures you'd be accustomed to, I would characterize as still \nbeing in place.  And so while we do benefit from that specialty growth through good volumes and it is beneficial for \nus on the gross profit line, it does continue to be modestly dilutive to the rate.  \n \n I would remind you though,  we also have a very good business in the community setting related to specialty \nproducts, and that's both our U.S.  oncology network and our unaffiliated community provider business.  And those \nare the businesses where we continue to see really good momentu m, really good growth and benefit from the \npipeline of both innovative products and frankly biosimilars, as they emerge and come to market.  \n \n", "original_text": "And so while we do benefit from that specialty growth through good volumes and it is beneficial for \nus on the gross profit line, it does continue to be modestly dilutive to the rate.  \n \n"}, "hash": "69b888ac78d4c3837cb9f31d03658b43bdf7dbe13efac04b40cd4757cd8a233d", "class_name": "RelatedNodeInfo"}}, "text": "Pharma business, the margin profiles and structures you'd be accustomed to, I would characterize as still \nbeing in place. ", "start_char_idx": 1245, "end_char_idx": 1368, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f721e429-722c-49bf-95c2-1f68faf90c3e": {"__data__": {"id_": "f721e429-722c-49bf-95c2-1f68faf90c3e", "embedding": null, "metadata": {"window": "So  when you think about the specialty as a segment, obviously \nthe pipeline of innovation continues to be heavily slanted towards these types of products.  In the old legacy core \nU.S.  Pharma business, the margin profiles and structures you'd be accustomed to, I would characterize as still \nbeing in place.  And so while we do benefit from that specialty growth through good volumes and it is beneficial for \nus on the gross profit line, it does continue to be modestly dilutive to the rate.  \n \n I would remind you though,  we also have a very good business in the community setting related to specialty \nproducts, and that's both our U.S.  oncology network and our unaffiliated community provider business.  And those \nare the businesses where we continue to see really good momentu m, really good growth and benefit from the \npipeline of both innovative products and frankly biosimilars, as they emerge and come to market.  \n \n", "original_text": "And so while we do benefit from that specialty growth through good volumes and it is beneficial for \nus on the gross profit line, it does continue to be modestly dilutive to the rate.  \n \n", "page_label": "13", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "96bdaac5-0d0b-446a-a4f2-842ca3d0f989", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d9a01bab1c7e7579e6b2264d464318b2b353793824d62a549e4f1bdfa87de423", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "70753d3c-6df6-4ba9-8796-a2a8e0e3afd3", "node_type": "1", "metadata": {"window": "A \nI'll take this one, and Britt can jump in if he'd like.  So  when you think about the specialty as a segment, obviously \nthe pipeline of innovation continues to be heavily slanted towards these types of products.  In the old legacy core \nU.S.  Pharma business, the margin profiles and structures you'd be accustomed to, I would characterize as still \nbeing in place.  And so while we do benefit from that specialty growth through good volumes and it is beneficial for \nus on the gross profit line, it does continue to be modestly dilutive to the rate.  \n \n I would remind you though,  we also have a very good business in the community setting related to specialty \nproducts, and that's both our U.S.  oncology network and our unaffiliated community provider business. ", "original_text": "Pharma business, the margin profiles and structures you'd be accustomed to, I would characterize as still \nbeing in place. ", "page_label": "13", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6da70480a50f25da971a7f5a2254392b5bd0fdcd530a48a810b2d62c8bd6f4fd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b9fe3ac8-33c3-42e1-a589-ff5eb52e0caa", "node_type": "1", "metadata": {"window": "In the old legacy core \nU.S.  Pharma business, the margin profiles and structures you'd be accustomed to, I would characterize as still \nbeing in place.  And so while we do benefit from that specialty growth through good volumes and it is beneficial for \nus on the gross profit line, it does continue to be modestly dilutive to the rate.  \n \n I would remind you though,  we also have a very good business in the community setting related to specialty \nproducts, and that's both our U.S.  oncology network and our unaffiliated community provider business.  And those \nare the businesses where we continue to see really good momentu m, really good growth and benefit from the \npipeline of both innovative products and frankly biosimilars, as they emerge and come to market.  \n \n And we have a very robust value proposition, obviously a complete value proposition in the case of U.S. ", "original_text": "I would remind you though,  we also have a very good business in the community setting related to specialty \nproducts, and that's both our U.S. "}, "hash": "8a22ac5131d5a9d3672e903555407d6952a2d091dba92e9c2483c9cf1fbbe6c2", "class_name": "RelatedNodeInfo"}}, "text": "And so while we do benefit from that specialty growth through good volumes and it is beneficial for \nus on the gross profit line, it does continue to be modestly dilutive to the rate.  \n \n", "start_char_idx": 1368, "end_char_idx": 1556, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b9fe3ac8-33c3-42e1-a589-ff5eb52e0caa": {"__data__": {"id_": "b9fe3ac8-33c3-42e1-a589-ff5eb52e0caa", "embedding": null, "metadata": {"window": "In the old legacy core \nU.S.  Pharma business, the margin profiles and structures you'd be accustomed to, I would characterize as still \nbeing in place.  And so while we do benefit from that specialty growth through good volumes and it is beneficial for \nus on the gross profit line, it does continue to be modestly dilutive to the rate.  \n \n I would remind you though,  we also have a very good business in the community setting related to specialty \nproducts, and that's both our U.S.  oncology network and our unaffiliated community provider business.  And those \nare the businesses where we continue to see really good momentu m, really good growth and benefit from the \npipeline of both innovative products and frankly biosimilars, as they emerge and come to market.  \n \n And we have a very robust value proposition, obviously a complete value proposition in the case of U.S. ", "original_text": "I would remind you though,  we also have a very good business in the community setting related to specialty \nproducts, and that's both our U.S. ", "page_label": "13", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "96bdaac5-0d0b-446a-a4f2-842ca3d0f989", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d9a01bab1c7e7579e6b2264d464318b2b353793824d62a549e4f1bdfa87de423", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f721e429-722c-49bf-95c2-1f68faf90c3e", "node_type": "1", "metadata": {"window": "So  when you think about the specialty as a segment, obviously \nthe pipeline of innovation continues to be heavily slanted towards these types of products.  In the old legacy core \nU.S.  Pharma business, the margin profiles and structures you'd be accustomed to, I would characterize as still \nbeing in place.  And so while we do benefit from that specialty growth through good volumes and it is beneficial for \nus on the gross profit line, it does continue to be modestly dilutive to the rate.  \n \n I would remind you though,  we also have a very good business in the community setting related to specialty \nproducts, and that's both our U.S.  oncology network and our unaffiliated community provider business.  And those \nare the businesses where we continue to see really good momentu m, really good growth and benefit from the \npipeline of both innovative products and frankly biosimilars, as they emerge and come to market.  \n \n", "original_text": "And so while we do benefit from that specialty growth through good volumes and it is beneficial for \nus on the gross profit line, it does continue to be modestly dilutive to the rate.  \n \n", "page_label": "13", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d63a7fdbc6e9a1495815381862816139c0f166f5c1c38cc5767965f793db3f37", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f714b9d4-6f2f-4c07-8c42-bc8ab12dd00a", "node_type": "1", "metadata": {"window": "Pharma business, the margin profiles and structures you'd be accustomed to, I would characterize as still \nbeing in place.  And so while we do benefit from that specialty growth through good volumes and it is beneficial for \nus on the gross profit line, it does continue to be modestly dilutive to the rate.  \n \n I would remind you though,  we also have a very good business in the community setting related to specialty \nproducts, and that's both our U.S.  oncology network and our unaffiliated community provider business.  And those \nare the businesses where we continue to see really good momentu m, really good growth and benefit from the \npipeline of both innovative products and frankly biosimilars, as they emerge and come to market.  \n \n And we have a very robust value proposition, obviously a complete value proposition in the case of U.S.  oncology \nand then a wide assortment of tools and services we offer to the unaffiliated community providers. ", "original_text": "oncology network and our unaffiliated community provider business. "}, "hash": "927fb512b77743d51742bfccd0ba5207f67aa7f651fc236e78b5d1c2fa24f20c", "class_name": "RelatedNodeInfo"}}, "text": "I would remind you though,  we also have a very good business in the community setting related to specialty \nproducts, and that's both our U.S. ", "start_char_idx": 1556, "end_char_idx": 1700, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f714b9d4-6f2f-4c07-8c42-bc8ab12dd00a": {"__data__": {"id_": "f714b9d4-6f2f-4c07-8c42-bc8ab12dd00a", "embedding": null, "metadata": {"window": "Pharma business, the margin profiles and structures you'd be accustomed to, I would characterize as still \nbeing in place.  And so while we do benefit from that specialty growth through good volumes and it is beneficial for \nus on the gross profit line, it does continue to be modestly dilutive to the rate.  \n \n I would remind you though,  we also have a very good business in the community setting related to specialty \nproducts, and that's both our U.S.  oncology network and our unaffiliated community provider business.  And those \nare the businesses where we continue to see really good momentu m, really good growth and benefit from the \npipeline of both innovative products and frankly biosimilars, as they emerge and come to market.  \n \n And we have a very robust value proposition, obviously a complete value proposition in the case of U.S.  oncology \nand then a wide assortment of tools and services we offer to the unaffiliated community providers. ", "original_text": "oncology network and our unaffiliated community provider business. ", "page_label": "13", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "96bdaac5-0d0b-446a-a4f2-842ca3d0f989", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d9a01bab1c7e7579e6b2264d464318b2b353793824d62a549e4f1bdfa87de423", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b9fe3ac8-33c3-42e1-a589-ff5eb52e0caa", "node_type": "1", "metadata": {"window": "In the old legacy core \nU.S.  Pharma business, the margin profiles and structures you'd be accustomed to, I would characterize as still \nbeing in place.  And so while we do benefit from that specialty growth through good volumes and it is beneficial for \nus on the gross profit line, it does continue to be modestly dilutive to the rate.  \n \n I would remind you though,  we also have a very good business in the community setting related to specialty \nproducts, and that's both our U.S.  oncology network and our unaffiliated community provider business.  And those \nare the businesses where we continue to see really good momentu m, really good growth and benefit from the \npipeline of both innovative products and frankly biosimilars, as they emerge and come to market.  \n \n And we have a very robust value proposition, obviously a complete value proposition in the case of U.S. ", "original_text": "I would remind you though,  we also have a very good business in the community setting related to specialty \nproducts, and that's both our U.S. ", "page_label": "13", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7a67d33908ec55077615d8bd1e211c015ef9d1da8fe7b261f26810ea7e1e95d6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "35fec73d-3d58-4728-afe1-a2eac57c6a89", "node_type": "1", "metadata": {"window": "And so while we do benefit from that specialty growth through good volumes and it is beneficial for \nus on the gross profit line, it does continue to be modestly dilutive to the rate.  \n \n I would remind you though,  we also have a very good business in the community setting related to specialty \nproducts, and that's both our U.S.  oncology network and our unaffiliated community provider business.  And those \nare the businesses where we continue to see really good momentu m, really good growth and benefit from the \npipeline of both innovative products and frankly biosimilars, as they emerge and come to market.  \n \n And we have a very robust value proposition, obviously a complete value proposition in the case of U.S.  oncology \nand then a wide assortment of tools and services we offer to the unaffiliated community providers.  And we think \nthat that value proposition continues to earn us the right and the ability to grow and to benefit from the specialty \npharmaceutical pipeline in ge neral.  \n ", "original_text": "And those \nare the businesses where we continue to see really good momentu m, really good growth and benefit from the \npipeline of both innovative products and frankly biosimilars, as they emerge and come to market.  \n \n"}, "hash": "f18796a1e8a32cbbae3c9ab8298e48bbb7c840aba720ce37488e50d352ffdb5e", "class_name": "RelatedNodeInfo"}}, "text": "oncology network and our unaffiliated community provider business. ", "start_char_idx": 1700, "end_char_idx": 1767, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "35fec73d-3d58-4728-afe1-a2eac57c6a89": {"__data__": {"id_": "35fec73d-3d58-4728-afe1-a2eac57c6a89", "embedding": null, "metadata": {"window": "And so while we do benefit from that specialty growth through good volumes and it is beneficial for \nus on the gross profit line, it does continue to be modestly dilutive to the rate.  \n \n I would remind you though,  we also have a very good business in the community setting related to specialty \nproducts, and that's both our U.S.  oncology network and our unaffiliated community provider business.  And those \nare the businesses where we continue to see really good momentu m, really good growth and benefit from the \npipeline of both innovative products and frankly biosimilars, as they emerge and come to market.  \n \n And we have a very robust value proposition, obviously a complete value proposition in the case of U.S.  oncology \nand then a wide assortment of tools and services we offer to the unaffiliated community providers.  And we think \nthat that value proposition continues to earn us the right and the ability to grow and to benefit from the specialty \npharmaceutical pipeline in ge neral.  \n ", "original_text": "And those \nare the businesses where we continue to see really good momentu m, really good growth and benefit from the \npipeline of both innovative products and frankly biosimilars, as they emerge and come to market.  \n \n", "page_label": "13", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "96bdaac5-0d0b-446a-a4f2-842ca3d0f989", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d9a01bab1c7e7579e6b2264d464318b2b353793824d62a549e4f1bdfa87de423", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f714b9d4-6f2f-4c07-8c42-bc8ab12dd00a", "node_type": "1", "metadata": {"window": "Pharma business, the margin profiles and structures you'd be accustomed to, I would characterize as still \nbeing in place.  And so while we do benefit from that specialty growth through good volumes and it is beneficial for \nus on the gross profit line, it does continue to be modestly dilutive to the rate.  \n \n I would remind you though,  we also have a very good business in the community setting related to specialty \nproducts, and that's both our U.S.  oncology network and our unaffiliated community provider business.  And those \nare the businesses where we continue to see really good momentu m, really good growth and benefit from the \npipeline of both innovative products and frankly biosimilars, as they emerge and come to market.  \n \n And we have a very robust value proposition, obviously a complete value proposition in the case of U.S.  oncology \nand then a wide assortment of tools and services we offer to the unaffiliated community providers. ", "original_text": "oncology network and our unaffiliated community provider business. ", "page_label": "13", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3eb666e07129744ecef2491957a3c4fefb49d9aa79211e53a5f61fe74a5db6ad", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "07007969-a1a8-4d2f-8f3b-6e709fa1bff7", "node_type": "1", "metadata": {"window": "I would remind you though,  we also have a very good business in the community setting related to specialty \nproducts, and that's both our U.S.  oncology network and our unaffiliated community provider business.  And those \nare the businesses where we continue to see really good momentu m, really good growth and benefit from the \npipeline of both innovative products and frankly biosimilars, as they emerge and come to market.  \n \n And we have a very robust value proposition, obviously a complete value proposition in the case of U.S.  oncology \nand then a wide assortment of tools and services we offer to the unaffiliated community providers.  And we think \nthat that value proposition continues to earn us the right and the ability to grow and to benefit from the specialty \npharmaceutical pipeline in ge neral.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Ross Muken with Evercore ISI.  \n ", "original_text": "And we have a very robust value proposition, obviously a complete value proposition in the case of U.S. "}, "hash": "2869a1cd0acf17983660b031c2ce8e9678009f1696b1c2b189be359feabd91cf", "class_name": "RelatedNodeInfo"}}, "text": "And those \nare the businesses where we continue to see really good momentu m, really good growth and benefit from the \npipeline of both innovative products and frankly biosimilars, as they emerge and come to market.  \n \n", "start_char_idx": 1767, "end_char_idx": 1987, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "07007969-a1a8-4d2f-8f3b-6e709fa1bff7": {"__data__": {"id_": "07007969-a1a8-4d2f-8f3b-6e709fa1bff7", "embedding": null, "metadata": {"window": "I would remind you though,  we also have a very good business in the community setting related to specialty \nproducts, and that's both our U.S.  oncology network and our unaffiliated community provider business.  And those \nare the businesses where we continue to see really good momentu m, really good growth and benefit from the \npipeline of both innovative products and frankly biosimilars, as they emerge and come to market.  \n \n And we have a very robust value proposition, obviously a complete value proposition in the case of U.S.  oncology \nand then a wide assortment of tools and services we offer to the unaffiliated community providers.  And we think \nthat that value proposition continues to earn us the right and the ability to grow and to benefit from the specialty \npharmaceutical pipeline in ge neral.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Ross Muken with Evercore ISI.  \n ", "original_text": "And we have a very robust value proposition, obviously a complete value proposition in the case of U.S. ", "page_label": "13", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "96bdaac5-0d0b-446a-a4f2-842ca3d0f989", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d9a01bab1c7e7579e6b2264d464318b2b353793824d62a549e4f1bdfa87de423", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "35fec73d-3d58-4728-afe1-a2eac57c6a89", "node_type": "1", "metadata": {"window": "And so while we do benefit from that specialty growth through good volumes and it is beneficial for \nus on the gross profit line, it does continue to be modestly dilutive to the rate.  \n \n I would remind you though,  we also have a very good business in the community setting related to specialty \nproducts, and that's both our U.S.  oncology network and our unaffiliated community provider business.  And those \nare the businesses where we continue to see really good momentu m, really good growth and benefit from the \npipeline of both innovative products and frankly biosimilars, as they emerge and come to market.  \n \n And we have a very robust value proposition, obviously a complete value proposition in the case of U.S.  oncology \nand then a wide assortment of tools and services we offer to the unaffiliated community providers.  And we think \nthat that value proposition continues to earn us the right and the ability to grow and to benefit from the specialty \npharmaceutical pipeline in ge neral.  \n ", "original_text": "And those \nare the businesses where we continue to see really good momentu m, really good growth and benefit from the \npipeline of both innovative products and frankly biosimilars, as they emerge and come to market.  \n \n", "page_label": "13", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "29ffff333c41fe1ce06c93b7bf9960219b914fc1fc26e6b2c07c0e242f8ddbb1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "78d77ab0-f494-4241-b4d0-8b05b5d2a54c", "node_type": "1", "metadata": {"window": "oncology network and our unaffiliated community provider business.  And those \nare the businesses where we continue to see really good momentu m, really good growth and benefit from the \npipeline of both innovative products and frankly biosimilars, as they emerge and come to market.  \n \n And we have a very robust value proposition, obviously a complete value proposition in the case of U.S.  oncology \nand then a wide assortment of tools and services we offer to the unaffiliated community providers.  And we think \nthat that value proposition continues to earn us the right and the ability to grow and to benefit from the specialty \npharmaceutical pipeline in ge neral.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Ross Muken with Evercore ISI.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRoss Muken  \nAnalyst, Evercore ISI  Q \nGood afternoon, guys. ", "original_text": "oncology \nand then a wide assortment of tools and services we offer to the unaffiliated community providers. "}, "hash": "c2ba0f4177377b87619ca73d7b2ef7f4163dab908b468655a27ccfc78ccdbe45", "class_name": "RelatedNodeInfo"}}, "text": "And we have a very robust value proposition, obviously a complete value proposition in the case of U.S. ", "start_char_idx": 1987, "end_char_idx": 2091, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "78d77ab0-f494-4241-b4d0-8b05b5d2a54c": {"__data__": {"id_": "78d77ab0-f494-4241-b4d0-8b05b5d2a54c", "embedding": null, "metadata": {"window": "oncology network and our unaffiliated community provider business.  And those \nare the businesses where we continue to see really good momentu m, really good growth and benefit from the \npipeline of both innovative products and frankly biosimilars, as they emerge and come to market.  \n \n And we have a very robust value proposition, obviously a complete value proposition in the case of U.S.  oncology \nand then a wide assortment of tools and services we offer to the unaffiliated community providers.  And we think \nthat that value proposition continues to earn us the right and the ability to grow and to benefit from the specialty \npharmaceutical pipeline in ge neral.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Ross Muken with Evercore ISI.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRoss Muken  \nAnalyst, Evercore ISI  Q \nGood afternoon, guys. ", "original_text": "oncology \nand then a wide assortment of tools and services we offer to the unaffiliated community providers. ", "page_label": "13", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "96bdaac5-0d0b-446a-a4f2-842ca3d0f989", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d9a01bab1c7e7579e6b2264d464318b2b353793824d62a549e4f1bdfa87de423", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "07007969-a1a8-4d2f-8f3b-6e709fa1bff7", "node_type": "1", "metadata": {"window": "I would remind you though,  we also have a very good business in the community setting related to specialty \nproducts, and that's both our U.S.  oncology network and our unaffiliated community provider business.  And those \nare the businesses where we continue to see really good momentu m, really good growth and benefit from the \npipeline of both innovative products and frankly biosimilars, as they emerge and come to market.  \n \n And we have a very robust value proposition, obviously a complete value proposition in the case of U.S.  oncology \nand then a wide assortment of tools and services we offer to the unaffiliated community providers.  And we think \nthat that value proposition continues to earn us the right and the ability to grow and to benefit from the specialty \npharmaceutical pipeline in ge neral.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Ross Muken with Evercore ISI.  \n ", "original_text": "And we have a very robust value proposition, obviously a complete value proposition in the case of U.S. ", "page_label": "13", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "58149d12cf1337f27a0f107766593235195eb95618de5b001273ad3e9550582e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "57ef4d73-c892-44cc-acd1-3b89523d787f", "node_type": "1", "metadata": {"window": "And those \nare the businesses where we continue to see really good momentu m, really good growth and benefit from the \npipeline of both innovative products and frankly biosimilars, as they emerge and come to market.  \n \n And we have a very robust value proposition, obviously a complete value proposition in the case of U.S.  oncology \nand then a wide assortment of tools and services we offer to the unaffiliated community providers.  And we think \nthat that value proposition continues to earn us the right and the ability to grow and to benefit from the specialty \npharmaceutical pipeline in ge neral.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Ross Muken with Evercore ISI.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRoss Muken  \nAnalyst, Evercore ISI  Q \nGood afternoon, guys.  So I just wanted to go back to kind of the Change in Other math again, because I don't \nthink I have it straight. ", "original_text": "And we think \nthat that value proposition continues to earn us the right and the ability to grow and to benefit from the specialty \npharmaceutical pipeline in ge neral.  \n "}, "hash": "40f098b7e35159323860ecfe30710baf9fd5084576be9bd0e8bd848e3e81eaae", "class_name": "RelatedNodeInfo"}}, "text": "oncology \nand then a wide assortment of tools and services we offer to the unaffiliated community providers. ", "start_char_idx": 2091, "end_char_idx": 2200, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "57ef4d73-c892-44cc-acd1-3b89523d787f": {"__data__": {"id_": "57ef4d73-c892-44cc-acd1-3b89523d787f", "embedding": null, "metadata": {"window": "And those \nare the businesses where we continue to see really good momentu m, really good growth and benefit from the \npipeline of both innovative products and frankly biosimilars, as they emerge and come to market.  \n \n And we have a very robust value proposition, obviously a complete value proposition in the case of U.S.  oncology \nand then a wide assortment of tools and services we offer to the unaffiliated community providers.  And we think \nthat that value proposition continues to earn us the right and the ability to grow and to benefit from the specialty \npharmaceutical pipeline in ge neral.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Ross Muken with Evercore ISI.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRoss Muken  \nAnalyst, Evercore ISI  Q \nGood afternoon, guys.  So I just wanted to go back to kind of the Change in Other math again, because I don't \nthink I have it straight. ", "original_text": "And we think \nthat that value proposition continues to earn us the right and the ability to grow and to benefit from the specialty \npharmaceutical pipeline in ge neral.  \n ", "page_label": "13", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "96bdaac5-0d0b-446a-a4f2-842ca3d0f989", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d9a01bab1c7e7579e6b2264d464318b2b353793824d62a549e4f1bdfa87de423", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "78d77ab0-f494-4241-b4d0-8b05b5d2a54c", "node_type": "1", "metadata": {"window": "oncology network and our unaffiliated community provider business.  And those \nare the businesses where we continue to see really good momentu m, really good growth and benefit from the \npipeline of both innovative products and frankly biosimilars, as they emerge and come to market.  \n \n And we have a very robust value proposition, obviously a complete value proposition in the case of U.S.  oncology \nand then a wide assortment of tools and services we offer to the unaffiliated community providers.  And we think \nthat that value proposition continues to earn us the right and the ability to grow and to benefit from the specialty \npharmaceutical pipeline in ge neral.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Ross Muken with Evercore ISI.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRoss Muken  \nAnalyst, Evercore ISI  Q \nGood afternoon, guys. ", "original_text": "oncology \nand then a wide assortment of tools and services we offer to the unaffiliated community providers. ", "page_label": "13", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "adc92baa6fe476807a172c49d5f1845784b86996ba4ee4d9349e905ff9cac1dc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b24f9f8b-ebe5-4774-ad11-b4e47587c52e", "node_type": "1", "metadata": {"window": "And we have a very robust value proposition, obviously a complete value proposition in the case of U.S.  oncology \nand then a wide assortment of tools and services we offer to the unaffiliated community providers.  And we think \nthat that value proposition continues to earn us the right and the ability to grow and to benefit from the specialty \npharmaceutical pipeline in ge neral.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Ross Muken with Evercore ISI.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRoss Muken  \nAnalyst, Evercore ISI  Q \nGood afternoon, guys.  So I just wanted to go back to kind of the Change in Other math again, because I don't \nthink I have it straight.  So in terms of the $108 million versus the prior year and then \u2013 and that's for Change, and \nthen sort of the full year guide, I'm not sure I understand sort of what caused the up -step in cadence and then sort \nof the notable down -step. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Ross Muken with Evercore ISI.  \n "}, "hash": "cd2f4e75ff7ebba2c3c64b8091af60572fe8fbb5691b5b86577e8e46e475de18", "class_name": "RelatedNodeInfo"}}, "text": "And we think \nthat that value proposition continues to earn us the right and the ability to grow and to benefit from the specialty \npharmaceutical pipeline in ge neral.  \n ", "start_char_idx": 2200, "end_char_idx": 2372, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b24f9f8b-ebe5-4774-ad11-b4e47587c52e": {"__data__": {"id_": "b24f9f8b-ebe5-4774-ad11-b4e47587c52e", "embedding": null, "metadata": {"window": "And we have a very robust value proposition, obviously a complete value proposition in the case of U.S.  oncology \nand then a wide assortment of tools and services we offer to the unaffiliated community providers.  And we think \nthat that value proposition continues to earn us the right and the ability to grow and to benefit from the specialty \npharmaceutical pipeline in ge neral.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Ross Muken with Evercore ISI.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRoss Muken  \nAnalyst, Evercore ISI  Q \nGood afternoon, guys.  So I just wanted to go back to kind of the Change in Other math again, because I don't \nthink I have it straight.  So in terms of the $108 million versus the prior year and then \u2013 and that's for Change, and \nthen sort of the full year guide, I'm not sure I understand sort of what caused the up -step in cadence and then sort \nof the notable down -step. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Ross Muken with Evercore ISI.  \n ", "page_label": "13", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "96bdaac5-0d0b-446a-a4f2-842ca3d0f989", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d9a01bab1c7e7579e6b2264d464318b2b353793824d62a549e4f1bdfa87de423", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "57ef4d73-c892-44cc-acd1-3b89523d787f", "node_type": "1", "metadata": {"window": "And those \nare the businesses where we continue to see really good momentu m, really good growth and benefit from the \npipeline of both innovative products and frankly biosimilars, as they emerge and come to market.  \n \n And we have a very robust value proposition, obviously a complete value proposition in the case of U.S.  oncology \nand then a wide assortment of tools and services we offer to the unaffiliated community providers.  And we think \nthat that value proposition continues to earn us the right and the ability to grow and to benefit from the specialty \npharmaceutical pipeline in ge neral.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Ross Muken with Evercore ISI.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRoss Muken  \nAnalyst, Evercore ISI  Q \nGood afternoon, guys.  So I just wanted to go back to kind of the Change in Other math again, because I don't \nthink I have it straight. ", "original_text": "And we think \nthat that value proposition continues to earn us the right and the ability to grow and to benefit from the specialty \npharmaceutical pipeline in ge neral.  \n ", "page_label": "13", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "177c75c6b5003847f5c51a279b3ecd180cbab2126d49cff508345dd322d2799e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3aae5a47-f51f-404e-9e82-7afb6d4d2010", "node_type": "1", "metadata": {"window": "oncology \nand then a wide assortment of tools and services we offer to the unaffiliated community providers.  And we think \nthat that value proposition continues to earn us the right and the ability to grow and to benefit from the specialty \npharmaceutical pipeline in ge neral.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Ross Muken with Evercore ISI.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRoss Muken  \nAnalyst, Evercore ISI  Q \nGood afternoon, guys.  So I just wanted to go back to kind of the Change in Other math again, because I don't \nthink I have it straight.  So in terms of the $108 million versus the prior year and then \u2013 and that's for Change, and \nthen sort of the full year guide, I'm not sure I understand sort of what caused the up -step in cadence and then sort \nof the notable down -step.  I know the ownership percentage is c hanging, but it still seemed like a big delta. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRoss Muken  \nAnalyst, Evercore ISI  Q \nGood afternoon, guys. "}, "hash": "1ed4e3ecec659991b50dbdb9d1f6e5798867ebe6d56c880220febb44529925e7", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Ross Muken with Evercore ISI.  \n ", "start_char_idx": 2372, "end_char_idx": 2692, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3aae5a47-f51f-404e-9e82-7afb6d4d2010": {"__data__": {"id_": "3aae5a47-f51f-404e-9e82-7afb6d4d2010", "embedding": null, "metadata": {"window": "oncology \nand then a wide assortment of tools and services we offer to the unaffiliated community providers.  And we think \nthat that value proposition continues to earn us the right and the ability to grow and to benefit from the specialty \npharmaceutical pipeline in ge neral.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Ross Muken with Evercore ISI.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRoss Muken  \nAnalyst, Evercore ISI  Q \nGood afternoon, guys.  So I just wanted to go back to kind of the Change in Other math again, because I don't \nthink I have it straight.  So in terms of the $108 million versus the prior year and then \u2013 and that's for Change, and \nthen sort of the full year guide, I'm not sure I understand sort of what caused the up -step in cadence and then sort \nof the notable down -step.  I know the ownership percentage is c hanging, but it still seemed like a big delta. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRoss Muken  \nAnalyst, Evercore ISI  Q \nGood afternoon, guys. ", "page_label": "13", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "96bdaac5-0d0b-446a-a4f2-842ca3d0f989", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d9a01bab1c7e7579e6b2264d464318b2b353793824d62a549e4f1bdfa87de423", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b24f9f8b-ebe5-4774-ad11-b4e47587c52e", "node_type": "1", "metadata": {"window": "And we have a very robust value proposition, obviously a complete value proposition in the case of U.S.  oncology \nand then a wide assortment of tools and services we offer to the unaffiliated community providers.  And we think \nthat that value proposition continues to earn us the right and the ability to grow and to benefit from the specialty \npharmaceutical pipeline in ge neral.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Ross Muken with Evercore ISI.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRoss Muken  \nAnalyst, Evercore ISI  Q \nGood afternoon, guys.  So I just wanted to go back to kind of the Change in Other math again, because I don't \nthink I have it straight.  So in terms of the $108 million versus the prior year and then \u2013 and that's for Change, and \nthen sort of the full year guide, I'm not sure I understand sort of what caused the up -step in cadence and then sort \nof the notable down -step. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Ross Muken with Evercore ISI.  \n ", "page_label": "13", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "287d9350217d22cbda9dcf79f78d2e1943c677078cc82ac3488fccf15b16b25c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "70e3dfb6-b2f2-4c6d-8079-e3a21fa2c973", "node_type": "1", "metadata": {"window": "And we think \nthat that value proposition continues to earn us the right and the ability to grow and to benefit from the specialty \npharmaceutical pipeline in ge neral.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Ross Muken with Evercore ISI.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRoss Muken  \nAnalyst, Evercore ISI  Q \nGood afternoon, guys.  So I just wanted to go back to kind of the Change in Other math again, because I don't \nthink I have it straight.  So in terms of the $108 million versus the prior year and then \u2013 and that's for Change, and \nthen sort of the full year guide, I'm not sure I understand sort of what caused the up -step in cadence and then sort \nof the notable down -step.  I know the ownership percentage is c hanging, but it still seemed like a big delta.  And I'm \nguessing that's essentially what caused the spike in the Other segment profit. ", "original_text": "So I just wanted to go back to kind of the Change in Other math again, because I don't \nthink I have it straight. "}, "hash": "bb36b4d28828361a10824786fb5dc448687e23d41adab8cc4b362c85357b627a", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRoss Muken  \nAnalyst, Evercore ISI  Q \nGood afternoon, guys. ", "start_char_idx": 2692, "end_char_idx": 3010, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "70e3dfb6-b2f2-4c6d-8079-e3a21fa2c973": {"__data__": {"id_": "70e3dfb6-b2f2-4c6d-8079-e3a21fa2c973", "embedding": null, "metadata": {"window": "And we think \nthat that value proposition continues to earn us the right and the ability to grow and to benefit from the specialty \npharmaceutical pipeline in ge neral.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Ross Muken with Evercore ISI.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRoss Muken  \nAnalyst, Evercore ISI  Q \nGood afternoon, guys.  So I just wanted to go back to kind of the Change in Other math again, because I don't \nthink I have it straight.  So in terms of the $108 million versus the prior year and then \u2013 and that's for Change, and \nthen sort of the full year guide, I'm not sure I understand sort of what caused the up -step in cadence and then sort \nof the notable down -step.  I know the ownership percentage is c hanging, but it still seemed like a big delta.  And I'm \nguessing that's essentially what caused the spike in the Other segment profit. ", "original_text": "So I just wanted to go back to kind of the Change in Other math again, because I don't \nthink I have it straight. ", "page_label": "13", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "96bdaac5-0d0b-446a-a4f2-842ca3d0f989", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d9a01bab1c7e7579e6b2264d464318b2b353793824d62a549e4f1bdfa87de423", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3aae5a47-f51f-404e-9e82-7afb6d4d2010", "node_type": "1", "metadata": {"window": "oncology \nand then a wide assortment of tools and services we offer to the unaffiliated community providers.  And we think \nthat that value proposition continues to earn us the right and the ability to grow and to benefit from the specialty \npharmaceutical pipeline in ge neral.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Ross Muken with Evercore ISI.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRoss Muken  \nAnalyst, Evercore ISI  Q \nGood afternoon, guys.  So I just wanted to go back to kind of the Change in Other math again, because I don't \nthink I have it straight.  So in terms of the $108 million versus the prior year and then \u2013 and that's for Change, and \nthen sort of the full year guide, I'm not sure I understand sort of what caused the up -step in cadence and then sort \nof the notable down -step.  I know the ownership percentage is c hanging, but it still seemed like a big delta. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRoss Muken  \nAnalyst, Evercore ISI  Q \nGood afternoon, guys. ", "page_label": "13", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fce8fac1417c024f4ef2320b2f5481e30c42a8e0992f2b9f101ee1bca9048d84", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e2e9b843-0416-483a-9daf-247dd8d3d37c", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Ross Muken with Evercore ISI.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRoss Muken  \nAnalyst, Evercore ISI  Q \nGood afternoon, guys.  So I just wanted to go back to kind of the Change in Other math again, because I don't \nthink I have it straight.  So in terms of the $108 million versus the prior year and then \u2013 and that's for Change, and \nthen sort of the full year guide, I'm not sure I understand sort of what caused the up -step in cadence and then sort \nof the notable down -step.  I know the ownership percentage is c hanging, but it still seemed like a big delta.  And I'm \nguessing that's essentially what caused the spike in the Other segment profit.  So I'm just trying to figure out sort \nof why that cadence was kind of funkier than what I think one would have expected.  \n ", "original_text": "So in terms of the $108 million versus the prior year and then \u2013 and that's for Change, and \nthen sort of the full year guide, I'm not sure I understand sort of what caused the up -step in cadence and then sort \nof the notable down -step. "}, "hash": "842f2aa528b630594d7bbe655b91f60a715ee787bd43f4eda0566a8a74475dd0", "class_name": "RelatedNodeInfo"}}, "text": "So I just wanted to go back to kind of the Change in Other math again, because I don't \nthink I have it straight. ", "start_char_idx": 3010, "end_char_idx": 3124, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e2e9b843-0416-483a-9daf-247dd8d3d37c": {"__data__": {"id_": "e2e9b843-0416-483a-9daf-247dd8d3d37c", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Ross Muken with Evercore ISI.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRoss Muken  \nAnalyst, Evercore ISI  Q \nGood afternoon, guys.  So I just wanted to go back to kind of the Change in Other math again, because I don't \nthink I have it straight.  So in terms of the $108 million versus the prior year and then \u2013 and that's for Change, and \nthen sort of the full year guide, I'm not sure I understand sort of what caused the up -step in cadence and then sort \nof the notable down -step.  I know the ownership percentage is c hanging, but it still seemed like a big delta.  And I'm \nguessing that's essentially what caused the spike in the Other segment profit.  So I'm just trying to figure out sort \nof why that cadence was kind of funkier than what I think one would have expected.  \n ", "original_text": "So in terms of the $108 million versus the prior year and then \u2013 and that's for Change, and \nthen sort of the full year guide, I'm not sure I understand sort of what caused the up -step in cadence and then sort \nof the notable down -step. ", "page_label": "13", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "96bdaac5-0d0b-446a-a4f2-842ca3d0f989", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d9a01bab1c7e7579e6b2264d464318b2b353793824d62a549e4f1bdfa87de423", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "70e3dfb6-b2f2-4c6d-8079-e3a21fa2c973", "node_type": "1", "metadata": {"window": "And we think \nthat that value proposition continues to earn us the right and the ability to grow and to benefit from the specialty \npharmaceutical pipeline in ge neral.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Ross Muken with Evercore ISI.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRoss Muken  \nAnalyst, Evercore ISI  Q \nGood afternoon, guys.  So I just wanted to go back to kind of the Change in Other math again, because I don't \nthink I have it straight.  So in terms of the $108 million versus the prior year and then \u2013 and that's for Change, and \nthen sort of the full year guide, I'm not sure I understand sort of what caused the up -step in cadence and then sort \nof the notable down -step.  I know the ownership percentage is c hanging, but it still seemed like a big delta.  And I'm \nguessing that's essentially what caused the spike in the Other segment profit. ", "original_text": "So I just wanted to go back to kind of the Change in Other math again, because I don't \nthink I have it straight. ", "page_label": "13", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5971d7a08ecc31ad2f5f52f561a301fce67adeeab7884bd1d4889835aaebc604", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "735947c9-fed3-4a0d-bd8b-ec7311ddddfa", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRoss Muken  \nAnalyst, Evercore ISI  Q \nGood afternoon, guys.  So I just wanted to go back to kind of the Change in Other math again, because I don't \nthink I have it straight.  So in terms of the $108 million versus the prior year and then \u2013 and that's for Change, and \nthen sort of the full year guide, I'm not sure I understand sort of what caused the up -step in cadence and then sort \nof the notable down -step.  I know the ownership percentage is c hanging, but it still seemed like a big delta.  And I'm \nguessing that's essentially what caused the spike in the Other segment profit.  So I'm just trying to figure out sort \nof why that cadence was kind of funkier than what I think one would have expected.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "I know the ownership percentage is c hanging, but it still seemed like a big delta. "}, "hash": "4d228c73b56ee5fb7e5ff57c999301ebfc60e48ccd5242b1cb91b4eed7a28c42", "class_name": "RelatedNodeInfo"}}, "text": "So in terms of the $108 million versus the prior year and then \u2013 and that's for Change, and \nthen sort of the full year guide, I'm not sure I understand sort of what caused the up -step in cadence and then sort \nof the notable down -step. ", "start_char_idx": 3124, "end_char_idx": 3363, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "735947c9-fed3-4a0d-bd8b-ec7311ddddfa": {"__data__": {"id_": "735947c9-fed3-4a0d-bd8b-ec7311ddddfa", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRoss Muken  \nAnalyst, Evercore ISI  Q \nGood afternoon, guys.  So I just wanted to go back to kind of the Change in Other math again, because I don't \nthink I have it straight.  So in terms of the $108 million versus the prior year and then \u2013 and that's for Change, and \nthen sort of the full year guide, I'm not sure I understand sort of what caused the up -step in cadence and then sort \nof the notable down -step.  I know the ownership percentage is c hanging, but it still seemed like a big delta.  And I'm \nguessing that's essentially what caused the spike in the Other segment profit.  So I'm just trying to figure out sort \nof why that cadence was kind of funkier than what I think one would have expected.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "I know the ownership percentage is c hanging, but it still seemed like a big delta. ", "page_label": "13", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "96bdaac5-0d0b-446a-a4f2-842ca3d0f989", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d9a01bab1c7e7579e6b2264d464318b2b353793824d62a549e4f1bdfa87de423", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e2e9b843-0416-483a-9daf-247dd8d3d37c", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And next will be Ross Muken with Evercore ISI.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRoss Muken  \nAnalyst, Evercore ISI  Q \nGood afternoon, guys.  So I just wanted to go back to kind of the Change in Other math again, because I don't \nthink I have it straight.  So in terms of the $108 million versus the prior year and then \u2013 and that's for Change, and \nthen sort of the full year guide, I'm not sure I understand sort of what caused the up -step in cadence and then sort \nof the notable down -step.  I know the ownership percentage is c hanging, but it still seemed like a big delta.  And I'm \nguessing that's essentially what caused the spike in the Other segment profit.  So I'm just trying to figure out sort \nof why that cadence was kind of funkier than what I think one would have expected.  \n ", "original_text": "So in terms of the $108 million versus the prior year and then \u2013 and that's for Change, and \nthen sort of the full year guide, I'm not sure I understand sort of what caused the up -step in cadence and then sort \nof the notable down -step. ", "page_label": "13", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "35fd44f900e06ec36f518166247edbf4445a6979fbe1a6c4b563659b8c4d5b98", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "18895a3e-4689-467d-b0a2-fae2a20f9cf8", "node_type": "1", "metadata": {"window": "So I just wanted to go back to kind of the Change in Other math again, because I don't \nthink I have it straight.  So in terms of the $108 million versus the prior year and then \u2013 and that's for Change, and \nthen sort of the full year guide, I'm not sure I understand sort of what caused the up -step in cadence and then sort \nof the notable down -step.  I know the ownership percentage is c hanging, but it still seemed like a big delta.  And I'm \nguessing that's essentially what caused the spike in the Other segment profit.  So I'm just trying to figure out sort \nof why that cadence was kind of funkier than what I think one would have expected.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nSure. ", "original_text": "And I'm \nguessing that's essentially what caused the spike in the Other segment profit. "}, "hash": "46a98cd4eba993e105c60493538ea09d60cddd83df11436cb8f45b013741302b", "class_name": "RelatedNodeInfo"}}, "text": "I know the ownership percentage is c hanging, but it still seemed like a big delta. ", "start_char_idx": 3363, "end_char_idx": 3447, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "18895a3e-4689-467d-b0a2-fae2a20f9cf8": {"__data__": {"id_": "18895a3e-4689-467d-b0a2-fae2a20f9cf8", "embedding": null, "metadata": {"window": "So I just wanted to go back to kind of the Change in Other math again, because I don't \nthink I have it straight.  So in terms of the $108 million versus the prior year and then \u2013 and that's for Change, and \nthen sort of the full year guide, I'm not sure I understand sort of what caused the up -step in cadence and then sort \nof the notable down -step.  I know the ownership percentage is c hanging, but it still seemed like a big delta.  And I'm \nguessing that's essentially what caused the spike in the Other segment profit.  So I'm just trying to figure out sort \nof why that cadence was kind of funkier than what I think one would have expected.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nSure. ", "original_text": "And I'm \nguessing that's essentially what caused the spike in the Other segment profit. ", "page_label": "13", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "96bdaac5-0d0b-446a-a4f2-842ca3d0f989", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d9a01bab1c7e7579e6b2264d464318b2b353793824d62a549e4f1bdfa87de423", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "735947c9-fed3-4a0d-bd8b-ec7311ddddfa", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRoss Muken  \nAnalyst, Evercore ISI  Q \nGood afternoon, guys.  So I just wanted to go back to kind of the Change in Other math again, because I don't \nthink I have it straight.  So in terms of the $108 million versus the prior year and then \u2013 and that's for Change, and \nthen sort of the full year guide, I'm not sure I understand sort of what caused the up -step in cadence and then sort \nof the notable down -step.  I know the ownership percentage is c hanging, but it still seemed like a big delta.  And I'm \nguessing that's essentially what caused the spike in the Other segment profit.  So I'm just trying to figure out sort \nof why that cadence was kind of funkier than what I think one would have expected.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "I know the ownership percentage is c hanging, but it still seemed like a big delta. ", "page_label": "13", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "198e777249ab18b63b1adf9122f9af7fc2adfeeeb552a0ae391a56539a5b2a9d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f0a20d25-bde2-4541-abae-55e423a46f08", "node_type": "1", "metadata": {"window": "So in terms of the $108 million versus the prior year and then \u2013 and that's for Change, and \nthen sort of the full year guide, I'm not sure I understand sort of what caused the up -step in cadence and then sort \nof the notable down -step.  I know the ownership percentage is c hanging, but it still seemed like a big delta.  And I'm \nguessing that's essentially what caused the spike in the Other segment profit.  So I'm just trying to figure out sort \nof why that cadence was kind of funkier than what I think one would have expected.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nSure.  Thanks for the question, Ross. ", "original_text": "So I'm just trying to figure out sort \nof why that cadence was kind of funkier than what I think one would have expected.  \n "}, "hash": "78c4e7fb07833bc7e2fe5974c974ba452f56bc066c60a22e9b0c010f97199a79", "class_name": "RelatedNodeInfo"}}, "text": "And I'm \nguessing that's essentially what caused the spike in the Other segment profit. ", "start_char_idx": 3447, "end_char_idx": 3535, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f0a20d25-bde2-4541-abae-55e423a46f08": {"__data__": {"id_": "f0a20d25-bde2-4541-abae-55e423a46f08", "embedding": null, "metadata": {"window": "So in terms of the $108 million versus the prior year and then \u2013 and that's for Change, and \nthen sort of the full year guide, I'm not sure I understand sort of what caused the up -step in cadence and then sort \nof the notable down -step.  I know the ownership percentage is c hanging, but it still seemed like a big delta.  And I'm \nguessing that's essentially what caused the spike in the Other segment profit.  So I'm just trying to figure out sort \nof why that cadence was kind of funkier than what I think one would have expected.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nSure.  Thanks for the question, Ross. ", "original_text": "So I'm just trying to figure out sort \nof why that cadence was kind of funkier than what I think one would have expected.  \n ", "page_label": "13", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "96bdaac5-0d0b-446a-a4f2-842ca3d0f989", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d9a01bab1c7e7579e6b2264d464318b2b353793824d62a549e4f1bdfa87de423", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "18895a3e-4689-467d-b0a2-fae2a20f9cf8", "node_type": "1", "metadata": {"window": "So I just wanted to go back to kind of the Change in Other math again, because I don't \nthink I have it straight.  So in terms of the $108 million versus the prior year and then \u2013 and that's for Change, and \nthen sort of the full year guide, I'm not sure I understand sort of what caused the up -step in cadence and then sort \nof the notable down -step.  I know the ownership percentage is c hanging, but it still seemed like a big delta.  And I'm \nguessing that's essentially what caused the spike in the Other segment profit.  So I'm just trying to figure out sort \nof why that cadence was kind of funkier than what I think one would have expected.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nSure. ", "original_text": "And I'm \nguessing that's essentially what caused the spike in the Other segment profit. ", "page_label": "13", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "450c3eb60955638d12de8390f68c53ae6d7de0ddc128243a227c1294928b3069", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ee4eb360-bb61-4c8e-a5ad-eab390abcc62", "node_type": "1", "metadata": {"window": "I know the ownership percentage is c hanging, but it still seemed like a big delta.  And I'm \nguessing that's essentially what caused the spike in the Other segment profit.  So I'm just trying to figure out sort \nof why that cadence was kind of funkier than what I think one would have expected.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nSure.  Thanks for the question, Ross.  So let me start with just the Other segment just generally. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  "}, "hash": "200edc6f4d722a20d08c890f58400b2b8ab66d4bc8b40f144685628f912f9b3c", "class_name": "RelatedNodeInfo"}}, "text": "So I'm just trying to figure out sort \nof why that cadence was kind of funkier than what I think one would have expected.  \n ", "start_char_idx": 3535, "end_char_idx": 3660, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ee4eb360-bb61-4c8e-a5ad-eab390abcc62": {"__data__": {"id_": "ee4eb360-bb61-4c8e-a5ad-eab390abcc62", "embedding": null, "metadata": {"window": "I know the ownership percentage is c hanging, but it still seemed like a big delta.  And I'm \nguessing that's essentially what caused the spike in the Other segment profit.  So I'm just trying to figure out sort \nof why that cadence was kind of funkier than what I think one would have expected.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nSure.  Thanks for the question, Ross.  So let me start with just the Other segment just generally. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "page_label": "13", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "96bdaac5-0d0b-446a-a4f2-842ca3d0f989", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d9a01bab1c7e7579e6b2264d464318b2b353793824d62a549e4f1bdfa87de423", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f0a20d25-bde2-4541-abae-55e423a46f08", "node_type": "1", "metadata": {"window": "So in terms of the $108 million versus the prior year and then \u2013 and that's for Change, and \nthen sort of the full year guide, I'm not sure I understand sort of what caused the up -step in cadence and then sort \nof the notable down -step.  I know the ownership percentage is c hanging, but it still seemed like a big delta.  And I'm \nguessing that's essentially what caused the spike in the Other segment profit.  So I'm just trying to figure out sort \nof why that cadence was kind of funkier than what I think one would have expected.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nSure.  Thanks for the question, Ross. ", "original_text": "So I'm just trying to figure out sort \nof why that cadence was kind of funkier than what I think one would have expected.  \n ", "page_label": "13", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "95d28cfd37f7afc8901af3da502a384fc669dcf388ae397f7e516ff5ec1951ce", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "be5644c4-50b8-45ca-9ce8-a2be7ecf3e3b", "node_type": "1", "metadata": {"window": "And I'm \nguessing that's essentially what caused the spike in the Other segment profit.  So I'm just trying to figure out sort \nof why that cadence was kind of funkier than what I think one would have expected.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nSure.  Thanks for the question, Ross.  So let me start with just the Other segment just generally.  Within that \nsegment, we have our Canadian business, we have our MRxTS businesses which are very strong businesses \nand growing very well for us, and we have our equity investment in Change. ", "original_text": "A \nSure. "}, "hash": "de0c6fc7803840d0f3e45fc47ebac6870cd3af380508a711be9a08802c4918f6", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "start_char_idx": 3660, "end_char_idx": 4005, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "be5644c4-50b8-45ca-9ce8-a2be7ecf3e3b": {"__data__": {"id_": "be5644c4-50b8-45ca-9ce8-a2be7ecf3e3b", "embedding": null, "metadata": {"window": "And I'm \nguessing that's essentially what caused the spike in the Other segment profit.  So I'm just trying to figure out sort \nof why that cadence was kind of funkier than what I think one would have expected.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nSure.  Thanks for the question, Ross.  So let me start with just the Other segment just generally.  Within that \nsegment, we have our Canadian business, we have our MRxTS businesses which are very strong businesses \nand growing very well for us, and we have our equity investment in Change. ", "original_text": "A \nSure. ", "page_label": "13", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "96bdaac5-0d0b-446a-a4f2-842ca3d0f989", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d9a01bab1c7e7579e6b2264d464318b2b353793824d62a549e4f1bdfa87de423", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ee4eb360-bb61-4c8e-a5ad-eab390abcc62", "node_type": "1", "metadata": {"window": "I know the ownership percentage is c hanging, but it still seemed like a big delta.  And I'm \nguessing that's essentially what caused the spike in the Other segment profit.  So I'm just trying to figure out sort \nof why that cadence was kind of funkier than what I think one would have expected.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nSure.  Thanks for the question, Ross.  So let me start with just the Other segment just generally. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "page_label": "13", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "07a32655f72ce758005ae10fb449b1fed141dfff99c9e0e701b72a745553b91f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "05786e8d-eb31-4c7a-9775-3ad8a7361c23", "node_type": "1", "metadata": {"window": "So I'm just trying to figure out sort \nof why that cadence was kind of funkier than what I think one would have expected.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nSure.  Thanks for the question, Ross.  So let me start with just the Other segment just generally.  Within that \nsegment, we have our Canadian business, we have our MRxTS businesses which are very strong businesses \nand growing very well for us, and we have our equity investment in Change.  Now at first, I'd point out that our \nCanadian business continued to perform well. ", "original_text": "Thanks for the question, Ross. "}, "hash": "3c0d9083c7280078a52119fc20aad13349900cae6a2df3c64c1b378b63960a3b", "class_name": "RelatedNodeInfo"}}, "text": "A \nSure. ", "start_char_idx": 4005, "end_char_idx": 4014, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "05786e8d-eb31-4c7a-9775-3ad8a7361c23": {"__data__": {"id_": "05786e8d-eb31-4c7a-9775-3ad8a7361c23", "embedding": null, "metadata": {"window": "So I'm just trying to figure out sort \nof why that cadence was kind of funkier than what I think one would have expected.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nSure.  Thanks for the question, Ross.  So let me start with just the Other segment just generally.  Within that \nsegment, we have our Canadian business, we have our MRxTS businesses which are very strong businesses \nand growing very well for us, and we have our equity investment in Change.  Now at first, I'd point out that our \nCanadian business continued to perform well. ", "original_text": "Thanks for the question, Ross. ", "page_label": "13", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "96bdaac5-0d0b-446a-a4f2-842ca3d0f989", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d9a01bab1c7e7579e6b2264d464318b2b353793824d62a549e4f1bdfa87de423", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "be5644c4-50b8-45ca-9ce8-a2be7ecf3e3b", "node_type": "1", "metadata": {"window": "And I'm \nguessing that's essentially what caused the spike in the Other segment profit.  So I'm just trying to figure out sort \nof why that cadence was kind of funkier than what I think one would have expected.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nSure.  Thanks for the question, Ross.  So let me start with just the Other segment just generally.  Within that \nsegment, we have our Canadian business, we have our MRxTS businesses which are very strong businesses \nand growing very well for us, and we have our equity investment in Change. ", "original_text": "A \nSure. ", "page_label": "13", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "95d4282a725c5890c67e5ff536783c1c375fb65bab8dcdc8714b996430727d17", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f5da1a8c-626c-4f69-98fd-e6c986386dfe", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nSure.  Thanks for the question, Ross.  So let me start with just the Other segment just generally.  Within that \nsegment, we have our Canadian business, we have our MRxTS businesses which are very strong businesses \nand growing very well for us, and we have our equity investment in Change.  Now at first, I'd point out that our \nCanadian business continued to perform well.  We certainly talked about the impact from the generic l egislation at \nthe beginning of the year. ", "original_text": "So let me start with just the Other segment just generally. "}, "hash": "6e5e4807fd3ac01ebcb21f2a4c411831a8ac4e8287bd29ccff52d8bf5ef59d0a", "class_name": "RelatedNodeInfo"}}, "text": "Thanks for the question, Ross. ", "start_char_idx": 4014, "end_char_idx": 4045, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f5da1a8c-626c-4f69-98fd-e6c986386dfe": {"__data__": {"id_": "f5da1a8c-626c-4f69-98fd-e6c986386dfe", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nSure.  Thanks for the question, Ross.  So let me start with just the Other segment just generally.  Within that \nsegment, we have our Canadian business, we have our MRxTS businesses which are very strong businesses \nand growing very well for us, and we have our equity investment in Change.  Now at first, I'd point out that our \nCanadian business continued to perform well.  We certainly talked about the impact from the generic l egislation at \nthe beginning of the year. ", "original_text": "So let me start with just the Other segment just generally. ", "page_label": "13", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "96bdaac5-0d0b-446a-a4f2-842ca3d0f989", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d9a01bab1c7e7579e6b2264d464318b2b353793824d62a549e4f1bdfa87de423", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "05786e8d-eb31-4c7a-9775-3ad8a7361c23", "node_type": "1", "metadata": {"window": "So I'm just trying to figure out sort \nof why that cadence was kind of funkier than what I think one would have expected.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nSure.  Thanks for the question, Ross.  So let me start with just the Other segment just generally.  Within that \nsegment, we have our Canadian business, we have our MRxTS businesses which are very strong businesses \nand growing very well for us, and we have our equity investment in Change.  Now at first, I'd point out that our \nCanadian business continued to perform well. ", "original_text": "Thanks for the question, Ross. ", "page_label": "13", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bf97fc5355f2471fa97909793b446109bfccaf34fa84d55ad4fb5a447d899e30", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3f6f205b-8b27-45b4-83b7-d34a1a1700db", "node_type": "1", "metadata": {"window": "A \nSure.  Thanks for the question, Ross.  So let me start with just the Other segment just generally.  Within that \nsegment, we have our Canadian business, we have our MRxTS businesses which are very strong businesses \nand growing very well for us, and we have our equity investment in Change.  Now at first, I'd point out that our \nCanadian business continued to perform well.  We certainly talked about the impact from the generic l egislation at \nthe beginning of the year.  And that team really did a great job in mitigating that and we're pleased with the \nperformance of Canada.  \n \n", "original_text": "Within that \nsegment, we have our Canadian business, we have our MRxTS businesses which are very strong businesses \nand growing very well for us, and we have our equity investment in Change. "}, "hash": "8b695fb23753fa14a6da2c3a10e758c39d1efcc45a266a8f55ed4b712e8b4680", "class_name": "RelatedNodeInfo"}}, "text": "So let me start with just the Other segment just generally. ", "start_char_idx": 4045, "end_char_idx": 4105, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3f6f205b-8b27-45b4-83b7-d34a1a1700db": {"__data__": {"id_": "3f6f205b-8b27-45b4-83b7-d34a1a1700db", "embedding": null, "metadata": {"window": "A \nSure.  Thanks for the question, Ross.  So let me start with just the Other segment just generally.  Within that \nsegment, we have our Canadian business, we have our MRxTS businesses which are very strong businesses \nand growing very well for us, and we have our equity investment in Change.  Now at first, I'd point out that our \nCanadian business continued to perform well.  We certainly talked about the impact from the generic l egislation at \nthe beginning of the year.  And that team really did a great job in mitigating that and we're pleased with the \nperformance of Canada.  \n \n", "original_text": "Within that \nsegment, we have our Canadian business, we have our MRxTS businesses which are very strong businesses \nand growing very well for us, and we have our equity investment in Change. ", "page_label": "13", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "96bdaac5-0d0b-446a-a4f2-842ca3d0f989", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d9a01bab1c7e7579e6b2264d464318b2b353793824d62a549e4f1bdfa87de423", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f5da1a8c-626c-4f69-98fd-e6c986386dfe", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nSure.  Thanks for the question, Ross.  So let me start with just the Other segment just generally.  Within that \nsegment, we have our Canadian business, we have our MRxTS businesses which are very strong businesses \nand growing very well for us, and we have our equity investment in Change.  Now at first, I'd point out that our \nCanadian business continued to perform well.  We certainly talked about the impact from the generic l egislation at \nthe beginning of the year. ", "original_text": "So let me start with just the Other segment just generally. ", "page_label": "13", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "78129a81f7e6a5b7ed5f8425f6525e2b073d9b6970834b04de4162541b54bc33", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7e404900-0e4f-41ac-afdf-da9f5b8c9211", "node_type": "1", "metadata": {"window": "Thanks for the question, Ross.  So let me start with just the Other segment just generally.  Within that \nsegment, we have our Canadian business, we have our MRxTS businesses which are very strong businesses \nand growing very well for us, and we have our equity investment in Change.  Now at first, I'd point out that our \nCanadian business continued to perform well.  We certainly talked about the impact from the generic l egislation at \nthe beginning of the year.  And that team really did a great job in mitigating that and we're pleased with the \nperformance of Canada.  \n \n Our MRxTS businesses continued to grow very well and we're continuing to make investments in those \nbusinesse s. Within our Change asset, we did have the ownership change from 70% to 58.5% effective in our \nsecond quarter, and in that second quarter you'll also see the impact from the de -levering. ", "original_text": "Now at first, I'd point out that our \nCanadian business continued to perform well. "}, "hash": "99cb54736b6d5327cd7610282663db5b515dbd9bee1b16c5127d27fab4761204", "class_name": "RelatedNodeInfo"}}, "text": "Within that \nsegment, we have our Canadian business, we have our MRxTS businesses which are very strong businesses \nand growing very well for us, and we have our equity investment in Change. ", "start_char_idx": 4105, "end_char_idx": 4296, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7e404900-0e4f-41ac-afdf-da9f5b8c9211": {"__data__": {"id_": "7e404900-0e4f-41ac-afdf-da9f5b8c9211", "embedding": null, "metadata": {"window": "Thanks for the question, Ross.  So let me start with just the Other segment just generally.  Within that \nsegment, we have our Canadian business, we have our MRxTS businesses which are very strong businesses \nand growing very well for us, and we have our equity investment in Change.  Now at first, I'd point out that our \nCanadian business continued to perform well.  We certainly talked about the impact from the generic l egislation at \nthe beginning of the year.  And that team really did a great job in mitigating that and we're pleased with the \nperformance of Canada.  \n \n Our MRxTS businesses continued to grow very well and we're continuing to make investments in those \nbusinesse s. Within our Change asset, we did have the ownership change from 70% to 58.5% effective in our \nsecond quarter, and in that second quarter you'll also see the impact from the de -levering. ", "original_text": "Now at first, I'd point out that our \nCanadian business continued to perform well. ", "page_label": "13", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "96bdaac5-0d0b-446a-a4f2-842ca3d0f989", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d9a01bab1c7e7579e6b2264d464318b2b353793824d62a549e4f1bdfa87de423", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3f6f205b-8b27-45b4-83b7-d34a1a1700db", "node_type": "1", "metadata": {"window": "A \nSure.  Thanks for the question, Ross.  So let me start with just the Other segment just generally.  Within that \nsegment, we have our Canadian business, we have our MRxTS businesses which are very strong businesses \nand growing very well for us, and we have our equity investment in Change.  Now at first, I'd point out that our \nCanadian business continued to perform well.  We certainly talked about the impact from the generic l egislation at \nthe beginning of the year.  And that team really did a great job in mitigating that and we're pleased with the \nperformance of Canada.  \n \n", "original_text": "Within that \nsegment, we have our Canadian business, we have our MRxTS businesses which are very strong businesses \nand growing very well for us, and we have our equity investment in Change. ", "page_label": "13", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "08994c09178e8ee9a9bf9ba19c5e78fe3f3ed4792072c964083b1456d71d964e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "44d301a6-ebef-48d2-a393-06c6410e78eb", "node_type": "1", "metadata": {"window": "So let me start with just the Other segment just generally.  Within that \nsegment, we have our Canadian business, we have our MRxTS businesses which are very strong businesses \nand growing very well for us, and we have our equity investment in Change.  Now at first, I'd point out that our \nCanadian business continued to perform well.  We certainly talked about the impact from the generic l egislation at \nthe beginning of the year.  And that team really did a great job in mitigating that and we're pleased with the \nperformance of Canada.  \n \n Our MRxTS businesses continued to grow very well and we're continuing to make investments in those \nbusinesse s. Within our Change asset, we did have the ownership change from 70% to 58.5% effective in our \nsecond quarter, and in that second quarter you'll also see the impact from the de -levering.  Within the first quarter ", "original_text": "We certainly talked about the impact from the generic l egislation at \nthe beginning of the year. "}, "hash": "1f358a2279c19bc65dd7dd1451851968a73fda880b71dba4554dca2a8b72b566", "class_name": "RelatedNodeInfo"}}, "text": "Now at first, I'd point out that our \nCanadian business continued to perform well. ", "start_char_idx": 4296, "end_char_idx": 4379, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "44d301a6-ebef-48d2-a393-06c6410e78eb": {"__data__": {"id_": "44d301a6-ebef-48d2-a393-06c6410e78eb", "embedding": null, "metadata": {"window": "So let me start with just the Other segment just generally.  Within that \nsegment, we have our Canadian business, we have our MRxTS businesses which are very strong businesses \nand growing very well for us, and we have our equity investment in Change.  Now at first, I'd point out that our \nCanadian business continued to perform well.  We certainly talked about the impact from the generic l egislation at \nthe beginning of the year.  And that team really did a great job in mitigating that and we're pleased with the \nperformance of Canada.  \n \n Our MRxTS businesses continued to grow very well and we're continuing to make investments in those \nbusinesse s. Within our Change asset, we did have the ownership change from 70% to 58.5% effective in our \nsecond quarter, and in that second quarter you'll also see the impact from the de -levering.  Within the first quarter ", "original_text": "We certainly talked about the impact from the generic l egislation at \nthe beginning of the year. ", "page_label": "13", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "96bdaac5-0d0b-446a-a4f2-842ca3d0f989", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d9a01bab1c7e7579e6b2264d464318b2b353793824d62a549e4f1bdfa87de423", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7e404900-0e4f-41ac-afdf-da9f5b8c9211", "node_type": "1", "metadata": {"window": "Thanks for the question, Ross.  So let me start with just the Other segment just generally.  Within that \nsegment, we have our Canadian business, we have our MRxTS businesses which are very strong businesses \nand growing very well for us, and we have our equity investment in Change.  Now at first, I'd point out that our \nCanadian business continued to perform well.  We certainly talked about the impact from the generic l egislation at \nthe beginning of the year.  And that team really did a great job in mitigating that and we're pleased with the \nperformance of Canada.  \n \n Our MRxTS businesses continued to grow very well and we're continuing to make investments in those \nbusinesse s. Within our Change asset, we did have the ownership change from 70% to 58.5% effective in our \nsecond quarter, and in that second quarter you'll also see the impact from the de -levering. ", "original_text": "Now at first, I'd point out that our \nCanadian business continued to perform well. ", "page_label": "13", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8f04311e8ec466574606226fbce7f2c7e8646aebfab9e495a2c7e5da2a850787", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "48bd958e-1585-47ce-a4e7-93a2fd43543b", "node_type": "1", "metadata": {"window": "Within that \nsegment, we have our Canadian business, we have our MRxTS businesses which are very strong businesses \nand growing very well for us, and we have our equity investment in Change.  Now at first, I'd point out that our \nCanadian business continued to perform well.  We certainly talked about the impact from the generic l egislation at \nthe beginning of the year.  And that team really did a great job in mitigating that and we're pleased with the \nperformance of Canada.  \n \n Our MRxTS businesses continued to grow very well and we're continuing to make investments in those \nbusinesse s. Within our Change asset, we did have the ownership change from 70% to 58.5% effective in our \nsecond quarter, and in that second quarter you'll also see the impact from the de -levering.  Within the first quarter ", "original_text": "And that team really did a great job in mitigating that and we're pleased with the \nperformance of Canada.  \n \n"}, "hash": "1d2003d31e043c9c6a87ea06b329314f12556a1e4a7fdeb9e7c219db60181a22", "class_name": "RelatedNodeInfo"}}, "text": "We certainly talked about the impact from the generic l egislation at \nthe beginning of the year. ", "start_char_idx": 4379, "end_char_idx": 4477, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "48bd958e-1585-47ce-a4e7-93a2fd43543b": {"__data__": {"id_": "48bd958e-1585-47ce-a4e7-93a2fd43543b", "embedding": null, "metadata": {"window": "Within that \nsegment, we have our Canadian business, we have our MRxTS businesses which are very strong businesses \nand growing very well for us, and we have our equity investment in Change.  Now at first, I'd point out that our \nCanadian business continued to perform well.  We certainly talked about the impact from the generic l egislation at \nthe beginning of the year.  And that team really did a great job in mitigating that and we're pleased with the \nperformance of Canada.  \n \n Our MRxTS businesses continued to grow very well and we're continuing to make investments in those \nbusinesse s. Within our Change asset, we did have the ownership change from 70% to 58.5% effective in our \nsecond quarter, and in that second quarter you'll also see the impact from the de -levering.  Within the first quarter ", "original_text": "And that team really did a great job in mitigating that and we're pleased with the \nperformance of Canada.  \n \n", "page_label": "13", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "96bdaac5-0d0b-446a-a4f2-842ca3d0f989", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d9a01bab1c7e7579e6b2264d464318b2b353793824d62a549e4f1bdfa87de423", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "44d301a6-ebef-48d2-a393-06c6410e78eb", "node_type": "1", "metadata": {"window": "So let me start with just the Other segment just generally.  Within that \nsegment, we have our Canadian business, we have our MRxTS businesses which are very strong businesses \nand growing very well for us, and we have our equity investment in Change.  Now at first, I'd point out that our \nCanadian business continued to perform well.  We certainly talked about the impact from the generic l egislation at \nthe beginning of the year.  And that team really did a great job in mitigating that and we're pleased with the \nperformance of Canada.  \n \n Our MRxTS businesses continued to grow very well and we're continuing to make investments in those \nbusinesse s. Within our Change asset, we did have the ownership change from 70% to 58.5% effective in our \nsecond quarter, and in that second quarter you'll also see the impact from the de -levering.  Within the first quarter ", "original_text": "We certainly talked about the impact from the generic l egislation at \nthe beginning of the year. ", "page_label": "13", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5f62cef3314ef69cedba869d94d841b6604bdb9233a16e66864ef437b154b9dc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3b2616de-bee8-476a-96fc-d3a31ac56803", "node_type": "1", "metadata": {"window": "Now at first, I'd point out that our \nCanadian business continued to perform well.  We certainly talked about the impact from the generic l egislation at \nthe beginning of the year.  And that team really did a great job in mitigating that and we're pleased with the \nperformance of Canada.  \n \n Our MRxTS businesses continued to grow very well and we're continuing to make investments in those \nbusinesse s. Within our Change asset, we did have the ownership change from 70% to 58.5% effective in our \nsecond quarter, and in that second quarter you'll also see the impact from the de -levering.  Within the first quarter ", "original_text": "Our MRxTS businesses continued to grow very well and we're continuing to make investments in those \nbusinesse s. Within our Change asset, we did have the ownership change from 70% to 58.5% effective in our \nsecond quarter, and in that second quarter you'll also see the impact from the de -levering. "}, "hash": "f200dc14e409b0c97c14f90a17b3b1997ba3de0f229a43aa67b3470c4d8889a7", "class_name": "RelatedNodeInfo"}}, "text": "And that team really did a great job in mitigating that and we're pleased with the \nperformance of Canada.  \n \n", "start_char_idx": 4477, "end_char_idx": 4588, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3b2616de-bee8-476a-96fc-d3a31ac56803": {"__data__": {"id_": "3b2616de-bee8-476a-96fc-d3a31ac56803", "embedding": null, "metadata": {"window": "Now at first, I'd point out that our \nCanadian business continued to perform well.  We certainly talked about the impact from the generic l egislation at \nthe beginning of the year.  And that team really did a great job in mitigating that and we're pleased with the \nperformance of Canada.  \n \n Our MRxTS businesses continued to grow very well and we're continuing to make investments in those \nbusinesse s. Within our Change asset, we did have the ownership change from 70% to 58.5% effective in our \nsecond quarter, and in that second quarter you'll also see the impact from the de -levering.  Within the first quarter ", "original_text": "Our MRxTS businesses continued to grow very well and we're continuing to make investments in those \nbusinesse s. Within our Change asset, we did have the ownership change from 70% to 58.5% effective in our \nsecond quarter, and in that second quarter you'll also see the impact from the de -levering. ", "page_label": "13", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "96bdaac5-0d0b-446a-a4f2-842ca3d0f989", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d9a01bab1c7e7579e6b2264d464318b2b353793824d62a549e4f1bdfa87de423", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "48bd958e-1585-47ce-a4e7-93a2fd43543b", "node_type": "1", "metadata": {"window": "Within that \nsegment, we have our Canadian business, we have our MRxTS businesses which are very strong businesses \nand growing very well for us, and we have our equity investment in Change.  Now at first, I'd point out that our \nCanadian business continued to perform well.  We certainly talked about the impact from the generic l egislation at \nthe beginning of the year.  And that team really did a great job in mitigating that and we're pleased with the \nperformance of Canada.  \n \n Our MRxTS businesses continued to grow very well and we're continuing to make investments in those \nbusinesse s. Within our Change asset, we did have the ownership change from 70% to 58.5% effective in our \nsecond quarter, and in that second quarter you'll also see the impact from the de -levering.  Within the first quarter ", "original_text": "And that team really did a great job in mitigating that and we're pleased with the \nperformance of Canada.  \n \n", "page_label": "13", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b9e93486e70de85ba0ad762be4a641b2184e896e461aa3b7c6f161f3e1a6de9b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2cf26659-1909-4723-af31-8d701595e02c", "node_type": "1", "metadata": {"window": "We certainly talked about the impact from the generic l egislation at \nthe beginning of the year.  And that team really did a great job in mitigating that and we're pleased with the \nperformance of Canada.  \n \n Our MRxTS businesses continued to grow very well and we're continuing to make investments in those \nbusinesse s. Within our Change asset, we did have the ownership change from 70% to 58.5% effective in our \nsecond quarter, and in that second quarter you'll also see the impact from the de -levering.  Within the first quarter ", "original_text": "Within the first quarter "}, "hash": "809bc7453fb977344112046b90fab96b123123df3a7615d9c74cff65f45173ea", "class_name": "RelatedNodeInfo"}}, "text": "Our MRxTS businesses continued to grow very well and we're continuing to make investments in those \nbusinesse s. Within our Change asset, we did have the ownership change from 70% to 58.5% effective in our \nsecond quarter, and in that second quarter you'll also see the impact from the de -levering. ", "start_char_idx": 4588, "end_char_idx": 4888, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2cf26659-1909-4723-af31-8d701595e02c": {"__data__": {"id_": "2cf26659-1909-4723-af31-8d701595e02c", "embedding": null, "metadata": {"window": "We certainly talked about the impact from the generic l egislation at \nthe beginning of the year.  And that team really did a great job in mitigating that and we're pleased with the \nperformance of Canada.  \n \n Our MRxTS businesses continued to grow very well and we're continuing to make investments in those \nbusinesse s. Within our Change asset, we did have the ownership change from 70% to 58.5% effective in our \nsecond quarter, and in that second quarter you'll also see the impact from the de -levering.  Within the first quarter ", "original_text": "Within the first quarter ", "page_label": "13", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "96bdaac5-0d0b-446a-a4f2-842ca3d0f989", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d9a01bab1c7e7579e6b2264d464318b2b353793824d62a549e4f1bdfa87de423", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3b2616de-bee8-476a-96fc-d3a31ac56803", "node_type": "1", "metadata": {"window": "Now at first, I'd point out that our \nCanadian business continued to perform well.  We certainly talked about the impact from the generic l egislation at \nthe beginning of the year.  And that team really did a great job in mitigating that and we're pleased with the \nperformance of Canada.  \n \n Our MRxTS businesses continued to grow very well and we're continuing to make investments in those \nbusinesse s. Within our Change asset, we did have the ownership change from 70% to 58.5% effective in our \nsecond quarter, and in that second quarter you'll also see the impact from the de -levering.  Within the first quarter ", "original_text": "Our MRxTS businesses continued to grow very well and we're continuing to make investments in those \nbusinesse s. Within our Change asset, we did have the ownership change from 70% to 58.5% effective in our \nsecond quarter, and in that second quarter you'll also see the impact from the de -levering. ", "page_label": "13", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b6ddf21ccd27f91cca8be46599688e3e359ab26d9e36be8b2773c82264641137", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3389ae03-c311-4f70-b95b-4daf29734aa2", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nthough, there are a couple of things that I  would point out.  First of all, Change had \u2013 as most companies, had the \nimplementation of the revenue recognition standard, and that created a timing element for the year.  For the full \nyear, that's not going to have an impact on McKesson, but it does have an impact earlier \u2013 favorable impact \nearlier in the year and [then it'll reverse out as the year goes on.  \n \n", "original_text": "McKesson Corp.  "}, "hash": "3ba274a8502b8c6c070f10df1fc3ef188262084f127122703aa8b10f5cec0171", "class_name": "RelatedNodeInfo"}}, "text": "Within the first quarter ", "start_char_idx": 4888, "end_char_idx": 4913, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3389ae03-c311-4f70-b95b-4daf29734aa2": {"__data__": {"id_": "3389ae03-c311-4f70-b95b-4daf29734aa2", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nthough, there are a couple of things that I  would point out.  First of all, Change had \u2013 as most companies, had the \nimplementation of the revenue recognition standard, and that created a timing element for the year.  For the full \nyear, that's not going to have an impact on McKesson, but it does have an impact earlier \u2013 favorable impact \nearlier in the year and [then it'll reverse out as the year goes on.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "14", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "99b53c78-61a9-4e06-89a5-d5a3295894da", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1fc1b41fb0a3728ca79532ff4fdf5f7b6d1ac601f71ff8e3fc1aa0d1723e043b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2cf26659-1909-4723-af31-8d701595e02c", "node_type": "1", "metadata": {"window": "We certainly talked about the impact from the generic l egislation at \nthe beginning of the year.  And that team really did a great job in mitigating that and we're pleased with the \nperformance of Canada.  \n \n Our MRxTS businesses continued to grow very well and we're continuing to make investments in those \nbusinesse s. Within our Change asset, we did have the ownership change from 70% to 58.5% effective in our \nsecond quarter, and in that second quarter you'll also see the impact from the de -levering.  Within the first quarter ", "original_text": "Within the first quarter ", "page_label": "13", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d2868195acb1c57ba1432daac3b350e2d79506eff1d54dd4010e4b4e521839a4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8d25075b-13df-4014-90f3-9c03c800be00", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nthough, there are a couple of things that I  would point out.  First of all, Change had \u2013 as most companies, had the \nimplementation of the revenue recognition standard, and that created a timing element for the year.  For the full \nyear, that's not going to have an impact on McKesson, but it does have an impact earlier \u2013 favorable impact \nearlier in the year and [then it'll reverse out as the year goes on.  \n \n And then, of course, as you think about that business, there is a mix of income between taxable and non -taxable \ndepending on the legal entity. ", "original_text": "(MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nthough, there are a couple of things that I  would point out. "}, "hash": "14ef8e212a0e621e5a51d27c82b8ce06c44b2d2270723bb5e15717ca912b144a", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8d25075b-13df-4014-90f3-9c03c800be00": {"__data__": {"id_": "8d25075b-13df-4014-90f3-9c03c800be00", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nthough, there are a couple of things that I  would point out.  First of all, Change had \u2013 as most companies, had the \nimplementation of the revenue recognition standard, and that created a timing element for the year.  For the full \nyear, that's not going to have an impact on McKesson, but it does have an impact earlier \u2013 favorable impact \nearlier in the year and [then it'll reverse out as the year goes on.  \n \n And then, of course, as you think about that business, there is a mix of income between taxable and non -taxable \ndepending on the legal entity. ", "original_text": "(MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nthough, there are a couple of things that I  would point out. ", "page_label": "14", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "99b53c78-61a9-4e06-89a5-d5a3295894da", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1fc1b41fb0a3728ca79532ff4fdf5f7b6d1ac601f71ff8e3fc1aa0d1723e043b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3389ae03-c311-4f70-b95b-4daf29734aa2", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nthough, there are a couple of things that I  would point out.  First of all, Change had \u2013 as most companies, had the \nimplementation of the revenue recognition standard, and that created a timing element for the year.  For the full \nyear, that's not going to have an impact on McKesson, but it does have an impact earlier \u2013 favorable impact \nearlier in the year and [then it'll reverse out as the year goes on.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "14", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fe888f50c3fea762a95bc012bb5b48fc0b43dfb0aeea93e86439887fec3318a2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "60f2227c-ba5a-407e-a0e0-62fd9cc79882", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nthough, there are a couple of things that I  would point out.  First of all, Change had \u2013 as most companies, had the \nimplementation of the revenue recognition standard, and that created a timing element for the year.  For the full \nyear, that's not going to have an impact on McKesson, but it does have an impact earlier \u2013 favorable impact \nearlier in the year and [then it'll reverse out as the year goes on.  \n \n And then, of course, as you think about that business, there is a mix of income between taxable and non -taxable \ndepending on the legal entity.  So what I would say is, primarily for the first quarter you see some timing impact \nfrom the revenue recognition standard and you see a mix of income between the entities of taxable and non -\ntaxable.  \n ", "original_text": "First of all, Change had \u2013 as most companies, had the \nimplementation of the revenue recognition standard, and that created a timing element for the year. "}, "hash": "59dee25ee2c46d1b9137a0ade7905f4902bf534682524093878ee8d5850d3cef", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nthough, there are a couple of things that I  would point out. ", "start_char_idx": 16, "end_char_idx": 243, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "60f2227c-ba5a-407e-a0e0-62fd9cc79882": {"__data__": {"id_": "60f2227c-ba5a-407e-a0e0-62fd9cc79882", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nthough, there are a couple of things that I  would point out.  First of all, Change had \u2013 as most companies, had the \nimplementation of the revenue recognition standard, and that created a timing element for the year.  For the full \nyear, that's not going to have an impact on McKesson, but it does have an impact earlier \u2013 favorable impact \nearlier in the year and [then it'll reverse out as the year goes on.  \n \n And then, of course, as you think about that business, there is a mix of income between taxable and non -taxable \ndepending on the legal entity.  So what I would say is, primarily for the first quarter you see some timing impact \nfrom the revenue recognition standard and you see a mix of income between the entities of taxable and non -\ntaxable.  \n ", "original_text": "First of all, Change had \u2013 as most companies, had the \nimplementation of the revenue recognition standard, and that created a timing element for the year. ", "page_label": "14", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "99b53c78-61a9-4e06-89a5-d5a3295894da", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1fc1b41fb0a3728ca79532ff4fdf5f7b6d1ac601f71ff8e3fc1aa0d1723e043b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8d25075b-13df-4014-90f3-9c03c800be00", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nthough, there are a couple of things that I  would point out.  First of all, Change had \u2013 as most companies, had the \nimplementation of the revenue recognition standard, and that created a timing element for the year.  For the full \nyear, that's not going to have an impact on McKesson, but it does have an impact earlier \u2013 favorable impact \nearlier in the year and [then it'll reverse out as the year goes on.  \n \n And then, of course, as you think about that business, there is a mix of income between taxable and non -taxable \ndepending on the legal entity. ", "original_text": "(MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nthough, there are a couple of things that I  would point out. ", "page_label": "14", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "396df9877e5463f63a4080bd600468032477b1c8e0ca7a4a05b085cf776d5f36", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "56296206-a80b-449b-bd6e-f6343beca97e", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nthough, there are a couple of things that I  would point out.  First of all, Change had \u2013 as most companies, had the \nimplementation of the revenue recognition standard, and that created a timing element for the year.  For the full \nyear, that's not going to have an impact on McKesson, but it does have an impact earlier \u2013 favorable impact \nearlier in the year and [then it'll reverse out as the year goes on.  \n \n And then, of course, as you think about that business, there is a mix of income between taxable and non -taxable \ndepending on the legal entity.  So what I would say is, primarily for the first quarter you see some timing impact \nfrom the revenue recognition standard and you see a mix of income between the entities of taxable and non -\ntaxable.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRoss Muken  \nAnalyst, Evercore ISI  Q \nGot it. ", "original_text": "For the full \nyear, that's not going to have an impact on McKesson, but it does have an impact earlier \u2013 favorable impact \nearlier in the year and [then it'll reverse out as the year goes on.  \n \n"}, "hash": "b6950fe304db1135b00619db2186c145466ba046d0cfc96229291cbcd4727066", "class_name": "RelatedNodeInfo"}}, "text": "First of all, Change had \u2013 as most companies, had the \nimplementation of the revenue recognition standard, and that created a timing element for the year. ", "start_char_idx": 243, "end_char_idx": 398, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "56296206-a80b-449b-bd6e-f6343beca97e": {"__data__": {"id_": "56296206-a80b-449b-bd6e-f6343beca97e", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nthough, there are a couple of things that I  would point out.  First of all, Change had \u2013 as most companies, had the \nimplementation of the revenue recognition standard, and that created a timing element for the year.  For the full \nyear, that's not going to have an impact on McKesson, but it does have an impact earlier \u2013 favorable impact \nearlier in the year and [then it'll reverse out as the year goes on.  \n \n And then, of course, as you think about that business, there is a mix of income between taxable and non -taxable \ndepending on the legal entity.  So what I would say is, primarily for the first quarter you see some timing impact \nfrom the revenue recognition standard and you see a mix of income between the entities of taxable and non -\ntaxable.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRoss Muken  \nAnalyst, Evercore ISI  Q \nGot it. ", "original_text": "For the full \nyear, that's not going to have an impact on McKesson, but it does have an impact earlier \u2013 favorable impact \nearlier in the year and [then it'll reverse out as the year goes on.  \n \n", "page_label": "14", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "99b53c78-61a9-4e06-89a5-d5a3295894da", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1fc1b41fb0a3728ca79532ff4fdf5f7b6d1ac601f71ff8e3fc1aa0d1723e043b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "60f2227c-ba5a-407e-a0e0-62fd9cc79882", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nthough, there are a couple of things that I  would point out.  First of all, Change had \u2013 as most companies, had the \nimplementation of the revenue recognition standard, and that created a timing element for the year.  For the full \nyear, that's not going to have an impact on McKesson, but it does have an impact earlier \u2013 favorable impact \nearlier in the year and [then it'll reverse out as the year goes on.  \n \n And then, of course, as you think about that business, there is a mix of income between taxable and non -taxable \ndepending on the legal entity.  So what I would say is, primarily for the first quarter you see some timing impact \nfrom the revenue recognition standard and you see a mix of income between the entities of taxable and non -\ntaxable.  \n ", "original_text": "First of all, Change had \u2013 as most companies, had the \nimplementation of the revenue recognition standard, and that created a timing element for the year. ", "page_label": "14", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "18ac352878855fbb4c04bcdfbe6e879562513147df408cb9418b13a28d8f681d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2606544e-c230-43ac-9fe1-2eb6e687bea0", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nthough, there are a couple of things that I  would point out.  First of all, Change had \u2013 as most companies, had the \nimplementation of the revenue recognition standard, and that created a timing element for the year.  For the full \nyear, that's not going to have an impact on McKesson, but it does have an impact earlier \u2013 favorable impact \nearlier in the year and [then it'll reverse out as the year goes on.  \n \n And then, of course, as you think about that business, there is a mix of income between taxable and non -taxable \ndepending on the legal entity.  So what I would say is, primarily for the first quarter you see some timing impact \nfrom the revenue recognition standard and you see a mix of income between the entities of taxable and non -\ntaxable.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRoss Muken  \nAnalyst, Evercore ISI  Q \nGot it.  And then maybe just thinking about sort of maybe business development activity or the M&A side of things. \n", "original_text": "And then, of course, as you think about that business, there is a mix of income between taxable and non -taxable \ndepending on the legal entity. "}, "hash": "c879de194beb96245e358f7e9a98dbeb9fefb4e9e45aa7a276bbbd6aac43c6e8", "class_name": "RelatedNodeInfo"}}, "text": "For the full \nyear, that's not going to have an impact on McKesson, but it does have an impact earlier \u2013 favorable impact \nearlier in the year and [then it'll reverse out as the year goes on.  \n \n", "start_char_idx": 398, "end_char_idx": 594, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2606544e-c230-43ac-9fe1-2eb6e687bea0": {"__data__": {"id_": "2606544e-c230-43ac-9fe1-2eb6e687bea0", "embedding": null, "metadata": {"window": "(MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nthough, there are a couple of things that I  would point out.  First of all, Change had \u2013 as most companies, had the \nimplementation of the revenue recognition standard, and that created a timing element for the year.  For the full \nyear, that's not going to have an impact on McKesson, but it does have an impact earlier \u2013 favorable impact \nearlier in the year and [then it'll reverse out as the year goes on.  \n \n And then, of course, as you think about that business, there is a mix of income between taxable and non -taxable \ndepending on the legal entity.  So what I would say is, primarily for the first quarter you see some timing impact \nfrom the revenue recognition standard and you see a mix of income between the entities of taxable and non -\ntaxable.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRoss Muken  \nAnalyst, Evercore ISI  Q \nGot it.  And then maybe just thinking about sort of maybe business development activity or the M&A side of things. \n", "original_text": "And then, of course, as you think about that business, there is a mix of income between taxable and non -taxable \ndepending on the legal entity. ", "page_label": "14", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "99b53c78-61a9-4e06-89a5-d5a3295894da", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1fc1b41fb0a3728ca79532ff4fdf5f7b6d1ac601f71ff8e3fc1aa0d1723e043b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "56296206-a80b-449b-bd6e-f6343beca97e", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nthough, there are a couple of things that I  would point out.  First of all, Change had \u2013 as most companies, had the \nimplementation of the revenue recognition standard, and that created a timing element for the year.  For the full \nyear, that's not going to have an impact on McKesson, but it does have an impact earlier \u2013 favorable impact \nearlier in the year and [then it'll reverse out as the year goes on.  \n \n And then, of course, as you think about that business, there is a mix of income between taxable and non -taxable \ndepending on the legal entity.  So what I would say is, primarily for the first quarter you see some timing impact \nfrom the revenue recognition standard and you see a mix of income between the entities of taxable and non -\ntaxable.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRoss Muken  \nAnalyst, Evercore ISI  Q \nGot it. ", "original_text": "For the full \nyear, that's not going to have an impact on McKesson, but it does have an impact earlier \u2013 favorable impact \nearlier in the year and [then it'll reverse out as the year goes on.  \n \n", "page_label": "14", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "02a4dc22cfaed1c53d0576d65b3e94db9ff2f145d5e6cc941321a38e9046d83e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "581b8ff0-a00c-48fd-8cf4-d12ce78a5d4b", "node_type": "1", "metadata": {"window": "First of all, Change had \u2013 as most companies, had the \nimplementation of the revenue recognition standard, and that created a timing element for the year.  For the full \nyear, that's not going to have an impact on McKesson, but it does have an impact earlier \u2013 favorable impact \nearlier in the year and [then it'll reverse out as the year goes on.  \n \n And then, of course, as you think about that business, there is a mix of income between taxable and non -taxable \ndepending on the legal entity.  So what I would say is, primarily for the first quarter you see some timing impact \nfrom the revenue recognition standard and you see a mix of income between the entities of taxable and non -\ntaxable.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRoss Muken  \nAnalyst, Evercore ISI  Q \nGot it.  And then maybe just thinking about sort of maybe business development activity or the M&A side of things. \n Lot of things in services including your own asset obviously had challenging multiples. ", "original_text": "So what I would say is, primarily for the first quarter you see some timing impact \nfrom the revenue recognition standard and you see a mix of income between the entities of taxable and non -\ntaxable.  \n "}, "hash": "6abd67827dea270530166f04a0fdbff9e1f9fc6355799cdf54d073e94958286f", "class_name": "RelatedNodeInfo"}}, "text": "And then, of course, as you think about that business, there is a mix of income between taxable and non -taxable \ndepending on the legal entity. ", "start_char_idx": 594, "end_char_idx": 739, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "581b8ff0-a00c-48fd-8cf4-d12ce78a5d4b": {"__data__": {"id_": "581b8ff0-a00c-48fd-8cf4-d12ce78a5d4b", "embedding": null, "metadata": {"window": "First of all, Change had \u2013 as most companies, had the \nimplementation of the revenue recognition standard, and that created a timing element for the year.  For the full \nyear, that's not going to have an impact on McKesson, but it does have an impact earlier \u2013 favorable impact \nearlier in the year and [then it'll reverse out as the year goes on.  \n \n And then, of course, as you think about that business, there is a mix of income between taxable and non -taxable \ndepending on the legal entity.  So what I would say is, primarily for the first quarter you see some timing impact \nfrom the revenue recognition standard and you see a mix of income between the entities of taxable and non -\ntaxable.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRoss Muken  \nAnalyst, Evercore ISI  Q \nGot it.  And then maybe just thinking about sort of maybe business development activity or the M&A side of things. \n Lot of things in services including your own asset obviously had challenging multiples. ", "original_text": "So what I would say is, primarily for the first quarter you see some timing impact \nfrom the revenue recognition standard and you see a mix of income between the entities of taxable and non -\ntaxable.  \n ", "page_label": "14", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "99b53c78-61a9-4e06-89a5-d5a3295894da", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1fc1b41fb0a3728ca79532ff4fdf5f7b6d1ac601f71ff8e3fc1aa0d1723e043b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2606544e-c230-43ac-9fe1-2eb6e687bea0", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nthough, there are a couple of things that I  would point out.  First of all, Change had \u2013 as most companies, had the \nimplementation of the revenue recognition standard, and that created a timing element for the year.  For the full \nyear, that's not going to have an impact on McKesson, but it does have an impact earlier \u2013 favorable impact \nearlier in the year and [then it'll reverse out as the year goes on.  \n \n And then, of course, as you think about that business, there is a mix of income between taxable and non -taxable \ndepending on the legal entity.  So what I would say is, primarily for the first quarter you see some timing impact \nfrom the revenue recognition standard and you see a mix of income between the entities of taxable and non -\ntaxable.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRoss Muken  \nAnalyst, Evercore ISI  Q \nGot it.  And then maybe just thinking about sort of maybe business development activity or the M&A side of things. \n", "original_text": "And then, of course, as you think about that business, there is a mix of income between taxable and non -taxable \ndepending on the legal entity. ", "page_label": "14", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "310d227c46398b72ca9afb804baa6c0dab544a0bbf0e91731fedd5be66b13733", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0696d89b-073e-40ea-86b3-8c33a0a29964", "node_type": "1", "metadata": {"window": "For the full \nyear, that's not going to have an impact on McKesson, but it does have an impact earlier \u2013 favorable impact \nearlier in the year and [then it'll reverse out as the year goes on.  \n \n And then, of course, as you think about that business, there is a mix of income between taxable and non -taxable \ndepending on the legal entity.  So what I would say is, primarily for the first quarter you see some timing impact \nfrom the revenue recognition standard and you see a mix of income between the entities of taxable and non -\ntaxable.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRoss Muken  \nAnalyst, Evercore ISI  Q \nGot it.  And then maybe just thinking about sort of maybe business development activity or the M&A side of things. \n Lot of things in services including your own asset obviously had challenging multiples.  There is a lot of political \nwings going on. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRoss Muken  \nAnalyst, Evercore ISI  Q \nGot it. "}, "hash": "9a048232cefb3d4276eb6230069b35a2cd440cd1f0f00ad7282864f3249cd07e", "class_name": "RelatedNodeInfo"}}, "text": "So what I would say is, primarily for the first quarter you see some timing impact \nfrom the revenue recognition standard and you see a mix of income between the entities of taxable and non -\ntaxable.  \n ", "start_char_idx": 739, "end_char_idx": 943, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0696d89b-073e-40ea-86b3-8c33a0a29964": {"__data__": {"id_": "0696d89b-073e-40ea-86b3-8c33a0a29964", "embedding": null, "metadata": {"window": "For the full \nyear, that's not going to have an impact on McKesson, but it does have an impact earlier \u2013 favorable impact \nearlier in the year and [then it'll reverse out as the year goes on.  \n \n And then, of course, as you think about that business, there is a mix of income between taxable and non -taxable \ndepending on the legal entity.  So what I would say is, primarily for the first quarter you see some timing impact \nfrom the revenue recognition standard and you see a mix of income between the entities of taxable and non -\ntaxable.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRoss Muken  \nAnalyst, Evercore ISI  Q \nGot it.  And then maybe just thinking about sort of maybe business development activity or the M&A side of things. \n Lot of things in services including your own asset obviously had challenging multiples.  There is a lot of political \nwings going on. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRoss Muken  \nAnalyst, Evercore ISI  Q \nGot it. ", "page_label": "14", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "99b53c78-61a9-4e06-89a5-d5a3295894da", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1fc1b41fb0a3728ca79532ff4fdf5f7b6d1ac601f71ff8e3fc1aa0d1723e043b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "581b8ff0-a00c-48fd-8cf4-d12ce78a5d4b", "node_type": "1", "metadata": {"window": "First of all, Change had \u2013 as most companies, had the \nimplementation of the revenue recognition standard, and that created a timing element for the year.  For the full \nyear, that's not going to have an impact on McKesson, but it does have an impact earlier \u2013 favorable impact \nearlier in the year and [then it'll reverse out as the year goes on.  \n \n And then, of course, as you think about that business, there is a mix of income between taxable and non -taxable \ndepending on the legal entity.  So what I would say is, primarily for the first quarter you see some timing impact \nfrom the revenue recognition standard and you see a mix of income between the entities of taxable and non -\ntaxable.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRoss Muken  \nAnalyst, Evercore ISI  Q \nGot it.  And then maybe just thinking about sort of maybe business development activity or the M&A side of things. \n Lot of things in services including your own asset obviously had challenging multiples. ", "original_text": "So what I would say is, primarily for the first quarter you see some timing impact \nfrom the revenue recognition standard and you see a mix of income between the entities of taxable and non -\ntaxable.  \n ", "page_label": "14", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "30638a32350bf638a3f8245879a3a289b97d04ea6fde252d6472ba806a2fd6e0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "feb7642c-4d50-4bd2-97cb-ff893d5836ca", "node_type": "1", "metadata": {"window": "And then, of course, as you think about that business, there is a mix of income between taxable and non -taxable \ndepending on the legal entity.  So what I would say is, primarily for the first quarter you see some timing impact \nfrom the revenue recognition standard and you see a mix of income between the entities of taxable and non -\ntaxable.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRoss Muken  \nAnalyst, Evercore ISI  Q \nGot it.  And then maybe just thinking about sort of maybe business development activity or the M&A side of things. \n Lot of things in services including your own asset obviously had challenging multiples.  There is a lot of political \nwings going on.  I guess, how do you sort of frame  what's the right time to be more active again on sort of tuck -in \nM&A? ", "original_text": "And then maybe just thinking about sort of maybe business development activity or the M&A side of things. \n"}, "hash": "8f323b69b254406e2715911f2c528fd6fec1601a1705cbf56bee0d47fe1cebe6", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRoss Muken  \nAnalyst, Evercore ISI  Q \nGot it. ", "start_char_idx": 943, "end_char_idx": 1247, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "feb7642c-4d50-4bd2-97cb-ff893d5836ca": {"__data__": {"id_": "feb7642c-4d50-4bd2-97cb-ff893d5836ca", "embedding": null, "metadata": {"window": "And then, of course, as you think about that business, there is a mix of income between taxable and non -taxable \ndepending on the legal entity.  So what I would say is, primarily for the first quarter you see some timing impact \nfrom the revenue recognition standard and you see a mix of income between the entities of taxable and non -\ntaxable.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRoss Muken  \nAnalyst, Evercore ISI  Q \nGot it.  And then maybe just thinking about sort of maybe business development activity or the M&A side of things. \n Lot of things in services including your own asset obviously had challenging multiples.  There is a lot of political \nwings going on.  I guess, how do you sort of frame  what's the right time to be more active again on sort of tuck -in \nM&A? ", "original_text": "And then maybe just thinking about sort of maybe business development activity or the M&A side of things. \n", "page_label": "14", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "99b53c78-61a9-4e06-89a5-d5a3295894da", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1fc1b41fb0a3728ca79532ff4fdf5f7b6d1ac601f71ff8e3fc1aa0d1723e043b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0696d89b-073e-40ea-86b3-8c33a0a29964", "node_type": "1", "metadata": {"window": "For the full \nyear, that's not going to have an impact on McKesson, but it does have an impact earlier \u2013 favorable impact \nearlier in the year and [then it'll reverse out as the year goes on.  \n \n And then, of course, as you think about that business, there is a mix of income between taxable and non -taxable \ndepending on the legal entity.  So what I would say is, primarily for the first quarter you see some timing impact \nfrom the revenue recognition standard and you see a mix of income between the entities of taxable and non -\ntaxable.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRoss Muken  \nAnalyst, Evercore ISI  Q \nGot it.  And then maybe just thinking about sort of maybe business development activity or the M&A side of things. \n Lot of things in services including your own asset obviously had challenging multiples.  There is a lot of political \nwings going on. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRoss Muken  \nAnalyst, Evercore ISI  Q \nGot it. ", "page_label": "14", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "99ee8fdce54f418a715e210f735bf79e2b99f6a2966d2dac99e801981eee92c1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d70e5eb2-420f-4a34-bd4a-96244558099b", "node_type": "1", "metadata": {"window": "So what I would say is, primarily for the first quarter you see some timing impact \nfrom the revenue recognition standard and you see a mix of income between the entities of taxable and non -\ntaxable.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRoss Muken  \nAnalyst, Evercore ISI  Q \nGot it.  And then maybe just thinking about sort of maybe business development activity or the M&A side of things. \n Lot of things in services including your own asset obviously had challenging multiples.  There is a lot of political \nwings going on.  I guess, how do you sort of frame  what's the right time to be more active again on sort of tuck -in \nM&A?  And how the risk reward sort of is there versus just continuing to buy your own equity which given its cash \nflow yield, seems like a reasonable investment?  \n ", "original_text": "Lot of things in services including your own asset obviously had challenging multiples. "}, "hash": "fc8174b27e0109e4d550b3905a4ed69291f55424d3f1b20c2bdde177e2e5390b", "class_name": "RelatedNodeInfo"}}, "text": "And then maybe just thinking about sort of maybe business development activity or the M&A side of things. \n", "start_char_idx": 1247, "end_char_idx": 1354, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d70e5eb2-420f-4a34-bd4a-96244558099b": {"__data__": {"id_": "d70e5eb2-420f-4a34-bd4a-96244558099b", "embedding": null, "metadata": {"window": "So what I would say is, primarily for the first quarter you see some timing impact \nfrom the revenue recognition standard and you see a mix of income between the entities of taxable and non -\ntaxable.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRoss Muken  \nAnalyst, Evercore ISI  Q \nGot it.  And then maybe just thinking about sort of maybe business development activity or the M&A side of things. \n Lot of things in services including your own asset obviously had challenging multiples.  There is a lot of political \nwings going on.  I guess, how do you sort of frame  what's the right time to be more active again on sort of tuck -in \nM&A?  And how the risk reward sort of is there versus just continuing to buy your own equity which given its cash \nflow yield, seems like a reasonable investment?  \n ", "original_text": "Lot of things in services including your own asset obviously had challenging multiples. ", "page_label": "14", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "99b53c78-61a9-4e06-89a5-d5a3295894da", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1fc1b41fb0a3728ca79532ff4fdf5f7b6d1ac601f71ff8e3fc1aa0d1723e043b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "feb7642c-4d50-4bd2-97cb-ff893d5836ca", "node_type": "1", "metadata": {"window": "And then, of course, as you think about that business, there is a mix of income between taxable and non -taxable \ndepending on the legal entity.  So what I would say is, primarily for the first quarter you see some timing impact \nfrom the revenue recognition standard and you see a mix of income between the entities of taxable and non -\ntaxable.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRoss Muken  \nAnalyst, Evercore ISI  Q \nGot it.  And then maybe just thinking about sort of maybe business development activity or the M&A side of things. \n Lot of things in services including your own asset obviously had challenging multiples.  There is a lot of political \nwings going on.  I guess, how do you sort of frame  what's the right time to be more active again on sort of tuck -in \nM&A? ", "original_text": "And then maybe just thinking about sort of maybe business development activity or the M&A side of things. \n", "page_label": "14", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7ab5a70412d0234a5720637af33740836c349cced077a007fa186d2ba8b24bd6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bb4774ec-8065-45c9-b119-babe59ef7374", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRoss Muken  \nAnalyst, Evercore ISI  Q \nGot it.  And then maybe just thinking about sort of maybe business development activity or the M&A side of things. \n Lot of things in services including your own asset obviously had challenging multiples.  There is a lot of political \nwings going on.  I guess, how do you sort of frame  what's the right time to be more active again on sort of tuck -in \nM&A?  And how the risk reward sort of is there versus just continuing to buy your own equity which given its cash \nflow yield, seems like a reasonable investment?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Exe cutive Officer & Director, McKesson Corp.  ", "original_text": "There is a lot of political \nwings going on. "}, "hash": "ea39367401b76a89b0414fb8ab681bc9a37b260d76f26f8824a43311c6d99ee8", "class_name": "RelatedNodeInfo"}}, "text": "Lot of things in services including your own asset obviously had challenging multiples. ", "start_char_idx": 1354, "end_char_idx": 1442, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bb4774ec-8065-45c9-b119-babe59ef7374": {"__data__": {"id_": "bb4774ec-8065-45c9-b119-babe59ef7374", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRoss Muken  \nAnalyst, Evercore ISI  Q \nGot it.  And then maybe just thinking about sort of maybe business development activity or the M&A side of things. \n Lot of things in services including your own asset obviously had challenging multiples.  There is a lot of political \nwings going on.  I guess, how do you sort of frame  what's the right time to be more active again on sort of tuck -in \nM&A?  And how the risk reward sort of is there versus just continuing to buy your own equity which given its cash \nflow yield, seems like a reasonable investment?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Exe cutive Officer & Director, McKesson Corp.  ", "original_text": "There is a lot of political \nwings going on. ", "page_label": "14", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "99b53c78-61a9-4e06-89a5-d5a3295894da", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1fc1b41fb0a3728ca79532ff4fdf5f7b6d1ac601f71ff8e3fc1aa0d1723e043b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d70e5eb2-420f-4a34-bd4a-96244558099b", "node_type": "1", "metadata": {"window": "So what I would say is, primarily for the first quarter you see some timing impact \nfrom the revenue recognition standard and you see a mix of income between the entities of taxable and non -\ntaxable.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRoss Muken  \nAnalyst, Evercore ISI  Q \nGot it.  And then maybe just thinking about sort of maybe business development activity or the M&A side of things. \n Lot of things in services including your own asset obviously had challenging multiples.  There is a lot of political \nwings going on.  I guess, how do you sort of frame  what's the right time to be more active again on sort of tuck -in \nM&A?  And how the risk reward sort of is there versus just continuing to buy your own equity which given its cash \nflow yield, seems like a reasonable investment?  \n ", "original_text": "Lot of things in services including your own asset obviously had challenging multiples. ", "page_label": "14", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5dfc6b3776aa9b10c6e9ac7faabf26bdb7f84de7705f04f0e5b362d0431a9b7a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "23af6603-2f0e-443b-ac65-c23b6b28b3ea", "node_type": "1", "metadata": {"window": "And then maybe just thinking about sort of maybe business development activity or the M&A side of things. \n Lot of things in services including your own asset obviously had challenging multiples.  There is a lot of political \nwings going on.  I guess, how do you sort of frame  what's the right time to be more active again on sort of tuck -in \nM&A?  And how the risk reward sort of is there versus just continuing to buy your own equity which given its cash \nflow yield, seems like a reasonable investment?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Exe cutive Officer & Director, McKesson Corp.   A \nYeah. ", "original_text": "I guess, how do you sort of frame  what's the right time to be more active again on sort of tuck -in \nM&A? "}, "hash": "63970d5793efdb48e7f12b8b37e9fbeea5fc04908123d523ab839c598548e649", "class_name": "RelatedNodeInfo"}}, "text": "There is a lot of political \nwings going on. ", "start_char_idx": 1442, "end_char_idx": 1487, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "23af6603-2f0e-443b-ac65-c23b6b28b3ea": {"__data__": {"id_": "23af6603-2f0e-443b-ac65-c23b6b28b3ea", "embedding": null, "metadata": {"window": "And then maybe just thinking about sort of maybe business development activity or the M&A side of things. \n Lot of things in services including your own asset obviously had challenging multiples.  There is a lot of political \nwings going on.  I guess, how do you sort of frame  what's the right time to be more active again on sort of tuck -in \nM&A?  And how the risk reward sort of is there versus just continuing to buy your own equity which given its cash \nflow yield, seems like a reasonable investment?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Exe cutive Officer & Director, McKesson Corp.   A \nYeah. ", "original_text": "I guess, how do you sort of frame  what's the right time to be more active again on sort of tuck -in \nM&A? ", "page_label": "14", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "99b53c78-61a9-4e06-89a5-d5a3295894da", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1fc1b41fb0a3728ca79532ff4fdf5f7b6d1ac601f71ff8e3fc1aa0d1723e043b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bb4774ec-8065-45c9-b119-babe59ef7374", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRoss Muken  \nAnalyst, Evercore ISI  Q \nGot it.  And then maybe just thinking about sort of maybe business development activity or the M&A side of things. \n Lot of things in services including your own asset obviously had challenging multiples.  There is a lot of political \nwings going on.  I guess, how do you sort of frame  what's the right time to be more active again on sort of tuck -in \nM&A?  And how the risk reward sort of is there versus just continuing to buy your own equity which given its cash \nflow yield, seems like a reasonable investment?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Exe cutive Officer & Director, McKesson Corp.  ", "original_text": "There is a lot of political \nwings going on. ", "page_label": "14", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8252152cfb4fd07f2741d307b3ac7ab706ba1637366958d5372232d843713529", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4a8a2ae4-c8d3-47be-8a97-16a7f589ab5e", "node_type": "1", "metadata": {"window": "Lot of things in services including your own asset obviously had challenging multiples.  There is a lot of political \nwings going on.  I guess, how do you sort of frame  what's the right time to be more active again on sort of tuck -in \nM&A?  And how the risk reward sort of is there versus just continuing to buy your own equity which given its cash \nflow yield, seems like a reasonable investment?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Exe cutive Officer & Director, McKesson Corp.   A \nYeah.  Thanks. ", "original_text": "And how the risk reward sort of is there versus just continuing to buy your own equity which given its cash \nflow yield, seems like a reasonable investment?  \n "}, "hash": "f0a2b0fc0edcfafcb12f4148c9da15610916465715df5be5fb94598b694c52b7", "class_name": "RelatedNodeInfo"}}, "text": "I guess, how do you sort of frame  what's the right time to be more active again on sort of tuck -in \nM&A? ", "start_char_idx": 1487, "end_char_idx": 1594, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4a8a2ae4-c8d3-47be-8a97-16a7f589ab5e": {"__data__": {"id_": "4a8a2ae4-c8d3-47be-8a97-16a7f589ab5e", "embedding": null, "metadata": {"window": "Lot of things in services including your own asset obviously had challenging multiples.  There is a lot of political \nwings going on.  I guess, how do you sort of frame  what's the right time to be more active again on sort of tuck -in \nM&A?  And how the risk reward sort of is there versus just continuing to buy your own equity which given its cash \nflow yield, seems like a reasonable investment?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Exe cutive Officer & Director, McKesson Corp.   A \nYeah.  Thanks. ", "original_text": "And how the risk reward sort of is there versus just continuing to buy your own equity which given its cash \nflow yield, seems like a reasonable investment?  \n ", "page_label": "14", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "99b53c78-61a9-4e06-89a5-d5a3295894da", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1fc1b41fb0a3728ca79532ff4fdf5f7b6d1ac601f71ff8e3fc1aa0d1723e043b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "23af6603-2f0e-443b-ac65-c23b6b28b3ea", "node_type": "1", "metadata": {"window": "And then maybe just thinking about sort of maybe business development activity or the M&A side of things. \n Lot of things in services including your own asset obviously had challenging multiples.  There is a lot of political \nwings going on.  I guess, how do you sort of frame  what's the right time to be more active again on sort of tuck -in \nM&A?  And how the risk reward sort of is there versus just continuing to buy your own equity which given its cash \nflow yield, seems like a reasonable investment?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Exe cutive Officer & Director, McKesson Corp.   A \nYeah. ", "original_text": "I guess, how do you sort of frame  what's the right time to be more active again on sort of tuck -in \nM&A? ", "page_label": "14", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "daa3807270bb49962f2db89563c868a5ca21ab499b0359c1aebdc106ddeb10d5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5f76fd75-128b-4e9e-b1bf-5cba51588a8a", "node_type": "1", "metadata": {"window": "There is a lot of political \nwings going on.  I guess, how do you sort of frame  what's the right time to be more active again on sort of tuck -in \nM&A?  And how the risk reward sort of is there versus just continuing to buy your own equity which given its cash \nflow yield, seems like a reasonable investment?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Exe cutive Officer & Director, McKesson Corp.   A \nYeah.  Thanks.  Thanks for the question. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Exe cutive Officer & Director, McKesson Corp.  "}, "hash": "ceafb50057e39011ef17d2655db2c1a9d812e23bf0d037c1f6f227f264c416a8", "class_name": "RelatedNodeInfo"}}, "text": "And how the risk reward sort of is there versus just continuing to buy your own equity which given its cash \nflow yield, seems like a reasonable investment?  \n ", "start_char_idx": 1594, "end_char_idx": 1754, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5f76fd75-128b-4e9e-b1bf-5cba51588a8a": {"__data__": {"id_": "5f76fd75-128b-4e9e-b1bf-5cba51588a8a", "embedding": null, "metadata": {"window": "There is a lot of political \nwings going on.  I guess, how do you sort of frame  what's the right time to be more active again on sort of tuck -in \nM&A?  And how the risk reward sort of is there versus just continuing to buy your own equity which given its cash \nflow yield, seems like a reasonable investment?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Exe cutive Officer & Director, McKesson Corp.   A \nYeah.  Thanks.  Thanks for the question. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Exe cutive Officer & Director, McKesson Corp.  ", "page_label": "14", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "99b53c78-61a9-4e06-89a5-d5a3295894da", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1fc1b41fb0a3728ca79532ff4fdf5f7b6d1ac601f71ff8e3fc1aa0d1723e043b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4a8a2ae4-c8d3-47be-8a97-16a7f589ab5e", "node_type": "1", "metadata": {"window": "Lot of things in services including your own asset obviously had challenging multiples.  There is a lot of political \nwings going on.  I guess, how do you sort of frame  what's the right time to be more active again on sort of tuck -in \nM&A?  And how the risk reward sort of is there versus just continuing to buy your own equity which given its cash \nflow yield, seems like a reasonable investment?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Exe cutive Officer & Director, McKesson Corp.   A \nYeah.  Thanks. ", "original_text": "And how the risk reward sort of is there versus just continuing to buy your own equity which given its cash \nflow yield, seems like a reasonable investment?  \n ", "page_label": "14", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cfd9bcda95b0439764d64ad773caa4dde43139b49679810492e32dcf3eb4ad7a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "432f58a7-1f2c-44a0-a79a-6eabf47d727c", "node_type": "1", "metadata": {"window": "I guess, how do you sort of frame  what's the right time to be more active again on sort of tuck -in \nM&A?  And how the risk reward sort of is there versus just continuing to buy your own equity which given its cash \nflow yield, seems like a reasonable investment?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Exe cutive Officer & Director, McKesson Corp.   A \nYeah.  Thanks.  Thanks for the question.  And I think we would characterize our M&A activity in recent quarters as \nbeing relatively light. ", "original_text": "A \nYeah. "}, "hash": "542674065aafbe4d98c469345cb33c00d8ecf90ebe7a71dd89c3eed61e579d5e", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Exe cutive Officer & Director, McKesson Corp.  ", "start_char_idx": 1754, "end_char_idx": 2084, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "432f58a7-1f2c-44a0-a79a-6eabf47d727c": {"__data__": {"id_": "432f58a7-1f2c-44a0-a79a-6eabf47d727c", "embedding": null, "metadata": {"window": "I guess, how do you sort of frame  what's the right time to be more active again on sort of tuck -in \nM&A?  And how the risk reward sort of is there versus just continuing to buy your own equity which given its cash \nflow yield, seems like a reasonable investment?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Exe cutive Officer & Director, McKesson Corp.   A \nYeah.  Thanks.  Thanks for the question.  And I think we would characterize our M&A activity in recent quarters as \nbeing relatively light. ", "original_text": "A \nYeah. ", "page_label": "14", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "99b53c78-61a9-4e06-89a5-d5a3295894da", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1fc1b41fb0a3728ca79532ff4fdf5f7b6d1ac601f71ff8e3fc1aa0d1723e043b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5f76fd75-128b-4e9e-b1bf-5cba51588a8a", "node_type": "1", "metadata": {"window": "There is a lot of political \nwings going on.  I guess, how do you sort of frame  what's the right time to be more active again on sort of tuck -in \nM&A?  And how the risk reward sort of is there versus just continuing to buy your own equity which given its cash \nflow yield, seems like a reasonable investment?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Exe cutive Officer & Director, McKesson Corp.   A \nYeah.  Thanks.  Thanks for the question. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Exe cutive Officer & Director, McKesson Corp.  ", "page_label": "14", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bbf799fe577ceaec2647cff61378cfc594c78636ee2a3413cd81811196ea00c7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bd09b410-ed91-44ee-83e7-8712b5befe0c", "node_type": "1", "metadata": {"window": "And how the risk reward sort of is there versus just continuing to buy your own equity which given its cash \nflow yield, seems like a reasonable investment?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Exe cutive Officer & Director, McKesson Corp.   A \nYeah.  Thanks.  Thanks for the question.  And I think we would characterize our M&A activity in recent quarters as \nbeing relatively light.  That doesn't mean that we're out of that space. ", "original_text": "Thanks. "}, "hash": "ffdadace699ce1b764a03f218a5fe5d270f8575b022fba791e980a8191615f72", "class_name": "RelatedNodeInfo"}}, "text": "A \nYeah. ", "start_char_idx": 2084, "end_char_idx": 2093, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bd09b410-ed91-44ee-83e7-8712b5befe0c": {"__data__": {"id_": "bd09b410-ed91-44ee-83e7-8712b5befe0c", "embedding": null, "metadata": {"window": "And how the risk reward sort of is there versus just continuing to buy your own equity which given its cash \nflow yield, seems like a reasonable investment?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Exe cutive Officer & Director, McKesson Corp.   A \nYeah.  Thanks.  Thanks for the question.  And I think we would characterize our M&A activity in recent quarters as \nbeing relatively light.  That doesn't mean that we're out of that space. ", "original_text": "Thanks. ", "page_label": "14", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "99b53c78-61a9-4e06-89a5-d5a3295894da", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1fc1b41fb0a3728ca79532ff4fdf5f7b6d1ac601f71ff8e3fc1aa0d1723e043b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "432f58a7-1f2c-44a0-a79a-6eabf47d727c", "node_type": "1", "metadata": {"window": "I guess, how do you sort of frame  what's the right time to be more active again on sort of tuck -in \nM&A?  And how the risk reward sort of is there versus just continuing to buy your own equity which given its cash \nflow yield, seems like a reasonable investment?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Exe cutive Officer & Director, McKesson Corp.   A \nYeah.  Thanks.  Thanks for the question.  And I think we would characterize our M&A activity in recent quarters as \nbeing relatively light. ", "original_text": "A \nYeah. ", "page_label": "14", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ee159c630c40beee2819c5e56191493c3717254afc9831a8e2d513814bb4ccbd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "555ed4b1-29e9-45ff-afae-9159a818e6d9", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Exe cutive Officer & Director, McKesson Corp.   A \nYeah.  Thanks.  Thanks for the question.  And I think we would characterize our M&A activity in recent quarters as \nbeing relatively light.  That doesn't mean that we're out of that space.  I think when we think about  capital \nallocation, we're always very focused on where are the opportunities to deploy capital, to build platforms and \nbusinesses and services for sustainable growth over the long term.  \n \n", "original_text": "Thanks for the question. "}, "hash": "e7431af356e3784f5c7e329b4308172fe33f6500ca0628b58c83514452d0c798", "class_name": "RelatedNodeInfo"}}, "text": "Thanks. ", "start_char_idx": 2093, "end_char_idx": 2101, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "555ed4b1-29e9-45ff-afae-9159a818e6d9": {"__data__": {"id_": "555ed4b1-29e9-45ff-afae-9159a818e6d9", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Exe cutive Officer & Director, McKesson Corp.   A \nYeah.  Thanks.  Thanks for the question.  And I think we would characterize our M&A activity in recent quarters as \nbeing relatively light.  That doesn't mean that we're out of that space.  I think when we think about  capital \nallocation, we're always very focused on where are the opportunities to deploy capital, to build platforms and \nbusinesses and services for sustainable growth over the long term.  \n \n", "original_text": "Thanks for the question. ", "page_label": "14", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "99b53c78-61a9-4e06-89a5-d5a3295894da", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1fc1b41fb0a3728ca79532ff4fdf5f7b6d1ac601f71ff8e3fc1aa0d1723e043b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bd09b410-ed91-44ee-83e7-8712b5befe0c", "node_type": "1", "metadata": {"window": "And how the risk reward sort of is there versus just continuing to buy your own equity which given its cash \nflow yield, seems like a reasonable investment?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Exe cutive Officer & Director, McKesson Corp.   A \nYeah.  Thanks.  Thanks for the question.  And I think we would characterize our M&A activity in recent quarters as \nbeing relatively light.  That doesn't mean that we're out of that space. ", "original_text": "Thanks. ", "page_label": "14", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "46a999fe035e1321b4a2d68159835d654337382e99e5692fa87c17fd7aabb2d6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b1cb49b6-4288-4d5f-9397-512f5dd2c576", "node_type": "1", "metadata": {"window": "A \nYeah.  Thanks.  Thanks for the question.  And I think we would characterize our M&A activity in recent quarters as \nbeing relatively light.  That doesn't mean that we're out of that space.  I think when we think about  capital \nallocation, we're always very focused on where are the opportunities to deploy capital, to build platforms and \nbusinesses and services for sustainable growth over the long term.  \n \n We are being very diligent to make sure that as we look at this proc ess, that is guided by our strategy, that's \nguided by our focal areas, it's guided by the markets and segments where we think we have good businesses, \nstrong teams, the right to win. ", "original_text": "And I think we would characterize our M&A activity in recent quarters as \nbeing relatively light. "}, "hash": "2d3fc158bcb078d7682a4d7c83289cb8817f0b912a12bba9ed7307e0ee2d000f", "class_name": "RelatedNodeInfo"}}, "text": "Thanks for the question. ", "start_char_idx": 2101, "end_char_idx": 2126, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b1cb49b6-4288-4d5f-9397-512f5dd2c576": {"__data__": {"id_": "b1cb49b6-4288-4d5f-9397-512f5dd2c576", "embedding": null, "metadata": {"window": "A \nYeah.  Thanks.  Thanks for the question.  And I think we would characterize our M&A activity in recent quarters as \nbeing relatively light.  That doesn't mean that we're out of that space.  I think when we think about  capital \nallocation, we're always very focused on where are the opportunities to deploy capital, to build platforms and \nbusinesses and services for sustainable growth over the long term.  \n \n We are being very diligent to make sure that as we look at this proc ess, that is guided by our strategy, that's \nguided by our focal areas, it's guided by the markets and segments where we think we have good businesses, \nstrong teams, the right to win. ", "original_text": "And I think we would characterize our M&A activity in recent quarters as \nbeing relatively light. ", "page_label": "14", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "99b53c78-61a9-4e06-89a5-d5a3295894da", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1fc1b41fb0a3728ca79532ff4fdf5f7b6d1ac601f71ff8e3fc1aa0d1723e043b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "555ed4b1-29e9-45ff-afae-9159a818e6d9", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Exe cutive Officer & Director, McKesson Corp.   A \nYeah.  Thanks.  Thanks for the question.  And I think we would characterize our M&A activity in recent quarters as \nbeing relatively light.  That doesn't mean that we're out of that space.  I think when we think about  capital \nallocation, we're always very focused on where are the opportunities to deploy capital, to build platforms and \nbusinesses and services for sustainable growth over the long term.  \n \n", "original_text": "Thanks for the question. ", "page_label": "14", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a63cc6ca52a7e3497a421a5e18ae434f8ef86c604c46876d158e42bddc0b7cf5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "097bd7d1-a542-4d61-93cb-d659c00f56a8", "node_type": "1", "metadata": {"window": "Thanks.  Thanks for the question.  And I think we would characterize our M&A activity in recent quarters as \nbeing relatively light.  That doesn't mean that we're out of that space.  I think when we think about  capital \nallocation, we're always very focused on where are the opportunities to deploy capital, to build platforms and \nbusinesses and services for sustainable growth over the long term.  \n \n We are being very diligent to make sure that as we look at this proc ess, that is guided by our strategy, that's \nguided by our focal areas, it's guided by the markets and segments where we think we have good businesses, \nstrong teams, the right to win.  And anywhere in those segments, we can find assets that are complementary  and \nan accelerant to our business, we're quite interested in those.  \n \n", "original_text": "That doesn't mean that we're out of that space. "}, "hash": "c362ed93ff3e856a77abbb2a6f8cc46e895cdb92007430bea820f9d365fef710", "class_name": "RelatedNodeInfo"}}, "text": "And I think we would characterize our M&A activity in recent quarters as \nbeing relatively light. ", "start_char_idx": 2126, "end_char_idx": 2224, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "097bd7d1-a542-4d61-93cb-d659c00f56a8": {"__data__": {"id_": "097bd7d1-a542-4d61-93cb-d659c00f56a8", "embedding": null, "metadata": {"window": "Thanks.  Thanks for the question.  And I think we would characterize our M&A activity in recent quarters as \nbeing relatively light.  That doesn't mean that we're out of that space.  I think when we think about  capital \nallocation, we're always very focused on where are the opportunities to deploy capital, to build platforms and \nbusinesses and services for sustainable growth over the long term.  \n \n We are being very diligent to make sure that as we look at this proc ess, that is guided by our strategy, that's \nguided by our focal areas, it's guided by the markets and segments where we think we have good businesses, \nstrong teams, the right to win.  And anywhere in those segments, we can find assets that are complementary  and \nan accelerant to our business, we're quite interested in those.  \n \n", "original_text": "That doesn't mean that we're out of that space. ", "page_label": "14", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "99b53c78-61a9-4e06-89a5-d5a3295894da", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1fc1b41fb0a3728ca79532ff4fdf5f7b6d1ac601f71ff8e3fc1aa0d1723e043b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b1cb49b6-4288-4d5f-9397-512f5dd2c576", "node_type": "1", "metadata": {"window": "A \nYeah.  Thanks.  Thanks for the question.  And I think we would characterize our M&A activity in recent quarters as \nbeing relatively light.  That doesn't mean that we're out of that space.  I think when we think about  capital \nallocation, we're always very focused on where are the opportunities to deploy capital, to build platforms and \nbusinesses and services for sustainable growth over the long term.  \n \n We are being very diligent to make sure that as we look at this proc ess, that is guided by our strategy, that's \nguided by our focal areas, it's guided by the markets and segments where we think we have good businesses, \nstrong teams, the right to win. ", "original_text": "And I think we would characterize our M&A activity in recent quarters as \nbeing relatively light. ", "page_label": "14", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7184c39b27375839295598d52fb865edfe4c3ff835df437c48e7e6d892a245db", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "50085506-966c-4ec9-9bab-2f1a5f898016", "node_type": "1", "metadata": {"window": "Thanks for the question.  And I think we would characterize our M&A activity in recent quarters as \nbeing relatively light.  That doesn't mean that we're out of that space.  I think when we think about  capital \nallocation, we're always very focused on where are the opportunities to deploy capital, to build platforms and \nbusinesses and services for sustainable growth over the long term.  \n \n We are being very diligent to make sure that as we look at this proc ess, that is guided by our strategy, that's \nguided by our focal areas, it's guided by the markets and segments where we think we have good businesses, \nstrong teams, the right to win.  And anywhere in those segments, we can find assets that are complementary  and \nan accelerant to our business, we're quite interested in those.  \n \n We obviously consider alternative uses of capital and returns to capital in making those calculations and final \ndeterminations of what's the best way to deploy that capital on behalf of our shareholders. ", "original_text": "I think when we think about  capital \nallocation, we're always very focused on where are the opportunities to deploy capital, to build platforms and \nbusinesses and services for sustainable growth over the long term.  \n \n"}, "hash": "77223ab7d443fe8e858dc48d582c5c8f4114bd532a3c604c7c9f979da0569390", "class_name": "RelatedNodeInfo"}}, "text": "That doesn't mean that we're out of that space. ", "start_char_idx": 2224, "end_char_idx": 2272, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "50085506-966c-4ec9-9bab-2f1a5f898016": {"__data__": {"id_": "50085506-966c-4ec9-9bab-2f1a5f898016", "embedding": null, "metadata": {"window": "Thanks for the question.  And I think we would characterize our M&A activity in recent quarters as \nbeing relatively light.  That doesn't mean that we're out of that space.  I think when we think about  capital \nallocation, we're always very focused on where are the opportunities to deploy capital, to build platforms and \nbusinesses and services for sustainable growth over the long term.  \n \n We are being very diligent to make sure that as we look at this proc ess, that is guided by our strategy, that's \nguided by our focal areas, it's guided by the markets and segments where we think we have good businesses, \nstrong teams, the right to win.  And anywhere in those segments, we can find assets that are complementary  and \nan accelerant to our business, we're quite interested in those.  \n \n We obviously consider alternative uses of capital and returns to capital in making those calculations and final \ndeterminations of what's the best way to deploy that capital on behalf of our shareholders. ", "original_text": "I think when we think about  capital \nallocation, we're always very focused on where are the opportunities to deploy capital, to build platforms and \nbusinesses and services for sustainable growth over the long term.  \n \n", "page_label": "14", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "99b53c78-61a9-4e06-89a5-d5a3295894da", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1fc1b41fb0a3728ca79532ff4fdf5f7b6d1ac601f71ff8e3fc1aa0d1723e043b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "097bd7d1-a542-4d61-93cb-d659c00f56a8", "node_type": "1", "metadata": {"window": "Thanks.  Thanks for the question.  And I think we would characterize our M&A activity in recent quarters as \nbeing relatively light.  That doesn't mean that we're out of that space.  I think when we think about  capital \nallocation, we're always very focused on where are the opportunities to deploy capital, to build platforms and \nbusinesses and services for sustainable growth over the long term.  \n \n We are being very diligent to make sure that as we look at this proc ess, that is guided by our strategy, that's \nguided by our focal areas, it's guided by the markets and segments where we think we have good businesses, \nstrong teams, the right to win.  And anywhere in those segments, we can find assets that are complementary  and \nan accelerant to our business, we're quite interested in those.  \n \n", "original_text": "That doesn't mean that we're out of that space. ", "page_label": "14", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5f61323243f25af6c4877573780d52bd996184da61fdf27de782478e11c83f5e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cbfe86b4-72d1-47b2-ae5b-e90c8ec61d15", "node_type": "1", "metadata": {"window": "And I think we would characterize our M&A activity in recent quarters as \nbeing relatively light.  That doesn't mean that we're out of that space.  I think when we think about  capital \nallocation, we're always very focused on where are the opportunities to deploy capital, to build platforms and \nbusinesses and services for sustainable growth over the long term.  \n \n We are being very diligent to make sure that as we look at this proc ess, that is guided by our strategy, that's \nguided by our focal areas, it's guided by the markets and segments where we think we have good businesses, \nstrong teams, the right to win.  And anywhere in those segments, we can find assets that are complementary  and \nan accelerant to our business, we're quite interested in those.  \n \n We obviously consider alternative uses of capital and returns to capital in making those calculations and final \ndeterminations of what's the best way to deploy that capital on behalf of our shareholders.  So, we continue to be \nactive, we continue to be in deal flow. ", "original_text": "We are being very diligent to make sure that as we look at this proc ess, that is guided by our strategy, that's \nguided by our focal areas, it's guided by the markets and segments where we think we have good businesses, \nstrong teams, the right to win. "}, "hash": "acf212b13d332fdce43f4745ca2d1d9907a9e58b52685204230fed70744e11de", "class_name": "RelatedNodeInfo"}}, "text": "I think when we think about  capital \nallocation, we're always very focused on where are the opportunities to deploy capital, to build platforms and \nbusinesses and services for sustainable growth over the long term.  \n \n", "start_char_idx": 2272, "end_char_idx": 2493, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cbfe86b4-72d1-47b2-ae5b-e90c8ec61d15": {"__data__": {"id_": "cbfe86b4-72d1-47b2-ae5b-e90c8ec61d15", "embedding": null, "metadata": {"window": "And I think we would characterize our M&A activity in recent quarters as \nbeing relatively light.  That doesn't mean that we're out of that space.  I think when we think about  capital \nallocation, we're always very focused on where are the opportunities to deploy capital, to build platforms and \nbusinesses and services for sustainable growth over the long term.  \n \n We are being very diligent to make sure that as we look at this proc ess, that is guided by our strategy, that's \nguided by our focal areas, it's guided by the markets and segments where we think we have good businesses, \nstrong teams, the right to win.  And anywhere in those segments, we can find assets that are complementary  and \nan accelerant to our business, we're quite interested in those.  \n \n We obviously consider alternative uses of capital and returns to capital in making those calculations and final \ndeterminations of what's the best way to deploy that capital on behalf of our shareholders.  So, we continue to be \nactive, we continue to be in deal flow. ", "original_text": "We are being very diligent to make sure that as we look at this proc ess, that is guided by our strategy, that's \nguided by our focal areas, it's guided by the markets and segments where we think we have good businesses, \nstrong teams, the right to win. ", "page_label": "14", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "99b53c78-61a9-4e06-89a5-d5a3295894da", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1fc1b41fb0a3728ca79532ff4fdf5f7b6d1ac601f71ff8e3fc1aa0d1723e043b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "50085506-966c-4ec9-9bab-2f1a5f898016", "node_type": "1", "metadata": {"window": "Thanks for the question.  And I think we would characterize our M&A activity in recent quarters as \nbeing relatively light.  That doesn't mean that we're out of that space.  I think when we think about  capital \nallocation, we're always very focused on where are the opportunities to deploy capital, to build platforms and \nbusinesses and services for sustainable growth over the long term.  \n \n We are being very diligent to make sure that as we look at this proc ess, that is guided by our strategy, that's \nguided by our focal areas, it's guided by the markets and segments where we think we have good businesses, \nstrong teams, the right to win.  And anywhere in those segments, we can find assets that are complementary  and \nan accelerant to our business, we're quite interested in those.  \n \n We obviously consider alternative uses of capital and returns to capital in making those calculations and final \ndeterminations of what's the best way to deploy that capital on behalf of our shareholders. ", "original_text": "I think when we think about  capital \nallocation, we're always very focused on where are the opportunities to deploy capital, to build platforms and \nbusinesses and services for sustainable growth over the long term.  \n \n", "page_label": "14", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bdb894a9aa966d37400ce2afbba5e2c2977335cb14ed48e258c4b626d214baa7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a34220a6-4868-4462-aa82-c648fb4f4a5d", "node_type": "1", "metadata": {"window": "That doesn't mean that we're out of that space.  I think when we think about  capital \nallocation, we're always very focused on where are the opportunities to deploy capital, to build platforms and \nbusinesses and services for sustainable growth over the long term.  \n \n We are being very diligent to make sure that as we look at this proc ess, that is guided by our strategy, that's \nguided by our focal areas, it's guided by the markets and segments where we think we have good businesses, \nstrong teams, the right to win.  And anywhere in those segments, we can find assets that are complementary  and \nan accelerant to our business, we're quite interested in those.  \n \n We obviously consider alternative uses of capital and returns to capital in making those calculations and final \ndeterminations of what's the best way to deploy that capital on behalf of our shareholders.  So, we continue to be \nactive, we continue to be in deal flow.  We continue to look carefully at the landscape with an eye to make sure it's \naligned strategically, that it's an investment, an accelerant, and that it is the smartest way to d eploy capital across \nthe various uses of capital that we have.  \n ", "original_text": "And anywhere in those segments, we can find assets that are complementary  and \nan accelerant to our business, we're quite interested in those.  \n \n"}, "hash": "72f520328d1a49f19d060acb5ff67cad794f15dfc5d761758f244cfbf47cf0a6", "class_name": "RelatedNodeInfo"}}, "text": "We are being very diligent to make sure that as we look at this proc ess, that is guided by our strategy, that's \nguided by our focal areas, it's guided by the markets and segments where we think we have good businesses, \nstrong teams, the right to win. ", "start_char_idx": 2493, "end_char_idx": 2747, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a34220a6-4868-4462-aa82-c648fb4f4a5d": {"__data__": {"id_": "a34220a6-4868-4462-aa82-c648fb4f4a5d", "embedding": null, "metadata": {"window": "That doesn't mean that we're out of that space.  I think when we think about  capital \nallocation, we're always very focused on where are the opportunities to deploy capital, to build platforms and \nbusinesses and services for sustainable growth over the long term.  \n \n We are being very diligent to make sure that as we look at this proc ess, that is guided by our strategy, that's \nguided by our focal areas, it's guided by the markets and segments where we think we have good businesses, \nstrong teams, the right to win.  And anywhere in those segments, we can find assets that are complementary  and \nan accelerant to our business, we're quite interested in those.  \n \n We obviously consider alternative uses of capital and returns to capital in making those calculations and final \ndeterminations of what's the best way to deploy that capital on behalf of our shareholders.  So, we continue to be \nactive, we continue to be in deal flow.  We continue to look carefully at the landscape with an eye to make sure it's \naligned strategically, that it's an investment, an accelerant, and that it is the smartest way to d eploy capital across \nthe various uses of capital that we have.  \n ", "original_text": "And anywhere in those segments, we can find assets that are complementary  and \nan accelerant to our business, we're quite interested in those.  \n \n", "page_label": "14", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "99b53c78-61a9-4e06-89a5-d5a3295894da", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1fc1b41fb0a3728ca79532ff4fdf5f7b6d1ac601f71ff8e3fc1aa0d1723e043b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cbfe86b4-72d1-47b2-ae5b-e90c8ec61d15", "node_type": "1", "metadata": {"window": "And I think we would characterize our M&A activity in recent quarters as \nbeing relatively light.  That doesn't mean that we're out of that space.  I think when we think about  capital \nallocation, we're always very focused on where are the opportunities to deploy capital, to build platforms and \nbusinesses and services for sustainable growth over the long term.  \n \n We are being very diligent to make sure that as we look at this proc ess, that is guided by our strategy, that's \nguided by our focal areas, it's guided by the markets and segments where we think we have good businesses, \nstrong teams, the right to win.  And anywhere in those segments, we can find assets that are complementary  and \nan accelerant to our business, we're quite interested in those.  \n \n We obviously consider alternative uses of capital and returns to capital in making those calculations and final \ndeterminations of what's the best way to deploy that capital on behalf of our shareholders.  So, we continue to be \nactive, we continue to be in deal flow. ", "original_text": "We are being very diligent to make sure that as we look at this proc ess, that is guided by our strategy, that's \nguided by our focal areas, it's guided by the markets and segments where we think we have good businesses, \nstrong teams, the right to win. ", "page_label": "14", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bae13cf3376299141d34b9a020f042b62722c67098077709e2abc4faa2e025e1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "de2eb216-e520-40e0-b207-4905360120d9", "node_type": "1", "metadata": {"window": "I think when we think about  capital \nallocation, we're always very focused on where are the opportunities to deploy capital, to build platforms and \nbusinesses and services for sustainable growth over the long term.  \n \n We are being very diligent to make sure that as we look at this proc ess, that is guided by our strategy, that's \nguided by our focal areas, it's guided by the markets and segments where we think we have good businesses, \nstrong teams, the right to win.  And anywhere in those segments, we can find assets that are complementary  and \nan accelerant to our business, we're quite interested in those.  \n \n We obviously consider alternative uses of capital and returns to capital in making those calculations and final \ndeterminations of what's the best way to deploy that capital on behalf of our shareholders.  So, we continue to be \nactive, we continue to be in deal flow.  We continue to look carefully at the landscape with an eye to make sure it's \naligned strategically, that it's an investment, an accelerant, and that it is the smartest way to d eploy capital across \nthe various uses of capital that we have.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRoss Muken  \nAnalyst, Evercore ISI  Q \nThanks, guys.  \n ", "original_text": "We obviously consider alternative uses of capital and returns to capital in making those calculations and final \ndeterminations of what's the best way to deploy that capital on behalf of our shareholders. "}, "hash": "5643c60bec38e4383e2f01d329b3fad09002c6ea144bc0445e328728783b422b", "class_name": "RelatedNodeInfo"}}, "text": "And anywhere in those segments, we can find assets that are complementary  and \nan accelerant to our business, we're quite interested in those.  \n \n", "start_char_idx": 2747, "end_char_idx": 2895, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "de2eb216-e520-40e0-b207-4905360120d9": {"__data__": {"id_": "de2eb216-e520-40e0-b207-4905360120d9", "embedding": null, "metadata": {"window": "I think when we think about  capital \nallocation, we're always very focused on where are the opportunities to deploy capital, to build platforms and \nbusinesses and services for sustainable growth over the long term.  \n \n We are being very diligent to make sure that as we look at this proc ess, that is guided by our strategy, that's \nguided by our focal areas, it's guided by the markets and segments where we think we have good businesses, \nstrong teams, the right to win.  And anywhere in those segments, we can find assets that are complementary  and \nan accelerant to our business, we're quite interested in those.  \n \n We obviously consider alternative uses of capital and returns to capital in making those calculations and final \ndeterminations of what's the best way to deploy that capital on behalf of our shareholders.  So, we continue to be \nactive, we continue to be in deal flow.  We continue to look carefully at the landscape with an eye to make sure it's \naligned strategically, that it's an investment, an accelerant, and that it is the smartest way to d eploy capital across \nthe various uses of capital that we have.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRoss Muken  \nAnalyst, Evercore ISI  Q \nThanks, guys.  \n ", "original_text": "We obviously consider alternative uses of capital and returns to capital in making those calculations and final \ndeterminations of what's the best way to deploy that capital on behalf of our shareholders. ", "page_label": "14", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "99b53c78-61a9-4e06-89a5-d5a3295894da", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1fc1b41fb0a3728ca79532ff4fdf5f7b6d1ac601f71ff8e3fc1aa0d1723e043b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a34220a6-4868-4462-aa82-c648fb4f4a5d", "node_type": "1", "metadata": {"window": "That doesn't mean that we're out of that space.  I think when we think about  capital \nallocation, we're always very focused on where are the opportunities to deploy capital, to build platforms and \nbusinesses and services for sustainable growth over the long term.  \n \n We are being very diligent to make sure that as we look at this proc ess, that is guided by our strategy, that's \nguided by our focal areas, it's guided by the markets and segments where we think we have good businesses, \nstrong teams, the right to win.  And anywhere in those segments, we can find assets that are complementary  and \nan accelerant to our business, we're quite interested in those.  \n \n We obviously consider alternative uses of capital and returns to capital in making those calculations and final \ndeterminations of what's the best way to deploy that capital on behalf of our shareholders.  So, we continue to be \nactive, we continue to be in deal flow.  We continue to look carefully at the landscape with an eye to make sure it's \naligned strategically, that it's an investment, an accelerant, and that it is the smartest way to d eploy capital across \nthe various uses of capital that we have.  \n ", "original_text": "And anywhere in those segments, we can find assets that are complementary  and \nan accelerant to our business, we're quite interested in those.  \n \n", "page_label": "14", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d9821a40789790da018260cf8fcd4f956f3a1d6b73df2dc8861e629127e14cf6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1e33ddf5-396c-4172-96e9-9c85b4d76c0c", "node_type": "1", "metadata": {"window": "We are being very diligent to make sure that as we look at this proc ess, that is guided by our strategy, that's \nguided by our focal areas, it's guided by the markets and segments where we think we have good businesses, \nstrong teams, the right to win.  And anywhere in those segments, we can find assets that are complementary  and \nan accelerant to our business, we're quite interested in those.  \n \n We obviously consider alternative uses of capital and returns to capital in making those calculations and final \ndeterminations of what's the best way to deploy that capital on behalf of our shareholders.  So, we continue to be \nactive, we continue to be in deal flow.  We continue to look carefully at the landscape with an eye to make sure it's \naligned strategically, that it's an investment, an accelerant, and that it is the smartest way to d eploy capital across \nthe various uses of capital that we have.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRoss Muken  \nAnalyst, Evercore ISI  Q \nThanks, guys.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And moving on to Stephen Baxter with Wolfe Research.  \n ", "original_text": "So, we continue to be \nactive, we continue to be in deal flow. "}, "hash": "327108d735daee01a002db8fa6de02dbf57986695d6118666852652772614e8b", "class_name": "RelatedNodeInfo"}}, "text": "We obviously consider alternative uses of capital and returns to capital in making those calculations and final \ndeterminations of what's the best way to deploy that capital on behalf of our shareholders. ", "start_char_idx": 2895, "end_char_idx": 3100, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1e33ddf5-396c-4172-96e9-9c85b4d76c0c": {"__data__": {"id_": "1e33ddf5-396c-4172-96e9-9c85b4d76c0c", "embedding": null, "metadata": {"window": "We are being very diligent to make sure that as we look at this proc ess, that is guided by our strategy, that's \nguided by our focal areas, it's guided by the markets and segments where we think we have good businesses, \nstrong teams, the right to win.  And anywhere in those segments, we can find assets that are complementary  and \nan accelerant to our business, we're quite interested in those.  \n \n We obviously consider alternative uses of capital and returns to capital in making those calculations and final \ndeterminations of what's the best way to deploy that capital on behalf of our shareholders.  So, we continue to be \nactive, we continue to be in deal flow.  We continue to look carefully at the landscape with an eye to make sure it's \naligned strategically, that it's an investment, an accelerant, and that it is the smartest way to d eploy capital across \nthe various uses of capital that we have.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRoss Muken  \nAnalyst, Evercore ISI  Q \nThanks, guys.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And moving on to Stephen Baxter with Wolfe Research.  \n ", "original_text": "So, we continue to be \nactive, we continue to be in deal flow. ", "page_label": "14", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "99b53c78-61a9-4e06-89a5-d5a3295894da", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1fc1b41fb0a3728ca79532ff4fdf5f7b6d1ac601f71ff8e3fc1aa0d1723e043b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "de2eb216-e520-40e0-b207-4905360120d9", "node_type": "1", "metadata": {"window": "I think when we think about  capital \nallocation, we're always very focused on where are the opportunities to deploy capital, to build platforms and \nbusinesses and services for sustainable growth over the long term.  \n \n We are being very diligent to make sure that as we look at this proc ess, that is guided by our strategy, that's \nguided by our focal areas, it's guided by the markets and segments where we think we have good businesses, \nstrong teams, the right to win.  And anywhere in those segments, we can find assets that are complementary  and \nan accelerant to our business, we're quite interested in those.  \n \n We obviously consider alternative uses of capital and returns to capital in making those calculations and final \ndeterminations of what's the best way to deploy that capital on behalf of our shareholders.  So, we continue to be \nactive, we continue to be in deal flow.  We continue to look carefully at the landscape with an eye to make sure it's \naligned strategically, that it's an investment, an accelerant, and that it is the smartest way to d eploy capital across \nthe various uses of capital that we have.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRoss Muken  \nAnalyst, Evercore ISI  Q \nThanks, guys.  \n ", "original_text": "We obviously consider alternative uses of capital and returns to capital in making those calculations and final \ndeterminations of what's the best way to deploy that capital on behalf of our shareholders. ", "page_label": "14", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "09360c1e9d00d4ce35e9f7303648e4112499fe80b9dce2b2323e1975b9834494", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4e5c57f7-077d-40c7-bd60-1a61439c7fdb", "node_type": "1", "metadata": {"window": "And anywhere in those segments, we can find assets that are complementary  and \nan accelerant to our business, we're quite interested in those.  \n \n We obviously consider alternative uses of capital and returns to capital in making those calculations and final \ndeterminations of what's the best way to deploy that capital on behalf of our shareholders.  So, we continue to be \nactive, we continue to be in deal flow.  We continue to look carefully at the landscape with an eye to make sure it's \naligned strategically, that it's an investment, an accelerant, and that it is the smartest way to d eploy capital across \nthe various uses of capital that we have.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRoss Muken  \nAnalyst, Evercore ISI  Q \nThanks, guys.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And moving on to Stephen Baxter with Wolfe Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nHi. ", "original_text": "We continue to look carefully at the landscape with an eye to make sure it's \naligned strategically, that it's an investment, an accelerant, and that it is the smartest way to d eploy capital across \nthe various uses of capital that we have.  \n "}, "hash": "06e43c6537b51780bd30facc04f8f45f310747ba277704d2ef5b0a49eefca500", "class_name": "RelatedNodeInfo"}}, "text": "So, we continue to be \nactive, we continue to be in deal flow. ", "start_char_idx": 3100, "end_char_idx": 3163, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4e5c57f7-077d-40c7-bd60-1a61439c7fdb": {"__data__": {"id_": "4e5c57f7-077d-40c7-bd60-1a61439c7fdb", "embedding": null, "metadata": {"window": "And anywhere in those segments, we can find assets that are complementary  and \nan accelerant to our business, we're quite interested in those.  \n \n We obviously consider alternative uses of capital and returns to capital in making those calculations and final \ndeterminations of what's the best way to deploy that capital on behalf of our shareholders.  So, we continue to be \nactive, we continue to be in deal flow.  We continue to look carefully at the landscape with an eye to make sure it's \naligned strategically, that it's an investment, an accelerant, and that it is the smartest way to d eploy capital across \nthe various uses of capital that we have.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRoss Muken  \nAnalyst, Evercore ISI  Q \nThanks, guys.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And moving on to Stephen Baxter with Wolfe Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nHi. ", "original_text": "We continue to look carefully at the landscape with an eye to make sure it's \naligned strategically, that it's an investment, an accelerant, and that it is the smartest way to d eploy capital across \nthe various uses of capital that we have.  \n ", "page_label": "14", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "99b53c78-61a9-4e06-89a5-d5a3295894da", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1fc1b41fb0a3728ca79532ff4fdf5f7b6d1ac601f71ff8e3fc1aa0d1723e043b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1e33ddf5-396c-4172-96e9-9c85b4d76c0c", "node_type": "1", "metadata": {"window": "We are being very diligent to make sure that as we look at this proc ess, that is guided by our strategy, that's \nguided by our focal areas, it's guided by the markets and segments where we think we have good businesses, \nstrong teams, the right to win.  And anywhere in those segments, we can find assets that are complementary  and \nan accelerant to our business, we're quite interested in those.  \n \n We obviously consider alternative uses of capital and returns to capital in making those calculations and final \ndeterminations of what's the best way to deploy that capital on behalf of our shareholders.  So, we continue to be \nactive, we continue to be in deal flow.  We continue to look carefully at the landscape with an eye to make sure it's \naligned strategically, that it's an investment, an accelerant, and that it is the smartest way to d eploy capital across \nthe various uses of capital that we have.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRoss Muken  \nAnalyst, Evercore ISI  Q \nThanks, guys.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And moving on to Stephen Baxter with Wolfe Research.  \n ", "original_text": "So, we continue to be \nactive, we continue to be in deal flow. ", "page_label": "14", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b2ef32280bca1eab9b6d0fde5c9008f358012c5378c11db484186655e7e182fc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "58373b31-2b5c-4240-bde9-a6c685db0f2c", "node_type": "1", "metadata": {"window": "We obviously consider alternative uses of capital and returns to capital in making those calculations and final \ndeterminations of what's the best way to deploy that capital on behalf of our shareholders.  So, we continue to be \nactive, we continue to be in deal flow.  We continue to look carefully at the landscape with an eye to make sure it's \naligned strategically, that it's an investment, an accelerant, and that it is the smartest way to d eploy capital across \nthe various uses of capital that we have.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRoss Muken  \nAnalyst, Evercore ISI  Q \nThanks, guys.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And moving on to Stephen Baxter with Wolfe Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nHi.  Thanks for the question . ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRoss Muken  \nAnalyst, Evercore ISI  Q \nThanks, guys.  \n "}, "hash": "427a9c284b6d2536fbd710b11df4b2805696e13dd5291c44c0828345d6c48cbe", "class_name": "RelatedNodeInfo"}}, "text": "We continue to look carefully at the landscape with an eye to make sure it's \naligned strategically, that it's an investment, an accelerant, and that it is the smartest way to d eploy capital across \nthe various uses of capital that we have.  \n ", "start_char_idx": 3163, "end_char_idx": 3408, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "58373b31-2b5c-4240-bde9-a6c685db0f2c": {"__data__": {"id_": "58373b31-2b5c-4240-bde9-a6c685db0f2c", "embedding": null, "metadata": {"window": "We obviously consider alternative uses of capital and returns to capital in making those calculations and final \ndeterminations of what's the best way to deploy that capital on behalf of our shareholders.  So, we continue to be \nactive, we continue to be in deal flow.  We continue to look carefully at the landscape with an eye to make sure it's \naligned strategically, that it's an investment, an accelerant, and that it is the smartest way to d eploy capital across \nthe various uses of capital that we have.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRoss Muken  \nAnalyst, Evercore ISI  Q \nThanks, guys.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And moving on to Stephen Baxter with Wolfe Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nHi.  Thanks for the question . ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRoss Muken  \nAnalyst, Evercore ISI  Q \nThanks, guys.  \n ", "page_label": "14", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "99b53c78-61a9-4e06-89a5-d5a3295894da", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1fc1b41fb0a3728ca79532ff4fdf5f7b6d1ac601f71ff8e3fc1aa0d1723e043b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4e5c57f7-077d-40c7-bd60-1a61439c7fdb", "node_type": "1", "metadata": {"window": "And anywhere in those segments, we can find assets that are complementary  and \nan accelerant to our business, we're quite interested in those.  \n \n We obviously consider alternative uses of capital and returns to capital in making those calculations and final \ndeterminations of what's the best way to deploy that capital on behalf of our shareholders.  So, we continue to be \nactive, we continue to be in deal flow.  We continue to look carefully at the landscape with an eye to make sure it's \naligned strategically, that it's an investment, an accelerant, and that it is the smartest way to d eploy capital across \nthe various uses of capital that we have.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRoss Muken  \nAnalyst, Evercore ISI  Q \nThanks, guys.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And moving on to Stephen Baxter with Wolfe Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nHi. ", "original_text": "We continue to look carefully at the landscape with an eye to make sure it's \naligned strategically, that it's an investment, an accelerant, and that it is the smartest way to d eploy capital across \nthe various uses of capital that we have.  \n ", "page_label": "14", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "85d1d628a53972235ec57bc34d6832203a6f03fb6356216b21afc3c68a57eae3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1c0220d6-e1fb-49bc-a4ad-f2f2d7d34502", "node_type": "1", "metadata": {"window": "So, we continue to be \nactive, we continue to be in deal flow.  We continue to look carefully at the landscape with an eye to make sure it's \naligned strategically, that it's an investment, an accelerant, and that it is the smartest way to d eploy capital across \nthe various uses of capital that we have.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRoss Muken  \nAnalyst, Evercore ISI  Q \nThanks, guys.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And moving on to Stephen Baxter with Wolfe Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nHi.  Thanks for the question .  I wanted to ask about the sell side environment. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And moving on to Stephen Baxter with Wolfe Research.  \n "}, "hash": "159b0d45a30b7b2e8f127363c56f59e5ff95af5d62c0b54235379ceba7d7f552", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRoss Muken  \nAnalyst, Evercore ISI  Q \nThanks, guys.  \n ", "start_char_idx": 3408, "end_char_idx": 3721, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1c0220d6-e1fb-49bc-a4ad-f2f2d7d34502": {"__data__": {"id_": "1c0220d6-e1fb-49bc-a4ad-f2f2d7d34502", "embedding": null, "metadata": {"window": "So, we continue to be \nactive, we continue to be in deal flow.  We continue to look carefully at the landscape with an eye to make sure it's \naligned strategically, that it's an investment, an accelerant, and that it is the smartest way to d eploy capital across \nthe various uses of capital that we have.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRoss Muken  \nAnalyst, Evercore ISI  Q \nThanks, guys.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And moving on to Stephen Baxter with Wolfe Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nHi.  Thanks for the question .  I wanted to ask about the sell side environment. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And moving on to Stephen Baxter with Wolfe Research.  \n ", "page_label": "14", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "99b53c78-61a9-4e06-89a5-d5a3295894da", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1fc1b41fb0a3728ca79532ff4fdf5f7b6d1ac601f71ff8e3fc1aa0d1723e043b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "58373b31-2b5c-4240-bde9-a6c685db0f2c", "node_type": "1", "metadata": {"window": "We obviously consider alternative uses of capital and returns to capital in making those calculations and final \ndeterminations of what's the best way to deploy that capital on behalf of our shareholders.  So, we continue to be \nactive, we continue to be in deal flow.  We continue to look carefully at the landscape with an eye to make sure it's \naligned strategically, that it's an investment, an accelerant, and that it is the smartest way to d eploy capital across \nthe various uses of capital that we have.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRoss Muken  \nAnalyst, Evercore ISI  Q \nThanks, guys.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And moving on to Stephen Baxter with Wolfe Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nHi.  Thanks for the question . ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRoss Muken  \nAnalyst, Evercore ISI  Q \nThanks, guys.  \n ", "page_label": "14", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "80f861a3e0bbedd5d6a9088ac445e8cfe62bff752b2242cd30f143f2847a10b7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "769ebc90-a0a3-4b06-a405-176983d36487", "node_type": "1", "metadata": {"window": "We continue to look carefully at the landscape with an eye to make sure it's \naligned strategically, that it's an investment, an accelerant, and that it is the smartest way to d eploy capital across \nthe various uses of capital that we have.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRoss Muken  \nAnalyst, Evercore ISI  Q \nThanks, guys.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And moving on to Stephen Baxter with Wolfe Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nHi.  Thanks for the question .  I wanted to ask about the sell side environment.  You've said in the past that in \ngeneral your contracts last about three years, so it appears you'd be coming up against some of the independent \npharmacy contracts that renewed during 2016. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nHi. "}, "hash": "09b3b9fecd4d783d8625c439a90bbea8d02d4ce27c1c9d3bbcd2f0d39681efd4", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And moving on to Stephen Baxter with Wolfe Research.  \n ", "start_char_idx": 3721, "end_char_idx": 4047, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "769ebc90-a0a3-4b06-a405-176983d36487": {"__data__": {"id_": "769ebc90-a0a3-4b06-a405-176983d36487", "embedding": null, "metadata": {"window": "We continue to look carefully at the landscape with an eye to make sure it's \naligned strategically, that it's an investment, an accelerant, and that it is the smartest way to d eploy capital across \nthe various uses of capital that we have.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRoss Muken  \nAnalyst, Evercore ISI  Q \nThanks, guys.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And moving on to Stephen Baxter with Wolfe Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nHi.  Thanks for the question .  I wanted to ask about the sell side environment.  You've said in the past that in \ngeneral your contracts last about three years, so it appears you'd be coming up against some of the independent \npharmacy contracts that renewed during 2016. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nHi. ", "page_label": "14", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "99b53c78-61a9-4e06-89a5-d5a3295894da", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1fc1b41fb0a3728ca79532ff4fdf5f7b6d1ac601f71ff8e3fc1aa0d1723e043b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1c0220d6-e1fb-49bc-a4ad-f2f2d7d34502", "node_type": "1", "metadata": {"window": "So, we continue to be \nactive, we continue to be in deal flow.  We continue to look carefully at the landscape with an eye to make sure it's \naligned strategically, that it's an investment, an accelerant, and that it is the smartest way to d eploy capital across \nthe various uses of capital that we have.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRoss Muken  \nAnalyst, Evercore ISI  Q \nThanks, guys.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And moving on to Stephen Baxter with Wolfe Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nHi.  Thanks for the question .  I wanted to ask about the sell side environment. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And moving on to Stephen Baxter with Wolfe Research.  \n ", "page_label": "14", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9940bc6c927253e718702edc23650d975e44394c7801eed593c43d3cc6131d93", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d86e1e72-5fc5-411c-a421-3eca1f533f47", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRoss Muken  \nAnalyst, Evercore ISI  Q \nThanks, guys.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And moving on to Stephen Baxter with Wolfe Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nHi.  Thanks for the question .  I wanted to ask about the sell side environment.  You've said in the past that in \ngeneral your contracts last about three years, so it appears you'd be coming up against some of the independent \npharmacy contracts that renewed during 2016.  It'd be helpful if you could give us a sense of what proportion of ", "original_text": "Thanks for the question . "}, "hash": "2f34a30fdcc1ffbc016f3b0c0ab23bbf65c32712ef66bfb90935a9acfde5b094", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nHi. ", "start_char_idx": 4047, "end_char_idx": 4357, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d86e1e72-5fc5-411c-a421-3eca1f533f47": {"__data__": {"id_": "d86e1e72-5fc5-411c-a421-3eca1f533f47", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRoss Muken  \nAnalyst, Evercore ISI  Q \nThanks, guys.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And moving on to Stephen Baxter with Wolfe Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nHi.  Thanks for the question .  I wanted to ask about the sell side environment.  You've said in the past that in \ngeneral your contracts last about three years, so it appears you'd be coming up against some of the independent \npharmacy contracts that renewed during 2016.  It'd be helpful if you could give us a sense of what proportion of ", "original_text": "Thanks for the question . ", "page_label": "14", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "99b53c78-61a9-4e06-89a5-d5a3295894da", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1fc1b41fb0a3728ca79532ff4fdf5f7b6d1ac601f71ff8e3fc1aa0d1723e043b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "769ebc90-a0a3-4b06-a405-176983d36487", "node_type": "1", "metadata": {"window": "We continue to look carefully at the landscape with an eye to make sure it's \naligned strategically, that it's an investment, an accelerant, and that it is the smartest way to d eploy capital across \nthe various uses of capital that we have.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRoss Muken  \nAnalyst, Evercore ISI  Q \nThanks, guys.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And moving on to Stephen Baxter with Wolfe Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nHi.  Thanks for the question .  I wanted to ask about the sell side environment.  You've said in the past that in \ngeneral your contracts last about three years, so it appears you'd be coming up against some of the independent \npharmacy contracts that renewed during 2016. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nHi. ", "page_label": "14", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c19ed242f6734132bba41f6856f0e8638c8f04740184aab8dc7505f3b39efacc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "85f39720-1030-4ae3-a996-4fa048fa8e29", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And moving on to Stephen Baxter with Wolfe Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nHi.  Thanks for the question .  I wanted to ask about the sell side environment.  You've said in the past that in \ngeneral your contracts last about three years, so it appears you'd be coming up against some of the independent \npharmacy contracts that renewed during 2016.  It'd be helpful if you could give us a sense of what proportion of ", "original_text": "I wanted to ask about the sell side environment. "}, "hash": "227dd75828c11826c9be822e5589563b7f8275b60987bed9ff7a02a414385f15", "class_name": "RelatedNodeInfo"}}, "text": "Thanks for the question . ", "start_char_idx": 4357, "end_char_idx": 4383, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "85f39720-1030-4ae3-a996-4fa048fa8e29": {"__data__": {"id_": "85f39720-1030-4ae3-a996-4fa048fa8e29", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And moving on to Stephen Baxter with Wolfe Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nHi.  Thanks for the question .  I wanted to ask about the sell side environment.  You've said in the past that in \ngeneral your contracts last about three years, so it appears you'd be coming up against some of the independent \npharmacy contracts that renewed during 2016.  It'd be helpful if you could give us a sense of what proportion of ", "original_text": "I wanted to ask about the sell side environment. ", "page_label": "14", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "99b53c78-61a9-4e06-89a5-d5a3295894da", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1fc1b41fb0a3728ca79532ff4fdf5f7b6d1ac601f71ff8e3fc1aa0d1723e043b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d86e1e72-5fc5-411c-a421-3eca1f533f47", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRoss Muken  \nAnalyst, Evercore ISI  Q \nThanks, guys.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And moving on to Stephen Baxter with Wolfe Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nHi.  Thanks for the question .  I wanted to ask about the sell side environment.  You've said in the past that in \ngeneral your contracts last about three years, so it appears you'd be coming up against some of the independent \npharmacy contracts that renewed during 2016.  It'd be helpful if you could give us a sense of what proportion of ", "original_text": "Thanks for the question . ", "page_label": "14", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6c0badb2568a21b833a9ef77424b094e7ef36ba9b2f7b295c514ce57b85053db", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7db55814-5927-4d9c-b1b7-5a3b1974557b", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nHi.  Thanks for the question .  I wanted to ask about the sell side environment.  You've said in the past that in \ngeneral your contracts last about three years, so it appears you'd be coming up against some of the independent \npharmacy contracts that renewed during 2016.  It'd be helpful if you could give us a sense of what proportion of ", "original_text": "You've said in the past that in \ngeneral your contracts last about three years, so it appears you'd be coming up against some of the independent \npharmacy contracts that renewed during 2016. "}, "hash": "d4653ca4ab4d9bb5cc345a2f4df1a5caa6080b3c77be2a572153f00fa6348156", "class_name": "RelatedNodeInfo"}}, "text": "I wanted to ask about the sell side environment. ", "start_char_idx": 4383, "end_char_idx": 4432, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7db55814-5927-4d9c-b1b7-5a3b1974557b": {"__data__": {"id_": "7db55814-5927-4d9c-b1b7-5a3b1974557b", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nHi.  Thanks for the question .  I wanted to ask about the sell side environment.  You've said in the past that in \ngeneral your contracts last about three years, so it appears you'd be coming up against some of the independent \npharmacy contracts that renewed during 2016.  It'd be helpful if you could give us a sense of what proportion of ", "original_text": "You've said in the past that in \ngeneral your contracts last about three years, so it appears you'd be coming up against some of the independent \npharmacy contracts that renewed during 2016. ", "page_label": "14", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "99b53c78-61a9-4e06-89a5-d5a3295894da", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1fc1b41fb0a3728ca79532ff4fdf5f7b6d1ac601f71ff8e3fc1aa0d1723e043b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "85f39720-1030-4ae3-a996-4fa048fa8e29", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And moving on to Stephen Baxter with Wolfe Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nHi.  Thanks for the question .  I wanted to ask about the sell side environment.  You've said in the past that in \ngeneral your contracts last about three years, so it appears you'd be coming up against some of the independent \npharmacy contracts that renewed during 2016.  It'd be helpful if you could give us a sense of what proportion of ", "original_text": "I wanted to ask about the sell side environment. ", "page_label": "14", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "678115a3d4f8940457d5ac69ded86a64e1530288c235a9d73864b59fd0aa5081", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "19a2643c-abbe-4d0b-a299-75b289e7fbd5", "node_type": "1", "metadata": {"window": "Thanks for the question .  I wanted to ask about the sell side environment.  You've said in the past that in \ngeneral your contracts last about three years, so it appears you'd be coming up against some of the independent \npharmacy contracts that renewed during 2016.  It'd be helpful if you could give us a sense of what proportion of ", "original_text": "It'd be helpful if you could give us a sense of what proportion of "}, "hash": "1a01cd83401d7c48469f1d89dfd098313904262e3be03002a0bfd0e8834fe2b5", "class_name": "RelatedNodeInfo"}}, "text": "You've said in the past that in \ngeneral your contracts last about three years, so it appears you'd be coming up against some of the independent \npharmacy contracts that renewed during 2016. ", "start_char_idx": 4432, "end_char_idx": 4623, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "19a2643c-abbe-4d0b-a299-75b289e7fbd5": {"__data__": {"id_": "19a2643c-abbe-4d0b-a299-75b289e7fbd5", "embedding": null, "metadata": {"window": "Thanks for the question .  I wanted to ask about the sell side environment.  You've said in the past that in \ngeneral your contracts last about three years, so it appears you'd be coming up against some of the independent \npharmacy contracts that renewed during 2016.  It'd be helpful if you could give us a sense of what proportion of ", "original_text": "It'd be helpful if you could give us a sense of what proportion of ", "page_label": "14", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "99b53c78-61a9-4e06-89a5-d5a3295894da", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1fc1b41fb0a3728ca79532ff4fdf5f7b6d1ac601f71ff8e3fc1aa0d1723e043b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7db55814-5927-4d9c-b1b7-5a3b1974557b", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nHi.  Thanks for the question .  I wanted to ask about the sell side environment.  You've said in the past that in \ngeneral your contracts last about three years, so it appears you'd be coming up against some of the independent \npharmacy contracts that renewed during 2016.  It'd be helpful if you could give us a sense of what proportion of ", "original_text": "You've said in the past that in \ngeneral your contracts last about three years, so it appears you'd be coming up against some of the independent \npharmacy contracts that renewed during 2016. ", "page_label": "14", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8de3ed258693f0aa11b249d6b91df003bae1bb0f7884dd6c2241c701d95ca5e2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "97b83d15-f957-4454-857b-c1f08c4e5ec3", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nthose contracts have been addressed at this point, and also any color you can provide on what the discussions \nlook like in terms of helping your pharmacy partners deal with the pressure they're under would  be very helpful. \n Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "McKesson Corp.  "}, "hash": "f62ded9a9e8a9b1cc7849b419fabdd01909fd47df01c9d1ce1f523eef3b559db", "class_name": "RelatedNodeInfo"}}, "text": "It'd be helpful if you could give us a sense of what proportion of ", "start_char_idx": 4623, "end_char_idx": 4690, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "97b83d15-f957-4454-857b-c1f08c4e5ec3": {"__data__": {"id_": "97b83d15-f957-4454-857b-c1f08c4e5ec3", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nthose contracts have been addressed at this point, and also any color you can provide on what the discussions \nlook like in terms of helping your pharmacy partners deal with the pressure they're under would  be very helpful. \n Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "McKesson Corp.  ", "page_label": "15", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "13b8fdec-8208-4134-8779-3d8404e4cdf3", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "da218591b6b4752f66e4d2d57ba5a62b671b9477284a7dd25158b77d027539bd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "19a2643c-abbe-4d0b-a299-75b289e7fbd5", "node_type": "1", "metadata": {"window": "Thanks for the question .  I wanted to ask about the sell side environment.  You've said in the past that in \ngeneral your contracts last about three years, so it appears you'd be coming up against some of the independent \npharmacy contracts that renewed during 2016.  It'd be helpful if you could give us a sense of what proportion of ", "original_text": "It'd be helpful if you could give us a sense of what proportion of ", "page_label": "14", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "95e487836b3aaf2116a5f6a3e5c08802c748a31969e030867cea4d9bec6615f0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a1407d58-f218-4a00-96aa-d59b8b332476", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nthose contracts have been addressed at this point, and also any color you can provide on what the discussions \nlook like in terms of helping your pharmacy partners deal with the pressure they're under would  be very helpful. \n Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah. ", "original_text": "(MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nthose contracts have been addressed at this point, and also any color you can provide on what the discussions \nlook like in terms of helping your pharmacy partners deal with the pressure they're under would  be very helpful. \n"}, "hash": "d6eae3ce6a2aa3f3e9bf9a5cca00d268aa75bc50121902afc1a77d936ec2b9bb", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a1407d58-f218-4a00-96aa-d59b8b332476": {"__data__": {"id_": "a1407d58-f218-4a00-96aa-d59b8b332476", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nthose contracts have been addressed at this point, and also any color you can provide on what the discussions \nlook like in terms of helping your pharmacy partners deal with the pressure they're under would  be very helpful. \n Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah. ", "original_text": "(MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nthose contracts have been addressed at this point, and also any color you can provide on what the discussions \nlook like in terms of helping your pharmacy partners deal with the pressure they're under would  be very helpful. \n", "page_label": "15", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "13b8fdec-8208-4134-8779-3d8404e4cdf3", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "da218591b6b4752f66e4d2d57ba5a62b671b9477284a7dd25158b77d027539bd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "97b83d15-f957-4454-857b-c1f08c4e5ec3", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nthose contracts have been addressed at this point, and also any color you can provide on what the discussions \nlook like in terms of helping your pharmacy partners deal with the pressure they're under would  be very helpful. \n Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "McKesson Corp.  ", "page_label": "15", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6d711c513c398432b1fd4a7f2ac20bd31d3e39a0921ed7595367f103e571b458", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cf1ffee4-a301-49c2-8f4c-b89d8802ffa3", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nthose contracts have been addressed at this point, and also any color you can provide on what the discussions \nlook like in terms of helping your pharmacy partners deal with the pressure they're under would  be very helpful. \n Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  So typically, as we've talked about, we would renew roughly a third of our contracts in any one given year. \n", "original_text": "Thanks.  \n "}, "hash": "1fbb2d98c17f78f35e0bdede86ed220ef89e1f75d45e16c720ca997a1f0f910d", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nthose contracts have been addressed at this point, and also any color you can provide on what the discussions \nlook like in terms of helping your pharmacy partners deal with the pressure they're under would  be very helpful. \n", "start_char_idx": 16, "end_char_idx": 407, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cf1ffee4-a301-49c2-8f4c-b89d8802ffa3": {"__data__": {"id_": "cf1ffee4-a301-49c2-8f4c-b89d8802ffa3", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nthose contracts have been addressed at this point, and also any color you can provide on what the discussions \nlook like in terms of helping your pharmacy partners deal with the pressure they're under would  be very helpful. \n Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  So typically, as we've talked about, we would renew roughly a third of our contracts in any one given year. \n", "original_text": "Thanks.  \n ", "page_label": "15", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "13b8fdec-8208-4134-8779-3d8404e4cdf3", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "da218591b6b4752f66e4d2d57ba5a62b671b9477284a7dd25158b77d027539bd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a1407d58-f218-4a00-96aa-d59b8b332476", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nthose contracts have been addressed at this point, and also any color you can provide on what the discussions \nlook like in terms of helping your pharmacy partners deal with the pressure they're under would  be very helpful. \n Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah. ", "original_text": "(MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nthose contracts have been addressed at this point, and also any color you can provide on what the discussions \nlook like in terms of helping your pharmacy partners deal with the pressure they're under would  be very helpful. \n", "page_label": "15", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d61058b21d83a63a208ca33fa98779377a76b7db69db00860b817cf3a51748ac", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a3f20c98-8c8a-4f9f-bb1e-e25e1aa83498", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nthose contracts have been addressed at this point, and also any color you can provide on what the discussions \nlook like in terms of helping your pharmacy partners deal with the pressure they're under would  be very helpful. \n Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  So typically, as we've talked about, we would renew roughly a third of our contracts in any one given year. \n We've recently got through two big retail national account renewals successfully, which was great news. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  "}, "hash": "f16dcd046b59dad73c5dbcad24d50c80500a63d27b42b6af153b84bf3b156bc2", "class_name": "RelatedNodeInfo"}}, "text": "Thanks.  \n ", "start_char_idx": 407, "end_char_idx": 418, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a3f20c98-8c8a-4f9f-bb1e-e25e1aa83498": {"__data__": {"id_": "a3f20c98-8c8a-4f9f-bb1e-e25e1aa83498", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nthose contracts have been addressed at this point, and also any color you can provide on what the discussions \nlook like in terms of helping your pharmacy partners deal with the pressure they're under would  be very helpful. \n Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  So typically, as we've talked about, we would renew roughly a third of our contracts in any one given year. \n We've recently got through two big retail national account renewals successfully, which was great news. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "15", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "13b8fdec-8208-4134-8779-3d8404e4cdf3", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "da218591b6b4752f66e4d2d57ba5a62b671b9477284a7dd25158b77d027539bd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cf1ffee4-a301-49c2-8f4c-b89d8802ffa3", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nthose contracts have been addressed at this point, and also any color you can provide on what the discussions \nlook like in terms of helping your pharmacy partners deal with the pressure they're under would  be very helpful. \n Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  So typically, as we've talked about, we would renew roughly a third of our contracts in any one given year. \n", "original_text": "Thanks.  \n ", "page_label": "15", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8bf9fb6e307fbca26b1baa63c98db05879d3da831512f8b178f21e8b6d0c3fbd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1158d0b9-66c4-48f4-ac08-001f325a2fdf", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nthose contracts have been addressed at this point, and also any color you can provide on what the discussions \nlook like in terms of helping your pharmacy partners deal with the pressure they're under would  be very helpful. \n Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  So typically, as we've talked about, we would renew roughly a third of our contracts in any one given year. \n We've recently got through two big retail national account renewals successfully, which was great news.  And I'd \nsay, I'd characterize this year as having a fairly normal portfolio of renewals and renewal activity. ", "original_text": "A \nYeah. "}, "hash": "7fad9ea802907ed80bf6d55c46d1dec2564621da3deec8407d7944a19d86d4e0", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "start_char_idx": 418, "end_char_idx": 747, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1158d0b9-66c4-48f4-ac08-001f325a2fdf": {"__data__": {"id_": "1158d0b9-66c4-48f4-ac08-001f325a2fdf", "embedding": null, "metadata": {"window": "(MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nthose contracts have been addressed at this point, and also any color you can provide on what the discussions \nlook like in terms of helping your pharmacy partners deal with the pressure they're under would  be very helpful. \n Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  So typically, as we've talked about, we would renew roughly a third of our contracts in any one given year. \n We've recently got through two big retail national account renewals successfully, which was great news.  And I'd \nsay, I'd characterize this year as having a fairly normal portfolio of renewals and renewal activity. ", "original_text": "A \nYeah. ", "page_label": "15", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "13b8fdec-8208-4134-8779-3d8404e4cdf3", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "da218591b6b4752f66e4d2d57ba5a62b671b9477284a7dd25158b77d027539bd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a3f20c98-8c8a-4f9f-bb1e-e25e1aa83498", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nthose contracts have been addressed at this point, and also any color you can provide on what the discussions \nlook like in terms of helping your pharmacy partners deal with the pressure they're under would  be very helpful. \n Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  So typically, as we've talked about, we would renew roughly a third of our contracts in any one given year. \n We've recently got through two big retail national account renewals successfully, which was great news. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "15", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "064aaa28aa23a62dcf5022f422e1101b0a7f26c7649e3e28ccedf39d6c401fc5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "029f0f85-f581-4298-a8e7-30b05af038f6", "node_type": "1", "metadata": {"window": "Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  So typically, as we've talked about, we would renew roughly a third of our contracts in any one given year. \n We've recently got through two big retail national account renewals successfully, which was great news.  And I'd \nsay, I'd characterize this year as having a fairly normal portfolio of renewals and renewal activity.  So I wouldn't \npoint to anything particularly unusual in that regard.  \n \n", "original_text": "So typically, as we've talked about, we would renew roughly a third of our contracts in any one given year. \n"}, "hash": "f88d1aacd7bf7f07f3c1cfdfd631e6dfc25e5986538a8502424085ace3bdf7fa", "class_name": "RelatedNodeInfo"}}, "text": "A \nYeah. ", "start_char_idx": 747, "end_char_idx": 756, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "029f0f85-f581-4298-a8e7-30b05af038f6": {"__data__": {"id_": "029f0f85-f581-4298-a8e7-30b05af038f6", "embedding": null, "metadata": {"window": "Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  So typically, as we've talked about, we would renew roughly a third of our contracts in any one given year. \n We've recently got through two big retail national account renewals successfully, which was great news.  And I'd \nsay, I'd characterize this year as having a fairly normal portfolio of renewals and renewal activity.  So I wouldn't \npoint to anything particularly unusual in that regard.  \n \n", "original_text": "So typically, as we've talked about, we would renew roughly a third of our contracts in any one given year. \n", "page_label": "15", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "13b8fdec-8208-4134-8779-3d8404e4cdf3", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "da218591b6b4752f66e4d2d57ba5a62b671b9477284a7dd25158b77d027539bd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1158d0b9-66c4-48f4-ac08-001f325a2fdf", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nthose contracts have been addressed at this point, and also any color you can provide on what the discussions \nlook like in terms of helping your pharmacy partners deal with the pressure they're under would  be very helpful. \n Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  So typically, as we've talked about, we would renew roughly a third of our contracts in any one given year. \n We've recently got through two big retail national account renewals successfully, which was great news.  And I'd \nsay, I'd characterize this year as having a fairly normal portfolio of renewals and renewal activity. ", "original_text": "A \nYeah. ", "page_label": "15", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "715f1b76eff03aa2e615cde274952be39a10bd1d5b3bb2a43e0956cdd021642b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c6a1594c-810e-4626-af69-1fcc88fdc18a", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  So typically, as we've talked about, we would renew roughly a third of our contracts in any one given year. \n We've recently got through two big retail national account renewals successfully, which was great news.  And I'd \nsay, I'd characterize this year as having a fairly normal portfolio of renewals and renewal activity.  So I wouldn't \npoint to anything particularly unusual in that regard.  \n \n We work with o ur partners over the life of these contracts. ", "original_text": "We've recently got through two big retail national account renewals successfully, which was great news. "}, "hash": "0db41b0de32dcce22104249913357c309ae3090d439bdcc0c69ba50be46ab319", "class_name": "RelatedNodeInfo"}}, "text": "So typically, as we've talked about, we would renew roughly a third of our contracts in any one given year. \n", "start_char_idx": 756, "end_char_idx": 865, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c6a1594c-810e-4626-af69-1fcc88fdc18a": {"__data__": {"id_": "c6a1594c-810e-4626-af69-1fcc88fdc18a", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  So typically, as we've talked about, we would renew roughly a third of our contracts in any one given year. \n We've recently got through two big retail national account renewals successfully, which was great news.  And I'd \nsay, I'd characterize this year as having a fairly normal portfolio of renewals and renewal activity.  So I wouldn't \npoint to anything particularly unusual in that regard.  \n \n We work with o ur partners over the life of these contracts. ", "original_text": "We've recently got through two big retail national account renewals successfully, which was great news. ", "page_label": "15", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "13b8fdec-8208-4134-8779-3d8404e4cdf3", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "da218591b6b4752f66e4d2d57ba5a62b671b9477284a7dd25158b77d027539bd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "029f0f85-f581-4298-a8e7-30b05af038f6", "node_type": "1", "metadata": {"window": "Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  So typically, as we've talked about, we would renew roughly a third of our contracts in any one given year. \n We've recently got through two big retail national account renewals successfully, which was great news.  And I'd \nsay, I'd characterize this year as having a fairly normal portfolio of renewals and renewal activity.  So I wouldn't \npoint to anything particularly unusual in that regard.  \n \n", "original_text": "So typically, as we've talked about, we would renew roughly a third of our contracts in any one given year. \n", "page_label": "15", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5975147c579d3affe3b4d4a2e46f2c65915bc199dae6f79644ab0640ce94b587", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8367034f-a156-41ca-b8eb-7375b766da49", "node_type": "1", "metadata": {"window": "A \nYeah.  So typically, as we've talked about, we would renew roughly a third of our contracts in any one given year. \n We've recently got through two big retail national account renewals successfully, which was great news.  And I'd \nsay, I'd characterize this year as having a fairly normal portfolio of renewals and renewal activity.  So I wouldn't \npoint to anything particularly unusual in that regard.  \n \n We work with o ur partners over the life of these contracts.  We're typically engaging in day -to-day discussions. ", "original_text": "And I'd \nsay, I'd characterize this year as having a fairly normal portfolio of renewals and renewal activity. "}, "hash": "164fec3f6450348c43d02ac61026c0c57958d9b31823396235d6baf4954867bd", "class_name": "RelatedNodeInfo"}}, "text": "We've recently got through two big retail national account renewals successfully, which was great news. ", "start_char_idx": 865, "end_char_idx": 969, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8367034f-a156-41ca-b8eb-7375b766da49": {"__data__": {"id_": "8367034f-a156-41ca-b8eb-7375b766da49", "embedding": null, "metadata": {"window": "A \nYeah.  So typically, as we've talked about, we would renew roughly a third of our contracts in any one given year. \n We've recently got through two big retail national account renewals successfully, which was great news.  And I'd \nsay, I'd characterize this year as having a fairly normal portfolio of renewals and renewal activity.  So I wouldn't \npoint to anything particularly unusual in that regard.  \n \n We work with o ur partners over the life of these contracts.  We're typically engaging in day -to-day discussions. ", "original_text": "And I'd \nsay, I'd characterize this year as having a fairly normal portfolio of renewals and renewal activity. ", "page_label": "15", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "13b8fdec-8208-4134-8779-3d8404e4cdf3", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "da218591b6b4752f66e4d2d57ba5a62b671b9477284a7dd25158b77d027539bd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c6a1594c-810e-4626-af69-1fcc88fdc18a", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  So typically, as we've talked about, we would renew roughly a third of our contracts in any one given year. \n We've recently got through two big retail national account renewals successfully, which was great news.  And I'd \nsay, I'd characterize this year as having a fairly normal portfolio of renewals and renewal activity.  So I wouldn't \npoint to anything particularly unusual in that regard.  \n \n We work with o ur partners over the life of these contracts. ", "original_text": "We've recently got through two big retail national account renewals successfully, which was great news. ", "page_label": "15", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e81ec70b1dfc3534e1d7288ef466f4732606274cb8f685d7d59b76f1d58b8d61", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bc8b37e4-28d1-4a80-8e47-2de3c626c70e", "node_type": "1", "metadata": {"window": "So typically, as we've talked about, we would renew roughly a third of our contracts in any one given year. \n We've recently got through two big retail national account renewals successfully, which was great news.  And I'd \nsay, I'd characterize this year as having a fairly normal portfolio of renewals and renewal activity.  So I wouldn't \npoint to anything particularly unusual in that regard.  \n \n We work with o ur partners over the life of these contracts.  We're typically engaging in day -to-day discussions.  We \nbegin conversations well in advance of any sort of sudden renewal activity. ", "original_text": "So I wouldn't \npoint to anything particularly unusual in that regard.  \n \n"}, "hash": "dafb9cd08dea06713f12305851983a8c0417be87cf21cd994d1c7e59a5583809", "class_name": "RelatedNodeInfo"}}, "text": "And I'd \nsay, I'd characterize this year as having a fairly normal portfolio of renewals and renewal activity. ", "start_char_idx": 969, "end_char_idx": 1080, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bc8b37e4-28d1-4a80-8e47-2de3c626c70e": {"__data__": {"id_": "bc8b37e4-28d1-4a80-8e47-2de3c626c70e", "embedding": null, "metadata": {"window": "So typically, as we've talked about, we would renew roughly a third of our contracts in any one given year. \n We've recently got through two big retail national account renewals successfully, which was great news.  And I'd \nsay, I'd characterize this year as having a fairly normal portfolio of renewals and renewal activity.  So I wouldn't \npoint to anything particularly unusual in that regard.  \n \n We work with o ur partners over the life of these contracts.  We're typically engaging in day -to-day discussions.  We \nbegin conversations well in advance of any sort of sudden renewal activity. ", "original_text": "So I wouldn't \npoint to anything particularly unusual in that regard.  \n \n", "page_label": "15", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "13b8fdec-8208-4134-8779-3d8404e4cdf3", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "da218591b6b4752f66e4d2d57ba5a62b671b9477284a7dd25158b77d027539bd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8367034f-a156-41ca-b8eb-7375b766da49", "node_type": "1", "metadata": {"window": "A \nYeah.  So typically, as we've talked about, we would renew roughly a third of our contracts in any one given year. \n We've recently got through two big retail national account renewals successfully, which was great news.  And I'd \nsay, I'd characterize this year as having a fairly normal portfolio of renewals and renewal activity.  So I wouldn't \npoint to anything particularly unusual in that regard.  \n \n We work with o ur partners over the life of these contracts.  We're typically engaging in day -to-day discussions. ", "original_text": "And I'd \nsay, I'd characterize this year as having a fairly normal portfolio of renewals and renewal activity. ", "page_label": "15", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "edcdc48e49d2fe394ca9f2d3f2c29a8e61968b34fef6e6b6181ee7af6119b2e3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7ebc2fce-d35f-4184-8969-c3adaaeaee83", "node_type": "1", "metadata": {"window": "We've recently got through two big retail national account renewals successfully, which was great news.  And I'd \nsay, I'd characterize this year as having a fairly normal portfolio of renewals and renewal activity.  So I wouldn't \npoint to anything particularly unusual in that regard.  \n \n We work with o ur partners over the life of these contracts.  We're typically engaging in day -to-day discussions.  We \nbegin conversations well in advance of any sort of sudden renewal activity.  So we really view it as kind of an \nongoing dialogue and an ongoing partnership over the course of these contracts. ", "original_text": "We work with o ur partners over the life of these contracts. "}, "hash": "828ae72230f3145ad4538e69e49e2b497b62584b6241144cafc3a0ac96ad5fb9", "class_name": "RelatedNodeInfo"}}, "text": "So I wouldn't \npoint to anything particularly unusual in that regard.  \n \n", "start_char_idx": 1080, "end_char_idx": 1154, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7ebc2fce-d35f-4184-8969-c3adaaeaee83": {"__data__": {"id_": "7ebc2fce-d35f-4184-8969-c3adaaeaee83", "embedding": null, "metadata": {"window": "We've recently got through two big retail national account renewals successfully, which was great news.  And I'd \nsay, I'd characterize this year as having a fairly normal portfolio of renewals and renewal activity.  So I wouldn't \npoint to anything particularly unusual in that regard.  \n \n We work with o ur partners over the life of these contracts.  We're typically engaging in day -to-day discussions.  We \nbegin conversations well in advance of any sort of sudden renewal activity.  So we really view it as kind of an \nongoing dialogue and an ongoing partnership over the course of these contracts. ", "original_text": "We work with o ur partners over the life of these contracts. ", "page_label": "15", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "13b8fdec-8208-4134-8779-3d8404e4cdf3", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "da218591b6b4752f66e4d2d57ba5a62b671b9477284a7dd25158b77d027539bd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bc8b37e4-28d1-4a80-8e47-2de3c626c70e", "node_type": "1", "metadata": {"window": "So typically, as we've talked about, we would renew roughly a third of our contracts in any one given year. \n We've recently got through two big retail national account renewals successfully, which was great news.  And I'd \nsay, I'd characterize this year as having a fairly normal portfolio of renewals and renewal activity.  So I wouldn't \npoint to anything particularly unusual in that regard.  \n \n We work with o ur partners over the life of these contracts.  We're typically engaging in day -to-day discussions.  We \nbegin conversations well in advance of any sort of sudden renewal activity. ", "original_text": "So I wouldn't \npoint to anything particularly unusual in that regard.  \n \n", "page_label": "15", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7340a29032e6ed18a744a2b025ed531ff94708f601de5f135928efad1441ea2d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cf10573a-f94e-4369-bec9-22fff159d661", "node_type": "1", "metadata": {"window": "And I'd \nsay, I'd characterize this year as having a fairly normal portfolio of renewals and renewal activity.  So I wouldn't \npoint to anything particularly unusual in that regard.  \n \n We work with o ur partners over the life of these contracts.  We're typically engaging in day -to-day discussions.  We \nbegin conversations well in advance of any sort of sudden renewal activity.  So we really view it as kind of an \nongoing dialogue and an ongoing partnership over the course of these contracts.  And you'll be well familiar with \nour track record of renewing these particularly larger deals.  \n \n", "original_text": "We're typically engaging in day -to-day discussions. "}, "hash": "4061c1bb0ae015bf21fd4957cd20f95dcb9e657cff1a26ed32544ee8d20a7b39", "class_name": "RelatedNodeInfo"}}, "text": "We work with o ur partners over the life of these contracts. ", "start_char_idx": 1154, "end_char_idx": 1215, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cf10573a-f94e-4369-bec9-22fff159d661": {"__data__": {"id_": "cf10573a-f94e-4369-bec9-22fff159d661", "embedding": null, "metadata": {"window": "And I'd \nsay, I'd characterize this year as having a fairly normal portfolio of renewals and renewal activity.  So I wouldn't \npoint to anything particularly unusual in that regard.  \n \n We work with o ur partners over the life of these contracts.  We're typically engaging in day -to-day discussions.  We \nbegin conversations well in advance of any sort of sudden renewal activity.  So we really view it as kind of an \nongoing dialogue and an ongoing partnership over the course of these contracts.  And you'll be well familiar with \nour track record of renewing these particularly larger deals.  \n \n", "original_text": "We're typically engaging in day -to-day discussions. ", "page_label": "15", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "13b8fdec-8208-4134-8779-3d8404e4cdf3", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "da218591b6b4752f66e4d2d57ba5a62b671b9477284a7dd25158b77d027539bd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7ebc2fce-d35f-4184-8969-c3adaaeaee83", "node_type": "1", "metadata": {"window": "We've recently got through two big retail national account renewals successfully, which was great news.  And I'd \nsay, I'd characterize this year as having a fairly normal portfolio of renewals and renewal activity.  So I wouldn't \npoint to anything particularly unusual in that regard.  \n \n We work with o ur partners over the life of these contracts.  We're typically engaging in day -to-day discussions.  We \nbegin conversations well in advance of any sort of sudden renewal activity.  So we really view it as kind of an \nongoing dialogue and an ongoing partnership over the course of these contracts. ", "original_text": "We work with o ur partners over the life of these contracts. ", "page_label": "15", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e3a573dda5b9ce9352bc80d562c15a586b5efca69cda3861b6792c9dd99480dd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8f797fa3-329b-4af9-92a6-d5bafa350ef8", "node_type": "1", "metadata": {"window": "So I wouldn't \npoint to anything particularly unusual in that regard.  \n \n We work with o ur partners over the life of these contracts.  We're typically engaging in day -to-day discussions.  We \nbegin conversations well in advance of any sort of sudden renewal activity.  So we really view it as kind of an \nongoing dialogue and an ongoing partnership over the course of these contracts.  And you'll be well familiar with \nour track record of renewing these particularly larger deals.  \n \n As it relates to independents in general and what are we doing to help independents, I would say, independents \nhave probably  long been at the core of McKesson as a company. ", "original_text": "We \nbegin conversations well in advance of any sort of sudden renewal activity. "}, "hash": "dacd1b0620e5f2c24f3740256f21eac0633487e308ed916e91c029a8b757d7de", "class_name": "RelatedNodeInfo"}}, "text": "We're typically engaging in day -to-day discussions. ", "start_char_idx": 1215, "end_char_idx": 1268, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8f797fa3-329b-4af9-92a6-d5bafa350ef8": {"__data__": {"id_": "8f797fa3-329b-4af9-92a6-d5bafa350ef8", "embedding": null, "metadata": {"window": "So I wouldn't \npoint to anything particularly unusual in that regard.  \n \n We work with o ur partners over the life of these contracts.  We're typically engaging in day -to-day discussions.  We \nbegin conversations well in advance of any sort of sudden renewal activity.  So we really view it as kind of an \nongoing dialogue and an ongoing partnership over the course of these contracts.  And you'll be well familiar with \nour track record of renewing these particularly larger deals.  \n \n As it relates to independents in general and what are we doing to help independents, I would say, independents \nhave probably  long been at the core of McKesson as a company. ", "original_text": "We \nbegin conversations well in advance of any sort of sudden renewal activity. ", "page_label": "15", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "13b8fdec-8208-4134-8779-3d8404e4cdf3", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "da218591b6b4752f66e4d2d57ba5a62b671b9477284a7dd25158b77d027539bd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cf10573a-f94e-4369-bec9-22fff159d661", "node_type": "1", "metadata": {"window": "And I'd \nsay, I'd characterize this year as having a fairly normal portfolio of renewals and renewal activity.  So I wouldn't \npoint to anything particularly unusual in that regard.  \n \n We work with o ur partners over the life of these contracts.  We're typically engaging in day -to-day discussions.  We \nbegin conversations well in advance of any sort of sudden renewal activity.  So we really view it as kind of an \nongoing dialogue and an ongoing partnership over the course of these contracts.  And you'll be well familiar with \nour track record of renewing these particularly larger deals.  \n \n", "original_text": "We're typically engaging in day -to-day discussions. ", "page_label": "15", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "871d96f4bd3804ebb8471c28e018fea09a004382263ce64b307f76adeee7b9b6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0cf8b158-881f-4c64-a650-918df54b0852", "node_type": "1", "metadata": {"window": "We work with o ur partners over the life of these contracts.  We're typically engaging in day -to-day discussions.  We \nbegin conversations well in advance of any sort of sudden renewal activity.  So we really view it as kind of an \nongoing dialogue and an ongoing partnership over the course of these contracts.  And you'll be well familiar with \nour track record of renewing these particularly larger deals.  \n \n As it relates to independents in general and what are we doing to help independents, I would say, independents \nhave probably  long been at the core of McKesson as a company.  It's key part of our commitment to community \npractice, as we think being central to addressing the access costs and quality issues this country faces. \n", "original_text": "So we really view it as kind of an \nongoing dialogue and an ongoing partnership over the course of these contracts. "}, "hash": "a98f40e540b7e449f6e9ffe2f3656dbef5e4faa2a6f54c168f28d09407e0c005", "class_name": "RelatedNodeInfo"}}, "text": "We \nbegin conversations well in advance of any sort of sudden renewal activity. ", "start_char_idx": 1268, "end_char_idx": 1348, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0cf8b158-881f-4c64-a650-918df54b0852": {"__data__": {"id_": "0cf8b158-881f-4c64-a650-918df54b0852", "embedding": null, "metadata": {"window": "We work with o ur partners over the life of these contracts.  We're typically engaging in day -to-day discussions.  We \nbegin conversations well in advance of any sort of sudden renewal activity.  So we really view it as kind of an \nongoing dialogue and an ongoing partnership over the course of these contracts.  And you'll be well familiar with \nour track record of renewing these particularly larger deals.  \n \n As it relates to independents in general and what are we doing to help independents, I would say, independents \nhave probably  long been at the core of McKesson as a company.  It's key part of our commitment to community \npractice, as we think being central to addressing the access costs and quality issues this country faces. \n", "original_text": "So we really view it as kind of an \nongoing dialogue and an ongoing partnership over the course of these contracts. ", "page_label": "15", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "13b8fdec-8208-4134-8779-3d8404e4cdf3", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "da218591b6b4752f66e4d2d57ba5a62b671b9477284a7dd25158b77d027539bd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8f797fa3-329b-4af9-92a6-d5bafa350ef8", "node_type": "1", "metadata": {"window": "So I wouldn't \npoint to anything particularly unusual in that regard.  \n \n We work with o ur partners over the life of these contracts.  We're typically engaging in day -to-day discussions.  We \nbegin conversations well in advance of any sort of sudden renewal activity.  So we really view it as kind of an \nongoing dialogue and an ongoing partnership over the course of these contracts.  And you'll be well familiar with \nour track record of renewing these particularly larger deals.  \n \n As it relates to independents in general and what are we doing to help independents, I would say, independents \nhave probably  long been at the core of McKesson as a company. ", "original_text": "We \nbegin conversations well in advance of any sort of sudden renewal activity. ", "page_label": "15", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "761c2dec4b0db2ead2c171c43d3d36f88bccc1f5d18b8515b5786ff165cd19f2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6184a7e8-be35-4f01-bb0f-05e949a0c500", "node_type": "1", "metadata": {"window": "We're typically engaging in day -to-day discussions.  We \nbegin conversations well in advance of any sort of sudden renewal activity.  So we really view it as kind of an \nongoing dialogue and an ongoing partnership over the course of these contracts.  And you'll be well familiar with \nour track record of renewing these particularly larger deals.  \n \n As it relates to independents in general and what are we doing to help independents, I would say, independents \nhave probably  long been at the core of McKesson as a company.  It's key part of our commitment to community \npractice, as we think being central to addressing the access costs and quality issues this country faces. \n Independents continue to benefit from the programs and s ervices that we invest in. ", "original_text": "And you'll be well familiar with \nour track record of renewing these particularly larger deals.  \n \n"}, "hash": "6542781b032ecd21887a9365512924960285931197c9c9b3b355236d224bdb47", "class_name": "RelatedNodeInfo"}}, "text": "So we really view it as kind of an \nongoing dialogue and an ongoing partnership over the course of these contracts. ", "start_char_idx": 1348, "end_char_idx": 1464, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6184a7e8-be35-4f01-bb0f-05e949a0c500": {"__data__": {"id_": "6184a7e8-be35-4f01-bb0f-05e949a0c500", "embedding": null, "metadata": {"window": "We're typically engaging in day -to-day discussions.  We \nbegin conversations well in advance of any sort of sudden renewal activity.  So we really view it as kind of an \nongoing dialogue and an ongoing partnership over the course of these contracts.  And you'll be well familiar with \nour track record of renewing these particularly larger deals.  \n \n As it relates to independents in general and what are we doing to help independents, I would say, independents \nhave probably  long been at the core of McKesson as a company.  It's key part of our commitment to community \npractice, as we think being central to addressing the access costs and quality issues this country faces. \n Independents continue to benefit from the programs and s ervices that we invest in. ", "original_text": "And you'll be well familiar with \nour track record of renewing these particularly larger deals.  \n \n", "page_label": "15", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "13b8fdec-8208-4134-8779-3d8404e4cdf3", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "da218591b6b4752f66e4d2d57ba5a62b671b9477284a7dd25158b77d027539bd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0cf8b158-881f-4c64-a650-918df54b0852", "node_type": "1", "metadata": {"window": "We work with o ur partners over the life of these contracts.  We're typically engaging in day -to-day discussions.  We \nbegin conversations well in advance of any sort of sudden renewal activity.  So we really view it as kind of an \nongoing dialogue and an ongoing partnership over the course of these contracts.  And you'll be well familiar with \nour track record of renewing these particularly larger deals.  \n \n As it relates to independents in general and what are we doing to help independents, I would say, independents \nhave probably  long been at the core of McKesson as a company.  It's key part of our commitment to community \npractice, as we think being central to addressing the access costs and quality issues this country faces. \n", "original_text": "So we really view it as kind of an \nongoing dialogue and an ongoing partnership over the course of these contracts. ", "page_label": "15", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3d12098547807dbc8094f39197c1c41056a64cce630b2ab4166586ccc2dc8687", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d7c72bca-ce2c-49e5-9a6b-0c777fdd130e", "node_type": "1", "metadata": {"window": "We \nbegin conversations well in advance of any sort of sudden renewal activity.  So we really view it as kind of an \nongoing dialogue and an ongoing partnership over the course of these contracts.  And you'll be well familiar with \nour track record of renewing these particularly larger deals.  \n \n As it relates to independents in general and what are we doing to help independents, I would say, independents \nhave probably  long been at the core of McKesson as a company.  It's key part of our commitment to community \npractice, as we think being central to addressing the access costs and quality issues this country faces. \n Independents continue to benefit from the programs and s ervices that we invest in.  They continue to consume \nthat in a sort of all -encompassing way through a relationship with Health Mart and our access reimbursement \nservices that come along with that. ", "original_text": "As it relates to independents in general and what are we doing to help independents, I would say, independents \nhave probably  long been at the core of McKesson as a company. "}, "hash": "4d3b6fa096ea302afbef26e085c019c54e96dca59d1cfbef62d0b27f7956065f", "class_name": "RelatedNodeInfo"}}, "text": "And you'll be well familiar with \nour track record of renewing these particularly larger deals.  \n \n", "start_char_idx": 1464, "end_char_idx": 1564, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d7c72bca-ce2c-49e5-9a6b-0c777fdd130e": {"__data__": {"id_": "d7c72bca-ce2c-49e5-9a6b-0c777fdd130e", "embedding": null, "metadata": {"window": "We \nbegin conversations well in advance of any sort of sudden renewal activity.  So we really view it as kind of an \nongoing dialogue and an ongoing partnership over the course of these contracts.  And you'll be well familiar with \nour track record of renewing these particularly larger deals.  \n \n As it relates to independents in general and what are we doing to help independents, I would say, independents \nhave probably  long been at the core of McKesson as a company.  It's key part of our commitment to community \npractice, as we think being central to addressing the access costs and quality issues this country faces. \n Independents continue to benefit from the programs and s ervices that we invest in.  They continue to consume \nthat in a sort of all -encompassing way through a relationship with Health Mart and our access reimbursement \nservices that come along with that. ", "original_text": "As it relates to independents in general and what are we doing to help independents, I would say, independents \nhave probably  long been at the core of McKesson as a company. ", "page_label": "15", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "13b8fdec-8208-4134-8779-3d8404e4cdf3", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "da218591b6b4752f66e4d2d57ba5a62b671b9477284a7dd25158b77d027539bd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6184a7e8-be35-4f01-bb0f-05e949a0c500", "node_type": "1", "metadata": {"window": "We're typically engaging in day -to-day discussions.  We \nbegin conversations well in advance of any sort of sudden renewal activity.  So we really view it as kind of an \nongoing dialogue and an ongoing partnership over the course of these contracts.  And you'll be well familiar with \nour track record of renewing these particularly larger deals.  \n \n As it relates to independents in general and what are we doing to help independents, I would say, independents \nhave probably  long been at the core of McKesson as a company.  It's key part of our commitment to community \npractice, as we think being central to addressing the access costs and quality issues this country faces. \n Independents continue to benefit from the programs and s ervices that we invest in. ", "original_text": "And you'll be well familiar with \nour track record of renewing these particularly larger deals.  \n \n", "page_label": "15", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dd05b25ced722830617225efcdd5ad4f6aa23b0e34fd4192dc439515c8d64254", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "71c0238c-8d83-4aa1-bedb-1ef8b93ffd29", "node_type": "1", "metadata": {"window": "So we really view it as kind of an \nongoing dialogue and an ongoing partnership over the course of these contracts.  And you'll be well familiar with \nour track record of renewing these particularly larger deals.  \n \n As it relates to independents in general and what are we doing to help independents, I would say, independents \nhave probably  long been at the core of McKesson as a company.  It's key part of our commitment to community \npractice, as we think being central to addressing the access costs and quality issues this country faces. \n Independents continue to benefit from the programs and s ervices that we invest in.  They continue to consume \nthat in a sort of all -encompassing way through a relationship with Health Mart and our access reimbursement \nservices that come along with that.  But we are constantly looking at how we innovate for them bo th in how they \ninteract with their patients, how they attract patients and draw footfall to their stores, how they monetize that \nfootfall both in front and behind the counter. ", "original_text": "It's key part of our commitment to community \npractice, as we think being central to addressing the access costs and quality issues this country faces. \n"}, "hash": "9201a41f12be6a1ff3ac68c3dacf223ea09726bb506ab29d78d424b5a3f8387b", "class_name": "RelatedNodeInfo"}}, "text": "As it relates to independents in general and what are we doing to help independents, I would say, independents \nhave probably  long been at the core of McKesson as a company. ", "start_char_idx": 1564, "end_char_idx": 1739, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "71c0238c-8d83-4aa1-bedb-1ef8b93ffd29": {"__data__": {"id_": "71c0238c-8d83-4aa1-bedb-1ef8b93ffd29", "embedding": null, "metadata": {"window": "So we really view it as kind of an \nongoing dialogue and an ongoing partnership over the course of these contracts.  And you'll be well familiar with \nour track record of renewing these particularly larger deals.  \n \n As it relates to independents in general and what are we doing to help independents, I would say, independents \nhave probably  long been at the core of McKesson as a company.  It's key part of our commitment to community \npractice, as we think being central to addressing the access costs and quality issues this country faces. \n Independents continue to benefit from the programs and s ervices that we invest in.  They continue to consume \nthat in a sort of all -encompassing way through a relationship with Health Mart and our access reimbursement \nservices that come along with that.  But we are constantly looking at how we innovate for them bo th in how they \ninteract with their patients, how they attract patients and draw footfall to their stores, how they monetize that \nfootfall both in front and behind the counter. ", "original_text": "It's key part of our commitment to community \npractice, as we think being central to addressing the access costs and quality issues this country faces. \n", "page_label": "15", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "13b8fdec-8208-4134-8779-3d8404e4cdf3", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "da218591b6b4752f66e4d2d57ba5a62b671b9477284a7dd25158b77d027539bd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d7c72bca-ce2c-49e5-9a6b-0c777fdd130e", "node_type": "1", "metadata": {"window": "We \nbegin conversations well in advance of any sort of sudden renewal activity.  So we really view it as kind of an \nongoing dialogue and an ongoing partnership over the course of these contracts.  And you'll be well familiar with \nour track record of renewing these particularly larger deals.  \n \n As it relates to independents in general and what are we doing to help independents, I would say, independents \nhave probably  long been at the core of McKesson as a company.  It's key part of our commitment to community \npractice, as we think being central to addressing the access costs and quality issues this country faces. \n Independents continue to benefit from the programs and s ervices that we invest in.  They continue to consume \nthat in a sort of all -encompassing way through a relationship with Health Mart and our access reimbursement \nservices that come along with that. ", "original_text": "As it relates to independents in general and what are we doing to help independents, I would say, independents \nhave probably  long been at the core of McKesson as a company. ", "page_label": "15", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "06e93617206a057524c36d93827c70f7be8895f48e878b313c9ae6d7d840aae2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "054459c9-4f42-4bf1-8cac-035e2ce0cde6", "node_type": "1", "metadata": {"window": "And you'll be well familiar with \nour track record of renewing these particularly larger deals.  \n \n As it relates to independents in general and what are we doing to help independents, I would say, independents \nhave probably  long been at the core of McKesson as a company.  It's key part of our commitment to community \npractice, as we think being central to addressing the access costs and quality issues this country faces. \n Independents continue to benefit from the programs and s ervices that we invest in.  They continue to consume \nthat in a sort of all -encompassing way through a relationship with Health Mart and our access reimbursement \nservices that come along with that.  But we are constantly looking at how we innovate for them bo th in how they \ninteract with their patients, how they attract patients and draw footfall to their stores, how they monetize that \nfootfall both in front and behind the counter.  And we work with them day in, day out on the just efficiency of the \noperation of  their business.  \n \n", "original_text": "Independents continue to benefit from the programs and s ervices that we invest in. "}, "hash": "118ef3e759bdf80e286bf57c04706248950d4cef616d97f4f44556bd833dab2d", "class_name": "RelatedNodeInfo"}}, "text": "It's key part of our commitment to community \npractice, as we think being central to addressing the access costs and quality issues this country faces. \n", "start_char_idx": 1739, "end_char_idx": 1892, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "054459c9-4f42-4bf1-8cac-035e2ce0cde6": {"__data__": {"id_": "054459c9-4f42-4bf1-8cac-035e2ce0cde6", "embedding": null, "metadata": {"window": "And you'll be well familiar with \nour track record of renewing these particularly larger deals.  \n \n As it relates to independents in general and what are we doing to help independents, I would say, independents \nhave probably  long been at the core of McKesson as a company.  It's key part of our commitment to community \npractice, as we think being central to addressing the access costs and quality issues this country faces. \n Independents continue to benefit from the programs and s ervices that we invest in.  They continue to consume \nthat in a sort of all -encompassing way through a relationship with Health Mart and our access reimbursement \nservices that come along with that.  But we are constantly looking at how we innovate for them bo th in how they \ninteract with their patients, how they attract patients and draw footfall to their stores, how they monetize that \nfootfall both in front and behind the counter.  And we work with them day in, day out on the just efficiency of the \noperation of  their business.  \n \n", "original_text": "Independents continue to benefit from the programs and s ervices that we invest in. ", "page_label": "15", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "13b8fdec-8208-4134-8779-3d8404e4cdf3", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "da218591b6b4752f66e4d2d57ba5a62b671b9477284a7dd25158b77d027539bd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "71c0238c-8d83-4aa1-bedb-1ef8b93ffd29", "node_type": "1", "metadata": {"window": "So we really view it as kind of an \nongoing dialogue and an ongoing partnership over the course of these contracts.  And you'll be well familiar with \nour track record of renewing these particularly larger deals.  \n \n As it relates to independents in general and what are we doing to help independents, I would say, independents \nhave probably  long been at the core of McKesson as a company.  It's key part of our commitment to community \npractice, as we think being central to addressing the access costs and quality issues this country faces. \n Independents continue to benefit from the programs and s ervices that we invest in.  They continue to consume \nthat in a sort of all -encompassing way through a relationship with Health Mart and our access reimbursement \nservices that come along with that.  But we are constantly looking at how we innovate for them bo th in how they \ninteract with their patients, how they attract patients and draw footfall to their stores, how they monetize that \nfootfall both in front and behind the counter. ", "original_text": "It's key part of our commitment to community \npractice, as we think being central to addressing the access costs and quality issues this country faces. \n", "page_label": "15", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c3da68f0d27c9dffde57f3dfd8efadfbb55e20e833954840759248aaac9e1997", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3e5184fe-d9bb-4377-9460-dbe0b1bfe7fe", "node_type": "1", "metadata": {"window": "As it relates to independents in general and what are we doing to help independents, I would say, independents \nhave probably  long been at the core of McKesson as a company.  It's key part of our commitment to community \npractice, as we think being central to addressing the access costs and quality issues this country faces. \n Independents continue to benefit from the programs and s ervices that we invest in.  They continue to consume \nthat in a sort of all -encompassing way through a relationship with Health Mart and our access reimbursement \nservices that come along with that.  But we are constantly looking at how we innovate for them bo th in how they \ninteract with their patients, how they attract patients and draw footfall to their stores, how they monetize that \nfootfall both in front and behind the counter.  And we work with them day in, day out on the just efficiency of the \noperation of  their business.  \n \n Community pharmacy today feels reimbursement pressure. ", "original_text": "They continue to consume \nthat in a sort of all -encompassing way through a relationship with Health Mart and our access reimbursement \nservices that come along with that. "}, "hash": "1e7ef6c5f634380eeb0bcc7379c049c5b6a4abf40e6bafcb0a513abff0786c87", "class_name": "RelatedNodeInfo"}}, "text": "Independents continue to benefit from the programs and s ervices that we invest in. ", "start_char_idx": 1892, "end_char_idx": 1976, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3e5184fe-d9bb-4377-9460-dbe0b1bfe7fe": {"__data__": {"id_": "3e5184fe-d9bb-4377-9460-dbe0b1bfe7fe", "embedding": null, "metadata": {"window": "As it relates to independents in general and what are we doing to help independents, I would say, independents \nhave probably  long been at the core of McKesson as a company.  It's key part of our commitment to community \npractice, as we think being central to addressing the access costs and quality issues this country faces. \n Independents continue to benefit from the programs and s ervices that we invest in.  They continue to consume \nthat in a sort of all -encompassing way through a relationship with Health Mart and our access reimbursement \nservices that come along with that.  But we are constantly looking at how we innovate for them bo th in how they \ninteract with their patients, how they attract patients and draw footfall to their stores, how they monetize that \nfootfall both in front and behind the counter.  And we work with them day in, day out on the just efficiency of the \noperation of  their business.  \n \n Community pharmacy today feels reimbursement pressure. ", "original_text": "They continue to consume \nthat in a sort of all -encompassing way through a relationship with Health Mart and our access reimbursement \nservices that come along with that. ", "page_label": "15", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "13b8fdec-8208-4134-8779-3d8404e4cdf3", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "da218591b6b4752f66e4d2d57ba5a62b671b9477284a7dd25158b77d027539bd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "054459c9-4f42-4bf1-8cac-035e2ce0cde6", "node_type": "1", "metadata": {"window": "And you'll be well familiar with \nour track record of renewing these particularly larger deals.  \n \n As it relates to independents in general and what are we doing to help independents, I would say, independents \nhave probably  long been at the core of McKesson as a company.  It's key part of our commitment to community \npractice, as we think being central to addressing the access costs and quality issues this country faces. \n Independents continue to benefit from the programs and s ervices that we invest in.  They continue to consume \nthat in a sort of all -encompassing way through a relationship with Health Mart and our access reimbursement \nservices that come along with that.  But we are constantly looking at how we innovate for them bo th in how they \ninteract with their patients, how they attract patients and draw footfall to their stores, how they monetize that \nfootfall both in front and behind the counter.  And we work with them day in, day out on the just efficiency of the \noperation of  their business.  \n \n", "original_text": "Independents continue to benefit from the programs and s ervices that we invest in. ", "page_label": "15", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3784286d03bf961bd465aac65a2bcce478fa8543f0ae34ead437fc0cc5025076", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c5b34caa-f9de-49ea-b1e6-404fc32c58a0", "node_type": "1", "metadata": {"window": "It's key part of our commitment to community \npractice, as we think being central to addressing the access costs and quality issues this country faces. \n Independents continue to benefit from the programs and s ervices that we invest in.  They continue to consume \nthat in a sort of all -encompassing way through a relationship with Health Mart and our access reimbursement \nservices that come along with that.  But we are constantly looking at how we innovate for them bo th in how they \ninteract with their patients, how they attract patients and draw footfall to their stores, how they monetize that \nfootfall both in front and behind the counter.  And we work with them day in, day out on the just efficiency of the \noperation of  their business.  \n \n Community pharmacy today feels reimbursement pressure.  It's felt that pressure every year I've been in the \nbusiness, and that's almost 23 years now. ", "original_text": "But we are constantly looking at how we innovate for them bo th in how they \ninteract with their patients, how they attract patients and draw footfall to their stores, how they monetize that \nfootfall both in front and behind the counter. "}, "hash": "893b5500fc4e884a4a725aad60d31ba62ee879504dedae1b842592026be7b547", "class_name": "RelatedNodeInfo"}}, "text": "They continue to consume \nthat in a sort of all -encompassing way through a relationship with Health Mart and our access reimbursement \nservices that come along with that. ", "start_char_idx": 1976, "end_char_idx": 2148, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c5b34caa-f9de-49ea-b1e6-404fc32c58a0": {"__data__": {"id_": "c5b34caa-f9de-49ea-b1e6-404fc32c58a0", "embedding": null, "metadata": {"window": "It's key part of our commitment to community \npractice, as we think being central to addressing the access costs and quality issues this country faces. \n Independents continue to benefit from the programs and s ervices that we invest in.  They continue to consume \nthat in a sort of all -encompassing way through a relationship with Health Mart and our access reimbursement \nservices that come along with that.  But we are constantly looking at how we innovate for them bo th in how they \ninteract with their patients, how they attract patients and draw footfall to their stores, how they monetize that \nfootfall both in front and behind the counter.  And we work with them day in, day out on the just efficiency of the \noperation of  their business.  \n \n Community pharmacy today feels reimbursement pressure.  It's felt that pressure every year I've been in the \nbusiness, and that's almost 23 years now. ", "original_text": "But we are constantly looking at how we innovate for them bo th in how they \ninteract with their patients, how they attract patients and draw footfall to their stores, how they monetize that \nfootfall both in front and behind the counter. ", "page_label": "15", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "13b8fdec-8208-4134-8779-3d8404e4cdf3", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "da218591b6b4752f66e4d2d57ba5a62b671b9477284a7dd25158b77d027539bd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3e5184fe-d9bb-4377-9460-dbe0b1bfe7fe", "node_type": "1", "metadata": {"window": "As it relates to independents in general and what are we doing to help independents, I would say, independents \nhave probably  long been at the core of McKesson as a company.  It's key part of our commitment to community \npractice, as we think being central to addressing the access costs and quality issues this country faces. \n Independents continue to benefit from the programs and s ervices that we invest in.  They continue to consume \nthat in a sort of all -encompassing way through a relationship with Health Mart and our access reimbursement \nservices that come along with that.  But we are constantly looking at how we innovate for them bo th in how they \ninteract with their patients, how they attract patients and draw footfall to their stores, how they monetize that \nfootfall both in front and behind the counter.  And we work with them day in, day out on the just efficiency of the \noperation of  their business.  \n \n Community pharmacy today feels reimbursement pressure. ", "original_text": "They continue to consume \nthat in a sort of all -encompassing way through a relationship with Health Mart and our access reimbursement \nservices that come along with that. ", "page_label": "15", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e09a9c121119718659ebbb9fb0b7d5621727d295047ad25091b422a74696b672", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a4dec43d-4155-4668-8791-8dd3809fd1f1", "node_type": "1", "metadata": {"window": "Independents continue to benefit from the programs and s ervices that we invest in.  They continue to consume \nthat in a sort of all -encompassing way through a relationship with Health Mart and our access reimbursement \nservices that come along with that.  But we are constantly looking at how we innovate for them bo th in how they \ninteract with their patients, how they attract patients and draw footfall to their stores, how they monetize that \nfootfall both in front and behind the counter.  And we work with them day in, day out on the just efficiency of the \noperation of  their business.  \n \n Community pharmacy today feels reimbursement pressure.  It's felt that pressure every year I've been in the \nbusiness, and that's almost 23 years now.  So we partner with them very closely to help mature their position to \nsurvive and adapt a nd innovate. ", "original_text": "And we work with them day in, day out on the just efficiency of the \noperation of  their business.  \n \n"}, "hash": "26993bd47b760909f80416ef27354e49f99edcef016a523475382c4b1f04e662", "class_name": "RelatedNodeInfo"}}, "text": "But we are constantly looking at how we innovate for them bo th in how they \ninteract with their patients, how they attract patients and draw footfall to their stores, how they monetize that \nfootfall both in front and behind the counter. ", "start_char_idx": 2148, "end_char_idx": 2387, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a4dec43d-4155-4668-8791-8dd3809fd1f1": {"__data__": {"id_": "a4dec43d-4155-4668-8791-8dd3809fd1f1", "embedding": null, "metadata": {"window": "Independents continue to benefit from the programs and s ervices that we invest in.  They continue to consume \nthat in a sort of all -encompassing way through a relationship with Health Mart and our access reimbursement \nservices that come along with that.  But we are constantly looking at how we innovate for them bo th in how they \ninteract with their patients, how they attract patients and draw footfall to their stores, how they monetize that \nfootfall both in front and behind the counter.  And we work with them day in, day out on the just efficiency of the \noperation of  their business.  \n \n Community pharmacy today feels reimbursement pressure.  It's felt that pressure every year I've been in the \nbusiness, and that's almost 23 years now.  So we partner with them very closely to help mature their position to \nsurvive and adapt a nd innovate. ", "original_text": "And we work with them day in, day out on the just efficiency of the \noperation of  their business.  \n \n", "page_label": "15", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "13b8fdec-8208-4134-8779-3d8404e4cdf3", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "da218591b6b4752f66e4d2d57ba5a62b671b9477284a7dd25158b77d027539bd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c5b34caa-f9de-49ea-b1e6-404fc32c58a0", "node_type": "1", "metadata": {"window": "It's key part of our commitment to community \npractice, as we think being central to addressing the access costs and quality issues this country faces. \n Independents continue to benefit from the programs and s ervices that we invest in.  They continue to consume \nthat in a sort of all -encompassing way through a relationship with Health Mart and our access reimbursement \nservices that come along with that.  But we are constantly looking at how we innovate for them bo th in how they \ninteract with their patients, how they attract patients and draw footfall to their stores, how they monetize that \nfootfall both in front and behind the counter.  And we work with them day in, day out on the just efficiency of the \noperation of  their business.  \n \n Community pharmacy today feels reimbursement pressure.  It's felt that pressure every year I've been in the \nbusiness, and that's almost 23 years now. ", "original_text": "But we are constantly looking at how we innovate for them bo th in how they \ninteract with their patients, how they attract patients and draw footfall to their stores, how they monetize that \nfootfall both in front and behind the counter. ", "page_label": "15", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "db012b3cf03ca247a4bffa059a994295132d1b1a3773260c775eff2541ef21fc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d59deb7e-78e3-4129-b787-e66717bccc91", "node_type": "1", "metadata": {"window": "They continue to consume \nthat in a sort of all -encompassing way through a relationship with Health Mart and our access reimbursement \nservices that come along with that.  But we are constantly looking at how we innovate for them bo th in how they \ninteract with their patients, how they attract patients and draw footfall to their stores, how they monetize that \nfootfall both in front and behind the counter.  And we work with them day in, day out on the just efficiency of the \noperation of  their business.  \n \n Community pharmacy today feels reimbursement pressure.  It's felt that pressure every year I've been in the \nbusiness, and that's almost 23 years now.  So we partner with them very closely to help mature their position to \nsurvive and adapt a nd innovate.  And independent community pharmacies do tend to be creative individual \nbusiness folks who find ways to meet unmet needs in the communities they serve.  \n ", "original_text": "Community pharmacy today feels reimbursement pressure. "}, "hash": "9b17e1ccf00c0f0006b830e9660186c73b50c09e50f24d1464189438da4bb5d9", "class_name": "RelatedNodeInfo"}}, "text": "And we work with them day in, day out on the just efficiency of the \noperation of  their business.  \n \n", "start_char_idx": 2387, "end_char_idx": 2490, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d59deb7e-78e3-4129-b787-e66717bccc91": {"__data__": {"id_": "d59deb7e-78e3-4129-b787-e66717bccc91", "embedding": null, "metadata": {"window": "They continue to consume \nthat in a sort of all -encompassing way through a relationship with Health Mart and our access reimbursement \nservices that come along with that.  But we are constantly looking at how we innovate for them bo th in how they \ninteract with their patients, how they attract patients and draw footfall to their stores, how they monetize that \nfootfall both in front and behind the counter.  And we work with them day in, day out on the just efficiency of the \noperation of  their business.  \n \n Community pharmacy today feels reimbursement pressure.  It's felt that pressure every year I've been in the \nbusiness, and that's almost 23 years now.  So we partner with them very closely to help mature their position to \nsurvive and adapt a nd innovate.  And independent community pharmacies do tend to be creative individual \nbusiness folks who find ways to meet unmet needs in the communities they serve.  \n ", "original_text": "Community pharmacy today feels reimbursement pressure. ", "page_label": "15", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "13b8fdec-8208-4134-8779-3d8404e4cdf3", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "da218591b6b4752f66e4d2d57ba5a62b671b9477284a7dd25158b77d027539bd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a4dec43d-4155-4668-8791-8dd3809fd1f1", "node_type": "1", "metadata": {"window": "Independents continue to benefit from the programs and s ervices that we invest in.  They continue to consume \nthat in a sort of all -encompassing way through a relationship with Health Mart and our access reimbursement \nservices that come along with that.  But we are constantly looking at how we innovate for them bo th in how they \ninteract with their patients, how they attract patients and draw footfall to their stores, how they monetize that \nfootfall both in front and behind the counter.  And we work with them day in, day out on the just efficiency of the \noperation of  their business.  \n \n Community pharmacy today feels reimbursement pressure.  It's felt that pressure every year I've been in the \nbusiness, and that's almost 23 years now.  So we partner with them very closely to help mature their position to \nsurvive and adapt a nd innovate. ", "original_text": "And we work with them day in, day out on the just efficiency of the \noperation of  their business.  \n \n", "page_label": "15", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9df8a0715001cb28e9979309aefc4a43fc523ef5bf6b5b8dca2d45db6c987558", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "73b4b0fb-d968-4dd3-8dc8-fdb179480f83", "node_type": "1", "metadata": {"window": "But we are constantly looking at how we innovate for them bo th in how they \ninteract with their patients, how they attract patients and draw footfall to their stores, how they monetize that \nfootfall both in front and behind the counter.  And we work with them day in, day out on the just efficiency of the \noperation of  their business.  \n \n Community pharmacy today feels reimbursement pressure.  It's felt that pressure every year I've been in the \nbusiness, and that's almost 23 years now.  So we partner with them very closely to help mature their position to \nsurvive and adapt a nd innovate.  And independent community pharmacies do tend to be creative individual \nbusiness folks who find ways to meet unmet needs in the communities they serve.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nOkay. ", "original_text": "It's felt that pressure every year I've been in the \nbusiness, and that's almost 23 years now. "}, "hash": "8a53c9ed93d8309876424683b52dd498214e71711d77353d9f08070051b43290", "class_name": "RelatedNodeInfo"}}, "text": "Community pharmacy today feels reimbursement pressure. ", "start_char_idx": 2490, "end_char_idx": 2545, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "73b4b0fb-d968-4dd3-8dc8-fdb179480f83": {"__data__": {"id_": "73b4b0fb-d968-4dd3-8dc8-fdb179480f83", "embedding": null, "metadata": {"window": "But we are constantly looking at how we innovate for them bo th in how they \ninteract with their patients, how they attract patients and draw footfall to their stores, how they monetize that \nfootfall both in front and behind the counter.  And we work with them day in, day out on the just efficiency of the \noperation of  their business.  \n \n Community pharmacy today feels reimbursement pressure.  It's felt that pressure every year I've been in the \nbusiness, and that's almost 23 years now.  So we partner with them very closely to help mature their position to \nsurvive and adapt a nd innovate.  And independent community pharmacies do tend to be creative individual \nbusiness folks who find ways to meet unmet needs in the communities they serve.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nOkay. ", "original_text": "It's felt that pressure every year I've been in the \nbusiness, and that's almost 23 years now. ", "page_label": "15", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "13b8fdec-8208-4134-8779-3d8404e4cdf3", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "da218591b6b4752f66e4d2d57ba5a62b671b9477284a7dd25158b77d027539bd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d59deb7e-78e3-4129-b787-e66717bccc91", "node_type": "1", "metadata": {"window": "They continue to consume \nthat in a sort of all -encompassing way through a relationship with Health Mart and our access reimbursement \nservices that come along with that.  But we are constantly looking at how we innovate for them bo th in how they \ninteract with their patients, how they attract patients and draw footfall to their stores, how they monetize that \nfootfall both in front and behind the counter.  And we work with them day in, day out on the just efficiency of the \noperation of  their business.  \n \n Community pharmacy today feels reimbursement pressure.  It's felt that pressure every year I've been in the \nbusiness, and that's almost 23 years now.  So we partner with them very closely to help mature their position to \nsurvive and adapt a nd innovate.  And independent community pharmacies do tend to be creative individual \nbusiness folks who find ways to meet unmet needs in the communities they serve.  \n ", "original_text": "Community pharmacy today feels reimbursement pressure. ", "page_label": "15", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4cfb21fc2b391d0f95d236031c9f3037db572603d680f830de10e496c4ee31a8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "259166a1-6404-4783-b8f3-2230edff5d83", "node_type": "1", "metadata": {"window": "And we work with them day in, day out on the just efficiency of the \noperation of  their business.  \n \n Community pharmacy today feels reimbursement pressure.  It's felt that pressure every year I've been in the \nbusiness, and that's almost 23 years now.  So we partner with them very closely to help mature their position to \nsurvive and adapt a nd innovate.  And independent community pharmacies do tend to be creative individual \nbusiness folks who find ways to meet unmet needs in the communities they serve.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nOkay.  Thanks. ", "original_text": "So we partner with them very closely to help mature their position to \nsurvive and adapt a nd innovate. "}, "hash": "850bec5cc88638a3146449a9d040153f434f044c8ed656f01a40063f22065f27", "class_name": "RelatedNodeInfo"}}, "text": "It's felt that pressure every year I've been in the \nbusiness, and that's almost 23 years now. ", "start_char_idx": 2545, "end_char_idx": 2640, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "259166a1-6404-4783-b8f3-2230edff5d83": {"__data__": {"id_": "259166a1-6404-4783-b8f3-2230edff5d83", "embedding": null, "metadata": {"window": "And we work with them day in, day out on the just efficiency of the \noperation of  their business.  \n \n Community pharmacy today feels reimbursement pressure.  It's felt that pressure every year I've been in the \nbusiness, and that's almost 23 years now.  So we partner with them very closely to help mature their position to \nsurvive and adapt a nd innovate.  And independent community pharmacies do tend to be creative individual \nbusiness folks who find ways to meet unmet needs in the communities they serve.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nOkay.  Thanks. ", "original_text": "So we partner with them very closely to help mature their position to \nsurvive and adapt a nd innovate. ", "page_label": "15", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "13b8fdec-8208-4134-8779-3d8404e4cdf3", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "da218591b6b4752f66e4d2d57ba5a62b671b9477284a7dd25158b77d027539bd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "73b4b0fb-d968-4dd3-8dc8-fdb179480f83", "node_type": "1", "metadata": {"window": "But we are constantly looking at how we innovate for them bo th in how they \ninteract with their patients, how they attract patients and draw footfall to their stores, how they monetize that \nfootfall both in front and behind the counter.  And we work with them day in, day out on the just efficiency of the \noperation of  their business.  \n \n Community pharmacy today feels reimbursement pressure.  It's felt that pressure every year I've been in the \nbusiness, and that's almost 23 years now.  So we partner with them very closely to help mature their position to \nsurvive and adapt a nd innovate.  And independent community pharmacies do tend to be creative individual \nbusiness folks who find ways to meet unmet needs in the communities they serve.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nOkay. ", "original_text": "It's felt that pressure every year I've been in the \nbusiness, and that's almost 23 years now. ", "page_label": "15", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "161bb1e32d516f77ecc1ae867e97451c0732289d430bf27b393dbd2e9279254a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "572245ba-cd69-4054-b06a-03cdf083ccbd", "node_type": "1", "metadata": {"window": "Community pharmacy today feels reimbursement pressure.  It's felt that pressure every year I've been in the \nbusiness, and that's almost 23 years now.  So we partner with them very closely to help mature their position to \nsurvive and adapt a nd innovate.  And independent community pharmacies do tend to be creative individual \nbusiness folks who find ways to meet unmet needs in the communities they serve.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nOkay.  Thanks.  I appreciate the color. ", "original_text": "And independent community pharmacies do tend to be creative individual \nbusiness folks who find ways to meet unmet needs in the communities they serve.  \n "}, "hash": "6cb1fba54947f93a9ae211d3d218649bf66c447861f746191d3378ed705b5b78", "class_name": "RelatedNodeInfo"}}, "text": "So we partner with them very closely to help mature their position to \nsurvive and adapt a nd innovate. ", "start_char_idx": 2640, "end_char_idx": 2744, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "572245ba-cd69-4054-b06a-03cdf083ccbd": {"__data__": {"id_": "572245ba-cd69-4054-b06a-03cdf083ccbd", "embedding": null, "metadata": {"window": "Community pharmacy today feels reimbursement pressure.  It's felt that pressure every year I've been in the \nbusiness, and that's almost 23 years now.  So we partner with them very closely to help mature their position to \nsurvive and adapt a nd innovate.  And independent community pharmacies do tend to be creative individual \nbusiness folks who find ways to meet unmet needs in the communities they serve.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nOkay.  Thanks.  I appreciate the color. ", "original_text": "And independent community pharmacies do tend to be creative individual \nbusiness folks who find ways to meet unmet needs in the communities they serve.  \n ", "page_label": "15", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "13b8fdec-8208-4134-8779-3d8404e4cdf3", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "da218591b6b4752f66e4d2d57ba5a62b671b9477284a7dd25158b77d027539bd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "259166a1-6404-4783-b8f3-2230edff5d83", "node_type": "1", "metadata": {"window": "And we work with them day in, day out on the just efficiency of the \noperation of  their business.  \n \n Community pharmacy today feels reimbursement pressure.  It's felt that pressure every year I've been in the \nbusiness, and that's almost 23 years now.  So we partner with them very closely to help mature their position to \nsurvive and adapt a nd innovate.  And independent community pharmacies do tend to be creative individual \nbusiness folks who find ways to meet unmet needs in the communities they serve.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nOkay.  Thanks. ", "original_text": "So we partner with them very closely to help mature their position to \nsurvive and adapt a nd innovate. ", "page_label": "15", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c3bbfa3524e8421566346931498cb2a065fad063beef0fc6c20a8baaa72b2eb5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "84fa0bf4-de08-449b-a013-530339307281", "node_type": "1", "metadata": {"window": "It's felt that pressure every year I've been in the \nbusiness, and that's almost 23 years now.  So we partner with them very closely to help mature their position to \nsurvive and adapt a nd innovate.  And independent community pharmacies do tend to be creative individual \nbusiness folks who find ways to meet unmet needs in the communities they serve.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nOkay.  Thanks.  I appreciate the color.  And th en just one quickly on capital deployment and the pacing of share \nrepurchase. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nOkay. "}, "hash": "694729b3dd810f125bb717b5ed9ba74ad1f688ca60176f5d0799b02ff1ee81a0", "class_name": "RelatedNodeInfo"}}, "text": "And independent community pharmacies do tend to be creative individual \nbusiness folks who find ways to meet unmet needs in the communities they serve.  \n ", "start_char_idx": 2744, "end_char_idx": 2899, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "84fa0bf4-de08-449b-a013-530339307281": {"__data__": {"id_": "84fa0bf4-de08-449b-a013-530339307281", "embedding": null, "metadata": {"window": "It's felt that pressure every year I've been in the \nbusiness, and that's almost 23 years now.  So we partner with them very closely to help mature their position to \nsurvive and adapt a nd innovate.  And independent community pharmacies do tend to be creative individual \nbusiness folks who find ways to meet unmet needs in the communities they serve.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nOkay.  Thanks.  I appreciate the color.  And th en just one quickly on capital deployment and the pacing of share \nrepurchase. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nOkay. ", "page_label": "15", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "13b8fdec-8208-4134-8779-3d8404e4cdf3", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "da218591b6b4752f66e4d2d57ba5a62b671b9477284a7dd25158b77d027539bd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "572245ba-cd69-4054-b06a-03cdf083ccbd", "node_type": "1", "metadata": {"window": "Community pharmacy today feels reimbursement pressure.  It's felt that pressure every year I've been in the \nbusiness, and that's almost 23 years now.  So we partner with them very closely to help mature their position to \nsurvive and adapt a nd innovate.  And independent community pharmacies do tend to be creative individual \nbusiness folks who find ways to meet unmet needs in the communities they serve.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nOkay.  Thanks.  I appreciate the color. ", "original_text": "And independent community pharmacies do tend to be creative individual \nbusiness folks who find ways to meet unmet needs in the communities they serve.  \n ", "page_label": "15", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e6aff4bff595150d1d9b79864a8677ceac71821f23e7f601b1eb6e6845e0ae1d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b5f976a1-adb4-4fe0-b8e6-b5d25541e59d", "node_type": "1", "metadata": {"window": "So we partner with them very closely to help mature their position to \nsurvive and adapt a nd innovate.  And independent community pharmacies do tend to be creative individual \nbusiness folks who find ways to meet unmet needs in the communities they serve.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nOkay.  Thanks.  I appreciate the color.  And th en just one quickly on capital deployment and the pacing of share \nrepurchase.  So, it looks like if you carried this magnitude of share repurchase through the balance of the year, \nyou'd end up with something a few million shares below where your guidance is , which looks like 185 million \nshares, unchanged versus previous. ", "original_text": "Thanks. "}, "hash": "833703b9ee1230e4036c389ee592648bc88cf154251c1d2876c4a579aa76da55", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nOkay. ", "start_char_idx": 2899, "end_char_idx": 3211, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b5f976a1-adb4-4fe0-b8e6-b5d25541e59d": {"__data__": {"id_": "b5f976a1-adb4-4fe0-b8e6-b5d25541e59d", "embedding": null, "metadata": {"window": "So we partner with them very closely to help mature their position to \nsurvive and adapt a nd innovate.  And independent community pharmacies do tend to be creative individual \nbusiness folks who find ways to meet unmet needs in the communities they serve.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nOkay.  Thanks.  I appreciate the color.  And th en just one quickly on capital deployment and the pacing of share \nrepurchase.  So, it looks like if you carried this magnitude of share repurchase through the balance of the year, \nyou'd end up with something a few million shares below where your guidance is , which looks like 185 million \nshares, unchanged versus previous. ", "original_text": "Thanks. ", "page_label": "15", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "13b8fdec-8208-4134-8779-3d8404e4cdf3", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "da218591b6b4752f66e4d2d57ba5a62b671b9477284a7dd25158b77d027539bd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "84fa0bf4-de08-449b-a013-530339307281", "node_type": "1", "metadata": {"window": "It's felt that pressure every year I've been in the \nbusiness, and that's almost 23 years now.  So we partner with them very closely to help mature their position to \nsurvive and adapt a nd innovate.  And independent community pharmacies do tend to be creative individual \nbusiness folks who find ways to meet unmet needs in the communities they serve.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nOkay.  Thanks.  I appreciate the color.  And th en just one quickly on capital deployment and the pacing of share \nrepurchase. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nOkay. ", "page_label": "15", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f1fc0474bb12d96bc6ab8190dd48651c5ecec2b4b60548ef018b9fe169244e56", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "24118389-8871-4bca-8bbf-cd2158516a57", "node_type": "1", "metadata": {"window": "And independent community pharmacies do tend to be creative individual \nbusiness folks who find ways to meet unmet needs in the communities they serve.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nOkay.  Thanks.  I appreciate the color.  And th en just one quickly on capital deployment and the pacing of share \nrepurchase.  So, it looks like if you carried this magnitude of share repurchase through the balance of the year, \nyou'd end up with something a few million shares below where your guidance is , which looks like 185 million \nshares, unchanged versus previous.  So I was wondering if you could help us understand the progression of share \nrepurchase and how you guys approach the balance between opportunism and planned activity throughout the \nyear. ", "original_text": "I appreciate the color. "}, "hash": "96030b9dd6bf219d0b0c6e55411c346f3ffd727cdf0313713d965a3eac06d9bc", "class_name": "RelatedNodeInfo"}}, "text": "Thanks. ", "start_char_idx": 407, "end_char_idx": 415, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "24118389-8871-4bca-8bbf-cd2158516a57": {"__data__": {"id_": "24118389-8871-4bca-8bbf-cd2158516a57", "embedding": null, "metadata": {"window": "And independent community pharmacies do tend to be creative individual \nbusiness folks who find ways to meet unmet needs in the communities they serve.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nOkay.  Thanks.  I appreciate the color.  And th en just one quickly on capital deployment and the pacing of share \nrepurchase.  So, it looks like if you carried this magnitude of share repurchase through the balance of the year, \nyou'd end up with something a few million shares below where your guidance is , which looks like 185 million \nshares, unchanged versus previous.  So I was wondering if you could help us understand the progression of share \nrepurchase and how you guys approach the balance between opportunism and planned activity throughout the \nyear. ", "original_text": "I appreciate the color. ", "page_label": "15", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "13b8fdec-8208-4134-8779-3d8404e4cdf3", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "da218591b6b4752f66e4d2d57ba5a62b671b9477284a7dd25158b77d027539bd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b5f976a1-adb4-4fe0-b8e6-b5d25541e59d", "node_type": "1", "metadata": {"window": "So we partner with them very closely to help mature their position to \nsurvive and adapt a nd innovate.  And independent community pharmacies do tend to be creative individual \nbusiness folks who find ways to meet unmet needs in the communities they serve.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nOkay.  Thanks.  I appreciate the color.  And th en just one quickly on capital deployment and the pacing of share \nrepurchase.  So, it looks like if you carried this magnitude of share repurchase through the balance of the year, \nyou'd end up with something a few million shares below where your guidance is , which looks like 185 million \nshares, unchanged versus previous. ", "original_text": "Thanks. ", "page_label": "15", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d5a534a238275d38bd60e76982a049d7db67123f223c1e889df542ccbbf40320", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b9e60d25-0c18-408a-8d45-0af10027420f", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nOkay.  Thanks.  I appreciate the color.  And th en just one quickly on capital deployment and the pacing of share \nrepurchase.  So, it looks like if you carried this magnitude of share repurchase through the balance of the year, \nyou'd end up with something a few million shares below where your guidance is , which looks like 185 million \nshares, unchanged versus previous.  So I was wondering if you could help us understand the progression of share \nrepurchase and how you guys approach the balance between opportunism and planned activity throughout the \nyear.  Tha nks. \n ", "original_text": "And th en just one quickly on capital deployment and the pacing of share \nrepurchase. "}, "hash": "ab40155ac2efeb5b92b8079b3a21a0564e606a35ec8a33f109920a48778e61c8", "class_name": "RelatedNodeInfo"}}, "text": "I appreciate the color. ", "start_char_idx": 3219, "end_char_idx": 3243, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b9e60d25-0c18-408a-8d45-0af10027420f": {"__data__": {"id_": "b9e60d25-0c18-408a-8d45-0af10027420f", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nOkay.  Thanks.  I appreciate the color.  And th en just one quickly on capital deployment and the pacing of share \nrepurchase.  So, it looks like if you carried this magnitude of share repurchase through the balance of the year, \nyou'd end up with something a few million shares below where your guidance is , which looks like 185 million \nshares, unchanged versus previous.  So I was wondering if you could help us understand the progression of share \nrepurchase and how you guys approach the balance between opportunism and planned activity throughout the \nyear.  Tha nks. \n ", "original_text": "And th en just one quickly on capital deployment and the pacing of share \nrepurchase. ", "page_label": "15", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "13b8fdec-8208-4134-8779-3d8404e4cdf3", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "da218591b6b4752f66e4d2d57ba5a62b671b9477284a7dd25158b77d027539bd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "24118389-8871-4bca-8bbf-cd2158516a57", "node_type": "1", "metadata": {"window": "And independent community pharmacies do tend to be creative individual \nbusiness folks who find ways to meet unmet needs in the communities they serve.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nOkay.  Thanks.  I appreciate the color.  And th en just one quickly on capital deployment and the pacing of share \nrepurchase.  So, it looks like if you carried this magnitude of share repurchase through the balance of the year, \nyou'd end up with something a few million shares below where your guidance is , which looks like 185 million \nshares, unchanged versus previous.  So I was wondering if you could help us understand the progression of share \nrepurchase and how you guys approach the balance between opportunism and planned activity throughout the \nyear. ", "original_text": "I appreciate the color. ", "page_label": "15", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a4b685d42052f354209d1fb0804a030430eb25cf0e56dcbfdcf9f615c49d9763", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "90ff2ff0-60c9-42d1-a93c-d7ca4c71c59a", "node_type": "1", "metadata": {"window": "Thanks.  I appreciate the color.  And th en just one quickly on capital deployment and the pacing of share \nrepurchase.  So, it looks like if you carried this magnitude of share repurchase through the balance of the year, \nyou'd end up with something a few million shares below where your guidance is , which looks like 185 million \nshares, unchanged versus previous.  So I was wondering if you could help us understand the progression of share \nrepurchase and how you guys approach the balance between opportunism and planned activity throughout the \nyear.  Tha nks. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "So, it looks like if you carried this magnitude of share repurchase through the balance of the year, \nyou'd end up with something a few million shares below where your guidance is , which looks like 185 million \nshares, unchanged versus previous. "}, "hash": "40074b4a4f639be2c7dbda5978c40effde9bfec17c00e2f937ef82c49d4dbc58", "class_name": "RelatedNodeInfo"}}, "text": "And th en just one quickly on capital deployment and the pacing of share \nrepurchase. ", "start_char_idx": 3243, "end_char_idx": 3329, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "90ff2ff0-60c9-42d1-a93c-d7ca4c71c59a": {"__data__": {"id_": "90ff2ff0-60c9-42d1-a93c-d7ca4c71c59a", "embedding": null, "metadata": {"window": "Thanks.  I appreciate the color.  And th en just one quickly on capital deployment and the pacing of share \nrepurchase.  So, it looks like if you carried this magnitude of share repurchase through the balance of the year, \nyou'd end up with something a few million shares below where your guidance is , which looks like 185 million \nshares, unchanged versus previous.  So I was wondering if you could help us understand the progression of share \nrepurchase and how you guys approach the balance between opportunism and planned activity throughout the \nyear.  Tha nks. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "So, it looks like if you carried this magnitude of share repurchase through the balance of the year, \nyou'd end up with something a few million shares below where your guidance is , which looks like 185 million \nshares, unchanged versus previous. ", "page_label": "15", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "13b8fdec-8208-4134-8779-3d8404e4cdf3", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "da218591b6b4752f66e4d2d57ba5a62b671b9477284a7dd25158b77d027539bd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b9e60d25-0c18-408a-8d45-0af10027420f", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nOkay.  Thanks.  I appreciate the color.  And th en just one quickly on capital deployment and the pacing of share \nrepurchase.  So, it looks like if you carried this magnitude of share repurchase through the balance of the year, \nyou'd end up with something a few million shares below where your guidance is , which looks like 185 million \nshares, unchanged versus previous.  So I was wondering if you could help us understand the progression of share \nrepurchase and how you guys approach the balance between opportunism and planned activity throughout the \nyear.  Tha nks. \n ", "original_text": "And th en just one quickly on capital deployment and the pacing of share \nrepurchase. ", "page_label": "15", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ea3fee91966596ccd29463593e16d1b62a79055e797c7f44003c3748f539062a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "625bc6f1-d8fd-4e56-9068-724992a0d3e1", "node_type": "1", "metadata": {"window": "I appreciate the color.  And th en just one quickly on capital deployment and the pacing of share \nrepurchase.  So, it looks like if you carried this magnitude of share repurchase through the balance of the year, \nyou'd end up with something a few million shares below where your guidance is , which looks like 185 million \nshares, unchanged versus previous.  So I was wondering if you could help us understand the progression of share \nrepurchase and how you guys approach the balance between opportunism and planned activity throughout the \nyear.  Tha nks. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah. ", "original_text": "So I was wondering if you could help us understand the progression of share \nrepurchase and how you guys approach the balance between opportunism and planned activity throughout the \nyear. "}, "hash": "6ffb345e4ca9f3f0833da562b8902624f7afe0b69e69d1b9e540c1a4eba8b57f", "class_name": "RelatedNodeInfo"}}, "text": "So, it looks like if you carried this magnitude of share repurchase through the balance of the year, \nyou'd end up with something a few million shares below where your guidance is , which looks like 185 million \nshares, unchanged versus previous. ", "start_char_idx": 3329, "end_char_idx": 3576, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "625bc6f1-d8fd-4e56-9068-724992a0d3e1": {"__data__": {"id_": "625bc6f1-d8fd-4e56-9068-724992a0d3e1", "embedding": null, "metadata": {"window": "I appreciate the color.  And th en just one quickly on capital deployment and the pacing of share \nrepurchase.  So, it looks like if you carried this magnitude of share repurchase through the balance of the year, \nyou'd end up with something a few million shares below where your guidance is , which looks like 185 million \nshares, unchanged versus previous.  So I was wondering if you could help us understand the progression of share \nrepurchase and how you guys approach the balance between opportunism and planned activity throughout the \nyear.  Tha nks. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah. ", "original_text": "So I was wondering if you could help us understand the progression of share \nrepurchase and how you guys approach the balance between opportunism and planned activity throughout the \nyear. ", "page_label": "15", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "13b8fdec-8208-4134-8779-3d8404e4cdf3", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "da218591b6b4752f66e4d2d57ba5a62b671b9477284a7dd25158b77d027539bd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "90ff2ff0-60c9-42d1-a93c-d7ca4c71c59a", "node_type": "1", "metadata": {"window": "Thanks.  I appreciate the color.  And th en just one quickly on capital deployment and the pacing of share \nrepurchase.  So, it looks like if you carried this magnitude of share repurchase through the balance of the year, \nyou'd end up with something a few million shares below where your guidance is , which looks like 185 million \nshares, unchanged versus previous.  So I was wondering if you could help us understand the progression of share \nrepurchase and how you guys approach the balance between opportunism and planned activity throughout the \nyear.  Tha nks. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "So, it looks like if you carried this magnitude of share repurchase through the balance of the year, \nyou'd end up with something a few million shares below where your guidance is , which looks like 185 million \nshares, unchanged versus previous. ", "page_label": "15", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a4c4ba5776e0e7486bc1720b9f9645bc1a2202a722d0962a125d53dff1031b99", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4440f4c7-f2e6-4da0-b671-0ba97260368b", "node_type": "1", "metadata": {"window": "And th en just one quickly on capital deployment and the pacing of share \nrepurchase.  So, it looks like if you carried this magnitude of share repurchase through the balance of the year, \nyou'd end up with something a few million shares below where your guidance is , which looks like 185 million \nshares, unchanged versus previous.  So I was wondering if you could help us understand the progression of share \nrepurchase and how you guys approach the balance between opportunism and planned activity throughout the \nyear.  Tha nks. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  Thanks for the question. ", "original_text": "Tha nks. \n "}, "hash": "fd6556b8a395f629dbc9ba98521be03499309d8667c1e0811e61868be6c0a9b6", "class_name": "RelatedNodeInfo"}}, "text": "So I was wondering if you could help us understand the progression of share \nrepurchase and how you guys approach the balance between opportunism and planned activity throughout the \nyear. ", "start_char_idx": 3576, "end_char_idx": 3765, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4440f4c7-f2e6-4da0-b671-0ba97260368b": {"__data__": {"id_": "4440f4c7-f2e6-4da0-b671-0ba97260368b", "embedding": null, "metadata": {"window": "And th en just one quickly on capital deployment and the pacing of share \nrepurchase.  So, it looks like if you carried this magnitude of share repurchase through the balance of the year, \nyou'd end up with something a few million shares below where your guidance is , which looks like 185 million \nshares, unchanged versus previous.  So I was wondering if you could help us understand the progression of share \nrepurchase and how you guys approach the balance between opportunism and planned activity throughout the \nyear.  Tha nks. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  Thanks for the question. ", "original_text": "Tha nks. \n ", "page_label": "15", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "13b8fdec-8208-4134-8779-3d8404e4cdf3", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "da218591b6b4752f66e4d2d57ba5a62b671b9477284a7dd25158b77d027539bd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "625bc6f1-d8fd-4e56-9068-724992a0d3e1", "node_type": "1", "metadata": {"window": "I appreciate the color.  And th en just one quickly on capital deployment and the pacing of share \nrepurchase.  So, it looks like if you carried this magnitude of share repurchase through the balance of the year, \nyou'd end up with something a few million shares below where your guidance is , which looks like 185 million \nshares, unchanged versus previous.  So I was wondering if you could help us understand the progression of share \nrepurchase and how you guys approach the balance between opportunism and planned activity throughout the \nyear.  Tha nks. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah. ", "original_text": "So I was wondering if you could help us understand the progression of share \nrepurchase and how you guys approach the balance between opportunism and planned activity throughout the \nyear. ", "page_label": "15", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "93d1873d68b3d6e744bd79b517346cf080c3937ffda1ed8fb3f1e942043a708f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "18bff6ab-d63d-4eae-8b43-6ec9afdb6d53", "node_type": "1", "metadata": {"window": "So, it looks like if you carried this magnitude of share repurchase through the balance of the year, \nyou'd end up with something a few million shares below where your guidance is , which looks like 185 million \nshares, unchanged versus previous.  So I was wondering if you could help us understand the progression of share \nrepurchase and how you guys approach the balance between opportunism and planned activity throughout the \nyear.  Tha nks. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  Thanks for the question.  I would just reaffirm that we've not changed our assumption on our diluted shares \nfor the end of the year. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  "}, "hash": "dddfb7ec3569ab1673d460834a65cb26d6c2f7a48963c156ed7de3b598c23880", "class_name": "RelatedNodeInfo"}}, "text": "Tha nks. \n ", "start_char_idx": 3765, "end_char_idx": 3776, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "18bff6ab-d63d-4eae-8b43-6ec9afdb6d53": {"__data__": {"id_": "18bff6ab-d63d-4eae-8b43-6ec9afdb6d53", "embedding": null, "metadata": {"window": "So, it looks like if you carried this magnitude of share repurchase through the balance of the year, \nyou'd end up with something a few million shares below where your guidance is , which looks like 185 million \nshares, unchanged versus previous.  So I was wondering if you could help us understand the progression of share \nrepurchase and how you guys approach the balance between opportunism and planned activity throughout the \nyear.  Tha nks. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  Thanks for the question.  I would just reaffirm that we've not changed our assumption on our diluted shares \nfor the end of the year. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "page_label": "15", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "13b8fdec-8208-4134-8779-3d8404e4cdf3", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "da218591b6b4752f66e4d2d57ba5a62b671b9477284a7dd25158b77d027539bd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4440f4c7-f2e6-4da0-b671-0ba97260368b", "node_type": "1", "metadata": {"window": "And th en just one quickly on capital deployment and the pacing of share \nrepurchase.  So, it looks like if you carried this magnitude of share repurchase through the balance of the year, \nyou'd end up with something a few million shares below where your guidance is , which looks like 185 million \nshares, unchanged versus previous.  So I was wondering if you could help us understand the progression of share \nrepurchase and how you guys approach the balance between opportunism and planned activity throughout the \nyear.  Tha nks. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  Thanks for the question. ", "original_text": "Tha nks. \n ", "page_label": "15", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d133c78aedf92f9f18ce41331debd3706b081f542238f4bf58733f9b4bc37950", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c010ae4d-a8df-4694-81af-2a3fb3884409", "node_type": "1", "metadata": {"window": "So I was wondering if you could help us understand the progression of share \nrepurchase and how you guys approach the balance between opportunism and planned activity throughout the \nyear.  Tha nks. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  Thanks for the question.  I would just reaffirm that we've not changed our assumption on our diluted shares \nfor the end of the year.  We don't have a set amount that you should think about for modeling to take it from \nquarter -to-quarter. ", "original_text": "A \nYeah. "}, "hash": "9951551d65971f8413cf924dec22986a0c8befb3d31135a6d7a48e7582d19ceb", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "start_char_idx": 3776, "end_char_idx": 4121, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c010ae4d-a8df-4694-81af-2a3fb3884409": {"__data__": {"id_": "c010ae4d-a8df-4694-81af-2a3fb3884409", "embedding": null, "metadata": {"window": "So I was wondering if you could help us understand the progression of share \nrepurchase and how you guys approach the balance between opportunism and planned activity throughout the \nyear.  Tha nks. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  Thanks for the question.  I would just reaffirm that we've not changed our assumption on our diluted shares \nfor the end of the year.  We don't have a set amount that you should think about for modeling to take it from \nquarter -to-quarter. ", "original_text": "A \nYeah. ", "page_label": "15", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "13b8fdec-8208-4134-8779-3d8404e4cdf3", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "da218591b6b4752f66e4d2d57ba5a62b671b9477284a7dd25158b77d027539bd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "18bff6ab-d63d-4eae-8b43-6ec9afdb6d53", "node_type": "1", "metadata": {"window": "So, it looks like if you carried this magnitude of share repurchase through the balance of the year, \nyou'd end up with something a few million shares below where your guidance is , which looks like 185 million \nshares, unchanged versus previous.  So I was wondering if you could help us understand the progression of share \nrepurchase and how you guys approach the balance between opportunism and planned activity throughout the \nyear.  Tha nks. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  Thanks for the question.  I would just reaffirm that we've not changed our assumption on our diluted shares \nfor the end of the year. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "page_label": "15", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4a9eb77e67d63e21a5e25d269adf995702ccc42f67bbbf734dc8f31eab4434d7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "86a1d470-d8b4-480d-9365-6ba67970aac5", "node_type": "1", "metadata": {"window": "Tha nks. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  Thanks for the question.  I would just reaffirm that we've not changed our assumption on our diluted shares \nfor the end of the year.  We don't have a set amount that you should think about for modeling to take it from \nquarter -to-quarter.  We think about  capital deployment \u2013 as Brian mentioned, we think about it, opportunities on \nstrategy. ", "original_text": "Thanks for the question. "}, "hash": "65b48cdf99971763728c19413a51e92f2a6ffc1e96488c37976f9e05b36800a7", "class_name": "RelatedNodeInfo"}}, "text": "A \nYeah. ", "start_char_idx": 747, "end_char_idx": 756, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "86a1d470-d8b4-480d-9365-6ba67970aac5": {"__data__": {"id_": "86a1d470-d8b4-480d-9365-6ba67970aac5", "embedding": null, "metadata": {"window": "Tha nks. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  Thanks for the question.  I would just reaffirm that we've not changed our assumption on our diluted shares \nfor the end of the year.  We don't have a set amount that you should think about for modeling to take it from \nquarter -to-quarter.  We think about  capital deployment \u2013 as Brian mentioned, we think about it, opportunities on \nstrategy. ", "original_text": "Thanks for the question. ", "page_label": "15", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "13b8fdec-8208-4134-8779-3d8404e4cdf3", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "da218591b6b4752f66e4d2d57ba5a62b671b9477284a7dd25158b77d027539bd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c010ae4d-a8df-4694-81af-2a3fb3884409", "node_type": "1", "metadata": {"window": "So I was wondering if you could help us understand the progression of share \nrepurchase and how you guys approach the balance between opportunism and planned activity throughout the \nyear.  Tha nks. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  Thanks for the question.  I would just reaffirm that we've not changed our assumption on our diluted shares \nfor the end of the year.  We don't have a set amount that you should think about for modeling to take it from \nquarter -to-quarter. ", "original_text": "A \nYeah. ", "page_label": "15", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "08f60b5782acd9cedd28a3658202fb373169d4753487a74c709042d9b2a16ece", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9c19d413-fe68-4666-b1d8-ff0a9b988b3c", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  Thanks for the question.  I would just reaffirm that we've not changed our assumption on our diluted shares \nfor the end of the year.  We don't have a set amount that you should think about for modeling to take it from \nquarter -to-quarter.  We think about  capital deployment \u2013 as Brian mentioned, we think about it, opportunities on \nstrategy.  And where we have opportunities to invest on strategy or invest internally, we do that. ", "original_text": "I would just reaffirm that we've not changed our assumption on our diluted shares \nfor the end of the year. "}, "hash": "52c75255144644210e25f75e3c31498145802fcf1ce22ed1edfa2862a71698ad", "class_name": "RelatedNodeInfo"}}, "text": "Thanks for the question. ", "start_char_idx": 4130, "end_char_idx": 4155, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9c19d413-fe68-4666-b1d8-ff0a9b988b3c": {"__data__": {"id_": "9c19d413-fe68-4666-b1d8-ff0a9b988b3c", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  Thanks for the question.  I would just reaffirm that we've not changed our assumption on our diluted shares \nfor the end of the year.  We don't have a set amount that you should think about for modeling to take it from \nquarter -to-quarter.  We think about  capital deployment \u2013 as Brian mentioned, we think about it, opportunities on \nstrategy.  And where we have opportunities to invest on strategy or invest internally, we do that. ", "original_text": "I would just reaffirm that we've not changed our assumption on our diluted shares \nfor the end of the year. ", "page_label": "15", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "13b8fdec-8208-4134-8779-3d8404e4cdf3", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "da218591b6b4752f66e4d2d57ba5a62b671b9477284a7dd25158b77d027539bd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "86a1d470-d8b4-480d-9365-6ba67970aac5", "node_type": "1", "metadata": {"window": "Tha nks. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  Thanks for the question.  I would just reaffirm that we've not changed our assumption on our diluted shares \nfor the end of the year.  We don't have a set amount that you should think about for modeling to take it from \nquarter -to-quarter.  We think about  capital deployment \u2013 as Brian mentioned, we think about it, opportunities on \nstrategy. ", "original_text": "Thanks for the question. ", "page_label": "15", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a36823cbdc55337230b6a4035896b4ba6d25be71775d28d68a4f5be9f65b8ba4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3dd823ec-8ca1-44be-9693-7e84d4a971fa", "node_type": "1", "metadata": {"window": "A \nYeah.  Thanks for the question.  I would just reaffirm that we've not changed our assumption on our diluted shares \nfor the end of the year.  We don't have a set amount that you should think about for modeling to take it from \nquarter -to-quarter.  We think about  capital deployment \u2013 as Brian mentioned, we think about it, opportunities on \nstrategy.  And where we have opportunities to invest on strategy or invest internally, we do that.  And certainly ", "original_text": "We don't have a set amount that you should think about for modeling to take it from \nquarter -to-quarter. "}, "hash": "800c7e735c3b36f3ba1bc080e67348048d2ed2fd710f9830730d3752a59175eb", "class_name": "RelatedNodeInfo"}}, "text": "I would just reaffirm that we've not changed our assumption on our diluted shares \nfor the end of the year. ", "start_char_idx": 4155, "end_char_idx": 4263, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3dd823ec-8ca1-44be-9693-7e84d4a971fa": {"__data__": {"id_": "3dd823ec-8ca1-44be-9693-7e84d4a971fa", "embedding": null, "metadata": {"window": "A \nYeah.  Thanks for the question.  I would just reaffirm that we've not changed our assumption on our diluted shares \nfor the end of the year.  We don't have a set amount that you should think about for modeling to take it from \nquarter -to-quarter.  We think about  capital deployment \u2013 as Brian mentioned, we think about it, opportunities on \nstrategy.  And where we have opportunities to invest on strategy or invest internally, we do that.  And certainly ", "original_text": "We don't have a set amount that you should think about for modeling to take it from \nquarter -to-quarter. ", "page_label": "15", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "13b8fdec-8208-4134-8779-3d8404e4cdf3", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "da218591b6b4752f66e4d2d57ba5a62b671b9477284a7dd25158b77d027539bd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9c19d413-fe68-4666-b1d8-ff0a9b988b3c", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  Thanks for the question.  I would just reaffirm that we've not changed our assumption on our diluted shares \nfor the end of the year.  We don't have a set amount that you should think about for modeling to take it from \nquarter -to-quarter.  We think about  capital deployment \u2013 as Brian mentioned, we think about it, opportunities on \nstrategy.  And where we have opportunities to invest on strategy or invest internally, we do that. ", "original_text": "I would just reaffirm that we've not changed our assumption on our diluted shares \nfor the end of the year. ", "page_label": "15", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6b520ded38f70969ab1ddad408af0bc42f1fdd10a57713abb0ab5813be38b589", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a66183c3-5db5-460c-91cb-d66a64b9b056", "node_type": "1", "metadata": {"window": "Thanks for the question.  I would just reaffirm that we've not changed our assumption on our diluted shares \nfor the end of the year.  We don't have a set amount that you should think about for modeling to take it from \nquarter -to-quarter.  We think about  capital deployment \u2013 as Brian mentioned, we think about it, opportunities on \nstrategy.  And where we have opportunities to invest on strategy or invest internally, we do that.  And certainly ", "original_text": "We think about  capital deployment \u2013 as Brian mentioned, we think about it, opportunities on \nstrategy. "}, "hash": "56e66f1fea5ab50b37a6057f5669d7f8a078431fe0ec5beb8c09f75006e05863", "class_name": "RelatedNodeInfo"}}, "text": "We don't have a set amount that you should think about for modeling to take it from \nquarter -to-quarter. ", "start_char_idx": 4263, "end_char_idx": 4369, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a66183c3-5db5-460c-91cb-d66a64b9b056": {"__data__": {"id_": "a66183c3-5db5-460c-91cb-d66a64b9b056", "embedding": null, "metadata": {"window": "Thanks for the question.  I would just reaffirm that we've not changed our assumption on our diluted shares \nfor the end of the year.  We don't have a set amount that you should think about for modeling to take it from \nquarter -to-quarter.  We think about  capital deployment \u2013 as Brian mentioned, we think about it, opportunities on \nstrategy.  And where we have opportunities to invest on strategy or invest internally, we do that.  And certainly ", "original_text": "We think about  capital deployment \u2013 as Brian mentioned, we think about it, opportunities on \nstrategy. ", "page_label": "15", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "13b8fdec-8208-4134-8779-3d8404e4cdf3", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "da218591b6b4752f66e4d2d57ba5a62b671b9477284a7dd25158b77d027539bd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3dd823ec-8ca1-44be-9693-7e84d4a971fa", "node_type": "1", "metadata": {"window": "A \nYeah.  Thanks for the question.  I would just reaffirm that we've not changed our assumption on our diluted shares \nfor the end of the year.  We don't have a set amount that you should think about for modeling to take it from \nquarter -to-quarter.  We think about  capital deployment \u2013 as Brian mentioned, we think about it, opportunities on \nstrategy.  And where we have opportunities to invest on strategy or invest internally, we do that.  And certainly ", "original_text": "We don't have a set amount that you should think about for modeling to take it from \nquarter -to-quarter. ", "page_label": "15", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dc0eadd31f4a1664c13019ae138ff7b1da9dede366bf5bf16043f997407f1bda", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "27b0798c-fa6d-4c58-8a70-67336488c882", "node_type": "1", "metadata": {"window": "I would just reaffirm that we've not changed our assumption on our diluted shares \nfor the end of the year.  We don't have a set amount that you should think about for modeling to take it from \nquarter -to-quarter.  We think about  capital deployment \u2013 as Brian mentioned, we think about it, opportunities on \nstrategy.  And where we have opportunities to invest on strategy or invest internally, we do that.  And certainly ", "original_text": "And where we have opportunities to invest on strategy or invest internally, we do that. "}, "hash": "703404a789ebf5d7271284bff57e88fbe7fd3dcf88864e05035de2f87259bfab", "class_name": "RelatedNodeInfo"}}, "text": "We think about  capital deployment \u2013 as Brian mentioned, we think about it, opportunities on \nstrategy. ", "start_char_idx": 4369, "end_char_idx": 4473, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "27b0798c-fa6d-4c58-8a70-67336488c882": {"__data__": {"id_": "27b0798c-fa6d-4c58-8a70-67336488c882", "embedding": null, "metadata": {"window": "I would just reaffirm that we've not changed our assumption on our diluted shares \nfor the end of the year.  We don't have a set amount that you should think about for modeling to take it from \nquarter -to-quarter.  We think about  capital deployment \u2013 as Brian mentioned, we think about it, opportunities on \nstrategy.  And where we have opportunities to invest on strategy or invest internally, we do that.  And certainly ", "original_text": "And where we have opportunities to invest on strategy or invest internally, we do that. ", "page_label": "15", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "13b8fdec-8208-4134-8779-3d8404e4cdf3", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "da218591b6b4752f66e4d2d57ba5a62b671b9477284a7dd25158b77d027539bd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a66183c3-5db5-460c-91cb-d66a64b9b056", "node_type": "1", "metadata": {"window": "Thanks for the question.  I would just reaffirm that we've not changed our assumption on our diluted shares \nfor the end of the year.  We don't have a set amount that you should think about for modeling to take it from \nquarter -to-quarter.  We think about  capital deployment \u2013 as Brian mentioned, we think about it, opportunities on \nstrategy.  And where we have opportunities to invest on strategy or invest internally, we do that.  And certainly ", "original_text": "We think about  capital deployment \u2013 as Brian mentioned, we think about it, opportunities on \nstrategy. ", "page_label": "15", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9b0f79faf94f8c5191d5ce7cff3af11f0bca9d7b2a756f06e2a3fd0984b0497c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7b0a1bf3-8a2d-40e4-a53a-4171481d983a", "node_type": "1", "metadata": {"window": "We don't have a set amount that you should think about for modeling to take it from \nquarter -to-quarter.  We think about  capital deployment \u2013 as Brian mentioned, we think about it, opportunities on \nstrategy.  And where we have opportunities to invest on strategy or invest internally, we do that.  And certainly ", "original_text": "And certainly "}, "hash": "b2b504a94d58bd16d2a2d9d89a4f1e151cf8974b9f3a288d939d645962fd2b41", "class_name": "RelatedNodeInfo"}}, "text": "And where we have opportunities to invest on strategy or invest internally, we do that. ", "start_char_idx": 4473, "end_char_idx": 4561, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7b0a1bf3-8a2d-40e4-a53a-4171481d983a": {"__data__": {"id_": "7b0a1bf3-8a2d-40e4-a53a-4171481d983a", "embedding": null, "metadata": {"window": "We don't have a set amount that you should think about for modeling to take it from \nquarter -to-quarter.  We think about  capital deployment \u2013 as Brian mentioned, we think about it, opportunities on \nstrategy.  And where we have opportunities to invest on strategy or invest internally, we do that.  And certainly ", "original_text": "And certainly ", "page_label": "15", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "13b8fdec-8208-4134-8779-3d8404e4cdf3", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "da218591b6b4752f66e4d2d57ba5a62b671b9477284a7dd25158b77d027539bd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "27b0798c-fa6d-4c58-8a70-67336488c882", "node_type": "1", "metadata": {"window": "I would just reaffirm that we've not changed our assumption on our diluted shares \nfor the end of the year.  We don't have a set amount that you should think about for modeling to take it from \nquarter -to-quarter.  We think about  capital deployment \u2013 as Brian mentioned, we think about it, opportunities on \nstrategy.  And where we have opportunities to invest on strategy or invest internally, we do that.  And certainly ", "original_text": "And where we have opportunities to invest on strategy or invest internally, we do that. ", "page_label": "15", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dffccb37cb0f0e7b7092e6605d82f5a7350bd4148fe5f5e3e16f000b547545a3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "73b8dd00-62fa-4bed-a366-bbdb1cda8ac8", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nwe've had an opportunity this quarter to return more to our shareh olders.  So, we make those decisions on a \nregular basis.  But in terms of our guide on shares for the end of the year, we've not changed that.  \n ", "original_text": "McKesson Corp.  "}, "hash": "cea5d9d34a6ab374240a7c5f1281809f92e73f824e197dd264275d2f7c57ae4e", "class_name": "RelatedNodeInfo"}}, "text": "And certainly ", "start_char_idx": 4561, "end_char_idx": 4575, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "73b8dd00-62fa-4bed-a366-bbdb1cda8ac8": {"__data__": {"id_": "73b8dd00-62fa-4bed-a366-bbdb1cda8ac8", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nwe've had an opportunity this quarter to return more to our shareh olders.  So, we make those decisions on a \nregular basis.  But in terms of our guide on shares for the end of the year, we've not changed that.  \n ", "original_text": "McKesson Corp.  ", "page_label": "16", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a46922f5-2d81-4fc9-93e8-95bec3c3587f", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "98a1b6b5b3444e21b734ba73861011986b152c17e03607d202d42ff610852ddd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7b0a1bf3-8a2d-40e4-a53a-4171481d983a", "node_type": "1", "metadata": {"window": "We don't have a set amount that you should think about for modeling to take it from \nquarter -to-quarter.  We think about  capital deployment \u2013 as Brian mentioned, we think about it, opportunities on \nstrategy.  And where we have opportunities to invest on strategy or invest internally, we do that.  And certainly ", "original_text": "And certainly ", "page_label": "15", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f2d4dfddbc544293843ac0167f643825bf2035459447eba9dbbf3e3d37296813", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "311b9447-e066-4461-bc40-e4f976a8aa71", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nwe've had an opportunity this quarter to return more to our shareh olders.  So, we make those decisions on a \nregular basis.  But in terms of our guide on shares for the end of the year, we've not changed that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question will come from Eric Percher with Nephron Research.  \n ", "original_text": "(MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nwe've had an opportunity this quarter to return more to our shareh olders. "}, "hash": "ccecce84ea28aa43a880b26569e9a814d01ce59f4062ba51dfeb4ad77861e2cb", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "311b9447-e066-4461-bc40-e4f976a8aa71": {"__data__": {"id_": "311b9447-e066-4461-bc40-e4f976a8aa71", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nwe've had an opportunity this quarter to return more to our shareh olders.  So, we make those decisions on a \nregular basis.  But in terms of our guide on shares for the end of the year, we've not changed that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question will come from Eric Percher with Nephron Research.  \n ", "original_text": "(MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nwe've had an opportunity this quarter to return more to our shareh olders. ", "page_label": "16", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a46922f5-2d81-4fc9-93e8-95bec3c3587f", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "98a1b6b5b3444e21b734ba73861011986b152c17e03607d202d42ff610852ddd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "73b8dd00-62fa-4bed-a366-bbdb1cda8ac8", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nwe've had an opportunity this quarter to return more to our shareh olders.  So, we make those decisions on a \nregular basis.  But in terms of our guide on shares for the end of the year, we've not changed that.  \n ", "original_text": "McKesson Corp.  ", "page_label": "16", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "522643671dd27e5a3c878ba2c75e87a0994b032905afa8ad2f2653e704b99205", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9b66039a-5a9b-4b8b-bf49-b0411d19dae9", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nwe've had an opportunity this quarter to return more to our shareh olders.  So, we make those decisions on a \nregular basis.  But in terms of our guide on shares for the end of the year, we've not changed that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question will come from Eric Percher with Nephron Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephr on Research LLC  Q \nThank you. ", "original_text": "So, we make those decisions on a \nregular basis. "}, "hash": "09045719b98bbcdc0858111ff7debd4dee7c0695cb09a8b3d6cb02a2ce2ff07c", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nwe've had an opportunity this quarter to return more to our shareh olders. ", "start_char_idx": 16, "end_char_idx": 256, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9b66039a-5a9b-4b8b-bf49-b0411d19dae9": {"__data__": {"id_": "9b66039a-5a9b-4b8b-bf49-b0411d19dae9", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nwe've had an opportunity this quarter to return more to our shareh olders.  So, we make those decisions on a \nregular basis.  But in terms of our guide on shares for the end of the year, we've not changed that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question will come from Eric Percher with Nephron Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephr on Research LLC  Q \nThank you. ", "original_text": "So, we make those decisions on a \nregular basis. ", "page_label": "16", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a46922f5-2d81-4fc9-93e8-95bec3c3587f", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "98a1b6b5b3444e21b734ba73861011986b152c17e03607d202d42ff610852ddd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "311b9447-e066-4461-bc40-e4f976a8aa71", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nwe've had an opportunity this quarter to return more to our shareh olders.  So, we make those decisions on a \nregular basis.  But in terms of our guide on shares for the end of the year, we've not changed that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question will come from Eric Percher with Nephron Research.  \n ", "original_text": "(MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nwe've had an opportunity this quarter to return more to our shareh olders. ", "page_label": "16", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "825b8f021ef4e6f92210205d5e808e4d6c639d582a2d5a3c7a74a5c6e85a329a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2fc31b10-5368-4d0f-81ed-1bbab934c2b3", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nwe've had an opportunity this quarter to return more to our shareh olders.  So, we make those decisions on a \nregular basis.  But in terms of our guide on shares for the end of the year, we've not changed that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question will come from Eric Percher with Nephron Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephr on Research LLC  Q \nThank you.  Like to go back to the gross margin question. ", "original_text": "But in terms of our guide on shares for the end of the year, we've not changed that.  \n "}, "hash": "a61714c10803f85d01fd9ede19e47b14244de054e138eec0917d27c35950570f", "class_name": "RelatedNodeInfo"}}, "text": "So, we make those decisions on a \nregular basis. ", "start_char_idx": 256, "end_char_idx": 305, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2fc31b10-5368-4d0f-81ed-1bbab934c2b3": {"__data__": {"id_": "2fc31b10-5368-4d0f-81ed-1bbab934c2b3", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nwe've had an opportunity this quarter to return more to our shareh olders.  So, we make those decisions on a \nregular basis.  But in terms of our guide on shares for the end of the year, we've not changed that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question will come from Eric Percher with Nephron Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephr on Research LLC  Q \nThank you.  Like to go back to the gross margin question. ", "original_text": "But in terms of our guide on shares for the end of the year, we've not changed that.  \n ", "page_label": "16", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a46922f5-2d81-4fc9-93e8-95bec3c3587f", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "98a1b6b5b3444e21b734ba73861011986b152c17e03607d202d42ff610852ddd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9b66039a-5a9b-4b8b-bf49-b0411d19dae9", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nwe've had an opportunity this quarter to return more to our shareh olders.  So, we make those decisions on a \nregular basis.  But in terms of our guide on shares for the end of the year, we've not changed that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question will come from Eric Percher with Nephron Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephr on Research LLC  Q \nThank you. ", "original_text": "So, we make those decisions on a \nregular basis. ", "page_label": "16", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0e088b0a8aca66c2b3ffdf6bd0955f59b25ccf66db24d0f583b04c413e1277a7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0b138cbf-7ca8-406c-a6c6-3f5f63b6bae8", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nwe've had an opportunity this quarter to return more to our shareh olders.  So, we make those decisions on a \nregular basis.  But in terms of our guide on shares for the end of the year, we've not changed that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question will come from Eric Percher with Nephron Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephr on Research LLC  Q \nThank you.  Like to go back to the gross margin question.  And maybe given the comments around independents, I \nknow that was one segment that hasn't been driving the same contribution that some of the other areas, the retail \nnationals and other less -profitable accounts may be. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question will come from Eric Percher with Nephron Research.  \n "}, "hash": "ac29527e498e49f3ded8daf4a1800b28addd43762667828ac7715cf21d4ba388", "class_name": "RelatedNodeInfo"}}, "text": "But in terms of our guide on shares for the end of the year, we've not changed that.  \n ", "start_char_idx": 305, "end_char_idx": 393, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0b138cbf-7ca8-406c-a6c6-3f5f63b6bae8": {"__data__": {"id_": "0b138cbf-7ca8-406c-a6c6-3f5f63b6bae8", "embedding": null, "metadata": {"window": "(MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nwe've had an opportunity this quarter to return more to our shareh olders.  So, we make those decisions on a \nregular basis.  But in terms of our guide on shares for the end of the year, we've not changed that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question will come from Eric Percher with Nephron Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephr on Research LLC  Q \nThank you.  Like to go back to the gross margin question.  And maybe given the comments around independents, I \nknow that was one segment that hasn't been driving the same contribution that some of the other areas, the retail \nnationals and other less -profitable accounts may be. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question will come from Eric Percher with Nephron Research.  \n ", "page_label": "16", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a46922f5-2d81-4fc9-93e8-95bec3c3587f", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "98a1b6b5b3444e21b734ba73861011986b152c17e03607d202d42ff610852ddd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2fc31b10-5368-4d0f-81ed-1bbab934c2b3", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nwe've had an opportunity this quarter to return more to our shareh olders.  So, we make those decisions on a \nregular basis.  But in terms of our guide on shares for the end of the year, we've not changed that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question will come from Eric Percher with Nephron Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephr on Research LLC  Q \nThank you.  Like to go back to the gross margin question. ", "original_text": "But in terms of our guide on shares for the end of the year, we've not changed that.  \n ", "page_label": "16", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "849f076998f12da9d87945664547fe420e27b699b48a94643633cf1a2b94ed65", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fc89f9ef-b26c-46a3-a747-1eb6ecd8e888", "node_type": "1", "metadata": {"window": "So, we make those decisions on a \nregular basis.  But in terms of our guide on shares for the end of the year, we've not changed that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question will come from Eric Percher with Nephron Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephr on Research LLC  Q \nThank you.  Like to go back to the gross margin question.  And maybe given the comments around independents, I \nknow that was one segment that hasn't been driving the same contribution that some of the other areas, the retail \nnationals and other less -profitable accounts may be.  As you think about the growth in revenue and what that \ntranslates into at a gross profit growth level at a period of time where independents aren't driving it and a period of \ntime where generic contributions aren't as  high, what do you see as the natural growth rate?  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephr on Research LLC  Q \nThank you. "}, "hash": "34e340ebd2ca8cf81243937d62b96cb7bf986153b8d0ec6c83778047f161e75e", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question will come from Eric Percher with Nephron Research.  \n ", "start_char_idx": 393, "end_char_idx": 739, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fc89f9ef-b26c-46a3-a747-1eb6ecd8e888": {"__data__": {"id_": "fc89f9ef-b26c-46a3-a747-1eb6ecd8e888", "embedding": null, "metadata": {"window": "So, we make those decisions on a \nregular basis.  But in terms of our guide on shares for the end of the year, we've not changed that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question will come from Eric Percher with Nephron Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephr on Research LLC  Q \nThank you.  Like to go back to the gross margin question.  And maybe given the comments around independents, I \nknow that was one segment that hasn't been driving the same contribution that some of the other areas, the retail \nnationals and other less -profitable accounts may be.  As you think about the growth in revenue and what that \ntranslates into at a gross profit growth level at a period of time where independents aren't driving it and a period of \ntime where generic contributions aren't as  high, what do you see as the natural growth rate?  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephr on Research LLC  Q \nThank you. ", "page_label": "16", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a46922f5-2d81-4fc9-93e8-95bec3c3587f", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "98a1b6b5b3444e21b734ba73861011986b152c17e03607d202d42ff610852ddd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0b138cbf-7ca8-406c-a6c6-3f5f63b6bae8", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nwe've had an opportunity this quarter to return more to our shareh olders.  So, we make those decisions on a \nregular basis.  But in terms of our guide on shares for the end of the year, we've not changed that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question will come from Eric Percher with Nephron Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephr on Research LLC  Q \nThank you.  Like to go back to the gross margin question.  And maybe given the comments around independents, I \nknow that was one segment that hasn't been driving the same contribution that some of the other areas, the retail \nnationals and other less -profitable accounts may be. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question will come from Eric Percher with Nephron Research.  \n ", "page_label": "16", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ec05bc7bc6eac30c63892f7cc315113755fbd52b5fcc3de6fe8b4a68a2c13ebb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ec40d994-aa1c-4491-af02-b2b5a865d70d", "node_type": "1", "metadata": {"window": "But in terms of our guide on shares for the end of the year, we've not changed that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question will come from Eric Percher with Nephron Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephr on Research LLC  Q \nThank you.  Like to go back to the gross margin question.  And maybe given the comments around independents, I \nknow that was one segment that hasn't been driving the same contribution that some of the other areas, the retail \nnationals and other less -profitable accounts may be.  As you think about the growth in revenue and what that \ntranslates into at a gross profit growth level at a period of time where independents aren't driving it and a period of \ntime where generic contributions aren't as  high, what do you see as the natural growth rate?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "Like to go back to the gross margin question. "}, "hash": "161ed8626e956839c7b2d13d8aabe0164c14fe1210879ceec1b71be85b2318a5", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephr on Research LLC  Q \nThank you. ", "start_char_idx": 739, "end_char_idx": 1057, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ec40d994-aa1c-4491-af02-b2b5a865d70d": {"__data__": {"id_": "ec40d994-aa1c-4491-af02-b2b5a865d70d", "embedding": null, "metadata": {"window": "But in terms of our guide on shares for the end of the year, we've not changed that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question will come from Eric Percher with Nephron Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephr on Research LLC  Q \nThank you.  Like to go back to the gross margin question.  And maybe given the comments around independents, I \nknow that was one segment that hasn't been driving the same contribution that some of the other areas, the retail \nnationals and other less -profitable accounts may be.  As you think about the growth in revenue and what that \ntranslates into at a gross profit growth level at a period of time where independents aren't driving it and a period of \ntime where generic contributions aren't as  high, what do you see as the natural growth rate?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "Like to go back to the gross margin question. ", "page_label": "16", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a46922f5-2d81-4fc9-93e8-95bec3c3587f", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "98a1b6b5b3444e21b734ba73861011986b152c17e03607d202d42ff610852ddd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fc89f9ef-b26c-46a3-a747-1eb6ecd8e888", "node_type": "1", "metadata": {"window": "So, we make those decisions on a \nregular basis.  But in terms of our guide on shares for the end of the year, we've not changed that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question will come from Eric Percher with Nephron Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephr on Research LLC  Q \nThank you.  Like to go back to the gross margin question.  And maybe given the comments around independents, I \nknow that was one segment that hasn't been driving the same contribution that some of the other areas, the retail \nnationals and other less -profitable accounts may be.  As you think about the growth in revenue and what that \ntranslates into at a gross profit growth level at a period of time where independents aren't driving it and a period of \ntime where generic contributions aren't as  high, what do you see as the natural growth rate?  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephr on Research LLC  Q \nThank you. ", "page_label": "16", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "029ea69a334b0ae2674093e22027f76a1793ed36d050611c48605b78ab2899b3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "42739259-1c89-4e21-a476-dc18e15135d3", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question will come from Eric Percher with Nephron Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephr on Research LLC  Q \nThank you.  Like to go back to the gross margin question.  And maybe given the comments around independents, I \nknow that was one segment that hasn't been driving the same contribution that some of the other areas, the retail \nnationals and other less -profitable accounts may be.  As you think about the growth in revenue and what that \ntranslates into at a gross profit growth level at a period of time where independents aren't driving it and a period of \ntime where generic contributions aren't as  high, what do you see as the natural growth rate?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nWell, Eric, what I would point to is, if you look at our consolidated gross margin, there's multiple factors to \nconsider in here. ", "original_text": "And maybe given the comments around independents, I \nknow that was one segment that hasn't been driving the same contribution that some of the other areas, the retail \nnationals and other less -profitable accounts may be. "}, "hash": "0fb5d91d80025fcea1dee2d979f99957c541a2bfaed89f499a1e8e59059fdca1", "class_name": "RelatedNodeInfo"}}, "text": "Like to go back to the gross margin question. ", "start_char_idx": 1057, "end_char_idx": 1103, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "42739259-1c89-4e21-a476-dc18e15135d3": {"__data__": {"id_": "42739259-1c89-4e21-a476-dc18e15135d3", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question will come from Eric Percher with Nephron Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephr on Research LLC  Q \nThank you.  Like to go back to the gross margin question.  And maybe given the comments around independents, I \nknow that was one segment that hasn't been driving the same contribution that some of the other areas, the retail \nnationals and other less -profitable accounts may be.  As you think about the growth in revenue and what that \ntranslates into at a gross profit growth level at a period of time where independents aren't driving it and a period of \ntime where generic contributions aren't as  high, what do you see as the natural growth rate?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nWell, Eric, what I would point to is, if you look at our consolidated gross margin, there's multiple factors to \nconsider in here. ", "original_text": "And maybe given the comments around independents, I \nknow that was one segment that hasn't been driving the same contribution that some of the other areas, the retail \nnationals and other less -profitable accounts may be. ", "page_label": "16", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a46922f5-2d81-4fc9-93e8-95bec3c3587f", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "98a1b6b5b3444e21b734ba73861011986b152c17e03607d202d42ff610852ddd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ec40d994-aa1c-4491-af02-b2b5a865d70d", "node_type": "1", "metadata": {"window": "But in terms of our guide on shares for the end of the year, we've not changed that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question will come from Eric Percher with Nephron Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephr on Research LLC  Q \nThank you.  Like to go back to the gross margin question.  And maybe given the comments around independents, I \nknow that was one segment that hasn't been driving the same contribution that some of the other areas, the retail \nnationals and other less -profitable accounts may be.  As you think about the growth in revenue and what that \ntranslates into at a gross profit growth level at a period of time where independents aren't driving it and a period of \ntime where generic contributions aren't as  high, what do you see as the natural growth rate?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "Like to go back to the gross margin question. ", "page_label": "16", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e6eb818a254e670c807aa3efac164863c17fd8082e16fe06da4b8c6b55448567", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "23e82a43-24fd-4134-a16a-ea4ab5eea7a2", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephr on Research LLC  Q \nThank you.  Like to go back to the gross margin question.  And maybe given the comments around independents, I \nknow that was one segment that hasn't been driving the same contribution that some of the other areas, the retail \nnationals and other less -profitable accounts may be.  As you think about the growth in revenue and what that \ntranslates into at a gross profit growth level at a period of time where independents aren't driving it and a period of \ntime where generic contributions aren't as  high, what do you see as the natural growth rate?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nWell, Eric, what I would point to is, if you look at our consolidated gross margin, there's multiple factors to \nconsider in here.  And one of the things that impacted our gross margin in the quarter was the weak retail results \nin our UK business within Europe. ", "original_text": "As you think about the growth in revenue and what that \ntranslates into at a gross profit growth level at a period of time where independents aren't driving it and a period of \ntime where generic contributions aren't as  high, what do you see as the natural growth rate?  \n "}, "hash": "9c880596208a41f98ae3cd4788eae54d30c3e4462a8184f676afc8b1028d11ea", "class_name": "RelatedNodeInfo"}}, "text": "And maybe given the comments around independents, I \nknow that was one segment that hasn't been driving the same contribution that some of the other areas, the retail \nnationals and other less -profitable accounts may be. ", "start_char_idx": 1103, "end_char_idx": 1325, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "23e82a43-24fd-4134-a16a-ea4ab5eea7a2": {"__data__": {"id_": "23e82a43-24fd-4134-a16a-ea4ab5eea7a2", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephr on Research LLC  Q \nThank you.  Like to go back to the gross margin question.  And maybe given the comments around independents, I \nknow that was one segment that hasn't been driving the same contribution that some of the other areas, the retail \nnationals and other less -profitable accounts may be.  As you think about the growth in revenue and what that \ntranslates into at a gross profit growth level at a period of time where independents aren't driving it and a period of \ntime where generic contributions aren't as  high, what do you see as the natural growth rate?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nWell, Eric, what I would point to is, if you look at our consolidated gross margin, there's multiple factors to \nconsider in here.  And one of the things that impacted our gross margin in the quarter was the weak retail results \nin our UK business within Europe. ", "original_text": "As you think about the growth in revenue and what that \ntranslates into at a gross profit growth level at a period of time where independents aren't driving it and a period of \ntime where generic contributions aren't as  high, what do you see as the natural growth rate?  \n ", "page_label": "16", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a46922f5-2d81-4fc9-93e8-95bec3c3587f", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "98a1b6b5b3444e21b734ba73861011986b152c17e03607d202d42ff610852ddd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "42739259-1c89-4e21-a476-dc18e15135d3", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question will come from Eric Percher with Nephron Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephr on Research LLC  Q \nThank you.  Like to go back to the gross margin question.  And maybe given the comments around independents, I \nknow that was one segment that hasn't been driving the same contribution that some of the other areas, the retail \nnationals and other less -profitable accounts may be.  As you think about the growth in revenue and what that \ntranslates into at a gross profit growth level at a period of time where independents aren't driving it and a period of \ntime where generic contributions aren't as  high, what do you see as the natural growth rate?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nWell, Eric, what I would point to is, if you look at our consolidated gross margin, there's multiple factors to \nconsider in here. ", "original_text": "And maybe given the comments around independents, I \nknow that was one segment that hasn't been driving the same contribution that some of the other areas, the retail \nnationals and other less -profitable accounts may be. ", "page_label": "16", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5239291f3d0ba8499f751d4a85242d12f8f2d0b34475249679023f9fb1127fe3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c52c2160-34da-4519-851b-c02335ea6097", "node_type": "1", "metadata": {"window": "Like to go back to the gross margin question.  And maybe given the comments around independents, I \nknow that was one segment that hasn't been driving the same contribution that some of the other areas, the retail \nnationals and other less -profitable accounts may be.  As you think about the growth in revenue and what that \ntranslates into at a gross profit growth level at a period of time where independents aren't driving it and a period of \ntime where generic contributions aren't as  high, what do you see as the natural growth rate?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nWell, Eric, what I would point to is, if you look at our consolidated gross margin, there's multiple factors to \nconsider in here.  And one of the things that impacted our gross margin in the quarter was the weak retail results \nin our UK business within Europe.  Now clearly, we had a large proportion of revenue being driven by our largest \nretail national account and we  had a very broad base of revenue growth across our business.  \n \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  "}, "hash": "95c04719139cb33cf1806a0676928b50fc9393984fed37545e8ee845d233e1fe", "class_name": "RelatedNodeInfo"}}, "text": "As you think about the growth in revenue and what that \ntranslates into at a gross profit growth level at a period of time where independents aren't driving it and a period of \ntime where generic contributions aren't as  high, what do you see as the natural growth rate?  \n ", "start_char_idx": 1325, "end_char_idx": 1599, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c52c2160-34da-4519-851b-c02335ea6097": {"__data__": {"id_": "c52c2160-34da-4519-851b-c02335ea6097", "embedding": null, "metadata": {"window": "Like to go back to the gross margin question.  And maybe given the comments around independents, I \nknow that was one segment that hasn't been driving the same contribution that some of the other areas, the retail \nnationals and other less -profitable accounts may be.  As you think about the growth in revenue and what that \ntranslates into at a gross profit growth level at a period of time where independents aren't driving it and a period of \ntime where generic contributions aren't as  high, what do you see as the natural growth rate?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nWell, Eric, what I would point to is, if you look at our consolidated gross margin, there's multiple factors to \nconsider in here.  And one of the things that impacted our gross margin in the quarter was the weak retail results \nin our UK business within Europe.  Now clearly, we had a large proportion of revenue being driven by our largest \nretail national account and we  had a very broad base of revenue growth across our business.  \n \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "page_label": "16", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a46922f5-2d81-4fc9-93e8-95bec3c3587f", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "98a1b6b5b3444e21b734ba73861011986b152c17e03607d202d42ff610852ddd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "23e82a43-24fd-4134-a16a-ea4ab5eea7a2", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephr on Research LLC  Q \nThank you.  Like to go back to the gross margin question.  And maybe given the comments around independents, I \nknow that was one segment that hasn't been driving the same contribution that some of the other areas, the retail \nnationals and other less -profitable accounts may be.  As you think about the growth in revenue and what that \ntranslates into at a gross profit growth level at a period of time where independents aren't driving it and a period of \ntime where generic contributions aren't as  high, what do you see as the natural growth rate?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nWell, Eric, what I would point to is, if you look at our consolidated gross margin, there's multiple factors to \nconsider in here.  And one of the things that impacted our gross margin in the quarter was the weak retail results \nin our UK business within Europe. ", "original_text": "As you think about the growth in revenue and what that \ntranslates into at a gross profit growth level at a period of time where independents aren't driving it and a period of \ntime where generic contributions aren't as  high, what do you see as the natural growth rate?  \n ", "page_label": "16", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2177cb4f2958168a8f50ffdbf21a1229070317e8ca1471b5183da2e3d15b3e16", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bd3685d2-5df1-424b-b453-2c51a61b7a47", "node_type": "1", "metadata": {"window": "And maybe given the comments around independents, I \nknow that was one segment that hasn't been driving the same contribution that some of the other areas, the retail \nnationals and other less -profitable accounts may be.  As you think about the growth in revenue and what that \ntranslates into at a gross profit growth level at a period of time where independents aren't driving it and a period of \ntime where generic contributions aren't as  high, what do you see as the natural growth rate?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nWell, Eric, what I would point to is, if you look at our consolidated gross margin, there's multiple factors to \nconsider in here.  And one of the things that impacted our gross margin in the quarter was the weak retail results \nin our UK business within Europe.  Now clearly, we had a large proportion of revenue being driven by our largest \nretail national account and we  had a very broad base of revenue growth across our business.  \n \n And overall, I would just say that one of the things that impacted to the negative side was not only the mix of \nrevenue, but the impact from a weak retail environment in the UK. ", "original_text": "A \nWell, Eric, what I would point to is, if you look at our consolidated gross margin, there's multiple factors to \nconsider in here. "}, "hash": "8ebf57d37b7e2ca281f5842abeff97a96fad1c6985f92c2f3176011d41c149fe", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "start_char_idx": 1599, "end_char_idx": 1944, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bd3685d2-5df1-424b-b453-2c51a61b7a47": {"__data__": {"id_": "bd3685d2-5df1-424b-b453-2c51a61b7a47", "embedding": null, "metadata": {"window": "And maybe given the comments around independents, I \nknow that was one segment that hasn't been driving the same contribution that some of the other areas, the retail \nnationals and other less -profitable accounts may be.  As you think about the growth in revenue and what that \ntranslates into at a gross profit growth level at a period of time where independents aren't driving it and a period of \ntime where generic contributions aren't as  high, what do you see as the natural growth rate?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nWell, Eric, what I would point to is, if you look at our consolidated gross margin, there's multiple factors to \nconsider in here.  And one of the things that impacted our gross margin in the quarter was the weak retail results \nin our UK business within Europe.  Now clearly, we had a large proportion of revenue being driven by our largest \nretail national account and we  had a very broad base of revenue growth across our business.  \n \n And overall, I would just say that one of the things that impacted to the negative side was not only the mix of \nrevenue, but the impact from a weak retail environment in the UK. ", "original_text": "A \nWell, Eric, what I would point to is, if you look at our consolidated gross margin, there's multiple factors to \nconsider in here. ", "page_label": "16", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a46922f5-2d81-4fc9-93e8-95bec3c3587f", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "98a1b6b5b3444e21b734ba73861011986b152c17e03607d202d42ff610852ddd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c52c2160-34da-4519-851b-c02335ea6097", "node_type": "1", "metadata": {"window": "Like to go back to the gross margin question.  And maybe given the comments around independents, I \nknow that was one segment that hasn't been driving the same contribution that some of the other areas, the retail \nnationals and other less -profitable accounts may be.  As you think about the growth in revenue and what that \ntranslates into at a gross profit growth level at a period of time where independents aren't driving it and a period of \ntime where generic contributions aren't as  high, what do you see as the natural growth rate?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nWell, Eric, what I would point to is, if you look at our consolidated gross margin, there's multiple factors to \nconsider in here.  And one of the things that impacted our gross margin in the quarter was the weak retail results \nin our UK business within Europe.  Now clearly, we had a large proportion of revenue being driven by our largest \nretail national account and we  had a very broad base of revenue growth across our business.  \n \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "page_label": "16", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a1b4f2ca95fda8b57bb4beee3c443f17c9447d299d23ff2864368b8ee99d6082", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2fc488af-843a-49a4-a7b6-c3c83118b091", "node_type": "1", "metadata": {"window": "As you think about the growth in revenue and what that \ntranslates into at a gross profit growth level at a period of time where independents aren't driving it and a period of \ntime where generic contributions aren't as  high, what do you see as the natural growth rate?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nWell, Eric, what I would point to is, if you look at our consolidated gross margin, there's multiple factors to \nconsider in here.  And one of the things that impacted our gross margin in the quarter was the weak retail results \nin our UK business within Europe.  Now clearly, we had a large proportion of revenue being driven by our largest \nretail national account and we  had a very broad base of revenue growth across our business.  \n \n And overall, I would just say that one of the things that impacted to the negative side was not only the mix of \nrevenue, but the impact from a weak retail environment in the UK.  When you think about our independent \ncustomers within U.S. ", "original_text": "And one of the things that impacted our gross margin in the quarter was the weak retail results \nin our UK business within Europe. "}, "hash": "d76ec3d6f3324ceb9282d0e665070bda2dcd4bfdde089ec7e59bf00aab70347c", "class_name": "RelatedNodeInfo"}}, "text": "A \nWell, Eric, what I would point to is, if you look at our consolidated gross margin, there's multiple factors to \nconsider in here. ", "start_char_idx": 1944, "end_char_idx": 2078, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2fc488af-843a-49a4-a7b6-c3c83118b091": {"__data__": {"id_": "2fc488af-843a-49a4-a7b6-c3c83118b091", "embedding": null, "metadata": {"window": "As you think about the growth in revenue and what that \ntranslates into at a gross profit growth level at a period of time where independents aren't driving it and a period of \ntime where generic contributions aren't as  high, what do you see as the natural growth rate?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nWell, Eric, what I would point to is, if you look at our consolidated gross margin, there's multiple factors to \nconsider in here.  And one of the things that impacted our gross margin in the quarter was the weak retail results \nin our UK business within Europe.  Now clearly, we had a large proportion of revenue being driven by our largest \nretail national account and we  had a very broad base of revenue growth across our business.  \n \n And overall, I would just say that one of the things that impacted to the negative side was not only the mix of \nrevenue, but the impact from a weak retail environment in the UK.  When you think about our independent \ncustomers within U.S. ", "original_text": "And one of the things that impacted our gross margin in the quarter was the weak retail results \nin our UK business within Europe. ", "page_label": "16", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a46922f5-2d81-4fc9-93e8-95bec3c3587f", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "98a1b6b5b3444e21b734ba73861011986b152c17e03607d202d42ff610852ddd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bd3685d2-5df1-424b-b453-2c51a61b7a47", "node_type": "1", "metadata": {"window": "And maybe given the comments around independents, I \nknow that was one segment that hasn't been driving the same contribution that some of the other areas, the retail \nnationals and other less -profitable accounts may be.  As you think about the growth in revenue and what that \ntranslates into at a gross profit growth level at a period of time where independents aren't driving it and a period of \ntime where generic contributions aren't as  high, what do you see as the natural growth rate?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nWell, Eric, what I would point to is, if you look at our consolidated gross margin, there's multiple factors to \nconsider in here.  And one of the things that impacted our gross margin in the quarter was the weak retail results \nin our UK business within Europe.  Now clearly, we had a large proportion of revenue being driven by our largest \nretail national account and we  had a very broad base of revenue growth across our business.  \n \n And overall, I would just say that one of the things that impacted to the negative side was not only the mix of \nrevenue, but the impact from a weak retail environment in the UK. ", "original_text": "A \nWell, Eric, what I would point to is, if you look at our consolidated gross margin, there's multiple factors to \nconsider in here. ", "page_label": "16", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "93eb690e5da07230d7be308d16d3862f2444cff3a5dacc837621df25958c85a9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9a97d9b0-1dc5-4e88-b394-b3f9c456b808", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nWell, Eric, what I would point to is, if you look at our consolidated gross margin, there's multiple factors to \nconsider in here.  And one of the things that impacted our gross margin in the quarter was the weak retail results \nin our UK business within Europe.  Now clearly, we had a large proportion of revenue being driven by our largest \nretail national account and we  had a very broad base of revenue growth across our business.  \n \n And overall, I would just say that one of the things that impacted to the negative side was not only the mix of \nrevenue, but the impact from a weak retail environment in the UK.  When you think about our independent \ncustomers within U.S.  Pharma, we haven't seen anything different this quarter from the previous couple of \nquarters. ", "original_text": "Now clearly, we had a large proportion of revenue being driven by our largest \nretail national account and we  had a very broad base of revenue growth across our business.  \n \n"}, "hash": "771bd0c2ef8cf0c9facba46c265db090ca66422df766ed26ba8c5a59150af5eb", "class_name": "RelatedNodeInfo"}}, "text": "And one of the things that impacted our gross margin in the quarter was the weak retail results \nin our UK business within Europe. ", "start_char_idx": 2078, "end_char_idx": 2209, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9a97d9b0-1dc5-4e88-b394-b3f9c456b808": {"__data__": {"id_": "9a97d9b0-1dc5-4e88-b394-b3f9c456b808", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nWell, Eric, what I would point to is, if you look at our consolidated gross margin, there's multiple factors to \nconsider in here.  And one of the things that impacted our gross margin in the quarter was the weak retail results \nin our UK business within Europe.  Now clearly, we had a large proportion of revenue being driven by our largest \nretail national account and we  had a very broad base of revenue growth across our business.  \n \n And overall, I would just say that one of the things that impacted to the negative side was not only the mix of \nrevenue, but the impact from a weak retail environment in the UK.  When you think about our independent \ncustomers within U.S.  Pharma, we haven't seen anything different this quarter from the previous couple of \nquarters. ", "original_text": "Now clearly, we had a large proportion of revenue being driven by our largest \nretail national account and we  had a very broad base of revenue growth across our business.  \n \n", "page_label": "16", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a46922f5-2d81-4fc9-93e8-95bec3c3587f", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "98a1b6b5b3444e21b734ba73861011986b152c17e03607d202d42ff610852ddd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2fc488af-843a-49a4-a7b6-c3c83118b091", "node_type": "1", "metadata": {"window": "As you think about the growth in revenue and what that \ntranslates into at a gross profit growth level at a period of time where independents aren't driving it and a period of \ntime where generic contributions aren't as  high, what do you see as the natural growth rate?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nWell, Eric, what I would point to is, if you look at our consolidated gross margin, there's multiple factors to \nconsider in here.  And one of the things that impacted our gross margin in the quarter was the weak retail results \nin our UK business within Europe.  Now clearly, we had a large proportion of revenue being driven by our largest \nretail national account and we  had a very broad base of revenue growth across our business.  \n \n And overall, I would just say that one of the things that impacted to the negative side was not only the mix of \nrevenue, but the impact from a weak retail environment in the UK.  When you think about our independent \ncustomers within U.S. ", "original_text": "And one of the things that impacted our gross margin in the quarter was the weak retail results \nin our UK business within Europe. ", "page_label": "16", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5515e8dd428b4f268c25f8b4511a621d26f895ad2733ec74a8e102807179f5b9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fb4d0cf5-b33c-4476-8de9-a18356c03be3", "node_type": "1", "metadata": {"window": "A \nWell, Eric, what I would point to is, if you look at our consolidated gross margin, there's multiple factors to \nconsider in here.  And one of the things that impacted our gross margin in the quarter was the weak retail results \nin our UK business within Europe.  Now clearly, we had a large proportion of revenue being driven by our largest \nretail national account and we  had a very broad base of revenue growth across our business.  \n \n And overall, I would just say that one of the things that impacted to the negative side was not only the mix of \nrevenue, but the impact from a weak retail environment in the UK.  When you think about our independent \ncustomers within U.S.  Pharma, we haven't seen anything different this quarter from the previous couple of \nquarters.  So I don't know that there's anything really to call out specific about that.  \n ", "original_text": "And overall, I would just say that one of the things that impacted to the negative side was not only the mix of \nrevenue, but the impact from a weak retail environment in the UK. "}, "hash": "2284541add4696040869cfa13c12f0fdeee70976c35e7b0e1d9121d7681bf7d0", "class_name": "RelatedNodeInfo"}}, "text": "Now clearly, we had a large proportion of revenue being driven by our largest \nretail national account and we  had a very broad base of revenue growth across our business.  \n \n", "start_char_idx": 2209, "end_char_idx": 2385, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fb4d0cf5-b33c-4476-8de9-a18356c03be3": {"__data__": {"id_": "fb4d0cf5-b33c-4476-8de9-a18356c03be3", "embedding": null, "metadata": {"window": "A \nWell, Eric, what I would point to is, if you look at our consolidated gross margin, there's multiple factors to \nconsider in here.  And one of the things that impacted our gross margin in the quarter was the weak retail results \nin our UK business within Europe.  Now clearly, we had a large proportion of revenue being driven by our largest \nretail national account and we  had a very broad base of revenue growth across our business.  \n \n And overall, I would just say that one of the things that impacted to the negative side was not only the mix of \nrevenue, but the impact from a weak retail environment in the UK.  When you think about our independent \ncustomers within U.S.  Pharma, we haven't seen anything different this quarter from the previous couple of \nquarters.  So I don't know that there's anything really to call out specific about that.  \n ", "original_text": "And overall, I would just say that one of the things that impacted to the negative side was not only the mix of \nrevenue, but the impact from a weak retail environment in the UK. ", "page_label": "16", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a46922f5-2d81-4fc9-93e8-95bec3c3587f", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "98a1b6b5b3444e21b734ba73861011986b152c17e03607d202d42ff610852ddd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9a97d9b0-1dc5-4e88-b394-b3f9c456b808", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nWell, Eric, what I would point to is, if you look at our consolidated gross margin, there's multiple factors to \nconsider in here.  And one of the things that impacted our gross margin in the quarter was the weak retail results \nin our UK business within Europe.  Now clearly, we had a large proportion of revenue being driven by our largest \nretail national account and we  had a very broad base of revenue growth across our business.  \n \n And overall, I would just say that one of the things that impacted to the negative side was not only the mix of \nrevenue, but the impact from a weak retail environment in the UK.  When you think about our independent \ncustomers within U.S.  Pharma, we haven't seen anything different this quarter from the previous couple of \nquarters. ", "original_text": "Now clearly, we had a large proportion of revenue being driven by our largest \nretail national account and we  had a very broad base of revenue growth across our business.  \n \n", "page_label": "16", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "585669abea7dc6482a85b5ab298c37055e7f052c0b8ec4dccf89db37238e7ec4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "18dec443-1e88-4e5f-9ad7-6012c5c3c3c4", "node_type": "1", "metadata": {"window": "And one of the things that impacted our gross margin in the quarter was the weak retail results \nin our UK business within Europe.  Now clearly, we had a large proportion of revenue being driven by our largest \nretail national account and we  had a very broad base of revenue growth across our business.  \n \n And overall, I would just say that one of the things that impacted to the negative side was not only the mix of \nrevenue, but the impact from a weak retail environment in the UK.  When you think about our independent \ncustomers within U.S.  Pharma, we haven't seen anything different this quarter from the previous couple of \nquarters.  So I don't know that there's anything really to call out specific about that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Offi cer & Director, McKesson Corp.  ", "original_text": "When you think about our independent \ncustomers within U.S. "}, "hash": "8ea8afdf01eedb09842ce8a7601d54a30d52b30c0b7eabba4737715b2c547c87", "class_name": "RelatedNodeInfo"}}, "text": "And overall, I would just say that one of the things that impacted to the negative side was not only the mix of \nrevenue, but the impact from a weak retail environment in the UK. ", "start_char_idx": 2385, "end_char_idx": 2564, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "18dec443-1e88-4e5f-9ad7-6012c5c3c3c4": {"__data__": {"id_": "18dec443-1e88-4e5f-9ad7-6012c5c3c3c4", "embedding": null, "metadata": {"window": "And one of the things that impacted our gross margin in the quarter was the weak retail results \nin our UK business within Europe.  Now clearly, we had a large proportion of revenue being driven by our largest \nretail national account and we  had a very broad base of revenue growth across our business.  \n \n And overall, I would just say that one of the things that impacted to the negative side was not only the mix of \nrevenue, but the impact from a weak retail environment in the UK.  When you think about our independent \ncustomers within U.S.  Pharma, we haven't seen anything different this quarter from the previous couple of \nquarters.  So I don't know that there's anything really to call out specific about that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Offi cer & Director, McKesson Corp.  ", "original_text": "When you think about our independent \ncustomers within U.S. ", "page_label": "16", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a46922f5-2d81-4fc9-93e8-95bec3c3587f", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "98a1b6b5b3444e21b734ba73861011986b152c17e03607d202d42ff610852ddd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fb4d0cf5-b33c-4476-8de9-a18356c03be3", "node_type": "1", "metadata": {"window": "A \nWell, Eric, what I would point to is, if you look at our consolidated gross margin, there's multiple factors to \nconsider in here.  And one of the things that impacted our gross margin in the quarter was the weak retail results \nin our UK business within Europe.  Now clearly, we had a large proportion of revenue being driven by our largest \nretail national account and we  had a very broad base of revenue growth across our business.  \n \n And overall, I would just say that one of the things that impacted to the negative side was not only the mix of \nrevenue, but the impact from a weak retail environment in the UK.  When you think about our independent \ncustomers within U.S.  Pharma, we haven't seen anything different this quarter from the previous couple of \nquarters.  So I don't know that there's anything really to call out specific about that.  \n ", "original_text": "And overall, I would just say that one of the things that impacted to the negative side was not only the mix of \nrevenue, but the impact from a weak retail environment in the UK. ", "page_label": "16", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7bbb0a10ae97c6332155e087031ab3d9bc32791464b04c71e4bbc3b278d6b136", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c856ba40-eacd-4851-9a92-3791f0720e74", "node_type": "1", "metadata": {"window": "Now clearly, we had a large proportion of revenue being driven by our largest \nretail national account and we  had a very broad base of revenue growth across our business.  \n \n And overall, I would just say that one of the things that impacted to the negative side was not only the mix of \nrevenue, but the impact from a weak retail environment in the UK.  When you think about our independent \ncustomers within U.S.  Pharma, we haven't seen anything different this quarter from the previous couple of \nquarters.  So I don't know that there's anything really to call out specific about that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Offi cer & Director, McKesson Corp.   A \nYeah. ", "original_text": "Pharma, we haven't seen anything different this quarter from the previous couple of \nquarters. "}, "hash": "abe10fba25c63e57bb4bb70053c0f008cae34d84033419f64a35de1819a1fb3c", "class_name": "RelatedNodeInfo"}}, "text": "When you think about our independent \ncustomers within U.S. ", "start_char_idx": 2564, "end_char_idx": 2624, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c856ba40-eacd-4851-9a92-3791f0720e74": {"__data__": {"id_": "c856ba40-eacd-4851-9a92-3791f0720e74", "embedding": null, "metadata": {"window": "Now clearly, we had a large proportion of revenue being driven by our largest \nretail national account and we  had a very broad base of revenue growth across our business.  \n \n And overall, I would just say that one of the things that impacted to the negative side was not only the mix of \nrevenue, but the impact from a weak retail environment in the UK.  When you think about our independent \ncustomers within U.S.  Pharma, we haven't seen anything different this quarter from the previous couple of \nquarters.  So I don't know that there's anything really to call out specific about that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Offi cer & Director, McKesson Corp.   A \nYeah. ", "original_text": "Pharma, we haven't seen anything different this quarter from the previous couple of \nquarters. ", "page_label": "16", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a46922f5-2d81-4fc9-93e8-95bec3c3587f", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "98a1b6b5b3444e21b734ba73861011986b152c17e03607d202d42ff610852ddd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "18dec443-1e88-4e5f-9ad7-6012c5c3c3c4", "node_type": "1", "metadata": {"window": "And one of the things that impacted our gross margin in the quarter was the weak retail results \nin our UK business within Europe.  Now clearly, we had a large proportion of revenue being driven by our largest \nretail national account and we  had a very broad base of revenue growth across our business.  \n \n And overall, I would just say that one of the things that impacted to the negative side was not only the mix of \nrevenue, but the impact from a weak retail environment in the UK.  When you think about our independent \ncustomers within U.S.  Pharma, we haven't seen anything different this quarter from the previous couple of \nquarters.  So I don't know that there's anything really to call out specific about that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Offi cer & Director, McKesson Corp.  ", "original_text": "When you think about our independent \ncustomers within U.S. ", "page_label": "16", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9dec2258f3052cc912d1e3af0e29c617a6ad3cf47be77bcd3cd9e2e6b1beb321", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e15f7205-ca03-4f49-975f-3dd1249c2f67", "node_type": "1", "metadata": {"window": "And overall, I would just say that one of the things that impacted to the negative side was not only the mix of \nrevenue, but the impact from a weak retail environment in the UK.  When you think about our independent \ncustomers within U.S.  Pharma, we haven't seen anything different this quarter from the previous couple of \nquarters.  So I don't know that there's anything really to call out specific about that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Offi cer & Director, McKesson Corp.   A \nYeah.  When we look at the kind of reimbursement environment that retail independents are facing, think we \ntalked last quarter about the fact that if we look at our data, and we really see in aggregate a very normal \nheadwin d that's been established, something that's kind of been consistent with prior years. ", "original_text": "So I don't know that there's anything really to call out specific about that.  \n "}, "hash": "41110c6eb21d728deeb0fd7febbc817dbaa38ee4aae47f521ae380382757eae9", "class_name": "RelatedNodeInfo"}}, "text": "Pharma, we haven't seen anything different this quarter from the previous couple of \nquarters. ", "start_char_idx": 2624, "end_char_idx": 2719, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e15f7205-ca03-4f49-975f-3dd1249c2f67": {"__data__": {"id_": "e15f7205-ca03-4f49-975f-3dd1249c2f67", "embedding": null, "metadata": {"window": "And overall, I would just say that one of the things that impacted to the negative side was not only the mix of \nrevenue, but the impact from a weak retail environment in the UK.  When you think about our independent \ncustomers within U.S.  Pharma, we haven't seen anything different this quarter from the previous couple of \nquarters.  So I don't know that there's anything really to call out specific about that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Offi cer & Director, McKesson Corp.   A \nYeah.  When we look at the kind of reimbursement environment that retail independents are facing, think we \ntalked last quarter about the fact that if we look at our data, and we really see in aggregate a very normal \nheadwin d that's been established, something that's kind of been consistent with prior years. ", "original_text": "So I don't know that there's anything really to call out specific about that.  \n ", "page_label": "16", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a46922f5-2d81-4fc9-93e8-95bec3c3587f", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "98a1b6b5b3444e21b734ba73861011986b152c17e03607d202d42ff610852ddd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c856ba40-eacd-4851-9a92-3791f0720e74", "node_type": "1", "metadata": {"window": "Now clearly, we had a large proportion of revenue being driven by our largest \nretail national account and we  had a very broad base of revenue growth across our business.  \n \n And overall, I would just say that one of the things that impacted to the negative side was not only the mix of \nrevenue, but the impact from a weak retail environment in the UK.  When you think about our independent \ncustomers within U.S.  Pharma, we haven't seen anything different this quarter from the previous couple of \nquarters.  So I don't know that there's anything really to call out specific about that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Offi cer & Director, McKesson Corp.   A \nYeah. ", "original_text": "Pharma, we haven't seen anything different this quarter from the previous couple of \nquarters. ", "page_label": "16", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6be44e6deeb7f022684e2c2e53f085eb9fde65eb9d737ca864e618bfde0917f7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "aab0b674-e1eb-4db0-bce8-03d55e5b900f", "node_type": "1", "metadata": {"window": "When you think about our independent \ncustomers within U.S.  Pharma, we haven't seen anything different this quarter from the previous couple of \nquarters.  So I don't know that there's anything really to call out specific about that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Offi cer & Director, McKesson Corp.   A \nYeah.  When we look at the kind of reimbursement environment that retail independents are facing, think we \ntalked last quarter about the fact that if we look at our data, and we really see in aggregate a very normal \nheadwin d that's been established, something that's kind of been consistent with prior years.  And on average, \nthat's a true statement now. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Offi cer & Director, McKesson Corp.  "}, "hash": "a9e990866f40ed61be0e7e635c9f3e863206e66e72aa5001234dc3b099e1aa1e", "class_name": "RelatedNodeInfo"}}, "text": "So I don't know that there's anything really to call out specific about that.  \n ", "start_char_idx": 2719, "end_char_idx": 2800, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "aab0b674-e1eb-4db0-bce8-03d55e5b900f": {"__data__": {"id_": "aab0b674-e1eb-4db0-bce8-03d55e5b900f", "embedding": null, "metadata": {"window": "When you think about our independent \ncustomers within U.S.  Pharma, we haven't seen anything different this quarter from the previous couple of \nquarters.  So I don't know that there's anything really to call out specific about that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Offi cer & Director, McKesson Corp.   A \nYeah.  When we look at the kind of reimbursement environment that retail independents are facing, think we \ntalked last quarter about the fact that if we look at our data, and we really see in aggregate a very normal \nheadwin d that's been established, something that's kind of been consistent with prior years.  And on average, \nthat's a true statement now. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Offi cer & Director, McKesson Corp.  ", "page_label": "16", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a46922f5-2d81-4fc9-93e8-95bec3c3587f", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "98a1b6b5b3444e21b734ba73861011986b152c17e03607d202d42ff610852ddd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e15f7205-ca03-4f49-975f-3dd1249c2f67", "node_type": "1", "metadata": {"window": "And overall, I would just say that one of the things that impacted to the negative side was not only the mix of \nrevenue, but the impact from a weak retail environment in the UK.  When you think about our independent \ncustomers within U.S.  Pharma, we haven't seen anything different this quarter from the previous couple of \nquarters.  So I don't know that there's anything really to call out specific about that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Offi cer & Director, McKesson Corp.   A \nYeah.  When we look at the kind of reimbursement environment that retail independents are facing, think we \ntalked last quarter about the fact that if we look at our data, and we really see in aggregate a very normal \nheadwin d that's been established, something that's kind of been consistent with prior years. ", "original_text": "So I don't know that there's anything really to call out specific about that.  \n ", "page_label": "16", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ab206f8db7e4940b5d9b8851dbff8da284c2895cf2c8547fd11f1176aee7bfde", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "76189c40-ee99-49c3-b091-a1b4b9d95486", "node_type": "1", "metadata": {"window": "Pharma, we haven't seen anything different this quarter from the previous couple of \nquarters.  So I don't know that there's anything really to call out specific about that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Offi cer & Director, McKesson Corp.   A \nYeah.  When we look at the kind of reimbursement environment that retail independents are facing, think we \ntalked last quarter about the fact that if we look at our data, and we really see in aggregate a very normal \nheadwin d that's been established, something that's kind of been consistent with prior years.  And on average, \nthat's a true statement now.  Within that average, there are, based on patient mix and contracts, the government, \nprivate, commercial, product mix and real ly the patient population [ph] in your catchment area (00:49:56) you can \nsee some winners and some losers. ", "original_text": "A \nYeah. "}, "hash": "0cfe1d767bffd418b24826b08b38b33b6b9aad1ccc0a8f07ee81a62854a399d3", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Offi cer & Director, McKesson Corp.  ", "start_char_idx": 2800, "end_char_idx": 3130, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "76189c40-ee99-49c3-b091-a1b4b9d95486": {"__data__": {"id_": "76189c40-ee99-49c3-b091-a1b4b9d95486", "embedding": null, "metadata": {"window": "Pharma, we haven't seen anything different this quarter from the previous couple of \nquarters.  So I don't know that there's anything really to call out specific about that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Offi cer & Director, McKesson Corp.   A \nYeah.  When we look at the kind of reimbursement environment that retail independents are facing, think we \ntalked last quarter about the fact that if we look at our data, and we really see in aggregate a very normal \nheadwin d that's been established, something that's kind of been consistent with prior years.  And on average, \nthat's a true statement now.  Within that average, there are, based on patient mix and contracts, the government, \nprivate, commercial, product mix and real ly the patient population [ph] in your catchment area (00:49:56) you can \nsee some winners and some losers. ", "original_text": "A \nYeah. ", "page_label": "16", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a46922f5-2d81-4fc9-93e8-95bec3c3587f", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "98a1b6b5b3444e21b734ba73861011986b152c17e03607d202d42ff610852ddd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "aab0b674-e1eb-4db0-bce8-03d55e5b900f", "node_type": "1", "metadata": {"window": "When you think about our independent \ncustomers within U.S.  Pharma, we haven't seen anything different this quarter from the previous couple of \nquarters.  So I don't know that there's anything really to call out specific about that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Offi cer & Director, McKesson Corp.   A \nYeah.  When we look at the kind of reimbursement environment that retail independents are facing, think we \ntalked last quarter about the fact that if we look at our data, and we really see in aggregate a very normal \nheadwin d that's been established, something that's kind of been consistent with prior years.  And on average, \nthat's a true statement now. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Offi cer & Director, McKesson Corp.  ", "page_label": "16", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "22adca74159f4b60922bc74ced82c2a1eb24f070819e2b9597279090bfdb85be", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "05ca42c2-69ee-49d1-9261-f45ed81622aa", "node_type": "1", "metadata": {"window": "So I don't know that there's anything really to call out specific about that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Offi cer & Director, McKesson Corp.   A \nYeah.  When we look at the kind of reimbursement environment that retail independents are facing, think we \ntalked last quarter about the fact that if we look at our data, and we really see in aggregate a very normal \nheadwin d that's been established, something that's kind of been consistent with prior years.  And on average, \nthat's a true statement now.  Within that average, there are, based on patient mix and contracts, the government, \nprivate, commercial, product mix and real ly the patient population [ph] in your catchment area (00:49:56) you can \nsee some winners and some losers.  But in the blended way, it really feels like the same steady reimbursement \nheadwind we've been accustomed to.  \n ", "original_text": "When we look at the kind of reimbursement environment that retail independents are facing, think we \ntalked last quarter about the fact that if we look at our data, and we really see in aggregate a very normal \nheadwin d that's been established, something that's kind of been consistent with prior years. "}, "hash": "43d48450a3d07c8bde83bb47dfad5c31f0c4e29268c1c826da30a2a1990eed7f", "class_name": "RelatedNodeInfo"}}, "text": "A \nYeah. ", "start_char_idx": 3130, "end_char_idx": 3139, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "05ca42c2-69ee-49d1-9261-f45ed81622aa": {"__data__": {"id_": "05ca42c2-69ee-49d1-9261-f45ed81622aa", "embedding": null, "metadata": {"window": "So I don't know that there's anything really to call out specific about that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Offi cer & Director, McKesson Corp.   A \nYeah.  When we look at the kind of reimbursement environment that retail independents are facing, think we \ntalked last quarter about the fact that if we look at our data, and we really see in aggregate a very normal \nheadwin d that's been established, something that's kind of been consistent with prior years.  And on average, \nthat's a true statement now.  Within that average, there are, based on patient mix and contracts, the government, \nprivate, commercial, product mix and real ly the patient population [ph] in your catchment area (00:49:56) you can \nsee some winners and some losers.  But in the blended way, it really feels like the same steady reimbursement \nheadwind we've been accustomed to.  \n ", "original_text": "When we look at the kind of reimbursement environment that retail independents are facing, think we \ntalked last quarter about the fact that if we look at our data, and we really see in aggregate a very normal \nheadwin d that's been established, something that's kind of been consistent with prior years. ", "page_label": "16", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a46922f5-2d81-4fc9-93e8-95bec3c3587f", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "98a1b6b5b3444e21b734ba73861011986b152c17e03607d202d42ff610852ddd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "76189c40-ee99-49c3-b091-a1b4b9d95486", "node_type": "1", "metadata": {"window": "Pharma, we haven't seen anything different this quarter from the previous couple of \nquarters.  So I don't know that there's anything really to call out specific about that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Offi cer & Director, McKesson Corp.   A \nYeah.  When we look at the kind of reimbursement environment that retail independents are facing, think we \ntalked last quarter about the fact that if we look at our data, and we really see in aggregate a very normal \nheadwin d that's been established, something that's kind of been consistent with prior years.  And on average, \nthat's a true statement now.  Within that average, there are, based on patient mix and contracts, the government, \nprivate, commercial, product mix and real ly the patient population [ph] in your catchment area (00:49:56) you can \nsee some winners and some losers. ", "original_text": "A \nYeah. ", "page_label": "16", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a65e0a2439eb30671f021ac874f914e889f488da0826b8a1e206633e87161003", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0a769f14-3a0c-417e-b4b0-9d31f09ed536", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Offi cer & Director, McKesson Corp.   A \nYeah.  When we look at the kind of reimbursement environment that retail independents are facing, think we \ntalked last quarter about the fact that if we look at our data, and we really see in aggregate a very normal \nheadwin d that's been established, something that's kind of been consistent with prior years.  And on average, \nthat's a true statement now.  Within that average, there are, based on patient mix and contracts, the government, \nprivate, commercial, product mix and real ly the patient population [ph] in your catchment area (00:49:56) you can \nsee some winners and some losers.  But in the blended way, it really feels like the same steady reimbursement \nheadwind we've been accustomed to.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nSo I think we see that and certainly the headwind in international and gross margin is evident. ", "original_text": "And on average, \nthat's a true statement now. "}, "hash": "16303d94162bc817bf16f20fdd51c87e0ea220ab5a8789fe2617f67e62333d0a", "class_name": "RelatedNodeInfo"}}, "text": "When we look at the kind of reimbursement environment that retail independents are facing, think we \ntalked last quarter about the fact that if we look at our data, and we really see in aggregate a very normal \nheadwin d that's been established, something that's kind of been consistent with prior years. ", "start_char_idx": 3139, "end_char_idx": 3444, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0a769f14-3a0c-417e-b4b0-9d31f09ed536": {"__data__": {"id_": "0a769f14-3a0c-417e-b4b0-9d31f09ed536", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Offi cer & Director, McKesson Corp.   A \nYeah.  When we look at the kind of reimbursement environment that retail independents are facing, think we \ntalked last quarter about the fact that if we look at our data, and we really see in aggregate a very normal \nheadwin d that's been established, something that's kind of been consistent with prior years.  And on average, \nthat's a true statement now.  Within that average, there are, based on patient mix and contracts, the government, \nprivate, commercial, product mix and real ly the patient population [ph] in your catchment area (00:49:56) you can \nsee some winners and some losers.  But in the blended way, it really feels like the same steady reimbursement \nheadwind we've been accustomed to.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nSo I think we see that and certainly the headwind in international and gross margin is evident. ", "original_text": "And on average, \nthat's a true statement now. ", "page_label": "16", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a46922f5-2d81-4fc9-93e8-95bec3c3587f", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "98a1b6b5b3444e21b734ba73861011986b152c17e03607d202d42ff610852ddd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "05ca42c2-69ee-49d1-9261-f45ed81622aa", "node_type": "1", "metadata": {"window": "So I don't know that there's anything really to call out specific about that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Offi cer & Director, McKesson Corp.   A \nYeah.  When we look at the kind of reimbursement environment that retail independents are facing, think we \ntalked last quarter about the fact that if we look at our data, and we really see in aggregate a very normal \nheadwin d that's been established, something that's kind of been consistent with prior years.  And on average, \nthat's a true statement now.  Within that average, there are, based on patient mix and contracts, the government, \nprivate, commercial, product mix and real ly the patient population [ph] in your catchment area (00:49:56) you can \nsee some winners and some losers.  But in the blended way, it really feels like the same steady reimbursement \nheadwind we've been accustomed to.  \n ", "original_text": "When we look at the kind of reimbursement environment that retail independents are facing, think we \ntalked last quarter about the fact that if we look at our data, and we really see in aggregate a very normal \nheadwin d that's been established, something that's kind of been consistent with prior years. ", "page_label": "16", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "93c7124db6d8fa7af960880723de055c0e8ee2027b2413f1e7d11eac0900dbea", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "84a1c69a-6568-4452-9823-1e3a5ae98613", "node_type": "1", "metadata": {"window": "A \nYeah.  When we look at the kind of reimbursement environment that retail independents are facing, think we \ntalked last quarter about the fact that if we look at our data, and we really see in aggregate a very normal \nheadwin d that's been established, something that's kind of been consistent with prior years.  And on average, \nthat's a true statement now.  Within that average, there are, based on patient mix and contracts, the government, \nprivate, commercial, product mix and real ly the patient population [ph] in your catchment area (00:49:56) you can \nsee some winners and some losers.  But in the blended way, it really feels like the same steady reimbursement \nheadwind we've been accustomed to.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nSo I think we see that and certainly the headwind in international and gross margin is evident.  But my question is \nreally where we don't see at a distribution and specialty segment level, what are your thoughts on the ability to \ndrive gross  profit growth relative to revenue growth? ", "original_text": "Within that average, there are, based on patient mix and contracts, the government, \nprivate, commercial, product mix and real ly the patient population [ph] in your catchment area (00:49:56) you can \nsee some winners and some losers. "}, "hash": "d0883fc41eb64a89a2ce3b02629c17465bf060889fd9d4498d31227309496d30", "class_name": "RelatedNodeInfo"}}, "text": "And on average, \nthat's a true statement now. ", "start_char_idx": 3444, "end_char_idx": 3490, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "84a1c69a-6568-4452-9823-1e3a5ae98613": {"__data__": {"id_": "84a1c69a-6568-4452-9823-1e3a5ae98613", "embedding": null, "metadata": {"window": "A \nYeah.  When we look at the kind of reimbursement environment that retail independents are facing, think we \ntalked last quarter about the fact that if we look at our data, and we really see in aggregate a very normal \nheadwin d that's been established, something that's kind of been consistent with prior years.  And on average, \nthat's a true statement now.  Within that average, there are, based on patient mix and contracts, the government, \nprivate, commercial, product mix and real ly the patient population [ph] in your catchment area (00:49:56) you can \nsee some winners and some losers.  But in the blended way, it really feels like the same steady reimbursement \nheadwind we've been accustomed to.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nSo I think we see that and certainly the headwind in international and gross margin is evident.  But my question is \nreally where we don't see at a distribution and specialty segment level, what are your thoughts on the ability to \ndrive gross  profit growth relative to revenue growth? ", "original_text": "Within that average, there are, based on patient mix and contracts, the government, \nprivate, commercial, product mix and real ly the patient population [ph] in your catchment area (00:49:56) you can \nsee some winners and some losers. ", "page_label": "16", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a46922f5-2d81-4fc9-93e8-95bec3c3587f", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "98a1b6b5b3444e21b734ba73861011986b152c17e03607d202d42ff610852ddd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0a769f14-3a0c-417e-b4b0-9d31f09ed536", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Offi cer & Director, McKesson Corp.   A \nYeah.  When we look at the kind of reimbursement environment that retail independents are facing, think we \ntalked last quarter about the fact that if we look at our data, and we really see in aggregate a very normal \nheadwin d that's been established, something that's kind of been consistent with prior years.  And on average, \nthat's a true statement now.  Within that average, there are, based on patient mix and contracts, the government, \nprivate, commercial, product mix and real ly the patient population [ph] in your catchment area (00:49:56) you can \nsee some winners and some losers.  But in the blended way, it really feels like the same steady reimbursement \nheadwind we've been accustomed to.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nSo I think we see that and certainly the headwind in international and gross margin is evident. ", "original_text": "And on average, \nthat's a true statement now. ", "page_label": "16", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ec425faac330fb5adcf6395980e8f134e6f0a907b2fbc314830938094acb932e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c4aaac39-17bd-41aa-8e15-c009f085b60b", "node_type": "1", "metadata": {"window": "When we look at the kind of reimbursement environment that retail independents are facing, think we \ntalked last quarter about the fact that if we look at our data, and we really see in aggregate a very normal \nheadwin d that's been established, something that's kind of been consistent with prior years.  And on average, \nthat's a true statement now.  Within that average, there are, based on patient mix and contracts, the government, \nprivate, commercial, product mix and real ly the patient population [ph] in your catchment area (00:49:56) you can \nsee some winners and some losers.  But in the blended way, it really feels like the same steady reimbursement \nheadwind we've been accustomed to.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nSo I think we see that and certainly the headwind in international and gross margin is evident.  But my question is \nreally where we don't see at a distribution and specialty segment level, what are your thoughts on the ability to \ndrive gross  profit growth relative to revenue growth?  That's really the question I was getting at.  \n ", "original_text": "But in the blended way, it really feels like the same steady reimbursement \nheadwind we've been accustomed to.  \n "}, "hash": "85b5ac6e98068f050044835bc244ce2fa0ef365b2e2c8d767ed7f26671ba08eb", "class_name": "RelatedNodeInfo"}}, "text": "Within that average, there are, based on patient mix and contracts, the government, \nprivate, commercial, product mix and real ly the patient population [ph] in your catchment area (00:49:56) you can \nsee some winners and some losers. ", "start_char_idx": 3490, "end_char_idx": 3725, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c4aaac39-17bd-41aa-8e15-c009f085b60b": {"__data__": {"id_": "c4aaac39-17bd-41aa-8e15-c009f085b60b", "embedding": null, "metadata": {"window": "When we look at the kind of reimbursement environment that retail independents are facing, think we \ntalked last quarter about the fact that if we look at our data, and we really see in aggregate a very normal \nheadwin d that's been established, something that's kind of been consistent with prior years.  And on average, \nthat's a true statement now.  Within that average, there are, based on patient mix and contracts, the government, \nprivate, commercial, product mix and real ly the patient population [ph] in your catchment area (00:49:56) you can \nsee some winners and some losers.  But in the blended way, it really feels like the same steady reimbursement \nheadwind we've been accustomed to.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nSo I think we see that and certainly the headwind in international and gross margin is evident.  But my question is \nreally where we don't see at a distribution and specialty segment level, what are your thoughts on the ability to \ndrive gross  profit growth relative to revenue growth?  That's really the question I was getting at.  \n ", "original_text": "But in the blended way, it really feels like the same steady reimbursement \nheadwind we've been accustomed to.  \n ", "page_label": "16", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a46922f5-2d81-4fc9-93e8-95bec3c3587f", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "98a1b6b5b3444e21b734ba73861011986b152c17e03607d202d42ff610852ddd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "84a1c69a-6568-4452-9823-1e3a5ae98613", "node_type": "1", "metadata": {"window": "A \nYeah.  When we look at the kind of reimbursement environment that retail independents are facing, think we \ntalked last quarter about the fact that if we look at our data, and we really see in aggregate a very normal \nheadwin d that's been established, something that's kind of been consistent with prior years.  And on average, \nthat's a true statement now.  Within that average, there are, based on patient mix and contracts, the government, \nprivate, commercial, product mix and real ly the patient population [ph] in your catchment area (00:49:56) you can \nsee some winners and some losers.  But in the blended way, it really feels like the same steady reimbursement \nheadwind we've been accustomed to.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nSo I think we see that and certainly the headwind in international and gross margin is evident.  But my question is \nreally where we don't see at a distribution and specialty segment level, what are your thoughts on the ability to \ndrive gross  profit growth relative to revenue growth? ", "original_text": "Within that average, there are, based on patient mix and contracts, the government, \nprivate, commercial, product mix and real ly the patient population [ph] in your catchment area (00:49:56) you can \nsee some winners and some losers. ", "page_label": "16", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1280c7697f1306c321da58df99e810c9c63514e44f47c37fffc5561db34941f1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "85a205c8-9e13-4e5b-9f66-b60676250700", "node_type": "1", "metadata": {"window": "And on average, \nthat's a true statement now.  Within that average, there are, based on patient mix and contracts, the government, \nprivate, commercial, product mix and real ly the patient population [ph] in your catchment area (00:49:56) you can \nsee some winners and some losers.  But in the blended way, it really feels like the same steady reimbursement \nheadwind we've been accustomed to.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nSo I think we see that and certainly the headwind in international and gross margin is evident.  But my question is \nreally where we don't see at a distribution and specialty segment level, what are your thoughts on the ability to \ndrive gross  profit growth relative to revenue growth?  That's really the question I was getting at.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nSo I think we see that and certainly the headwind in international and gross margin is evident. "}, "hash": "38b8f3f9160acb885fa43c36a38b5972a0dfd0e847548d822a6895237cc86c22", "class_name": "RelatedNodeInfo"}}, "text": "But in the blended way, it really feels like the same steady reimbursement \nheadwind we've been accustomed to.  \n ", "start_char_idx": 3725, "end_char_idx": 3839, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "85a205c8-9e13-4e5b-9f66-b60676250700": {"__data__": {"id_": "85a205c8-9e13-4e5b-9f66-b60676250700", "embedding": null, "metadata": {"window": "And on average, \nthat's a true statement now.  Within that average, there are, based on patient mix and contracts, the government, \nprivate, commercial, product mix and real ly the patient population [ph] in your catchment area (00:49:56) you can \nsee some winners and some losers.  But in the blended way, it really feels like the same steady reimbursement \nheadwind we've been accustomed to.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nSo I think we see that and certainly the headwind in international and gross margin is evident.  But my question is \nreally where we don't see at a distribution and specialty segment level, what are your thoughts on the ability to \ndrive gross  profit growth relative to revenue growth?  That's really the question I was getting at.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nSo I think we see that and certainly the headwind in international and gross margin is evident. ", "page_label": "16", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a46922f5-2d81-4fc9-93e8-95bec3c3587f", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "98a1b6b5b3444e21b734ba73861011986b152c17e03607d202d42ff610852ddd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c4aaac39-17bd-41aa-8e15-c009f085b60b", "node_type": "1", "metadata": {"window": "When we look at the kind of reimbursement environment that retail independents are facing, think we \ntalked last quarter about the fact that if we look at our data, and we really see in aggregate a very normal \nheadwin d that's been established, something that's kind of been consistent with prior years.  And on average, \nthat's a true statement now.  Within that average, there are, based on patient mix and contracts, the government, \nprivate, commercial, product mix and real ly the patient population [ph] in your catchment area (00:49:56) you can \nsee some winners and some losers.  But in the blended way, it really feels like the same steady reimbursement \nheadwind we've been accustomed to.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nSo I think we see that and certainly the headwind in international and gross margin is evident.  But my question is \nreally where we don't see at a distribution and specialty segment level, what are your thoughts on the ability to \ndrive gross  profit growth relative to revenue growth?  That's really the question I was getting at.  \n ", "original_text": "But in the blended way, it really feels like the same steady reimbursement \nheadwind we've been accustomed to.  \n ", "page_label": "16", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9782f20c022b9cb1ca6fb6c59d454b7fddbf946857e309c347eeeafbe20508c8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dc35a1cd-054d-40c4-b610-8705c8de2dd5", "node_type": "1", "metadata": {"window": "Within that average, there are, based on patient mix and contracts, the government, \nprivate, commercial, product mix and real ly the patient population [ph] in your catchment area (00:49:56) you can \nsee some winners and some losers.  But in the blended way, it really feels like the same steady reimbursement \nheadwind we've been accustomed to.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nSo I think we see that and certainly the headwind in international and gross margin is evident.  But my question is \nreally where we don't see at a distribution and specialty segment level, what are your thoughts on the ability to \ndrive gross  profit growth relative to revenue growth?  That's really the question I was getting at.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nWell, as we've talked about previously, Eric, the growth of specialty products  is going to have a dilutive impact on \nthe rate. ", "original_text": "But my question is \nreally where we don't see at a distribution and specialty segment level, what are your thoughts on the ability to \ndrive gross  profit growth relative to revenue growth? "}, "hash": "b9b1e48fb8a75f2d3ecc11d0722113c94f25290ea195f25ba79a23b4cbb00314", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nSo I think we see that and certainly the headwind in international and gross margin is evident. ", "start_char_idx": 3839, "end_char_idx": 4241, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dc35a1cd-054d-40c4-b610-8705c8de2dd5": {"__data__": {"id_": "dc35a1cd-054d-40c4-b610-8705c8de2dd5", "embedding": null, "metadata": {"window": "Within that average, there are, based on patient mix and contracts, the government, \nprivate, commercial, product mix and real ly the patient population [ph] in your catchment area (00:49:56) you can \nsee some winners and some losers.  But in the blended way, it really feels like the same steady reimbursement \nheadwind we've been accustomed to.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nSo I think we see that and certainly the headwind in international and gross margin is evident.  But my question is \nreally where we don't see at a distribution and specialty segment level, what are your thoughts on the ability to \ndrive gross  profit growth relative to revenue growth?  That's really the question I was getting at.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nWell, as we've talked about previously, Eric, the growth of specialty products  is going to have a dilutive impact on \nthe rate. ", "original_text": "But my question is \nreally where we don't see at a distribution and specialty segment level, what are your thoughts on the ability to \ndrive gross  profit growth relative to revenue growth? ", "page_label": "16", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a46922f5-2d81-4fc9-93e8-95bec3c3587f", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "98a1b6b5b3444e21b734ba73861011986b152c17e03607d202d42ff610852ddd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "85a205c8-9e13-4e5b-9f66-b60676250700", "node_type": "1", "metadata": {"window": "And on average, \nthat's a true statement now.  Within that average, there are, based on patient mix and contracts, the government, \nprivate, commercial, product mix and real ly the patient population [ph] in your catchment area (00:49:56) you can \nsee some winners and some losers.  But in the blended way, it really feels like the same steady reimbursement \nheadwind we've been accustomed to.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nSo I think we see that and certainly the headwind in international and gross margin is evident.  But my question is \nreally where we don't see at a distribution and specialty segment level, what are your thoughts on the ability to \ndrive gross  profit growth relative to revenue growth?  That's really the question I was getting at.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nSo I think we see that and certainly the headwind in international and gross margin is evident. ", "page_label": "16", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dd03977fb0c239f856ec24ad933b3bd00f8b696838ac2804a75981b3d3ad1e7d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f616489e-0137-47b0-8aec-a39a51378709", "node_type": "1", "metadata": {"window": "But in the blended way, it really feels like the same steady reimbursement \nheadwind we've been accustomed to.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nSo I think we see that and certainly the headwind in international and gross margin is evident.  But my question is \nreally where we don't see at a distribution and specialty segment level, what are your thoughts on the ability to \ndrive gross  profit growth relative to revenue growth?  That's really the question I was getting at.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nWell, as we've talked about previously, Eric, the growth of specialty products  is going to have a dilutive impact on \nthe rate.  It's certainly very good for us from a margin dollars perspective. ", "original_text": "That's really the question I was getting at.  \n "}, "hash": "5d9d35bc59d9bf77936206e796b087516e2258ffd7f412227bb92b693893dc59", "class_name": "RelatedNodeInfo"}}, "text": "But my question is \nreally where we don't see at a distribution and specialty segment level, what are your thoughts on the ability to \ndrive gross  profit growth relative to revenue growth? ", "start_char_idx": 4241, "end_char_idx": 4431, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f616489e-0137-47b0-8aec-a39a51378709": {"__data__": {"id_": "f616489e-0137-47b0-8aec-a39a51378709", "embedding": null, "metadata": {"window": "But in the blended way, it really feels like the same steady reimbursement \nheadwind we've been accustomed to.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nSo I think we see that and certainly the headwind in international and gross margin is evident.  But my question is \nreally where we don't see at a distribution and specialty segment level, what are your thoughts on the ability to \ndrive gross  profit growth relative to revenue growth?  That's really the question I was getting at.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nWell, as we've talked about previously, Eric, the growth of specialty products  is going to have a dilutive impact on \nthe rate.  It's certainly very good for us from a margin dollars perspective. ", "original_text": "That's really the question I was getting at.  \n ", "page_label": "16", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a46922f5-2d81-4fc9-93e8-95bec3c3587f", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "98a1b6b5b3444e21b734ba73861011986b152c17e03607d202d42ff610852ddd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dc35a1cd-054d-40c4-b610-8705c8de2dd5", "node_type": "1", "metadata": {"window": "Within that average, there are, based on patient mix and contracts, the government, \nprivate, commercial, product mix and real ly the patient population [ph] in your catchment area (00:49:56) you can \nsee some winners and some losers.  But in the blended way, it really feels like the same steady reimbursement \nheadwind we've been accustomed to.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nSo I think we see that and certainly the headwind in international and gross margin is evident.  But my question is \nreally where we don't see at a distribution and specialty segment level, what are your thoughts on the ability to \ndrive gross  profit growth relative to revenue growth?  That's really the question I was getting at.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nWell, as we've talked about previously, Eric, the growth of specialty products  is going to have a dilutive impact on \nthe rate. ", "original_text": "But my question is \nreally where we don't see at a distribution and specialty segment level, what are your thoughts on the ability to \ndrive gross  profit growth relative to revenue growth? ", "page_label": "16", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4ca4f0894a0ce89aa80a3956f9f3e900b6ff68dddb8c1b6e6b6b018190c5f99e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8954c01b-dec4-4ec8-ac2b-8f7906cccfcf", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nSo I think we see that and certainly the headwind in international and gross margin is evident.  But my question is \nreally where we don't see at a distribution and specialty segment level, what are your thoughts on the ability to \ndrive gross  profit growth relative to revenue growth?  That's really the question I was getting at.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nWell, as we've talked about previously, Eric, the growth of specialty products  is going to have a dilutive impact on \nthe rate.  It's certainly very good for us from a margin dollars perspective.  As I think about that, the U.S. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  "}, "hash": "479b090035ebea31172975bc667db566b21d6b930b81ca0e48c90531928c6254", "class_name": "RelatedNodeInfo"}}, "text": "That's really the question I was getting at.  \n ", "start_char_idx": 4431, "end_char_idx": 4479, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8954c01b-dec4-4ec8-ac2b-8f7906cccfcf": {"__data__": {"id_": "8954c01b-dec4-4ec8-ac2b-8f7906cccfcf", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nSo I think we see that and certainly the headwind in international and gross margin is evident.  But my question is \nreally where we don't see at a distribution and specialty segment level, what are your thoughts on the ability to \ndrive gross  profit growth relative to revenue growth?  That's really the question I was getting at.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nWell, as we've talked about previously, Eric, the growth of specialty products  is going to have a dilutive impact on \nthe rate.  It's certainly very good for us from a margin dollars perspective.  As I think about that, the U.S. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "page_label": "16", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a46922f5-2d81-4fc9-93e8-95bec3c3587f", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "98a1b6b5b3444e21b734ba73861011986b152c17e03607d202d42ff610852ddd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f616489e-0137-47b0-8aec-a39a51378709", "node_type": "1", "metadata": {"window": "But in the blended way, it really feels like the same steady reimbursement \nheadwind we've been accustomed to.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nSo I think we see that and certainly the headwind in international and gross margin is evident.  But my question is \nreally where we don't see at a distribution and specialty segment level, what are your thoughts on the ability to \ndrive gross  profit growth relative to revenue growth?  That's really the question I was getting at.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nWell, as we've talked about previously, Eric, the growth of specialty products  is going to have a dilutive impact on \nthe rate.  It's certainly very good for us from a margin dollars perspective. ", "original_text": "That's really the question I was getting at.  \n ", "page_label": "16", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "70eac11f82be9d982b45dcbe63319e55670517ecb7dc2ce1a2be4177e14959e2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "32c37288-6c8a-4582-8e5b-e2a98cc7446e", "node_type": "1", "metadata": {"window": "But my question is \nreally where we don't see at a distribution and specialty segment level, what are your thoughts on the ability to \ndrive gross  profit growth relative to revenue growth?  That's really the question I was getting at.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nWell, as we've talked about previously, Eric, the growth of specialty products  is going to have a dilutive impact on \nthe rate.  It's certainly very good for us from a margin dollars perspective.  As I think about that, the U.S.  Pharma ", "original_text": "A \nWell, as we've talked about previously, Eric, the growth of specialty products  is going to have a dilutive impact on \nthe rate. "}, "hash": "630e380563eef31b6f5d679be1efad41ea8240a43abcbecd7e554b1003a1e66f", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "start_char_idx": 1599, "end_char_idx": 1944, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "32c37288-6c8a-4582-8e5b-e2a98cc7446e": {"__data__": {"id_": "32c37288-6c8a-4582-8e5b-e2a98cc7446e", "embedding": null, "metadata": {"window": "But my question is \nreally where we don't see at a distribution and specialty segment level, what are your thoughts on the ability to \ndrive gross  profit growth relative to revenue growth?  That's really the question I was getting at.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nWell, as we've talked about previously, Eric, the growth of specialty products  is going to have a dilutive impact on \nthe rate.  It's certainly very good for us from a margin dollars perspective.  As I think about that, the U.S.  Pharma ", "original_text": "A \nWell, as we've talked about previously, Eric, the growth of specialty products  is going to have a dilutive impact on \nthe rate. ", "page_label": "16", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a46922f5-2d81-4fc9-93e8-95bec3c3587f", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "98a1b6b5b3444e21b734ba73861011986b152c17e03607d202d42ff610852ddd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8954c01b-dec4-4ec8-ac2b-8f7906cccfcf", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nSo I think we see that and certainly the headwind in international and gross margin is evident.  But my question is \nreally where we don't see at a distribution and specialty segment level, what are your thoughts on the ability to \ndrive gross  profit growth relative to revenue growth?  That's really the question I was getting at.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nWell, as we've talked about previously, Eric, the growth of specialty products  is going to have a dilutive impact on \nthe rate.  It's certainly very good for us from a margin dollars perspective.  As I think about that, the U.S. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "page_label": "16", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "88c52f9cbeaaaa15e274d9fbc80ea9b6ffaf143f01bbe69fe368216a764254da", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "66f0cb8a-3b70-4797-861d-c39e44bb0c83", "node_type": "1", "metadata": {"window": "That's really the question I was getting at.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nWell, as we've talked about previously, Eric, the growth of specialty products  is going to have a dilutive impact on \nthe rate.  It's certainly very good for us from a margin dollars perspective.  As I think about that, the U.S.  Pharma ", "original_text": "It's certainly very good for us from a margin dollars perspective. "}, "hash": "fedc59bd2cc2f310eb0939963408ff08cf1d12865d2a776f5b83f43cf74009d7", "class_name": "RelatedNodeInfo"}}, "text": "A \nWell, as we've talked about previously, Eric, the growth of specialty products  is going to have a dilutive impact on \nthe rate. ", "start_char_idx": 4824, "end_char_idx": 4956, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "66f0cb8a-3b70-4797-861d-c39e44bb0c83": {"__data__": {"id_": "66f0cb8a-3b70-4797-861d-c39e44bb0c83", "embedding": null, "metadata": {"window": "That's really the question I was getting at.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nWell, as we've talked about previously, Eric, the growth of specialty products  is going to have a dilutive impact on \nthe rate.  It's certainly very good for us from a margin dollars perspective.  As I think about that, the U.S.  Pharma ", "original_text": "It's certainly very good for us from a margin dollars perspective. ", "page_label": "16", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a46922f5-2d81-4fc9-93e8-95bec3c3587f", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "98a1b6b5b3444e21b734ba73861011986b152c17e03607d202d42ff610852ddd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "32c37288-6c8a-4582-8e5b-e2a98cc7446e", "node_type": "1", "metadata": {"window": "But my question is \nreally where we don't see at a distribution and specialty segment level, what are your thoughts on the ability to \ndrive gross  profit growth relative to revenue growth?  That's really the question I was getting at.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nWell, as we've talked about previously, Eric, the growth of specialty products  is going to have a dilutive impact on \nthe rate.  It's certainly very good for us from a margin dollars perspective.  As I think about that, the U.S.  Pharma ", "original_text": "A \nWell, as we've talked about previously, Eric, the growth of specialty products  is going to have a dilutive impact on \nthe rate. ", "page_label": "16", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2cfce6b59bfab0b15fcfb5431844835e48ceec6266aa2a7e8debda08a1a1f7ba", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6a1db8f6-5017-44ec-8fa7-4b85795003df", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nWell, as we've talked about previously, Eric, the growth of specialty products  is going to have a dilutive impact on \nthe rate.  It's certainly very good for us from a margin dollars perspective.  As I think about that, the U.S.  Pharma ", "original_text": "As I think about that, the U.S. "}, "hash": "31785d053a17fae6aa73153f5a07f660afa5d4f5ffed7e81e096fd9ec1daacf4", "class_name": "RelatedNodeInfo"}}, "text": "It's certainly very good for us from a margin dollars perspective. ", "start_char_idx": 4956, "end_char_idx": 5023, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6a1db8f6-5017-44ec-8fa7-4b85795003df": {"__data__": {"id_": "6a1db8f6-5017-44ec-8fa7-4b85795003df", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nWell, as we've talked about previously, Eric, the growth of specialty products  is going to have a dilutive impact on \nthe rate.  It's certainly very good for us from a margin dollars perspective.  As I think about that, the U.S.  Pharma ", "original_text": "As I think about that, the U.S. ", "page_label": "16", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a46922f5-2d81-4fc9-93e8-95bec3c3587f", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "98a1b6b5b3444e21b734ba73861011986b152c17e03607d202d42ff610852ddd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "66f0cb8a-3b70-4797-861d-c39e44bb0c83", "node_type": "1", "metadata": {"window": "That's really the question I was getting at.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nWell, as we've talked about previously, Eric, the growth of specialty products  is going to have a dilutive impact on \nthe rate.  It's certainly very good for us from a margin dollars perspective.  As I think about that, the U.S.  Pharma ", "original_text": "It's certainly very good for us from a margin dollars perspective. ", "page_label": "16", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "90ddb00ab92a37635e4424be67fd9404038e09bf76e18f0a5147e1c64ddcd044", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c5d913ec-ba1a-4f68-9d6c-7305856e12e8", "node_type": "1", "metadata": {"window": "A \nWell, as we've talked about previously, Eric, the growth of specialty products  is going to have a dilutive impact on \nthe rate.  It's certainly very good for us from a margin dollars perspective.  As I think about that, the U.S.  Pharma ", "original_text": "Pharma "}, "hash": "db52564eac222f8b2f77c7df0aba2ebb634dea801fcd49ce186c1179d7d53caf", "class_name": "RelatedNodeInfo"}}, "text": "As I think about that, the U.S. ", "start_char_idx": 5023, "end_char_idx": 5055, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c5d913ec-ba1a-4f68-9d6c-7305856e12e8": {"__data__": {"id_": "c5d913ec-ba1a-4f68-9d6c-7305856e12e8", "embedding": null, "metadata": {"window": "A \nWell, as we've talked about previously, Eric, the growth of specialty products  is going to have a dilutive impact on \nthe rate.  It's certainly very good for us from a margin dollars perspective.  As I think about that, the U.S.  Pharma ", "original_text": "Pharma ", "page_label": "16", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a46922f5-2d81-4fc9-93e8-95bec3c3587f", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "98a1b6b5b3444e21b734ba73861011986b152c17e03607d202d42ff610852ddd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6a1db8f6-5017-44ec-8fa7-4b85795003df", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nWell, as we've talked about previously, Eric, the growth of specialty products  is going to have a dilutive impact on \nthe rate.  It's certainly very good for us from a margin dollars perspective.  As I think about that, the U.S.  Pharma ", "original_text": "As I think about that, the U.S. ", "page_label": "16", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b5efff5f31199aa250f2e0d5159a2cd04a552222a78d1b9e4716cc2c59b93f2e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b1376b87-fbd4-4dbd-9692-946fbf710f36", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nand Specialty Solutions business, again, it's a business that is broad -based from a distribution pers pective both in \nthe nature of the products and the customers.  \n \n But also the specialty businesses that Brian talked about, our U.S.  oncology asset, our provider base that we \nhave and also the manufacturer life capabilities, the services that we provide to t he manufacturer, those also add \nto our gross margin profile. ", "original_text": "McKesson Corp.  "}, "hash": "3458eb87b1649a784f99af4dc9203dc6ec36c3a85f7808d186b5f92f81c4c867", "class_name": "RelatedNodeInfo"}}, "text": "Pharma ", "start_char_idx": 5055, "end_char_idx": 5062, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b1376b87-fbd4-4dbd-9692-946fbf710f36": {"__data__": {"id_": "b1376b87-fbd4-4dbd-9692-946fbf710f36", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nand Specialty Solutions business, again, it's a business that is broad -based from a distribution pers pective both in \nthe nature of the products and the customers.  \n \n But also the specialty businesses that Brian talked about, our U.S.  oncology asset, our provider base that we \nhave and also the manufacturer life capabilities, the services that we provide to t he manufacturer, those also add \nto our gross margin profile. ", "original_text": "McKesson Corp.  ", "page_label": "17", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "52005ab0-77df-4b49-85b8-14f3209e5047", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f5563f58c22cdecb7c089e3847eb84e722efd51b739c8caf9dde7f87fa2a66fd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c5d913ec-ba1a-4f68-9d6c-7305856e12e8", "node_type": "1", "metadata": {"window": "A \nWell, as we've talked about previously, Eric, the growth of specialty products  is going to have a dilutive impact on \nthe rate.  It's certainly very good for us from a margin dollars perspective.  As I think about that, the U.S.  Pharma ", "original_text": "Pharma ", "page_label": "16", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "66764a78aedb32b21ad20b212243025487ce92ff25ecc1d882eeddba92d1d669", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0e9f9718-6aeb-4073-a601-822bfc1c8344", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nand Specialty Solutions business, again, it's a business that is broad -based from a distribution pers pective both in \nthe nature of the products and the customers.  \n \n But also the specialty businesses that Brian talked about, our U.S.  oncology asset, our provider base that we \nhave and also the manufacturer life capabilities, the services that we provide to t he manufacturer, those also add \nto our gross margin profile.  So when I think about it, our distribution business is very scaled, it certainly is \nimpacted by the product mix. ", "original_text": "(MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nand Specialty Solutions business, again, it's a business that is broad -based from a distribution pers pective both in \nthe nature of the products and the customers.  \n \n"}, "hash": "c0f7bd4bc57edc0a291ccfeedcb46ab79c1456069bd651e99d6cfbefd229a0fb", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0e9f9718-6aeb-4073-a601-822bfc1c8344": {"__data__": {"id_": "0e9f9718-6aeb-4073-a601-822bfc1c8344", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nand Specialty Solutions business, again, it's a business that is broad -based from a distribution pers pective both in \nthe nature of the products and the customers.  \n \n But also the specialty businesses that Brian talked about, our U.S.  oncology asset, our provider base that we \nhave and also the manufacturer life capabilities, the services that we provide to t he manufacturer, those also add \nto our gross margin profile.  So when I think about it, our distribution business is very scaled, it certainly is \nimpacted by the product mix. ", "original_text": "(MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nand Specialty Solutions business, again, it's a business that is broad -based from a distribution pers pective both in \nthe nature of the products and the customers.  \n \n", "page_label": "17", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "52005ab0-77df-4b49-85b8-14f3209e5047", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f5563f58c22cdecb7c089e3847eb84e722efd51b739c8caf9dde7f87fa2a66fd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b1376b87-fbd4-4dbd-9692-946fbf710f36", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nand Specialty Solutions business, again, it's a business that is broad -based from a distribution pers pective both in \nthe nature of the products and the customers.  \n \n But also the specialty businesses that Brian talked about, our U.S.  oncology asset, our provider base that we \nhave and also the manufacturer life capabilities, the services that we provide to t he manufacturer, those also add \nto our gross margin profile. ", "original_text": "McKesson Corp.  ", "page_label": "17", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6b18e69c1d183f2fd6ccca39166837d80439365ac6934f6e3340f7951b75105e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3273266b-52f5-4690-a262-dd1d2a8139b5", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nand Specialty Solutions business, again, it's a business that is broad -based from a distribution pers pective both in \nthe nature of the products and the customers.  \n \n But also the specialty businesses that Brian talked about, our U.S.  oncology asset, our provider base that we \nhave and also the manufacturer life capabilities, the services that we provide to t he manufacturer, those also add \nto our gross margin profile.  So when I think about it, our distribution business is very scaled, it certainly is \nimpacted by the product mix.  But the fact that it's broad -based in terms of our U.S. ", "original_text": "But also the specialty businesses that Brian talked about, our U.S. "}, "hash": "b1f0fc1e42c174f08720e729d96d7b6d9cd3313558a7101e78c14273834accd3", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nand Specialty Solutions business, again, it's a business that is broad -based from a distribution pers pective both in \nthe nature of the products and the customers.  \n \n", "start_char_idx": 16, "end_char_idx": 351, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3273266b-52f5-4690-a262-dd1d2a8139b5": {"__data__": {"id_": "3273266b-52f5-4690-a262-dd1d2a8139b5", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nand Specialty Solutions business, again, it's a business that is broad -based from a distribution pers pective both in \nthe nature of the products and the customers.  \n \n But also the specialty businesses that Brian talked about, our U.S.  oncology asset, our provider base that we \nhave and also the manufacturer life capabilities, the services that we provide to t he manufacturer, those also add \nto our gross margin profile.  So when I think about it, our distribution business is very scaled, it certainly is \nimpacted by the product mix.  But the fact that it's broad -based in terms of our U.S. ", "original_text": "But also the specialty businesses that Brian talked about, our U.S. ", "page_label": "17", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "52005ab0-77df-4b49-85b8-14f3209e5047", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f5563f58c22cdecb7c089e3847eb84e722efd51b739c8caf9dde7f87fa2a66fd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0e9f9718-6aeb-4073-a601-822bfc1c8344", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nand Specialty Solutions business, again, it's a business that is broad -based from a distribution pers pective both in \nthe nature of the products and the customers.  \n \n But also the specialty businesses that Brian talked about, our U.S.  oncology asset, our provider base that we \nhave and also the manufacturer life capabilities, the services that we provide to t he manufacturer, those also add \nto our gross margin profile.  So when I think about it, our distribution business is very scaled, it certainly is \nimpacted by the product mix. ", "original_text": "(MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nand Specialty Solutions business, again, it's a business that is broad -based from a distribution pers pective both in \nthe nature of the products and the customers.  \n \n", "page_label": "17", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7b6209a851b39f09a2ffde4b1dbb779285548c1d90713518528a9e7357e2c1c0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3a289b4e-131f-4e09-b6f8-7bc9f20f595f", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nand Specialty Solutions business, again, it's a business that is broad -based from a distribution pers pective both in \nthe nature of the products and the customers.  \n \n But also the specialty businesses that Brian talked about, our U.S.  oncology asset, our provider base that we \nhave and also the manufacturer life capabilities, the services that we provide to t he manufacturer, those also add \nto our gross margin profile.  So when I think about it, our distribution business is very scaled, it certainly is \nimpacted by the product mix.  But the fact that it's broad -based in terms of our U.S.  oncology asset, our other \nspecialty assets and then our manufacturer services asset, I think that really does give us the opportunity to \ndevelop that gross profit over time.  \n ", "original_text": "oncology asset, our provider base that we \nhave and also the manufacturer life capabilities, the services that we provide to t he manufacturer, those also add \nto our gross margin profile. "}, "hash": "f99985c703c30c6c9ebe7e452e7b2bbd0f46ae6020bf69175cf8c57e8d904b3b", "class_name": "RelatedNodeInfo"}}, "text": "But also the specialty businesses that Brian talked about, our U.S. ", "start_char_idx": 351, "end_char_idx": 419, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3a289b4e-131f-4e09-b6f8-7bc9f20f595f": {"__data__": {"id_": "3a289b4e-131f-4e09-b6f8-7bc9f20f595f", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nand Specialty Solutions business, again, it's a business that is broad -based from a distribution pers pective both in \nthe nature of the products and the customers.  \n \n But also the specialty businesses that Brian talked about, our U.S.  oncology asset, our provider base that we \nhave and also the manufacturer life capabilities, the services that we provide to t he manufacturer, those also add \nto our gross margin profile.  So when I think about it, our distribution business is very scaled, it certainly is \nimpacted by the product mix.  But the fact that it's broad -based in terms of our U.S.  oncology asset, our other \nspecialty assets and then our manufacturer services asset, I think that really does give us the opportunity to \ndevelop that gross profit over time.  \n ", "original_text": "oncology asset, our provider base that we \nhave and also the manufacturer life capabilities, the services that we provide to t he manufacturer, those also add \nto our gross margin profile. ", "page_label": "17", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "52005ab0-77df-4b49-85b8-14f3209e5047", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f5563f58c22cdecb7c089e3847eb84e722efd51b739c8caf9dde7f87fa2a66fd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3273266b-52f5-4690-a262-dd1d2a8139b5", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nand Specialty Solutions business, again, it's a business that is broad -based from a distribution pers pective both in \nthe nature of the products and the customers.  \n \n But also the specialty businesses that Brian talked about, our U.S.  oncology asset, our provider base that we \nhave and also the manufacturer life capabilities, the services that we provide to t he manufacturer, those also add \nto our gross margin profile.  So when I think about it, our distribution business is very scaled, it certainly is \nimpacted by the product mix.  But the fact that it's broad -based in terms of our U.S. ", "original_text": "But also the specialty businesses that Brian talked about, our U.S. ", "page_label": "17", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9b64d58e02b0eec96e554f517877cd3a3dda39b566dc894887907eb1dd41d798", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7f1b5678-2b12-4e28-9ed8-304c4111fd27", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nand Specialty Solutions business, again, it's a business that is broad -based from a distribution pers pective both in \nthe nature of the products and the customers.  \n \n But also the specialty businesses that Brian talked about, our U.S.  oncology asset, our provider base that we \nhave and also the manufacturer life capabilities, the services that we provide to t he manufacturer, those also add \nto our gross margin profile.  So when I think about it, our distribution business is very scaled, it certainly is \nimpacted by the product mix.  But the fact that it's broad -based in terms of our U.S.  oncology asset, our other \nspecialty assets and then our manufacturer services asset, I think that really does give us the opportunity to \ndevelop that gross profit over time.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  \n ", "original_text": "So when I think about it, our distribution business is very scaled, it certainly is \nimpacted by the product mix. "}, "hash": "a2d8d1c4d97910922e402cf61a29e2b7b73702f9fba853d71d58e7e76f8dad4c", "class_name": "RelatedNodeInfo"}}, "text": "oncology asset, our provider base that we \nhave and also the manufacturer life capabilities, the services that we provide to t he manufacturer, those also add \nto our gross margin profile. ", "start_char_idx": 419, "end_char_idx": 608, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7f1b5678-2b12-4e28-9ed8-304c4111fd27": {"__data__": {"id_": "7f1b5678-2b12-4e28-9ed8-304c4111fd27", "embedding": null, "metadata": {"window": "(MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nand Specialty Solutions business, again, it's a business that is broad -based from a distribution pers pective both in \nthe nature of the products and the customers.  \n \n But also the specialty businesses that Brian talked about, our U.S.  oncology asset, our provider base that we \nhave and also the manufacturer life capabilities, the services that we provide to t he manufacturer, those also add \nto our gross margin profile.  So when I think about it, our distribution business is very scaled, it certainly is \nimpacted by the product mix.  But the fact that it's broad -based in terms of our U.S.  oncology asset, our other \nspecialty assets and then our manufacturer services asset, I think that really does give us the opportunity to \ndevelop that gross profit over time.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  \n ", "original_text": "So when I think about it, our distribution business is very scaled, it certainly is \nimpacted by the product mix. ", "page_label": "17", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "52005ab0-77df-4b49-85b8-14f3209e5047", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f5563f58c22cdecb7c089e3847eb84e722efd51b739c8caf9dde7f87fa2a66fd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3a289b4e-131f-4e09-b6f8-7bc9f20f595f", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nand Specialty Solutions business, again, it's a business that is broad -based from a distribution pers pective both in \nthe nature of the products and the customers.  \n \n But also the specialty businesses that Brian talked about, our U.S.  oncology asset, our provider base that we \nhave and also the manufacturer life capabilities, the services that we provide to t he manufacturer, those also add \nto our gross margin profile.  So when I think about it, our distribution business is very scaled, it certainly is \nimpacted by the product mix.  But the fact that it's broad -based in terms of our U.S.  oncology asset, our other \nspecialty assets and then our manufacturer services asset, I think that really does give us the opportunity to \ndevelop that gross profit over time.  \n ", "original_text": "oncology asset, our provider base that we \nhave and also the manufacturer life capabilities, the services that we provide to t he manufacturer, those also add \nto our gross margin profile. ", "page_label": "17", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c82aabb6c92ef907cf5a9721cadf64aa31bc030b279e2b4930276b43c2843f75", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e0ec2fc4-3696-438d-b01f-6e86cfc384a6", "node_type": "1", "metadata": {"window": "But also the specialty businesses that Brian talked about, our U.S.  oncology asset, our provider base that we \nhave and also the manufacturer life capabilities, the services that we provide to t he manufacturer, those also add \nto our gross margin profile.  So when I think about it, our distribution business is very scaled, it certainly is \nimpacted by the product mix.  But the fact that it's broad -based in terms of our U.S.  oncology asset, our other \nspecialty assets and then our manufacturer services asset, I think that really does give us the opportunity to \ndevelop that gross profit over time.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question will come from  Brian Tanquilut with Jefferies.  \n ", "original_text": "But the fact that it's broad -based in terms of our U.S. "}, "hash": "2daaf1e57d1c7647211eb94fd674b56bff745754e3178080600c7c1b0f252f14", "class_name": "RelatedNodeInfo"}}, "text": "So when I think about it, our distribution business is very scaled, it certainly is \nimpacted by the product mix. ", "start_char_idx": 608, "end_char_idx": 722, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e0ec2fc4-3696-438d-b01f-6e86cfc384a6": {"__data__": {"id_": "e0ec2fc4-3696-438d-b01f-6e86cfc384a6", "embedding": null, "metadata": {"window": "But also the specialty businesses that Brian talked about, our U.S.  oncology asset, our provider base that we \nhave and also the manufacturer life capabilities, the services that we provide to t he manufacturer, those also add \nto our gross margin profile.  So when I think about it, our distribution business is very scaled, it certainly is \nimpacted by the product mix.  But the fact that it's broad -based in terms of our U.S.  oncology asset, our other \nspecialty assets and then our manufacturer services asset, I think that really does give us the opportunity to \ndevelop that gross profit over time.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question will come from  Brian Tanquilut with Jefferies.  \n ", "original_text": "But the fact that it's broad -based in terms of our U.S. ", "page_label": "17", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "52005ab0-77df-4b49-85b8-14f3209e5047", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f5563f58c22cdecb7c089e3847eb84e722efd51b739c8caf9dde7f87fa2a66fd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7f1b5678-2b12-4e28-9ed8-304c4111fd27", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nand Specialty Solutions business, again, it's a business that is broad -based from a distribution pers pective both in \nthe nature of the products and the customers.  \n \n But also the specialty businesses that Brian talked about, our U.S.  oncology asset, our provider base that we \nhave and also the manufacturer life capabilities, the services that we provide to t he manufacturer, those also add \nto our gross margin profile.  So when I think about it, our distribution business is very scaled, it certainly is \nimpacted by the product mix.  But the fact that it's broad -based in terms of our U.S.  oncology asset, our other \nspecialty assets and then our manufacturer services asset, I think that really does give us the opportunity to \ndevelop that gross profit over time.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  \n ", "original_text": "So when I think about it, our distribution business is very scaled, it certainly is \nimpacted by the product mix. ", "page_label": "17", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "910d8c94b94777f41f3d873cf06789b299c69d100f9c7d7f72dfc62160861dd4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7bcec675-b27f-4604-808e-0a49e2b00fb8", "node_type": "1", "metadata": {"window": "oncology asset, our provider base that we \nhave and also the manufacturer life capabilities, the services that we provide to t he manufacturer, those also add \nto our gross margin profile.  So when I think about it, our distribution business is very scaled, it certainly is \nimpacted by the product mix.  But the fact that it's broad -based in terms of our U.S.  oncology asset, our other \nspecialty assets and then our manufacturer services asset, I think that really does give us the opportunity to \ndevelop that gross profit over time.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question will come from  Brian Tanquilut with Jefferies.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Gil Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey. ", "original_text": "oncology asset, our other \nspecialty assets and then our manufacturer services asset, I think that really does give us the opportunity to \ndevelop that gross profit over time.  \n "}, "hash": "36c341f243e873649c8fce5dc7af1a4332b909b1700e3ee438be78e5075305e5", "class_name": "RelatedNodeInfo"}}, "text": "But the fact that it's broad -based in terms of our U.S. ", "start_char_idx": 722, "end_char_idx": 779, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7bcec675-b27f-4604-808e-0a49e2b00fb8": {"__data__": {"id_": "7bcec675-b27f-4604-808e-0a49e2b00fb8", "embedding": null, "metadata": {"window": "oncology asset, our provider base that we \nhave and also the manufacturer life capabilities, the services that we provide to t he manufacturer, those also add \nto our gross margin profile.  So when I think about it, our distribution business is very scaled, it certainly is \nimpacted by the product mix.  But the fact that it's broad -based in terms of our U.S.  oncology asset, our other \nspecialty assets and then our manufacturer services asset, I think that really does give us the opportunity to \ndevelop that gross profit over time.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question will come from  Brian Tanquilut with Jefferies.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Gil Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey. ", "original_text": "oncology asset, our other \nspecialty assets and then our manufacturer services asset, I think that really does give us the opportunity to \ndevelop that gross profit over time.  \n ", "page_label": "17", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "52005ab0-77df-4b49-85b8-14f3209e5047", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f5563f58c22cdecb7c089e3847eb84e722efd51b739c8caf9dde7f87fa2a66fd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e0ec2fc4-3696-438d-b01f-6e86cfc384a6", "node_type": "1", "metadata": {"window": "But also the specialty businesses that Brian talked about, our U.S.  oncology asset, our provider base that we \nhave and also the manufacturer life capabilities, the services that we provide to t he manufacturer, those also add \nto our gross margin profile.  So when I think about it, our distribution business is very scaled, it certainly is \nimpacted by the product mix.  But the fact that it's broad -based in terms of our U.S.  oncology asset, our other \nspecialty assets and then our manufacturer services asset, I think that really does give us the opportunity to \ndevelop that gross profit over time.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question will come from  Brian Tanquilut with Jefferies.  \n ", "original_text": "But the fact that it's broad -based in terms of our U.S. ", "page_label": "17", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1aed53e173198096583b6ad058a8ec07bd64decc3e21cc876631c6be27f5e209", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "73074eaf-2e55-4555-9522-a786929096ea", "node_type": "1", "metadata": {"window": "So when I think about it, our distribution business is very scaled, it certainly is \nimpacted by the product mix.  But the fact that it's broad -based in terms of our U.S.  oncology asset, our other \nspecialty assets and then our manufacturer services asset, I think that really does give us the opportunity to \ndevelop that gross profit over time.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question will come from  Brian Tanquilut with Jefferies.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Gil Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey.  Good afternoon, guys. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  \n "}, "hash": "945a7ff99c6b6f080a8872ecaf233a2a74c37a82efba4c17a06b1b0090aedb3d", "class_name": "RelatedNodeInfo"}}, "text": "oncology asset, our other \nspecialty assets and then our manufacturer services asset, I think that really does give us the opportunity to \ndevelop that gross profit over time.  \n ", "start_char_idx": 779, "end_char_idx": 958, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "73074eaf-2e55-4555-9522-a786929096ea": {"__data__": {"id_": "73074eaf-2e55-4555-9522-a786929096ea", "embedding": null, "metadata": {"window": "So when I think about it, our distribution business is very scaled, it certainly is \nimpacted by the product mix.  But the fact that it's broad -based in terms of our U.S.  oncology asset, our other \nspecialty assets and then our manufacturer services asset, I think that really does give us the opportunity to \ndevelop that gross profit over time.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question will come from  Brian Tanquilut with Jefferies.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Gil Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey.  Good afternoon, guys. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  \n ", "page_label": "17", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "52005ab0-77df-4b49-85b8-14f3209e5047", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f5563f58c22cdecb7c089e3847eb84e722efd51b739c8caf9dde7f87fa2a66fd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7bcec675-b27f-4604-808e-0a49e2b00fb8", "node_type": "1", "metadata": {"window": "oncology asset, our provider base that we \nhave and also the manufacturer life capabilities, the services that we provide to t he manufacturer, those also add \nto our gross margin profile.  So when I think about it, our distribution business is very scaled, it certainly is \nimpacted by the product mix.  But the fact that it's broad -based in terms of our U.S.  oncology asset, our other \nspecialty assets and then our manufacturer services asset, I think that really does give us the opportunity to \ndevelop that gross profit over time.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question will come from  Brian Tanquilut with Jefferies.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Gil Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey. ", "original_text": "oncology asset, our other \nspecialty assets and then our manufacturer services asset, I think that really does give us the opportunity to \ndevelop that gross profit over time.  \n ", "page_label": "17", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5d3e9bc21654ac1730a47a602773550b4cc26c7af00f97e13efbb971cb91f490", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d46f2903-b7f5-4c00-b8f6-4b06eea7f21a", "node_type": "1", "metadata": {"window": "But the fact that it's broad -based in terms of our U.S.  oncology asset, our other \nspecialty assets and then our manufacturer services asset, I think that really does give us the opportunity to \ndevelop that gross profit over time.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question will come from  Brian Tanquilut with Jefferies.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Gil Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey.  Good afternoon, guys.  Congratulations. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question will come from  Brian Tanquilut with Jefferies.  \n "}, "hash": "73f713b496f93474d24d44506bd5798669b2862cdf0e1db4cb31e34e92a2fc2e", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  \n ", "start_char_idx": 958, "end_char_idx": 1278, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d46f2903-b7f5-4c00-b8f6-4b06eea7f21a": {"__data__": {"id_": "d46f2903-b7f5-4c00-b8f6-4b06eea7f21a", "embedding": null, "metadata": {"window": "But the fact that it's broad -based in terms of our U.S.  oncology asset, our other \nspecialty assets and then our manufacturer services asset, I think that really does give us the opportunity to \ndevelop that gross profit over time.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question will come from  Brian Tanquilut with Jefferies.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Gil Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey.  Good afternoon, guys.  Congratulations. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question will come from  Brian Tanquilut with Jefferies.  \n ", "page_label": "17", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "52005ab0-77df-4b49-85b8-14f3209e5047", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f5563f58c22cdecb7c089e3847eb84e722efd51b739c8caf9dde7f87fa2a66fd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "73074eaf-2e55-4555-9522-a786929096ea", "node_type": "1", "metadata": {"window": "So when I think about it, our distribution business is very scaled, it certainly is \nimpacted by the product mix.  But the fact that it's broad -based in terms of our U.S.  oncology asset, our other \nspecialty assets and then our manufacturer services asset, I think that really does give us the opportunity to \ndevelop that gross profit over time.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question will come from  Brian Tanquilut with Jefferies.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Gil Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey.  Good afternoon, guys. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  \n ", "page_label": "17", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "64a27b2a9ef8f8171cc51453005f69a8cf547ef74c5ced00382bac9c09c47108", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4395105b-3830-4a17-9693-a888cc6ff21c", "node_type": "1", "metadata": {"window": "oncology asset, our other \nspecialty assets and then our manufacturer services asset, I think that really does give us the opportunity to \ndevelop that gross profit over time.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question will come from  Brian Tanquilut with Jefferies.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Gil Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey.  Good afternoon, guys.  Congratulations.  Britt, just wanted to follow -up on Ricky's question from earlier, clarify \nthat question again. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Gil Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey. "}, "hash": "e8d93138ed485a5ef07fbd37cf2648a4a5a55786f4c534a29e9b5e464803c2d3", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question will come from  Brian Tanquilut with Jefferies.  \n ", "start_char_idx": 1278, "end_char_idx": 1621, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4395105b-3830-4a17-9693-a888cc6ff21c": {"__data__": {"id_": "4395105b-3830-4a17-9693-a888cc6ff21c", "embedding": null, "metadata": {"window": "oncology asset, our other \nspecialty assets and then our manufacturer services asset, I think that really does give us the opportunity to \ndevelop that gross profit over time.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question will come from  Brian Tanquilut with Jefferies.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Gil Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey.  Good afternoon, guys.  Congratulations.  Britt, just wanted to follow -up on Ricky's question from earlier, clarify \nthat question again. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Gil Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey. ", "page_label": "17", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "52005ab0-77df-4b49-85b8-14f3209e5047", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f5563f58c22cdecb7c089e3847eb84e722efd51b739c8caf9dde7f87fa2a66fd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d46f2903-b7f5-4c00-b8f6-4b06eea7f21a", "node_type": "1", "metadata": {"window": "But the fact that it's broad -based in terms of our U.S.  oncology asset, our other \nspecialty assets and then our manufacturer services asset, I think that really does give us the opportunity to \ndevelop that gross profit over time.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question will come from  Brian Tanquilut with Jefferies.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Gil Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey.  Good afternoon, guys.  Congratulations. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question will come from  Brian Tanquilut with Jefferies.  \n ", "page_label": "17", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f94ebb7c452d3ff4dd8aaf9943903da5861507e18200d5859b9b7988f5386bd1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3c7deed5-e191-45a0-a142-5807eb0d5602", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question will come from  Brian Tanquilut with Jefferies.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Gil Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey.  Good afternoon, guys.  Congratulations.  Britt, just wanted to follow -up on Ricky's question from earlier, clarify \nthat question again.  So you put up an 8% growth number in  the U.S. ", "original_text": "Good afternoon, guys. "}, "hash": "20a3ef8656c8abd3d987a843a4242cfa04c58120ede380059fd5e8c851cd4f38", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Gil Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey. ", "start_char_idx": 1621, "end_char_idx": 1932, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3c7deed5-e191-45a0-a142-5807eb0d5602": {"__data__": {"id_": "3c7deed5-e191-45a0-a142-5807eb0d5602", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question will come from  Brian Tanquilut with Jefferies.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Gil Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey.  Good afternoon, guys.  Congratulations.  Britt, just wanted to follow -up on Ricky's question from earlier, clarify \nthat question again.  So you put up an 8% growth number in  the U.S. ", "original_text": "Good afternoon, guys. ", "page_label": "17", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "52005ab0-77df-4b49-85b8-14f3209e5047", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f5563f58c22cdecb7c089e3847eb84e722efd51b739c8caf9dde7f87fa2a66fd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4395105b-3830-4a17-9693-a888cc6ff21c", "node_type": "1", "metadata": {"window": "oncology asset, our other \nspecialty assets and then our manufacturer services asset, I think that really does give us the opportunity to \ndevelop that gross profit over time.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question will come from  Brian Tanquilut with Jefferies.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Gil Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey.  Good afternoon, guys.  Congratulations.  Britt, just wanted to follow -up on Ricky's question from earlier, clarify \nthat question again. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Gil Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey. ", "page_label": "17", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6c1334090944c52b23629bd7e7e616c7dd4b694d35fcf292682dfefcbfc91332", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9623da39-c154-4be3-a587-865cdb7d5e5f", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question will come from  Brian Tanquilut with Jefferies.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Gil Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey.  Good afternoon, guys.  Congratulations.  Britt, just wanted to follow -up on Ricky's question from earlier, clarify \nthat question again.  So you put up an 8% growth number in  the U.S.  for Q1 and yet you're maintaining the \nguidance kind of like low - to mid -single digits. ", "original_text": "Congratulations. "}, "hash": "f82933a51f665a4052cf92ee86ea6cf9b413d8bf2a85d79800de57a6a2d938bf", "class_name": "RelatedNodeInfo"}}, "text": "Good afternoon, guys. ", "start_char_idx": 1932, "end_char_idx": 1954, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9623da39-c154-4be3-a587-865cdb7d5e5f": {"__data__": {"id_": "9623da39-c154-4be3-a587-865cdb7d5e5f", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question will come from  Brian Tanquilut with Jefferies.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Gil Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey.  Good afternoon, guys.  Congratulations.  Britt, just wanted to follow -up on Ricky's question from earlier, clarify \nthat question again.  So you put up an 8% growth number in  the U.S.  for Q1 and yet you're maintaining the \nguidance kind of like low - to mid -single digits. ", "original_text": "Congratulations. ", "page_label": "17", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "52005ab0-77df-4b49-85b8-14f3209e5047", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f5563f58c22cdecb7c089e3847eb84e722efd51b739c8caf9dde7f87fa2a66fd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3c7deed5-e191-45a0-a142-5807eb0d5602", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question will come from  Brian Tanquilut with Jefferies.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Gil Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey.  Good afternoon, guys.  Congratulations.  Britt, just wanted to follow -up on Ricky's question from earlier, clarify \nthat question again.  So you put up an 8% growth number in  the U.S. ", "original_text": "Good afternoon, guys. ", "page_label": "17", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a8dd5981bb1cd3273dfc9c96459b80a06332587c86b31d5c11556258646869b9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cffe6587-a1ba-4b98-8201-7927a70d9dc5", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Gil Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey.  Good afternoon, guys.  Congratulations.  Britt, just wanted to follow -up on Ricky's question from earlier, clarify \nthat question again.  So you put up an 8% growth number in  the U.S.  for Q1 and yet you're maintaining the \nguidance kind of like low - to mid -single digits.  So is there anything we should be thinking about that could drive a \ndeceleration in growth? ", "original_text": "Britt, just wanted to follow -up on Ricky's question from earlier, clarify \nthat question again. "}, "hash": "915bc79d897b43bb94c829952c1c260eb8cc9aba99089e1c098202606a398272", "class_name": "RelatedNodeInfo"}}, "text": "Congratulations. ", "start_char_idx": 1954, "end_char_idx": 1971, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cffe6587-a1ba-4b98-8201-7927a70d9dc5": {"__data__": {"id_": "cffe6587-a1ba-4b98-8201-7927a70d9dc5", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Gil Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey.  Good afternoon, guys.  Congratulations.  Britt, just wanted to follow -up on Ricky's question from earlier, clarify \nthat question again.  So you put up an 8% growth number in  the U.S.  for Q1 and yet you're maintaining the \nguidance kind of like low - to mid -single digits.  So is there anything we should be thinking about that could drive a \ndeceleration in growth? ", "original_text": "Britt, just wanted to follow -up on Ricky's question from earlier, clarify \nthat question again. ", "page_label": "17", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "52005ab0-77df-4b49-85b8-14f3209e5047", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f5563f58c22cdecb7c089e3847eb84e722efd51b739c8caf9dde7f87fa2a66fd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9623da39-c154-4be3-a587-865cdb7d5e5f", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question will come from  Brian Tanquilut with Jefferies.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Gil Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey.  Good afternoon, guys.  Congratulations.  Britt, just wanted to follow -up on Ricky's question from earlier, clarify \nthat question again.  So you put up an 8% growth number in  the U.S.  for Q1 and yet you're maintaining the \nguidance kind of like low - to mid -single digits. ", "original_text": "Congratulations. ", "page_label": "17", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "547f846c359cf727102d0c3281a829a55ec077f3f963ff9854ba3d9f406a8a98", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9ad85895-83fa-4f7d-9888-2d027b65bbe6", "node_type": "1", "metadata": {"window": "Good afternoon, guys.  Congratulations.  Britt, just wanted to follow -up on Ricky's question from earlier, clarify \nthat question again.  So you put up an 8% growth number in  the U.S.  for Q1 and yet you're maintaining the \nguidance kind of like low - to mid -single digits.  So is there anything we should be thinking about that could drive a \ndeceleration in growth?  I mean, you've talked about specialty being strong. ", "original_text": "So you put up an 8% growth number in  the U.S. "}, "hash": "95a8eee2317b4734d856822cec498e21f0863141c9ea9cdc461ed98cfe2bd876", "class_name": "RelatedNodeInfo"}}, "text": "Britt, just wanted to follow -up on Ricky's question from earlier, clarify \nthat question again. ", "start_char_idx": 1971, "end_char_idx": 2068, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9ad85895-83fa-4f7d-9888-2d027b65bbe6": {"__data__": {"id_": "9ad85895-83fa-4f7d-9888-2d027b65bbe6", "embedding": null, "metadata": {"window": "Good afternoon, guys.  Congratulations.  Britt, just wanted to follow -up on Ricky's question from earlier, clarify \nthat question again.  So you put up an 8% growth number in  the U.S.  for Q1 and yet you're maintaining the \nguidance kind of like low - to mid -single digits.  So is there anything we should be thinking about that could drive a \ndeceleration in growth?  I mean, you've talked about specialty being strong. ", "original_text": "So you put up an 8% growth number in  the U.S. ", "page_label": "17", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "52005ab0-77df-4b49-85b8-14f3209e5047", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f5563f58c22cdecb7c089e3847eb84e722efd51b739c8caf9dde7f87fa2a66fd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cffe6587-a1ba-4b98-8201-7927a70d9dc5", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Gil Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey.  Good afternoon, guys.  Congratulations.  Britt, just wanted to follow -up on Ricky's question from earlier, clarify \nthat question again.  So you put up an 8% growth number in  the U.S.  for Q1 and yet you're maintaining the \nguidance kind of like low - to mid -single digits.  So is there anything we should be thinking about that could drive a \ndeceleration in growth? ", "original_text": "Britt, just wanted to follow -up on Ricky's question from earlier, clarify \nthat question again. ", "page_label": "17", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e2595242e5a7da84d15ef8cfc953881f1ad514cb4ec2656e2a908615c41fa3d5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "80aaeb29-403f-47ed-b8d0-812e097c4e1c", "node_type": "1", "metadata": {"window": "Congratulations.  Britt, just wanted to follow -up on Ricky's question from earlier, clarify \nthat question again.  So you put up an 8% growth number in  the U.S.  for Q1 and yet you're maintaining the \nguidance kind of like low - to mid -single digits.  So is there anything we should be thinking about that could drive a \ndeceleration in growth?  I mean, you've talked about specialty being strong.  Or is there any thing to call out there?  \n ", "original_text": "for Q1 and yet you're maintaining the \nguidance kind of like low - to mid -single digits. "}, "hash": "b09054535326fa61bb6cfebd31f0efef84bdf8a9e742dc168c9cae1afbb4bc55", "class_name": "RelatedNodeInfo"}}, "text": "So you put up an 8% growth number in  the U.S. ", "start_char_idx": 2068, "end_char_idx": 2115, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "80aaeb29-403f-47ed-b8d0-812e097c4e1c": {"__data__": {"id_": "80aaeb29-403f-47ed-b8d0-812e097c4e1c", "embedding": null, "metadata": {"window": "Congratulations.  Britt, just wanted to follow -up on Ricky's question from earlier, clarify \nthat question again.  So you put up an 8% growth number in  the U.S.  for Q1 and yet you're maintaining the \nguidance kind of like low - to mid -single digits.  So is there anything we should be thinking about that could drive a \ndeceleration in growth?  I mean, you've talked about specialty being strong.  Or is there any thing to call out there?  \n ", "original_text": "for Q1 and yet you're maintaining the \nguidance kind of like low - to mid -single digits. ", "page_label": "17", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "52005ab0-77df-4b49-85b8-14f3209e5047", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f5563f58c22cdecb7c089e3847eb84e722efd51b739c8caf9dde7f87fa2a66fd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9ad85895-83fa-4f7d-9888-2d027b65bbe6", "node_type": "1", "metadata": {"window": "Good afternoon, guys.  Congratulations.  Britt, just wanted to follow -up on Ricky's question from earlier, clarify \nthat question again.  So you put up an 8% growth number in  the U.S.  for Q1 and yet you're maintaining the \nguidance kind of like low - to mid -single digits.  So is there anything we should be thinking about that could drive a \ndeceleration in growth?  I mean, you've talked about specialty being strong. ", "original_text": "So you put up an 8% growth number in  the U.S. ", "page_label": "17", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0e81c5af80a2d287c52620c4d34d0a18b2acd1678a0db6f803821262fb7001be", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9f6d815e-f616-4725-8885-8ea99782d73d", "node_type": "1", "metadata": {"window": "Britt, just wanted to follow -up on Ricky's question from earlier, clarify \nthat question again.  So you put up an 8% growth number in  the U.S.  for Q1 and yet you're maintaining the \nguidance kind of like low - to mid -single digits.  So is there anything we should be thinking about that could drive a \ndeceleration in growth?  I mean, you've talked about specialty being strong.  Or is there any thing to call out there?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "So is there anything we should be thinking about that could drive a \ndeceleration in growth? "}, "hash": "51042978336d528cb3e3aa22a1e5e5d8903fe7e45f2c749dbc025a8567a64cfe", "class_name": "RelatedNodeInfo"}}, "text": "for Q1 and yet you're maintaining the \nguidance kind of like low - to mid -single digits. ", "start_char_idx": 2115, "end_char_idx": 2205, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9f6d815e-f616-4725-8885-8ea99782d73d": {"__data__": {"id_": "9f6d815e-f616-4725-8885-8ea99782d73d", "embedding": null, "metadata": {"window": "Britt, just wanted to follow -up on Ricky's question from earlier, clarify \nthat question again.  So you put up an 8% growth number in  the U.S.  for Q1 and yet you're maintaining the \nguidance kind of like low - to mid -single digits.  So is there anything we should be thinking about that could drive a \ndeceleration in growth?  I mean, you've talked about specialty being strong.  Or is there any thing to call out there?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "So is there anything we should be thinking about that could drive a \ndeceleration in growth? ", "page_label": "17", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "52005ab0-77df-4b49-85b8-14f3209e5047", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f5563f58c22cdecb7c089e3847eb84e722efd51b739c8caf9dde7f87fa2a66fd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "80aaeb29-403f-47ed-b8d0-812e097c4e1c", "node_type": "1", "metadata": {"window": "Congratulations.  Britt, just wanted to follow -up on Ricky's question from earlier, clarify \nthat question again.  So you put up an 8% growth number in  the U.S.  for Q1 and yet you're maintaining the \nguidance kind of like low - to mid -single digits.  So is there anything we should be thinking about that could drive a \ndeceleration in growth?  I mean, you've talked about specialty being strong.  Or is there any thing to call out there?  \n ", "original_text": "for Q1 and yet you're maintaining the \nguidance kind of like low - to mid -single digits. ", "page_label": "17", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1ef3c23325adea0375b3a3e95534862002277d779586e172fc09a99be4d2a674", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5219b8d2-ae6a-41fb-9fc7-1a10f2d3eb92", "node_type": "1", "metadata": {"window": "So you put up an 8% growth number in  the U.S.  for Q1 and yet you're maintaining the \nguidance kind of like low - to mid -single digits.  So is there anything we should be thinking about that could drive a \ndeceleration in growth?  I mean, you've talked about specialty being strong.  Or is there any thing to call out there?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah. ", "original_text": "I mean, you've talked about specialty being strong. "}, "hash": "5698eeac35e6cbbb86eb866456c1f2edee3aa93fe86bf570d4da4763f85ff6d9", "class_name": "RelatedNodeInfo"}}, "text": "So is there anything we should be thinking about that could drive a \ndeceleration in growth? ", "start_char_idx": 2205, "end_char_idx": 2298, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5219b8d2-ae6a-41fb-9fc7-1a10f2d3eb92": {"__data__": {"id_": "5219b8d2-ae6a-41fb-9fc7-1a10f2d3eb92", "embedding": null, "metadata": {"window": "So you put up an 8% growth number in  the U.S.  for Q1 and yet you're maintaining the \nguidance kind of like low - to mid -single digits.  So is there anything we should be thinking about that could drive a \ndeceleration in growth?  I mean, you've talked about specialty being strong.  Or is there any thing to call out there?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah. ", "original_text": "I mean, you've talked about specialty being strong. ", "page_label": "17", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "52005ab0-77df-4b49-85b8-14f3209e5047", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f5563f58c22cdecb7c089e3847eb84e722efd51b739c8caf9dde7f87fa2a66fd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9f6d815e-f616-4725-8885-8ea99782d73d", "node_type": "1", "metadata": {"window": "Britt, just wanted to follow -up on Ricky's question from earlier, clarify \nthat question again.  So you put up an 8% growth number in  the U.S.  for Q1 and yet you're maintaining the \nguidance kind of like low - to mid -single digits.  So is there anything we should be thinking about that could drive a \ndeceleration in growth?  I mean, you've talked about specialty being strong.  Or is there any thing to call out there?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "So is there anything we should be thinking about that could drive a \ndeceleration in growth? ", "page_label": "17", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d573763574872d03828c54013d71eaf9d0197fced2799dfffa485d9cf3c8eaa9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "28365aa8-7438-4ce8-a2eb-414f381d019c", "node_type": "1", "metadata": {"window": "for Q1 and yet you're maintaining the \nguidance kind of like low - to mid -single digits.  So is there anything we should be thinking about that could drive a \ndeceleration in growth?  I mean, you've talked about specialty being strong.  Or is there any thing to call out there?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  The thing that I would point out is, I think we saw a larger proportion of revenue from our largest retail \nnational accounts in the qua rter. ", "original_text": "Or is there any thing to call out there?  \n "}, "hash": "0ebc6f7583eee18ecde33e9730cbb1b14eb74fe7ee014b29c6df40fc57ae0a79", "class_name": "RelatedNodeInfo"}}, "text": "I mean, you've talked about specialty being strong. ", "start_char_idx": 2298, "end_char_idx": 2350, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "28365aa8-7438-4ce8-a2eb-414f381d019c": {"__data__": {"id_": "28365aa8-7438-4ce8-a2eb-414f381d019c", "embedding": null, "metadata": {"window": "for Q1 and yet you're maintaining the \nguidance kind of like low - to mid -single digits.  So is there anything we should be thinking about that could drive a \ndeceleration in growth?  I mean, you've talked about specialty being strong.  Or is there any thing to call out there?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  The thing that I would point out is, I think we saw a larger proportion of revenue from our largest retail \nnational accounts in the qua rter. ", "original_text": "Or is there any thing to call out there?  \n ", "page_label": "17", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "52005ab0-77df-4b49-85b8-14f3209e5047", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f5563f58c22cdecb7c089e3847eb84e722efd51b739c8caf9dde7f87fa2a66fd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5219b8d2-ae6a-41fb-9fc7-1a10f2d3eb92", "node_type": "1", "metadata": {"window": "So you put up an 8% growth number in  the U.S.  for Q1 and yet you're maintaining the \nguidance kind of like low - to mid -single digits.  So is there anything we should be thinking about that could drive a \ndeceleration in growth?  I mean, you've talked about specialty being strong.  Or is there any thing to call out there?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah. ", "original_text": "I mean, you've talked about specialty being strong. ", "page_label": "17", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4aea2accbc01b48bf0c297fd05f2af7f7d99cc3014502c850acde0ba61c240a7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2fcd2bce-91cb-45d8-9af2-2163639242d7", "node_type": "1", "metadata": {"window": "So is there anything we should be thinking about that could drive a \ndeceleration in growth?  I mean, you've talked about specialty being strong.  Or is there any thing to call out there?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  The thing that I would point out is, I think we saw a larger proportion of revenue from our largest retail \nnational accounts in the qua rter.  We still expect to see very strong revenue growth in the mid -single digit range for \nthe year. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  "}, "hash": "498fb1f7b1eb38e192970bd0b3774e75587053a339d252b56cec0db174cad50e", "class_name": "RelatedNodeInfo"}}, "text": "Or is there any thing to call out there?  \n ", "start_char_idx": 2350, "end_char_idx": 2394, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2fcd2bce-91cb-45d8-9af2-2163639242d7": {"__data__": {"id_": "2fcd2bce-91cb-45d8-9af2-2163639242d7", "embedding": null, "metadata": {"window": "So is there anything we should be thinking about that could drive a \ndeceleration in growth?  I mean, you've talked about specialty being strong.  Or is there any thing to call out there?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  The thing that I would point out is, I think we saw a larger proportion of revenue from our largest retail \nnational accounts in the qua rter.  We still expect to see very strong revenue growth in the mid -single digit range for \nthe year. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "page_label": "17", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "52005ab0-77df-4b49-85b8-14f3209e5047", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f5563f58c22cdecb7c089e3847eb84e722efd51b739c8caf9dde7f87fa2a66fd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "28365aa8-7438-4ce8-a2eb-414f381d019c", "node_type": "1", "metadata": {"window": "for Q1 and yet you're maintaining the \nguidance kind of like low - to mid -single digits.  So is there anything we should be thinking about that could drive a \ndeceleration in growth?  I mean, you've talked about specialty being strong.  Or is there any thing to call out there?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  The thing that I would point out is, I think we saw a larger proportion of revenue from our largest retail \nnational accounts in the qua rter. ", "original_text": "Or is there any thing to call out there?  \n ", "page_label": "17", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bb57ffd28b43acde02829fc95ee020e6e68816757a5abc8bcdea4557b945108a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "819df6e8-8e20-4280-a9be-478704e76b25", "node_type": "1", "metadata": {"window": "I mean, you've talked about specialty being strong.  Or is there any thing to call out there?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  The thing that I would point out is, I think we saw a larger proportion of revenue from our largest retail \nnational accounts in the qua rter.  We still expect to see very strong revenue growth in the mid -single digit range for \nthe year.  I think as you just think about a quarterization of that, we saw a larger proportion of that coming from our \nlargest accounts and that had obviously a very favorable impact in the quarter.  \n ", "original_text": "A \nYeah. "}, "hash": "95b621d2bb96052026e0fafddbdd1b092de5a5e19d9a4fe543c8eaa8d53dda8d", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "start_char_idx": 2394, "end_char_idx": 2739, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "819df6e8-8e20-4280-a9be-478704e76b25": {"__data__": {"id_": "819df6e8-8e20-4280-a9be-478704e76b25", "embedding": null, "metadata": {"window": "I mean, you've talked about specialty being strong.  Or is there any thing to call out there?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  The thing that I would point out is, I think we saw a larger proportion of revenue from our largest retail \nnational accounts in the qua rter.  We still expect to see very strong revenue growth in the mid -single digit range for \nthe year.  I think as you just think about a quarterization of that, we saw a larger proportion of that coming from our \nlargest accounts and that had obviously a very favorable impact in the quarter.  \n ", "original_text": "A \nYeah. ", "page_label": "17", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "52005ab0-77df-4b49-85b8-14f3209e5047", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f5563f58c22cdecb7c089e3847eb84e722efd51b739c8caf9dde7f87fa2a66fd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2fcd2bce-91cb-45d8-9af2-2163639242d7", "node_type": "1", "metadata": {"window": "So is there anything we should be thinking about that could drive a \ndeceleration in growth?  I mean, you've talked about specialty being strong.  Or is there any thing to call out there?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  The thing that I would point out is, I think we saw a larger proportion of revenue from our largest retail \nnational accounts in the qua rter.  We still expect to see very strong revenue growth in the mid -single digit range for \nthe year. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "page_label": "17", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7ba5c7a1baab2e5cd584fa61937731bd19ba8358c64ecdcbaf8d20a691cb75ae", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "88e55e8b-1519-4474-b12c-fd1762a36177", "node_type": "1", "metadata": {"window": "Or is there any thing to call out there?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  The thing that I would point out is, I think we saw a larger proportion of revenue from our largest retail \nnational accounts in the qua rter.  We still expect to see very strong revenue growth in the mid -single digit range for \nthe year.  I think as you just think about a quarterization of that, we saw a larger proportion of that coming from our \nlargest accounts and that had obviously a very favorable impact in the quarter.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Gil Tanquilut  \nAnalyst, Jefferies LLC  Q \nAll right. ", "original_text": "The thing that I would point out is, I think we saw a larger proportion of revenue from our largest retail \nnational accounts in the qua rter. "}, "hash": "55f77b68759cba34e1a258d3b8b4f1ac1df912de16aecad59434944c1e54b654", "class_name": "RelatedNodeInfo"}}, "text": "A \nYeah. ", "start_char_idx": 2739, "end_char_idx": 2748, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "88e55e8b-1519-4474-b12c-fd1762a36177": {"__data__": {"id_": "88e55e8b-1519-4474-b12c-fd1762a36177", "embedding": null, "metadata": {"window": "Or is there any thing to call out there?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  The thing that I would point out is, I think we saw a larger proportion of revenue from our largest retail \nnational accounts in the qua rter.  We still expect to see very strong revenue growth in the mid -single digit range for \nthe year.  I think as you just think about a quarterization of that, we saw a larger proportion of that coming from our \nlargest accounts and that had obviously a very favorable impact in the quarter.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Gil Tanquilut  \nAnalyst, Jefferies LLC  Q \nAll right. ", "original_text": "The thing that I would point out is, I think we saw a larger proportion of revenue from our largest retail \nnational accounts in the qua rter. ", "page_label": "17", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "52005ab0-77df-4b49-85b8-14f3209e5047", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f5563f58c22cdecb7c089e3847eb84e722efd51b739c8caf9dde7f87fa2a66fd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "819df6e8-8e20-4280-a9be-478704e76b25", "node_type": "1", "metadata": {"window": "I mean, you've talked about specialty being strong.  Or is there any thing to call out there?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  The thing that I would point out is, I think we saw a larger proportion of revenue from our largest retail \nnational accounts in the qua rter.  We still expect to see very strong revenue growth in the mid -single digit range for \nthe year.  I think as you just think about a quarterization of that, we saw a larger proportion of that coming from our \nlargest accounts and that had obviously a very favorable impact in the quarter.  \n ", "original_text": "A \nYeah. ", "page_label": "17", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "55faea3fca9e3826b8f61189f51b2a4fe7fddf1ae522b9290b88f5f7985308cb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4f148a53-e350-42d0-9464-9d4a7c98ff97", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  The thing that I would point out is, I think we saw a larger proportion of revenue from our largest retail \nnational accounts in the qua rter.  We still expect to see very strong revenue growth in the mid -single digit range for \nthe year.  I think as you just think about a quarterization of that, we saw a larger proportion of that coming from our \nlargest accounts and that had obviously a very favorable impact in the quarter.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Gil Tanquilut  \nAnalyst, Jefferies LLC  Q \nAll right.  Got it. ", "original_text": "We still expect to see very strong revenue growth in the mid -single digit range for \nthe year. "}, "hash": "0a9e0a114f0c085e3f34fc368363b6bff07b26e98658686fa31c676f36c8a4a0", "class_name": "RelatedNodeInfo"}}, "text": "The thing that I would point out is, I think we saw a larger proportion of revenue from our largest retail \nnational accounts in the qua rter. ", "start_char_idx": 2748, "end_char_idx": 2891, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4f148a53-e350-42d0-9464-9d4a7c98ff97": {"__data__": {"id_": "4f148a53-e350-42d0-9464-9d4a7c98ff97", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  The thing that I would point out is, I think we saw a larger proportion of revenue from our largest retail \nnational accounts in the qua rter.  We still expect to see very strong revenue growth in the mid -single digit range for \nthe year.  I think as you just think about a quarterization of that, we saw a larger proportion of that coming from our \nlargest accounts and that had obviously a very favorable impact in the quarter.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Gil Tanquilut  \nAnalyst, Jefferies LLC  Q \nAll right.  Got it. ", "original_text": "We still expect to see very strong revenue growth in the mid -single digit range for \nthe year. ", "page_label": "17", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "52005ab0-77df-4b49-85b8-14f3209e5047", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f5563f58c22cdecb7c089e3847eb84e722efd51b739c8caf9dde7f87fa2a66fd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "88e55e8b-1519-4474-b12c-fd1762a36177", "node_type": "1", "metadata": {"window": "Or is there any thing to call out there?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  The thing that I would point out is, I think we saw a larger proportion of revenue from our largest retail \nnational accounts in the qua rter.  We still expect to see very strong revenue growth in the mid -single digit range for \nthe year.  I think as you just think about a quarterization of that, we saw a larger proportion of that coming from our \nlargest accounts and that had obviously a very favorable impact in the quarter.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Gil Tanquilut  \nAnalyst, Jefferies LLC  Q \nAll right. ", "original_text": "The thing that I would point out is, I think we saw a larger proportion of revenue from our largest retail \nnational accounts in the qua rter. ", "page_label": "17", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "21a32791968e18233fcad490267883514b71d4aee18fc22bd17eae1eda935e7c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7ebb15b5-cd47-48de-84d3-209128423467", "node_type": "1", "metadata": {"window": "A \nYeah.  The thing that I would point out is, I think we saw a larger proportion of revenue from our largest retail \nnational accounts in the qua rter.  We still expect to see very strong revenue growth in the mid -single digit range for \nthe year.  I think as you just think about a quarterization of that, we saw a larger proportion of that coming from our \nlargest accounts and that had obviously a very favorable impact in the quarter.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Gil Tanquilut  \nAnalyst, Jefferies LLC  Q \nAll right.  Got it.  All right. ", "original_text": "I think as you just think about a quarterization of that, we saw a larger proportion of that coming from our \nlargest accounts and that had obviously a very favorable impact in the quarter.  \n "}, "hash": "3ad23f747299da2c5b9d57d8e107aa1361320e4ae95c06d8341172cd016021ee", "class_name": "RelatedNodeInfo"}}, "text": "We still expect to see very strong revenue growth in the mid -single digit range for \nthe year. ", "start_char_idx": 2891, "end_char_idx": 2987, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7ebb15b5-cd47-48de-84d3-209128423467": {"__data__": {"id_": "7ebb15b5-cd47-48de-84d3-209128423467", "embedding": null, "metadata": {"window": "A \nYeah.  The thing that I would point out is, I think we saw a larger proportion of revenue from our largest retail \nnational accounts in the qua rter.  We still expect to see very strong revenue growth in the mid -single digit range for \nthe year.  I think as you just think about a quarterization of that, we saw a larger proportion of that coming from our \nlargest accounts and that had obviously a very favorable impact in the quarter.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Gil Tanquilut  \nAnalyst, Jefferies LLC  Q \nAll right.  Got it.  All right. ", "original_text": "I think as you just think about a quarterization of that, we saw a larger proportion of that coming from our \nlargest accounts and that had obviously a very favorable impact in the quarter.  \n ", "page_label": "17", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "52005ab0-77df-4b49-85b8-14f3209e5047", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f5563f58c22cdecb7c089e3847eb84e722efd51b739c8caf9dde7f87fa2a66fd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4f148a53-e350-42d0-9464-9d4a7c98ff97", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  The thing that I would point out is, I think we saw a larger proportion of revenue from our largest retail \nnational accounts in the qua rter.  We still expect to see very strong revenue growth in the mid -single digit range for \nthe year.  I think as you just think about a quarterization of that, we saw a larger proportion of that coming from our \nlargest accounts and that had obviously a very favorable impact in the quarter.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Gil Tanquilut  \nAnalyst, Jefferies LLC  Q \nAll right.  Got it. ", "original_text": "We still expect to see very strong revenue growth in the mid -single digit range for \nthe year. ", "page_label": "17", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c8c5a912ec8b46220be87a1574f832b3a66fde1246f9eacc644a96271f7c5852", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6d941b09-1b8e-4ee2-a89b-a3fd72fbff1b", "node_type": "1", "metadata": {"window": "The thing that I would point out is, I think we saw a larger proportion of revenue from our largest retail \nnational accounts in the qua rter.  We still expect to see very strong revenue growth in the mid -single digit range for \nthe year.  I think as you just think about a quarterization of that, we saw a larger proportion of that coming from our \nlargest accounts and that had obviously a very favorable impact in the quarter.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Gil Tanquilut  \nAnalyst, Jefferies LLC  Q \nAll right.  Got it.  All right.  Thanks, guys.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Gil Tanquilut  \nAnalyst, Jefferies LLC  Q \nAll right. "}, "hash": "e0b7164734aaf5aba48a5ba965351dd65b6c4a928dc2c6fb7ed7f2bbe7b74d64", "class_name": "RelatedNodeInfo"}}, "text": "I think as you just think about a quarterization of that, we saw a larger proportion of that coming from our \nlargest accounts and that had obviously a very favorable impact in the quarter.  \n ", "start_char_idx": 2987, "end_char_idx": 3180, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6d941b09-1b8e-4ee2-a89b-a3fd72fbff1b": {"__data__": {"id_": "6d941b09-1b8e-4ee2-a89b-a3fd72fbff1b", "embedding": null, "metadata": {"window": "The thing that I would point out is, I think we saw a larger proportion of revenue from our largest retail \nnational accounts in the qua rter.  We still expect to see very strong revenue growth in the mid -single digit range for \nthe year.  I think as you just think about a quarterization of that, we saw a larger proportion of that coming from our \nlargest accounts and that had obviously a very favorable impact in the quarter.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Gil Tanquilut  \nAnalyst, Jefferies LLC  Q \nAll right.  Got it.  All right.  Thanks, guys.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Gil Tanquilut  \nAnalyst, Jefferies LLC  Q \nAll right. ", "page_label": "17", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "52005ab0-77df-4b49-85b8-14f3209e5047", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f5563f58c22cdecb7c089e3847eb84e722efd51b739c8caf9dde7f87fa2a66fd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7ebb15b5-cd47-48de-84d3-209128423467", "node_type": "1", "metadata": {"window": "A \nYeah.  The thing that I would point out is, I think we saw a larger proportion of revenue from our largest retail \nnational accounts in the qua rter.  We still expect to see very strong revenue growth in the mid -single digit range for \nthe year.  I think as you just think about a quarterization of that, we saw a larger proportion of that coming from our \nlargest accounts and that had obviously a very favorable impact in the quarter.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Gil Tanquilut  \nAnalyst, Jefferies LLC  Q \nAll right.  Got it.  All right. ", "original_text": "I think as you just think about a quarterization of that, we saw a larger proportion of that coming from our \nlargest accounts and that had obviously a very favorable impact in the quarter.  \n ", "page_label": "17", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bcc7e33c545ef74cfa6056ead79293a103a17251e844cd12b3b63e8bcc115b3d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ac3af9ad-81c7-42c0-b2dc-23556a512d9d", "node_type": "1", "metadata": {"window": "We still expect to see very strong revenue growth in the mid -single digit range for \nthe year.  I think as you just think about a quarterization of that, we saw a larger proportion of that coming from our \nlargest accounts and that had obviously a very favorable impact in the quarter.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Gil Tanquilut  \nAnalyst, Jefferies LLC  Q \nAll right.  Got it.  All right.  Thanks, guys.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "Got it. "}, "hash": "fefa8bf2ffb64fee7ab54aea41419f45c31e292601b9241db76dfd28a745d96a", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Gil Tanquilut  \nAnalyst, Jefferies LLC  Q \nAll right. ", "start_char_idx": 3180, "end_char_idx": 3497, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ac3af9ad-81c7-42c0-b2dc-23556a512d9d": {"__data__": {"id_": "ac3af9ad-81c7-42c0-b2dc-23556a512d9d", "embedding": null, "metadata": {"window": "We still expect to see very strong revenue growth in the mid -single digit range for \nthe year.  I think as you just think about a quarterization of that, we saw a larger proportion of that coming from our \nlargest accounts and that had obviously a very favorable impact in the quarter.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Gil Tanquilut  \nAnalyst, Jefferies LLC  Q \nAll right.  Got it.  All right.  Thanks, guys.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "Got it. ", "page_label": "17", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "52005ab0-77df-4b49-85b8-14f3209e5047", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f5563f58c22cdecb7c089e3847eb84e722efd51b739c8caf9dde7f87fa2a66fd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6d941b09-1b8e-4ee2-a89b-a3fd72fbff1b", "node_type": "1", "metadata": {"window": "The thing that I would point out is, I think we saw a larger proportion of revenue from our largest retail \nnational accounts in the qua rter.  We still expect to see very strong revenue growth in the mid -single digit range for \nthe year.  I think as you just think about a quarterization of that, we saw a larger proportion of that coming from our \nlargest accounts and that had obviously a very favorable impact in the quarter.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Gil Tanquilut  \nAnalyst, Jefferies LLC  Q \nAll right.  Got it.  All right.  Thanks, guys.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Gil Tanquilut  \nAnalyst, Jefferies LLC  Q \nAll right. ", "page_label": "17", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bf49273b14e5cce9c1b1f22cac29eab6fc0bf37c6adcd67f176a82bab2fc5bc3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b87ad8bb-e3a3-447e-ab47-5c3894ff0bb8", "node_type": "1", "metadata": {"window": "I think as you just think about a quarterization of that, we saw a larger proportion of that coming from our \nlargest accounts and that had obviously a very favorable impact in the quarter.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Gil Tanquilut  \nAnalyst, Jefferies LLC  Q \nAll right.  Got it.  All right.  Thanks, guys.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nThanks, Brian.  \n ", "original_text": "All right. "}, "hash": "3799a8d55e41ab5cf01d588be87ce8ff58937be9bb30f415e11acbaeff010d85", "class_name": "RelatedNodeInfo"}}, "text": "Got it. ", "start_char_idx": 3497, "end_char_idx": 3505, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b87ad8bb-e3a3-447e-ab47-5c3894ff0bb8": {"__data__": {"id_": "b87ad8bb-e3a3-447e-ab47-5c3894ff0bb8", "embedding": null, "metadata": {"window": "I think as you just think about a quarterization of that, we saw a larger proportion of that coming from our \nlargest accounts and that had obviously a very favorable impact in the quarter.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Gil Tanquilut  \nAnalyst, Jefferies LLC  Q \nAll right.  Got it.  All right.  Thanks, guys.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nThanks, Brian.  \n ", "original_text": "All right. ", "page_label": "17", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "52005ab0-77df-4b49-85b8-14f3209e5047", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f5563f58c22cdecb7c089e3847eb84e722efd51b739c8caf9dde7f87fa2a66fd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ac3af9ad-81c7-42c0-b2dc-23556a512d9d", "node_type": "1", "metadata": {"window": "We still expect to see very strong revenue growth in the mid -single digit range for \nthe year.  I think as you just think about a quarterization of that, we saw a larger proportion of that coming from our \nlargest accounts and that had obviously a very favorable impact in the quarter.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Gil Tanquilut  \nAnalyst, Jefferies LLC  Q \nAll right.  Got it.  All right.  Thanks, guys.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "Got it. ", "page_label": "17", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a5343ced90cc73a194fc8332a1f51fced6ac36a666500635b8ab75f9c453adbd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "758758bf-10e1-44c3-97cd-7b8d19feb2af", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Gil Tanquilut  \nAnalyst, Jefferies LLC  Q \nAll right.  Got it.  All right.  Thanks, guys.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nThanks, Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Our next question will come from Robert Jones with Goldman Sachs.  \n ", "original_text": "Thanks, guys.  \n "}, "hash": "b57f682687bebd746f85d86ecff01b45b585d1b5551d548cb59cf8b8e06be6fd", "class_name": "RelatedNodeInfo"}}, "text": "All right. ", "start_char_idx": 3486, "end_char_idx": 3497, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "758758bf-10e1-44c3-97cd-7b8d19feb2af": {"__data__": {"id_": "758758bf-10e1-44c3-97cd-7b8d19feb2af", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Gil Tanquilut  \nAnalyst, Jefferies LLC  Q \nAll right.  Got it.  All right.  Thanks, guys.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nThanks, Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Our next question will come from Robert Jones with Goldman Sachs.  \n ", "original_text": "Thanks, guys.  \n ", "page_label": "17", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "52005ab0-77df-4b49-85b8-14f3209e5047", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f5563f58c22cdecb7c089e3847eb84e722efd51b739c8caf9dde7f87fa2a66fd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b87ad8bb-e3a3-447e-ab47-5c3894ff0bb8", "node_type": "1", "metadata": {"window": "I think as you just think about a quarterization of that, we saw a larger proportion of that coming from our \nlargest accounts and that had obviously a very favorable impact in the quarter.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Gil Tanquilut  \nAnalyst, Jefferies LLC  Q \nAll right.  Got it.  All right.  Thanks, guys.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nThanks, Brian.  \n ", "original_text": "All right. ", "page_label": "17", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3830a07c50b7cd473f1ec708c9b3a6ab989c65c8bfceaa285426f7275a4fb309", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dc98f7b0-ba75-4d1f-9764-5d9452b01e74", "node_type": "1", "metadata": {"window": "Got it.  All right.  Thanks, guys.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nThanks, Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Our next question will come from Robert Jones with Goldman Sachs.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  "}, "hash": "d833ce4c190d241f021e227a722da2c2e9f3f772642df9460ab00064a919fce7", "class_name": "RelatedNodeInfo"}}, "text": "Thanks, guys.  \n ", "start_char_idx": 3516, "end_char_idx": 3533, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dc98f7b0-ba75-4d1f-9764-5d9452b01e74": {"__data__": {"id_": "dc98f7b0-ba75-4d1f-9764-5d9452b01e74", "embedding": null, "metadata": {"window": "Got it.  All right.  Thanks, guys.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nThanks, Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Our next question will come from Robert Jones with Goldman Sachs.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "page_label": "17", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "52005ab0-77df-4b49-85b8-14f3209e5047", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f5563f58c22cdecb7c089e3847eb84e722efd51b739c8caf9dde7f87fa2a66fd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "758758bf-10e1-44c3-97cd-7b8d19feb2af", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Gil Tanquilut  \nAnalyst, Jefferies LLC  Q \nAll right.  Got it.  All right.  Thanks, guys.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nThanks, Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Our next question will come from Robert Jones with Goldman Sachs.  \n ", "original_text": "Thanks, guys.  \n ", "page_label": "17", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b47e4f7076d1a47374447ec406d2b5ed66c9679ba64149c0901df1ecf7bd0351", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "74023c62-ed49-4d83-b76d-7059d2013fc9", "node_type": "1", "metadata": {"window": "All right.  Thanks, guys.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nThanks, Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Our next question will come from Robert Jones with Goldman Sachs.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nGreat. ", "original_text": "A \nThanks, Brian.  \n "}, "hash": "2ff45a297d4c152eb83caa072a0da30e9025d728339cbb02570599e30dd2530f", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "start_char_idx": 2394, "end_char_idx": 2739, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "74023c62-ed49-4d83-b76d-7059d2013fc9": {"__data__": {"id_": "74023c62-ed49-4d83-b76d-7059d2013fc9", "embedding": null, "metadata": {"window": "All right.  Thanks, guys.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nThanks, Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Our next question will come from Robert Jones with Goldman Sachs.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nGreat. ", "original_text": "A \nThanks, Brian.  \n ", "page_label": "17", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "52005ab0-77df-4b49-85b8-14f3209e5047", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f5563f58c22cdecb7c089e3847eb84e722efd51b739c8caf9dde7f87fa2a66fd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dc98f7b0-ba75-4d1f-9764-5d9452b01e74", "node_type": "1", "metadata": {"window": "Got it.  All right.  Thanks, guys.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nThanks, Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Our next question will come from Robert Jones with Goldman Sachs.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "page_label": "17", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5a16e88b3d1eec82eda4c215583d6bdd60de08bf6e6af84d4889f357935b9ff5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f4d1e70f-27f0-4bb9-94ba-bbf6b22a228c", "node_type": "1", "metadata": {"window": "Thanks, guys.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nThanks, Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Our next question will come from Robert Jones with Goldman Sachs.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nGreat.  Thanks for the questions. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Our next question will come from Robert Jones with Goldman Sachs.  \n "}, "hash": "fa39f60c354ead5bad0d85861bdbe64a3ef48c62dd8f1d72908fd56a5e40cdb8", "class_name": "RelatedNodeInfo"}}, "text": "A \nThanks, Brian.  \n ", "start_char_idx": 3878, "end_char_idx": 3899, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f4d1e70f-27f0-4bb9-94ba-bbf6b22a228c": {"__data__": {"id_": "f4d1e70f-27f0-4bb9-94ba-bbf6b22a228c", "embedding": null, "metadata": {"window": "Thanks, guys.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nThanks, Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Our next question will come from Robert Jones with Goldman Sachs.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nGreat.  Thanks for the questions. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Our next question will come from Robert Jones with Goldman Sachs.  \n ", "page_label": "17", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "52005ab0-77df-4b49-85b8-14f3209e5047", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f5563f58c22cdecb7c089e3847eb84e722efd51b739c8caf9dde7f87fa2a66fd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "74023c62-ed49-4d83-b76d-7059d2013fc9", "node_type": "1", "metadata": {"window": "All right.  Thanks, guys.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nThanks, Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Our next question will come from Robert Jones with Goldman Sachs.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nGreat. ", "original_text": "A \nThanks, Brian.  \n ", "page_label": "17", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f324a7561a0da452783df182019176723de9f6b0b5102e27f1c893e86ef5bac7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "aa14f16d-4412-46c6-ba68-4e5e965cedd9", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nThanks, Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Our next question will come from Robert Jones with Goldman Sachs.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nGreat.  Thanks for the questions.  I guess similar one, Britt, on the corporate expense side. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co. "}, "hash": "4edffde37ed7bc2fc1dbad2b8587027e12b09f139ac7b810139a53de3414117a", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Our next question will come from Robert Jones with Goldman Sachs.  \n ", "start_char_idx": 3899, "end_char_idx": 4238, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "aa14f16d-4412-46c6-ba68-4e5e965cedd9": {"__data__": {"id_": "aa14f16d-4412-46c6-ba68-4e5e965cedd9", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nThanks, Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Our next question will come from Robert Jones with Goldman Sachs.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nGreat.  Thanks for the questions.  I guess similar one, Britt, on the corporate expense side. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co. ", "page_label": "17", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "52005ab0-77df-4b49-85b8-14f3209e5047", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f5563f58c22cdecb7c089e3847eb84e722efd51b739c8caf9dde7f87fa2a66fd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f4d1e70f-27f0-4bb9-94ba-bbf6b22a228c", "node_type": "1", "metadata": {"window": "Thanks, guys.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nThanks, Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Our next question will come from Robert Jones with Goldman Sachs.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nGreat.  Thanks for the questions. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Our next question will come from Robert Jones with Goldman Sachs.  \n ", "page_label": "17", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3d506fe4ba0b8c0e1344c8adffa0e693b4b2dc2742e3adb7a953a24ef8df93a2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1ced5fbf-5224-4441-939e-5594d436924f", "node_type": "1", "metadata": {"window": "A \nThanks, Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Our next question will come from Robert Jones with Goldman Sachs.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nGreat.  Thanks for the questions.  I guess similar one, Britt, on the corporate expense side.  You're pointing towards \nthe lower end. ", "original_text": "LLC  Q \nGreat. "}, "hash": "282a81f10cbbf14314c1c2df7227993868a1d56800836688b24594bdaad59f13", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co. ", "start_char_idx": 4238, "end_char_idx": 4542, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1ced5fbf-5224-4441-939e-5594d436924f": {"__data__": {"id_": "1ced5fbf-5224-4441-939e-5594d436924f", "embedding": null, "metadata": {"window": "A \nThanks, Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Our next question will come from Robert Jones with Goldman Sachs.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nGreat.  Thanks for the questions.  I guess similar one, Britt, on the corporate expense side.  You're pointing towards \nthe lower end. ", "original_text": "LLC  Q \nGreat. ", "page_label": "17", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "52005ab0-77df-4b49-85b8-14f3209e5047", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f5563f58c22cdecb7c089e3847eb84e722efd51b739c8caf9dde7f87fa2a66fd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "aa14f16d-4412-46c6-ba68-4e5e965cedd9", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nThanks, Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Our next question will come from Robert Jones with Goldman Sachs.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nGreat.  Thanks for the questions.  I guess similar one, Britt, on the corporate expense side. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co. ", "page_label": "17", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "628efd879e79e76fbe9f54f2239abe1ccbeb18ecde72e497b99a57c41c230971", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2a5e5fd4-286c-4fd3-a591-eb6532e247e5", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Our next question will come from Robert Jones with Goldman Sachs.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nGreat.  Thanks for the questions.  I guess similar one, Britt, on the corporate expense side.  You're pointing towards \nthe lower end.  But just looki ng at where you ended up in the quarter, it still seems like quite a big ramp through \nthe year to get there. ", "original_text": "Thanks for the questions. "}, "hash": "0ab0d26ca6c95f715962df1598d6e0378a7339cc8d904f20b4cb6f0dde466517", "class_name": "RelatedNodeInfo"}}, "text": "LLC  Q \nGreat. ", "start_char_idx": 4542, "end_char_idx": 4557, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2a5e5fd4-286c-4fd3-a591-eb6532e247e5": {"__data__": {"id_": "2a5e5fd4-286c-4fd3-a591-eb6532e247e5", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Our next question will come from Robert Jones with Goldman Sachs.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nGreat.  Thanks for the questions.  I guess similar one, Britt, on the corporate expense side.  You're pointing towards \nthe lower end.  But just looki ng at where you ended up in the quarter, it still seems like quite a big ramp through \nthe year to get there. ", "original_text": "Thanks for the questions. ", "page_label": "17", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "52005ab0-77df-4b49-85b8-14f3209e5047", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f5563f58c22cdecb7c089e3847eb84e722efd51b739c8caf9dde7f87fa2a66fd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1ced5fbf-5224-4441-939e-5594d436924f", "node_type": "1", "metadata": {"window": "A \nThanks, Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Our next question will come from Robert Jones with Goldman Sachs.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nGreat.  Thanks for the questions.  I guess similar one, Britt, on the corporate expense side.  You're pointing towards \nthe lower end. ", "original_text": "LLC  Q \nGreat. ", "page_label": "17", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "70c5813fc1dd3113b80e405f7ab33eb38054b6ec52d21c774f2af390e93424d3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e3393ffe-5536-405a-b351-1d9f5c1b14d2", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nGreat.  Thanks for the questions.  I guess similar one, Britt, on the corporate expense side.  You're pointing towards \nthe lower end.  But just looki ng at where you ended up in the quarter, it still seems like quite a big ramp through \nthe year to get there.  Anything you know of or that you anticipate on the corporate expense side that it would be \nterribly different than what we saw in the quarter?  ", "original_text": "I guess similar one, Britt, on the corporate expense side. "}, "hash": "b367999138fd21e5e5abf90a7ad1aa5acaade3a77983185d5c6f4886b51faadc", "class_name": "RelatedNodeInfo"}}, "text": "Thanks for the questions. ", "start_char_idx": 4557, "end_char_idx": 4583, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e3393ffe-5536-405a-b351-1d9f5c1b14d2": {"__data__": {"id_": "e3393ffe-5536-405a-b351-1d9f5c1b14d2", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nGreat.  Thanks for the questions.  I guess similar one, Britt, on the corporate expense side.  You're pointing towards \nthe lower end.  But just looki ng at where you ended up in the quarter, it still seems like quite a big ramp through \nthe year to get there.  Anything you know of or that you anticipate on the corporate expense side that it would be \nterribly different than what we saw in the quarter?  ", "original_text": "I guess similar one, Britt, on the corporate expense side. ", "page_label": "17", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "52005ab0-77df-4b49-85b8-14f3209e5047", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f5563f58c22cdecb7c089e3847eb84e722efd51b739c8caf9dde7f87fa2a66fd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2a5e5fd4-286c-4fd3-a591-eb6532e247e5", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Our next question will come from Robert Jones with Goldman Sachs.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nGreat.  Thanks for the questions.  I guess similar one, Britt, on the corporate expense side.  You're pointing towards \nthe lower end.  But just looki ng at where you ended up in the quarter, it still seems like quite a big ramp through \nthe year to get there. ", "original_text": "Thanks for the questions. ", "page_label": "17", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d3882c634c6653ad17eacae9e9a1a4ce646ee774d96ce628279ee736db704b95", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c25c1c0a-19a3-46f9-8051-c41830352382", "node_type": "1", "metadata": {"window": "LLC  Q \nGreat.  Thanks for the questions.  I guess similar one, Britt, on the corporate expense side.  You're pointing towards \nthe lower end.  But just looki ng at where you ended up in the quarter, it still seems like quite a big ramp through \nthe year to get there.  Anything you know of or that you anticipate on the corporate expense side that it would be \nterribly different than what we saw in the quarter?  ", "original_text": "You're pointing towards \nthe lower end. "}, "hash": "78e33e23ec8b9ceb11aa4d0a6f60cc6ba42b0a1fb22a4d213e259fdb1adf225a", "class_name": "RelatedNodeInfo"}}, "text": "I guess similar one, Britt, on the corporate expense side. ", "start_char_idx": 4583, "end_char_idx": 4642, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c25c1c0a-19a3-46f9-8051-c41830352382": {"__data__": {"id_": "c25c1c0a-19a3-46f9-8051-c41830352382", "embedding": null, "metadata": {"window": "LLC  Q \nGreat.  Thanks for the questions.  I guess similar one, Britt, on the corporate expense side.  You're pointing towards \nthe lower end.  But just looki ng at where you ended up in the quarter, it still seems like quite a big ramp through \nthe year to get there.  Anything you know of or that you anticipate on the corporate expense side that it would be \nterribly different than what we saw in the quarter?  ", "original_text": "You're pointing towards \nthe lower end. ", "page_label": "17", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "52005ab0-77df-4b49-85b8-14f3209e5047", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f5563f58c22cdecb7c089e3847eb84e722efd51b739c8caf9dde7f87fa2a66fd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e3393ffe-5536-405a-b351-1d9f5c1b14d2", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nGreat.  Thanks for the questions.  I guess similar one, Britt, on the corporate expense side.  You're pointing towards \nthe lower end.  But just looki ng at where you ended up in the quarter, it still seems like quite a big ramp through \nthe year to get there.  Anything you know of or that you anticipate on the corporate expense side that it would be \nterribly different than what we saw in the quarter?  ", "original_text": "I guess similar one, Britt, on the corporate expense side. ", "page_label": "17", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a82b46f9b460797bc90117e669e42246ddcb3fc932e06f34e768b24e37206b24", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f12d03b5-5058-45b7-82f0-9b8a554003ad", "node_type": "1", "metadata": {"window": "Thanks for the questions.  I guess similar one, Britt, on the corporate expense side.  You're pointing towards \nthe lower end.  But just looki ng at where you ended up in the quarter, it still seems like quite a big ramp through \nthe year to get there.  Anything you know of or that you anticipate on the corporate expense side that it would be \nterribly different than what we saw in the quarter?  ", "original_text": "But just looki ng at where you ended up in the quarter, it still seems like quite a big ramp through \nthe year to get there. "}, "hash": "043758a41f7abd3fe37e9a4b71b4f2a54078c0c5bb9e1ae7fe5838bd05032530", "class_name": "RelatedNodeInfo"}}, "text": "You're pointing towards \nthe lower end. ", "start_char_idx": 4642, "end_char_idx": 4682, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f12d03b5-5058-45b7-82f0-9b8a554003ad": {"__data__": {"id_": "f12d03b5-5058-45b7-82f0-9b8a554003ad", "embedding": null, "metadata": {"window": "Thanks for the questions.  I guess similar one, Britt, on the corporate expense side.  You're pointing towards \nthe lower end.  But just looki ng at where you ended up in the quarter, it still seems like quite a big ramp through \nthe year to get there.  Anything you know of or that you anticipate on the corporate expense side that it would be \nterribly different than what we saw in the quarter?  ", "original_text": "But just looki ng at where you ended up in the quarter, it still seems like quite a big ramp through \nthe year to get there. ", "page_label": "17", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "52005ab0-77df-4b49-85b8-14f3209e5047", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f5563f58c22cdecb7c089e3847eb84e722efd51b739c8caf9dde7f87fa2a66fd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c25c1c0a-19a3-46f9-8051-c41830352382", "node_type": "1", "metadata": {"window": "LLC  Q \nGreat.  Thanks for the questions.  I guess similar one, Britt, on the corporate expense side.  You're pointing towards \nthe lower end.  But just looki ng at where you ended up in the quarter, it still seems like quite a big ramp through \nthe year to get there.  Anything you know of or that you anticipate on the corporate expense side that it would be \nterribly different than what we saw in the quarter?  ", "original_text": "You're pointing towards \nthe lower end. ", "page_label": "17", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1b8f53f39adf2b61a9102695e29c89fe875b10c1777c7df8990a873cb53e7e85", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3584ba78-423f-4639-8c11-d753dc566a27", "node_type": "1", "metadata": {"window": "I guess similar one, Britt, on the corporate expense side.  You're pointing towards \nthe lower end.  But just looki ng at where you ended up in the quarter, it still seems like quite a big ramp through \nthe year to get there.  Anything you know of or that you anticipate on the corporate expense side that it would be \nterribly different than what we saw in the quarter?  ", "original_text": "Anything you know of or that you anticipate on the corporate expense side that it would be \nterribly different than what we saw in the quarter?  "}, "hash": "6cc7ad09d06623a6fedf43c2ab1d5a97edbeb2f47e0975a6b20297d25b7a7080", "class_name": "RelatedNodeInfo"}}, "text": "But just looki ng at where you ended up in the quarter, it still seems like quite a big ramp through \nthe year to get there. ", "start_char_idx": 4682, "end_char_idx": 4807, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3584ba78-423f-4639-8c11-d753dc566a27": {"__data__": {"id_": "3584ba78-423f-4639-8c11-d753dc566a27", "embedding": null, "metadata": {"window": "I guess similar one, Britt, on the corporate expense side.  You're pointing towards \nthe lower end.  But just looki ng at where you ended up in the quarter, it still seems like quite a big ramp through \nthe year to get there.  Anything you know of or that you anticipate on the corporate expense side that it would be \nterribly different than what we saw in the quarter?  ", "original_text": "Anything you know of or that you anticipate on the corporate expense side that it would be \nterribly different than what we saw in the quarter?  ", "page_label": "17", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "52005ab0-77df-4b49-85b8-14f3209e5047", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f5563f58c22cdecb7c089e3847eb84e722efd51b739c8caf9dde7f87fa2a66fd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f12d03b5-5058-45b7-82f0-9b8a554003ad", "node_type": "1", "metadata": {"window": "Thanks for the questions.  I guess similar one, Britt, on the corporate expense side.  You're pointing towards \nthe lower end.  But just looki ng at where you ended up in the quarter, it still seems like quite a big ramp through \nthe year to get there.  Anything you know of or that you anticipate on the corporate expense side that it would be \nterribly different than what we saw in the quarter?  ", "original_text": "But just looki ng at where you ended up in the quarter, it still seems like quite a big ramp through \nthe year to get there. ", "page_label": "17", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3060f4a784d1bde5aea6c87924c295ecd0c8d919eeb3c3c769d602d8a4c0fb85", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "647d5015-1fdf-459d-99ea-a6cd023bed96", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nAnd then I guess, Brian, just I'll throw my follow up out there.  I'm sorry if I missed this in the prepared remarks, but \nlarge proposed generic merger out there.  Curious if \u2013 or how impactful that would be on not only ClarusONE, but \non McKesson in general? ", "original_text": "McKesson Corp.  "}, "hash": "87e3987655a91556e59d73cc32e3b7f45304ab92d6e823556aca5ab36901a1a0", "class_name": "RelatedNodeInfo"}}, "text": "Anything you know of or that you anticipate on the corporate expense side that it would be \nterribly different than what we saw in the quarter?  ", "start_char_idx": 4807, "end_char_idx": 4952, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "647d5015-1fdf-459d-99ea-a6cd023bed96": {"__data__": {"id_": "647d5015-1fdf-459d-99ea-a6cd023bed96", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nAnd then I guess, Brian, just I'll throw my follow up out there.  I'm sorry if I missed this in the prepared remarks, but \nlarge proposed generic merger out there.  Curious if \u2013 or how impactful that would be on not only ClarusONE, but \non McKesson in general? ", "original_text": "McKesson Corp.  ", "page_label": "18", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d406cdc0-bde8-4f77-904b-5510bc1d21f8", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "af9ca07d9269079ab120aa3b62cf2eda5667c442e9df8286debac86be8187b13", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3584ba78-423f-4639-8c11-d753dc566a27", "node_type": "1", "metadata": {"window": "I guess similar one, Britt, on the corporate expense side.  You're pointing towards \nthe lower end.  But just looki ng at where you ended up in the quarter, it still seems like quite a big ramp through \nthe year to get there.  Anything you know of or that you anticipate on the corporate expense side that it would be \nterribly different than what we saw in the quarter?  ", "original_text": "Anything you know of or that you anticipate on the corporate expense side that it would be \nterribly different than what we saw in the quarter?  ", "page_label": "17", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "46826323a705f3f8a7b5d9f36d9e89c21a73d80cb291b8e02ee7547bd10a5edc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dc99d47b-8a8f-4e01-9a38-42262ec90328", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nAnd then I guess, Brian, just I'll throw my follow up out there.  I'm sorry if I missed this in the prepared remarks, but \nlarge proposed generic merger out there.  Curious if \u2013 or how impactful that would be on not only ClarusONE, but \non McKesson in general?  If  you had a view, that'd be great. ", "original_text": "(MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nAnd then I guess, Brian, just I'll throw my follow up out there. "}, "hash": "9f405de9dbe7770feb8c538479837464724f35fe5241722ccbcf56c1e2e54277", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dc99d47b-8a8f-4e01-9a38-42262ec90328": {"__data__": {"id_": "dc99d47b-8a8f-4e01-9a38-42262ec90328", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nAnd then I guess, Brian, just I'll throw my follow up out there.  I'm sorry if I missed this in the prepared remarks, but \nlarge proposed generic merger out there.  Curious if \u2013 or how impactful that would be on not only ClarusONE, but \non McKesson in general?  If  you had a view, that'd be great. ", "original_text": "(MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nAnd then I guess, Brian, just I'll throw my follow up out there. ", "page_label": "18", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d406cdc0-bde8-4f77-904b-5510bc1d21f8", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "af9ca07d9269079ab120aa3b62cf2eda5667c442e9df8286debac86be8187b13", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "647d5015-1fdf-459d-99ea-a6cd023bed96", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nAnd then I guess, Brian, just I'll throw my follow up out there.  I'm sorry if I missed this in the prepared remarks, but \nlarge proposed generic merger out there.  Curious if \u2013 or how impactful that would be on not only ClarusONE, but \non McKesson in general? ", "original_text": "McKesson Corp.  ", "page_label": "18", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c6aa9bc46857092d7c0a7bfbe8831ddafaa99bb00cf7908f5f21b185588515a6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "620ec572-e986-4f7b-92fe-2ccf76f78f38", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nAnd then I guess, Brian, just I'll throw my follow up out there.  I'm sorry if I missed this in the prepared remarks, but \nlarge proposed generic merger out there.  Curious if \u2013 or how impactful that would be on not only ClarusONE, but \non McKesson in general?  If  you had a view, that'd be great.  Thanks.  \n ", "original_text": "I'm sorry if I missed this in the prepared remarks, but \nlarge proposed generic merger out there. "}, "hash": "834c8a49061c2087bb1ff7c2a8c006a7e8131802ef4f2f8e5245d564a049c9a0", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nAnd then I guess, Brian, just I'll throw my follow up out there. ", "start_char_idx": 16, "end_char_idx": 248, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "620ec572-e986-4f7b-92fe-2ccf76f78f38": {"__data__": {"id_": "620ec572-e986-4f7b-92fe-2ccf76f78f38", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nAnd then I guess, Brian, just I'll throw my follow up out there.  I'm sorry if I missed this in the prepared remarks, but \nlarge proposed generic merger out there.  Curious if \u2013 or how impactful that would be on not only ClarusONE, but \non McKesson in general?  If  you had a view, that'd be great.  Thanks.  \n ", "original_text": "I'm sorry if I missed this in the prepared remarks, but \nlarge proposed generic merger out there. ", "page_label": "18", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d406cdc0-bde8-4f77-904b-5510bc1d21f8", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "af9ca07d9269079ab120aa3b62cf2eda5667c442e9df8286debac86be8187b13", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dc99d47b-8a8f-4e01-9a38-42262ec90328", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nAnd then I guess, Brian, just I'll throw my follow up out there.  I'm sorry if I missed this in the prepared remarks, but \nlarge proposed generic merger out there.  Curious if \u2013 or how impactful that would be on not only ClarusONE, but \non McKesson in general?  If  you had a view, that'd be great. ", "original_text": "(MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nAnd then I guess, Brian, just I'll throw my follow up out there. ", "page_label": "18", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fa61d9a5312c03a4b95a94a625311cddebf881a3286da6dc6488a7bf75a24068", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "22943383-05bf-4b52-a07d-7e11781f82a4", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nAnd then I guess, Brian, just I'll throw my follow up out there.  I'm sorry if I missed this in the prepared remarks, but \nlarge proposed generic merger out there.  Curious if \u2013 or how impactful that would be on not only ClarusONE, but \non McKesson in general?  If  you had a view, that'd be great.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "Curious if \u2013 or how impactful that would be on not only ClarusONE, but \non McKesson in general? "}, "hash": "a42af651617000175479d02f505866d2a4c0583d39932bf4a45d968f6ff085e9", "class_name": "RelatedNodeInfo"}}, "text": "I'm sorry if I missed this in the prepared remarks, but \nlarge proposed generic merger out there. ", "start_char_idx": 248, "end_char_idx": 346, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "22943383-05bf-4b52-a07d-7e11781f82a4": {"__data__": {"id_": "22943383-05bf-4b52-a07d-7e11781f82a4", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nAnd then I guess, Brian, just I'll throw my follow up out there.  I'm sorry if I missed this in the prepared remarks, but \nlarge proposed generic merger out there.  Curious if \u2013 or how impactful that would be on not only ClarusONE, but \non McKesson in general?  If  you had a view, that'd be great.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "Curious if \u2013 or how impactful that would be on not only ClarusONE, but \non McKesson in general? ", "page_label": "18", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d406cdc0-bde8-4f77-904b-5510bc1d21f8", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "af9ca07d9269079ab120aa3b62cf2eda5667c442e9df8286debac86be8187b13", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "620ec572-e986-4f7b-92fe-2ccf76f78f38", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nAnd then I guess, Brian, just I'll throw my follow up out there.  I'm sorry if I missed this in the prepared remarks, but \nlarge proposed generic merger out there.  Curious if \u2013 or how impactful that would be on not only ClarusONE, but \non McKesson in general?  If  you had a view, that'd be great.  Thanks.  \n ", "original_text": "I'm sorry if I missed this in the prepared remarks, but \nlarge proposed generic merger out there. ", "page_label": "18", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a616c062fd4e7624b621228f59f460f66e4df317cea0ee2529a6bb0a2bc70f0b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e19a29fb-4fd0-41ba-9226-803c518a3ee7", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nAnd then I guess, Brian, just I'll throw my follow up out there.  I'm sorry if I missed this in the prepared remarks, but \nlarge proposed generic merger out there.  Curious if \u2013 or how impactful that would be on not only ClarusONE, but \non McKesson in general?  If  you had a view, that'd be great.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nThanks for the question. ", "original_text": "If  you had a view, that'd be great. "}, "hash": "e3f34bbe0d2c992471a50bc53ee4d251aa7b88a573a42f8d09c193ae161f286b", "class_name": "RelatedNodeInfo"}}, "text": "Curious if \u2013 or how impactful that would be on not only ClarusONE, but \non McKesson in general? ", "start_char_idx": 346, "end_char_idx": 442, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e19a29fb-4fd0-41ba-9226-803c518a3ee7": {"__data__": {"id_": "e19a29fb-4fd0-41ba-9226-803c518a3ee7", "embedding": null, "metadata": {"window": "(MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nAnd then I guess, Brian, just I'll throw my follow up out there.  I'm sorry if I missed this in the prepared remarks, but \nlarge proposed generic merger out there.  Curious if \u2013 or how impactful that would be on not only ClarusONE, but \non McKesson in general?  If  you had a view, that'd be great.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nThanks for the question. ", "original_text": "If  you had a view, that'd be great. ", "page_label": "18", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d406cdc0-bde8-4f77-904b-5510bc1d21f8", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "af9ca07d9269079ab120aa3b62cf2eda5667c442e9df8286debac86be8187b13", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "22943383-05bf-4b52-a07d-7e11781f82a4", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nAnd then I guess, Brian, just I'll throw my follow up out there.  I'm sorry if I missed this in the prepared remarks, but \nlarge proposed generic merger out there.  Curious if \u2013 or how impactful that would be on not only ClarusONE, but \non McKesson in general?  If  you had a view, that'd be great.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "Curious if \u2013 or how impactful that would be on not only ClarusONE, but \non McKesson in general? ", "page_label": "18", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "49427838de60c0f58b16d148325c7685128685608f576801128e37b2ee49ceea", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "54a9015e-8c64-4308-adc5-c852337f181f", "node_type": "1", "metadata": {"window": "I'm sorry if I missed this in the prepared remarks, but \nlarge proposed generic merger out there.  Curious if \u2013 or how impactful that would be on not only ClarusONE, but \non McKesson in general?  If  you had a view, that'd be great.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nThanks for the question.  I'll start and then I'll turn it over to Brian. ", "original_text": "Thanks.  \n "}, "hash": "f31674e9a8e470716753b003f8eb77a1c48f4499d08555b228b6c6f0a01bec70", "class_name": "RelatedNodeInfo"}}, "text": "If  you had a view, that'd be great. ", "start_char_idx": 442, "end_char_idx": 479, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "54a9015e-8c64-4308-adc5-c852337f181f": {"__data__": {"id_": "54a9015e-8c64-4308-adc5-c852337f181f", "embedding": null, "metadata": {"window": "I'm sorry if I missed this in the prepared remarks, but \nlarge proposed generic merger out there.  Curious if \u2013 or how impactful that would be on not only ClarusONE, but \non McKesson in general?  If  you had a view, that'd be great.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nThanks for the question.  I'll start and then I'll turn it over to Brian. ", "original_text": "Thanks.  \n ", "page_label": "18", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d406cdc0-bde8-4f77-904b-5510bc1d21f8", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "af9ca07d9269079ab120aa3b62cf2eda5667c442e9df8286debac86be8187b13", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e19a29fb-4fd0-41ba-9226-803c518a3ee7", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nAnd then I guess, Brian, just I'll throw my follow up out there.  I'm sorry if I missed this in the prepared remarks, but \nlarge proposed generic merger out there.  Curious if \u2013 or how impactful that would be on not only ClarusONE, but \non McKesson in general?  If  you had a view, that'd be great.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nThanks for the question. ", "original_text": "If  you had a view, that'd be great. ", "page_label": "18", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5f2bdf4997150ab86dbfda9d9dd2b36179b8649f64d92bc0a9798b4210e39728", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fe1cc393-bc94-42aa-811b-dcdf6089d910", "node_type": "1", "metadata": {"window": "Curious if \u2013 or how impactful that would be on not only ClarusONE, but \non McKesson in general?  If  you had a view, that'd be great.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nThanks for the question.  I'll start and then I'll turn it over to Brian.  As we think about our corporate expenses, at \nthe be ginning of the year we talked about the things that are driving the higher corporate expense year -over-year. \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  "}, "hash": "fba7a79fcaeb9b5a5c4810ad75d0464bbb8707d507d5aa8dd4c8fb276daceccb", "class_name": "RelatedNodeInfo"}}, "text": "Thanks.  \n ", "start_char_idx": 479, "end_char_idx": 490, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fe1cc393-bc94-42aa-811b-dcdf6089d910": {"__data__": {"id_": "fe1cc393-bc94-42aa-811b-dcdf6089d910", "embedding": null, "metadata": {"window": "Curious if \u2013 or how impactful that would be on not only ClarusONE, but \non McKesson in general?  If  you had a view, that'd be great.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nThanks for the question.  I'll start and then I'll turn it over to Brian.  As we think about our corporate expenses, at \nthe be ginning of the year we talked about the things that are driving the higher corporate expense year -over-year. \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "page_label": "18", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d406cdc0-bde8-4f77-904b-5510bc1d21f8", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "af9ca07d9269079ab120aa3b62cf2eda5667c442e9df8286debac86be8187b13", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "54a9015e-8c64-4308-adc5-c852337f181f", "node_type": "1", "metadata": {"window": "I'm sorry if I missed this in the prepared remarks, but \nlarge proposed generic merger out there.  Curious if \u2013 or how impactful that would be on not only ClarusONE, but \non McKesson in general?  If  you had a view, that'd be great.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nThanks for the question.  I'll start and then I'll turn it over to Brian. ", "original_text": "Thanks.  \n ", "page_label": "18", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cffe3cbc73fc5aef60b4a9ddd95b56bd860eda231463fc369c692b4e48d6fc45", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c709644f-4e89-43ae-8b8f-c5ce67824d6f", "node_type": "1", "metadata": {"window": "If  you had a view, that'd be great.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nThanks for the question.  I'll start and then I'll turn it over to Brian.  As we think about our corporate expenses, at \nthe be ginning of the year we talked about the things that are driving the higher corporate expense year -over-year. \n We talked about the increase in opioid litigation costs. ", "original_text": "A \nThanks for the question. "}, "hash": "7edc4bb33665528545ecd9b39518f8f28cfec3e43dc1a457ef1ce23f7f1cf982", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "start_char_idx": 490, "end_char_idx": 835, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c709644f-4e89-43ae-8b8f-c5ce67824d6f": {"__data__": {"id_": "c709644f-4e89-43ae-8b8f-c5ce67824d6f", "embedding": null, "metadata": {"window": "If  you had a view, that'd be great.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nThanks for the question.  I'll start and then I'll turn it over to Brian.  As we think about our corporate expenses, at \nthe be ginning of the year we talked about the things that are driving the higher corporate expense year -over-year. \n We talked about the increase in opioid litigation costs. ", "original_text": "A \nThanks for the question. ", "page_label": "18", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d406cdc0-bde8-4f77-904b-5510bc1d21f8", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "af9ca07d9269079ab120aa3b62cf2eda5667c442e9df8286debac86be8187b13", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fe1cc393-bc94-42aa-811b-dcdf6089d910", "node_type": "1", "metadata": {"window": "Curious if \u2013 or how impactful that would be on not only ClarusONE, but \non McKesson in general?  If  you had a view, that'd be great.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nThanks for the question.  I'll start and then I'll turn it over to Brian.  As we think about our corporate expenses, at \nthe be ginning of the year we talked about the things that are driving the higher corporate expense year -over-year. \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "page_label": "18", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "456732b1ed0a31e3248f9f19b150a0ed991feef9b33fc56c9882fd7b12568a40", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e860c1e8-2f85-44cf-a54f-d1e9e58bc641", "node_type": "1", "metadata": {"window": "Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nThanks for the question.  I'll start and then I'll turn it over to Brian.  As we think about our corporate expenses, at \nthe be ginning of the year we talked about the things that are driving the higher corporate expense year -over-year. \n We talked about the increase in opioid litigation costs.  We talked about the increased investments that we were \nmaking in technology, particularly infrastructure and data and analytics. ", "original_text": "I'll start and then I'll turn it over to Brian. "}, "hash": "302193bd308ae614105c71958d5c6ddaf0b489384f27de7d2c1e607c0f32b126", "class_name": "RelatedNodeInfo"}}, "text": "A \nThanks for the question. ", "start_char_idx": 835, "end_char_idx": 863, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e860c1e8-2f85-44cf-a54f-d1e9e58bc641": {"__data__": {"id_": "e860c1e8-2f85-44cf-a54f-d1e9e58bc641", "embedding": null, "metadata": {"window": "Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nThanks for the question.  I'll start and then I'll turn it over to Brian.  As we think about our corporate expenses, at \nthe be ginning of the year we talked about the things that are driving the higher corporate expense year -over-year. \n We talked about the increase in opioid litigation costs.  We talked about the increased investments that we were \nmaking in technology, particularly infrastructure and data and analytics. ", "original_text": "I'll start and then I'll turn it over to Brian. ", "page_label": "18", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d406cdc0-bde8-4f77-904b-5510bc1d21f8", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "af9ca07d9269079ab120aa3b62cf2eda5667c442e9df8286debac86be8187b13", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c709644f-4e89-43ae-8b8f-c5ce67824d6f", "node_type": "1", "metadata": {"window": "If  you had a view, that'd be great.  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nThanks for the question.  I'll start and then I'll turn it over to Brian.  As we think about our corporate expenses, at \nthe be ginning of the year we talked about the things that are driving the higher corporate expense year -over-year. \n We talked about the increase in opioid litigation costs. ", "original_text": "A \nThanks for the question. ", "page_label": "18", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "57d03d238fe9f99b494c8fa1f97bcdb7622643a5fef542a4844ba0de8c3b63fd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dc7f16b7-ae19-448d-81e0-3d3a89667d83", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nThanks for the question.  I'll start and then I'll turn it over to Brian.  As we think about our corporate expenses, at \nthe be ginning of the year we talked about the things that are driving the higher corporate expense year -over-year. \n We talked about the increase in opioid litigation costs.  We talked about the increased investments that we were \nmaking in technology, particularly infrastructure and data and analytics.  We still intend to make those investments \nthroughout the year. ", "original_text": "As we think about our corporate expenses, at \nthe be ginning of the year we talked about the things that are driving the higher corporate expense year -over-year. \n"}, "hash": "cae2422c73b387c28661a4c0c4ed806ca8bd0de3556b10c903420af94539d2dc", "class_name": "RelatedNodeInfo"}}, "text": "I'll start and then I'll turn it over to Brian. ", "start_char_idx": 863, "end_char_idx": 911, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dc7f16b7-ae19-448d-81e0-3d3a89667d83": {"__data__": {"id_": "dc7f16b7-ae19-448d-81e0-3d3a89667d83", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nThanks for the question.  I'll start and then I'll turn it over to Brian.  As we think about our corporate expenses, at \nthe be ginning of the year we talked about the things that are driving the higher corporate expense year -over-year. \n We talked about the increase in opioid litigation costs.  We talked about the increased investments that we were \nmaking in technology, particularly infrastructure and data and analytics.  We still intend to make those investments \nthroughout the year. ", "original_text": "As we think about our corporate expenses, at \nthe be ginning of the year we talked about the things that are driving the higher corporate expense year -over-year. \n", "page_label": "18", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d406cdc0-bde8-4f77-904b-5510bc1d21f8", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "af9ca07d9269079ab120aa3b62cf2eda5667c442e9df8286debac86be8187b13", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e860c1e8-2f85-44cf-a54f-d1e9e58bc641", "node_type": "1", "metadata": {"window": "Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nThanks for the question.  I'll start and then I'll turn it over to Brian.  As we think about our corporate expenses, at \nthe be ginning of the year we talked about the things that are driving the higher corporate expense year -over-year. \n We talked about the increase in opioid litigation costs.  We talked about the increased investments that we were \nmaking in technology, particularly infrastructure and data and analytics. ", "original_text": "I'll start and then I'll turn it over to Brian. ", "page_label": "18", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1e925aa4286697846234ed5e95aa37b7996bc9615a78978b8e9adb0e8b21c8e2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c6b30a01-aa59-440d-87e2-82e9d9934bc2", "node_type": "1", "metadata": {"window": "A \nThanks for the question.  I'll start and then I'll turn it over to Brian.  As we think about our corporate expenses, at \nthe be ginning of the year we talked about the things that are driving the higher corporate expense year -over-year. \n We talked about the increase in opioid litigation costs.  We talked about the increased investments that we were \nmaking in technology, particularly infrastructure and data and analytics.  We still intend to make those investments \nthroughout the year.  We had a favorable timing -related impact in the first quarter, but our intention is to continue \nto invest in those capabilities as we go throughout the re st of the year.  \n \n", "original_text": "We talked about the increase in opioid litigation costs. "}, "hash": "583a7259cf2f22de0fedd3b883620e9e8dae643f6723ccd94f1bd20e39621e78", "class_name": "RelatedNodeInfo"}}, "text": "As we think about our corporate expenses, at \nthe be ginning of the year we talked about the things that are driving the higher corporate expense year -over-year. \n", "start_char_idx": 911, "end_char_idx": 1075, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c6b30a01-aa59-440d-87e2-82e9d9934bc2": {"__data__": {"id_": "c6b30a01-aa59-440d-87e2-82e9d9934bc2", "embedding": null, "metadata": {"window": "A \nThanks for the question.  I'll start and then I'll turn it over to Brian.  As we think about our corporate expenses, at \nthe be ginning of the year we talked about the things that are driving the higher corporate expense year -over-year. \n We talked about the increase in opioid litigation costs.  We talked about the increased investments that we were \nmaking in technology, particularly infrastructure and data and analytics.  We still intend to make those investments \nthroughout the year.  We had a favorable timing -related impact in the first quarter, but our intention is to continue \nto invest in those capabilities as we go throughout the re st of the year.  \n \n", "original_text": "We talked about the increase in opioid litigation costs. ", "page_label": "18", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d406cdc0-bde8-4f77-904b-5510bc1d21f8", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "af9ca07d9269079ab120aa3b62cf2eda5667c442e9df8286debac86be8187b13", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dc7f16b7-ae19-448d-81e0-3d3a89667d83", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nThanks for the question.  I'll start and then I'll turn it over to Brian.  As we think about our corporate expenses, at \nthe be ginning of the year we talked about the things that are driving the higher corporate expense year -over-year. \n We talked about the increase in opioid litigation costs.  We talked about the increased investments that we were \nmaking in technology, particularly infrastructure and data and analytics.  We still intend to make those investments \nthroughout the year. ", "original_text": "As we think about our corporate expenses, at \nthe be ginning of the year we talked about the things that are driving the higher corporate expense year -over-year. \n", "page_label": "18", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0940c4b1f11eee6d65b76219e1f4c01b036d594d1ed29eb4189c7880b914801b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "20642ff4-6e9d-432b-82d4-7cee9423a74f", "node_type": "1", "metadata": {"window": "I'll start and then I'll turn it over to Brian.  As we think about our corporate expenses, at \nthe be ginning of the year we talked about the things that are driving the higher corporate expense year -over-year. \n We talked about the increase in opioid litigation costs.  We talked about the increased investments that we were \nmaking in technology, particularly infrastructure and data and analytics.  We still intend to make those investments \nthroughout the year.  We had a favorable timing -related impact in the first quarter, but our intention is to continue \nto invest in those capabilities as we go throughout the re st of the year.  \n \n We also \u2013 in my remarks, I talked about our opioid litigation cost projection for the full year still remaining at $150 \nmillion. ", "original_text": "We talked about the increased investments that we were \nmaking in technology, particularly infrastructure and data and analytics. "}, "hash": "862adeb1628c435ed2488b80b6b4a4d4afbc61fd4ce84f7574cb1a008985d408", "class_name": "RelatedNodeInfo"}}, "text": "We talked about the increase in opioid litigation costs. ", "start_char_idx": 1075, "end_char_idx": 1132, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "20642ff4-6e9d-432b-82d4-7cee9423a74f": {"__data__": {"id_": "20642ff4-6e9d-432b-82d4-7cee9423a74f", "embedding": null, "metadata": {"window": "I'll start and then I'll turn it over to Brian.  As we think about our corporate expenses, at \nthe be ginning of the year we talked about the things that are driving the higher corporate expense year -over-year. \n We talked about the increase in opioid litigation costs.  We talked about the increased investments that we were \nmaking in technology, particularly infrastructure and data and analytics.  We still intend to make those investments \nthroughout the year.  We had a favorable timing -related impact in the first quarter, but our intention is to continue \nto invest in those capabilities as we go throughout the re st of the year.  \n \n We also \u2013 in my remarks, I talked about our opioid litigation cost projection for the full year still remaining at $150 \nmillion. ", "original_text": "We talked about the increased investments that we were \nmaking in technology, particularly infrastructure and data and analytics. ", "page_label": "18", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d406cdc0-bde8-4f77-904b-5510bc1d21f8", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "af9ca07d9269079ab120aa3b62cf2eda5667c442e9df8286debac86be8187b13", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c6b30a01-aa59-440d-87e2-82e9d9934bc2", "node_type": "1", "metadata": {"window": "A \nThanks for the question.  I'll start and then I'll turn it over to Brian.  As we think about our corporate expenses, at \nthe be ginning of the year we talked about the things that are driving the higher corporate expense year -over-year. \n We talked about the increase in opioid litigation costs.  We talked about the increased investments that we were \nmaking in technology, particularly infrastructure and data and analytics.  We still intend to make those investments \nthroughout the year.  We had a favorable timing -related impact in the first quarter, but our intention is to continue \nto invest in those capabilities as we go throughout the re st of the year.  \n \n", "original_text": "We talked about the increase in opioid litigation costs. ", "page_label": "18", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "31b65cfd5420160d296498db76ce927a90057e543bc9cc45d2c8c2c51ff066cc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8aebc115-e52f-4181-be26-d80bf254bc57", "node_type": "1", "metadata": {"window": "As we think about our corporate expenses, at \nthe be ginning of the year we talked about the things that are driving the higher corporate expense year -over-year. \n We talked about the increase in opioid litigation costs.  We talked about the increased investments that we were \nmaking in technology, particularly infrastructure and data and analytics.  We still intend to make those investments \nthroughout the year.  We had a favorable timing -related impact in the first quarter, but our intention is to continue \nto invest in those capabilities as we go throughout the re st of the year.  \n \n We also \u2013 in my remarks, I talked about our opioid litigation cost projection for the full year still remaining at $150 \nmillion.  And then the thing that I did talk about that is, included in our corporate expenses was the one -time \nbenefit we had from investing activities which reduced our corporate expenses in the quarter, and that allowed us \nto take our guide for corporate expenses down to the low end of the range that we provided at the beginning of \nthe year.  \n ", "original_text": "We still intend to make those investments \nthroughout the year. "}, "hash": "18854ccd44d26cfd6b7284bb2c15f840d7c467d39741a5287327f69f8e7beb69", "class_name": "RelatedNodeInfo"}}, "text": "We talked about the increased investments that we were \nmaking in technology, particularly infrastructure and data and analytics. ", "start_char_idx": 1132, "end_char_idx": 1262, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8aebc115-e52f-4181-be26-d80bf254bc57": {"__data__": {"id_": "8aebc115-e52f-4181-be26-d80bf254bc57", "embedding": null, "metadata": {"window": "As we think about our corporate expenses, at \nthe be ginning of the year we talked about the things that are driving the higher corporate expense year -over-year. \n We talked about the increase in opioid litigation costs.  We talked about the increased investments that we were \nmaking in technology, particularly infrastructure and data and analytics.  We still intend to make those investments \nthroughout the year.  We had a favorable timing -related impact in the first quarter, but our intention is to continue \nto invest in those capabilities as we go throughout the re st of the year.  \n \n We also \u2013 in my remarks, I talked about our opioid litigation cost projection for the full year still remaining at $150 \nmillion.  And then the thing that I did talk about that is, included in our corporate expenses was the one -time \nbenefit we had from investing activities which reduced our corporate expenses in the quarter, and that allowed us \nto take our guide for corporate expenses down to the low end of the range that we provided at the beginning of \nthe year.  \n ", "original_text": "We still intend to make those investments \nthroughout the year. ", "page_label": "18", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d406cdc0-bde8-4f77-904b-5510bc1d21f8", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "af9ca07d9269079ab120aa3b62cf2eda5667c442e9df8286debac86be8187b13", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "20642ff4-6e9d-432b-82d4-7cee9423a74f", "node_type": "1", "metadata": {"window": "I'll start and then I'll turn it over to Brian.  As we think about our corporate expenses, at \nthe be ginning of the year we talked about the things that are driving the higher corporate expense year -over-year. \n We talked about the increase in opioid litigation costs.  We talked about the increased investments that we were \nmaking in technology, particularly infrastructure and data and analytics.  We still intend to make those investments \nthroughout the year.  We had a favorable timing -related impact in the first quarter, but our intention is to continue \nto invest in those capabilities as we go throughout the re st of the year.  \n \n We also \u2013 in my remarks, I talked about our opioid litigation cost projection for the full year still remaining at $150 \nmillion. ", "original_text": "We talked about the increased investments that we were \nmaking in technology, particularly infrastructure and data and analytics. ", "page_label": "18", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2c2f5709a8baf3b9cdd2585ec0b35e3cdb606e7a1136c3b842d4c8cf46f6428f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "76071aea-db6e-47e6-9b35-115a27c926b5", "node_type": "1", "metadata": {"window": "We talked about the increase in opioid litigation costs.  We talked about the increased investments that we were \nmaking in technology, particularly infrastructure and data and analytics.  We still intend to make those investments \nthroughout the year.  We had a favorable timing -related impact in the first quarter, but our intention is to continue \nto invest in those capabilities as we go throughout the re st of the year.  \n \n We also \u2013 in my remarks, I talked about our opioid litigation cost projection for the full year still remaining at $150 \nmillion.  And then the thing that I did talk about that is, included in our corporate expenses was the one -time \nbenefit we had from investing activities which reduced our corporate expenses in the quarter, and that allowed us \nto take our guide for corporate expenses down to the low end of the range that we provided at the beginning of \nthe year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Exe cutive Officer & Director, McKesson Corp.  ", "original_text": "We had a favorable timing -related impact in the first quarter, but our intention is to continue \nto invest in those capabilities as we go throughout the re st of the year.  \n \n"}, "hash": "58ca5d9fb7231255dc564c6d4bf80618d35fb91e5329863bd20a433dfb78a683", "class_name": "RelatedNodeInfo"}}, "text": "We still intend to make those investments \nthroughout the year. ", "start_char_idx": 1262, "end_char_idx": 1326, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "76071aea-db6e-47e6-9b35-115a27c926b5": {"__data__": {"id_": "76071aea-db6e-47e6-9b35-115a27c926b5", "embedding": null, "metadata": {"window": "We talked about the increase in opioid litigation costs.  We talked about the increased investments that we were \nmaking in technology, particularly infrastructure and data and analytics.  We still intend to make those investments \nthroughout the year.  We had a favorable timing -related impact in the first quarter, but our intention is to continue \nto invest in those capabilities as we go throughout the re st of the year.  \n \n We also \u2013 in my remarks, I talked about our opioid litigation cost projection for the full year still remaining at $150 \nmillion.  And then the thing that I did talk about that is, included in our corporate expenses was the one -time \nbenefit we had from investing activities which reduced our corporate expenses in the quarter, and that allowed us \nto take our guide for corporate expenses down to the low end of the range that we provided at the beginning of \nthe year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Exe cutive Officer & Director, McKesson Corp.  ", "original_text": "We had a favorable timing -related impact in the first quarter, but our intention is to continue \nto invest in those capabilities as we go throughout the re st of the year.  \n \n", "page_label": "18", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d406cdc0-bde8-4f77-904b-5510bc1d21f8", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "af9ca07d9269079ab120aa3b62cf2eda5667c442e9df8286debac86be8187b13", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8aebc115-e52f-4181-be26-d80bf254bc57", "node_type": "1", "metadata": {"window": "As we think about our corporate expenses, at \nthe be ginning of the year we talked about the things that are driving the higher corporate expense year -over-year. \n We talked about the increase in opioid litigation costs.  We talked about the increased investments that we were \nmaking in technology, particularly infrastructure and data and analytics.  We still intend to make those investments \nthroughout the year.  We had a favorable timing -related impact in the first quarter, but our intention is to continue \nto invest in those capabilities as we go throughout the re st of the year.  \n \n We also \u2013 in my remarks, I talked about our opioid litigation cost projection for the full year still remaining at $150 \nmillion.  And then the thing that I did talk about that is, included in our corporate expenses was the one -time \nbenefit we had from investing activities which reduced our corporate expenses in the quarter, and that allowed us \nto take our guide for corporate expenses down to the low end of the range that we provided at the beginning of \nthe year.  \n ", "original_text": "We still intend to make those investments \nthroughout the year. ", "page_label": "18", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "42381b729c8c19f0247b7fb39c09bf5988b0c56612376c014864885091af6019", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d8067823-1a97-44eb-87f8-a0da2ca9c667", "node_type": "1", "metadata": {"window": "We talked about the increased investments that we were \nmaking in technology, particularly infrastructure and data and analytics.  We still intend to make those investments \nthroughout the year.  We had a favorable timing -related impact in the first quarter, but our intention is to continue \nto invest in those capabilities as we go throughout the re st of the year.  \n \n We also \u2013 in my remarks, I talked about our opioid litigation cost projection for the full year still remaining at $150 \nmillion.  And then the thing that I did talk about that is, included in our corporate expenses was the one -time \nbenefit we had from investing activities which reduced our corporate expenses in the quarter, and that allowed us \nto take our guide for corporate expenses down to the low end of the range that we provided at the beginning of \nthe year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Exe cutive Officer & Director, McKesson Corp.   A \nRobert, to your second question \u2013 and we actually did not comment on it I think in our opening remarks. ", "original_text": "We also \u2013 in my remarks, I talked about our opioid litigation cost projection for the full year still remaining at $150 \nmillion. "}, "hash": "eb910d030d479a5d699cb806ac3c8d889080dff36d6fa8ed9e68334d2e65e48c", "class_name": "RelatedNodeInfo"}}, "text": "We had a favorable timing -related impact in the first quarter, but our intention is to continue \nto invest in those capabilities as we go throughout the re st of the year.  \n \n", "start_char_idx": 1326, "end_char_idx": 1503, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d8067823-1a97-44eb-87f8-a0da2ca9c667": {"__data__": {"id_": "d8067823-1a97-44eb-87f8-a0da2ca9c667", "embedding": null, "metadata": {"window": "We talked about the increased investments that we were \nmaking in technology, particularly infrastructure and data and analytics.  We still intend to make those investments \nthroughout the year.  We had a favorable timing -related impact in the first quarter, but our intention is to continue \nto invest in those capabilities as we go throughout the re st of the year.  \n \n We also \u2013 in my remarks, I talked about our opioid litigation cost projection for the full year still remaining at $150 \nmillion.  And then the thing that I did talk about that is, included in our corporate expenses was the one -time \nbenefit we had from investing activities which reduced our corporate expenses in the quarter, and that allowed us \nto take our guide for corporate expenses down to the low end of the range that we provided at the beginning of \nthe year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Exe cutive Officer & Director, McKesson Corp.   A \nRobert, to your second question \u2013 and we actually did not comment on it I think in our opening remarks. ", "original_text": "We also \u2013 in my remarks, I talked about our opioid litigation cost projection for the full year still remaining at $150 \nmillion. ", "page_label": "18", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d406cdc0-bde8-4f77-904b-5510bc1d21f8", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "af9ca07d9269079ab120aa3b62cf2eda5667c442e9df8286debac86be8187b13", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "76071aea-db6e-47e6-9b35-115a27c926b5", "node_type": "1", "metadata": {"window": "We talked about the increase in opioid litigation costs.  We talked about the increased investments that we were \nmaking in technology, particularly infrastructure and data and analytics.  We still intend to make those investments \nthroughout the year.  We had a favorable timing -related impact in the first quarter, but our intention is to continue \nto invest in those capabilities as we go throughout the re st of the year.  \n \n We also \u2013 in my remarks, I talked about our opioid litigation cost projection for the full year still remaining at $150 \nmillion.  And then the thing that I did talk about that is, included in our corporate expenses was the one -time \nbenefit we had from investing activities which reduced our corporate expenses in the quarter, and that allowed us \nto take our guide for corporate expenses down to the low end of the range that we provided at the beginning of \nthe year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Exe cutive Officer & Director, McKesson Corp.  ", "original_text": "We had a favorable timing -related impact in the first quarter, but our intention is to continue \nto invest in those capabilities as we go throughout the re st of the year.  \n \n", "page_label": "18", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "363e9b97cd865f2511cf800834d49380a7c4788a44fb6709176cbf74729a3cf7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "54b76778-7667-48cf-a840-b589adae317c", "node_type": "1", "metadata": {"window": "We still intend to make those investments \nthroughout the year.  We had a favorable timing -related impact in the first quarter, but our intention is to continue \nto invest in those capabilities as we go throughout the re st of the year.  \n \n We also \u2013 in my remarks, I talked about our opioid litigation cost projection for the full year still remaining at $150 \nmillion.  And then the thing that I did talk about that is, included in our corporate expenses was the one -time \nbenefit we had from investing activities which reduced our corporate expenses in the quarter, and that allowed us \nto take our guide for corporate expenses down to the low end of the range that we provided at the beginning of \nthe year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Exe cutive Officer & Director, McKesson Corp.   A \nRobert, to your second question \u2013 and we actually did not comment on it I think in our opening remarks.  So, thank \nyou for the question on the Pfizer -Mylan merger. ", "original_text": "And then the thing that I did talk about that is, included in our corporate expenses was the one -time \nbenefit we had from investing activities which reduced our corporate expenses in the quarter, and that allowed us \nto take our guide for corporate expenses down to the low end of the range that we provided at the beginning of \nthe year.  \n "}, "hash": "74c701dbf23e4a3d6337e852f34a746aa4acc16d885a76ecbcd8d0c914884b65", "class_name": "RelatedNodeInfo"}}, "text": "We also \u2013 in my remarks, I talked about our opioid litigation cost projection for the full year still remaining at $150 \nmillion. ", "start_char_idx": 1503, "end_char_idx": 1633, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "54b76778-7667-48cf-a840-b589adae317c": {"__data__": {"id_": "54b76778-7667-48cf-a840-b589adae317c", "embedding": null, "metadata": {"window": "We still intend to make those investments \nthroughout the year.  We had a favorable timing -related impact in the first quarter, but our intention is to continue \nto invest in those capabilities as we go throughout the re st of the year.  \n \n We also \u2013 in my remarks, I talked about our opioid litigation cost projection for the full year still remaining at $150 \nmillion.  And then the thing that I did talk about that is, included in our corporate expenses was the one -time \nbenefit we had from investing activities which reduced our corporate expenses in the quarter, and that allowed us \nto take our guide for corporate expenses down to the low end of the range that we provided at the beginning of \nthe year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Exe cutive Officer & Director, McKesson Corp.   A \nRobert, to your second question \u2013 and we actually did not comment on it I think in our opening remarks.  So, thank \nyou for the question on the Pfizer -Mylan merger. ", "original_text": "And then the thing that I did talk about that is, included in our corporate expenses was the one -time \nbenefit we had from investing activities which reduced our corporate expenses in the quarter, and that allowed us \nto take our guide for corporate expenses down to the low end of the range that we provided at the beginning of \nthe year.  \n ", "page_label": "18", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d406cdc0-bde8-4f77-904b-5510bc1d21f8", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "af9ca07d9269079ab120aa3b62cf2eda5667c442e9df8286debac86be8187b13", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d8067823-1a97-44eb-87f8-a0da2ca9c667", "node_type": "1", "metadata": {"window": "We talked about the increased investments that we were \nmaking in technology, particularly infrastructure and data and analytics.  We still intend to make those investments \nthroughout the year.  We had a favorable timing -related impact in the first quarter, but our intention is to continue \nto invest in those capabilities as we go throughout the re st of the year.  \n \n We also \u2013 in my remarks, I talked about our opioid litigation cost projection for the full year still remaining at $150 \nmillion.  And then the thing that I did talk about that is, included in our corporate expenses was the one -time \nbenefit we had from investing activities which reduced our corporate expenses in the quarter, and that allowed us \nto take our guide for corporate expenses down to the low end of the range that we provided at the beginning of \nthe year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Exe cutive Officer & Director, McKesson Corp.   A \nRobert, to your second question \u2013 and we actually did not comment on it I think in our opening remarks. ", "original_text": "We also \u2013 in my remarks, I talked about our opioid litigation cost projection for the full year still remaining at $150 \nmillion. ", "page_label": "18", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2299e2701d773f8c3e213e317d6719f94284ab813013c67ffed025bbc5f4df79", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ba84bd36-b42a-45b5-93ca-07dd6bdf84cc", "node_type": "1", "metadata": {"window": "We had a favorable timing -related impact in the first quarter, but our intention is to continue \nto invest in those capabilities as we go throughout the re st of the year.  \n \n We also \u2013 in my remarks, I talked about our opioid litigation cost projection for the full year still remaining at $150 \nmillion.  And then the thing that I did talk about that is, included in our corporate expenses was the one -time \nbenefit we had from investing activities which reduced our corporate expenses in the quarter, and that allowed us \nto take our guide for corporate expenses down to the low end of the range that we provided at the beginning of \nthe year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Exe cutive Officer & Director, McKesson Corp.   A \nRobert, to your second question \u2013 and we actually did not comment on it I think in our opening remarks.  So, thank \nyou for the question on the Pfizer -Mylan merger.  So I would start by saying that we have strong r elationships with \nboth of these organizations and they've been important partners for us at McKesson and in ClarusONE. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Exe cutive Officer & Director, McKesson Corp.  "}, "hash": "bfdd04fb14a808cb72c4822cbebd867ea1892dd62f3bd898a73ffe757e806190", "class_name": "RelatedNodeInfo"}}, "text": "And then the thing that I did talk about that is, included in our corporate expenses was the one -time \nbenefit we had from investing activities which reduced our corporate expenses in the quarter, and that allowed us \nto take our guide for corporate expenses down to the low end of the range that we provided at the beginning of \nthe year.  \n ", "start_char_idx": 1633, "end_char_idx": 1977, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ba84bd36-b42a-45b5-93ca-07dd6bdf84cc": {"__data__": {"id_": "ba84bd36-b42a-45b5-93ca-07dd6bdf84cc", "embedding": null, "metadata": {"window": "We had a favorable timing -related impact in the first quarter, but our intention is to continue \nto invest in those capabilities as we go throughout the re st of the year.  \n \n We also \u2013 in my remarks, I talked about our opioid litigation cost projection for the full year still remaining at $150 \nmillion.  And then the thing that I did talk about that is, included in our corporate expenses was the one -time \nbenefit we had from investing activities which reduced our corporate expenses in the quarter, and that allowed us \nto take our guide for corporate expenses down to the low end of the range that we provided at the beginning of \nthe year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Exe cutive Officer & Director, McKesson Corp.   A \nRobert, to your second question \u2013 and we actually did not comment on it I think in our opening remarks.  So, thank \nyou for the question on the Pfizer -Mylan merger.  So I would start by saying that we have strong r elationships with \nboth of these organizations and they've been important partners for us at McKesson and in ClarusONE. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Exe cutive Officer & Director, McKesson Corp.  ", "page_label": "18", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d406cdc0-bde8-4f77-904b-5510bc1d21f8", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "af9ca07d9269079ab120aa3b62cf2eda5667c442e9df8286debac86be8187b13", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "54b76778-7667-48cf-a840-b589adae317c", "node_type": "1", "metadata": {"window": "We still intend to make those investments \nthroughout the year.  We had a favorable timing -related impact in the first quarter, but our intention is to continue \nto invest in those capabilities as we go throughout the re st of the year.  \n \n We also \u2013 in my remarks, I talked about our opioid litigation cost projection for the full year still remaining at $150 \nmillion.  And then the thing that I did talk about that is, included in our corporate expenses was the one -time \nbenefit we had from investing activities which reduced our corporate expenses in the quarter, and that allowed us \nto take our guide for corporate expenses down to the low end of the range that we provided at the beginning of \nthe year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Exe cutive Officer & Director, McKesson Corp.   A \nRobert, to your second question \u2013 and we actually did not comment on it I think in our opening remarks.  So, thank \nyou for the question on the Pfizer -Mylan merger. ", "original_text": "And then the thing that I did talk about that is, included in our corporate expenses was the one -time \nbenefit we had from investing activities which reduced our corporate expenses in the quarter, and that allowed us \nto take our guide for corporate expenses down to the low end of the range that we provided at the beginning of \nthe year.  \n ", "page_label": "18", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e32379c41c43ee488e6edcd445241def3477dc6b73e19ce085d2c33ca083ed58", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2fa86c2f-83ed-41c6-af08-36ebff6081f3", "node_type": "1", "metadata": {"window": "We also \u2013 in my remarks, I talked about our opioid litigation cost projection for the full year still remaining at $150 \nmillion.  And then the thing that I did talk about that is, included in our corporate expenses was the one -time \nbenefit we had from investing activities which reduced our corporate expenses in the quarter, and that allowed us \nto take our guide for corporate expenses down to the low end of the range that we provided at the beginning of \nthe year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Exe cutive Officer & Director, McKesson Corp.   A \nRobert, to your second question \u2013 and we actually did not comment on it I think in our opening remarks.  So, thank \nyou for the question on the Pfizer -Mylan merger.  So I would start by saying that we have strong r elationships with \nboth of these organizations and they've been important partners for us at McKesson and in ClarusONE.  The \nrationale for the merger, as I understand it, is broadening of the portfolio. ", "original_text": "A \nRobert, to your second question \u2013 and we actually did not comment on it I think in our opening remarks. "}, "hash": "5e7a18d6cb9fb3f78978d43eaa913f6ce94877ea7904122b2767ab3722abe281", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Exe cutive Officer & Director, McKesson Corp.  ", "start_char_idx": 1977, "end_char_idx": 2307, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2fa86c2f-83ed-41c6-af08-36ebff6081f3": {"__data__": {"id_": "2fa86c2f-83ed-41c6-af08-36ebff6081f3", "embedding": null, "metadata": {"window": "We also \u2013 in my remarks, I talked about our opioid litigation cost projection for the full year still remaining at $150 \nmillion.  And then the thing that I did talk about that is, included in our corporate expenses was the one -time \nbenefit we had from investing activities which reduced our corporate expenses in the quarter, and that allowed us \nto take our guide for corporate expenses down to the low end of the range that we provided at the beginning of \nthe year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Exe cutive Officer & Director, McKesson Corp.   A \nRobert, to your second question \u2013 and we actually did not comment on it I think in our opening remarks.  So, thank \nyou for the question on the Pfizer -Mylan merger.  So I would start by saying that we have strong r elationships with \nboth of these organizations and they've been important partners for us at McKesson and in ClarusONE.  The \nrationale for the merger, as I understand it, is broadening of the portfolio. ", "original_text": "A \nRobert, to your second question \u2013 and we actually did not comment on it I think in our opening remarks. ", "page_label": "18", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d406cdc0-bde8-4f77-904b-5510bc1d21f8", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "af9ca07d9269079ab120aa3b62cf2eda5667c442e9df8286debac86be8187b13", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ba84bd36-b42a-45b5-93ca-07dd6bdf84cc", "node_type": "1", "metadata": {"window": "We had a favorable timing -related impact in the first quarter, but our intention is to continue \nto invest in those capabilities as we go throughout the re st of the year.  \n \n We also \u2013 in my remarks, I talked about our opioid litigation cost projection for the full year still remaining at $150 \nmillion.  And then the thing that I did talk about that is, included in our corporate expenses was the one -time \nbenefit we had from investing activities which reduced our corporate expenses in the quarter, and that allowed us \nto take our guide for corporate expenses down to the low end of the range that we provided at the beginning of \nthe year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Exe cutive Officer & Director, McKesson Corp.   A \nRobert, to your second question \u2013 and we actually did not comment on it I think in our opening remarks.  So, thank \nyou for the question on the Pfizer -Mylan merger.  So I would start by saying that we have strong r elationships with \nboth of these organizations and they've been important partners for us at McKesson and in ClarusONE. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Exe cutive Officer & Director, McKesson Corp.  ", "page_label": "18", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4a57a97d2cfd19dd4982d134620d256d9dbf49e0d60c1655dee94f4000c26212", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "faa52f20-cbee-49f9-86aa-665b60b36c4f", "node_type": "1", "metadata": {"window": "And then the thing that I did talk about that is, included in our corporate expenses was the one -time \nbenefit we had from investing activities which reduced our corporate expenses in the quarter, and that allowed us \nto take our guide for corporate expenses down to the low end of the range that we provided at the beginning of \nthe year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Exe cutive Officer & Director, McKesson Corp.   A \nRobert, to your second question \u2013 and we actually did not comment on it I think in our opening remarks.  So, thank \nyou for the question on the Pfizer -Mylan merger.  So I would start by saying that we have strong r elationships with \nboth of these organizations and they've been important partners for us at McKesson and in ClarusONE.  The \nrationale for the merger, as I understand it, is broadening of the portfolio.  There is some cost synergy, some \nefficiency.  \n \n", "original_text": "So, thank \nyou for the question on the Pfizer -Mylan merger. "}, "hash": "f124b8f889030846f29fe46b55b4ffe42aa43629936244b572912f1d27a49ce7", "class_name": "RelatedNodeInfo"}}, "text": "A \nRobert, to your second question \u2013 and we actually did not comment on it I think in our opening remarks. ", "start_char_idx": 2307, "end_char_idx": 2414, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "faa52f20-cbee-49f9-86aa-665b60b36c4f": {"__data__": {"id_": "faa52f20-cbee-49f9-86aa-665b60b36c4f", "embedding": null, "metadata": {"window": "And then the thing that I did talk about that is, included in our corporate expenses was the one -time \nbenefit we had from investing activities which reduced our corporate expenses in the quarter, and that allowed us \nto take our guide for corporate expenses down to the low end of the range that we provided at the beginning of \nthe year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Exe cutive Officer & Director, McKesson Corp.   A \nRobert, to your second question \u2013 and we actually did not comment on it I think in our opening remarks.  So, thank \nyou for the question on the Pfizer -Mylan merger.  So I would start by saying that we have strong r elationships with \nboth of these organizations and they've been important partners for us at McKesson and in ClarusONE.  The \nrationale for the merger, as I understand it, is broadening of the portfolio.  There is some cost synergy, some \nefficiency.  \n \n", "original_text": "So, thank \nyou for the question on the Pfizer -Mylan merger. ", "page_label": "18", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d406cdc0-bde8-4f77-904b-5510bc1d21f8", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "af9ca07d9269079ab120aa3b62cf2eda5667c442e9df8286debac86be8187b13", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2fa86c2f-83ed-41c6-af08-36ebff6081f3", "node_type": "1", "metadata": {"window": "We also \u2013 in my remarks, I talked about our opioid litigation cost projection for the full year still remaining at $150 \nmillion.  And then the thing that I did talk about that is, included in our corporate expenses was the one -time \nbenefit we had from investing activities which reduced our corporate expenses in the quarter, and that allowed us \nto take our guide for corporate expenses down to the low end of the range that we provided at the beginning of \nthe year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Exe cutive Officer & Director, McKesson Corp.   A \nRobert, to your second question \u2013 and we actually did not comment on it I think in our opening remarks.  So, thank \nyou for the question on the Pfizer -Mylan merger.  So I would start by saying that we have strong r elationships with \nboth of these organizations and they've been important partners for us at McKesson and in ClarusONE.  The \nrationale for the merger, as I understand it, is broadening of the portfolio. ", "original_text": "A \nRobert, to your second question \u2013 and we actually did not comment on it I think in our opening remarks. ", "page_label": "18", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e864f4a17a238cf641f7b436f107540c9389f14a03f01067957f0e615ac2e41a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b3f0f703-fec2-4b27-99ba-d14b5842c87d", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Exe cutive Officer & Director, McKesson Corp.   A \nRobert, to your second question \u2013 and we actually did not comment on it I think in our opening remarks.  So, thank \nyou for the question on the Pfizer -Mylan merger.  So I would start by saying that we have strong r elationships with \nboth of these organizations and they've been important partners for us at McKesson and in ClarusONE.  The \nrationale for the merger, as I understand it, is broadening of the portfolio.  There is some cost synergy, some \nefficiency.  \n \n And frankly, at the scale that we operate and buy being partnered with large -scaled healthy organizations that are \ncapable of continuity of supply and competitive pricing, it can be a good thing. ", "original_text": "So I would start by saying that we have strong r elationships with \nboth of these organizations and they've been important partners for us at McKesson and in ClarusONE. "}, "hash": "59137a03f8a36184ef756cf9a609f163b6864f0b0d9ec41aed81b841fc5dc29e", "class_name": "RelatedNodeInfo"}}, "text": "So, thank \nyou for the question on the Pfizer -Mylan merger. ", "start_char_idx": 2414, "end_char_idx": 2475, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b3f0f703-fec2-4b27-99ba-d14b5842c87d": {"__data__": {"id_": "b3f0f703-fec2-4b27-99ba-d14b5842c87d", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Exe cutive Officer & Director, McKesson Corp.   A \nRobert, to your second question \u2013 and we actually did not comment on it I think in our opening remarks.  So, thank \nyou for the question on the Pfizer -Mylan merger.  So I would start by saying that we have strong r elationships with \nboth of these organizations and they've been important partners for us at McKesson and in ClarusONE.  The \nrationale for the merger, as I understand it, is broadening of the portfolio.  There is some cost synergy, some \nefficiency.  \n \n And frankly, at the scale that we operate and buy being partnered with large -scaled healthy organizations that are \ncapable of continuity of supply and competitive pricing, it can be a good thing. ", "original_text": "So I would start by saying that we have strong r elationships with \nboth of these organizations and they've been important partners for us at McKesson and in ClarusONE. ", "page_label": "18", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d406cdc0-bde8-4f77-904b-5510bc1d21f8", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "af9ca07d9269079ab120aa3b62cf2eda5667c442e9df8286debac86be8187b13", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "faa52f20-cbee-49f9-86aa-665b60b36c4f", "node_type": "1", "metadata": {"window": "And then the thing that I did talk about that is, included in our corporate expenses was the one -time \nbenefit we had from investing activities which reduced our corporate expenses in the quarter, and that allowed us \nto take our guide for corporate expenses down to the low end of the range that we provided at the beginning of \nthe year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Exe cutive Officer & Director, McKesson Corp.   A \nRobert, to your second question \u2013 and we actually did not comment on it I think in our opening remarks.  So, thank \nyou for the question on the Pfizer -Mylan merger.  So I would start by saying that we have strong r elationships with \nboth of these organizations and they've been important partners for us at McKesson and in ClarusONE.  The \nrationale for the merger, as I understand it, is broadening of the portfolio.  There is some cost synergy, some \nefficiency.  \n \n", "original_text": "So, thank \nyou for the question on the Pfizer -Mylan merger. ", "page_label": "18", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0a182aa910de6367b484ffbe43b45e6faa4ef3ef80205374fedc895fa2d66c6b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "61475dbf-b0ff-4dbe-9d7a-c73f8b153351", "node_type": "1", "metadata": {"window": "A \nRobert, to your second question \u2013 and we actually did not comment on it I think in our opening remarks.  So, thank \nyou for the question on the Pfizer -Mylan merger.  So I would start by saying that we have strong r elationships with \nboth of these organizations and they've been important partners for us at McKesson and in ClarusONE.  The \nrationale for the merger, as I understand it, is broadening of the portfolio.  There is some cost synergy, some \nefficiency.  \n \n And frankly, at the scale that we operate and buy being partnered with large -scaled healthy organizations that are \ncapable of continuity of supply and competitive pricing, it can be a good thing.  So we'll evaluate how this merger \ncomes together, we'll continue  to be in dialogue with them, but I wouldn't say that poses any imminent concerns \nfrom our perspective.  \n ", "original_text": "The \nrationale for the merger, as I understand it, is broadening of the portfolio. "}, "hash": "11d51cc3f7f17d9eb2153206fbdd1c3013453ff8ecfb81ae2636ad14eecc43e9", "class_name": "RelatedNodeInfo"}}, "text": "So I would start by saying that we have strong r elationships with \nboth of these organizations and they've been important partners for us at McKesson and in ClarusONE. ", "start_char_idx": 2475, "end_char_idx": 2644, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "61475dbf-b0ff-4dbe-9d7a-c73f8b153351": {"__data__": {"id_": "61475dbf-b0ff-4dbe-9d7a-c73f8b153351", "embedding": null, "metadata": {"window": "A \nRobert, to your second question \u2013 and we actually did not comment on it I think in our opening remarks.  So, thank \nyou for the question on the Pfizer -Mylan merger.  So I would start by saying that we have strong r elationships with \nboth of these organizations and they've been important partners for us at McKesson and in ClarusONE.  The \nrationale for the merger, as I understand it, is broadening of the portfolio.  There is some cost synergy, some \nefficiency.  \n \n And frankly, at the scale that we operate and buy being partnered with large -scaled healthy organizations that are \ncapable of continuity of supply and competitive pricing, it can be a good thing.  So we'll evaluate how this merger \ncomes together, we'll continue  to be in dialogue with them, but I wouldn't say that poses any imminent concerns \nfrom our perspective.  \n ", "original_text": "The \nrationale for the merger, as I understand it, is broadening of the portfolio. ", "page_label": "18", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d406cdc0-bde8-4f77-904b-5510bc1d21f8", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "af9ca07d9269079ab120aa3b62cf2eda5667c442e9df8286debac86be8187b13", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b3f0f703-fec2-4b27-99ba-d14b5842c87d", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Exe cutive Officer & Director, McKesson Corp.   A \nRobert, to your second question \u2013 and we actually did not comment on it I think in our opening remarks.  So, thank \nyou for the question on the Pfizer -Mylan merger.  So I would start by saying that we have strong r elationships with \nboth of these organizations and they've been important partners for us at McKesson and in ClarusONE.  The \nrationale for the merger, as I understand it, is broadening of the portfolio.  There is some cost synergy, some \nefficiency.  \n \n And frankly, at the scale that we operate and buy being partnered with large -scaled healthy organizations that are \ncapable of continuity of supply and competitive pricing, it can be a good thing. ", "original_text": "So I would start by saying that we have strong r elationships with \nboth of these organizations and they've been important partners for us at McKesson and in ClarusONE. ", "page_label": "18", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8ddc79683d25545b8f81334102c76bc64111a2b58c2c7a7574fa098893d3ace9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "98b00137-4f5b-4bce-b67f-50d7b3fac616", "node_type": "1", "metadata": {"window": "So, thank \nyou for the question on the Pfizer -Mylan merger.  So I would start by saying that we have strong r elationships with \nboth of these organizations and they've been important partners for us at McKesson and in ClarusONE.  The \nrationale for the merger, as I understand it, is broadening of the portfolio.  There is some cost synergy, some \nefficiency.  \n \n And frankly, at the scale that we operate and buy being partnered with large -scaled healthy organizations that are \ncapable of continuity of supply and competitive pricing, it can be a good thing.  So we'll evaluate how this merger \ncomes together, we'll continue  to be in dialogue with them, but I wouldn't say that poses any imminent concerns \nfrom our perspective.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question will come from Charles Rhyee with Cowen & Company.  \n ", "original_text": "There is some cost synergy, some \nefficiency.  \n \n"}, "hash": "c4979aa0bd83cae1672d98bb56ae29ac1544dd6c748282616113b5941ed3c6ee", "class_name": "RelatedNodeInfo"}}, "text": "The \nrationale for the merger, as I understand it, is broadening of the portfolio. ", "start_char_idx": 2644, "end_char_idx": 2727, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "98b00137-4f5b-4bce-b67f-50d7b3fac616": {"__data__": {"id_": "98b00137-4f5b-4bce-b67f-50d7b3fac616", "embedding": null, "metadata": {"window": "So, thank \nyou for the question on the Pfizer -Mylan merger.  So I would start by saying that we have strong r elationships with \nboth of these organizations and they've been important partners for us at McKesson and in ClarusONE.  The \nrationale for the merger, as I understand it, is broadening of the portfolio.  There is some cost synergy, some \nefficiency.  \n \n And frankly, at the scale that we operate and buy being partnered with large -scaled healthy organizations that are \ncapable of continuity of supply and competitive pricing, it can be a good thing.  So we'll evaluate how this merger \ncomes together, we'll continue  to be in dialogue with them, but I wouldn't say that poses any imminent concerns \nfrom our perspective.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question will come from Charles Rhyee with Cowen & Company.  \n ", "original_text": "There is some cost synergy, some \nefficiency.  \n \n", "page_label": "18", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d406cdc0-bde8-4f77-904b-5510bc1d21f8", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "af9ca07d9269079ab120aa3b62cf2eda5667c442e9df8286debac86be8187b13", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "61475dbf-b0ff-4dbe-9d7a-c73f8b153351", "node_type": "1", "metadata": {"window": "A \nRobert, to your second question \u2013 and we actually did not comment on it I think in our opening remarks.  So, thank \nyou for the question on the Pfizer -Mylan merger.  So I would start by saying that we have strong r elationships with \nboth of these organizations and they've been important partners for us at McKesson and in ClarusONE.  The \nrationale for the merger, as I understand it, is broadening of the portfolio.  There is some cost synergy, some \nefficiency.  \n \n And frankly, at the scale that we operate and buy being partnered with large -scaled healthy organizations that are \ncapable of continuity of supply and competitive pricing, it can be a good thing.  So we'll evaluate how this merger \ncomes together, we'll continue  to be in dialogue with them, but I wouldn't say that poses any imminent concerns \nfrom our perspective.  \n ", "original_text": "The \nrationale for the merger, as I understand it, is broadening of the portfolio. ", "page_label": "18", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "37291a92dd584a9f724d0479c9f356068396a7f2b6da895e35721d6543651dda", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a0f2260b-444e-4483-9bf5-d4f51456ae69", "node_type": "1", "metadata": {"window": "So I would start by saying that we have strong r elationships with \nboth of these organizations and they've been important partners for us at McKesson and in ClarusONE.  The \nrationale for the merger, as I understand it, is broadening of the portfolio.  There is some cost synergy, some \nefficiency.  \n \n And frankly, at the scale that we operate and buy being partnered with large -scaled healthy organizations that are \ncapable of continuity of supply and competitive pricing, it can be a good thing.  So we'll evaluate how this merger \ncomes together, we'll continue  to be in dialogue with them, but I wouldn't say that poses any imminent concerns \nfrom our perspective.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question will come from Charles Rhyee with Cowen & Company.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co. ", "original_text": "And frankly, at the scale that we operate and buy being partnered with large -scaled healthy organizations that are \ncapable of continuity of supply and competitive pricing, it can be a good thing. "}, "hash": "3a10d9a111c3707cc9040d889d874284b08eabb5e1d6f942318f609d3c782bf6", "class_name": "RelatedNodeInfo"}}, "text": "There is some cost synergy, some \nefficiency.  \n \n", "start_char_idx": 2727, "end_char_idx": 2777, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a0f2260b-444e-4483-9bf5-d4f51456ae69": {"__data__": {"id_": "a0f2260b-444e-4483-9bf5-d4f51456ae69", "embedding": null, "metadata": {"window": "So I would start by saying that we have strong r elationships with \nboth of these organizations and they've been important partners for us at McKesson and in ClarusONE.  The \nrationale for the merger, as I understand it, is broadening of the portfolio.  There is some cost synergy, some \nefficiency.  \n \n And frankly, at the scale that we operate and buy being partnered with large -scaled healthy organizations that are \ncapable of continuity of supply and competitive pricing, it can be a good thing.  So we'll evaluate how this merger \ncomes together, we'll continue  to be in dialogue with them, but I wouldn't say that poses any imminent concerns \nfrom our perspective.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question will come from Charles Rhyee with Cowen & Company.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co. ", "original_text": "And frankly, at the scale that we operate and buy being partnered with large -scaled healthy organizations that are \ncapable of continuity of supply and competitive pricing, it can be a good thing. ", "page_label": "18", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d406cdc0-bde8-4f77-904b-5510bc1d21f8", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "af9ca07d9269079ab120aa3b62cf2eda5667c442e9df8286debac86be8187b13", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "98b00137-4f5b-4bce-b67f-50d7b3fac616", "node_type": "1", "metadata": {"window": "So, thank \nyou for the question on the Pfizer -Mylan merger.  So I would start by saying that we have strong r elationships with \nboth of these organizations and they've been important partners for us at McKesson and in ClarusONE.  The \nrationale for the merger, as I understand it, is broadening of the portfolio.  There is some cost synergy, some \nefficiency.  \n \n And frankly, at the scale that we operate and buy being partnered with large -scaled healthy organizations that are \ncapable of continuity of supply and competitive pricing, it can be a good thing.  So we'll evaluate how this merger \ncomes together, we'll continue  to be in dialogue with them, but I wouldn't say that poses any imminent concerns \nfrom our perspective.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question will come from Charles Rhyee with Cowen & Company.  \n ", "original_text": "There is some cost synergy, some \nefficiency.  \n \n", "page_label": "18", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "45702193342af23d4946fd9e89095574b683059c4c6371f797293fea09c9a6f0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "daee053a-7133-4c3c-81f0-fcd840a45fd9", "node_type": "1", "metadata": {"window": "The \nrationale for the merger, as I understand it, is broadening of the portfolio.  There is some cost synergy, some \nefficiency.  \n \n And frankly, at the scale that we operate and buy being partnered with large -scaled healthy organizations that are \ncapable of continuity of supply and competitive pricing, it can be a good thing.  So we'll evaluate how this merger \ncomes together, we'll continue  to be in dialogue with them, but I wouldn't say that poses any imminent concerns \nfrom our perspective.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question will come from Charles Rhyee with Cowen & Company.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYeah. ", "original_text": "So we'll evaluate how this merger \ncomes together, we'll continue  to be in dialogue with them, but I wouldn't say that poses any imminent concerns \nfrom our perspective.  \n "}, "hash": "65b17b1cf9385a10f8c9d24709a6e7c36372ababf75eadbc8619b62316fd4d39", "class_name": "RelatedNodeInfo"}}, "text": "And frankly, at the scale that we operate and buy being partnered with large -scaled healthy organizations that are \ncapable of continuity of supply and competitive pricing, it can be a good thing. ", "start_char_idx": 2777, "end_char_idx": 2975, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "daee053a-7133-4c3c-81f0-fcd840a45fd9": {"__data__": {"id_": "daee053a-7133-4c3c-81f0-fcd840a45fd9", "embedding": null, "metadata": {"window": "The \nrationale for the merger, as I understand it, is broadening of the portfolio.  There is some cost synergy, some \nefficiency.  \n \n And frankly, at the scale that we operate and buy being partnered with large -scaled healthy organizations that are \ncapable of continuity of supply and competitive pricing, it can be a good thing.  So we'll evaluate how this merger \ncomes together, we'll continue  to be in dialogue with them, but I wouldn't say that poses any imminent concerns \nfrom our perspective.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question will come from Charles Rhyee with Cowen & Company.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYeah. ", "original_text": "So we'll evaluate how this merger \ncomes together, we'll continue  to be in dialogue with them, but I wouldn't say that poses any imminent concerns \nfrom our perspective.  \n ", "page_label": "18", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d406cdc0-bde8-4f77-904b-5510bc1d21f8", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "af9ca07d9269079ab120aa3b62cf2eda5667c442e9df8286debac86be8187b13", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a0f2260b-444e-4483-9bf5-d4f51456ae69", "node_type": "1", "metadata": {"window": "So I would start by saying that we have strong r elationships with \nboth of these organizations and they've been important partners for us at McKesson and in ClarusONE.  The \nrationale for the merger, as I understand it, is broadening of the portfolio.  There is some cost synergy, some \nefficiency.  \n \n And frankly, at the scale that we operate and buy being partnered with large -scaled healthy organizations that are \ncapable of continuity of supply and competitive pricing, it can be a good thing.  So we'll evaluate how this merger \ncomes together, we'll continue  to be in dialogue with them, but I wouldn't say that poses any imminent concerns \nfrom our perspective.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question will come from Charles Rhyee with Cowen & Company.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co. ", "original_text": "And frankly, at the scale that we operate and buy being partnered with large -scaled healthy organizations that are \ncapable of continuity of supply and competitive pricing, it can be a good thing. ", "page_label": "18", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "490831e6eb2b72ba58f3eff794429fa1db87e619cf1a5ebf3dc881d1b2ad3651", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "96257127-257b-4391-a024-7522c5ce6c74", "node_type": "1", "metadata": {"window": "There is some cost synergy, some \nefficiency.  \n \n And frankly, at the scale that we operate and buy being partnered with large -scaled healthy organizations that are \ncapable of continuity of supply and competitive pricing, it can be a good thing.  So we'll evaluate how this merger \ncomes together, we'll continue  to be in dialogue with them, but I wouldn't say that poses any imminent concerns \nfrom our perspective.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question will come from Charles Rhyee with Cowen & Company.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYeah.  Hey, thanks for taking the questions. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question will come from Charles Rhyee with Cowen & Company.  \n "}, "hash": "24e42271fe2288c70c07d413c1f7ca383ea62f16a2b679ce84a20b8d543d945b", "class_name": "RelatedNodeInfo"}}, "text": "So we'll evaluate how this merger \ncomes together, we'll continue  to be in dialogue with them, but I wouldn't say that poses any imminent concerns \nfrom our perspective.  \n ", "start_char_idx": 2975, "end_char_idx": 3149, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "96257127-257b-4391-a024-7522c5ce6c74": {"__data__": {"id_": "96257127-257b-4391-a024-7522c5ce6c74", "embedding": null, "metadata": {"window": "There is some cost synergy, some \nefficiency.  \n \n And frankly, at the scale that we operate and buy being partnered with large -scaled healthy organizations that are \ncapable of continuity of supply and competitive pricing, it can be a good thing.  So we'll evaluate how this merger \ncomes together, we'll continue  to be in dialogue with them, but I wouldn't say that poses any imminent concerns \nfrom our perspective.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question will come from Charles Rhyee with Cowen & Company.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYeah.  Hey, thanks for taking the questions. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question will come from Charles Rhyee with Cowen & Company.  \n ", "page_label": "18", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d406cdc0-bde8-4f77-904b-5510bc1d21f8", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "af9ca07d9269079ab120aa3b62cf2eda5667c442e9df8286debac86be8187b13", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "daee053a-7133-4c3c-81f0-fcd840a45fd9", "node_type": "1", "metadata": {"window": "The \nrationale for the merger, as I understand it, is broadening of the portfolio.  There is some cost synergy, some \nefficiency.  \n \n And frankly, at the scale that we operate and buy being partnered with large -scaled healthy organizations that are \ncapable of continuity of supply and competitive pricing, it can be a good thing.  So we'll evaluate how this merger \ncomes together, we'll continue  to be in dialogue with them, but I wouldn't say that poses any imminent concerns \nfrom our perspective.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question will come from Charles Rhyee with Cowen & Company.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYeah. ", "original_text": "So we'll evaluate how this merger \ncomes together, we'll continue  to be in dialogue with them, but I wouldn't say that poses any imminent concerns \nfrom our perspective.  \n ", "page_label": "18", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "382816af1fc2b0437806915776699be375fdd19cbbbebd21d24219653396f466", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "501e0a88-3086-4a8b-a791-db9c7bddaee2", "node_type": "1", "metadata": {"window": "And frankly, at the scale that we operate and buy being partnered with large -scaled healthy organizations that are \ncapable of continuity of supply and competitive pricing, it can be a good thing.  So we'll evaluate how this merger \ncomes together, we'll continue  to be in dialogue with them, but I wouldn't say that poses any imminent concerns \nfrom our perspective.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question will come from Charles Rhyee with Cowen & Company.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYeah.  Hey, thanks for taking the questions.  I think you touched on biosimilars being a benefit particularly in the \noncology network. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co. "}, "hash": "ae75ad25d918bb89bdb127d3e6abcb8771b181e097e5adefc71855bd2d1c975b", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question will come from Charles Rhyee with Cowen & Company.  \n ", "start_char_idx": 3149, "end_char_idx": 3495, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "501e0a88-3086-4a8b-a791-db9c7bddaee2": {"__data__": {"id_": "501e0a88-3086-4a8b-a791-db9c7bddaee2", "embedding": null, "metadata": {"window": "And frankly, at the scale that we operate and buy being partnered with large -scaled healthy organizations that are \ncapable of continuity of supply and competitive pricing, it can be a good thing.  So we'll evaluate how this merger \ncomes together, we'll continue  to be in dialogue with them, but I wouldn't say that poses any imminent concerns \nfrom our perspective.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question will come from Charles Rhyee with Cowen & Company.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYeah.  Hey, thanks for taking the questions.  I think you touched on biosimilars being a benefit particularly in the \noncology network. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co. ", "page_label": "18", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d406cdc0-bde8-4f77-904b-5510bc1d21f8", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "af9ca07d9269079ab120aa3b62cf2eda5667c442e9df8286debac86be8187b13", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "96257127-257b-4391-a024-7522c5ce6c74", "node_type": "1", "metadata": {"window": "There is some cost synergy, some \nefficiency.  \n \n And frankly, at the scale that we operate and buy being partnered with large -scaled healthy organizations that are \ncapable of continuity of supply and competitive pricing, it can be a good thing.  So we'll evaluate how this merger \ncomes together, we'll continue  to be in dialogue with them, but I wouldn't say that poses any imminent concerns \nfrom our perspective.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question will come from Charles Rhyee with Cowen & Company.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYeah.  Hey, thanks for taking the questions. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question will come from Charles Rhyee with Cowen & Company.  \n ", "page_label": "18", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "deff427b314f5492820cefd6dd3dd6b4854bb7db2da2104716b610f456859a5e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "652c074b-36e9-4cf9-9931-248533306276", "node_type": "1", "metadata": {"window": "So we'll evaluate how this merger \ncomes together, we'll continue  to be in dialogue with them, but I wouldn't say that poses any imminent concerns \nfrom our perspective.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question will come from Charles Rhyee with Cowen & Company.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYeah.  Hey, thanks for taking the questions.  I think you touched on biosimilars being a benefit particularly in the \noncology network.  Can you talk about sort of your outlook here? ", "original_text": "LLC  Q \nYeah. "}, "hash": "af802d2012dd75bc5faaebea8e829cfd71eba7c8cb5b80ac1250310257b04f05", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co. ", "start_char_idx": 3495, "end_char_idx": 3789, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "652c074b-36e9-4cf9-9931-248533306276": {"__data__": {"id_": "652c074b-36e9-4cf9-9931-248533306276", "embedding": null, "metadata": {"window": "So we'll evaluate how this merger \ncomes together, we'll continue  to be in dialogue with them, but I wouldn't say that poses any imminent concerns \nfrom our perspective.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question will come from Charles Rhyee with Cowen & Company.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYeah.  Hey, thanks for taking the questions.  I think you touched on biosimilars being a benefit particularly in the \noncology network.  Can you talk about sort of your outlook here? ", "original_text": "LLC  Q \nYeah. ", "page_label": "18", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d406cdc0-bde8-4f77-904b-5510bc1d21f8", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "af9ca07d9269079ab120aa3b62cf2eda5667c442e9df8286debac86be8187b13", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "501e0a88-3086-4a8b-a791-db9c7bddaee2", "node_type": "1", "metadata": {"window": "And frankly, at the scale that we operate and buy being partnered with large -scaled healthy organizations that are \ncapable of continuity of supply and competitive pricing, it can be a good thing.  So we'll evaluate how this merger \ncomes together, we'll continue  to be in dialogue with them, but I wouldn't say that poses any imminent concerns \nfrom our perspective.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question will come from Charles Rhyee with Cowen & Company.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYeah.  Hey, thanks for taking the questions.  I think you touched on biosimilars being a benefit particularly in the \noncology network. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co. ", "page_label": "18", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d08040d40be4e731b3abadf3c125fd03e2b9fb60cc5fb0903e98ef44af3219ea", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c25aa8aa-6965-4891-98f3-0d96c997d38c", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question will come from Charles Rhyee with Cowen & Company.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYeah.  Hey, thanks for taking the questions.  I think you touched on biosimilars being a benefit particularly in the \noncology network.  Can you talk about sort of your outlook here?  I think there's some talks about I think insulin \nmoving over to jurisdiction by, I guess, [ph] the biologics group in FDA, SBIR (00:56:07) and that could pave the \nway for interchangeability at least with biosimilar insulin. ", "original_text": "Hey, thanks for taking the questions. "}, "hash": "5cdc4bd223a981f2c32dc2c920b2d8a223390a0749f9ca573035e5253a5f0201", "class_name": "RelatedNodeInfo"}}, "text": "LLC  Q \nYeah. ", "start_char_idx": 3789, "end_char_idx": 3803, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c25aa8aa-6965-4891-98f3-0d96c997d38c": {"__data__": {"id_": "c25aa8aa-6965-4891-98f3-0d96c997d38c", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question will come from Charles Rhyee with Cowen & Company.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYeah.  Hey, thanks for taking the questions.  I think you touched on biosimilars being a benefit particularly in the \noncology network.  Can you talk about sort of your outlook here?  I think there's some talks about I think insulin \nmoving over to jurisdiction by, I guess, [ph] the biologics group in FDA, SBIR (00:56:07) and that could pave the \nway for interchangeability at least with biosimilar insulin. ", "original_text": "Hey, thanks for taking the questions. ", "page_label": "18", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d406cdc0-bde8-4f77-904b-5510bc1d21f8", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "af9ca07d9269079ab120aa3b62cf2eda5667c442e9df8286debac86be8187b13", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "652c074b-36e9-4cf9-9931-248533306276", "node_type": "1", "metadata": {"window": "So we'll evaluate how this merger \ncomes together, we'll continue  to be in dialogue with them, but I wouldn't say that poses any imminent concerns \nfrom our perspective.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question will come from Charles Rhyee with Cowen & Company.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYeah.  Hey, thanks for taking the questions.  I think you touched on biosimilars being a benefit particularly in the \noncology network.  Can you talk about sort of your outlook here? ", "original_text": "LLC  Q \nYeah. ", "page_label": "18", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "96d2f0f160cf4881ffa5add1592051e63923611d76691132e3501811411a1ff9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ac7a77ff-c73d-4168-aa7c-5b2b7f0782f6", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYeah.  Hey, thanks for taking the questions.  I think you touched on biosimilars being a benefit particularly in the \noncology network.  Can you talk about sort of your outlook here?  I think there's some talks about I think insulin \nmoving over to jurisdiction by, I guess, [ph] the biologics group in FDA, SBIR (00:56:07) and that could pave the \nway for interchangeability at least with biosimilar insulin.  Maybe your thoughts on where you're seeing sort of that \nregulatory landscape right now? ", "original_text": "I think you touched on biosimilars being a benefit particularly in the \noncology network. "}, "hash": "6f9f60c67931491b92ae505cfb206f7eb6b4414d1fc4ffde9af638db7c1b6889", "class_name": "RelatedNodeInfo"}}, "text": "Hey, thanks for taking the questions. ", "start_char_idx": 3803, "end_char_idx": 3841, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ac7a77ff-c73d-4168-aa7c-5b2b7f0782f6": {"__data__": {"id_": "ac7a77ff-c73d-4168-aa7c-5b2b7f0782f6", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYeah.  Hey, thanks for taking the questions.  I think you touched on biosimilars being a benefit particularly in the \noncology network.  Can you talk about sort of your outlook here?  I think there's some talks about I think insulin \nmoving over to jurisdiction by, I guess, [ph] the biologics group in FDA, SBIR (00:56:07) and that could pave the \nway for interchangeability at least with biosimilar insulin.  Maybe your thoughts on where you're seeing sort of that \nregulatory landscape right now? ", "original_text": "I think you touched on biosimilars being a benefit particularly in the \noncology network. ", "page_label": "18", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d406cdc0-bde8-4f77-904b-5510bc1d21f8", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "af9ca07d9269079ab120aa3b62cf2eda5667c442e9df8286debac86be8187b13", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c25aa8aa-6965-4891-98f3-0d96c997d38c", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : And our next question will come from Charles Rhyee with Cowen & Company.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYeah.  Hey, thanks for taking the questions.  I think you touched on biosimilars being a benefit particularly in the \noncology network.  Can you talk about sort of your outlook here?  I think there's some talks about I think insulin \nmoving over to jurisdiction by, I guess, [ph] the biologics group in FDA, SBIR (00:56:07) and that could pave the \nway for interchangeability at least with biosimilar insulin. ", "original_text": "Hey, thanks for taking the questions. ", "page_label": "18", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "34761e820bf8e7267304e66fad362717e230eb4d62b83c8d3587c44d8f266e25", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "43a9d434-b077-4977-886c-d2040252d3a7", "node_type": "1", "metadata": {"window": "LLC  Q \nYeah.  Hey, thanks for taking the questions.  I think you touched on biosimilars being a benefit particularly in the \noncology network.  Can you talk about sort of your outlook here?  I think there's some talks about I think insulin \nmoving over to jurisdiction by, I guess, [ph] the biologics group in FDA, SBIR (00:56:07) and that could pave the \nway for interchangeability at least with biosimilar insulin.  Maybe your thoughts on where you're seeing sort of that \nregulatory landscape right now?  And how you think about that opportunity an d what it means further down the \nroad for you?  \n ", "original_text": "Can you talk about sort of your outlook here? "}, "hash": "5cece10ce55d9371ab42b235ac81ece3a9c992178c8563c65f609654c5913f66", "class_name": "RelatedNodeInfo"}}, "text": "I think you touched on biosimilars being a benefit particularly in the \noncology network. ", "start_char_idx": 3841, "end_char_idx": 3931, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "43a9d434-b077-4977-886c-d2040252d3a7": {"__data__": {"id_": "43a9d434-b077-4977-886c-d2040252d3a7", "embedding": null, "metadata": {"window": "LLC  Q \nYeah.  Hey, thanks for taking the questions.  I think you touched on biosimilars being a benefit particularly in the \noncology network.  Can you talk about sort of your outlook here?  I think there's some talks about I think insulin \nmoving over to jurisdiction by, I guess, [ph] the biologics group in FDA, SBIR (00:56:07) and that could pave the \nway for interchangeability at least with biosimilar insulin.  Maybe your thoughts on where you're seeing sort of that \nregulatory landscape right now?  And how you think about that opportunity an d what it means further down the \nroad for you?  \n ", "original_text": "Can you talk about sort of your outlook here? ", "page_label": "18", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d406cdc0-bde8-4f77-904b-5510bc1d21f8", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "af9ca07d9269079ab120aa3b62cf2eda5667c442e9df8286debac86be8187b13", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ac7a77ff-c73d-4168-aa7c-5b2b7f0782f6", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYeah.  Hey, thanks for taking the questions.  I think you touched on biosimilars being a benefit particularly in the \noncology network.  Can you talk about sort of your outlook here?  I think there's some talks about I think insulin \nmoving over to jurisdiction by, I guess, [ph] the biologics group in FDA, SBIR (00:56:07) and that could pave the \nway for interchangeability at least with biosimilar insulin.  Maybe your thoughts on where you're seeing sort of that \nregulatory landscape right now? ", "original_text": "I think you touched on biosimilars being a benefit particularly in the \noncology network. ", "page_label": "18", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "881de8bac3f48c3020dc235efe55bf1a3135a829cc9c65c5d01e2a254739b701", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "318cca3b-37e7-4b48-ad77-bf4a2e9772e5", "node_type": "1", "metadata": {"window": "Hey, thanks for taking the questions.  I think you touched on biosimilars being a benefit particularly in the \noncology network.  Can you talk about sort of your outlook here?  I think there's some talks about I think insulin \nmoving over to jurisdiction by, I guess, [ph] the biologics group in FDA, SBIR (00:56:07) and that could pave the \nway for interchangeability at least with biosimilar insulin.  Maybe your thoughts on where you're seeing sort of that \nregulatory landscape right now?  And how you think about that opportunity an d what it means further down the \nroad for you?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "I think there's some talks about I think insulin \nmoving over to jurisdiction by, I guess, [ph] the biologics group in FDA, SBIR (00:56:07) and that could pave the \nway for interchangeability at least with biosimilar insulin. "}, "hash": "7b31debe11ec58a6709b79b1b9330a30d92820d0b8fea7b3495a73a9246dddc5", "class_name": "RelatedNodeInfo"}}, "text": "Can you talk about sort of your outlook here? ", "start_char_idx": 3931, "end_char_idx": 3977, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "318cca3b-37e7-4b48-ad77-bf4a2e9772e5": {"__data__": {"id_": "318cca3b-37e7-4b48-ad77-bf4a2e9772e5", "embedding": null, "metadata": {"window": "Hey, thanks for taking the questions.  I think you touched on biosimilars being a benefit particularly in the \noncology network.  Can you talk about sort of your outlook here?  I think there's some talks about I think insulin \nmoving over to jurisdiction by, I guess, [ph] the biologics group in FDA, SBIR (00:56:07) and that could pave the \nway for interchangeability at least with biosimilar insulin.  Maybe your thoughts on where you're seeing sort of that \nregulatory landscape right now?  And how you think about that opportunity an d what it means further down the \nroad for you?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "I think there's some talks about I think insulin \nmoving over to jurisdiction by, I guess, [ph] the biologics group in FDA, SBIR (00:56:07) and that could pave the \nway for interchangeability at least with biosimilar insulin. ", "page_label": "18", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d406cdc0-bde8-4f77-904b-5510bc1d21f8", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "af9ca07d9269079ab120aa3b62cf2eda5667c442e9df8286debac86be8187b13", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "43a9d434-b077-4977-886c-d2040252d3a7", "node_type": "1", "metadata": {"window": "LLC  Q \nYeah.  Hey, thanks for taking the questions.  I think you touched on biosimilars being a benefit particularly in the \noncology network.  Can you talk about sort of your outlook here?  I think there's some talks about I think insulin \nmoving over to jurisdiction by, I guess, [ph] the biologics group in FDA, SBIR (00:56:07) and that could pave the \nway for interchangeability at least with biosimilar insulin.  Maybe your thoughts on where you're seeing sort of that \nregulatory landscape right now?  And how you think about that opportunity an d what it means further down the \nroad for you?  \n ", "original_text": "Can you talk about sort of your outlook here? ", "page_label": "18", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "022685a556311237d1a2522c0b734be18d54838d4bfeee48ff18c3ca78c8df64", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a9f51504-9e66-4fc0-ad92-b41f33afb706", "node_type": "1", "metadata": {"window": "I think you touched on biosimilars being a benefit particularly in the \noncology network.  Can you talk about sort of your outlook here?  I think there's some talks about I think insulin \nmoving over to jurisdiction by, I guess, [ph] the biologics group in FDA, SBIR (00:56:07) and that could pave the \nway for interchangeability at least with biosimilar insulin.  Maybe your thoughts on where you're seeing sort of that \nregulatory landscape right now?  And how you think about that opportunity an d what it means further down the \nroad for you?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A ", "original_text": "Maybe your thoughts on where you're seeing sort of that \nregulatory landscape right now? "}, "hash": "9f056a263c13eabae40da8b8f3a4b2ff3b59cd69c46e91d6ac2547e7a00d5d84", "class_name": "RelatedNodeInfo"}}, "text": "I think there's some talks about I think insulin \nmoving over to jurisdiction by, I guess, [ph] the biologics group in FDA, SBIR (00:56:07) and that could pave the \nway for interchangeability at least with biosimilar insulin. ", "start_char_idx": 3977, "end_char_idx": 4203, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a9f51504-9e66-4fc0-ad92-b41f33afb706": {"__data__": {"id_": "a9f51504-9e66-4fc0-ad92-b41f33afb706", "embedding": null, "metadata": {"window": "I think you touched on biosimilars being a benefit particularly in the \noncology network.  Can you talk about sort of your outlook here?  I think there's some talks about I think insulin \nmoving over to jurisdiction by, I guess, [ph] the biologics group in FDA, SBIR (00:56:07) and that could pave the \nway for interchangeability at least with biosimilar insulin.  Maybe your thoughts on where you're seeing sort of that \nregulatory landscape right now?  And how you think about that opportunity an d what it means further down the \nroad for you?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A ", "original_text": "Maybe your thoughts on where you're seeing sort of that \nregulatory landscape right now? ", "page_label": "18", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d406cdc0-bde8-4f77-904b-5510bc1d21f8", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "af9ca07d9269079ab120aa3b62cf2eda5667c442e9df8286debac86be8187b13", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "318cca3b-37e7-4b48-ad77-bf4a2e9772e5", "node_type": "1", "metadata": {"window": "Hey, thanks for taking the questions.  I think you touched on biosimilars being a benefit particularly in the \noncology network.  Can you talk about sort of your outlook here?  I think there's some talks about I think insulin \nmoving over to jurisdiction by, I guess, [ph] the biologics group in FDA, SBIR (00:56:07) and that could pave the \nway for interchangeability at least with biosimilar insulin.  Maybe your thoughts on where you're seeing sort of that \nregulatory landscape right now?  And how you think about that opportunity an d what it means further down the \nroad for you?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "I think there's some talks about I think insulin \nmoving over to jurisdiction by, I guess, [ph] the biologics group in FDA, SBIR (00:56:07) and that could pave the \nway for interchangeability at least with biosimilar insulin. ", "page_label": "18", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d9ffb93a18c373617642b402067f1e83d5543429f943dfd6c1063b415ed834fb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a03e4187-ae42-434a-8736-8948872a688a", "node_type": "1", "metadata": {"window": "Can you talk about sort of your outlook here?  I think there's some talks about I think insulin \nmoving over to jurisdiction by, I guess, [ph] the biologics group in FDA, SBIR (00:56:07) and that could pave the \nway for interchangeability at least with biosimilar insulin.  Maybe your thoughts on where you're seeing sort of that \nregulatory landscape right now?  And how you think about that opportunity an d what it means further down the \nroad for you?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A ", "original_text": "And how you think about that opportunity an d what it means further down the \nroad for you?  \n "}, "hash": "ee168f7afde9f720ca75e01c6622d62bbb1c064418d7efb9a6c5860e534d63f4", "class_name": "RelatedNodeInfo"}}, "text": "Maybe your thoughts on where you're seeing sort of that \nregulatory landscape right now? ", "start_char_idx": 4203, "end_char_idx": 4292, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a03e4187-ae42-434a-8736-8948872a688a": {"__data__": {"id_": "a03e4187-ae42-434a-8736-8948872a688a", "embedding": null, "metadata": {"window": "Can you talk about sort of your outlook here?  I think there's some talks about I think insulin \nmoving over to jurisdiction by, I guess, [ph] the biologics group in FDA, SBIR (00:56:07) and that could pave the \nway for interchangeability at least with biosimilar insulin.  Maybe your thoughts on where you're seeing sort of that \nregulatory landscape right now?  And how you think about that opportunity an d what it means further down the \nroad for you?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A ", "original_text": "And how you think about that opportunity an d what it means further down the \nroad for you?  \n ", "page_label": "18", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d406cdc0-bde8-4f77-904b-5510bc1d21f8", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "af9ca07d9269079ab120aa3b62cf2eda5667c442e9df8286debac86be8187b13", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a9f51504-9e66-4fc0-ad92-b41f33afb706", "node_type": "1", "metadata": {"window": "I think you touched on biosimilars being a benefit particularly in the \noncology network.  Can you talk about sort of your outlook here?  I think there's some talks about I think insulin \nmoving over to jurisdiction by, I guess, [ph] the biologics group in FDA, SBIR (00:56:07) and that could pave the \nway for interchangeability at least with biosimilar insulin.  Maybe your thoughts on where you're seeing sort of that \nregulatory landscape right now?  And how you think about that opportunity an d what it means further down the \nroad for you?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A ", "original_text": "Maybe your thoughts on where you're seeing sort of that \nregulatory landscape right now? ", "page_label": "18", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c1b0a5f87951cd2f197f1f5b3f63365f5d139537e46dd38286933537d0cba8f0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "624dda82-1e27-4b54-9c0d-4dd1aefd05e0", "node_type": "1", "metadata": {"window": "I think there's some talks about I think insulin \nmoving over to jurisdiction by, I guess, [ph] the biologics group in FDA, SBIR (00:56:07) and that could pave the \nway for interchangeability at least with biosimilar insulin.  Maybe your thoughts on where you're seeing sort of that \nregulatory landscape right now?  And how you think about that opportunity an d what it means further down the \nroad for you?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  "}, "hash": "5bd1067b71bb825adac2a0796e3a76615dab0a5f0334f8a79a2c639fd6a01711", "class_name": "RelatedNodeInfo"}}, "text": "And how you think about that opportunity an d what it means further down the \nroad for you?  \n ", "start_char_idx": 4292, "end_char_idx": 4387, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "624dda82-1e27-4b54-9c0d-4dd1aefd05e0": {"__data__": {"id_": "624dda82-1e27-4b54-9c0d-4dd1aefd05e0", "embedding": null, "metadata": {"window": "I think there's some talks about I think insulin \nmoving over to jurisdiction by, I guess, [ph] the biologics group in FDA, SBIR (00:56:07) and that could pave the \nway for interchangeability at least with biosimilar insulin.  Maybe your thoughts on where you're seeing sort of that \nregulatory landscape right now?  And how you think about that opportunity an d what it means further down the \nroad for you?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "18", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d406cdc0-bde8-4f77-904b-5510bc1d21f8", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "af9ca07d9269079ab120aa3b62cf2eda5667c442e9df8286debac86be8187b13", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a03e4187-ae42-434a-8736-8948872a688a", "node_type": "1", "metadata": {"window": "Can you talk about sort of your outlook here?  I think there's some talks about I think insulin \nmoving over to jurisdiction by, I guess, [ph] the biologics group in FDA, SBIR (00:56:07) and that could pave the \nway for interchangeability at least with biosimilar insulin.  Maybe your thoughts on where you're seeing sort of that \nregulatory landscape right now?  And how you think about that opportunity an d what it means further down the \nroad for you?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A ", "original_text": "And how you think about that opportunity an d what it means further down the \nroad for you?  \n ", "page_label": "18", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e4952ecb4fbf227651c638b2ac053e8a91fbb37ecb99b098dcabbcdb4aaaa01b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "73093fe2-1271-4446-a4ae-d99bed48571f", "node_type": "1", "metadata": {"window": "Maybe your thoughts on where you're seeing sort of that \nregulatory landscape right now?  And how you think about that opportunity an d what it means further down the \nroad for you?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A ", "original_text": "A "}, "hash": "de6f08d856fca2f21caa0087ff4c89448510e9d56b591f2746849252aad42696", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "start_char_idx": 4387, "end_char_idx": 4716, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "73093fe2-1271-4446-a4ae-d99bed48571f": {"__data__": {"id_": "73093fe2-1271-4446-a4ae-d99bed48571f", "embedding": null, "metadata": {"window": "Maybe your thoughts on where you're seeing sort of that \nregulatory landscape right now?  And how you think about that opportunity an d what it means further down the \nroad for you?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A ", "original_text": "A ", "page_label": "18", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d406cdc0-bde8-4f77-904b-5510bc1d21f8", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "af9ca07d9269079ab120aa3b62cf2eda5667c442e9df8286debac86be8187b13", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "624dda82-1e27-4b54-9c0d-4dd1aefd05e0", "node_type": "1", "metadata": {"window": "I think there's some talks about I think insulin \nmoving over to jurisdiction by, I guess, [ph] the biologics group in FDA, SBIR (00:56:07) and that could pave the \nway for interchangeability at least with biosimilar insulin.  Maybe your thoughts on where you're seeing sort of that \nregulatory landscape right now?  And how you think about that opportunity an d what it means further down the \nroad for you?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "18", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "14d9471c5a9b8a6722000684fc065265468cd72671f4d1232edfcb3f59ef53ed", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7c96dbb1-dad0-47ad-84cc-6de297d4840b", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nWell, I mean, the biosimilar landscape in general, we feel pretty positive about.  More choices, more substitutability \nor interchangeabi lity.  That gives clinicians more choices, hopefully it gives. ", "original_text": "McKesson Corp.  "}, "hash": "dde8935dcb1388af5db6006ff5a5f9bc07e40251abd0c8748c369aef3a8208d1", "class_name": "RelatedNodeInfo"}}, "text": "A ", "start_char_idx": 835, "end_char_idx": 837, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7c96dbb1-dad0-47ad-84cc-6de297d4840b": {"__data__": {"id_": "7c96dbb1-dad0-47ad-84cc-6de297d4840b", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nWell, I mean, the biosimilar landscape in general, we feel pretty positive about.  More choices, more substitutability \nor interchangeabi lity.  That gives clinicians more choices, hopefully it gives. ", "original_text": "McKesson Corp.  ", "page_label": "19", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9a5a1cb5-b0d2-459d-9254-d18b99cabab3", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6a841e5456e63a5311a6369d25f04a4e227304d818d637e1167905fecde357d2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "73093fe2-1271-4446-a4ae-d99bed48571f", "node_type": "1", "metadata": {"window": "Maybe your thoughts on where you're seeing sort of that \nregulatory landscape right now?  And how you think about that opportunity an d what it means further down the \nroad for you?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A ", "original_text": "A ", "page_label": "18", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f74240767d9cc1ba3891ab64c68c2c9b5d35e167c389066bdceb7eb072d65ac9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7b454d5e-1cde-47e5-89e7-34e919163ee0", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nWell, I mean, the biosimilar landscape in general, we feel pretty positive about.  More choices, more substitutability \nor interchangeabi lity.  That gives clinicians more choices, hopefully it gives.  It helps address the cost challenges \nthat we see in the marketplace. ", "original_text": "(MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nWell, I mean, the biosimilar landscape in general, we feel pretty positive about. "}, "hash": "faf8dbcffaa08b113a789273466617f1d37d485cf01a9559c5b0d643c91a143b", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7b454d5e-1cde-47e5-89e7-34e919163ee0": {"__data__": {"id_": "7b454d5e-1cde-47e5-89e7-34e919163ee0", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nWell, I mean, the biosimilar landscape in general, we feel pretty positive about.  More choices, more substitutability \nor interchangeabi lity.  That gives clinicians more choices, hopefully it gives.  It helps address the cost challenges \nthat we see in the marketplace. ", "original_text": "(MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nWell, I mean, the biosimilar landscape in general, we feel pretty positive about. ", "page_label": "19", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9a5a1cb5-b0d2-459d-9254-d18b99cabab3", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6a841e5456e63a5311a6369d25f04a4e227304d818d637e1167905fecde357d2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7c96dbb1-dad0-47ad-84cc-6de297d4840b", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nWell, I mean, the biosimilar landscape in general, we feel pretty positive about.  More choices, more substitutability \nor interchangeabi lity.  That gives clinicians more choices, hopefully it gives. ", "original_text": "McKesson Corp.  ", "page_label": "19", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bb881c7eaa1aa605ab615b70eabbb8677dd81eae2be4254e58bb059fc1e70070", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "625e44a9-64f2-46df-b23a-013fbe57b56a", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nWell, I mean, the biosimilar landscape in general, we feel pretty positive about.  More choices, more substitutability \nor interchangeabi lity.  That gives clinicians more choices, hopefully it gives.  It helps address the cost challenges \nthat we see in the marketplace.  And we think with the footprint of providers that we have in the community, we're \nparticularly well -positioned to take advant age of those trends. ", "original_text": "More choices, more substitutability \nor interchangeabi lity. "}, "hash": "b3ecd163ea3d91afa9d41b006eed38afb37f3eba1cb0d279c646163d8ce60f83", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nWell, I mean, the biosimilar landscape in general, we feel pretty positive about. ", "start_char_idx": 16, "end_char_idx": 263, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "625e44a9-64f2-46df-b23a-013fbe57b56a": {"__data__": {"id_": "625e44a9-64f2-46df-b23a-013fbe57b56a", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nWell, I mean, the biosimilar landscape in general, we feel pretty positive about.  More choices, more substitutability \nor interchangeabi lity.  That gives clinicians more choices, hopefully it gives.  It helps address the cost challenges \nthat we see in the marketplace.  And we think with the footprint of providers that we have in the community, we're \nparticularly well -positioned to take advant age of those trends. ", "original_text": "More choices, more substitutability \nor interchangeabi lity. ", "page_label": "19", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9a5a1cb5-b0d2-459d-9254-d18b99cabab3", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6a841e5456e63a5311a6369d25f04a4e227304d818d637e1167905fecde357d2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7b454d5e-1cde-47e5-89e7-34e919163ee0", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nWell, I mean, the biosimilar landscape in general, we feel pretty positive about.  More choices, more substitutability \nor interchangeabi lity.  That gives clinicians more choices, hopefully it gives.  It helps address the cost challenges \nthat we see in the marketplace. ", "original_text": "(MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nWell, I mean, the biosimilar landscape in general, we feel pretty positive about. ", "page_label": "19", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "53b4cc80cabb016867ffcc119da16ac4bd4e4949f7b2aaf05044d0c0954d3138", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "322abead-569f-4c26-adcf-b8efd18acf7c", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nWell, I mean, the biosimilar landscape in general, we feel pretty positive about.  More choices, more substitutability \nor interchangeabi lity.  That gives clinicians more choices, hopefully it gives.  It helps address the cost challenges \nthat we see in the marketplace.  And we think with the footprint of providers that we have in the community, we're \nparticularly well -positioned to take advant age of those trends.  So, we also continue to work with innovators.  \n \n", "original_text": "That gives clinicians more choices, hopefully it gives. "}, "hash": "0c04d7ce21197d49fa0a1f623af4f069b1f94472dda95fd293436422060d933b", "class_name": "RelatedNodeInfo"}}, "text": "More choices, more substitutability \nor interchangeabi lity. ", "start_char_idx": 263, "end_char_idx": 324, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "322abead-569f-4c26-adcf-b8efd18acf7c": {"__data__": {"id_": "322abead-569f-4c26-adcf-b8efd18acf7c", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nWell, I mean, the biosimilar landscape in general, we feel pretty positive about.  More choices, more substitutability \nor interchangeabi lity.  That gives clinicians more choices, hopefully it gives.  It helps address the cost challenges \nthat we see in the marketplace.  And we think with the footprint of providers that we have in the community, we're \nparticularly well -positioned to take advant age of those trends.  So, we also continue to work with innovators.  \n \n", "original_text": "That gives clinicians more choices, hopefully it gives. ", "page_label": "19", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9a5a1cb5-b0d2-459d-9254-d18b99cabab3", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6a841e5456e63a5311a6369d25f04a4e227304d818d637e1167905fecde357d2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "625e44a9-64f2-46df-b23a-013fbe57b56a", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nWell, I mean, the biosimilar landscape in general, we feel pretty positive about.  More choices, more substitutability \nor interchangeabi lity.  That gives clinicians more choices, hopefully it gives.  It helps address the cost challenges \nthat we see in the marketplace.  And we think with the footprint of providers that we have in the community, we're \nparticularly well -positioned to take advant age of those trends. ", "original_text": "More choices, more substitutability \nor interchangeabi lity. ", "page_label": "19", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b400ec57e14de0fe798309981090c7fc11568744136d3f41edb2924c3667077f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bce2c15e-230b-45ff-bbe4-b9ffac198a03", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nWell, I mean, the biosimilar landscape in general, we feel pretty positive about.  More choices, more substitutability \nor interchangeabi lity.  That gives clinicians more choices, hopefully it gives.  It helps address the cost challenges \nthat we see in the marketplace.  And we think with the footprint of providers that we have in the community, we're \nparticularly well -positioned to take advant age of those trends.  So, we also continue to work with innovators.  \n \n First and foremost, as we think about these, it's a patient outcome. ", "original_text": "It helps address the cost challenges \nthat we see in the marketplace. "}, "hash": "56aa718ffd8dbe20227a32f5960d005a838d6a524f09fbb8313a7c8707b7982c", "class_name": "RelatedNodeInfo"}}, "text": "That gives clinicians more choices, hopefully it gives. ", "start_char_idx": 324, "end_char_idx": 380, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bce2c15e-230b-45ff-bbe4-b9ffac198a03": {"__data__": {"id_": "bce2c15e-230b-45ff-bbe4-b9ffac198a03", "embedding": null, "metadata": {"window": "(MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nWell, I mean, the biosimilar landscape in general, we feel pretty positive about.  More choices, more substitutability \nor interchangeabi lity.  That gives clinicians more choices, hopefully it gives.  It helps address the cost challenges \nthat we see in the marketplace.  And we think with the footprint of providers that we have in the community, we're \nparticularly well -positioned to take advant age of those trends.  So, we also continue to work with innovators.  \n \n First and foremost, as we think about these, it's a patient outcome. ", "original_text": "It helps address the cost challenges \nthat we see in the marketplace. ", "page_label": "19", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9a5a1cb5-b0d2-459d-9254-d18b99cabab3", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6a841e5456e63a5311a6369d25f04a4e227304d818d637e1167905fecde357d2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "322abead-569f-4c26-adcf-b8efd18acf7c", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nWell, I mean, the biosimilar landscape in general, we feel pretty positive about.  More choices, more substitutability \nor interchangeabi lity.  That gives clinicians more choices, hopefully it gives.  It helps address the cost challenges \nthat we see in the marketplace.  And we think with the footprint of providers that we have in the community, we're \nparticularly well -positioned to take advant age of those trends.  So, we also continue to work with innovators.  \n \n", "original_text": "That gives clinicians more choices, hopefully it gives. ", "page_label": "19", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6f929ee7296224fed2dd24a00eba3f22ff0bfdf3081f68d5df130e9264a2c22c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "89c21bba-0ba3-4484-ab43-d7a0a5973721", "node_type": "1", "metadata": {"window": "More choices, more substitutability \nor interchangeabi lity.  That gives clinicians more choices, hopefully it gives.  It helps address the cost challenges \nthat we see in the marketplace.  And we think with the footprint of providers that we have in the community, we're \nparticularly well -positioned to take advant age of those trends.  So, we also continue to work with innovators.  \n \n First and foremost, as we think about these, it's a patient outcome.  It's a clinical -oriented decision. ", "original_text": "And we think with the footprint of providers that we have in the community, we're \nparticularly well -positioned to take advant age of those trends. "}, "hash": "3fd44b58b44b7047116ea72a176bdd352fbffaf68bc26d25cb925868538a7e16", "class_name": "RelatedNodeInfo"}}, "text": "It helps address the cost challenges \nthat we see in the marketplace. ", "start_char_idx": 380, "end_char_idx": 450, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "89c21bba-0ba3-4484-ab43-d7a0a5973721": {"__data__": {"id_": "89c21bba-0ba3-4484-ab43-d7a0a5973721", "embedding": null, "metadata": {"window": "More choices, more substitutability \nor interchangeabi lity.  That gives clinicians more choices, hopefully it gives.  It helps address the cost challenges \nthat we see in the marketplace.  And we think with the footprint of providers that we have in the community, we're \nparticularly well -positioned to take advant age of those trends.  So, we also continue to work with innovators.  \n \n First and foremost, as we think about these, it's a patient outcome.  It's a clinical -oriented decision. ", "original_text": "And we think with the footprint of providers that we have in the community, we're \nparticularly well -positioned to take advant age of those trends. ", "page_label": "19", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9a5a1cb5-b0d2-459d-9254-d18b99cabab3", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6a841e5456e63a5311a6369d25f04a4e227304d818d637e1167905fecde357d2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bce2c15e-230b-45ff-bbe4-b9ffac198a03", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nWell, I mean, the biosimilar landscape in general, we feel pretty positive about.  More choices, more substitutability \nor interchangeabi lity.  That gives clinicians more choices, hopefully it gives.  It helps address the cost challenges \nthat we see in the marketplace.  And we think with the footprint of providers that we have in the community, we're \nparticularly well -positioned to take advant age of those trends.  So, we also continue to work with innovators.  \n \n First and foremost, as we think about these, it's a patient outcome. ", "original_text": "It helps address the cost challenges \nthat we see in the marketplace. ", "page_label": "19", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9bfe510c37dffd69dea6c7889d34b1c8a24a5ba0b826bc3a9c7c5d064d8693ba", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8b41f4b7-4b51-465e-9cf9-b8ac58e9ca2f", "node_type": "1", "metadata": {"window": "That gives clinicians more choices, hopefully it gives.  It helps address the cost challenges \nthat we see in the marketplace.  And we think with the footprint of providers that we have in the community, we're \nparticularly well -positioned to take advant age of those trends.  So, we also continue to work with innovators.  \n \n First and foremost, as we think about these, it's a patient outcome.  It's a clinical -oriented decision.  It's what \nproduct is best on the formulary to meet the clinical need. ", "original_text": "So, we also continue to work with innovators.  \n \n"}, "hash": "5ff138ac46edde2f5cf245fdb2cdbfdea341953a46c66d83f3657143566ad8ed", "class_name": "RelatedNodeInfo"}}, "text": "And we think with the footprint of providers that we have in the community, we're \nparticularly well -positioned to take advant age of those trends. ", "start_char_idx": 450, "end_char_idx": 599, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8b41f4b7-4b51-465e-9cf9-b8ac58e9ca2f": {"__data__": {"id_": "8b41f4b7-4b51-465e-9cf9-b8ac58e9ca2f", "embedding": null, "metadata": {"window": "That gives clinicians more choices, hopefully it gives.  It helps address the cost challenges \nthat we see in the marketplace.  And we think with the footprint of providers that we have in the community, we're \nparticularly well -positioned to take advant age of those trends.  So, we also continue to work with innovators.  \n \n First and foremost, as we think about these, it's a patient outcome.  It's a clinical -oriented decision.  It's what \nproduct is best on the formulary to meet the clinical need. ", "original_text": "So, we also continue to work with innovators.  \n \n", "page_label": "19", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9a5a1cb5-b0d2-459d-9254-d18b99cabab3", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6a841e5456e63a5311a6369d25f04a4e227304d818d637e1167905fecde357d2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "89c21bba-0ba3-4484-ab43-d7a0a5973721", "node_type": "1", "metadata": {"window": "More choices, more substitutability \nor interchangeabi lity.  That gives clinicians more choices, hopefully it gives.  It helps address the cost challenges \nthat we see in the marketplace.  And we think with the footprint of providers that we have in the community, we're \nparticularly well -positioned to take advant age of those trends.  So, we also continue to work with innovators.  \n \n First and foremost, as we think about these, it's a patient outcome.  It's a clinical -oriented decision. ", "original_text": "And we think with the footprint of providers that we have in the community, we're \nparticularly well -positioned to take advant age of those trends. ", "page_label": "19", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7a4e3a777b5b4e57c4bda2803c8f0090ee8a51fe1c61a7a80ad4dc34f755365e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "247234e5-53a3-4231-8c91-01baf79a40e9", "node_type": "1", "metadata": {"window": "It helps address the cost challenges \nthat we see in the marketplace.  And we think with the footprint of providers that we have in the community, we're \nparticularly well -positioned to take advant age of those trends.  So, we also continue to work with innovators.  \n \n First and foremost, as we think about these, it's a patient outcome.  It's a clinical -oriented decision.  It's what \nproduct is best on the formulary to meet the clinical need.  To the extent there are a variety of choices and \ninterchangeability, that tends to be good for a company like us with the markets and channels that we serve. ", "original_text": "First and foremost, as we think about these, it's a patient outcome. "}, "hash": "f329c1a01441a0078a7929ce3cffdfc67d40fe73b1c88bfe30bb4d4bf6d04c16", "class_name": "RelatedNodeInfo"}}, "text": "So, we also continue to work with innovators.  \n \n", "start_char_idx": 599, "end_char_idx": 649, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "247234e5-53a3-4231-8c91-01baf79a40e9": {"__data__": {"id_": "247234e5-53a3-4231-8c91-01baf79a40e9", "embedding": null, "metadata": {"window": "It helps address the cost challenges \nthat we see in the marketplace.  And we think with the footprint of providers that we have in the community, we're \nparticularly well -positioned to take advant age of those trends.  So, we also continue to work with innovators.  \n \n First and foremost, as we think about these, it's a patient outcome.  It's a clinical -oriented decision.  It's what \nproduct is best on the formulary to meet the clinical need.  To the extent there are a variety of choices and \ninterchangeability, that tends to be good for a company like us with the markets and channels that we serve. ", "original_text": "First and foremost, as we think about these, it's a patient outcome. ", "page_label": "19", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9a5a1cb5-b0d2-459d-9254-d18b99cabab3", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6a841e5456e63a5311a6369d25f04a4e227304d818d637e1167905fecde357d2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8b41f4b7-4b51-465e-9cf9-b8ac58e9ca2f", "node_type": "1", "metadata": {"window": "That gives clinicians more choices, hopefully it gives.  It helps address the cost challenges \nthat we see in the marketplace.  And we think with the footprint of providers that we have in the community, we're \nparticularly well -positioned to take advant age of those trends.  So, we also continue to work with innovators.  \n \n First and foremost, as we think about these, it's a patient outcome.  It's a clinical -oriented decision.  It's what \nproduct is best on the formulary to meet the clinical need. ", "original_text": "So, we also continue to work with innovators.  \n \n", "page_label": "19", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2f4adede4686cc1059421fc4d18e163b8f8a25cda84322c24fbbf89319ba821c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1b8d02a4-baca-4587-a2a0-a15de1b74290", "node_type": "1", "metadata": {"window": "And we think with the footprint of providers that we have in the community, we're \nparticularly well -positioned to take advant age of those trends.  So, we also continue to work with innovators.  \n \n First and foremost, as we think about these, it's a patient outcome.  It's a clinical -oriented decision.  It's what \nproduct is best on the formulary to meet the clinical need.  To the extent there are a variety of choices and \ninterchangeability, that tends to be good for a company like us with the markets and channels that we serve.  That \nchoice tends to be a positive thing for us.  \n ", "original_text": "It's a clinical -oriented decision. "}, "hash": "2a27eb7c948e827343027ab5bd2879d2b5edb1cba3d211a8f9e31d206ca1e5bd", "class_name": "RelatedNodeInfo"}}, "text": "First and foremost, as we think about these, it's a patient outcome. ", "start_char_idx": 649, "end_char_idx": 718, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1b8d02a4-baca-4587-a2a0-a15de1b74290": {"__data__": {"id_": "1b8d02a4-baca-4587-a2a0-a15de1b74290", "embedding": null, "metadata": {"window": "And we think with the footprint of providers that we have in the community, we're \nparticularly well -positioned to take advant age of those trends.  So, we also continue to work with innovators.  \n \n First and foremost, as we think about these, it's a patient outcome.  It's a clinical -oriented decision.  It's what \nproduct is best on the formulary to meet the clinical need.  To the extent there are a variety of choices and \ninterchangeability, that tends to be good for a company like us with the markets and channels that we serve.  That \nchoice tends to be a positive thing for us.  \n ", "original_text": "It's a clinical -oriented decision. ", "page_label": "19", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9a5a1cb5-b0d2-459d-9254-d18b99cabab3", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6a841e5456e63a5311a6369d25f04a4e227304d818d637e1167905fecde357d2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "247234e5-53a3-4231-8c91-01baf79a40e9", "node_type": "1", "metadata": {"window": "It helps address the cost challenges \nthat we see in the marketplace.  And we think with the footprint of providers that we have in the community, we're \nparticularly well -positioned to take advant age of those trends.  So, we also continue to work with innovators.  \n \n First and foremost, as we think about these, it's a patient outcome.  It's a clinical -oriented decision.  It's what \nproduct is best on the formulary to meet the clinical need.  To the extent there are a variety of choices and \ninterchangeability, that tends to be good for a company like us with the markets and channels that we serve. ", "original_text": "First and foremost, as we think about these, it's a patient outcome. ", "page_label": "19", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c516a3e5ca6482474804abf1431cc3d229e3781dd8303936415f5355b0d25d87", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2fa34c8f-d286-4ee2-b5d6-b3ba6e8c356e", "node_type": "1", "metadata": {"window": "So, we also continue to work with innovators.  \n \n First and foremost, as we think about these, it's a patient outcome.  It's a clinical -oriented decision.  It's what \nproduct is best on the formulary to meet the clinical need.  To the extent there are a variety of choices and \ninterchangeability, that tends to be good for a company like us with the markets and channels that we serve.  That \nchoice tends to be a positive thing for us.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co. ", "original_text": "It's what \nproduct is best on the formulary to meet the clinical need. "}, "hash": "ade8895482cd5dcecceee52519e06b28fdbd2a0cb6f72c2f1479ec7368677795", "class_name": "RelatedNodeInfo"}}, "text": "It's a clinical -oriented decision. ", "start_char_idx": 718, "end_char_idx": 754, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2fa34c8f-d286-4ee2-b5d6-b3ba6e8c356e": {"__data__": {"id_": "2fa34c8f-d286-4ee2-b5d6-b3ba6e8c356e", "embedding": null, "metadata": {"window": "So, we also continue to work with innovators.  \n \n First and foremost, as we think about these, it's a patient outcome.  It's a clinical -oriented decision.  It's what \nproduct is best on the formulary to meet the clinical need.  To the extent there are a variety of choices and \ninterchangeability, that tends to be good for a company like us with the markets and channels that we serve.  That \nchoice tends to be a positive thing for us.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co. ", "original_text": "It's what \nproduct is best on the formulary to meet the clinical need. ", "page_label": "19", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9a5a1cb5-b0d2-459d-9254-d18b99cabab3", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6a841e5456e63a5311a6369d25f04a4e227304d818d637e1167905fecde357d2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1b8d02a4-baca-4587-a2a0-a15de1b74290", "node_type": "1", "metadata": {"window": "And we think with the footprint of providers that we have in the community, we're \nparticularly well -positioned to take advant age of those trends.  So, we also continue to work with innovators.  \n \n First and foremost, as we think about these, it's a patient outcome.  It's a clinical -oriented decision.  It's what \nproduct is best on the formulary to meet the clinical need.  To the extent there are a variety of choices and \ninterchangeability, that tends to be good for a company like us with the markets and channels that we serve.  That \nchoice tends to be a positive thing for us.  \n ", "original_text": "It's a clinical -oriented decision. ", "page_label": "19", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e360f91a51caaea085b8ecd975031889fe5e0809fb73c90c849eb2b31960ed80", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "93bc6a2f-ccc0-4c2e-94c2-d08940bbfe46", "node_type": "1", "metadata": {"window": "First and foremost, as we think about these, it's a patient outcome.  It's a clinical -oriented decision.  It's what \nproduct is best on the formulary to meet the clinical need.  To the extent there are a variety of choices and \ninterchangeability, that tends to be good for a company like us with the markets and channels that we serve.  That \nchoice tends to be a positive thing for us.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nIs that something t hat you think is coming close and that you're trying to plan ahead of that, or is that you feel is \nstill a ways off?  \n ", "original_text": "To the extent there are a variety of choices and \ninterchangeability, that tends to be good for a company like us with the markets and channels that we serve. "}, "hash": "54cfbacc51eb190ebcfb644af3a6fc6d5653873a51c2c5f34ea5dd32e1f3fbd8", "class_name": "RelatedNodeInfo"}}, "text": "It's what \nproduct is best on the formulary to meet the clinical need. ", "start_char_idx": 754, "end_char_idx": 825, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "93bc6a2f-ccc0-4c2e-94c2-d08940bbfe46": {"__data__": {"id_": "93bc6a2f-ccc0-4c2e-94c2-d08940bbfe46", "embedding": null, "metadata": {"window": "First and foremost, as we think about these, it's a patient outcome.  It's a clinical -oriented decision.  It's what \nproduct is best on the formulary to meet the clinical need.  To the extent there are a variety of choices and \ninterchangeability, that tends to be good for a company like us with the markets and channels that we serve.  That \nchoice tends to be a positive thing for us.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nIs that something t hat you think is coming close and that you're trying to plan ahead of that, or is that you feel is \nstill a ways off?  \n ", "original_text": "To the extent there are a variety of choices and \ninterchangeability, that tends to be good for a company like us with the markets and channels that we serve. ", "page_label": "19", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9a5a1cb5-b0d2-459d-9254-d18b99cabab3", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6a841e5456e63a5311a6369d25f04a4e227304d818d637e1167905fecde357d2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2fa34c8f-d286-4ee2-b5d6-b3ba6e8c356e", "node_type": "1", "metadata": {"window": "So, we also continue to work with innovators.  \n \n First and foremost, as we think about these, it's a patient outcome.  It's a clinical -oriented decision.  It's what \nproduct is best on the formulary to meet the clinical need.  To the extent there are a variety of choices and \ninterchangeability, that tends to be good for a company like us with the markets and channels that we serve.  That \nchoice tends to be a positive thing for us.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co. ", "original_text": "It's what \nproduct is best on the formulary to meet the clinical need. ", "page_label": "19", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b70e298e8e7ac9e8165b80c2d19bcd022849a83e67bc855bb49a3f04cecf4c9a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "040cee23-ebb9-4fbb-8f5b-1c15f9d6d07b", "node_type": "1", "metadata": {"window": "It's a clinical -oriented decision.  It's what \nproduct is best on the formulary to meet the clinical need.  To the extent there are a variety of choices and \ninterchangeability, that tends to be good for a company like us with the markets and channels that we serve.  That \nchoice tends to be a positive thing for us.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nIs that something t hat you think is coming close and that you're trying to plan ahead of that, or is that you feel is \nstill a ways off?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "That \nchoice tends to be a positive thing for us.  \n "}, "hash": "0a2ab06ef2025bcae02e15184b107140f87df0e3b3a0728365682ac4a576361e", "class_name": "RelatedNodeInfo"}}, "text": "To the extent there are a variety of choices and \ninterchangeability, that tends to be good for a company like us with the markets and channels that we serve. ", "start_char_idx": 825, "end_char_idx": 984, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "040cee23-ebb9-4fbb-8f5b-1c15f9d6d07b": {"__data__": {"id_": "040cee23-ebb9-4fbb-8f5b-1c15f9d6d07b", "embedding": null, "metadata": {"window": "It's a clinical -oriented decision.  It's what \nproduct is best on the formulary to meet the clinical need.  To the extent there are a variety of choices and \ninterchangeability, that tends to be good for a company like us with the markets and channels that we serve.  That \nchoice tends to be a positive thing for us.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nIs that something t hat you think is coming close and that you're trying to plan ahead of that, or is that you feel is \nstill a ways off?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "That \nchoice tends to be a positive thing for us.  \n ", "page_label": "19", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9a5a1cb5-b0d2-459d-9254-d18b99cabab3", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6a841e5456e63a5311a6369d25f04a4e227304d818d637e1167905fecde357d2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "93bc6a2f-ccc0-4c2e-94c2-d08940bbfe46", "node_type": "1", "metadata": {"window": "First and foremost, as we think about these, it's a patient outcome.  It's a clinical -oriented decision.  It's what \nproduct is best on the formulary to meet the clinical need.  To the extent there are a variety of choices and \ninterchangeability, that tends to be good for a company like us with the markets and channels that we serve.  That \nchoice tends to be a positive thing for us.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nIs that something t hat you think is coming close and that you're trying to plan ahead of that, or is that you feel is \nstill a ways off?  \n ", "original_text": "To the extent there are a variety of choices and \ninterchangeability, that tends to be good for a company like us with the markets and channels that we serve. ", "page_label": "19", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "61ee2deac86f8fe176c782e31f5f261c28b05946bfa8960dcb6de17b9836c5f5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4ce503e7-838f-4fe6-aebd-f8b26e862a32", "node_type": "1", "metadata": {"window": "It's what \nproduct is best on the formulary to meet the clinical need.  To the extent there are a variety of choices and \ninterchangeability, that tends to be good for a company like us with the markets and channels that we serve.  That \nchoice tends to be a positive thing for us.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nIs that something t hat you think is coming close and that you're trying to plan ahead of that, or is that you feel is \nstill a ways off?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThat's really hard to comment on the \u2013 what the regulatory pathwa ys will be and timing. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co. "}, "hash": "8935e0ff53098c31147d48f930128be2a6fcbf396acc15360e2bc59b18b6ef6f", "class_name": "RelatedNodeInfo"}}, "text": "That \nchoice tends to be a positive thing for us.  \n ", "start_char_idx": 984, "end_char_idx": 1037, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4ce503e7-838f-4fe6-aebd-f8b26e862a32": {"__data__": {"id_": "4ce503e7-838f-4fe6-aebd-f8b26e862a32", "embedding": null, "metadata": {"window": "It's what \nproduct is best on the formulary to meet the clinical need.  To the extent there are a variety of choices and \ninterchangeability, that tends to be good for a company like us with the markets and channels that we serve.  That \nchoice tends to be a positive thing for us.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nIs that something t hat you think is coming close and that you're trying to plan ahead of that, or is that you feel is \nstill a ways off?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThat's really hard to comment on the \u2013 what the regulatory pathwa ys will be and timing. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co. ", "page_label": "19", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9a5a1cb5-b0d2-459d-9254-d18b99cabab3", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6a841e5456e63a5311a6369d25f04a4e227304d818d637e1167905fecde357d2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "040cee23-ebb9-4fbb-8f5b-1c15f9d6d07b", "node_type": "1", "metadata": {"window": "It's a clinical -oriented decision.  It's what \nproduct is best on the formulary to meet the clinical need.  To the extent there are a variety of choices and \ninterchangeability, that tends to be good for a company like us with the markets and channels that we serve.  That \nchoice tends to be a positive thing for us.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nIs that something t hat you think is coming close and that you're trying to plan ahead of that, or is that you feel is \nstill a ways off?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "That \nchoice tends to be a positive thing for us.  \n ", "page_label": "19", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6940a0315126aaee99868f434a89a625cca682b7120eb011ed1915ac5f798a57", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5795a836-fd16-4e62-b6ab-8ab38e64121b", "node_type": "1", "metadata": {"window": "To the extent there are a variety of choices and \ninterchangeability, that tends to be good for a company like us with the markets and channels that we serve.  That \nchoice tends to be a positive thing for us.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nIs that something t hat you think is coming close and that you're trying to plan ahead of that, or is that you feel is \nstill a ways off?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThat's really hard to comment on the \u2013 what the regulatory pathwa ys will be and timing.  And our recent \nexperience in the policy arena tells us anything, it gets very difficult to forecast. ", "original_text": "LLC  Q \nIs that something t hat you think is coming close and that you're trying to plan ahead of that, or is that you feel is \nstill a ways off?  \n "}, "hash": "2f8119ea6df2656f1c61ec476eccc159aa9d5d722f6e42bf86f0009fff7c0e60", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co. ", "start_char_idx": 1037, "end_char_idx": 1331, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5795a836-fd16-4e62-b6ab-8ab38e64121b": {"__data__": {"id_": "5795a836-fd16-4e62-b6ab-8ab38e64121b", "embedding": null, "metadata": {"window": "To the extent there are a variety of choices and \ninterchangeability, that tends to be good for a company like us with the markets and channels that we serve.  That \nchoice tends to be a positive thing for us.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nIs that something t hat you think is coming close and that you're trying to plan ahead of that, or is that you feel is \nstill a ways off?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThat's really hard to comment on the \u2013 what the regulatory pathwa ys will be and timing.  And our recent \nexperience in the policy arena tells us anything, it gets very difficult to forecast. ", "original_text": "LLC  Q \nIs that something t hat you think is coming close and that you're trying to plan ahead of that, or is that you feel is \nstill a ways off?  \n ", "page_label": "19", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9a5a1cb5-b0d2-459d-9254-d18b99cabab3", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6a841e5456e63a5311a6369d25f04a4e227304d818d637e1167905fecde357d2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4ce503e7-838f-4fe6-aebd-f8b26e862a32", "node_type": "1", "metadata": {"window": "It's what \nproduct is best on the formulary to meet the clinical need.  To the extent there are a variety of choices and \ninterchangeability, that tends to be good for a company like us with the markets and channels that we serve.  That \nchoice tends to be a positive thing for us.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nIs that something t hat you think is coming close and that you're trying to plan ahead of that, or is that you feel is \nstill a ways off?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThat's really hard to comment on the \u2013 what the regulatory pathwa ys will be and timing. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co. ", "page_label": "19", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "31327358dcb88f7c41a4f02549844cf071b06dc78047e1a9665b96a9687e0665", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5892fca8-2116-4504-b9af-2a678475068a", "node_type": "1", "metadata": {"window": "That \nchoice tends to be a positive thing for us.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nIs that something t hat you think is coming close and that you're trying to plan ahead of that, or is that you feel is \nstill a ways off?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThat's really hard to comment on the \u2013 what the regulatory pathwa ys will be and timing.  And our recent \nexperience in the policy arena tells us anything, it gets very difficult to forecast.  What may come out, there's lots of \ndiscussion what may come out ultimately and what it may look like in its final form. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  "}, "hash": "4e4b1f6bfdc7dd89f4ecb06d8b9a5b8a1cda0a1ae9f718c3adb4e27bae849ebc", "class_name": "RelatedNodeInfo"}}, "text": "LLC  Q \nIs that something t hat you think is coming close and that you're trying to plan ahead of that, or is that you feel is \nstill a ways off?  \n ", "start_char_idx": 1331, "end_char_idx": 1480, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5892fca8-2116-4504-b9af-2a678475068a": {"__data__": {"id_": "5892fca8-2116-4504-b9af-2a678475068a", "embedding": null, "metadata": {"window": "That \nchoice tends to be a positive thing for us.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nIs that something t hat you think is coming close and that you're trying to plan ahead of that, or is that you feel is \nstill a ways off?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThat's really hard to comment on the \u2013 what the regulatory pathwa ys will be and timing.  And our recent \nexperience in the policy arena tells us anything, it gets very difficult to forecast.  What may come out, there's lots of \ndiscussion what may come out ultimately and what it may look like in its final form. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "19", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9a5a1cb5-b0d2-459d-9254-d18b99cabab3", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6a841e5456e63a5311a6369d25f04a4e227304d818d637e1167905fecde357d2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5795a836-fd16-4e62-b6ab-8ab38e64121b", "node_type": "1", "metadata": {"window": "To the extent there are a variety of choices and \ninterchangeability, that tends to be good for a company like us with the markets and channels that we serve.  That \nchoice tends to be a positive thing for us.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nIs that something t hat you think is coming close and that you're trying to plan ahead of that, or is that you feel is \nstill a ways off?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThat's really hard to comment on the \u2013 what the regulatory pathwa ys will be and timing.  And our recent \nexperience in the policy arena tells us anything, it gets very difficult to forecast. ", "original_text": "LLC  Q \nIs that something t hat you think is coming close and that you're trying to plan ahead of that, or is that you feel is \nstill a ways off?  \n ", "page_label": "19", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dd831c211cdad57604ce169f40204d58f1e9e22fd2520e7a27ee2507ab7b8417", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "02372e67-d6ec-47f5-81d1-842355943734", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nIs that something t hat you think is coming close and that you're trying to plan ahead of that, or is that you feel is \nstill a ways off?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThat's really hard to comment on the \u2013 what the regulatory pathwa ys will be and timing.  And our recent \nexperience in the policy arena tells us anything, it gets very difficult to forecast.  What may come out, there's lots of \ndiscussion what may come out ultimately and what it may look like in its final form.  It would pro bably not be my \nbest judgment to try to predict that for you.  \n ", "original_text": "A \nThat's really hard to comment on the \u2013 what the regulatory pathwa ys will be and timing. "}, "hash": "7a3dcb5fc86141b766d75276a427e08bfa71726295e226c936bbfc38cb04f9c5", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "start_char_idx": 1480, "end_char_idx": 1809, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "02372e67-d6ec-47f5-81d1-842355943734": {"__data__": {"id_": "02372e67-d6ec-47f5-81d1-842355943734", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nIs that something t hat you think is coming close and that you're trying to plan ahead of that, or is that you feel is \nstill a ways off?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThat's really hard to comment on the \u2013 what the regulatory pathwa ys will be and timing.  And our recent \nexperience in the policy arena tells us anything, it gets very difficult to forecast.  What may come out, there's lots of \ndiscussion what may come out ultimately and what it may look like in its final form.  It would pro bably not be my \nbest judgment to try to predict that for you.  \n ", "original_text": "A \nThat's really hard to comment on the \u2013 what the regulatory pathwa ys will be and timing. ", "page_label": "19", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9a5a1cb5-b0d2-459d-9254-d18b99cabab3", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6a841e5456e63a5311a6369d25f04a4e227304d818d637e1167905fecde357d2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5892fca8-2116-4504-b9af-2a678475068a", "node_type": "1", "metadata": {"window": "That \nchoice tends to be a positive thing for us.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nIs that something t hat you think is coming close and that you're trying to plan ahead of that, or is that you feel is \nstill a ways off?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThat's really hard to comment on the \u2013 what the regulatory pathwa ys will be and timing.  And our recent \nexperience in the policy arena tells us anything, it gets very difficult to forecast.  What may come out, there's lots of \ndiscussion what may come out ultimately and what it may look like in its final form. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "19", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "482fd872be0e5e171f5bc964185c6b42f949a3630450cb5be1bbd25525ce05f3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6f0b3450-ed1a-4d34-a9e8-6b90374c2d23", "node_type": "1", "metadata": {"window": "LLC  Q \nIs that something t hat you think is coming close and that you're trying to plan ahead of that, or is that you feel is \nstill a ways off?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThat's really hard to comment on the \u2013 what the regulatory pathwa ys will be and timing.  And our recent \nexperience in the policy arena tells us anything, it gets very difficult to forecast.  What may come out, there's lots of \ndiscussion what may come out ultimately and what it may look like in its final form.  It would pro bably not be my \nbest judgment to try to predict that for you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co. ", "original_text": "And our recent \nexperience in the policy arena tells us anything, it gets very difficult to forecast. "}, "hash": "753990afc2b4b00c9ffb02f4101640a171cb97bb77985b08eeb69b616750a338", "class_name": "RelatedNodeInfo"}}, "text": "A \nThat's really hard to comment on the \u2013 what the regulatory pathwa ys will be and timing. ", "start_char_idx": 1809, "end_char_idx": 1901, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6f0b3450-ed1a-4d34-a9e8-6b90374c2d23": {"__data__": {"id_": "6f0b3450-ed1a-4d34-a9e8-6b90374c2d23", "embedding": null, "metadata": {"window": "LLC  Q \nIs that something t hat you think is coming close and that you're trying to plan ahead of that, or is that you feel is \nstill a ways off?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThat's really hard to comment on the \u2013 what the regulatory pathwa ys will be and timing.  And our recent \nexperience in the policy arena tells us anything, it gets very difficult to forecast.  What may come out, there's lots of \ndiscussion what may come out ultimately and what it may look like in its final form.  It would pro bably not be my \nbest judgment to try to predict that for you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co. ", "original_text": "And our recent \nexperience in the policy arena tells us anything, it gets very difficult to forecast. ", "page_label": "19", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9a5a1cb5-b0d2-459d-9254-d18b99cabab3", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6a841e5456e63a5311a6369d25f04a4e227304d818d637e1167905fecde357d2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "02372e67-d6ec-47f5-81d1-842355943734", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nIs that something t hat you think is coming close and that you're trying to plan ahead of that, or is that you feel is \nstill a ways off?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThat's really hard to comment on the \u2013 what the regulatory pathwa ys will be and timing.  And our recent \nexperience in the policy arena tells us anything, it gets very difficult to forecast.  What may come out, there's lots of \ndiscussion what may come out ultimately and what it may look like in its final form.  It would pro bably not be my \nbest judgment to try to predict that for you.  \n ", "original_text": "A \nThat's really hard to comment on the \u2013 what the regulatory pathwa ys will be and timing. ", "page_label": "19", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7784aa778d8cccf9386fc29bae12db75848377b71573ca326e61f0b127085a09", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "37b6f6fa-9c63-4ee4-8505-b5cbb329ae94", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThat's really hard to comment on the \u2013 what the regulatory pathwa ys will be and timing.  And our recent \nexperience in the policy arena tells us anything, it gets very difficult to forecast.  What may come out, there's lots of \ndiscussion what may come out ultimately and what it may look like in its final form.  It would pro bably not be my \nbest judgment to try to predict that for you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nOkay. ", "original_text": "What may come out, there's lots of \ndiscussion what may come out ultimately and what it may look like in its final form. "}, "hash": "fd77aba9e9222f77520fe7400b8f6b93dfb49216f9f6a68d219f735d0b8b583b", "class_name": "RelatedNodeInfo"}}, "text": "And our recent \nexperience in the policy arena tells us anything, it gets very difficult to forecast. ", "start_char_idx": 1901, "end_char_idx": 2003, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "37b6f6fa-9c63-4ee4-8505-b5cbb329ae94": {"__data__": {"id_": "37b6f6fa-9c63-4ee4-8505-b5cbb329ae94", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThat's really hard to comment on the \u2013 what the regulatory pathwa ys will be and timing.  And our recent \nexperience in the policy arena tells us anything, it gets very difficult to forecast.  What may come out, there's lots of \ndiscussion what may come out ultimately and what it may look like in its final form.  It would pro bably not be my \nbest judgment to try to predict that for you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nOkay. ", "original_text": "What may come out, there's lots of \ndiscussion what may come out ultimately and what it may look like in its final form. ", "page_label": "19", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9a5a1cb5-b0d2-459d-9254-d18b99cabab3", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6a841e5456e63a5311a6369d25f04a4e227304d818d637e1167905fecde357d2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6f0b3450-ed1a-4d34-a9e8-6b90374c2d23", "node_type": "1", "metadata": {"window": "LLC  Q \nIs that something t hat you think is coming close and that you're trying to plan ahead of that, or is that you feel is \nstill a ways off?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThat's really hard to comment on the \u2013 what the regulatory pathwa ys will be and timing.  And our recent \nexperience in the policy arena tells us anything, it gets very difficult to forecast.  What may come out, there's lots of \ndiscussion what may come out ultimately and what it may look like in its final form.  It would pro bably not be my \nbest judgment to try to predict that for you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co. ", "original_text": "And our recent \nexperience in the policy arena tells us anything, it gets very difficult to forecast. ", "page_label": "19", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dfca00b7a9622168af45c57ca8b6aee6280681fa665a13c11ccb47e76580e177", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e64f016e-394a-4daf-b8ef-ef37a5e49470", "node_type": "1", "metadata": {"window": "A \nThat's really hard to comment on the \u2013 what the regulatory pathwa ys will be and timing.  And our recent \nexperience in the policy arena tells us anything, it gets very difficult to forecast.  What may come out, there's lots of \ndiscussion what may come out ultimately and what it may look like in its final form.  It would pro bably not be my \nbest judgment to try to predict that for you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nOkay.  Fair enough. ", "original_text": "It would pro bably not be my \nbest judgment to try to predict that for you.  \n "}, "hash": "cf673ab63c074540f2ab309747535d2aa5347d07875909ca6e423c0ae4a8cdc2", "class_name": "RelatedNodeInfo"}}, "text": "What may come out, there's lots of \ndiscussion what may come out ultimately and what it may look like in its final form. ", "start_char_idx": 2003, "end_char_idx": 2124, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e64f016e-394a-4daf-b8ef-ef37a5e49470": {"__data__": {"id_": "e64f016e-394a-4daf-b8ef-ef37a5e49470", "embedding": null, "metadata": {"window": "A \nThat's really hard to comment on the \u2013 what the regulatory pathwa ys will be and timing.  And our recent \nexperience in the policy arena tells us anything, it gets very difficult to forecast.  What may come out, there's lots of \ndiscussion what may come out ultimately and what it may look like in its final form.  It would pro bably not be my \nbest judgment to try to predict that for you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nOkay.  Fair enough. ", "original_text": "It would pro bably not be my \nbest judgment to try to predict that for you.  \n ", "page_label": "19", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9a5a1cb5-b0d2-459d-9254-d18b99cabab3", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6a841e5456e63a5311a6369d25f04a4e227304d818d637e1167905fecde357d2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "37b6f6fa-9c63-4ee4-8505-b5cbb329ae94", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThat's really hard to comment on the \u2013 what the regulatory pathwa ys will be and timing.  And our recent \nexperience in the policy arena tells us anything, it gets very difficult to forecast.  What may come out, there's lots of \ndiscussion what may come out ultimately and what it may look like in its final form.  It would pro bably not be my \nbest judgment to try to predict that for you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nOkay. ", "original_text": "What may come out, there's lots of \ndiscussion what may come out ultimately and what it may look like in its final form. ", "page_label": "19", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d3b6070f5709a85b22a4c085956d5a0f57000a42d892afc1892b2cdd5d521630", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7e823e27-9de4-4143-9fed-171db845fe98", "node_type": "1", "metadata": {"window": "And our recent \nexperience in the policy arena tells us anything, it gets very difficult to forecast.  What may come out, there's lots of \ndiscussion what may come out ultimately and what it may look like in its final form.  It would pro bably not be my \nbest judgment to try to predict that for you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nOkay.  Fair enough.  And just one last question. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co. "}, "hash": "4f623fd6708506b031abf3e0ef8f1dc79f615ef6a548177d283dfe60eb8a5ada", "class_name": "RelatedNodeInfo"}}, "text": "It would pro bably not be my \nbest judgment to try to predict that for you.  \n ", "start_char_idx": 2124, "end_char_idx": 2203, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7e823e27-9de4-4143-9fed-171db845fe98": {"__data__": {"id_": "7e823e27-9de4-4143-9fed-171db845fe98", "embedding": null, "metadata": {"window": "And our recent \nexperience in the policy arena tells us anything, it gets very difficult to forecast.  What may come out, there's lots of \ndiscussion what may come out ultimately and what it may look like in its final form.  It would pro bably not be my \nbest judgment to try to predict that for you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nOkay.  Fair enough.  And just one last question. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co. ", "page_label": "19", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9a5a1cb5-b0d2-459d-9254-d18b99cabab3", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6a841e5456e63a5311a6369d25f04a4e227304d818d637e1167905fecde357d2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e64f016e-394a-4daf-b8ef-ef37a5e49470", "node_type": "1", "metadata": {"window": "A \nThat's really hard to comment on the \u2013 what the regulatory pathwa ys will be and timing.  And our recent \nexperience in the policy arena tells us anything, it gets very difficult to forecast.  What may come out, there's lots of \ndiscussion what may come out ultimately and what it may look like in its final form.  It would pro bably not be my \nbest judgment to try to predict that for you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nOkay.  Fair enough. ", "original_text": "It would pro bably not be my \nbest judgment to try to predict that for you.  \n ", "page_label": "19", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b8d8c1c8c7b0ee05f9828ce08f92bb8a6ca0cc78b4ed87f459c34ab764796728", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "adc92f81-68d1-4640-b8e5-4a6c7c9aa728", "node_type": "1", "metadata": {"window": "What may come out, there's lots of \ndiscussion what may come out ultimately and what it may look like in its final form.  It would pro bably not be my \nbest judgment to try to predict that for you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nOkay.  Fair enough.  And just one last question.  You talked about the FX impact being sort of net neutral. ", "original_text": "LLC  Q \nOkay. "}, "hash": "a39f813913e057e7a9d98723aac43b9bb4081bda4346746948d97245c836297d", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co. ", "start_char_idx": 1037, "end_char_idx": 1331, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "adc92f81-68d1-4640-b8e5-4a6c7c9aa728": {"__data__": {"id_": "adc92f81-68d1-4640-b8e5-4a6c7c9aa728", "embedding": null, "metadata": {"window": "What may come out, there's lots of \ndiscussion what may come out ultimately and what it may look like in its final form.  It would pro bably not be my \nbest judgment to try to predict that for you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nOkay.  Fair enough.  And just one last question.  You talked about the FX impact being sort of net neutral. ", "original_text": "LLC  Q \nOkay. ", "page_label": "19", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9a5a1cb5-b0d2-459d-9254-d18b99cabab3", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6a841e5456e63a5311a6369d25f04a4e227304d818d637e1167905fecde357d2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7e823e27-9de4-4143-9fed-171db845fe98", "node_type": "1", "metadata": {"window": "And our recent \nexperience in the policy arena tells us anything, it gets very difficult to forecast.  What may come out, there's lots of \ndiscussion what may come out ultimately and what it may look like in its final form.  It would pro bably not be my \nbest judgment to try to predict that for you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nOkay.  Fair enough.  And just one last question. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co. ", "page_label": "19", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b87f0bf06a5e2bce778f5070157666c2022eacc8576d64980d0a550c35ea6d65", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cdcebb9b-60e8-44ed-96a5-a032687feea0", "node_type": "1", "metadata": {"window": "It would pro bably not be my \nbest judgment to try to predict that for you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nOkay.  Fair enough.  And just one last question.  You talked about the FX impact being sort of net neutral.  But if I \nlook, it seems like \u2013 particularly the pound and the euro have been getting weaker relative to the dollar. ", "original_text": "Fair enough. "}, "hash": "f83db46329adfc8acb4d1f6cada0f8d7c18ffae7d3e74cf089de0c2beb946500", "class_name": "RelatedNodeInfo"}}, "text": "LLC  Q \nOkay. ", "start_char_idx": 2497, "end_char_idx": 2511, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cdcebb9b-60e8-44ed-96a5-a032687feea0": {"__data__": {"id_": "cdcebb9b-60e8-44ed-96a5-a032687feea0", "embedding": null, "metadata": {"window": "It would pro bably not be my \nbest judgment to try to predict that for you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nOkay.  Fair enough.  And just one last question.  You talked about the FX impact being sort of net neutral.  But if I \nlook, it seems like \u2013 particularly the pound and the euro have been getting weaker relative to the dollar. ", "original_text": "Fair enough. ", "page_label": "19", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9a5a1cb5-b0d2-459d-9254-d18b99cabab3", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6a841e5456e63a5311a6369d25f04a4e227304d818d637e1167905fecde357d2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "adc92f81-68d1-4640-b8e5-4a6c7c9aa728", "node_type": "1", "metadata": {"window": "What may come out, there's lots of \ndiscussion what may come out ultimately and what it may look like in its final form.  It would pro bably not be my \nbest judgment to try to predict that for you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nOkay.  Fair enough.  And just one last question.  You talked about the FX impact being sort of net neutral. ", "original_text": "LLC  Q \nOkay. ", "page_label": "19", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8eb0fc75fded592b0fb29861dcf087ff3a002e6c80cb432d5be57dfb7fa8a7bc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0e391754-0520-465a-8def-929dbee3689d", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nOkay.  Fair enough.  And just one last question.  You talked about the FX impact being sort of net neutral.  But if I \nlook, it seems like \u2013 particularly the pound and the euro have been getting weaker relative to the dollar.  How are \nyou guys thinking about that? ", "original_text": "And just one last question. "}, "hash": "df35747c1e6447d3c71f221061bb01a60d447c388a6dbb9d37ed3687b8fdb6bc", "class_name": "RelatedNodeInfo"}}, "text": "Fair enough. ", "start_char_idx": 2511, "end_char_idx": 2524, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0e391754-0520-465a-8def-929dbee3689d": {"__data__": {"id_": "0e391754-0520-465a-8def-929dbee3689d", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nOkay.  Fair enough.  And just one last question.  You talked about the FX impact being sort of net neutral.  But if I \nlook, it seems like \u2013 particularly the pound and the euro have been getting weaker relative to the dollar.  How are \nyou guys thinking about that? ", "original_text": "And just one last question. ", "page_label": "19", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9a5a1cb5-b0d2-459d-9254-d18b99cabab3", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6a841e5456e63a5311a6369d25f04a4e227304d818d637e1167905fecde357d2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cdcebb9b-60e8-44ed-96a5-a032687feea0", "node_type": "1", "metadata": {"window": "It would pro bably not be my \nbest judgment to try to predict that for you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nOkay.  Fair enough.  And just one last question.  You talked about the FX impact being sort of net neutral.  But if I \nlook, it seems like \u2013 particularly the pound and the euro have been getting weaker relative to the dollar. ", "original_text": "Fair enough. ", "page_label": "19", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "84cafc9cc3576a1315a215c5dc330674eb344a53de7bed7608eb47e1e64e0e52", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ed9e43f8-a94b-4b7f-867b-4f4174f84a62", "node_type": "1", "metadata": {"window": "LLC  Q \nOkay.  Fair enough.  And just one last question.  You talked about the FX impact being sort of net neutral.  But if I \nlook, it seems like \u2013 particularly the pound and the euro have been getting weaker relative to the dollar.  How are \nyou guys thinking about that?  Or sort of what's your expectations around that? ", "original_text": "You talked about the FX impact being sort of net neutral. "}, "hash": "e41e2fc989e0684c6e78c0714f8d0e15867e518608eba6e821644b2ced9f9cd6", "class_name": "RelatedNodeInfo"}}, "text": "And just one last question. ", "start_char_idx": 2524, "end_char_idx": 2552, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ed9e43f8-a94b-4b7f-867b-4f4174f84a62": {"__data__": {"id_": "ed9e43f8-a94b-4b7f-867b-4f4174f84a62", "embedding": null, "metadata": {"window": "LLC  Q \nOkay.  Fair enough.  And just one last question.  You talked about the FX impact being sort of net neutral.  But if I \nlook, it seems like \u2013 particularly the pound and the euro have been getting weaker relative to the dollar.  How are \nyou guys thinking about that?  Or sort of what's your expectations around that? ", "original_text": "You talked about the FX impact being sort of net neutral. ", "page_label": "19", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9a5a1cb5-b0d2-459d-9254-d18b99cabab3", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6a841e5456e63a5311a6369d25f04a4e227304d818d637e1167905fecde357d2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0e391754-0520-465a-8def-929dbee3689d", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nOkay.  Fair enough.  And just one last question.  You talked about the FX impact being sort of net neutral.  But if I \nlook, it seems like \u2013 particularly the pound and the euro have been getting weaker relative to the dollar.  How are \nyou guys thinking about that? ", "original_text": "And just one last question. ", "page_label": "19", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1fb606691712879a92272884c86997a431bd9f4b39d6c5e295aaa72937789e6e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "78a14cab-bcee-46bf-96b6-4156ad8e3905", "node_type": "1", "metadata": {"window": "Fair enough.  And just one last question.  You talked about the FX impact being sort of net neutral.  But if I \nlook, it seems like \u2013 particularly the pound and the euro have been getting weaker relative to the dollar.  How are \nyou guys thinking about that?  Or sort of what's your expectations around that?  Thanks.  \n ", "original_text": "But if I \nlook, it seems like \u2013 particularly the pound and the euro have been getting weaker relative to the dollar. "}, "hash": "35e543b0db47651f91e5793b19e0a36892c3749db81a148d439374053f9ab8cc", "class_name": "RelatedNodeInfo"}}, "text": "You talked about the FX impact being sort of net neutral. ", "start_char_idx": 2552, "end_char_idx": 2610, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "78a14cab-bcee-46bf-96b6-4156ad8e3905": {"__data__": {"id_": "78a14cab-bcee-46bf-96b6-4156ad8e3905", "embedding": null, "metadata": {"window": "Fair enough.  And just one last question.  You talked about the FX impact being sort of net neutral.  But if I \nlook, it seems like \u2013 particularly the pound and the euro have been getting weaker relative to the dollar.  How are \nyou guys thinking about that?  Or sort of what's your expectations around that?  Thanks.  \n ", "original_text": "But if I \nlook, it seems like \u2013 particularly the pound and the euro have been getting weaker relative to the dollar. ", "page_label": "19", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9a5a1cb5-b0d2-459d-9254-d18b99cabab3", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6a841e5456e63a5311a6369d25f04a4e227304d818d637e1167905fecde357d2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ed9e43f8-a94b-4b7f-867b-4f4174f84a62", "node_type": "1", "metadata": {"window": "LLC  Q \nOkay.  Fair enough.  And just one last question.  You talked about the FX impact being sort of net neutral.  But if I \nlook, it seems like \u2013 particularly the pound and the euro have been getting weaker relative to the dollar.  How are \nyou guys thinking about that?  Or sort of what's your expectations around that? ", "original_text": "You talked about the FX impact being sort of net neutral. ", "page_label": "19", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "828a65764818f815b477e5387ace5f287c4e61cf4a1be9d10e5e93b937758d17", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ac9cbc0f-26ec-4c81-97f7-4bdad17b16bf", "node_type": "1", "metadata": {"window": "And just one last question.  You talked about the FX impact being sort of net neutral.  But if I \nlook, it seems like \u2013 particularly the pound and the euro have been getting weaker relative to the dollar.  How are \nyou guys thinking about that?  Or sort of what's your expectations around that?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "How are \nyou guys thinking about that? "}, "hash": "9e60258ee217d370116c348c2a1ad97eea41cc1f965475ff2da80c0b5e403a0b", "class_name": "RelatedNodeInfo"}}, "text": "But if I \nlook, it seems like \u2013 particularly the pound and the euro have been getting weaker relative to the dollar. ", "start_char_idx": 2610, "end_char_idx": 2727, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ac9cbc0f-26ec-4c81-97f7-4bdad17b16bf": {"__data__": {"id_": "ac9cbc0f-26ec-4c81-97f7-4bdad17b16bf", "embedding": null, "metadata": {"window": "And just one last question.  You talked about the FX impact being sort of net neutral.  But if I \nlook, it seems like \u2013 particularly the pound and the euro have been getting weaker relative to the dollar.  How are \nyou guys thinking about that?  Or sort of what's your expectations around that?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "How are \nyou guys thinking about that? ", "page_label": "19", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9a5a1cb5-b0d2-459d-9254-d18b99cabab3", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6a841e5456e63a5311a6369d25f04a4e227304d818d637e1167905fecde357d2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "78a14cab-bcee-46bf-96b6-4156ad8e3905", "node_type": "1", "metadata": {"window": "Fair enough.  And just one last question.  You talked about the FX impact being sort of net neutral.  But if I \nlook, it seems like \u2013 particularly the pound and the euro have been getting weaker relative to the dollar.  How are \nyou guys thinking about that?  Or sort of what's your expectations around that?  Thanks.  \n ", "original_text": "But if I \nlook, it seems like \u2013 particularly the pound and the euro have been getting weaker relative to the dollar. ", "page_label": "19", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e13446f3d8ee643081c566c0e2715b3ad1e9af7f92274e064387aca0bd3a47c7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "01ead8fb-c1b7-451c-9d8c-7cfe66a0c2b6", "node_type": "1", "metadata": {"window": "You talked about the FX impact being sort of net neutral.  But if I \nlook, it seems like \u2013 particularly the pound and the euro have been getting weaker relative to the dollar.  How are \nyou guys thinking about that?  Or sort of what's your expectations around that?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah. ", "original_text": "Or sort of what's your expectations around that? "}, "hash": "283a73b23fecca3dea556c6454d7e2d3695901c81a2e880e599224e387082998", "class_name": "RelatedNodeInfo"}}, "text": "How are \nyou guys thinking about that? ", "start_char_idx": 2727, "end_char_idx": 2766, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "01ead8fb-c1b7-451c-9d8c-7cfe66a0c2b6": {"__data__": {"id_": "01ead8fb-c1b7-451c-9d8c-7cfe66a0c2b6", "embedding": null, "metadata": {"window": "You talked about the FX impact being sort of net neutral.  But if I \nlook, it seems like \u2013 particularly the pound and the euro have been getting weaker relative to the dollar.  How are \nyou guys thinking about that?  Or sort of what's your expectations around that?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah. ", "original_text": "Or sort of what's your expectations around that? ", "page_label": "19", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9a5a1cb5-b0d2-459d-9254-d18b99cabab3", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6a841e5456e63a5311a6369d25f04a4e227304d818d637e1167905fecde357d2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ac9cbc0f-26ec-4c81-97f7-4bdad17b16bf", "node_type": "1", "metadata": {"window": "And just one last question.  You talked about the FX impact being sort of net neutral.  But if I \nlook, it seems like \u2013 particularly the pound and the euro have been getting weaker relative to the dollar.  How are \nyou guys thinking about that?  Or sort of what's your expectations around that?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "How are \nyou guys thinking about that? ", "page_label": "19", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e4aef8d211e37539b5d198fe6bf26b01acdddbee9acd4a3cf7d269dba2c6ac0a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7e51d3f7-fc85-4e20-a1d3-0636fa52f415", "node_type": "1", "metadata": {"window": "But if I \nlook, it seems like \u2013 particularly the pound and the euro have been getting weaker relative to the dollar.  How are \nyou guys thinking about that?  Or sort of what's your expectations around that?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  I don't want to predict the direction of the pound. ", "original_text": "Thanks.  \n "}, "hash": "e9465a4cadfc00da4ba50fcc6f10a09c38ec24bdca33ffcabfb081bd1677ddcf", "class_name": "RelatedNodeInfo"}}, "text": "Or sort of what's your expectations around that? ", "start_char_idx": 2766, "end_char_idx": 2815, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7e51d3f7-fc85-4e20-a1d3-0636fa52f415": {"__data__": {"id_": "7e51d3f7-fc85-4e20-a1d3-0636fa52f415", "embedding": null, "metadata": {"window": "But if I \nlook, it seems like \u2013 particularly the pound and the euro have been getting weaker relative to the dollar.  How are \nyou guys thinking about that?  Or sort of what's your expectations around that?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  I don't want to predict the direction of the pound. ", "original_text": "Thanks.  \n ", "page_label": "19", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9a5a1cb5-b0d2-459d-9254-d18b99cabab3", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6a841e5456e63a5311a6369d25f04a4e227304d818d637e1167905fecde357d2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "01ead8fb-c1b7-451c-9d8c-7cfe66a0c2b6", "node_type": "1", "metadata": {"window": "You talked about the FX impact being sort of net neutral.  But if I \nlook, it seems like \u2013 particularly the pound and the euro have been getting weaker relative to the dollar.  How are \nyou guys thinking about that?  Or sort of what's your expectations around that?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah. ", "original_text": "Or sort of what's your expectations around that? ", "page_label": "19", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b5fef1478b6415d53d239707e4a3a1f980c8397dd0c1cf2aa6085dddc287e4ed", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8bc7fb80-0714-45df-86db-5734cbbfaa5c", "node_type": "1", "metadata": {"window": "How are \nyou guys thinking about that?  Or sort of what's your expectations around that?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  I don't want to predict the direction of the pound.  On a consolidated basis, it doesn't have a material impact. \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  "}, "hash": "6c79c12b801cdac24fc60a0ba81b412df24bc01d900cf7a2af15926380a80683", "class_name": "RelatedNodeInfo"}}, "text": "Thanks.  \n ", "start_char_idx": 2815, "end_char_idx": 2826, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8bc7fb80-0714-45df-86db-5734cbbfaa5c": {"__data__": {"id_": "8bc7fb80-0714-45df-86db-5734cbbfaa5c", "embedding": null, "metadata": {"window": "How are \nyou guys thinking about that?  Or sort of what's your expectations around that?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  I don't want to predict the direction of the pound.  On a consolidated basis, it doesn't have a material impact. \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "page_label": "19", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9a5a1cb5-b0d2-459d-9254-d18b99cabab3", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6a841e5456e63a5311a6369d25f04a4e227304d818d637e1167905fecde357d2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7e51d3f7-fc85-4e20-a1d3-0636fa52f415", "node_type": "1", "metadata": {"window": "But if I \nlook, it seems like \u2013 particularly the pound and the euro have been getting weaker relative to the dollar.  How are \nyou guys thinking about that?  Or sort of what's your expectations around that?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  I don't want to predict the direction of the pound. ", "original_text": "Thanks.  \n ", "page_label": "19", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a39031b83e6337863e1ac2dac9c5bdd00c90c40fc1d2c92fcd8b961ab9b154cb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "03c3cbfb-f95d-4a03-a836-f7532bfb6011", "node_type": "1", "metadata": {"window": "Or sort of what's your expectations around that?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  I don't want to predict the direction of the pound.  On a consolidated basis, it doesn't have a material impact. \n But as I called out, it did have an impact on revenues within the Europe segment for the quarter. ", "original_text": "A \nYeah. "}, "hash": "63348125b6f6acde308c848fc6cc6d12edcdbd976fdf3d382711f8507556923a", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "start_char_idx": 2826, "end_char_idx": 3171, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "03c3cbfb-f95d-4a03-a836-f7532bfb6011": {"__data__": {"id_": "03c3cbfb-f95d-4a03-a836-f7532bfb6011", "embedding": null, "metadata": {"window": "Or sort of what's your expectations around that?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  I don't want to predict the direction of the pound.  On a consolidated basis, it doesn't have a material impact. \n But as I called out, it did have an impact on revenues within the Europe segment for the quarter. ", "original_text": "A \nYeah. ", "page_label": "19", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9a5a1cb5-b0d2-459d-9254-d18b99cabab3", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6a841e5456e63a5311a6369d25f04a4e227304d818d637e1167905fecde357d2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8bc7fb80-0714-45df-86db-5734cbbfaa5c", "node_type": "1", "metadata": {"window": "How are \nyou guys thinking about that?  Or sort of what's your expectations around that?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  I don't want to predict the direction of the pound.  On a consolidated basis, it doesn't have a material impact. \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "page_label": "19", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3beb725ab54098da36ce35608f3bbb210699df3756d3f7924d87dc272e708696", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "99d4ef8f-58e5-4a12-af6d-b9bffb2f1655", "node_type": "1", "metadata": {"window": "Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  I don't want to predict the direction of the pound.  On a consolidated basis, it doesn't have a material impact. \n But as I called out, it did have an impact on revenues within the Europe segment for the quarter.  So, obviously \nwe'll watch that very car efully. ", "original_text": "I don't want to predict the direction of the pound. "}, "hash": "f7dc0feb98f9a02f2b84ff0bdef3675ab7e36c9f6f1bb6e9ff1291e71cf5a299", "class_name": "RelatedNodeInfo"}}, "text": "A \nYeah. ", "start_char_idx": 3171, "end_char_idx": 3180, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "99d4ef8f-58e5-4a12-af6d-b9bffb2f1655": {"__data__": {"id_": "99d4ef8f-58e5-4a12-af6d-b9bffb2f1655", "embedding": null, "metadata": {"window": "Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  I don't want to predict the direction of the pound.  On a consolidated basis, it doesn't have a material impact. \n But as I called out, it did have an impact on revenues within the Europe segment for the quarter.  So, obviously \nwe'll watch that very car efully. ", "original_text": "I don't want to predict the direction of the pound. ", "page_label": "19", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9a5a1cb5-b0d2-459d-9254-d18b99cabab3", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6a841e5456e63a5311a6369d25f04a4e227304d818d637e1167905fecde357d2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "03c3cbfb-f95d-4a03-a836-f7532bfb6011", "node_type": "1", "metadata": {"window": "Or sort of what's your expectations around that?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  I don't want to predict the direction of the pound.  On a consolidated basis, it doesn't have a material impact. \n But as I called out, it did have an impact on revenues within the Europe segment for the quarter. ", "original_text": "A \nYeah. ", "page_label": "19", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c349bdd6233666ccc4f51ad09f86810b9f46b889bcc9341e6dafe995f5e25b28", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2081005e-0e3c-4402-bec1-409fb6bcce56", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  I don't want to predict the direction of the pound.  On a consolidated basis, it doesn't have a material impact. \n But as I called out, it did have an impact on revenues within the Europe segment for the quarter.  So, obviously \nwe'll watch that very car efully.  But as we think about it on a consolidated basis, we don't see an impact.  \n ", "original_text": "On a consolidated basis, it doesn't have a material impact. \n"}, "hash": "94b5f30419b8e77c4e13745a78f0ed9d845b6c3ee536aa05d5e87fc2f7c64baa", "class_name": "RelatedNodeInfo"}}, "text": "I don't want to predict the direction of the pound. ", "start_char_idx": 3180, "end_char_idx": 3232, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2081005e-0e3c-4402-bec1-409fb6bcce56": {"__data__": {"id_": "2081005e-0e3c-4402-bec1-409fb6bcce56", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  I don't want to predict the direction of the pound.  On a consolidated basis, it doesn't have a material impact. \n But as I called out, it did have an impact on revenues within the Europe segment for the quarter.  So, obviously \nwe'll watch that very car efully.  But as we think about it on a consolidated basis, we don't see an impact.  \n ", "original_text": "On a consolidated basis, it doesn't have a material impact. \n", "page_label": "19", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9a5a1cb5-b0d2-459d-9254-d18b99cabab3", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6a841e5456e63a5311a6369d25f04a4e227304d818d637e1167905fecde357d2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "99d4ef8f-58e5-4a12-af6d-b9bffb2f1655", "node_type": "1", "metadata": {"window": "Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  I don't want to predict the direction of the pound.  On a consolidated basis, it doesn't have a material impact. \n But as I called out, it did have an impact on revenues within the Europe segment for the quarter.  So, obviously \nwe'll watch that very car efully. ", "original_text": "I don't want to predict the direction of the pound. ", "page_label": "19", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8fa731daee54ea90634f15259f41696191909d5eabd77219f4bc25c4f98390f4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d6e7769d-8900-4e83-8ca6-89f9e21e98d0", "node_type": "1", "metadata": {"window": "A \nYeah.  I don't want to predict the direction of the pound.  On a consolidated basis, it doesn't have a material impact. \n But as I called out, it did have an impact on revenues within the Europe segment for the quarter.  So, obviously \nwe'll watch that very car efully.  But as we think about it on a consolidated basis, we don't see an impact.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co. ", "original_text": "But as I called out, it did have an impact on revenues within the Europe segment for the quarter. "}, "hash": "5dc831cacb5ecb4d06d1e571272ca46ba534c63f7c74bd689b74441ea860879d", "class_name": "RelatedNodeInfo"}}, "text": "On a consolidated basis, it doesn't have a material impact. \n", "start_char_idx": 3232, "end_char_idx": 3293, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d6e7769d-8900-4e83-8ca6-89f9e21e98d0": {"__data__": {"id_": "d6e7769d-8900-4e83-8ca6-89f9e21e98d0", "embedding": null, "metadata": {"window": "A \nYeah.  I don't want to predict the direction of the pound.  On a consolidated basis, it doesn't have a material impact. \n But as I called out, it did have an impact on revenues within the Europe segment for the quarter.  So, obviously \nwe'll watch that very car efully.  But as we think about it on a consolidated basis, we don't see an impact.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co. ", "original_text": "But as I called out, it did have an impact on revenues within the Europe segment for the quarter. ", "page_label": "19", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9a5a1cb5-b0d2-459d-9254-d18b99cabab3", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6a841e5456e63a5311a6369d25f04a4e227304d818d637e1167905fecde357d2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2081005e-0e3c-4402-bec1-409fb6bcce56", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  I don't want to predict the direction of the pound.  On a consolidated basis, it doesn't have a material impact. \n But as I called out, it did have an impact on revenues within the Europe segment for the quarter.  So, obviously \nwe'll watch that very car efully.  But as we think about it on a consolidated basis, we don't see an impact.  \n ", "original_text": "On a consolidated basis, it doesn't have a material impact. \n", "page_label": "19", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8be47d5c47941dd530b735d53c7df1786318e146c7028cb173015b9c0ab5584e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "43eeae17-4da6-4370-b582-4d60648881ed", "node_type": "1", "metadata": {"window": "I don't want to predict the direction of the pound.  On a consolidated basis, it doesn't have a material impact. \n But as I called out, it did have an impact on revenues within the Europe segment for the quarter.  So, obviously \nwe'll watch that very car efully.  But as we think about it on a consolidated basis, we don't see an impact.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nGreat. ", "original_text": "So, obviously \nwe'll watch that very car efully. "}, "hash": "ee84eed84817054e41bec9ae57c6de8bf7f98fe6af52f91fcd00b06f39bf5271", "class_name": "RelatedNodeInfo"}}, "text": "But as I called out, it did have an impact on revenues within the Europe segment for the quarter. ", "start_char_idx": 3293, "end_char_idx": 3391, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "43eeae17-4da6-4370-b582-4d60648881ed": {"__data__": {"id_": "43eeae17-4da6-4370-b582-4d60648881ed", "embedding": null, "metadata": {"window": "I don't want to predict the direction of the pound.  On a consolidated basis, it doesn't have a material impact. \n But as I called out, it did have an impact on revenues within the Europe segment for the quarter.  So, obviously \nwe'll watch that very car efully.  But as we think about it on a consolidated basis, we don't see an impact.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nGreat. ", "original_text": "So, obviously \nwe'll watch that very car efully. ", "page_label": "19", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9a5a1cb5-b0d2-459d-9254-d18b99cabab3", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6a841e5456e63a5311a6369d25f04a4e227304d818d637e1167905fecde357d2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d6e7769d-8900-4e83-8ca6-89f9e21e98d0", "node_type": "1", "metadata": {"window": "A \nYeah.  I don't want to predict the direction of the pound.  On a consolidated basis, it doesn't have a material impact. \n But as I called out, it did have an impact on revenues within the Europe segment for the quarter.  So, obviously \nwe'll watch that very car efully.  But as we think about it on a consolidated basis, we don't see an impact.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co. ", "original_text": "But as I called out, it did have an impact on revenues within the Europe segment for the quarter. ", "page_label": "19", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c381969ab1508fb0a9df8ce4661fa2678d6b6d2b850c17991f241b706a905a4c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fce8fa95-a939-410b-8898-b46cc478d699", "node_type": "1", "metadata": {"window": "On a consolidated basis, it doesn't have a material impact. \n But as I called out, it did have an impact on revenues within the Europe segment for the quarter.  So, obviously \nwe'll watch that very car efully.  But as we think about it on a consolidated basis, we don't see an impact.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nGreat.  Thank you.  \n ", "original_text": "But as we think about it on a consolidated basis, we don't see an impact.  \n "}, "hash": "9679cac410e7f63cfc18d0d579d63d8081ec2c09aa9cf1e7c4aac15d1273a725", "class_name": "RelatedNodeInfo"}}, "text": "So, obviously \nwe'll watch that very car efully. ", "start_char_idx": 3391, "end_char_idx": 3440, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fce8fa95-a939-410b-8898-b46cc478d699": {"__data__": {"id_": "fce8fa95-a939-410b-8898-b46cc478d699", "embedding": null, "metadata": {"window": "On a consolidated basis, it doesn't have a material impact. \n But as I called out, it did have an impact on revenues within the Europe segment for the quarter.  So, obviously \nwe'll watch that very car efully.  But as we think about it on a consolidated basis, we don't see an impact.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nGreat.  Thank you.  \n ", "original_text": "But as we think about it on a consolidated basis, we don't see an impact.  \n ", "page_label": "19", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9a5a1cb5-b0d2-459d-9254-d18b99cabab3", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6a841e5456e63a5311a6369d25f04a4e227304d818d637e1167905fecde357d2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "43eeae17-4da6-4370-b582-4d60648881ed", "node_type": "1", "metadata": {"window": "I don't want to predict the direction of the pound.  On a consolidated basis, it doesn't have a material impact. \n But as I called out, it did have an impact on revenues within the Europe segment for the quarter.  So, obviously \nwe'll watch that very car efully.  But as we think about it on a consolidated basis, we don't see an impact.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nGreat. ", "original_text": "So, obviously \nwe'll watch that very car efully. ", "page_label": "19", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e752e71e4c20f515d355f4f82c092722b62e4179a81602155bba8086eb45ea2e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6be6acbc-169e-4910-9217-739cf7da827b", "node_type": "1", "metadata": {"window": "But as I called out, it did have an impact on revenues within the Europe segment for the quarter.  So, obviously \nwe'll watch that very car efully.  But as we think about it on a consolidated basis, we don't see an impact.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nGreat.  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co. "}, "hash": "cefb9c510d6bfa650c1195fa3d43d3589ed39ea48efcdf6f9fcb36aee62ea108", "class_name": "RelatedNodeInfo"}}, "text": "But as we think about it on a consolidated basis, we don't see an impact.  \n ", "start_char_idx": 3440, "end_char_idx": 3517, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6be6acbc-169e-4910-9217-739cf7da827b": {"__data__": {"id_": "6be6acbc-169e-4910-9217-739cf7da827b", "embedding": null, "metadata": {"window": "But as I called out, it did have an impact on revenues within the Europe segment for the quarter.  So, obviously \nwe'll watch that very car efully.  But as we think about it on a consolidated basis, we don't see an impact.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nGreat.  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co. ", "page_label": "19", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9a5a1cb5-b0d2-459d-9254-d18b99cabab3", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6a841e5456e63a5311a6369d25f04a4e227304d818d637e1167905fecde357d2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fce8fa95-a939-410b-8898-b46cc478d699", "node_type": "1", "metadata": {"window": "On a consolidated basis, it doesn't have a material impact. \n But as I called out, it did have an impact on revenues within the Europe segment for the quarter.  So, obviously \nwe'll watch that very car efully.  But as we think about it on a consolidated basis, we don't see an impact.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nGreat.  Thank you.  \n ", "original_text": "But as we think about it on a consolidated basis, we don't see an impact.  \n ", "page_label": "19", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e77704f4ab41f6d7a3cda81339154848e8d53c01a7fa0727553778f7d5ecb395", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "313072b8-2983-4b6c-92b8-39da00d743ae", "node_type": "1", "metadata": {"window": "So, obviously \nwe'll watch that very car efully.  But as we think about it on a consolidated basis, we don't see an impact.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nGreat.  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  \n ", "original_text": "LLC  Q \nGreat. "}, "hash": "0c15703e1f25979805a8f2556dcdd7e36a3f83d60f7f1b0a868686c24e03d871", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co. ", "start_char_idx": 1037, "end_char_idx": 1331, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "313072b8-2983-4b6c-92b8-39da00d743ae": {"__data__": {"id_": "313072b8-2983-4b6c-92b8-39da00d743ae", "embedding": null, "metadata": {"window": "So, obviously \nwe'll watch that very car efully.  But as we think about it on a consolidated basis, we don't see an impact.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nGreat.  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  \n ", "original_text": "LLC  Q \nGreat. ", "page_label": "19", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9a5a1cb5-b0d2-459d-9254-d18b99cabab3", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6a841e5456e63a5311a6369d25f04a4e227304d818d637e1167905fecde357d2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6be6acbc-169e-4910-9217-739cf7da827b", "node_type": "1", "metadata": {"window": "But as I called out, it did have an impact on revenues within the Europe segment for the quarter.  So, obviously \nwe'll watch that very car efully.  But as we think about it on a consolidated basis, we don't see an impact.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nGreat.  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co. ", "page_label": "19", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a099db0cf35cf0218097aded750f66d9bd8b1887de7021b8dacd97987d28cfc7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "74e0a36a-7ead-40fa-aa7c-74dee7ac6c7f", "node_type": "1", "metadata": {"window": "But as we think about it on a consolidated basis, we don't see an impact.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nGreat.  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  ", "original_text": "Thank you.  \n "}, "hash": "1dc29607573c08ae6d132cbbd536b0afae1451a6b079c64bbd083a8963aa9239", "class_name": "RelatedNodeInfo"}}, "text": "LLC  Q \nGreat. ", "start_char_idx": 3811, "end_char_idx": 3826, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "74e0a36a-7ead-40fa-aa7c-74dee7ac6c7f": {"__data__": {"id_": "74e0a36a-7ead-40fa-aa7c-74dee7ac6c7f", "embedding": null, "metadata": {"window": "But as we think about it on a consolidated basis, we don't see an impact.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nGreat.  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  ", "original_text": "Thank you.  \n ", "page_label": "19", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9a5a1cb5-b0d2-459d-9254-d18b99cabab3", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6a841e5456e63a5311a6369d25f04a4e227304d818d637e1167905fecde357d2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "313072b8-2983-4b6c-92b8-39da00d743ae", "node_type": "1", "metadata": {"window": "So, obviously \nwe'll watch that very car efully.  But as we think about it on a consolidated basis, we don't see an impact.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nGreat.  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  \n ", "original_text": "LLC  Q \nGreat. ", "page_label": "19", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4d8d78b0230fc4881d394ac29a90915dc5a58001964b6f5fef9761cab15f367a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f0c52f6a-0e09-4467-9d0f-3448837e2126", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nGreat.  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nOperator, we have time for one more question.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  "}, "hash": "a19ab3a3f06c994af6bbe7787620052e54675865377861acd1e32d0165b26f17", "class_name": "RelatedNodeInfo"}}, "text": "Thank you.  \n ", "start_char_idx": 3826, "end_char_idx": 3840, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f0c52f6a-0e09-4467-9d0f-3448837e2126": {"__data__": {"id_": "f0c52f6a-0e09-4467-9d0f-3448837e2126", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nGreat.  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nOperator, we have time for one more question.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "page_label": "19", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9a5a1cb5-b0d2-459d-9254-d18b99cabab3", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6a841e5456e63a5311a6369d25f04a4e227304d818d637e1167905fecde357d2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "74e0a36a-7ead-40fa-aa7c-74dee7ac6c7f", "node_type": "1", "metadata": {"window": "But as we think about it on a consolidated basis, we don't see an impact.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nGreat.  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  ", "original_text": "Thank you.  \n ", "page_label": "19", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1cdb148ce101c740f888339af28af43245100260a344612b233929fe2d1333f1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0ecefec5-57eb-4898-bc31-31ba61aefc35", "node_type": "1", "metadata": {"window": "LLC  Q \nGreat.  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nOperator, we have time for one more question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n ", "original_text": "A \nYeah.  \n "}, "hash": "f0d4826f7b77b2e655aa8988ccc0f66ea332267ebcee2ef79e73ab1090fdf5c1", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "start_char_idx": 2826, "end_char_idx": 3171, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0ecefec5-57eb-4898-bc31-31ba61aefc35": {"__data__": {"id_": "0ecefec5-57eb-4898-bc31-31ba61aefc35", "embedding": null, "metadata": {"window": "LLC  Q \nGreat.  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nOperator, we have time for one more question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n ", "original_text": "A \nYeah.  \n ", "page_label": "19", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9a5a1cb5-b0d2-459d-9254-d18b99cabab3", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6a841e5456e63a5311a6369d25f04a4e227304d818d637e1167905fecde357d2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f0c52f6a-0e09-4467-9d0f-3448837e2126", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nGreat.  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nOperator, we have time for one more question.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "page_label": "19", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e5fd6b7d35a6a9a1ba24be40de2b03472ab204cd31cc52f0230ef6059912ff0d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "eb14726c-2ed7-43ce-bc4e-a1a784dfdedd", "node_type": "1", "metadata": {"window": "Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nOperator, we have time for one more question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  "}, "hash": "734707c647eb8a0ef1a075c1f0bbf8d8d409c547a7e6bcae47939b670661acbf", "class_name": "RelatedNodeInfo"}}, "text": "A \nYeah.  \n ", "start_char_idx": 4185, "end_char_idx": 4197, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "eb14726c-2ed7-43ce-bc4e-a1a784dfdedd": {"__data__": {"id_": "eb14726c-2ed7-43ce-bc4e-a1a784dfdedd", "embedding": null, "metadata": {"window": "Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nOperator, we have time for one more question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  ", "page_label": "19", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9a5a1cb5-b0d2-459d-9254-d18b99cabab3", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6a841e5456e63a5311a6369d25f04a4e227304d818d637e1167905fecde357d2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0ecefec5-57eb-4898-bc31-31ba61aefc35", "node_type": "1", "metadata": {"window": "LLC  Q \nGreat.  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nOperator, we have time for one more question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n ", "original_text": "A \nYeah.  \n ", "page_label": "19", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e7950bf68afa3b1fea23a6b68c4050a58319c8da10908a2c1e25fde3da973c4d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7f79b906-734d-4f2c-831f-909522462212", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nOperator, we have time for one more question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n ", "original_text": "A \nOperator, we have time for one more question.  \n "}, "hash": "8e821d5df211f8b2548cf76e60d599e616ec59df0b3c760073cf7c6d2f4fb380", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  ", "start_char_idx": 4197, "end_char_idx": 4527, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7f79b906-734d-4f2c-831f-909522462212": {"__data__": {"id_": "7f79b906-734d-4f2c-831f-909522462212", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nOperator, we have time for one more question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n ", "original_text": "A \nOperator, we have time for one more question.  \n ", "page_label": "19", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9a5a1cb5-b0d2-459d-9254-d18b99cabab3", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6a841e5456e63a5311a6369d25f04a4e227304d818d637e1167905fecde357d2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "eb14726c-2ed7-43ce-bc4e-a1a784dfdedd", "node_type": "1", "metadata": {"window": "Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nOperator, we have time for one more question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  ", "page_label": "19", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ec7f995cc03325ea36a2567b6bc994c5fecf328d872c8b1a87df4e7255be928b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f4e96e1a-867d-4f51-9e29-f20e2bdd32ad", "node_type": "1", "metadata": {"window": "A \nYeah.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nOperator, we have time for one more question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n "}, "hash": "15abe28defa86d72dea22133bf684ed13e363aebe1503f5dfb4869ca91100916", "class_name": "RelatedNodeInfo"}}, "text": "A \nOperator, we have time for one more question.  \n ", "start_char_idx": 4527, "end_char_idx": 4579, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f4e96e1a-867d-4f51-9e29-f20e2bdd32ad": {"__data__": {"id_": "f4e96e1a-867d-4f51-9e29-f20e2bdd32ad", "embedding": null, "metadata": {"window": "A \nYeah.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nOperator, we have time for one more question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n ", "page_label": "19", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9a5a1cb5-b0d2-459d-9254-d18b99cabab3", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6a841e5456e63a5311a6369d25f04a4e227304d818d637e1167905fecde357d2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7f79b906-734d-4f2c-831f-909522462212", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nOperator, we have time for one more question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n ", "original_text": "A \nOperator, we have time for one more question.  \n ", "page_label": "19", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8ee18230f52fde73f2f227986d8c57e394b81bfea73739704c29d38fbb6ddad6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a18fb39d-23f9-46dd-a397-78e2b74df3e2", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nOperator : Certainly.  That question will come from Eric Coldwell with Robert W. Baird.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric W. Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  ", "original_text": "McKesson Corp.  "}, "hash": "4429fc39b467650dc14b054ceb7b766ed526cb4caaf67c9b3e24db6b0fa007b5", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n ", "start_char_idx": 4579, "end_char_idx": 4837, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a18fb39d-23f9-46dd-a397-78e2b74df3e2": {"__data__": {"id_": "a18fb39d-23f9-46dd-a397-78e2b74df3e2", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nOperator : Certainly.  That question will come from Eric Coldwell with Robert W. Baird.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric W. Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  ", "original_text": "McKesson Corp.  ", "page_label": "20", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4e2cffb7-52f8-4787-88a1-36ae788b9cf5", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e8eff96e0b9e3d1243536b9a9e25c9e45de90c1d5111b67106c1655eea65c0c8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f4e96e1a-867d-4f51-9e29-f20e2bdd32ad", "node_type": "1", "metadata": {"window": "A \nYeah.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.   A \nOperator, we have time for one more question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n ", "page_label": "19", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5cc6aeba190e3a58d7eadc29d0b4f1def3e9eef489c7b9077ceca3cbfcf835d5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cf591735-1297-4de4-9463-6904f10dd6c6", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nOperator : Certainly.  That question will come from Eric Coldwell with Robert W. Baird.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric W. Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nOkay. ", "original_text": "(MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nOperator : Certainly. "}, "hash": "4c824944aef5da1736da351b746ff7d56d623e89aa51b91f25733cc7f4e662fa", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cf591735-1297-4de4-9463-6904f10dd6c6": {"__data__": {"id_": "cf591735-1297-4de4-9463-6904f10dd6c6", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nOperator : Certainly.  That question will come from Eric Coldwell with Robert W. Baird.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric W. Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nOkay. ", "original_text": "(MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nOperator : Certainly. ", "page_label": "20", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4e2cffb7-52f8-4787-88a1-36ae788b9cf5", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e8eff96e0b9e3d1243536b9a9e25c9e45de90c1d5111b67106c1655eea65c0c8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a18fb39d-23f9-46dd-a397-78e2b74df3e2", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nOperator : Certainly.  That question will come from Eric Coldwell with Robert W. Baird.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric W. Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  ", "original_text": "McKesson Corp.  ", "page_label": "20", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5db098620362f5850cae86577c91f74e4b767f8962095261d93dc064f3e1ed26", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b84552a4-3530-4f50-965d-84286ad087c0", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nOperator : Certainly.  That question will come from Eric Coldwell with Robert W. Baird.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric W. Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nOkay.  Thanks very much, and good evening. ", "original_text": "That question will come from Eric Coldwell with Robert W. Baird.  \n "}, "hash": "6be739cf230031dc20c1af5a687a57884877884bbe35709e3184a2df8516dfbb", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nOperator : Certainly. ", "start_char_idx": 16, "end_char_idx": 203, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b84552a4-3530-4f50-965d-84286ad087c0": {"__data__": {"id_": "b84552a4-3530-4f50-965d-84286ad087c0", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nOperator : Certainly.  That question will come from Eric Coldwell with Robert W. Baird.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric W. Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nOkay.  Thanks very much, and good evening. ", "original_text": "That question will come from Eric Coldwell with Robert W. Baird.  \n ", "page_label": "20", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4e2cffb7-52f8-4787-88a1-36ae788b9cf5", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e8eff96e0b9e3d1243536b9a9e25c9e45de90c1d5111b67106c1655eea65c0c8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cf591735-1297-4de4-9463-6904f10dd6c6", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nOperator : Certainly.  That question will come from Eric Coldwell with Robert W. Baird.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric W. Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nOkay. ", "original_text": "(MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nOperator : Certainly. ", "page_label": "20", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "83b14fabd267c8242ad267fe934bf2da98f23cf63b2971d05a8086a437223aef", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6bd7de86-9a07-4a9d-bae7-0fbd08c7452a", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nOperator : Certainly.  That question will come from Eric Coldwell with Robert W. Baird.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric W. Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nOkay.  Thanks very much, and good evening.  Most of my main ones were covered, but I'll shift gears a bit. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric W. Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  "}, "hash": "13f43c6c3b681bbd750a003d9928bf32ec324f006bb9749d2eb0f6bdacf07768", "class_name": "RelatedNodeInfo"}}, "text": "That question will come from Eric Coldwell with Robert W. Baird.  \n ", "start_char_idx": 203, "end_char_idx": 271, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6bd7de86-9a07-4a9d-bae7-0fbd08c7452a": {"__data__": {"id_": "6bd7de86-9a07-4a9d-bae7-0fbd08c7452a", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nOperator : Certainly.  That question will come from Eric Coldwell with Robert W. Baird.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric W. Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nOkay.  Thanks very much, and good evening.  Most of my main ones were covered, but I'll shift gears a bit. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric W. Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  ", "page_label": "20", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4e2cffb7-52f8-4787-88a1-36ae788b9cf5", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e8eff96e0b9e3d1243536b9a9e25c9e45de90c1d5111b67106c1655eea65c0c8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b84552a4-3530-4f50-965d-84286ad087c0", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nOperator : Certainly.  That question will come from Eric Coldwell with Robert W. Baird.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric W. Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nOkay.  Thanks very much, and good evening. ", "original_text": "That question will come from Eric Coldwell with Robert W. Baird.  \n ", "page_label": "20", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "412172cfd857dc06c9c0593512d019f845fd05fd300886b13651ee05ddf5bbd0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dc76c41a-cece-4f99-b0b6-ed72a75445f9", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nOperator : Certainly.  That question will come from Eric Coldwell with Robert W. Baird.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric W. Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nOkay.  Thanks very much, and good evening.  Most of my main ones were covered, but I'll shift gears a bit.  I'd like \nyour thoughts on generic introductions for the rest of the year. ", "original_text": "Q \nOkay. "}, "hash": "f5503a3e0b66fad9fa272d62cd6836b381f3aa5d245a0e2c7c1b550485dd746f", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric W. Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  ", "start_char_idx": 271, "end_char_idx": 585, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dc76c41a-cece-4f99-b0b6-ed72a75445f9": {"__data__": {"id_": "dc76c41a-cece-4f99-b0b6-ed72a75445f9", "embedding": null, "metadata": {"window": "(MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nOperator : Certainly.  That question will come from Eric Coldwell with Robert W. Baird.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric W. Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nOkay.  Thanks very much, and good evening.  Most of my main ones were covered, but I'll shift gears a bit.  I'd like \nyour thoughts on generic introductions for the rest of the year. ", "original_text": "Q \nOkay. ", "page_label": "20", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4e2cffb7-52f8-4787-88a1-36ae788b9cf5", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e8eff96e0b9e3d1243536b9a9e25c9e45de90c1d5111b67106c1655eea65c0c8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6bd7de86-9a07-4a9d-bae7-0fbd08c7452a", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nOperator : Certainly.  That question will come from Eric Coldwell with Robert W. Baird.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric W. Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nOkay.  Thanks very much, and good evening.  Most of my main ones were covered, but I'll shift gears a bit. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric W. Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  ", "page_label": "20", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "eca7490abad8d2ec63f97398c7609d9b9f4c13866d62a8370412f1a2d9223682", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7eb25e81-6a97-4faf-b8fc-926a4dde97ab", "node_type": "1", "metadata": {"window": "That question will come from Eric Coldwell with Robert W. Baird.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric W. Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nOkay.  Thanks very much, and good evening.  Most of my main ones were covered, but I'll shift gears a bit.  I'd like \nyour thoughts on generic introductions for the rest of the year.  If possible, expected to be a good guy or a bad guy \nto profitability on a yea r-over-year basis?  \n \n", "original_text": "Thanks very much, and good evening. "}, "hash": "ca61d5599aeb46c1bf18df9ab1c4e3fc1ce8902ae3abd555fcfcfc795eafef89", "class_name": "RelatedNodeInfo"}}, "text": "Q \nOkay. ", "start_char_idx": 585, "end_char_idx": 594, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7eb25e81-6a97-4faf-b8fc-926a4dde97ab": {"__data__": {"id_": "7eb25e81-6a97-4faf-b8fc-926a4dde97ab", "embedding": null, "metadata": {"window": "That question will come from Eric Coldwell with Robert W. Baird.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric W. Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nOkay.  Thanks very much, and good evening.  Most of my main ones were covered, but I'll shift gears a bit.  I'd like \nyour thoughts on generic introductions for the rest of the year.  If possible, expected to be a good guy or a bad guy \nto profitability on a yea r-over-year basis?  \n \n", "original_text": "Thanks very much, and good evening. ", "page_label": "20", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4e2cffb7-52f8-4787-88a1-36ae788b9cf5", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e8eff96e0b9e3d1243536b9a9e25c9e45de90c1d5111b67106c1655eea65c0c8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dc76c41a-cece-4f99-b0b6-ed72a75445f9", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nOperator : Certainly.  That question will come from Eric Coldwell with Robert W. Baird.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric W. Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nOkay.  Thanks very much, and good evening.  Most of my main ones were covered, but I'll shift gears a bit.  I'd like \nyour thoughts on generic introductions for the rest of the year. ", "original_text": "Q \nOkay. ", "page_label": "20", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a4dbc8c954c837461c51bda5d1e85dfde40f40960e1e4ba5af6cd6d440a86662", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "faadcea3-e5be-4f50-b6e6-4160d2b65e70", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric W. Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nOkay.  Thanks very much, and good evening.  Most of my main ones were covered, but I'll shift gears a bit.  I'd like \nyour thoughts on generic introductions for the rest of the year.  If possible, expected to be a good guy or a bad guy \nto profitability on a yea r-over-year basis?  \n \n And then specifically, if I dare ask, Lyrica comes out with roughly 10 manufacturers of very low initial price. ", "original_text": "Most of my main ones were covered, but I'll shift gears a bit. "}, "hash": "38899c819794651810237275114e8392189953bffe1c2b311bd08b2e21f6eec6", "class_name": "RelatedNodeInfo"}}, "text": "Thanks very much, and good evening. ", "start_char_idx": 594, "end_char_idx": 630, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "faadcea3-e5be-4f50-b6e6-4160d2b65e70": {"__data__": {"id_": "faadcea3-e5be-4f50-b6e6-4160d2b65e70", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric W. Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nOkay.  Thanks very much, and good evening.  Most of my main ones were covered, but I'll shift gears a bit.  I'd like \nyour thoughts on generic introductions for the rest of the year.  If possible, expected to be a good guy or a bad guy \nto profitability on a yea r-over-year basis?  \n \n And then specifically, if I dare ask, Lyrica comes out with roughly 10 manufacturers of very low initial price. ", "original_text": "Most of my main ones were covered, but I'll shift gears a bit. ", "page_label": "20", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4e2cffb7-52f8-4787-88a1-36ae788b9cf5", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e8eff96e0b9e3d1243536b9a9e25c9e45de90c1d5111b67106c1655eea65c0c8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7eb25e81-6a97-4faf-b8fc-926a4dde97ab", "node_type": "1", "metadata": {"window": "That question will come from Eric Coldwell with Robert W. Baird.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric W. Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nOkay.  Thanks very much, and good evening.  Most of my main ones were covered, but I'll shift gears a bit.  I'd like \nyour thoughts on generic introductions for the rest of the year.  If possible, expected to be a good guy or a bad guy \nto profitability on a yea r-over-year basis?  \n \n", "original_text": "Thanks very much, and good evening. ", "page_label": "20", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "41f8a269a7fce6677e950f9530fb707bf173e4e8d8bcdd80ba349a3ea266b140", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "939fd782-ba53-4bd7-ba45-e4dd5395343e", "node_type": "1", "metadata": {"window": "Q \nOkay.  Thanks very much, and good evening.  Most of my main ones were covered, but I'll shift gears a bit.  I'd like \nyour thoughts on generic introductions for the rest of the year.  If possible, expected to be a good guy or a bad guy \nto profitability on a yea r-over-year basis?  \n \n And then specifically, if I dare ask, Lyrica comes out with roughly 10 manufacturers of very low initial price.  How \ndid that impact \u2013 pretty big product. ", "original_text": "I'd like \nyour thoughts on generic introductions for the rest of the year. "}, "hash": "bbd228ecca72701082c89c7ca3100ef6d04bfc08af133d1d29be0c4708517a60", "class_name": "RelatedNodeInfo"}}, "text": "Most of my main ones were covered, but I'll shift gears a bit. ", "start_char_idx": 630, "end_char_idx": 693, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "939fd782-ba53-4bd7-ba45-e4dd5395343e": {"__data__": {"id_": "939fd782-ba53-4bd7-ba45-e4dd5395343e", "embedding": null, "metadata": {"window": "Q \nOkay.  Thanks very much, and good evening.  Most of my main ones were covered, but I'll shift gears a bit.  I'd like \nyour thoughts on generic introductions for the rest of the year.  If possible, expected to be a good guy or a bad guy \nto profitability on a yea r-over-year basis?  \n \n And then specifically, if I dare ask, Lyrica comes out with roughly 10 manufacturers of very low initial price.  How \ndid that impact \u2013 pretty big product. ", "original_text": "I'd like \nyour thoughts on generic introductions for the rest of the year. ", "page_label": "20", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4e2cffb7-52f8-4787-88a1-36ae788b9cf5", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e8eff96e0b9e3d1243536b9a9e25c9e45de90c1d5111b67106c1655eea65c0c8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "faadcea3-e5be-4f50-b6e6-4160d2b65e70", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric W. Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nOkay.  Thanks very much, and good evening.  Most of my main ones were covered, but I'll shift gears a bit.  I'd like \nyour thoughts on generic introductions for the rest of the year.  If possible, expected to be a good guy or a bad guy \nto profitability on a yea r-over-year basis?  \n \n And then specifically, if I dare ask, Lyrica comes out with roughly 10 manufacturers of very low initial price. ", "original_text": "Most of my main ones were covered, but I'll shift gears a bit. ", "page_label": "20", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d8bf173333dd489616e41d60142b9f8a004c662193448a7af01cbc34984cbc47", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d6ec9846-fdc1-40ec-a703-9d1361a505cf", "node_type": "1", "metadata": {"window": "Thanks very much, and good evening.  Most of my main ones were covered, but I'll shift gears a bit.  I'd like \nyour thoughts on generic introductions for the rest of the year.  If possible, expected to be a good guy or a bad guy \nto profitability on a yea r-over-year basis?  \n \n And then specifically, if I dare ask, Lyrica comes out with roughly 10 manufacturers of very low initial price.  How \ndid that impact \u2013 pretty big product.  How did that impact your thinking on generic profitability and trends in that \nmark et seeing so many manufacturers launch such a deep discount to the brand?  \n ", "original_text": "If possible, expected to be a good guy or a bad guy \nto profitability on a yea r-over-year basis?  \n \n"}, "hash": "eb015706b55b0bcce7f707ea31e714e32e5627d905abb3932c9ab134ba73856b", "class_name": "RelatedNodeInfo"}}, "text": "I'd like \nyour thoughts on generic introductions for the rest of the year. ", "start_char_idx": 693, "end_char_idx": 768, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d6ec9846-fdc1-40ec-a703-9d1361a505cf": {"__data__": {"id_": "d6ec9846-fdc1-40ec-a703-9d1361a505cf", "embedding": null, "metadata": {"window": "Thanks very much, and good evening.  Most of my main ones were covered, but I'll shift gears a bit.  I'd like \nyour thoughts on generic introductions for the rest of the year.  If possible, expected to be a good guy or a bad guy \nto profitability on a yea r-over-year basis?  \n \n And then specifically, if I dare ask, Lyrica comes out with roughly 10 manufacturers of very low initial price.  How \ndid that impact \u2013 pretty big product.  How did that impact your thinking on generic profitability and trends in that \nmark et seeing so many manufacturers launch such a deep discount to the brand?  \n ", "original_text": "If possible, expected to be a good guy or a bad guy \nto profitability on a yea r-over-year basis?  \n \n", "page_label": "20", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4e2cffb7-52f8-4787-88a1-36ae788b9cf5", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e8eff96e0b9e3d1243536b9a9e25c9e45de90c1d5111b67106c1655eea65c0c8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "939fd782-ba53-4bd7-ba45-e4dd5395343e", "node_type": "1", "metadata": {"window": "Q \nOkay.  Thanks very much, and good evening.  Most of my main ones were covered, but I'll shift gears a bit.  I'd like \nyour thoughts on generic introductions for the rest of the year.  If possible, expected to be a good guy or a bad guy \nto profitability on a yea r-over-year basis?  \n \n And then specifically, if I dare ask, Lyrica comes out with roughly 10 manufacturers of very low initial price.  How \ndid that impact \u2013 pretty big product. ", "original_text": "I'd like \nyour thoughts on generic introductions for the rest of the year. ", "page_label": "20", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "50268c1c5c78e28330847e3dfee027e6c547312275e318465715a4fe06b06500", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9eea5199-05d3-43c9-b4f8-c7861d03c86a", "node_type": "1", "metadata": {"window": "Most of my main ones were covered, but I'll shift gears a bit.  I'd like \nyour thoughts on generic introductions for the rest of the year.  If possible, expected to be a good guy or a bad guy \nto profitability on a yea r-over-year basis?  \n \n And then specifically, if I dare ask, Lyrica comes out with roughly 10 manufacturers of very low initial price.  How \ndid that impact \u2013 pretty big product.  How did that impact your thinking on generic profitability and trends in that \nmark et seeing so many manufacturers launch such a deep discount to the brand?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "And then specifically, if I dare ask, Lyrica comes out with roughly 10 manufacturers of very low initial price. "}, "hash": "58c0172ce01c92388c26b09dec818fdfab2522306d3b8292e0743b890cad9e79", "class_name": "RelatedNodeInfo"}}, "text": "If possible, expected to be a good guy or a bad guy \nto profitability on a yea r-over-year basis?  \n \n", "start_char_idx": 768, "end_char_idx": 870, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9eea5199-05d3-43c9-b4f8-c7861d03c86a": {"__data__": {"id_": "9eea5199-05d3-43c9-b4f8-c7861d03c86a", "embedding": null, "metadata": {"window": "Most of my main ones were covered, but I'll shift gears a bit.  I'd like \nyour thoughts on generic introductions for the rest of the year.  If possible, expected to be a good guy or a bad guy \nto profitability on a yea r-over-year basis?  \n \n And then specifically, if I dare ask, Lyrica comes out with roughly 10 manufacturers of very low initial price.  How \ndid that impact \u2013 pretty big product.  How did that impact your thinking on generic profitability and trends in that \nmark et seeing so many manufacturers launch such a deep discount to the brand?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "And then specifically, if I dare ask, Lyrica comes out with roughly 10 manufacturers of very low initial price. ", "page_label": "20", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4e2cffb7-52f8-4787-88a1-36ae788b9cf5", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e8eff96e0b9e3d1243536b9a9e25c9e45de90c1d5111b67106c1655eea65c0c8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d6ec9846-fdc1-40ec-a703-9d1361a505cf", "node_type": "1", "metadata": {"window": "Thanks very much, and good evening.  Most of my main ones were covered, but I'll shift gears a bit.  I'd like \nyour thoughts on generic introductions for the rest of the year.  If possible, expected to be a good guy or a bad guy \nto profitability on a yea r-over-year basis?  \n \n And then specifically, if I dare ask, Lyrica comes out with roughly 10 manufacturers of very low initial price.  How \ndid that impact \u2013 pretty big product.  How did that impact your thinking on generic profitability and trends in that \nmark et seeing so many manufacturers launch such a deep discount to the brand?  \n ", "original_text": "If possible, expected to be a good guy or a bad guy \nto profitability on a yea r-over-year basis?  \n \n", "page_label": "20", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9cc1360125cf5e29e93c1bb5f9306393e6274799f16fe12e7cad44ab8f140644", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5ab59ac4-0f29-4b56-8574-908759f19335", "node_type": "1", "metadata": {"window": "I'd like \nyour thoughts on generic introductions for the rest of the year.  If possible, expected to be a good guy or a bad guy \nto profitability on a yea r-over-year basis?  \n \n And then specifically, if I dare ask, Lyrica comes out with roughly 10 manufacturers of very low initial price.  How \ndid that impact \u2013 pretty big product.  How did that impact your thinking on generic profitability and trends in that \nmark et seeing so many manufacturers launch such a deep discount to the brand?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah. ", "original_text": "How \ndid that impact \u2013 pretty big product. "}, "hash": "391ef7b927b2d9852ef9e037e098b955d4f45ade3feeb51d87f658805def8deb", "class_name": "RelatedNodeInfo"}}, "text": "And then specifically, if I dare ask, Lyrica comes out with roughly 10 manufacturers of very low initial price. ", "start_char_idx": 870, "end_char_idx": 982, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5ab59ac4-0f29-4b56-8574-908759f19335": {"__data__": {"id_": "5ab59ac4-0f29-4b56-8574-908759f19335", "embedding": null, "metadata": {"window": "I'd like \nyour thoughts on generic introductions for the rest of the year.  If possible, expected to be a good guy or a bad guy \nto profitability on a yea r-over-year basis?  \n \n And then specifically, if I dare ask, Lyrica comes out with roughly 10 manufacturers of very low initial price.  How \ndid that impact \u2013 pretty big product.  How did that impact your thinking on generic profitability and trends in that \nmark et seeing so many manufacturers launch such a deep discount to the brand?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah. ", "original_text": "How \ndid that impact \u2013 pretty big product. ", "page_label": "20", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4e2cffb7-52f8-4787-88a1-36ae788b9cf5", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e8eff96e0b9e3d1243536b9a9e25c9e45de90c1d5111b67106c1655eea65c0c8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9eea5199-05d3-43c9-b4f8-c7861d03c86a", "node_type": "1", "metadata": {"window": "Most of my main ones were covered, but I'll shift gears a bit.  I'd like \nyour thoughts on generic introductions for the rest of the year.  If possible, expected to be a good guy or a bad guy \nto profitability on a yea r-over-year basis?  \n \n And then specifically, if I dare ask, Lyrica comes out with roughly 10 manufacturers of very low initial price.  How \ndid that impact \u2013 pretty big product.  How did that impact your thinking on generic profitability and trends in that \nmark et seeing so many manufacturers launch such a deep discount to the brand?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "And then specifically, if I dare ask, Lyrica comes out with roughly 10 manufacturers of very low initial price. ", "page_label": "20", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "aef3f1e0b7fd0de1af87ade23bfc3c3b75f73243e55e59dc101ccd25ab1e3350", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0a2bdbaf-7154-486b-949c-4815b692db1e", "node_type": "1", "metadata": {"window": "If possible, expected to be a good guy or a bad guy \nto profitability on a yea r-over-year basis?  \n \n And then specifically, if I dare ask, Lyrica comes out with roughly 10 manufacturers of very low initial price.  How \ndid that impact \u2013 pretty big product.  How did that impact your thinking on generic profitability and trends in that \nmark et seeing so many manufacturers launch such a deep discount to the brand?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Thanks for that question. ", "original_text": "How did that impact your thinking on generic profitability and trends in that \nmark et seeing so many manufacturers launch such a deep discount to the brand?  \n "}, "hash": "2b7304876f8bbe3d71e47a05f7ec47cef8137a1688275b0d735deb1b4869b4f3", "class_name": "RelatedNodeInfo"}}, "text": "How \ndid that impact \u2013 pretty big product. ", "start_char_idx": 982, "end_char_idx": 1025, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0a2bdbaf-7154-486b-949c-4815b692db1e": {"__data__": {"id_": "0a2bdbaf-7154-486b-949c-4815b692db1e", "embedding": null, "metadata": {"window": "If possible, expected to be a good guy or a bad guy \nto profitability on a yea r-over-year basis?  \n \n And then specifically, if I dare ask, Lyrica comes out with roughly 10 manufacturers of very low initial price.  How \ndid that impact \u2013 pretty big product.  How did that impact your thinking on generic profitability and trends in that \nmark et seeing so many manufacturers launch such a deep discount to the brand?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Thanks for that question. ", "original_text": "How did that impact your thinking on generic profitability and trends in that \nmark et seeing so many manufacturers launch such a deep discount to the brand?  \n ", "page_label": "20", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4e2cffb7-52f8-4787-88a1-36ae788b9cf5", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e8eff96e0b9e3d1243536b9a9e25c9e45de90c1d5111b67106c1655eea65c0c8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5ab59ac4-0f29-4b56-8574-908759f19335", "node_type": "1", "metadata": {"window": "I'd like \nyour thoughts on generic introductions for the rest of the year.  If possible, expected to be a good guy or a bad guy \nto profitability on a yea r-over-year basis?  \n \n And then specifically, if I dare ask, Lyrica comes out with roughly 10 manufacturers of very low initial price.  How \ndid that impact \u2013 pretty big product.  How did that impact your thinking on generic profitability and trends in that \nmark et seeing so many manufacturers launch such a deep discount to the brand?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah. ", "original_text": "How \ndid that impact \u2013 pretty big product. ", "page_label": "20", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7953906fc6bff5edc09face0e2e9d2366732c91638578131c847f4b322312fcd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "552542a3-4607-4f23-8627-c107b4a36230", "node_type": "1", "metadata": {"window": "And then specifically, if I dare ask, Lyrica comes out with roughly 10 manufacturers of very low initial price.  How \ndid that impact \u2013 pretty big product.  How did that impact your thinking on generic profitability and trends in that \nmark et seeing so many manufacturers launch such a deep discount to the brand?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Thanks for that question.  Generic launches, as we've talked about, do not have the size of impact that  they \nused to have. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  "}, "hash": "12c55fb15369d9ddf6f5db8eeb181d2bd98675c8a3c53f8f3b230e1ad769489f", "class_name": "RelatedNodeInfo"}}, "text": "How did that impact your thinking on generic profitability and trends in that \nmark et seeing so many manufacturers launch such a deep discount to the brand?  \n ", "start_char_idx": 1025, "end_char_idx": 1186, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "552542a3-4607-4f23-8627-c107b4a36230": {"__data__": {"id_": "552542a3-4607-4f23-8627-c107b4a36230", "embedding": null, "metadata": {"window": "And then specifically, if I dare ask, Lyrica comes out with roughly 10 manufacturers of very low initial price.  How \ndid that impact \u2013 pretty big product.  How did that impact your thinking on generic profitability and trends in that \nmark et seeing so many manufacturers launch such a deep discount to the brand?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Thanks for that question.  Generic launches, as we've talked about, do not have the size of impact that  they \nused to have. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "20", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4e2cffb7-52f8-4787-88a1-36ae788b9cf5", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e8eff96e0b9e3d1243536b9a9e25c9e45de90c1d5111b67106c1655eea65c0c8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0a2bdbaf-7154-486b-949c-4815b692db1e", "node_type": "1", "metadata": {"window": "If possible, expected to be a good guy or a bad guy \nto profitability on a yea r-over-year basis?  \n \n And then specifically, if I dare ask, Lyrica comes out with roughly 10 manufacturers of very low initial price.  How \ndid that impact \u2013 pretty big product.  How did that impact your thinking on generic profitability and trends in that \nmark et seeing so many manufacturers launch such a deep discount to the brand?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Thanks for that question. ", "original_text": "How did that impact your thinking on generic profitability and trends in that \nmark et seeing so many manufacturers launch such a deep discount to the brand?  \n ", "page_label": "20", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "922148f79333d3f4489690709d4998ce9f1d155c121d185755f0091850361788", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d89e7915-d76c-498b-b1f3-49cc259205ae", "node_type": "1", "metadata": {"window": "How \ndid that impact \u2013 pretty big product.  How did that impact your thinking on generic profitability and trends in that \nmark et seeing so many manufacturers launch such a deep discount to the brand?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Thanks for that question.  Generic launches, as we've talked about, do not have the size of impact that  they \nused to have.  They have a modest impact on our profitability. ", "original_text": "A \nYeah. "}, "hash": "b7a14130bfc6583c0d3a18f9d884b1af26e9d23e6da881c0ae41da2f37b1b2aa", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "start_char_idx": 1186, "end_char_idx": 1515, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d89e7915-d76c-498b-b1f3-49cc259205ae": {"__data__": {"id_": "d89e7915-d76c-498b-b1f3-49cc259205ae", "embedding": null, "metadata": {"window": "How \ndid that impact \u2013 pretty big product.  How did that impact your thinking on generic profitability and trends in that \nmark et seeing so many manufacturers launch such a deep discount to the brand?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Thanks for that question.  Generic launches, as we've talked about, do not have the size of impact that  they \nused to have.  They have a modest impact on our profitability. ", "original_text": "A \nYeah. ", "page_label": "20", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4e2cffb7-52f8-4787-88a1-36ae788b9cf5", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e8eff96e0b9e3d1243536b9a9e25c9e45de90c1d5111b67106c1655eea65c0c8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "552542a3-4607-4f23-8627-c107b4a36230", "node_type": "1", "metadata": {"window": "And then specifically, if I dare ask, Lyrica comes out with roughly 10 manufacturers of very low initial price.  How \ndid that impact \u2013 pretty big product.  How did that impact your thinking on generic profitability and trends in that \nmark et seeing so many manufacturers launch such a deep discount to the brand?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Thanks for that question.  Generic launches, as we've talked about, do not have the size of impact that  they \nused to have. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "20", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "71401a8da51f7da3d85ffa11e23aa715d2d390d9791c61b20e0ff1eecd0e19ec", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a85cafb5-785c-4b31-93a7-c6220f4bfc2f", "node_type": "1", "metadata": {"window": "How did that impact your thinking on generic profitability and trends in that \nmark et seeing so many manufacturers launch such a deep discount to the brand?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Thanks for that question.  Generic launches, as we've talked about, do not have the size of impact that  they \nused to have.  They have a modest impact on our profitability.  So we don't see that having any change from our \nprevious views on that. ", "original_text": "Thanks for that question. "}, "hash": "f95a44cbb5780451aa714d6eefb49a4e754a3ba3dfc21621fc265edaeb809257", "class_name": "RelatedNodeInfo"}}, "text": "A \nYeah. ", "start_char_idx": 1515, "end_char_idx": 1524, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a85cafb5-785c-4b31-93a7-c6220f4bfc2f": {"__data__": {"id_": "a85cafb5-785c-4b31-93a7-c6220f4bfc2f", "embedding": null, "metadata": {"window": "How did that impact your thinking on generic profitability and trends in that \nmark et seeing so many manufacturers launch such a deep discount to the brand?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Thanks for that question.  Generic launches, as we've talked about, do not have the size of impact that  they \nused to have.  They have a modest impact on our profitability.  So we don't see that having any change from our \nprevious views on that. ", "original_text": "Thanks for that question. ", "page_label": "20", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4e2cffb7-52f8-4787-88a1-36ae788b9cf5", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e8eff96e0b9e3d1243536b9a9e25c9e45de90c1d5111b67106c1655eea65c0c8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d89e7915-d76c-498b-b1f3-49cc259205ae", "node_type": "1", "metadata": {"window": "How \ndid that impact \u2013 pretty big product.  How did that impact your thinking on generic profitability and trends in that \nmark et seeing so many manufacturers launch such a deep discount to the brand?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Thanks for that question.  Generic launches, as we've talked about, do not have the size of impact that  they \nused to have.  They have a modest impact on our profitability. ", "original_text": "A \nYeah. ", "page_label": "20", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "835c5665a711c0d072cf269208b217d27c9d57b9ae7cd23bc552f897873d0095", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "94148a94-941d-4c66-90e8-ff62b51f2708", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Thanks for that question.  Generic launches, as we've talked about, do not have the size of impact that  they \nused to have.  They have a modest impact on our profitability.  So we don't see that having any change from our \nprevious views on that.  In terms of Lyrica, we're very fortunate to have a strong sourcing organization like \nClarusONE, where we can partner  with multiple manufacturers. ", "original_text": "Generic launches, as we've talked about, do not have the size of impact that  they \nused to have. "}, "hash": "fbe4509b859fbf6e563066a6dba642ca5189b2f028cebe0f9f195ad558380aa2", "class_name": "RelatedNodeInfo"}}, "text": "Thanks for that question. ", "start_char_idx": 1524, "end_char_idx": 1550, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "94148a94-941d-4c66-90e8-ff62b51f2708": {"__data__": {"id_": "94148a94-941d-4c66-90e8-ff62b51f2708", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Thanks for that question.  Generic launches, as we've talked about, do not have the size of impact that  they \nused to have.  They have a modest impact on our profitability.  So we don't see that having any change from our \nprevious views on that.  In terms of Lyrica, we're very fortunate to have a strong sourcing organization like \nClarusONE, where we can partner  with multiple manufacturers. ", "original_text": "Generic launches, as we've talked about, do not have the size of impact that  they \nused to have. ", "page_label": "20", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4e2cffb7-52f8-4787-88a1-36ae788b9cf5", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e8eff96e0b9e3d1243536b9a9e25c9e45de90c1d5111b67106c1655eea65c0c8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a85cafb5-785c-4b31-93a7-c6220f4bfc2f", "node_type": "1", "metadata": {"window": "How did that impact your thinking on generic profitability and trends in that \nmark et seeing so many manufacturers launch such a deep discount to the brand?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Thanks for that question.  Generic launches, as we've talked about, do not have the size of impact that  they \nused to have.  They have a modest impact on our profitability.  So we don't see that having any change from our \nprevious views on that. ", "original_text": "Thanks for that question. ", "page_label": "20", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0dd8ff70799c6e354f6acd6a2e11a0d5792039b3b257b77a39da52698918b558", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "60eb20e3-fa49-4a88-b2fe-e37f9bee834f", "node_type": "1", "metadata": {"window": "A \nYeah.  Thanks for that question.  Generic launches, as we've talked about, do not have the size of impact that  they \nused to have.  They have a modest impact on our profitability.  So we don't see that having any change from our \nprevious views on that.  In terms of Lyrica, we're very fortunate to have a strong sourcing organization like \nClarusONE, where we can partner  with multiple manufacturers.  We don't see that Lyrica is going to change the \ndirection of our generics profitability; it'll certainly be a benefit for us and it'll certainly be a benefit from our \ncustomers. ", "original_text": "They have a modest impact on our profitability. "}, "hash": "14148fc1f835cc9ab9082d32f5f88d333277f7a8fae30c5b950bcf06985e6dca", "class_name": "RelatedNodeInfo"}}, "text": "Generic launches, as we've talked about, do not have the size of impact that  they \nused to have. ", "start_char_idx": 1550, "end_char_idx": 1648, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "60eb20e3-fa49-4a88-b2fe-e37f9bee834f": {"__data__": {"id_": "60eb20e3-fa49-4a88-b2fe-e37f9bee834f", "embedding": null, "metadata": {"window": "A \nYeah.  Thanks for that question.  Generic launches, as we've talked about, do not have the size of impact that  they \nused to have.  They have a modest impact on our profitability.  So we don't see that having any change from our \nprevious views on that.  In terms of Lyrica, we're very fortunate to have a strong sourcing organization like \nClarusONE, where we can partner  with multiple manufacturers.  We don't see that Lyrica is going to change the \ndirection of our generics profitability; it'll certainly be a benefit for us and it'll certainly be a benefit from our \ncustomers. ", "original_text": "They have a modest impact on our profitability. ", "page_label": "20", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4e2cffb7-52f8-4787-88a1-36ae788b9cf5", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e8eff96e0b9e3d1243536b9a9e25c9e45de90c1d5111b67106c1655eea65c0c8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "94148a94-941d-4c66-90e8-ff62b51f2708", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  Thanks for that question.  Generic launches, as we've talked about, do not have the size of impact that  they \nused to have.  They have a modest impact on our profitability.  So we don't see that having any change from our \nprevious views on that.  In terms of Lyrica, we're very fortunate to have a strong sourcing organization like \nClarusONE, where we can partner  with multiple manufacturers. ", "original_text": "Generic launches, as we've talked about, do not have the size of impact that  they \nused to have. ", "page_label": "20", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5cfd8e0916bbc17e42270a313747579e1fce1a2ec3055be6df70d595895c7d15", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fcd5f1eb-0d98-4d05-bd0e-097da08cc77d", "node_type": "1", "metadata": {"window": "Thanks for that question.  Generic launches, as we've talked about, do not have the size of impact that  they \nused to have.  They have a modest impact on our profitability.  So we don't see that having any change from our \nprevious views on that.  In terms of Lyrica, we're very fortunate to have a strong sourcing organization like \nClarusONE, where we can partner  with multiple manufacturers.  We don't see that Lyrica is going to change the \ndirection of our generics profitability; it'll certainly be a benefit for us and it'll certainly be a benefit from our \ncustomers.  But it'll have a modest impact at most.  \n ", "original_text": "So we don't see that having any change from our \nprevious views on that. "}, "hash": "58b806019ea497e4535bf59b64148375f0024dcc4f99b5b77c5e1122180f9143", "class_name": "RelatedNodeInfo"}}, "text": "They have a modest impact on our profitability. ", "start_char_idx": 1648, "end_char_idx": 1696, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fcd5f1eb-0d98-4d05-bd0e-097da08cc77d": {"__data__": {"id_": "fcd5f1eb-0d98-4d05-bd0e-097da08cc77d", "embedding": null, "metadata": {"window": "Thanks for that question.  Generic launches, as we've talked about, do not have the size of impact that  they \nused to have.  They have a modest impact on our profitability.  So we don't see that having any change from our \nprevious views on that.  In terms of Lyrica, we're very fortunate to have a strong sourcing organization like \nClarusONE, where we can partner  with multiple manufacturers.  We don't see that Lyrica is going to change the \ndirection of our generics profitability; it'll certainly be a benefit for us and it'll certainly be a benefit from our \ncustomers.  But it'll have a modest impact at most.  \n ", "original_text": "So we don't see that having any change from our \nprevious views on that. ", "page_label": "20", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4e2cffb7-52f8-4787-88a1-36ae788b9cf5", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e8eff96e0b9e3d1243536b9a9e25c9e45de90c1d5111b67106c1655eea65c0c8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "60eb20e3-fa49-4a88-b2fe-e37f9bee834f", "node_type": "1", "metadata": {"window": "A \nYeah.  Thanks for that question.  Generic launches, as we've talked about, do not have the size of impact that  they \nused to have.  They have a modest impact on our profitability.  So we don't see that having any change from our \nprevious views on that.  In terms of Lyrica, we're very fortunate to have a strong sourcing organization like \nClarusONE, where we can partner  with multiple manufacturers.  We don't see that Lyrica is going to change the \ndirection of our generics profitability; it'll certainly be a benefit for us and it'll certainly be a benefit from our \ncustomers. ", "original_text": "They have a modest impact on our profitability. ", "page_label": "20", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d670f51329fbb27afba39ff231d160d575943a5ff10e9e63f243fa0ed33b1d14", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b81cfd5d-1d30-46e2-a761-a4e4f2e385eb", "node_type": "1", "metadata": {"window": "Generic launches, as we've talked about, do not have the size of impact that  they \nused to have.  They have a modest impact on our profitability.  So we don't see that having any change from our \nprevious views on that.  In terms of Lyrica, we're very fortunate to have a strong sourcing organization like \nClarusONE, where we can partner  with multiple manufacturers.  We don't see that Lyrica is going to change the \ndirection of our generics profitability; it'll certainly be a benefit for us and it'll certainly be a benefit from our \ncustomers.  But it'll have a modest impact at most.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric W . ", "original_text": "In terms of Lyrica, we're very fortunate to have a strong sourcing organization like \nClarusONE, where we can partner  with multiple manufacturers. "}, "hash": "9fb3da5179274b7d45608466698515ef04b6edfd7a7a5f87a7f19b08455498ed", "class_name": "RelatedNodeInfo"}}, "text": "So we don't see that having any change from our \nprevious views on that. ", "start_char_idx": 1696, "end_char_idx": 1769, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b81cfd5d-1d30-46e2-a761-a4e4f2e385eb": {"__data__": {"id_": "b81cfd5d-1d30-46e2-a761-a4e4f2e385eb", "embedding": null, "metadata": {"window": "Generic launches, as we've talked about, do not have the size of impact that  they \nused to have.  They have a modest impact on our profitability.  So we don't see that having any change from our \nprevious views on that.  In terms of Lyrica, we're very fortunate to have a strong sourcing organization like \nClarusONE, where we can partner  with multiple manufacturers.  We don't see that Lyrica is going to change the \ndirection of our generics profitability; it'll certainly be a benefit for us and it'll certainly be a benefit from our \ncustomers.  But it'll have a modest impact at most.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric W . ", "original_text": "In terms of Lyrica, we're very fortunate to have a strong sourcing organization like \nClarusONE, where we can partner  with multiple manufacturers. ", "page_label": "20", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4e2cffb7-52f8-4787-88a1-36ae788b9cf5", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e8eff96e0b9e3d1243536b9a9e25c9e45de90c1d5111b67106c1655eea65c0c8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fcd5f1eb-0d98-4d05-bd0e-097da08cc77d", "node_type": "1", "metadata": {"window": "Thanks for that question.  Generic launches, as we've talked about, do not have the size of impact that  they \nused to have.  They have a modest impact on our profitability.  So we don't see that having any change from our \nprevious views on that.  In terms of Lyrica, we're very fortunate to have a strong sourcing organization like \nClarusONE, where we can partner  with multiple manufacturers.  We don't see that Lyrica is going to change the \ndirection of our generics profitability; it'll certainly be a benefit for us and it'll certainly be a benefit from our \ncustomers.  But it'll have a modest impact at most.  \n ", "original_text": "So we don't see that having any change from our \nprevious views on that. ", "page_label": "20", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4635d2f278b5a709b55e9126a93ec9b3c5b1db9f358357484cdf16ac31392ce2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7884a2a2-2151-48fb-839b-16d4108af8a4", "node_type": "1", "metadata": {"window": "They have a modest impact on our profitability.  So we don't see that having any change from our \nprevious views on that.  In terms of Lyrica, we're very fortunate to have a strong sourcing organization like \nClarusONE, where we can partner  with multiple manufacturers.  We don't see that Lyrica is going to change the \ndirection of our generics profitability; it'll certainly be a benefit for us and it'll certainly be a benefit from our \ncustomers.  But it'll have a modest impact at most.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric W .  Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  ", "original_text": "We don't see that Lyrica is going to change the \ndirection of our generics profitability; it'll certainly be a benefit for us and it'll certainly be a benefit from our \ncustomers. "}, "hash": "14a74e24c0bc8bbe534d65164a217f58f09be9aa07f4870dec59b34b281033c3", "class_name": "RelatedNodeInfo"}}, "text": "In terms of Lyrica, we're very fortunate to have a strong sourcing organization like \nClarusONE, where we can partner  with multiple manufacturers. ", "start_char_idx": 1769, "end_char_idx": 1917, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7884a2a2-2151-48fb-839b-16d4108af8a4": {"__data__": {"id_": "7884a2a2-2151-48fb-839b-16d4108af8a4", "embedding": null, "metadata": {"window": "They have a modest impact on our profitability.  So we don't see that having any change from our \nprevious views on that.  In terms of Lyrica, we're very fortunate to have a strong sourcing organization like \nClarusONE, where we can partner  with multiple manufacturers.  We don't see that Lyrica is going to change the \ndirection of our generics profitability; it'll certainly be a benefit for us and it'll certainly be a benefit from our \ncustomers.  But it'll have a modest impact at most.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric W .  Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  ", "original_text": "We don't see that Lyrica is going to change the \ndirection of our generics profitability; it'll certainly be a benefit for us and it'll certainly be a benefit from our \ncustomers. ", "page_label": "20", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4e2cffb7-52f8-4787-88a1-36ae788b9cf5", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e8eff96e0b9e3d1243536b9a9e25c9e45de90c1d5111b67106c1655eea65c0c8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b81cfd5d-1d30-46e2-a761-a4e4f2e385eb", "node_type": "1", "metadata": {"window": "Generic launches, as we've talked about, do not have the size of impact that  they \nused to have.  They have a modest impact on our profitability.  So we don't see that having any change from our \nprevious views on that.  In terms of Lyrica, we're very fortunate to have a strong sourcing organization like \nClarusONE, where we can partner  with multiple manufacturers.  We don't see that Lyrica is going to change the \ndirection of our generics profitability; it'll certainly be a benefit for us and it'll certainly be a benefit from our \ncustomers.  But it'll have a modest impact at most.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric W . ", "original_text": "In terms of Lyrica, we're very fortunate to have a strong sourcing organization like \nClarusONE, where we can partner  with multiple manufacturers. ", "page_label": "20", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4f8980748e8612cf09644e9e264731988854e51ff6f5318040cb72f520fa56bc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "43673ca7-0155-4223-b70a-90a1545c9043", "node_type": "1", "metadata": {"window": "So we don't see that having any change from our \nprevious views on that.  In terms of Lyrica, we're very fortunate to have a strong sourcing organization like \nClarusONE, where we can partner  with multiple manufacturers.  We don't see that Lyrica is going to change the \ndirection of our generics profitability; it'll certainly be a benefit for us and it'll certainly be a benefit from our \ncustomers.  But it'll have a modest impact at most.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric W .  Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nGreat.  \n ", "original_text": "But it'll have a modest impact at most.  \n "}, "hash": "e6ae3986afc70449e06d5fe864d760fe6ef00176a708e140ada2f47f16f782ff", "class_name": "RelatedNodeInfo"}}, "text": "We don't see that Lyrica is going to change the \ndirection of our generics profitability; it'll certainly be a benefit for us and it'll certainly be a benefit from our \ncustomers. ", "start_char_idx": 1917, "end_char_idx": 2097, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "43673ca7-0155-4223-b70a-90a1545c9043": {"__data__": {"id_": "43673ca7-0155-4223-b70a-90a1545c9043", "embedding": null, "metadata": {"window": "So we don't see that having any change from our \nprevious views on that.  In terms of Lyrica, we're very fortunate to have a strong sourcing organization like \nClarusONE, where we can partner  with multiple manufacturers.  We don't see that Lyrica is going to change the \ndirection of our generics profitability; it'll certainly be a benefit for us and it'll certainly be a benefit from our \ncustomers.  But it'll have a modest impact at most.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric W .  Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nGreat.  \n ", "original_text": "But it'll have a modest impact at most.  \n ", "page_label": "20", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4e2cffb7-52f8-4787-88a1-36ae788b9cf5", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e8eff96e0b9e3d1243536b9a9e25c9e45de90c1d5111b67106c1655eea65c0c8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7884a2a2-2151-48fb-839b-16d4108af8a4", "node_type": "1", "metadata": {"window": "They have a modest impact on our profitability.  So we don't see that having any change from our \nprevious views on that.  In terms of Lyrica, we're very fortunate to have a strong sourcing organization like \nClarusONE, where we can partner  with multiple manufacturers.  We don't see that Lyrica is going to change the \ndirection of our generics profitability; it'll certainly be a benefit for us and it'll certainly be a benefit from our \ncustomers.  But it'll have a modest impact at most.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric W .  Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  ", "original_text": "We don't see that Lyrica is going to change the \ndirection of our generics profitability; it'll certainly be a benefit for us and it'll certainly be a benefit from our \ncustomers. ", "page_label": "20", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0aa1b52617c2a879fade57346c3c39b271e0d9b42526024941aedaa1ac4f943d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7c01c7c9-2740-452c-ae9f-4e398355343b", "node_type": "1", "metadata": {"window": "In terms of Lyrica, we're very fortunate to have a strong sourcing organization like \nClarusONE, where we can partner  with multiple manufacturers.  We don't see that Lyrica is going to change the \ndirection of our generics profitability; it'll certainly be a benefit for us and it'll certainly be a benefit from our \ncustomers.  But it'll have a modest impact at most.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric W .  Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nGreat.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric W . "}, "hash": "2b7a9b58958a033387395bc0caf2dcdcbeef62d0fadb1142969c00d97886dd9e", "class_name": "RelatedNodeInfo"}}, "text": "But it'll have a modest impact at most.  \n ", "start_char_idx": 2097, "end_char_idx": 2140, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7c01c7c9-2740-452c-ae9f-4e398355343b": {"__data__": {"id_": "7c01c7c9-2740-452c-ae9f-4e398355343b", "embedding": null, "metadata": {"window": "In terms of Lyrica, we're very fortunate to have a strong sourcing organization like \nClarusONE, where we can partner  with multiple manufacturers.  We don't see that Lyrica is going to change the \ndirection of our generics profitability; it'll certainly be a benefit for us and it'll certainly be a benefit from our \ncustomers.  But it'll have a modest impact at most.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric W .  Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nGreat.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric W . ", "page_label": "20", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4e2cffb7-52f8-4787-88a1-36ae788b9cf5", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e8eff96e0b9e3d1243536b9a9e25c9e45de90c1d5111b67106c1655eea65c0c8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "43673ca7-0155-4223-b70a-90a1545c9043", "node_type": "1", "metadata": {"window": "So we don't see that having any change from our \nprevious views on that.  In terms of Lyrica, we're very fortunate to have a strong sourcing organization like \nClarusONE, where we can partner  with multiple manufacturers.  We don't see that Lyrica is going to change the \ndirection of our generics profitability; it'll certainly be a benefit for us and it'll certainly be a benefit from our \ncustomers.  But it'll have a modest impact at most.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric W .  Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nGreat.  \n ", "original_text": "But it'll have a modest impact at most.  \n ", "page_label": "20", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e3d8c6d74389cb10588d7ef605229778fd31aa728ebed5d4eb4df0c8aa2d3b42", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a461aea1-91cf-4e0f-90fd-ab8338b32ebd", "node_type": "1", "metadata": {"window": "We don't see that Lyrica is going to change the \ndirection of our generics profitability; it'll certainly be a benefit for us and it'll certainly be a benefit from our \ncustomers.  But it'll have a modest impact at most.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric W .  Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nGreat.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Well, thank you, everyone, for your questions. ", "original_text": "Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  "}, "hash": "4714510d6d0918d71bbe72137b6e8af9261cd2f3581165084aacc16fbcc4124f", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric W . ", "start_char_idx": 2140, "end_char_idx": 2406, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a461aea1-91cf-4e0f-90fd-ab8338b32ebd": {"__data__": {"id_": "a461aea1-91cf-4e0f-90fd-ab8338b32ebd", "embedding": null, "metadata": {"window": "We don't see that Lyrica is going to change the \ndirection of our generics profitability; it'll certainly be a benefit for us and it'll certainly be a benefit from our \ncustomers.  But it'll have a modest impact at most.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric W .  Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nGreat.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Well, thank you, everyone, for your questions. ", "original_text": "Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  ", "page_label": "20", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4e2cffb7-52f8-4787-88a1-36ae788b9cf5", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e8eff96e0b9e3d1243536b9a9e25c9e45de90c1d5111b67106c1655eea65c0c8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7c01c7c9-2740-452c-ae9f-4e398355343b", "node_type": "1", "metadata": {"window": "In terms of Lyrica, we're very fortunate to have a strong sourcing organization like \nClarusONE, where we can partner  with multiple manufacturers.  We don't see that Lyrica is going to change the \ndirection of our generics profitability; it'll certainly be a benefit for us and it'll certainly be a benefit from our \ncustomers.  But it'll have a modest impact at most.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric W .  Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nGreat.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric W . ", "page_label": "20", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3b7e03c8c5ea39702b1f9961d7b226acb2d104b4fe45149396209c52acf714f7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "666da054-0928-42ee-bfb1-16fc6cf442a6", "node_type": "1", "metadata": {"window": "But it'll have a modest impact at most.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric W .  Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nGreat.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Well, thank you, everyone, for your questions.  And thank you, Justine, for facilitating this call. ", "original_text": "Q \nGreat.  \n "}, "hash": "ef99dd8e61b496ed2ee61101e491e3043f55d9926a8898088fd370d7feb9b3fa", "class_name": "RelatedNodeInfo"}}, "text": "Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  ", "start_char_idx": 536, "end_char_idx": 585, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "666da054-0928-42ee-bfb1-16fc6cf442a6": {"__data__": {"id_": "666da054-0928-42ee-bfb1-16fc6cf442a6", "embedding": null, "metadata": {"window": "But it'll have a modest impact at most.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric W .  Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nGreat.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Well, thank you, everyone, for your questions.  And thank you, Justine, for facilitating this call. ", "original_text": "Q \nGreat.  \n ", "page_label": "20", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4e2cffb7-52f8-4787-88a1-36ae788b9cf5", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e8eff96e0b9e3d1243536b9a9e25c9e45de90c1d5111b67106c1655eea65c0c8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a461aea1-91cf-4e0f-90fd-ab8338b32ebd", "node_type": "1", "metadata": {"window": "We don't see that Lyrica is going to change the \ndirection of our generics profitability; it'll certainly be a benefit for us and it'll certainly be a benefit from our \ncustomers.  But it'll have a modest impact at most.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric W .  Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nGreat.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Well, thank you, everyone, for your questions. ", "original_text": "Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  ", "page_label": "20", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c9686622f072df5c516ea66f3c46f09eec8d95905249c5a00b0b1303ab3c984f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "805eb283-3993-4bfa-a42d-877a1eb24a56", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric W .  Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nGreat.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Well, thank you, everyone, for your questions.  And thank you, Justine, for facilitating this call.  I want to thank \neveryone on  the call today for your time. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n"}, "hash": "3e71d08a71135c2d78042886af24ca229ec4cfc048f5e6da1cba3d82565bd7de", "class_name": "RelatedNodeInfo"}}, "text": "Q \nGreat.  \n ", "start_char_idx": 2455, "end_char_idx": 2468, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "805eb283-3993-4bfa-a42d-877a1eb24a56": {"__data__": {"id_": "805eb283-3993-4bfa-a42d-877a1eb24a56", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric W .  Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nGreat.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Well, thank you, everyone, for your questions.  And thank you, Justine, for facilitating this call.  I want to thank \neveryone on  the call today for your time. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "page_label": "20", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4e2cffb7-52f8-4787-88a1-36ae788b9cf5", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e8eff96e0b9e3d1243536b9a9e25c9e45de90c1d5111b67106c1655eea65c0c8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "666da054-0928-42ee-bfb1-16fc6cf442a6", "node_type": "1", "metadata": {"window": "But it'll have a modest impact at most.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric W .  Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nGreat.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Well, thank you, everyone, for your questions.  And thank you, Justine, for facilitating this call. ", "original_text": "Q \nGreat.  \n ", "page_label": "20", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0d56d7568e245ef11bb3c0a42aa2011acb43262f1ec83bfbd50b1785952992f1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "826289f2-8e5e-4618-a4f3-701bd8d51131", "node_type": "1", "metadata": {"window": "Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nGreat.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Well, thank you, everyone, for your questions.  And thank you, Justine, for facilitating this call.  I want to thank \neveryone on  the call today for your time.  McKesson's off to a strong start for our fiscal 2020, and I'm real excited \nabout the opportunities ahead of us.  \n \n", "original_text": "Well, thank you, everyone, for your questions. "}, "hash": "9804e37a4177d437294d42f91030cba903d2a2f50d3549551388792d6c469bd4", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "start_char_idx": 2468, "end_char_idx": 2798, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "826289f2-8e5e-4618-a4f3-701bd8d51131": {"__data__": {"id_": "826289f2-8e5e-4618-a4f3-701bd8d51131", "embedding": null, "metadata": {"window": "Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nGreat.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Well, thank you, everyone, for your questions.  And thank you, Justine, for facilitating this call.  I want to thank \neveryone on  the call today for your time.  McKesson's off to a strong start for our fiscal 2020, and I'm real excited \nabout the opportunities ahead of us.  \n \n", "original_text": "Well, thank you, everyone, for your questions. ", "page_label": "20", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4e2cffb7-52f8-4787-88a1-36ae788b9cf5", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e8eff96e0b9e3d1243536b9a9e25c9e45de90c1d5111b67106c1655eea65c0c8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "805eb283-3993-4bfa-a42d-877a1eb24a56", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric W .  Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nGreat.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Well, thank you, everyone, for your questions.  And thank you, Justine, for facilitating this call.  I want to thank \neveryone on  the call today for your time. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "page_label": "20", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5dde4a88030c8e59c91d5b9c64e0b64dcc4a21edde197b3b91cca6d3ca9502a7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7e1fdc27-587a-45a1-b731-631b17be0154", "node_type": "1", "metadata": {"window": "Q \nGreat.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Well, thank you, everyone, for your questions.  And thank you, Justine, for facilitating this call.  I want to thank \neveryone on  the call today for your time.  McKesson's off to a strong start for our fiscal 2020, and I'm real excited \nabout the opportunities ahead of us.  \n \n I do want to take a minute to recognize the outstanding performance of really all of the McKesson employees and \nteam members and their contributions to help our customers improve lives and deliver opportunities to make \nbetter health possible. ", "original_text": "And thank you, Justine, for facilitating this call. "}, "hash": "22db5c852d0c34f4e2466094db4c6571e8435a4d239e72119cba6cf132ef66a2", "class_name": "RelatedNodeInfo"}}, "text": "Well, thank you, everyone, for your questions. ", "start_char_idx": 2798, "end_char_idx": 2845, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7e1fdc27-587a-45a1-b731-631b17be0154": {"__data__": {"id_": "7e1fdc27-587a-45a1-b731-631b17be0154", "embedding": null, "metadata": {"window": "Q \nGreat.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Well, thank you, everyone, for your questions.  And thank you, Justine, for facilitating this call.  I want to thank \neveryone on  the call today for your time.  McKesson's off to a strong start for our fiscal 2020, and I'm real excited \nabout the opportunities ahead of us.  \n \n I do want to take a minute to recognize the outstanding performance of really all of the McKesson employees and \nteam members and their contributions to help our customers improve lives and deliver opportunities to make \nbetter health possible. ", "original_text": "And thank you, Justine, for facilitating this call. ", "page_label": "20", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4e2cffb7-52f8-4787-88a1-36ae788b9cf5", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e8eff96e0b9e3d1243536b9a9e25c9e45de90c1d5111b67106c1655eea65c0c8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "826289f2-8e5e-4618-a4f3-701bd8d51131", "node_type": "1", "metadata": {"window": "Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nGreat.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Well, thank you, everyone, for your questions.  And thank you, Justine, for facilitating this call.  I want to thank \neveryone on  the call today for your time.  McKesson's off to a strong start for our fiscal 2020, and I'm real excited \nabout the opportunities ahead of us.  \n \n", "original_text": "Well, thank you, everyone, for your questions. ", "page_label": "20", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "876dc33ca9c0a41166102e12d9174108861eb9d55c43eccbb851b227165bcae6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "187a4616-bed2-4683-8219-77b26954a26e", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Well, thank you, everyone, for your questions.  And thank you, Justine, for facilitating this call.  I want to thank \neveryone on  the call today for your time.  McKesson's off to a strong start for our fiscal 2020, and I'm real excited \nabout the opportunities ahead of us.  \n \n I do want to take a minute to recognize the outstanding performance of really all of the McKesson employees and \nteam members and their contributions to help our customers improve lives and deliver opportunities to make \nbetter health possible.  So thank you, Team McKesson. ", "original_text": "I want to thank \neveryone on  the call today for your time. "}, "hash": "da60905d715d75cbec9a0e878fdb05d979dec56d025141153a2d6c6f63fa7366", "class_name": "RelatedNodeInfo"}}, "text": "And thank you, Justine, for facilitating this call. ", "start_char_idx": 2845, "end_char_idx": 2897, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "187a4616-bed2-4683-8219-77b26954a26e": {"__data__": {"id_": "187a4616-bed2-4683-8219-77b26954a26e", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Well, thank you, everyone, for your questions.  And thank you, Justine, for facilitating this call.  I want to thank \neveryone on  the call today for your time.  McKesson's off to a strong start for our fiscal 2020, and I'm real excited \nabout the opportunities ahead of us.  \n \n I do want to take a minute to recognize the outstanding performance of really all of the McKesson employees and \nteam members and their contributions to help our customers improve lives and deliver opportunities to make \nbetter health possible.  So thank you, Team McKesson. ", "original_text": "I want to thank \neveryone on  the call today for your time. ", "page_label": "20", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4e2cffb7-52f8-4787-88a1-36ae788b9cf5", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e8eff96e0b9e3d1243536b9a9e25c9e45de90c1d5111b67106c1655eea65c0c8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7e1fdc27-587a-45a1-b731-631b17be0154", "node_type": "1", "metadata": {"window": "Q \nGreat.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Well, thank you, everyone, for your questions.  And thank you, Justine, for facilitating this call.  I want to thank \neveryone on  the call today for your time.  McKesson's off to a strong start for our fiscal 2020, and I'm real excited \nabout the opportunities ahead of us.  \n \n I do want to take a minute to recognize the outstanding performance of really all of the McKesson employees and \nteam members and their contributions to help our customers improve lives and deliver opportunities to make \nbetter health possible. ", "original_text": "And thank you, Justine, for facilitating this call. ", "page_label": "20", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c6dd59f58432dbd89e3b8818bf235ad46a20f59c3e1e424baff26f95f14caace", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9d8b23eb-37d1-4365-ad02-bc7f87c3e57f", "node_type": "1", "metadata": {"window": "Well, thank you, everyone, for your questions.  And thank you, Justine, for facilitating this call.  I want to thank \neveryone on  the call today for your time.  McKesson's off to a strong start for our fiscal 2020, and I'm real excited \nabout the opportunities ahead of us.  \n \n I do want to take a minute to recognize the outstanding performance of really all of the McKesson employees and \nteam members and their contributions to help our customers improve lives and deliver opportunities to make \nbetter health possible.  So thank you, Team McKesson.  Have a good evening, everyone.  \n ", "original_text": "McKesson's off to a strong start for our fiscal 2020, and I'm real excited \nabout the opportunities ahead of us.  \n \n"}, "hash": "4b97c915c785a5dbb2ec295a5d4cf628676d3d2bcc95648c5687b90e8b61bbd7", "class_name": "RelatedNodeInfo"}}, "text": "I want to thank \neveryone on  the call today for your time. ", "start_char_idx": 2897, "end_char_idx": 2957, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9d8b23eb-37d1-4365-ad02-bc7f87c3e57f": {"__data__": {"id_": "9d8b23eb-37d1-4365-ad02-bc7f87c3e57f", "embedding": null, "metadata": {"window": "Well, thank you, everyone, for your questions.  And thank you, Justine, for facilitating this call.  I want to thank \neveryone on  the call today for your time.  McKesson's off to a strong start for our fiscal 2020, and I'm real excited \nabout the opportunities ahead of us.  \n \n I do want to take a minute to recognize the outstanding performance of really all of the McKesson employees and \nteam members and their contributions to help our customers improve lives and deliver opportunities to make \nbetter health possible.  So thank you, Team McKesson.  Have a good evening, everyone.  \n ", "original_text": "McKesson's off to a strong start for our fiscal 2020, and I'm real excited \nabout the opportunities ahead of us.  \n \n", "page_label": "20", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4e2cffb7-52f8-4787-88a1-36ae788b9cf5", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e8eff96e0b9e3d1243536b9a9e25c9e45de90c1d5111b67106c1655eea65c0c8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "187a4616-bed2-4683-8219-77b26954a26e", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Well, thank you, everyone, for your questions.  And thank you, Justine, for facilitating this call.  I want to thank \neveryone on  the call today for your time.  McKesson's off to a strong start for our fiscal 2020, and I'm real excited \nabout the opportunities ahead of us.  \n \n I do want to take a minute to recognize the outstanding performance of really all of the McKesson employees and \nteam members and their contributions to help our customers improve lives and deliver opportunities to make \nbetter health possible.  So thank you, Team McKesson. ", "original_text": "I want to thank \neveryone on  the call today for your time. ", "page_label": "20", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "67a734fcf5d34b7db2d3d90abe8a2e5e7461979f1da5f872a25a51d8f842a39d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cffa482e-5834-45b5-a9a1-7d2926c0ffb1", "node_type": "1", "metadata": {"window": "And thank you, Justine, for facilitating this call.  I want to thank \neveryone on  the call today for your time.  McKesson's off to a strong start for our fiscal 2020, and I'm real excited \nabout the opportunities ahead of us.  \n \n I do want to take a minute to recognize the outstanding performance of really all of the McKesson employees and \nteam members and their contributions to help our customers improve lives and deliver opportunities to make \nbetter health possible.  So thank you, Team McKesson.  Have a good evening, everyone.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Well, thank you for joining today's conference call.  ", "original_text": "I do want to take a minute to recognize the outstanding performance of really all of the McKesson employees and \nteam members and their contributions to help our customers improve lives and deliver opportunities to make \nbetter health possible. "}, "hash": "620662baae48767f9f24305ef7e3efd61e16af4db727b11a6063f9345c352004", "class_name": "RelatedNodeInfo"}}, "text": "McKesson's off to a strong start for our fiscal 2020, and I'm real excited \nabout the opportunities ahead of us.  \n \n", "start_char_idx": 2957, "end_char_idx": 3074, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cffa482e-5834-45b5-a9a1-7d2926c0ffb1": {"__data__": {"id_": "cffa482e-5834-45b5-a9a1-7d2926c0ffb1", "embedding": null, "metadata": {"window": "And thank you, Justine, for facilitating this call.  I want to thank \neveryone on  the call today for your time.  McKesson's off to a strong start for our fiscal 2020, and I'm real excited \nabout the opportunities ahead of us.  \n \n I do want to take a minute to recognize the outstanding performance of really all of the McKesson employees and \nteam members and their contributions to help our customers improve lives and deliver opportunities to make \nbetter health possible.  So thank you, Team McKesson.  Have a good evening, everyone.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Well, thank you for joining today's conference call.  ", "original_text": "I do want to take a minute to recognize the outstanding performance of really all of the McKesson employees and \nteam members and their contributions to help our customers improve lives and deliver opportunities to make \nbetter health possible. ", "page_label": "20", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4e2cffb7-52f8-4787-88a1-36ae788b9cf5", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e8eff96e0b9e3d1243536b9a9e25c9e45de90c1d5111b67106c1655eea65c0c8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9d8b23eb-37d1-4365-ad02-bc7f87c3e57f", "node_type": "1", "metadata": {"window": "Well, thank you, everyone, for your questions.  And thank you, Justine, for facilitating this call.  I want to thank \neveryone on  the call today for your time.  McKesson's off to a strong start for our fiscal 2020, and I'm real excited \nabout the opportunities ahead of us.  \n \n I do want to take a minute to recognize the outstanding performance of really all of the McKesson employees and \nteam members and their contributions to help our customers improve lives and deliver opportunities to make \nbetter health possible.  So thank you, Team McKesson.  Have a good evening, everyone.  \n ", "original_text": "McKesson's off to a strong start for our fiscal 2020, and I'm real excited \nabout the opportunities ahead of us.  \n \n", "page_label": "20", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3aec3383a712fc35b0c33e730d4e3c86c21044efab2700313ae0baab90cfad6f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "16b8bd1e-00ec-41e1-bd14-7ad6084c8b9f", "node_type": "1", "metadata": {"window": "I want to thank \neveryone on  the call today for your time.  McKesson's off to a strong start for our fiscal 2020, and I'm real excited \nabout the opportunities ahead of us.  \n \n I do want to take a minute to recognize the outstanding performance of really all of the McKesson employees and \nteam members and their contributions to help our customers improve lives and deliver opportunities to make \nbetter health possible.  So thank you, Team McKesson.  Have a good evening, everyone.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Well, thank you for joining today's conference call.   You may now disconnect and have a great day.  \n \n \n \n \n \n ", "original_text": "So thank you, Team McKesson. "}, "hash": "ebd29be63a53831d198458de4a40a499ce3ea4c0f1ee62070eb62749556f7021", "class_name": "RelatedNodeInfo"}}, "text": "I do want to take a minute to recognize the outstanding performance of really all of the McKesson employees and \nteam members and their contributions to help our customers improve lives and deliver opportunities to make \nbetter health possible. ", "start_char_idx": 3074, "end_char_idx": 3319, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "16b8bd1e-00ec-41e1-bd14-7ad6084c8b9f": {"__data__": {"id_": "16b8bd1e-00ec-41e1-bd14-7ad6084c8b9f", "embedding": null, "metadata": {"window": "I want to thank \neveryone on  the call today for your time.  McKesson's off to a strong start for our fiscal 2020, and I'm real excited \nabout the opportunities ahead of us.  \n \n I do want to take a minute to recognize the outstanding performance of really all of the McKesson employees and \nteam members and their contributions to help our customers improve lives and deliver opportunities to make \nbetter health possible.  So thank you, Team McKesson.  Have a good evening, everyone.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Well, thank you for joining today's conference call.   You may now disconnect and have a great day.  \n \n \n \n \n \n ", "original_text": "So thank you, Team McKesson. ", "page_label": "20", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4e2cffb7-52f8-4787-88a1-36ae788b9cf5", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e8eff96e0b9e3d1243536b9a9e25c9e45de90c1d5111b67106c1655eea65c0c8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cffa482e-5834-45b5-a9a1-7d2926c0ffb1", "node_type": "1", "metadata": {"window": "And thank you, Justine, for facilitating this call.  I want to thank \neveryone on  the call today for your time.  McKesson's off to a strong start for our fiscal 2020, and I'm real excited \nabout the opportunities ahead of us.  \n \n I do want to take a minute to recognize the outstanding performance of really all of the McKesson employees and \nteam members and their contributions to help our customers improve lives and deliver opportunities to make \nbetter health possible.  So thank you, Team McKesson.  Have a good evening, everyone.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Well, thank you for joining today's conference call.  ", "original_text": "I do want to take a minute to recognize the outstanding performance of really all of the McKesson employees and \nteam members and their contributions to help our customers improve lives and deliver opportunities to make \nbetter health possible. ", "page_label": "20", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "17e42fa8da37ef0d30fd954167d014b9d24d1925dde8ad6a54f1ddfc6edf07d1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "685cef84-b3d6-4b2b-9b07-2f48c44810a6", "node_type": "1", "metadata": {"window": "McKesson's off to a strong start for our fiscal 2020, and I'm real excited \nabout the opportunities ahead of us.  \n \n I do want to take a minute to recognize the outstanding performance of really all of the McKesson employees and \nteam members and their contributions to help our customers improve lives and deliver opportunities to make \nbetter health possible.  So thank you, Team McKesson.  Have a good evening, everyone.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Well, thank you for joining today's conference call.   You may now disconnect and have a great day.  \n \n \n \n \n \n ", "original_text": "Have a good evening, everyone.  \n "}, "hash": "9d0f1ee9a75f31868bc7b74e74f9f3628e59e77a3e03b7555664fd744b31525d", "class_name": "RelatedNodeInfo"}}, "text": "So thank you, Team McKesson. ", "start_char_idx": 3319, "end_char_idx": 3348, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "685cef84-b3d6-4b2b-9b07-2f48c44810a6": {"__data__": {"id_": "685cef84-b3d6-4b2b-9b07-2f48c44810a6", "embedding": null, "metadata": {"window": "McKesson's off to a strong start for our fiscal 2020, and I'm real excited \nabout the opportunities ahead of us.  \n \n I do want to take a minute to recognize the outstanding performance of really all of the McKesson employees and \nteam members and their contributions to help our customers improve lives and deliver opportunities to make \nbetter health possible.  So thank you, Team McKesson.  Have a good evening, everyone.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Well, thank you for joining today's conference call.   You may now disconnect and have a great day.  \n \n \n \n \n \n ", "original_text": "Have a good evening, everyone.  \n ", "page_label": "20", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4e2cffb7-52f8-4787-88a1-36ae788b9cf5", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e8eff96e0b9e3d1243536b9a9e25c9e45de90c1d5111b67106c1655eea65c0c8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "16b8bd1e-00ec-41e1-bd14-7ad6084c8b9f", "node_type": "1", "metadata": {"window": "I want to thank \neveryone on  the call today for your time.  McKesson's off to a strong start for our fiscal 2020, and I'm real excited \nabout the opportunities ahead of us.  \n \n I do want to take a minute to recognize the outstanding performance of really all of the McKesson employees and \nteam members and their contributions to help our customers improve lives and deliver opportunities to make \nbetter health possible.  So thank you, Team McKesson.  Have a good evening, everyone.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Well, thank you for joining today's conference call.   You may now disconnect and have a great day.  \n \n \n \n \n \n ", "original_text": "So thank you, Team McKesson. ", "page_label": "20", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "99fb22e3500994209a9242cc13e2e59d9bbe17c15b607f307af42eb9d698dc7f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b6da276a-9b9b-476b-ab13-dc25273939a5", "node_type": "1", "metadata": {"window": "I do want to take a minute to recognize the outstanding performance of really all of the McKesson employees and \nteam members and their contributions to help our customers improve lives and deliver opportunities to make \nbetter health possible.  So thank you, Team McKesson.  Have a good evening, everyone.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Well, thank you for joining today's conference call.   You may now disconnect and have a great day.  \n \n \n \n \n \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Well, thank you for joining today's conference call.  "}, "hash": "7680dbfe6ef7b8334daffa7b364f67b735041818e6eed54554359c7a115cde60", "class_name": "RelatedNodeInfo"}}, "text": "Have a good evening, everyone.  \n ", "start_char_idx": 3348, "end_char_idx": 3382, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b6da276a-9b9b-476b-ab13-dc25273939a5": {"__data__": {"id_": "b6da276a-9b9b-476b-ab13-dc25273939a5", "embedding": null, "metadata": {"window": "I do want to take a minute to recognize the outstanding performance of really all of the McKesson employees and \nteam members and their contributions to help our customers improve lives and deliver opportunities to make \nbetter health possible.  So thank you, Team McKesson.  Have a good evening, everyone.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Well, thank you for joining today's conference call.   You may now disconnect and have a great day.  \n \n \n \n \n \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Well, thank you for joining today's conference call.  ", "page_label": "20", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4e2cffb7-52f8-4787-88a1-36ae788b9cf5", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e8eff96e0b9e3d1243536b9a9e25c9e45de90c1d5111b67106c1655eea65c0c8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "685cef84-b3d6-4b2b-9b07-2f48c44810a6", "node_type": "1", "metadata": {"window": "McKesson's off to a strong start for our fiscal 2020, and I'm real excited \nabout the opportunities ahead of us.  \n \n I do want to take a minute to recognize the outstanding performance of really all of the McKesson employees and \nteam members and their contributions to help our customers improve lives and deliver opportunities to make \nbetter health possible.  So thank you, Team McKesson.  Have a good evening, everyone.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Well, thank you for joining today's conference call.   You may now disconnect and have a great day.  \n \n \n \n \n \n ", "original_text": "Have a good evening, everyone.  \n ", "page_label": "20", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8c083f7b38bec87736c78fa39f30e3203a21bcdb55cd24994c8d9e05a6b8d548", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dc9c4966-0abb-4410-8f8c-b6bba49234bc", "node_type": "1", "metadata": {"window": "So thank you, Team McKesson.  Have a good evening, everyone.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Well, thank you for joining today's conference call.   You may now disconnect and have a great day.  \n \n \n \n \n \n ", "original_text": "You may now disconnect and have a great day.  \n \n \n \n \n \n "}, "hash": "8c420532a402c759d9763887c71f6e66bbbacfa94445d7e50915f05b975a221b", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Well, thank you for joining today's conference call.  ", "start_char_idx": 3382, "end_char_idx": 3706, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dc9c4966-0abb-4410-8f8c-b6bba49234bc": {"__data__": {"id_": "dc9c4966-0abb-4410-8f8c-b6bba49234bc", "embedding": null, "metadata": {"window": "So thank you, Team McKesson.  Have a good evening, everyone.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Well, thank you for joining today's conference call.   You may now disconnect and have a great day.  \n \n \n \n \n \n ", "original_text": "You may now disconnect and have a great day.  \n \n \n \n \n \n ", "page_label": "20", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4e2cffb7-52f8-4787-88a1-36ae788b9cf5", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e8eff96e0b9e3d1243536b9a9e25c9e45de90c1d5111b67106c1655eea65c0c8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b6da276a-9b9b-476b-ab13-dc25273939a5", "node_type": "1", "metadata": {"window": "I do want to take a minute to recognize the outstanding performance of really all of the McKesson employees and \nteam members and their contributions to help our customers improve lives and deliver opportunities to make \nbetter health possible.  So thank you, Team McKesson.  Have a good evening, everyone.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Well, thank you for joining today's conference call.   You may now disconnect and have a great day.  \n \n \n \n \n \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Well, thank you for joining today's conference call.  ", "page_label": "20", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5ee3e76d81a4f58f138d860422e6468064f0891069273c978b828a30ee88cf4d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2ad70149-c89c-4e87-a8bf-8a63d122b30b", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   21 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \n \n \n \n \nDisclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available  data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You  must evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on  the accuracy, completeness, safety or usefulness of such information. ", "original_text": "McKesson Corp.  "}, "hash": "b7887336e275cd6af42cacf19872e1090bc8df78bd2ab7c295b4e86d1de7bd95", "class_name": "RelatedNodeInfo"}}, "text": "You may now disconnect and have a great day.  \n \n \n \n \n \n ", "start_char_idx": 3706, "end_char_idx": 3764, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2ad70149-c89c-4e87-a8bf-8a63d122b30b": {"__data__": {"id_": "2ad70149-c89c-4e87-a8bf-8a63d122b30b", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   21 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \n \n \n \n \nDisclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available  data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You  must evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on  the accuracy, completeness, safety or usefulness of such information. ", "original_text": "McKesson Corp.  ", "page_label": "21", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1c9437ad-0883-4253-bf98-af42f1639095", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ab51138e4bf7b185c337bb4a9d7c39875988a5e2a6f9a5c79274e320d01065bb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dc9c4966-0abb-4410-8f8c-b6bba49234bc", "node_type": "1", "metadata": {"window": "So thank you, Team McKesson.  Have a good evening, everyone.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \n \nOperator : Well, thank you for joining today's conference call.   You may now disconnect and have a great day.  \n \n \n \n \n \n ", "original_text": "You may now disconnect and have a great day.  \n \n \n \n \n \n ", "page_label": "20", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a10f3386848c42c6116c48279e473f7998be8d3103c9aaa092b5af3f0380dddb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c9f1279a-1acd-4a9d-82e8-20ce38090601", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   21 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \n \n \n \n \nDisclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available  data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You  must evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on  the accuracy, completeness, safety or usefulness of such information.  This information is not intended to be used as the prim ary basis \nof investment decisions. ", "original_text": "(MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   21 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \n \n \n \n \nDisclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available  data. \n"}, "hash": "105a64e7c27bb1bcd9e0468dab58af8f6037ba20adf673bfda04b23415d818c7", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c9f1279a-1acd-4a9d-82e8-20ce38090601": {"__data__": {"id_": "c9f1279a-1acd-4a9d-82e8-20ce38090601", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   21 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \n \n \n \n \nDisclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available  data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You  must evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on  the accuracy, completeness, safety or usefulness of such information.  This information is not intended to be used as the prim ary basis \nof investment decisions. ", "original_text": "(MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   21 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \n \n \n \n \nDisclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available  data. \n", "page_label": "21", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1c9437ad-0883-4253-bf98-af42f1639095", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ab51138e4bf7b185c337bb4a9d7c39875988a5e2a6f9a5c79274e320d01065bb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2ad70149-c89c-4e87-a8bf-8a63d122b30b", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   21 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \n \n \n \n \nDisclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available  data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You  must evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on  the accuracy, completeness, safety or usefulness of such information. ", "original_text": "McKesson Corp.  ", "page_label": "21", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a2c0b79d58c8f119758088b9769888160a76b1eb4570012307bc9d5faa426b5b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "89e93d99-3aa3-46db-905c-cc33ef61117b", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   21 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \n \n \n \n \nDisclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available  data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You  must evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on  the accuracy, completeness, safety or usefulness of such information.  This information is not intended to be used as the prim ary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any in vestor. ", "original_text": "As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information. "}, "hash": "085974f6016abe7ee52b245cec740d70fd90ccdd5c9ebf3696054c4fcd2745f6", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   21 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \n \n \n \n \nDisclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available  data. \n", "start_char_idx": 16, "end_char_idx": 401, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "89e93d99-3aa3-46db-905c-cc33ef61117b": {"__data__": {"id_": "89e93d99-3aa3-46db-905c-cc33ef61117b", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   21 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \n \n \n \n \nDisclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available  data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You  must evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on  the accuracy, completeness, safety or usefulness of such information.  This information is not intended to be used as the prim ary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any in vestor. ", "original_text": "As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information. ", "page_label": "21", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1c9437ad-0883-4253-bf98-af42f1639095", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ab51138e4bf7b185c337bb4a9d7c39875988a5e2a6f9a5c79274e320d01065bb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c9f1279a-1acd-4a9d-82e8-20ce38090601", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   21 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \n \n \n \n \nDisclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available  data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You  must evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on  the accuracy, completeness, safety or usefulness of such information.  This information is not intended to be used as the prim ary basis \nof investment decisions. ", "original_text": "(MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   21 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \n \n \n \n \nDisclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available  data. \n", "page_label": "21", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "20165c42d19615bbe736e1b70ee2edf0831d81054bdc978f14f357cac7c3b505", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "44da7178-bd4b-4e4e-97a6-c44420841157", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   21 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \n \n \n \n \nDisclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available  data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You  must evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on  the accuracy, completeness, safety or usefulness of such information.  This information is not intended to be used as the prim ary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any in vestor.  This report is published solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be i llegal. ", "original_text": "You  must evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on  the accuracy, completeness, safety or usefulness of such information. "}, "hash": "729837cfc1297aac647723b7376f0097ac6e8c2ab0d47002f6a2c46807924b6a", "class_name": "RelatedNodeInfo"}}, "text": "As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information. ", "start_char_idx": 401, "end_char_idx": 523, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "44da7178-bd4b-4e4e-97a6-c44420841157": {"__data__": {"id_": "44da7178-bd4b-4e4e-97a6-c44420841157", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   21 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \n \n \n \n \nDisclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available  data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You  must evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on  the accuracy, completeness, safety or usefulness of such information.  This information is not intended to be used as the prim ary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any in vestor.  This report is published solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be i llegal. ", "original_text": "You  must evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on  the accuracy, completeness, safety or usefulness of such information. ", "page_label": "21", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1c9437ad-0883-4253-bf98-af42f1639095", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ab51138e4bf7b185c337bb4a9d7c39875988a5e2a6f9a5c79274e320d01065bb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "89e93d99-3aa3-46db-905c-cc33ef61117b", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   21 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \n \n \n \n \nDisclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available  data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You  must evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on  the accuracy, completeness, safety or usefulness of such information.  This information is not intended to be used as the prim ary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any in vestor. ", "original_text": "As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information. ", "page_label": "21", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "83888c7362ed8eec2889fe088a8d87ff0e8b00b660a284d621d83d26032ab028", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a2c3a3a0-064b-4adf-94ea-a86739944d4d", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   21 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \n \n \n \n \nDisclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available  data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You  must evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on  the accuracy, completeness, safety or usefulness of such information.  This information is not intended to be used as the prim ary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any in vestor.  This report is published solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be i llegal.  Any \ninformation expressed herein on this date is subject to change without notice. ", "original_text": "This information is not intended to be used as the prim ary basis \nof investment decisions. "}, "hash": "6780e3fe12ea219e9f83ccfb4bffd0836e5b15ba5f935fdea9271e4c72b137e1", "class_name": "RelatedNodeInfo"}}, "text": "You  must evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on  the accuracy, completeness, safety or usefulness of such information. ", "start_char_idx": 523, "end_char_idx": 724, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a2c3a3a0-064b-4adf-94ea-a86739944d4d": {"__data__": {"id_": "a2c3a3a0-064b-4adf-94ea-a86739944d4d", "embedding": null, "metadata": {"window": "(MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   21 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \n \n \n \n \nDisclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available  data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You  must evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on  the accuracy, completeness, safety or usefulness of such information.  This information is not intended to be used as the prim ary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any in vestor.  This report is published solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be i llegal.  Any \ninformation expressed herein on this date is subject to change without notice. ", "original_text": "This information is not intended to be used as the prim ary basis \nof investment decisions. ", "page_label": "21", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1c9437ad-0883-4253-bf98-af42f1639095", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ab51138e4bf7b185c337bb4a9d7c39875988a5e2a6f9a5c79274e320d01065bb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "44da7178-bd4b-4e4e-97a6-c44420841157", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   21 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \n \n \n \n \nDisclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available  data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You  must evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on  the accuracy, completeness, safety or usefulness of such information.  This information is not intended to be used as the prim ary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any in vestor.  This report is published solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be i llegal. ", "original_text": "You  must evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on  the accuracy, completeness, safety or usefulness of such information. ", "page_label": "21", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "de4637987fdaca25b20bc94b94c58f63c9b75ee3128383537ab441493d0bcce0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c451d20f-427d-4c62-9b56-31f843565b0e", "node_type": "1", "metadata": {"window": "As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You  must evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on  the accuracy, completeness, safety or usefulness of such information.  This information is not intended to be used as the prim ary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any in vestor.  This report is published solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be i llegal.  Any \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nformation do not represent the opinions or beliefs of FactSet \nCallStreet, LLC. ", "original_text": "It should not be construed as advice designed to meet the particular investment needs of any in vestor. "}, "hash": "4e444fa8620bb7b4e850b24cadaedc03eacf86d38883797469d35e8eb8281189", "class_name": "RelatedNodeInfo"}}, "text": "This information is not intended to be used as the prim ary basis \nof investment decisions. ", "start_char_idx": 724, "end_char_idx": 816, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c451d20f-427d-4c62-9b56-31f843565b0e": {"__data__": {"id_": "c451d20f-427d-4c62-9b56-31f843565b0e", "embedding": null, "metadata": {"window": "As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You  must evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on  the accuracy, completeness, safety or usefulness of such information.  This information is not intended to be used as the prim ary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any in vestor.  This report is published solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be i llegal.  Any \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nformation do not represent the opinions or beliefs of FactSet \nCallStreet, LLC. ", "original_text": "It should not be construed as advice designed to meet the particular investment needs of any in vestor. ", "page_label": "21", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1c9437ad-0883-4253-bf98-af42f1639095", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ab51138e4bf7b185c337bb4a9d7c39875988a5e2a6f9a5c79274e320d01065bb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a2c3a3a0-064b-4adf-94ea-a86739944d4d", "node_type": "1", "metadata": {"window": "(MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   21 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \n \n \n \n \nDisclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available  data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You  must evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on  the accuracy, completeness, safety or usefulness of such information.  This information is not intended to be used as the prim ary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any in vestor.  This report is published solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be i llegal.  Any \ninformation expressed herein on this date is subject to change without notice. ", "original_text": "This information is not intended to be used as the prim ary basis \nof investment decisions. ", "page_label": "21", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6d554f23505e47f766370d74b246e302fbe5a2e925a70f300b2cfb41710fb23f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3a056e66-d7a5-4a0c-8052-5cd1eb3ee79f", "node_type": "1", "metadata": {"window": "You  must evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on  the accuracy, completeness, safety or usefulness of such information.  This information is not intended to be used as the prim ary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any in vestor.  This report is published solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be i llegal.  Any \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nformation do not represent the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more  of its employees, including the writer of this report, may have a position in any of the securities discussed herein.  \n \n", "original_text": "This report is published solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be i llegal. "}, "hash": "4b7a7e4eb6ecd63594d04084ac98bec229c0b7352d6b3364b0bb3e0a2d3b04db", "class_name": "RelatedNodeInfo"}}, "text": "It should not be construed as advice designed to meet the particular investment needs of any in vestor. ", "start_char_idx": 816, "end_char_idx": 920, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3a056e66-d7a5-4a0c-8052-5cd1eb3ee79f": {"__data__": {"id_": "3a056e66-d7a5-4a0c-8052-5cd1eb3ee79f", "embedding": null, "metadata": {"window": "You  must evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on  the accuracy, completeness, safety or usefulness of such information.  This information is not intended to be used as the prim ary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any in vestor.  This report is published solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be i llegal.  Any \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nformation do not represent the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more  of its employees, including the writer of this report, may have a position in any of the securities discussed herein.  \n \n", "original_text": "This report is published solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be i llegal. ", "page_label": "21", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1c9437ad-0883-4253-bf98-af42f1639095", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ab51138e4bf7b185c337bb4a9d7c39875988a5e2a6f9a5c79274e320d01065bb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c451d20f-427d-4c62-9b56-31f843565b0e", "node_type": "1", "metadata": {"window": "As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You  must evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on  the accuracy, completeness, safety or usefulness of such information.  This information is not intended to be used as the prim ary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any in vestor.  This report is published solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be i llegal.  Any \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nformation do not represent the opinions or beliefs of FactSet \nCallStreet, LLC. ", "original_text": "It should not be construed as advice designed to meet the particular investment needs of any in vestor. ", "page_label": "21", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fe0a1765b79a8af4531af9c3fea05a9d370fd5708f8ba5f008ecbe6b88226e0b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2d6e94c3-c376-4c17-87a5-239d49776b0f", "node_type": "1", "metadata": {"window": "This information is not intended to be used as the prim ary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any in vestor.  This report is published solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be i llegal.  Any \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nformation do not represent the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more  of its employees, including the writer of this report, may have a position in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet , LLC AND ITS \nLICENSORS, BUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY , INCLUDING WITHOUT \nLIMITATION ANY IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY,  COMPLETENESS, AND NON -INFRINGEMENT. ", "original_text": "Any \ninformation expressed herein on this date is subject to change without notice. "}, "hash": "0e945f403c61fc5ec3d24495358c8ce50504984d504ed0da92118dd6bd15b9a3", "class_name": "RelatedNodeInfo"}}, "text": "This report is published solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be i llegal. ", "start_char_idx": 920, "end_char_idx": 1179, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2d6e94c3-c376-4c17-87a5-239d49776b0f": {"__data__": {"id_": "2d6e94c3-c376-4c17-87a5-239d49776b0f", "embedding": null, "metadata": {"window": "This information is not intended to be used as the prim ary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any in vestor.  This report is published solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be i llegal.  Any \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nformation do not represent the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more  of its employees, including the writer of this report, may have a position in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet , LLC AND ITS \nLICENSORS, BUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY , INCLUDING WITHOUT \nLIMITATION ANY IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY,  COMPLETENESS, AND NON -INFRINGEMENT. ", "original_text": "Any \ninformation expressed herein on this date is subject to change without notice. ", "page_label": "21", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1c9437ad-0883-4253-bf98-af42f1639095", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ab51138e4bf7b185c337bb4a9d7c39875988a5e2a6f9a5c79274e320d01065bb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3a056e66-d7a5-4a0c-8052-5cd1eb3ee79f", "node_type": "1", "metadata": {"window": "You  must evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on  the accuracy, completeness, safety or usefulness of such information.  This information is not intended to be used as the prim ary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any in vestor.  This report is published solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be i llegal.  Any \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nformation do not represent the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more  of its employees, including the writer of this report, may have a position in any of the securities discussed herein.  \n \n", "original_text": "This report is published solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be i llegal. ", "page_label": "21", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d9a11684f567f3c1868df97a2503f714fc8ad564cc27ca8b48c2e678c001934a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c6097956-085b-48f8-a6ac-1540628eb013", "node_type": "1", "metadata": {"window": "It should not be construed as advice designed to meet the particular investment needs of any in vestor.  This report is published solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be i llegal.  Any \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nformation do not represent the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more  of its employees, including the writer of this report, may have a position in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet , LLC AND ITS \nLICENSORS, BUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY , INCLUDING WITHOUT \nLIMITATION ANY IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY,  COMPLETENESS, AND NON -INFRINGEMENT.  TO THE \nMAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, A FFILIATES, BUSINESS \nASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY INDIRECT,  INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT \nLIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, SECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MAL FUNCTION, USE, \nDATA OR OTHER INTANGIBLE LOSSES OR COMMER CIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES IS ADVISED OF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR \nIN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT MATTER HEREOF.  \n \n", "original_text": "Any opinions or assertions contained in this i nformation do not represent the opinions or beliefs of FactSet \nCallStreet, LLC. "}, "hash": "a2cdd14551a5a10f04e388d5f359747cc486d37d2f0d78a4a41b266add9cef0f", "class_name": "RelatedNodeInfo"}}, "text": "Any \ninformation expressed herein on this date is subject to change without notice. ", "start_char_idx": 1179, "end_char_idx": 1263, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c6097956-085b-48f8-a6ac-1540628eb013": {"__data__": {"id_": "c6097956-085b-48f8-a6ac-1540628eb013", "embedding": null, "metadata": {"window": "It should not be construed as advice designed to meet the particular investment needs of any in vestor.  This report is published solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be i llegal.  Any \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nformation do not represent the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more  of its employees, including the writer of this report, may have a position in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet , LLC AND ITS \nLICENSORS, BUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY , INCLUDING WITHOUT \nLIMITATION ANY IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY,  COMPLETENESS, AND NON -INFRINGEMENT.  TO THE \nMAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, A FFILIATES, BUSINESS \nASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY INDIRECT,  INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT \nLIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, SECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MAL FUNCTION, USE, \nDATA OR OTHER INTANGIBLE LOSSES OR COMMER CIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES IS ADVISED OF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR \nIN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT MATTER HEREOF.  \n \n", "original_text": "Any opinions or assertions contained in this i nformation do not represent the opinions or beliefs of FactSet \nCallStreet, LLC. ", "page_label": "21", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1c9437ad-0883-4253-bf98-af42f1639095", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ab51138e4bf7b185c337bb4a9d7c39875988a5e2a6f9a5c79274e320d01065bb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2d6e94c3-c376-4c17-87a5-239d49776b0f", "node_type": "1", "metadata": {"window": "This information is not intended to be used as the prim ary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any in vestor.  This report is published solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be i llegal.  Any \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nformation do not represent the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more  of its employees, including the writer of this report, may have a position in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet , LLC AND ITS \nLICENSORS, BUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY , INCLUDING WITHOUT \nLIMITATION ANY IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY,  COMPLETENESS, AND NON -INFRINGEMENT. ", "original_text": "Any \ninformation expressed herein on this date is subject to change without notice. ", "page_label": "21", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "86cda17f745020ad4da9e26d7fd1fb5ec775bc5d5ee6e6490af8b0f3394ccef5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "11e9aff3-475a-4fb8-8b62-011a73153d77", "node_type": "1", "metadata": {"window": "This report is published solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be i llegal.  Any \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nformation do not represent the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more  of its employees, including the writer of this report, may have a position in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet , LLC AND ITS \nLICENSORS, BUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY , INCLUDING WITHOUT \nLIMITATION ANY IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY,  COMPLETENESS, AND NON -INFRINGEMENT.  TO THE \nMAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, A FFILIATES, BUSINESS \nASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY INDIRECT,  INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT \nLIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, SECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MAL FUNCTION, USE, \nDATA OR OTHER INTANGIBLE LOSSES OR COMMER CIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES IS ADVISED OF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR \nIN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT MATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted Fact Set CallStreet, LLC 2019  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC. \n", "original_text": "FactSet CallStreet, LLC, or one or more  of its employees, including the writer of this report, may have a position in any of the securities discussed herein.  \n \n"}, "hash": "cba26cf2db0b5ce5624ed3e0ac9d143ffa65d28d0843c5f1e83c102db327e961", "class_name": "RelatedNodeInfo"}}, "text": "Any opinions or assertions contained in this i nformation do not represent the opinions or beliefs of FactSet \nCallStreet, LLC. ", "start_char_idx": 1263, "end_char_idx": 1391, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "11e9aff3-475a-4fb8-8b62-011a73153d77": {"__data__": {"id_": "11e9aff3-475a-4fb8-8b62-011a73153d77", "embedding": null, "metadata": {"window": "This report is published solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be i llegal.  Any \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nformation do not represent the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more  of its employees, including the writer of this report, may have a position in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet , LLC AND ITS \nLICENSORS, BUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY , INCLUDING WITHOUT \nLIMITATION ANY IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY,  COMPLETENESS, AND NON -INFRINGEMENT.  TO THE \nMAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, A FFILIATES, BUSINESS \nASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY INDIRECT,  INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT \nLIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, SECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MAL FUNCTION, USE, \nDATA OR OTHER INTANGIBLE LOSSES OR COMMER CIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES IS ADVISED OF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR \nIN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT MATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted Fact Set CallStreet, LLC 2019  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC. \n", "original_text": "FactSet CallStreet, LLC, or one or more  of its employees, including the writer of this report, may have a position in any of the securities discussed herein.  \n \n", "page_label": "21", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1c9437ad-0883-4253-bf98-af42f1639095", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ab51138e4bf7b185c337bb4a9d7c39875988a5e2a6f9a5c79274e320d01065bb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c6097956-085b-48f8-a6ac-1540628eb013", "node_type": "1", "metadata": {"window": "It should not be construed as advice designed to meet the particular investment needs of any in vestor.  This report is published solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be i llegal.  Any \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nformation do not represent the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more  of its employees, including the writer of this report, may have a position in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet , LLC AND ITS \nLICENSORS, BUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY , INCLUDING WITHOUT \nLIMITATION ANY IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY,  COMPLETENESS, AND NON -INFRINGEMENT.  TO THE \nMAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, A FFILIATES, BUSINESS \nASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY INDIRECT,  INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT \nLIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, SECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MAL FUNCTION, USE, \nDATA OR OTHER INTANGIBLE LOSSES OR COMMER CIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES IS ADVISED OF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR \nIN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT MATTER HEREOF.  \n \n", "original_text": "Any opinions or assertions contained in this i nformation do not represent the opinions or beliefs of FactSet \nCallStreet, LLC. ", "page_label": "21", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6130e01a62b5d3ddfd4e4bb49ca34561fde85b256c4421a3d59a1bfc79bd110c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2e2ab5cc-78ff-446e-94ec-c46f7beab53b", "node_type": "1", "metadata": {"window": "Any \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nformation do not represent the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more  of its employees, including the writer of this report, may have a position in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet , LLC AND ITS \nLICENSORS, BUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY , INCLUDING WITHOUT \nLIMITATION ANY IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY,  COMPLETENESS, AND NON -INFRINGEMENT.  TO THE \nMAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, A FFILIATES, BUSINESS \nASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY INDIRECT,  INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT \nLIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, SECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MAL FUNCTION, USE, \nDATA OR OTHER INTANGIBLE LOSSES OR COMMER CIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES IS ADVISED OF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR \nIN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT MATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted Fact Set CallStreet, LLC 2019  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC. \n All other trademarks mentioned are trademarks of their respective companies. ", "original_text": "THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet , LLC AND ITS \nLICENSORS, BUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY , INCLUDING WITHOUT \nLIMITATION ANY IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY,  COMPLETENESS, AND NON -INFRINGEMENT. "}, "hash": "fb3f16fe32af3da28fcab0515f6f45d5b1daef6965b22cbc33f7a613d3fc4fa7", "class_name": "RelatedNodeInfo"}}, "text": "FactSet CallStreet, LLC, or one or more  of its employees, including the writer of this report, may have a position in any of the securities discussed herein.  \n \n", "start_char_idx": 1391, "end_char_idx": 1554, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2e2ab5cc-78ff-446e-94ec-c46f7beab53b": {"__data__": {"id_": "2e2ab5cc-78ff-446e-94ec-c46f7beab53b", "embedding": null, "metadata": {"window": "Any \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nformation do not represent the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more  of its employees, including the writer of this report, may have a position in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet , LLC AND ITS \nLICENSORS, BUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY , INCLUDING WITHOUT \nLIMITATION ANY IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY,  COMPLETENESS, AND NON -INFRINGEMENT.  TO THE \nMAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, A FFILIATES, BUSINESS \nASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY INDIRECT,  INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT \nLIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, SECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MAL FUNCTION, USE, \nDATA OR OTHER INTANGIBLE LOSSES OR COMMER CIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES IS ADVISED OF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR \nIN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT MATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted Fact Set CallStreet, LLC 2019  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC. \n All other trademarks mentioned are trademarks of their respective companies. ", "original_text": "THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet , LLC AND ITS \nLICENSORS, BUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY , INCLUDING WITHOUT \nLIMITATION ANY IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY,  COMPLETENESS, AND NON -INFRINGEMENT. ", "page_label": "21", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1c9437ad-0883-4253-bf98-af42f1639095", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ab51138e4bf7b185c337bb4a9d7c39875988a5e2a6f9a5c79274e320d01065bb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "11e9aff3-475a-4fb8-8b62-011a73153d77", "node_type": "1", "metadata": {"window": "This report is published solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be i llegal.  Any \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nformation do not represent the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more  of its employees, including the writer of this report, may have a position in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet , LLC AND ITS \nLICENSORS, BUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY , INCLUDING WITHOUT \nLIMITATION ANY IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY,  COMPLETENESS, AND NON -INFRINGEMENT.  TO THE \nMAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, A FFILIATES, BUSINESS \nASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY INDIRECT,  INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT \nLIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, SECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MAL FUNCTION, USE, \nDATA OR OTHER INTANGIBLE LOSSES OR COMMER CIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES IS ADVISED OF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR \nIN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT MATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted Fact Set CallStreet, LLC 2019  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC. \n", "original_text": "FactSet CallStreet, LLC, or one or more  of its employees, including the writer of this report, may have a position in any of the securities discussed herein.  \n \n", "page_label": "21", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7b8763b823356680c2ae17319e58914c3ee01fe4686f5dc4aa4dd848b5a6a32d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3adf8d3f-f01f-4f8d-8098-4090256bebc2", "node_type": "1", "metadata": {"window": "Any opinions or assertions contained in this i nformation do not represent the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more  of its employees, including the writer of this report, may have a position in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet , LLC AND ITS \nLICENSORS, BUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY , INCLUDING WITHOUT \nLIMITATION ANY IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY,  COMPLETENESS, AND NON -INFRINGEMENT.  TO THE \nMAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, A FFILIATES, BUSINESS \nASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY INDIRECT,  INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT \nLIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, SECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MAL FUNCTION, USE, \nDATA OR OTHER INTANGIBLE LOSSES OR COMMER CIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES IS ADVISED OF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR \nIN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT MATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted Fact Set CallStreet, LLC 2019  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC. \n All other trademarks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "TO THE \nMAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, A FFILIATES, BUSINESS \nASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY INDIRECT,  INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT \nLIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, SECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MAL FUNCTION, USE, \nDATA OR OTHER INTANGIBLE LOSSES OR COMMER CIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES IS ADVISED OF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR \nIN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT MATTER HEREOF.  \n \n"}, "hash": "71e9d52c95e09b608b082b74b8260f24097a3de8167802e1bd3cbb6917a0e89c", "class_name": "RelatedNodeInfo"}}, "text": "THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet , LLC AND ITS \nLICENSORS, BUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY , INCLUDING WITHOUT \nLIMITATION ANY IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY,  COMPLETENESS, AND NON -INFRINGEMENT. ", "start_char_idx": 1554, "end_char_idx": 1990, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3adf8d3f-f01f-4f8d-8098-4090256bebc2": {"__data__": {"id_": "3adf8d3f-f01f-4f8d-8098-4090256bebc2", "embedding": null, "metadata": {"window": "Any opinions or assertions contained in this i nformation do not represent the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more  of its employees, including the writer of this report, may have a position in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet , LLC AND ITS \nLICENSORS, BUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY , INCLUDING WITHOUT \nLIMITATION ANY IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY,  COMPLETENESS, AND NON -INFRINGEMENT.  TO THE \nMAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, A FFILIATES, BUSINESS \nASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY INDIRECT,  INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT \nLIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, SECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MAL FUNCTION, USE, \nDATA OR OTHER INTANGIBLE LOSSES OR COMMER CIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES IS ADVISED OF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR \nIN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT MATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted Fact Set CallStreet, LLC 2019  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC. \n All other trademarks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "TO THE \nMAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, A FFILIATES, BUSINESS \nASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY INDIRECT,  INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT \nLIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, SECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MAL FUNCTION, USE, \nDATA OR OTHER INTANGIBLE LOSSES OR COMMER CIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES IS ADVISED OF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR \nIN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT MATTER HEREOF.  \n \n", "page_label": "21", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1c9437ad-0883-4253-bf98-af42f1639095", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ab51138e4bf7b185c337bb4a9d7c39875988a5e2a6f9a5c79274e320d01065bb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2e2ab5cc-78ff-446e-94ec-c46f7beab53b", "node_type": "1", "metadata": {"window": "Any \ninformation expressed herein on this date is subject to change without notice.  Any opinions or assertions contained in this i nformation do not represent the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more  of its employees, including the writer of this report, may have a position in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet , LLC AND ITS \nLICENSORS, BUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY , INCLUDING WITHOUT \nLIMITATION ANY IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY,  COMPLETENESS, AND NON -INFRINGEMENT.  TO THE \nMAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, A FFILIATES, BUSINESS \nASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY INDIRECT,  INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT \nLIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, SECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MAL FUNCTION, USE, \nDATA OR OTHER INTANGIBLE LOSSES OR COMMER CIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES IS ADVISED OF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR \nIN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT MATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted Fact Set CallStreet, LLC 2019  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC. \n All other trademarks mentioned are trademarks of their respective companies. ", "original_text": "THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet , LLC AND ITS \nLICENSORS, BUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY , INCLUDING WITHOUT \nLIMITATION ANY IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY,  COMPLETENESS, AND NON -INFRINGEMENT. ", "page_label": "21", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "72d1ae420976814322999cd07df968976abc59f92ac225f3cdbcf2679152e367", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "edcc37f0-9a01-41ec-a683-bf04eda6cf2b", "node_type": "1", "metadata": {"window": "FactSet CallStreet, LLC, or one or more  of its employees, including the writer of this report, may have a position in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet , LLC AND ITS \nLICENSORS, BUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY , INCLUDING WITHOUT \nLIMITATION ANY IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY,  COMPLETENESS, AND NON -INFRINGEMENT.  TO THE \nMAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, A FFILIATES, BUSINESS \nASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY INDIRECT,  INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT \nLIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, SECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MAL FUNCTION, USE, \nDATA OR OTHER INTANGIBLE LOSSES OR COMMER CIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES IS ADVISED OF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR \nIN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT MATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted Fact Set CallStreet, LLC 2019  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC. \n All other trademarks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "The contents and appearance of this report are Copyrighted Fact Set CallStreet, LLC 2019  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC. \n"}, "hash": "08673003d1537707e1edd2b1d7eb2662c86e937153150de16f4c95b8d4199930", "class_name": "RelatedNodeInfo"}}, "text": "TO THE \nMAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, A FFILIATES, BUSINESS \nASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY INDIRECT,  INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT \nLIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, SECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MAL FUNCTION, USE, \nDATA OR OTHER INTANGIBLE LOSSES OR COMMER CIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES IS ADVISED OF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR \nIN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT MATTER HEREOF.  \n \n", "start_char_idx": 1990, "end_char_idx": 2670, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "edcc37f0-9a01-41ec-a683-bf04eda6cf2b": {"__data__": {"id_": "edcc37f0-9a01-41ec-a683-bf04eda6cf2b", "embedding": null, "metadata": {"window": "FactSet CallStreet, LLC, or one or more  of its employees, including the writer of this report, may have a position in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet , LLC AND ITS \nLICENSORS, BUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY , INCLUDING WITHOUT \nLIMITATION ANY IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY,  COMPLETENESS, AND NON -INFRINGEMENT.  TO THE \nMAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, A FFILIATES, BUSINESS \nASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY INDIRECT,  INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT \nLIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, SECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MAL FUNCTION, USE, \nDATA OR OTHER INTANGIBLE LOSSES OR COMMER CIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES IS ADVISED OF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR \nIN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT MATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted Fact Set CallStreet, LLC 2019  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC. \n All other trademarks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "The contents and appearance of this report are Copyrighted Fact Set CallStreet, LLC 2019  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC. \n", "page_label": "21", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1c9437ad-0883-4253-bf98-af42f1639095", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ab51138e4bf7b185c337bb4a9d7c39875988a5e2a6f9a5c79274e320d01065bb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3adf8d3f-f01f-4f8d-8098-4090256bebc2", "node_type": "1", "metadata": {"window": "Any opinions or assertions contained in this i nformation do not represent the opinions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more  of its employees, including the writer of this report, may have a position in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet , LLC AND ITS \nLICENSORS, BUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY , INCLUDING WITHOUT \nLIMITATION ANY IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY,  COMPLETENESS, AND NON -INFRINGEMENT.  TO THE \nMAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, A FFILIATES, BUSINESS \nASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY INDIRECT,  INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT \nLIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, SECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MAL FUNCTION, USE, \nDATA OR OTHER INTANGIBLE LOSSES OR COMMER CIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES IS ADVISED OF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR \nIN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT MATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted Fact Set CallStreet, LLC 2019  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC. \n All other trademarks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "TO THE \nMAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, A FFILIATES, BUSINESS \nASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY INDIRECT,  INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT \nLIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, SECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MAL FUNCTION, USE, \nDATA OR OTHER INTANGIBLE LOSSES OR COMMER CIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES IS ADVISED OF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR \nIN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT MATTER HEREOF.  \n \n", "page_label": "21", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fd6a14cbd8dcef276f9081c0055196b8d273c81c5711f665f32cdad6d966bca4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7e539bb3-fca1-428e-b4a0-292e05888a71", "node_type": "1", "metadata": {"window": "THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet , LLC AND ITS \nLICENSORS, BUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY , INCLUDING WITHOUT \nLIMITATION ANY IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY,  COMPLETENESS, AND NON -INFRINGEMENT.  TO THE \nMAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, A FFILIATES, BUSINESS \nASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY INDIRECT,  INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT \nLIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, SECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MAL FUNCTION, USE, \nDATA OR OTHER INTANGIBLE LOSSES OR COMMER CIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES IS ADVISED OF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR \nIN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT MATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted Fact Set CallStreet, LLC 2019  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC. \n All other trademarks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "All other trademarks mentioned are trademarks of their respective companies. "}, "hash": "7b67874dcd8e6cf19d27eaeb0f1c50f1d5cf6f7fefcd6adcb269231b25d2222d", "class_name": "RelatedNodeInfo"}}, "text": "The contents and appearance of this report are Copyrighted Fact Set CallStreet, LLC 2019  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC. \n", "start_char_idx": 2670, "end_char_idx": 2861, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7e539bb3-fca1-428e-b4a0-292e05888a71": {"__data__": {"id_": "7e539bb3-fca1-428e-b4a0-292e05888a71", "embedding": null, "metadata": {"window": "THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet , LLC AND ITS \nLICENSORS, BUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY , INCLUDING WITHOUT \nLIMITATION ANY IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY,  COMPLETENESS, AND NON -INFRINGEMENT.  TO THE \nMAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, A FFILIATES, BUSINESS \nASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY INDIRECT,  INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT \nLIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, SECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MAL FUNCTION, USE, \nDATA OR OTHER INTANGIBLE LOSSES OR COMMER CIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES IS ADVISED OF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR \nIN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT MATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted Fact Set CallStreet, LLC 2019  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC. \n All other trademarks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "All other trademarks mentioned are trademarks of their respective companies. ", "page_label": "21", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1c9437ad-0883-4253-bf98-af42f1639095", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ab51138e4bf7b185c337bb4a9d7c39875988a5e2a6f9a5c79274e320d01065bb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "edcc37f0-9a01-41ec-a683-bf04eda6cf2b", "node_type": "1", "metadata": {"window": "FactSet CallStreet, LLC, or one or more  of its employees, including the writer of this report, may have a position in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet , LLC AND ITS \nLICENSORS, BUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY , INCLUDING WITHOUT \nLIMITATION ANY IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY,  COMPLETENESS, AND NON -INFRINGEMENT.  TO THE \nMAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, A FFILIATES, BUSINESS \nASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY INDIRECT,  INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT \nLIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, SECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MAL FUNCTION, USE, \nDATA OR OTHER INTANGIBLE LOSSES OR COMMER CIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES IS ADVISED OF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR \nIN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT MATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted Fact Set CallStreet, LLC 2019  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC. \n All other trademarks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "The contents and appearance of this report are Copyrighted Fact Set CallStreet, LLC 2019  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC. \n", "page_label": "21", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "edf85f90fdaf1e56f0d62ad2064ed46dbaff0258121e7bfb881f65ad4a264ddf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b4a98240-813b-4859-89e6-994cda0641d7", "node_type": "1", "metadata": {"window": "TO THE \nMAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, A FFILIATES, BUSINESS \nASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY INDIRECT,  INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT \nLIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, SECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MAL FUNCTION, USE, \nDATA OR OTHER INTANGIBLE LOSSES OR COMMER CIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES IS ADVISED OF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR \nIN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT MATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted Fact Set CallStreet, LLC 2019  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC. \n All other trademarks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "All rights reserved.  "}, "hash": "4d27ce225cb069553cebec2cd2e8f077181fd2e608ffca05c89d9d9325021e2f", "class_name": "RelatedNodeInfo"}}, "text": "All other trademarks mentioned are trademarks of their respective companies. ", "start_char_idx": 2861, "end_char_idx": 2938, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b4a98240-813b-4859-89e6-994cda0641d7": {"__data__": {"id_": "b4a98240-813b-4859-89e6-994cda0641d7", "embedding": null, "metadata": {"window": "TO THE \nMAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, A FFILIATES, BUSINESS \nASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY INDIRECT,  INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT \nLIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, SECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MAL FUNCTION, USE, \nDATA OR OTHER INTANGIBLE LOSSES OR COMMER CIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES IS ADVISED OF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR \nIN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT MATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted Fact Set CallStreet, LLC 2019  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC. \n All other trademarks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "All rights reserved.  ", "page_label": "21", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1c9437ad-0883-4253-bf98-af42f1639095", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ab51138e4bf7b185c337bb4a9d7c39875988a5e2a6f9a5c79274e320d01065bb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7e539bb3-fca1-428e-b4a0-292e05888a71", "node_type": "1", "metadata": {"window": "THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet , LLC AND ITS \nLICENSORS, BUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY , INCLUDING WITHOUT \nLIMITATION ANY IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY,  COMPLETENESS, AND NON -INFRINGEMENT.  TO THE \nMAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, A FFILIATES, BUSINESS \nASSOCIATES, LICENSORS OR SUPPLIERS WILL BE LIABLE FOR ANY INDIRECT,  INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOUT \nLIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, SECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MAL FUNCTION, USE, \nDATA OR OTHER INTANGIBLE LOSSES OR COMMER CIAL DAMAGES, EVEN IF ANY OF SUCH PARTIES IS ADVISED OF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR \nIN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT MATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted Fact Set CallStreet, LLC 2019  CallStreet and FactSet CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC. \n All other trademarks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "All other trademarks mentioned are trademarks of their respective companies. ", "page_label": "21", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "551c796a35d9d69b37f01015b2afa36d233d09ce5d2b50ba1f18ecc9e7d27a5a", "class_name": "RelatedNodeInfo"}}, "text": "All rights reserved.  ", "start_char_idx": 2938, "end_char_idx": 2960, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}}, "docstore/metadata": {"2d1dcccb-3e02-46e0-abde-55680070466f": {"doc_hash": "ca7c1c6e7bbf2fe00fcbe016852094d982b4d7681faaa7b3dc5304c2b2e4c051", "ref_doc_id": "eec7d66c-3454-4514-a032-b03193f8a1ea"}, "a0fe1be5-d0ec-4ba8-b3d0-1b9b60524dc9": {"doc_hash": "d3be67f5117efbe3418957d50b816ff3d1bb8ca705aeebca46c3eb9b039ff1bb", "ref_doc_id": "eec7d66c-3454-4514-a032-b03193f8a1ea"}, "042d8547-70e6-4b64-8f8b-b17e83e56818": {"doc_hash": "4d5a2511878e048b91b34b5eb878093ade95624db342637bd3753830f1566170", "ref_doc_id": "ddcd894d-3a7b-418b-b056-c1eebfbff48a"}, "d1bfb804-0d26-45bd-a7f8-7c8995ed6bfb": {"doc_hash": "836e94779146bc19f5bb6ade25e1cf623ffc583e5f87b3d687149e03031acf07", "ref_doc_id": "ddcd894d-3a7b-418b-b056-c1eebfbff48a"}, "137edc29-0866-49af-a115-71690aa287f1": {"doc_hash": "4c42d51721573b2c9e1f9ae15536f4650dc8e4b64a85b4e620d3e05a936cc2b5", "ref_doc_id": "ddcd894d-3a7b-418b-b056-c1eebfbff48a"}, "e9093e6c-2bb6-47cc-94fb-4158f0563efb": {"doc_hash": "2a3c6aa6a1bfcc964ff22e7233ec8e92caa591596cfb18eccf454be65708b51c", "ref_doc_id": "ddcd894d-3a7b-418b-b056-c1eebfbff48a"}, "6b38cf73-8d96-4feb-a60b-7d3f1a4f6b17": {"doc_hash": "9b5ff6fd8453f09e08a8deddf47f6119c0029a1f94bea66bb484d8ec2191da65", "ref_doc_id": "ddcd894d-3a7b-418b-b056-c1eebfbff48a"}, "2d4f0610-1d29-4956-9851-f97d9aac6562": {"doc_hash": "465da3132b2083d7035bb8b188b219d4fc71f1a1beadc46cc238db233101c640", "ref_doc_id": "ddcd894d-3a7b-418b-b056-c1eebfbff48a"}, "f1bf7e7f-5b9b-4083-9fce-384e3629541e": {"doc_hash": "c9521f78c5a276512af0d22fff33aa4ba9a63e864ac1081cb4de8ec04fb44a00", "ref_doc_id": "ddcd894d-3a7b-418b-b056-c1eebfbff48a"}, "afe63832-3b76-47a7-8870-b2fddf186363": {"doc_hash": "f34a98a87bdb8837e9fe4b9cf3a2ac00e8a87f085d96dfbacd97f3d9a6adb42f", "ref_doc_id": "ddcd894d-3a7b-418b-b056-c1eebfbff48a"}, "c94e8c4b-317a-49c0-a8e9-34204d6247f9": {"doc_hash": "5060935750eae594aff18e6da96bd4a8206b42ec0e60b210e187650b1614b563", "ref_doc_id": "510e1ab1-9110-4db6-842c-2a73346ced15"}, "5f6b894a-10d3-4b4c-8aca-dcd10b821458": {"doc_hash": "0983f3482e0a3ac3776293289d10f732b810466107b72b4f4a334a5551662c6c", "ref_doc_id": "510e1ab1-9110-4db6-842c-2a73346ced15"}, "4a548413-05f6-466f-bbac-14ea5ca94e28": {"doc_hash": "14d4912fcbdba2aa050c648688bca7dcebaba5e64d3474b72f86a1bdd436ba45", "ref_doc_id": "510e1ab1-9110-4db6-842c-2a73346ced15"}, "a6d40933-9750-409c-ad15-988033bd0423": {"doc_hash": "1355e3d7f89f47c8980e750ba6faf34fb6e2ffef14551764a571d4f63f0a9ccd", "ref_doc_id": "510e1ab1-9110-4db6-842c-2a73346ced15"}, "04b603d8-3aaa-4ddf-a1b4-dfdc70dee8af": {"doc_hash": "cbec86cf827e783e6c251610d7be10acbfec6aaad67073d11f39a42d2bfe64cb", "ref_doc_id": "510e1ab1-9110-4db6-842c-2a73346ced15"}, "6b4227af-0b0c-41f4-898f-5c90e3baebd5": {"doc_hash": "0d012ecbb99c54432880a7ca6d4cbc338f1a41ac189e6e48b9b491ee144d64cf", "ref_doc_id": "510e1ab1-9110-4db6-842c-2a73346ced15"}, "65359aa5-d207-4662-b88e-38fcda29bbac": {"doc_hash": "8c3f2c49cf36b69e21b4276e6bd3436c673154c0b2d825e10a9519e2204a8861", "ref_doc_id": "510e1ab1-9110-4db6-842c-2a73346ced15"}, "dbf544b8-b4b2-4f4e-8493-df208f552536": {"doc_hash": "1bdeb2fa6f49df11c55fea1d8ac13efb92b1ee3ea98228e0965d7b300eac5417", "ref_doc_id": "510e1ab1-9110-4db6-842c-2a73346ced15"}, "3761d2ed-93be-42c2-8ab3-d6e17f14ab1f": {"doc_hash": "f079b86f8c5773a30986217d4bed48507983585d61561a56e258022df4d7c7eb", "ref_doc_id": "510e1ab1-9110-4db6-842c-2a73346ced15"}, "ddc62d7f-414d-432a-82a4-6e576ca8518d": {"doc_hash": "c344d96678120a5edd0428de14792f32ad33e9751293e80b9c31607b3ba114b1", "ref_doc_id": "510e1ab1-9110-4db6-842c-2a73346ced15"}, "6825a9c2-9943-45d3-8548-947c26484975": {"doc_hash": "f3d87cec0879ee6b377a9fef25086faaa98d5a0a5d9f8a5d5eb8440cd5682c35", "ref_doc_id": "510e1ab1-9110-4db6-842c-2a73346ced15"}, "0ac50c5f-036f-4466-8f15-ec86b2ccf906": {"doc_hash": "34fe31135f8f083e37fa1fdd2e3201e7809d166fdd3a59a5f35e0276a8423eef", "ref_doc_id": "510e1ab1-9110-4db6-842c-2a73346ced15"}, "f14b3c48-5f97-4c9d-9fb5-a3e8d35c4e3f": {"doc_hash": "78ddc3fad70ddb5f6070766f52ee746f358e1bfc5f15646ae5ed62705f86301e", "ref_doc_id": "510e1ab1-9110-4db6-842c-2a73346ced15"}, "540ca450-1e83-42c3-a043-160f09e87f0c": {"doc_hash": "b599738eb3d3e24dbcfaebcd6a46f24e44d457f56c11e36d18dcbebc27570f62", "ref_doc_id": "510e1ab1-9110-4db6-842c-2a73346ced15"}, "f2f3411f-2105-433d-8628-34b271d7b98e": {"doc_hash": "ea0d5024594c52c02a0a1297d1efc1fa08535ea0f62f3eab7ec20fcace6e8224", "ref_doc_id": "510e1ab1-9110-4db6-842c-2a73346ced15"}, "845d54cc-a4b7-436a-b879-d5a0c34075b3": {"doc_hash": "1675f4102396583c0ffc83ed2ca1ea5bd13bf8b299f9cebf0a381f51642587af", "ref_doc_id": "510e1ab1-9110-4db6-842c-2a73346ced15"}, "2ea94fe1-e35b-4702-b7b8-6053495abbd8": {"doc_hash": "5afa54095b0863314641ce0d81f0518f72a7697597103b96a4ffe57ed466b4ae", "ref_doc_id": "510e1ab1-9110-4db6-842c-2a73346ced15"}, "a5aa0458-4fd8-443a-9b71-02263ec53191": {"doc_hash": "b43c7609b931f663171e35fb1fb031aecb29a6e6622d8d1b685903729f1bbf1f", "ref_doc_id": "510e1ab1-9110-4db6-842c-2a73346ced15"}, "703cece9-a1a1-4c14-b3c0-18d2342a6dd5": {"doc_hash": "f4dcc7c221a3759f757ecca55651673e15532f16e08d70adfa30a741f36d580d", "ref_doc_id": "510e1ab1-9110-4db6-842c-2a73346ced15"}, "3839b9ce-9e53-40fa-ba33-5477fdc60ef3": {"doc_hash": "a7e5dba542c8e91de86158e77e83f9653e1f71110c68b8b18c534286c401dc9a", "ref_doc_id": "510e1ab1-9110-4db6-842c-2a73346ced15"}, "7a530be8-360f-486a-9fcc-85e479f7dd3b": {"doc_hash": "dd45261b197361c9f8d1a8717d8f8842e3efad83ff523927e65e5b1b5ef041ea", "ref_doc_id": "510e1ab1-9110-4db6-842c-2a73346ced15"}, "b79b7c91-e179-48c8-a243-9e50dc60b8af": {"doc_hash": "871446acb8bac0aa1ae716797a5cd8404d6fb8b9de9fcf5c6a8c5d26797f35c0", "ref_doc_id": "510e1ab1-9110-4db6-842c-2a73346ced15"}, "0f3a01b7-e381-4705-a971-cb610e1b0e43": {"doc_hash": "0eada1b70843209c1285c20379a2943fbc766f620dfa2781aadf84e995803646", "ref_doc_id": "510e1ab1-9110-4db6-842c-2a73346ced15"}, "8403517e-0c7d-42e3-98c3-7569ecfa508f": {"doc_hash": "e7d290780a87fb1adafe19ac7b431955d17de4efb882be652970c4331e22af28", "ref_doc_id": "510e1ab1-9110-4db6-842c-2a73346ced15"}, "ee0d08db-6fa2-44f2-b5cb-354e79460d6c": {"doc_hash": "37de916329798eebb9c3258ec07804ac8a680313156da200de282e2882b154a0", "ref_doc_id": "510e1ab1-9110-4db6-842c-2a73346ced15"}, "912d1d33-24da-40d2-ac43-adb2554a1f0a": {"doc_hash": "8a656131b1b91dcb12eb536228dc4e93efb5faeac060bd9d8df2baced95d3fcf", "ref_doc_id": "510e1ab1-9110-4db6-842c-2a73346ced15"}, "23d1f47f-b84c-4484-a9b6-6d471b9ca078": {"doc_hash": "42fb3762c97e8d44a7149ed28168b66f9188df1b0745ffb06353e3172ec3bc56", "ref_doc_id": "510e1ab1-9110-4db6-842c-2a73346ced15"}, "8241b658-ff7f-4c11-9c80-c405798b4663": {"doc_hash": "37ceada24de9ba41c9c0ae478e709beadb921e4c457c8db058d1655a868d20f9", "ref_doc_id": "510e1ab1-9110-4db6-842c-2a73346ced15"}, "173384bc-a7af-419a-b31e-4fb0de064c61": {"doc_hash": "06dbfbfab01452cfa6095661213a6ca3c3230927ae2e54eafbceab76247bb663", "ref_doc_id": "510e1ab1-9110-4db6-842c-2a73346ced15"}, "49220002-ecf8-441a-952f-c7585d1a2e3c": {"doc_hash": "e9240708def0528acdcdc49f48f5c57e83f92c652c54c1a4626205404290795f", "ref_doc_id": "510e1ab1-9110-4db6-842c-2a73346ced15"}, "de974110-2bb8-48eb-b188-4ec7d734a672": {"doc_hash": "a4e4306bed3d840e1b5758a5c61162412e790b9b869d2696541ace96a7a05528", "ref_doc_id": "510e1ab1-9110-4db6-842c-2a73346ced15"}, "f59075a0-c3ff-43fa-be60-f8e271ea2cfd": {"doc_hash": "c7a23cba7f44de85036162b1463e97c9a3d01c45159c15e76cff75a0ee06f2ed", "ref_doc_id": "bdb1c12e-5d92-4655-a0ce-a7bbe0044e67"}, "fcaef1ae-b5f0-47a1-b6f7-9bbcd9f3fece": {"doc_hash": "8f61ff268d36e56ed1e75eafc8cfd7ddb0ad3a51a51096793f639d60fb74c65e", "ref_doc_id": "bdb1c12e-5d92-4655-a0ce-a7bbe0044e67"}, "95e67569-2322-44d3-8ae1-d96c53212b59": {"doc_hash": "7d8869ccad7778ccb494eb095524d20182adb019b79707e136e04725dc9f6535", "ref_doc_id": "bdb1c12e-5d92-4655-a0ce-a7bbe0044e67"}, "898deb2c-2255-4de3-967e-ce52864b7d43": {"doc_hash": "ff0e1dc15d7c7861602e8fa2dc5ec3fa5ba872ef6a0dcb064233cc6b6b39e03b", "ref_doc_id": "bdb1c12e-5d92-4655-a0ce-a7bbe0044e67"}, "87d9acdf-98c7-4ae2-a90c-3d3109d5890e": {"doc_hash": "fb97e19bf6cefce988fc075fb5bcb1e85abed4b8a7c33ee29538159fa046f696", "ref_doc_id": "bdb1c12e-5d92-4655-a0ce-a7bbe0044e67"}, "2d58f180-c875-43fc-919a-9c78245ddf59": {"doc_hash": "45d74ad70737f3da58ca933f8b36db1dc4c8b8f1fd4efc943582bc4434cf43e0", "ref_doc_id": "bdb1c12e-5d92-4655-a0ce-a7bbe0044e67"}, "242df766-237e-4e47-8008-345462602d18": {"doc_hash": "fec646bd6c7962da770f00ba1b4a2d8b52e902e4a1b88a4ffd0a20e18823fe63", "ref_doc_id": "bdb1c12e-5d92-4655-a0ce-a7bbe0044e67"}, "217834d1-f017-405a-9575-d32274bb2a3e": {"doc_hash": "5712b0494b86c28643852bb407f544ba26f373d8d24b9d95f4cc275b90ffe313", "ref_doc_id": "bdb1c12e-5d92-4655-a0ce-a7bbe0044e67"}, "298c53fb-0134-404f-abdf-03d0bc27b627": {"doc_hash": "9663c3ce0cfd9d7f9b4b59d78b6938001aaedb87194f81a37995a0635771c806", "ref_doc_id": "bdb1c12e-5d92-4655-a0ce-a7bbe0044e67"}, "066bad57-a56b-433e-8fce-4387dddfcbce": {"doc_hash": "906e17e138b12773f916e48fceeb50c5057582136cccba9e3f1dfcdfdfd3fa79", "ref_doc_id": "bdb1c12e-5d92-4655-a0ce-a7bbe0044e67"}, "4bc03c69-e4b8-4d53-84ab-9496f2cf992e": {"doc_hash": "7611768f1e66c8c308f952f97e2b80a5e87fe9e7ea27fd11e96ad417845da6e6", "ref_doc_id": "bdb1c12e-5d92-4655-a0ce-a7bbe0044e67"}, "a9fbeda9-d3f2-4f1e-bdae-65b47d387e3d": {"doc_hash": "c8e9c1ef373bcbf940853c189815387a458eee9b5263db2c04c38efb48f36c01", "ref_doc_id": "bdb1c12e-5d92-4655-a0ce-a7bbe0044e67"}, "5c2ff04f-d323-48d2-91d4-09ca737c6794": {"doc_hash": "9137e6cddbdf645ea9d9163ee88322645d4dd993b2b217d92f0919e6053f5627", "ref_doc_id": "bdb1c12e-5d92-4655-a0ce-a7bbe0044e67"}, "8b4829b8-3b18-46d4-ac7b-96f2c7771563": {"doc_hash": "21840d98267a3fe9e80578f2d895adb314e3f8093aa6253e6a80141f56165f5e", "ref_doc_id": "bdb1c12e-5d92-4655-a0ce-a7bbe0044e67"}, "6eb55a15-dab4-4ecd-9dc4-3c438e9911df": {"doc_hash": "05b43d95b45829629b62a545df0c33354f9de2bd472115a93c2a71346635ef5a", "ref_doc_id": "bdb1c12e-5d92-4655-a0ce-a7bbe0044e67"}, "7e737d75-e56b-4e89-ae11-0684ad8abe86": {"doc_hash": "976ce0bc336ef32dc95525232080d17927b1ee4326eca160fa3a628d74bf62c5", "ref_doc_id": "bdb1c12e-5d92-4655-a0ce-a7bbe0044e67"}, "57cd1e23-7774-470c-8a8b-bd7ba510b206": {"doc_hash": "d7223f0ae20f00c5c64bf30afc3c62e3fcfa87ff9edd4c8fb9d7bd151eb52bff", "ref_doc_id": "bdb1c12e-5d92-4655-a0ce-a7bbe0044e67"}, "8d2f9994-83e2-47a8-8f00-54240a431d37": {"doc_hash": "1be76fecd922aba0ba36fb4d4bdb5af9b5a8d7e9cc7c6733c5f17ae19d3baf34", "ref_doc_id": "bdb1c12e-5d92-4655-a0ce-a7bbe0044e67"}, "3944dc64-9e91-4729-99b5-9ef44d1f01c6": {"doc_hash": "a06edf6f7f2887ce28fbc8cd30938b732fc8d5edefbc7ff38de74f4ed7953495", "ref_doc_id": "bdb1c12e-5d92-4655-a0ce-a7bbe0044e67"}, "cfa28579-ab4a-4fee-873f-1e7a317ff886": {"doc_hash": "82e3e9e929b91046a72a2a6ca7c15b7d72640ea09311e9ddd745fbe89fd4c036", "ref_doc_id": "bdb1c12e-5d92-4655-a0ce-a7bbe0044e67"}, "2181b13a-7841-4233-bd5b-240511f0bd06": {"doc_hash": "09d070ba2412d9ae788df9609ec7b716800c6402a93e3d38ce53bdfbe17e5845", "ref_doc_id": "bdb1c12e-5d92-4655-a0ce-a7bbe0044e67"}, "789ec73e-ce22-4c6e-b2be-da716b1bf211": {"doc_hash": "874d577369ef0cc4e2232d08894b1d9f1146101ea08518dd5af5e48442fda847", "ref_doc_id": "bdb1c12e-5d92-4655-a0ce-a7bbe0044e67"}, "00dfda7b-15c7-4616-9fb9-150e804f4cfb": {"doc_hash": "d468cd52305eca01c26761a6f5f0b8ab6c53a71274a34cdd264717eee1117ccf", "ref_doc_id": "bdb1c12e-5d92-4655-a0ce-a7bbe0044e67"}, "1a102e81-2d73-4f3f-a832-112d767301bf": {"doc_hash": "9faf016cc16e004941f99e425d1fe7c800a93b3f717120c94e6a8d443f634be2", "ref_doc_id": "bdb1c12e-5d92-4655-a0ce-a7bbe0044e67"}, "334e2248-5a39-4019-911e-a1f5576b5fc6": {"doc_hash": "1d23900626b3a009d688dd82f5d7d26b829b143ff45b96c8d1ff742f45c5e826", "ref_doc_id": "bdb1c12e-5d92-4655-a0ce-a7bbe0044e67"}, "ccf78060-5d2c-41ad-843a-4e7ebfd20161": {"doc_hash": "0390ce853e656f1cf2e4dd9a7fa28a91b9457ac25f388df733e7d0aa053e544a", "ref_doc_id": "bdb1c12e-5d92-4655-a0ce-a7bbe0044e67"}, "3f72e92b-d01d-4023-91cd-03bc06cb7682": {"doc_hash": "5303da0b4a4424ad87ec1c10645deef1c2cf1397a5f869162325d6428e4cea05", "ref_doc_id": "bdb1c12e-5d92-4655-a0ce-a7bbe0044e67"}, "7d104f6a-b1cf-47f7-b320-94ac2a52073d": {"doc_hash": "a87dc378042d04a0b5bdf456b484ae4482a263978e3c47cf1d85f42cc8ed6dd4", "ref_doc_id": "bdb1c12e-5d92-4655-a0ce-a7bbe0044e67"}, "78597274-6618-442f-b136-8f09dac5cf11": {"doc_hash": "8baef23fcbe7c534886621a25f4067a3a41b21cec3398357ca260f44a97ea482", "ref_doc_id": "bdb1c12e-5d92-4655-a0ce-a7bbe0044e67"}, "2fa9a331-7749-4406-8074-a6cf7efea413": {"doc_hash": "b305d06fdd214ac64aeff19116b18ffd1ee815e295c90c1c1e66a066768d0666", "ref_doc_id": "bdb1c12e-5d92-4655-a0ce-a7bbe0044e67"}, "4e579875-9e14-4d0e-9450-8c0f82e47a4c": {"doc_hash": "1a77e5291b089c9d46a4e3ee2b4721188c96e585b39670fa2dffdfdfb9a042b7", "ref_doc_id": "bdb1c12e-5d92-4655-a0ce-a7bbe0044e67"}, "54ba985a-d148-4b52-b06c-409a13bc5b10": {"doc_hash": "fccdbacedbebe0ea2f718f92897fb35dd25f506a9f14d76f68faf73539de54c4", "ref_doc_id": "bdb1c12e-5d92-4655-a0ce-a7bbe0044e67"}, "45e3c679-800a-4112-a3e6-495bfa752306": {"doc_hash": "a7251c2bae627bc730d71964c702d44daaebea87030c6e7431b17e34a3d4632e", "ref_doc_id": "fa648db0-cb11-4d5d-95db-126c70dfc60f"}, "0b9c0736-bb70-42d6-bfdc-13f1fb3fd114": {"doc_hash": "8f9e6b76c947a5bb05b74c22a619e6abdd79f70524c1042e79aa75cd909f4d3d", "ref_doc_id": "fa648db0-cb11-4d5d-95db-126c70dfc60f"}, "f85d4de8-a923-41a0-91cc-c36ea7ad67d4": {"doc_hash": "c9bdeaa25aa6b3317cbf628e619715a9ed6607563deff671b0d3ffe111affc02", "ref_doc_id": "fa648db0-cb11-4d5d-95db-126c70dfc60f"}, "bb3c5391-6453-4972-a842-38324bf16c1e": {"doc_hash": "5c0e1631fdb1851ba4111586537c015f76d30829fc8f40744e4b9a2505678066", "ref_doc_id": "fa648db0-cb11-4d5d-95db-126c70dfc60f"}, "ff9dfb3f-5250-4739-b81b-032b85308639": {"doc_hash": "44b17e970b18fb49762ff3318d0a10516a67b86b9d57c42b7a0320b2a71cfd57", "ref_doc_id": "fa648db0-cb11-4d5d-95db-126c70dfc60f"}, "24e0617d-aa36-460f-a3dd-c16333e1b571": {"doc_hash": "1a9871ee84bea4d5ca2253dba79c32c12e499a40f75e39cfbd1df0635c732680", "ref_doc_id": "fa648db0-cb11-4d5d-95db-126c70dfc60f"}, "85787496-f0d0-46dd-90c5-85b55314a160": {"doc_hash": "2deb80d541839c48b1c0721020e49c9680948c885a5f3dff564e22f6d3f062f3", "ref_doc_id": "fa648db0-cb11-4d5d-95db-126c70dfc60f"}, "f6c7733a-0b1d-4941-a768-1335bf498f0a": {"doc_hash": "bdde1c6544d01053f653999e4625ed41c46c06e41dd2de68f7d57abffc556233", "ref_doc_id": "fa648db0-cb11-4d5d-95db-126c70dfc60f"}, "8a213aea-cba9-4051-af4a-ae935d9c8e4d": {"doc_hash": "2d58e86aec114e2f43f3947e23bf09e0e5b51a75cb952b1561122afcc2b737c8", "ref_doc_id": "fa648db0-cb11-4d5d-95db-126c70dfc60f"}, "5bda2734-c4fc-4c73-831c-e3aa1c26cf3e": {"doc_hash": "559dd968b1c6b244f0fb6b1b16f556b539b062f0a6eee0a02a0a010f6b4bb0b7", "ref_doc_id": "fa648db0-cb11-4d5d-95db-126c70dfc60f"}, "537858a7-42fc-4fae-92e8-76413fe0ce80": {"doc_hash": "eea3153b76db482f020b88266e7e4e080d1e49d0f0da575e8a028fd64cfa2d46", "ref_doc_id": "fa648db0-cb11-4d5d-95db-126c70dfc60f"}, "1bcfc1ac-4381-4dae-867d-386e3bc27f98": {"doc_hash": "263b45dae06ba4d4cff359faf848e83e5d2375e018ec9bcc1672b64c39f62494", "ref_doc_id": "fa648db0-cb11-4d5d-95db-126c70dfc60f"}, "29d7850c-8458-4464-803e-12a11044813d": {"doc_hash": "5bd195f05da0fa0b0aa3412f8ab7528b854142a3f52d3d96a720db08075fb72d", "ref_doc_id": "fa648db0-cb11-4d5d-95db-126c70dfc60f"}, "058006ce-aa5c-445d-abe2-9d3eef8d84a9": {"doc_hash": "dcfc36a3c7a0b49d2f7acc84f18e7def274055d90a28c784ae175ba6cd6c120d", "ref_doc_id": "fa648db0-cb11-4d5d-95db-126c70dfc60f"}, "36206bc7-5142-4b5e-8696-abe87db3102d": {"doc_hash": "85d3550e358fc5ce797c177233eaef3e05ee3e04396fded22812d9cf2aa16cb0", "ref_doc_id": "fa648db0-cb11-4d5d-95db-126c70dfc60f"}, "63eb23c9-0685-419e-a720-8640f93a97ec": {"doc_hash": "a1829b84c4dbb8445f3610f47f7266d7d8f14fa4f4e65a75dad77a42b87c596e", "ref_doc_id": "fa648db0-cb11-4d5d-95db-126c70dfc60f"}, "0673fb43-ef6a-4289-b293-61356273ba1a": {"doc_hash": "497d9a67070ec6db089aa1c66a8ffe4db9785837e7118d1cdcee5e69d7e45853", "ref_doc_id": "fa648db0-cb11-4d5d-95db-126c70dfc60f"}, "e9254940-bcd2-4c34-b682-de7b9ed04074": {"doc_hash": "b5361638803614b070c5cc266ab6a12e9cd5d1fb2c900847694ae41d1e1af0c0", "ref_doc_id": "fa648db0-cb11-4d5d-95db-126c70dfc60f"}, "b1bc4d2d-8225-408a-b0b3-a77cbc18c478": {"doc_hash": "c7c8749cb2cc29733d23cc3a46d860139cbb84212c6ed102f631b8dfb2a6cd0b", "ref_doc_id": "fa648db0-cb11-4d5d-95db-126c70dfc60f"}, "f25c81c3-0a73-4b5f-9388-9692af8073f8": {"doc_hash": "15168bf97d781d20d64b44d167395fbb094668b79ed4b1bc30fd5604ea0f33e8", "ref_doc_id": "fa648db0-cb11-4d5d-95db-126c70dfc60f"}, "a3a2277c-688a-4d68-8d9e-94488789f010": {"doc_hash": "ea2276ed9c047c305001474da24127491cc15646ecc3b24d5a113353342cdb07", "ref_doc_id": "fa648db0-cb11-4d5d-95db-126c70dfc60f"}, "95bf8a2b-9d7c-421a-92ca-8ac05f27a45c": {"doc_hash": "1e6e0b4132570f95fb3c69e4126566dd32ea5253bbe060ffeb895f14320d3b48", "ref_doc_id": "fa648db0-cb11-4d5d-95db-126c70dfc60f"}, "d49520e5-d56b-4012-9c4e-1c21b8a67585": {"doc_hash": "cc42504df7e1f273851b228147fbbcfb5e4c23c5c7bbb3771c973d75631361d8", "ref_doc_id": "fa648db0-cb11-4d5d-95db-126c70dfc60f"}, "87684e1d-97f7-44b4-8cdf-88d9ef9d3239": {"doc_hash": "16fec55671e5daaaa77af8f5165f5bb415a2b8de672f10a1988585cb1ed4f8c8", "ref_doc_id": "fa648db0-cb11-4d5d-95db-126c70dfc60f"}, "ce7fb8af-0d4f-4cc3-a45c-c6c926a2fda9": {"doc_hash": "6fd9542c35de64dbb380a1bd8f86c903b3ef9857ec165677f3ab244f525d0f77", "ref_doc_id": "fa648db0-cb11-4d5d-95db-126c70dfc60f"}, "198dcd87-3bfa-4c18-95ae-0d1244513a75": {"doc_hash": "dfa26b9d1137461af7b6353241dc6449d52e7123a720196608b25e507337216e", "ref_doc_id": "fa648db0-cb11-4d5d-95db-126c70dfc60f"}, "340369b9-e29f-48ae-bae5-cd7d242349f8": {"doc_hash": "69562cca007382790787efe52d195d1f85f58f1955e88040b98a71010ce07ad4", "ref_doc_id": "fa648db0-cb11-4d5d-95db-126c70dfc60f"}, "d64f37bc-55df-4648-8d80-3d91ff8b614e": {"doc_hash": "9761d301b76076db0732842573ca4c283a2b03b499b5e8544322fd161bdcf107", "ref_doc_id": "fa648db0-cb11-4d5d-95db-126c70dfc60f"}, "8dc0a584-fd6d-4354-aff9-71e7cf9da50e": {"doc_hash": "e660da78a38a599efe8eb836b59ce5d2eb90774204cb95f919de8941571364d5", "ref_doc_id": "fa648db0-cb11-4d5d-95db-126c70dfc60f"}, "4c80ef3b-9f39-4835-8fde-5d0625a0286a": {"doc_hash": "0e0032e084dc100b1f7d3d9bc5c4b02ac82a10876ae2ea9200f4c01767e66489", "ref_doc_id": "fa648db0-cb11-4d5d-95db-126c70dfc60f"}, "651d7927-2379-4a11-8a45-c9c419c71943": {"doc_hash": "d5572dc6ab0095a4bd4527774f9a1e786523751e6c1dc5aa14a72648d5fa2aa9", "ref_doc_id": "fa648db0-cb11-4d5d-95db-126c70dfc60f"}, "7848ed03-ba91-4498-bb31-de74029a260b": {"doc_hash": "638750de0b888bbe046c2ea700bed3efa705622a8158fb5258d7a0ac475c6e9e", "ref_doc_id": "74aa42ba-8aa4-40bb-8e6b-4b4438973fe6"}, "d12cb688-a1d9-4cd0-b62d-cc3856b9fb1a": {"doc_hash": "e859e9bbb0225ae0c112480b48da36c674d61367a23b0f7f69b7055d9fb6b2c7", "ref_doc_id": "74aa42ba-8aa4-40bb-8e6b-4b4438973fe6"}, "d4ee4b0a-26f9-4a51-8b54-2c2908268571": {"doc_hash": "43de855c8c89355246891fc543c15aeff2d4891b565479845735b87146071af0", "ref_doc_id": "74aa42ba-8aa4-40bb-8e6b-4b4438973fe6"}, "19838fb3-dcee-4060-9667-3945e4e8f602": {"doc_hash": "e0aabbdb6a1c4f3c9f70032f74763da787a3b379615a79717f9d758f90aab695", "ref_doc_id": "74aa42ba-8aa4-40bb-8e6b-4b4438973fe6"}, "3d5d61d8-dd77-474b-9d6f-8d593083c8be": {"doc_hash": "19c73dd8cf6a299e97d342b2d18ebb40110b87a093a237926f748018abaa6966", "ref_doc_id": "74aa42ba-8aa4-40bb-8e6b-4b4438973fe6"}, "80f4cb25-9810-47fd-9ee9-c85528b9692c": {"doc_hash": "0589611ae27feb5f1f8f4ab6618d0ff7ed689b25c513af3a4d5e0428388be902", "ref_doc_id": "74aa42ba-8aa4-40bb-8e6b-4b4438973fe6"}, "66f535e7-4850-4596-8324-b10779e4628d": {"doc_hash": "e276bdeb41187e734c87c2cf8486b99a63165ba199e02a2d043bfb27541ae7e4", "ref_doc_id": "74aa42ba-8aa4-40bb-8e6b-4b4438973fe6"}, "d6ed34b8-6f2d-4c70-a5b5-4d952d94f18d": {"doc_hash": "939ee3546fc581ffc45a60f5353b6e8bcdb01daedb499457ad1589aeaff23807", "ref_doc_id": "74aa42ba-8aa4-40bb-8e6b-4b4438973fe6"}, "83464f70-87d8-493c-a37c-c84d2560c026": {"doc_hash": "b0b8f2e4a8d96b5f849e7499821696f3e32cbd6ade2155d4a7872759bfcdb611", "ref_doc_id": "74aa42ba-8aa4-40bb-8e6b-4b4438973fe6"}, "0d7a9d36-ad02-43b3-bd87-6a82804acc76": {"doc_hash": "d3034dc6adc19255807d24d505b78938e56b1dc90c56da99553bed60111f8743", "ref_doc_id": "74aa42ba-8aa4-40bb-8e6b-4b4438973fe6"}, "e9e98cff-6a63-4461-96dc-2e1097b54401": {"doc_hash": "ed22bcbf6f61fbb09d813bd9c6ba1addcd7c843382e4eacc4030f21ce63a3380", "ref_doc_id": "74aa42ba-8aa4-40bb-8e6b-4b4438973fe6"}, "2c15394b-eede-4a15-8c7d-c43e95e8ddb2": {"doc_hash": "7d4142835173786da3b87420b24397c45bba5a9c3eecfd5b1339d216db6b6044", "ref_doc_id": "74aa42ba-8aa4-40bb-8e6b-4b4438973fe6"}, "396cb89d-55f0-4a4d-adbe-fada4fa9735a": {"doc_hash": "9edbfff5ecd59999c93d1884b915ed293d5cfec0c895ea1c25b4ef4e0ca74bb0", "ref_doc_id": "74aa42ba-8aa4-40bb-8e6b-4b4438973fe6"}, "f5238269-abeb-4cb9-aee6-d9746877019e": {"doc_hash": "3deea2281ac4facad0baf207498af15e6eee4c115a14e02cef3f149429a10ba0", "ref_doc_id": "74aa42ba-8aa4-40bb-8e6b-4b4438973fe6"}, "dcb9e7a2-cc72-46cc-a500-e2b27cd176fe": {"doc_hash": "527357beee8d71166da60f72aed76a975c2a2d651042356c7037c50cf4348462", "ref_doc_id": "74aa42ba-8aa4-40bb-8e6b-4b4438973fe6"}, "7d853738-d27f-47e6-ab10-83c61ffb4873": {"doc_hash": "719d1f82cba1028af434bdcde5843040c3d20637f8b095570fbb8bd3749b9ffa", "ref_doc_id": "74aa42ba-8aa4-40bb-8e6b-4b4438973fe6"}, "64d55880-895b-4823-a959-254b43d00846": {"doc_hash": "fd3090db861bbf7f2db331c11f7f53358b56e8c9a149efe8bc3374167f2b10ea", "ref_doc_id": "74aa42ba-8aa4-40bb-8e6b-4b4438973fe6"}, "e8693b1a-7cb2-4e79-adb2-ec1c8a343185": {"doc_hash": "ad29982a31afdd251b8764a8e30fc47a4f11439ebe1e64783ea5dcb392aad31d", "ref_doc_id": "74aa42ba-8aa4-40bb-8e6b-4b4438973fe6"}, "c4ae4d27-c9bb-466e-bd49-8e9745a6eb5b": {"doc_hash": "7d6daf8774c81fcfb9d57397b16be9025a79eeb2f1bd2dafbce08eaa4073a677", "ref_doc_id": "74aa42ba-8aa4-40bb-8e6b-4b4438973fe6"}, "7cdc9798-4237-41cf-a16e-5d9208f2084e": {"doc_hash": "8bce247c77ea5df6f722125ae3ead08fd5a164842b4052aa3ca1f8687090e29f", "ref_doc_id": "74aa42ba-8aa4-40bb-8e6b-4b4438973fe6"}, "195946fe-780d-44f7-b4cd-9ac12e66ce81": {"doc_hash": "4d4b891edef06183b54d2518532da2a62b939647a1e2b240fbd05057be7f78c6", "ref_doc_id": "74aa42ba-8aa4-40bb-8e6b-4b4438973fe6"}, "d9292600-28fa-4da5-8467-c7999482b5da": {"doc_hash": "ef2c26c39652ad5b199da55fb780cdb2fd2c0d73390d3a3b92cc110dc44eef49", "ref_doc_id": "74aa42ba-8aa4-40bb-8e6b-4b4438973fe6"}, "4e63fdfb-b136-48d2-9687-c59a508a732d": {"doc_hash": "9d1ff4147e5d5be3e0f8cc1a507d74daa252669a003ce173a2051cb911e65601", "ref_doc_id": "74aa42ba-8aa4-40bb-8e6b-4b4438973fe6"}, "4c034a36-849c-44ad-ab57-eff0ba32e3a7": {"doc_hash": "a06e34070c253ebcd10864b7155f9f0ba22054ee136754a31e50cec6ff414448", "ref_doc_id": "74aa42ba-8aa4-40bb-8e6b-4b4438973fe6"}, "2b5aae8c-706f-485d-9f68-ffd29966148f": {"doc_hash": "a11de9e40a07c06addd1219b904841b54d96fcf6861064864e209174e9c04c8d", "ref_doc_id": "74aa42ba-8aa4-40bb-8e6b-4b4438973fe6"}, "539dbe6e-196d-44f9-971d-82e1f37eb2e8": {"doc_hash": "6d6cfdb83d8b08aa29df7984cb1c5f0e773c44706ef29a8e1764659ce2766f9c", "ref_doc_id": "74aa42ba-8aa4-40bb-8e6b-4b4438973fe6"}, "8601b132-b9c1-4904-af0c-c9d5deabac06": {"doc_hash": "df8f6d192d29e7e96ca53d2e27984bdc92732464ab1cda71eac490724977879c", "ref_doc_id": "74aa42ba-8aa4-40bb-8e6b-4b4438973fe6"}, "0a4a53e1-92b3-4b69-bcec-d7367f636132": {"doc_hash": "94fdb554a6505ca181ca5ea326eb799329577f6229507144918e41bd46a9e0a6", "ref_doc_id": "74aa42ba-8aa4-40bb-8e6b-4b4438973fe6"}, "58a58dbc-b08d-4315-b3df-80d2ef81abf9": {"doc_hash": "477e9b5fdcbc5a53c34760b837d8d924a1efcae2d3d7cf684fbee47db00158fa", "ref_doc_id": "35248f45-6429-4b21-a274-8a0d5bf89987"}, "812e151e-2542-4084-865f-a4e97193495e": {"doc_hash": "9d17d8c3e0f8a0a15be17aa9b1b3bb8bf0fb70d0e481f8d4c16e4149405ef4d2", "ref_doc_id": "35248f45-6429-4b21-a274-8a0d5bf89987"}, "f4bdb64e-7f79-4927-849d-4db90a62a851": {"doc_hash": "ecec10176f210a0d65eefe3b78a61f03b23351f5deb81a2876b8756cfae236f0", "ref_doc_id": "35248f45-6429-4b21-a274-8a0d5bf89987"}, "50f18d3c-d78e-4cb9-b46f-3c1143589def": {"doc_hash": "80d5ebdf9e7e38656057641998a9ebb33326715eddb123503b0a6edb15c5c9ec", "ref_doc_id": "35248f45-6429-4b21-a274-8a0d5bf89987"}, "89553ef2-aaf5-4be4-a353-edc08b44f2cc": {"doc_hash": "09a49e360eef1888816d8be2271728e365a914794daa0b27699fe4565d605ebc", "ref_doc_id": "35248f45-6429-4b21-a274-8a0d5bf89987"}, "a46b753d-74f2-45f8-8de4-d33e15ae82c5": {"doc_hash": "e4700d65aeec0ddadaca8a7a748ea58c9c04df5360ec90bb73b11210f7d8ec9d", "ref_doc_id": "35248f45-6429-4b21-a274-8a0d5bf89987"}, "fa6880b7-70c1-46b7-9856-eab1aa168626": {"doc_hash": "255219ac63f5c22bfd475349aa882e977c3a432adea2ac473db4303b1e129255", "ref_doc_id": "35248f45-6429-4b21-a274-8a0d5bf89987"}, "d2c05ecd-a7ff-4f74-aa20-74508ba888aa": {"doc_hash": "d2070053ed614239ec98b35a4d4860c511b798293eb09099d266209db5a094d7", "ref_doc_id": "35248f45-6429-4b21-a274-8a0d5bf89987"}, "30ca020c-5455-4475-b476-e6bc5021f654": {"doc_hash": "c8256a830e0a411e16f0477bd5c6b2c317b925f350366353e390eadcea9f0809", "ref_doc_id": "35248f45-6429-4b21-a274-8a0d5bf89987"}, "edfc314c-bd41-4ff1-9265-3ffa35910abd": {"doc_hash": "f149e4eb0e3f447af6a7c8bdea819a9a62505ae1e41dc887d3c118a8b7d656f8", "ref_doc_id": "35248f45-6429-4b21-a274-8a0d5bf89987"}, "7405a68b-0a9a-4474-9943-28183b3d7097": {"doc_hash": "05a026b961757b727d2f51a0ea4586c9abc46e20b29ffa7bf20daa715391dccf", "ref_doc_id": "35248f45-6429-4b21-a274-8a0d5bf89987"}, "e0890805-d8f0-47da-83fd-020088c35590": {"doc_hash": "5bb28d5269e63d77c83bb2ce82fd0c5c4ae0d9ac9ad4a5f9a0b7c5ba9f5f2064", "ref_doc_id": "35248f45-6429-4b21-a274-8a0d5bf89987"}, "a472dc04-577a-4825-8b50-f8864b22efa5": {"doc_hash": "f96253dc30822158d7b20cb9b03f64c3cf4d19759157903e1b367f0cf8e987cb", "ref_doc_id": "35248f45-6429-4b21-a274-8a0d5bf89987"}, "b6d3d68c-1684-4714-bbc1-010c44f1b824": {"doc_hash": "1dd7e8ccaf5a86298411ba3dd457d293cb0949319af4a2b35f6385bc4178a4be", "ref_doc_id": "35248f45-6429-4b21-a274-8a0d5bf89987"}, "24ddf7bb-2192-4193-82a1-017339c0b92c": {"doc_hash": "ed81d2bd7d41dbc845d9a69125ad1cda15252855b87b27ac574b240691f867e4", "ref_doc_id": "35248f45-6429-4b21-a274-8a0d5bf89987"}, "3b4b21be-d688-44fd-84b9-ec8a09419254": {"doc_hash": "8d94bf8c844f24ca338297a7e72a8d67a3e3d3795c4e0fec20ae823b27da3450", "ref_doc_id": "35248f45-6429-4b21-a274-8a0d5bf89987"}, "13144fd7-2eed-42d3-8864-e90b17cd7d5d": {"doc_hash": "e2bd5faaa94aa887945962469bfac4730b35a809cd3c102c6c59e2e696a858b0", "ref_doc_id": "35248f45-6429-4b21-a274-8a0d5bf89987"}, "8b81511c-9f77-496b-8532-45877feb53d4": {"doc_hash": "007d3821c5f108cf05bf5f9fcb338ff49fdde4cf25015741596d2fa66fab2d2e", "ref_doc_id": "35248f45-6429-4b21-a274-8a0d5bf89987"}, "e82ab1d9-fd01-4e4b-84e5-8cf815327437": {"doc_hash": "5593e2d13805f2c8f87a42c74118a0c6d16e10c5f5ca869643f9407eab32567f", "ref_doc_id": "35248f45-6429-4b21-a274-8a0d5bf89987"}, "d6a4d243-6d7d-404d-b62e-c138d441dc93": {"doc_hash": "28525c393245b951b91d99353da3ee16f03ca5be7232d0ccc849ce5a77971ae2", "ref_doc_id": "35248f45-6429-4b21-a274-8a0d5bf89987"}, "7a14bf58-bbcf-46c3-8681-16391e566fe4": {"doc_hash": "b88ac4850f82762ffd1ea6ec666567aa8c3b34d1b743a796a816377542b67bb3", "ref_doc_id": "35248f45-6429-4b21-a274-8a0d5bf89987"}, "d0d5c4c8-e56c-4559-942f-c1451bd5c1e2": {"doc_hash": "e6a7a326341982809a0ad6059b084ef3cd8b6fff5341d679c582dd7ca5a009ff", "ref_doc_id": "35248f45-6429-4b21-a274-8a0d5bf89987"}, "29fc1cf6-a79c-4b0a-b2ff-d71328832b3f": {"doc_hash": "bbe44d3c14e93eb280f2a27aedeb58f63748f8266bcbb5a44f6712a51647b87e", "ref_doc_id": "35248f45-6429-4b21-a274-8a0d5bf89987"}, "23776c64-afac-4f1d-8e10-f9b54eb3b83a": {"doc_hash": "1fa1768ab8fc93841f2ce33f6c056de5f7699e02fde25494d2acfcb72f8801e7", "ref_doc_id": "35248f45-6429-4b21-a274-8a0d5bf89987"}, "8ae70278-5ff8-4591-9717-ec181cb7de50": {"doc_hash": "2c558122c23ce4d80f19632dc8a437a493477671d4650f62a59288a1a9565166", "ref_doc_id": "35248f45-6429-4b21-a274-8a0d5bf89987"}, "4502874e-f391-4fe6-896e-7854f8559b5c": {"doc_hash": "d7332e87b4c33ecd02c1ae1870dc07f2894f035a84c33b8e93814cf8c6daae11", "ref_doc_id": "35248f45-6429-4b21-a274-8a0d5bf89987"}, "f0083b3e-0fbc-42b9-b444-c24fc86e3882": {"doc_hash": "21fbe6f23fe2dc5e39ab5e62a79418493b016c7aa2344cad3a5205416a8b4b77", "ref_doc_id": "35248f45-6429-4b21-a274-8a0d5bf89987"}, "5435749e-9d0a-48de-bfae-739546af6dca": {"doc_hash": "a1b9d8e7764adaad939847e04ef40b1ae41a87f76e051b9b23b252dcdfac40d7", "ref_doc_id": "35248f45-6429-4b21-a274-8a0d5bf89987"}, "c8229b65-2bda-47d0-bccc-fce54fe3117b": {"doc_hash": "99a20cddc9fe1223a09c2e089734b8fbc13f7464c488c2d6146b35680d7af187", "ref_doc_id": "35248f45-6429-4b21-a274-8a0d5bf89987"}, "8017e292-c84a-4d87-8736-eb240ab45205": {"doc_hash": "8502c21115c7c17ea63733dc0cc4409194f1c07172dbd2b5d772523aed516224", "ref_doc_id": "35248f45-6429-4b21-a274-8a0d5bf89987"}, "80a2bea2-8f79-4384-8614-0af09979e2ce": {"doc_hash": "0d9ae1e6772870a599ef85c09b5165125c05eff952e34345777a8d989e6b3eb7", "ref_doc_id": "35248f45-6429-4b21-a274-8a0d5bf89987"}, "dcc3c2ef-0fd4-4e25-a7fa-bb58165f3beb": {"doc_hash": "e1f1e6728278f1a1ae42d39dcf9b822e3244f69c10103f3714d7aea812af9e5d", "ref_doc_id": "35248f45-6429-4b21-a274-8a0d5bf89987"}, "306f4786-9b13-43c3-afba-a19ebbf2d0c8": {"doc_hash": "ad1382a64fc18a0dd2d508944697a91504f07abe6cbe651b7a24c342464566a9", "ref_doc_id": "35248f45-6429-4b21-a274-8a0d5bf89987"}, "c35d176f-8605-4d05-96ad-e30d0f300ae9": {"doc_hash": "0277c863540ceedb9c4742b2ed52cf1c5b34ea549ad684622b642ab10f2d399f", "ref_doc_id": "68a8ea83-af8c-4d84-b574-69c27c2d1620"}, "5676d38f-85d5-49f5-92ec-1920e9318d62": {"doc_hash": "b7c06e47bd52a73be1cd9a049f3a4ec99e1c12aa1be0bd4cd072432b4b93b28a", "ref_doc_id": "68a8ea83-af8c-4d84-b574-69c27c2d1620"}, "988fea0d-f71e-49ed-bc3e-70cefb82da27": {"doc_hash": "34c2144c799fb7998a7f72202cabe5af53dd8e81f905f66b71d7ed6ddf59f85e", "ref_doc_id": "68a8ea83-af8c-4d84-b574-69c27c2d1620"}, "df50c38d-32a1-42e9-957f-e689dc6b3999": {"doc_hash": "07a89ec281f786b7298aaba01b0f2bd90687dee4ba00d389c857ca947321c50b", "ref_doc_id": "68a8ea83-af8c-4d84-b574-69c27c2d1620"}, "27683b6a-c7a5-454f-bbe7-bb8a704d6a7f": {"doc_hash": "5298ec4001546c725e35e78f62b5f42c62d01d4dc83ead1d8b21ba327a8b9c30", "ref_doc_id": "68a8ea83-af8c-4d84-b574-69c27c2d1620"}, "dd7f1690-258e-4e80-ae7f-e615eb035879": {"doc_hash": "8ed2fa6a81df9c92c0b27f1ca90d901ed0e621680cc2d77c3d46fd61406c1a18", "ref_doc_id": "68a8ea83-af8c-4d84-b574-69c27c2d1620"}, "bc140cf5-7238-45bd-be39-1b15080e6c8b": {"doc_hash": "1a6d8b93aa321ca121c57c24c2d1226f549cce20b35bd64a4563863a18e068b0", "ref_doc_id": "68a8ea83-af8c-4d84-b574-69c27c2d1620"}, "72eaffd6-305a-48da-8af0-22969316c03b": {"doc_hash": "f9a12033f0a5045e6986101f0a70241d64369e2895ad1f2dba09ace3062d2dc2", "ref_doc_id": "68a8ea83-af8c-4d84-b574-69c27c2d1620"}, "68b2b4c3-1745-4804-8376-0702abd7db54": {"doc_hash": "a80ecf1d6c08811f4e89f9a953fe23fce36cd966b5a35668ad948518bce39d8a", "ref_doc_id": "68a8ea83-af8c-4d84-b574-69c27c2d1620"}, "b41df749-69ce-4033-8f8a-a3a987f0d261": {"doc_hash": "27d919841e242957ba0f0869d5201de74ab49095ffe46f82b50602dcb86cb86c", "ref_doc_id": "68a8ea83-af8c-4d84-b574-69c27c2d1620"}, "899de88f-9883-4b62-9289-82b3a67d8683": {"doc_hash": "e8f9ec83c73a86a79eee97c5d91de441bc0ca68fa7f4c6df627a553da9a705cb", "ref_doc_id": "68a8ea83-af8c-4d84-b574-69c27c2d1620"}, "95615329-8ee7-4b7f-8d73-a0ad967debaf": {"doc_hash": "2e0f6ca65b429a5d3396df0261b3c893b574f0459ddb13b4b449e591790b8900", "ref_doc_id": "68a8ea83-af8c-4d84-b574-69c27c2d1620"}, "2691fd8f-96f3-4413-97ef-a8af8e0f8012": {"doc_hash": "829a4d7f924805f555b8088679460bb81fe7fca3093be1ec9a5867ea01ff6772", "ref_doc_id": "68a8ea83-af8c-4d84-b574-69c27c2d1620"}, "cdd9d0a3-e9f6-413b-b113-1cde4ad6b6c6": {"doc_hash": "cf61676167b9811ebf4b93a4698268982105de04fb2117ead0c1b8dc6e249413", "ref_doc_id": "68a8ea83-af8c-4d84-b574-69c27c2d1620"}, "813b5037-8a7c-4015-bfbf-04fa8de582e9": {"doc_hash": "a4ea643623a8aebf59461792bb9f60e3d16b39fe41de4308083a1bbe20431eeb", "ref_doc_id": "68a8ea83-af8c-4d84-b574-69c27c2d1620"}, "1fbb3e6e-2b69-47b8-bf12-b4252545c8f2": {"doc_hash": "ef932b15af3dab23edf9d2f168f52daa6d647dd5ef72cfc5de6d8e6ba1241c55", "ref_doc_id": "68a8ea83-af8c-4d84-b574-69c27c2d1620"}, "1722b56d-c6fd-469c-b271-e08e8c6f0ad9": {"doc_hash": "5a419bac2fea693e4cea3fc926e826351a1587861e233f27ecb770d0159ff0ce", "ref_doc_id": "68a8ea83-af8c-4d84-b574-69c27c2d1620"}, "08bbe29e-e651-4275-b888-31366a511d91": {"doc_hash": "2b9a7d1469107ef9e7942ce348919fb4aaa5e802f490a786714a13e5dc2f52e5", "ref_doc_id": "68a8ea83-af8c-4d84-b574-69c27c2d1620"}, "35ef4042-baba-4fe4-8590-ea33dd55ec92": {"doc_hash": "3aeb8b48a1b79444b6e734f05408a58a7d49c6747f6584f5219374fc3d4d15c8", "ref_doc_id": "68a8ea83-af8c-4d84-b574-69c27c2d1620"}, "bb97e640-5e20-4ee8-9e9a-9d4cbb68a854": {"doc_hash": "b7175d1831bfb6c709c143d1e936d841153086c57fd3db8b3f78b1dbb9a69baf", "ref_doc_id": "68a8ea83-af8c-4d84-b574-69c27c2d1620"}, "40b6cc91-5f58-4340-b75b-97d01f92d4b1": {"doc_hash": "2de88212f64ea892d2cda097ea2505dcbc560424820d691350a8933b7462e396", "ref_doc_id": "68a8ea83-af8c-4d84-b574-69c27c2d1620"}, "be6f9a45-8cb6-4c82-b1df-01645de87b00": {"doc_hash": "585423c25c339f8dec3651b636b51d0053711d37bd36ea6ec83ba34632aaed09", "ref_doc_id": "68a8ea83-af8c-4d84-b574-69c27c2d1620"}, "9082fab7-eed0-4f89-a1d3-8abdf71ab30d": {"doc_hash": "57e6cc97b4f6cc6387b7da4891fcb32dfc8a550e554d856a7182c0c37d88b315", "ref_doc_id": "68a8ea83-af8c-4d84-b574-69c27c2d1620"}, "27efbbb2-d3e9-4673-bbd2-2755ebe5e703": {"doc_hash": "4c64bbefdd7a426575a7fc3dc42275f65dbf38fb4ec1a78c85ea86054295f847", "ref_doc_id": "68a8ea83-af8c-4d84-b574-69c27c2d1620"}, "645214e4-363f-466d-b99a-92fff05efe3c": {"doc_hash": "8c8ebc43f5cbf3b963ef4cd3b9cee183aaa860f2967ebd66f30d297a67d9f468", "ref_doc_id": "68a8ea83-af8c-4d84-b574-69c27c2d1620"}, "7d0c7e51-09f0-464c-9509-21cfc0182b3a": {"doc_hash": "111626358ba4a468a750eb26cfcd75700e14263cd76195baf36b65c73f0af8df", "ref_doc_id": "68a8ea83-af8c-4d84-b574-69c27c2d1620"}, "11416211-744c-47e9-8a91-e2825214e143": {"doc_hash": "9092093417d40de225635d04ecb5f437fbeab2042fbdba9a59e6827b78ada753", "ref_doc_id": "68a8ea83-af8c-4d84-b574-69c27c2d1620"}, "aa605a4a-e5e0-4d9c-8531-663236e34ecd": {"doc_hash": "30e25d2a9bce0221a6d9e24d884984638751a9d5516785a47eb744741115b2d1", "ref_doc_id": "c9d94875-256d-4a67-9245-80e627b9c808"}, "cbb64798-76bf-4a06-b792-f369de2c2281": {"doc_hash": "def1984b136fecfd8cad067ae7c0fed1dcea697a045a56b7676a758d96383c61", "ref_doc_id": "c9d94875-256d-4a67-9245-80e627b9c808"}, "9bb5f699-fbd0-4399-913c-f4765e4f391a": {"doc_hash": "4b261ac7d0c625bd38189f10f959322108899b88a5e9fb1ea7404b2d6c1bbe47", "ref_doc_id": "c9d94875-256d-4a67-9245-80e627b9c808"}, "0182c1fd-e27b-453e-99d6-6972ac923a24": {"doc_hash": "22b5ff08b0f2e5b5630b96fff4cf01625190cf2b92c117f262b76205ca32e75b", "ref_doc_id": "c9d94875-256d-4a67-9245-80e627b9c808"}, "66253091-2f01-4f13-a3a6-2635dbd75d1f": {"doc_hash": "f01eafa91875b02324747384ca71e576fcdcd787e9a48745043c2fe558eb8c18", "ref_doc_id": "c9d94875-256d-4a67-9245-80e627b9c808"}, "e7f62783-1f91-46be-b926-f1d4a2cb251a": {"doc_hash": "d01c02b1404add706f8b4f0e37a5305a36ae93a82500e9c3fe9b9fe0f6521ace", "ref_doc_id": "c9d94875-256d-4a67-9245-80e627b9c808"}, "702c79bc-a22a-4913-8e2d-46727b97e016": {"doc_hash": "ea69ee03f5768e2c707fbccd05dbf232db89b7a1e3d0c5b92b5efeaed034172d", "ref_doc_id": "c9d94875-256d-4a67-9245-80e627b9c808"}, "2895a36e-5475-40a9-9c1f-a4e80894cdfe": {"doc_hash": "2b6704140010d4008274eab36d1910aa79e995d5b8eda332401e1ab809236d7e", "ref_doc_id": "c9d94875-256d-4a67-9245-80e627b9c808"}, "c41fffd7-53af-423c-a843-b96f9a7ca6e6": {"doc_hash": "4063cf8c0db8bc5c217b6d724e6d2caa759712703d484d24832132a687e46f14", "ref_doc_id": "c9d94875-256d-4a67-9245-80e627b9c808"}, "61add928-15da-45cf-89b9-b17335401cec": {"doc_hash": "318b65fd10749cdfc10a66f2ff7c912c305b4a2a8601d308790753c0292d318b", "ref_doc_id": "c9d94875-256d-4a67-9245-80e627b9c808"}, "50df6136-6c34-40fd-9ef7-274c7de8d89a": {"doc_hash": "bfc32e6167292a4cb0c7d3341a22100936ba4a21064a1fa0bae385eb6cb5711a", "ref_doc_id": "c9d94875-256d-4a67-9245-80e627b9c808"}, "cb7dacdd-868a-464f-bd71-1ac41a32f048": {"doc_hash": "419c7a4ce580a7c430f4bb44cee1caf13e777fd8debb452d20be020d12b00a36", "ref_doc_id": "c9d94875-256d-4a67-9245-80e627b9c808"}, "73368973-f3a5-4df3-a1cf-8eb94c714933": {"doc_hash": "c45fdf6db65ea86f15110fbe93db0e36480ae8901b7a53ee3731d1f744b4c2e2", "ref_doc_id": "c9d94875-256d-4a67-9245-80e627b9c808"}, "48db25ce-d226-4004-8f64-4449a47ffca0": {"doc_hash": "d4a63ae69ff7c924abe0135496b182d9fec278ad0e5b9f837c06e0d7272362b2", "ref_doc_id": "c9d94875-256d-4a67-9245-80e627b9c808"}, "8f5fb490-f85f-4038-88ad-0dd772b11bab": {"doc_hash": "c6130b0f02ff3bbe429f97174741a2e03423547fb83b02755e49943a9bb893e3", "ref_doc_id": "c9d94875-256d-4a67-9245-80e627b9c808"}, "ea121744-c5a3-4b1b-8771-2c5a67df3050": {"doc_hash": "c3a7f9886defd88b0312e1d1a7ac8ea074c1c8d1b70269803f88badea2d1d8be", "ref_doc_id": "c9d94875-256d-4a67-9245-80e627b9c808"}, "84acfb9b-7417-41a2-8d6c-4afea7fac76b": {"doc_hash": "663c53795bd687300d29844f0bc843b8652e71ace8d2ef38f363d61137505f97", "ref_doc_id": "c9d94875-256d-4a67-9245-80e627b9c808"}, "ad53b70f-a64d-48dd-9057-84b194140119": {"doc_hash": "4599cc8e19744f20928698a6e79d64e94428b00c688e1b17162c6e3d113dc86d", "ref_doc_id": "c9d94875-256d-4a67-9245-80e627b9c808"}, "e283a170-2651-499d-b5d7-8121981eab9e": {"doc_hash": "961049e7aebf7f45eaefcaa73ffc449bea41e5d1bd180cd79453b9ef4d77b22a", "ref_doc_id": "c9d94875-256d-4a67-9245-80e627b9c808"}, "08e60536-6359-45d6-a4e3-f7de1f44b6d7": {"doc_hash": "e91d5b10285a1d7991035ad157a702647a1cbd848239dfa351a8569f3f085dcb", "ref_doc_id": "c9d94875-256d-4a67-9245-80e627b9c808"}, "d1c44e23-aeb2-4752-a867-48f09cc9b8a5": {"doc_hash": "cf33cf97e1e720fac633966a766e79d3d89621435d0a9a58f4820372401f6175", "ref_doc_id": "c9d94875-256d-4a67-9245-80e627b9c808"}, "9998aaf8-7048-4205-ae56-0926ddc18f20": {"doc_hash": "1b5d424be1b3a7b5fdf844b3a5542cc3dc82bd3ca12e33e8b947505da7600ffe", "ref_doc_id": "c9d94875-256d-4a67-9245-80e627b9c808"}, "e1268fae-62fe-4bbb-a3d8-8ea658347b4f": {"doc_hash": "ee28f0ede2c02e35ce9dde7fac6f7c8255bc2c38e2fad5ab659d738662d09dc3", "ref_doc_id": "c9d94875-256d-4a67-9245-80e627b9c808"}, "1ce836ef-6b2d-4d74-9a2a-5dd5229b1e07": {"doc_hash": "0ff92f57db9eb6e0b3332547a6a7b264eb4d3e13833cdb468abfcce620ccc355", "ref_doc_id": "c9d94875-256d-4a67-9245-80e627b9c808"}, "8c77052c-7dc0-4445-8dd8-610afc9d195b": {"doc_hash": "3f797faf56a2ade3ea53f77a494ad3d459b82aeeccc7348815bbe27346a1a160", "ref_doc_id": "c9d94875-256d-4a67-9245-80e627b9c808"}, "5296fe89-659d-4365-acc4-7c3be8c4ee63": {"doc_hash": "f5a52ee6843cb9a2c35b46023d809c8b8f73ae2cd184643fe40dcb84a7849134", "ref_doc_id": "c9d94875-256d-4a67-9245-80e627b9c808"}, "5ee95490-b243-4078-a345-1eb18bff7987": {"doc_hash": "1d28ac877935d84547405bc30dc1f4b5e20b39c7f37a07fdf0229af31585f9e3", "ref_doc_id": "c9d94875-256d-4a67-9245-80e627b9c808"}, "bf7e8794-b6f6-4c09-a71b-3b958c066d67": {"doc_hash": "f04f402bb5b3109d4f0a5418aaaf3af8d7d6f0c560f228083090ebf169fb07b7", "ref_doc_id": "c9d94875-256d-4a67-9245-80e627b9c808"}, "4bf78e3d-536b-4092-a4a6-95664d1de595": {"doc_hash": "e4a31d924716b13e8dbf08de95709c646a6dedfba629eb0f4d251f6e22b9be96", "ref_doc_id": "c9d94875-256d-4a67-9245-80e627b9c808"}, "f45499d6-d081-40a1-b1d0-422296e2399a": {"doc_hash": "41cbdd3f6f59af1102a628bb1c0f78aaa58fe88114725304e373f40a1d863a73", "ref_doc_id": "c9d94875-256d-4a67-9245-80e627b9c808"}, "614acf3a-15a9-4cf6-83b6-bdccd7a7710c": {"doc_hash": "c591095d02316b6ffc5654a81a070cc49c5cd27250e617e3ab588c92abe1ae57", "ref_doc_id": "6959410c-ab10-4777-9191-d5a85e8e51b3"}, "28ddf599-8ffe-480a-aa56-7453f8f20064": {"doc_hash": "23cbad9e2af49f4a40a23da757ae502f1f68949b960f372b74324e4d64bf17e7", "ref_doc_id": "6959410c-ab10-4777-9191-d5a85e8e51b3"}, "dbdd1526-49cd-43e0-b62f-f6564f88aaf3": {"doc_hash": "f2e0f54e4338d1c45a37df707e2ae7e8eb244ba02b82b2a67ee899ff431c08a0", "ref_doc_id": "6959410c-ab10-4777-9191-d5a85e8e51b3"}, "2d29e897-1c64-4be9-9da7-4442e681fe8d": {"doc_hash": "ae41ca95b4b6dadffb317647b0a044782ad1438ef7578ee10dba28e075a6f3df", "ref_doc_id": "6959410c-ab10-4777-9191-d5a85e8e51b3"}, "74f88487-d730-45ca-8988-2657062d55d0": {"doc_hash": "0e191bbf6b81f7ca0174005a6bb6ce2b77b9bade80546ecb4ea4dbcbdd14436e", "ref_doc_id": "6959410c-ab10-4777-9191-d5a85e8e51b3"}, "c2c6b4e3-e4fe-42b7-a552-f1b87bae3519": {"doc_hash": "04def6f60d2e6e10673e10d0d1bdb404948006ddbe644a8428ccc5dbdb38c433", "ref_doc_id": "6959410c-ab10-4777-9191-d5a85e8e51b3"}, "e67c6b9f-c752-4a46-9753-be4eb04af28f": {"doc_hash": "b8a8d9a95f02385207fe01e023d83603e1d59a1a40fd9c04cca623bcebefba5a", "ref_doc_id": "6959410c-ab10-4777-9191-d5a85e8e51b3"}, "be72a50b-dcf5-40de-8089-cf02972df366": {"doc_hash": "7e124b482e33146de323f7aed7c9ce29525719b9f62acf8bb17ea917a093e914", "ref_doc_id": "6959410c-ab10-4777-9191-d5a85e8e51b3"}, "49f20cdd-0e14-4779-8c93-407bc72f3edd": {"doc_hash": "d2f8b5baa2fb2fd42ab759b3ef6e24fb5fd32c01ecc5e630fdaf3a542205970d", "ref_doc_id": "6959410c-ab10-4777-9191-d5a85e8e51b3"}, "298fae9c-25c8-4649-ba91-a2cd6ef6b10b": {"doc_hash": "44686fe3c6f3f3adc6bc69c0bf6a3ddabad422811913838a551095ab5678063e", "ref_doc_id": "6959410c-ab10-4777-9191-d5a85e8e51b3"}, "f4f4ee72-5fb1-4115-832f-c796654b75f4": {"doc_hash": "2a6c8e8c2bfcb98b1ee99fb533345ec25de7f73eccada6034c571095adc96ecc", "ref_doc_id": "6959410c-ab10-4777-9191-d5a85e8e51b3"}, "1939870f-bf3f-4cea-ad30-f85349061b09": {"doc_hash": "a4145f18f5eb052059ba61eb38106802da83d4415c0e072bf1e09017b97ef1c2", "ref_doc_id": "6959410c-ab10-4777-9191-d5a85e8e51b3"}, "c551284b-4ee1-4ee5-a253-669eec379c72": {"doc_hash": "fc9e7a756d5afc36972fa7d6bb7f1f82f23065194a70ad7be8ac7a0e509f9d18", "ref_doc_id": "6959410c-ab10-4777-9191-d5a85e8e51b3"}, "6c5b71a7-30f2-4297-92d4-3b8ce14c0d3c": {"doc_hash": "3d5167f9596724570c7fafcfc6d466f0ec4c15f8117cce94156f10a3930fba1d", "ref_doc_id": "6959410c-ab10-4777-9191-d5a85e8e51b3"}, "454a65ea-76d4-4a0b-a4a7-b419a3195415": {"doc_hash": "e99c3ca3c514aae50f79118d738044ed28b519bd98d83015c8967d73fd613a0c", "ref_doc_id": "6959410c-ab10-4777-9191-d5a85e8e51b3"}, "c37f7900-20a5-4ccf-b9e8-bf11b38a33d0": {"doc_hash": "35ab8b7a6d33c9dbb3f4dd60a0ffb2faba053a447fa32839a603508e8c1029a2", "ref_doc_id": "6959410c-ab10-4777-9191-d5a85e8e51b3"}, "f86169d6-a261-4e7c-ab13-8cf1a4d24369": {"doc_hash": "42bf17d20a244186c0418012f32a8dd4f11768137993517b0df6b06273f556bc", "ref_doc_id": "6959410c-ab10-4777-9191-d5a85e8e51b3"}, "32088665-46f8-420d-8c47-2644800736f2": {"doc_hash": "d857c1b7a5ef10b62c349298d9dfa08447fff3ae9638d50bf3f64699c1ad500c", "ref_doc_id": "6959410c-ab10-4777-9191-d5a85e8e51b3"}, "2b69c167-97d0-4287-b347-69062c7fdaa6": {"doc_hash": "2c46a0f7414f62569c73821c7f50932ef5d48d50bb1a7c52fc85db67075585d1", "ref_doc_id": "6959410c-ab10-4777-9191-d5a85e8e51b3"}, "884a0316-f23f-4584-ac43-aa9bcf9d0300": {"doc_hash": "a5ae7adb73ad09fe8f76da7e80b1177b79dfe5b18fd67857f1debf6012b1ddff", "ref_doc_id": "6959410c-ab10-4777-9191-d5a85e8e51b3"}, "ac555476-e7a1-43ad-8933-e8711c8eee73": {"doc_hash": "8ff9d7dd3ba103be728e90f479c1024667f53ab246c6a804a8d5ca0b66336b36", "ref_doc_id": "6959410c-ab10-4777-9191-d5a85e8e51b3"}, "27bcd57a-1383-4138-8eb5-c030871d09b1": {"doc_hash": "09daaf511941b289378f0bef844f5645fd5cbe7225e02ec08e950d096224e80f", "ref_doc_id": "6959410c-ab10-4777-9191-d5a85e8e51b3"}, "ba007c2a-3505-4179-8f56-ba0b01f850db": {"doc_hash": "df3486847aa29f5ac6014f0f1483d9bda447c80f5fbb5807b42b49d261050a9e", "ref_doc_id": "6959410c-ab10-4777-9191-d5a85e8e51b3"}, "39edd615-fd5f-4d29-8850-295961aaf7be": {"doc_hash": "dcc7c8b5baa6e83e44b86fd7171936fefcd1aae1989510400142a0132a4cda3e", "ref_doc_id": "6959410c-ab10-4777-9191-d5a85e8e51b3"}, "1bb7b9e0-6aad-4ac0-b82e-dfb57ce79ae4": {"doc_hash": "f7031f7f984b86939e87ad02bf3f5da0bbdd3b97d7ac6239a0bb56e30c14b4c4", "ref_doc_id": "6959410c-ab10-4777-9191-d5a85e8e51b3"}, "8fc60855-dd7c-47be-b88f-33e12d253d69": {"doc_hash": "0aec40d9f15fffa6307c574426b7e450ea14c1a95e28f683da91428d655c0660", "ref_doc_id": "6959410c-ab10-4777-9191-d5a85e8e51b3"}, "c96cc293-41fb-4185-a322-2a9ec2bfc690": {"doc_hash": "2dd81434a0b0dbe9ff593b89c530308e127d0344c4d06796fbff8a7cd0b00777", "ref_doc_id": "6959410c-ab10-4777-9191-d5a85e8e51b3"}, "366cb060-8221-40f2-a3fb-2e1e403658ad": {"doc_hash": "e950f22cd20ae43b527fd2dfe98f05cc683e449c094da84602d36c36c0363291", "ref_doc_id": "6959410c-ab10-4777-9191-d5a85e8e51b3"}, "0886c3e0-4219-4c7e-a4d4-1ac46a69bbe1": {"doc_hash": "354ed63fe04b1bfa57a525052942d429cbaa4f9b30f97a06b24f9e56f6a9131f", "ref_doc_id": "6959410c-ab10-4777-9191-d5a85e8e51b3"}, "92d9df4a-0692-4eea-b526-9d4f1eda11d9": {"doc_hash": "8bc6e0ea40d220a0d0886907fa1907edc5d70bbd689a793965fc0b2b50e5c499", "ref_doc_id": "6959410c-ab10-4777-9191-d5a85e8e51b3"}, "5f0e99f9-7aef-4b52-9044-6230fc2a373b": {"doc_hash": "09c872f45db231ca021b3d857ef91c73830c45a55707ae2d404866e81664be79", "ref_doc_id": "6959410c-ab10-4777-9191-d5a85e8e51b3"}, "af2d9adb-c565-46fc-bdde-7e5c1f5f52a6": {"doc_hash": "4e59a75af1d7ec632da2b7cfc2a771f53c6af9521835080088d6dd3e297acfa0", "ref_doc_id": "6959410c-ab10-4777-9191-d5a85e8e51b3"}, "ac8c212d-87bf-468b-9443-2f9cbae6a5a9": {"doc_hash": "96ea03287a1160c0fcbd265e45945d5556f15548bec044da19adc224468fed7c", "ref_doc_id": "6959410c-ab10-4777-9191-d5a85e8e51b3"}, "66ae863d-2dc8-47fa-a147-d5dd91d59426": {"doc_hash": "dbd7fbd75e117587b29a3bf074a927a10fc217c116c4e19c2fb1e48c845a3bf8", "ref_doc_id": "6959410c-ab10-4777-9191-d5a85e8e51b3"}, "95061b7a-d257-4cbf-9511-e6947c798fcb": {"doc_hash": "20cb9be34862f5e99272f9916744011195a29448ca0e025afa0844880f84b6d9", "ref_doc_id": "6959410c-ab10-4777-9191-d5a85e8e51b3"}, "f1b29493-3089-4be7-a51e-2ae052e9e55c": {"doc_hash": "ecd6dbda5dd2ef3cc640c716c59296286fe5adf57ba2a1c109863280974c08e7", "ref_doc_id": "6959410c-ab10-4777-9191-d5a85e8e51b3"}, "536f4375-d85e-4eb0-87d4-00ac6a5fc56b": {"doc_hash": "af8fb72219825193afc3599bd707d8a27968eaa48a73292bd2bce1040487c6c9", "ref_doc_id": "6959410c-ab10-4777-9191-d5a85e8e51b3"}, "d9baee15-bebc-4e37-b0d5-0279b35e932d": {"doc_hash": "f4e7431a9d7b08ae47f7d7dedc2895ae36bced2d2cf4239ef6a886dfd3b6646d", "ref_doc_id": "6959410c-ab10-4777-9191-d5a85e8e51b3"}, "b885786c-9ec7-444c-8631-d01811330fc2": {"doc_hash": "400e9eebd5cccc30f2e81c2a4ca883eb1faf8286111f23da60e83d36d6d6093b", "ref_doc_id": "35c2d8f8-957b-4d5b-8738-b472dc90faf7"}, "6b2d0de1-f3c8-4da1-b0ff-0515235a6f28": {"doc_hash": "27aea82d0ed40517216afaf7f6f897b1e886c3a3d0bdfac1bc6bc1b551205066", "ref_doc_id": "35c2d8f8-957b-4d5b-8738-b472dc90faf7"}, "0f784f26-91bf-44a7-a0de-65da5d0ef0b5": {"doc_hash": "999f94d78c6eb401706844eca03b3a502075a82700fd9742699487e6134f2143", "ref_doc_id": "35c2d8f8-957b-4d5b-8738-b472dc90faf7"}, "3be69ea5-89f1-456f-8203-74e7784c8d81": {"doc_hash": "636934f05959cf58462bdaf6a60c9724af5d146776b6239905bc01c519420cce", "ref_doc_id": "35c2d8f8-957b-4d5b-8738-b472dc90faf7"}, "50de4cdc-0905-4fc2-9ecf-6189c0ea260e": {"doc_hash": "eb661c4424236cfe465c65cb901c1842f1ab03ec9fbcd2ff5959bbcf0c9eb8ec", "ref_doc_id": "35c2d8f8-957b-4d5b-8738-b472dc90faf7"}, "64f70d00-0dbc-4b75-9781-d05a3aa15500": {"doc_hash": "18a476dde82c3e49a5121aab50a7a1bfa97e2e60d175dc494cc88dd089d38671", "ref_doc_id": "35c2d8f8-957b-4d5b-8738-b472dc90faf7"}, "854b7bb7-f874-45a2-845f-9fb6d8144061": {"doc_hash": "eac443eb6d5373ed5e72c3a91972138ade022dbcdc515dee8ebf2c6e74ae5170", "ref_doc_id": "35c2d8f8-957b-4d5b-8738-b472dc90faf7"}, "4b5a537a-5fa1-47bb-a3ef-b6af42358830": {"doc_hash": "858b2088ebc315964a6383fdc1c362cd5e8f539db1b727aa633902cb9ee0ff57", "ref_doc_id": "35c2d8f8-957b-4d5b-8738-b472dc90faf7"}, "273e426a-abc2-409a-9056-fac88e8a27c0": {"doc_hash": "270b9f095aa112ac61ed7f71cf92c113fb5b4a15195ac2c2f2552428b79bc28b", "ref_doc_id": "35c2d8f8-957b-4d5b-8738-b472dc90faf7"}, "bc42432a-0d17-49c3-b02d-45d569317371": {"doc_hash": "a8ffd4dcf261c2e4f7c4b2d9bacedf515faaca55edf05d91a9128825d2f11635", "ref_doc_id": "35c2d8f8-957b-4d5b-8738-b472dc90faf7"}, "3cd02148-2513-468e-83b0-d8eaf4b39f3c": {"doc_hash": "8879d48b3db2f3bf1b01778384eb1d5b6a76b62e2cd1be063e6e9b4a74f8175d", "ref_doc_id": "35c2d8f8-957b-4d5b-8738-b472dc90faf7"}, "c4c3892d-debe-47cc-8d32-4308c6c97e2b": {"doc_hash": "1f716f14ca318c199673de2b9634ba4901e32273c7e0fc74ba7413b05734acc7", "ref_doc_id": "35c2d8f8-957b-4d5b-8738-b472dc90faf7"}, "479e150c-c137-471d-b412-233342bb212d": {"doc_hash": "2971c83287114fe75a30d8a3773c76008352290e74706c95b0227abf83e74e83", "ref_doc_id": "35c2d8f8-957b-4d5b-8738-b472dc90faf7"}, "468ed811-09eb-4b00-a6ba-241a993e98a0": {"doc_hash": "912592d681323d2749c25aefba822cd1ae9c8edc49550af39186f6f50cd7ec60", "ref_doc_id": "35c2d8f8-957b-4d5b-8738-b472dc90faf7"}, "35b297ee-c556-4245-ab12-662fde91a3ef": {"doc_hash": "6b21841f01b6d64a87f839ba1ca517ddf7effdc94498d3faf11b3782f255dd29", "ref_doc_id": "35c2d8f8-957b-4d5b-8738-b472dc90faf7"}, "bb066e5b-9ba8-41cb-8e49-58ce2f5489c4": {"doc_hash": "fc481faec93f4592c7d76929469762f1418b191af6771c77a1a590edb381c6a8", "ref_doc_id": "35c2d8f8-957b-4d5b-8738-b472dc90faf7"}, "47dc4911-494c-42ee-a2b8-f354785539ae": {"doc_hash": "181ec42296c6111b72ae6b1cb04e893bb31d9efdc4a8f8ff22e28c18725c41a7", "ref_doc_id": "35c2d8f8-957b-4d5b-8738-b472dc90faf7"}, "bd279ce8-3116-4a81-acaa-e20ea3ff98f6": {"doc_hash": "4c1d3666dc413a7091d8500c16436bbd4af6b1cef6c9cdd109f659555b8ac6c2", "ref_doc_id": "35c2d8f8-957b-4d5b-8738-b472dc90faf7"}, "1c48794a-870b-496e-ab03-70a15136e414": {"doc_hash": "9de2810a39d7a6ca4f9344a2e5155d4255ec60a4a0c5cb670989c1f13236e325", "ref_doc_id": "35c2d8f8-957b-4d5b-8738-b472dc90faf7"}, "db81ef93-afd8-4b45-81f1-65d2f9a5344b": {"doc_hash": "25a721815129f67e3e5eca1ab2ac0da266910fd74f79616c226b31c14f82ec4f", "ref_doc_id": "35c2d8f8-957b-4d5b-8738-b472dc90faf7"}, "8d1e0cf1-5d63-4f07-b998-e7392bbf3d85": {"doc_hash": "9192f8c4ed1828b33f32173953d99875d51475e345ff1f12da7428d320e7d8fc", "ref_doc_id": "35c2d8f8-957b-4d5b-8738-b472dc90faf7"}, "aa33a422-3aee-4720-ac28-2083369241b1": {"doc_hash": "de30b26e8e71066214c3eb07234106c39e8a6724e98854ee7e99e91ac67159f7", "ref_doc_id": "35c2d8f8-957b-4d5b-8738-b472dc90faf7"}, "a3317d4a-3c1f-4860-b894-71d87b904b46": {"doc_hash": "5cbe58ed773a219b9a48c9f267c1b415220a0bab1906a632dcddaeecaf331b75", "ref_doc_id": "35c2d8f8-957b-4d5b-8738-b472dc90faf7"}, "85e5e580-b589-4860-8e32-c8cef7b3b93d": {"doc_hash": "600653551738ca2cce434660033e0e986bb74cc8862e5802e94d4d1beda6f32f", "ref_doc_id": "35c2d8f8-957b-4d5b-8738-b472dc90faf7"}, "2747792e-035b-4106-a123-3c9e712b541a": {"doc_hash": "9ca72ad269cb8fcbabbe41ff0fe55e49849a27887cb81a7dd154448bda2380ed", "ref_doc_id": "35c2d8f8-957b-4d5b-8738-b472dc90faf7"}, "e883e528-df0a-48e4-b4b0-ce26b7723ac0": {"doc_hash": "59e850c1b3d962e8b6e852db61dcd8486f8b4f2a725d2b5cf067442735bdca74", "ref_doc_id": "35c2d8f8-957b-4d5b-8738-b472dc90faf7"}, "2faeb3c7-aefd-47fb-9a82-1ef435be68e1": {"doc_hash": "336e6b6731c0ba1ad1ac19155dacf2fbef35787f186ae24d9eacc02ad69db7b8", "ref_doc_id": "35c2d8f8-957b-4d5b-8738-b472dc90faf7"}, "377a1de2-81b7-49cf-81e9-0485f9482662": {"doc_hash": "7ef59962acecb806a772f6af0abaf0138007e225a77f0bf65e8821334e39665e", "ref_doc_id": "35c2d8f8-957b-4d5b-8738-b472dc90faf7"}, "df13586f-3827-4c7e-8d0c-3115fb8cb73b": {"doc_hash": "fdf139b7af9527c7bcc9b747ef8ef64b3633fceb9f9bc67115e5537e84536a9c", "ref_doc_id": "35c2d8f8-957b-4d5b-8738-b472dc90faf7"}, "a3e3f8b4-f1f0-4495-a0ff-691d2ab152b6": {"doc_hash": "05249fbafb87f72e2eb2312ea63ec43c766943fb8ad7337fa3042d06a7332905", "ref_doc_id": "35c2d8f8-957b-4d5b-8738-b472dc90faf7"}, "a794ca7d-f311-4641-a210-200a4428c589": {"doc_hash": "fa57bae47ef469b19a9a7c3204706e11c10731f942ee4171332a97a108c7d0c2", "ref_doc_id": "35c2d8f8-957b-4d5b-8738-b472dc90faf7"}, "518955ef-f08e-451d-a041-82995e04529c": {"doc_hash": "adfb5287b6b7894eccb99f57161e14d04899c56e5b3075f96d88af350e9b0ee5", "ref_doc_id": "35c2d8f8-957b-4d5b-8738-b472dc90faf7"}, "ab19b7a4-4252-48b3-b281-ae3d6058b8ae": {"doc_hash": "202b90ab968b653d317190cd51b33176255dcc0ebc93b47522bec0f8757d619d", "ref_doc_id": "35c2d8f8-957b-4d5b-8738-b472dc90faf7"}, "4be43cdc-1608-4d77-a77b-795c78f6f6be": {"doc_hash": "67cc29b530e5e399f0dd0fda5d210ef8da2a3c3eba88dcb3c2fbe6657c9f30bc", "ref_doc_id": "35c2d8f8-957b-4d5b-8738-b472dc90faf7"}, "74317d02-ac3e-458e-9c91-0967d06137bc": {"doc_hash": "4c8e77f4335f12f9e980d8b75d8305d851f1750f0e4be0f9a64a77fdbc1f4bc5", "ref_doc_id": "35c2d8f8-957b-4d5b-8738-b472dc90faf7"}, "4cebd535-62cb-479e-a3ae-4fa9e11de700": {"doc_hash": "3992f5efb36e9f9bac704ab7870c83616a6974a420758e41710b08b564c2e129", "ref_doc_id": "cc6b623a-67fb-4def-b7c6-1646af81356a"}, "151e5f23-2d8a-43d8-baea-b6400d4c32cf": {"doc_hash": "491c4353fc81ef3811c98756a7d354f9b9c19fae6b293ef5e61ea74823bc80aa", "ref_doc_id": "cc6b623a-67fb-4def-b7c6-1646af81356a"}, "bd318f62-409b-45a9-a4eb-17426a0eb570": {"doc_hash": "027982c6a929e6ac74f8c8dad3a34bb7463c9528f40be4a4bf9cdcba49d3b18a", "ref_doc_id": "cc6b623a-67fb-4def-b7c6-1646af81356a"}, "ccbea32b-0272-4ae8-843b-e85ec72f18c1": {"doc_hash": "50af8ed03a7da0fa2340a031a6f8fc3360c0991d97ebd03fe1afe4c8f8c97d24", "ref_doc_id": "cc6b623a-67fb-4def-b7c6-1646af81356a"}, "8f87e018-301f-4610-9252-c9eaad5928af": {"doc_hash": "8217db19708fa7545b8ecef764e0bce9364d49e8ab4c4172aafea04aa899fda4", "ref_doc_id": "cc6b623a-67fb-4def-b7c6-1646af81356a"}, "fb47711d-2f21-4e9c-bf67-1e60ee40dc49": {"doc_hash": "3d08ec33a5473eea38fcaf86d402ee59f60e7a28db58284da02829e9748bf9c2", "ref_doc_id": "cc6b623a-67fb-4def-b7c6-1646af81356a"}, "627fa0ff-72f5-44f8-9d45-443f85b4f6a2": {"doc_hash": "12925a9c8ddfe661b8cfef47f8aeb4d64fd139f358351082a7ca2e58e8c01b2d", "ref_doc_id": "cc6b623a-67fb-4def-b7c6-1646af81356a"}, "c1fad619-f966-4ad1-874e-2b5f6815acde": {"doc_hash": "e9536635d778f460eb5e45888f21ee0e7d635cb6d32b267a630e85a72b4feeb3", "ref_doc_id": "cc6b623a-67fb-4def-b7c6-1646af81356a"}, "a0d0c792-6d79-4915-86fe-2d0895f2af17": {"doc_hash": "aff4231a93f3c0001b4f2f579510d05cd3aea4afd68320f63384c031120c0b9a", "ref_doc_id": "cc6b623a-67fb-4def-b7c6-1646af81356a"}, "ef9cc6e7-44db-4362-ac50-63a7296184be": {"doc_hash": "682d8cf45818c6cf05fe8fee5b60fcd70f1a7058f775ed493bef8dae4101b631", "ref_doc_id": "cc6b623a-67fb-4def-b7c6-1646af81356a"}, "c4b1b850-9ee1-452a-9735-67ba524bb266": {"doc_hash": "ed768fb44428a08350b9d5950c27eef37944bb1c31450003009a77b1f1e1cda8", "ref_doc_id": "cc6b623a-67fb-4def-b7c6-1646af81356a"}, "d1e11199-8d41-4d25-bd25-5647c2e784e6": {"doc_hash": "94d66c6578343563d32981e21968ceeaadfb0beae1c9f05b89d5ec0c3742023f", "ref_doc_id": "cc6b623a-67fb-4def-b7c6-1646af81356a"}, "ea71d05f-aa3d-4570-a38a-b96137cf6391": {"doc_hash": "8d9eb3fddc67c0446eb74473bf754fd28cc4bf0e8f3da8afa402b0222ff12005", "ref_doc_id": "cc6b623a-67fb-4def-b7c6-1646af81356a"}, "dcb71f60-18cd-457d-b1dd-57a041e511a1": {"doc_hash": "4dbaeeca35f68613e3c5083e9270839268abf98578ceb96764908a14a2ebca66", "ref_doc_id": "cc6b623a-67fb-4def-b7c6-1646af81356a"}, "ff654a67-8a39-4b50-bca6-7f5e83a3749c": {"doc_hash": "7bbfd9a029de1ba6296ebad488baef1dfaae834430c8fd6b04316e0e920e8c7c", "ref_doc_id": "cc6b623a-67fb-4def-b7c6-1646af81356a"}, "2ac32cbc-14aa-4775-9770-25275775c33d": {"doc_hash": "315024eb4584e148cfc14e2f334bb7a3968e8a2712aa98c3f169102410ca422b", "ref_doc_id": "cc6b623a-67fb-4def-b7c6-1646af81356a"}, "8a303eaf-55b6-472a-9c0d-43ffb7b20ad6": {"doc_hash": "08523ebdbb87093a3c0d54ccb6300272c69c3f13d4b8a05db3e6df5cc9c1a2ff", "ref_doc_id": "cc6b623a-67fb-4def-b7c6-1646af81356a"}, "f43155f1-8ce1-415a-844c-f81027f79e42": {"doc_hash": "4d74e7f0d98d43db020bb136ebbbeeb24d444f79697fda4f8e9358b41af3822f", "ref_doc_id": "cc6b623a-67fb-4def-b7c6-1646af81356a"}, "c89b9b16-03a5-44ad-9d77-2acee6250e61": {"doc_hash": "b49825041a43493a8278807d8925d916f6f03b5d6a1bba2ab1644154e9485fcb", "ref_doc_id": "cc6b623a-67fb-4def-b7c6-1646af81356a"}, "1159090b-8052-4c86-a0a7-87ad4e707f0c": {"doc_hash": "e868aed1c1236561e57582e07382cdfca446b8b8ea4132134579b2dd9a9d125f", "ref_doc_id": "cc6b623a-67fb-4def-b7c6-1646af81356a"}, "2d0d09da-ed72-4093-8e37-3023053fc28a": {"doc_hash": "5bc2f7cab45db5bed5d12f06eccd2e830b40058a4a7ec40a93e13e6c8941c262", "ref_doc_id": "cc6b623a-67fb-4def-b7c6-1646af81356a"}, "eb127ca6-a270-478a-9526-c9311e574093": {"doc_hash": "f7d7c7e8bf1808986fd6edebae0cb85b2e6f12be36fc3f09f9f5925005a6ba02", "ref_doc_id": "cc6b623a-67fb-4def-b7c6-1646af81356a"}, "8d165ebc-1af8-4b0f-9131-8e40c1f5c379": {"doc_hash": "70afbdcb88c925360b6a2ac3d6a9e8137c9e172f152349b12f46f860d0171047", "ref_doc_id": "cc6b623a-67fb-4def-b7c6-1646af81356a"}, "c6e023ea-ea58-4ccf-ba1d-94d2d4d01776": {"doc_hash": "76a070a8f80e9045ed0233ea402aeb1f57059cb48efb7fa35f5f6c60d7673c82", "ref_doc_id": "cc6b623a-67fb-4def-b7c6-1646af81356a"}, "54e7dde3-0d5e-4132-bf34-a4abd0669395": {"doc_hash": "62f19979ecabcd216348559b6e68e65376ec7ac7bca8b1eb754b01d19008e4a9", "ref_doc_id": "cc6b623a-67fb-4def-b7c6-1646af81356a"}, "a3a52f21-46ff-4e00-96b4-670b79f9e583": {"doc_hash": "4f85921b4b7dfb377a28fa6b9534263db3d2bf6072c24726d167c8c8b85038c2", "ref_doc_id": "cc6b623a-67fb-4def-b7c6-1646af81356a"}, "91c12713-0b72-40df-a520-731eac0263da": {"doc_hash": "984b92d8147dfb25f322f4c3f2fe5b3477e048ab330a1a2ede0f5e61ed152b7f", "ref_doc_id": "cc6b623a-67fb-4def-b7c6-1646af81356a"}, "e40f1d1c-f051-4c8b-bb88-03a8c01b3752": {"doc_hash": "f75e9b80173f68bc2016e8637caed75f4ac03261ca97829b117957eb291b2739", "ref_doc_id": "cc6b623a-67fb-4def-b7c6-1646af81356a"}, "566a6a1a-7a14-4711-838f-71f75e52483f": {"doc_hash": "2e70a1e78265bbd8574523ddfc6d369ced5d4aa0292153227a734f8ada92d478", "ref_doc_id": "cc6b623a-67fb-4def-b7c6-1646af81356a"}, "55327c0f-94d0-4d84-9c0f-7b1c219433f3": {"doc_hash": "9c33d59a2a737ced7dbb2f653689537857eb1b1385b21c40219d3ecc3bb29448", "ref_doc_id": "cc6b623a-67fb-4def-b7c6-1646af81356a"}, "428672d8-6806-45fb-8d24-9183662d8c5b": {"doc_hash": "1c48a4f4859aea53a9e7cddcbc6a2aeb1f2082728a4222c969522d2e303ff0a3", "ref_doc_id": "cc6b623a-67fb-4def-b7c6-1646af81356a"}, "0718d8a2-d0f8-4c87-a7c7-8ca5e57beb83": {"doc_hash": "457abf9dfa6b9aa4aab0ffc5c5aa9a741081f5f5cb3336423b7cde3d5236ef40", "ref_doc_id": "cc6b623a-67fb-4def-b7c6-1646af81356a"}, "bbe721ca-e603-4a49-aab1-ca501c0d6b59": {"doc_hash": "08b5d10414ff3a6a7aca57953bf4c93c8873ae3bc9979a28e2323047d1fb511b", "ref_doc_id": "cc6b623a-67fb-4def-b7c6-1646af81356a"}, "2dda4f68-40b4-4813-af0e-3ad77aeb83a0": {"doc_hash": "f8007632926fad371a792845a29b82ea288f4002b54334b3ff96b40de1db8977", "ref_doc_id": "cc6b623a-67fb-4def-b7c6-1646af81356a"}, "04054c87-39f1-46aa-8a72-6511e1f5d32e": {"doc_hash": "f0b69c211ec4942d35aa182611161f0d5ede7998924175ae1e30b551e6f62a46", "ref_doc_id": "cc6b623a-67fb-4def-b7c6-1646af81356a"}, "e181e04d-9c91-44ea-95fe-837fe2324522": {"doc_hash": "7fe595067c330079d88b06201c09b99c6bd4ccfb60a01e050e4a4f509b2fd41d", "ref_doc_id": "cc6b623a-67fb-4def-b7c6-1646af81356a"}, "8369262a-3eb5-4ddf-978c-b2d774c7e0de": {"doc_hash": "f89d23b6801e58beaf2901e1da9d131fe3e3c843343b2c5b03f14fd4ca581c55", "ref_doc_id": "cc6b623a-67fb-4def-b7c6-1646af81356a"}, "14465b3f-6e21-487b-8ba9-c8ed3776d96a": {"doc_hash": "5a80a2374ebbda85971f7959693490b8c2551a244b65c7bd29cfe7f0fb02b969", "ref_doc_id": "cc6b623a-67fb-4def-b7c6-1646af81356a"}, "43bc3b6f-ac54-4391-ade6-dc6333dc0684": {"doc_hash": "83645a7dc341aaca9faf80c6b161e541b8632f116c39962b910c2205db8d0ad3", "ref_doc_id": "cc6b623a-67fb-4def-b7c6-1646af81356a"}, "2258f1df-1c5a-418f-a18e-d6f198195ae3": {"doc_hash": "76c720f789e95c11200cc8e01438e7f05f2a9e282cc323c7a9c16effba0095c2", "ref_doc_id": "cc6b623a-67fb-4def-b7c6-1646af81356a"}, "2c0c606b-1bce-4d72-8d10-8c1face69fda": {"doc_hash": "25dc96c8bba8eb8fdace508e5892faaae04e038a9562e2ff03741f8601986797", "ref_doc_id": "cc6b623a-67fb-4def-b7c6-1646af81356a"}, "18ecde31-c3b8-4a78-aa9d-15909c15cae3": {"doc_hash": "5ec6533118228f9d9b1727fe71c8c27c66e56a2a59f26e502f5ab1869b3fc417", "ref_doc_id": "96bdaac5-0d0b-446a-a4f2-842ca3d0f989"}, "5bcfa5be-f7c6-43f4-9d05-4051af52ef6f": {"doc_hash": "9043a5d438b6e67ec0dc3e78c97eeccbd23ec6a17ef4f24ba6ea3c3e6df08aaf", "ref_doc_id": "96bdaac5-0d0b-446a-a4f2-842ca3d0f989"}, "83c01bd2-cbda-4200-818e-10902be97bac": {"doc_hash": "b7eaa640d23018b6c31e2214cd68143785a9482558b5568d78004d58300bcc4f", "ref_doc_id": "96bdaac5-0d0b-446a-a4f2-842ca3d0f989"}, "5d6c5ba8-d63f-4946-a20e-0d9f715c11e5": {"doc_hash": "f2b3c6f2855930a6c5e2dc4b7702d3280faef42b3b3a94b1191dbb8b3ead0b74", "ref_doc_id": "96bdaac5-0d0b-446a-a4f2-842ca3d0f989"}, "a1323848-6d9f-4657-8f8f-5192366e4d68": {"doc_hash": "dd0057f3834b1668304e45d471897ea53afa06497dc8120c5f414f16fbc838db", "ref_doc_id": "96bdaac5-0d0b-446a-a4f2-842ca3d0f989"}, "507dcfc2-7dbc-430e-9483-5ab5d4b07911": {"doc_hash": "5ee21b021fb099babef68f3eebffc333a70938cafdcf66f3a339120811db059c", "ref_doc_id": "96bdaac5-0d0b-446a-a4f2-842ca3d0f989"}, "1f3cd0f3-0507-492e-baae-cfb09b181d7c": {"doc_hash": "f1706b40af37d70fdcaee0d821a0667a543c302eef47f0b8b8713e264fa8158f", "ref_doc_id": "96bdaac5-0d0b-446a-a4f2-842ca3d0f989"}, "3b0380de-3d34-4099-ba06-8be0dcfdb58a": {"doc_hash": "6c7f1970e69d99bf49dc8e1b43e5b0d0b23c9ff47bb77f9618a7ec8fcb7fd1ec", "ref_doc_id": "96bdaac5-0d0b-446a-a4f2-842ca3d0f989"}, "33abf695-0813-4dae-8c31-fabe77c4f3ba": {"doc_hash": "107144bb33be867d994419d2daa338a338ddb805106557ab4cfa8b027de4d438", "ref_doc_id": "96bdaac5-0d0b-446a-a4f2-842ca3d0f989"}, "f9b41b16-ef2f-4456-864c-e8cb43b830dc": {"doc_hash": "fc0591561cf51a2b2ce6ecbffde4862a86f61678e0e03f05966dd24699e228fe", "ref_doc_id": "96bdaac5-0d0b-446a-a4f2-842ca3d0f989"}, "f63dfece-8a2d-482a-9fa9-79d80c5c1d2e": {"doc_hash": "a2057ba7d3626874a3ee633cc68c0eeec976be6524d7e3fc6115eb498dd849c7", "ref_doc_id": "96bdaac5-0d0b-446a-a4f2-842ca3d0f989"}, "70753d3c-6df6-4ba9-8796-a2a8e0e3afd3": {"doc_hash": "6da70480a50f25da971a7f5a2254392b5bd0fdcd530a48a810b2d62c8bd6f4fd", "ref_doc_id": "96bdaac5-0d0b-446a-a4f2-842ca3d0f989"}, "f721e429-722c-49bf-95c2-1f68faf90c3e": {"doc_hash": "d63a7fdbc6e9a1495815381862816139c0f166f5c1c38cc5767965f793db3f37", "ref_doc_id": "96bdaac5-0d0b-446a-a4f2-842ca3d0f989"}, "b9fe3ac8-33c3-42e1-a589-ff5eb52e0caa": {"doc_hash": "7a67d33908ec55077615d8bd1e211c015ef9d1da8fe7b261f26810ea7e1e95d6", "ref_doc_id": "96bdaac5-0d0b-446a-a4f2-842ca3d0f989"}, "f714b9d4-6f2f-4c07-8c42-bc8ab12dd00a": {"doc_hash": "3eb666e07129744ecef2491957a3c4fefb49d9aa79211e53a5f61fe74a5db6ad", "ref_doc_id": "96bdaac5-0d0b-446a-a4f2-842ca3d0f989"}, "35fec73d-3d58-4728-afe1-a2eac57c6a89": {"doc_hash": "29ffff333c41fe1ce06c93b7bf9960219b914fc1fc26e6b2c07c0e242f8ddbb1", "ref_doc_id": "96bdaac5-0d0b-446a-a4f2-842ca3d0f989"}, "07007969-a1a8-4d2f-8f3b-6e709fa1bff7": {"doc_hash": "58149d12cf1337f27a0f107766593235195eb95618de5b001273ad3e9550582e", "ref_doc_id": "96bdaac5-0d0b-446a-a4f2-842ca3d0f989"}, "78d77ab0-f494-4241-b4d0-8b05b5d2a54c": {"doc_hash": "adc92baa6fe476807a172c49d5f1845784b86996ba4ee4d9349e905ff9cac1dc", "ref_doc_id": "96bdaac5-0d0b-446a-a4f2-842ca3d0f989"}, "57ef4d73-c892-44cc-acd1-3b89523d787f": {"doc_hash": "177c75c6b5003847f5c51a279b3ecd180cbab2126d49cff508345dd322d2799e", "ref_doc_id": "96bdaac5-0d0b-446a-a4f2-842ca3d0f989"}, "b24f9f8b-ebe5-4774-ad11-b4e47587c52e": {"doc_hash": "287d9350217d22cbda9dcf79f78d2e1943c677078cc82ac3488fccf15b16b25c", "ref_doc_id": "96bdaac5-0d0b-446a-a4f2-842ca3d0f989"}, "3aae5a47-f51f-404e-9e82-7afb6d4d2010": {"doc_hash": "fce8fac1417c024f4ef2320b2f5481e30c42a8e0992f2b9f101ee1bca9048d84", "ref_doc_id": "96bdaac5-0d0b-446a-a4f2-842ca3d0f989"}, "70e3dfb6-b2f2-4c6d-8079-e3a21fa2c973": {"doc_hash": "5971d7a08ecc31ad2f5f52f561a301fce67adeeab7884bd1d4889835aaebc604", "ref_doc_id": "96bdaac5-0d0b-446a-a4f2-842ca3d0f989"}, "e2e9b843-0416-483a-9daf-247dd8d3d37c": {"doc_hash": "35fd44f900e06ec36f518166247edbf4445a6979fbe1a6c4b563659b8c4d5b98", "ref_doc_id": "96bdaac5-0d0b-446a-a4f2-842ca3d0f989"}, "735947c9-fed3-4a0d-bd8b-ec7311ddddfa": {"doc_hash": "198e777249ab18b63b1adf9122f9af7fc2adfeeeb552a0ae391a56539a5b2a9d", "ref_doc_id": "96bdaac5-0d0b-446a-a4f2-842ca3d0f989"}, "18895a3e-4689-467d-b0a2-fae2a20f9cf8": {"doc_hash": "450c3eb60955638d12de8390f68c53ae6d7de0ddc128243a227c1294928b3069", "ref_doc_id": "96bdaac5-0d0b-446a-a4f2-842ca3d0f989"}, "f0a20d25-bde2-4541-abae-55e423a46f08": {"doc_hash": "95d28cfd37f7afc8901af3da502a384fc669dcf388ae397f7e516ff5ec1951ce", "ref_doc_id": "96bdaac5-0d0b-446a-a4f2-842ca3d0f989"}, "ee4eb360-bb61-4c8e-a5ad-eab390abcc62": {"doc_hash": "07a32655f72ce758005ae10fb449b1fed141dfff99c9e0e701b72a745553b91f", "ref_doc_id": "96bdaac5-0d0b-446a-a4f2-842ca3d0f989"}, "be5644c4-50b8-45ca-9ce8-a2be7ecf3e3b": {"doc_hash": "95d4282a725c5890c67e5ff536783c1c375fb65bab8dcdc8714b996430727d17", "ref_doc_id": "96bdaac5-0d0b-446a-a4f2-842ca3d0f989"}, "05786e8d-eb31-4c7a-9775-3ad8a7361c23": {"doc_hash": "bf97fc5355f2471fa97909793b446109bfccaf34fa84d55ad4fb5a447d899e30", "ref_doc_id": "96bdaac5-0d0b-446a-a4f2-842ca3d0f989"}, "f5da1a8c-626c-4f69-98fd-e6c986386dfe": {"doc_hash": "78129a81f7e6a5b7ed5f8425f6525e2b073d9b6970834b04de4162541b54bc33", "ref_doc_id": "96bdaac5-0d0b-446a-a4f2-842ca3d0f989"}, "3f6f205b-8b27-45b4-83b7-d34a1a1700db": {"doc_hash": "08994c09178e8ee9a9bf9ba19c5e78fe3f3ed4792072c964083b1456d71d964e", "ref_doc_id": "96bdaac5-0d0b-446a-a4f2-842ca3d0f989"}, "7e404900-0e4f-41ac-afdf-da9f5b8c9211": {"doc_hash": "8f04311e8ec466574606226fbce7f2c7e8646aebfab9e495a2c7e5da2a850787", "ref_doc_id": "96bdaac5-0d0b-446a-a4f2-842ca3d0f989"}, "44d301a6-ebef-48d2-a393-06c6410e78eb": {"doc_hash": "5f62cef3314ef69cedba869d94d841b6604bdb9233a16e66864ef437b154b9dc", "ref_doc_id": "96bdaac5-0d0b-446a-a4f2-842ca3d0f989"}, "48bd958e-1585-47ce-a4e7-93a2fd43543b": {"doc_hash": "b9e93486e70de85ba0ad762be4a641b2184e896e461aa3b7c6f161f3e1a6de9b", "ref_doc_id": "96bdaac5-0d0b-446a-a4f2-842ca3d0f989"}, "3b2616de-bee8-476a-96fc-d3a31ac56803": {"doc_hash": "b6ddf21ccd27f91cca8be46599688e3e359ab26d9e36be8b2773c82264641137", "ref_doc_id": "96bdaac5-0d0b-446a-a4f2-842ca3d0f989"}, "2cf26659-1909-4723-af31-8d701595e02c": {"doc_hash": "d2868195acb1c57ba1432daac3b350e2d79506eff1d54dd4010e4b4e521839a4", "ref_doc_id": "96bdaac5-0d0b-446a-a4f2-842ca3d0f989"}, "3389ae03-c311-4f70-b95b-4daf29734aa2": {"doc_hash": "fe888f50c3fea762a95bc012bb5b48fc0b43dfb0aeea93e86439887fec3318a2", "ref_doc_id": "99b53c78-61a9-4e06-89a5-d5a3295894da"}, "8d25075b-13df-4014-90f3-9c03c800be00": {"doc_hash": "396df9877e5463f63a4080bd600468032477b1c8e0ca7a4a05b085cf776d5f36", "ref_doc_id": "99b53c78-61a9-4e06-89a5-d5a3295894da"}, "60f2227c-ba5a-407e-a0e0-62fd9cc79882": {"doc_hash": "18ac352878855fbb4c04bcdfbe6e879562513147df408cb9418b13a28d8f681d", "ref_doc_id": "99b53c78-61a9-4e06-89a5-d5a3295894da"}, "56296206-a80b-449b-bd6e-f6343beca97e": {"doc_hash": "02a4dc22cfaed1c53d0576d65b3e94db9ff2f145d5e6cc941321a38e9046d83e", "ref_doc_id": "99b53c78-61a9-4e06-89a5-d5a3295894da"}, "2606544e-c230-43ac-9fe1-2eb6e687bea0": {"doc_hash": "310d227c46398b72ca9afb804baa6c0dab544a0bbf0e91731fedd5be66b13733", "ref_doc_id": "99b53c78-61a9-4e06-89a5-d5a3295894da"}, "581b8ff0-a00c-48fd-8cf4-d12ce78a5d4b": {"doc_hash": "30638a32350bf638a3f8245879a3a289b97d04ea6fde252d6472ba806a2fd6e0", "ref_doc_id": "99b53c78-61a9-4e06-89a5-d5a3295894da"}, "0696d89b-073e-40ea-86b3-8c33a0a29964": {"doc_hash": "99ee8fdce54f418a715e210f735bf79e2b99f6a2966d2dac99e801981eee92c1", "ref_doc_id": "99b53c78-61a9-4e06-89a5-d5a3295894da"}, "feb7642c-4d50-4bd2-97cb-ff893d5836ca": {"doc_hash": "7ab5a70412d0234a5720637af33740836c349cced077a007fa186d2ba8b24bd6", "ref_doc_id": "99b53c78-61a9-4e06-89a5-d5a3295894da"}, "d70e5eb2-420f-4a34-bd4a-96244558099b": {"doc_hash": "5dfc6b3776aa9b10c6e9ac7faabf26bdb7f84de7705f04f0e5b362d0431a9b7a", "ref_doc_id": "99b53c78-61a9-4e06-89a5-d5a3295894da"}, "bb4774ec-8065-45c9-b119-babe59ef7374": {"doc_hash": "8252152cfb4fd07f2741d307b3ac7ab706ba1637366958d5372232d843713529", "ref_doc_id": "99b53c78-61a9-4e06-89a5-d5a3295894da"}, "23af6603-2f0e-443b-ac65-c23b6b28b3ea": {"doc_hash": "daa3807270bb49962f2db89563c868a5ca21ab499b0359c1aebdc106ddeb10d5", "ref_doc_id": "99b53c78-61a9-4e06-89a5-d5a3295894da"}, "4a8a2ae4-c8d3-47be-8a97-16a7f589ab5e": {"doc_hash": "cfd9bcda95b0439764d64ad773caa4dde43139b49679810492e32dcf3eb4ad7a", "ref_doc_id": "99b53c78-61a9-4e06-89a5-d5a3295894da"}, "5f76fd75-128b-4e9e-b1bf-5cba51588a8a": {"doc_hash": "bbf799fe577ceaec2647cff61378cfc594c78636ee2a3413cd81811196ea00c7", "ref_doc_id": "99b53c78-61a9-4e06-89a5-d5a3295894da"}, "432f58a7-1f2c-44a0-a79a-6eabf47d727c": {"doc_hash": "ee159c630c40beee2819c5e56191493c3717254afc9831a8e2d513814bb4ccbd", "ref_doc_id": "99b53c78-61a9-4e06-89a5-d5a3295894da"}, "bd09b410-ed91-44ee-83e7-8712b5befe0c": {"doc_hash": "46a999fe035e1321b4a2d68159835d654337382e99e5692fa87c17fd7aabb2d6", "ref_doc_id": "99b53c78-61a9-4e06-89a5-d5a3295894da"}, "555ed4b1-29e9-45ff-afae-9159a818e6d9": {"doc_hash": "a63cc6ca52a7e3497a421a5e18ae434f8ef86c604c46876d158e42bddc0b7cf5", "ref_doc_id": "99b53c78-61a9-4e06-89a5-d5a3295894da"}, "b1cb49b6-4288-4d5f-9397-512f5dd2c576": {"doc_hash": "7184c39b27375839295598d52fb865edfe4c3ff835df437c48e7e6d892a245db", "ref_doc_id": "99b53c78-61a9-4e06-89a5-d5a3295894da"}, "097bd7d1-a542-4d61-93cb-d659c00f56a8": {"doc_hash": "5f61323243f25af6c4877573780d52bd996184da61fdf27de782478e11c83f5e", "ref_doc_id": "99b53c78-61a9-4e06-89a5-d5a3295894da"}, "50085506-966c-4ec9-9bab-2f1a5f898016": {"doc_hash": "bdb894a9aa966d37400ce2afbba5e2c2977335cb14ed48e258c4b626d214baa7", "ref_doc_id": "99b53c78-61a9-4e06-89a5-d5a3295894da"}, "cbfe86b4-72d1-47b2-ae5b-e90c8ec61d15": {"doc_hash": "bae13cf3376299141d34b9a020f042b62722c67098077709e2abc4faa2e025e1", "ref_doc_id": "99b53c78-61a9-4e06-89a5-d5a3295894da"}, "a34220a6-4868-4462-aa82-c648fb4f4a5d": {"doc_hash": "d9821a40789790da018260cf8fcd4f956f3a1d6b73df2dc8861e629127e14cf6", "ref_doc_id": "99b53c78-61a9-4e06-89a5-d5a3295894da"}, "de2eb216-e520-40e0-b207-4905360120d9": {"doc_hash": "09360c1e9d00d4ce35e9f7303648e4112499fe80b9dce2b2323e1975b9834494", "ref_doc_id": "99b53c78-61a9-4e06-89a5-d5a3295894da"}, "1e33ddf5-396c-4172-96e9-9c85b4d76c0c": {"doc_hash": "b2ef32280bca1eab9b6d0fde5c9008f358012c5378c11db484186655e7e182fc", "ref_doc_id": "99b53c78-61a9-4e06-89a5-d5a3295894da"}, "4e5c57f7-077d-40c7-bd60-1a61439c7fdb": {"doc_hash": "85d1d628a53972235ec57bc34d6832203a6f03fb6356216b21afc3c68a57eae3", "ref_doc_id": "99b53c78-61a9-4e06-89a5-d5a3295894da"}, "58373b31-2b5c-4240-bde9-a6c685db0f2c": {"doc_hash": "80f861a3e0bbedd5d6a9088ac445e8cfe62bff752b2242cd30f143f2847a10b7", "ref_doc_id": "99b53c78-61a9-4e06-89a5-d5a3295894da"}, "1c0220d6-e1fb-49bc-a4ad-f2f2d7d34502": {"doc_hash": "9940bc6c927253e718702edc23650d975e44394c7801eed593c43d3cc6131d93", "ref_doc_id": "99b53c78-61a9-4e06-89a5-d5a3295894da"}, "769ebc90-a0a3-4b06-a405-176983d36487": {"doc_hash": "c19ed242f6734132bba41f6856f0e8638c8f04740184aab8dc7505f3b39efacc", "ref_doc_id": "99b53c78-61a9-4e06-89a5-d5a3295894da"}, "d86e1e72-5fc5-411c-a421-3eca1f533f47": {"doc_hash": "6c0badb2568a21b833a9ef77424b094e7ef36ba9b2f7b295c514ce57b85053db", "ref_doc_id": "99b53c78-61a9-4e06-89a5-d5a3295894da"}, "85f39720-1030-4ae3-a996-4fa048fa8e29": {"doc_hash": "678115a3d4f8940457d5ac69ded86a64e1530288c235a9d73864b59fd0aa5081", "ref_doc_id": "99b53c78-61a9-4e06-89a5-d5a3295894da"}, "7db55814-5927-4d9c-b1b7-5a3b1974557b": {"doc_hash": "8de3ed258693f0aa11b249d6b91df003bae1bb0f7884dd6c2241c701d95ca5e2", "ref_doc_id": "99b53c78-61a9-4e06-89a5-d5a3295894da"}, "19a2643c-abbe-4d0b-a299-75b289e7fbd5": {"doc_hash": "95e487836b3aaf2116a5f6a3e5c08802c748a31969e030867cea4d9bec6615f0", "ref_doc_id": "99b53c78-61a9-4e06-89a5-d5a3295894da"}, "97b83d15-f957-4454-857b-c1f08c4e5ec3": {"doc_hash": "6d711c513c398432b1fd4a7f2ac20bd31d3e39a0921ed7595367f103e571b458", "ref_doc_id": "13b8fdec-8208-4134-8779-3d8404e4cdf3"}, "a1407d58-f218-4a00-96aa-d59b8b332476": {"doc_hash": "d61058b21d83a63a208ca33fa98779377a76b7db69db00860b817cf3a51748ac", "ref_doc_id": "13b8fdec-8208-4134-8779-3d8404e4cdf3"}, "cf1ffee4-a301-49c2-8f4c-b89d8802ffa3": {"doc_hash": "8bf9fb6e307fbca26b1baa63c98db05879d3da831512f8b178f21e8b6d0c3fbd", "ref_doc_id": "13b8fdec-8208-4134-8779-3d8404e4cdf3"}, "a3f20c98-8c8a-4f9f-bb1e-e25e1aa83498": {"doc_hash": "064aaa28aa23a62dcf5022f422e1101b0a7f26c7649e3e28ccedf39d6c401fc5", "ref_doc_id": "13b8fdec-8208-4134-8779-3d8404e4cdf3"}, "1158d0b9-66c4-48f4-ac08-001f325a2fdf": {"doc_hash": "715f1b76eff03aa2e615cde274952be39a10bd1d5b3bb2a43e0956cdd021642b", "ref_doc_id": "13b8fdec-8208-4134-8779-3d8404e4cdf3"}, "029f0f85-f581-4298-a8e7-30b05af038f6": {"doc_hash": "5975147c579d3affe3b4d4a2e46f2c65915bc199dae6f79644ab0640ce94b587", "ref_doc_id": "13b8fdec-8208-4134-8779-3d8404e4cdf3"}, "c6a1594c-810e-4626-af69-1fcc88fdc18a": {"doc_hash": "e81ec70b1dfc3534e1d7288ef466f4732606274cb8f685d7d59b76f1d58b8d61", "ref_doc_id": "13b8fdec-8208-4134-8779-3d8404e4cdf3"}, "8367034f-a156-41ca-b8eb-7375b766da49": {"doc_hash": "edcdc48e49d2fe394ca9f2d3f2c29a8e61968b34fef6e6b6181ee7af6119b2e3", "ref_doc_id": "13b8fdec-8208-4134-8779-3d8404e4cdf3"}, "bc8b37e4-28d1-4a80-8e47-2de3c626c70e": {"doc_hash": "7340a29032e6ed18a744a2b025ed531ff94708f601de5f135928efad1441ea2d", "ref_doc_id": "13b8fdec-8208-4134-8779-3d8404e4cdf3"}, "7ebc2fce-d35f-4184-8969-c3adaaeaee83": {"doc_hash": "e3a573dda5b9ce9352bc80d562c15a586b5efca69cda3861b6792c9dd99480dd", "ref_doc_id": "13b8fdec-8208-4134-8779-3d8404e4cdf3"}, "cf10573a-f94e-4369-bec9-22fff159d661": {"doc_hash": "871d96f4bd3804ebb8471c28e018fea09a004382263ce64b307f76adeee7b9b6", "ref_doc_id": "13b8fdec-8208-4134-8779-3d8404e4cdf3"}, "8f797fa3-329b-4af9-92a6-d5bafa350ef8": {"doc_hash": "761c2dec4b0db2ead2c171c43d3d36f88bccc1f5d18b8515b5786ff165cd19f2", "ref_doc_id": "13b8fdec-8208-4134-8779-3d8404e4cdf3"}, "0cf8b158-881f-4c64-a650-918df54b0852": {"doc_hash": "3d12098547807dbc8094f39197c1c41056a64cce630b2ab4166586ccc2dc8687", "ref_doc_id": "13b8fdec-8208-4134-8779-3d8404e4cdf3"}, "6184a7e8-be35-4f01-bb0f-05e949a0c500": {"doc_hash": "dd05b25ced722830617225efcdd5ad4f6aa23b0e34fd4192dc439515c8d64254", "ref_doc_id": "13b8fdec-8208-4134-8779-3d8404e4cdf3"}, "d7c72bca-ce2c-49e5-9a6b-0c777fdd130e": {"doc_hash": "06e93617206a057524c36d93827c70f7be8895f48e878b313c9ae6d7d840aae2", "ref_doc_id": "13b8fdec-8208-4134-8779-3d8404e4cdf3"}, "71c0238c-8d83-4aa1-bedb-1ef8b93ffd29": {"doc_hash": "c3da68f0d27c9dffde57f3dfd8efadfbb55e20e833954840759248aaac9e1997", "ref_doc_id": "13b8fdec-8208-4134-8779-3d8404e4cdf3"}, "054459c9-4f42-4bf1-8cac-035e2ce0cde6": {"doc_hash": "3784286d03bf961bd465aac65a2bcce478fa8543f0ae34ead437fc0cc5025076", "ref_doc_id": "13b8fdec-8208-4134-8779-3d8404e4cdf3"}, "3e5184fe-d9bb-4377-9460-dbe0b1bfe7fe": {"doc_hash": "e09a9c121119718659ebbb9fb0b7d5621727d295047ad25091b422a74696b672", "ref_doc_id": "13b8fdec-8208-4134-8779-3d8404e4cdf3"}, "c5b34caa-f9de-49ea-b1e6-404fc32c58a0": {"doc_hash": "db012b3cf03ca247a4bffa059a994295132d1b1a3773260c775eff2541ef21fc", "ref_doc_id": "13b8fdec-8208-4134-8779-3d8404e4cdf3"}, "a4dec43d-4155-4668-8791-8dd3809fd1f1": {"doc_hash": "9df8a0715001cb28e9979309aefc4a43fc523ef5bf6b5b8dca2d45db6c987558", "ref_doc_id": "13b8fdec-8208-4134-8779-3d8404e4cdf3"}, "d59deb7e-78e3-4129-b787-e66717bccc91": {"doc_hash": "4cfb21fc2b391d0f95d236031c9f3037db572603d680f830de10e496c4ee31a8", "ref_doc_id": "13b8fdec-8208-4134-8779-3d8404e4cdf3"}, "73b4b0fb-d968-4dd3-8dc8-fdb179480f83": {"doc_hash": "161bb1e32d516f77ecc1ae867e97451c0732289d430bf27b393dbd2e9279254a", "ref_doc_id": "13b8fdec-8208-4134-8779-3d8404e4cdf3"}, "259166a1-6404-4783-b8f3-2230edff5d83": {"doc_hash": "c3bbfa3524e8421566346931498cb2a065fad063beef0fc6c20a8baaa72b2eb5", "ref_doc_id": "13b8fdec-8208-4134-8779-3d8404e4cdf3"}, "572245ba-cd69-4054-b06a-03cdf083ccbd": {"doc_hash": "e6aff4bff595150d1d9b79864a8677ceac71821f23e7f601b1eb6e6845e0ae1d", "ref_doc_id": "13b8fdec-8208-4134-8779-3d8404e4cdf3"}, "84fa0bf4-de08-449b-a013-530339307281": {"doc_hash": "f1fc0474bb12d96bc6ab8190dd48651c5ecec2b4b60548ef018b9fe169244e56", "ref_doc_id": "13b8fdec-8208-4134-8779-3d8404e4cdf3"}, "b5f976a1-adb4-4fe0-b8e6-b5d25541e59d": {"doc_hash": "d5a534a238275d38bd60e76982a049d7db67123f223c1e889df542ccbbf40320", "ref_doc_id": "13b8fdec-8208-4134-8779-3d8404e4cdf3"}, "24118389-8871-4bca-8bbf-cd2158516a57": {"doc_hash": "a4b685d42052f354209d1fb0804a030430eb25cf0e56dcbfdcf9f615c49d9763", "ref_doc_id": "13b8fdec-8208-4134-8779-3d8404e4cdf3"}, "b9e60d25-0c18-408a-8d45-0af10027420f": {"doc_hash": "ea3fee91966596ccd29463593e16d1b62a79055e797c7f44003c3748f539062a", "ref_doc_id": "13b8fdec-8208-4134-8779-3d8404e4cdf3"}, "90ff2ff0-60c9-42d1-a93c-d7ca4c71c59a": {"doc_hash": "a4c4ba5776e0e7486bc1720b9f9645bc1a2202a722d0962a125d53dff1031b99", "ref_doc_id": "13b8fdec-8208-4134-8779-3d8404e4cdf3"}, "625bc6f1-d8fd-4e56-9068-724992a0d3e1": {"doc_hash": "93d1873d68b3d6e744bd79b517346cf080c3937ffda1ed8fb3f1e942043a708f", "ref_doc_id": "13b8fdec-8208-4134-8779-3d8404e4cdf3"}, "4440f4c7-f2e6-4da0-b671-0ba97260368b": {"doc_hash": "d133c78aedf92f9f18ce41331debd3706b081f542238f4bf58733f9b4bc37950", "ref_doc_id": "13b8fdec-8208-4134-8779-3d8404e4cdf3"}, "18bff6ab-d63d-4eae-8b43-6ec9afdb6d53": {"doc_hash": "4a9eb77e67d63e21a5e25d269adf995702ccc42f67bbbf734dc8f31eab4434d7", "ref_doc_id": "13b8fdec-8208-4134-8779-3d8404e4cdf3"}, "c010ae4d-a8df-4694-81af-2a3fb3884409": {"doc_hash": "08f60b5782acd9cedd28a3658202fb373169d4753487a74c709042d9b2a16ece", "ref_doc_id": "13b8fdec-8208-4134-8779-3d8404e4cdf3"}, "86a1d470-d8b4-480d-9365-6ba67970aac5": {"doc_hash": "a36823cbdc55337230b6a4035896b4ba6d25be71775d28d68a4f5be9f65b8ba4", "ref_doc_id": "13b8fdec-8208-4134-8779-3d8404e4cdf3"}, "9c19d413-fe68-4666-b1d8-ff0a9b988b3c": {"doc_hash": "6b520ded38f70969ab1ddad408af0bc42f1fdd10a57713abb0ab5813be38b589", "ref_doc_id": "13b8fdec-8208-4134-8779-3d8404e4cdf3"}, "3dd823ec-8ca1-44be-9693-7e84d4a971fa": {"doc_hash": "dc0eadd31f4a1664c13019ae138ff7b1da9dede366bf5bf16043f997407f1bda", "ref_doc_id": "13b8fdec-8208-4134-8779-3d8404e4cdf3"}, "a66183c3-5db5-460c-91cb-d66a64b9b056": {"doc_hash": "9b0f79faf94f8c5191d5ce7cff3af11f0bca9d7b2a756f06e2a3fd0984b0497c", "ref_doc_id": "13b8fdec-8208-4134-8779-3d8404e4cdf3"}, "27b0798c-fa6d-4c58-8a70-67336488c882": {"doc_hash": "dffccb37cb0f0e7b7092e6605d82f5a7350bd4148fe5f5e3e16f000b547545a3", "ref_doc_id": "13b8fdec-8208-4134-8779-3d8404e4cdf3"}, "7b0a1bf3-8a2d-40e4-a53a-4171481d983a": {"doc_hash": "f2d4dfddbc544293843ac0167f643825bf2035459447eba9dbbf3e3d37296813", "ref_doc_id": "13b8fdec-8208-4134-8779-3d8404e4cdf3"}, "73b8dd00-62fa-4bed-a366-bbdb1cda8ac8": {"doc_hash": "522643671dd27e5a3c878ba2c75e87a0994b032905afa8ad2f2653e704b99205", "ref_doc_id": "a46922f5-2d81-4fc9-93e8-95bec3c3587f"}, "311b9447-e066-4461-bc40-e4f976a8aa71": {"doc_hash": "825b8f021ef4e6f92210205d5e808e4d6c639d582a2d5a3c7a74a5c6e85a329a", "ref_doc_id": "a46922f5-2d81-4fc9-93e8-95bec3c3587f"}, "9b66039a-5a9b-4b8b-bf49-b0411d19dae9": {"doc_hash": "0e088b0a8aca66c2b3ffdf6bd0955f59b25ccf66db24d0f583b04c413e1277a7", "ref_doc_id": "a46922f5-2d81-4fc9-93e8-95bec3c3587f"}, "2fc31b10-5368-4d0f-81ed-1bbab934c2b3": {"doc_hash": "849f076998f12da9d87945664547fe420e27b699b48a94643633cf1a2b94ed65", "ref_doc_id": "a46922f5-2d81-4fc9-93e8-95bec3c3587f"}, "0b138cbf-7ca8-406c-a6c6-3f5f63b6bae8": {"doc_hash": "ec05bc7bc6eac30c63892f7cc315113755fbd52b5fcc3de6fe8b4a68a2c13ebb", "ref_doc_id": "a46922f5-2d81-4fc9-93e8-95bec3c3587f"}, "fc89f9ef-b26c-46a3-a747-1eb6ecd8e888": {"doc_hash": "029ea69a334b0ae2674093e22027f76a1793ed36d050611c48605b78ab2899b3", "ref_doc_id": "a46922f5-2d81-4fc9-93e8-95bec3c3587f"}, "ec40d994-aa1c-4491-af02-b2b5a865d70d": {"doc_hash": "e6eb818a254e670c807aa3efac164863c17fd8082e16fe06da4b8c6b55448567", "ref_doc_id": "a46922f5-2d81-4fc9-93e8-95bec3c3587f"}, "42739259-1c89-4e21-a476-dc18e15135d3": {"doc_hash": "5239291f3d0ba8499f751d4a85242d12f8f2d0b34475249679023f9fb1127fe3", "ref_doc_id": "a46922f5-2d81-4fc9-93e8-95bec3c3587f"}, "23e82a43-24fd-4134-a16a-ea4ab5eea7a2": {"doc_hash": "2177cb4f2958168a8f50ffdbf21a1229070317e8ca1471b5183da2e3d15b3e16", "ref_doc_id": "a46922f5-2d81-4fc9-93e8-95bec3c3587f"}, "c52c2160-34da-4519-851b-c02335ea6097": {"doc_hash": "a1b4f2ca95fda8b57bb4beee3c443f17c9447d299d23ff2864368b8ee99d6082", "ref_doc_id": "a46922f5-2d81-4fc9-93e8-95bec3c3587f"}, "bd3685d2-5df1-424b-b453-2c51a61b7a47": {"doc_hash": "93eb690e5da07230d7be308d16d3862f2444cff3a5dacc837621df25958c85a9", "ref_doc_id": "a46922f5-2d81-4fc9-93e8-95bec3c3587f"}, "2fc488af-843a-49a4-a7b6-c3c83118b091": {"doc_hash": "5515e8dd428b4f268c25f8b4511a621d26f895ad2733ec74a8e102807179f5b9", "ref_doc_id": "a46922f5-2d81-4fc9-93e8-95bec3c3587f"}, "9a97d9b0-1dc5-4e88-b394-b3f9c456b808": {"doc_hash": "585669abea7dc6482a85b5ab298c37055e7f052c0b8ec4dccf89db37238e7ec4", "ref_doc_id": "a46922f5-2d81-4fc9-93e8-95bec3c3587f"}, "fb4d0cf5-b33c-4476-8de9-a18356c03be3": {"doc_hash": "7bbb0a10ae97c6332155e087031ab3d9bc32791464b04c71e4bbc3b278d6b136", "ref_doc_id": "a46922f5-2d81-4fc9-93e8-95bec3c3587f"}, "18dec443-1e88-4e5f-9ad7-6012c5c3c3c4": {"doc_hash": "9dec2258f3052cc912d1e3af0e29c617a6ad3cf47be77bcd3cd9e2e6b1beb321", "ref_doc_id": "a46922f5-2d81-4fc9-93e8-95bec3c3587f"}, "c856ba40-eacd-4851-9a92-3791f0720e74": {"doc_hash": "6be44e6deeb7f022684e2c2e53f085eb9fde65eb9d737ca864e618bfde0917f7", "ref_doc_id": "a46922f5-2d81-4fc9-93e8-95bec3c3587f"}, "e15f7205-ca03-4f49-975f-3dd1249c2f67": {"doc_hash": "ab206f8db7e4940b5d9b8851dbff8da284c2895cf2c8547fd11f1176aee7bfde", "ref_doc_id": "a46922f5-2d81-4fc9-93e8-95bec3c3587f"}, "aab0b674-e1eb-4db0-bce8-03d55e5b900f": {"doc_hash": "22adca74159f4b60922bc74ced82c2a1eb24f070819e2b9597279090bfdb85be", "ref_doc_id": "a46922f5-2d81-4fc9-93e8-95bec3c3587f"}, "76189c40-ee99-49c3-b091-a1b4b9d95486": {"doc_hash": "a65e0a2439eb30671f021ac874f914e889f488da0826b8a1e206633e87161003", "ref_doc_id": "a46922f5-2d81-4fc9-93e8-95bec3c3587f"}, "05ca42c2-69ee-49d1-9261-f45ed81622aa": {"doc_hash": "93c7124db6d8fa7af960880723de055c0e8ee2027b2413f1e7d11eac0900dbea", "ref_doc_id": "a46922f5-2d81-4fc9-93e8-95bec3c3587f"}, "0a769f14-3a0c-417e-b4b0-9d31f09ed536": {"doc_hash": "ec425faac330fb5adcf6395980e8f134e6f0a907b2fbc314830938094acb932e", "ref_doc_id": "a46922f5-2d81-4fc9-93e8-95bec3c3587f"}, "84a1c69a-6568-4452-9823-1e3a5ae98613": {"doc_hash": "1280c7697f1306c321da58df99e810c9c63514e44f47c37fffc5561db34941f1", "ref_doc_id": "a46922f5-2d81-4fc9-93e8-95bec3c3587f"}, "c4aaac39-17bd-41aa-8e15-c009f085b60b": {"doc_hash": "9782f20c022b9cb1ca6fb6c59d454b7fddbf946857e309c347eeeafbe20508c8", "ref_doc_id": "a46922f5-2d81-4fc9-93e8-95bec3c3587f"}, "85a205c8-9e13-4e5b-9f66-b60676250700": {"doc_hash": "dd03977fb0c239f856ec24ad933b3bd00f8b696838ac2804a75981b3d3ad1e7d", "ref_doc_id": "a46922f5-2d81-4fc9-93e8-95bec3c3587f"}, "dc35a1cd-054d-40c4-b610-8705c8de2dd5": {"doc_hash": "4ca4f0894a0ce89aa80a3956f9f3e900b6ff68dddb8c1b6e6b6b018190c5f99e", "ref_doc_id": "a46922f5-2d81-4fc9-93e8-95bec3c3587f"}, "f616489e-0137-47b0-8aec-a39a51378709": {"doc_hash": "70eac11f82be9d982b45dcbe63319e55670517ecb7dc2ce1a2be4177e14959e2", "ref_doc_id": "a46922f5-2d81-4fc9-93e8-95bec3c3587f"}, "8954c01b-dec4-4ec8-ac2b-8f7906cccfcf": {"doc_hash": "88c52f9cbeaaaa15e274d9fbc80ea9b6ffaf143f01bbe69fe368216a764254da", "ref_doc_id": "a46922f5-2d81-4fc9-93e8-95bec3c3587f"}, "32c37288-6c8a-4582-8e5b-e2a98cc7446e": {"doc_hash": "2cfce6b59bfab0b15fcfb5431844835e48ceec6266aa2a7e8debda08a1a1f7ba", "ref_doc_id": "a46922f5-2d81-4fc9-93e8-95bec3c3587f"}, "66f0cb8a-3b70-4797-861d-c39e44bb0c83": {"doc_hash": "90ddb00ab92a37635e4424be67fd9404038e09bf76e18f0a5147e1c64ddcd044", "ref_doc_id": "a46922f5-2d81-4fc9-93e8-95bec3c3587f"}, "6a1db8f6-5017-44ec-8fa7-4b85795003df": {"doc_hash": "b5efff5f31199aa250f2e0d5159a2cd04a552222a78d1b9e4716cc2c59b93f2e", "ref_doc_id": "a46922f5-2d81-4fc9-93e8-95bec3c3587f"}, "c5d913ec-ba1a-4f68-9d6c-7305856e12e8": {"doc_hash": "66764a78aedb32b21ad20b212243025487ce92ff25ecc1d882eeddba92d1d669", "ref_doc_id": "a46922f5-2d81-4fc9-93e8-95bec3c3587f"}, "b1376b87-fbd4-4dbd-9692-946fbf710f36": {"doc_hash": "6b18e69c1d183f2fd6ccca39166837d80439365ac6934f6e3340f7951b75105e", "ref_doc_id": "52005ab0-77df-4b49-85b8-14f3209e5047"}, "0e9f9718-6aeb-4073-a601-822bfc1c8344": {"doc_hash": "7b6209a851b39f09a2ffde4b1dbb779285548c1d90713518528a9e7357e2c1c0", "ref_doc_id": "52005ab0-77df-4b49-85b8-14f3209e5047"}, "3273266b-52f5-4690-a262-dd1d2a8139b5": {"doc_hash": "9b64d58e02b0eec96e554f517877cd3a3dda39b566dc894887907eb1dd41d798", "ref_doc_id": "52005ab0-77df-4b49-85b8-14f3209e5047"}, "3a289b4e-131f-4e09-b6f8-7bc9f20f595f": {"doc_hash": "c82aabb6c92ef907cf5a9721cadf64aa31bc030b279e2b4930276b43c2843f75", "ref_doc_id": "52005ab0-77df-4b49-85b8-14f3209e5047"}, "7f1b5678-2b12-4e28-9ed8-304c4111fd27": {"doc_hash": "910d8c94b94777f41f3d873cf06789b299c69d100f9c7d7f72dfc62160861dd4", "ref_doc_id": "52005ab0-77df-4b49-85b8-14f3209e5047"}, "e0ec2fc4-3696-438d-b01f-6e86cfc384a6": {"doc_hash": "1aed53e173198096583b6ad058a8ec07bd64decc3e21cc876631c6be27f5e209", "ref_doc_id": "52005ab0-77df-4b49-85b8-14f3209e5047"}, "7bcec675-b27f-4604-808e-0a49e2b00fb8": {"doc_hash": "5d3e9bc21654ac1730a47a602773550b4cc26c7af00f97e13efbb971cb91f490", "ref_doc_id": "52005ab0-77df-4b49-85b8-14f3209e5047"}, "73074eaf-2e55-4555-9522-a786929096ea": {"doc_hash": "64a27b2a9ef8f8171cc51453005f69a8cf547ef74c5ced00382bac9c09c47108", "ref_doc_id": "52005ab0-77df-4b49-85b8-14f3209e5047"}, "d46f2903-b7f5-4c00-b8f6-4b06eea7f21a": {"doc_hash": "f94ebb7c452d3ff4dd8aaf9943903da5861507e18200d5859b9b7988f5386bd1", "ref_doc_id": "52005ab0-77df-4b49-85b8-14f3209e5047"}, "4395105b-3830-4a17-9693-a888cc6ff21c": {"doc_hash": "6c1334090944c52b23629bd7e7e616c7dd4b694d35fcf292682dfefcbfc91332", "ref_doc_id": "52005ab0-77df-4b49-85b8-14f3209e5047"}, "3c7deed5-e191-45a0-a142-5807eb0d5602": {"doc_hash": "a8dd5981bb1cd3273dfc9c96459b80a06332587c86b31d5c11556258646869b9", "ref_doc_id": "52005ab0-77df-4b49-85b8-14f3209e5047"}, "9623da39-c154-4be3-a587-865cdb7d5e5f": {"doc_hash": "547f846c359cf727102d0c3281a829a55ec077f3f963ff9854ba3d9f406a8a98", "ref_doc_id": "52005ab0-77df-4b49-85b8-14f3209e5047"}, "cffe6587-a1ba-4b98-8201-7927a70d9dc5": {"doc_hash": "e2595242e5a7da84d15ef8cfc953881f1ad514cb4ec2656e2a908615c41fa3d5", "ref_doc_id": "52005ab0-77df-4b49-85b8-14f3209e5047"}, "9ad85895-83fa-4f7d-9888-2d027b65bbe6": {"doc_hash": "0e81c5af80a2d287c52620c4d34d0a18b2acd1678a0db6f803821262fb7001be", "ref_doc_id": "52005ab0-77df-4b49-85b8-14f3209e5047"}, "80aaeb29-403f-47ed-b8d0-812e097c4e1c": {"doc_hash": "1ef3c23325adea0375b3a3e95534862002277d779586e172fc09a99be4d2a674", "ref_doc_id": "52005ab0-77df-4b49-85b8-14f3209e5047"}, "9f6d815e-f616-4725-8885-8ea99782d73d": {"doc_hash": "d573763574872d03828c54013d71eaf9d0197fced2799dfffa485d9cf3c8eaa9", "ref_doc_id": "52005ab0-77df-4b49-85b8-14f3209e5047"}, "5219b8d2-ae6a-41fb-9fc7-1a10f2d3eb92": {"doc_hash": "4aea2accbc01b48bf0c297fd05f2af7f7d99cc3014502c850acde0ba61c240a7", "ref_doc_id": "52005ab0-77df-4b49-85b8-14f3209e5047"}, "28365aa8-7438-4ce8-a2eb-414f381d019c": {"doc_hash": "bb57ffd28b43acde02829fc95ee020e6e68816757a5abc8bcdea4557b945108a", "ref_doc_id": "52005ab0-77df-4b49-85b8-14f3209e5047"}, "2fcd2bce-91cb-45d8-9af2-2163639242d7": {"doc_hash": "7ba5c7a1baab2e5cd584fa61937731bd19ba8358c64ecdcbaf8d20a691cb75ae", "ref_doc_id": "52005ab0-77df-4b49-85b8-14f3209e5047"}, "819df6e8-8e20-4280-a9be-478704e76b25": {"doc_hash": "55faea3fca9e3826b8f61189f51b2a4fe7fddf1ae522b9290b88f5f7985308cb", "ref_doc_id": "52005ab0-77df-4b49-85b8-14f3209e5047"}, "88e55e8b-1519-4474-b12c-fd1762a36177": {"doc_hash": "21a32791968e18233fcad490267883514b71d4aee18fc22bd17eae1eda935e7c", "ref_doc_id": "52005ab0-77df-4b49-85b8-14f3209e5047"}, "4f148a53-e350-42d0-9464-9d4a7c98ff97": {"doc_hash": "c8c5a912ec8b46220be87a1574f832b3a66fde1246f9eacc644a96271f7c5852", "ref_doc_id": "52005ab0-77df-4b49-85b8-14f3209e5047"}, "7ebb15b5-cd47-48de-84d3-209128423467": {"doc_hash": "bcc7e33c545ef74cfa6056ead79293a103a17251e844cd12b3b63e8bcc115b3d", "ref_doc_id": "52005ab0-77df-4b49-85b8-14f3209e5047"}, "6d941b09-1b8e-4ee2-a89b-a3fd72fbff1b": {"doc_hash": "bf49273b14e5cce9c1b1f22cac29eab6fc0bf37c6adcd67f176a82bab2fc5bc3", "ref_doc_id": "52005ab0-77df-4b49-85b8-14f3209e5047"}, "ac3af9ad-81c7-42c0-b2dc-23556a512d9d": {"doc_hash": "a5343ced90cc73a194fc8332a1f51fced6ac36a666500635b8ab75f9c453adbd", "ref_doc_id": "52005ab0-77df-4b49-85b8-14f3209e5047"}, "b87ad8bb-e3a3-447e-ab47-5c3894ff0bb8": {"doc_hash": "3830a07c50b7cd473f1ec708c9b3a6ab989c65c8bfceaa285426f7275a4fb309", "ref_doc_id": "52005ab0-77df-4b49-85b8-14f3209e5047"}, "758758bf-10e1-44c3-97cd-7b8d19feb2af": {"doc_hash": "b47e4f7076d1a47374447ec406d2b5ed66c9679ba64149c0901df1ecf7bd0351", "ref_doc_id": "52005ab0-77df-4b49-85b8-14f3209e5047"}, "dc98f7b0-ba75-4d1f-9764-5d9452b01e74": {"doc_hash": "5a16e88b3d1eec82eda4c215583d6bdd60de08bf6e6af84d4889f357935b9ff5", "ref_doc_id": "52005ab0-77df-4b49-85b8-14f3209e5047"}, "74023c62-ed49-4d83-b76d-7059d2013fc9": {"doc_hash": "f324a7561a0da452783df182019176723de9f6b0b5102e27f1c893e86ef5bac7", "ref_doc_id": "52005ab0-77df-4b49-85b8-14f3209e5047"}, "f4d1e70f-27f0-4bb9-94ba-bbf6b22a228c": {"doc_hash": "3d506fe4ba0b8c0e1344c8adffa0e693b4b2dc2742e3adb7a953a24ef8df93a2", "ref_doc_id": "52005ab0-77df-4b49-85b8-14f3209e5047"}, "aa14f16d-4412-46c6-ba68-4e5e965cedd9": {"doc_hash": "628efd879e79e76fbe9f54f2239abe1ccbeb18ecde72e497b99a57c41c230971", "ref_doc_id": "52005ab0-77df-4b49-85b8-14f3209e5047"}, "1ced5fbf-5224-4441-939e-5594d436924f": {"doc_hash": "70c5813fc1dd3113b80e405f7ab33eb38054b6ec52d21c774f2af390e93424d3", "ref_doc_id": "52005ab0-77df-4b49-85b8-14f3209e5047"}, "2a5e5fd4-286c-4fd3-a591-eb6532e247e5": {"doc_hash": "d3882c634c6653ad17eacae9e9a1a4ce646ee774d96ce628279ee736db704b95", "ref_doc_id": "52005ab0-77df-4b49-85b8-14f3209e5047"}, "e3393ffe-5536-405a-b351-1d9f5c1b14d2": {"doc_hash": "a82b46f9b460797bc90117e669e42246ddcb3fc932e06f34e768b24e37206b24", "ref_doc_id": "52005ab0-77df-4b49-85b8-14f3209e5047"}, "c25c1c0a-19a3-46f9-8051-c41830352382": {"doc_hash": "1b8f53f39adf2b61a9102695e29c89fe875b10c1777c7df8990a873cb53e7e85", "ref_doc_id": "52005ab0-77df-4b49-85b8-14f3209e5047"}, "f12d03b5-5058-45b7-82f0-9b8a554003ad": {"doc_hash": "3060f4a784d1bde5aea6c87924c295ecd0c8d919eeb3c3c769d602d8a4c0fb85", "ref_doc_id": "52005ab0-77df-4b49-85b8-14f3209e5047"}, "3584ba78-423f-4639-8c11-d753dc566a27": {"doc_hash": "46826323a705f3f8a7b5d9f36d9e89c21a73d80cb291b8e02ee7547bd10a5edc", "ref_doc_id": "52005ab0-77df-4b49-85b8-14f3209e5047"}, "647d5015-1fdf-459d-99ea-a6cd023bed96": {"doc_hash": "c6aa9bc46857092d7c0a7bfbe8831ddafaa99bb00cf7908f5f21b185588515a6", "ref_doc_id": "d406cdc0-bde8-4f77-904b-5510bc1d21f8"}, "dc99d47b-8a8f-4e01-9a38-42262ec90328": {"doc_hash": "fa61d9a5312c03a4b95a94a625311cddebf881a3286da6dc6488a7bf75a24068", "ref_doc_id": "d406cdc0-bde8-4f77-904b-5510bc1d21f8"}, "620ec572-e986-4f7b-92fe-2ccf76f78f38": {"doc_hash": "a616c062fd4e7624b621228f59f460f66e4df317cea0ee2529a6bb0a2bc70f0b", "ref_doc_id": "d406cdc0-bde8-4f77-904b-5510bc1d21f8"}, "22943383-05bf-4b52-a07d-7e11781f82a4": {"doc_hash": "49427838de60c0f58b16d148325c7685128685608f576801128e37b2ee49ceea", "ref_doc_id": "d406cdc0-bde8-4f77-904b-5510bc1d21f8"}, "e19a29fb-4fd0-41ba-9226-803c518a3ee7": {"doc_hash": "5f2bdf4997150ab86dbfda9d9dd2b36179b8649f64d92bc0a9798b4210e39728", "ref_doc_id": "d406cdc0-bde8-4f77-904b-5510bc1d21f8"}, "54a9015e-8c64-4308-adc5-c852337f181f": {"doc_hash": "cffe3cbc73fc5aef60b4a9ddd95b56bd860eda231463fc369c692b4e48d6fc45", "ref_doc_id": "d406cdc0-bde8-4f77-904b-5510bc1d21f8"}, "fe1cc393-bc94-42aa-811b-dcdf6089d910": {"doc_hash": "456732b1ed0a31e3248f9f19b150a0ed991feef9b33fc56c9882fd7b12568a40", "ref_doc_id": "d406cdc0-bde8-4f77-904b-5510bc1d21f8"}, "c709644f-4e89-43ae-8b8f-c5ce67824d6f": {"doc_hash": "57d03d238fe9f99b494c8fa1f97bcdb7622643a5fef542a4844ba0de8c3b63fd", "ref_doc_id": "d406cdc0-bde8-4f77-904b-5510bc1d21f8"}, "e860c1e8-2f85-44cf-a54f-d1e9e58bc641": {"doc_hash": "1e925aa4286697846234ed5e95aa37b7996bc9615a78978b8e9adb0e8b21c8e2", "ref_doc_id": "d406cdc0-bde8-4f77-904b-5510bc1d21f8"}, "dc7f16b7-ae19-448d-81e0-3d3a89667d83": {"doc_hash": "0940c4b1f11eee6d65b76219e1f4c01b036d594d1ed29eb4189c7880b914801b", "ref_doc_id": "d406cdc0-bde8-4f77-904b-5510bc1d21f8"}, "c6b30a01-aa59-440d-87e2-82e9d9934bc2": {"doc_hash": "31b65cfd5420160d296498db76ce927a90057e543bc9cc45d2c8c2c51ff066cc", "ref_doc_id": "d406cdc0-bde8-4f77-904b-5510bc1d21f8"}, "20642ff4-6e9d-432b-82d4-7cee9423a74f": {"doc_hash": "2c2f5709a8baf3b9cdd2585ec0b35e3cdb606e7a1136c3b842d4c8cf46f6428f", "ref_doc_id": "d406cdc0-bde8-4f77-904b-5510bc1d21f8"}, "8aebc115-e52f-4181-be26-d80bf254bc57": {"doc_hash": "42381b729c8c19f0247b7fb39c09bf5988b0c56612376c014864885091af6019", "ref_doc_id": "d406cdc0-bde8-4f77-904b-5510bc1d21f8"}, "76071aea-db6e-47e6-9b35-115a27c926b5": {"doc_hash": "363e9b97cd865f2511cf800834d49380a7c4788a44fb6709176cbf74729a3cf7", "ref_doc_id": "d406cdc0-bde8-4f77-904b-5510bc1d21f8"}, "d8067823-1a97-44eb-87f8-a0da2ca9c667": {"doc_hash": "2299e2701d773f8c3e213e317d6719f94284ab813013c67ffed025bbc5f4df79", "ref_doc_id": "d406cdc0-bde8-4f77-904b-5510bc1d21f8"}, "54b76778-7667-48cf-a840-b589adae317c": {"doc_hash": "e32379c41c43ee488e6edcd445241def3477dc6b73e19ce085d2c33ca083ed58", "ref_doc_id": "d406cdc0-bde8-4f77-904b-5510bc1d21f8"}, "ba84bd36-b42a-45b5-93ca-07dd6bdf84cc": {"doc_hash": "4a57a97d2cfd19dd4982d134620d256d9dbf49e0d60c1655dee94f4000c26212", "ref_doc_id": "d406cdc0-bde8-4f77-904b-5510bc1d21f8"}, "2fa86c2f-83ed-41c6-af08-36ebff6081f3": {"doc_hash": "e864f4a17a238cf641f7b436f107540c9389f14a03f01067957f0e615ac2e41a", "ref_doc_id": "d406cdc0-bde8-4f77-904b-5510bc1d21f8"}, "faa52f20-cbee-49f9-86aa-665b60b36c4f": {"doc_hash": "0a182aa910de6367b484ffbe43b45e6faa4ef3ef80205374fedc895fa2d66c6b", "ref_doc_id": "d406cdc0-bde8-4f77-904b-5510bc1d21f8"}, "b3f0f703-fec2-4b27-99ba-d14b5842c87d": {"doc_hash": "8ddc79683d25545b8f81334102c76bc64111a2b58c2c7a7574fa098893d3ace9", "ref_doc_id": "d406cdc0-bde8-4f77-904b-5510bc1d21f8"}, "61475dbf-b0ff-4dbe-9d7a-c73f8b153351": {"doc_hash": "37291a92dd584a9f724d0479c9f356068396a7f2b6da895e35721d6543651dda", "ref_doc_id": "d406cdc0-bde8-4f77-904b-5510bc1d21f8"}, "98b00137-4f5b-4bce-b67f-50d7b3fac616": {"doc_hash": "45702193342af23d4946fd9e89095574b683059c4c6371f797293fea09c9a6f0", "ref_doc_id": "d406cdc0-bde8-4f77-904b-5510bc1d21f8"}, "a0f2260b-444e-4483-9bf5-d4f51456ae69": {"doc_hash": "490831e6eb2b72ba58f3eff794429fa1db87e619cf1a5ebf3dc881d1b2ad3651", "ref_doc_id": "d406cdc0-bde8-4f77-904b-5510bc1d21f8"}, "daee053a-7133-4c3c-81f0-fcd840a45fd9": {"doc_hash": "382816af1fc2b0437806915776699be375fdd19cbbbebd21d24219653396f466", "ref_doc_id": "d406cdc0-bde8-4f77-904b-5510bc1d21f8"}, "96257127-257b-4391-a024-7522c5ce6c74": {"doc_hash": "deff427b314f5492820cefd6dd3dd6b4854bb7db2da2104716b610f456859a5e", "ref_doc_id": "d406cdc0-bde8-4f77-904b-5510bc1d21f8"}, "501e0a88-3086-4a8b-a791-db9c7bddaee2": {"doc_hash": "d08040d40be4e731b3abadf3c125fd03e2b9fb60cc5fb0903e98ef44af3219ea", "ref_doc_id": "d406cdc0-bde8-4f77-904b-5510bc1d21f8"}, "652c074b-36e9-4cf9-9931-248533306276": {"doc_hash": "96d2f0f160cf4881ffa5add1592051e63923611d76691132e3501811411a1ff9", "ref_doc_id": "d406cdc0-bde8-4f77-904b-5510bc1d21f8"}, "c25aa8aa-6965-4891-98f3-0d96c997d38c": {"doc_hash": "34761e820bf8e7267304e66fad362717e230eb4d62b83c8d3587c44d8f266e25", "ref_doc_id": "d406cdc0-bde8-4f77-904b-5510bc1d21f8"}, "ac7a77ff-c73d-4168-aa7c-5b2b7f0782f6": {"doc_hash": "881de8bac3f48c3020dc235efe55bf1a3135a829cc9c65c5d01e2a254739b701", "ref_doc_id": "d406cdc0-bde8-4f77-904b-5510bc1d21f8"}, "43a9d434-b077-4977-886c-d2040252d3a7": {"doc_hash": "022685a556311237d1a2522c0b734be18d54838d4bfeee48ff18c3ca78c8df64", "ref_doc_id": "d406cdc0-bde8-4f77-904b-5510bc1d21f8"}, "318cca3b-37e7-4b48-ad77-bf4a2e9772e5": {"doc_hash": "d9ffb93a18c373617642b402067f1e83d5543429f943dfd6c1063b415ed834fb", "ref_doc_id": "d406cdc0-bde8-4f77-904b-5510bc1d21f8"}, "a9f51504-9e66-4fc0-ad92-b41f33afb706": {"doc_hash": "c1b0a5f87951cd2f197f1f5b3f63365f5d139537e46dd38286933537d0cba8f0", "ref_doc_id": "d406cdc0-bde8-4f77-904b-5510bc1d21f8"}, "a03e4187-ae42-434a-8736-8948872a688a": {"doc_hash": "e4952ecb4fbf227651c638b2ac053e8a91fbb37ecb99b098dcabbcdb4aaaa01b", "ref_doc_id": "d406cdc0-bde8-4f77-904b-5510bc1d21f8"}, "624dda82-1e27-4b54-9c0d-4dd1aefd05e0": {"doc_hash": "14d9471c5a9b8a6722000684fc065265468cd72671f4d1232edfcb3f59ef53ed", "ref_doc_id": "d406cdc0-bde8-4f77-904b-5510bc1d21f8"}, "73093fe2-1271-4446-a4ae-d99bed48571f": {"doc_hash": "f74240767d9cc1ba3891ab64c68c2c9b5d35e167c389066bdceb7eb072d65ac9", "ref_doc_id": "d406cdc0-bde8-4f77-904b-5510bc1d21f8"}, "7c96dbb1-dad0-47ad-84cc-6de297d4840b": {"doc_hash": "bb881c7eaa1aa605ab615b70eabbb8677dd81eae2be4254e58bb059fc1e70070", "ref_doc_id": "9a5a1cb5-b0d2-459d-9254-d18b99cabab3"}, "7b454d5e-1cde-47e5-89e7-34e919163ee0": {"doc_hash": "53b4cc80cabb016867ffcc119da16ac4bd4e4949f7b2aaf05044d0c0954d3138", "ref_doc_id": "9a5a1cb5-b0d2-459d-9254-d18b99cabab3"}, "625e44a9-64f2-46df-b23a-013fbe57b56a": {"doc_hash": "b400ec57e14de0fe798309981090c7fc11568744136d3f41edb2924c3667077f", "ref_doc_id": "9a5a1cb5-b0d2-459d-9254-d18b99cabab3"}, "322abead-569f-4c26-adcf-b8efd18acf7c": {"doc_hash": "6f929ee7296224fed2dd24a00eba3f22ff0bfdf3081f68d5df130e9264a2c22c", "ref_doc_id": "9a5a1cb5-b0d2-459d-9254-d18b99cabab3"}, "bce2c15e-230b-45ff-bbe4-b9ffac198a03": {"doc_hash": "9bfe510c37dffd69dea6c7889d34b1c8a24a5ba0b826bc3a9c7c5d064d8693ba", "ref_doc_id": "9a5a1cb5-b0d2-459d-9254-d18b99cabab3"}, "89c21bba-0ba3-4484-ab43-d7a0a5973721": {"doc_hash": "7a4e3a777b5b4e57c4bda2803c8f0090ee8a51fe1c61a7a80ad4dc34f755365e", "ref_doc_id": "9a5a1cb5-b0d2-459d-9254-d18b99cabab3"}, "8b41f4b7-4b51-465e-9cf9-b8ac58e9ca2f": {"doc_hash": "2f4adede4686cc1059421fc4d18e163b8f8a25cda84322c24fbbf89319ba821c", "ref_doc_id": "9a5a1cb5-b0d2-459d-9254-d18b99cabab3"}, "247234e5-53a3-4231-8c91-01baf79a40e9": {"doc_hash": "c516a3e5ca6482474804abf1431cc3d229e3781dd8303936415f5355b0d25d87", "ref_doc_id": "9a5a1cb5-b0d2-459d-9254-d18b99cabab3"}, "1b8d02a4-baca-4587-a2a0-a15de1b74290": {"doc_hash": "e360f91a51caaea085b8ecd975031889fe5e0809fb73c90c849eb2b31960ed80", "ref_doc_id": "9a5a1cb5-b0d2-459d-9254-d18b99cabab3"}, "2fa34c8f-d286-4ee2-b5d6-b3ba6e8c356e": {"doc_hash": "b70e298e8e7ac9e8165b80c2d19bcd022849a83e67bc855bb49a3f04cecf4c9a", "ref_doc_id": "9a5a1cb5-b0d2-459d-9254-d18b99cabab3"}, "93bc6a2f-ccc0-4c2e-94c2-d08940bbfe46": {"doc_hash": "61ee2deac86f8fe176c782e31f5f261c28b05946bfa8960dcb6de17b9836c5f5", "ref_doc_id": "9a5a1cb5-b0d2-459d-9254-d18b99cabab3"}, "040cee23-ebb9-4fbb-8f5b-1c15f9d6d07b": {"doc_hash": "6940a0315126aaee99868f434a89a625cca682b7120eb011ed1915ac5f798a57", "ref_doc_id": "9a5a1cb5-b0d2-459d-9254-d18b99cabab3"}, "4ce503e7-838f-4fe6-aebd-f8b26e862a32": {"doc_hash": "31327358dcb88f7c41a4f02549844cf071b06dc78047e1a9665b96a9687e0665", "ref_doc_id": "9a5a1cb5-b0d2-459d-9254-d18b99cabab3"}, "5795a836-fd16-4e62-b6ab-8ab38e64121b": {"doc_hash": "dd831c211cdad57604ce169f40204d58f1e9e22fd2520e7a27ee2507ab7b8417", "ref_doc_id": "9a5a1cb5-b0d2-459d-9254-d18b99cabab3"}, "5892fca8-2116-4504-b9af-2a678475068a": {"doc_hash": "482fd872be0e5e171f5bc964185c6b42f949a3630450cb5be1bbd25525ce05f3", "ref_doc_id": "9a5a1cb5-b0d2-459d-9254-d18b99cabab3"}, "02372e67-d6ec-47f5-81d1-842355943734": {"doc_hash": "7784aa778d8cccf9386fc29bae12db75848377b71573ca326e61f0b127085a09", "ref_doc_id": "9a5a1cb5-b0d2-459d-9254-d18b99cabab3"}, "6f0b3450-ed1a-4d34-a9e8-6b90374c2d23": {"doc_hash": "dfca00b7a9622168af45c57ca8b6aee6280681fa665a13c11ccb47e76580e177", "ref_doc_id": "9a5a1cb5-b0d2-459d-9254-d18b99cabab3"}, "37b6f6fa-9c63-4ee4-8505-b5cbb329ae94": {"doc_hash": "d3b6070f5709a85b22a4c085956d5a0f57000a42d892afc1892b2cdd5d521630", "ref_doc_id": "9a5a1cb5-b0d2-459d-9254-d18b99cabab3"}, "e64f016e-394a-4daf-b8ef-ef37a5e49470": {"doc_hash": "b8d8c1c8c7b0ee05f9828ce08f92bb8a6ca0cc78b4ed87f459c34ab764796728", "ref_doc_id": "9a5a1cb5-b0d2-459d-9254-d18b99cabab3"}, "7e823e27-9de4-4143-9fed-171db845fe98": {"doc_hash": "b87f0bf06a5e2bce778f5070157666c2022eacc8576d64980d0a550c35ea6d65", "ref_doc_id": "9a5a1cb5-b0d2-459d-9254-d18b99cabab3"}, "adc92f81-68d1-4640-b8e5-4a6c7c9aa728": {"doc_hash": "8eb0fc75fded592b0fb29861dcf087ff3a002e6c80cb432d5be57dfb7fa8a7bc", "ref_doc_id": "9a5a1cb5-b0d2-459d-9254-d18b99cabab3"}, "cdcebb9b-60e8-44ed-96a5-a032687feea0": {"doc_hash": "84cafc9cc3576a1315a215c5dc330674eb344a53de7bed7608eb47e1e64e0e52", "ref_doc_id": "9a5a1cb5-b0d2-459d-9254-d18b99cabab3"}, "0e391754-0520-465a-8def-929dbee3689d": {"doc_hash": "1fb606691712879a92272884c86997a431bd9f4b39d6c5e295aaa72937789e6e", "ref_doc_id": "9a5a1cb5-b0d2-459d-9254-d18b99cabab3"}, "ed9e43f8-a94b-4b7f-867b-4f4174f84a62": {"doc_hash": "828a65764818f815b477e5387ace5f287c4e61cf4a1be9d10e5e93b937758d17", "ref_doc_id": "9a5a1cb5-b0d2-459d-9254-d18b99cabab3"}, "78a14cab-bcee-46bf-96b6-4156ad8e3905": {"doc_hash": "e13446f3d8ee643081c566c0e2715b3ad1e9af7f92274e064387aca0bd3a47c7", "ref_doc_id": "9a5a1cb5-b0d2-459d-9254-d18b99cabab3"}, "ac9cbc0f-26ec-4c81-97f7-4bdad17b16bf": {"doc_hash": "e4aef8d211e37539b5d198fe6bf26b01acdddbee9acd4a3cf7d269dba2c6ac0a", "ref_doc_id": "9a5a1cb5-b0d2-459d-9254-d18b99cabab3"}, "01ead8fb-c1b7-451c-9d8c-7cfe66a0c2b6": {"doc_hash": "b5fef1478b6415d53d239707e4a3a1f980c8397dd0c1cf2aa6085dddc287e4ed", "ref_doc_id": "9a5a1cb5-b0d2-459d-9254-d18b99cabab3"}, "7e51d3f7-fc85-4e20-a1d3-0636fa52f415": {"doc_hash": "a39031b83e6337863e1ac2dac9c5bdd00c90c40fc1d2c92fcd8b961ab9b154cb", "ref_doc_id": "9a5a1cb5-b0d2-459d-9254-d18b99cabab3"}, "8bc7fb80-0714-45df-86db-5734cbbfaa5c": {"doc_hash": "3beb725ab54098da36ce35608f3bbb210699df3756d3f7924d87dc272e708696", "ref_doc_id": "9a5a1cb5-b0d2-459d-9254-d18b99cabab3"}, "03c3cbfb-f95d-4a03-a836-f7532bfb6011": {"doc_hash": "c349bdd6233666ccc4f51ad09f86810b9f46b889bcc9341e6dafe995f5e25b28", "ref_doc_id": "9a5a1cb5-b0d2-459d-9254-d18b99cabab3"}, "99d4ef8f-58e5-4a12-af6d-b9bffb2f1655": {"doc_hash": "8fa731daee54ea90634f15259f41696191909d5eabd77219f4bc25c4f98390f4", "ref_doc_id": "9a5a1cb5-b0d2-459d-9254-d18b99cabab3"}, "2081005e-0e3c-4402-bec1-409fb6bcce56": {"doc_hash": "8be47d5c47941dd530b735d53c7df1786318e146c7028cb173015b9c0ab5584e", "ref_doc_id": "9a5a1cb5-b0d2-459d-9254-d18b99cabab3"}, "d6e7769d-8900-4e83-8ca6-89f9e21e98d0": {"doc_hash": "c381969ab1508fb0a9df8ce4661fa2678d6b6d2b850c17991f241b706a905a4c", "ref_doc_id": "9a5a1cb5-b0d2-459d-9254-d18b99cabab3"}, "43eeae17-4da6-4370-b582-4d60648881ed": {"doc_hash": "e752e71e4c20f515d355f4f82c092722b62e4179a81602155bba8086eb45ea2e", "ref_doc_id": "9a5a1cb5-b0d2-459d-9254-d18b99cabab3"}, "fce8fa95-a939-410b-8898-b46cc478d699": {"doc_hash": "e77704f4ab41f6d7a3cda81339154848e8d53c01a7fa0727553778f7d5ecb395", "ref_doc_id": "9a5a1cb5-b0d2-459d-9254-d18b99cabab3"}, "6be6acbc-169e-4910-9217-739cf7da827b": {"doc_hash": "a099db0cf35cf0218097aded750f66d9bd8b1887de7021b8dacd97987d28cfc7", "ref_doc_id": "9a5a1cb5-b0d2-459d-9254-d18b99cabab3"}, "313072b8-2983-4b6c-92b8-39da00d743ae": {"doc_hash": "4d8d78b0230fc4881d394ac29a90915dc5a58001964b6f5fef9761cab15f367a", "ref_doc_id": "9a5a1cb5-b0d2-459d-9254-d18b99cabab3"}, "74e0a36a-7ead-40fa-aa7c-74dee7ac6c7f": {"doc_hash": "1cdb148ce101c740f888339af28af43245100260a344612b233929fe2d1333f1", "ref_doc_id": "9a5a1cb5-b0d2-459d-9254-d18b99cabab3"}, "f0c52f6a-0e09-4467-9d0f-3448837e2126": {"doc_hash": "e5fd6b7d35a6a9a1ba24be40de2b03472ab204cd31cc52f0230ef6059912ff0d", "ref_doc_id": "9a5a1cb5-b0d2-459d-9254-d18b99cabab3"}, "0ecefec5-57eb-4898-bc31-31ba61aefc35": {"doc_hash": "e7950bf68afa3b1fea23a6b68c4050a58319c8da10908a2c1e25fde3da973c4d", "ref_doc_id": "9a5a1cb5-b0d2-459d-9254-d18b99cabab3"}, "eb14726c-2ed7-43ce-bc4e-a1a784dfdedd": {"doc_hash": "ec7f995cc03325ea36a2567b6bc994c5fecf328d872c8b1a87df4e7255be928b", "ref_doc_id": "9a5a1cb5-b0d2-459d-9254-d18b99cabab3"}, "7f79b906-734d-4f2c-831f-909522462212": {"doc_hash": "8ee18230f52fde73f2f227986d8c57e394b81bfea73739704c29d38fbb6ddad6", "ref_doc_id": "9a5a1cb5-b0d2-459d-9254-d18b99cabab3"}, "f4e96e1a-867d-4f51-9e29-f20e2bdd32ad": {"doc_hash": "5cc6aeba190e3a58d7eadc29d0b4f1def3e9eef489c7b9077ceca3cbfcf835d5", "ref_doc_id": "9a5a1cb5-b0d2-459d-9254-d18b99cabab3"}, "a18fb39d-23f9-46dd-a397-78e2b74df3e2": {"doc_hash": "5db098620362f5850cae86577c91f74e4b767f8962095261d93dc064f3e1ed26", "ref_doc_id": "4e2cffb7-52f8-4787-88a1-36ae788b9cf5"}, "cf591735-1297-4de4-9463-6904f10dd6c6": {"doc_hash": "83b14fabd267c8242ad267fe934bf2da98f23cf63b2971d05a8086a437223aef", "ref_doc_id": "4e2cffb7-52f8-4787-88a1-36ae788b9cf5"}, "b84552a4-3530-4f50-965d-84286ad087c0": {"doc_hash": "412172cfd857dc06c9c0593512d019f845fd05fd300886b13651ee05ddf5bbd0", "ref_doc_id": "4e2cffb7-52f8-4787-88a1-36ae788b9cf5"}, "6bd7de86-9a07-4a9d-bae7-0fbd08c7452a": {"doc_hash": "eca7490abad8d2ec63f97398c7609d9b9f4c13866d62a8370412f1a2d9223682", "ref_doc_id": "4e2cffb7-52f8-4787-88a1-36ae788b9cf5"}, "dc76c41a-cece-4f99-b0b6-ed72a75445f9": {"doc_hash": "a4dbc8c954c837461c51bda5d1e85dfde40f40960e1e4ba5af6cd6d440a86662", "ref_doc_id": "4e2cffb7-52f8-4787-88a1-36ae788b9cf5"}, "7eb25e81-6a97-4faf-b8fc-926a4dde97ab": {"doc_hash": "41f8a269a7fce6677e950f9530fb707bf173e4e8d8bcdd80ba349a3ea266b140", "ref_doc_id": "4e2cffb7-52f8-4787-88a1-36ae788b9cf5"}, "faadcea3-e5be-4f50-b6e6-4160d2b65e70": {"doc_hash": "d8bf173333dd489616e41d60142b9f8a004c662193448a7af01cbc34984cbc47", "ref_doc_id": "4e2cffb7-52f8-4787-88a1-36ae788b9cf5"}, "939fd782-ba53-4bd7-ba45-e4dd5395343e": {"doc_hash": "50268c1c5c78e28330847e3dfee027e6c547312275e318465715a4fe06b06500", "ref_doc_id": "4e2cffb7-52f8-4787-88a1-36ae788b9cf5"}, "d6ec9846-fdc1-40ec-a703-9d1361a505cf": {"doc_hash": "9cc1360125cf5e29e93c1bb5f9306393e6274799f16fe12e7cad44ab8f140644", "ref_doc_id": "4e2cffb7-52f8-4787-88a1-36ae788b9cf5"}, "9eea5199-05d3-43c9-b4f8-c7861d03c86a": {"doc_hash": "aef3f1e0b7fd0de1af87ade23bfc3c3b75f73243e55e59dc101ccd25ab1e3350", "ref_doc_id": "4e2cffb7-52f8-4787-88a1-36ae788b9cf5"}, "5ab59ac4-0f29-4b56-8574-908759f19335": {"doc_hash": "7953906fc6bff5edc09face0e2e9d2366732c91638578131c847f4b322312fcd", "ref_doc_id": "4e2cffb7-52f8-4787-88a1-36ae788b9cf5"}, "0a2bdbaf-7154-486b-949c-4815b692db1e": {"doc_hash": "922148f79333d3f4489690709d4998ce9f1d155c121d185755f0091850361788", "ref_doc_id": "4e2cffb7-52f8-4787-88a1-36ae788b9cf5"}, "552542a3-4607-4f23-8627-c107b4a36230": {"doc_hash": "71401a8da51f7da3d85ffa11e23aa715d2d390d9791c61b20e0ff1eecd0e19ec", "ref_doc_id": "4e2cffb7-52f8-4787-88a1-36ae788b9cf5"}, "d89e7915-d76c-498b-b1f3-49cc259205ae": {"doc_hash": "835c5665a711c0d072cf269208b217d27c9d57b9ae7cd23bc552f897873d0095", "ref_doc_id": "4e2cffb7-52f8-4787-88a1-36ae788b9cf5"}, "a85cafb5-785c-4b31-93a7-c6220f4bfc2f": {"doc_hash": "0dd8ff70799c6e354f6acd6a2e11a0d5792039b3b257b77a39da52698918b558", "ref_doc_id": "4e2cffb7-52f8-4787-88a1-36ae788b9cf5"}, "94148a94-941d-4c66-90e8-ff62b51f2708": {"doc_hash": "5cfd8e0916bbc17e42270a313747579e1fce1a2ec3055be6df70d595895c7d15", "ref_doc_id": "4e2cffb7-52f8-4787-88a1-36ae788b9cf5"}, "60eb20e3-fa49-4a88-b2fe-e37f9bee834f": {"doc_hash": "d670f51329fbb27afba39ff231d160d575943a5ff10e9e63f243fa0ed33b1d14", "ref_doc_id": "4e2cffb7-52f8-4787-88a1-36ae788b9cf5"}, "fcd5f1eb-0d98-4d05-bd0e-097da08cc77d": {"doc_hash": "4635d2f278b5a709b55e9126a93ec9b3c5b1db9f358357484cdf16ac31392ce2", "ref_doc_id": "4e2cffb7-52f8-4787-88a1-36ae788b9cf5"}, "b81cfd5d-1d30-46e2-a761-a4e4f2e385eb": {"doc_hash": "4f8980748e8612cf09644e9e264731988854e51ff6f5318040cb72f520fa56bc", "ref_doc_id": "4e2cffb7-52f8-4787-88a1-36ae788b9cf5"}, "7884a2a2-2151-48fb-839b-16d4108af8a4": {"doc_hash": "0aa1b52617c2a879fade57346c3c39b271e0d9b42526024941aedaa1ac4f943d", "ref_doc_id": "4e2cffb7-52f8-4787-88a1-36ae788b9cf5"}, "43673ca7-0155-4223-b70a-90a1545c9043": {"doc_hash": "e3d8c6d74389cb10588d7ef605229778fd31aa728ebed5d4eb4df0c8aa2d3b42", "ref_doc_id": "4e2cffb7-52f8-4787-88a1-36ae788b9cf5"}, "7c01c7c9-2740-452c-ae9f-4e398355343b": {"doc_hash": "3b7e03c8c5ea39702b1f9961d7b226acb2d104b4fe45149396209c52acf714f7", "ref_doc_id": "4e2cffb7-52f8-4787-88a1-36ae788b9cf5"}, "a461aea1-91cf-4e0f-90fd-ab8338b32ebd": {"doc_hash": "c9686622f072df5c516ea66f3c46f09eec8d95905249c5a00b0b1303ab3c984f", "ref_doc_id": "4e2cffb7-52f8-4787-88a1-36ae788b9cf5"}, "666da054-0928-42ee-bfb1-16fc6cf442a6": {"doc_hash": "0d56d7568e245ef11bb3c0a42aa2011acb43262f1ec83bfbd50b1785952992f1", "ref_doc_id": "4e2cffb7-52f8-4787-88a1-36ae788b9cf5"}, "805eb283-3993-4bfa-a42d-877a1eb24a56": {"doc_hash": "5dde4a88030c8e59c91d5b9c64e0b64dcc4a21edde197b3b91cca6d3ca9502a7", "ref_doc_id": "4e2cffb7-52f8-4787-88a1-36ae788b9cf5"}, "826289f2-8e5e-4618-a4f3-701bd8d51131": {"doc_hash": "876dc33ca9c0a41166102e12d9174108861eb9d55c43eccbb851b227165bcae6", "ref_doc_id": "4e2cffb7-52f8-4787-88a1-36ae788b9cf5"}, "7e1fdc27-587a-45a1-b731-631b17be0154": {"doc_hash": "c6dd59f58432dbd89e3b8818bf235ad46a20f59c3e1e424baff26f95f14caace", "ref_doc_id": "4e2cffb7-52f8-4787-88a1-36ae788b9cf5"}, "187a4616-bed2-4683-8219-77b26954a26e": {"doc_hash": "67a734fcf5d34b7db2d3d90abe8a2e5e7461979f1da5f872a25a51d8f842a39d", "ref_doc_id": "4e2cffb7-52f8-4787-88a1-36ae788b9cf5"}, "9d8b23eb-37d1-4365-ad02-bc7f87c3e57f": {"doc_hash": "3aec3383a712fc35b0c33e730d4e3c86c21044efab2700313ae0baab90cfad6f", "ref_doc_id": "4e2cffb7-52f8-4787-88a1-36ae788b9cf5"}, "cffa482e-5834-45b5-a9a1-7d2926c0ffb1": {"doc_hash": "17e42fa8da37ef0d30fd954167d014b9d24d1925dde8ad6a54f1ddfc6edf07d1", "ref_doc_id": "4e2cffb7-52f8-4787-88a1-36ae788b9cf5"}, "16b8bd1e-00ec-41e1-bd14-7ad6084c8b9f": {"doc_hash": "99fb22e3500994209a9242cc13e2e59d9bbe17c15b607f307af42eb9d698dc7f", "ref_doc_id": "4e2cffb7-52f8-4787-88a1-36ae788b9cf5"}, "685cef84-b3d6-4b2b-9b07-2f48c44810a6": {"doc_hash": "8c083f7b38bec87736c78fa39f30e3203a21bcdb55cd24994c8d9e05a6b8d548", "ref_doc_id": "4e2cffb7-52f8-4787-88a1-36ae788b9cf5"}, "b6da276a-9b9b-476b-ab13-dc25273939a5": {"doc_hash": "5ee3e76d81a4f58f138d860422e6468064f0891069273c978b828a30ee88cf4d", "ref_doc_id": "4e2cffb7-52f8-4787-88a1-36ae788b9cf5"}, "dc9c4966-0abb-4410-8f8c-b6bba49234bc": {"doc_hash": "a10f3386848c42c6116c48279e473f7998be8d3103c9aaa092b5af3f0380dddb", "ref_doc_id": "4e2cffb7-52f8-4787-88a1-36ae788b9cf5"}, "2ad70149-c89c-4e87-a8bf-8a63d122b30b": {"doc_hash": "a2c0b79d58c8f119758088b9769888160a76b1eb4570012307bc9d5faa426b5b", "ref_doc_id": "1c9437ad-0883-4253-bf98-af42f1639095"}, "c9f1279a-1acd-4a9d-82e8-20ce38090601": {"doc_hash": "20165c42d19615bbe736e1b70ee2edf0831d81054bdc978f14f357cac7c3b505", "ref_doc_id": "1c9437ad-0883-4253-bf98-af42f1639095"}, "89e93d99-3aa3-46db-905c-cc33ef61117b": {"doc_hash": "83888c7362ed8eec2889fe088a8d87ff0e8b00b660a284d621d83d26032ab028", "ref_doc_id": "1c9437ad-0883-4253-bf98-af42f1639095"}, "44da7178-bd4b-4e4e-97a6-c44420841157": {"doc_hash": "de4637987fdaca25b20bc94b94c58f63c9b75ee3128383537ab441493d0bcce0", "ref_doc_id": "1c9437ad-0883-4253-bf98-af42f1639095"}, "a2c3a3a0-064b-4adf-94ea-a86739944d4d": {"doc_hash": "6d554f23505e47f766370d74b246e302fbe5a2e925a70f300b2cfb41710fb23f", "ref_doc_id": "1c9437ad-0883-4253-bf98-af42f1639095"}, "c451d20f-427d-4c62-9b56-31f843565b0e": {"doc_hash": "fe0a1765b79a8af4531af9c3fea05a9d370fd5708f8ba5f008ecbe6b88226e0b", "ref_doc_id": "1c9437ad-0883-4253-bf98-af42f1639095"}, "3a056e66-d7a5-4a0c-8052-5cd1eb3ee79f": {"doc_hash": "d9a11684f567f3c1868df97a2503f714fc8ad564cc27ca8b48c2e678c001934a", "ref_doc_id": "1c9437ad-0883-4253-bf98-af42f1639095"}, "2d6e94c3-c376-4c17-87a5-239d49776b0f": {"doc_hash": "86cda17f745020ad4da9e26d7fd1fb5ec775bc5d5ee6e6490af8b0f3394ccef5", "ref_doc_id": "1c9437ad-0883-4253-bf98-af42f1639095"}, "c6097956-085b-48f8-a6ac-1540628eb013": {"doc_hash": "6130e01a62b5d3ddfd4e4bb49ca34561fde85b256c4421a3d59a1bfc79bd110c", "ref_doc_id": "1c9437ad-0883-4253-bf98-af42f1639095"}, "11e9aff3-475a-4fb8-8b62-011a73153d77": {"doc_hash": "7b8763b823356680c2ae17319e58914c3ee01fe4686f5dc4aa4dd848b5a6a32d", "ref_doc_id": "1c9437ad-0883-4253-bf98-af42f1639095"}, "2e2ab5cc-78ff-446e-94ec-c46f7beab53b": {"doc_hash": "72d1ae420976814322999cd07df968976abc59f92ac225f3cdbcf2679152e367", "ref_doc_id": "1c9437ad-0883-4253-bf98-af42f1639095"}, "3adf8d3f-f01f-4f8d-8098-4090256bebc2": {"doc_hash": "fd6a14cbd8dcef276f9081c0055196b8d273c81c5711f665f32cdad6d966bca4", "ref_doc_id": "1c9437ad-0883-4253-bf98-af42f1639095"}, "edcc37f0-9a01-41ec-a683-bf04eda6cf2b": {"doc_hash": "edf85f90fdaf1e56f0d62ad2064ed46dbaff0258121e7bfb881f65ad4a264ddf", "ref_doc_id": "1c9437ad-0883-4253-bf98-af42f1639095"}, "7e539bb3-fca1-428e-b4a0-292e05888a71": {"doc_hash": "551c796a35d9d69b37f01015b2afa36d233d09ce5d2b50ba1f18ecc9e7d27a5a", "ref_doc_id": "1c9437ad-0883-4253-bf98-af42f1639095"}, "b4a98240-813b-4859-89e6-994cda0641d7": {"doc_hash": "13c0d2486dcb6931003439fb25a30a967d03f8d33faa4b0145d2001e51c3f6f7", "ref_doc_id": "1c9437ad-0883-4253-bf98-af42f1639095"}}, "docstore/ref_doc_info": {"eec7d66c-3454-4514-a032-b03193f8a1ea": {"node_ids": ["2d1dcccb-3e02-46e0-abde-55680070466f", "a0fe1be5-d0ec-4ba8-b3d0-1b9b60524dc9"], "metadata": {"window": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 21 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n31-Jul-2019  \nMcKesson Corp.   (MCK ) \nQ1 2020 Earnings Call    ", "original_text": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 21 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n31-Jul-2019  \nMcKesson Corp.  ", "page_label": "1", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "ddcd894d-3a7b-418b-b056-c1eebfbff48a": {"node_ids": ["042d8547-70e6-4b64-8f8b-b17e83e56818", "d1bfb804-0d26-45bd-a7f8-7c8995ed6bfb", "137edc29-0866-49af-a115-71690aa287f1", "e9093e6c-2bb6-47cc-94fb-4158f0563efb", "6b38cf73-8d96-4feb-a60b-7d3f1a4f6b17", "2d4f0610-1d29-4956-9851-f97d9aac6562", "f1bf7e7f-5b9b-4083-9fce-384e3629541e", "afe63832-3b76-47a7-8870-b2fddf186363"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSenior Vice President, Investor Relations, McKesson Corp.  \n Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n ", "original_text": "McKesson Corp.  ", "page_label": "2", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "510e1ab1-9110-4db6-842c-2a73346ced15": {"node_ids": ["c94e8c4b-317a-49c0-a8e9-34204d6247f9", "5f6b894a-10d3-4b4c-8aca-dcd10b821458", "4a548413-05f6-466f-bbac-14ea5ca94e28", "a6d40933-9750-409c-ad15-988033bd0423", "04b603d8-3aaa-4ddf-a1b4-dfdc70dee8af", "6b4227af-0b0c-41f4-898f-5c90e3baebd5", "65359aa5-d207-4662-b88e-38fcda29bbac", "dbf544b8-b4b2-4f4e-8493-df208f552536", "3761d2ed-93be-42c2-8ab3-d6e17f14ab1f", "ddc62d7f-414d-432a-82a4-6e576ca8518d", "6825a9c2-9943-45d3-8548-947c26484975", "0ac50c5f-036f-4466-8f15-ec86b2ccf906", "f14b3c48-5f97-4c9d-9fb5-a3e8d35c4e3f", "540ca450-1e83-42c3-a043-160f09e87f0c", "f2f3411f-2105-433d-8628-34b271d7b98e", "845d54cc-a4b7-436a-b879-d5a0c34075b3", "2ea94fe1-e35b-4702-b7b8-6053495abbd8", "a5aa0458-4fd8-443a-9b71-02263ec53191", "703cece9-a1a1-4c14-b3c0-18d2342a6dd5", "3839b9ce-9e53-40fa-ba33-5477fdc60ef3", "7a530be8-360f-486a-9fcc-85e479f7dd3b", "b79b7c91-e179-48c8-a243-9e50dc60b8af", "0f3a01b7-e381-4705-a971-cb610e1b0e43", "8403517e-0c7d-42e3-98c3-7569ecfa508f", "ee0d08db-6fa2-44f2-b5cb-354e79460d6c", "912d1d33-24da-40d2-ac43-adb2554a1f0a", "23d1f47f-b84c-4484-a9b6-6d471b9ca078", "8241b658-ff7f-4c11-9c80-c405798b4663", "173384bc-a7af-419a-b31e-4fb0de064c61", "49220002-ecf8-441a-952f-c7585d1a2e3c", "de974110-2bb8-48eb-b188-4ec7d734a672"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Good day, and welcome to the McKesson Q1 Earnings Call.  Today's conference is being recorded.  \n \n At this time, I'd like to turn the conference over to Holly Weiss. ", "original_text": "McKesson Corp.  ", "page_label": "3", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "bdb1c12e-5d92-4655-a0ce-a7bbe0044e67": {"node_ids": ["f59075a0-c3ff-43fa-be60-f8e271ea2cfd", "fcaef1ae-b5f0-47a1-b6f7-9bbcd9f3fece", "95e67569-2322-44d3-8ae1-d96c53212b59", "898deb2c-2255-4de3-967e-ce52864b7d43", "87d9acdf-98c7-4ae2-a90c-3d3109d5890e", "2d58f180-c875-43fc-919a-9c78245ddf59", "242df766-237e-4e47-8008-345462602d18", "217834d1-f017-405a-9575-d32274bb2a3e", "298c53fb-0134-404f-abdf-03d0bc27b627", "066bad57-a56b-433e-8fce-4387dddfcbce", "4bc03c69-e4b8-4d53-84ab-9496f2cf992e", "a9fbeda9-d3f2-4f1e-bdae-65b47d387e3d", "5c2ff04f-d323-48d2-91d4-09ca737c6794", "8b4829b8-3b18-46d4-ac7b-96f2c7771563", "6eb55a15-dab4-4ecd-9dc4-3c438e9911df", "7e737d75-e56b-4e89-ae11-0684ad8abe86", "57cd1e23-7774-470c-8a8b-bd7ba510b206", "8d2f9994-83e2-47a8-8f00-54240a431d37", "3944dc64-9e91-4729-99b5-9ef44d1f01c6", "cfa28579-ab4a-4fee-873f-1e7a317ff886", "2181b13a-7841-4233-bd5b-240511f0bd06", "789ec73e-ce22-4c6e-b2be-da716b1bf211", "00dfda7b-15c7-4616-9fb9-150e804f4cfb", "1a102e81-2d73-4f3f-a832-112d767301bf", "334e2248-5a39-4019-911e-a1f5576b5fc6", "ccf78060-5d2c-41ad-843a-4e7ebfd20161", "3f72e92b-d01d-4023-91cd-03bc06cb7682", "7d104f6a-b1cf-47f7-b320-94ac2a52073d", "78597274-6618-442f-b136-8f09dac5cf11", "2fa9a331-7749-4406-8074-a6cf7efea413", "4e579875-9e14-4d0e-9450-8c0f82e47a4c", "54ba985a-d148-4b52-b06c-409a13bc5b10"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nTalking about generics for a moment.  Similar to the last few quarters, our ClarusONE sourcing platform continues \nto deliver yield in line with our expectations.  With its scale, we're able to buy at prices that are competitive with our \npeers. ", "original_text": "McKesson Corp.  ", "page_label": "4", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "fa648db0-cb11-4d5d-95db-126c70dfc60f": {"node_ids": ["45e3c679-800a-4112-a3e6-495bfa752306", "0b9c0736-bb70-42d6-bfdc-13f1fb3fd114", "f85d4de8-a923-41a0-91cc-c36ea7ad67d4", "bb3c5391-6453-4972-a842-38324bf16c1e", "ff9dfb3f-5250-4739-b81b-032b85308639", "24e0617d-aa36-460f-a3dd-c16333e1b571", "85787496-f0d0-46dd-90c5-85b55314a160", "f6c7733a-0b1d-4941-a768-1335bf498f0a", "8a213aea-cba9-4051-af4a-ae935d9c8e4d", "5bda2734-c4fc-4c73-831c-e3aa1c26cf3e", "537858a7-42fc-4fae-92e8-76413fe0ce80", "1bcfc1ac-4381-4dae-867d-386e3bc27f98", "29d7850c-8458-4464-803e-12a11044813d", "058006ce-aa5c-445d-abe2-9d3eef8d84a9", "36206bc7-5142-4b5e-8696-abe87db3102d", "63eb23c9-0685-419e-a720-8640f93a97ec", "0673fb43-ef6a-4289-b293-61356273ba1a", "e9254940-bcd2-4c34-b682-de7b9ed04074", "b1bc4d2d-8225-408a-b0b3-a77cbc18c478", "f25c81c3-0a73-4b5f-9388-9692af8073f8", "a3a2277c-688a-4d68-8d9e-94488789f010", "95bf8a2b-9d7c-421a-92ca-8ac05f27a45c", "d49520e5-d56b-4012-9c4e-1c21b8a67585", "87684e1d-97f7-44b4-8cdf-88d9ef9d3239", "ce7fb8af-0d4f-4cc3-a45c-c6c926a2fda9", "198dcd87-3bfa-4c18-95ae-0d1244513a75", "340369b9-e29f-48ae-bae5-cd7d242349f8", "d64f37bc-55df-4648-8d80-3d91ff8b614e", "8dc0a584-fd6d-4354-aff9-71e7cf9da50e", "4c80ef3b-9f39-4835-8fde-5d0625a0286a", "651d7927-2379-4a11-8a45-c9c419c71943"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nI now want to touch upon drug pricing reform and the policy landscape.  I had the opportunity recently to spend a  \nfew days in Washington, D.C.  McKesson continues to engage as a key stakeholder in educating policymakers to \naddress issues that may impact patients, our industry, and community -based pharmacy and medical practices, \nand helping to drive the necessary chang e to support access, quality and affordability for a sustainable health \ncare system. ", "original_text": "McKesson Corp.  ", "page_label": "5", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "74aa42ba-8aa4-40bb-8e6b-4b4438973fe6": {"node_ids": ["7848ed03-ba91-4498-bb31-de74029a260b", "d12cb688-a1d9-4cd0-b62d-cc3856b9fb1a", "d4ee4b0a-26f9-4a51-8b54-2c2908268571", "19838fb3-dcee-4060-9667-3945e4e8f602", "3d5d61d8-dd77-474b-9d6f-8d593083c8be", "80f4cb25-9810-47fd-9ee9-c85528b9692c", "66f535e7-4850-4596-8324-b10779e4628d", "d6ed34b8-6f2d-4c70-a5b5-4d952d94f18d", "83464f70-87d8-493c-a37c-c84d2560c026", "0d7a9d36-ad02-43b3-bd87-6a82804acc76", "e9e98cff-6a63-4461-96dc-2e1097b54401", "2c15394b-eede-4a15-8c7d-c43e95e8ddb2", "396cb89d-55f0-4a4d-adbe-fada4fa9735a", "f5238269-abeb-4cb9-aee6-d9746877019e", "dcb9e7a2-cc72-46cc-a500-e2b27cd176fe", "7d853738-d27f-47e6-ab10-83c61ffb4873", "64d55880-895b-4823-a959-254b43d00846", "e8693b1a-7cb2-4e79-adb2-ec1c8a343185", "c4ae4d27-c9bb-466e-bd49-8e9745a6eb5b", "7cdc9798-4237-41cf-a16e-5d9208f2084e", "195946fe-780d-44f7-b4cd-9ac12e66ce81", "d9292600-28fa-4da5-8467-c7999482b5da", "4e63fdfb-b136-48d2-9687-c59a508a732d", "4c034a36-849c-44ad-ab57-eff0ba32e3a7", "2b5aae8c-706f-485d-9f68-ffd29966148f", "539dbe6e-196d-44f9-971d-82e1f37eb2e8", "8601b132-b9c1-4904-af0c-c9d5deabac06", "0a4a53e1-92b3-4b69-bcec-d7367f636132"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nsystem that uses patient prescription history to identify patients at risk of opioid overuse, abuse, addiction or \nmisuse; and actively advocating for public policies that will help address the opioid epidemic.  \n \n In addition, we contributed $100 million to establish the Foundation for Opioid Response Effort, a foundation \ndedicated solely to driving solutions for the epidemic.  I'm proud of our teams and our team members w ho ensure \nthe safety and security of our supply chain day in, day out.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "6", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "35248f45-6429-4b21-a274-8a0d5bf89987": {"node_ids": ["58a58dbc-b08d-4315-b3df-80d2ef81abf9", "812e151e-2542-4084-865f-a4e97193495e", "f4bdb64e-7f79-4927-849d-4db90a62a851", "50f18d3c-d78e-4cb9-b46f-3c1143589def", "89553ef2-aaf5-4be4-a353-edc08b44f2cc", "a46b753d-74f2-45f8-8de4-d33e15ae82c5", "fa6880b7-70c1-46b7-9856-eab1aa168626", "d2c05ecd-a7ff-4f74-aa20-74508ba888aa", "30ca020c-5455-4475-b476-e6bc5021f654", "edfc314c-bd41-4ff1-9265-3ffa35910abd", "7405a68b-0a9a-4474-9943-28183b3d7097", "e0890805-d8f0-47da-83fd-020088c35590", "a472dc04-577a-4825-8b50-f8864b22efa5", "b6d3d68c-1684-4714-bbc1-010c44f1b824", "24ddf7bb-2192-4193-82a1-017339c0b92c", "3b4b21be-d688-44fd-84b9-ec8a09419254", "13144fd7-2eed-42d3-8864-e90b17cd7d5d", "8b81511c-9f77-496b-8532-45877feb53d4", "e82ab1d9-fd01-4e4b-84e5-8cf815327437", "d6a4d243-6d7d-404d-b62e-c138d441dc93", "7a14bf58-bbcf-46c3-8681-16391e566fe4", "d0d5c4c8-e56c-4559-942f-c1451bd5c1e2", "29fc1cf6-a79c-4b0a-b2ff-d71328832b3f", "23776c64-afac-4f1d-8e10-f9b54eb3b83a", "8ae70278-5ff8-4591-9717-ec181cb7de50", "4502874e-f391-4fe6-896e-7854f8559b5c", "f0083b3e-0fbc-42b9-b444-c24fc86e3882", "5435749e-9d0a-48de-bfae-739546af6dca", "c8229b65-2bda-47d0-bccc-fce54fe3117b", "8017e292-c84a-4d87-8736-eb240ab45205", "80a2bea2-8f79-4384-8614-0af09979e2ce", "dcc3c2ef-0fd4-4e25-a7fa-bb58165f3beb", "306f4786-9b13-43c3-afba-a19ebbf2d0c8"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nNext, I'll discuss our segment results which can be found on sl ides 5 through 8; and I'd like to start with U.S. \n Pharmaceutical and Specialty Solutions.  First quarter revenues were $44.2 billion, up 8% year -over-year, driven \nby solid contributions from our largest retail national pharmacy customers, growth across our specialty businesses \nand continued solid performance within our health systems segment, partially offset by branded to generic \nconversions. ", "original_text": "McKesson Corp.  ", "page_label": "7", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "68a8ea83-af8c-4d84-b574-69c27c2d1620": {"node_ids": ["c35d176f-8605-4d05-96ad-e30d0f300ae9", "5676d38f-85d5-49f5-92ec-1920e9318d62", "988fea0d-f71e-49ed-bc3e-70cefb82da27", "df50c38d-32a1-42e9-957f-e689dc6b3999", "27683b6a-c7a5-454f-bbe7-bb8a704d6a7f", "dd7f1690-258e-4e80-ae7f-e615eb035879", "bc140cf5-7238-45bd-be39-1b15080e6c8b", "72eaffd6-305a-48da-8af0-22969316c03b", "68b2b4c3-1745-4804-8376-0702abd7db54", "b41df749-69ce-4033-8f8a-a3a987f0d261", "899de88f-9883-4b62-9289-82b3a67d8683", "95615329-8ee7-4b7f-8d73-a0ad967debaf", "2691fd8f-96f3-4413-97ef-a8af8e0f8012", "cdd9d0a3-e9f6-413b-b113-1cde4ad6b6c6", "813b5037-8a7c-4015-bfbf-04fa8de582e9", "1fbb3e6e-2b69-47b8-bf12-b4252545c8f2", "1722b56d-c6fd-469c-b271-e08e8c6f0ad9", "08bbe29e-e651-4275-b888-31366a511d91", "35ef4042-baba-4fe4-8590-ea33dd55ec92", "bb97e640-5e20-4ee8-9e9a-9d4cbb68a854", "40b6cc91-5f58-4340-b75b-97d01f92d4b1", "be6f9a45-8cb6-4c82-b1df-01645de87b00", "9082fab7-eed0-4f89-a1d3-8abdf71ab30d", "27efbbb2-d3e9-4673-bbd2-2755ebe5e703", "645214e4-363f-466d-b99a-92fff05efe3c", "7d0c7e51-09f0-464c-9509-21cfc0182b3a", "11416211-744c-47e9-8a91-e2825214e143"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nAs a result of the IPO, McKesson's equity ownership in Change Healthcare is approximately 58.5%, effective \nbeginning with McKesson's second quarter.  When taking into account McKesso n's new equity ownership \npercentage as well as Change Healthcare's repayment of long -term debt following the completion of its IPO, we \nanticipate the adjusted equity income attributable to our interest in Change Healthcare in fiscal 2020 to be \nunchanged fr om the prior range of $250 million to $270 million, which it assumes 70% ownership throughout fiscal \n2020.  \n \n I would point out that our adjusted equity interest assumption for Change Healthcare as well as our future results \nand commentary on Change Healthca re will be specific to McKesson's ownership interest based on the \nMcKesson definition of adjusted earnings, our equity ownership percentage in Change Healthcare, and the period \nfor which we are reporting which again will be on a one -month lag. ", "original_text": "McKesson Corp.  ", "page_label": "8", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "c9d94875-256d-4a67-9245-80e627b9c808": {"node_ids": ["aa605a4a-e5e0-4d9c-8531-663236e34ecd", "cbb64798-76bf-4a06-b792-f369de2c2281", "9bb5f699-fbd0-4399-913c-f4765e4f391a", "0182c1fd-e27b-453e-99d6-6972ac923a24", "66253091-2f01-4f13-a3a6-2635dbd75d1f", "e7f62783-1f91-46be-b926-f1d4a2cb251a", "702c79bc-a22a-4913-8e2d-46727b97e016", "2895a36e-5475-40a9-9c1f-a4e80894cdfe", "c41fffd7-53af-423c-a843-b96f9a7ca6e6", "61add928-15da-45cf-89b9-b17335401cec", "50df6136-6c34-40fd-9ef7-274c7de8d89a", "cb7dacdd-868a-464f-bd71-1ac41a32f048", "73368973-f3a5-4df3-a1cf-8eb94c714933", "48db25ce-d226-4004-8f64-4449a47ffca0", "8f5fb490-f85f-4038-88ad-0dd772b11bab", "ea121744-c5a3-4b1b-8771-2c5a67df3050", "84acfb9b-7417-41a2-8d6c-4afea7fac76b", "ad53b70f-a64d-48dd-9057-84b194140119", "e283a170-2651-499d-b5d7-8121981eab9e", "08e60536-6359-45d6-a4e3-f7de1f44b6d7", "d1c44e23-aeb2-4752-a867-48f09cc9b8a5", "9998aaf8-7048-4205-ae56-0926ddc18f20", "e1268fae-62fe-4bbb-a3d8-8ea658347b4f", "1ce836ef-6b2d-4d74-9a2a-5dd5229b1e07", "8c77052c-7dc0-4445-8dd8-610afc9d195b", "5296fe89-659d-4365-acc4-7c3be8c4ee63", "5ee95490-b243-4078-a345-1eb18bff7987", "bf7e8794-b6f6-4c09-a71b-3b958c066d67", "4bf78e3d-536b-4092-a4a6-95664d1de595", "f45499d6-d081-40a1-b1d0-422296e2399a"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \napproved an increase to our quarterly dividend of $0.02 to $0.41, an increase of 5% which will be payable to \nshareholders in October.  \n \n In closing, we are ple ased with the strong start to the year.  In the first quarter, we had growth across the majority \nof our businesses which more than offset the weakness in the retail pharmacy market in the UK. ", "original_text": "McKesson Corp.  ", "page_label": "9", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "6959410c-ab10-4777-9191-d5a85e8e51b3": {"node_ids": ["614acf3a-15a9-4cf6-83b6-bdccd7a7710c", "28ddf599-8ffe-480a-aa56-7453f8f20064", "dbdd1526-49cd-43e0-b62f-f6564f88aaf3", "2d29e897-1c64-4be9-9da7-4442e681fe8d", "74f88487-d730-45ca-8988-2657062d55d0", "c2c6b4e3-e4fe-42b7-a552-f1b87bae3519", "e67c6b9f-c752-4a46-9753-be4eb04af28f", "be72a50b-dcf5-40de-8089-cf02972df366", "49f20cdd-0e14-4779-8c93-407bc72f3edd", "298fae9c-25c8-4649-ba91-a2cd6ef6b10b", "f4f4ee72-5fb1-4115-832f-c796654b75f4", "1939870f-bf3f-4cea-ad30-f85349061b09", "c551284b-4ee1-4ee5-a253-669eec379c72", "6c5b71a7-30f2-4297-92d4-3b8ce14c0d3c", "454a65ea-76d4-4a0b-a4a7-b419a3195415", "c37f7900-20a5-4ccf-b9e8-bf11b38a33d0", "f86169d6-a261-4e7c-ab13-8cf1a4d24369", "32088665-46f8-420d-8c47-2644800736f2", "2b69c167-97d0-4287-b347-69062c7fdaa6", "884a0316-f23f-4584-ac43-aa9bcf9d0300", "ac555476-e7a1-43ad-8933-e8711c8eee73", "27bcd57a-1383-4138-8eb5-c030871d09b1", "ba007c2a-3505-4179-8f56-ba0b01f850db", "39edd615-fd5f-4d29-8850-295961aaf7be", "1bb7b9e0-6aad-4ac0-b82e-dfb57ce79ae4", "8fc60855-dd7c-47be-b88f-33e12d253d69", "c96cc293-41fb-4185-a322-2a9ec2bfc690", "366cb060-8221-40f2-a3fb-2e1e403658ad", "0886c3e0-4219-4c7e-a4d4-1ac46a69bbe1", "92d9df4a-0692-4eea-b526-9d4f1eda11d9", "5f0e99f9-7aef-4b52-9044-6230fc2a373b", "af2d9adb-c565-46fc-bdde-7e5c1f5f52a6", "ac8c212d-87bf-468b-9443-2f9cbae6a5a9", "66ae863d-2dc8-47fa-a147-d5dd91d59426", "95061b7a-d257-4cbf-9511-e6947c798fcb", "f1b29493-3089-4be7-a51e-2ae052e9e55c", "536f4375-d85e-4eb0-87d4-00ac6a5fc56b", "d9baee15-bebc-4e37-b0d5-0279b35e932d"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nAnd then just as a follow -up.  Clearly, what they're trying to solve for here is overall drug pricing.  You or Britt, can \nyou talk about what we saw on the quarter around drug price inflation on the branded side as well as the \ngenerics? ", "original_text": "McKesson Corp.  ", "page_label": "10", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "35c2d8f8-957b-4d5b-8738-b472dc90faf7": {"node_ids": ["b885786c-9ec7-444c-8631-d01811330fc2", "6b2d0de1-f3c8-4da1-b0ff-0515235a6f28", "0f784f26-91bf-44a7-a0de-65da5d0ef0b5", "3be69ea5-89f1-456f-8203-74e7784c8d81", "50de4cdc-0905-4fc2-9ecf-6189c0ea260e", "64f70d00-0dbc-4b75-9781-d05a3aa15500", "854b7bb7-f874-45a2-845f-9fb6d8144061", "4b5a537a-5fa1-47bb-a3ef-b6af42358830", "273e426a-abc2-409a-9056-fac88e8a27c0", "bc42432a-0d17-49c3-b02d-45d569317371", "3cd02148-2513-468e-83b0-d8eaf4b39f3c", "c4c3892d-debe-47cc-8d32-4308c6c97e2b", "479e150c-c137-471d-b412-233342bb212d", "468ed811-09eb-4b00-a6ba-241a993e98a0", "35b297ee-c556-4245-ab12-662fde91a3ef", "bb066e5b-9ba8-41cb-8e49-58ce2f5489c4", "47dc4911-494c-42ee-a2b8-f354785539ae", "bd279ce8-3116-4a81-acaa-e20ea3ff98f6", "1c48794a-870b-496e-ab03-70a15136e414", "db81ef93-afd8-4b45-81f1-65d2f9a5344b", "8d1e0cf1-5d63-4f07-b998-e7392bbf3d85", "aa33a422-3aee-4720-ac28-2083369241b1", "a3317d4a-3c1f-4860-b894-71d87b904b46", "85e5e580-b589-4860-8e32-c8cef7b3b93d", "2747792e-035b-4106-a123-3c9e712b541a", "e883e528-df0a-48e4-b4b0-ce26b7723ac0", "2faeb3c7-aefd-47fb-9a82-1ef435be68e1", "377a1de2-81b7-49cf-81e9-0485f9482662", "df13586f-3827-4c7e-8d0c-3115fb8cb73b", "a3e3f8b4-f1f0-4495-a0ff-691d2ab152b6", "a794ca7d-f311-4641-a210-200a4428c589", "518955ef-f08e-451d-a041-82995e04529c", "ab19b7a4-4252-48b3-b281-ae3d6058b8ae", "4be43cdc-1608-4d77-a77b-795c78f6f6be", "74317d02-ac3e-458e-9c91-0967d06137bc"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nMichael Cherny  \nAnalyst, Bank of America Merrill Lynch  Q \nAnd just on the contribution from Change, is the way to think about it the fact that the numbers didn't change \ndespite the fact that you had lower ownership stake versus guidance, simply driven by the outperformance \ncontribution for 1Q?  Or is there anything else that changed in terms of just the methodology aside from just a pure \nless ownership stake?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Of ficer, McKesson Corp.  ", "original_text": "McKesson Corp.  ", "page_label": "11", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "cc6b623a-67fb-4def-b7c6-1646af81356a": {"node_ids": ["4cebd535-62cb-479e-a3ae-4fa9e11de700", "151e5f23-2d8a-43d8-baea-b6400d4c32cf", "bd318f62-409b-45a9-a4eb-17426a0eb570", "ccbea32b-0272-4ae8-843b-e85ec72f18c1", "8f87e018-301f-4610-9252-c9eaad5928af", "fb47711d-2f21-4e9c-bf67-1e60ee40dc49", "627fa0ff-72f5-44f8-9d45-443f85b4f6a2", "c1fad619-f966-4ad1-874e-2b5f6815acde", "a0d0c792-6d79-4915-86fe-2d0895f2af17", "ef9cc6e7-44db-4362-ac50-63a7296184be", "c4b1b850-9ee1-452a-9735-67ba524bb266", "d1e11199-8d41-4d25-bd25-5647c2e784e6", "ea71d05f-aa3d-4570-a38a-b96137cf6391", "dcb71f60-18cd-457d-b1dd-57a041e511a1", "ff654a67-8a39-4b50-bca6-7f5e83a3749c", "2ac32cbc-14aa-4775-9770-25275775c33d", "8a303eaf-55b6-472a-9c0d-43ffb7b20ad6", "f43155f1-8ce1-415a-844c-f81027f79e42", "c89b9b16-03a5-44ad-9d77-2acee6250e61", "1159090b-8052-4c86-a0a7-87ad4e707f0c", "2d0d09da-ed72-4093-8e37-3023053fc28a", "eb127ca6-a270-478a-9526-c9311e574093", "8d165ebc-1af8-4b0f-9131-8e40c1f5c379", "c6e023ea-ea58-4ccf-ba1d-94d2d4d01776", "54e7dde3-0d5e-4132-bf34-a4abd0669395", "a3a52f21-46ff-4e00-96b4-670b79f9e583", "91c12713-0b72-40df-a520-731eac0263da", "e40f1d1c-f051-4c8b-bb88-03a8c01b3752", "566a6a1a-7a14-4711-838f-71f75e52483f", "55327c0f-94d0-4d84-9c0f-7b1c219433f3", "428672d8-6806-45fb-8d24-9183662d8c5b", "0718d8a2-d0f8-4c87-a7c7-8ca5e57beb83", "bbe721ca-e603-4a49-aab1-ca501c0d6b59", "2dda4f68-40b4-4813-af0e-3ad77aeb83a0", "04054c87-39f1-46aa-8a72-6511e1f5d32e", "e181e04d-9c91-44ea-95fe-837fe2324522", "8369262a-3eb5-4ddf-978c-b2d774c7e0de", "14465b3f-6e21-487b-8ba9-c8ed3776d96a", "43bc3b6f-ac54-4391-ade6-dc6333dc0684", "2258f1df-1c5a-418f-a18e-d6f198195ae3", "2c0c606b-1bce-4d72-8d10-8c1face69fda"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah.  We don't break that down specifically, Kevin. ", "original_text": "McKesson Corp.  ", "page_label": "12", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "96bdaac5-0d0b-446a-a4f2-842ca3d0f989": {"node_ids": ["18ecde31-c3b8-4a78-aa9d-15909c15cae3", "5bcfa5be-f7c6-43f4-9d05-4051af52ef6f", "83c01bd2-cbda-4200-818e-10902be97bac", "5d6c5ba8-d63f-4946-a20e-0d9f715c11e5", "a1323848-6d9f-4657-8f8f-5192366e4d68", "507dcfc2-7dbc-430e-9483-5ab5d4b07911", "1f3cd0f3-0507-492e-baae-cfb09b181d7c", "3b0380de-3d34-4099-ba06-8be0dcfdb58a", "33abf695-0813-4dae-8c31-fabe77c4f3ba", "f9b41b16-ef2f-4456-864c-e8cb43b830dc", "f63dfece-8a2d-482a-9fa9-79d80c5c1d2e", "70753d3c-6df6-4ba9-8796-a2a8e0e3afd3", "f721e429-722c-49bf-95c2-1f68faf90c3e", "b9fe3ac8-33c3-42e1-a589-ff5eb52e0caa", "f714b9d4-6f2f-4c07-8c42-bc8ab12dd00a", "35fec73d-3d58-4728-afe1-a2eac57c6a89", "07007969-a1a8-4d2f-8f3b-6e709fa1bff7", "78d77ab0-f494-4241-b4d0-8b05b5d2a54c", "57ef4d73-c892-44cc-acd1-3b89523d787f", "b24f9f8b-ebe5-4774-ad11-b4e47587c52e", "3aae5a47-f51f-404e-9e82-7afb6d4d2010", "70e3dfb6-b2f2-4c6d-8079-e3a21fa2c973", "e2e9b843-0416-483a-9daf-247dd8d3d37c", "735947c9-fed3-4a0d-bd8b-ec7311ddddfa", "18895a3e-4689-467d-b0a2-fae2a20f9cf8", "f0a20d25-bde2-4541-abae-55e423a46f08", "ee4eb360-bb61-4c8e-a5ad-eab390abcc62", "be5644c4-50b8-45ca-9ce8-a2be7ecf3e3b", "05786e8d-eb31-4c7a-9775-3ad8a7361c23", "f5da1a8c-626c-4f69-98fd-e6c986386dfe", "3f6f205b-8b27-45b4-83b7-d34a1a1700db", "7e404900-0e4f-41ac-afdf-da9f5b8c9211", "44d301a6-ebef-48d2-a393-06c6410e78eb", "48bd958e-1585-47ce-a4e7-93a2fd43543b", "3b2616de-bee8-476a-96fc-d3a31ac56803", "2cf26659-1909-4723-af31-8d701595e02c"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nspecialty?  And whether you've seen any contractual changes in the last year that would explain the im provement \nin benefit?  Because I'm assuming that it's not coming from branded inflation. ", "original_text": "McKesson Corp.  ", "page_label": "13", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "99b53c78-61a9-4e06-89a5-d5a3295894da": {"node_ids": ["3389ae03-c311-4f70-b95b-4daf29734aa2", "8d25075b-13df-4014-90f3-9c03c800be00", "60f2227c-ba5a-407e-a0e0-62fd9cc79882", "56296206-a80b-449b-bd6e-f6343beca97e", "2606544e-c230-43ac-9fe1-2eb6e687bea0", "581b8ff0-a00c-48fd-8cf4-d12ce78a5d4b", "0696d89b-073e-40ea-86b3-8c33a0a29964", "feb7642c-4d50-4bd2-97cb-ff893d5836ca", "d70e5eb2-420f-4a34-bd4a-96244558099b", "bb4774ec-8065-45c9-b119-babe59ef7374", "23af6603-2f0e-443b-ac65-c23b6b28b3ea", "4a8a2ae4-c8d3-47be-8a97-16a7f589ab5e", "5f76fd75-128b-4e9e-b1bf-5cba51588a8a", "432f58a7-1f2c-44a0-a79a-6eabf47d727c", "bd09b410-ed91-44ee-83e7-8712b5befe0c", "555ed4b1-29e9-45ff-afae-9159a818e6d9", "b1cb49b6-4288-4d5f-9397-512f5dd2c576", "097bd7d1-a542-4d61-93cb-d659c00f56a8", "50085506-966c-4ec9-9bab-2f1a5f898016", "cbfe86b4-72d1-47b2-ae5b-e90c8ec61d15", "a34220a6-4868-4462-aa82-c648fb4f4a5d", "de2eb216-e520-40e0-b207-4905360120d9", "1e33ddf5-396c-4172-96e9-9c85b4d76c0c", "4e5c57f7-077d-40c7-bd60-1a61439c7fdb", "58373b31-2b5c-4240-bde9-a6c685db0f2c", "1c0220d6-e1fb-49bc-a4ad-f2f2d7d34502", "769ebc90-a0a3-4b06-a405-176983d36487", "d86e1e72-5fc5-411c-a421-3eca1f533f47", "85f39720-1030-4ae3-a996-4fa048fa8e29", "7db55814-5927-4d9c-b1b7-5a3b1974557b", "19a2643c-abbe-4d0b-a299-75b289e7fbd5"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nthough, there are a couple of things that I  would point out.  First of all, Change had \u2013 as most companies, had the \nimplementation of the revenue recognition standard, and that created a timing element for the year.  For the full \nyear, that's not going to have an impact on McKesson, but it does have an impact earlier \u2013 favorable impact \nearlier in the year and [then it'll reverse out as the year goes on.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "14", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "13b8fdec-8208-4134-8779-3d8404e4cdf3": {"node_ids": ["97b83d15-f957-4454-857b-c1f08c4e5ec3", "a1407d58-f218-4a00-96aa-d59b8b332476", "cf1ffee4-a301-49c2-8f4c-b89d8802ffa3", "a3f20c98-8c8a-4f9f-bb1e-e25e1aa83498", "1158d0b9-66c4-48f4-ac08-001f325a2fdf", "029f0f85-f581-4298-a8e7-30b05af038f6", "c6a1594c-810e-4626-af69-1fcc88fdc18a", "8367034f-a156-41ca-b8eb-7375b766da49", "bc8b37e4-28d1-4a80-8e47-2de3c626c70e", "7ebc2fce-d35f-4184-8969-c3adaaeaee83", "cf10573a-f94e-4369-bec9-22fff159d661", "8f797fa3-329b-4af9-92a6-d5bafa350ef8", "0cf8b158-881f-4c64-a650-918df54b0852", "6184a7e8-be35-4f01-bb0f-05e949a0c500", "d7c72bca-ce2c-49e5-9a6b-0c777fdd130e", "71c0238c-8d83-4aa1-bedb-1ef8b93ffd29", "054459c9-4f42-4bf1-8cac-035e2ce0cde6", "3e5184fe-d9bb-4377-9460-dbe0b1bfe7fe", "c5b34caa-f9de-49ea-b1e6-404fc32c58a0", "a4dec43d-4155-4668-8791-8dd3809fd1f1", "d59deb7e-78e3-4129-b787-e66717bccc91", "73b4b0fb-d968-4dd3-8dc8-fdb179480f83", "259166a1-6404-4783-b8f3-2230edff5d83", "572245ba-cd69-4054-b06a-03cdf083ccbd", "84fa0bf4-de08-449b-a013-530339307281", "b5f976a1-adb4-4fe0-b8e6-b5d25541e59d", "24118389-8871-4bca-8bbf-cd2158516a57", "b9e60d25-0c18-408a-8d45-0af10027420f", "90ff2ff0-60c9-42d1-a93c-d7ca4c71c59a", "625bc6f1-d8fd-4e56-9068-724992a0d3e1", "4440f4c7-f2e6-4da0-b671-0ba97260368b", "18bff6ab-d63d-4eae-8b43-6ec9afdb6d53", "c010ae4d-a8df-4694-81af-2a3fb3884409", "86a1d470-d8b4-480d-9365-6ba67970aac5", "9c19d413-fe68-4666-b1d8-ff0a9b988b3c", "3dd823ec-8ca1-44be-9693-7e84d4a971fa", "a66183c3-5db5-460c-91cb-d66a64b9b056", "27b0798c-fa6d-4c58-8a70-67336488c882", "7b0a1bf3-8a2d-40e4-a53a-4171481d983a"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nthose contracts have been addressed at this point, and also any color you can provide on what the discussions \nlook like in terms of helping your pharmacy partners deal with the pressure they're under would  be very helpful. \n Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "McKesson Corp.  ", "page_label": "15", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "a46922f5-2d81-4fc9-93e8-95bec3c3587f": {"node_ids": ["73b8dd00-62fa-4bed-a366-bbdb1cda8ac8", "311b9447-e066-4461-bc40-e4f976a8aa71", "9b66039a-5a9b-4b8b-bf49-b0411d19dae9", "2fc31b10-5368-4d0f-81ed-1bbab934c2b3", "0b138cbf-7ca8-406c-a6c6-3f5f63b6bae8", "fc89f9ef-b26c-46a3-a747-1eb6ecd8e888", "ec40d994-aa1c-4491-af02-b2b5a865d70d", "42739259-1c89-4e21-a476-dc18e15135d3", "23e82a43-24fd-4134-a16a-ea4ab5eea7a2", "c52c2160-34da-4519-851b-c02335ea6097", "bd3685d2-5df1-424b-b453-2c51a61b7a47", "2fc488af-843a-49a4-a7b6-c3c83118b091", "9a97d9b0-1dc5-4e88-b394-b3f9c456b808", "fb4d0cf5-b33c-4476-8de9-a18356c03be3", "18dec443-1e88-4e5f-9ad7-6012c5c3c3c4", "c856ba40-eacd-4851-9a92-3791f0720e74", "e15f7205-ca03-4f49-975f-3dd1249c2f67", "aab0b674-e1eb-4db0-bce8-03d55e5b900f", "76189c40-ee99-49c3-b091-a1b4b9d95486", "05ca42c2-69ee-49d1-9261-f45ed81622aa", "0a769f14-3a0c-417e-b4b0-9d31f09ed536", "84a1c69a-6568-4452-9823-1e3a5ae98613", "c4aaac39-17bd-41aa-8e15-c009f085b60b", "85a205c8-9e13-4e5b-9f66-b60676250700", "dc35a1cd-054d-40c4-b610-8705c8de2dd5", "f616489e-0137-47b0-8aec-a39a51378709", "8954c01b-dec4-4ec8-ac2b-8f7906cccfcf", "32c37288-6c8a-4582-8e5b-e2a98cc7446e", "66f0cb8a-3b70-4797-861d-c39e44bb0c83", "6a1db8f6-5017-44ec-8fa7-4b85795003df", "c5d913ec-ba1a-4f68-9d6c-7305856e12e8"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nwe've had an opportunity this quarter to return more to our shareh olders.  So, we make those decisions on a \nregular basis.  But in terms of our guide on shares for the end of the year, we've not changed that.  \n ", "original_text": "McKesson Corp.  ", "page_label": "16", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "52005ab0-77df-4b49-85b8-14f3209e5047": {"node_ids": ["b1376b87-fbd4-4dbd-9692-946fbf710f36", "0e9f9718-6aeb-4073-a601-822bfc1c8344", "3273266b-52f5-4690-a262-dd1d2a8139b5", "3a289b4e-131f-4e09-b6f8-7bc9f20f595f", "7f1b5678-2b12-4e28-9ed8-304c4111fd27", "e0ec2fc4-3696-438d-b01f-6e86cfc384a6", "7bcec675-b27f-4604-808e-0a49e2b00fb8", "73074eaf-2e55-4555-9522-a786929096ea", "d46f2903-b7f5-4c00-b8f6-4b06eea7f21a", "4395105b-3830-4a17-9693-a888cc6ff21c", "3c7deed5-e191-45a0-a142-5807eb0d5602", "9623da39-c154-4be3-a587-865cdb7d5e5f", "cffe6587-a1ba-4b98-8201-7927a70d9dc5", "9ad85895-83fa-4f7d-9888-2d027b65bbe6", "80aaeb29-403f-47ed-b8d0-812e097c4e1c", "9f6d815e-f616-4725-8885-8ea99782d73d", "5219b8d2-ae6a-41fb-9fc7-1a10f2d3eb92", "28365aa8-7438-4ce8-a2eb-414f381d019c", "2fcd2bce-91cb-45d8-9af2-2163639242d7", "819df6e8-8e20-4280-a9be-478704e76b25", "88e55e8b-1519-4474-b12c-fd1762a36177", "4f148a53-e350-42d0-9464-9d4a7c98ff97", "7ebb15b5-cd47-48de-84d3-209128423467", "6d941b09-1b8e-4ee2-a89b-a3fd72fbff1b", "ac3af9ad-81c7-42c0-b2dc-23556a512d9d", "b87ad8bb-e3a3-447e-ab47-5c3894ff0bb8", "758758bf-10e1-44c3-97cd-7b8d19feb2af", "dc98f7b0-ba75-4d1f-9764-5d9452b01e74", "74023c62-ed49-4d83-b76d-7059d2013fc9", "f4d1e70f-27f0-4bb9-94ba-bbf6b22a228c", "aa14f16d-4412-46c6-ba68-4e5e965cedd9", "1ced5fbf-5224-4441-939e-5594d436924f", "2a5e5fd4-286c-4fd3-a591-eb6532e247e5", "e3393ffe-5536-405a-b351-1d9f5c1b14d2", "c25c1c0a-19a3-46f9-8051-c41830352382", "f12d03b5-5058-45b7-82f0-9b8a554003ad", "3584ba78-423f-4639-8c11-d753dc566a27"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nand Specialty Solutions business, again, it's a business that is broad -based from a distribution pers pective both in \nthe nature of the products and the customers.  \n \n But also the specialty businesses that Brian talked about, our U.S.  oncology asset, our provider base that we \nhave and also the manufacturer life capabilities, the services that we provide to t he manufacturer, those also add \nto our gross margin profile. ", "original_text": "McKesson Corp.  ", "page_label": "17", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "d406cdc0-bde8-4f77-904b-5510bc1d21f8": {"node_ids": ["647d5015-1fdf-459d-99ea-a6cd023bed96", "dc99d47b-8a8f-4e01-9a38-42262ec90328", "620ec572-e986-4f7b-92fe-2ccf76f78f38", "22943383-05bf-4b52-a07d-7e11781f82a4", "e19a29fb-4fd0-41ba-9226-803c518a3ee7", "54a9015e-8c64-4308-adc5-c852337f181f", "fe1cc393-bc94-42aa-811b-dcdf6089d910", "c709644f-4e89-43ae-8b8f-c5ce67824d6f", "e860c1e8-2f85-44cf-a54f-d1e9e58bc641", "dc7f16b7-ae19-448d-81e0-3d3a89667d83", "c6b30a01-aa59-440d-87e2-82e9d9934bc2", "20642ff4-6e9d-432b-82d4-7cee9423a74f", "8aebc115-e52f-4181-be26-d80bf254bc57", "76071aea-db6e-47e6-9b35-115a27c926b5", "d8067823-1a97-44eb-87f8-a0da2ca9c667", "54b76778-7667-48cf-a840-b589adae317c", "ba84bd36-b42a-45b5-93ca-07dd6bdf84cc", "2fa86c2f-83ed-41c6-af08-36ebff6081f3", "faa52f20-cbee-49f9-86aa-665b60b36c4f", "b3f0f703-fec2-4b27-99ba-d14b5842c87d", "61475dbf-b0ff-4dbe-9d7a-c73f8b153351", "98b00137-4f5b-4bce-b67f-50d7b3fac616", "a0f2260b-444e-4483-9bf5-d4f51456ae69", "daee053a-7133-4c3c-81f0-fcd840a45fd9", "96257127-257b-4391-a024-7522c5ce6c74", "501e0a88-3086-4a8b-a791-db9c7bddaee2", "652c074b-36e9-4cf9-9931-248533306276", "c25aa8aa-6965-4891-98f3-0d96c997d38c", "ac7a77ff-c73d-4168-aa7c-5b2b7f0782f6", "43a9d434-b077-4977-886c-d2040252d3a7", "318cca3b-37e7-4b48-ad77-bf4a2e9772e5", "a9f51504-9e66-4fc0-ad92-b41f33afb706", "a03e4187-ae42-434a-8736-8948872a688a", "624dda82-1e27-4b54-9c0d-4dd1aefd05e0", "73093fe2-1271-4446-a4ae-d99bed48571f"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \nAnd then I guess, Brian, just I'll throw my follow up out there.  I'm sorry if I missed this in the prepared remarks, but \nlarge proposed generic merger out there.  Curious if \u2013 or how impactful that would be on not only ClarusONE, but \non McKesson in general? ", "original_text": "McKesson Corp.  ", "page_label": "18", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "9a5a1cb5-b0d2-459d-9254-d18b99cabab3": {"node_ids": ["7c96dbb1-dad0-47ad-84cc-6de297d4840b", "7b454d5e-1cde-47e5-89e7-34e919163ee0", "625e44a9-64f2-46df-b23a-013fbe57b56a", "322abead-569f-4c26-adcf-b8efd18acf7c", "bce2c15e-230b-45ff-bbe4-b9ffac198a03", "89c21bba-0ba3-4484-ab43-d7a0a5973721", "8b41f4b7-4b51-465e-9cf9-b8ac58e9ca2f", "247234e5-53a3-4231-8c91-01baf79a40e9", "1b8d02a4-baca-4587-a2a0-a15de1b74290", "2fa34c8f-d286-4ee2-b5d6-b3ba6e8c356e", "93bc6a2f-ccc0-4c2e-94c2-d08940bbfe46", "040cee23-ebb9-4fbb-8f5b-1c15f9d6d07b", "4ce503e7-838f-4fe6-aebd-f8b26e862a32", "5795a836-fd16-4e62-b6ab-8ab38e64121b", "5892fca8-2116-4504-b9af-2a678475068a", "02372e67-d6ec-47f5-81d1-842355943734", "6f0b3450-ed1a-4d34-a9e8-6b90374c2d23", "37b6f6fa-9c63-4ee4-8505-b5cbb329ae94", "e64f016e-394a-4daf-b8ef-ef37a5e49470", "7e823e27-9de4-4143-9fed-171db845fe98", "adc92f81-68d1-4640-b8e5-4a6c7c9aa728", "cdcebb9b-60e8-44ed-96a5-a032687feea0", "0e391754-0520-465a-8def-929dbee3689d", "ed9e43f8-a94b-4b7f-867b-4f4174f84a62", "78a14cab-bcee-46bf-96b6-4156ad8e3905", "ac9cbc0f-26ec-4c81-97f7-4bdad17b16bf", "01ead8fb-c1b7-451c-9d8c-7cfe66a0c2b6", "7e51d3f7-fc85-4e20-a1d3-0636fa52f415", "8bc7fb80-0714-45df-86db-5734cbbfaa5c", "03c3cbfb-f95d-4a03-a836-f7532bfb6011", "99d4ef8f-58e5-4a12-af6d-b9bffb2f1655", "2081005e-0e3c-4402-bec1-409fb6bcce56", "d6e7769d-8900-4e83-8ca6-89f9e21e98d0", "43eeae17-4da6-4370-b582-4d60648881ed", "fce8fa95-a939-410b-8898-b46cc478d699", "6be6acbc-169e-4910-9217-739cf7da827b", "313072b8-2983-4b6c-92b8-39da00d743ae", "74e0a36a-7ead-40fa-aa7c-74dee7ac6c7f", "f0c52f6a-0e09-4467-9d0f-3448837e2126", "0ecefec5-57eb-4898-bc31-31ba61aefc35", "eb14726c-2ed7-43ce-bc4e-a1a784dfdedd", "7f79b906-734d-4f2c-831f-909522462212", "f4e96e1a-867d-4f51-9e29-f20e2bdd32ad"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nWell, I mean, the biosimilar landscape in general, we feel pretty positive about.  More choices, more substitutability \nor interchangeabi lity.  That gives clinicians more choices, hopefully it gives. ", "original_text": "McKesson Corp.  ", "page_label": "19", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "4e2cffb7-52f8-4787-88a1-36ae788b9cf5": {"node_ids": ["a18fb39d-23f9-46dd-a397-78e2b74df3e2", "cf591735-1297-4de4-9463-6904f10dd6c6", "b84552a4-3530-4f50-965d-84286ad087c0", "6bd7de86-9a07-4a9d-bae7-0fbd08c7452a", "dc76c41a-cece-4f99-b0b6-ed72a75445f9", "7eb25e81-6a97-4faf-b8fc-926a4dde97ab", "faadcea3-e5be-4f50-b6e6-4160d2b65e70", "939fd782-ba53-4bd7-ba45-e4dd5395343e", "d6ec9846-fdc1-40ec-a703-9d1361a505cf", "9eea5199-05d3-43c9-b4f8-c7861d03c86a", "5ab59ac4-0f29-4b56-8574-908759f19335", "0a2bdbaf-7154-486b-949c-4815b692db1e", "552542a3-4607-4f23-8627-c107b4a36230", "d89e7915-d76c-498b-b1f3-49cc259205ae", "a85cafb5-785c-4b31-93a7-c6220f4bfc2f", "94148a94-941d-4c66-90e8-ff62b51f2708", "60eb20e3-fa49-4a88-b2fe-e37f9bee834f", "fcd5f1eb-0d98-4d05-bd0e-097da08cc77d", "b81cfd5d-1d30-46e2-a761-a4e4f2e385eb", "7884a2a2-2151-48fb-839b-16d4108af8a4", "43673ca7-0155-4223-b70a-90a1545c9043", "7c01c7c9-2740-452c-ae9f-4e398355343b", "a461aea1-91cf-4e0f-90fd-ab8338b32ebd", "666da054-0928-42ee-bfb1-16fc6cf442a6", "805eb283-3993-4bfa-a42d-877a1eb24a56", "826289f2-8e5e-4618-a4f3-701bd8d51131", "7e1fdc27-587a-45a1-b731-631b17be0154", "187a4616-bed2-4683-8219-77b26954a26e", "9d8b23eb-37d1-4365-ad02-bc7f87c3e57f", "cffa482e-5834-45b5-a9a1-7d2926c0ffb1", "16b8bd1e-00ec-41e1-bd14-7ad6084c8b9f", "685cef84-b3d6-4b2b-9b07-2f48c44810a6", "b6da276a-9b9b-476b-ab13-dc25273939a5", "dc9c4966-0abb-4410-8f8c-b6bba49234bc"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \nOperator : Certainly.  That question will come from Eric Coldwell with Robert W. Baird.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ......................   \nEric W. Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  ", "original_text": "McKesson Corp.  ", "page_label": "20", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "1c9437ad-0883-4253-bf98-af42f1639095": {"node_ids": ["2ad70149-c89c-4e87-a8bf-8a63d122b30b", "c9f1279a-1acd-4a9d-82e8-20ce38090601", "89e93d99-3aa3-46db-905c-cc33ef61117b", "44da7178-bd4b-4e4e-97a6-c44420841157", "a2c3a3a0-064b-4adf-94ea-a86739944d4d", "c451d20f-427d-4c62-9b56-31f843565b0e", "3a056e66-d7a5-4a0c-8052-5cd1eb3ee79f", "2d6e94c3-c376-4c17-87a5-239d49776b0f", "c6097956-085b-48f8-a6ac-1540628eb013", "11e9aff3-475a-4fb8-8b62-011a73153d77", "2e2ab5cc-78ff-446e-94ec-c46f7beab53b", "3adf8d3f-f01f-4f8d-8098-4090256bebc2", "edcc37f0-9a01-41ec-a683-bf04eda6cf2b", "7e539bb3-fca1-428e-b4a0-292e05888a71", "b4a98240-813b-4859-89e6-994cda0641d7"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ1 2020 Earnings Call  Corrected Transcript  \n31-Jul-2019   \n \n1-877-FACTSET   www.callstreet.com   21 \nCopyright \u00a9 2001 -2019  FactSet  CallStreet, LLC  \n \n \n \n \n \n \nDisclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available  data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You  must evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on  the accuracy, completeness, safety or usefulness of such information. ", "original_text": "McKesson Corp.  ", "page_label": "21", "file_name": "MCK-Q1-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q1-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 376387, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}}}